Studie 017

(CTN017-FCE20124)

Studienbericht

Pharmacia Document 9550085

Reboxetine CLINICAL STUDY 017 20 November 1995

Multicentre, Multinational Double-Blind Study of the Activity and Tolerability of Reboxetine *vs* Imipramine in Patients Suffering from Major Depressive Episodes

(Phase III)

Final report of study
CTN017-FCE20124

Authors
Dubini A, Giorgetti C, Petroccione A;
Berzewski H, Van Moffaert M, Gagiano CA

Pharmacia Document 9550085

STUDY CO-ORDINATION, MANAGEMENT AND REPORTING

Study Director

Adriana Dubini, Pharm.D.
Pharmacia, CNS R&D
Milan, Italy

signature 20.11.95 date

Medical Research Associate

Carla Giorgetti, Biol.D.
Pharmacia, CNS R&D
Milan, Italy

signature 20-11-95 date

Statistics

Anna Petroccione, M.D.
Pharmacia, Oncology R&D
Biometrics and Data Management
Milan, Italy

signature 20.11.95 date

Pharmacia **Document 9550085**

Clinical Investigator and Member of the Steering Committee:

Dr. med. Horst Berzewski
Leiter der psychiatrischen Ambulanz und Krisenintensivstation,
Freie Universität Berlin,
Universitätsklinikum Benjamin Franklin,
Berlin, Germany

Berzewski 11.12.95
signature **date**

Clinical Investigator and Member of the Steering Committee:

Prof. Myriam Van Moffaert
Universitair Ziekenhuis Gent,
Polikliniek Psychiatrie (K 13),
De Pintelaan, Gent,
Belgium

signature 28-11-97 date

Pharmacia **Document 9550085**

Clinical Investigator:

Prof. C.A. Gagiano
Department of Psychiatry,
The University of
The Orange Free State,
Bloemfontein,
Republic of South Africa

C.A.G. 29-11-95

signature **date**

TABLE OF CONTENTS

	Page
COVER PAGE	1
STUDY CO-ORDINATION, MANAGEMENT AND REPORTING	2
TABLE OF CONTENTS	6
LIST OF ABBREVIATION AND TERMS	17
SYNOPSIS	18
1. INTRODUCTION	22
2. STUDY OBJECTIVES	24
3. INVESTIGATIONAL PLAN	24
3.1 Study Design and Plan - Description and Rationale	24
3.1.1 OVERVIEW AND JUSTIFICATION	24
3.1.2 PROTOCOL AMENDMENTS	25
3.2 Ethics	25
3.2.1 ETHICS COMMITTEE	25
3.2.2 PATIENT INFORMATION	26
3.3 Study Population	26
3.3.1 INCLUSION CRITERIA	26
3.3.2 EXCLUSION CRITERIA	27
3.3.3 WITHDRAWAL CRITERIA	28
3.3.4 SAMPLE SIZE - NUMBER OF PATIENTS PLANNED	28
3.4 Treatments	28
3.4.1 TREATMENTS TO BE COMPARED	28
3.4.2 IDENTITY OF TEST TREATMENTS	29
3.4.3 DOSE SELECTION AND TIMING	29
3.4.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUPS	29
3.4.5 TREATMENT SUPPLY AND BLINDING	30
3.5 Treatment Procedures	30
3.5.1 CONCOMITANT THERAPY	30
3.5.2 TREATMENT ACCOUNTABILITY AND COMPLIANCE	31
3.6 Efficacy and Safety Variables	31
3.6.1 EFFICACY	31
3.6.1.1 Hamilton Depression Rating Scale	31
3.6.1.2 Clinical Global Impression	33
3.6.1.3 Montgomery and Asberg Depression Rating Scale	33
3.6.1.4 Patient Global Impression	34
3.6.2 SAFETY	34
3.6.2.1 Adverse Events	35
3.6.2.2 Clinical and Laboratory Tests	36
3.7 Study Procedures and Flow Chart	37

	Page
3.7.1 SCHEDULE OF ASSESSMENTS	37
3.7.2 PROCEDURES AT EACH VISIT	37
3.8 GCP Compliance, Data Quality Assurance	**38**
3.9 Statistical Analysis	**38**
3.9.1 SAMPLE SIZE CONSIDERATIONS	38
3.9.2 STATISTICAL AND ANALYTICAL PLANS	39
3.9.2.1 Baseline Comparability of Treatments Groups	39
3.9.2.2 Efficacy Analyses	39
3.9.2.3 Safety	41
3.9.2.4 Changes in the Conduct of the Study or Planned Analysis	43
3.10 Data Management	**43**
4. STUDY PATIENTS	**44**
4.1 Disposition of Patients	**44**
4.2 Protocol Deviations	**45**
4.3 Demographic Data	**46**
4.3.1 DIAGNOSIS AND HISTORY OF THE DEPRESSIVE DISORDER	47
4.3.2 SEVERITY OF DEPRESSION	47
4.3.3 PREVIOUS ANTIDEPRESSANT TREATMENTS	48
4.3.4 MEDICAL HISTORY	48
5. STUDY MEDICATION AND COMPLIANCE	**49**
6. CONCOMITANT MEDICATIONS	**50**
7. EFFICACY RESULTS	**51**
7.1 Hamilton Depression Rating Scale	**50**
7.2 Clinical Global Impression	**51**
7.2.1 SEVERITY OF ILLNESS	51
7.2.2 GLOBAL IMPROVEMENT	52
7.2.3 EFFICACY INDEX	52
7.3 Montgomery and Asberg Depression Rating Scale	**52**
7.4 Efficacy Conclusions	**53**
8. SAFETY RESULTS	**53**
8.1 Safety Population and Extent of Exposure	**53**
8.1.1 NUMBER OF PATIENTS IN SAFETY ANALYSIS	53
8.1.2 TOTAL DRUG EXPOSURE	53
8.2 Adverse Events	**54**
8.2.1 ANALYSIS OF ADVERSE EVENTS	54

	Page
8.2.1.1 Absolute and Per Cent Frequency	54
8.2.1.2 Occurrence	55
8.2.1.3 Overall Risk	55
8.2.1.4 Dose-Relationship	55
8.2.1.5 Maximal Severity	55
8.2.1.6 Duration	56
8.2.1.7 Symptomatic Treatment	56
8.2.1.8 Modification of Study Medication and Patient Outcome	56
8.2.1.9 Prevalence	56
8.2.1.10 Relationship Between Adverse Events and Study Medication	57
8.2.2 ADVERSE EVENT SUMMARY	57
8.2.2.1 Severity of Adverse Events	57
8.2.2.2 Age- and Gender-Related Effects	58
8.2.2.3 Frequently Reported Adverse Events	58
8.2.3 SERIOUS ADVERSE EVENTS, DEATHS AND ADVERSE EVENTS ASSOCIATED WITH WITHDRAWAL	60
8.2.3.1 Serious Adverse Events and Deaths	60
8.2.3.2 Adverse Events Associated with Withdrawal	60
8.3 Laboratory Tests	**62**
8.3.1 SUMMARY STATISTICS OF LABORATORY VALUES	62
8.3.2 URINALYSIS	62
8.3.3 ABNORMAL LABORATORY VALUES	62
8.3.4 ABNORMAL LABORATORY VALUES OF CLINICAL RELEVANCE	62
8.4 Vital Signs	**63**
8.4.1 BLOOD PRESSURE AND HEART RATE	63
8.4.2 BODY WEIGHT	63
8.4.3 BODY TEMPERATURE	64
8.5 Electrocardiogram	**64**
8.6 Safety Conclusions	**65**
9. DISCUSSION	**66**
10. CONCLUSION	**68**
11. REFERENCES	**69**

Tables		**71**
Table 1	Number of patients by centre, visit and treatment	72
Table 2	Patient disposition	74
Table 3	End of study: reasons for discontinuation and visit at which discontinuation occurred, by assigned treatment	75
Table 4	Protocol violations at admission	76
Table 5	Randomisation: assigned treatment *vs* randomised treatment	77
Table 6	Compliance to schedule time as per protocol	78
Table 7	Concomitant drugs not allowed by protocol grouped by active principle. Number of patients	80
Table 8	Concomitant drugs not allowed by protocol grouped by class. Number of patients	81
Table 9	Demography by assigned treatment - age, weight, height	82
Table 10	Demography by assigned treatment - race	83
Table 11	Diagnosis and history of mental disorders by sex and assigned treatment	84
Table 12	Diagnosis and history of mental disorders by sex and assigned treatment	86
Table 13	Previous antidepressive treatment by active principle	89
Table 14	Medical history and admission examination findings of screened patients by sex and assigned treatment	91
Table 15	Medical history and admission examination findings of screened patients by body system, sex and assigned treatment	97
Table 16	Experimental treatment: number of patients according to dose taken on each day and on days of assessment during therapy by assigned treatment	98
Table 16.1	Experimental treatment: number of patients who switched from low to high dose by assigned treatment	100
Table 17	Experimental treatment: distribution of patients according to capsules taken by assigned treatment	101
Table 18	Concomitant drugs by active principle: number of patients taking at least one concomitant medication by assigned treatment and initial period of administration	102
Table 19	Hamilton Depression Rating Scale: summary statistics on total score according to time interval by assigned treatment	108
Table 20	Factorialisation Hamilton Depression Rating Scale: summary statistics on score of each factor according to time interval by	

	assigned treatment	109
Table 21	Hamilton Depression Rating Scale: summary statistics on score of each item according to time interval by assigned treatment	113
Table 22	Hamilton Depression Rating Scale: summary statistics on total score at last assessment by assigned treatment	134
Table 23	Factorialisation Hamilton Depression Rating Scale: summary statistics on score of each factor at last assessment by assigned treatment	135
Table 24	Hamilton Depression Rating Scale: summary statistics on score of each item at last assessment by assigned treatment	139
Table 25	Efficacy: classification of patients according to protocol criteria on total score of Hamilton Depression Rating Scale over time by assigned treatment	160
Table 26	Efficacy: classification of patients according to protocol criteria on total score of Hamilton Depression Rating Scale at last assessment *vs* Day 0 by assigned treatment	161
Table 27	Clinical Global Impression: Severity of Illness according to time interval by assigned treatment	162
Table 28	Clinical Global Impression: Severity of Illness at last assessment by assigned treatment	163
Table 29	Clinical Global Impression: Severity of Illness shift table (last value *vs* Day 0) by assigned treatment	164
Table 30	Clinical Global Impression: Global Improvement according to time interval by assigned treatment	165
Table 31	Clinical Global Impression: Global Improvement at last assessment by assigned treatment	166
Table 32	Clinical Global Impression: Efficacy Index according to time interval by assigned treatment	167
Table 33	Clinical Global Impression: Efficacy Index at last assessment by assigned treatment	168
Table 34	Montgomery Asberg Depression Rating Scale: summary statistics on total score according to time interval by assigned treatment	169
Table 35	Montgomery Asberg Depression Rating Scale: summary statistics on score of each item according to time interval by assigned treatment	170
Table 36	Montgomery Asberg Depression Rating Scale: summary statistics on total score at last assessment by assigned treatment	180
Table 37	Montgomery Asberg Depression Rating Scale: summary statistics on score of each item at last assessment by assigned treatment	181
Table 38	Adverse events: frequency (95% CI) of patients who complained of at least one adverse event during therapy by sex and assigned	

	treatment	191
Table 39	Adverse events: frequency (95% CI) of patients who complained of at least one adverse event during therapy by age and assigned treatment	192
Table 40	Adverse events: frequency (95% CI) of patients who complained of at least one adverse event during therapy by DSM III-R classification and assigned treatment	193
Table 41	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment and sex	194
Table 42	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment, body system and sex	201
Table 43	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment and sex, grouped by body system	220
Table 44	Adverse events: occurrence of adverse events according to time of onset by assigned treatment	222
Table 45	Adverse events: occurrence of adverse events according to time of onset by assigned treatment and body system	229
Table 46	Adverse events: occurrence of adverse events according to time of onset by assigned treatment and grouped by body system	248
Table 47	Adverse events: number of adverse events according to dose taken the day of onset and three days before by severity and assigned treatment	250
Table 48	Adverse events: number of patients who complained of at least one adverse event by maximal severity level, sex, age, DSM-III-R	267
Table 49	Number of patients who complained of adverse events by maximal severity level, sex and assigned treatment	268
Table 50	Number of patients who complained of adverse events, grouped by body system, by maximal severity level, sex and assigned treatment	280
Table 51	Adverse events: duration of episodes by assigned treatment	284
Table 52	Adverse events: number of adverse events by symptomatic treatment and assigned treatment	287
Table 53	Adverse events by action on study drug and assigned treatment	292
Table 54	Adverse events: disappeared after action on study drug and reappeared on resuming treatment by assigned treatment	298
Table 55	Adverse events: outcome of events at the end of the therapy by action on study drug and assigned treatment	301
Table 56	Adverse events: prevalence of adverse events according to time	

	interval by assigned treatment	313
Table 57	Adverse events: prevalence of adverse events according to time interval by assigned treatment and body system	321
Table 58	Adverse events: prevalence of adverse events according to time interval by assigned treatment and grouped by body system	340
Table 59	Adverse events by relationship to the experimental treatment and assigned treatment	343
Table 60	Adverse events present at last day of treatment and their relationship to study medication (only patients who withdrew from the study for adverse events)	349
Table 61	Laboratory test: haematology and blood chemistry statistical analysis according to time interval by assigned treatment	354
Table 62	Urinalysis: number and percentage of patients according to time interval, by assigned treatment and sex	371
Table 63	Urinalysis: number and percentage of patients at last assessment, by assigned treatment and sex	373
Table 64	Urinalysis: shift table - number of patients with absent or present urinalysis value at each evaluation time as compared to pre-treatment evaluation, by assigned treatment	375
Table 65	Urinalysis: shift table - number of patients with absent or present urinalysis value at last assessment as compared to pre-treatment evaluation, by assigned treatment	377
Table 66	Urinalysis: shift table - number of patients with abnormal or normal urinalysis value at each evaluation time as compared to pre-treatment evaluation, by assigned treatment (specific gravity)	379
Table 67	Urinalysis: shift table - number of patients with abnormal or normal urinalysis value at last assessment as compared to pre-treatment evaluation, by assigned treatment (specific gravity)	381
Table 68	Laboratory test: haematology and blood chemistry - shift table. Number of patients with values below, within or above the normal range according to time interval as compared to pre-treatment, by assigned treatment	383
Table 69	Laboratory test: number and percentage of patients with laboratory abnormalities of clinical relevance	391
Table 70	Blood pressure and heart rate: summary statistics according to time interval by assigned treatment	397
Table 71	Blood pressure and heart rate: summary statistics on changes from baseline observed during treatment according to time interval by assigned treatment	399
Table 72	Blood pressure and heart rate: number and percentage of patients	

	with decrease or increase *vs* baseline of clinical relevance according to time interval by assigned treatment	401
Table 73	Blood pressure and heart rate: absolute number of patients showing clinically relevant changes, compared to baseline, once, twice or more times during the therapy	403
Table 74	Blood pressure: number and percentage of patients with orthostatic hypotension before and during the study according to time interval by assigned treatment	404
Table 75	Body weight: summary statistics according to time interval by assigned treatment and sex	405
Table 76	Body weight: number and percentage of patients with values lower or higher than pre-treatment at each evaluation time, by assigned treatment and sex	407
Table 77	ECG: number and percentage of patients with abnormal ECG according to time intervals, by assigned treatment and sex	409
Table 78	ECG: shift table - number of patients with normal or abnormal ECG value at each evaluation time as compared to pre-treatment evaluation, by assigned treatment	410
Table 79	ECG: shift table - number of patients with normal or abnormal ECG value at last assessment as compared to pre-treatment evaluation, by assigned treatment	411
Table 80	ECG: number and percentage of ECG abnormalities observed during the study, by assigned treatment	412
Table 81	ECG: shift table - number of patients with absent or present ECG abnormalities at last assessment as compared to pre-treatment evaluation, by assigned treatment	413
Table 82	ECG: number and percentage of ECG abnormalities, by abnormality group, observed during the study by assigned treatment	419
Table 83	ECG: shift table - number of patients with absent or present ECG abnormalities, by abnormality group, at last assessment as compared to pre-treatment evaluation, by assigned treatment	420

Figures		**421**
Figure 1	Mean decreases of Hamilton total score at last assessment. Point estimates and confidence intervals	422
Figure 2	Cumulative probability of 50% decrease in HAMD total score	423
Figure 3	Severe patients judged by CGI severity at baseline. Mean decreases of Hamilton total score at last assessment. Point estimates and 95% confidence intervals	424
Figure 4	Melancholic patients. Mean decreases of Hamilton total score at last assessment. Point estimates and 95% confidence intervals	425
Figure 5	Cumulative risk of developing the first adverse event during treatment	426
Figure 6	Cumulative risk of developing agitation/anxiety/nervousness	427
Figure 7	Cumulative risk of developing asthenia/fatigue	428
Figure 8	Cumulative risk of developing bronchitis	429
Figure 9	Cumulative risk of developing constipation	430
Figure 10	Cumulative risk of developing headache/migraine	431
Figure 11	Cumulative risk of developing hypotension and related symptoms	432
Figure 12	Cumulative risk of developing insomnia	433
Figure 13	Cumulative risk of developing dry mouth	434
Figure 14	Cumulative risk of developing nausea and related symptoms	435
Figure 15	Cumulative risk of developing somnolence	436
Figure 16	Cumulative risk of developing increased sweating	437
Figure 17	Cumulative risk of developing tachycardia	438
Figure 18	Cumulative risk of developing tremor	439
Figure 19	Cumulative risk of developing urinary hesitancy/retention	440
Figure 20	Percentage of patients with at least one adverse event when exposed to treatment according to time intervals	441

12.	**Appendices**	442
12.1	Study Information	443
12.1.1	Protocol and Protocol Amendments	444
12.1.2	CRF Sample	509
12.1.3	Ethics Committees or Investigational Review Boards: Approvals, List of Members, Patient Information and Consent Forms	510
12.1.4	Clinical Investigators List, Signatures and Curricula Vitae	511
12.1.5	Certificates of Analysis	513
12.1.6	Audit Certificate	523
12.1.7	Randomization List	525
12.1.8	Laboratory Reference Values and Criteria Used to Judge Laboratory Abnormalities as Clinically Relevant	534
12.1.9	Adverse Events Grouped in Clusters	537
12.1.10	ECG Codes	540
12.1.11	Statistical Analysis Programs Listings	542
12.1.12	Selection of Statistical Analysis Outputs	551
12.2	Patient Information	584
12.2.1	Serious Adverse Events - Case Histories	585
12.2.2	Individual Data Listings	591
Listing 1.0	Patient identification	
Listing 2.0	History of mental disorder and present episode	
Listing 3.0	DSM-III-R: diagnostic criteria for the major depressive episode	
Listing 4.0	Medical history and admission examination findings	
Listing 5.0	Chest X-ray	
Listing 6.0	Previous antidepressive treatment	
Listing 6.1	Duration of drug-free wash-out period	
Listing 7.0	Inclusion/exclusion criteria	

Listing 8.0	Concomitant drugs	
Listing 9.0	Experimental treatment: daily dose and cumulative compliance	
Listing 10.0	Assigned *vs* randomised treatment	
Listing 11.0	Reasons for discontinuation of the treatment	
Listing 12.0	Hamilton Depression Rating Scale	
Listing 12.1	Hamilton Depression Rating Scale: factors and total score	
Listing 13.0	Montgomery and Asberg Depression Rating Scale	
Listing 16.0	Clinical Global Impression	
Listing 17.0	Adverse events: detail and summary	
Listing 18.0	Laboratory data	
Listing 19.0	Urinalysis	
Listing 20.0	Vital signs and assessment dates	
Listing 21.0	ECG tracings	
12.2.3	CRFs	1465

LIST OF ABBREVIATIONS AND TERMS

ANOVA	analysis of variance
b.i.d	twice daily
BUN	blood urea nitrogen
CGI	clinical global impression
CI	confidence interval
CRF	case record form
DSM-III-R	diagnostic and statistical manual - third edition - revised
ECG	electrocardiogram
ECT	electroconvulsive therapy
gamma GT	gamma glutamyl transpeptidase
GCP	Good Clinical Practice
HAMD	Hamilton depression rating scale
IRB	Institutional Review Board
MADRS	Montgomery and Asberg depression rating scale
SD	standard deviation
SGOT	serum glutamic-oxaloacetic transaminase
SGPT	serum glutamic-pyruvic transaminase
T4	thyroxine
TSH	thyroid-stimulating hormone

REBOXETINE - PROTOCOL 20124/017
SYNOPSIS

Name of Company: Pharmacia Spa **Name of finished product:** **Name of active ingredient(s):** Reboxetine	**Individual study table referring to part IV of the dossier** **Ref.:** **Vol.:** **Page:**	**(For national authority use only)**
Title of study: Multicentre, multinational double-blind study of the activity and tolerability of reboxetine *vs* imipramine in patients suffering from Major Depressive Episodes		
Investigators: Dr H Berzewski, Dr M Wolfersdorf, Dr J Fischer, Dr R Uebelhack, Dr W Konig, Dr M Derely, Dr J Wilmotte, Dr M Van Moffaert, Dr R Spiers, Dr J Bollen, Prof CA Gagiano, Dr M Berk, Dr DAB Wilson, Dr H Hauer, Dr M El Mallah, Dr M O'Connolly, Dr P Adler, Dr K Schroter, Dr G Stumpf, Dr P Weinholz, Dr H Wiswedel, Prof A Levin.		
Study centres: Universitätsklinikum Steglitz, Freie Universität Berlin, Berlin, Germany; Abt. Psychiatrie I - Univ Ulm, Ravensburg-Weissenau, Germany; Bürgerhospital, Psychiatrische Klinik, Stuttgart, Germany; Poliklinik der Charité Nervenklinik, Berlin, Germany; Psychiatrisches Landeskrankenhaus, Weinsberg, Germany; Clinique La Ramée, Neuropsychiatric Hospital, Brussels, Belgium; Hôpital Civil Vincent Van Gogh, Marchienne-au-Pont, Belgium; Universitair Ziekenhuis Gent, Psychiatrische Kliniek, Gent, Belgium; St Camillus Ziekenhuis, St Denijs-Westrem, Belgium; Sancta Maria Psychiatr Ziekenhuis, Sint Truiden, Belgium; Department of Psychiatry, University of Orange Free State, Bloemfontein, South Africa; Johannesburg Medical School, Psychiatry Department, Parktown, South Africa; Department of Psychiatry, Groote Schuur Hospital, Cape Town, South Africa; An der Aurach 8, Emskirchen, Germany; Seltsamplatz 3, Forchheim, Germany; Haimendorfstrasse 4, Schwabach-Wolkersdorf, Germany; Schnieglingerstrasse 36a, Nürnberg, Germany; Altdorfer Strasse 11, Lauf/Pegnitz, Germany; Volkacher Strasse 31, Nürnberg, Germany; Brauhofgasse 1, Erlangen-Frauenaurach, Germany; Friedenstrasse 12, Fürth/Bay, Germany; Fort England Hospital, Grahamstown, South Africa.		
Publication (reference): None		
Study period: December 1990 - September 1992	**Clinical Phase:** III	
Objectives: To assess the activity and tolerability of reboxetine in comparison with imipramine in patients suffering from Major Depressive Episodes.		
Methodology: In this prospective, double-blind, randomised, controlled, parallel group, multicentre and multinational trial, patients underwent an initial wash-out period of 4-14 days (≥3 weeks in case of fluoxetine administration), after which they received reboxetine 4 mg b.i.d., or imipramine 150 mg (50 mg in the morning and 100 mg in the evening) for six weeks (imipramine was given at a dose of 50 mg b.i.d. for the first three days of the study). At the end of the initial 3 weeks of treatment, patients could be switched to a higher dose regimen, corresponding to 10 mg reboxetine and 200 mg imipramine up to the end of treatment. Patients willing to continue after completion of 6 weeks' treatment were maintained, under blind conditions, on the same medication until the last patient recruited had completed the study and all the CRFs had been collected. The response to treatment was assessed using the Hamilton Depression Rating Scale (HAMD), Clinical Global Impression (CGI), and the Montgomery and Asberg Depression Rating Scale (MADRS). Safety and tolerability were assessed by the reporting of any adverse events and assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests and ECG.		
Number of subjects (planned and analysed): 200 patients were to be recruited in the study. Two hundred and fifty-six patients (167 females and 89 males) from 22 centres were randomised to treatment with either reboxetine (130) or imipramine (126).		

Name of Company: Pharmacia Spa Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)

Diagnosis and main criteria for inclusion: Patients were diagnosed according to the DSM-III-R classification. The severity of depression was quantified using the HAMD scale. Criteria for inclusion were as follows: (1) Patients of either sex, of any race, aged 18 to 65 years, with a diagnosis of Major Depressive Episode, not accompanied by psychotic features (DSM-III-R) with the current episode having been present for 1-4 months; (2) Initial (pre-treatment) total score for the HAMD 21-item ≥22.

Test product: Capsules containing RBX methanesulphonate tablets

Unit dose: 4 mg (two 2 mg tablets) or 6 mg (three 2 mg tablets) of reboxetine (free base)

Mode of administration: by oral route, b.i.d.

Batch no: SF1131, SF1264, SF1132, SF1291

Duration of treatment: 6 weeks

Reference therapy: Imipramine 25 mg tablets in indistinguishable capsules

Unit Dose: 50 mg or 100 mg imipramine

Mode of administration: by oral route, b.i.d.

Batch no: SF1130, SF1265, SF1129, SF1151, SF1263

Criteria for evaluation:

Efficacy

Study end-point: difference of HAMD total score at last assessment *vs* baseline

Response: HAMD total score decrease equal to or greater than 50% compared to the baseline value (Visit 0)

Remission: HAMD total score lower than or equal to 10 (absolute value)

Time to response: number of days at onset of response confirmed at all subsequent available assessments

HAMD total scores and factor scores, MADRS total scores, CGI classification

Safety

Adverse events, vital signs (supine and standing blood pressure and heart rate), laboratory tests, and ECG.

Clinically relevant modifications of blood pressure (BP) and heart rate (HR) (≥20% *vs* baseline), or such modifications associated with critical values (≥160 or ≤100 mmHg for systolic BP; ≥100 or ≤70 mmHg for diastolic BP; ≥100 or ≤50 beats/min for HR). Orthostatic hypotension (decrease of systolic BP >20 mmHg from lying to standing). Clinically relevant changes of laboratory tests abnormal ECG findings according to standardised criteria.

Statistical Method:

Efficacy

Mean changes of HAMD total score at last valid observation respect to baseline was the study end-point. Ninety-five per cent confidence interval (CI) of the mean changes in each treatment group and of the between treatment difference were calculated.

The same sets of analyses were carried out on the subset of severe (CGI-Severity of Illness, moderately to severely ill at baseline) and melancholic patients (DSM IV criteria). Ninety-five per cent CI of the proportions of response and remission in each treatment group and of the between treatment difference were computed.The cumulative probability of the onset of response (time to response) was computed adopting the Kaplan-Maier method and the between treatment comparison was carried out by the log-rank test.

Secondary efficacy variables, including HAMD and MADRS total scores and CGI were summarized by descriptive statistics at each visit and at last valid observation.

Name of Company: Pharmacia Spa Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)

Safety

For all laboratory tests frequency of patients shifted from values below, within or above the normal range at baseline to values below, within or above the normal range at each visit were computed. The Stuart Maxwell test was applied to test the changes in the distribution across categories at each visit *vs* baseline.

Continuous values of laboratory tests were standardized according to a method proposed by Chuang-Stein and the Wilcoxon Rank Signed test for paired data was applied in order to compare the values during treatment with those recorded at baseline.

The cumulative risk of developing the first adverse event as well as individual adverse events or adverse event clusters during the treatment period was estimated by the Kaplan-Meier method and the difference between treaments was tested by the log-rank test.

Results

Two hundred and fifty-six patients entered the study. During the study, 130 patients received reboxetine, and 126 received imipramine. Ninety-eight reboxetine and 90 imipramine recipients completed the study while 32 (24.6%) and 36 (28.6%) patients dropped out of the study, respectively. Newly emerged adverse events or intercurrent illnesses were the main reason for discontinuation in 13 (10.0%) and 18 (14.3%) patients of the reboxetine and imipramine groups, respectively. Deterioration was the main reason for withdrawal in 8 and 7 patients of the reboxetine and imipramine groups, respectively. Remaining cases included mainly unco-operative patients (7, 5 reboxetine, imipramine). One death occurred on reboxetine (suicide).

Efficacy

The mean HAMD total score was reduced from 28.8 at Day 0 to 13.0 at last assessment, in the 127 patients treated with reboxetine who had at least one assessment in addition to baseline (3 patients had only baseline data), and to 9.6 at Day 42 in the 98 patients who completed the study. In the 121 patients treated with imipramine with at least one assessment in addition to baseline (5 patients had only baseline data), the mean HAMD total score was reduced from 28.0 at Day 0 to 13.7 at last assessment, and to 10.4 at Day 42 in the 92 patients still on treatment. The mean decrease difference between the two treatments at last assessment was 1.5 points (95% CI -1÷4).

At last assessment, 68.5% of the reboxetine-treated patients and 56.2% of the imipramine-treated patients were classified as responders, while 52.0% and 45.5%, respectively, were seen to be in remission. The between treatment difference in the proportion of response was 12.3% (95% CI 0.3÷24.3). The cumulative probability of response (Kaplan-Meier analysis) on reboxetine was significantly higher (p=0.0126) compared to imipramine.

At the last assessment, the percentage of patients classified as 'very much improved' or 'much improved' (CGI-Global Improvement) was 66.9% in the reboxetine group and 62.0% in the imipramine group. The percentage of much to very much deteriorated cases was higher in the imipramine group (6.6 %) than in the reboxetine group (3.1 %).

Name of Company: Pharmacia Spa Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)

Efficacy (continued):

The mean total MADRS score was reduced from 17.2 at Day 0 to 7.9 at last assessment in the 127 reboxetine group patients with at least one assessment in addition to baseline, and to 5.9 at Day 42 in the 98 reboxetine patients who completed the study. In patients randomised to imipramine, values changed from 16.9 at Day 0 to 8.0 at last assessment (121 patients), and to 6.0 at Day 42 (92 assessed patients).

The results of the additional analyses on the sub-populations of severe and melancholic patients indicate that both treatments were similarly effective in terms of improvement of the clinical picture, as seen by the decrease of HAMD scale at the last available assessment.

Safety:

All the 256 patients who received study treatment were included in the safety analysis, i.e. 130 reboxetine, 126 imipramine.

The occurrence of newly reported adverse events was similar in both groups during the study; 106/130 (81.5%) reboxetine group patients reported 267 adverse events compared with 103/126 (81.7%) imipramine patients who reported 303 adverse events. Discontinuation due to newly emerged adverse events was more frequent on imipramine (14.3%) than on reboxetine (10%). Most frequently reported were: dry mouth (25% reboxetine and 36% imipramine); headache/migraine (16%, 14%); hypotension and related symptoms (10%, 18%) and nausea and related symptoms (15%, 11%).

There was a significantly higher cumulative risk on imipramine than on reboxetine of developing dry mouth, hypotension and related symptoms and tremor.

The majority of adverse events were moderate. Adverse events were reported more frequently by men than women. The most relevant between-gender differences were related to the frequency of increased sweating, complained of mainly by male patients, and nausea and related symptoms, complained of mainly by female patients. One patient on reboxetine died (suicide) and 3 patients reported serious adverse events (parasuicide by overdose on reboxetine, supraventricular tachycardia and A-V block first degree, both on imipramine).

There was no indication of modifications in laboratory tests that were of clinical significance.

Vital signs were not modified to any significant extent and the only difference between the two treatment groups was observed in the absolute frequency of clinically relevant decrease of both systolic and diastolic blood pressure, which was higher on imipramine than on reboxetine on standing (11% and 4% of evaluated patients, respectively). The absolute frequency of heart rate values increased to ≥100 beats/min was slightly higher on reboxetine than on imipramine, particularly on standing (27% and 21% of evaluated patients, respectively). However, the majority of these relevant increases occurred occasionally (reported once).

No indication of effect on cardiac function emerged from the ECG recordings.

Conclusions:

The efficacy of reboxetine therapy in patients suffering from Major Depressive Episodes, as measured by the improvement of HAMD, MADRS and CGI scales, was similar to that of imipramine. The cumulative probability of response (≥50% decrease of HAMD total score) was significantly higher on reboxetine than on imipramine. The tolerability of reboxetine was highly acceptable, as shown in the safety profile in terms of modification of vital signs, haematology and blood chemistry tests and ECG examinations, and also in the superiority of reboxetine to imipramine in terms of the frequency of occurrence of dry mouth and hypotension and related symptoms, and the incidence of discontinuation due to adverse events.

1. INTRODUCTION

Reboxetine (FCE 20124 or (2RS, αRS)-2-[α-(2-ethoxy-phenoxy) benzyl] morpholine) is a new chemical compound which is highly potent in the pharmacological and biochemical tests predictive of antidepressant efficacy such as reserpine antagonism, norepinephrine reuptake inhibition and REM sleep latency increase [1]. Reboxetine also demonstrates the ability to prevent the effects of clonidine after a single oral dose in an animal model where tricyclic antidepressants were active only upon repeated administration [1]. Therefore, reboxetine was hypothesized to exert antidepressant efficacy of faster onset than the antidepressants currently available in depressed patients.

Pharmacodinamics in healthy volunteers were studied using single oral doses from 0.2 to 5 mg. The administration of 5 mg was associated with orthostatic hypotension and tachycardia [2]. Single doses of 1 and 3 mg were compared to imipramine 75 mg and placebo in a Q-EEG and psychometric study. Reboxetine induced dose-related modifications of EEG power bands and psychometric performance suggestive of psychostimulating properties, while following imipramine changes consistent with its known sedative activity were apparent [3].

The pharmacokinetic properties of reboxetine, evaluated in healthy volunteers [4], showed that average peak levels were observed at 2 hours after oral administration, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 hours and 73% of the AUC following an oral dose was accounted for by unchanged reboxetine.

An early phase II, 4-week, multicentre study in 98 patients in which reboxetine was administered at doses of between 4 and 12 mg, showed that it was well tolerated at doses of up to 10 mg/day [5].

A double-blind, parallel, multicentre study in 258 patients hospitalised due to a major depressive episode compared maximum doses of 8 mg reboxetine with 200 mg of desipramine and placebo over a period of 4 weeks [6]. Reboxetine was found to be more effective than placebo with decreases of ≥50% in Hamilton Depression Rating Scale (HAMD) at the end of treatment in 63% of patients compared with 36% for placebo and 46% for desipramine. These decreases were present after 14 days of treatment in 31% of reboxetine patients and 22% of desipramine patients. More reboxetine patients complained of headache and urinary retention, whereas more desipramine patients experienced dry mouth, sweating and blurred vision. Cardiovascular adverse events were relatively rare but appeared with slightly higher frequency in the desipramine group (hypotension and tachycardia).

Phase II results obtained in controlled conditions in patients suffering from major depressive disorders indicate that reboxetine is an effective antidepressant agent with a favourable therapeutic index with respect to desipramine. The present study was designed to extend information obtained from other controlled studies and to collect

comparative evidence of reboxetine's safety and efficacy *vs* another tricyclic antidepressant, imipramine [7]. This comparison was expected to provide a proper appraisal of the activity and tolerability of reboxetine.

2. STUDY OBJECTIVES

To assess the activity and tolerability of reboxetine in comparison with imipramine in patients suffering from major depressive episodes.

3. INVESTIGATIONAL PLAN

3.1 Study Design and Plan - Description and Rationale

3.1.1 OVERVIEW AND JUSTIFICATION

This phase III study was designed as a prospective, double-blind, randomised, controlled, parallel-group, multicentre trial. Its aim was to compare the efficacy and tolerability of reboxetine with that of imipramine, administered orally for 6 weeks, in adult patients with major depressive episodes. The design of the study is shown overleaf.

A total of 200 patients with major depressive episodes was to be recruited in accordance with the inclusion and exclusion criteria, and an informed consent obtained from each patient prior to screening.

At screening, a full medical history and physical examination (including chest X-ray and electrocardiogram (ECG)) were carried out and vital signs and laboratory values were measured. Patients were classified according to the DSM-III-R diagnostic classification and the severity of depression was quantified using the Hamilton Depression Rating scale (HAMD).

After an initial wash-out period of 4-14 days, patients received one of 2 treatments: oral reboxetine 4 mg b.i.d., or imipramine 50 mg in the morning and 100 mg in the evening for 6 weeks (imipramine was given at a dose of 50 mg b.i.d. for the first 3 days of the study). In the case of inefficacy or unsatisfactory response, combined with good tolerability, after 3 weeks of treatment, the total daily dose was increased to 10 mg for reboxetine and 200 mg for imipramine for the remaining 3 weeks of the study.

The primary study end-point was defined as the absolute HAMD total score decrease *vs* Day 0 at last assessment. Response (a decrease of at least 50% in the total HAMD score) and remission (a total HAMD score of 10 or less) were considered to be additional study end-points and their rates at last assessment were to be compared between treatment groups.

Other variables used for measuring efficacy were the Clinical Global Impression (CGI) and the Montgomery and Asberg Depression Rating Scale (MADRS).

Safety and tolerability were assessed by the reporting of any adverse events and measurements of vital signs (blood pressure and heart rate, supine and standing), ECG and laboratory tests.

Patients willing to continue receiving the test treatment after completion of the 6 week treatment period were maintained on the same medication under blind conditions until the completion of the last patient in the study and collection of the Case Record Forms (CRFs).

A follow-up visit was to be carried out for each patient one month after treatment discontinuation in order to monitor possible withdrawal reactions and collect information on any events since treatment discontinuation.

A copy of the final protocol can be found in Appendix 12.1.1.



3.1.2 PROTOCOL AMENDMENTS

There was one protocol amendment, which extended the wash-out period to 3-4 weeks in case of previous fluoxetine administration.

A copy of the protocol amendment can be found in Appendix 12.1.1.

3.2 Ethics

3.2.1 ETHICS COMMITTEE

Approval from the Ethics Committees or Institutional Review Boards (IRBs) of the participating centres, in accordance with the regulations and requirements of individual countries, had to be obtained before the study could be undertaken. It was the responsibility of each of the investigators to submit the study protocol with its attachments to the Ethics Committee/IRB. A central approval allowing the clinical evaluation of the product was required and obtained in South Africa, while local approvals were required and obtained in Belgium, Germany and South Africa. For most centres in Germany, the approval was obtained on a draft version of the protocol,

marginally different from the final one (the most relevant differences concerned two exclusion criteria, cyclothymia and high risk of suicide, present in the final version).

The Central/IRBs notifications of approval are kept in the trial master file.

The written approval of the Ethics Committee or IRB had to include the names and professions of all its members. In accordance with local requirements, the investigators were responsible for informing the Ethics Committees of any emergent problems, serious adverse events or protocol amendments.

3.2.2 PATIENT INFORMATION

Before entering the study, an explanation of the nature, duration, purpose of the study and action of the compound had to be given to each patient in such a manner that he/she was made aware of the potential risks, inconveniences or adverse events that could occur, and could express his/her informed consent to participation. The proposed consent form is enclosed (Enclosure 3 of Appendix 12.1.1). The translations in the national languages and the individual centres forms containing the possible changes requested by the Ethics Committees, if any, are kept in the study master file. The forms were signed by the patient or the next of kin, and/or the investigator. In the latter case, the signature of a witness was required to testify that full information was given to the patient.

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure was confidential. These documents could not be disclosed to a third party without the written consent of the Sponsor. The submission of these documents to the Ethics Committee was expressly permitted. The investigators agreed that the Sponsor maintained the right to utilise the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

3.3 Study Population

Adult patients who were under in-patient care or attending out-patient or day-hospital clinics of the participating centres were selected in accordance with the following inclusion and exclusion criteria.

3.3.1 INCLUSION CRITERIA

The criteria for participation in this study were as follows:

- Patients of either sex, of any race, aged 18 to 65 years
- A diagnosis of acute major depressive episodes, not accompanied by psychotic features (DSM-III-R) [8]; the current episode was to have been present for at least one month but no more than 4 months

- The initial (pre-treatment) total score for the 21-item HAMD [9] had to be ≥22
- Informed consent was obtained from the patient or next of kin, and/or the investigator (see Section 3.2.2)

3.3.2 EXCLUSION CRITERIA

Exclusion criteria for patients recruited to this study were as follows:

- Dysthymia/cyclothymia
- History of major depressive episodes associated with endocrine disorders: hypo- or hyper-thyroidism (defined as values at least 10% outside normal parameters for TSH and T_4), adrenal insufficiency, etc.
- Pregnancy (excluded by a pregnancy test at the end of the wash-out period)
- Refusal by female patients of childbearing age to use effective contraception during the study period
- Past history of drug hypersensitivity
- Participation in a clinical study with an investigational compound in the 4 weeks preceding the study
- Evidence of Substance Use Disorder (DSM-III-R), currently or within the past 6 months
- Chronic respiratory insufficiency (excluded by physical examination and X-ray)
- History or presence of gastrointestinal, hepatic or renal disease, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs
- History of seizures or brain injury; current evidence of clinically important haematopoietic or cardiovascular diseases; current evidence of urinary retention or glaucoma
- Symptoms of any other important clinical illness in the 4 weeks preceding the study
- Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission
- Electroconvulsive therapy (ECT) in the previous 6 months
- High risk of suicide

3.3.3 WITHDRAWAL CRITERIA

Patients could be withdrawn from the study at any time for the following reasons:

- Voluntary withdrawal by the patient
- Unacceptable toxicity, defined as the occurrence of serious adverse events (see Section 3.6.2.1)
- Lack of efficacy, defined as patients who showed worsening of the global clinical picture (CGI - see Section 3.6.1.2) after at least 2 weeks of treatment
- Shift to mania

In the case of treatment discontinuation, the final set of tests was carried out wherever possible.

3.3.4 SAMPLE SIZE - NUMBER OF PATIENTS PLANNED

Each of the planned 10 centres participating in the study were to recruit, within a period of 1 year, a sample of 20 patients, so that a total of 200 patients was to be recruited overall.

Some of the centres which initially agreed to participate in the study never did so for logistic reasons and were replaced with other centres. During the study, 8 centres in Germany and 1 in Belgium were recruited in order to reach the foreseen patient sample.

As shown in the Principal Investigators and Affiliation list (Appendix 12.1.4), 22 centres located in 3 countries (Germany, Belgium and South Africa) participated in the study. In 17 of these centres the number of patients admitted was lower than 20, while recruitment was extended in 3 centres (nos. 9, 14/10 and 15) to above the foreseen patient sample. Recruitment was stopped after randomisation of 256 patients, slightly above the calculated sample size for an "intent to treat" analysis.

Patients who dropped out of the study for any reason were not substituted. For those patients selected for the study who dropped out at any time, documentation was provided.

3.4 Treatments

3.4.1 TREATMENTS TO BE COMPARED

After an initial wash-out period of 4-7 days (14 days in the case of monoamine oxidase inhibitor administration and, after the amendment, 3-4 weeks in the case of previous fluoxetine administration) patients received one of 2 possible treatments for 6 weeks: oral reboxetine 4 mg b.i.d., or imipramine 50 mg in the morning and 100 mg in the

evening (imipramine was given at a dose of 50 mg b.i.d. for the first 3 days of the study). In the case of inefficacy or unsatisfactory response, with good tolerability, after 3 weeks of treatment, the dose of reboxetine was increased to 10 mg daily and the dose of imipramine increased to 100 mg b.i.d. for the remaining 3 weeks of the study.

3.4.2 IDENTITY OF TEST TREATMENTS

Indistinguishable capsules containing either reboxetine 4 mg (two x 2 mg tablets) (Batch No: SF1131, SF1264) or 6 mg (three x 2 mg tablets) (Batch No: SF1132, SF1291) or imipramine 50 mg (two x 25 mg tablets) (Batch No: SF1130, SF1265) plus excipients or imipramine 100 mg (four x 25 mg tablets) (Batch No: SF1129, SF1151, SF1263) were supplied by the Sponsor. Copies of certificates of analysis for the test treatments are presented in Appendix 12.1.5.

3.4.3 DOSE SELECTION AND TIMING

All patients recruited for the study received either one capsule of reboxetine 4 mg b.i.d. (morning and evening), or one capsule of imipramine 50 mg (morning) plus one capsule imipramine 100 mg (evening) for 6 weeks. For the first 3 days of the study, imipramine was given as one 50 mg capsule in the morning and one 50 mg capsule in the evening. For patients who showed an ineffective or unsatisfactory response (worsening, no change or minimal improvement in the CGI; see Section 3.6.1.2) with good tolerability (especially non-symptomatic hypotension) after 3 weeks of treatment, the dose of reboxetine was increased to 10 mg daily (4 mg in the morning and 6 mg in the evening) and the dose of imipramine increased to 100 mg b.i.d., for the remaining 3 weeks of the study. In those patients who then displayed poor tolerance at this increased dose, the dose was reduced to the previously well-tolerated level.

The treatment was administered at least 2 hours before or after meals.

The daily dose of reboxetine was chosen on the basis of the results of the previously mentioned open-dose finding study [5], in which daily doses of 8 to 10 mg were found to be associated with the best therapeutic index, and of the controlled Phase II study *vs* desipramine and placebo [6], where the 8 mg/day dose regimen was proved to possess antidepressant efficacy. The daily dose of imipramine was selected on the basis of published evidence from controlled studies [7] and of manufacturer recommendations [10].

3.4.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUPS

A randomisation list balanced within each centre and every 4 assignment was originally generated for patient allocation either to reboxetine or imipramine. In this list, in order to make the patient unequivocally identified across centres by his assignment number, a progressive number from 1 to 480 was generated. The test treatments were labelled according to the randomisation sequence number. Each randomised patient was then

identified by the corresponding treatment number. In spite of the anticipated break down by centre of such a sequential list, in order to minimise the waste of drug supply, the latter was shipped to the centres by full block of 4 treatments each.

Patient allocation to treatment was done by the principal investigator at the end of the wash-out period on the basis of the patient's time of entry into the study and on the available treatment packages.

Randomisation list was prepared by Biometrics and Data Management Department of Pharmacia, Milan by SAS PROC plan (version 5.18-6.06) and kept in a safe place until the study was completed in the last patient and the CRFs were collected.

3.4.5 TREATMENT SUPPLY AND BLINDING

To ensure the double-blind nature of the study, indistinguishable test treatment in identical cartons was to be identified using double labels indicating the protocol number, patient number, treatment period, batch number and expiry date (Enclosure 4 of Appendix 12.1.1). The detachable half of the label was to be included in the appropriate place in the CRF when used.

Six cartons showing the patient number and the appropriate week of treatment (week 1-6) were prepared for each patient. Each carton contained the medication necessary for 1 week of treatment (i.e. 16 capsules, one capsule b.i.d. and 2 additional capsules for possible losses). An additional 3 cartons showing the patient number, the appropriate week of treatment (week 4-6) and the level of dosage (dose 2) were prepared for each patient in case of possible dosage increases during the last 3 weeks of the study.

3.5 Treatment Procedures

The investigators were given individual sealed envelopes containing the information on patient's treatment, and these were to be opened only in case of emergency necessitating treatment identification. In the event of an emergency, the investigators were to notify the study monitor immediately (within 24 hours), and were to report a full description of the reasons for opening the code on the adverse event form in the CRF. The sealed individual codes were to be returned to the Sponsor at the end of the study.

3.5.1 CONCOMITANT THERAPY

With the exception of hypnotics used for sleep induction on an 'as required' basis, no concomitant medication was allowed on entry to the study. In the case of events arising during the course of the study, non-psychotropic medications which were considered necessary for the patient's welfare could be administered and were not considered protocol violations. The medication, dosage and frequency of administration was recorded on the CRF. Chloral hydrate (0.5-1 g) was permitted at bed-time as a sleep inducer on an 'as required' basis.

3.5.2 TREATMENT ACCOUNTABILITY AND COMPLIANCE

All drug supplies were handled under the direct responsibility of the investigators and held by the Hospital Pharmacy. The study monitors checked drug storage conditions during site visits.

The investigators were responsible for drug accountability and kept a record of the test compounds received from the Sponsor as well as the drugs dispensed to each patient on the occasion of each visit. The upper label from each of the weekly cartons dispensed to each patient was detached and fixed in the appropriate space in the CRF. On the same occasion, cartons of the previous supply were returned by the patient. These used cartons were returned to the study monitors during site visits. All unused medication was to be returned to the Sponsor at the end of the study.

3.6 Efficacy and Safety Variables

At screening, a full medical history and physical examination (including chest X-ray and ECG) were carried out and vital signs and laboratory values were measured. Patients were classified according to the DSM-III-R classification and the severity of depression was evaluated using the HAMD scale and CGI.

3.6.1 EFFICACY

Every randomised patient was evaluable for efficacy analysis.

Patients were seen at regular intervals throughout the study and the following efficacy assessments carried out at the specified intervals. All psychiatric evaluations and ratings were to be carried out by the same observer for a given patient and in the same setting and at the same time of day if possible.

3.6.1.1 Hamilton Depression Rating Scale

The severity of depression was quantified using the HAMD at screening, and on Days 0, 7, 14, 21, 28, 35 and 42.

The HAMD scale [9] contained 21 items, each of which was scored (0-2, 0-3 or 0-4) to reflect whether the symptom was absent, trivial, mild, moderate or severe. Some of the items were more heavily weighted than others. The scores for all the symptoms were added together to give a global judgement of the severity of the depression.

A decrease of at least 50% in the total HAMD score compared with Day 0 was considered to be an index of response, whereas a total HAMD score of 10 or less was considered an index of remission.

The 21-item list of the HAMD used in this study is as follows:

	Item	Score range	Factor
1.	Depressed mood	(0-4)	V
2.	Feelings of guilt	(0-4)	III
3.	Suicide	(0-4)	III
4.	Insomnia early	(0-2)	VI
5.	Insomnia middle	(0-2)	VI
6.	Insomnia late	(0-2)	VI
7.	Work and activities	(0-4)	V
8.	Retardation	(0-4)	V
9.	Agitation	(0-4)	III
10.	Anxiety (psychic)	(0-4)	I
11.	Anxiety (somatic)	(0-4)	I
12.	Somatic symptoms gastrointestinal	(0-2)	I
13.	Somatic symptoms general	(0-2)	I
14.	Genital symptoms	(0-2)	V
15.	Hypochondriasis	(0-4)	I
16.	Loss of weight	(0-2)	II
17.	Insight	(0-2)	I
18.	Diurnal variation	(0-2)	IV
19.	Depersonalisation and derealisation	(0-4)	III
20.	Paranoid symptoms	(0-3)	III
21.	Obsessional symptoms	(0-2)	III

More detailed definitions of the items included in the scale can be found in Enclosure 6 of Appendix 12.1.1.

Factorialisation was carried out according to the ECDEU manual [11], to yield 6 factors: Anxiety/somatisation (I), Weight (II), Cognitive Disturbances (III), Diurnal Variation (IV), Retardation (V), Sleep Disturbances (VI).

3.6.1.2 Clinical Global Impression

Severity of illness was assessed by the investigator using the CGI at screening, and on Days 0, 7, 14, 21, 28, 35 and 42. The following scale was used:

1. = normal, not at all ill
2. = borderline mentally ill
3. = mildly ill
4. = moderately ill
5. = markedly ill
6. = severely ill
7. = amongst the most extremely ill patients

The investigator also evaluated the effect of treatment at each visit, with reference to the patients' condition at the start of the study, according to the following scale:

1. = very much improved
2. = much improved
3. = minimally improved
4. = no change
5. = minimally worse
6. = much worse
7. = very much worse

An Efficacy Index was then assessed by the investigator, as described in [11], as the ratio between the subjective evaluation of improvement, scored from 1 (unchanged or worsened) to 4 (marked improvement), and the subjective evaluation of tolerability from 1 (no side effects) to 4 (side effects outweigh therapeutic effect). The Efficacy Index score ranges from 0.25 (no global benefit) to 4 (maximal global benefit). Details of the Efficacy Index can be found in Enclosure 7 of Appendix 12.1.1.

3.6.1.3 Montgomery and Asberg Depression Rating Scale

The MADRS [12] was measured on Days 0, 7, 14, 21, 28, 35 and 42.

This scale consists of ten items relating to depression selected from the 67 items in the Comprehensive Psychiatric Rating Scale [13]. The items contained in the MADRS were selected on the grounds that they were sensitive to change. The ten items were as follows:

1. Reported sadness
2. Inner tension
3. Apparent sadness
4. Suicidal thoughts
5. Inertia
6. Inability to feel
7. Pessimistic thoughts
8. Concentration difficulties
9. Reduced sleep
10. Reduced appetite

The scale requires a structured interview for completion. A score of 0 to 3 for each item was used as in reference 13.

More detailed definitions of the items included in the scale can be found in Enclosure 8 of Appendix 12.1.1.

3.6.1.4 Patient Global Impression

As per protocol, each patient had to fill in the Patient Global Impression scale on Days 0, 7, 14, 21, 28, 35 and 42. The results collected were not evaluated due to the very low number of patients completing the assessments.

3.6.2 SAFETY

Every patient who received one dose of test treatment was included in the safety evaluation.

3.6.2.1 Adverse Events

Spontaneously reported

Patients were notified of any possible adverse events they might experience and were instructed to report any such adverse event to the investigators immediately.

The occurrence of adverse events was recorded on Days 0, 7, 14, 21, 28, 35 and 42.

Any newly observed sign or symptom (including clinically relevant laboratory abnormalities), noticed by the investigators or reported by the patients were reported, regardless of presumed relationship to the study medication, in the appropriate section of the CRF.

For each adverse event, the following information was entered in the CRF: description, date of onset, date of stopping, severity, drug cause-effect relationship, outcome, effect of withdrawal of treatment and rechallenge. The investigators also had to note if the double-blind code had been broken, the action taken regarding the test drug (none, dose reduced or discontinued) and any treatment given as a result of the adverse event.

Severity was coded as follows:

1. = mild - awareness of sign or symptom, but easily tolerated
2. = moderate - discomfort enough to cause interference with usual activity
3. = severe - incapacitating with inability to work or do usual activity
4. = unknown

Relationship to test drug was coded as definite, probable, possible, doubtful, unknown or not related; as a guideline to coding the Karch and Lasagna modified criteria were used as shown in Enclosure 11 of Appendix 12.1.1.

All serious* and/or unexpected** adverse events had to be reported to study monitors immediately (within 24 hours), and the details recorded on an Adverse Event Report Form. **Serious adverse event** was defined as any experience that was (potentially) fatal or life-threatening, disabling, incapacitating, requiring inpatient hospitalisation, causing a congenital anomaly or cancer, or due to an overdose. **Unexpected adverse event** was

---

* Code of Federal Regulation, Vol 21, Part 312. Revised as of April 1 1987, page 75.

** Bem JL, Breckenridge AM, Mann RD, Rawlins MD. Review of yellow cards (1986): report to the Committee on the Safety of Medicines. BR J Clin Pharmac 1988; 26: 679-689.

defined as any adverse experience that was not identified in nature, severity or frequency in the current Investigator's brochure for the study.

The same procedure applied for all patients who died during the course of the study or within 30 days of completion, irrespective of whether the event was judged as related to treatment. If an autopsy was performed, a copy of the pathological report was to be sent to the Sponsor.

Adverse events reported through a check-list

The presence or absence of adverse events was noted on a check list especially designed for the identification of events frequently reported in patients on antidepressant medication. The checklist is shown in Enclosure 10 of Appendix 12.1.1. These events could be either reported by the patient or observed by the investigator.

For each adverse event, the same procedure as for spontaneously reported adverse events was followed in terms of recording of information in the CRF (Adverse Event Report Form) and reporting of the 'serious' or 'unexpected' adverse event to the Sponsor.

3.6.2.2 Clinical and Laboratory Tests

Vital signs

Body weight and temperature as well as blood pressure and heart rate (supine and standing) were measured at screening, and on Days 0, 7, 14, 21, 28, 35 and 42.

Supine blood pressure and heart rate were measured in the morning after 5 minutes in the supine position and standing blood pressure and heart rate were measured 1 to 2 minutes after standing up.

ECG

An ECG was recorded at screening, on Days 21 and 42.

Laboratory Tests

Laboratory tests were recorded at screening, on Days 21 and 42.

The laboratory tests comprised the following: full blood count, serum electrolytes, liver enzymes, urinalysis, blood sugar, serum alkaline phosphatase, blood urea nitrogen (BUN), serum creatinine, uric acid, bilirubin, total serum protein and electrophoresis, serum cholesterol and triglycerides, and at screening only, TSH and T_4.

Laboratory tests were also measured for patients who withdrew prematurely because of a serious adverse event.

3.7 Study Procedures and Flow Chart

3.7.1 SCHEDULE OF ASSESSMENTS

Assessment	Pre-Treatment Screening	Treatment Day 0	7	14	21	28	35	42
Diagnosis: DSM-III-R	x							
Medical history	x							
Physical examination	x							
Chest X-ray	x							
ECG	x				x			x
Laboratory tests	x				x			x
Vital signs	x	x	x	x	x	x	x	x
21-item HAMD	x	x	x	x	x	x	x	x
CGI		x	x	x	x	x	x	x
MADRS		x	x	x	x	x	x	x
Compliance check			x	x	x	x	x	x
Dispensing medication			x	x	x	x	x	x
Adverse events			x	x	x	x	x	x

3.7.2 PROCEDURES AT EACH VISIT

At screening, a full medical history and physical examination (including chest X-ray and ECG) were carried out and vital signs and laboratory values were measured. Patients were classified according to DSM-III-R and the severity of depression was measured using the HAMD scale and CGI.

One month after treatment discontinuation, a follow-up visit was carried out for each patient in order to monitor possible withdrawal reactions and to collect information on any adverse events that had occurred during this period. For ethical reasons, patients willing to continue receiving study drug after completion of the 6 week treatment period were maintained on the same medication in blind conditions until the study was completed in the last patient and the CRFs were collected. Efficacy was assessed by HAMD and CGI at monthly visits. Adverse events and vital signs were also recorded at monthly intervals and ECG and laboratory values at 3-monthly intervals. The medications were prepared as described in Section 3.4.5, but in monthly, instead of weekly, units.

3.8 GCP Compliance, Data Quality Assurance

The study was carried out before the formal adoption of GCPs by European Regulatory Authorities and in the absence of Company SOPs. However, operating procedures for study monitoring and co-ordination were defined and are described in Attachment A of Appendix 12.1.1.

The study was conducted as stated in the declaration of Helsinki (as amended in the Venice version) and according to the procedures stated in the Attachment A of Appendix 12.1.1. Inter-rater reliability sessions with training purpose on the instrument used for the assessment of change, and particularly on the HAMD, were carried out during the investigators meetings organised by country and/or the monitoring visits by employing 4 videotaped interviews.

During the Study monitoring visits, made at regular intervals at which the monitor validated the content of the CRF against source documents, on the basis of the agreed procedures, were made at regular intervals. Operating procedures for study monitoring and co-ordination are described in Attachment A of Appendix 12.1.1.

Trial master file and report audits were carried out by the Company Quality Assurance Unit.

3.9 Statistical Analysis

3.9.1 SAMPLE SIZE CONSIDERATIONS

This trial mainly aimed at gathering information on the comparative effectiveness of imipramine and reboxetine additional to the information provided by a similar 3-arm placebo controlled study conducted at the same time. Ethical and the local medical practice prevented some countries (centers) from partecipating in the placebo controlled trial, thus rising the need of an identical separate trial excluding the placebo arm. Results of this trial were expected to be compared with the ones obtained by the 3 arm trial and joint conclusion on the reboxetine and imipramine efficacy could be eventually driven .

For the above mentioned reasons, the study had mainly estimation rather than testing purposes and therefore the number of patients made available by the participating centers was challenged against the length of the end-point variable 95% confidence interval that such a size was able to provide with.

The difference between baseline and the last postbaseline HAMD score, HAMD decrease (see below for detailed definition), was taken as the outcome variable.

From the phase II trial and from the literature [14] it seemed reasonable to assume that each treatment group showed a variability (expressed as standard deviation) of 9 points.

The participating centers were able to recruit approximately 200 patients, among which approximately 10% were expected to drop before the first postbaseline visit. Under such

assumption the expected length of the confidence interval of the between treatment difference of HAMD decrease was to be of 5.3 points of HAMD scale, 2.65 points each side.

Referring to secondary study end-points based on proportions, the same sample size allowed a length of confidence of 0.30 considering a proportion of 0.5 in each treatment group and the normal approximation method.

3.9.2 STATISTICAL AND ANALYTICAL PLANS

3.9.2.1 Baseline Comparability of Treatments Groups

Baseline characteristics (e.g. age, diagnosis, age at onset, number of previous episodes) which might have influenced the main end-point of the study were summarised considering all the patients entered into the study and subsequently randomised either to reboxetine or to imipramine arm.

3.9.2.2 Efficacy Analyses

Definitions

The following definitions applies to the set of data analysed:

HAMD decrease	The difference between the end of treatment and baseline measurements in HAMD-21 total score. Either the last per-protocol assessment when the patient completed the study, or the last assessment before dropping out was taken as the end of treatment.
Remission	HAMD-21 total score lower than or equal to 10 (absolute value).
Response	HAMD-21 total score decrease equal to or greater than 50% of the pre-treatment value (Baseline: visit 0). According to this definition and based on the inclusion criterion which required a HAMD-21 total score at entry at least equal to or greater than 22, all patients who achieved a remission (as defined above) were included into the broader category of response (22*0.5=11).
Time to response	Number of days elapsing between the first visit date (Baseline) and the date when the patient first achieved the response (according to the above definition) which was afterwards maintained until the end of the study or withdrawal. This definition excludes patients who achieved occasional response, but were not classified as such at the last observation.

Severe patients	Patients scoring 5 to 6 (markedly to severely ill) on CGI-Severity of Illness scale [11] at entry.
Melancholic patients	On the basis of applicable DSM-IV criteria [15]: presence of item 2, i.e. loss of pleasure in all or almost all daily activities in the DSM-III-R classification at entry, and of at least three of the following items in the Day 0 HAMD scale: late insomnia (item 6) of maximal severity; agitation (item 9) or retardation (item 6) of at least moderate severity; definite loss of weight (item 16) or loss of appetite (item 12) of maximal severity; diurnal variation with worsening in the morning (item 18); excessive or inappropriate guilt (score 2 or 3 of item 2).

Methods

The data set analysed included all the patients entered, with the only exception of those patients who did not have at least one post-baseline evaluation.

Efficacy variables, including total scores of Hamilton, Montgomery and Asberg Depression Rating Scale, and CGI, were summarised by descriptive statistics (mean, median, standard deviation (-SD-), minimum, maximum, or distribution of frequency of scores) as calculated both at each visit and at the last valid observation, for the two treatment groups. In particular, in order to describe the time pattern of last valid observation values, one table reports descriptive statistics, visit by visit for only those patient who dropped out of the study at that particular time.

The frequency of patients improved, unchanged or deteriorated as for the CGI-Severity of Illness at last valid observation in comparison with baseline was also presented.

The primary end-point for efficacy analysis was HAMD decrease. Ninety-five per cent confidence interval of the between treatment difference was the basis for the efficacy conclusions [16].

Additionally, in order to allow a comparison between the results of this study and those of the above mentioned placebo controlled study, the following analyses have been carried out in both studies.

Although not strictly necessary to the analysis of differences from baseline, homogeneity of baseline HAMD-21 total scores across treatment groups was tested by ANOVA in order to assess the comparability of the disease severity within the two treatment groups.

No transformation of the original variable was deemed necessary, as it results from the outcome variable of the difference between two random variates, and as such is known to tend to be normally distributed; homogeneity of variances was tested by F test.

ANOVA for the comparison of the HAMD decreases in the two treatment groups was performed in order to obtain a more precise estimate of the variability.

Ninety-five per cent confidence intervals of the mean difference of each treatment were computed using the standard error (SE) obtained by the ANOVA.

The same sets of analyses were carried out on the subset of severe and melancholic patients as defined above.

Complementary to the quantitative analysis of HAMD-21 total score, the qualitative analysis classifying the patients according to the above definition as either responder or failure at last valid assessment was carried out. Ninety-five per cent confidence intervals of the proportions in each treatment and of the between treatment difference were computed [17].

The cumulative probability of the onset of response (time to response) was computed adopting the Kaplan-Meier method and the between treatment comparisons were carried out by the log-rank test [18].

3.9.2.3 Safety

Vital signs as measured at each assessment time were summarised by descriptive statistics.

Patients with orthostatic hypotension (a decrease ≥30 mmHg of systolic blood pressure from lying to standing) were described. Moreover, the frequency of patients showing clinically relevant (20% or more *vs* baseline) change or a modification accompanied by absolute critical values (≥160 or ≤100 mmHg for systolic blood pressure; ≥100 or ≤70 mmHg for diastolic blood pressure; ≥100 or ≤50 beats/min for heart rate) at each evaluation time were tabulated.

ECG have been summarised in frequency tables showing normal/abnormal findings at each visit.

Changes from baseline (i.e. normal to abnormal and vice versa) have been displayed.

For all the laboratory examinations and within each of the two treatments, the following analyses have been provided:

- frequency and percentage of patients whose values were below, equal or above the normal range at each visit. Either MacNemar test or Stuart Maxwell test [19] has

been applied in order to test if the distribution across categories at baseline differs from the distribution at each visit.

- continuous values of laboratory tests were standardised according to a method proposed by Chuang-Stein [20], using as reference mainly the values reported on the Cecil Textbook of Medicine [21] (Appendix 12.1.8); the Wilcoxon Rank Signed test for paired data was applied in order to compare the values during treatment with those recorded at baseline [22].

The usage of statistical tests in this framework aimed mainly at providing screening tools for selecting the relevant changes within each single examination; to this purpose the tests were considered as statistically significant if $p<0.01$.

Besides, abnormal values of laboratory tests defined as clinically relevant (Appendix 12.1.8) were specially considered and the frequency of patients showing them were computed according to time interval.

Clinically relevant abnormalities were judged on the basis of the concordance with other examinations evaluating the same organ function. In the analysis of the adverse events the attention has been focused on treatment emergent signs and symptoms, i.e. events that were not present at baseline and appeared during treatment or, if present at baseline, became more severe during treatment. The analyses were essentially descriptive and, for each treatment group, were performed both in terms of patients complaining of adverse events and the events themselves.

The analyses were performed taking into account the occurrence of at least one sign or symptom, the occurrence of at least one event for each body system or for selected aggregations of symptoms (clusters) likely to share the same underlying mechanism or described with synonyms. When severity of the events was considered, the worst reported degree was selected. In order to explore possible differences, patients were also classified by sex, age and diagnosis.

The cumulative risk of developing the first adverse event, as well as individual adverse event and adverse event clusters (newly emerged in 5% or more of patients in at least one treatment group) was estimated by Kaplan-Meier method and the between treatment comparison was estimated by the log-rank test. Furthermore the weekly frequency of patients experiencing adverse events (either because of the onset of new events or because of the persistence of those previously developed) was assessed.

The events have been described by frequency tables according to duration, onset time, symptomatic treatment, relationship to study medication, study drug adjustment, dechallenge/rechallenge after action on study drug and outcome. The duration of any event was computed as the number of days from its onset up to its recovery or, in the absence of recovery date, up to the last reporting date (approximate duration).

3.9.2.4 Changes in the Conduct of the Study or Planned Analysis

No deviation of the main end-point was introduced into the final analysis.

In general, analyses carried out were consistent with the ones anticipated in the protocol with a few exceptions:

a) subset analyses of severe and melancholic patients was introduced.

b) safety was presented in a more articulated fashion that anticipated into the protocol.

Both the deviations were introduced to give a better picture of the product profile and no extra claim is being done on the results obtained.

3.10 Data Management

Data management was carried out in the Biometrics and Data Management Department of Pharmacia, Milan.

CRFs data were entered into a IBM 3090 computer (according to the arrival flow) through data entry masks generated by SAS FSP release 6.06 and 6.07.

Subsequently, data were scrubbed by an electronic procedure set up to this purpose which generated listings of discrepancies between the actual value entered and predefined algorithms. Computer programs generated to this purpose are archived in Biometrics and Data Management Department.

These listings were reviewed by clinical personnel and editing of CRFs were requested at the Investigator site, whenever appropriate.

Corrections were entered iterating the loop until the files were completely cleaned.

ECG tracings were classified and subsequently grouped according to the codes reported in Appendix 12.1.10. Previous and concomitant diseases were coded according to the ICD9 dictionary [23]; concomitant drugs according to the Drug Reference List [24]; adverse events according to the WHO-ART dictionary [25]. In the absence of an adeguate code and preferred term, "urinary hesistancy" was coded as "micturition disorder" and "blurred vision" as "vision abnormal". The mentioned events therefore appear in the tables under the indicated terms.

Reporting as well as statistical analyses were carried out with SAS PROCs (version 6.07), apart from Stuart-Maxwell test and confidence interval calculation. The programs relevant to the latter ones are given in Appendix 12.1.11. A selection of statistical analysis outputs is shown in Appendix 12.1.12.

4. STUDY PATIENTS

4.1 Disposition of Patients

Treatment randomisation for each patient is given in Appendix 12.1.7.

Two hundred and fifty-six patients were admitted to the study from December 1990 to September 1992 and randomised to treatment by investigators at 22 centres, as shown in Table 1.

As shown in Table 2, a total of 188 patients (73.4%) completed the study and 68 (26.6%) withdrew; 32 (24.6%) in the reboxetine group, and 36 (28.6%) in the imipramine group. Frequency and timing of withdrawal are shown as primary reason for withdrawal in Table 3.

Adverse events or intercurrent illnesses were the main reason for withdrawal in 12 and 20 patients of the reboxetine and imipramine groups, respectively. However, in two cases on imipramine, the intercurrent illness (influenza) and the event (somnolence) causing discontinuation had emerged before starting the experimental treatment. Therefore, the discontinuation rate for newly emergent adverse events is 14.3% on imipramine and 10.0% on reboxetine, including the death which occurred. Adverse events associated with discontinuation in individual cases are discussed in the Adverse Event Section (Section 8.2.3.2). Deterioration was the main reason for withdrawal in 8 and 7 patients of the reboxetine and imipramine groups, respectively. Remaining cases included mainly uncooperative patients (7 and 5 on reboxetine and imipramine, respectively).

The disposition of patients is shown in the following figure and in Table 2.

Disposition of patients



4.2 Protocol Deviations

Compliance with entry criteria

The frequency of non-compliance with inclusion/exclusion criteria of relevance for inferential purpose is given in Table 4. The most frequent reason (17.5% in the reboxetine group and 16.1% in the imipramine group) for possible non-compliance with one of the exclusion criteria was related to abnormalities of thyroid function tests, possibly suggestive of an underlying, undiagnosed endocrine disorder. Diagnosed endocrine disorder was present in 4 of the reboxetine and none of the imipramine group patients. Concomitant medications not allowed according to the protocol during the wash-out period were administered to 4.6% of the reboxetine group patients and 7.1% of the imipramine group patients. With the exception of thyroid function test abnormalities, non-compliance with these entry criteria was infrequent. The index episode duration was shorter than four weeks in 4 reboxetine and 2 imipramine group patients and was longer than four months only in one reboxetine group patient. In one imipramine group patient, the pregnancy test at admission was found to be positive, but treatment had already been started with administration of only one capsule of test drug.

Randomisation

Distribution and use of study medication were to be done, as previously mentioned, in blocks of 4 treatments, used in sequence from the smallest to the highest number according to patient temporal entry into the study. In order to provide a discrepancy log with respect to the randomisation sequence, patients were listed according to their study entry date and the treatment foreseen to be assigned according to the random sequence of the blocks available at the centre was matched by a sequential criterion. Mismatching between the foreseen treatment and the treatment actually received was identified as a randomisation error.

As reported in Table 5, errors in randomisation procedures led to administration of non-randomised treatment to some patients, at a similar frequency in both treatment groups. Of the 127 patients randomised to reboxetine, 22 received imipramine; of the 129 patients randomised to imipramine, 25 received reboxetine.

Assessment intervals

The summary statistics of the efficacy and safety assessment intervals in days from treatment start are shown in Table 6. There were a few deviations from scheduled times and were mainly related to laboratory and ECG evaluations at screening. The deviation rate was similar in both treatment groups.

Concomitant medications

The frequency of administration of non-protocolled concomitant medications (because of their psychotropic properties) is given by active agent in Table 7, and by class in Table 8. Long-acting benzodiazepines were administered to five reboxetine group patients and six imipramine group patients. Overall, unprotocolled psychotropic medications were administered to 6 reboxetine group patients and to 6 imipramine group patients.

Other

One reboxetine patient had a positive pregnancy test during the study (Day 21) and was subsequently withdrawn due to this protocol violation. The patient delivered a normal healthy newborn at term.

4.3 Demographic Data

Summary statistics of demographic data are given by treatment group in Table 9 (sex, age, weight, height) and Table 10 (race), and summarised below.

Summary of demographic data

		Reboxetine (n = 130)		Imipramine (n = 126)	
		n	(%)	n	(%)
Sex	Female	84	64.6	83	65.9
	Male	46	35.4	43	34.1
	Total	130	100	126	100
Race	Caucasian	117	90.0	118	93.7
	Black	10	7.7	8	6.3
	Other	3	2.3	0	0
	Total	130	100	126	100
		mean	SD*	mean	SD*
Age (years)		45.4	12.0	42.4	13.6
Height (cm)		167.4	8.0	167.8	8.9
Weight (kg)		68.7	11.4	69.4	13.8

*SD standard deviation

The majority of patients were female; the ratio of females to males was similar in both groups. The vast majority of patients were Caucasian. The two treatment groups were well matched for age, height, weight and race.

4.3.1 DIAGNOSIS AND HISTORY OF THE DEPRESSIVE DISORDER

The frequency of the DSM-III-R diagnostic classification, the summary statistics of the history of the depressive disorder, and the characteristics of the index episode are given by treatment, and sex, in Tables 11 and 12. Recurrent Major Depressive Disorder (DSM-III-R No. 296.3) was diagnosed for the majority of patients in each treatment group (60.8% reboxetine and 54.8% imipramine). A Major Depressive Episode (DSM-III-R No 296.2) was diagnosed in all remaining cases.

The age of onset, the median number of previous episodes of depression, the median duration of the last episode and the median duration of the present episode of the patients at entry into the study are shown below.

Previous history of depression

	Reboxetine			Imipramine		
	n	Median	(range)	n	Median	(range)
Age at onset (years)	100	40.00	(15-64)	101	39.00	(17-64)
Number of previous episodes	72	2.00	(1-40)	66	2.00	(1-11)
Duration of the last episode (weeks)	71	12.00	(3-128)	68	16.00	(2-60)
Duration of the present episode (weeks)	129	7.00	(1-48)	126	8.00	(2-16)

The treatment groups were well matched with regard to the age at onset of depression, the duration of the present episode and the number of previous episodes, while the duration of the last episode of depression was slightly higher in the imipramine group.

As shown in Table 12, the onset of the index episode was acute or subacute in the majority of the patients in each treatment group (70.0% of the reboxetine group patients, and 65.1% of the imipramine group patients). A precipitating external stress was absent more frequently in the reboxetine group (40.0%) than in the imipramine group (28.6%).

4.3.2 SEVERITY OF DEPRESSION

The severity of the depression, according to the HAMD, MADRS and CGI scales, at the various assessment intervals during the study is displayed in terms of summary statistics in Tables 19 to 37 and summarised below. There was no significant difference between the treatment groups at Day 0 with regard to the mean HAMD total scores. Similarly, there were no significant group differences for the initial CGI and MADRS scores.

Severity of depression at Day 0

	Reboxetine			Imipramine		
	n	mean	SD*	n	mean	SD*
HAMD	127	28.8	4.8	121	28.0	5.2
MADRS	127	17.2	3.3	121	16.9	3.0
	n	(%)		n	(%)	
CGI Severity						
Normal	0	(0.0%)		0	(0.0%)	
Borderline mentally ill	0	(0.0%)		0	(0.0%)	
Mildly ill	2	(1.6%)		1	(0.8%)	
Moderately ill	26	(20.5%)		33	(27.3%)	
Markedly ill	73	(57.5%)		63	(52.1%)	
Severely ill	25	(19.7%)		22	(18.2%)	
Extremely ill	1	(0.8%)		2	(1.7%)	

*SD standard deviation

On the whole, there were no major imbalances between the two treatment groups in terms of demography, psychiatric medical history and characteristics of the index episode.

4.3.3 PREVIOUS ANTIDEPRESSANT TREATMENTS

Frequency of treatment of previous or index episode with different antidepressant drugs is given by active principle in Table 13. As expected, tricyclic antidepressants were the most frequently prescribed drugs; mianserine and selective serotonin reuptake inhibitors were also quite common; monoamine oxidase inhibitors were infrequently mentioned. Active principles are similarly represented in both treatment groups.

4.3.4 MEDICAL HISTORY

The medical history and medical examination findings at entry of the study are summarised by single disease entity in Table 14, and by affected body system in Table 15. A minority of the patients had history or presence of diseases other than the affective disorder at admission. No imbalances between the treatment groups are apparent.

5. STUDY MEDICATION AND COMPLIANCE

The frequency of administration of different doses of each experimental treatment on each study day is given by treatment in Table 16. The per protocol dose was administered to the vast majority of the patients. On Day 1, 11/130 (8.5%) of the reboxetine group patients and 20/126 (15.9%) of the imipramine group patients received half of the protocolled number of daily capsules, because they started their treatment in the evening. This resulted in a Day 1 dose of 4 mg of reboxetine and a Day 1 dose of 50 mg of imipramine. Over the next few days, a maximum of 5 and 4 patients per day, in the reboxetine and imipramine group respectively, had their number of daily capsules decreased (for the reasons indicated in the individual data listing for the experimental treatment). These were mainly missed intake, lost medication or emergence of signs/symptoms of intolerance. Over the same period, a maximum of one patient per day in the reboxetine and 2 in the imipramine group had their daily dose increased to 12 mg/day reboxetine and to a maximum of 300 mg/day imipramine. These were due to a mistakenly intake of double capsules in the morning and/or evening.

As summarised in Table 16.1, at the end of the initial 3 weeks of treatment, 13 patients of the reboxetine group (10% of the admitted), and 16 of the imipramine group (12.7% of the admitted) had the daily dose increased according to the protocol provisions to a dose corresponding to 10 mg of reboxetine and 200 mg of imipramine (level 2 dose). Over the following period, 9 additional patients on reboxetine and 6 on imipramine were switched to level 2 dose, while a maximum of 5 patients per day in the reboxetine and 4 in the imipramine group had their number of daily capsules decreased (for the reasons indicated in the individual data listing for the experimental treatment). These were mainly missed intake, lost medication or emergence of sign/symptoms of intolerance. During this period, on several treatment days, 3 reboxetine group patients and 5 imipramine group patients mistakenly took both dose levels 1 and 2, corresponding to 18 mg/day reboxetine and 350 mg/day imipramine. One patient took 20 mg/day reboxetine due to a mistaken intake of double capsules of dose level 2. Signs of intolerance were reported with reboxetine and included headache, nausea and fatigue. Dry mouth, headache, dizziness, tremor, somnolence and abnormal vision were reported with imipramine (see Adverse Event Section).

Comparison of the daily dose administered (as reported in the Compliance Section of the CRF in terms of number of capsules taken per day) with the expected dose (as indicated in the Experimental Treatment Section of the CRF in terms of number of capsules foreseen per day) allowed calculation of the compliance with the treatment regimen. Full compliance was defined where there was full agreement between the dose prescribed (the per protocol dose, or a lower dose in case of adverse events) and the dose reported to have been taken. The total compliance over the treatment period was calculated for each patient and the patients were classified accordingly (Table 17). One hundred per cent compliance was reported in 64.6% of the reboxetine group patients, and 63.5% of the imipramine group patients. Only in a few cases the reported compliance was lower than

80% (2 patients in the reboxetine group and 4 in the imipramine group) or between 80% and 89% (3 patients per group in the reboxetine and imipramine groups).

6. CONCOMITANT MEDICATIONS

The absolute frequencies, of those patients who, during the treatment period, received concomitant medications, either as a continuation of baseline therapy or as a newly introduced medication for treatment emergent events, is shown in Table 18. In addition to those non-protocolled psychotropic medications discussed previously in Section 4.2, other drugs were occasionally administered, generally following the emergence of adverse events, at similar frequency in both treatment groups.

7. EFFICACY RESULTS

7.1 Hamilton Depression Rating Scale

Summary statistics of HAMD assessment at each visit in the observed cases are shown in Table 19 (total scores), Table 20 (factors) and Table 21 (individual items). Summary statistics of the last assessment are given in Table 22 (total scores), Table 23 (factors) and Table 24 (individual items). The mean HAMD total score was reduced from 28.8 at Day 0 to 13.0 at last assessment (mean decrease 15.8, 95% CI 14.0 ÷ 17.5), in the 127 patients treated with reboxetine who had at least one assessment in addition to baseline (3 patients had only baseline data), and to 9.6 at Day 42 in the 98 patients who completed the study. In the 121 patients treated with imipramine with at least one assessment in addition to baseline (5 patients had only baseline data), the mean HAMD total score was reduced from 28.0 at Day 0 to 13.7 at last assessment (mean decrease 14.3, 95% CI 12.5 ÷ 16.1), and to 10.4 at Day 42 in the 92 patients still on treatment. The mean decrease difference between the two treatments at last assessment was 1.5 points (95% CI -1.0 ÷ 4.0).

In order to give a better insight into of the estimated mean decrease, the two-tailed 95% confidence interval for each arm are shown in Figure 1.

The pattern of improvement of HAMD factors was similar in the reboxetine-treated and imipramine-treated patients. At the last assessment, small differences were seen in: Factor I Anxiety/somatisation (median difference *vs* Day 0 of 0.83 [reboxetine group] and 0.67 [imipramine group]); and Factor III Cognitive Disturbance (median difference *vs* Day 0 of 0.67 [reboxetine group] and 0.50 [imipramine group]).

Absolute and per cent frequency of patients who achieved response or remission is shown (with 95% confidence intervals) by treatment group over time in Table 25 and at last assessment in Table 26. The percentage of responders at each visit is higher in the reboxetine group in comparison with the imipramine group mainly from Day 21 to Day 42: 45.5%-83.7% on reboxetine *vs* 38.3%-70.7% on imipramine. The percentage of

patients in remission was also slightly higher in the reboxetine group at each visit, being at Day 42, 63.3% on reboxetine and 56.5% on imipramine.

At last assessment (Table 26) 68.5% of the reboxetine-treated patients and 56.2% of the imipramine-treated patients were classified as responders, while 52.0% and 45.5%, respectively, were seen to be in remission. The between treatment difference in the proportion of response was 12.3% (95% CI 0.3 + 24.3).

The cumulative probability of response (confirmed at all available subsequent assessments) is plotted according to the Kaplan-Meier method in Figure 2. Patients on reboxetine had a cumulative rate of response significantly different (p=0.0126) from patients on imipramine. The time to response appears to be somewhat quicker on reboxetine than on imipramine.

Additional analyses were carried out on the sub-populations of patients classified as markedly to severely ill at admission (according to the CGI-Severity of Illness scale) and on those characterised as melancholic at admission (possible for 219 of the 256 patients admitted, in view of the missing information on time frame of diurnal variation, scored as present at the relevant HAMD item).

The mean decrease at last assessment of the HAMD total score in patients classified as markedly to severely ill at admission in the two treatment groups (99 reboxetine and 87 imipramine) is shown, together with the 95% confidence interval, in Figure 3. Results are very similar to those reported for the total population (Figure 1), the mean decrease difference between the two treatments being 2.0 points (95% CI -1.0 + 5.0).

The mean decrease at last assessment of the HAMD total score in those patients which could be classified as melancholic at admission in the two treatment groups (melancholic/non-melancholic: 51/60 reboxetine, 44/64 imipramine), is shown, together with the 95% confidence interval, in Figure 4. Also in this subpopulation, the mean decrease of the HAMD total score is higher in reboxetine than in imipramine group patients and the difference is 1.6 points (95% CI -3.0 + 6.3).

7.2 Clinical Global Impression

7.2.1 SEVERITY OF ILLNESS

The distribution of the CGI severity scores at each visit in the observed cases is presented by treatment group in Table 27, while the distribution of the scores at the last assessment during the study are provided in Table 28. The overall distribution pattern was similar in the two treatment groups. The proportion of normal or borderline cases is somewhat higher in the reboxetine group mainly at Day 14 and Day 21(14.5% *vs* 5.6% and 24.8% *vs* 13.1%, respectively). This proportion, at last assessment, was 44.1% with

reboxetine and 42.1% with imipramine. Small differences between the two treatment groups were seen in the proportion of markedly ill cases (9.4% with reboxetine and 14.9% with imipramine) at last assessment.

A shift table of the last value *vs* Day 0 (Table 29) showed that the CGI severity of illness had decreased in 80.3% of reboxetine group patients, increased in 3.1% and remained the same for 16.5%, whereas the CGI severity of illness had decreased in 73.6% of imipramine group patients, increased in 5.8% and remained the same in 20.7%.

7.2.2 GLOBAL IMPROVEMENT

The distribution of Global Improvement scores in CGI at each visit is shown by treatment group in Table 30. The distribution of last assessment scores is shown in Table 31.

The overall distribution pattern was similar in the two treatment groups. The percentage of patients who were 'very much improved' or 'much improved' at the last assessment was 66.9% in the reboxetine group and 62.0% in the imipramine group. The percentage of 'much to very much deteriorated' cases was higher in the imipramine group (6.6%) than in the reboxetine group (3.1%).

7.2.3 EFFICACY INDEX

The CGI efficacy index, which was assessed in order to relate therapeutic efficacy and tolerability, is shown by treatment group at each visit in Table 32. The distribution of last assessment values is shown in Table 33. The most relevant difference between the two treatments is seen in the proportion of cases where marked efficacy was present in the absence of side-effects (index=4) from Day 14 to Day 42: 12.0%-41.8% of reboxetine-treated cases *vs* 2.8%-29.3% of imipramine-treated cases. At last assessment, side-effects were judged to outweigh efficacy in 18.1% of the reboxetine patient group and 18.2% of the imipramine patient group. Treatment group differences are seen in the proportion of cases where some advantages were seen in terms of efficacy *vs* side-effects (index=2): 14.2% of the reboxetine-treated cases *vs* 23.1% of the imipramine-treated cases; and in the proportion of cases where marked efficacy was present in the absence of side-effects (index=4): 33.9% of the reboxetine-treated cases *vs* 22.3% of the imipramine-treated cases.

7.3 Montgomery and Asberg Depression Rating Scale

Summary statistics of MADRS assessment at each visit in the observed cases are shown in Table 34 (total scores) and Table 35 (individual items). Summary statistics of the last assessment are given in Table 36 (total scores) and Table 37 (individual items).

The mean total MADRS score was reduced from 17.2 at Day 0 to 7.9 at last assessment in the 127 reboxetine group patients with at least one assessment in addition to baseline,

and to 5.9 at Day 42 in the 98 reboxetine patients who completed the study. In patients treated with imipramine, values changed from 16.9 at Day 0 to 8.0 at last assessment (121 patients), and to 6.0 at Day 42 (92 assessed patients).

The pattern of improvement in MADRS items was similar in the reboxetine-treated and imipramine-treated patients.

7.4 Efficacy Conclusions

The results of the planned analysis of the study end-point, i.e. the difference *vs* baseline of the HAMD total score at the last assessment, prove the antidepressant efficacy of reboxetine in the treatment of major depressive episodes. The positive control, imipramine, was similar to reboxetine in terms of frequency, rate and extent of the induced clinical improvement. Patients classified as responders were somewhat more common in the reboxetine group than in the imipramine group and patients on reboxetine had a cumulative rate of response significantly greater than patients on imipramine.

Secondary efficacy assessments indicate similar improvement in both treatment groups, with a slightly higher proportion of maximal efficacy index (index=4) in the reboxetine-treated patients.

The results of the additional analyses on the sub-populations of severe and melancholic patients indicate that both treatments were similarly effective in terms of improvement of the clinical picture, as evaluated by the HAMD scale at the last available assessment.

As for the laboratory tests, vital signs and ECG, only the patients with at least one assessment in addition to baseline are evaluated.

8. SAFETY RESULTS

8.1 Safety Population and Extent of Exposure

8.1.1 NUMBER OF PATIENTS IN SAFETY ANALYSIS

All the patients who received study treatment were included in the safety analysis, i.e. 130 reboxetine patients and 126 imipramine patients.

8.1.2 TOTAL DRUG EXPOSURE

As shown in Table 16 , of the 130 and 126 patients exposed to reboxetine and imipramine, 107 and 99, respectively, were treated for at least 3 weeks, while 98 and 90 were treated for 6 weeks and completed the study.

8.2 Adverse Events

8.2.1 ANALYSIS OF ADVERSE EVENTS

The number of patients with adverse events and the number of adverse events during the study are grouped by sex in Table 38, by age classes in Table 39 and by DSM-III-R diagnosis in Table 40. Eighty-one point five per cent of the reboxetine patients and 81.7% of the imipramine patients exposed had 267 and 303 adverse events and an average of 2.5 and 2.9 adverse events, respectively. Males suffered from adverse events more frequently than females on both reboxetine (87.0% *vs* 78.6%) and imipramine (86.0% *vs* 79.5%). Patients aged 18 to 30 years had adverse events more frequently than patients who were aged 31 to 45 or over 45 for reboxetine (84.2%, 83.3%, 79.7%, respectively) and for imipramine (85.3%, 73.5%, 84.5%, respectively).

Patients with no history of previous depressive illness, diagnosed as Major Depressive Episodes (296.2) complained of adverse events less frequently than recurrent cases (296.3) at a similar rate in both treatment groups.

8.2.1.1 Absolute and Per Cent Frequency

The absolute and per cent frequency of patients suffering from adverse events is grouped by event and sex in Tables 41 (all events) and 42 (split by body system with relevant events grouped in clusters) and by body system and sex in Table 43. Amongst the most frequently reported events (>5% of exposed patients in at least one group), the events more frequently reported on reboxetine than imipramine were: headache/migraine (16.2%,*vs* 14.3%), nausea and related symptoms (14.6% *vs* 11.1%) and urinary hesitancy/retention (7.7% *vs* 4.8%)

Adverse events more frequently reported on imipramine than on reboxetine were: dry mouth (35.7% *vs* 24.6%), hypotension and related symptoms (18.3% *vs* 10.0%), insomnia (11.1% *vs* 7.7%), tachycardia (10.3% *vs* 6.2%), tremor (10.3% *vs* 1.5%), and somnolence (7.1% *vs* 3.1%).

The most relevant between-gender difference was related to the frequency of increased sweating, complained of mainly by male patients (23.9% of male *vs* 8.3% of female patients on reboxetine; 20.9% of male *vs* 10.8% of female patients on imipramine), nausea and related symptoms, complained of mainly by female patients (17.9% *vs* 8.7% of male patients on reboxetine, 12.0% *vs* 9.3% of male patients on imipramine), tachycardia, complained of mainly by male patients on reboxetine (10.9% *vs* 3.6% of female patients), and urinary hesitancy/retention, complained of mainly by male on reboxetine (19.6% *vs* 1.2% of female patients).

The most frequent, therefore, were disorders of the autonomic nervous system (NS) (34.6% and 44.4% on reboxetine and imipramine, respectively) which is also the most frequently affected system in both female and male patients with adverse events,

cardiovascular disorders (22.3%, 33.3%, respectively), gastro-intestinal (GI) system disorders (26.2%, 24.6%, respectively), central and peripheral NS disorders (20.0%, 25.4%, respectively), and psychiatric disorders (17.7%, 23.0%, respectively).

8.2.1.2 Occurrence

The occurrence of adverse events is grouped by week of onset and event/event clusters or body system in Tables 44, 45 and 46, respectively. The most frequent events on reboxetine and imipramine emerged initially during treatment, within the first week (autonomic NS disorders, 58.5%, 71.0%, respectively; cardiovascular disorders, 31.7%, 47.3%; GI system disorders, 61.9%, 52.6%; psychiatric disorders, 59.4%, 40.0%; central and peripheral NS disorders, 29.4%, 45.2%).

8.2.1.3 Overall Risk

The cumulative risk of developing the first adverse event, as well as adverse event clusters or individual events reported in at least 5 patients in at least one treatment group is described according to the Kaplan-Meier method and analysed by the log-rank test in Figures 5 to 19. As shown in Figure 5, the risk of developing at least one adverse event in the reboxetine group is the same as that in the imipramine group. As for individual events or clusters, the cumulative risk is significantly higher on imipramine than on reboxetine for dry mouth, hypotension and related symptoms and tremor.

8.2.1.4 Dose-Relationship

The absolute frequency of adverse events is grouped by maximal severity and by dose taken on the onset day and in the three preceding days in Table 47. For none of the events and treatments there is any indication of increased frequency or severity in patients (see Table 16) switched according to the protocol to the higher dose level, corresponding to 10mg/day reboxetine and to 200 mg/day imipramine.

8.2.1.5 Maximal Severity

The maximal severity of adverse events is grouped by sex, age and DSM-III-R classification in Table 48 and by event or body system in Tables 49 and 50, respectively. Events were most frequently of moderate severity on reboxetine and imipramine (49.1% and 48.5%, respectively), particularly in females (51.5% and 50.0%), but also in males (45.0% and 45.9%), severe events being reported in 28.3% and 30.1% of the patients with at least one event on reboxetine and imipramine, respectively. The severity of adverse events for the majority of the affected body systems was moderate for both reboxetine and imipramine. However, in both groups, mildness characterised the severity of adverse events for the autonomic nervous system (46.7% reboxetine, 44.6% imipramine) and urinary system disorders (46.2% and 42.9%). There did not seem to be any effect of age or depressive illness (as diagnosed at entry) on the severity on adverse events.

8.2.1.6 Duration

Summary statistics of the duration of adverse events are described in Table 51. The median duration was 7 days for reboxetine and 8 days for imipramine. Among the most frequent events, the median duration was higher in the reboxetine group than in the imipramine group for tachycardia (8 days, 3 days) and urinary hesitancy (24 days, 3 days), and higher in the imipramine group than in the reboxetine group for increased sweating (19 days, 8 days), insomnia (17 days, 8 days), and constipation (21 days, 10 days).

8.2.1.7 Symptomatic Treatment

As shown in Table 52, 23.6% and 18.2% of the events on reboxetine and imipramine, respectively, required symptomatic treatment in 39.6% and 36.9% of the affected patients. Events most frequently requiring symptomatic treatment were insomnia on both imipramine and reboxetine (12 out of 16 and 8 out of 11 events, respectively) and hypertension on reboxetine (6 out of 7 events).

8.2.1.8 Modification of Study Medication and Patient Outcome

As shown in Table 53, no change in study medication was required for 82.0% and 77.9% of the events, in the reboxetine and imipramine groups, respectively, while the daily dose was reduced in 2.2% and 4.3% of the cases, respectively, or the treatment temporarily interrupted in 3.0% and 1.0%. According to the adverse event outcome reported by the investigators, 12.0% and 16.2% of the cases in the reboxetine and imipramine groups contributed to withdrawal. This was most frequently seen for headache/migraine on imipramine (23.8% of the 21 events) and reboxetine (14.8% of the 27 events), for urinary hesitancy/retention on imipramine (42.9% of the 7 events) and reboxetine (36.4% of the 11 events), for asthenia/fatigue on imipramine (71.4% of the 7 events) and for nausea and related symptoms on reboxetine (25.0% of the 20 events). The individual cases of patients withdrawn due to adverse events are described in Section 8.2.3.2.

As shown in Table 54, of the 46 and 65 events requiring modification of the study medication in the reboxetine and imipramine groups, the vast majority (65.2% and 75.4%, respectively) disappeared following the modification of the regimen.
The patient outcome, grouped by event and action taken on study medication in Table 55, corresponds to full recovery in 69.6% and 73.8% of the reboxetine and imipramine cases following modification of the treatment regimen, and in 67.0% and 63.0% of the cases of unchanged study medication, the event being still present at last assessment in 29.4% and 34.9% of the latter cases.

8.2.1.9 Prevalence

The prevalence of adverse events is grouped by week of treatment and event, event cluster or body system in Tables 56, 57 and 58. Among the most frequent events, in

keeping with the selection of the most tolerant population over the treatment period, the proportion of affected patients tended to decrease during treatment, particularly during the last two weeks, in both treatment groups, with the exception of tachycardia and urinary hesitancy in the reboxetine group, and increased sweating, insomnia and tremor in the imipramine group. In addition, in the reboxetine group, the incidence of headache increased during the early part of the study, before declining rapidly towards the end of the study.

The overall prevalence of adverse events in both treatment groups is shown in Figure 20. The proportion of patients affected by at least one adverse event during the different weeks of treatment was slightly higher on imipramine than on reboxetine, particularly during the final 3 weeks of treatment.

8.2.1.10 Relationship Between Adverse Events and Study Medication

The relationship between adverse events and study medication, as judged by the investigators on the basis of Karch and Lasagna modified criteria (Enclosure 11 of Appendix 12.1.1) is described in Table 59. The majority of events on reboxetine and imipramine (39.7% and 40.9%, respectively) were judged possibly related, while 24.0% and 29.4%, respectively, were judged probably related, and 7.9% and 9.6%, respectively, were judged definitely related. Among the most frequent events, the maximal frequency of definite/probable relationship was present for dry mouth (57.6%, 68.8%) nausea and related symptoms (50.0%, 57.1%), hypotension and related symptoms (42.9%, 34.6%), insomnia (54.6%, 25.0%) on reboxetine and imipramine, respectively, as well as for urinary hesitancy/retention (54.5%) on reboxetine and asthenia/fatigue (85.7%) on imipramine.

8.2.2 ADVERSE EVENT SUMMARY

Of the 130 reboxetine patients and 126 imipramine patients who received study medication, 106 (81.5%) and 103 (81.7%) patients reported a total of 267 and 303 adverse events, respectively (2.5, 2.9 per patient) (Table 38). The cumulative risk of occurrence of the first adverse event was not significantly different between treatment groups (Figure 5). The prevalence of adverse events during the study indicates a slightly higher proportion of patients with adverse events in the imipramine than in the reboxetine group, particularly in the final 3 weeks of treatment (Figure 20).

8.2.2.1 Severity of Adverse Events

The maximum severity of adverse events is presented in Tables 48-50 and summarised as follows:

Severity of adverse events

No. of patients					
Reboxetine			Imipramine		
Mild	Moderate	Severe	Mild	Moderate	Severe
24	52	30	22	50	31

The majority of adverse events were mild or moderate in both groups with little or no difference in the prevalence of each severity group between treatments.

8.2.2.2 Age- and Gender-Related Effects

Males suffered from adverse events more frequently than females on reboxetine (87.0% *vs* 78.6%) and on imipramine (86.0% *vs* 79.5%) (Table 38). Patients aged 18 to 30 years had adverse events more frequently than patients who were aged 31 to 45 or over 45 for reboxetine (84.2%, 83.3%, 79.7%, respectively) and for imipramine (85.3%, 73.5%, 84.5%, respectively) (Table 39). The most relevant between-gender differences were related to the frequency of increased sweating, complained of mainly by male patients (23.9% reboxetine, 20.9% imipramine), and nausea and related symptoms, complained of mainly by female patients (17.9% reboxetine, 12.0% imipramine) (Table 42).

8.2.2.3 Frequently Reported Adverse Events

Adverse events which occurred in 5% or more of the patients during the study are presented by body system in the following table:

Adverse events occurring in 5% or more of patients

Body system	Adverse event	Reboxetine (n=130)		Imipramine (n=126)	
		No. of patients with event	% of patients exposed	No. of patients with event	% of patients exposed
GI disorders	Nausea and related symptoms	19	15	14	11
	Constipation	13	10	13	10
Psychiatric disorders	Insomnia	10	8	14	11
	Agitation / anxiety / nervousness	9	7	9	7
	Somnolence	4	3	9	7
Autonomic NS disorders	Dry mouth	32	25	45	36
	Increased sweating	18	14	18	14
General cardiovascular disorders	Hypotension and related symptoms	13	10	23	18
	Tachycardia	8	6	13	10
Central and peripheral NS disorders	Headache / migraine	21	16	18	14
	Tremor	2	2	13	10
Respiratory system disorders	Bronchitis	6	5	1	1
Body as a whole/general disorder	Asthenia/fatigue	5	4	6	5
Urinary system disorders	Urinary hesitancy/retention	10	8	6	5

The estimate of the cumulative risk of adverse events, according to the Kaplan-Meier method and log-rank test, is the same in both treatment groups. For individual events or clusters, the cumulative risk for dry mouth and tremor is significantly higher on imipramine than on reboxetine. Dry mouth was the most common adverse event with 25% of reboxetine patients and 36% of imipramine patients reporting this event.

8.2.3 SERIOUS ADVERSE EVENTS, DEATHS AND ADVERSE EVENTS ASSOCIATED WITH WITHDRAWAL

8.2.3.1 Serious Adverse Events and Deaths

One patient from the reboxetine group died (suicide), and three patients suffered from serious adverse events: parasuicide by overdose (on reboxetine), supraventricular tachycardia and A-V block first degree (both on imipramine). Case histories for these patients are provided in Appendix 12.2.1.

8.2.3.2 Adverse Events Associated with Withdrawal

Thirty-one patients (13 on reboxetine, 10.0%; 18 on imipramine, 14.3%) had adverse events or intercurrent illnesses as the main reason of withdrawal from the study (Table 60). The nature of the adverse events is summarised as follows:

Adverse events leading to withdrawal

Treatment	Patient number	Adverse event	Relationship to study drug
Reboxetine	50, 51, 277, 330	Insomnia	Probable, Probable, Probable, Probable
	280, 355, 358	Dizziness	Probable, Probable, Missing
	197, 271, 355	Headache	Doubtful, Possible, Probable
	330, 355	Nausea	Probable, Probable
	277, 358	Increased sweating	Probable, Missing
	50, 353	Suicide attempt	None, Definite
	194, 237	Urinary retention	Probable, Possible
	355	Dyspepsia	Probable
	355	Abdominal pain	Probable
	280	Dry mouth	Probable
	280	Somnolence	Probable
	277	Hypothyroidism	None
	277	Agitation	Probable
	271	Hypertension	Possible
	197	Asthenia	Doubtful

Reboxetine	129	Urinary hesitancy	Probable
	51	Delusion	Probable
	50	Hyperuricaemia	Possible
	50	Bundle branch block	Possible
Imipramine	8, 34, 209, 382, 429	Headache	Possible, None, Probable, Probable, Probable
	8, 209, 273, 379, 429	Dry mouth	Possible, Possible, Possible, Probable, Probable
	8, 273, 307, 376	Tremor	Possible, Possible, Probable, Probable
	209, 308, 429	Fatigue	Probable, Probable, Probable
	8, 357, 429	Dizziness	Possible, Probable, Probable
	196, 307, 360	Agitation	Possible, Probable, Probable
	357, 429	Asthenia	Probable, Probable
	308, 429	Nausea	Probable, Probable
	273, 379	Confusion	Possible, Probable
	196, 360	Insomnia	Possible, Probable
	8, 357	Somnolence	Possible, Probable
	8, 308	Increased sweating	Possible, Probable
	261, 273	Urinary retention	Possible, Possible
	36, 270	Tachycardia	Possible, Unknown
	429	Anorexia	Probable
	427	Oesophagitis	Possible
	379	Taste perversion	Probable
	376	Dysphagia	Probable
	360	Hot flushes	Probable
	357	Sinusitis	Possible
	308	Urinary tract infection	None
	273	Loss of taste	Possible
	196	Rash	Probable
	44	Delusion	Doubtful
	34	Back pain	None
	36	Manic reaction	Definite
	8	Abnormal vision	Probable

In addition 2 patients of the imipramine group withdrew from the study for adverse event/intercurrent illness without having a newly emerged adverse event: one patient

(No.45) dropped out due to somnolence present before the start of treatment, and a second patient (No.276) due to influenza present from one week before the start of treatment.

8.3 Laboratory tests

8.3.1 SUMMARY STATISTICS OF LABORATORY VALUES

As shown in Table 61, in the reboxetine group, compared to baseline, there was a significant ($p<0.01$) increase after 6 weeks of treatment in platelets (median difference 18.60 x 10^3 /mm^3) and in uric acid (median difference 0.31 mg/dl). There was a significant decrease in serum chloride after 3 and 6 weeks of treatment (median difference -0.31 mEq/l and -0.69 mEq/l, respectively).

Similarly, in the imipramine group, compared to baseline, there was a significant increase in alkaline phosphatase after 3 and 6 weeks of treatment (median difference 4.13 U/l and 4.85 U/l, respectively).

8.3.2 URINALYSIS

Frequency of abnormal findings at baseline and during the treatment period or at last assessment are shown in Tables 62 and 63, respectively. No indication of increased frequencies of abnormal findings as compared to baseline emerges. In fact there is no indication of increased proportions of patients shifted from baseline to presence of albumin, sugar, WBC and RBC as compared to baseline both at the various assessment intervals (Table 64) and at last available assessment (Table 65). The same considerations hold for specific gravity (Tables 66 and 67).

8.3.3 ABNORMAL LABORATORY VALUES

The number and percentage of patients shifted from values within, below or above the normal range to values within, below or above the latter are given by period in Table 68. There were no statistically significant shifts ($p<0.01$) in the distribution of the frequencies (either towards the higher or lower values) in the reboxetine or imipramine groups.

8.3.4 ABNORMAL LABORATORY VALUES OF CLINICAL RELEVANCE

The distribution pattern of patients with clinically relevant abnormal values is given by variable and period of treatment in Table 69. Frequency of clinically relevant abnormal values was similarly low in the two treatment groups over the study period; no significantly increased frequency over baseline was present for any of the variables measured in the reboxetine and imipramine patient groups.

8.4 Vital Signs

8.4.1 BLOOD PRESSURE AND HEART RATE

Summary statistics of blood pressure and heart rate values and changes *vs* baseline at each visit during the study are presented in Tables 70 to 74. There were no important trends apparent in mean and median blood pressure and heart rate values and changes during the study.

The absolute and per cent frequency of patients at each visit showing a modification of 20% or more *vs* baseline is given in Table 72, while the absolute frequency of patients showing such a modification accompanied by absolute critical values (≥160 or ≤100 mmHg for systolic blood pressure; ≥100 or ≤70 mmHg for diastolic blood pressure; ≥100 or ≤50 beats/min for heart rate) once, twice or more times is given in Table 73.

As shown in Table 73, the frequency of clinically relevant decrease of blood pressure, particularly the diastolic pressure, was higher than the frequency of relevant increase similarly in both groups. The only difference between the two treatment groups concerned the frequency of relevant decrease of both the systolic and diastolic pressure on standing, which was higher on imipramine than on reboxetine (13 cases *vs* 5, representing 11% and 4% of evaluated patients, respectively). As for heart rate, the frequency of patients with at least 20% increased values, associated with values ≥100 beats/min, was higher, particularly on standing, in the reboxetine group (34 cases, representing 27% of evaluated patients) compared with the imipramine group (25 cases, representing 21% of evaluated patients). Relevant increases occurred occasionally (reported once) in the majority of the cases on both groups.

The number and percentage of patients with orthostatic hypotension at each visit is presented in Table 74. At baseline the event was present in 3 patients in the reboxetine group and 1 in the imipramine group. Subsequently the event had a low frequency at all visits, affecting a maximum of 4.6% of the reboxetine patients on Day 21 and 5.8% of the imipramine patients on Day 7.

8.4.2 BODY WEIGHT

Summary statistics of the body weight values (Kg) at the various assessment intervals are given in Table 75, while the absolute and per cent frequency of patients showing higher (>2.5 Kg), lower (<2.5 Kg) or similar values *vs* baseline at the various assessment intervals is given in Table 76. No trends toward modification and no difference between the reboxetine and imipramine groups were apparent.

8.4.3 BODY TEMPERATURE

Individual data are reported in Appendix 12.2.2, Listing 20.0. No modifications of note were evident.

8.5 Electrocardiogram

As shown in Table 77, 209 patients had their ECG recorded at baseline, 8.6% of whom showed at least one ECG abnormality (9.0% reboxetine and 8.2% imipramine). During the study, 202 patients had their ECG recorded after 3 weeks of treatment, and 177 after 6 weeks of treatment. Of these patients, 11.3% (Days 1-21) and 18.5% (Days 22 to 42) had at least one ECG abnormality recorded during treatment, in the reboxetine group. The equivalent proportions in the imipramine group were 11.5% (Days 1 to 21) and 12.9% (Days 22 to 42). In the reboxetine group, the proportion of male patients with at least one abnormality was slightly higher than the same proportion of female patients. This is due to the higher frequency of tachycardia complained of mainly by male patients on reboxetine, as already commented in section 8.2.1.1. As shown in Table 78, during the study, the frequency of at least one newly emerged abnormality in patients with normal tracing at baseline was always consistently lower than the frequency of normalisation of ECG recordings in patients with at least one abnormality at entry in both treatment groups. At the last assessment of the study (Table 79), of the 18 patients (10 reboxetine and 8 imipramine) who had had at least one abnormality at baseline, 50% on reboxetine and 50% on imipramine were reported as normal. Among the 191 patients (101 reboxetine and 90 imipramine) with normal tracings at baseline, 15.8% on reboxetine and 8.9% on imipramine showed at least one abnormality during the study.

The frequency of individual abnormalities at admission and during the study is shown by treatment group in Table 80. At screening, individual abnormalities are present in a maximum of 3.6% (sinus tachycardia >100) of the 111 evaluated cases of the reboxetine and in 2% (several types) of the 98 evaluated cases in the imipramine group. During the treatment, the frequencies of all observed abnormalities were not modified to any significant extent in either treatment group. As shown in Table 81, at the last assessment, for all abnormalities and both treatment groups, the proportion of newly observed cases among normal baseline cases is lower than the proportion of normalised cases among abnormal baseline cases. Newly emerged abnormalities never reported at baseline occurred with a slightly higher frequency in the reboxetine compared with the imipramine group; the most common of these was sinus tachycardia (9 reboxetine and 4 imipramine).

The frequency of randomised patients with at least one abnormality by abnormality group during the study is shown in Table 82. At screening, from 0.9% (ischaemic signs) to 5.4% (rhythm disorders) of the evaluated patients in the reboxetine group and 1.0% (ischaemic signs and other disorders) to 5.1% (rhythm disorders) in the imipramine group showed at least one abnormality of the indicated groups. During the treatment, the frequencies were not modified to any significant extent in any of the treatment

groups. As shown in Table 83, at last assessment, the proportion of newly emerged cases was similar in the two treatment groups, with the exception of newly emerged rhythm disorders in 11 cases on reboxetine and 7 on imipramine, and of newly emerged ischaemic signs in 1 case on reboxetine. In both groups, the proportion of normalised cases was consistently higher than the proportion of newly emerged cases.

8.6 Safety Conclusions

All the 256 patients who received study treatment were included in the safety analysis (130 reboxetine, 126 imipramine).

The occurrence of newly reported adverse events was similar in both groups during the study; 106/130 reboxetine group patients reported 267 adverse events compared with 103/126 imipramine patients who reported 303 adverse events. Discontinuation due to adverse event was more frequent on imipramine (14%) than on reboxetine (10%). Most frequently reported were: dry mouth (25% reboxetine and 36% imipramine); headache/migraine (16%, 14%); and nausea and related symptoms (15%, 11%). The majority of adverse events were moderate in both treatment groups. Adverse events were reported more frequently by men than women in both treatment groups. The most relevant between-gender differences were related to the frequency of increased sweating, complained of mainly by male patients, and nausea and related symptoms, complained of mainly by female patients.

The estimate of the cumulative risk of adverse events according to the Kaplan-Meier method and log-rank test is significantly higher on imipramine than reboxetine for dry mouth and tremor.

One patient of the reboxetine group died (suicide) and three patients suffered from serious adverse events: parasuicide by overdose (on reboxetine), supraventricular tachycardia and A-V block first degree (both on imipramine).

There was no indication of modifications in laboratory tests that were of clinical significance.

Vital signs were not modified to any significant extent and the only difference between the two treatment groups was observed in the absolute frequency of clinically relevant decrease of both systolic and diastolic blood pressure, which was higher on imipramine than on reboxetine on standing (11% and 4% of evaluated patients, respectively). The absolute frequency of heart rate values increased to ≥100 beats/min was slightly higher on reboxetine than on imipramine, particularly on standing (27% and 21% of evaluated patients, respectively). However, the majority of these relevant increases occurred occasionally (reported once).

No indication of effect on cardiac function emerged from ECG recordings.

9. DISCUSSION

Two hundred and fifty-six patients (130 reboxetine, 126 imipramine) were admitted to the study from December 1990 to September 1992 and randomised to treatment by investigators at 22 centres. A total of 188 patients (73.4%) completed the study and 68 (26.6%) withdrew; 32 (24.6%) in the reboxetine group, and 36 (28.6%) in the imipramine group.

The response to treatment was assessed using the Hamilton Depression Rating Scale (HAMD), Clinical Global Impression (CGI) and the Montgomery and Asberg Depression Rating Scale (MADRS).

The mean HAMD total score was reduced from 28.8 at Day 0 to 13.0 at last assessment (mean decrease 15.8, 95% CI 14.0 ÷ 17.5), in the 127 patients treated with reboxetine who had at least one assessment in addition to baseline, and to 9.6 at Day 42 in the 98 patients who completed the study. In the 121 patients treated with imipramine with at least one assessment in addition to baseline, the mean HAMD total score was reduced from 28.0 at Day 0 to 13.7 at last assessment (mean decrease 14.3, 95% CI 12.5 ÷ 16.1), and to 10.4 at Day 42 in the 92 patients still on treatment. The between treatment difference at last assessment was 1.5 points (95% CI -1.0 ÷ 4.0).

At last assessment, 68.5% of the reboxetine-treated patients and 56.2% of the imipramine-treated patients were classified as responders, while 52.0% and 45.5%, respectively, were seen to be in remission. The between treatment difference in the proportion of response was 12.3% (95% CI 0.3 ÷ 24.3).

In agreement with the above, the cumulative probability of response (Kaplan-Meier analysis) on reboxetine was significantly higher (p=0.0126) compared to imipramine.

The results of the additional analyses on the sub-populations of severe and melancholic patients indicate that both treatments were similarly effective in terms of improvement of the clinical picture, as evaluated by the HAMD scale at the last available assessment.

The results of the analysis of the secondary efficacy variables confirmed the above commented findings. At the last assessment, the percentage of patients classified as 'very much improved' or 'much improved' (CGI-Global Improvement) was somewhat higher in the reboxetine group (66.9%) than in the imipramine group (62.0%). The percentage of 'much to very much deteriorated' cases was higher in the imipramine group (6.6 %) than in the reboxetine group (3.1 %). In addition, the proportion of cases where efficacy outweighted side effects (CGI-Efficacy Index = 4) was higher in the reboxetine group than in the imipramine group from the second week of treatment up to the end of the study (from 12.0% to 41.8% in the reboxetine *vs* 2.8% to 29.3% in the imipramine group). Similarly, at last assessment, the proportion of these cases was higher on reboxetine (33.9%) than on imipramine (22.3 %).

Similarly,the mean total MADRS score was reduced from 17.2 at Day 0 to 7.9 at last assessment in the 127 reboxetine group patients with at least one assessment in addition to baseline, and to 5.9 at Day 42 in the 98 reboxetine patients who completed the study.

In patients treated with imipramine, values changed from 16.9 at Day 0 to 8.0 at last assessment (121 patients), and to 6.0 at Day 42 (92 assessed patients).

All the 256 patients who received study treatment were included in the safety analysis (130 reboxetine, 126 imipramine).

Safety and tolerability were assessed by the reporting of any adverse event and the assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests and ECG.

The occurrence of newly reported adverse events was similar in both groups during the study; 106/130 reboxetine group patients reported 267 adverse events compared with 103/126 imipramine patients who reported 303 adverse events. However, the prevalence of adverse events during the different weeks of treatment, was slightly higher on imipramine than on reboxetine mainly during the final 3 weeks of treatment. Discontinuation due to newly emerged adverse event was more frequent on imipramine (14%) than on reboxetine (10%). Most frequently reported were: dry mouth (25% reboxetine and 36% imipramine); headache/migraine (16%, 14%); hypotension and related symptoms (10%, 18%); and nausea and related symptoms (15%, 11%). The majority of adverse events were moderate and adverse events were reported more frequently by men than women in both the treatment groups. The most relevant between-gender differences were related to the frequency of increased sweating, complained of mainly by male patients, and nausea and related symptoms, complained of mainly by female patients in both treatment groups.

The estimate of the cumulative risk of adverse events according to the Kaplan-Meier method and log-rank test is significantly higher on imipramine than on reboxetine for dry mouth, hypotension and related symptoms and tremor.

One patient on the reboxetine group died (suicide) and three patients suffered from serious adverse events: parasuicide by overdose (on reboxetine), supraventricular tachycardia and A-V block first degree (both on imipramine).

There was no indication of modifications in laboratory tests that were of clinical significance in either treatment group.

Vital signs were not modified to any significant extent and the only difference between the two treatment groups was observed in the absolute frequency of clinically relevant decrease of both systolic and diastolic blood pressure, which was higher on imipramine than on reboxetine on standing (11% and 4% of evaluated patients, respectively). The absolute frequency of heart rate values increased to ≥100 beats/min was slightly higher on reboxetine than on imipramine, particularly on standing (27% and 21% of evaluated patients, respectively). However, the majority of these relevant increases occurred occasionally (reported once).

No indication of effect on cardiac function emerged from ECG recordings in either treatment group.

10. CONCLUSION

The efficacy of reboxetine therapy in patients suffering from Major Depressive Episodes, as measured by the improvement of HAMD, MADRS and CGI scales, was similar to that of imipramine. However, the cumulative probability of response (≥50% decrease of HAMD total score) was significantly higher on reboxetine than on imipramine.

The tolerability of reboxetine was highly acceptable, as shown in the safety profile in terms of modification of vital signs, haematology and blood chemistry tests and ECG examinations, and also in the superiority of reboxetine to imipramine in terms of the frequency of occurrence of dry mouth, hypotension and related symptoms and tremor, and of discontinuation due to adverse events.

11. REFERENCES

1. Reboxetine Investigator's Brochure, Farmitalia Carlo Erba, CNS Line, July 1988.
2. Herrman WM, Schneider J, Boden S, Wagner W, Rohmel J, Grunmach J. Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study. Pharmacia Internal Report FCE 20124/602i, June 1984.
3. Herrman WM, Schneider J, Irrgang U, Rosener B, Willman J, Rohmel J, et al. Reboxetine - Quantitative pharmaco-EEG and pharmaco-psychological study. Pharmacia Internal Report FCE 20124/603i, January 1985.
4. Dubini A, Goldaniga GC, Montesanti L, Savoia L, Tamassia V, Vicario GP. Disposition and fate of ^{14}C-reboxetine administered orally to healthy volunteers. Pharmacia Internal Report FCE 20124/604i, March 1985.
5. Dubini A, Ban T. Open dose range finding study in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/701i, April 1989.
6. Dubini A, Ban T, Morey LC. Phase II controlled study of the activity and tolerability of reboxetine in comparison with placebo and desipramine in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/702i, February 1991.
7. Angst J, Bech P, Boyer P, Bruinvels J, Engel R, Helmchen H et al. Consensus conference on the methodology of clinical trials of antidepressants, Zurich, March 1988: Report of the Consensus Committee. Pharmacopsychiat 1989; 22: 3-7.
8. American Psychiatric Association. Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Third edition revised, American Psychiatric Association, Washington DC, 1987.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
10. Tofranil. In: Physicians' Desk Reference (PDR). 43rd edition, Medical Economics Company Inc, Oradell, NJ, 1989.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. Rockville, Maryland: 1976.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.

13. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological psychiatric rating scale (CPRS). Acta Psychiatrica Scand (Suppl) 1978; 271: 5-27.

14. Stark P, Hardison CD. A Review of Multicentre Controlled Studies of Fluoxetine *vs* Imipramine and Placebo in Outpatients with Major Dapressive Disorder. J Clin Psychiatry 1985; 46 (3, Sec 2): 53-58.

15. American Psychiatric Association. Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Fourth edition, American Psychiatric Association, Washington DC, 1994.

16. Gill JL. Design and Analysis of Experiments in the Animal and Medical Sciences. Ames, Iowa, USA: The Iowa State University Press, 1978: 53-56.

17. Peace KE. Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker, Inc, 1988: 478.

18. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980: 16-19.

19. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons, 1973: 72-80.

20. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multi-center clinical trials. Drug Information Journal 1992; 26: 77-84.

21. Wyngaarden JB, Smith LH, Bennett JC, Editors. Cecil Textbook of Medicine. Philadelphia: Saunders, 1988.

22. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973: 26-38.

23. Collaborating Center for International Drug Monitoring. Manual of the international statistical classification of diseases, injuries, and causes of death. Geneva: World Health Organization, 1977.

24. Collaborating Center for International Drug Monitoring. Drug Reference List. Geneva: World Health Organization, 1989.

25. Collaborating Center for International Drug Monitoring. Adverse Reactions Terminology. International monitoring of adverse reactions to drugs. Geneva: World Health Organization, 1989.

TABLES

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	Imipramine	6	6	6	5	5	5	5	5
	Reboxetine	6	6	6	6	6	5	4	4
2	Imipramine	10	10	10	8	8	8	7	7
	Reboxetine	10	10	10	10	9	9	9	9
3	Imipramine	4	4	4	4	4	4	4	4
	Reboxetine	5	5	5	5	5	5	4	4
4	Imipramine	2	2	2	2	2	1	1	1
	Reboxetine	1	1	1	1	1	1	1	1
6	Reboxetine	2	2	2	2	2	2	2	2
7	Imipramine	1	1	1	1	1	1	1	1
	Reboxetine	2	2	2					
8	Imipramine	4	4	4	4	4	3	3	3
	Reboxetine	4	4	4	4	2	2	2	2
9	Imipramine	23	23	23	18	18	17	16	16
	Reboxetine	23	23	23	19	17	14	13	13
9/A	Imipramine	10	10	10	9	8	5	4	4
	Reboxetine	10	10	10	8	8	7	7	6
10	Imipramine	6	6	6	5	5	4	4	4
	Reboxetine	6	6	6	6	6	6	6	6
11	Imipramine	7	7	7	7	7	7	6	6
	Reboxetine	6	6	6	5	5	5	5	5
12	Imipramine	2	2	2	2	2	2	2	2
	Reboxetine	3	3	3	3	3	3	3	2
13	Imipramine	4	4	4	2	2	2	2	2

(CONTINUED)

PHARMACIA CRS RSD

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 1

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	Reboxetine	5	5	5	4	4	4	4	2
14	Imipramine	5	5	5	5	5	5	5	5
	Reboxetine	5	5	5	5	5	5	5	5
14/1	Imipramine	2	2	2	1	1	1	1	1
	Reboxetine	3	3	3	2	2	2	2	2
14/2	Imipramine	2	2	2	2	2	2	2	2
14/3	Imipramine	4	4	4	4	4	3	2	2
	Reboxetine	3	3	3	3	3	3	3	3
14/4	Imipramine	3	3	3	3	3	3	3	3
	Reboxetine	2	2	2	2	2	2	2	2
14/7	Imipramine	8	8	8	8	8	8	8	8
	Reboxetine	6	6	6	6	6	6	6	6
14/8	Reboxetine	3	3	3	3	3	3	3	3
14/10	Imipramine	11	11	11	11	11	11	11	11
	Reboxetine	14	14	14	14	14	14	14	14
15	Imipramine	12	12	12	9	8	7	6	6
	Reboxetine	11	11	11	11	10	9	9	9
Total	Imipramine	126	126	126	110	108	99	93	93
	Reboxetine	130	130	130	119	115	107	104	100
	Total	256	256	256	229	221	206	197	193

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 2

PATIENT DISPOSITION

	Treatment assigned				Total	
	Ixipramine		Reboxetine			
	No.	%	No.	%	No.	%
Screened	126	100.00	130	100.00	256	100.00
Exposed	126	100.00	130	100.00	256	100.00
Completed	90	71.43	98	75.38	188	73.44
Dropped	36	28.57	32	24.62	68	26.56

PHARMACIA CNS0000085

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 3

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURED, BY ASSIGNED TREATMENT

Assigned treatment / Reasons		Total		Last visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	ADVERSE EVENT (*)	20	100	13	65.0	1	5.0			4	20.0			2	10.0
	PROTOCOL VIOLATION	1	100	1	100										
	LOST TO FOLLOW UP	2	100					2	100						
	DETERIORATION	7	100	1	14.3	1	14.3	4	57.1					1	14.3
	PATIENT UNCOOPERATIVE	5	100	1	20.0			3	60.0	1	20.0				
	OTHER	1	100							1	100				
	Total	36	100	16	44.4	2	5.6	9	25.0	6	16.7			3	8.3
Reboxetine	ADVERSE EVENT (*)	12	100	7	58.3	2	16.7			1	8.3	2	16.7		
	DEATH	1	100											1	100
	PROTOCOL VIOLATION	3	100			2	66.7	1	33.3						
	DETERIORATION	8	100	2	25.0			3	37.5	1	12.5	2	25.0		
	PATIENT UNCOOPERATIVE	7	100	2	28.6	2	28.6	2	28.6	1	14.3				
	OTHER	1	100											1	100
	Total	32	100	11	34.4	6	18.8	6	18.8	3	9.4	4	12.5	2	6.3

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124//017

TABLE No.: 4

PROTOCOL VIOLATIONS AT ADMISSION

	Imipramine		Reboxetine	
	No.	%	No.	%
Patients exposed	126	100.00	130	100.00
Age > 65 years	1	0.79		
Pregnancy	1	0.79		
Thyroid function tests abnormal*	19	•16.10	21	•17.50
Thyroid function tests missing	8	6.35	10	7.69
Evidence of Substance Use Disorder			1	0.79
Associated endocrine disorder			4	3.08
Not allowed concomitant medication °	9	7.14	6	4.62
Index episode < 4 weeks	2	1.59	4	3.08
Index episode > 4 months			1	0.79
Index episode duration: unknown			1	0.79
Clinically relevant associated pathology			1	0.79

* relative deviation from limits of normal range < 10% and > 10%
• % frequency out of assessed
° during wash-out

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 5

RANDOMISATION: ASSIGNED TREATMENT vs RANDOMISED TREATMENT

Assigned treatment	Randomised treatment		Total
	Imipramine	Reboxetine	
Imipramine	104	22	126
Reboxetine	25	105	130
Total	129	127	256

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017

TABLE No.: 6

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Assigned treatment: Reboxetine

		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Assessment time	No.	130	130	119	113	107	104	100	98
	Min	-21	-1	6	13	20	27	34	40
	Max	1	2	11	18	25	32	37	44
	Median	-4	0	7	14	21	28	35	43
	95%	1	1	8	15	22	29	36	44
Laboratory test	No.	128				107			98
	Min	-67				16			40
	Max	2				25			47
	Median	-3				21			43
	95%	1				22			44
E.C.G.	No.	124				102			96
	Min	-41				18			40
	Max	2				37			49
	Median	-3				21			42
	95%	1				22			44

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 6

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Assigned treatment: Imipramine

		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Assessment time	No.	126	126	110	108	99	93	93	90
	Min	-20	-4	7	13	20	26	33	41
	Max	1	1	10	17	24	31	38	46
	Median	-3	1	8	15	21	28	35	43
	95%	1	1	8	15	22	29	36	43
Laboratory test	No.	126				97			88
	Min	-20				19			40
	Max	5				28			50
	Median	-2				22			43
	95%	1				25			43
E.C.G.	No.	124				94			87
	Min	-20				14			37
	Max	2				29			49
	Median	-3				21			42
	95%	1				25			43

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 7

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY ACTIVE PRINCIPLE
NUMBER OF PATIENTS

Class / Active principle		Reboxetine	Imipramine
BZD long acting	DIAZEPAM	6	2
	LORAZEPAM	1	3
	LORMETAZEPAM	1	1
	CLOBAZEPIC ACID	1	
	Total	9	6
Antidepressants	MELITRACEN	1	
	Total	1	

PHARMACIA CNS R&D

ZEBORINSTINE - PROTOCOL 2012A/017
Table No.: 8

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY CLASS
NUMBER OF PATIENTS

	Assigned treatment	
	Zolpremine	Reboxetine
At least one	6	6
Antidepressants		1
BDZ long acting	6	5

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Table No.: 9

DEMOGRAPHY BY ASSIGNED TREATMENT - AGE, WEIGHT, HEIGHT

Assigned treatment		Age			Weight			Height		
		Sex			Sex			Sex		
		Female	Male	Total	Female	Male	Total	Female	Male	Total
Imipramine	No	83	43	126	83	43	126	83	42	125
	Mean	43.51	40.19	42.37	64.95	77.83	69.35	163.42	176.55	167.83
	S.D.	13.38	13.78	13.55	11.55	14.03	13.83	6.17	6.63	8.86
	Min	20.00	19.00	19.00	47.00	37.50	37.50	148.00	160.00	148.00
	Max	66.00	65.00	66.00	103.00	123.00	123.00	181.00	194.00	194.00
Reboxetine	No	84	46	130	83	46	129	83	46	129
	Mean	45.55	45.13	45.40	64.53	76.26	68.71	164.37	172.92	167.42
	S.D.	12.47	11.36	12.04	8.60	11.93	11.37	6.03	8.23	8.00
	Min	18.00	19.00	18.00	43.50	49.80	43.50	147.00	142.00	142.00
	Max	65.00	64.00	65.00	83.00	120.00	120.00	176.00	189.00	189.00
Total	No	167	89	256	166	89	255	166	88	254
	Mean	44.53	42.74	43.91	64.74	77.02	69.03	163.89	174.65	167.62
	S.D.	12.93	12.76	12.87	10.15	12.94	12.62	6.10	7.69	8.42
	Min	18.00	19.00	18.00	43.50	37.50	37.50	147.00	142.00	142.00
	Max	66.00	65.00	66.00	103.00	123.00	123.00	181.00	194.00	194.00

weight and height at screening visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Table No.: 10

DEMOGRAPHY BY ASSIGNED TREATMENT - RACE

Assigned treatment / Sex		Race									
		Caucasian		Black		Asian		Other		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%
Imipramine	Female	79	95.18	4	4.82					83	100.00
	Male	39	90.70	4	9.30					43	100.00
	Total	118	93.65	8	6.35					126	100.00
Reboxetine	Female	75	89.29	8	9.52	1	1.19			84	100.00
	Male	42	91.30	2	4.35	1	2.17	1	2.17	46	100.00
	Total	117	90.00	10	7.69	2	1.54	1	0.77	130	100.00
Total	Female	154	92.22	12	7.19	1	0.60			167	100.00
	Male	81	91.01	6	6.74	1	1.12	1	1.12	89	100.00
	Total	235	91.80	18	7.03	2	0.78	1	0.39	256	100.00

PHARMACIA CNS R&D

RISPERIDONE - PROTOCOL 2012A/017

TABLE No.: 11

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

		Sex									
		Female			Male			Total			
		Haloperidol	Risperidone	Total	Haloperidol	Risperidone	Total	Haloperidol	Risperidone	Total	
DSM-III-R diagnosis	296.2 No.	34	32	66	23	19	42	57	51	108	
	296.3 No.	49	52	101	20	27	47	69	79	148	
Age at onset (years)	No.	69	67	136	32	33	65	101	100	201	
	Mean	40.20	39.63	39.92	36.09	39.52	37.85	38.90	39.59	39.24	
	STD	13.87	13.54	13.66	13.60	12.79	13.20	13.65	13.23	13.52	
	Median	40.00	40.00	40.00	30.00	41.00	37.00	39.00	40.00	40.00	
	Min	16	16	16	17	15	15	17	15	15	
	Max	64	64	64	61	64	64	64	64	64	
	unknown	14	17	31	11	13	24	25	30	55	
Number of previous episodes	No.	47	47	94	19	25	44	66	72	138	
	Mean	2.57	3.62	3.10	3.53	4.24	3.93	2.85	3.83	3.36	
	STD	2.24	3.35	2.86	3.42	7.94	6.34	2.64	5.35	4.29	
	Median	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	Min	1	1	1	1	1	1	1	1	1	
	Max	10	15	15	11	40	40	11	40	40	

PHARMACIA CNS R&D

RESONIUM - PROTOCOL 2012A/017

TABLE No.: 11

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

		Sex									
		Female			Male			Total			
		Imipramine	Reboxetine	Total	Imipramine	Reboxetine	Total	Imipramine	Reboxetine	Total	
Duration of last episode (weeks)	No.	48	45	93	20	26	46	68	71	139	
	Mean	20.08	15.27	17.75	18.20	19.96	19.20	19.53	16.99	18.23	
	STD	14.90	10.36	13.06	14.67	24.20	20.42	14.75	16.79	15.62	
	Median	16.00	12.00	16.00	14.00	12.00	12.00	16.00	12.00	16.00	
	Min	2	3	2	4	4	4	2	3	2	
	Max	56	52	56	60	125	125	60	125	125	
Duration of present episode (weeks)	No.	83	83	166	43	46	89	126	129	255	
	Mean	8.43	8.75	8.61	8.79	7.11	7.93	8.59	8.17	8.37	
	STD	3.94	5.81	4.95	3.79	3.48	3.71	3.89	5.15	4.57	
	Median	8.00	8.00	8.00	8.00	6.00	8.00	8.00	7.00	8.00	
	Min	2	1	1	3	2	2	2	1	1	
	Max	16	48	48	16	16	16	16	48	48	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 12

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

Sex: Female

		Imipramine		Reboxetine		Total	
		No	%	No	%	No	%
Charact. of present episode	Exacerbation of chronic cond.	5	6.02	11	13.10	16	9.58
	Recurrence of similar prev. cond.	44	53.01	42	50.00	86	51.50
	Different from any prev. cond.	1	1.20	5	5.95	6	3.59
	First occurence	33	39.76	26	30.95	59	35.33
	Total	83	100.00	84	100.00	167	100.00
Onset of present episode	Acute (< 2 weeks)	7	8.43	5	5.95	12	7.19
	Subacute (>= 2 & < 12 weeks)	50	60.24	52	61.90	102	61.08
	Insidious (>= 3 months)	26	31.33	26	30.95	52	31.14
	Unknown			1	1.19	1	0.60
	Total	83	100.00	84	100.00	167	100.00
Precipit. external stress	Absent	23	27.71	34	40.48	57	34.13
	Probably present	35	42.17	28	33.33	63	37.72
	Definitely present	25	30.12	22	26.19	47	28.14
	Total	83	100.00	84	100.00	167	100.00

PHARMACIA CNS R&D

EBOXETINE - PROTOCOL 20124/017
TABLE No.: 12

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

Sex: Male

		Imipramine		Reboxetine		Total	
		No	%	No	%	No	%
Charact. of present episode	Exacerbation of chronic cond.	4	9.30	4	8.70	8	8.99
	Recurrence of similar prev. cond.	16	37.21	23	50.00	39	43.82
	Different from any prev. cond.	5	11.63	1	2.17	6	6.74
	First occurrence	18	41.86	18	39.13	36	40.45
	Total	43	100.00	46	100.00	89	100.00
Onset of present episode	Acute (< 2 weeks)	4	9.30	6	13.04	10	11.24
	Subacute (>= 2 & < 12 weeks)	21	48.84	28	60.87	49	55.06
	Insidious (>= 3 months)	18	41.86	12	26.09	30	33.71
	Total	43	100.00	46	100.00	89	100.00
Precipit. external stress	Absent	13	30.23	18	39.13	31	34.83
	Probably present	16	37.21	17	36.96	33	37.08
	Definitely present	14	32.56	11	23.91	25	28.09
	Total	43	100.00	46	100.00	89	100.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 12

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY SEX AND ASSIGNED TREATMENT

All patients

		Imipramine		Reboxetine		Total	
		No	%	No	%	No	%
Charact. of present episode	Exacerbation of chronic cond.	9	7.14	15	11.54	24	9.38
	Recurrence of similar prev. cond.	60	47.62	65	50.00	125	48.83
	Different from any prev. cond.	6	4.76	6	4.62	12	4.69
	First occurence	51	40.48	44	33.85	95	37.11
	Total	126	100.00	130	100.00	256	100.00
Onset of present episode	Acute (< 2 weeks)	11	8.73	11	8.46	22	8.59
	Subacute (>= 2 & < 12 weeks)	71	56.35	80	61.54	151	58.98
	Insidious (>= 3 months)	44	34.92	38	29.23	82	32.03
	Unknown			1	0.77	1	0.39
	Total	126	100.00	130	100.00	256	100.00
Precipit. external stress	Absent	36	28.57	52	40.00	88	34.38
	Probably present	51	40.48	45	34.62	96	37.50
	Definitely present	39	30.95	33	25.38	72	28.13
	Total	126	100.00	130	100.00	256	100.00

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 13

PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Assigned treatment				Total	
	Reboxetine		Idpcamine			
	No	%	No	%	No	%
Screened patient	130	100.0	126	100.0	256	100.0
AMITRIPTYLINE	21	16.2	16	12.7	37	14.5
KIANSERIN	15	11.5	10	7.9	25	9.8
DOSULEPIN	9	6.9	15	11.9	24	9.4
MAPROTILINE	9	6.9	12	9.5	21	8.2
CLOMIPRAMINE	8	6.2	8	6.3	16	6.3
FLUOXETINE	9	6.9	6	4.8	15	5.9
TRAZODONE	6	4.6	4	3.2	10	3.9
IMIPRAMINE	6	4.6	4	3.2	10	3.9
DOXEPIN	4	3.1	5	4.0	9	3.5
CITALOPRAM	1	0.8	5	4.0	6	2.3
NOCLOBEMIDE	3	2.3	2	1.6	5	2.0
FLUVOXAMINE	3	2.3	1	0.8	4	1.6
LITHIUM	3	2.3	1	0.8	4	1.6
TRIMIPRAMINE	3	2.3	1	0.8	4	1.6
MELITRACEN	2	1.5	1	0.8	3	1.2
VLOXAZINE	1	0.8	2	1.6	3	1.2
DESIPRAMINE	1	0.8	2	1.6	3	1.2
OPIPRAMOL			2	1.6	2	0.8
TRANYLCYPROMINE	1	0.8	1	0.8	2	0.8
NORTRIPTYLINE	1	0.8	1	0.8	2	0.8
PHENELZINE			1	0.8	1	0.4
OXITRIPTAN	1	0.8			1	0.4

(CONTINUED)

9550085

PHARMACIA CMS R&D

PERGOLIDE - PROTOCOL 20124/017
TABLE No.: 13

PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Assigned treatment:				Total	
	Reboxetine		Imipramine			
	No	%	No	%	No	%
PARKINSTINE	1	0.8			1	0.4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female						Male						Total					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
Screened patients	84	100	83	100	167	100	46	100	43	100	89	100	130	100	126	100	256	100
OTHER GU NEOPLASM NOS	5	6.0	2	2.4	7	4.2	1	2.2			1	1.1	6	4.6	2	1.6	8	3.1
UTERINE LEIOMYOMA	2	2.4	4	4.8	6	3.6							2	1.5	4	3.2	6	2.3
HYPERTENSION NOS	2	2.4	4	4.8	6	3.6	3	6.5	1	2.3	4	4.5	5	3.8	5	4.0	10	3.9
SPONDYLOSIS NOS	2	2.4	4	4.8	6	3.6							2	1.5	4	3.2	6	2.3
HYPOTENSION NOS	3	3.6	1	1.2	4	2.4							3	2.3	1	0.8	4	1.6
PURE HYPERCHOLESTEROLEM	1	1.2	2	2.4	3	1.8	1	2.2			1	1.1	2	1.5	2	1.6	4	1.6
ANEMIA NOS	2	2.4			2	1.2							2	1.5			2	0.8
VARICOSE VEIN OF LEG NOS	2	2.4			2	1.2							2	1.5			2	0.8
GASTRITIS/DUODENITIS NOS	2	2.4			2	1.2							2	1.5			2	0.8
CHOLELITHIASIS NOS	2	2.4	1	1.2	3	1.8	1	2.2	1	2.3	2	2.2	3	2.3	2	1.6	5	2.0
URIN TRACT INFECTION NOS	2	2.4			2	1.2							2	1.5			2	0.8
ARTHROPATHY NOS	2	2.4			2	1.2							2	1.5			2	0.8
ANGINA PECTORIS									2	4.7	2	2.2			2	1.6	2	0.8
NONTOX NODUL GOITER NOS							2	4.3			2	2.2	2	1.5			2	0.8
DIABETES MELLITUS UNCOMP							2	4.3			2	2.2	2	1.5			2	0.8
MALIGN NEOPL BREAST NOS			1	1.2	1	0.6									1	0.8	1	0.4
MALIGN NEOPL OVARY			1	1.2	1	0.6									1	0.8	1	0.4
THYROTOXICOSIS			1	1.2	1	0.6									1	0.8	1	0.4
DIABETES MELLITUS			1	1.2	1	0.6			1	2.3	1	1.1			2	1.6	2	0.8
HYPERLIPIDEMIA NEC/NOS	1	1.2	1	1.2	2	1.2							1	0.8	1	0.8	2	0.8
PHOBIC DISORDERS			1	1.2	1	0.6									1	0.8	1	0.4

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female						Male						Total					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
CONTACT DERMATITIS			1	1.2	1	0.6									1	0.8	1	0.4
INTERVERTEBRAL DISC DIS			1	1.2	1	0.6									1	0.8	1	0.4
LUMBAGO	1	1.2	1	1.2	2	1.2	1	2.2			1	1.1	2	1.5	1	0.8	3	1.2
OSTEOCHONDROPATHY NOS			1	1.2	1	0.6									1	0.8	1	0.4
OSTEOPOROSIS			1	1.2	1	0.6									1	0.8	1	0.4
URINARY SYSTEM SYMPTOMS			1	1.2	1	0.6									1	0.8	1	0.4
DIARRHEA OF INFECT ORIG	1	1.2			1	0.6							1	0.8			1	0.4
SCARLET FEVER	1	1.2			1	0.6							1	0.8			1	0.4
MAL NEO CERVIX UTERI NOS	1	1.2			1	0.6							1	0.8			1	0.4
NEOPLASM NOS, SITE NEC	1	1.2			1	0.6							1	0.8			1	0.4
NONTOXIC NODULAR GOITER	1	1.2			1	0.6							1	0.8			1	0.4
HYPOTHYROIDISM NOS	1	1.2			1	0.6							1	0.8			1	0.4
IRON DEFICIENCY ANEMIAS	1	1.2			1	0.6							1	0.8			1	0.4
ALCOHOL DEPENDENCE SYNDR	1	1.2			1	0.6							1	0.8			1	0.4
PSYCHOGENIC SKIN DISEASE	1	1.2			1	0.6							1	0.8			1	0.4
CARPAL TUNNEL SYNDROME	1	1.2			1	0.6							1	0.8			1	0.4
ACUTE IRIDOCYCLITIS	1	1.2			1	0.6							1	0.8			1	0.4
DIS TYMPANIC MEMB NEC	1	1.2			1	0.6							1	0.8			1	0.4
MENIERE DISEASE	1	1.2			1	0.6							1	0.8			1	0.4
OTOSCLEROSIS NOS	1	1.2			1	0.6							1	0.8			1	0.4
RHEUM FEV W/O HRT INVOLV	1	1.2			1	0.6							1	0.8			1	0.4
ACUTE TONSILLITIS	1	1.2			1	0.6	1	2.2			1	1.1	2	1.5			2	0.8

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female						Male						Total					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
TINNITUS			1	1.2	1	0.6	1	2.2			1	1.1	1	0.8	1	0.8	2	0.8
TRANSIENT CEREB ISCHEMIA			1	1.2	1	0.6									1	0.8	1	0.4
VARICOSE VEINS, LEG			1	1.2	1	0.6									1	0.8	1	0.4
ORTHOSTATIC HYPOTENSION			1	1.2	1	0.6									1	0.8	1	0.4
BRONCHITIS NOS			1	1.2	1	0.6									1	0.8	1	0.4
ASTHMA NOS			1	1.2	1	0.6	1	2.2	1	2.3	2	2.2	1	0.8	2	1.6	3	1.2
DUODENAL ULCER NOS	1	1.2	1	1.2	2	1.2	1	2.2			1	1.1	2	1.5	1	0.8	3	1.2
PEPTIC ULCER NOS			1	1.2	1	0.6									1	0.8	1	0.4
ATROPHIC GASTRITIS			1	1.2	1	0.6			1	2.3	1	1.1			2	1.6	2	0.8
DIAPHRAGMATIC HERNIA			1	1.2	1	0.6			1	2.3	1	1.1			2	1.6	2	0.8
DIVERTICULA OF COLON			1	1.2	1	0.6									1	0.8	1	0.4
IRRITABLE COLON			1	1.2	1	0.6									1	0.8	1	0.4
ANAL FISTULA			1	1.2	1	0.6									1	0.8	1	0.4
RECTAL PROLAPSE			1	1.2	1	0.6									1	0.8	1	0.4
CHOLEDOCHOLITHIASIS NOS			1	1.2	1	0.6									1	0.8	1	0.4
ACUTE PANCREATITIS			1	1.2	1	0.6									1	0.8	1	0.4
FEMALE PELVIC INFLAM DIS			1	1.2	1	0.6									1	0.8	1	0.4
PROLAPSE OF VAGINAL WALL			1	1.2	1	0.6									1	0.8	1	0.4
NONINFL DIS OVA/ADNX NOS			1	1.2	1	0.6									1	0.8	1	0.4
EXCESSIVE MENSTRUATION			1	1.2	1	0.6									1	0.8	1	0.4
UNSPECIFIED ABORTION			1	1.2	1	0.6									1	0.8	1	0.4
CESAREAN DELIVERY NOS	1	1.2	1	1.2	2	1.2							1	0.8	1	0.8	2	0.8

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female						Male						Total					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
PNEUMONIA, ORGANISM NOS	1	1.2			1	0.6							1	0.8			1	0.4
STOMACH ULCER NOS	1	1.2			1	0.6	1	2.2			1	1.1	2	1.5			2	0.8
INTESTINAL DISORDER NOS	1	1.2			1	0.6							1	0.8			1	0.4
HEPATITIS NOS	1	1.2			1	0.6							1	0.8			1	0.4
ATONY OF BLADDER	1	1.2			1	0.6							1	0.8			1	0.4
NONINFLAM DIS OVAR/ADNEX	1	1.2			1	0.6							1	0.8			1	0.4
METRORRHAGIA	1	1.2			1	0.6							1	0.8			1	0.4
THORAC/LUMB DISC DISPLAC	1	1.2			1	0.6	1	2.2			1	1.1	2	1.5			2	0.8
DISC DISPLACEMENT NOS	1	1.2			1	0.6							1	0.8			1	0.4
CERVICAL DISC DEGEN	1	1.2			1	0.6							1	0.8			1	0.4
DISC DEGENERATION NOS	1	1.2			1	0.6							1	0.8			1	0.4
CERVICOCRANIAL SYNDROME	1	1.2			1	0.6							1	0.8			1	0.4
LUMBOSACRAL NEURITIS NOS	1	1.2			1	0.6							1	0.8			1	0.4
JAUNDICE NOS	1	1.2			1	0.6							1	0.8			1	0.4
OTHER BRAIN INJURY	1	1.2			1	0.6							1	0.8			1	0.4
BRAIN INJURY NEC	1	1.2			1	0.6							1	0.8			1	0.4
UNC BEHAV NEO BONE									1	2.3	1	1.1			1	0.8	1	0.4
SCIATIC NERVE LESION									1	2.3	1	1.1			1	0.8	1	0.4
OTITIS MEDIA NOS									1	2.3	1	1.1			1	0.8	1	0.4
ESSENTIAL HYPERTENSION									1	2.3	1	1.1			1	0.8	1	0.4
ATHEROSCLEROSIS NOS									1	2.3	1	1.1			1	0.8	1	0.4
CIRCULATORY DISEASE NOS									1	2.3	1	1.1			1	0.8	1	0.4

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female						Male						Total					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
ALLERGIC RHINITIS NOS									1	2.3	1	1.1			1	0.8	1	0.4
OBSTRUCT CHR BRONCHITIS									1	2.3	1	1.1			1	0.8	1	0.4
STOMACH FUNCTION DIS NOS									1	2.3	1	1.1			1	0.8	1	0.4
CHR LIVER DIS/CIRRHOSIS									1	2.3	1	1.1			1	0.8	1	0.4
CHRONIC PROSTATITIS							1	2.2	1	2.3	2	2.2	1	0.8	1	0.8	2	0.8
POLYARTHRITIS NOS									1	2.3	1	1.1			1	0.8	1	0.4
MONOARTHRITIS NOS									1	2.3	1	1.1			1	0.8	1	0.4
NEURALGIA/NEURITIS NOS									1	2.3	1	1.1			1	0.8	1	0.4
OTH MUSCULOSKELET ANOMAL									1	2.3	1	1.1			1	0.8	1	0.4
DIZZINESS AND GIDDINESS									1	2.3	1	1.1			1	0.8	1	0.4
OTH SALMONELLA INFECTION							1	2.2			1	1.1	1	0.8			1	0.4
BREAST NEOPLASM NOS							1	2.2			1	1.1	1	0.8			1	0.4
GOUT NOS							1	2.2			1	1.1	1	0.8			1	0.4
AUTOIMMUNE DISEASE NEC							1	2.2			1	1.1	1	0.8			1	0.4
PSYCHOSEXUAL DYSFUNCTION							1	2.2			1	1.1	1	0.8			1	0.4
AUTONOMIC NERVE DIS NEC							1	2.2			1	1.1	1	0.8			1	0.4
ACUTE MYOCARDIAL INFARCT							1	2.2			1	1.1	1	0.8			1	0.4
OLD MYOCARDIAL INFARCT							1	2.2			1	1.1	1	0.8			1	0.4
CHRONIC TONSILLITIS							1	2.2			1	1.1	1	0.8			1	0.4
ASTHMA							1	2.2			1	1.1	1	0.8			1	0.4
ACUTE APPENDICITIS							1	2.2			1	1.1	1	0.8			1	0.4
APPENDICITIS NOS							1	2.2			1	1.1	1	0.8			1	0.4

(CONTINUED)

PHARMACIA CRS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 14

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY SEX AND ASSIGNED TREATMENT

Previous diseases	Female						Male						Total					
	Reboxetine		Ingrenine		Total		Reboxetine		Ingrenine		Total		Reboxetine		Ingrenine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
INGUINAL HERNIA							1	2.2			1	1.1	1	0.8			1	0.4
MALE INFERTILITY							1	2.2			1	1.1	1	0.8			1	0.4
OTHER PSORIASIS							1	2.2			1	1.1	1	0.8			1	0.4
OSTEOARTHROSIS NOS							1	2.2			1	1.1	1	0.8			1	0.4
CERVICAL SYNDROME NEC							1	2.2			1	1.1	1	0.8			1	0.4
BACKACHE NOS							1	2.2			1	1.1	1	0.8			1	0.4
SHOULDER REGION DIS NEC							1	2.2			1	1.1	1	0.8			1	0.4
ENTHESOPATHY OF ELBOW							1	2.2			1	1.1	1	0.8			1	0.4
ABN BLOOD CHEMISTRY NEC							1	2.2			1	1.1	1	0.8			1	0.4
FX ANKLE NOS-CLOSED							1	2.2			1	1.1	1	0.8			1	0.4
SPINAL CORD INJURY NOS							1	2.2			1	1.1	1	0.8			1	0.4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 15

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY BODY SYSTEM, SEX AND ASSIGNED TREATMENT

Previous diseases (body system)	Female						Male						Total					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.
Screened Patients	84	100	83	100	167	100	46	100	43	100	89	100	130	100	126	100	256	100
NEOPLASM	9	10.7	8	9.6	17	10.2	2	4.3	1	2.3	3	3.4	11	8.5	9	7.1	20	7.8
CIRCULATORY SYSTEM	7	8.3	7	8.4	14	8.4	5	10.9	5	11.6	10	11.2	12	9.2	12	9.5	24	9.4
MUSCOLOSKELETAL SYS. AND CONNETIVE TISSUE	8	9.5	7	8.4	15	9.0	5	10.9	3	7.0	8	9.0	13	10.0	10	7.9	23	9.0
ENDOCR., NUTRIT. AND METAB. DISEASES	4	4.8	5	6.0	9	5.4	6	13.0	1	2.3	7	7.9	10	7.7	6	4.8	16	6.3
BLOOD AND BLOOD-FORMING ORGANS	3	3.6			3	1.8							3	2.3			3	1.2
DIGESTIVE SYSTEM	8	9.5	9	10.8	17	10.2	6	13.0	5	11.6	11	12.4	14	10.8	14	11.1	28	10.9
GENITOURINARY SYSTEM	4	4.8	4	4.8	8	4.8	2	4.3	1	2.3	3	3.4	6	4.6	5	4.0	11	4.3
MENTAL DISORDERS	2	2.4	1	1.2	3	1.8	1	2.2			1	1.1	3	2.3	1	0.8	4	1.6
NERVOUS SYSTEM AND SENSE ORGANS	5	6.0	1	1.2	6	3.6	2	4.3	2	4.7	4	4.5	7	5.4	3	2.4	10	3.9
RESPIRATORY SYSTEM	2	2.4	2	2.4	4	2.4	4	8.7	3	7.0	7	7.9	6	4.6	5	4.0	11	4.3
PREGNANCY,CHILDBIRTH AND PUERPERIUM	1	1.2	2	2.4	3	1.8							1	0.8	2	1.6	3	1.2
SKIN AND SUBCUTANEOUS TISSUE			1	1.2	1	0.6	1	2.2			1	1.1	1	0.8	1	0.8	2	0.8
SYMPTOMS, SIGNS AND ILL DEFINED CONDITIONS	1	1.2	1	1.2	2	1.2	1	2.2	1	2.3	2	2.2	2	1.5	2	1.6	4	1.6
INFECTIOUS AND PARASITTIC DISEASE	2	2.4			2	1.2	1	2.2			1	1.1	3	2.3			3	1.2
INJURY AND POISONING	2	2.4			2	1.2	2	4.3			2	2.2	4	3.1			4	1.6
CONGENITAL ANOMALIES									1	2.3	1	1.1			1	0.8	1	0.4

PHARMACIA CN@5@0085

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 16

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

days of treatment		Dose (mg/day)																		Total	
		0		4		6		8		10		12		14		16		20			
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Day 0	1			11	8.5			119	91.5											130	100
	2							128	100											128	100
	3			4	3.1			124	96.9											128	100
	4			1	0.8			125	99.2											126	100
	5	1	0.8	2	1.6			121	97.6											124	100
	6	2	1.6	1	0.8			120	97.6											123	100
	7	1	0.8	3	2.5			116	96.7											120	100
	8							1	100											1	100
Day 7	1	1	0.8					118	99.2											119	100
	2			4	3.4			114	96.6											118	100
	3							116	100											116	100
	4			1	0.9			114	99.1											115	100
	5			1	0.9			114	99.1											115	100
	6			2	1.8			111	97.4			1	0.9							114	100
	7	1	0.9	1	0.9			111	98.2											113	100
	8							3	100											3	100
Day 14	1			3	2.7			110	97.3											113	100
	2	1	0.9	2	1.8			110	97.3											113	100
	3	1	0.9	4	3.5			108	95.6											113	100
	4	1	0.9	3	2.7			109	96.5											113	100
	5	1	0.9	1	0.9			110	98.2											112	100
	6			2	1.8			108	97.3			1	0.9							111	100
	7			3	2.8			105	97.2											108	100
	8			1	100															1	100
Day 21	1	1	0.9	1	0.9			94	87.9	9	8.4					1	0.9	1	0.9	107	100
	2	1	0.9	2	1.9			92	86.8	9	8.5					1	0.9	1	0.9	106	100
	3			2	1.9			93	87.7	9	8.5					1	0.9	1	0.9	106	100
	4	1	0.9					92	86.8	9	8.5			2	1.9	2	1.9			106	100
	5	1	0.9	1	0.9			91	85.8	10	9.4					3	2.8			106	100
	6			1	0.9			92	86.8	10	9.4					3	2.8			106	100
	7			1	1.0			91	87.5	9	8.7					3	2.9			104	100
	8							3	100											3	100
Day 28	1							89	85.6	12	11.5					3	2.9			104	100
	2			3	2.9			86	82.7	12	11.5					3	2.9			104	100
	3			1	1.0			87	84.5	12	11.7					3	2.9			103	100
	4			2	2.0			85	83.3	12	11.8					3	2.9			102	100
	5	1	1.0	1	1.0			85	83.3	12	11.8					3	2.9			102	100
	6			1	1.0	1	1.0	86	84.3	11	10.8					3	2.9			102	100
	7			2	2.0			84	83.2	12	11.9					3	3.0			101	100
Day 35	1							83	83.0	14	14.0			1	1.0	2	2.0			100	100
	2			1	1.0	1	1.0	82	82.0	13	13.0			1	1.0	2	2.0			100	100
	3	1	1.0	4	4.0			80	80.0	12	12.0			1	1.0	2	2.0			100	100
	4			4	4.0			79	79.0	14	14.0			1	1.0	2	2.0			100	100
	5			4	4.0			79	79.0	14	14.0			1	1.0	2	2.0			100	100
	6			1	1.0			81	81.8	14	14.1			1	1.0	2	2.0			99	100
	7			3	3.1			80	81.6	13	13.3			1	1.0	1	1.0			98	100
	8			8	57.1			4	28.6	2	14.3									14	100
	9			1	100															1	100

PHARMACIA CNDS90085

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 16

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

days of treatment		Dose (mg/day)																Total	
		0		50		100		150		200		250		300		350			
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Day 0	1			20	15.9	106	84.1											126	100
	2			4	3.2	120	96.8											124	100
	3			2	1.7	119	98.3											121	100
	4			3	2.5			114	96.6					1	0.8			118	100
	5			2	1.8			111	97.4			1	0.9					114	100
	6	1	0.9	2	1.8	1	0.9	109	95.6	1	0.9							114	100
	7	1	0.9	1	0.9			111	98.2									113	100
	8							5	100									5	100
	9							1	100									1	100
Day 7	1					1	0.9	107	97.3	2	1.8							110	100
	2			3	2.7			106	96.4	1	0.9							110	100
	3							108	99.1	1	0.9							109	100
	4			1	0.9			107	98.2	1	0.9							109	100
	5	1	0.9					107	98.2	1	0.9							109	100
	6							108	99.1	1	0.9							109	100
	7	1	0.9	1	0.9			104	97.2	1	0.9							107	100
	8							2	100									2	100
Day 14	1					1	0.9	106	98.1			1	0.9					108	100
	2			1	0.9	1	0.9	105	97.2							1	0.9	108	100
	3							106	99.1							1	0.9	107	100
	4					1	0.9	104	98.1							1	0.9	106	100
	5			1	0.9	2	1.9	102	96.2							1	0.9	106	100
	6					1	1.0	103	98.1							1	1.0	105	100
	7	1	1.0	3	2.9			98	93.3			1	1.0			2	1.9	105	100
Day 21	1			1	1.0			80	80.8	13	13.1	1	1.0	1	1.0	3	3.0	99	100
	2	1	1.0			1	1.0	78	79.6	13	13.3					5	5.1	98	100
	3					1	1.0	79	81.4	12	12.4					5	5.2	97	100
	4			1	1.0	2	2.1	78	80.4	11	11.3					5	5.2	97	100
	5	2	2.1	1	1.0			75	78.1	13	13.5	1	1.0			4	4.2	96	100
	6	2	2.1					76	80.0	13	13.7					4	4.2	95	100
	7	1	1.1	1	1.1	1	1.1	76	80.9	11	11.7					4	4.3	94	100
	8			2	100													2	100
Day 28	1	1	1.1					75	80.6	13	14.0					4	4.3	93	100
	2			1	1.1			73	78.5	13	14.0	3	3.2			3	3.2	93	100
	3			1	1.1			75	80.6	13	14.0					4	4.3	93	100
	4							76	81.7	13	14.0					4	4.3	93	100
	5			1	1.1	1	1.1	74	79.6	13	14.0					4	4.3	93	100
	6							76	81.7	13	14.0					4	4.3	93	100
	7					1	1.1	75	81.5	11	12.0	1	1.1			4	4.3	92	100
	8			1	50.0			1	50.0									2	100
Day 35	1			1	1.1	2	2.2	73	78.5	14	15.1	2	2.2			1	1.1	93	100
	2			2	2.2	2	2.2	74	80.4	13	14.1					1	1.1	92	100
	3			2	2.2	1	1.1	74	80.4	14	15.2					1	1.1	92	100
	4			1	1.1			75	82.4	14	15.4					1	1.1	91	100
	5			1	1.1	1	1.1	74	82.2	13	14.4					1	1.1	90	100
	6			1	1.1			74	82.2	14	15.6					1	1.1	90	100
	7			1	1.1			73	82.0	14	15.7					1	1.1	89	100
	8			7	50.0			6	42.9	1	7.1							14	100
	9			1	100													1	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/047
TABLE No.: 16.1

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS WHO SWITCHED FROM LOW TO HIGH DOSE BY ASSIGNED TREATMENT

		Total		visit of first change in dose						
		No	%	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	
Isipramine	always low dose	101	80.16	101						
	at least one high dose	25	19.84		1	2	16	4	2	
	Total	126	100.00	101	1	2	16	4	2	
Reboxetine	always low dose	108	83.08	108						
	at least one high dose	22	16.92				13	5	4	
	Total	130	100.00	108			13	5	4	

PHARMACIA CNS BSD

REBOXETINE - PROTOCOL 2012A/017

TABLE No.: 17

EXPERIMENTAL TREATMENT: DISTRIBUTION OF PATIENTS ACCORDING TO CAPSULES TAKEN BY ASSIGNED TREATMENT

	Compliance										Total	
	< 80 %		80 - 89 %		90 - 95 %		95 - 99 %		100 %			
	No	%	No	%	No	%	No	%	No	%	No	%
Indpramine	4	3.2	3	2.4	8	6.3	31	24.6	80	63.5	126	100.0
Reboxetine	2	1.5	3	2.3	10	7.7	31	23.8	84	64.6	130	100.0
Total	6	2.3	6	2.3	18	7.0	62	24.2	164	64.1	256	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment		During treatment		Total	
	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
	No.	No.	No.	No.	No.	No.
CHLORAL HYDRATE	17	23	10	13	27	36
CLOMETHIAZOLE	1	3	7	5	8	8
PARACETAMOL			7	7	7	7
NARVELON	5	3			5	3
ACETYLSALICYLIC ACID	1		2	4	3	4
DIAZEPAM			2	2	2	2
LEVOTHYROXINE		3		1		4
SENNA			2	2	2	2
CODIPRONT			1	3	1	3
LACTULOSE			2	2	2	2
LORAZEPAM			3	1	3	1
DICLOFENAC		2	2		2	2
SERENOA REPENS		1	1	2	1	3
VERAPAMIL	1			2	1	2
DIHYDROERGOTAMINE		1	1	1	1	2
ACETYLCYSTEINE			1	2	1	2
BACTRIM				3		3
AMOXICILLIN	1		1	1	2	1
LOPERAMIDE			1	2	1	2
PIROXICAM		1	1	1	1	2
ENALAPRIL	2	1			2	1
NITRENDIPINE	2	1			2	1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment		During treatment		Total	
	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
	No.	No.	No.	No.	No.	No.
ALLOPURINOL		2				2
ASCORBIC ACID				2		2
CODEINE			1	1	1	1
METOCLOPRAMIDE			1	1	1	1
DOXYCYCLINE				2		2
IBUPROFEN			1	1	1	1
SALBUTAMOL	1		1		2	
GLYCEROL				2		2
NODURETIC		1		1		2
BECLOMETASONE	1	1			1	1
NIFEDIPINE				2		2
SODIUM PICOSULFATE			1	1	1	1
BROMAZEPAM		2				2
LORMETAZEPAM	1	1			1	1
ACTIFED				1		1
HYOSCINE				1		1
THEOPHYLLINE	1				1	
COLCHICINE	1				1	
CYCLIZINE			1		1	
PREDNISOLONE			1		1	
DIGITOXIN				1		1
ERYTHROMYCIN			1		1	

(CONTINUED)

PHARMACIA CEE BAD

RESONIUM - PROTOCOL 20124/017
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment		During treatment		Total	
	Indpramine	Reboxetine	Indpramine	Reboxetine	Indpramine	Reboxetine
	No.	No.	No.	No.	No.	No.
EPHEDRINE				1		1
EUGYNON		1				1
HYDERGIN	1				1	
PROPRANOLOL			1		1	
RESERPINE/PLINE		1				1
MEFENAMIC ACID				1		1
TRICLOFOS			1		1	
TROXERUTIN		1				1
CAFERGOT				1		1
SACCHARATED IRON OXIDE		1				1
ESTROGENS CONJUGATED			1		1	
HYDROXYPROGESTERONE	1				1	
DYAZIDE	1				1	
CROMOGLICIC ACID	1				1	
STILNOX			1		1	
CALCIUM CARBONATE				1		1
FLUPENTIXOL		1				1
PANADEINE CO	1				1	
MAGNESIUM HYDROXIDE		1				1
MAGALDRATE				1		1
BETAHISTINE	1				1	
GLIBENCLAMIDE	1				1	

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment		During treatment		Total	
	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
	No.	No.	No.	No.	No.	No.
NIFURTOINOL				1		1
CITRIC ACID				1		1
TERBUTALINE	1				1	
TILIDINE			1		1	
GINKGO TREE LEAVES EXTRACT	1				1	
COLD CAPSULES			1		1	
BISOXATIN				1		1
CLORAZEPIC ACID				1		1
FLAVOXATE		1				1
PENTOXIFYLLINE				1		1
CETYLPYRIDINIUM				1		1
RINOMAR			1		1	
CODIS				1		1
PRAZOSIN		1				1
SITOSTEROLS		1				1
GYNODIAN-DEPOT	1				1	
MELITRACEN		1				1
METOPROLOL	1				1	
DEMETINDE			1		1	
GLIPIZIDE		1				1
CIMETIDINE		1				1
CARBOCISTEINE				1		1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 18

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment		During treatment		Total	
	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
	No.	No.	No.	No.	No.	No.
ATENOLOL				1		1
SUPRADYN				1		1
DOMPERIDONE	1				1	
CAPTOPRIL			1		1	
PINAVERIUM	1				1	
FLUNARIZINE		1				1
DIANE		1				1
BEZAFIBRATE	1				1	
AMBROXOL		1				1
SULFARLEM-CHOLINE			1		1	
SINUPRET				1		1
ARABANTIN	1				1	
PANKREATAN COMP.	1				1	
EFFORTIL PLUS	1				1	
ACETYLDIGOXIN		1				1
CLOTIAZEPAM			1		1	
ANEXINIUM	1				1	
INSULIN HUMAN		1				1
OXACEPROL	1				1	
MAGNESIUM VERLA DRAGEES		1				1
OMEPRAZOLE	1				1	
PROSTATIN		1				1

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 16

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND INITIAL PERIOD OF ADMINISTRATION

Concomitant drugs	Before treatment		During treatment		Total	
	Indpramine	Reboxetine	Indpramine	Reboxetine	Indpramine	Reboxetine
	No.	No.	No.	No.	No.	No.
CIPROFLOXACIN				1		1
CALCIUM	1				1	
HYDROXYZEMORINE		1				1
RISPERIDAL	1				1	
BISOPROLOL				1		1
ZIDOVUDINE			1		1	
VENALOT - SLOW RELEASE		1				1
CIMAPRINE			1		1	
PRAVASTATIN		1				1
BERBERINE	1				1	
RANITPEIL	1				1	
LOVASTATIN				1		1
LORAZAMINE				1		1
METOPROTH		1				1
ROCITHROMYCIN				1		1
CYCLOSPOROSPINAL				1		1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 19

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Mean	28.27	28.02	23.75	19.64	17.06	14.15	12.49	10.36
	Median	27	27	25	21	16	13	11	9
	STD	5.60	5.15	7.03	8.38	8.17	8.57	8.17	8.19
	Min	22	19	3	1	1	0	0	0
	Max	43	45	41	40	39	39	37	40
	Mean diff. vs day0 (*)			4.26	8.55	11.20	14.18	15.58	17.64
Reboxetine	No	127	127	127	117	112	107	103	98
	Mean	29.12	28.76	23.54	18.80	15.64	13.50	11.21	9.59
	Median	28	28	23	19	15	13	10	8
	STD	4.82	4.84	7.44	8.85	8.58	8.35	7.47	7.52
	Min	22	16	1	0	0	0	0	0
	Max	50	50	41	40	40	40	37	36
	Mean diff. vs day0 (*)			5.22	10.07	13.34	15.46	17.61	19.27

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1.33	1.33	1.33	1.17	0.83	0.67	0.67	0.50
	Min	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.33	2.33	2.17	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.25	0.50	0.67	0.67	0.83
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1.50	1.50	1.17	1.00	0.83	0.83	0.67	0.50
	Min	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.50	2.50	2.17	2.33	2.33	2.33	1.83	1.83
	Median diff. vs day0 (*)			0.17	0.50	0.67	0.67	0.83	0.92

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1.00	0.83	0.67	0.67	0.50	0.33	0.33	0.17
	Min	0.00	0.17	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.50	2.50	2.00	1.83	1.83	2.17	1.83	2.00
	Median diff. vs day0 (=)			0.17	0.33	0.33	0.50	0.50	0.67
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	0.83	1.00	0.67	0.50	0.33	0.33	0.17	0.17
	Min	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.33	2.33	2.00	2.00	2.00	1.83	1.83	2.00
	Median diff. vs day0 (=)			0.17	0.33	0.50	0.67	0.67	0.83

Median (=): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 20

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: RETARDATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2.00	2.00	1.75	1.50	1.25	1.00	0.75	0.50
	Min	0.75	0.50	0.25	0.00	0.00	0.00	0.00	0.00
	Max	3.25	3.25	3.00	3.00	3.00	3.00	3.25	3.00
	Median diff. vs day0 (*)			0.25	0.50	0.75	1.00	1.25	1.50
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2.25	2.00	1.75	1.50	1.00	0.75	0.75	0.50
	Min	0.50	0.75	0.00	0.00	0.00	0.00	0.00	0.00
	Max	3.25	3.25	3.25	3.00	2.75	2.75	2.25	2.00
	Median diff. vs day0 (*)			0.25	0.50	1.00	1.25	1.25	1.50

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017

TABLE No.: 20

FACTORIALITRATION HAMILTON DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE

Assigned treatment		Visit:								
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Indpramine	No	121	121	121	108	107	98	93	92
	Median	1.33	1.33	1.00	1.00	1.00	0.67	0.67	0.33
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.33	0.33	0.67	0.67	0.67
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1.67	1.67	1.33	1.00	1.00	0.67	0.67	0.67
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)			0.00	0.33	0.67	0.67	0.67	0.83

Median (*): median of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: DEPRESSED MOOD

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	3	3	3	2	2	1	1	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	4	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	3	3	2	2	1	1	1	1
	Min	1	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	4	3

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: GUILT

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2	2	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SUICIDE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	3	2
Reboxetine	No	127	127	127	117	112	107	105	98
	Median	1	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	3	3	3	3	2	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSOMNIA EARLY

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSOMNIA MIDDLE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSOMNIA LATE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1	1	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: WORK AND ACTIVITIES

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	3	3	2	2	2	1	1	1
	Min	1	0	0	0	0	0	0	0
	Max	4	4	4	4	4	4	4	4
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	3	3	2	2	1	1	1	1
	Min	0	1	0	0	0	0	0	0
	Max	4	4	4	4	4	4	4	4

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: RETARDATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: AGITATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	4	3	3	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	4	3	4	3	3	3	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: ANXIETY PSYCHIC

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2	2	2	2	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	4	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	4	4	4	4	4

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: ANXIETY SOMATIC

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	3	3	3	4	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	2	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	4	4	4	3	4	3	3	3

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SOMATIC GASTROINTESTINAL

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SOMATIC GENERAL

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	96	93	92
	Median	2	2	2	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (#): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: GENITAL SYMPTOMS

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	2	2	1	1	1	1	1	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20129/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: HYPOCHONDRIASIS

Assigned treatment			Visit								
			Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine		No	121	121	121	108	107	96	93	92
		Median	1	1	1	1	1	0	0	0
		Min	0	0	0	0	0	0	0	0
		Max	3	3	3	3	3	3	3	3
Reboxetine		No	127	127	127	117	112	107	103	98
		Median	1	1	1	1	1	1	0	0
		Min	0	0	0	0	0	0	0	0
		Max	3	3	3	3	3	4	3	3

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: LOSS OF WEIGHT

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSIGHT

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	1
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1	1	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	1	1

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: DIURNAL VARIATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	1	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	1	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: DEPERSONALIZATION

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	96	93	92
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3	3
Reboxetine	No	127	127	127	117	112	107	105	98
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: PARANOID

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	98	93	92
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	3	2	2	3
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	3	3	2	2	2	1	1	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/047
TABLE No.: 21

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: OBSESSIONAL/COMPULSIVE

Assigned treatment		Visit							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	121	108	107	96	93	92
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2
Reboxetine	No	127	127	127	117	112	107	103	98
	Median	0	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 22

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Mean	24.92	18.00	23.00	24.80	36.00	10.36	13.68
	Median	25	18	25	31	36	9	12
	STD	8.49	16.97	7.73	12.48		8.19	10.31
	Min	14	6	7	5	36	0	0
	Max	48	30	30	34	36	40	48
	Mean diff. vs day0 (*)	1.92	4.50	4.33	8.40	-1.00	17.64	14.34
Reboxetine	No	10	5	5	4	5	98	127
	Mean	24.30	29.20	24.40	26.25	18.60	9.59	12.98
	Median	23	28	29	26	17	8	10
	STD	8.53	9.34	14.05	10.34	9.56	7.52	10.24
	Min	10	16	0	14	9	0	0
	Max	37	40	35	39	29	36	40
	Mean diff. vs day0 (*)	3.20	-2.80	5.20	6.00	9.60	19.27	15.78

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1.33	1.17	1.50	1.50	1.50	0.50	0.67
	Min	0.83	0.67	0.00	0.50	1.50	0.00	0.00
	Max	2.17	1.67	2.00	1.67	1.50	2.00	2.17
	Median diff. vs day0 (*)	0.17	-0.08	0.00	0.17	0.00	0.83	0.67
Reboxetine	No	10	5	5	4	5	98	127
	Median	1.42	1.50	1.67	1.33	1.00	0.50	0.67
	Min	0.83	1.17	0.00	1.00	0.33	0.00	0.00
	Max	1.67	2.33	1.67	2.00	1.67	1.83	2.33
	Median diff. vs day0 (*)	0.00	-0.17	0.00	0.33	0.00	0.92	0.83

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	0.75	0.67	0.67	1.00	1.83	0.17	0.33
	Min	0.50	0.17	0.33	0.00	1.83	0.00	0.00
	Max	1.67	1.17	1.83	2.17	1.83	2.00	2.17
	Median diff. vs day0 (*)	-0.08	0.00	0.00	0.17	0.00	0.67	0.50
Reboxetine	No	10	5	5	4	5	98	127
	Median	1.00	0.67	1.00	0.92	0.33	0.17	0.17
	Min	0.17	0.33	0.00	0.67	0.00	0.00	0.00
	Max	1.67	1.83	1.33	1.67	1.00	2.00	2.00
	Median diff. vs day0 (*)	0.08	-0.17	0.17	0.25	0.33	0.83	0.67

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: RETARDATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1.88	1.13	1.75	1.50	3.25	0.50	0.75
	Min	0.75	0.25	0.25	0.25	3.25	0.00	0.00
	Max	3.00	2.00	2.25	2.50	3.25	3.00	3.25
	Median diff. vs day0 (*)	0.00	0.63	0.25	0.75	-1.75	1.50	1.25
Reboxetine	No	10	5	5	4	5	98	127
	Median	1.75	2.00	2.00	1.63	1.50	0.50	0.75
	Min	0.25	1.50	0.00	0.25	0.50	0.00	0.00
	Max	3.00	3.00	2.75	2.25	2.25	2.00	3.00
	Median diff. vs day0 (*)	0.38	-0.25	-0.25	0.75	0.75	1.50	1.25

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 23

FACTORIALISATION HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1.00	0.83	1.00	2.00	1.00	0.33	0.67
	Min	0.00	0.00	0.00	0.00	1.00	0.00	0.00
	Max	2.00	1.67	2.00	2.00	1.00	2.00	2.00
	Median diff. vs day0 (*)	0.00	0.33	0.33	0.00	1.00	0.67	0.67
Reboxetine	No	10	5	5	4	5	98	127
	Median	1.17	1.67	1.33	1.67	1.00	0.67	0.67
	Min	0.00	0.33	0.00	0.67	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.17	0.33	0.83	0.67

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: DEPRESSED MOOD

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	3	2	3	3	4	1	1
	Min	1	0	0	0	4	0	0
	Max	4	3	4	4	4	3	4
Reboxetine	No	10	5	5	4	5	98	127
	Median	3	3	3	2	3	1	1
	Min	1	2	0	1	1	0	0
	Max	4	4	3	3	4	3	4

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: GUILT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	1	1	2	3	0	0
	Min	0	0	0	0	3	0	0
	Max	3	1	2	3	3	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	1	2	2	1	0	0
	Min	0	0	0	2	0	0	0
	Max	3	3	2	2	1	2	3

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SUICIDE

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Indpramine	No	12	2	9	5	1	92	121
	Median	1	1	1	1	3	0	0
	Min	0	0	0	0	3	0	0
	Max	3	1	3	3	3	2	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	3	2	2	2	2	3

Median (#): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSOMNIA EARLY

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Inigrexine	No	12	2	9	5	1	92	121
	Median	2	1	1	2	0	0	1
	Min	0	0	0	0	0	0	0
	Max	2	1	2	2	0	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	2	1	2	1	1	1
	Min	0	1	0	0	0	0	0
	Max	2	2	2	2	2	2	2

Median (#): mean of differences vs day0

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSOMNIA MIDDLE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	1	1	2	1	0	1
	Min	0	0	0	0	1	0	0
	Max	2	2	2	2	1	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	1	1	2	1	0	1
	Min	0	0	0	2	0	0	0
	Max	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSOMNIA LATE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	1	1	2	2	0	0
	Min	0	0	0	0	2	0	0
	Max	2	2	2	2	2	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	2	2	2	1	1	1
	Min	0	0	0	0	0	0	0
	Max	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: WORK AND ACTIVITIES

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	3	2	2	2	4	1	1
	Min	0	1	0	1	4	0	0
	Max	4	3	4	3	4	4	4
Reboxetine	No	10	5	5	4	5	98	127
	Median	3	3	3	3	1	1	1
	Min	0	2	0	0	1	0	0
	Max	4	4	4	4	2	4	4

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: RETARDATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	0	0	0	3	0	0
	Min	0	0	0	0	3	0	0
	Max	3	0	1	1	3	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	1	2	2	3

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/0147
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ABTRATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	2	1	1	1	0	1
	Min	0	0	0	0	1	0	0
	Max	3	3	4	2	1	3	4
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	1	1	1	0	1
	Min	0	1	0	1	0	0	0
	Max	3	3	3	3	2	2	3

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ANXIETY PSYCHIC .

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	2	2	2	3	1	1
	Min	1	1	0	1	3	0	0
	Max	3	2	3	3	3	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	3	2	2	1	1	1
	Min	1	2	0	1	0	0	0
	Max	4	4	3	3	3	4	4

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: ANXIETY SOMATIC

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	2	2	2	0	1	1
	Min	0	1	0	1	0	0	0
	Max	3	2	2	2	0	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	2	2	2	1	0	1
	Min	1	0	0	1	1	0	0
	Max	3	2	2	3	3	3	3

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SOMATIC GASTROINTESTINAL

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	1	1	1	2	0	0
	Min	0	1	0	0	2	0	0
	Max	2	1	2	1	2	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	2	1	1	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SOMATIC GENERAL

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	2	2	2	2	0	1
	Min	1	1	0	0	2	0	0
	Max	2	2	2	2	2	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	2	2	2	1	0	1
	Min	0	1	0	1	1	0	0
	Max	2	2	2	2	2	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: GENITAL SYMPTOMS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	1	1	2	2	0	1
	Min	0	0	0	0	2	0	0
	Max	2	2	2	2	2	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	2	1	1	1	0	0
	Min	0	1	0	0	0	0	0
	Max	2	2	2	2	2	2	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: HYPOCHONDRIASIS

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	2	2	2	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	0	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	1	2	2	1	0	0
	Min	0	0	0	1	0	0	0
	Max	3	3	2	3	2	3	3

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: LOSS OF WEIGHT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	0	2	0	0	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	0	0	1	0	2	2

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSIGHT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	0	0	0	2	0	0
	Min	0	0	0	0	2	0	0
	Max	2	0	1	1	2	1	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	0	1	0	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	1	1	1	1	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: DIURNAL VARIATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	0	0	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	0	2	2	0	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	0	0	0	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	1	2	2	2	2

Median (=): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: DEPERSONALIZATION

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	0	1	0	0	3	0	0
	Min	0	0	0	0	3	0	0
	Max	2	2	1	3	3	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	2	3	1	2	3

Median (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: PARANOID

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	0	0	0	0	1	0	0
	Min	0	0	0	0	1	0	0
	Max	1	0	1	2	1	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	0	0	0	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	1	1	1	2	2

Median (*): mean of differences vs day0

9550085

PHARMACIA CNS R&D

EGOMATINE - PROTOCOL 20124/017
TABLE No.: 24

HAMILTON DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: OBSESSIONAL/COMPULSIVE

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	0	1	0	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	1	1	1	2	0	2	2
Reboxetine	No	10	5	5	4	5	98	127
	Median	0	0	1	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	2	0	1	1	1	2	2

Median (*): mean of differences vs day0

PHARMACIA 0[illegible]0085

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 25

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE OVER TIME BY ASSIGNED TREATMENT

Assigned treatment		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	Patients No.	121	108	107	98	93	92
	Responders No.	9	28	41	53	59	65
	Responders %	7.4	25.9	38.3	54.1	63.4	70.7
	95% L.L.	3.5	18.0	29.1	43.7	52.8	60.2
	95% U.L.	13.7	35.2	48.2	64.2	73.2	79.7
	Remissions No.	4	18	23	40	41	52
	Remissions %	3.3	16.7	21.5	40.8	44.1	56.5
	95% L.L.	0.9	10.2	14.1	31.0	33.8	45.8
	95% U.L.	8.2	25.1	30.5	51.2	54.8	66.8
Reboxetine	Patients No.	127	117	112	107	103	98
	Responders No.	14	35	51	67	79	82
	Responders %	11.0	29.9	45.5	62.6	76.7	83.7
	95% L.L.	6.2	21.8	36.1	52.7	67.3	74.8
	95% U.L.	17.8	39.1	55.2	71.8	84.5	90.4
	Remissions No.	6	23	33	45	53	62
	Remissions %	4.7	19.7	29.5	42.1	51.5	63.3
	95% L.L.	1.8	12.9	21.2	32.6	41.4	52.9
	95% U.L.	10.0	28.0	38.8	52.0	61.4	72.8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 26

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE AT LAST ASSESSMENT VERSUS DAY 0 BY ASSIGNED TREATMENT

	Assigned treatment	
	Imipramine	Reboxetine
Patients No.	121	127
Responders No.	68	87
Responders %	56.2	68.5
95% L.L.	46.9	59.7
95% U.L.	65.2	76.5
Remissions No.	55	66
Remissions %	45.5	52.0
95% L.L.	36.4	42.9
95% U.L.	54.8	60.9

BETWEEN TREATMENT DIFFERENCE AND 95% CONFIDENCE INTERVAL

RESPONDERS (%) : 12.3 (0.3 ; 24.3)
REMISSIONS (%) : 6.5 (-5.9 ; 18.9)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 27

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment/Severity of illness		Visit													
		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	NORMAL					2	1.9	5	4.7	9	9.1	14	15.1	24	26.1
	BORDERLINE MENTALLY ILL			3	2.5	4	3.7	9	8.4	20	20.2	20	21.5	25	27.2
	MILDLY ILL	1	0.8	13	10.7	22	20.6	27	25.2	26	26.3	24	25.8	18	19.6
	MODERATELY ILL	33	27.3	32	26.4	31	29.0	35	32.7	23	23.2	20	21.5	17	18.5
	MARKEDLY ILL	63	52.1	63	52.1	43	40.2	26	24.3	16	16.2	12	12.9	7	7.6
	SEVERELY ILL	22	18.2	9	7.4	5	4.7	5	4.7	5	5.1	2	2.2	1	1.1
	EXTREMELY ILL	2	1.7	1	0.8							1	1.1		
	Total	121	100.0	121	100.0	107	100.0	107	100.0	99	100.0	93	100.0	92	100.0
Reboxetine	NORMAL			1	0.8	3	2.6	6	5.3	10	9.3	16	15.5	26	26.5
	BORDERLINE MENTALLY ILL			2	1.6	14	12.0	22	19.5	22	20.6	25	24.3	29	29.6
	MILDLY ILL	2	1.6	20	15.7	22	18.8	23	20.4	33	30.8	34	33.0	22	22.4
	MODERATELY ILL	26	20.5	36	28.3	33	28.2	34	30.1	27	25.2	18	17.5	15	15.3
	MARKEDLY ILL	73	57.5	51	40.2	38	32.5	23	20.4	12	11.2	9	8.7	5	5.1
	SEVERELY ILL	25	19.7	15	11.8	6	5.1	5	4.4	2	1.9	1	1.0	1	1.0
	EXTREMELY ILL	1	0.8	2	1.6	1	0.9			1	0.9				
	Total	127	100.0	127	100.0	117	100.0	113	100.0	107	100.0	103	100.0	98	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 28

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment/Severity of illness		Total		Last Visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	NORMAL	24	19.8											24	26.1
	BORDERLINE MENTALLY ILL	27	22.3			1	50.0			1	16.7			25	27.2
	MILDLY ILL	20	16.5	1	8.3			1	12.5					18	19.6
	MODERATELY ILL	25	20.7	4	33.3			2	25.0	2	33.3			17	18.5
	MARKEDLY ILL	18	14.9	4	33.3	1	50.0	5	62.5	1	16.7			7	7.6
	SEVERELY ILL	5	4.1	2	16.7					2	33.3			1	1.1
	EXTREMELY ILL	2	1.7	1	8.3							1	100.0		
	Total	121	100.0	12	100.0	2	100.0	8	100.0	6	100.0	1	100.0	92	100.0
Reboxetine	NORMAL	27	21.3					1	16.7					26	26.5
	BORDERLINE MENTALLY ILL	29	22.8											29	29.6
	MILDLY ILL	27	21.3	2	20.0		.			2	50.0	1	20.0	22	22.4
	MODERATELY ILL	24	18.9	4	40.0	3	75.0	1	16.7			1	20.0	15	15.3
	MARKEDLY ILL	12	9.4	2	20.0			1	16.7	1	25.0	3	60.0	5	5.1
	SEVERELY ILL	6	4.7	2	20.0			3	50.0					1	1.0
	EXTREMELY ILL	2	1.6			1	25.0			1	25.0				
	Total	127	100.0	10	100.0	4	100.0	6	100.0	4	100.0	5	100.0	98	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 29

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS SHIFT TABLE (LAST VALUE VS DAY 0) BY ASSIGNED TREATMENT

Assigned treatment/Shift severity		Total		Last visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	DECREASED	89	73.6	2	16.7	1	50.0	2	25.0	3	50.0			51	88.0
	NO CHANGE	25	20.7	8	66.7			4	50.0	3	50.0			10	10.9
	INCREASED	7	5.8	2	16.7	1	50.0	2	25.0			1	100.0	1	1.1
	Total	121	100.0	12	100.0	2	100.0	8	100.0	6	100.0	1	100.0	92	100.0
Reboxetine	DECREASED	102	80.3	3	30.0	2	50.0	2	33.3	3	75.0	3	60.0	89	90.8
	NO CHANGE	21	16.5	7	70.0	1	25.0	2	33.3	1	25.0	1	20.0	9	9.2
	INCREASED	4	3.1			1	25.0	2	33.3			1	20.0		
	Total	127	100.0	10	100.0	4	100.0	6	100.0	4	100.0	5	100.0	98	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 38

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment/Global improvement		Visit															
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42					
		No	%	No	%	No	%	No	%	No	%	No	%				
Imipramine	VERY MUCH IMPROVED	1	0.8	7	6.5	7	6.5	16	16.2	20	21.5	34	37.0				
	MUCH IMPROVED	16	13.2	30	27.8	44	41.1	45	45.5	50	53.8	39	42.4				
	MINIMALLY IMPROVED	36	29.8	46	42.6	38	35.5	29	29.3	15	16.1	13	14.1				
	NO CHANGE	53	43.8	16	14.8	11	10.3	6	6.1	4	4.3	4	4.3				
	MINIMALLY WORSE	11	9.1	6	5.6	4	3.7	1	1.0	1	1.1	2	2.2				
	MUCH WORSE	3	2.5	2	1.9	3	2.8	2	2.0	2	2.2						
	VERY MUCH WORSE	1	0.8	1	0.9					1	1.1						
	Total	121	100.0	108	100.0	107	100.0	99	100.0	93	100.0	92	100.0				
Reboxetine	VERY MUCH IMPROVED	2	1.6	12	10.3	17	15.0	20	18.7	30	29.1	41	41.8				
	MUCH IMPROVED	23	18.1	31	26.5	51	45.1	56	52.3	49	47.6	40	40.8				
	MINIMALLY IMPROVED	41	32.3	53	45.3	34	30.1	23	21.5	16	15.5	11	11.2				
	NO CHANGE	50	39.4	12	10.3	6	5.3	4	3.7	5	4.9	5	5.1				
	MINIMALLY WORSE	9	7.1	7	6.0	3	2.7	3	2.8	3	2.9	1	1.0				
	MUCH WORSE	2	1.6	1	0.9	2	1.8	1	0.9								
	VERY MUCH WORSE			1	0.9												
	Total	127	100.0	117	100.0	113	100.0	107	100.0	103	100.0	98	100.0				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 31

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment/Global improvement		Total		Last visit											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	VERY MUCH IMPROVED	36	29.8			1	50.0			1	16.7			34	37.0
	MUCH IMPROVED	39	32.2											39	42.4
	MINIMALLY IMPROVED	18	14.9	2	16.7			1	12.5	2	33.3			13	14.1
	NO CHANGE	12	9.9	3	25.0			3	37.5	2	33.3			4	4.3
	MINIMALLY WORSE	8	6.6	4	33.3	1	50.0	1	12.5					2	2.2
	MUCH WORSE	7	5.8	3	25.0			3	37.5	1	16.7				
	VERY MUCH WORSE	1	0.8									1	100.0		
	Total	121	100.0	12	100.0	2	100.0	8	100.0	6	100.0	1	100.0	92	100.0
Reboxetine	VERY MUCH IMPROVED	42	33.1					1	16.7					41	41.8
	MUCH IMPROVED	43	33.9	2	20.0							1	20.0	40	40.8
	MINIMALLY IMPROVED	17	13.4	1	10.0	1	25.0	1	16.7	2	50.0	1	20.0	11	11.2
	NO CHANGE	13	10.2	3	30.0	1	25.0	2	33.3			2	40.0	5	5.1
	MINIMALLY WORSE	6	6.3	3	30.0	1	25.0	1	16.7	1	25.0	1	20.0	1	1.0
	MUCH WORSE	3	2.4	1	10.0			1	16.7	1	25.0				
	VERY MUCH WORSE	1	0.8			1	25.0								
	Total	127	100.0	10	100.0	4	100.0	6	100.0	4	100.0	5	100.0	98	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 32

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX
ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment / Efficacy index (*)		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	< 1	44	36.7	11	10.2	10	9.3	8	8.1	6	6.5	4	4.3
	1	49	40.8	34	31.5	23	21.5	12	12.1	12	12.9	8	8.7
	1.33 - 1.5	8	6.7	18	16.7	21	19.6	21	21.2	12	12.9	12	13.0
	2	16	13.3	32	29.6	29	27.1	32	32.3	23	24.7	25	27.2
	3	3	2.5	10	9.3	19	17.8	15	15.2	21	22.6	16	17.4
	4			3	2.8	5	4.7	11	11.1	19	20.4	27	29.3
	Total	120	100	108	100	107	100	99	100	93	100	92	100
Reboxetine	< 1	39	30.7	16	13.7	10	8.8	10	9.3	6	5.8	4	4.1
	1	41	32.3	32	27.4	22	19.5	14	13.1	10	9.7	6	6.1
	1.33 - 1.5	13	10.2	14	12.0	28	24.8	16	15.0	19	18.4	13	13.3
	2	20	15.7	29	24.8	13	11.5	12	11.2	12	11.7	17	17.3
	3	11	8.7	12	10.3	24	21.2	28	26.2	22	21.4	17	17.3
	4	3	2.4	14	12.0	16	14.2	27	25.2	34	33.0	41	41.8
	Total	127	100	117	100	113	100	107	100	103	100	98	100

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 33

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX
AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment / Efficacy index (*)		total		Last Assessment											
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	< 1	22	18.18	10	83.33	1	50.00	2	25.00	4	66.67	1	100.0	4	4.35
	1	15	12.40	2	16.67			5	62.50					8	8.70
	1.33 - 1.5	12	9.92											12	13.04
	2	28	23.14			1	50.00			2	33.33			25	27.17
	3	17	14.05					1	12.50					16	17.39
	4	27	22.31											27	29.35
	Total	121	100.0	12	100.0	2	100.0	8	100.0	6	100.0	1	100.0	92	100.0
Reboxetine	< 1	23	18.11	7	70.00	3	75.00	3	50.00	3	75.00	3	60.00	4	4.08
	1	11	8.66			1	25.00	2	33.33	1	25.00	1	20.00	6	6.12
	1.33 - 1.5	14	11.02	1	10.00									13	13.27
	2	18	14.17	1	10.00									17	17.35
	3	18	14.17	1	10.00									17	17.35
	4	43	33.86					1	16.67			1	20.00	41	41.84
	Total	127	100.0	10	100.0	4	100.0	6	100.0	4	100.0	5	100.0	98	100.0

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 34

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	98	93	92
	Mean	16.91	14.69	12.19	10.38	8.55	7.76	6.03
	Median	17	16	13	10	8	7	5
	STD	2.98	4.62	5.26	5.28	5.38	5.53	4.94
	Min	8	3	0	0	0	0	0
	Max	25	26	23	21	21	26	21
	Mean diff. vs day0 (*)		2.21	4.90	6.73	8.62	9.27	11.05
Reboxetine	No	127	127	117	112	107	103	98
	Mean	17.21	14.43	11.64	9.40	8.40	7.10	5.89
	Median	18	15	12	9	8	6	5
	STD	3.25	4.80	5.64	5.04	5.28	4.79	4.56
	Min	4	1	0	0	0	0	0
	Max	28	26	27	22	24	20	20
	Mean diff. vs day0 (*)		2.78	5.66	8.02	9.07	10.39	11.62

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D

DEPRESSION - PROTOCOL 20124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: REPORTED SADNESS

Assigned treatment		Visit:							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Zalprasidone	No	121	121	108	107	96	93	92
	Median	2	2	2	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2
Haloperidol	No	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	0
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INNER TENSION

Assigned treatment		Visit							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	96	93	92
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	3	3	3
Reboxetine	No	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: APPARENT SADNESS

Assigned treatment		Visit							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	96	93	92
	Median	2	2	1	1	1	1	0
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	2
Reboxetine	No	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	3	2	2

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: SUICIDAL THOUGHTS

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	98	93	92
	Median	1	1	1	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	2	2	2
Reboxetine	No	127	127	117	112	107	103	98
	Median	1	1	0	0	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	2	3	2	3	2	2

PHARMACIA CNS 260

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INSERTIA

Assigned treatment		Visit							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	96	93	92
	Median	2	2	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	3	2	2

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 28124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: INABILITY TO FEEL

Assigned treatment		Visit							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	98	93	92
	Median	2	2	2	1	1	1	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Reboxetine	No	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: PESSIMISTIC THOUGHTS

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	98	93	92
	Median	2	1	1	1	1	1	1
	Min	1	0	0	0	0	0	0
	Max	3	3	2	2	3	3	2
Reboxetine	No	127	127	117	112	107	103	98
	Median	2	1	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	3	3	2

PHARMACIA CNS R&D

ESCITALOPRAM - PROTOCOL 20124/017

TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: CONCENTRATIONS DIFFICULTIES

Assigned treatment		Visit							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Escitalopram	No	121	121	108	107	96	93	92
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3
Paroxetine	No	127	127	117	112	107	103	98
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	3	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: REDUCED SLEEP

Assigned treatment		Visit						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	96	93	92
	Median	2	2	1	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	2	2
Reboxetine	No	127	127	117	112	107	103	98
	Median	2	2	2	1	1	1	1
	Min	0	0	0	0	0	0	0
	Max	3	3	3	3	3	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Item: REDUCED APPETITE

Assigned treatment		Visit							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	No	121	121	108	107	95	93	92
	Median	1	1	1	1	0	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	2	2	3	3	2
Reboxetine	No	127	127	117	112	107	103	98
	Median	1	1	1	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	3	3	3	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 36

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Mean	14.42	11.00	14.11	12.40	26.00	6.03	7.98
	Median	15	11	16	14	26	5	6
	STD	4.42	9.90	5.37	5.03		4.94	6.12
	Min	5	4	4	5	26	0	0
	Max	24	18	19	18	26	21	26
	Mean diff. vs day0 (*)	0.92	4.50	2.33	7.00	-12.00	11.05	8.93
Reboxetine	No	10	5	5	4	5	98	127
	Mean	14.50	18.20	12.60	15.25	12.40	5.89	7.87
	Median	15	18	17	14	13	5	7
	STD	4.79	5.36	8.08	6.75	3.58	4.56	6.03
	Min	9	13	0	9	7	0	0
	Max	21	27	19	24	16	20	27
	Mean diff. vs day0 (*)	1.70	-3.60	3.60	2.00	4.60	11.62	9.35

Mean (*): mean of differences vs day0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: REPORTED SADNESS

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	1	2	1	3	1	1
	Min	1	0	0	0	3	0	0
	Max	3	2	3	3	3	2	3
Reboxetine	No	10	5	5	4	5	95	127
	Median	2	3	2	2	1	0	1
	Min	1	2	0	1	1	0	0
	Max	3	3	3	3	2	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INNER TENSION

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	2	2	1	3	1	1
	Min	1	1	1	1	5	0	0
	Max	2	2	2	2	3	3	3
Reboxetine	No	10	5	5	4	5	95	127
	Median	1	2	2	2	1	1	1
	Min	1	2	0	1	1	0	0
	Max	3	3	3	2	2	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: APPARENT SADNESS

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	1	2	2	3	0	1
	Min	0	0	1	1	3	0	0
	Max	3	2	3	2	3	2	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	2	2	1	2	0	1
	Min	1	1	0	1	1	0	0
	Max	3	3	2	3	2	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE: .
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: SUICIDAL THOUGHTS

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Indpramine	No	12	2	9	5	1	92	121
	Median	1	1	1	1	2	0	0
	Min	0	0	0	0	2	0	0
	Max	2	1	3	2	2	2	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	1	1	1	0	0
	Min	1	0	0	0	0	0	0
	Max	2	3	1	2	2	2	3

PHARMACIA CNS R&D

REMINYL - PROTOCOL 20124/017

TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INSETIA

Assigned treatment			Last assessment							
			Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Galantamine		No	12	2	9	5	1	92	121
		Median	2	2	2	1	3	1	1
		Min	1	1	0	1	3	0	0
		Max	3	2	2	2	3	3	3
Reboxetine		No	10	5	5	4	5	95	127
		Median	2	2	2	2	1	1	1
		Min	0	1	0	0	1	0	0
		Max	3	3	2	3	2	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: INABILITY TO FEEL

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	2	2	1	3	0	1
	Min	0	1	0	0	3	0	0
	Max	2	2	2	2	3	3	3
Reboxetine	No	10	5	5	4	5	96	127
	Median	1	2	2	2	1	1	1
	Min	1	1	0	0	1	0	0
	Max	2	3	3	2	2	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017

TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:

SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: PESSIMISTIC THOUGHTS

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	2	1	1	2	3	1	1
	Min	1	0	0	1	3	0	0
	Max	2	2	2	2	3	2	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	1	1	2	1	1	1
	Min	1	1	0	2	1	0	0
	Max	2	3	2	3	1	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: CONCENTRATIONS DIFFICULTIES

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	1	1	1	2	1	1
	Min	1	0	0	0	2	0	0
	Max	3	2	3	2	2	3	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	2	2	2	2	1	1	1
	Min	0	1	0	0	0	0	0
	Max	2	3	2	2	2	2	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: REDUCED SLEEP

Assigned treatment		Last assessment							
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Isipramine	No	12	2	9	5	1	92	121
	Median	2	1	2	2	1	1	1
	Min	0	0	0	0	1	0	0
	Max	3	2	2	3	1	2	3
Reboxetine	No	10	5	5	4	5	95	127
	Median	2	2	2	2	2	1	1
	Min	0	1	0	2	0	0	0
	Max	3	3	2	3	2	3	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 37

MONTGOMERY ASBERG DEPRESSION RATING SCALE:
SUMMARY STATISTICS ON SCORE OF EACH ITEM AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Item: REDUCED APPETITE

Assigned treatment		Last assessment						
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Total
Imipramine	No	12	2	9	5	1	92	121
	Median	1	1	1	1	3	0	0
	Min	0	1	0	0	3	0	0
	Max	3	1	2	1	3	2	3
Reboxetine	No	10	5	5	4	5	98	127
	Median	1	1	0	1	1	0	0
	Min	0	0	0	0	0	0	0
	Max	2	2	1	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 38

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY SEX AND ASSIGNED TREATMENT

	Assigned treatment					
	Imipramine			Reboxetine		
	Female	Male	Total	Female	Male	Total
Pt exposed	83	43	126	84	46	130
Pt with adverse events	66	37	103	66	40	106
% on exposed	79.51	86.04	81.74	78.57	86.95	81.53
95% L.L.	69.24	72.07	73.88	68.26	73.74	73.79
95% U.L.	87.59	94.70	88.06	86.78	95.06	87.80
No. of adverse events	183	120	303	168	99	267
Ratio A.E. on Pt with A.E.	2.77	3.24	2.94	2.54	2.47	2.51

PHARMACIA CRS R40

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 39

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY AGE AND ASSIGNED TREATMENT

	Assigned treatment								
	Idrevastine				Reboxetine				
	Total	18 - 30	31 - 45	> 45	Total	18 - 30	31 - 45	> 45
Pt exposed	126	34	34	58	130	19	42	69
Pt with adverse events	103	29	25	49	106	16	35	55
% on exposed	81.74	85.29	73.52	84.48	81.53	84.21	83.33	79.71
95% L.L.	73.88	68.94	55.64	72.58	73.79	60.42	68.64	68.31
95% U.L.	88.06	95.05	87.12	92.65	87.80	96.62	93.03	88.44
No. of adverse events	303	80	71	152	267	35	92	140
Ratio A.E. on Pt with A.E.	2.94	2.75	2.84	3.10	2.51	2.18	2.62	2.54

PHARMACIA CNS R&D

SERTRALINE - PROTOCOL 20124/017

TABLE No.: 40

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY DSM III CLASSIFICATION AND ASSIGNED TREATMENT

	Assigned treatment					
	Imipramine			Sertraline		
	Total	296.2	296.3	Total	296.2	296.3
Pt exposed	126	57	69	130	51	79
Pt with adverse events	103	46	57	106	41	65
% on exposed	81.74	80.70	82.60	81.53	80.39	82.27
95% L.L.	73.88	68.09	71.59	73.79	66.88	72.06
95% U.L.	88.06	89.95	90.68	87.80	90.18	89.96
No. of adverse events	303	132	171	267	93	174
Ratio A.E. on Pt with A.E.	2.94	2.86	3.00	2.51	2.26	2.67

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
Pt exposed	Imipramine	83	100.0				43	100.0				126	100.0			
	Reboxetine	84	100.0				46	100.0				130	100.0			
Pt with a.e.	Imipramine	66	79.5	100.0	183	2.77	37	86.0	100.0	120	3.24	103	81.7	100.0	303	2.94
	Reboxetine	66	78.6	100.0	168	2.54	40	87.0	100.0	99	2.47	106	81.5	100.0	267	2.51
MOUTH DRY	Imipramine	26	31.3	39.3	26	1.00	19	44.2	51.3	22	1.15	45	35.7	43.6	48	1.06
	Reboxetine	21	25.0	31.8	21	1.00	11	23.9	27.5	12	1.09	32	24.6	30.1	33	1.03
HEADACHE	Imipramine	10	12.0	15.1	11	1.10	8	18.6	21.6	10	1.25	18	14.3	17.4	21	1.16
	Reboxetine	12	14.3	18.1	15	1.25	9	19.6	22.5	12	1.33	21	16.2	19.8	27	1.28
SWEATING INCREASED	Imipramine	9	10.8	13.6	9	1.00	9	20.9	24.3	11	1.22	18	14.3	17.4	20	1.11
	Reboxetine	7	8.3	10.6	7	1.00	11	23.9	27.5	13	1.18	18	13.8	16.9	20	1.11
DIZZINESS	Imipramine	10	12.0	15.1	10	1.00	8	18.6	21.6	9	1.12	18	14.3	17.4	19	1.05
	Reboxetine	9	10.7	13.6	9	1.00	3	6.5	7.5	4	1.33	12	9.2	11.3	13	1.08
NAUSEA	Imipramine	9	10.8	13.6	9	1.00	4	9.3	10.8	4	1.00	13	10.3	12.6	13	1.00
	Reboxetine	13	15.5	19.6	13	1.00	3	6.5	7.5	3	1.00	16	12.3	15.0	16	1.00
CONSTIPATION	Imipramine	8	9.6	12.1	8	1.00	5	11.6	13.5	5	1.00	13	10.3	12.6	13	1.00
	Reboxetine	9	10.7	13.6	9	1.00	4	8.7	10.0	4	1.00	13	10.0	12.2	13	1.00
INSOMNIA	Imipramine	7	8.4	10.6	7	1.00	7	16.3	18.9	9	1.28	14	11.1	13.5	16	1.14
	Reboxetine	8	9.5	12.1	9	1.12	2	4.3	5.0	2	1.00	10	7.7	9.4	11	1.10
TACHYCARDIA	Imipramine	10	12.0	15.1	12	1.20	3	7.0	8.1	3	1.00	13	10.3	12.6	15	1.15
	Reboxetine	3	3.6	4.5	5	1.66	5	10.9	12.5	5	1.00	8	6.2	7.5	10	1.25
TREMOR	Imipramine	8	9.6	12.1	8	1.00	5	11.6	13.5	5	1.00	13	10.3	12.6	13	1.00
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
AGITATION	Imipramine	6	7.2	9.0	6	1.00	3	7.0	8.1	3	1.00	9	7.1	8.7	9	1.00
	Reboxetine	4	4.8	6.0	4	1.00	2	4.3	5.0	4	2.00	6	4.6	5.6	8	1.33
SOMNOLENCE	Imipramine	5	6.0	7.5	6	1.20	4	9.3	10.8	4	1.00	9	7.1	8.7	10	1.11
	Reboxetine	2	2.4	3.0	2	1.00	2	4.3	5.0	2	1.00	4	3.1	3.7	4	1.00
MICTURITION DISORDER	Imipramine	2	2.4	3.0	2	1.00	1	2.3	2.7	1	1.00	3	2.4	2.9	3	1.00
	Reboxetine	1	1.2	1.5	1	1.00	7	15.2	17.5	7	1.00	8	6.2	7.5	8	1.00
PALPITATION	Imipramine	3	3.6	4.5	4	1.33	2	4.7	5.4	2	1.00	5	4.0	4.8	6	1.20
	Reboxetine	5	6.0	7.5	5	1.00						5	3.8	4.7	5	1.00
FATIGUE	Imipramine	3	3.6	4.5	3	1.00	2	4.7	5.4	2	1.00	5	4.0	4.8	5	1.00
	Reboxetine	3	3.6	4.5	4	1.33	1	2.2	2.5	1	1.00	4	3.1	3.7	5	1.25
VISION ABNORMAL	Imipramine	1	1.2	1.5	1	1.00	3	7.0	8.1	3	1.00	4	3.2	3.8	4	1.00
	Reboxetine	3	3.6	4.5	3	1.00	1	2.2	2.5	1	1.00	4	3.1	3.7	4	1.00
BRONCHITIS	Imipramine	1	1.2	1.5	2	2.00						1	0.8	0.9	2	2.00
	Reboxetine	5	6.0	7.5	5	1.00	1	2.2	2.5	1	1.00	6	4.6	5.6	6	1.00
URINARY RETENTION	Imipramine	4	4.8	6.0	4	1.00						4	3.2	3.8	4	1.00
	Reboxetine						2	4.3	5.0	3	1.50	2	1.5	1.8	3	1.50
HYPERTENSION	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine	4	4.8	6.0	5	1.25	1	2.2	2.5	2	2.00	5	3.8	4.7	7	1.40
INFLUENZA-LIKE SYMPTOMS	Imipramine	2	2.4	3.0	3	1.50						2	1.6	1.9	3	1.50
	Reboxetine	2	2.4	3.0	2	1.00	2	4.3	5.0	2	1.00	4	3.1	3.7	4	1.00
RASH	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	3	3.6	4.5	3	1.00						3	2.3	2.8	3	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
PARAESTHESIA	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	1	1.00	2	1.6	1.9	2	1.00
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	2	2.00	3	2.3	2.8	4	1.33
HYPOTENSION	Imipramine	2	2.4	3.0	2	1.00	3	7.0	8.1	4	1.33	5	4.0	4.8	6	1.20
LIBIDO DECREASED	Imipramine						2	4.7	5.4	2	1.00	2	1.6	1.9	2	1.00
	Reboxetine						3	6.5	7.5	3	1.00	3	2.3	2.8	3	1.00
ABDOMINAL PAIN	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	1	1.00	3	2.3	2.8	3	1.00
FLATULENCE	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	3	3.6	4.5	3	1.00						3	2.3	2.8	3	1.00
TASTE PERVERSION	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
UPPER RESP TRACT INFECTION	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	2	2.00	2	1.6	1.9	3	1.50
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
BACK PAIN	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	2	2.00	2	1.6	1.9	3	1.50
	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
ARTHRALGIA	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
ANOREXIA	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
FLUSHING	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HYPOTENSION POSTURAL	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
NERVOUSNESS	Reboxetine	3	3.6	4.5	3	1.00						3	2.3	2.8	3	1.00
DYSPEPSIA	Reboxetine	3	3.6	4.5	3	1.00						3	2.3	2.8	3	1.00
GAMMA-GT INCREASED	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
SINUSITIS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
URINARY TRACT INFECTION	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	2	2.4	3.0	3	1.50						2	1.5	1.8	3	1.50
ASTHENIA	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
HYPOAESTHESIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
ACCOMMODATION ABNORMAL	Imipramine						2	4.7	5.4	2	1.00	2	1.6	1.9	2	1.00
DIARRHOEA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
VOMITING	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
CONFUSION	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
DELUSION	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
DELUSION	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
SUICIDE ATTEMPT	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
GASTROENTERITIS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HEPATIC ENZYMES INCREASED	Imipramine	1	1.2	1.5	2	2.00						1	0.8	0.9	2	2.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPERCHOLESTEROLAEMIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPERURICAEMIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
ECG ABNORMAL	Reboxetine						2	4.3	5.0	2	1.00	2	1.5	1.8	2	1.00
RHINITIS	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
SPUTUM INCREASED	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	1	1.00	2	1.6	1.9	2	1.00
MENSTRUAL DISORDER	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
CHEST PAIN	Imipramine						2	4.7	5.4	2	1.00	2	1.6	1.9	2	1.00
FEVER	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
HOT FLUSHES	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	1	1.00	2	1.6	1.9	2	1.00
ALOPECIA	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
DERMATITIS FUNGAL	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
PRURITUS	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ARTEROSIS	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
HYPERKINESSIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPOKINESIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
VERTIGO	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
SALIVA INCREASED	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
TINNITUS	Imipramine	1	1.2	1.5	2	2.00						1	0.8	0.9	2	2.00
TASTE LOSS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
ANXIETY	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
MANIC REACTION	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
APPETITE INCREASED	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
DYSPHAGIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
OESOPHAGITIS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
SGPT INCREASED	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
GLOBULINS INCREASED	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPERLIPAEMIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPOTHYROIDISM	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
AV BLOCK	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
BUNDLE BRANCH BLOCK	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
EXTRASYSTOLES	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 41

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt.	% on exp.	% on Pt with AE	No of AE	Ratio (*)
COUGHING	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
ASTHMA	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
LEUKOCYTOSIS	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
CYSTITIS HAEMORRHAGIC	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
CERVICITIS	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
PAIN	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
OTITIS MEDIA	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
HERPES SIMPLEX	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
MOUTH DRY	Imipramine	26	31.3	39.3	26	1.00	19	44.2	51.3	22	1.15	45	35.7	43.6	48	1.06
	Reboxetine	21	25.0	31.8	21	1.00	11	23.9	27.5	12	1.09	32	24.6	30.1	33	1.03
SWEATING INCREASED	Imipramine	9	10.8	13.6	9	1.00	9	20.9	24.3	11	1.22	18	14.3	17.4	20	1.11
	Reboxetine	7	8.3	10.6	7	1.00	11	23.9	27.5	13	1.18	18	13.8	16.9	20	1.11
SALIVA INCREASED	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ASTHENIA / FATIGUE	Imipramine	4	4.8	6.0	5	1.25	2	4.7	5.4	2	1.00	6	4.8	5.8	7	1.16
	Reboxetine	3	3.6	4.5	4	1.33	2	4.3	5.0	2	1.00	5	3.8	4.7	6	1.20
INFLUENZA-LIKE SYMPTOMS	Imipramine	2	2.4	3.0	3	1.50						2	1.6	1.9	3	1.50
	Reboxetine	2	2.4	3.0	2	1.00	2	4.3	5.0	2	1.00	4	3.1	3.7	4	1.00
CHEST PAIN	Imipramine						2	4.7	5.4	2	1.00	2	1.6	1.9	2	1.00
FEVER	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
PAIN	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	14	16.9	21.2	14	1.00	9	20.9	24.3	13	1.44	23	18.3	22.3	27	1.17
	Reboxetine	10	11.9	15.1	10	1.00	3	6.5	7.5	4	1.33	13	10.0	12.2	14	1.07
TACHYCARDIA	Imipramine	10	12.0	15.1	12	1.20	3	7.0	8.1	3	1.00	13	10.3	12.6	15	1.15
	Reboxetine	3	3.6	4.5	5	1.66	5	10.9	12.5	5	1.00	8	6.2	7.5	10	1.25
PALPITATION	Imipramine	3	3.6	4.5	4	1.33	2	4.7	5.4	2	1.00	5	4.0	4.8	6	1.20
	Reboxetine	5	6.0	7.5	5	1.00						5	3.8	4.7	5	1.00
HYPERTENSION	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine	4	4.8	6.0	5	1.25	1	2.2	2.5	2	2.00	5	3.8	4.7	7	1.40
FLUSHING / HOT FLASHING	Imipramine	1	1.2	1.5	1	1.00	2	4.7	5.4	2	1.00	3	2.4	2.9	3	1.00
	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
ECG ABNORMAL	Reboxetine						2	4.3	5.0	2	1.00	2	1.5	1.8	2	1.00
AV BLOCK	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
BUNDLE BRANCH BLOCK	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
EXTRASYSTOLES	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HEADACHE / MIGRAINE	Imipramine	10	12.0	15.1	11	1.10	8	18.6	21.6	10	1.25	18	14.3	17.4	21	1.16
	Reboxetine	12	14.5	18.1	15	1.25	9	19.6	22.5	12	1.33	21	16.2	19.8	27	1.28
TREMOR	Imipramine	8	9.6	12.1	8	1.00	5	11.6	13.5	5	1.00	13	10.3	12.6	13	1.00
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
PARAESTHESIA	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	1	1.00	2	1.6	1.9	2	1.00
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	2	2.00	3	2.3	2.8	4	1.33
CONFUSION	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
HYPOAESTHESIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPERKINESIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPOKINESIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
VERTIGO	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: ENDOCRINE DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HYPOTHYROIDISM	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
NAUSEA AND RELATED SYMPTOMS	Imipramine	10	12.0	15.1	10	1.00	4	9.3	10.8	4	1.00	14	11.1	13.5	14	1.00
	Reboxetine	15	17.9	22.7	16	1.06	4	8.7	10.8	4	1.00	19	14.6	17.9	20	1.05
CONSTIPATION	Imipramine	8	9.6	12.1	8	1.00	5	11.6	13.5	5	1.00	13	10.3	12.6	13	1.00
	Reboxetine	9	10.7	13.6	9	1.00	4	8.7	10.8	4	1.00	13	10.0	12.2	13	1.00
ABDOMINAL PAIN	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	1	1.00	3	2.3	2.8	3	1.00
FLATULENCE	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	3	3.6	4.5	3	1.00						3	2.3	2.8	3	1.00
ANOREXIA	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
DIARRHOEA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
GASTROENTERITIS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
APPETITE INCREASED	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
DYSPHAGIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
OESOPHAGITIS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CRS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
TINNITUS	Imipramine	1	1.2	1.5	2	2.00	1	0.8	0.9	2	2.00

(*) number of adverse events on patients who complained of adverse events
(same adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
LEUKOCYTOSIS	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
INCREASED LIVER ENZYMES	Imipramine	2	2.4	3.0	4	2.00						2	1.6	1.9	4	2.00
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	1	1.00	3	2.3	2.8	3	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HYPERCHOLESTEROLAEMIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPERURICAEMIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
GLOBULINS INCREASED	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HYPERLIPAEMIA	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: MUSCOLO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
BACK PAIN	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	2	2.00	2	1.6	1.9	3	1.50
	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
ARTHRALGIA	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
ARTHROSIS	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
INSOMNIA	Imipramine	7	8.4	10.6	7	1.00	7	16.3	18.9	9	1.28	14	11.1	13.5	16	1.14
	Reboxetine	8	9.5	12.1	9	1.12	2	4.3	5.0	2	1.00	10	7.7	9.4	11	1.10
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	6	7.2	9.0	7	1.16	3	7.0	8.1	3	1.00	9	7.1	8.7	10	1.11
	Reboxetine	7	8.3	10.6	7	1.00	2	4.3	5.0	4	2.00	9	6.9	8.4	11	1.22
SOMNOLENCE	Imipramine	5	6.0	7.5	6	1.20	4	9.3	10.8	4	1.00	9	7.1	8.7	10	1.11
	Reboxetine	2	2.4	3.0	2	1.00	2	4.3	5.0	2	1.00	4	3.1	3.7	4	1.00
LIBIDO DECREASED	Imipramine						2	4.7	5.4	2	1.00	2	1.6	1.9	2	1.00
	Reboxetine						3	6.5	7.5	3	1.00	3	2.3	2.8	3	1.00
DELUSION	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
SUICIDE ATTEMPT	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
MANIC REACTION	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: REPRODUCTIVE DISORDERS, FEMALE

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
MENSTRUAL DISORDER	Imipramine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00
CERVICITIS	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment		Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HERPES SIMPLEX	Reboxetine	1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
OTITIS MEDIA	Imipramine	1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
BRONCHITIS	Imipramine	1	1.2	1.5	2	2.00						1	0.8	0.9	2	2.00
	Reboxetine	5	6.0	7.5	5	1.00	1	2.2	2.5	1	1.00	6	4.6	5.6	6	1.00
UPPER RESP TRACT INFECTION	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	2	2.00	2	1.6	1.9	3	1.50
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
SINUSITIS	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	1	1.2	1.5	1	1.00	1	2.2	2.5	1	1.00	2	1.5	1.8	2	1.00
RHINITIS	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
SPUTUM INCREASED	Imipramine	1	1.2	1.5	1	1.00	1	2.3	2.7	1	1.00	2	1.6	1.9	2	1.00
ASTHMA	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
COUGHING	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
ERYTHEMA / RASH	Imipramine	2	2.4	3.0	2	1.00	2	1.6	1.9	2	1.00
	Reboxetine	3	3.6	4.5	3	1.00	3	2.3	2.8	3	1.00
ALOPECIA	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00
DERMATITIS FUNGAL	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00
PRURITUS	Reboxetine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CRO BRD

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment		Female					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
TASTE PERVERSION	Imipramine	2	2.4	3.0	2	1.00	2	1.6	1.9	2	1.00
	Reboxetine	2	2.4	3.0	2	1.00	2	1.5	1.8	2	1.00
TASTE LOSS	Imipramine	1	1.2	1.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(same adverse events are grouped in clusters)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
URINARY HESITANCY / RETENTION	Imipramine	5	6.0	7.5	6	1.20	1	2.3	2.7	1	1.00	6	4.8	5.8	7	1.16
	Reboxetine	1	1.2	1.5	1	1.00	9	19.6	22.5	10	1.11	10	7.7	9.4	11	1.10
URINARY TRACT INFECTION	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	2	2.4	3.0	3	1.50						2	1.5	1.8	3	1.50
CYSTITIS HAEMORRHAGIC	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 42

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: VISION DISORDERS

Adverse events/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
BLURRED VISION	Imipramine	1	1.2	1.5	1	1.00	4	9.3	10.8	5	1.25	5	4.0	4.8	6	1.20
	Reboxetine	3	3.6	4.5	3	1.00	1	2.2	2.5	1	1.00	4	3.1	3.7	4	1.00

(*) number of adverse events on patients who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 43

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
Pt exposed	Imipramine	83	100.0				43	100.0				126	100.0			
	Reboxetine	84	100.0				46	100.0				130	100.0			
Pt with a.e.	Imipramine	66	79.5	100.0	183	2.77	37	86.0	100.0	120	3.24	103	81.7	100.0	303	2.94
	Reboxetine	66	78.6	100.0	168	2.54	40	87.0	100.0	99	2.47	106	81.5	100.0	267	2.51
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	33	39.8	50.0	35	1.06	23	53.5	62.1	34	1.47	56	44.4	54.3	69	1.23
	Reboxetine	26	31.0	39.3	28	1.07	19	41.3	47.5	25	1.31	45	34.6	42.4	53	1.17
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	27	32.5	40.9	33	1.22	15	34.9	40.5	22	1.46	42	33.3	40.7	55	1.30
	Reboxetine	18	21.4	27.2	26	1.44	11	23.9	27.5	15	1.36	29	22.3	27.3	41	1.41
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	24	28.9	36.3	29	1.20	7	16.3	18.9	9	1.28	31	24.6	30.0	38	1.22
	Reboxetine	25	29.8	37.8	32	1.28	9	19.6	22.5	10	1.11	34	26.2	32.0	42	1.23
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	22	26.5	33.3	26	1.18	10	23.3	27.0	16	1.60	32	25.4	31.0	42	1.31
	Reboxetine	17	20.2	25.7	20	1.17	9	19.6	22.5	14	1.55	26	20.0	24.5	34	1.30
PSYCHIATRIC DISORDERS	Imipramine	14	16.9	21.2	21	1.50	15	34.9	40.5	19	1.26	29	23.0	28.1	40	1.37
	Reboxetine	14	16.7	21.2	20	1.42	9	19.6	22.5	12	1.33	23	17.7	21.6	32	1.39
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	6	7.2	9.0	8	1.33	5	11.6	13.5	5	1.00	11	8.7	10.6	13	1.18
	Reboxetine	6	7.1	9.0	7	1.16	5	10.9	12.5	5	1.00	11	8.5	10.3	12	1.09
URINARY SYSTEM DISORDERS	Imipramine	6	7.2	9.0	7	1.16	1	2.3	2.7	1	1.00	7	5.6	6.7	8	1.14
	Reboxetine	3	3.6	4.5	4	1.33	10	21.7	25.0	11	1.10	13	10.0	12.2	15	1.15
RESPIRATORY SYSTEM DISORDERS	Imipramine	4	4.8	6.0	5	1.25	4	9.3	10.8	5	1.25	8	6.3	7.7	10	1.25
	Reboxetine	9	10.7	13.6	10	1.11	2	4.3	5.0	2	1.00	11	8.5	10.3	12	1.09
VISION DISORDERS	Imipramine	1	1.2	1.5	1	1.00	4	9.3	10.8	5	1.25	5	4.0	4.8	6	1.20
	Reboxetine	3	3.6	4.5	3	1.00	1	2.2	2.5	1	1.00	4	3.1	3.7	4	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 43

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment		Female					Male					Total				
		No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
MUSCOLO-SKELETAL SYSTEM DISORDERS	Imipramine	3	3.6	4.5	3	1.00	2	4.7	5.4	3	1.50	5	4.0	4.8	6	1.20
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	1	1.00	3	2.3	2.8	3	1.00
SKIN AND APPENDAGES DISORDERS	Imipramine	2	2.4	3.0	2	1.00						2	1.6	1.9	2	1.00
	Reboxetine	6	7.1	9.0	6	1.00						6	4.6	5.6	6	1.00
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine	2	2.4	3.0	4	2.00						2	1.6	1.9	4	2.00
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	1	1.00	3	2.3	2.8	3	1.00
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	2	2.4	3.0	3	1.50						2	1.6	1.9	3	1.50
	Reboxetine	2	2.4	3.0	2	1.00	1	2.2	2.5	1	1.00	3	2.3	2.8	3	1.00
SPECIAL SENSES OTHER, DISORDERS	Imipramine	3	3.6	4.5	3	1.00						3	2.4	2.9	3	1.00
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
REPRODUCTIVE DISORDERS, FEMALE	Imipramine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
	Reboxetine	2	2.4	3.0	2	1.00						2	1.5	1.8	2	1.00
RESISTANCE MECHANISM DISORDERS	Imipramine						1	2.3	2.7	1	1.00	1	0.8	0.9	1	1.00
	Reboxetine						1	2.2	2.5	1	1.00	1	0.8	0.9	1	1.00
ENDOCRINE DISORDERS	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00
HEARING AND VESTIBULAR DISORDERS	Imipramine	1	1.2	1.5	2	2.00						1	0.8	0.9	2	2.00
HEMATOLOGY DISORDERS	Reboxetine	1	1.2	1.5	1	1.00						1	0.8	0.9	1	1.00

(*) number of adverse events on patients who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 44

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
MOUTH DRY	Imipramine	48	100	36	75.0	3	6.3	3	6.3	2	4.2	3	6.3	1	2.1		
	Reboxetine	33	100	19	57.6	5	15.2	2	6.1	4	12.1	1	3.0	2	6.1		
SWEATING INCREASED	Imipramine	20	100	12	60.0	1	5.0	3	15.0	1	5.0	1	5.0	2	10.0		
	Reboxetine	20	100	12	60.0	2	10.0	2	10.0	2	10.0	1	5.0	1	5.0		
HEADACHE	Imipramine	21	100	8	38.1	4	19.0	1	4.8	3	14.3	4	19.0	1	4.8		
	Reboxetine	27	100	8	29.6	4	14.8	3	11.1	4	14.8	5	18.5	2	7.4	1	3.7
CONSTIPATION	Imipramine	13	100	8	61.5	3	23.1	1	7.7	1	7.7						
	Reboxetine	13	100	7	53.8	2	15.4	2	15.4	1	7.7	1	7.7				
INSOMNIA	Imipramine	16	100	5	31.3	3	18.8	3	18.8	4	25.0			1	6.3		
	Reboxetine	11	100	7	63.6	4	36.4										
DIZZINESS	Imipramine	19	100	12	63.2	3	15.8	2	10.5	2	10.5						
	Reboxetine	13	100	6	46.2			3	23.1	2	15.4	1	7.7	1	7.7		
TACHYCARDIA	Imipramine	15	100	7	46.7			3	20.0	3	20.0	1	6.7	1	6.7		
	Reboxetine	10	100	2	20.0	1	10.0	1	10.0			3	30.0	2	20.0	1	10.0
NAUSEA	Imipramine	13	100	9	69.2	4	30.8										
	Reboxetine	16	100	11	68.8	2	12.5			1	6.3			2	12.5		
TREMOR	Imipramine	13	100	7	53.8	3	23.1	1	7.7			1	7.7	1	7.7		
	Reboxetine	2	100	1	50.0			1	50.0								
MICTURITION DISORDER	Imipramine	3	100	1	33.3							2	66.7				
	Reboxetine	8	100	4	50.0	3	37.5					1	12.5				
VISION ABNORMAL	Imipramine	4	100	3	75.0					1	25.0						
	Reboxetine	4	100	4	100												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 44

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
AGITATION	Imipramine	9	100	5	55.6	1	11.1	1	11.1	1	11.1	1	11.1				
	Reboxetine	8	100	6	75.0	2	25.0										
SOMNOLENCE	Imipramine	10	100	5	50.0	1	10.0			1	10.0	3	30.0				
	Reboxetine	4	100	3	75.0							1	25.0				
PALPITATION	Imipramine	6	100	1	16.7	2	33.3	1	16.7	1	16.7	1	16.7				
	Reboxetine	5	100	2	40.0	1	20.0	2	40.0								
LIBIDO DECREASED	Imipramine	2	100							1	50.0	1	50.0				
	Reboxetine	3	100	1	33.3			2	66.7								
FLATULENCE	Imipramine	2	100	1	50.0	1	50.0										
	Reboxetine	3	100	2	66.7	1	33.3										
HYPERTENSION	Imipramine	1	100											1	100		
	Reboxetine	7	100	1	14.3	2	28.6	1	14.3	1	14.3			2	28.6		
FATIGUE	Imipramine	5	100	4	80.0							1	20.0				
	Reboxetine	5	100	2	40.0	1	20.0			1	20.0			1	20.0		
PARAESTHESIA	Imipramine	2	100	2	100												
	Reboxetine	4	100	1	25.0	2	50.0					1	25.0				
TASTE PERVERSION	Imipramine	2	100	2	100												
	Reboxetine	2	100	1	50.0					1	50.0						
BRONCHITIS	Imipramine	2	100			1	50.0					1	50.0				
	Reboxetine	6	100			1	16.7	2	33.3			1	16.7	2	33.3		
INFLUENZA-LIKE SYMPTOMS	Imipramine	3	100			2	66.7							1	33.3		
	Reboxetine	4	100			1	25.0	1	25.0			1	25.0	1	25.0		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 44

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
GAMMA-GT INCREASED	Imipramine	2	100					2	100								
	Reboxetine	1	100					1	100								
HYPOTENSION	Imipramine	6	100	2	33.3	1	16.7	3	50.0								
URINARY RETENTION	Imipramine	4	100	1	25.0					2	50.0	1	25.0				
	Reboxetine	3	100	2	66.7	1	33.3										
HYPERCHOLESTEROLAEMIA	Imipramine	1	100	1	100												
	Reboxetine	1	100							1	100						
HYPOTENSION POSTURAL	Imipramine	2	100	2	100												
	Reboxetine	1	100	1	100												
RASH	Imipramine	2	100			1	50.0							1	50.0		
	Reboxetine	3	100	1	33.3			1	33.3			1	33.3				
UPPER RESP TRACT INFECTION	Imipramine	3	100			1	33.3							2	66.7		
	Reboxetine	2	100					1	50.0			1	50.0				
HYPERURICAEMIA	Imipramine	1	100					1	100								
	Reboxetine	1	100					1	100								
SALIVA INCREASED	Imipramine	1	100	1	100												
DYSPEPSIA	Reboxetine	3	100	1	33.3	1	33.3	1	33.3								
URINARY TRACT INFECTION	Imipramine	1	100					1	100								
	Reboxetine	3	100	1	33.3			1	33.3	1	33.3						
HEPATIC ENZYMES INCREASED	Imipramine	2	100					1	50.0					1	50.0		
	Reboxetine	1	100					1	100								
BACK PAIN	Imipramine	3	100	1	33.3							1	33.3	1	33.3		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 44

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
BACK PAIN	Reboxetine	2	100	1	50.0	1	50.0										
FLUSHING	Imipramine	1	100					1	100								
	Reboxetine	2	100	1	50.0			1	50.0								
ABDOMINAL PAIN	Imipramine	2	100			1	50.0							1	50.0		
	Reboxetine	3	100	2	66.7							1	33.3				
TINNITUS	Imipramine	2	100	1	50.0			1	50.0								
ANOREXIA	Imipramine	2	100	2	100												
	Reboxetine	1	100	1	100												
TASTE LOSS	Imipramine	1	100	1	100												
SINUSITIS	Imipramine	1	100	1	100												
	Reboxetine	2	100							1	50.0	1	50.0				
ASTHENIA	Imipramine	2	100	2	100												
	Reboxetine	1	100	1	100												
DIARRHOEA	Imipramine	1	100									1	100				
	Reboxetine	1	100	1	100												
ARTHRALGIA	Imipramine	2	100					1	50.0	1	50.0						
	Reboxetine	1	100									1	100				
AV BLOCK	Imipramine	1	100					1	100								
BUNDLE BRANCH BLOCK	Reboxetine	1	100					1	100								
APPETITE INCREASED	Imipramine	1	100							1	100						
GLOBULINS INCREASED	Reboxetine	1	100							1	100						
ACCOMMODATION ABNORMAL	Imipramine	2	100	2	100												

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 44

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
CONFUSION	Imipramine	2	100	1	50.0			1	50.0								
NERVOUSNESS	Reboxetine	3	100	2	66.7			1	33.3								
CERVICITIS	Reboxetine	1	100	1	100												
HYPOAESTHESIA	Imipramine	1	100			1	100										
	Reboxetine	1	100									1	100				
MENSTRUAL DISORDER	Imipramine	1	100							1	100						
	Reboxetine	1	100					1	100								
FEVER	Imipramine	1	100							1	100						
	Reboxetine	1	100					1	100								
DELUSION	Imipramine	1	100	1	100												
	Reboxetine	1	100			1	100										
CHEST PAIN	Imipramine	2	100	1	50.0	1	50.0										
HOT FLUSHES	Imipramine	2	100	2	100												
PRURITUS	Reboxetine	1	100	1	100												
VOMITING	Imipramine	1	100									1	100				
	Reboxetine	1	100	1	100												
PAIN	Reboxetine	1	100	1	100												
HERPES SIMPLEX	Reboxetine	1	100			1	100										
MANIC REACTION	Imipramine	1	100					1	100								
SPUTUM INCREASED	Imipramine	2	100					1	50.0	1	50.0						
RHINITIS	Reboxetine	2	100					1	50.0	1	50.0						
OESOPHAGITIS	Imipramine	1	100							1	100						

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 44

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Adverse events	Assigned treatment																
COUGHING	Imipramine	1	100							1	100						
ARTHROSIS	Imipramine	1	100									1	100				
GASTROENTERITIS	Imipramine	1	100									1	100				
	Reboxetine	1	100									1	100				
ALOPECIA	Reboxetine	1	100									1	100				
DERMATITIS FUNGAL	Reboxetine	1	100									1	100				
SUICIDE ATTEMPT	Reboxetine	2	100									1	50.0	1	50.0		
ECG ABNORMAL	Reboxetine	2	100											2	100		
HYPERKINESIA	Imipramine	1	100	1	100												
HYPOTHYROIDISM	Reboxetine	1	100	1	100												
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	100			1	100										
DYSPHAGIA	Imipramine	1	100			1	100										
HYPERLIPAEMIA	Imipramine	1	100					1	100								
ASTHMA	Imipramine	1	100					1	100								
OTITIS MEDIA	Imipramine	1	100					1	100								
VERTIGO	Imipramine	1	100							1	100						
ANXIETY	Imipramine	1	100							1	100						
HYPOKINESIA	Imipramine	1	100									1	100				
CYSTITIS HAEMORRHAGIC	Reboxetine	1	100									1	100				
EXTRASYSTOLES	Imipramine	1	100											1	100		
SGPT INCREASED	Reboxetine	1	100											1	100		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017

TABLE No.: 44

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

			Total		Days of treatment															
					0-7		8-14		15-21		22-28		29-35		36-42		> 42			
			No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
Adverse events		Assigned treatment																		
LEUKOCYTOSIS		Reboxetine	1	100													1	100		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
MOUTH DRY	Imipramine	48	100	36	75.0	3	6.3	3	6.3	2	4.2	3	6.3	1	2.1		
	Reboxetine	33	100	19	57.6	5	15.2	2	6.1	4	12.1	1	3.0	2	6.1		
SWEATING INCREASED	Imipramine	20	100	12	60.0	1	5.0	3	15.0	1	5.0	1	5.0	2	10.0		
	Reboxetine	20	100	12	60.0	2	10.0	2	10.0	2	10.0	1	5.0	1	5.0		
SALIVA INCREASED	Imipramine	1	100	1	100												

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
ASTHENIA / FATIGUE	Imipramine	7	100	6	85.7							1	14.3						
	Reboxetine	6	100	3	50.0	1	16.7			1	16.7			1	16.7				
INFLUENZA-LIKE SYMPTOMS	Imipramine	3	100			2	66.7							1	33.3				
	Reboxetine	4	100			1	25.0	1	25.0			1	25.0	1	25.0				
FEVER	Imipramine	1	100							1	100								
	Reboxetine	1	100					1	100										
CHEST PAIN	Imipramine	2	100	1	50.0	1	50.0												
PAIN	Reboxetine	1	100	1	100														

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	27	100	16	59.3	4	14.8	5	18.5	2	7.4						
	Reboxetine	14	100	7	50.0			3	21.4	2	14.3	1	7.1	1	7.1		
TACHYCARDIA	Imipramine	15	100	7	46.7			3	20.0	3	20.0	1	6.7	1	6.7		
	Reboxetine	10	100	2	20.0	1	10.0	1	10.0			3	30.0	2	20.0	1	10.0
PALPITATION	Imipramine	6	100	1	16.7	2	33.3	1	16.7	1	16.7	1	16.7				
	Reboxetine	5	100	2	40.0	1	20.0	2	40.0								
HYPERTENSION	Imipramine	1	100											1	100		
	Reboxetine	7	100	1	14.3	2	28.6	1	14.3	1	14.3			2	28.6		
FLUSHING / HOT FLUSHES	Imipramine	3	100	2	66.7			1	33.3								
	Reboxetine	2	100	1	50.0			1	50.0								
AV BLOCK	Imipramine	1	100					1	100								
BUNDLE BRANCH BLOCK	Reboxetine	1	100					1	100								
ECG ABNORMAL	Reboxetine	2	100											2	100		
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	100			1	100										
EXTRASYSTOLES	Imipramine	1	100											1	100		

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HEADACHE / MIGRAINE	Imipramine	21	100	8	38.1	4	19.0	1	4.8	3	14.3	4	19.0	1	4.8		
	Reboxetine	27	100	8	29.6	4	14.8	3	11.1	4	14.8	5	18.5	2	7.4	1	3.7
TREMOR	Imipramine	13	100	7	53.8	3	23.1	1	7.7			1	7.7	1	7.7		
	Reboxetine	2	100	1	50.0			1	50.0								
PARAESTHESIA	Imipramine	2	100	2	100												
	Reboxetine	4	100	1	25.0	2	50.0					1	25.0				
CONFUSION	Imipramine	2	100	1	50.0			1	50.0								
HYPOAESTHESIA	Imipramine	1	100			1	100										
	Reboxetine	1	100									1	100				
HYPERKINESIA	Imipramine	1	100	1	100												
VERTIGO	Imipramine	1	100							1	100						
HYPOKINESIA	Imipramine	1	100									1	100				

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: ENDOCRINE DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HYPOTHYROIDISM	Reboxetine	1	100	1	100												

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
CONSTIPATION	Imipramine	13	100	8	61.5	3	23.1	1	7.7	1	7.7						
	Reboxetine	13	100	7	53.8	2	15.4	2	15.4	1	7.7	1	7.7				
NAUSEA AND RELATED SYMPTOMS	Imipramine	14	100	9	64.3	4	28.6					1	7.1				
	Reboxetine	20	100	13	65.0	3	15.0	1	5.0	1	5.0			2	10.0		
FLATULENCE	Imipramine	2	100	1	50.0	1	50.0										
	Reboxetine	3	100	2	66.7	1	33.3										
ABDOMINAL PAIN	Imipramine	2	100			1	50.0							1	50.0		
	Reboxetine	3	100	2	66.7							1	33.3				
ANOREXIA	Imipramine	2	100	2	100												
	Reboxetine	1	100	1	100												
DIARRHOEA	Imipramine	1	100									1	100				
	Reboxetine	1	100	1	100												
APPETITE INCREASED	Imipramine	1	100							1	100						
OESOPHAGITIS	Imipramine	1	100							1	100						
GASTROENTERITIS	Imipramine	1	100									1	100				
	Reboxetine	1	100									1	100				
DYSPHAGIA	Imipramine	1	100			1	100										

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
TINNITUS	Indpramine	2	100	1	50.0			1	50.0								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
LEUKOCYTOSIS	Reboxetine	1	100													1	100

(some adverse events are grouped in cluster)

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
INCREASED LIVER ENZYMES	Imipramine	4	100					3	75.0					1	25.0		
	Reboxetine	3	100					2	66.7					1	33.3		

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HYPERCHOLESTEROLAEMIA	Imipramine	1	100	1	100												
	Reboxetine	1	100							1	100						
HYPERURICAEMIA	Imipramine	1	100					1	100								
	Reboxetine	1	100					1	100								
GLOBULINS INCREASED	Reboxetine	1	100							1	100						
HYPERLIPAEMIA	Imipramine	1	100					1	100								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: MUSCOLO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
BACK PAIN	Imipramine	3	100	1	33.3							1	33.3	1	33.3		
	Reboxetine	2	100	1	50.0	1	50.0										
ARTHRALGIA	Imipramine	2	100					1	50.0	1	50.0						
	Reboxetine	1	100									1	100				
ARTHROSIS	Imipramine	1	100									1	100				

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 45

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
INSOMNIA	Imipramine	16	100	5	31.3	3	18.8	3	18.8	4	25.0			1	6.3		
	Reboxetine	11	100	7	63.6	4	36.4										
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	10	100	5	50.0	1	10.0	1	10.0	2	20.0	1	10.0				
	Reboxetine	11	100	8	72.7	2	18.2	1	9.1								
SOMNOLENCE	Imipramine	10	100	5	50.0	1	10.0			1	10.0	3	30.0				
	Reboxetine	4	100	3	75.0							1	25.0				
LIBIDO DECREASED	Imipramine	2	100							1	50.0	1	50.0				
	Reboxetine	3	100	1	33.3			2	66.7								
DELUSION	Imipramine	1	100	1	100												
	Reboxetine	1	100			1	100										
MANIC REACTION	Imipramine	1	100					1	100								
SUICIDE ATTEMPT	Reboxetine	2	100									1	50.0	1	50.0		

(same adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: REPRODUCTIVE DISORDERS, FEMALE

Adverse events/Assigned treatment		Total		Days of treatment															
				0-7		8-14		15-21		22-28		29-35		36-42		> 42			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
CERVICITIS	Reboxetine	1	100	1	100														
MENSTRUAL DISORDER	Infrequ	1	100							1	100								
	Reboxetine	1	100					1	100										

(some adverse events are grouped in clusters)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HERPES SIMPLEX	Reboxetine	1	100			1	100										
OTITIS MEDIA	Imipramine	1	100					1	100								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
BRONCHITIS	Inigrandine	2	100			1	50.0					1	50.0				
	Reboxetine	6	100			1	16.7	2	33.3			1	16.7	2	33.3		
UPPER RESP TRACT INFECTION	Inigrandine	3	100			1	33.3							2	66.7		
	Reboxetine	2	100					1	50.0			1	50.0				
SINUSITIS	Inigrandine	1	100	1	100												
	Reboxetine	2	100							1	50.0	1	50.0				
SPUTUM INCREASED	Inigrandine	2	100					1	50.0	1	50.0						
RHINITIS	Reboxetine	2	100					1	50.0	1	50.0						
COUGHING	Inigrandine	1	100							1	100						
ASTHMA	Inigrandine	1	100					1	100								

(some adverse events are grouped in clusters)

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
ERYTHEMA / RASH	Imipramine	2	100			1	50.0							1	50.0		
	Reboxetine	3	100	1	33.3			1	33.3			1	33.3				
PRURITUS	Reboxetine	1	100	1	100												
ALOPECIA	Reboxetine	1	100									1	100				
DERMATITIS FUNGAL	Reboxetine	1	100									1	100				

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment																	
				0-7		8-14		15-21		22-28		29-35		36-42		> 42					
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%				
TASTE PERVERSION	Indpramine	2	100	2	100																
	Reboxetine	2	100	1	50.0					1	50.0										
TASTE LOSS	Indpramine	1	100	1	100																

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
URINARY HESITANCY / RETENTION	Imipramine	7	100	2	28.6					2	28.6	3	42.9				
	Reboxetine	11	100	6	54.5	4	36.4					1	9.1				
URINARY TRACT INFECTION	Imipramine	1	100					1	100								
	Reboxetine	3	100	1	33.3			1	33.3	1	33.3						
CYSTITIS HAEMORRHAGIC	Reboxetine	1	100									1	100				

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 45

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: VISION DISORDERS

Adverse events/Assigned treatment		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
BLURRED VISION	Ixlpramine	6	100	5	83.3					1	16.7						
	Reboxetine	4	100	4	100												

(some adverse events are grouped in clusters)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 46

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Body system	Assigned treatment																
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	69	100	49	71.0	4	5.8	6	8.7	3	4.3	4	5.8	3	4.3		
	Reboxetine	53	100	31	58.5	7	13.2	4	7.5	6	11.3	2	3.8	3	5.7		
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	55	100	26	47.3	7	12.7	11	20.0	6	10.9	2	3.6	3	5.5		
	Reboxetine	41	100	13	31.7	4	9.8	9	22.0	3	7.3	4	9.8	7	17.1	1	2.4
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	38	100	20	52.6	10	26.3	1	2.6	3	7.9	3	7.9	1	2.6		
	Reboxetine	42	100	26	61.9	6	14.3	3	7.1	2	4.8	3	7.1	2	4.8		
PSYCHIATRIC DISORDERS	Imipramine	40	100	16	40.0	5	12.5	5	12.5	8	20.0	5	12.5	1	2.5		
	Reboxetine	32	100	19	59.4	7	21.9	3	9.4			2	6.3	1	3.1		
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	42	100	19	45.2	8	19.0	3	7.1	4	9.5	6	14.3	2	4.8		
	Reboxetine	34	100	10	29.4	6	17.6	4	11.8	4	11.8	7	20.6	2	5.9	1	2.9
URINARY SYSTEM DISORDERS	Imipramine	8	100	2	25.0			1	12.5	2	25.0	3	37.5				
	Reboxetine	15	100	7	46.7	4	26.7	1	6.7	1	6.7	2	13.3				
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	13	100	7	53.8	3	23.1			1	7.7	1	7.7	1	7.7		
	Reboxetine	12	100	4	33.3	2	16.7	2	16.7	1	8.3	1	8.3	2	16.7		
VISION DISORDERS	Imipramine	6	100	5	83.3					1	16.7						
	Reboxetine	4	100	4	100												
RESPIRATORY SYSTEM DISORDERS	Imipramine	10	100	1	10.0	2	20.0	2	20.0	2	20.0	1	10.0	2	20.0		
	Reboxetine	12	100			1	8.3	4	33.3	2	16.7	3	25.0	2	16.7		
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	3	100	1	33.3			2	66.7								
	Reboxetine	3	100					1	33.3	2	66.7						

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 46

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Total		Days of treatment													
				0-7		8-14		15-21		22-28		29-35		36-42		> 42	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
Body system	Assigned treatment																
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine	4	100					3	75.0					1	25.0		
	Reboxetine	3	100					2	66.7					1	33.3		
SPECIAL SENSES OTHER, DISORDERS	Imipramine	3	100	3	100												
	Reboxetine	2	100	1	50.0					1	50.0						
SKIN AND APPENDAGES DISORDERS	Imipramine	2	100			1	50.0							1	50.0		
	Reboxetine	6	100	2	33.3			1	16.7			3	50.0				
MUSCOLO-SKELETAL SYSTEM DISORDERS	Imipramine	6	100	1	16.7			1	16.7	1	16.7	2	33.3	1	16.7		
	Reboxetine	3	100	1	33.3	1	33.3					1	33.3				
REPRODUCTIVE DISORDERS, FEMALE	Imipramine	1	100							1	100						
	Reboxetine	2	100	1	50.0			1	50.0								
HEARING AND VESTIBULAR DISORDERS	Imipramine	2	100	1	50.0			1	50.0								
RESISTANCE MECHANISM DISORDERS	Imipramine	1	100					1	100								
	Reboxetine	1	100			1	100										
ENDOCRINE DISORDERS	Reboxetine	1	100	1	100												
HEMATOLOGY DISORDERS	Reboxetine	1	100													1	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
All adverse events	Mild	95	90	5		89	5	1
	Moderate	127	122	2	3	123	2	2
	Severe	43	43			43		
	Unknown	2	2			2		
	Total	267	257	7	3	257	7	3
MOUTH DRY	Mild	16	15	1		15	1	
	Moderate	12	12			12		
	Severe	5	5			5		
	Total	33	32	1		32	1	
HEADACHE	Mild	7	7			6		1
	Moderate	14	13		1	13		1
	Severe	6	6			6		
	Total	27	26		1	25		2
SWEATING INCREASED	Mild	10	10			10		
	Moderate	6	6			6		
	Severe	3	3			3		
	Unknown	1	1			1		
	Total	20	20			20		
DIZZINESS	Mild	7	7			7		
	Moderate	5	5			5		
	Unknown	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (=)	High dose	Overdose	Low dose (=)	High dose	Overdose
DIZZINESS	Total	13	13			13		
INSOMNIA	Moderate	4	4			4		
	Severe	7	7			7		
	Total	11	11			11		
TACHYCARDIA	Mild	5	3	2		3	2	
	Moderate	5	5			5		
	Total	10	8	2		8	2	
TREMOR	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
CONSTIPATION	Mild	3	3			3		
	Moderate	9	9			9		
	Severe	1	1			1		
	Total	13	13			13		
NAUSEA	Mild	6	6			6		
	Moderate	8	7		1	7		1
	Severe	2	2			2		
	Total	16	15		1	15		1
SOMNOLENCE	Mild	2	2			2		
	Moderate	2	2			2		
	Total	4	4			4		

(CONTINUED)

(=) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
AGITATION	Mild	1	1			1		
	Moderate	3	3			3		
	Severe	4	4			4		
	Total	8	8			8		
PALPITATION	Mild	1	1			1		
	Moderate	4	4			4		
	Total	5	5			5		
FATIGUE	Mild	1	1			1		
	Moderate	4	3		1	4		
	Total	5	4		1	5		
URINARY RETENTION	Moderate	1	1			1		
	Severe	2	2			2		
	Total	3	3			3		
VISION ABNORMAL	Mild	2	2			2		
	Moderate	1	1			1		
	Severe	1	1			1		
	Total	4	4			4		
UPPER RESP TRACT INFECTION	Mild	2	1	1		1	1	
	Total	2	1	1		1	1	
MICTURITION DISORDER	Mild	6	6			6		
	Moderate	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
MICTURITION DISORDER	Severe	1	1			1		
	Total	8	8			8		
INFLUENZA-LIKE SYMPTOMS	Mild	1	1			1		
	Moderate	3	3			3		
	Total	4	4			4		
BACK PAIN	Mild	2	2			2		
	Total	2	2			2		
RASH	Mild	2	2			2		
	Moderate	1		1			1	
	Total	3	2	1		2	1	
PARAESTHESIA	Mild	1	1			1		
	Moderate	3	3			3		
	Total	4	4			4		
FLATULENCE	Moderate	2	2			2		
	Severe	1	1			1		
	Total	3	3			3		
GAMMA-GT INCREASED	Mild	1	1			1		
	Total	1	1			1		
HEPATIC ENZYMES INCREASED	Mild	1	1			1		
	Total	1	1			1		
ARTHRALGIA	Moderate	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ARTHRALGIA	Total	1	1			1		
ANOREXIA	Moderate	1	1			1		
	Total	1	1			1		
HYPOTENSION POSTURAL	Mild	1	1			1		
	Total	1	1			1		
TASTE PERVERSION	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
LIBIDO DECREASED	Moderate	3	3			3		
	Total	3	3			3		
ABDOMINAL PAIN	Mild	1	1			1		
	Moderate	2	2			2		
	Total	3	3			3		
BRONCHITIS	Moderate	6	6			6		
	Total	6	6			6		
ASTHENIA	Moderate	1	1			1		
	Total	1	1			1		
HYPOAESTHESIA	Mild	1	1			1		
	Total	1	1			1		
FLUSHING	Mild	1	1			1		
	Severe	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (=)	High dose	Overdose	Low dose (=)	High dose	Overdose
FLUSHING	Total	2	2			2		
SINUSITIS	Moderate	2	2			2		
	Total	2	2			2		
URINARY TRACT INFECTION	Mild	1	1			1		
	Moderate	2	2			2		
	Total	3	3			3		
VOMITING	Moderate	1	1			1		
	Total	1	1			1		
GASTROENTERITIS	Moderate	1	1				1	
	Total	1	1				1	
HYPERCHOLESTEROLAEMIA	Moderate	1	1			1		
	Total	1	1			1		
HYPERURICAEMIA	Moderate	1	1			1		
	Total	1	1			1		
FEVER	Moderate	1	1			1		
	Total	1	1			1		
DIARRHOEA	Severe	1	1			1		
	Total	1	1			1		
DELUSION	Severe	1	1			1		
	Total	1	1			1		
HYPERTENSION	Mild	2	1	1		1	1	

(CONTINUED)

(=) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (=)	High dose	Overdose	Low dose (=)	High dose	Overdose
HYPERTENSION	Moderate	3	3			3		
	Severe	2	2			2		
	Total	7	6	1		6	1	
MENSTRUAL DISORDER	Moderate	1	1			1		
	Total	1	1			1		
NERVOUSNESS	Moderate	2	2			2		
	Severe	1	1			1		
	Total	3	3			3		
DYSPEPSIA	Moderate	3	3			3		
	Total	3	3			3		
ECG ABNORMAL	Mild	2	2			2		
	Total	2	2			2		
RHINITIS	Mild	2	2			2		
	Total	2	2			2		
SUICIDE ATTEMPT	Moderate	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
ALOPECIA	Mild	1	1			1		
	Total	1	1			1		
SGPT INCREASED	Mild	1	1			1		
	Total	1	1			1		

(CONTINUED)

(=) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
GLOBULINS INCREASED	Mild	1	1			1		
	Total	1	1			1		
LEUKOCYTOSIS	Mild	1	1			1		
	Total	1	1			1		
CERVICITIS	Mild	1	1			1		
	Total	1	1			1		
DERMATITIS FUNGAL	Moderate	1	1			1		
	Total	1	1			1		
PRURITUS	Moderate	1	1			1		
	Total	1	1			1		
BUNDLE BRANCH BLOCK	Moderate	1	1			1		
	Total	1	1			1		
CYSTITIS HAEMORRHAGIC	Moderate	1		1		1		
	Total	1		1		1		
HYPOTHYROIDISM	Severe	1	1			1		
	Total	1	1			1		
PAIN	Severe	1	1			1		
	Total	1	1			1		
HERPES SIMPLEX	Severe	1	1			1		
	Total	1	1			1		

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (=)	High dose	Overdose	Low dose (=)	High dose	Overdose
All adverse events	Mild	120	114	3	3	117	3	
	Moderate	134	128	1	5	132	1	1
	Severe	47	46	1		47		
	Unknown	2	2			2		
	Total	303	290	5	8	298	4	1
MOUTH DRY	Mild	21	20		1	21		
	Moderate	22	21		1	22		
	Severe	5	5			5		
	Total	48	46		2	48		
HEADACHE	Mild	5	5			5		
	Moderate	14	13		1	14		
	Severe	2	2			2		
	Total	21	20		1	21		
SWEATING INCREASED	Mild	10	10			10		
	Moderate	7	7			7		
	Severe	3	3			3		
	Total	20	20			20		
DIZZINESS	Mild	11	10		1	11		
	Moderate	6	6			6		
	Severe	2	2			2		
	Total	19	18		1	19		

(CONTINUED)

(=) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
INSOMNIA	Mild	4	4			4		
	Moderate	9	9			9		
	Severe	3	3			3		
	Total	16	16			16		
TACHYCARDIA	Mild	5	5			5		
	Moderate	9	9			9		
	Severe	1	1			1		
	Total	15	15			15		
TREMOR	Mild	5	4	1		4	1	
	Moderate	5	4		1	4		1
	Severe	3	3			3		
	Total	13	11	1	1	11	1	1
CONSTIPATION	Mild	7	6	1		6	1	
	Moderate	5	5			5		
	Severe	1	1			1		
	Total	13	12	1		12	1	
NAUSEA	Mild	6	6			6		
	Moderate	6	6			6		
	Severe	1	1			1		
	Total	13	13			13		
SOMNOLENCE	Mild	5	4		1	5		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
SOMNOLENCE	Moderate	3	2		1	3		
	Severe	2	2			2		
	Total	10	8		2	10		
AGITATION	Mild	3	3			3		
	Moderate	3	3			3		
	Severe	3	3			3		
	Total	9	9			9		
HYPOTENSION	Mild	2	2			2		
	Moderate	4	4			4		
	Total	6	6			6		
PALPITATION	Mild	4	4			4		
	Moderate	1	1			1		
	Severe	1	1			1		
	Total	6	6			6		
FATIGUE	Mild	1	1			1		
	Severe	4	4			4		
	Total	5	5			5		
URINARY RETENTION	Mild	1	1			1		
	Moderate	2	2			2		
	Severe	1	1			1		
	Total	4	4			4		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (=)	High dose	Overdose	Low dose (=)	High dose	Overdose
VISION ABNORMAL	Mild	2	2			2		
	Moderate	2	1		1	2		
	Total	4	3		1	4		
UPPER RESP TRACT INFECTION	Mild	3	3			3		
	Total	3	3			3		
MICTURITION DISORDER	Mild	1	1			1		
	Moderate	2	2			2		
	Total	3	3			3		
INFLUENZA-LIKE SYMPTOMS	Mild	2	2			2		
	Moderate	1	1			1		
	Total	3	3			3		
BACK PAIN	Moderate	2	2			2		
	Severe	1	1			1		
	Total	3	3			3		
RASH	Mild	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
PARAESTHESIA	Mild	2	2			2		
	Total	2	2			2		
ACCOMMODATION ABNORMAL	Mild	2	2			2		
	Total	2	2			2		

(CONTINUED)

(=) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
TINNITUS	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
FLATULENCE	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
GAMMA-GT INCREASED	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
HEPATIC ENZYMES INCREASED	Mild	1		1			1	
	Moderate	1	1			1		
	Total	2	1	1		1	1	
SPUTUM INCREASED	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
HOT FLUSHES	Mild	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
ARTHRALGIA	Moderate	2	1	1		1	1	
	Total	2	1	1		1	1	
ANOREXIA	Moderate	2	2			2		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ANOREXIA	Total	2	2			2		
HYPOTENSION PORTURAL	Moderate	2	2			2		
	Total	2	2			2		
TASTE PERVERSION	Moderate	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
CONFUSION	Moderate	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
LIBIDO DECREASED	Moderate	2	2			2		
	Total	2	2			2		
ABDOMINAL PAIN	Moderate	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
BRONCHITIS	Moderate	2	2			2		
	Total	2	2			2		
CHEST PAIN	Moderate	2	2			2		
	Total	2	2			2		
ASTHENIA	Severe	2	2			2		
	Total	2	2			2		
HYPOAESTHESIA	Mild	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
HYPOAESTHESIA	Total	1	1			1		
VERTIGO	Mild	1	1			1		
	Total	1	1			1		
FLUSHING	Mild	1	1			1		
	Total	1	1			1		
SALIVA INCREASED	Mild	1	1			1		
	Total	1	1			1		
HYPERLIPAEMIA	Mild	1	1			1		
	Total	1	1			1		
AV BLOCK	Mild	1	1			1		
	Total	1	1			1		
EXTRASYSTOLES	Mild	1	1			1		
	Total	1	1			1		
SINUSITIS	Mild	1	1			1		
	Total	1	1			1		
ASTHMA	Mild	1	1			1		
	Total	1	1			1		
URINARY TRACT INFECTION	Mild	1	1			1		
	Total	1	1			1		
OTITIS MEDIA	Mild	1	1			1		
	Total	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
HYPERKINESIA	Moderate	1	1			1		
	Total	1	1			1		
VOMITING	Moderate	1	1			1		
	Total	1	1			1		
TACHYCARDIA SUPRAVENTRICULAR	Moderate	1	1			1		
	Total	1	1			1		
ANXIETY	Moderate	1	1			1		
	Total	1	1			1		
APPETITE INCREASED	Moderate	1	1			1		
	Total	1	1			1		
DYSPHAGIA	Moderate	1	1			1		
	Total	1	1			1		
GASTROENTERITIS	Moderate	1	1			1		
	Total	1	1			1		
HYPERCHOLESTEROLAEMIA	Moderate	1	1			1		
	Total	1	1			1		
HYPERURICAEMIA	Moderate	1	1			1		
	Total	1	1			1		
COUGHING	Moderate	1	1			1		
	Total	1	1			1		
FEVER	Moderate	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity		Adverse events	Dose taken on onset date			Highest dose taken from 3 days before		
		Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
FEVER	Total	1	1			1		
ARTHROSIS	Severe	1	1			1		
	Total	1	1			1		
HYPOKINESIA	Severe	1	1			1		
	Total	1	1			1		
DIARRHOEA	Severe	1	1			1		
	Total	1	1			1		
TASTE LOSS	Severe	1	1			1		
	Total	1	1			1		
DELUSION	Severe	1	1			1		
	Total	1	1			1		
MANIC REACTION	Severe	1	1			1		
	Total	1	1			1		
OESOPHAGITIS	Severe	1		1		1		
	Total	1		1		1		
HYPERTENSION	Unknown	1	1			1		
	Total	1	1			1		
MENSTRUAL DISORDER	Unknown	1	1			1		
	Total	1	1			1		

(*) all remainder patients
REBOXETINE - low dose <= 8 mg/day, high dose > 8 mg/day
IMIPRAMINE - low dose <= 150 mg/day, high dose > 150 mg/day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 48

ADVERSE EVENTS: NUMBER OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT BY MAXIMAL SEVERITY LEVEL, SEX, AGE, DSMIII

Assigned treatment / Severity level		Sex						Age						DSM III			
		Total		Female		Male		18 - 30		31 - 45		> 45		296.2		296.3	
		No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%	No. Pt	%
Imipramine	Mild	22	21.4	11	16.7	11	29.7	8	27.6	6	24.0	8	16.3	10	21.7	12	21.1
	Moderate	50	48.5	33	50.0	17	45.9	13	44.8	11	44.0	26	53.1	22	47.8	28	49.1
	Severe	31	30.1	22	33.3	9	24.3	8	27.6	8	32.0	15	30.6	14	30.4	17	29.8
	Total	103	100.0	66	100.0	37	100.0	29	100.0	25	100.0	49	100.0	46	100.0	57	100.0
Reboxetine	Mild	24	22.6	14	21.2	10	25.0	7	43.8	9	25.7	8	14.5	11	26.8	13	20.0
	Moderate	52	49.1	34	51.5	18	45.0	7	43.8	14	40.0	31	56.4	24	58.5	28	43.1
	Severe	30	28.3	18	27.3	12	30.0	2	12.5	12	34.3	16	29.1	6	14.6	24	36.9
	Total	106	100.0	66	100.0	40	100.0	16	100.0	35	100.0	55	100.0	41	100.0	65	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
All adverse events	Mild	11	16.7	16.7	11	29.7	29.7	22	21.4	21.4	14	21.2	21.2	10	25.0	25.0	24	22.6	22.6
	Moderate	33	50.0	50.0	17	45.9	45.9	50	48.5	48.5	34	51.5	51.5	18	45.0	45.0	52	49.1	49.1
	Severe	22	33.3	33.3	9	24.3	24.3	31	30.1	30.1	18	27.3	27.3	12	30.0	30.0	30	28.3	28.3
	Total	66	100	100	37	100	100	103	100	100	66	100	100	40	100	100	106	100	100
MOUTH DRY	Mild	11	42.3	16.7	8	42.1	21.6	19	42.2	18.4	8	38.1	12.1	8	72.7	20.0	16	50.0	15.1
	Moderate	11	42.3	16.7	10	52.6	27.0	21	46.7	20.4	8	38.1	12.1	3	27.3	7.5	11	34.4	10.4
	Severe	4	15.4	6.1	1	5.3	2.7	5	11.1	4.9	5	23.8	7.6				5	15.6	4.7
	Total	26	100	39.4	19	100	51.4	45	100	43.7	21	100	31.8	11	100	27.5	32	100	30.2
HEADACHE	Mild	2	20.0	3.0	2	25.0	5.4	4	22.2	3.9	3	25.0	4.5	2	22.2	5.0	5	23.8	4.7
	Moderate	8	80.0	12.1	4	50.0	10.8	12	66.7	11.7	7	58.3	10.6	3	33.3	7.5	10	47.6	9.4
	Severe				2	25.0	5.4	2	11.1	1.9	2	16.7	3.0	4	44.4	10.0	6	28.6	5.7
	Total	10	100	15.2	8	100	21.6	18	100	17.5	12	100	18.2	9	100	22.5	21	100	19.8
SWEATING INCREASED	Mild	5	55.6	7.6	4	44.4	10.8	9	50.0	8.7	3	42.9	4.5	6	54.5	15.0	9	50.0	8.5
	Moderate	3	33.3	4.5	3	33.3	8.1	6	33.3	5.8	2	28.6	3.0	4	36.4	10.0	6	33.3	5.7
	Severe	1	11.1	1.5	2	22.2	5.4	3	16.7	2.9	2	28.6	3.0	1	9.1	2.5	3	16.7	2.8
	Total	9	100	13.6	9	100	24.3	18	100	17.5	7	100	10.6	11	100	27.5	18	100	17.0
DIZZINESS	Mild	5	50.0	7.6	5	62.5	13.5	10	55.6	9.7	6	66.7	9.1	1	33.3	2.5	7	58.3	6.6
	Moderate	4	40.0	6.1	2	25.0	5.4	6	33.3	5.8	3	33.3	4.5	2	66.7	5.0	5	41.7	4.7
	Severe	1	10.0	1.5	1	12.5	2.7	2	11.1	1.9									
	Total	10	100	15.2	8	100	21.6	18	100	17.5	9	100	13.6	3	100	7.5	12	100	11.3

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment															
		Imipramine									Reboxetine						
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
NAUSEA	Mild	3	33.3	4.5	3	75.0	8.1	6	46.2	5.8	3	23.1	4.5	3	100	7.5	6	37.5	5.7
	Moderate	5	55.6	7.6	1	25.0	2.7	6	46.2	5.8	8	61.5	12.1				8	50.0	7.5
	Severe	1	11.1	1.5				1	7.7	1.0	2	15.4	3.0				2	12.5	1.9
	Total	9	100	13.6	4	100	10.8	13	100	12.6	13	100	19.7	3	100	7.5	16	100	15.1
CONSTIPATION	Mild	2	25.0	3.0	5	100	13.5	7	53.8	6.8	2	22.2	3.0	1	25.0	2.5	3	23.1	2.8
	Moderate	5	62.5	7.6				5	38.5	4.9	6	66.7	9.1	3	75.0	7.5	9	69.2	8.5
	Severe	1	12.5	1.5				1	7.7	1.0	1	11.1	1.5				1	7.7	0.9
	Total	8	100	12.1	5	100	13.5	13	100	12.6	9	100	13.6	4	100	10.0	13	100	12.3
INSOMNIA	Mild				2	28.6	5.4	2	14.3	1.9									
	Moderate	4	57.1	6.1	5	71.4	13.5	9	64.3	8.7	3	37.5	4.5	1	50.0	2.5	4	40.0	3.8
	Severe	3	42.9	4.5				3	21.4	2.9	5	62.5	7.6	1	50.0	2.5	6	60.0	5.7
	Total	7	100	10.6	7	100	18.9	14	100	13.6	8	100	12.1	2	100	5.0	10	100	9.4
TACHYCARDIA	Mild	2	20.0	3.0	1	33.3	2.7	3	23.1	2.9	1	33.3	1.5	2	40.0	5.0	3	37.5	2.8
	Moderate	7	70.0	10.6	2	66.7	5.4	9	69.2	8.7	2	66.7	3.0	3	60.0	7.5	5	62.5	4.7
	Severe	1	10.0	1.5				1	7.7	1.0									
	Total	10	100	15.2	3	100	8.1	13	100	12.6	3	100	4.5	5	100	12.5	8	100	7.5
TREMOR	Mild	3	37.5	4.5	2	40.0	5.4	5	38.5	4.9	1	50.0	1.5				1	50.0	0.9
	Moderate	2	25.0	3.0	3	60.0	8.1	5	38.5	4.9	1	50.0	1.5				1	50.0	0.9
	Severe	3	37.5	4.5				3	23.1	2.9									
	Total	8	100	12.1	5	100	13.5	13	100	12.6	2	100	3.0				2	100	1.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
AGITATION	Mild	2	33.3	3.0	1	33.3	2.7	3	33.3	2.9	1	25.0	1.5				1	16.7	0.9
	Moderate	2	33.3	3.0	1	33.3	2.7	3	33.3	2.9	1	25.0	1.5	1	50.0	2.5	2	33.3	1.9
	Severe	2	33.3	3.0	1	33.3	2.7	3	33.3	2.9	2	50.0	3.0	1	50.0	2.5	3	50.0	2.8
	Total	6	100	9.1	3	100	8.1	9	100	8.7	4	100	6.1	2	100	5.0	6	100	5.7
SOMNOLENCE	Mild	2	40.0	3.0	2	50.0	5.4	4	44.4	3.9	1	50.0	1.5	1	50.0	2.5	2	50.0	1.9
	Moderate	1	20.0	1.5	2	50.0	5.4	3	33.3	2.9	1	50.0	1.5	1	50.0	2.5	2	50.0	1.9
	Severe	2	40.0	3.0				2	22.2	1.9									
	Total	5	100	7.6	4	100	10.8	9	100	8.7	2	100	3.0	2	100	5.0	4	100	3.8
MICTURITION DISORDER	Mild	1	50.0	1.5				1	33.3	1.0	1	100	1.5	5	71.4	12.5	6	75.0	5.7
	Moderate	1	50.0	1.5	1	100	2.7	2	66.7	1.9				1	14.3	2.5	1	12.5	0.9
	Severe													1	14.3	2.5	1	12.5	0.9
	Total	2	100	3.0	1	100	2.7	3	100	2.9	1	100	1.5	7	100	17.5	8	100	7.5
PALPITATION	Mild	2	66.7	3.0	1	50.0	2.7	3	60.0	2.9	1	20.0	1.5				1	20.0	0.9
	Moderate				1	50.0	2.7	1	20.0	1.0	4	80.0	6.1				4	80.0	3.8
	Severe	1	33.3	1.5				1	20.0	1.0									
	Total	3	100	4.5	2	100	5.4	5	100	4.9	5	100	7.6				5	100	4.7
FATIGUE	Mild				1	50.0	2.7	1	20.0	1.0				1	100	2.5	1	25.0	0.9
	Moderate										3	100	4.5				3	75.0	2.8
	Severe	3	100	4.5	1	50.0	2.7	4	80.0	3.9									
	Total	3	100	4.5	2	100	5.4	5	100	4.9	3	100	4.5	1	100	2.5	4	100	3.8

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
VISION ABNORMAL	Mild				2	66.7	5.4	2	50.0	1.9	2	66.7	3.0				2	50.0	1.9
	Moderate	1	100	1.5	1	33.3	2.7	2	50.0	1.9	1	33.3	1.5				1	25.0	0.9
	Severe													1	100	2.5	1	25.0	0.9
	Total	1	100	1.5	3	100	8.1	4	100	3.9	3	100	4.5	1	100	2.5	4	100	3.8
BRONCHITIS	Moderate	1	100	1.5				1	100	1.0	5	100	7.6	1	100	2.5	6	100	5.7
	Total	1	100	1.5				1	100	1.0	5	100	7.6	1	100	2.5	6	100	5.7
URINARY RETENTION	Mild	1	25.0	1.5				1	25.0	1.0									
	Moderate	2	50.0	3.0				2	50.0	1.9									
	Severe	1	25.0	1.5				1	25.0	1.0				2	100	5.0	2	100	1.9
	Total	4	100	6.1				4	100	3.9				2	100	5.0	2	100	1.9
HYPERTENSION	Mild										1	25.0	1.5				1	20.0	0.9
	Moderate										2	50.0	3.0				2	40.0	1.9
	Severe										1	25.0	1.5	1	100	2.5	2	40.0	1.9
	Missing				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0	4	100	6.1	1	100	2.5	5	100	4.7
INFLUENZA-LIKE SYMPTOMS	Mild	1	50.0	1.5				1	50.0	1.0	1	50.0	1.5				1	25.0	0.9
	Moderate	1	50.0	1.5				1	50.0	1.0	1	50.0	1.5	2	100	5.0	3	75.0	2.8
	Total	2	100	3.0				2	100	1.9	2	100	3.0	2	100	5.0	4	100	3.8
RASH	Mild	1	50.0	1.5				1	50.0	1.0	2	66.7	3.0				2	66.7	1.9
	Moderate										1	33.3	1.5				1	33.3	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
RASH	Severe	1	50.0	1.5				1	50.0	1.0									
	Total	2	100	3.0				2	100	1.9	3	100	4.5				3	100	2.8
PARAESTHESIA	Mild	1	100	1.5	1	100	2.7	2	100	1.9									
	Moderate										2	100	3.0	1	100	2.5	3	100	2.8
	Total	1	100	1.5	1	100	2.7	2	100	1.9	2	100	3.0	1	100	2.5	3	100	2.8
HYPOTENSION	Mild				2	66.7	5.4	2	40.0	1.9									
	Moderate	2	100	3.0	1	33.3	2.7	3	60.0	2.9									
	Total	2	100	3.0	3	100	8.1	5	100	4.9									
LIBIDO DECREASED	Moderate				2	100	5.4	2	100	1.9				3	100	7.5	3	100	2.8
	Total				2	100	5.4	2	100	1.9				3	100	7.5	3	100	2.8
ABDOMINAL PAIN	Mild										1	50.0	1.5				1	33.3	0.9
	Moderate	1	50.0	1.5				1	50.0	1.0	1	50.0	1.5	1	100	2.5	2	66.7	1.9
	Severe	1	50.0	1.5				1	50.0	1.0									
	Total	2	100	3.0				2	100	1.9	2	100	3.0	1	100	2.5	3	100	2.8
FLATULENCE	Mild	1	50.0	1.5				1	50.0	1.0									
	Moderate	1	50.0	1.5				1	50.0	1.0	2	66.7	3.0				2	66.7	1.9
	Severe										1	33.3	1.5				1	33.3	0.9
	Total	2	100	3.0				2	100	1.9	3	100	4.5				3	100	2.8
TASTE PERVERSION	Mild										1	50.0	1.5				1	50.0	0.9
	Moderate	1	50.0	1.5				1	50.0	1.0	1	50.0	1.5				1	50.0	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
TASTE PERVERSION	Severe	1	50.0	1.5				1	50.0	1.0									
	Total	2	100	3.0				2	100	1.9	2	100	3.0				2	100	1.9
UPPER RESP TRACT INFECTION	Mild	1	100	1.5	1	100	2.7	2	100	1.9	2	100	3.0				2	100	1.9
	Total	1	100	1.5	1	100	2.7	2	100	1.9	2	100	3.0				2	100	1.9
BACK PAIN	Mild										1	100	1.5	1	100	2.5	2	100	1.9
	Moderate	1	100	1.5				1	50.0	1.0									
	Severe				1	100	2.7	1	50.0	1.0									
	Total	1	100	1.5	1	100	2.7	2	100	1.9	1	100	1.5	1	100	2.5	2	100	1.9
ARTHRALGIA	Moderate	2	100	3.0				2	100	1.9	1	100	1.5				1	100	0.9
	Total	2	100	3.0				2	100	1.9	1	100	1.5				1	100	0.9
ANOREXIA	Moderate	2	100	3.0				2	100	1.9				1	100	2.5	1	100	0.9
	Total	2	100	3.0				2	100	1.9				1	100	2.5	1	100	0.9
FLUSHING	Mild				1	100	2.7	1	100	1.0				1	100	2.5	1	50.0	0.9
	Severe										1	100	1.5				1	50.0	0.9
	Total				1	100	2.7	1	100	1.0	1	100	1.5	1	100	2.5	2	100	1.9
HYPOTENSION POSTURAL	Mild										1	100	1.5				1	100	0.9
	Moderate	2	100	3.0				2	100	1.9									
	Total	2	100	3.0				2	100	1.9	1	100	1.5				1	100	0.9
NERVOUSNESS	Moderate										2	66.7	3.0				2	66.7	1.9
	Severe										1	33.3	1.5				1	33.3	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
NERVOUSNESS	Total										3	100	4.5				3	100	2.8
DYSPEPSIA	Moderate										3	100	4.5				3	100	2.8
	Total										3	100	4.5				3	100	2.8
GAMMA-GT INCREASED	Mild	1	50.0	1.5				1	50.0	1.0	1	100	1.5				1	100	0.9
	Moderate	1	50.0	1.5				1	50.0	1.0									
	Total	2	100	3.0				2	100	1.9	1	100	1.5				1	100	0.9
SINUSITIS	Mild	1	100	1.5				1	100	1.0									
	Moderate										1	100	1.5	1	100	2.5	2	100	1.9
	Total	1	100	1.5				1	100	1.0	1	100	1.5	1	100	2.5	2	100	1.9
URINARY TRACT INFECTION	Mild	1	100	1.5				1	100	1.0									
	Moderate										2	100	3.0				2	100	1.9
	Total	1	100	1.5				1	100	1.0	2	100	3.0				2	100	1.9
ASTHENIA	Moderate													1	100	2.5	1	100	0.9
	Severe	2	100	3.0				2	100	1.9									
	Total	2	100	3.0				2	100	1.9				1	100	2.5	1	100	0.9
HYPOAESTHESIA	Mild	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
	Total	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
ACCOMMODATION ABNORMAL	Mild				2	100	5.4	2	100	1.9									
	Total				2	100	5.4	2	100	1.9									
DIARRHOEA	Severe	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
DIARRHOEA	Total	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
VOMITING	Moderate	1	100	1.5				1	100	1.0				1	100	2.5	1	100	0.9
	Total	1	100	1.5				1	100	1.0				1	100	2.5	1	100	0.9
CONFUSION	Moderate	1	50.0	1.5				1	50.0	1.0									
	Severe	1	50.0	1.5				1	50.0	1.0									
	Total	2	100	3.0				2	100	1.9									
DELUSION	Severe				1	100	2.7	1	100	1.0	1	100	1.5				1	100	0.9
	Total				1	100	2.7	1	100	1.0	1	100	1.5				1	100	0.9
SUICIDE ATTEMPT	Moderate										1	100	1.5				1	50.0	0.9
	Severe													1	100	2.5	1	50.0	0.9
	Total										1	100	1.5	1	100	2.5	2	100	1.9
GASTROENTERITIS	Moderate	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
	Total	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
HEPATIC ENZYMES INCREASED	Mild										1	100	1.5				1	100	0.9
	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
HYPERCHOLESTEROLAEMIA	Moderate	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
	Total	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
HYPERURICAEMIA	Moderate	1	100	1.5				1	100	1.0				1	100	2.5	1	100	0.9
	Total	1	100	1.5				1	100	1.0				1	100	2.5	1	100	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
ECG ABNORMAL	Mild													2	100	5.0	2	100	1.9
	Total													2	100	5.0	2	100	1.9
RHINITIS	Mild										2	100	3.0				2	100	1.9
	Total										2	100	3.0				2	100	1.9
SPUTUM INCREASED	Mild				1	100	2.7	1	50.0	1.0									
	Moderate	1	100	1.5				1	50.0	1.0									
	Total	1	100	1.5	1	100	2.7	2	100	1.9									
MENSTRUAL DISORDER	Moderate										1	100	1.5				1	100	0.9
	Missing	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0	1	100	1.5				1	100	0.9
CHEST PAIN	Moderate				2	100	5.4	2	100	1.9									
	Total				2	100	5.4	2	100	1.9									
FEVER	Moderate				1	100	2.7	1	100	1.0				1	100	2.5	1	100	0.9
	Total				1	100	2.7	1	100	1.0				1	100	2.5	1	100	0.9
HOT FLUSHES	Mild				1	100	2.7	1	50.0	1.0									
	Severe	1	100	1.5				1	50.0	1.0									
	Total	1	100	1.5	1	100	2.7	2	100	1.9									
ALOPECIA	Mild										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
DERMATITIS FUNGAL	Moderate										1	100	1.5				1	100	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
DERMATITIS FUNGAL	Total										1	100	1.5				1	100	0.9
PRURITUS	Moderate										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
ARTHROSIS	Severe				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0									
HYPERKINESIA	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
HYPOKINESIA	Severe	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
VERTIGO	Mild	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
SALIVA INCREASED	Mild				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0									
TACHYCARDIA SUPRAVENTRICULAR	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
TINNITUS	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
TASTE LOSS	Severe	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
ANXIETY	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
MANIC REACTION	Severe	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
APPETITE INCREASED	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
DYSPHAGIA	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
OESOPHAGITIS	Severe	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
SGPT INCREASED	Mild													1	100	2.5	1	100	0.9
	Total													1	100	2.5	1	100	0.9
GLOBULINS INCREASED	Mild										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
HYPERLIPAEMIA	Mild	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
HYPOTHYROIDISM	Severe										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
AV BLOCK	Mild				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0									

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 49

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity		Assigned treatment																		
		Imipramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
BUNDLE BRANCH BLOCK	Moderate													1	100	2.5	1	100	0.9
	Total													1	100	2.5	1	100	0.9
EXTRASYSTOLES	Mild	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
COUGHING	Moderate				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0									
ASTHMA	Mild				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0									
LEUKOCYTOSIS	Mild										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
CYSTITIS HAEMORRHAGIC	Moderate													1	100	2.5	1	100	0.9
	Total													1	100	2.5	1	100	0.9
CERVICITIS	Mild										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
PAIN	Severe										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
OTITIS MEDIA	Mild				1	100	2.7	1	100	1.0									
	Total				1	100	2.7	1	100	1.0									
HERPES SIMPLEX	Severe													1	100	2.5	1	100	0.9
	Total													1	100	2.5	1	100	0.9

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 50

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
All adverse events	Mild	11	16.7	16.7	11	29.7	29.7	22	21.4	21.4	14	21.2	21.2	10	25.0	25.0	24	22.6	22.6
	Moderate	33	50.0	50.0	17	45.9	45.9	50	48.5	48.5	34	51.5	51.5	18	45.0	45.0	52	49.1	49.1
	Severe	22	33.3	33.3	9	24.3	24.3	31	30.1	30.1	18	27.3	27.3	12	30.0	30.0	30	28.3	28.3
	Total	66	100	100	37	100	100	103	100	100	66	100	100	40	100	100	106	100	100
AUTONOMIC NERVOUS SYSTEM DISORDERS	Mild	15	45.5	22.7	10	43.5	27.0	25	44.6	24.3	10	38.5	15.2	11	57.9	27.5	21	46.7	19.8
	Moderate	13	39.4	19.7	11	47.8	29.7	24	42.9	23.3	9	34.6	13.6	7	36.8	17.5	16	35.6	15.1
	Severe	5	15.2	7.6	2	8.7	5.4	7	12.5	6.8	7	26.9	10.6	1	5.3	2.5	8	17.8	7.5
	Total	33	100	50.0	23	100	62.2	56	100	54.4	26	100	39.4	19	100	47.5	45	100	42.5
CARDIOVASCULAR DISORDERS, GENERAL	Mild	8	29.6	12.1	9	60.0	24.3	17	40.5	16.5	8	44.4	12.1	5	45.5	12.5	13	44.8	12.3
	Moderate	15	55.6	22.7	5	33.3	13.5	20	47.6	19.4	8	44.4	12.1	5	45.5	12.5	13	44.8	12.3
	Severe	4	14.8	6.1	1	6.7	2.7	5	11.9	4.9	2	11.1	3.0	1	9.1	2.5	3	10.3	2.8
	Total	27	100	40.9	15	100	40.5	42	100	40.8	18	100	27.3	11	100	27.5	29	100	27.4
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	5	20.8	7.6	6	85.7	16.2	11	35.5	10.7	5	20.0	7.6	3	33.3	7.5	8	23.5	7.5
	Moderate	14	58.3	21.2	1	14.3	2.7	15	48.4	14.6	15	60.0	22.7	6	66.7	15.0	21	61.8	19.8
	Severe	5	20.8	7.6				5	16.1	4.9	5	20.0	7.6				5	14.7	4.7
	Total	24	100	36.4	7	100	18.9	31	100	30.1	25	100	37.9	9	100	22.5	34	100	32.1
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Mild	6	27.3	9.1	2	20.0	5.4	8	25.0	7.8	5	29.4	7.6	2	22.2	5.0	7	26.9	6.6
	Moderate	11	50.0	16.7	6	60.0	16.2	17	53.1	16.5	10	58.8	15.2	3	33.3	7.5	13	50.0	12.3
	Severe	5	22.7	7.6	2	20.0	5.4	7	21.9	6.8	2	11.8	3.0	4	44.4	10.0	6	23.1	5.7
	Total	22	100	33.3	10	100	27.0	32	100	31.1	17	100	25.8	9	100	22.5	26	100	24.5

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 50

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
PSYCHIATRIC DISORDERS	Mild	3	21.4	4.5	4	26.7	10.8	7	24.1	6.8	2	14.3	3.0	1	11.1	2.5	3	13.0	2.8
	Moderate	4	28.6	6.1	9	60.0	24.3	13	44.8	12.6	6	42.9	9.1	6	66.7	15.0	12	52.2	11.3
	Severe	7	50.0	10.6	2	13.3	5.4	9	31.0	8.7	6	42.9	9.1	2	22.2	5.0	8	34.8	7.5
	Total	14	100	21.2	15	100	40.5	29	100	28.2	14	100	21.2	9	100	22.5	23	100	21.7
BODY AS A WHOLE-GENERAL DISORDERS	Mild	1	16.7	1.5	1	20.0	2.7	2	18.2	1.9	1	16.7	1.5	1	20.0	2.5	2	18.2	1.9
	Moderate	1	16.7	1.5	3	60.0	8.1	4	36.4	3.9	4	66.7	6.1	4	80.0	10.0	8	72.7	7.5
	Severe	4	66.7	6.1	1	20.0	2.7	5	45.5	4.9	1	16.7	1.5				1	9.1	0.9
	Total	6	100	9.1	5	100	13.5	11	100	10.7	6	100	9.1	5	100	12.5	11	100	10.4
URINARY SYSTEM DISORDERS	Mild	3	50.0	4.5				3	42.9	2.9	1	33.3	1.5	5	50.0	12.5	6	46.2	5.7
	Moderate	2	33.3	3.0	1	100	2.7	3	42.9	2.9	2	66.7	3.0	2	20.0	5.0	4	30.8	3.8
	Severe	1	16.7	1.5				1	14.3	1.0				3	30.0	7.5	3	23.1	2.8
	Total	6	100	9.1	1	100	2.7	7	100	6.8	3	100	4.5	10	100	25.0	13	100	12.3
RESPIRATORY SYSTEM DISORDERS	Mild	2	50.0	3.0	3	75.0	8.1	5	62.5	4.9	3	33.3	4.5				3	27.3	2.8
	Moderate	2	50.0	3.0	1	25.0	2.7	3	37.5	2.9	6	66.7	9.1	2	100	5.0	8	72.7	7.5
	Total	4	100	6.1	4	100	10.8	8	100	7.8	9	100	13.6	2	100	5.0	11	100	10.4
VISION DISORDERS	Mild				3	75.0	8.1	3	60.0	2.9	2	66.7	3.0				2	50.0	1.9
	Moderate	1	100	1.5	1	25.0	2.7	2	40.0	1.9	1	33.3	1.5				1	25.0	0.9
	Severe													1	100	2.5	1	25.0	0.9
	Total	1	100	1.5	4	100	10.8	5	100	4.9	3	100	4.5	1	100	2.5	4	100	3.8

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 50

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																		
		Imigramine									Reboxetine									
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
MUSCOLO-SKELETAL SYSTEM DISORDERS	Mild										1	50.0	1.5	1	100	2.5	2	66.7	1.9
	Moderate	3	100	4.5				3	60.0	2.9	1	50.0	1.5				1	33.3	0.9
	Severe				2	100	5.4	2	40.0	1.9									
	Total	3	100	4.5	2	100	5.4	5	100	4.9	2	100	3.0	1	100	2.5	3	100	2.8
SKIN AND APPENDAGES DISORDERS	Mild	1	50.0	1.5				1	50.0	1.0	3	50.0	4.5				3	50.0	2.8
	Moderate										3	50.0	4.5				3	50.0	2.8
	Severe	1	50.0	1.5				1	50.0	1.0									
	Total	2	100	3.0				2	100	1.9	6	100	9.1				6	100	5.7
LIVER AND BILIAR SYSTEM DISORDERS	Mild										2	100	3.0	1	100	2.5	3	100	2.8
	Moderate	2	100	3.0				2	100	1.9									
	Total	2	100	3.0				2	100	1.9	2	100	3.0	1	100	2.5	3	100	2.8
METABOLIC AND NUTRITION-AL DISORDERS	Mild										1	50.0	1.5				1	33.3	0.9
	Moderate	2	100	3.0				2	100	1.9	1	50.0	1.5	1	100	2.5	2	66.7	1.9
	Total	2	100	3.0				2	100	1.9	2	100	3.0	1	100	2.5	3	100	2.8
SPECIAL SENSES OTHER, DISORDERS	Mild										1	50.0	1.5				1	50.0	0.9
	Moderate	1	33.3	1.5				1	33.3	1.0	1	50.0	1.5				1	50.0	0.9
	Severe	2	66.7	3.0				2	66.7	1.9									
	Total	3	100	4.5				3	100	2.9	2	100	3.0				2	100	1.9
REPRODUCT-IVE DISORDERS, FEMALE	Mild										1	50.0	1.5				1	50.0	0.9
	Moderate										1	50.0	1.5				1	50.0	0.9

(CONTINUED)

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 50

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity		Assigned treatment																	
		Imipramine									Reboxetine								
		Female			Male			Total			Female			Male			Total		
		No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %	No. Pt.	%	(*) %
REPRODUCTIVE DISORDERS, FEMALE	Missing	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0	2	100	3.0				2	100	1.9
RESISTANCE MECHANISM DISORDERS	Mild				1	100	2.7	1	100	1.0									
	Severe													1	100	2.5	1	100	0.9
	Total				1	100	2.7	1	100	1.0				1	100	2.5	1	100	0.9
ENDOCRINE DISORDERS	Severe										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9
HEARING AND VESTIBULAR DISORDERS	Moderate	1	100	1.5				1	100	1.0									
	Total	1	100	1.5				1	100	1.0									
HEMATOLOGY DISORDERS	Mild										1	100	1.5				1	100	0.9
	Total										1	100	1.5				1	100	0.9

(*) % on all patients with adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 51

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
SUICIDE ATTEMPT	Reboxetine	2	1	1	1	1
GASTROENTERITIS	Imipramine	1	6	6	6	6
	Reboxetine	1	6	6	6	6
HYPERCHOLESTEROLAEMIA	Imipramine	1	42	42	42	42
	Reboxetine	1	18	18	18	18
HYPERURICAEMIA	Imipramine	1	22	22	22	22
	Reboxetine	1	22	22	22	22
ECG ABNORMAL	Reboxetine	2	1	1	1	1
RHINITIS	Reboxetine	2	2	4	6	6
SPUTUM INCREASED	Imipramine	2	4	4	4	4
MENSTRUAL DISORDER	Imipramine	1	7	7	7	7
	Reboxetine	1	7	7	7	7
CHEST PAIN	Imipramine	2	1	2	2	2
FEVER	Imipramine	1	5	5	5	5
	Reboxetine	1	2	2	2	2
HOT FLUSHES	Imipramine	2	6	6	6	6
ALOPECIA	Reboxetine	1	12	12	12	12
DERMATITIS FUNGAL	Reboxetine	1	5	5	5	5
PRURITUS	Reboxetine	1	9	9	9	9
ARTHROSIS	Imipramine	1	8	8	8	8
HYPERKINESIA	Imipramine	1	1	1	1	1
HYPOKINESIA	Imipramine	1	3	3	3	3

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 51

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
VERTIGO	Imipramine	1	1	1	1	1
SALIVA INCREASED	Imipramine	1	42	42	42	42
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	1	1	1	1
TASTE LOSS	Imipramine	1	21	21	21	21
ANXIETY	Imipramine	1	6	6	6	6
MANIC REACTION	Imipramine	1	8	8	8	8
APPETITE INCREASED	Imipramine	1	23	23	23	23
DYSPHAGIA	Imipramine	1	7	7	7	7
OESOPHAGITIS	Imipramine	1	7	7	7	7
SGPT INCREASED	Reboxetine	1	1	1	1	1
GLOBULINS INCREASED	Reboxetine	1	22	22	22	22
HYPERLIPAEMIA	Imipramine	1	5	5	5	5
HYPOTHYROIDISM	Reboxetine	1	6	6	6	6
AV BLOCK	Imipramine	1	22	22	22	22
BUNDLE BRANCH BLOCK	Reboxetine	1	22	22	22	22
EXTRASYSTOLES	Imipramine	1	1	1	1	1
COUGHING	Imipramine	1	5	5	5	5
ASTHMA	Imipramine	1	1	1	1	1
LEUKOCYTOSIS	Reboxetine	1	1	1	1	1
CYSTITIS HAEMORRHAGIC	Reboxetine	1	7	7	7	7
CERVICITIS	Reboxetine	1	10	10	10	10
PAIN	Reboxetine	1	4	4	4	4

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: S1

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		No of Episodes	Duration of episodes (days)			
			Min	50%	90%	Max
OTITIS MEDIA	Imipramine	1	2	2	2	2
HERPES SIMPLEX	Reboxetine	1	8	8	8	8

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 52

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No. of pt. with A.E.	38	36.9	65	63.1	103	100.0	42	39.6	64	60.4	106	100.0
No. of adverse events	55	18.2	248	81.8	303	100.0	63	23.6	204	76.4	267	100.0
MOUTH DRY	1	2.1	47	97.9	48	100.0			33	100.0	33	100.0
HEADACHE	5	23.8	16	76.2	21	100.0	11	40.7	16	59.3	27	100.0
SWEATING INCREASED			20	100.0	20	100.0			20	100.0	20	100.0
DIZZINESS	1	5.3	18	94.7	19	100.0			13	100.0	13	100.0
NAUSEA	2	15.4	11	84.6	13	100.0			16	100.0	16	100.0
INSOMNIA	12	75.0	4	25.0	16	100.0	8	72.7	3	27.3	11	100.0
CONSTIPATION	5	38.5	8	61.5	13	100.0	2	15.4	11	84.6	13	100.0
TACHYCARDIA	2	13.3	13	86.7	15	100.0	4	40.0	6	60.0	10	100.0
AGITATION	2	22.2	7	77.8	9	100.0	4	50.0	4	50.0	8	100.0
TREMOR	1	7.7	12	92.3	13	100.0			2	100.0	2	100.0
SOMNOLENCE			10	100.0	10	100.0			4	100.0	4	100.0
PALPITATION			6	100.0	6	100.0			5	100.0	5	100.0
MICTURITION DISORDER			3	100.0	3	100.0	1	12.5	7	87.5	8	100.0
FATIGUE			5	100.0	5	100.0			5	100.0	5	100.0
HYPERTENSION	1	100.0			1	100.0	6	85.7	1	14.3	7	100.0
VISION ABNORMAL			4	100.0	4	100.0			4	100.0	4	100.0
BRONCHITIS	1	50.0	1	50.0	2	100.0	6	100.0			6	100.0
URINARY RETENTION			4	100.0	4	100.0	1	33.3	2	66.7	3	100.0
INFLUENZA-LIKE SYMPTOMS	1	33.3	2	66.7	3	100.0	1	25.0	3	75.0	4	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: S2

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PARAESTHESIA			2	100.0	2	100.0			4	100.0	4	100.0
HYPOTENSION	2	33.3	4	66.7	6	100.0						
RASH			2	100.0	2	100.0			3	100.0	3	100.0
ABDOMINAL PAIN			2	100.0	2	100.0	1	33.3	2	66.7	3	100.0
FLATULENCE			2	100.0	2	100.0	1	33.3	2	66.7	3	100.0
UPPER RESP TRACT INFECTION	3	100.0			3	100.0	2	100.0			2	100.0
BACK PAIN	3	100.0			3	100.0	1	50.0	1	50.0	2	100.0
LIBIDO DECREASED	1	50.0	1	50.0	2	100.0	2	66.7	1	33.3	3	100.0
TASTE PERVERSION			2	100.0	2	100.0			2	100.0	2	100.0
URINARY TRACT INFECTION			1	100.0	1	100.0	2	66.7	1	33.3	3	100.0
ARTHRALGIA	2	100.0			2	100.0	1	100.0			1	100.0
ANOREXIA			2	100.0	2	100.0			1	100.0	1	100.0
FLUSHING			1	100.0	1	100.0			2	100.0	2	100.0
HYPOTENSION POSTURAL			2	100.0	2	100.0			1	100.0	1	100.0
NERVOUSNESS									3	100.0	3	100.0
DYSPEPSIA							1	33.3	2	66.7	3	100.0
GAMMA-GT INCREASED			2	100.0	2	100.0			1	100.0	1	100.0
HEPATIC ENZYMES INCREASED			2	100.0	2	100.0			1	100.0	1	100.0
SINUSITIS			1	100.0	1	100.0	2	100.0			2	100.0
ASTHENIA			2	100.0	2	100.0			1	100.0	1	100.0
HYPOAESTHESIA			1	100.0	1	100.0			1	100.0	1	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 52

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
DIARRHOEA			1	100.0	1	100.0	1	100.0			1	100.0
VOMITING	1	100.0			1	100.0			1	100.0	1	100.0
TINNITUS			2	100.0	2	100.0						
CONFUSION			2	100.0	2	100.0						
DELUSION			1	100.0	1	100.0			1	100.0	1	100.0
SUICIDE ATTEMPT									2	100.0	2	100.0
GASTROENTERITIS	1	100.0			1	100.0	1	100.0			1	100.0
HYPERCHOLESTEROLAEMIA			1	100.0	1	100.0	1	100.0			1	100.0
HYPERURICAEMIA			1	100.0	1	100.0			1	100.0	1	100.0
RHINITIS							1	50.0	1	50.0	2	100.0
SPUTUM INCREASED	1	50.0	1	50.0	2	100.0						
MENSTRUAL DISORDER			1	100.0	1	100.0			1	100.0	1	100.0
HOT FLUSHES			2	100.0	2	100.0						
ACCOMMODATION ABNORMAL			2	100.0	2	100.0						
ECG ABNORMAL									2	100.0	2	100.0
CHEST PAIN			2	100.0	2	100.0						
FEVER	1	100.0			1	100.0			1	100.0	1	100.0
ALOPECIA									1	100.0	1	100.0
DERMATITIS FUNGAL							1	100.0			1	100.0
PRURITUS									1	100.0	1	100.0
HYPERKINESIA			1	100.0	1	100.0						

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 52

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPOKINESIA	1	100.0			1	100.0						
VERTIGO			1	100.0	1	100.0						
TACHYCARDIA SUPRAVENTRICULAR			1	100.0	1	100.0						
TASTE LOSS	1	100.0			1	100.0						
ANXIETY			1	100.0	1	100.0						
MANIC REACTION			1	100.0	1	100.0						
APPETITE INCREASED			1	100.0	1	100.0						
DYSPHAGIA			1	100.0	1	100.0						
OESOPHAGITIS			1	100.0	1	100.0						
GLOBULINS INCREASED									1	100.0	1	100.0
HYPERLIPAEMIA			1	100.0	1	100.0						
HYPOTHYROIDISM									1	100.0	1	100.0
EXTRASYSTOLES			1	100.0	1	100.0						
LEUKOCYTOSIS									1	100.0	1	100.0
CERVICITIS									1	100.0	1	100.0
PAIN									1	100.0	1	100.0
ARTHROSIS	1	100.0			1	100.0						
SALIVA INCREASED			1	100.0	1	100.0						
SGPT INCREASED									1	100.0	1	100.0
AV BLOCK			1	100.0	1	100.0						
BUNDLE BRANCH BLOCK									1	100.0	1	100.0

(CONTINUED)

PHARMACIA CNS R&D

MEBOXETINE - PROTOCOL 20124/017
TABLE No.: 52

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Moboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
COUGHING	1	100.0			1	100.0						
ASTHMA	1	100.0			1	100.0						
CYSTITIS HAEMORRHAGIC							1	100.0			1	100.0
OTITIS MEDIA	1	100.0			1	100.0						
HERPES SIMPLEX									1	100.0	1	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 53

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Imipramine	236	77.9	13	4.3	3	1.0	49	16.2	2	0.7	303	100.0
	Reboxetine	219	82.0	6	2.2	8	3.0	32	12.0	2	0.7	267	100.0
MOUTH DRY	Imipramine	42	87.5	1	2.1			5	10.4			48	100.0
	Reboxetine	30	90.9	1	3.0	1	3.0	1	3.0			33	100.0
HEADACHE / MIGRAINE	Imipramine	15	71.4	1	4.8			5	23.8			21	100.0
	Reboxetine	22	81.5			1	3.7	4	14.8			27	100.0
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	23	85.2			1	3.7	3	11.1			27	100.0
	Reboxetine	10	71.4			1	7.1	2	14.3	1	7.1	14	100.0
SWEATING INCREASED	Imipramine	18	90.0					2	10.0			20	100.0
	Reboxetine	14	70.0			2	10.0	3	15.0	1	5.0	20	100.0
NAUSEA AND RELATED SYMPTOMS	Imipramine	10	71.4	1	7.1	1	7.1	2	14.3			14	100.0
	Reboxetine	15	75.0					5	25.0			20	100.0
INSOMNIA	Imipramine	15	93.8					1	6.3			16	100.0
	Reboxetine	9	81.8					2	18.2			11	100.0
CONSTIPATION	Imipramine	12	92.3	1	7.7							13	100.0
	Reboxetine	12	92.3	1	7.7							13	100.0
TACHYCARDIA	Imipramine	14	93.3	1	6.7							15	100.0
	Reboxetine	10	100.0									10	100.0
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	8	80.0					2	20.0			10	100.0
	Reboxetine	9	81.8			1	9.1	1	9.1			11	100.0
URINARY HESITANCY / RETENTION	Imipramine	2	28.6	2	28.6			3	42.9			7	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 53

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
URINARY HESITANCY / RETENTION	Reboxetine	5	45.5	1	9.1	1	9.1	4	36.4			11	100.0
TREMOR	Imipramine	8	61.5	1	7.7			4	30.8			13	100.0
	Reboxetine	2	100.0									2	100.0
SOMNOLENCE	Imipramine	5	50.0	3	30.0			2	20.0			10	100.0
	Reboxetine	3	75.0					1	25.0			4	100.0
ASTHENIA / FATIGUE	Imipramine	1	14.3	1	14.3			5	71.4			7	100.0
	Reboxetine	4	66.7	1	16.7			1	16.7			6	100.0
PALPITATION	Imipramine	4	66.7	1	16.7	1	16.7					6	100.0
	Reboxetine	3	60.0			1	20.0	1	20.0			5	100.0
BLURRED VISION	Imipramine	5	83.3					1	16.7			6	100.0
	Reboxetine	2	50.0	2	50.0							4	100.0
HYPERTENSION	Imipramine									1	100.0	1	100.0
	Reboxetine	6	85.7					1	14.3			7	100.0
BRONCHITIS	Imipramine	2	100.0									2	100.0
	Reboxetine	6	100.0									6	100.0
INFLUENZA-LIKE SYMPTOMS	Imipramine	3	100.0									3	100.0
	Reboxetine	4	100.0									4	100.0
INCREASED LIVER ENZYMES	Imipramine	4	100.0									4	100.0
	Reboxetine	3	100.0									3	100.0
PARAESTHESIA	Imipramine	2	100.0									2	100.0
	Reboxetine	4	100.0									4	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 53

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
FLUSHING / HOT FLASHING	Imipramine	2	66.7					1	33.3			3	100.0
	Reboxetine	2	100.0									2	100.0
ABDOMINAL PAIN	Imipramine	2	100.0									2	100.0
	Reboxetine	2	66.7					1	33.3			3	100.0
FLATULENCE	Imipramine	1	50.0					1	50.0			2	100.0
	Reboxetine	2	66.7					1	33.3			3	100.0
BACK PAIN	Imipramine	2	66.7					1	33.3			3	100.0
	Reboxetine	2	100.0									2	100.0
LIBIDO DECREASED	Imipramine	2	100.0									2	100.0
	Reboxetine	3	100.0									3	100.0
UPPER RESP TRACT INFECTION	Imipramine	3	100.0									3	100.0
	Reboxetine	2	100.0									2	100.0
ERYTHEMA / RASH	Imipramine	1	50.0					1	50.0			2	100.0
	Reboxetine	3	100.0									3	100.0
TASTE PERVERSION	Imipramine	1	50.0					1	50.0			2	100.0
	Reboxetine	1	50.0					1	50.0			2	100.0
URINARY TRACT INFECTION	Imipramine							1	100.0			1	100.0
	Reboxetine	3	100.0									3	100.0
ANOREXIA	Imipramine	1	50.0					1	50.0			2	100.0
	Reboxetine	1	100.0									1	100.0
ARTHRALGIA	Imipramine	2	100.0									2	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 5S

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ARTHRALGIA	Reboxetine	1	100.0									1	100.0
SINUSITIS	Imipramine							1	100.0			1	100.0
	Reboxetine	2	100.0									2	100.0
CHEST PAIN	Imipramine	2	100.0									2	100.0
FEVER	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
ECG ABNORMAL	Reboxetine	2	100.0									2	100.0
HYPOAESTHESIA	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
DIARRHOEA	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
GASTROENTERITIS	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
TINNITUS	Imipramine	2	100.0									2	100.0
HYPERCHOLESTEROLAEMIA	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
HYPERURICAEMIA	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
SUICIDE ATTEMPT	Reboxetine	1	50.0					1	50.0			2	100.0
MENSTRUAL DISORDER	Imipramine									1	100.0	1	100.0
	Reboxetine	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 5S

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
RHINITIS	Reboxetine	2	100.0									2	100.0
SPUTUM INCREASED	Imipramine	2	100.0									2	100.0
CONFUSION	Imipramine							2	100.0			2	100.0
DELUSION	Imipramine							1	100.0			1	100.0
	Reboxetine							1	100.0			1	100.0
SALIVA INCREASED	Imipramine	1	100.0									1	100.0
PAIN	Reboxetine	1	100.0									1	100.0
AV BLOCK	Imipramine	1	100.0									1	100.0
BUNDLE BRANCH BLOCK	Reboxetine	1	100.0									1	100.0
EXTRASYSTOLES	Imipramine	1	100.0									1	100.0
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	100.0									1	100.0
HYPERKINESIA	Imipramine	1	100.0									1	100.0
HYPOKINESIA	Imipramine	1	100.0									1	100.0
VERTIGO	Imipramine	1	100.0									1	100.0
APPETITE INCREASED	Imipramine	1	100.0									1	100.0
DYSPHAGIA	Imipramine	1	100.0									1	100.0
LEUKOCYTOSIS	Reboxetine	1	100.0									1	100.0
GLOBULINS INCREASED	Reboxetine	1	100.0									1	100.0
HYPERLIPAEMIA	Imipramine	1	100.0									1	100.0
ARTHROSIS	Imipramine	1	100.0									1	100.0
CERVICITIS	Reboxetine	1	100.0									1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 53

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Study drug															
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HERPES SIMPLEX	Reboxetine	1	100.0									1	100.0
OTITIS MEDIA	Imipramine	1	100.0									1	100.0
ASTHMA	Imipramine	1	100.0									1	100.0
COUGHING	Imipramine	1	100.0									1	100.0
ALOPECIA	Reboxetine	1	100.0									1	100.0
DERMATITIS FUNGAL	Reboxetine	1	100.0									1	100.0
PRURITUS	Reboxetine	1	100.0									1	100.0
CYSTITIS HAEMORRHAGIC	Reboxetine	1	100.0									1	100.0
HYPOTHYROIDISM	Reboxetine							1	100.0			1	100.0
OESOPHAGITIS	Imipramine							1	100.0			1	100.0
MANIC REACTION	Imipramine							1	100.0			1	100.0
TASTE LOSS	Imipramine							1	100.0			1	100.0

(some adverse events are grouped in clusters)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 54

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug								Temporarily interrupted							
		Disappeared								Reappeared							
		NO		YES		Not applicable		Total		NO		YES		Not applicable		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Reboxetine	15	32.6	30	65.2	1	2.2	46	100.0	3	37.5			5	62.5	8	100.0
	Imipramine	14	21.5	49	75.4	2	3.1	65	100.0	1	33.3			2	66.7	3	100.0
HEADACHE / MIGRAINE	Reboxetine	3	60.0	2	40.0			5	100.0					1	100.0	1	100.0
	Imipramine	1	16.7	5	83.3			6	100.0								
URINARY HESITANCY / RETENTION	Reboxetine	1	16.7	4	66.7	1	16.7	6	100.0					1	100.0	1	100.0
	Imipramine	1	20.0	4	80.0			5	100.0								
MOUTH DRY	Reboxetine	2	66.7	1	33.3			3	100.0					1	100.0	1	100.0
	Imipramine	2	33.3	4	66.7			6	100.0								
NAUSEA AND RELATED SYMPTOMS	Reboxetine	1	20.0	4	80.0			5	100.0								
	Imipramine	1	25.0	2	50.0	1	25.0	4	100.0					1	100.0	1	100.0
ASTHENIA / FATIGUE	Reboxetine			2	100.0			2	100.0								
	Imipramine	2	33.3	4	66.7			6	100.0								
SWEATING INCREASED	Reboxetine	1	20.0	4	80.0			5	100.0	1	50.0			1	50.0	2	100.0
	Imipramine	1	50.0	1	50.0			2	100.0								
HYPOTENSION AND RELATED SYMPTOMS	Reboxetine	1	33.3	2	66.7			3	100.0	1	100.0					1	100.0
	Imipramine	1	25.0	3	75.0			4	100.0					1	100.0	1	100.0
SOMNOLENCE	Reboxetine	1	100.0					1	100.0								
	Imipramine	2	40.0	3	60.0			5	100.0								
TREMOR	Imipramine	1	20.0	4	80.0			5	100.0								
PALPITATION	Reboxetine			2	100.0			2	100.0	1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 54

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug								Temporarily interrupted							
		Disappeared								Reappeared							
		NO		YES		Not applicable		Total		NO		YES		Not applicable		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PALPITATION	Imipramine			2	100.0			2	100.0	1	100.0					1	100.0
AGITATION / ANXIETY / NERVOUSNESS	Reboxetine			2	100.0			2	100.0					1	100.0	1	100.0
	Imipramine			2	100.0			2	100.0								
INSOMNIA	Reboxetine			2	100.0			2	100.0								
	Imipramine			1	100.0			1	100.0								
BLURRED VISION	Reboxetine	2	100.0					2	100.0								
	Imipramine			1	100.0			1	100.0								
CONFUSION	Imipramine			2	100.0			2	100.0								
CONSTIPATION	Reboxetine	1	100.0					1	100.0								
	Imipramine			1	100.0			1	100.0								
FLATULENCE	Reboxetine			1	100.0			1	100.0								
	Imipramine	1	100.0					1	100.0								
DELUSION	Reboxetine	1	100.0					1	100.0								
	Imipramine					1	100.0	1	100.0								
TASTE PERVERSION	Reboxetine			1	100.0			1	100.0								
	Imipramine			1	100.0			1	100.0								
FLUSHING / HOT FLUSHES	Imipramine			1	100.0			1	100.0								
HYPERTENSION	Reboxetine			1	100.0			1	100.0								
TACHYCARDIA	Imipramine			1	100.0			1	100.0								
HYPOTHYROIDISM	Reboxetine	1	100.0					1	100.0								

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 54

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug								Temporarily interrupted							
		Disappeared								Reappeared							
		NO		YES		Not applicable		Total		NO		YES		Not applicable		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ABDOMINAL PAIN	Reboxetine			1	100.0			1	100.0								
ANOREXIA	Imipramine			1	100.0			1	100.0								
OESOPHAGITIS	Imipramine			1	100.0			1	100.0								
BACK PAIN	Imipramine			1	100.0			1	100.0								
MANIC REACTION	Imipramine			1	100.0			1	100.0								
SUICIDE ATTEMPT	Reboxetine			1	100.0			1	100.0								
SINUSITIS	Imipramine			1	100.0			1	100.0								
ERYTHEMA / RASH	Imipramine	1	100.0					1	100.0								
TASTE LOSS	Imipramine			1	100.0			1	100.0								
URINARY TRACT INFECTION	Imipramine			1	100.0			1	100.0								

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Imipramine	48	73.8			17	26.2					65	100	150	63.0	4	1.7	83	34.9			1	0.4	238	100
	Reboxetine	32	69.6			14	30.4					46	100	148	67.0	2	0.9	65	29.4	1	0.5	5	2.3	221	100
MOUTH DRY	Imipramine	4	66.7			2	33.3					6	100	21	50.0			21	50.0					42	100
	Reboxetine	1	33.3			2	66.7					3	100	17	56.7			13	43.3					30	100
HEADACHE / MIGRAINE	Imipramine	5	83.3			1	16.7					6	100	11	73.3			4	26.7					15	100
	Reboxetine	2	40.0			3	60.0					5	100	17	77.3			4	18.2			1	4.5	22	100
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	3	75.0			1	25.0					4	100	19	82.6	2	8.7	2	8.7					23	100
	Reboxetine	2	66.7			1	33.3					3	100	8	72.7			2	18.2			1	9.1	11	100
SWEATING INCREASED	Imipramine	1	50.0			1	50.0					2	100	6	33.3			12	66.7					18	100
	Reboxetine	5	100									5	100	8	53.3			6	40.0			1	6.7	15	100
NAUSEA AND RELATED SYMPTOMS	Imipramine	3	75.0			1	25.0					4	100	9	90.0			1	10.0					10	100
	Reboxetine	4	80.0			1	20.0					5	100	12	80.0			3	20.0					15	100
INSOMNIA	Imipramine	1	100									1	100	6	40.0	2	13.3	7	46.7					15	100
	Reboxetine	2	100									2	100	3	33.3			6	66.7					9	100
CONSTIPATION	Imipramine	1	100									1	100	7	58.3			5	41.7					12	100
	Reboxetine					1	100					1	100	8	66.7	1	8.3	3	25.0					12	100
TACHYCARDIA	Imipramine	1	100									1	100	7	50.0			7	50.0					14	100
	Reboxetine													5	50.0	1	10.0	4	40.0					10	100
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	2	100									2	100	7	87.5			1	12.5					8	100
	Reboxetine	2	100									2	100	9	100									9	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
URINARY HESITANCY / RETENTION	Imipramine	4	80.0			1	20.0					5	100	2	100									2	100
	Reboxetine	5	83.3			1	16.7					6	100	4	80.0			1	20.0					5	100
TREMOR	Imipramine	4	80.0			1	20.0					5	100	4	50.0			4	50.0					8	100
	Reboxetine													1	50.0			1	50.0					2	100
SOMNOLENCE	Imipramine	3	60.0			2	40.0					5	100	5	100									5	100
	Reboxetine					1	100					1	100	2	66.7			1	33.3					3	100
ASTHENIA / FATIGUE	Imipramine	4	66.7			2	33.3					6	100	1	100									1	100
	Reboxetine	2	100									2	100	3	75.0			1	25.0					4	100
PALPITATION	Imipramine	2	100									2	100	3	75.0			1	25.0					4	100
	Reboxetine	2	100									2	100	3	100									3	100
BLURRED VISION	Imipramine	1	100									1	100	3	60.0			2	40.0					5	100
	Reboxetine					2	100					2	100	1	50.0			1	50.0					2	100
HYPERTENSION	Imipramine																					1	100	1	100
	Reboxetine	1	100									1	100	4	66.7			2	33.3					6	100
BRONCHITIS	Imipramine													2	100									2	100
	Reboxetine													6	100									6	100
INFLUENZA-LIKE SYMPTOMS	Imipramine													2	66.7			1	33.3					3	100
	Reboxetine													4	100									4	100
INCREASED LIVER ENZYMES	Imipramine																	4	100					4	100
	Reboxetine													1	33.3			2	66.7					3	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing									
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PARAESTHESIA	Imipramine													2	100									2	100
	Reboxetine													3	75.0			1	25.0					4	100
FLUSHING / HOT FLASHING	Imipramine	1	100									1	100	2	100									2	100
	Reboxetine													1	50.0			1	50.0					2	100
ABDOMINAL PAIN	Imipramine													2	100									2	100
	Reboxetine	1	100									1	100					2	100					2	100
FLATULENCE	Imipramine					1	100					1	100					1	100					1	100
	Reboxetine	1	100									1	100	1	50.0			1	50.0					2	100
BACK PAIN	Imipramine	1	100									1	100	2	100									2	100
	Reboxetine													2	100				-					2	100
LIBIDO DECREASED	Imipramine													1	50.0			1	50.0					2	100
	Reboxetine																	3	100					3	100
UPPER RESP TRACT INFECTION	Imipramine													3	100									3	100
	Reboxetine													2	100									2	100
ERYTHEMA / RASH	Imipramine					1	100					1	100	1	100									1	100
	Reboxetine													1	33.3			2	66.7					3	100
TASTE PERVERSION	Imipramine	1	100									1	100	1	100									1	100
	Reboxetine	1	100									1	100	1	100									1	100
URINARY TRACT INFECTION	Imipramine	1	100									1	100												
	Reboxetine													3	100									3	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ANOREXIA	Imipramine	1	100									1	100					1	100					1	100
	Reboxetine													1	100									1	100
ARTHRALGIA	Imipramine													2	100									2	100
	Reboxetine													1	100									1	100
SINUSITIS	Imipramine	1	100									1	100												
	Reboxetine													2	100									2	100
CHEST PAIN	Imipramine													2	100									2	100
FEVER	Imipramine													1	100									1	100
	Reboxetine													1	100									1	100
ECG ABNORMAL	Reboxetine																					2	100	2	100
CONFUSION	Imipramine	2	100									2	100												
HYPOAESTHESIA	Imipramine													1	100									1	100
	Reboxetine													1	100									1	100
DIARRHOEA	Imipramine													1	100									1	100
	Reboxetine													1	100									1	100
GASTROENTERITIS	Imipramine													1	100									1	100
	Reboxetine													1	100									1	100
TINNITUS	Imipramine													2	100									2	100
HYPERCHOLESTEROL-AEMIA	Imipramine																	1	100					1	100
	Reboxetine																	1	100					1	100

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPERURICAEMIA	Imipramine																	1	100					1	100
	Reboxetine																	1	100					1	100
DELUSION	Imipramine					1	100					1	100												
	Reboxetine					1	100					1	100												
SUICIDE ATTEMPT	Reboxetine	1	100									1	100							1	100			1	100
MENSTRUAL DISORDER	Imipramine													1	100									1	100
	Reboxetine													1	100									1	100
RHINITIS	Reboxetine													2	100									2	100
SPUTUM INCREASED	Imipramine													2	100									2	100
SALIVA INCREASED	Imipramine																	1	100					1	100
PAIN	Reboxetine													1	100									1	100
AV BLOCK	Imipramine																	1	100					1	100
BUNDLE BRANCH BLOCK	Reboxetine																	1	100					1	100
EXTRASYSTOLES	Imipramine																	1	100					1	100
TACHYCARDIA SUPRAVENTRICULAR	Imipramine													1	100									1	100
HYPERKINESIA	Imipramine													1	100									1	100
HYPOKINESIA	Imipramine													1	100									1	100
VERTIGO	Imipramine													1	100									1	100
HYPOTHYROIDISM	Reboxetine					1	100					1	100												

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Modified study drug												Unchanged study drug or Missing									
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
APPETITE INCREASED	Imipramine																	1	100					1	100
DYSPHAGIA	Imipramine																	1	100					1	100
OESOPHAGITIS	Imipramine					1	100					1	100												
LEUKOCYTOSIS	Reboxetine																	1	100					1	100
GLOBULINS INCREASED	Reboxetine																	1	100					1	100
HYPERLIPAEMIA	Imipramine													1	100									1	100
ARTHROSIS	Imipramine																	1	100					1	100
MANIC REACTION	Imipramine					1	100					1	100												
CERVICITIS	Reboxetine													1	100									1	100
HERPES SIMPLEX	Reboxetine													1	100									1	100
OTITIS MEDIA	Imipramine													1	100									1	100
ASTHMA	Imipramine													1	100									1	100
COUGHING	Imipramine													1	100									1	100
ALOPECIA	Reboxetine													1	100									1	100
DERMATITIS FUNGAL	Reboxetine													1	100									1	100
PRURITUS	Reboxetine													1	100									1	100
TASTE LOSS	Imipramine	1	100									1	100												
CYSTITIS HAEMORRHAGIC	Reboxetine													1	100									1	100

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Imipramine	198	65.3	4	1.3	100	33.0			1	0.3	303	100.0
	Reboxetine	180	67.4	2	0.7	79	29.6	1	0.4	5	1.9	267	100.0
MOUTH DRY	Imipramine	25	52.1			23	47.9					48	100.0
	Reboxetine	18	54.5			15	45.5					33	100.0
HEADACHE / MIGRAINE	Imipramine	16	76.2			5	23.8					21	100.0
	Reboxetine	19	70.4			7	25.9			1	3.7	27	100.0
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	22	81.5	2	7.4	3	11.1					27	100.0
	Reboxetine	10	71.4			3	21.4			1	7.1	14	100.0
SWEATING INCREASED	Imipramine	7	35.0			13	65.0					20	100.0
	Reboxetine	13	65.0			6	30.0			1	5.0	20	100.0
NAUSEA AND RELATED SYMPTOMS	Imipramine	12	85.7			2	14.3					14	100.0
	Reboxetine	16	80.0			4	20.0					20	100.0
INSOMNIA	Imipramine	7	43.8	2	12.5	7	43.8					16	100.0
	Reboxetine	5	45.5			6	54.5					11	100.0
CONSTIPATION	Imipramine	8	61.5			5	38.5					13	100.0
	Reboxetine	8	61.5	1	7.7	4	30.8					13	100.0
TACHYCARDIA	Imipramine	8	53.3			7	46.7					15	100.0
	Reboxetine	5	50.0	1	10.0	4	40.0					10	100.0
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	9	90.0			1	10.0					10	100.0
	Reboxetine	11	100.0									11	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
URINARY HESITANCY / RETENTION	Imipramine	6	85.7			1	14.3					7	100.0
	Reboxetine	9	81.8			2	18.2					11	100.0
TREMOR	Imipramine	8	61.5			5	38.5					13	100.0
	Reboxetine	1	50.0			1	50.0					2	100.0
SOMNOLENCE	Imipramine	8	80.0			2	20.0					10	100.0
	Reboxetine	2	50.0			2	50.0					4	100.0
ASTHENIA / FATIGUE	Imipramine	5	71.4			2	28.6					7	100.0
	Reboxetine	5	83.3			1	16.7					6	100.0
PALPITATION	Imipramine	5	83.3			1	16.7					6	100.0
	Reboxetine	5	100.0									5	100.0
BLURRED VISION	Imipramine	4	66.7			2	33.3					6	100.0
	Reboxetine	1	25.0			3	75.0					4	100.0
HYPERTENSION	Imipramine									1	100.0	1	100.0
	Reboxetine	5	71.4			2	28.6					7	100.0
BRONCHITIS	Imipramine	2	100.0									2	100.0
	Reboxetine	6	100.0									6	100.0
INFLUENZA-LIKE SYMPTOMS	Imipramine	2	66.7			1	33.3					3	100.0
	Reboxetine	4	100.0									4	100.0
INCREASED LIVER ENZYMES	Imipramine					4	100.0					4	100.0
	Reboxetine	1	33.3			2	66.7					3	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
PARAESTHESIA	Imipramine	2	100.0									2	100.0
	Reboxetine	3	75.0			1	25.0					4	100.0
FLUSHING / HOT FLASHING	Imipramine	3	100.0									3	100.0
	Reboxetine	1	50.0			1	50.0					2	100.0
ABDOMINAL PAIN	Imipramine	2	100.0									2	100.0
	Reboxetine	1	33.3			2	66.7					3	100.0
FLATULENCE	Imipramine					2	100.0					2	100.0
	Reboxetine	2	66.7			1	33.3					3	100.0
BACK PAIN	Imipramine	3	100.0									3	100.0
	Reboxetine	2	100.0									2	100.0
LIBIDO DECREASED	Imipramine	1	50.0			1	50.0					2	100.0
	Reboxetine					3	100.0					3	100.0
UPPER RESP TRACT INFECTION	Imipramine	3	100.0									3	100.0
	Reboxetine	2	100.0									2	100.0
ERYTHEMA / RASH	Imipramine	1	50.0			1	50.0					2	100.0
	Reboxetine	1	33.3			2	66.7					3	100.0
TASTE PERVERSION	Imipramine	2	100.0									2	100.0
	Reboxetine	2	100.0									2	100.0
URINARY TRACT INFECTION	Imipramine	1	100.0									1	100.0
	Reboxetine	3	100.0									3	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ANOREXIA	Imipramine	1	50.0			1	50.0					2	100.0
	Reboxetine	1	100.0									1	100.0
ARTHRALGIA	Imipramine	2	100.0									2	100.0
	Reboxetine	1	100.0									1	100.0
SINUSITIS	Imipramine	1	100.0									1	100.0
	Reboxetine	2	100.0									2	100.0
CHEST PAIN	Imipramine	2	100.0									2	100.0
FEVER	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
ECG ABNORMAL	Reboxetine									2	100.0	2	100.0
CONFUSION	Imipramine	2	100.0									2	100.0
HYPOAESTHESIA	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
DIARRHOEA	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
GASTROENTERITIS	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
TINNITUS	Imipramine	2	100.0									2	100.0
HYPERCHOLESTEROLAEMIA	Imipramine					1	100.0					1	100.0
	Reboxetine					1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPERURICAEMIA	Imipramine					1	100.0					1	100.0
	Reboxetine					1	100.0					1	100.0
DELUSION	Imipramine					1	100.0					1	100.0
	Reboxetine					1	100.0					1	100.0
SUICIDE ATTEMPT	Reboxetine	1	50.0					1	50.0			2	100.0
MENSTRUAL DISORDER	Imipramine	1	100.0									1	100.0
	Reboxetine	1	100.0									1	100.0
RHINITIS	Reboxetine	2	100.0									2	100.0
SPUTUM INCREASED	Imipramine	2	100.0									2	100.0
SALIVA INCREASED	Imipramine					1	100.0					1	100.0
PAIN	Reboxetine	1	100.0									1	100.0
AV BLOCK	Imipramine					1	100.0					1	100.0
BUNDLE BRANCH BLOCK	Reboxetine					1	100.0					1	100.0
EXTRASYSTOLES	Imipramine					1	100.0					1	100.0
TACHYCARDIA SUPRAVENTRICULAR	Imipramine	1	100.0									1	100.0
HYPEREMESIA	Imipramine	1	100.0									1	100.0
HYPOKINESIA	Imipramine	1	100.0									1	100.0
VERTIGO	Imipramine	1	100.0									1	100.0
HYPOTHYROIDISM	Reboxetine					1	100.0					1	100.0
APPETITE INCREASED	Imipramine					1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 55

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		All adverse events											
		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
DYSPHAGIA	Imipramine					1	100.0					1	100.0
OESOPHAGITIS	Imipramine					1	100.0					1	100.0
LEUKOCYTOSIS	Reboxetine					1	100.0					1	100.0
GLOBULINS INCREASED	Reboxetine					1	100.0					1	100.0
HYPERLIPAEMIA	Imipramine	1	100.0									1	100.0
ARTHROSIS	Imipramine					1	100.0					1	100.0
MANIC REACTION	Imipramine					1	100.0					1	100.0
CERVICITIS	Reboxetine	1	100.0									1	100.0
HERPES SIMPLEX	Reboxetine	1	100.0									1	100.0
OTITIS MEDIA	Imipramine	1	100.0									1	100.0
ASTENA	Imipramine	1	100.0									1	100.0
COUGHING	Imipramine	1	100.0									1	100.0
ALOPECIA	Reboxetine	1	100.0									1	100.0
DERMATITIS FUNGAL	Reboxetine	1	100.0									1	100.0
PRURITUS	Reboxetine	1	100.0									1	100.0
TASTE LOSS	Imipramine	1	100.0									1	100.0
CYSTITIS HAEMORRHAGIC	Reboxetine	1	100.0									1	100.0

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
Pt exposed	Imipramine	126	100	2.01	110	100	1.84	109	100	2.03	100	100	1.90	95	100	2.03	93	100	1.82	14	100	1.56
	Reboxetine	130	100	1.64	119	100	1.61	113	100	1.65	107	100	1.64	104	100	1.75	100	100	1.77	21	100	1.32
MOUTH DRY	Imipramine	36	28.6	1.00	29	26.4	1.00	26	23.9	1.00	23	23.0	1.00	24	25.3	1.04	20	21.5	1.05	11	78.6	1.09
	Reboxetine	19	14.6	1.00	21	17.6	1.00	19	16.8	1.00	15	14.0	1.00	14	13.5	1.00	12	12.0	1.00	8	38.1	1.00
SWEATING INCREASED	Imipramine	12	9.5	1.00	12	10.9	1.00	13	11.9	1.00	10	10.0	1.00	10	10.5	1.00	12	12.9	1.00	6	42.9	1.00
	Reboxetine	12	9.2	1.00	9	7.6	1.00	9	8.0	1.00	7	6.5	1.00	7	6.7	1.00	6	6.0	1.00	2	9.5	1.00
HEADACHE	Imipramine	8	6.3	1.00	6	5.5	1.00	6	5.5	1.00	8	8.0	1.00	7	7.4	1.00	5	5.4	1.00	3	21.4	1.00
	Reboxetine	8	6.2	1.00	9	7.6	1.00	8	7.1	1.00	10	9.3	1.00	10	9.6	1.00	3	3.0	1.00	1	4.8	1.00
CONSTIPATION	Imipramine	8	6.3	1.00	10	9.1	1.00	8	7.3	1.00	8	8.0	1.00	7	7.4	1.00	6	6.5	1.00	1	7.1	1.00
	Reboxetine	7	5.4	1.00	6	5.0	1.00	8	7.1	1.00	7	6.5	1.00	7	6.7	1.00	5	5.0	1.00	4	19.0	1.00
INSOMNIA	Imipramine	5	4.0	1.00	7	6.4	1.00	10	9.2	1.00	10	10.0	1.00	8	8.4	1.00	8	8.6	1.00	1	7.1	1.00
	Reboxetine	7	5.4	1.00	7	5.9	1.00	5	4.4	1.00	5	4.7	1.00	5	4.8	1.00	3	3.0	1.00	1	4.8	1.00
DIZZINESS	Imipramine	12	9.5	1.00	9	8.2	1.00	7	6.4	1.00	8	8.0	1.00	5	5.3	1.00	3	3.2	1.00	1	7.1	1.00
	Reboxetine	6	4.6	1.00	1	0.8	1.00	4	3.5	1.00	3	2.8	1.00	2	1.9	1.00	2	2.0	1.00	2	9.5	1.00
TACHYCARDIA	Imipramine	7	5.6	1.00	6	5.5	1.00	7	6.4	1.00	7	7.0	1.00	6	6.3	1.00	4	4.3	1.00			
	Reboxetine	2	1.5	1.00	3	2.5	1.00	4	3.5	1.00	4	3.7	1.00	3	2.9	1.33	4	4.0	1.00	1	4.8	1.00
NAUSEA	Imipramine	9	7.1	1.00	7	6.4	1.00	6	5.5	1.00	4	4.0	1.00	2	2.1	1.00	2	2.2	1.00			
	Reboxetine	11	8.5	1.00	4	3.4	1.00	2	1.8	1.00	1	0.9	1.00	1	1.0	1.00	3	3.0	1.00	1	4.8	1.00
TREMOR	Imipramine	7	5.6	1.00	8	7.3	1.00	8	7.3	1.00	7	7.0	1.00	5	5.3	1.00	6	6.5	1.00	3	21.4	1.00
	Reboxetine	1	0.8	1.00	1	0.8	1.00	2	1.8	1.00												

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
MICTURITION DISORDER	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00				2	2.1	1.00						
	Reboxetine	4	3.1	1.00	6	5.0	1.00	6	5.3	1.00	5	4.7	1.00	5	4.8	1.00	3	3.0	1.00	3	14.3	1.00
VISION ABNORMAL	Imipramine	3	2.4	1.00	2	1.8	1.00	1	0.9	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00	2	14.3	1.00
	Reboxetine	4	3.1	1.00	4	3.4	1.00	4	3.5	1.00	3	2.8	1.00	3	2.9	1.00	2	2.0	1.00	2	9.5	1.00
AGITATION	Imipramine	5	4.0	1.00	3	2.7	1.00	2	1.8	1.00	2	2.0	1.00	2	2.1	1.00	1	1.1	1.00			
	Reboxetine	6	4.6	1.00	4	3.4	1.00	2	1.8	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
SOMNOLENCE	Imipramine	5	4.0	1.00	4	3.6	1.00	2	1.8	1.00	2	2.0	1.00	4	4.2	1.00	2	2.2	1.00			
	Reboxetine	3	2.3	1.00	1	0.8	1.00	1	0.9	1.00				1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
PALPITATION	Imipramine	1	0.8	1.00	3	2.7	1.00	3	2.8	1.00	2	2.0	1.00	1	1.1	1.00						
	Reboxetine	2	1.5	1.00	3	2.5	1.00	4	3.5	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00			
LIBIDO DECREASED	Imipramine										1	1.0	1.00	2	2.1	1.00	1	1.1	1.00	1	7.1	1.00
	Reboxetine	1	0.8	1.00	1	0.8	1.00	3	2.7	1.00	3	2.8	1.00	3	2.9	1.00	3	3.0	1.00	3	14.3	1.00
FLATULENCE	Imipramine	1	0.8	1.00	2	1.8	1.00	2	1.8	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
	Reboxetine	2	1.5	1.00	2	1.7	1.00	2	1.8	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00			
HYPERTENSION	Imipramine																1	1.1	1.00	1	7.1	1.00
	Reboxetine	1	0.8	1.00	3	2.5	1.00	4	3.5	1.00	4	3.7	1.00	3	2.9	1.00	2	2.0	1.50			
FATIGUE	Imipramine	4	3.2	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	2	1.5	1.00	2	1.7	1.00	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
PARAESTHESIA	Imipramine	2	1.6	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.8	1.00	3	2.5	1.00	1	0.9	1.00				1	1.0	1.00	1	1.0	1.00	1	4.8	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
TASTE PERVERSION	Imipramine	2	1.6	1.00	1	0.9	1.00																
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00	2	9.5	1.00
BRONCHITIS	Imipramine				1	0.9	1.00							1	1.1	1.00							
	Reboxetine				1	0.8	1.00	3	2.7	1.00	1	0.9	1.00	1	1.0	1.00	2	2.0	1.00	2	9.5	1.00
INFLUENZA-LIKE SYMPTOMS	Imipramine				2	1.8	1.00	2	1.8	1.00							1	1.1	1.00	1	7.1	1.00
	Reboxetine				1	0.8	1.00	2	1.8	1.00				1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
GAMMA-GT INCREASED	Imipramine							2	1.8	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00			
	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
HYPOTENSION	Imipramine	2	1.6	1.00	2	1.8	1.00	3	2.8	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
URINARY RETENTION	Imipramine	1	0.8	1.00	1	0.9	1.00				2	2.0	1.00	2	2.1	1.00						
	Reboxetine	2	1.5	1.00	2	1.7	1.00															
HYPERCHOLESTEROLAEMIA	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
	Reboxetine										1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
HYPOTENSION POSTURAL	Imipramine	2	1.6	1.00	2	1.8	1.00	2	1.8	1.00	1	1.0	1.00									
	Reboxetine	1	0.8	1.00	1	0.8	1.00															
RASH	Imipramine				1	0.9	1.00										1	1.1	1.00			
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
UPPER RESP TRACT INFECTION	Imipramine				1	0.9	1.00										2	2.2	1.00	1	7.1	1.00
	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
HYPERURICAEMIA	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
SALIVA INCREASED	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
DYSPEPSIA	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
URINARY TRACT INFECTION	Imipramine							1	0.9	1.00												
	Reboxetine	1	0.8	1.00				1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00			
HEPATIC ENZYMES INCREASED	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	2.00			
	Reboxetine							1	0.9	1.00	1	0.9	1.00									
BACK PAIN	Imipramine	1	0.8	1.00										1	1.1	1.00	1	1.1	1.00			
	Reboxetine	1	0.8	1.00	2	1.7	1.00															
FLUSHING	Imipramine							1	0.9	1.00	1	1.0	1.00									
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00									
ABDOMINAL PAIN	Imipramine				1	0.9	1.00										1	1.1	1.00			
	Reboxetine	2	1.5	1.00										1	1.0	1.00	1	1.0	1.00			
TINNITUS	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
ANOREXIA	Imipramine	2	1.6	1.00																		
	Reboxetine	1	0.8	1.00	1	0.8	1.00															
TASTE LOSS	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00									
SINUSITIS	Imipramine	1	0.8	1.00																		

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
SINUSITIS	Reboxetine										1	0.9	1.00	2	1.9	1.00							
ASTHENIA	Imipramine	2	1.6	1.00	1	0.9	1.00																
	Reboxetine	1	0.8	1.00																			
DIARRHOEA	Imipramine													1	1.1	1.00							
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00													
ARTHRALGIA	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00							
	Reboxetine													1	1.0	1.00							
AV BLOCK	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
BUNDLE BRANCH BLOCK	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
APPETITE INCREASED	Imipramine										1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
GLOBULINS INCREASED	Reboxetine										1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
ACCOMMODATION ABNORMAL	Imipramine	2	1.6	1.00	1	0.9	1.00															
CONFUSION	Imipramine	1	0.8	1.00				1	0.9	1.00	1	1.0	1.00									
NERVOUSNESS	Reboxetine	2	1.5	1.00				1	0.9	1.00												
CERVICITIS	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00												
HYPOAESTHESIA	Imipramine				1	0.9	1.00	1	0.9	1.00												
	Reboxetine													1	1.0	1.00						

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
MENSTRUAL DISORDER	Imipramine										1	1.0	1.00										
	Reboxetine							1	0.9	1.00	1	0.9	1.00										
FEVER	Imipramine										1	1.0	1.00	1	1.1	1.00							
	Reboxetine							1	0.9	1.00													
DELUSION	Imipramine	1	0.8	1.00																			
	Reboxetine				1	0.8	1.00																
CHEST PAIN	Imipramine	1	0.8	1.00	1	0.9	1.00																
HOT FLUSHES	Imipramine	2	1.6	1.00																			
PRURITUS	Reboxetine	1	0.8	1.00	1	0.8	1.00																
VOMITING	Imipramine													1	1.1	1.00							
	Reboxetine	1	0.8	1.00																			
PAIN	Reboxetine	1	0.8	1.00	1	0.8	1.00																
HERPES SIMPLEX	Reboxetine				1	0.8	1.00	1	0.9	1.00													
MANIC REACTION	Imipramine							1	0.9	1.00	1	1.0	1.00										
SPUTUM INCREASED	Imipramine							1	0.9	1.00	1	1.0	1.00										
RHINITIS	Reboxetine							1	0.9	1.00	1	0.9	1.00										
OESOPHAGITIS	Imipramine										1	1.0	1.00	1	1.1	1.00							
COUGHING	Imipramine										1	1.0	1.00	1	1.1	1.00							

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																				
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																					
ARTHROSIS	Imipramine													1	1.1	1.00	1	1.1	1.00			
GASTROENTERITIS	Imipramine													1	1.1	1.00						
	Reboxetine													1	1.0	1.00						
ALOPECIA	Reboxetine													1	1.0	1.00	1	1.0	1.00			
DERMATITIS FUNGAL	Reboxetine													1	1.0	1.00	1	1.0	1.00			
SUICIDE ATTEMPT	Reboxetine													1	1.0	1.00	1	1.0	1.00			
ECG ABNORMAL	Reboxetine																2	2.0	1.00			
HYPERKINESIA	Imipramine	1	0.8	1.00																		
HYPOTHYROIDISM	Reboxetine	1	0.8	1.00																		
TACHYCARDIA SUPRAVENTRICULAR	Imipramine				1	0.9	1.00															
DYSPHAGIA	Imipramine				1	0.9	1.00															
HYPERLIPAEMIA	Imipramine							1	0.9	1.00												
ASTHMA	Imipramine							1	0.9	1.00												
OTITIS MEDIA	Imipramine							1	0.9	1.00												
VERTIGO	Imipramine										1	1.0	1.00									
ANXIETY	Imipramine										1	1.0	1.00									
HYPOKINESIA	Imipramine													1	1.1	1.00						

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)	No Pt.	% on exp.	(*)
Adverse events	Assigned treatment																						
CYSTITIS HAEMORRHAGIC	Reboxetine													1	1.0	1.00							
EXTRASYSTOLES	Imipramine																1	1.1	1.00				
SGPT INCREASED	Reboxetine																1	1.0	1.00				
LEUKOCYTOSIS	Reboxetine																			1	4.8	1.00	

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
MOUTH DRY	Imipramine	36	28.6	1.00	29	26.4	1.00	26	23.9	1.00	25	23.8	1.00	24	25.3	1.04	20	21.5	1.05	11	78.6	1.09
	Reboxetine	19	14.6	1.00	21	17.6	1.00	19	16.8	1.00	15	14.8	1.00	14	13.5	1.00	12	12.0	1.00	8	38.1	1.00
SWEATING INCREASED	Imipramine	12	9.5	1.00	12	10.9	1.00	13	11.9	1.00	10	10.0	1.00	10	10.5	1.00	12	12.9	1.00	6	42.9	1.00
	Reboxetine	12	9.2	1.00	9	7.6	1.00	9	8.0	1.00	7	6.5	1.00	7	6.7	1.00	6	6.0	1.00	2	9.5	1.00
SALIVA INCREASED	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
ASTHENIA / FATIGUE	Imipramine	5	4.0	1.20	2	1.8	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	3	2.3	1.00	2	1.7	1.00	1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
INFLUENZA-LIKE SYMPTOMS	Imipramine				2	1.8	1.00	2	1.8	1.00							1	1.1	1.00	1	7.1	1.00
	Reboxetine				1	0.8	1.00	2	1.8	1.00				1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
FEVER	Imipramine										1	1.0	1.00	1	1.1	1.00						
	Reboxetine							1	0.9	1.00												
CHEST PAIN	Imipramine	1	0.8	1.00	1	0.9	1.00															
PAIN	Reboxetine	1	0.8	1.00	1	0.8	1.00															

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	15	11.9	1.06	12	10.9	1.08	11	10.1	1.09	9	9.0	1.11	5	5.3	1.20	3	3.2	1.33	1	7.1	2.00
	Reboxetine	7	5.4	1.00	2	1.7	1.00	4	3.5	1.00	3	2.8	1.00	2	1.9	1.00	2	2.0	1.00	2	9.5	1.00
TACHYCARDIA	Imipramine	7	5.6	1.00	6	5.5	1.00	7	6.4	1.00	7	7.0	1.00	6	6.3	1.00	4	4.3	1.00			
	Reboxetine	2	1.5	1.00	3	2.5	1.00	4	3.5	1.00	4	3.7	1.00	3	2.9	1.33	4	4.0	1.00	1	4.8	1.00
PALPITATION	Imipramine	1	0.8	1.00	3	2.7	1.00	3	2.8	1.00	2	2.0	1.00	1	1.1	1.00						
	Reboxetine	2	1.5	1.00	3	2.5	1.00	4	3.5	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00			
HYPERTENSION	Imipramine																1	1.1	1.00	1	7.1	1.00
	Reboxetine	1	0.8	1.00	3	2.5	1.00	4	3.5	1.00	4	3.7	1.00	3	2.9	1.00	2	2.0	1.50			
FLUSHING / HOT FLUSHES	Imipramine	2	1.6	1.00				1	0.9	1.00	1	1.0	1.00									
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00									
AV BLOCK	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
BUNDLE BRANCH BLOCK	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
ECG ABNORMAL	Reboxetine																2	2.0	1.00			
TACHYCARDIA SUPRAVENTRICULAR	Imipramine				1	0.9	1.00															
EXTRASYSTOLES	Imipramine																1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
HEADACHE / MIGRAINE	Imipramine	8	6.3	1.00	6	5.5	1.00	6	5.5	1.00	8	8.0	1.00	7	7.4	1.00	5	5.4	1.00	3	21.4	1.00
	Reboxetine	8	6.2	1.00	9	7.6	1.00	8	7.1	1.00	10	9.3	1.00	10	9.6	1.00	3	3.0	1.00	1	4.8	1.00
TREMOR	Imipramine	7	5.6	1.00	8	7.3	1.00	8	7.3	1.00	7	7.0	1.00	5	5.3	1.00	6	6.5	1.00	3	21.4	1.00
	Reboxetine	1	0.8	1.00	1	0.8	1.00	2	1.8	1.00												
PARAESTHESIA	Imipramine	2	1.6	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine	1	0.8	1.00	3	2.5	1.00	1	0.9	1.00				1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
CONFUSION	Imipramine	1	0.8	1.00				1	0.9	1.00	1	1.0	1.00									
HYPOAESTHESIA	Imipramine				1	0.9	1.00	1	0.9	1.00												
	Reboxetine													1	1.0	1.00						
HYPERKINESIA	Imipramine	1	0.8	1.00																		
VERTIGO	Imipramine										1	1.0	1.00									
HYPOKINESIA	Imipramine													1	1.1	1.00						

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: ENDOCRINE DISORDERS

Adverse events/Assigned treatment		Days of treatment																							
		0-7			8-14			15-21			22-28			29-35			36-42			> 42				
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)		
HYPOTHYROIDISM	Reboxetine	1	0.8	1.00																					

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
CONSTIPATION	Imipramine	8	6.3	1.00	10	9.1	1.00	8	7.3	1.00	8	8.0	1.00	7	7.4	1.00	6	6.5	1.00	1	7.1	1.00
	Reboxetine	7	5.4	1.00	6	5.0	1.00	8	7.1	1.00	7	6.5	1.00	7	6.7	1.00	5	5.0	1.00	4	19.0	1.00
NAUSEA AND RELATED SYMPTOMS	Imipramine	9	7.1	1.00	7	6.4	1.00	6	5.5	1.00	4	4.0	1.00	3	3.2	1.00	2	2.2	1.00			
	Reboxetine	12	9.2	1.08	5	4.2	1.00	3	2.7	1.00	2	1.9	1.00	2	1.9	1.00	4	4.0	1.00	2	9.5	1.00
FLATULENCE	Imipramine	1	0.8	1.00	2	1.8	1.00	2	1.8	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
	Reboxetine	2	1.5	1.00	2	1.7	1.00	2	1.8	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00			
ABDOMINAL PAIN	Imipramine				1	0.9	1.00										1	1.1	1.00			
	Reboxetine	2	1.5	1.00										1	1.0	1.00	1	1.0	1.00			
ANOREXIA	Imipramine	2	1.6	1.00																		
	Reboxetine	1	0.8	1.00	1	0.8	1.00															
DIARRHOEA	Imipramine													1	1.1	1.00						
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00												
APPETITE INCREASED	Imipramine										1	1.0	1.00	1	1.1	1.00	1	1.1	1.00	1	7.1	1.00
OESOPHAGITIS	Imipramine										1	1.0	1.00	1	1.1	1.00						
GASTROENTERITIS	Imipramine													1	1.1	1.00						
	Reboxetine													1	1.0	1.00						
DYSPHAGIA	Imipramine				1	0.9	1.00															

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
TINNITUS	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
LEUKOCYTOSIS	Reboxetine																			1	4.8	1.00

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
INCREASED LIVER ENZYMES	Imipramine							2	1.8	1.50	2	2.0	1.50	2	2.1	1.50	2	2.2	2.00			
	Reboxetine							2	1.8	1.00	2	1.9	1.00	1	1.0	1.00	2	2.0	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
HYPERCHOLESTEROLAEMIA	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
	Reboxetine										1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
HYPERURICAEMIA	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00	1	1.1	1.00			
	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
GLOBULINS INCREASED	Reboxetine										1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
HYPERLIPAEMIA	Imipramine							1	0.9	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: MUSCOLO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
BACK PAIN	Imipramine	1	0.8	1.00										1	1.1	1.00	1	1.1	1.00			
	Reboxetine	1	0.8	1.00	2	1.7	1.00															
ARTHRALGIA	Imipramine							1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
	Reboxetine													1	1.0	1.00						
ARTHROSIS	Imipramine													1	1.1	1.00	1	1.1	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
INSOMNIA	Imipramine	5	4.0	1.00	7	6.4	1.00	10	9.2	1.00	10	10.0	1.00	8	8.4	1.00	6	6.6	1.00	1	7.1	1.00
	Reboxetine	7	5.4	1.00	7	5.9	1.00	5	4.4	1.00	5	4.7	1.00	5	4.8	1.00	3	3.0	1.00	1	4.8	1.00
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	5	4.0	1.00	3	2.7	1.00	2	1.8	1.00	3	3.0	1.00	2	2.1	1.00	1	1.1	1.00			
	Reboxetine	8	6.2	1.00	4	3.4	1.00	3	2.7	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
SOMNOLENCE	Imipramine	5	4.0	1.00	4	3.6	1.00	2	1.8	1.00	2	2.0	1.00	4	4.2	1.00	2	2.2	1.00			
	Reboxetine	3	2.3	1.00	1	0.8	1.00	1	0.9	1.00				1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
LIBIDO DECREASED	Imipramine										1	1.0	1.00	2	2.1	1.00	1	1.1	1.00	1	7.1	1.00
	Reboxetine	1	0.8	1.00	1	0.8	1.00	3	2.7	1.00	3	2.8	1.00	3	2.9	1.00	3	3.0	1.00	3	14.3	1.00
DELUSION	Imipramine	1	0.8	1.00																		
	Reboxetine				1	0.8	1.00															
MANIC REACTION	Imipramine							1	0.9	1.00	1	1.0	1.00									
SUICIDE ATTEMPT	Reboxetine													1	1.0	1.00	1	1.0	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: REPRODUCTIVE DISORDERS, FEMALE

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
CERVICITIS	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00												
MENSTRUAL DISORDER	Imipramine										1	1.0	1.00									
	Reboxetine							1	0.9	1.00	1	0.9	1.00									

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
HERPES SIMPLEX	Reboxetine				1	0.8	1.00	1	0.9	1.00												
OTITIS MEDIA	Imipramine							1	0.9	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
BRONCHITIS	Imipramine				1	0.9	1.00							1	1.1	1.00						
	Reboxetine				1	0.8	1.00	3	2.7	1.00	1	0.9	1.00	1	1.0	1.00	2	2.0	1.00	2	9.5	1.00
UPPER RESP TRACT INFECTION	Imipramine				1	0.9	1.00										2	2.2	1.00	1	7.1	1.00
	Reboxetine							1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00			
SINUSITIS	Imipramine	1	0.8	1.00																		
	Reboxetine										1	0.9	1.00	2	1.9	1.00						
SPUTUM INCREASED	Imipramine							1	0.9	1.00	1	1.0	1.00									
RHINITIS	Reboxetine							1	0.9	1.00	1	0.9	1.00									
COUGHING	Imipramine										1	1.0	1.00	1	1.1	1.00						
ASTHMA	Imipramine							1	0.9	1.00												

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
ERYTHEMA / RASH	Imipramine				1	0.9	1.00										1	1.1	1.00			
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.0	1.00	1	4.8	1.00
PRURITUS	Reboxetine	1	0.8	1.00	1	0.8	1.00															
ALOPECIA	Reboxetine													1	1.0	1.00	1	1.0	1.00			
DERMATITIS FUNGAL	Reboxetine													1	1.0	1.00	1	1.0	1.00			

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
TASTE PERVERSION	Imipramine	2	1.6	1.00	1	0.9	1.00															
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00	2	9.5	1.00
TASTE LOSS	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00									

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
URINARY HESITANCY / RETENTION	Imipramine	2	1.6	1.00	2	1.8	1.00	1	0.9	1.00	2	2.0	1.00	3	3.2	1.33						
	Reboxetine	6	4.6	1.00	8	6.7	1.00	6	5.3	1.00	5	4.7	1.00	5	4.8	1.00	3	3.0	1.00	3	14.3	1.00
URINARY TRACT INFECTION	Imipramine							1	0.9	1.00												
	Reboxetine	1	0.8	1.00				1	0.9	1.00	2	1.9	1.00	1	1.0	1.00	1	1.0	1.00			
CYSTITIS HAEMORRHAGIC	Reboxetine													1	1.0	1.00						

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 57

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: VISION DISORDERS

Adverse events/Assigned treatment		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)	No Pt	% on exp.	(*)
BLURRED VISION	Imipramine	4	3.2	1.25	3	2.7	1.00	1	0.9	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00	2	14.3	1.00
	Reboxetine	4	3.1	1.00	4	3.4	1.00	4	3.5	1.00	3	2.8	1.00	3	2.9	1.00	2	2.0	1.00	2	9.5	1.00

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 58

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)
Body system	Assigned treatment																						
Pt exposed	Imipramine	126	100	2.01	110	100	1.84	109	100	2.03	100	100	1.90	95	100	2.03	93	100	1.82	14	100	1.56
	Reboxetine	130	100	1.64	119	100	1.61	113	100	1.65	107	100	1.64	104	100	1.75	100	100	1.77	21	100	1.32
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	44	34.9	1.11	37	33.6	1.13	35	32.1	1.14	31	31.0	1.09	32	33.7	1.12	29	31.2	1.17	16	114	1.18
	Reboxetine	27	20.8	1.14	26	21.8	1.15	25	22.1	1.12	22	20.6	1.00	21	20.2	1.00	17	17.0	1.05	10	47.6	1.00
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	25	19.8	1.04	22	20.0	1.04	21	19.3	1.14	18	18.0	1.16	11	11.6	1.27	9	9.7	1.22	2	14.3	1.50
	Reboxetine	12	9.2	1.08	10	8.4	1.20	14	12.4	1.28	12	11.2	1.25	8	7.7	1.50	11	11.0	1.27	3	14.3	1.00
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	18	14.3	1.11	19	17.3	1.10	14	12.8	1.14	15	15.0	1.00	13	13.7	1.15	11	11.8	1.00	2	14.3	1.00
	Reboxetine	22	16.9	1.18	15	12.6	1.00	13	11.5	1.07	9	8.4	1.22	11	10.6	1.18	10	10.0	1.20	5	23.8	1.20
PSYCHIATRIC DISORDERS	Imipramine	14	11.1	1.14	14	12.7	1.00	14	12.8	1.07	13	13.0	1.30	14	14.7	1.14	11	11.8	1.09	2	14.3	1.00
	Reboxetine	16	12.3	1.18	12	10.1	1.16	11	9.7	1.09	8	7.5	1.12	10	9.6	1.10	8	8.0	1.12	5	23.8	1.00
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	17	13.5	1.11	15	13.6	1.06	15	13.8	1.13	16	16.0	1.12	11	11.6	1.27	9	9.7	1.22	5	35.7	1.20
	Reboxetine	10	7.7	1.00	13	10.9	1.00	11	9.7	1.00	10	9.3	1.00	12	11.5	1.00	4	4.0	1.00	2	9.5	1.00
URINARY SYSTEM DISORDERS	Imipramine	2	1.6	1.00	2	1.8	1.00	2	1.8	1.00	2	2.0	1.00	3	3.2	1.33						
	Reboxetine	7	5.4	1.00	8	6.7	1.00	7	6.2	1.00	7	6.5	1.00	7	6.7	1.00	4	4.0	1.00	3	14.3	1.00
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	6	4.8	1.16	5	4.5	1.00	3	2.8	1.00	2	2.0	1.00	2	2.1	1.00	1	1.1	1.00	1	7.1	1.00
	Reboxetine	4	3.1	1.00	4	3.4	1.00	4	3.5	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00	2	9.5	1.00
VISION DISORDERS	Imipramine	4	3.2	1.25	3	2.7	1.00	1	0.9	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00	2	14.3	1.00
	Reboxetine	4	3.1	1.00	4	3.4	1.00	4	3.5	1.00	3	2.8	1.00	3	2.9	1.00	2	2.0	1.00	2	9.5	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 58

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
		No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)
Body system	Assigned treatment																						
RESPIRATORY SYSTEM DISORDERS	Imipramine	1	0.8	1.00	2	1.8	1.00	2	1.8	1.00	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00	1	7.1	1.00
	Reboxetine				1	0.8	1.00	5	4.4	1.00	4	3.7	1.00	4	3.8	1.00	3	3.0	1.00	2	9.5	1.00
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	1	0.8	1.00	1	0.9	1.00	2	1.8	1.50	2	2.0	1.00	2	2.1	1.00	2	2.2	1.00			
	Reboxetine							1	0.9	1.00	3	2.8	1.00	3	2.9	1.00	3	3.0	1.00	2	9.5	1.00
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine							2	1.8	1.50	2	2.0	1.50	2	2.1	1.50	2	2.2	2.00			
	Reboxetine							2	1.8	1.00	2	1.9	1.00	1	1.0	1.00	2	2.0	1.00			
SPECIAL SENSES OTHER, DISORDERS	Imipramine	3	2.4	1.00	2	1.8	1.00	1	0.9	1.00	1	1.0	1.00									
	Reboxetine	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	2	1.9	1.00	2	1.9	1.00	2	2.0	1.00	2	9.5	1.00
SKIN AND APPENDAGES DISORDERS	Imipramine				1	0.9	1.00										1	1.1	1.00			
	Reboxetine	2	1.5	1.00	2	1.7	1.00	1	0.9	1.00	1	0.9	1.00	3	2.9	1.00	3	3.0	1.00	1	4.8	1.00
MUSCOLO-SKELETAL SYSTEM DISORDERS	Imipramine	1	0.8	1.00				1	0.9	1.00	1	1.0	1.00	3	3.2	1.00	2	2.2	1.00			
	Reboxetine	1	0.8	1.00	2	1.7	1.00							1	1.0	1.00						
REPRODUCTIVE DISORDERS, FEMALE	Imipramine										1	1.0	1.00									
	Reboxetine	1	0.8	1.00	1	0.8	1.00	2	1.8	1.00	1	0.9	1.00									
HEARING AND VESTIBULAR DISORDERS	Imipramine	1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00						
RESISTANCE MECHANISM DISORDERS	Imipramine							1	0.9	1.00												
	Reboxetine				1	0.8	1.00	1	0.9	1.00												

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

		Days of treatment																					
		0-7			8-14			15-21			22-28			29-35			36-42			> 42		
Body system	Assigned treatment	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)	No Pt	% on exp	(*)
ENDOCRINE DISORDERS	Reboxetine	1	0.8	1.00																		
HEMATOLOGY DISORDERS	Reboxetine																			1	4.8	1.00

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 59

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Total adverse events	Imipramine	29	9.6	89	29.4	124	40.9	27	8.9	27	8.9	6	2.0	1	0.3	303	100.0
	Reboxetine	21	7.9	64	24.0	106	39.7	42	15.7	25	9.4	6	2.2	3	1.1	267	100.0
MOUTH DRY	Imipramine	10	20.8	23	47.9	15	31.3									48	100.0
	Reboxetine	7	21.2	12	36.4	13	39.4			1	3.0					33	100.0
HEADACHE / MIGRAINE	Imipramine			5	23.8	10	47.6	3	14.3	3	14.3					21	100.0
	Reboxetine			2	7.4	9	33.3	13	48.1	1	3.7	1	3.7	1	3.7	27	100.0
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	3	11.1	6	22.2	15	55.6	2	7.4			1	3.7			27	100.0
	Reboxetine	2	14.3	4	28.6	4	28.6	2	14.3	1	7.1			1	7.1	14	100.0
SWEATING INCREASED	Imipramine			9	45.0	11	55.0									20	100.0
	Reboxetine	1	5.0	9	45.0	7	35.0	2	10.0					1	5.0	20	100.0
NAUSEA AND RELATED SYMPTOMS	Imipramine	4	28.6	4	28.6	5	35.7	1	7.1							14	100.0
	Reboxetine	6	30.0	4	20.0	7	35.0	3	15.0							20	100.0
INSOMNIA	Imipramine	1	6.3	3	18.8	4	25.0	4	25.0	3	18.8	1	6.3			16	100.0
	Reboxetine	2	18.2	4	36.4	2	18.2	3	27.3							11	100.0
CONSTIPATION	Imipramine	2	15.4	3	23.1	8	61.5									13	100.0
	Reboxetine			2	15.4	8	61.5	3	23.1							13	100.0
TACHYCARDIA	Imipramine			4	26.7	8	53.3	2	13.3			1	6.7			15	100.0
	Reboxetine			2	20.0	8	80.0									10	100.0
AGITATION / ANXIETY / NERVOUSNESS	Imipramine	2	20.0	2	20.0	6	60.0									10	100.0
	Reboxetine	1	9.1	2	18.2	6	54.5	1	9.1	1	9.1					11	100.0
URINARY HESITANCY / RETENTION	Imipramine	2	28.6			5	71.4									7	100.0
	Reboxetine			6	54.5	5	45.5									11	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 59

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
TREMOR	Imipramine	1	7.7	4	30.8	8	61.5									13	100.0
	Reboxetine					2	100.0									2	100.0
SOMNOLENCE	Imipramine	2	20.0	4	40.0	4	40.0									10	100.0
	Reboxetine			2	50.0	2	50.0									4	100.0
ASTHENIA / FATIGUE	Imipramine	1	14.3	5	71.4	1	14.3									7	100.0
	Reboxetine			2	33.3	2	33.3	2	33.3							6	100.0
PALPITATION	Imipramine			3	50.0	2	33.3	1	16.7							6	100.0
	Reboxetine					5	100.0									5	100.0
BLURRED VISION	Imipramine			5	83.3	1	16.7									6	100.0
	Reboxetine	1	25.0	1	25.0	2	50.0									4	100.0
HYPERTENSION	Imipramine													1	100.0	1	100.0
	Reboxetine			2	28.6	4	57.1					1	14.3			7	100.0
BRONCHITIS	Imipramine									2	100.0					2	100.0
	Reboxetine									6	100.0					6	100.0
INCREASED LIVER ENZYMES	Imipramine					4	100.0									4	100.0
	Reboxetine			1	33.3	1	33.3	1	33.3							3	100.0
INFLUENZA-LIKE SYMPTOMS	Imipramine							1	33.3	2	66.7					3	100.0
	Reboxetine							2	50.0	2	50.0					4	100.0
PARAESTHESIA	Imipramine							1	50.0	1	50.0					2	100.0
	Reboxetine			1	25.0	3	75.0									4	100.0
FLUSHING / HOT FLASHING	Imipramine			1	33.3	2	66.7									3	100.0
	Reboxetine			1	50.0							1	50.0			2	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 59

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
ABDOMINAL PAIN	Imipramine					1	50.0	1	50.0							2	100.0
	Reboxetine			1	33.3	1	33.3			1	33.3					3	100.0
FLATULENCE	Imipramine			1	50.0	1	50.0									2	100.0
	Reboxetine			2	66.7	1	33.3									3	100.0
LIBIDO DECREASED	Imipramine			1	50.0			1	50.0							2	100.0
	Reboxetine			1	33.3	2	66.7									3	100.0
ERYTHEMA / RASH	Imipramine			1	50.0							1	50.0			2	100.0
	Reboxetine							2	66.7	1	33.3					3	100.0
BACK PAIN	Imipramine									3	100.0					3	100.0
	Reboxetine					2	100.0									2	100.0
UPPER RESP TRACT INFECTION	Imipramine									3	100.0					3	100.0
	Reboxetine									2	100.0					2	100.0
TASTE PERVERSION	Imipramine			2	100.0											2	100.0
	Reboxetine			1	50.0			1	50.0							2	100.0
URINARY TRACT INFECTION	Imipramine									1	100.0					1	100.0
	Reboxetine					1	33.3			2	66.7					3	100.0
ANOREXIA	Imipramine			1	50.0			1	50.0							2	100.0
	Reboxetine					1	100.0									1	100.0
SINUSITIS	Imipramine					1	100.0									1	100.0
	Reboxetine							1	50.0	1	50.0					2	100.0
ARTHRALGIA	Imipramine									2	100.0					2	100.0
	Reboxetine									1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 59

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SUICIDE ATTEMPT	Reboxetine	1	50.0							1	50.0					2	100.0
CONFUSION	Imipramine			1	50.0	1	50.0									2	100.0
DELUSION	Imipramine							1	100.0							1	100.0
	Reboxetine			1	100.0											1	100.0
FEVER	Imipramine							1	100.0							1	100.0
	Reboxetine					1	100.0									1	100.0
ECG ABNORMAL	Reboxetine					1	50.0	1	50.0							2	100.0
DIARRHOEA	Imipramine									1	100.0					1	100.0
	Reboxetine					1	100.0									1	100.0
TINNITUS	Imipramine					1	50.0	1	50.0							2	100.0
HYPERCHOLESTEROLAEMIA	Imipramine					1	100.0									1	100.0
	Reboxetine											1	100.0			1	100.0
HYPERURICAEMIA	Imipramine					1	100.0									1	100.0
	Reboxetine					1	100.0									1	100.0
MENSTRUAL DISORDER	Imipramine									1	100.0					1	100.0
	Reboxetine					1	100.0									1	100.0
CHEST PAIN	Imipramine							2	100.0							2	100.0
HYPOAESTHESIA	Imipramine											1	100.0			1	100.0
	Reboxetine							1	100.0							1	100.0
RHINITIS	Reboxetine							1	50.0	1	50.0					2	100.0
GASTROENTERITIS	Imipramine									1	100.0					1	100.0
	Reboxetine									1	100.0					1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 59

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPUTUM INCREASED	Imipramine									2	100.0					2	100.0
MANIC REACTION	Imipramine	1	100.0													1	100.0
DYSPHAGIA	Imipramine			1	100.0											1	100.0
PRURITUS	Reboxetine			1	100.0											1	100.0
SALIVA INCREASED	Imipramine					1	100.0									1	100.0
BUNDLE BRANCH BLOCK	Reboxetine					1	100.0									1	100.0
EXTRASYSTOLES	Imipramine					1	100.0									1	100.0
TACHYCARDIA SUPRAVENTRICULAR	Imipramine					1	100.0									1	100.0
HYPERKINESIA	Imipramine					1	100.0									1	100.0
VERTIGO	Imipramine					1	100.0									1	100.0
APPETITE INCREASED	Imipramine					1	100.0									1	100.0
OESOPHAGITIS	Imipramine					1	100.0									1	100.0
LEUKOCYTOSIS	Reboxetine					1	100.0									1	100.0
ALOPECIA	Reboxetine					1	100.0									1	100.0
TASTE LOSS	Imipramine					1	100.0									1	100.0
HYPOKINESIA	Imipramine							1	100.0							1	100.0
GLOBULINS INCREASED	Reboxetine							1	100.0							1	100.0
HERPES SIMPLEX	Reboxetine							1	100.0							1	100.0
OTITIS MEDIA	Imipramine							1	100.0							1	100.0
ASTHMA	Imipramine							1	100.0							1	100.0
COUGHING	Imipramine							1	100.0							1	100.0
DERMATITIS FUNGAL	Reboxetine							1	100.0							1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 59

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment		Relationship															
		Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPOTHYROIDISM	Reboxetine									1	100.0					1	100.0
HYPERLIPAEMIA	Imipramine									1	100.0					1	100.0
ARTHROSIS	Imipramine									1	100.0					1	100.0
CYSTITIS HAEMORRHAGIC	Reboxetine									1	100.0					1	100.0
PAIN	Reboxetine											1	100.0			1	100.0
AV BLOCK	Imipramine											1	100.0			1	100.0
CERVICITIS	Reboxetine											1	100.0			1	100.0

(some adverse events are grouped in cluster)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 60

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Definite	Probable	Doubtful	None	Unknown	Missing	
All adverse events		Ass. treatment									
		Imipramine		18	1	28	1	3	1		52
		Reboxetine		5	1	18	2	2		2	30
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
1 - 8 (Male)	3	DIZZINESS	Imipramine	1							1
		HEADACHE	Imipramine	1							1
		TREMOR	Imipramine	1							1
		SWEATING INCREASED	Imipramine	1							1
		MOUTH DRY	Imipramine	1							1
		VISION ABNORMAL	Imipramine			1					1
		SOMNOLENCE	Imipramine	1							1
2 - 34 (Male)	38	HEADACHE	Imipramine					1			1
		BACK PAIN	Imipramine					1			1
2 - 36 (Female)	22	TACHYCARDIA	Imipramine	1							1
		MANIC REACTION	Imipramine		1						1
2 - 44 (Male)	1	DELUSION	Imipramine				1				1
2 - 50 (Male)	40	INSOMNIA	Reboxetine			1					1
		SUICIDE ATTEMPT	Reboxetine					1			1
		HYPERURICAEMIA	Reboxetine	1							1
		BUNDLE BRANCH BLOCK	Reboxetine	1							1
2 - 51 (Female)	12	DELUSION	Reboxetine			1					1
		INSOMNIA	Reboxetine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 60

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Definite	Probable	Doubtful	None	Unknown	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
7 - 194 (Male)	4	URINARY RETENTION	Reboxetine			1					1
7 - 196 (Female)	39	INSOMNIA	Imipramine	1							1
		RASH	Imipramine			1					1
		AGITATION	Imipramine	1							1
9 - 197 (Male)	4	HEADACHE	Reboxetine				1				1
		ASTHENIA	Reboxetine				1				1
9 - 209 (Male)	4	HEADACHE	Imipramine			1					1
		MOUTH DRY	Imipramine	1							1
		FATIGUE	Imipramine			1					1
9 - 237 (Male)	10	URINARY RETENTION	Reboxetine	1							1
9 - 261 (Female)	7	URINARY RETENTION	Imipramine	1							1
9 - 270 (Female)	7	TACHYCARDIA	Imipramine						1		1
9 - 271 (Female)	22	HEADACHE	Reboxetine	1							1
		HYPERTENSION	Reboxetine	1							1
9 - 273 (Female)	22	TREMOR	Imipramine	1							1
		MOUTH DRY	Imipramine	1							1
		URINARY RETENTION	Imipramine	1							1
		TASTE LOSS	Imipramine	1							1
		CONFUSION	Imipramine	1							1
9/A - 277 (Female)	5	SWEATING INCREASED	Reboxetine			1					1
		INSOMNIA	Reboxetine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 60

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Definite	Probable	Doubtful	None	Unknown	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
9/A - 277 (Female)	5	AGITATION	Reboxetine			1					1
		HYPOTHYROIDISM	Reboxetine					1			1
9/A - 280 (Female)	7	DIZZINESS	Reboxetine			1					1
		MOUTH DRY	Reboxetine			1					1
		SOMNOLENCE	Reboxetine			1					1
9/A - 307 (Female)	4	TREMOR	Imipramine			1					1
		AGITATION	Imipramine			1					1
9/A - 308 (Female)	25	SWEATING INCREASED	Imipramine			1					1
		FATIGUE	Imipramine			1					1
		NAUSEA	Imipramine			1					1
		URINARY TRACT INFECTION	Imipramine					1			1
11 - 330 (Female)	3	INSOMNIA	Reboxetine			1					1
		NAUSEA	Reboxetine			1					1
13 - 353 (Female)	33	SUICIDE ATTEMPT	Reboxetine		1						1
13 - 355 (Female)	3	DIZZINESS	Reboxetine			1					1
		HEADACHE	Reboxetine			1					1
		NAUSEA	Reboxetine			1					1
		ABDOMINAL PAIN	Reboxetine			1					1
		DYSPEPSIA	Reboxetine			1					1
13 - 357 (Female)	5	DIZZINESS	Imipramine			1					1
		SOMNOLENCE	Imipramine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 60

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							Total
				Possible	Definite	Probable	Doubtful	None	Unknown	Missing	
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
13 - 357 (Female)	5	ASTHENIA	Imipramine			1					1
		SINUSITIS	Imipramine	1							1
13 - 358 (Male)	31	DIZZINESS	Reboxetine							1	1
		SWEATING INCREASED	Reboxetine							1	1
13 - 360 (Female)	3	INSOMNIA	Imipramine			1					1
		AGITATION	Imipramine			1					1
		HOT FLUSHES	Imipramine			1					1
14/1 - 129 (Male)	1	MICTURITION DISORDER	Reboxetine			1					1
14/1 - 429 (Female)	4	DIZZINESS	Imipramine			1					1
		HEADACHE	Imipramine			1					1
		MOUTH DRY	Imipramine			1					1
		ASTHENIA	Imipramine			1					1
		FATIGUE	Imipramine			1					1
		NAUSEA	Imipramine			1					1
		ANOREXIA	Imipramine			1					1
14/3 - 427 (Female)	28	OESOPHAGITIS	Imipramine	1							1
15 - 376 (Female)	9	TREMOR	Imipramine			1					1
		DYSPHAGIA	Imipramine			1					1
15 - 379 (Female)	2	MOUTH DRY	Imipramine			1					1
		CONFUSION	Imipramine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 60

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

				Relationship							
				Possible	Definite	Probable	Doubtful	None	Unknown	Missing	Total
Centre - Patient	Days of Treatment	Adverse events	Ass. treatment								
15 - 379 (Female)	2	TASTE PERVERSION	Imipramine			1					1
15 - 382 (Male)	2	HEADACHE	Imipramine			1					1

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
HB	Evaluated	105	103	88	115	114	98
	Mean	14.47	14.48	14.40	14.48	14.67	14.34
	STD	1.10	1.22	1.23	1.22	1.77	1.18
	Min	11.50	10.29	10.29	11.60	11.27	11.70
	Max	17.25	17.20	17.25	18.03	29.04	17.12
	Median	14.50	14.56	14.44	14.40	14.50	14.31
	Median diff.		0.00	-0.15		0.10	0.00
	P value		0.9638	0.1223		0.4915	0.3634
HT	Evaluated	105	103	88	115	113	98
	Mean	42.90	42.91	42.62	42.86	42.93	42.18
	STD	5.34	5.37	5.38	5.10	4.96	4.22
	Min	32.67	32.67	30.24	33.30	33.50	33.50
	Max	61.50	61.75	57.50	60.80	62.30	52.60
	Median	41.50	41.64	41.90	41.60	42.29	41.63
	Median diff.		0.00	-0.16		0.06	-0.24
	P value		0.8045	0.1070		0.5886	0.0480
RBC	Evaluated	105	103	88	115	114	98
	Mean	4.60	4.57	4.64	4.63	4.67	4.62
	STD	0.48	0.51	0.46	0.54	0.55	0.49
	Min	3.28	3.52	3.72	3.52	3.38	3.66
	Max	5.91	6.46	5.83	6.54	6.74	6.04

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
RBC	Median	4.49	4.49	4.59	4.56	4.65	4.61
	Median diff.		0.00	0.00		0.03	0.00
	P value		0.7502	0.6319		0.2253	0.5027
PLATELETS	Evaluated	95	93	82	110	108	92
	Mean	297.53	300.55	307.50	297.76	317.69	328.47
	STD	78.10	75.18	73.18	90.33	87.50	89.36
	Min	30.75	78.33	145.00	40.50	140.00	169.00
	Max	486.25	481.25	532.50	598.33	585.00	640.00
	Median	288.00	290.00	295.50	290.09	309.17	315.00
	Median diff.		0.00	6.63		4.49	18.60
	P value		0.8127	0.1508		0.0119	0.0007

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
WBC	Evaluated	104	103	87	115	114	98
	Mean	8.04	7.90	7.95	8.15	8.02	7.64
	STD	1.92	1.94	2.31	2.65	2.05	2.24
	Min	4.01	2.39	4.01	0.76	2.78	2.88
	Max	16.53	12.56	20.91	19.02	15.33	14.90
	Median	7.99	7.85	7.43	8.01	8.08	7.55
	Median diff.		-0.26	-0.09		-0.13	0.00
	P value		0.2977	0.3405		0.5394	0.5072
WBC: N	Evaluated	93	89	78	108	105	91
	Mean	62.44	62.62	62.35	62.39	63.08	63.03
	STD	5.33	5.82	5.53	5.52	6.79	8.34
	Min	29.00	31.00	47.00	50.60	52.00	51.00
	Max	77.00	78.40	91.00	91.00	99.00	115.00
	Median	63.09	63.27	61.52	62.09	62.09	62.00
	Median diff.		0.00	-0.67		0.29	0.00
	P value		0.5636	0.3396		0.4123	0.4942
WBC: E	Evaluated	98	93	84	112	109	95
	Mean	1.73	1.68	1.66	1.66	1.63	1.54
	STD	1.32	1.32	1.47	1.32	1.22	1.42
	Min	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00
	Max	9.00	8.00	8.33	7.40	9.00	8.33

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
NBC: E	Median	1.51	1.54	1.61	1.50	1.60	1.48
	Median diff.		0.00	0.00		0.00	0.00
	P value		0.5028	0.8247		0.6334	0.9909
NBC: B	Evaluated	97	92	82	110	107	95
	Mean	0.39	0.32	0.39	0.32	0.39	0.40
	STD	0.49	0.46	0.46	0.41	0.48	0.49
	Min	0.00	0.00	0.00	0.00	0.00	0.00
	Max	3.00	3.00	2.25	2.25	2.25	1.50
	Median	0.21	0.07	0.30	0.11	0.24	0.25
	Median diff.		0.00	0.00		0.00	0.00
	P value		0.3454	0.8294		0.2267	0.1843
NBC: L	Evaluated	98	94	83	114	111	96
	Mean	27.88	27.94	28.05	28.32	27.46	27.97
	STD	4.34	4.09	4.31	5.03	5.15	5.56
	Min	13.00	19.20	13.00	15.00	11.00	5.00
	Max	41.00	38.67	38.67	42.33	39.67	43.67
	Median	27.29	27.67	28.20	28.03	27.00	27.73
	Median diff.		-0.29	0.00		-0.30	-0.50
	P value		0.6694	0.4812		0.1435	0.1411
NBC: M	Evaluated	98	94	83	114	111	96
	Mean	4.81	4.79	5.01	4.88	4.96	5.05

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
NEC: M	STD	1.82	1.75	2.09	1.74	2.09	1.98
	Min	1.00	1.00	0.00	-1.00	1.00	1.00
	Max	11.00	11.00	12.00	10.33	12.00	11.00
	Median	4.43	4.55	4.89	4.96	4.66	4.89
	Median diff.		0.00	0.00		0.00	0.00
	P value		0.9455	0.4900		0.7262	0.4836

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
CREATININE	Evaluated	103	101	89	115	113	97
	Mean	0.85	0.89	0.88	0.85	0.85	0.84
	STD	0.19	0.18	0.18	0.18	0.17	0.19
	Min	0.05	0.44	0.46	0.49	0.43	0.11
	Max	1.33	1.50	1.31	1.54	1.35	1.55
	Median	0.84	0.87	0.86	0.85	0.86	0.88
	Median diff.		0.00	0.01		0.00	0.00
	P value		0.0163	0.1277		0.7717	0.6345
UREA	Evaluated	39	38	29	40	40	30
	Mean	24.10	23.88	24.29	23.79	25.42	23.87
	STD	6.22	7.14	6.03	5.45	8.40	6.30
	Min	14.20	13.40	13.54	14.02	11.80	15.00
	Max	47.00	54.20	36.60	36.60	47.00	37.40
	Median	25.24	23.05	24.60	23.92	24.38	23.54
	Median diff.		0.48	0.48		1.48	-0.24
	P value		0.7226	0.9735		0.0803	0.5501
BUN	Evaluated	55	54	52	61	61	55
	Mean	13.21	12.92	13.26	14.38	12.96	12.74
	STD	2.99	3.44	3.34	5.70	3.39	3.39
	Min	6.45	5.35	8.43	7.27	3.15	3.70
	Max	20.20	20.20	23.50	39.45	19.65	22.40

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
BUN	Median	12.50	12.42	12.53	13.60	13.05	12.28
	Median diff.		0.00	0.00		-0.17	-0.44
	P value		0.8138	0.9381		0.2857	0.1097
URIC ACID	Evaluated	93	92	84	100	98	83
	Mean	4.94	4.96	5.07	4.71	4.80	5.22
	STD	1.41	1.37	1.50	1.51	1.43	1.31
	Min	1.82	1.90	1.90	0.05	1.05	1.64
	Max	8.09	8.10	10.23	7.96	8.88	7.71
	Median	4.83	4.92	5.11	4.64	4.79	5.29
	Median diff.		0.00	0.03		0.11	0.31
	P value		0.6219	0.5595		0.2202	0.0010

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
TOT. PROTEINS	Evaluated	102	99	88	112	110	95
	Mean	7.46	7.46	7.35	7.39	7.40	7.41
	STD	0.63	0.82	0.64	0.59	0.66	0.76
	Min	6.08	4.82	5.77	6.01	6.04	6.24
	Max	10.49	12.10	9.13	9.25	10.63	11.06
	Median	7.35	7.44	7.29	7.39	7.31	7.35
	Median diff.		0.00	-0.09		0.00	0.00
	P value		0.5775	0.4849		0.6986	1.0000
ALBUMINE	Evaluated	98	94	82	108	107	92
	Mean	4.20	4.29	4.31	4.20	4.21	4.29
	STD	0.64	0.47	0.63	0.57	0.61	0.55
	Min	1.31	3.30	2.94	2.70	1.59	2.59
	Max	5.90	5.65	6.16	5.44	5.69	5.80
	Median	4.21	4.34	4.27	4.19	4.19	4.25
	Median diff.		0.05	0.02		0.00	0.03
	P value		0.2397	0.2849		0.5836	0.2259
TOT BILIRUBIN	Evaluated	101	99	88	111	110	93
	Mean	0.54	0.52	0.55	0.57	0.58	0.55
	STD	0.19	0.19	0.21	0.20	0.25	0.21
	Min	0.04	0.04	0.09	0.09	0.09	-0.01
	Max	1.09	1.09	1.00	1.06	1.86	1.08

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
TOT BILIRUBIN	Median	0.52	0.52	0.54	0.58	0.55	0.52
	Median diff.		0.00	0.00		-0.02	-0.02
	P value		0.5416	0.8288		0.3994	0.2553
DIR BILIRUBIN	Evaluated	57	53	47	67	64	52
	Mean	0.07	0.07	0.07	0.06	0.07	0.06
	STD	0.06	0.05	0.07	0.05	0.05	0.06
	Min	-0.04	-0.04	-0.04	-0.04	-0.04	-0.10
	Max	0.31	0.45	0.38	0.30	0.20	0.22
	Median	0.05	0.04	0.05	0.06	0.06	0.05
	Median diff.		0.00	0.00		0.00	0.00
	P value		0.5142	0.2766		0.7534	0.4475

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
SGOT	Evaluated	105	103	91	115	113	97
	Mean	18.84	20.88	19.88	18.62	19.11	19.94
	STD	6.63	25.69	6.87	6.26	7.92	6.14
	Min	-7.65	-7.65	8.82	-4.12	8.59	11.25
	Max	42.31	271.54	45.38	39.23	76.25	48.91
	Median	18.00	17.75	18.46	17.69	17.69	18.57
	Median diff.		0.00	0.00		0.00	0.88
	P value		0.7402	0.0497		0.2617	0.0198
SGPT	Evaluated	105	103	91	115	113	97
	Mean	17.19	21.61	19.96	17.25	17.92	18.92
	STD	10.71	43.88	15.94	9.29	10.83	10.46
	Min	2.06	-0.36	2.86	3.21	0.83	0.54
	Max	65.29	450.19	113.82	65.29	56.47	55.00
	Median	15.00	14.69	16.67	15.29	15.29	16.43
	Median diff.		0.00	0.56		0.89	1.39
	P value		0.9728	0.0804		0.3638	0.0818
GAMMA GT	Evaluated	105	103	90	115	112	96
	Mean	29.50	27.96	30.47	28.13	29.52	27.91
	STD	21.00	19.41	18.94	21.28	30.23	17.03
	Min	6.90	7.95	6.90	5.27	8.00	8.00
	Max	114.97	120.91	109.33	195.36	294.14	133.86

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
GAMMA GT	Median	22.67	22.67	26.00	24.00	24.11	24.00
	Median diff.		0.00	0.00		0.00	0.00
	P value		.0.2644	0.3157		0.8151	0.7998
LDH	Evaluated	91	88	79	100	99	84
	Mean	315.97	310.76	309.50	310.71	302.00	319.71
	STD	80.69	89.24	85.80	105.07	84.29	109.42
	Min	128.33	98.00	65.33	0.00	73.50	10.80
	Max	664.44	636.63	565.89	632.21	632.21	718.42
	Median	316.35	304.71	305.05	310.15	287.00	324.62
	Median diff.		0.00	2.21		0.00	1.98
	P value		0.7929	0.9612		0.4527	0.7652
ALK. PHOSPH.	Evaluated	104	101	90	113	112	95
	Mean	101.67	107.14	108.87	104.28	110.95	106.79
	STD	32.74	32.87	41.05	38.29	44.30	34.44
	Min	17.39	15.41	-16.31	50.60	51.05	48.58
	Max	278.60	270.05	318.50	324.20	449.60	244.40
	Median	98.17	102.42	105.72	97.24	105.08	101.17
	Median diff.		4.13	4.85		2.07	3.11
	P value		0.0013	0.0032		0.0243	0.0225

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
GLOBULINS ALPHA 1	Evaluated	88	84	77	99	97	84
	Mean	0.18	0.17	0.18	0.18	0.17	0.19
	STD	0.07	0.08	0.08	0.09	0.10	0.09
	Min	0.03	0.02	0.04	0.01	0.00	-0.03
	Max	0.53	0.47	0.42	0.46	0.47	0.54
	Median	0.17	0.16	0.17	0.17	0.16	0.19
	Median diff.		0.00	0.00		0.00	0.00
	P value		0.0302	0.2519		0.2146	0.4481
GLOBULINS ALPHA 2	Evaluated	88	84	77	99	97	84
	Mean	0.83	0.80	0.84	0.84	0.84	0.82
	STD	0.16	0.16	0.20	0.15	0.18	0.16
	Min	0.50	0.48	0.51	0.47	0.53	0.35
	Max	1.31	1.26	1.51	1.28	1.59	1.30
	Median	0.80	0.80	0.81	0.84	0.83	0.81
	Median diff.		-0.01	0.00		0.00	-0.04
	P value		0.1347	0.7621		0.2272	0.2805
GLOBULINS BETA	Evaluated	88	84	77	99	97	84
	Mean	0.99	0.95	0.98	0.97	0.96	0.97
	STD	0.18	0.16	0.19	0.16	0.16	0.17
	Min	0.61	0.46	0.46	0.62	0.62	0.56
	Max	1.59	1.36	1.61	1.46	1.58	1.46

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
GLOBULINS BETA	Median	0.99	0.96	0.97	0.95	0.94	0.94
	Median diff.		-0.04	0.00		0.00	0.00
	P value		0.0274	0.8985		0.3343	0.7838
GLOBULINS GAMMA	Evaluated	88	84	77	98	96	84
	Mean	1.12	1.14	1.08	1.13	1.13	1.11
	STD	0.29	0.25	0.29	0.26	0.30	0.27
	Min	0.49	0.73	0.15	0.55	0.49	0.27
	Max	2.23	1.91	1.96	1.69	2.70	1.76
	Median	1.11	1.14	1.11	1.10	1.10	1.09
	Median diff.		0.00	0.00		0.00	-0.00
	P value		0.6454	0.3397		0.8587	0.4675

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
TOT. CHOLEST.	Evaluated	103	100	89	112	110	93
	Mean	253.79	253.41	264.05	272.25	270.10	271.64
	STD	60.07	60.57	64.69	66.44	66.05	68.74
	Min	144.58	129.68	141.45	160.44	162.77	158.84
	Max	435.30	465.20	515.37	583.13	551.23	585.07
	Median	247.16	251.44	253.31	264.84	255.93	258.98
	Median diff.		0.00	12.76		0.87	-2.11
	P value		0.8247	0.0276		0.9139	0.7237
TRIGLYCERIDES	Evaluated	100	97	85	109	107	90
	Mean	155.65	157.05	182.44	174.36	161.27	148.90
	STD	157.10	143.62	156.64	220.79	252.32	190.44
	Min	-494.86	-494.86	-199.43	-136.29	-107.67	-362.86
	Max	807.71	772.80	888.29	1840.28	2293.49	1285.10
	Median	131.93	131.37	133.72	120.01	109.76	105.93
	Median diff.		1.95	5.42		-4.23	-9.13
	P value		0.9077	0.1943		0.1031	0.0352
GLUCOSE	Evaluated	101	96	87	112	112	93
	Mean	90.23	90.10	91.22	92.16	93.81	94.02
	STD	14.53	15.79	20.86	15.76	20.50	18.04
	Min	56.21	50.91	62.58	64.75	63.88	48.13
	Max	142.63	172.38	221.45	157.50	242.50	181.13

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
GLUCOSE	Median	90.00	89.25	88.48	90.19	90.65	91.70
	Median diff.		-0.60	0.00		0.78	1.40
	P value		0.9702	0.7151		0.4532	0.3830

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Imipramine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
NA+	Evaluated	103	100	88	112	112	95
	Mean	140.96	140.60	141.32	141.17	140.96	140.94
	STD	2.47	2.95	3.25	2.39	2.89	2.46
	Min	135.09	123.71	133.27	134.00	133.27	132.00
	Max	148.00	148.73	156.63	150.00	151.00	146.00
	Median	141.00	140.55	141.00	141.00	141.00	141.00
	Median diff.		0.00	0.00		-0.15	0.00
	P value		0.3412	0.5878		0.2931	0.5398
CL-	Evaluated	90	87	75	96	96	81
	Mean	101.84	101.48	101.96	102.09	101.48	101.06
	STD	2.44	2.50	2.28	2.74	2.53	3.19
	Min	95.60	91.60	95.60	94.80	92.67	90.00
	Max	108.67	109.20	107.60	111.33	110.44	107.78
	Median	102.00	101.56	102.00	102.31	101.67	101.73
	Median diff.		0.00	0.00		-0.31	-0.69
	P value		0.1184	0.6414		0.0060	0.0002
K+	Evaluated	99	97	83	109	108	94
	Mean	4.18	4.30	4.17	4.17	4.28	4.11
	STD	0.44	0.75	0.46	0.47	0.60	0.55
	Min	3.12	2.81	3.12	3.41	3.39	1.44
	Max	5.63	8.83	5.84	6.23	7.51	6.43

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 61

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment					
		Reboxetine			Reboxetine		
		Days of treatment			Days of treatment		
		Screen	1-21	22-42	Screen	1-21	22-42
K+	Median	4.17	4.20	4.14	4.11	4.21	4.10
	Median diff.		0.00	0.05		0.05	-0.05
	P value		0.7045	0.4966		0.0918	0.5478
Ca++	Evaluated	103	99	88	114	111	95
	Mean	4.89	4.87	4.89	4.95	4.93	4.92
	STD	0.34	0.34	0.31	0.30	0.40	0.32
	Min	3.88	3.86	4.25	3.70	3.54	4.00
	Max	5.67	5.85	5.93	5.56	6.64	5.85
	Median	4.92	4.95	4.90	4.98	4.96	4.95
	Median diff.		0.00	0.00		0.00	0.00
	P value		0.5996	0.9562		0.9732	0.8014
PO4--	Evaluated	85	82	72	93	93	75
	Mean	1.23	1.25	1.24	1.25	1.27	1.25
	STD	0.18	0.22	0.14	0.15	0.15	0.17
	Min	0.76	0.87	0.84	0.80	0.77	0.91
	Max	2.01	2.66	1.55	1.85	1.68	1.75
	Median	1.24	1.24	1.25	1.24	1.27	1.22
	Median diff.		0.00	0.02		0.02	0.01
	P value		0.6480	0.4499		0.1764	0.6667

P VALUE: PROBABILITY FROM THE WILCOXON RANK SIGNED TEST

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 62

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Urinalysis		Days of treatment																	
		Screening						1-21 days						22-42 days					
		Female		Male		Total		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	39	100.0	17	100.0	56	100.0	37	94.9	16	94.1	53	94.6	33	89.2	13	92.9	46	90.2
	Not done							2	5.1	1	5.9	3	5.4	4	10.8	1	7.1	5	9.8
	Total	39	100.0	17	100.0	56	100.0	39	100.0	17	100.0	56	100.0	37	100.0	14	100.0	51	100.0
ALBUMIN	Absent	59	95.2	29	87.9	88	92.6	59	95.2	28	84.8	87	91.6	49	90.7	19	70.4	68	84.0
	Present	3	4.8	4	12.1	7	7.4	1	1.6	3	9.1	4	4.2	2	3.7	2	7.4	4	4.9
	Not done							2	3.2	2	6.1	4	4.2	3	5.6	6	22.2	9	11.1
	Total	62	100.0	33	100.0	95	100.0	62	100.0	33	100.0	95	100.0	54	100.0	27	100.0	81	100.0
SUGAR	Absent	62	100.0	33	100.0	95	100.0	59	95.2	30	90.9	89	93.7	51	94.4	22	81.5	73	90.1
	Present							1	1.6	1	3.0	2	2.1			1	3.7	1	1.2
	Not done							2	3.2	2	6.1	4	4.2	3	5.6	4	14.8	7	8.6
	Total	62	100.0	33	100.0	95	100.0	62	100.0	33	100.0	95	100.0	54	100.0	27	100.0	81	100.0
RBC	Absent	52	82.5	28	87.5	80	84.2	51	81.0	27	84.4	78	82.1	45	83.3	19	73.1	64	80.0
	Present	11	17.5	4	12.5	15	15.8	11	17.5	3	9.4	14	14.7	6	11.1	4	15.4	10	12.5
	Not done							1	1.6	2	6.3	3	3.2	3	5.6	3	11.5	6	7.5
	Total	63	100.0	32	100.0	95	100.0	63	100.0	32	100.0	95	100.0	54	100.0	26	100.0	80	100.0
WBC	Absent	39	63.9	26	81.3	65	69.9	41	67.2	26	81.3	67	72.0	37	69.8	21	80.8	58	73.4
	Present	22	36.1	6	18.8	28	30.1	19	31.1	4	12.5	23	24.7	12	22.6	2	7.7	14	17.7
	Not done							1	1.6	2	6.3	3	3.2	4	7.5	3	11.5	7	8.9
	Total	61	100.0	32	100.0	93	100.0	61	100.0	32	100.0	93	100.0	53	100.0	26	100.0	79	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 62

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Urinalysis		Days of treatment																	
		Screening						1-21 days						22-42 days					
		Female		Male		Total		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	35	100.0	15	100.0	50	100.0	34	100.0	13	86.7	47	95.9	27	90.0	15	100.0	42	93.3
	Not done									2	13.3	2	4.1	3	10.0			3	6.7
	Total	35	100.0	15	100.0	50	100.0	34	100.0	15	100.0	49	100.0	30	100.0	15	100.0	45	100.0
ALBUMIN	Absent	53	96.4	31	96.9	84	96.6	49	90.7	27	84.4	76	88.4	45	95.7	26	89.7	71	93.4
	Present	2	3.6	1	3.1	3	3.4	3	5.6	4	12.5	7	8.1	1	2.1	2	6.9	3	3.9
	Not done							2	3.7	1	3.1	3	3.5	1	2.1	1	3.4	2	2.6
	Total	55	100.0	32	100.0	87	100.0	54	100.0	32	100.0	86	100.0	47	100.0	29	100.0	76	100.0
SUGAR	Absent	58	100.0	31	96.9	89	98.9	52	91.2	31	96.9	83	93.3	46	92.0	26	89.7	72	91.1
	Present			1	3.1	1	1.1	2	3.5			2	2.2	1	2.0	1	3.4	2	2.5
	Not done							3	5.3	1	3.1	4	4.5	3	6.0	2	6.9	5	6.3
	Total	58	100.0	32	100.0	90	100.0	57	100.0	32	100.0	89	100.0	50	100.0	29	100.0	79	100.0
RBC	Absent	50	86.2	29	87.9	79	86.8	47	82.5	28	84.8	75	83.3	44	88.0	25	83.3	69	86.3
	Present	8	13.8	4	12.1	12	13.2	8	14.0	4	12.1	12	13.3	3	6.0	3	10.0	6	7.5
	Not done							2	3.5	1	3.0	3	3.3	3	6.0	2	6.7	5	6.3
	Total	58	100.0	33	100.0	91	100.0	57	100.0	33	100.0	90	100.0	50	100.0	30	100.0	80	100.0
WBC	Absent	39	68.4	22	68.8	61	68.5	42	75.0	23	71.9	65	73.9	36	73.5	19	65.5	55	70.5
	Present	18	31.6	10	31.3	28	31.5	12	21.4	7	21.9	19	21.6	10	20.4	8	27.6	18	23.1
	Not done							2	3.6	2	6.3	4	4.5	3	6.1	2	6.9	5	6.4
	Total	57	100.0	32	100.0	89	100.0	56	100.0	32	100.0	88	100.0	49	100.0	29	100.0	78	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 6S

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Urinalysis		Total						Last assessment											
								1-21 days						22-42 days					
		Female		Male		Total		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	35	89.7	16	94.1	51	91.1	2	100.0	3	100.0	5	100.0	33	89.2	13	92.9	46	90.2
	Not done	4	10.3	1	5.9	5	8.9							4	10.8	1	7.1	5	9.8
	Total	39	100.0	17	100.0	56	100.0	2	100.0	3	100.0	5	100.0	37	100.0	14	100.0	51	100.0
ALBUMIN	Absent	57	91.9	25	75.8	82	86.3	8	100.0	6	100.0	14	100.0	49	90.7	19	70.4	68	84.0
	Present	2	3.2	2	6.1	4	4.2							2	3.7	2	7.4	4	4.9
	Not done	3	4.8	6	18.2	9	9.5							3	5.6	6	22.2	9	11.1
	Total	62	100.0	33	100.0	95	100.0	8	100.0	6	100.0	14	100.0	54	100.0	27	100.0	81	100.0
SUGAR	Absent	58	93.5	28	84.8	86	90.5	7	87.5	6	100.0	13	92.9	51	94.4	22	81.5	73	90.1
	Present	1	1.6	1	3.0	2	2.1	1	12.5			1	7.1			1	3.7	1	1.2
	Not done	3	4.8	4	12.1	7	7.4							3	5.6	4	14.8	7	8.6
	Total	62	100.0	33	100.0	95	100.0	8	100.0	6	100.0	14	100.0	54	100.0	27	100.0	81	100.0
RBC	Absent	52	82.5	23	71.9	75	78.9	7	77.8	4	66.7	11	73.3	45	83.3	19	73.1	64	80.0
	Present	8	12.7	6	18.8	14	14.7	2	22.2	2	33.3	4	26.7	6	11.1	4	15.4	10	12.5
	Not done	3	4.8	3	9.4	6	6.3							3	5.6	3	11.5	6	7.5
	Total	63	100.0	32	100.0	95	100.0	9	100.0	6	100.0	15	100.0	54	100.0	26	100.0	80	100.0
WBC	Absent	40	65.6	25	78.1	65	69.9	3	37.5	4	66.7	7	50.0	37	69.8	21	80.8	58	73.4
	Present	17	27.9	4	12.5	21	22.6	5	62.5	2	33.3	7	50.0	12	22.6	2	7.7	14	17.7
	Not done	4	6.6	3	9.4	7	7.5							4	7.5	3	11.5	7	8.9
	Total	61	100.0	32	100.0	93	100.0	8	100.0	6	100.0	14	100.0	53	100.0	26	100.0	79	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 63

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Urinalysis		Total						Last assessment											
								1-21 days						22-42 days					
		Female		Male		Total		Female		Male		Total		Female		Male		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
SPECIFIC GRAVITY	Normal	32	91.4	15	100.0	47	94.0	5	100.0			5	100.0	27	90.0	15	100.0	42	93.3
	Not done	3	8.6			3	6.0							3	10.0			3	6.7
	Total	35	100.0	15	100.0	50	100.0	5	100.0			5	100.0	30	100.0	15	100.0	45	100.0
ALBUMIN	Absent	53	96.4	29	90.6	82	94.3	8	100.0	3	100.0	11	100.0	45	95.7	26	89.7	71	93.4
	Present	1	1.8	2	6.3	3	3.4							1	2.1	2	6.9	3	3.9
	Not done	1	1.8	1	3.1	2	2.3							1	2.1	1	3.4	2	2.6
	Total	55	100.0	32	100.0	87	100.0	8	100.0	3	100.0	11	100.0	47	100.0	29	100.0	76	100.0
SUGAR	Absent	54	93.1	29	90.6	83	92.2	8	100.0	3	100.0	11	100.0	46	92.0	26	89.7	72	91.1
	Present	1	1.7	1	3.1	2	2.2							1	2.0	1	3.4	2	2.5
	Not done	3	5.2	2	6.3	5	5.6							3	6.0	2	6.9	5	6.3
	Total	58	100.0	32	100.0	90	100.0	8	100.0	3	100.0	11	100.0	50	100.0	29	100.0	79	100.0
RBC	Absent	50	86.2	28	84.8	78	85.7	6	75.0	3	100.0	9	81.8	44	88.0	25	83.3	69	86.3
	Present	5	8.6	3	9.1	8	8.8	2	25.0			2	18.2	3	6.0	3	10.0	6	7.5
	Not done	3	5.2	2	6.1	5	5.5							3	6.0	2	6.7	5	6.3
	Total	58	100.0	33	100.0	91	100.0	8	100.0	3	100.0	11	100.0	50	100.0	30	100.0	80	100.0
WBC	Absent	41	71.9	21	65.6	62	69.7	5	62.5	2	66.7	7	63.6	36	73.5	19	65.5	55	70.5
	Present	13	22.8	9	28.1	22	24.7	3	37.5	1	33.3	4	36.4	10	20.4	8	27.6	18	23.1
	Not done	3	5.3	2	6.3	5	5.6							3	6.1	2	6.9	5	6.4
	Total	57	100.0	32	100.0	89	100.0	8	100.0	3	100.0	11	100.0	49	100.0	29	100.0	78	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 64

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline		Days of treatment									
		1-21 days				22-42 days					
		Absent	Present	Not done	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	84	1	3	88	66	4	5	75
	Present	3	3	1	7	2		4	6
	Total	87	4	4	95	68	4	9	81
SUGAR	Absent	89	2	4	95	73	1	7	81
	Total	89	2	4	95	73	1	7	81
RBC	Absent	69	8	3	80	60	4	4	68
	Present	9	6		15	4	6	2	12
	Total	78	14	3	95	64	10	6	80
WBC	Absent	54	10	1	65	49	5	2	56
	Present	13	15	2	28	9	9	5	23
	Total	67	25	3	93	58	14	7	79

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 64

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline		Days of treatment							
		1-21 days				22-42 days			
		Absent	Present	Not done	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	73	7	3	83	69	3	2	74
	Present	3			3	2			2
	Total	76	7	3	86	71	3	2	76
SUGAR	Absent	82	2	4	88	72	1	5	78
	Present	1			1		1		1
	Total	83	2	4	89	72	2	5	79
RBC	Absent	69	6	3	78	61	3	5	69
	Present	6	6		12	8	3		11
	Total	75	12	3	90	69	6	5	80
WBC	Absent	51	6	3	60	44	5	5	54
	Present	14	13	1	28	11	13		24
	Total	65	19	4	88	55	18	5	78

PHARMACIA CRO R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 65

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline		Total				Last assessment									
						1-21 days				22-42 days					
		Absent	Present	Not done	Total	Absent	Present	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	79	4	5	88	13		13	66	4	5	75
	Present	3		4	7	1		1	2		4	6
	Total	82	4	9	95	14		14	68	4	9	81
SUGAR	Absent	86	2	7	95	13	1	14	73	1	7	81
	Total	86	2	7	95	13	1	14	73	1	7	81
KSC	Absent	70	6	4	80	10	2	12	60	4	4	68
	Present	5	8	2	15	1	2	3	4	6	2	12
	Total	75	14	6	95	11	4	15	64	10	6	80
KBC	Absent	54	9	2	65	5	4	9	49	5	2	56
	Present	11	12	5	28	2	3	5	9	9	5	23
	Total	65	21	7	93	7	7	14	58	14	7	79

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 65

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline		Total				Last assessment						
						1-21 days			22-42 days			
		Absent	Present	Not done	Total	Absent	Present	Total	Absent	Present	Not done	Total
ALBUMIN	Absent	79	3	2	84	10		10	69	3	2	74
	Present	3			3	1		1	2			2
	Total	82	3	2	87	11		11	71	3	2	76
SUGAR	Absent	83	1	5	89	11		11	72	1	5	78
	Present		1		1					1		1
	Total	83	2	5	90	11		11	72	2	5	79
RBC	Absent	70	4	5	79	9	1	10	61	3	5	69
	Present	8	4		12		1	1	8	3		11
	Total	78	8	5	91	9	2	11	69	6	5	80
WBC	Absent	49	7	5	61	5	2	7	44	5	5	54
	Present	13	15		28	2	2	4	11	13		24
	Total	62	22	5	89	7	4	11	55	18	5	78

PHARMACIA CRS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 66

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Reboxetine

Urinalysis test at baseline		Days of treatment					
		1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	53	3	56	46	5	51
	Total	53	3	56	46	5	51

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 66

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Imipramine

Urinalysis test at baseline		Days of treatment					
		1-21 days			22-42 days		
		Normal	Not done	Total	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	47	2	49	42	3	45
	Total	47	2	49	42	3	45

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 67

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Reboxetine

Urinalysis test at baseline			Total			Last assessment							
						1-21 days			22-42 days				
			Normal	Not done	Total	Normal	Total		Normal	Not done	Total		
SPECIFIC GRAVITY	Normal		51	5	56	5	5		46	5	51		
	Total		51	5	56	5	5		46	5	51		

PHARMACIA CNS R&D

REMONDYNE - PROTOCOL 20124/017

TABLE No.: 67

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT (SPECIFIC GRAVITY)

Assigned treatment: Intravenous

Urinalysis test at baseline			Total			Last assessment							
						1-21 days			22-42 days				
			Normal	Not done	Total	Normal	Total		Normal	Not done	Total		
SPECIFIC GRAVITY	Normal		47	3	50	5	5		42	3	45		
	Total		47	3	50	5	5		42	3	45		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
HB	LOW	2	1			2	1			3	2			2	2		
	NORMAL		98	1		1	83			1	104	1		3	88	1	
	HIGH		1		0.607		1		0.607		1	2	0.846		2		0.766
HT	LOW	5	1			5	1			6	5			6	4	1	
	NORMAL	3	87			2	73	1		1	93			1	79	1	
	HIGH		3	4	0.135		2	4	0.717		4	4	0.036		3	3	0.198
RBC	LOW	4	6			3	6			6	6			6	6		
	NORMAL	8	82	1		4	72	1		3	92	2		4	78	1	
	HIGH		1	1	0.867		2		0.693		1	4	0.513		2	1	0.693
PLATELETS	LOW		3			1	2				4	1			5		
	NORMAL	1	74	5			68	2		1	81	7			66	8	
	HIGH		7	3	0.513		4	5	0.264		5	9	0.213		4	9	0.042

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
MBC	LOW		1				1			1	3	1		1	4		
	NORMAL	4	88	5		1	76	5		2	94	2		1	81	3	
	HIGH		3	2	0.317		3	1	0.779		7	4	0.276	1	5	2	0.382
MBC: N	LOW	2	3	1			4	1		6	3	2		5	4	1	
	NORMAL	4	65	5		4	59	3		2	81	2		4	65	3	
	HIGH		4	5	0.817	1	3	3	1.000		2	7	0.466		4	5	0.945
MBC: E	LOW	10	1			10	1			8	7			8	8		
	NORMAL	6	67	3		5	60	3		6	75	5		8	63	1	
	HIGH	1	2	3	0.100		2	3	0.239	1	6	1	0.846		4	3	0.407
MBC: B	LOW																
	NORMAL		75	8			69	5			96	5			79	10	
	HIGH		9		1.000		7	1	0.774		4	2	1.000		5	1	0.302
MBC: L	LOW	3	3			2	4			7	3			3	5	1	
	NORMAL	6	67	4		4	59	5		6	76	5		6	62	4	
	HIGH	1	5	5	0.395	1	7	1	0.684	1	7	6	0.346	1	6	8	0.832
MBC: H	LOW	3	2	1		3	3	1		5	1	1		1	5	1	
	NORMAL	1	74	6		5	57	6		6	82	8		5	71	8	
	HIGH	1	5	1	0.892		5	3	0.784		3	5	0.062		1	4	0.041

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
CREATININE	LOW	1	2			1	1			1				1			
	NORMAL		91	5			79	6		1	108	1		2	92		
	HIGH		1	1	0.097		2		0.223		1	1	0.607		1	1	0.223
UREA	LOW	1	1				2			1					1		
	NORMAL	2	31	2		1	24	1		3	30	5			26	2	
	HIGH		1		0.717		1		0.846			1	0.018			1	0.223
BUN	LOW		1					1									
	NORMAL	2	45	4			47	2		3	51	1		1	45	3	
	HIGH		2		0.607			2	0.223		3	3	0.135	1	4	1	0.344
URIC ACID	LOW	2	3			3	1			3	6			3	3		
	NORMAL	1	71	6		1	66	4		2	75	5			66	5	
	HIGH		4	5	0.497		3	6	0.981	1	4	2	0.603		2	4	0.117

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
TOT. PROTEINS	LOW	1	2			1	2			2	1				3		
	NORMAL	4	83	4		4	72	6		4	97	1		3	82	4	
	HIGH		1	4	0.291		2	1	0.264			5	0.247		1	2	0.407
ALBUMINE	LOW	2	7			3	4			4	5			1	6		
	NORMAL	2	71	3		5	59	2		5	78	4		4	67	4	
	HIGH		5	4	0.194		3	6	0.856		7	4	0.664		6	4	0.670
TOT BILIRUBIN	LOW	1									1				2		
	NORMAL	1	94	1		1	85			2	103	2		1	86	3	
	HIGH		2		0.513		2		0.223		1	1	0.717		1		0.513
DIR BILIRUBIN	LOW	1	1			1	1			1	1						
	NORMAL		49	1			43	1			61			2	49	1	
	HIGH			1	0.368			1	0.368		1		0.368				0.223

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
SGOT	LOW	1				1				1	1				2		
	NORMAL	1	91	5			80	6			103	2			86	4	
	HIGH		4	1	0.574		2	2	0.289		3	3	0.549		2	3	0.264
SGPT	LOW	1	3			1	1	1			2			1	1		
	NORMAL	1	82	7		1	71	8		3	92	8		1	79	9	
	HIGH		5	4	0.513		6	2	0.664		3	5	0.290		3	3	0.223
GAMMA GT	LOW	1				1					2				1	1	
	NORMAL	1	81	3		1	68	7			95	4			79	6	
	HIGH		10	7	0.092		7	6	0.607		4	7	0.368		6	3	0.368
LDH	LOW	2	3			2	3			5	6			3	5		
	NORMAL	2	70	5		1	64	3		3	70	3		3	58	3	
	HIGH		3	3	0.705		1	5	0.368		7	5	0.273		8	4	0.250
ALK. PHOSPH.	LOW	2				1	1			1	2			2	1		
	NORMAL		96	1		1	85				101	3		2	83	3	
	HIGH			2	1.000			2	1.000		1	4	0.223		2	2	0.766

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
GLOBULINS ALPHA 1	LOW	5	3			4	3			9	2			8	3		
	NORMAL	8	64	3		5	61	3		9	65	3		3	58	3	
	HIGH		1		0.195			1	0.174	1	5	3	0.051		5	4	0.779
GLOBULINS ALPHA 2	LOW	2	2			1	2	1		2	3			3	2		
	NORMAL	6	57	4		7	49	5		2	66	10		1	59	7	
	HIGH		10	3	0.102		7	5	0.443		7	7	0.694		7	5	0.846
GLOBULINS BETA	LOW	1	2			1	1			1	1				2		
	NORMAL	2	57	5		3	49	8		3	65	10		2	59	8	
	HIGH		11	6	0.325		7	8	0.587		8	9	0.543		7	6	0.967
GLOBULINS GAMMA	LOW	2	7			4	5			4	6			4	5		
	NORMAL	2	66	3		6	57	2		3	78	3		3	68	2	
	HIGH		3	1	0.249		3		0.865		2		0.549	1	1		0.944

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
TOT. CHOLEST.	LOW	1	1				1										
	NORMAL	1	50	13		1	46	11			56	6			43	7	
	HIGH		7	27	0.407		12	18	0.978		10	38	0.454		14	29	0.189
TRIGLYCERIDES	LOW	3	3	1		2	3			4	4			6	2		
	NORMAL	2	58	2		2	44	7		5	69	6		5	57	4	
	HIGH		9	19	0.132	1	6	20	1.000		8	11	0.820	1	4	11	0.363
GLUCOSE	LOW	2	4			2	3	1		1	2				1		
	NORMAL	3	71	7		4	62	7		1	85	5		2	68	7	
	HIGH		6	3	0.896		4	4	0.510		11	7	0.275		9	6	0.747

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 68

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment															
		Imipramine								Reboxetine							
		Days of treatment								Days of treatment							
		1-21				22-42				1-21				22-42			
		Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
NA+	LOW	1	1				2				1				1		
	NORMAL	1	93	2		2	79	3		5	102	2		2	90		
	HIGH		2		1.000		1	1	0.607		2		0.264		2		0.311
CL-	LOW	1	2				1			4				2	1		
	NORMAL	3	77	2		3	66	3		3	84	1		10	64	2	
	HIGH		2		0.905		2		0.549		3	1	0.135		2		0.025
K+	LOW	1	1			2					1			1			
	NORMAL	3	86	5		2	78	1		2	99	2		4	85	2	
	HIGH			1	0.050				0.223		3	1	0.766		2		0.135
Ca++	LOW	5	7			2	8			4	1				5		
	NORMAL	5	79	1		6	68	2		5	96	4		5	82	2	
	HIGH		2		0.717		2		0.867		1		0.107		1		0.846
PO4--	LOW	2	4			3	4			1	2			1	2		
	NORMAL	5	64	3		1	61	1		2	79	6		2	61	7	
	HIGH		4		0.881		2		0.344		3		0.607		2		0.249

P val : probability from Maxwell's test

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 69

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
HB	Imipramine	Eval.	105	100.0	103	100.0	88	100.0
		down			1	1.0	1	1.1
HT	Imipramine	Eval.	105	100.0	103	100.0	88	100.0
		down					1	1.1
RBC	Reboxetine	Eval.	115	100.0	114	100.0	98	100.0
		down	1	0.9	1	0.9	1	1.0
PLATELETS	Imipramine	Eval.	95	100.0	93	100.0	82	100.0
		down	1	1.1				
		up					1	1.2
	Reboxetine	Eval.	110	100.0	108	100.0	92	100.0
		down	1	0.9				
		up	1	0.9	2	1.9	2	2.2
WBC	Imipramine	Eval.	104	100.0	103	100.0	87	100.0
		up	1	1.0			1	1.1
	Reboxetine	Eval.	115	100.0	114	100.0	98	100.0
		down	1	0.9				
		up	2	1.7	1	0.9	1	1.0
WBC: N	Imipramine	Eval.	93	100.0	89	100.0	78	100.0
		down	2	2.2				
	Reboxetine	Eval.	108	100.0	105	100.0	91	100.0
		up					1	1.1
WBC: E	Imipramine	Eval.	98	100.0	93	100.0	84	100.0
		up	5	5.1	5	5.4	5	6.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 69

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
NEC: E	Reboxetine	Eval.	112	100.0	109	100.0	95	100.0
		up	7	6.3	1	0.9	4	4.2
NEC: B	Imipramine	Eval.	97	100.0	92	100.0	82	100.0
		up	7	7.2	3	3.3	4	4.9
	Reboxetine	Eval.	110	100.0	107	100.0	95	100.0
		up	5	4.5	6	5.6	11	11.6
NEC: L	Imipramine	Eval.	98	100.0	94	100.0	83	100.0
		down	3	3.1	1	1.1	1	1.2
		up	1	1.0	1	1.1	1	1.2
	Reboxetine	Eval.	114	100.0	111	100.0	96	100.0
		down	2	1.8	3	2.7	1	1.0
		up	4	3.5			2	2.1
NEC: N	Imipramine	Eval.	98	100.0	94	100.0	83	100.0
		up	4	4.1	2	2.1	3	3.6
	Reboxetine	Eval.	114	100.0	111	100.0	96	100.0
		up	3	2.6	6	5.4	5	5.2
UREA	Imipramine	Eval.	39	100.0	38	100.0	29	100.0
		up			1	2.6		
BUN	Reboxetine	Eval.	61	100.0	61	100.0	55	100.0
		up	3	4.9				
URIC ACID	Imipramine	Eval.	93	100.0	92	100.0	84	100.0
		up	1	1.1			1	1.2
	Reboxetine	Eval.	100	100.0	98	100.0	83	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 69

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
URIC ACID	Reboxetine	up	1	1.0	2	2.0		
TOT. PROTEINS	Imipramine	Eval.	102	100.0	99	100.0	88	100.0
		up			1	1.0		
TOT BILIRUBIN	Reboxetine	Eval.	111	100.0	110	100.0	93	100.0
		up			1	0.9		
DIR BILIRUBIN	Imipramine	Eval.	57	100.0	53	100.0	47	100.0
		up			1	1.9		
SGOT	Imipramine	Eval.	105	100.0	103	100.0	91	100.0
		up			1	1.0		
	Reboxetine	Eval.	115	100.0	113	100.0	97	100.0
		up			1	0.9		
SGPT	Imipramine	Eval.	105	100.0	103	100.0	91	100.0
		up	1	1.0	1	1.0	3	3.3
	Reboxetine	Eval.	115	100.0	113	100.0	97	100.0
		up	1	0.9				
GAMMA GT	Imipramine	Eval.	105	100.0	103	100.0	90	100.0
		up	4	3.8	3	2.9	4	4.4
	Reboxetine	Eval.	115	100.0	112	100.0	96	100.0
		up	2	1.7	3	2.7	1	1.0
ALK. PHOSPH.	Reboxetine	Eval.	113	100.0	112	100.0	95	100.0
		up			1	0.9		
GLOBULINS ALPHA 1	Imipramine	Eval.	88	100.0	84	100.0	77	100.0
		down			1	1.2		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 69

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
GLOBULINS ALPHA 1	Imipramine	up	1	1.1	1	1.2		
	Reboxetine	Eval.	99	100.0	97	100.0	84	100.0
		down	1	1.0	3	3.1	2	2.4
		up	1	1.0	4	4.1	1	1.2
GLOBULINS ALPHA 2	Imipramine	Eval.	88	100.0	84	100.0	77	100.0
		up					3	3.9
	Reboxetine	Eval.	99	100.0	97	100.0	84	100.0
		up	1	1.0	2	2.1	1	1.2
GLOBULINS BETA	Imipramine	Eval.	88	100.0	84	100.0	77	100.0
		up	2	2.3			2	2.6
	Reboxetine	Eval.	99	100.0	97	100.0	84	100.0
		up	2	2.0	1	1.0	1	1.2
GLOBULINS GAMMA	Imipramine	Eval.	88	100.0	84	100.0	77	100.0
		down					2	2.6
		up	1	1.1				
	Reboxetine	Eval.	98	100.0	96	100.0	84	100.0
		down			1	1.0	1	1.2
		up			1	1.0		
TOT. CHOLEST.	Imipramine	Eval.	103	100.0	100	100.0	89	100.0
		up	4	3.9	3	3.0	5	5.6
	Reboxetine	Eval.	112	100.0	110	100.0	93	100.0
		up	10	8.9	11	10.0	7	7.5
TRIGLYCERIDES	Imipramine	Eval.	100	100.0	97	100.0	85	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 69

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment					
			Screen		1-21		22-42	
			No	%	No	%	No	%
TRIGLYCERIDES	Imipramine	up	14	14.0	10	10.3	14	16.5
	Reboxetine	Eval.	109	100.0	107	100.0	90	100.0
		up	12	11.0	8	7.5	6	6.7
GLUCOSE	Imipramine	Eval.	101	100.0	96	100.0	87	100.0
		down			1	1.0		
		up	3	3.0	2	2.1	2	2.3
	Reboxetine	Eval.	112	100.0	112	100.0	93	100.0
		down					1	1.1
		up	3	2.7	4	3.6	3	3.2
NA+	Imipramine	Eval.	103	100.0	100	100.0	88	100.0
		down			1	1.0		
		up					1	1.1
K+	Imipramine	Eval.	99	100.0	97	100.0	83	100.0
		down			1	1.0		
		up			3	3.1		
	Reboxetine	Eval.	109	100.0	108	100.0	94	100.0
		down					1	1.1
		up	1	0.9	2	1.9	1	1.1
Ca++	Reboxetine	Eval.	114	100.0	111	100.0	95	100.0
		up			1	0.9		
PO4--	Imipramine	Eval.	85	100.0	82	100.0	72	100.0
		down	5	5.9	1	1.2	1	1.4
		up	1	1.2	2	2.4		

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017

TABLE No.: 69

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment			Days of treatment							
			Screen		1-21		22-42			
			No	%	No	%	No	%		
PGA--	Reboxetine	Eval.	93	100.0	93	100.0	75	100.0		
		down	1	1.1	1	1.1	1	1.3		
		up	1	1.1	1	1.1	2	2.7		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 70

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs		LYING							STANDING						
		time interval							time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	128	127	114	108	107	103	95	127	126	115	108	107	103	95
	Mean	126.2	125.6	126.5	127.2	125.9	127.3	129.6	123.6	121.1	120.3	122.1	121.4	123.4	125.0
	STD	17.4	18.9	15.4	16.8	14.4	15.3	15.0	17.8	17.9	16.5	17.5	16.3	16.8	16.7
	Median	120.0	120.0	125.0	125.0	125.0	125.0	130.0	120.0	120.0	120.0	121.0	120.0	120.0	120.0
	Min	95.0	85.0	95.0	90.0	95.0	90.0	90.0	90.0	80.0	85.0	80.0	90.0	90.0	85.0
	Max	210.0	210.0	160.0	190.0	160.0	200.0	165.0	210.0	200.0	160.0	170.0	160.0	200.0	170.0
D.B.P.	Evaluated	128	127	114	108	107	103	95	127	126	115	108	106	103	95
	Mean	78.9	78.1	78.7	79.3	77.7	78.4	79.1	79.5	78.9	78.4	79.2	78.9	79.7	80.3
	STD	11.5	12.4	11.1	11.7	9.2	9.6	9.5	11.9	12.6	11.8	12.8	10.4	10.8	10.9
	Median	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	60.0	50.0	45.0	45.0	60.0	60.0	45.0	50.0	45.0	50.0	45.0	55.0	60.0	40.0
	Max	130.0	145.0	105.0	110.0	100.0	120.0	100.0	135.0	140.0	110.0	115.0	110.0	120.0	110.0
Heart Rate	Evaluated	126	124	113	107	106	101	94	125	122	112	104	106	101	93
	Mean	75.7	79.4	79.0	78.1	79.5	79.8	79.2	82.2	85.9	86.6	85.2	84.3	86.1	86.1
	STD	9.2	11.2	10.1	11.6	11.8	12.0	11.7	10.5	12.5	12.3	12.6	13.0	13.0	14.1
	Median	76.0	78.0	78.0	76.0	80.0	80.0	76.0	80.0	84.0	84.0	84.0	84.0	84.0	84.0
	Min	54.0	60.0	60.0	54.0	56.0	60.0	60.0	56.0	60.0	60.0	64.0	64.0	64.0	63.0
	Max	100.0	108.0	110.0	116.0	128.0	120.0	120.0	120.0	132.0	120.0	126.0	124.0	125.0	134.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 70

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs		LYING							STANDING						
		time interval							time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	118	117	106	106	96	92	90	120	120	107	106	96	92	90
	Mean	127.5	127.6	125.9	126.9	126.2	128.4	127.3	125.6	121.9	120.6	123.4	123.0	124.1	123.6
	STD	15.8	17.5	16.7	18.2	15.0	16.9	18.0	15.5	17.7	17.1	19.9	17.2	15.4	17.5
	Median	125.0	125.0	125.0	125.0	120.0	120.0	125.0	125.0	120.0	120.0	120.0	120.0	120.0	120.0
	Min	90.0	75.0	88.0	90.0	100.0	100.0	80.0	85.0	65.0	75.0	75.0	85.0	90.0	90.0
	Max	170.0	170.0	180.0	180.0	165.0	180.0	180.0	165.0	160.0	160.0	200.0	170.0	170.0	180.0
D.B.P.	Evaluated	118	117	106	106	96	92	90	120	120	107	106	96	92	90
	Mean	77.5	78.3	77.1	79.3	77.6	79.0	78.3	79.7	78.4	77.1	79.1	79.1	80.5	80.1
	STD	10.1	12.8	11.2	10.9	10.3	11.3	12.4	10.7	12.2	11.7	13.2	11.4	11.9	12.5
	Median	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	60.0	40.0	60.0	60.0	50.0	60.0	50.0	55.0	40.0	50.0	45.0	50.0	50.0	60.0
	Max	110.0	120.0	120.0	120.0	105.0	120.0	120.0	105.0	110.0	120.0	120.0	120.0	140.0	120.0
Heart Rate	Evaluated	117	116	104	106	94	90	89	117	115	103	104	92	88	87
	Mean	76.4	79.6	79.6	80.7	80.3	79.4	78.6	82.0	87.5	86.5	88.2	87.2	85.5	85.0
	STD	9.9	13.3	11.6	12.2	12.2	12.9	11.0	11.4	15.3	14.1	15.4	15.2	15.0	13.6
	Median	76.0	78.0	76.0	80.0	80.0	76.0	76.0	80.0	84.0	84.0	85.0	84.0	82.5	84.0
	Min	54.0	52.0	60.0	56.0	58.0	56.0	51.0	60.0	60.0	60.0	60.0	64.0	64.0	60.0
	Max	104.0	150.0	116.0	115.0	112.0	120.0	112.0	116.0	156.0	120.0	132.0	120.0	134.0	132.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 71

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs		LYING						STANDING					
		Time interval						Time interval					
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	127	114	108	107	103	95	126	115	108	107	103	95
	Mean	-0.9	-0.4	0.1	-0.9	0.5	2.2	-2.7	-3.8	-2.2	-2.4	-0.3	0.3
	STD	15.4	17.7	19.1	15.1	16.0	16.8	14.7	15.9	17.8	16.3	16.6	17.0
	Median	0.0	0.0	0.0	0.0	0.0	5.0	0.0	-5.0	0.0	0.0	0.0	0.0
	Min	-50.0	-70.0	-85.0	-65.0	-70.0	-50.0	-50.0	-70.0	-85.0	-65.0	-65.0	-50.0
	Max	40.0	60.0	60.0	40.0	100.0	40.0	50.0	45.0	45.0	60.0	80.0	50.0
D.B.P.	Evaluated	127	114	108	107	103	95	126	115	108	106	103	95
	Mean	-0.9	-0.3	0.3	-1.0	0.1	0.5	-0.8	-1.0	-0.4	-0.3	0.7	1.1
	STD	10.7	13.9	12.4	11.3	12.6	11.2	10.8	14.1	12.9	10.9	13.3	12.2
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-45.0	-59.0	-45.0	-40.0	-40.0	-35.0	-35.0	-64.0	-45.0	-35.0	-40.0	-40.0
	Max	20.0	35.0	35.0	30.0	55.0	30.0	30.0	40.0	35.0	30.0	60.0	25.0
Heart Rate	Evaluated	124	113	107	106	101	94	122	112	104	106	101	93
	Mean	3.8	3.2	2.4	3.7	3.7	3.5	3.7	4.0	2.4	3.6	3.4	3.6
	STD	10.7	11.1	12.1	12.6	12.4	13.3	11.6	11.4	13.1	12.1	12.6	14.9
	Median	2.0	0.0	0.0	2.0	4.0	0.0	2.0	0.0	0.0	0.0	3.0	2.0
	Min	-26.0	-20.0	-30.0	-24.0	-22.0	-25.0	-20.0	-20.0	-40.0	-24.0	-20.0	-28.0
	Max	32.0	38.0	32.0	48.0	32.0	48.0	44.0	40.0	46.0	40.0	40.0	70.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 71

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs		LYING						STANDING					
		Time interval						Time interval					
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	117	106	106	96	92	90	120	107	106	96	92	90
	Mean	-0.0	-1.2	-0.6	-1.2	-0.1	-1.3	-3.7	-4.4	-2.1	-2.4	-2.4	-2.8
	STD	13.8	16.0	14.9	11.9	15.4	15.6	15.6	17.3	16.0	14.9	15.4	16.5
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-45.0	-60.0	-55.0	-35.0	-50.0	-35.0	-65.0	-70.0	-50.0	-45.0	-60.0	-50.0
	Max	40.0	50.0	40.0	30.0	50.0	50.0	30.0	35.0	40.0	35.0	40.0	35.0
D.B.P.	Evaluated	117	106	106	96	92	90	120	107	106	96	92	90
	Mean	0.8	0.6	2.7	0.7	1.7	1.2	-1.3	-2.0	-0.2	-0.8	0.3	0.2
	STD	10.5	10.3	11.0	9.9	11.0	11.0	11.1	11.3	11.4	11.1	12.5	11.2
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-45.0	-30.0	-20.0	-35.0	-20.0	-25.0	-45.0	-30.0	-25.0	-40.0	-30.0	-30.0
	Max	30.0	40.0	30.0	30.0	40.0	30.0	20.0	30.0	30.0	30.0	50.0	30.0
Heart Rate	Evaluated	116	104	106	94	90	89	115	103	104	92	88	87
	Mean	3.4	3.5	4.3	3.9	3.1	2.7	5.5	4.4	6.1	4.7	3.3	3.1
	STD	11.6	10.6	11.2	11.1	10.8	11.4	13.3	13.3	14.0	11.6	12.1	13.5
	Median	1.0	4.0	4.0	2.0	2.0	2.0	4.0	2.0	4.0	4.0	3.0	4.0
	Min	-12.0	-26.0	-20.0	-24.0	-20.0	-32.0	-22.0	-28.0	-32.0	-28.0	-20.0	-28.0
	Max	78.0	38.0	46.0	32.0	40.0	36.0	84.0	48.0	49.0	44.0	50.0	56.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 72

BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE vs BASELINE OF CLINICAL RELEVANCE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs			LYING						STANDING					
			time intervals						time intervals					
			Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	No	127	114	108	107	103	95	126	115	108	107	103	95
	Decrease (1)	No	3	2	2	2	1	1	5	3	2	3	3	3
		%	2.4	1.8	1.9	1.9	1.0	1.1	4.0	2.6	1.9	2.8	2.9	3.2
	Increase (2)	No	8	2	2	2	4	5	1	2	1	4	2	3
		%	6.3	1.8	1.9	1.9	3.9	5.3	0.8	1.7	0.9	3.7	1.9	3.2
D.B.P.	Evaluated	No	127	114	108	107	103	95	126	115	108	107	103	95
	Decrease (1)	No	5	4	2	4	2	2	4	9	2	6	2	2
		%	3.9	3.5	1.9	3.7	1.9	2.1	3.2	7.8	1.9	5.6	1.9	2.1
	Increase (2)	No	5	7	5	7	8	6	5	9	7	6	11	9
		%	3.9	6.1	4.6	6.5	7.8	6.3	4.0	7.8	6.5	5.6	10.7	9.5
Both	Evaluated	No	127	114	108	107	103	95	126	115	108	107	103	95
	Decrease (1)	No	4	7	4	2	4	3	5	5	5	2	2	3
		%	3.1	6.1	3.7	1.9	3.9	3.2	4.0	4.3	4.6	1.9	1.9	3.2
	Increase (2)	No	1	4	7		2	2	3	3	4	1	2	4
		%	0.8	3.5	6.5		1.9	2.1	2.4	2.6	3.7	0.9	1.9	4.2
Heart rate	Evaluated	No	124	113	107	106	101	94	123	113	107	106	101	94
	Decrease (1)	No	3	1	4	4	1	3	1	1	2		1	3
		%	2.4	0.9	3.7	3.8	1.0	3.2	0.8	0.9	1.9		1.0	3.2
	Increase (2)	No	24	17	17	17	19	19	16	16	14	13	13	17
		%	19.4	15.0	15.9	16.0	18.8	20.2	13.0	14.2	13.1	12.3	12.9	18.1

(1) decrease => 20 % of baseline value
(2) increase => 20 % of baseline value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 72

BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE vs BASELINE OF CLINICAL RELEVANCE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs			LYING						STANDING					
			time intervals						time intervals					
			Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
S.B.P.	Evaluated	No	117	106	106	96	92	90	120	107	106	96	92	90
	Decrease (1)	No	1	3	2	1	2	3	3	4	5	2	2	6
		%	0.9	2.8	1.9	1.0	2.2	3.3	2.5	3.7	4.7	2.1	2.2	6.7
	Increase (2)	No	3	1	2	2	2	3	2	2	3	3	3	3
		%	2.6	0.9	1.9	2.1	2.2	3.3	1.7	1.9	2.8	3.1	3.3	3.3
D.B.P.	Evaluated	No	117	106	106	96	92	90	120	107	106	96	92	90
	Decrease (1)	No	4	1	3	4	3	2	6	6	5	1	4	3
		%	3.4	0.9	2.8	4.2	3.3	2.2	5.0	5.6	4.7	1.0	4.3	3.3
	Increase (2)	No	6	6	10	7	5	10	6	4	8	8	10	7
		%	5.1	5.7	9.4	7.3	5.4	11.1	5.0	3.7	7.5	8.3	10.9	7.8
Both	Evaluated	No	117	106	106	96	92	90	120	107	106	96	92	90
	Decrease (1)	No	1	1	2			3	5	5	3	3		1
		%	0.9	0.9	1.9			3.3	4.2	4.7	2.8	3.1		1.1
	Increase (2)	No	2	1	3		2	1	1	2	3	1	3	2
		%	1.7	0.9	2.8		2.2	1.1	0.8	1.9	2.8	1.0	3.3	2.2
Heart rate	Evaluated	No	116	104	106	94	90	89	118	105	106	94	90	90
	Decrease (1)	No		1	1	2		3	1	1	2	1	1	4
		%		1.0	0.9	2.1		3.4	0.8	1.0	1.9	1.1	1.1	4.4
	Increase (2)	No	13	12	12	17	9	10	19	15	19	15	9	10
		%	11.2	11.5	11.3	18.1	10.0	11.2	16.1	14.3	17.9	16.0	10.0	11.1

(1) decrease => 20 % of baseline value
(2) increase => 20 % of baseline value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 73

BLOOD PRESSURE AND HEART RATE: ABSOLUTE NUMBER OF PATIENTS SHOWING CLINICALLY RELEVANT CHANGES, COMPARED TO BASELINE, ONCE, TWICE OR MORE TIMES DURING THE THERAPY

Assigned treatment / Vital signs			LYING			STANDING		
			1 time	2 times	3 times or more	1 time	2 times	3 times or more
Imipramine	S.B.P. (1)	Decrease	1			2	3	
		Increase	3					
	D.B.P. (2)	Decrease	3	2	3	9	3	2
		Increase	7	3	1	4	2	1
	BOTH (1 & 2)	Decrease	4			12	1	
		Increase	2		1	3		1
	HEART RATE (3)	Increase	10	4	2	12	5	8
Reboxetine	S.B.P. (1)	Decrease	5			4	2	1
		Increase	4			6		1
	D.B.P. (2)	Decrease	10	4	3	12	3	2
		Increase	8	1	1	7	3	1
	BOTH (1 & 2)	Decrease	3	1		3		2
		Increase	1		1	1		
	HEART RATE (3)	Increase	15	7	1	20	5	9

(1) decrease => 20 % vs baseline value and systolic value <= 100 mmHg
increase => 20 % vs baseline value and systolic value >= 160 mmHg
(2) decrease => 20 % vs baseline value and diastolic value <= 70 mmHg
increase => 20 % vs baseline value and diastolic value >= 100 mmHg
(3) decrease => 20 % vs baseline value and heart rate value <= 50 beats/min
increase => 20 % vs baseline value and heart rate value >= 100 beats/min

PHARMACIA CNS BRD

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 74

BLOOD PRESSURE: NUMBER AND PERCENTAGE OF PATIENTS WITH ORTHOSTATIC HYPOTENSION (*) BEFORE AND DURING THE STUDY ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment / Vital signs		According to time interval							
		Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Imipramine	Eval.	120	120	120	107	106	96	92	90
	No.	1	1	7	4	3	2	3	4
	%	0.8	0.8	5.8	3.7	2.8	2.1	3.3	4.4
	Mean	30.0	30.0	34.3	36.3	36.7	35.0	36.7	38.0
	Max.	30.0	30.0	40.0	40.0	50.0	40.0	40.0	45.0
Reboxetine	Eval.	128	129	128	115	108	107	103	95
	No.	1	3	5	5	5	2	2	3
	%	0.8	2.3	3.9	4.3	4.6	1.9	1.9	3.2
	Mean	30.0	31.7	35.0	42.0	36.0	35.0	30.0	30.0
	Max.	30.0	35.0	45.0	50.0	50.0	40.0	30.0	30.0

(*) orthostatic hypotension = decrease of systolic blood pressure in standing position => 30 mm Hg as compared to lying position

PHARMACIA CNS BBU

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 75

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Sex		Time interval							
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Female	Evaluated	83	82	72	66	67	65	59
	Mean	64.7	64.7	64.3	64.7	64.1	64.4	64.8
	STD	8.7	8.7	8.3	8.6	8.5	8.9	9.0
	Median	64.5	64.0	64.0	63.8	63.6	63.4	64.4
	Min	44.0	44.0	43.0	42.5	43.0	43.5	43.5
	Max	83.7	83.5	83.9	84.2	83.9	83.4	83.9
Male	Evaluated	46	46	43	41	38	36	34
	Mean	76.3	76.2	74.8	74.4	74.1	74.6	74.4
	STD	12.1	12.1	10.5	10.4	10.4	10.4	10.5
	Median	78.3	77.7	77.2	75.5	74.0	74.2	74.0
	Min	49.8	50.0	50.0	50.0	50.0	50.0	50.0
	Max	120.0	120.0	97.0	95.0	95.0	97.0	97.0
Total	Evaluated	129	128	115	107	105	101	93
	Mean	68.8	68.8	68.2	68.4	67.7	68.0	68.3
	STD	11.4	11.5	10.5	10.4	10.4	10.6	10.6
	Median	67.0	67.4	65.8	67.3	66.5	67.5	67.8
	Min	44.0	44.0	43.0	42.5	43.0	43.5	43.5
	Max	120.0	120.0	97.0	95.0	95.0	97.0	97.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 75

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Sex		Time interval						
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Female	Evaluated	78	77	67	68	62	57	57
	Mean	65.3	65.3	63.6	64.4	65.6	65.4	65.8
	STD	11.5	11.5	9.9	11.4	11.3	11.1	11.0
	Median	64.0	64.0	62.2	62.7	64.3	64.5	65.0
	Min	47.0	47.0	47.0	47.5	46.5	48.0	47.0
	Max	102.0	102.0	95.0	103.0	103.0	103.0	102.0
Male	Evaluated	41	41	38	37	34	33	32
	Mean	78.5	78.2	78.7	78.0	78.8	78.9	79.1
	STD	14.3	13.9	13.6	13.6	14.6	14.7	15.2
	Median	78.0	78.0	79.0	78.5	79.7	79.5	79.8
	Min	37.5	36.5	38.0	38.0	37.0	35.3	36.0
	Max	123.0	117.0	115.0	114.0	114.0	114.0	116.0
Total	Evaluated	119	118	105	105	96	90	89
	Mean	69.8	69.8	69.1	69.2	70.3	70.3	70.6
	STD	14.0	13.8	13.5	13.8	14.0	14.1	14.1
	Median	68.7	68.5	68.1	68.0	69.6	69.0	69.4
	Min	37.5	36.5	38.0	38.0	37.0	35.3	36.0
	Max	123.0	117.0	115.0	114.0	114.0	114.0	116.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 76

BODY WEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Sex		Time interval											
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Female	Lower	1	1.2			4	6.1	4	6.0	7	10.8	7	11.9
	Same	78	95.1	68	94.4	59	89.4	59	88.1	56	86.2	49	83.1
	Higher	3	3.7	4	5.6	3	4.5	4	6.0	2	3.1	3	5.1
	Total	82	100.0	72	100.0	66	100.0	67	100.0	65	100.0	59	100.0
Male	Lower					1	2.4	2	5.3	3	8.3	3	8.8
	Same	46	100.0	41	95.3	38	92.7	34	89.5	31	86.1	28	82.4
	Higher			2	4.7	2	4.9	2	5.3	2	5.6	3	8.8
	Total	46	100.0	43	100.0	41	100.0	38	100.0	36	100.0	34	100.0
Total	Lower	1	0.8			5	4.7	6	5.7	10	9.9	10	10.8
	Same	124	96.9	109	94.8	97	90.7	93	88.6	87	86.1	77	82.8
	Higher	3	2.3	6	5.2	5	4.7	6	5.7	4	4.0	6	6.5
	Total	128	100.0	115	100.0	107	100.0	105	100.0	101	100.0	93	100.0

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 76

BODY HEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Sex		Time interval											
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42	
		No	%	No	%	No	%	No	%	No	%	No	%
Female	Lower	4	5.2	2	3.0	5	7.4	4	6.5	4	7.0	3	5.3
	Same	69	89.6	63	94.0	60	88.2	55	88.7	47	82.5	49	86.0
	Higher	4	5.2	2	3.0	3	4.4	3	4.8	6	10.5	5	8.8
	Total	77	100.0	67	100.0	68	100.0	62	100.0	57	100.0	57	100.0
Male	Lower			1	2.6	1	2.7	2	5.9	4	12.1	3	9.4
	Same	39	95.1	36	94.7	32	86.5	29	85.3	26	78.8	26	81.3
	Higher	2	4.9	1	2.6	4	10.8	3	8.8	3	9.1	3	9.4
	Total	41	100.0	38	100.0	37	100.0	34	100.0	33	100.0	32	100.0
Total	Lower	4	3.4	3	2.9	6	5.7	6	6.3	8	8.9	6	6.7
	Same	108	91.5	99	94.3	92	87.6	84	87.5	73	81.1	75	84.3
	Higher	6	5.1	3	2.9	7	6.7	6	6.3	9	10.0	8	9.0
	Total	118	100.0	105	100.0	105	100.0	96	100.0	90	100.0	89	100.0

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 77

E.C.G.: NUMBER AND PERCENTAGE OF PATIENTS WITH ABNORMAL E.C.G. ACCORDING TO TIME INTERVALS, BY ASSIGNED TREATMENT AND SEX

Assigned treatment/Sex			Female			Male			Total		
			Screening	1-21 days	22-42 days	Screening	1-21 days	22-42 days	Screening	1-21 days	22-42 days
Isipramine	Eval.	No.	64	64	53	34	32	32	98	96	85
	Normal	No.	61	59	48	29	26	26	90	85	74
		%	95.31	92.19	90.57	85.29	81.25	81.25	91.84	88.54	87.06
	Abnormal	No.	3	5	5	5	6	6	8	11	11
		%	4.69	7.81	9.43	14.71	18.75	18.75	8.16	11.46	12.94
Reboxetine	Eval.	No.	71	67	59	40	39	33	111	106	92
	Normal	No.	67	64	54	34	30	21	101	94	75
		%	94.37	95.52	91.53	85.00	76.92	63.64	90.99	88.68	81.52
	Abnormal	No.	4	3	5	6	9	12	10	12	17
		%	5.63	4.48	8.47	15.00	23.08	36.36	9.01	11.32	18.48

PHARMACIA CRB R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 78

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment/E.C.G. at Baseline			Time interval			
			1-21 days		22-42 days	
			Abnormal	Normal	Abnormal	Normal
Isipramine	Abnormal	No.	3	4	4	3
		%	42.9	57.1	57.1	42.9
	Normal	No.	6	61	7	71
		%	9.0	91.0	9.0	91.0
	Total	No.	11	65	11	74
		%	11.5	88.5	12.9	87.1
Reboxetine	Abnormal	No.	4	5	4	3
		%	44.4	55.6	57.1	42.9
	Normal	No.	6	89	13	72
		%	6.2	91.8	15.3	84.7
	Total	No.	12	94	17	75
		%	11.3	88.7	18.5	81.5

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 79

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment/E.C.G. at Baseline		Last assessment					
		Abnormal		Normal		Total	
		No.	%	No.	%	No.	%
Imipramine	Abnormal	4	50.0	4	50.0	8	100.0
	Normal	8	8.9	82	91.1	90	100.0
	Total	12	12.2	86	87.8	98	100.0
Reboxetine	Abnormal	5	50.0	5	50.0	10	100.0
	Normal	16	15.8	85	84.2	101	100.0
	Total	21	18.9	90	81.1	111	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 80

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY, BY ASSIGNED TREATMENT

E.C.G. abnormality type	Imipramine						Reboxetine					
	Screening		1-21 days		22-42 days		Screening		1-21 days		22-42 days	
	No	%	No	%	No	%	No	%	No	%	No	%
Evaluated Pt	98	100.0	96	100.0	85	100.0	111	100.0	106	100.0	92	100.0
A-V BLOCK 1ST DEGREE	2	2.0	3	3.1	1	1.2	1	0.9			1	1.1
ATRIAL ECTOPIC BEATS - OCCASIONAL	1	1.0									1	1.1
CONDUCTION DISORDER											1	1.1
LEFT ANTERIOR HEMIBLOCK	1	1.0					1	0.9	1	0.9		
LEFT BUNDLE BRANCH BLOCK									2	1.9		
LEFT POSTERIOR HEMIBLOCK											1	1.1
LEFT VENTRICULAR HYPERTROPHY					1	1.2						
MYOCARDIAL ISCHEMIA	1	1.0			1	1.2						
OTHER									1	0.9	1	1.1
PREVIOUS MYOCARDIAL INFARCTION	1	1.0	1	1.0	1	1.2	3	2.7	2	1.9	2	2.2
RIGHT BUNDLE BRANCH BLOCK					1	1.2			1	0.9	1	1.1
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK			1	1.0			1	0.9				
REPOLARIZATION DISTURBANCES							1	0.9			1	1.1
SINUS BRADYCARDIA (< 60)	2	2.0	1	1.0	2	2.4	1	0.9	1	0.9	1	1.1
SINUS TACHYCARDIA (> 100)	2	2.0	6	6.3	4	4.7	4	3.6	4	3.8	8	8.7
VENTRICULAR ECTOPIC BEATS - OCCASIONAL			1	1.0	3	3.5	1	0.9	1	0.9		

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 61

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
A-V BLOCK 1ST DEGREE	Absent	110	100.0			110	100.0
	Present			1	100.0	1	100.0
	Total	110	99.1	1	0.9	111	100.0
ATRIAL ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	110	99.1	1	0.9	111	100.0
	Present						
	Total	110	99.1	1	0.9	111	100.0
CONDUCTION DISORDER	Baseline						
	Absent	110	99.1	1	0.9	111	100.0
	Present						
	Total	110	99.1	1	0.9	111	100.0
LEFT ANTERIOR HEMIBLOCK	Baseline						
	Absent	110	100.0			110	100.0
	Present	1	100.0			1	100.0
	Total	111	100.0			111	100.0
LEFT BUNDLE BRANCH BLOCK	Baseline						
	Absent	110	99.1	1	0.9	111	100.0
	Present						
	Total	110	99.1	1	0.9	111	100.0
LEFT POSTERIOR HEMIBLOCK	Baseline						
	Absent	110	99.1	1	0.9	111	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 81

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment: Absent		Last assessment: Present		Total	
E.C.G. Abnormality	Baseline	No	%	No	%	No	%
LEFT POSTERIOR HEMIBLOCK	Present						
	Total	110	99.1	1	0.9	111	100.0
LEFT VENTRICULAR HYPERTROPHY	Baseline						
	Absent	111	100.0			111	100.0
	Total	111	100.0			111	100.0
MYOCARDIAL ISCHEMIA	Baseline						
	Absent	111	100.0			111	100.0
	Total	111	100.0			111	100.0
OTHER	Baseline						
	Absent	109	98.2	2	1.8	111	100.0
	Present						
	Total	109	98.2	2	1.8	111	100.0
PREVIOUS MYOCARDIAL INFARCTION	Baseline						
	Absent	108	100.0			108	100.0
	Present	1	33.3	2	66.7	3	100.0
	Total	109	98.2	2	1.8	111	100.0
RIGHT BUNDLE BRANCH BLOCK	Baseline						
	Absent	110	99.1	1	0.9	111	100.0
	Present						
	Total	110	99.1	1	0.9	111	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 81

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Absent	110	100.0			110	100.0
	Present	1	100.0			1	100.0
	Total	111	100.0			111	100.0
HYPOVENTILATION DISTURBANCES	Baseline						
	Absent	109	99.1	1	0.9	110	100.0
	Present	1	100.0			1	100.0
	Total	110	99.1	1	0.9	111	100.0
SINUS BRADYCARDIA (< 60)	Baseline						
	Absent	109	99.1	1	0.9	110	100.0
	Present	1	100.0			1	100.0
	Total	110	99.1	1	0.9	111	100.0
SINUS TACHYCARDIA (> 100)	Baseline						
	Absent	98	91.6	9	8.4	107	100.0
	Present	3	75.0	1	25.0	4	100.0
	Total	101	91.0	10	9.0	111	100.0
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	110	100.0			110	100.0
	Present	1	100.0			1	100.0
	Total	111	100.0			111	100.0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
TABLE No.: 81

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
A-V BLOCK 1ST DEGREE	Absent	95	99.0	1	1.0	96	100.0
	Present	2	100.0			2	100.0
	Total	97	99.0	1	1.0	98	100.0
ATRIAL ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	97	100.0			97	100.0
	Present	1	100.0			1	100.0
	Total	98	100.0			98	100.0
CONDUCTION DISORDER	Baseline						
	Absent	98	100.0			98	100.0
	Total	98	100.0			98	100.0
LEFT ANTERIOR HEMIBLOCK	Baseline						
	Absent	97	100.0			97	100.0
	Present	1	100.0			1	100.0
	Total	98	100.0			98	100.0
LEFT BUNDLE BRANCH BLOCK	Baseline						
	Absent	98	100.0			98	100.0
	Total	98	100.0			98	100.0
LEFT POSTERIOR HEMIBLOCK	Baseline						
	Absent	98	100.0			98	100.0
	Total	98	100.0			98	100.0

(CONTINUED)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 81

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
LEFT VENTRICULAR HYPERTROPHY	Absent	97	99.0	1	1.0	98	100.0
	Present						
	Total	97	99.0	1	1.0	98	100.0
MYOCARDIAL ISCHEMIA	Baseline						
	Absent	97	100.0			97	100.0
	Present			1	100.0	1	100.0
	Total	97	99.0	1	1.0	98	100.0
OTHER	Baseline						
	Absent	98	100.0			98	100.0
	Total	98	100.0			98	100.0
PREVIOUS MYOCARDIAL INFARCTION	Baseline						
	Absent	96	99.0	1	1.0	97	100.0
	Present	1	100.0			1	100.0
	Total	97	99.0	1	1.0	98	100.0
RIGHT BUNDLE BRANCH BLOCK	Baseline						
	Absent	97	99.0	1	1.0	98	100.0
	Present						
	Total	97	99.0	1	1.0	98	100.0
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Baseline						
	Absent	98	100.0			98	100.0
	Total	98	100.0			98	100.0

(CONTINUED)

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment				Total	
		Absent		Present			
		No	%	No	%	No	%
E.C.G. Abnormality	Baseline						
BIPOLARIZATION DISTURBANCES	Absent	98	100.0			98	100.0
	Total	98	100.0			98	100.0
SINUS BRADYCARDIA (< 60)	Baseline						
	Absent	95	99.0	1	1.0	96	100.0
	Present	1	50.0	1	50.0	2	100.0
	Total	96	98.0	2	2.0	98	100.0
SINUS TACHYCARDIA (> 100)	Baseline						
	Absent	92	95.8	4	4.2	96	100.0
	Present	1	50.0	1	50.0	2	100.0
	Total	93	94.9	5	5.1	98	100.0
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Baseline						
	Absent	95	96.9	3	3.1	98	100.0
	Present						
	Total	95	96.9	3	3.1	98	100.0

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 82

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES, BY ABNORMALITY GROUP, OBSERVED DURING THE STUDY BY ASSIGNED TREATMENT

Group of abnormalities	Imipramine						Reboxetine					
	Screening		1-21 days		22-42 days		Screening		1-21 days		22-42 days	
	No	%	No	%	No	%	No	%	No	%	No	%
Evaluated Pt.	98	100.0	96	100.0	85	100.0	111	100.0	106	100.0	92	100.0
Rhythm disorders	5	5.1	8	8.3	8	9.4	6	5.4	6	5.7	10	10.9
Conduction disorders	3	3.1	4	4.2	2	2.4	3	2.7	4	3.8	4	4.3
Ischemic signs	1	1.0			1	1.2	1	0.9			1	1.1
Other disorders	1	1.0	1	1.0	1	1.2	3	2.7	3	2.8	3	3.3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
TABLE No.: 83

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES, BY ABNORMALITY GROUP, AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

E.C.G. Abnormality / Baseline		Last assessment											
		Imipramine						Reboxetine					
		Absent		Present		Total		Absent		Present		Total	
		No	%	No	%	No	%	No	%	No	%	No	%
Rhythm disorders	Absent	86	92.5	7	7.5	93	100	94	89.5	11	10.5	105	100
	Present	3	60.0	2	40.0	5	100	5	83.3	1	16.7	6	100
	Total	89	90.8	9	9.2	98	100	99	89.2	12	10.8	111	100
Conduction disorders	Absent	93	97.9	2	2.1	95	100	103	97.2	3	2.8	106	100
	Present	3	100			3	100	1	33.3	2	66.7	3	100
	Total	96	98.0	2	2.0	98	100	104	95.5	5	4.5	111	100
Ischemic signs	Absent	97	100			97	100	109	99.1	1	0.9	110	100
	Present			1	100	1	100	1	100			1	100
	Total	97	99.0	1	1.0	98	100	110	99.1	1	0.9	111	100
Other disorders	Absent	96	99.0	1	1.0	97	100	106	98.1	2	1.9	108	100
	Present	1	100			1	100	1	33.3	2	66.7	3	100
	Total	97	99.0	1	1.0	98	100	107	96.4	4	3.6	111	100

FIGURES

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT
POINT ESTIMATES AND CONFIDENCE INTERVALS

Figure No.: 1



9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/4/017

CUMULATIVE PROBABILITY OF 50% DECREASE IN HAMD TOTAL SCORE

Figure No.: 2



423

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/017

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE

MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT

POINT ESTIMATES AND 95% CONFIDENCE INTERVALS

Figure No.: 3

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

MELANCHOLIC PATIENTS MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT

POINT ESTIMATES AND 95% CONFIDENCE INTERVALS

Figure No.: 4

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/017

CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT

Figure No.: 5



9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/4/017

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

Figure No.: 6



Log – Rank Test RBX vs IMI: (1 df) = 0.0109 P = 0.9167





9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

Figure No.: 9



Log–Rank Test RBX vs IMI: (1 df) = 0.0313 P = 0.8596

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

Figure No.: 10

Log–Rank Test RBX vs IMI: (1 df) = 0.0746 P = 0.7848

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

Figure No.: 11



Log–Rank Test RBX vs IMI: (1 df) = 3.8965 P = 0.0484

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING INSOMNIA

Figure No.: 12



Log–Rank Test RBX vs IMI: (1 df) = 0.9252 P = 0.3361

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING MOUTH DRY

Figure No.: 13



Log–Rank Test RBX vs IMI: (1 df) = 4.6064 P = 0.0319

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

Figure No.: 14



Log–Rank Test RBX vs IMI: (1 df) = 0.5755 P = 0.4481

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING SOMNOLENCE

Figure No.: 15



Log–Rank Test RBX vs IMI: (1 df) = 2.3541 P = 0.1250

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

Figure No.: 16

Log – Rank Test RBX vs IMI: (1 df) = 0.0323 P = 0.8573

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING TACHYCARDIA

Figure No.: 17



Log–Rank Test RBX vs IMI: (1 df) = 2.4496 P = 0.1176



9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/017

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

Figure No.: 19



Log–Rank Test RBX vs IMI: (1 df) = 0.8580 P = 0.3543

9550085

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 2012/4/017

PERCENTAGE OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT ON EXPOSED ACCORDING TO TIME INTERVAL

Figure No.: 20



441

12. APPENDICES

12.1 Study Information

12.1.1 PROTOCOL AND PROTOCOL AMENDMENTS

9550085

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

FARMITALIA CARLO ERBA
R&D - C.N.S. LINE

COMPOUND:		REBOXETINE
PROTOCOL No.	:	20124/017
VERSION	:	Final, September 14, 1990
PHASE	:	III
TITLE	:	**Multicenter, multinational double-blind study of the activity and tolerability of reboxetine vs imipramine in patients suffering from Major Depressive Episodes.**
INVESTIGATORS	:	see enclosure 1
PRODUCT LEADER	:	Dr. Marek Jarema Farmitalia Carlo Erba CNS Dpt Via Carlo Imbonati, 24 20159 Milano Phone: (39-2) 69952749
STUDY MONITOR	:	see 17.0

DATA MANAGEMENT CENTER: Biostatistics and Data Management
FICE Milan

This protocol contains strictly confidential information which is not to be communicated or published unless previously authorized by Farmitalia Carlo Erba R&D.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CMS LINE

TABLE OF CONTENTS

1.0	PROTOCOL SUMMARY	Page	1
2.0	INTRODUCTION	"	1
3.0	RATIONALE	"	4
4.0	OBJECTIVES	"	4
5.0	DESIGN	"	4
5.1	Description	"	4
5.2	Number of subjects proposed	"	4
5.3	Logistics	"	5
6.0	STUDY POPULATION	"	5
6.1	Source of Subjects	"	5
6.2	Inclusion Criteria	"	5
6.3	Exclusion Criteria	"	5
6.4	Identification of subjects	"	6
7.0	RANDOMIZATION AND REGISTRATION PROCEDURES (when applicable)	"	6
8.0	EXPERIMENTAL TREATMENTS	"	6
8.1	Test preparation	"	6
8.2	Labelling	"	7
8.3	Packaging	"	7
8.4	Drug supplies storage	"	7
8.5	Dispensing, use and disposition of test drugs during and at the end of the study	"	8
9.0	STUDY CONDUCT	"	8
9.1	Pre-treatment period	"	8
9.2	Treatment period	"	8
9.2.1	Dose/route of administration/ treatment schedule	"	8
9.2.2	Duration of treatment	"	9
9.2.3	Indications for early termination of test therapy	"	9
9.2.4	Dropouts/Replacement of subjects	"	9
9.2.5	Concomitant therapy	"	9
9.2.6	Indications for opening the code	"	10
9.3	Follow-up	"	10
9.4	Study time table	"	10
10.0	EFFICACY ASSESSMENTS	"	11
10.1	Variables to be measured for efficacy assessment	"	11
10.2	Efficacy definition	"	11
10.3	Criteria for subject evaluability	"	11

11.0	SAFETY ASSESSMENT	"	11
11.1	Variables to be measured for safety assessment	"	11
11.2	Criteria for subject evaluability	"	12
12.0	ADVERSE EVENTS	"	12
13.0	EVALUATION SCHEDULE	"	13
14.0	STATISTICAL CONSIDERATIONS	"	13
14.1	Sample size	"	13
14.2	STATISTICAL ANALYSIS	"	14
15.0	ETHICAL ASPECTS	"	15
15.1	Ethical committee	"	15
15.2	Informed consent	"	15
16.0	PROTOCOL AMENDEMENTS	"	15
17.0	STUDY MONITORING	"	16
18.0	DRUG SUPPLY AND DRUG INVENTORY	"	16
19.0	ADMINISTRATIVE ASPECTS	"	17
19.1	Insurance policy	"	17
19.2	Curriculum vitae	"	17
19.3	Data collection in the Case Record Form	"	17
19.4	Use and publications of the data obtained from the study	"	17
20.0	STUDY REPORT	"	18
20.1	Clinical Study Final Report	"	18
20.2	Use and publication of the study result	"	18
21.0	END OF THE STUDY	"	18
22.0	STUDY COORDINATION	"	18
23.0	REFERENCES	"	18
24.0	SIGNATURES	"	19

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

1.0 PROTOCOL SUMMARY

The study, aimed at the evaluation of the efficacy and tolerability of reboxetine in comparison with imipramine in patients suffering from Major Depressive Episodes, will be carried out on a multinational basis, according to a double-blind parallel group design, in 200 patients. After an initial washout period of 1-2 weeks, patients will receive either reboxetine or imipramine, administered according to a fixed-flexible dose regimen, for 6 weeks. Efficacy (Clinical Global Impression, Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Patient Global Impression) and tolerability (newly observed signs and symptoms, lab tests and ECG) will be assessed every 1-2 weeks. At the end of the 6 weeks treatment period a long-term follow-up could be undertaken.

2.0 INTRODUCTION

Reboxetine (FCE 20124 or RS, RS 2-[α-(2-ethoxy-phenoxy) benzyl]) morpholine methanesulphonate) is a chemically new compound highly potent in pharmacological and biochemical tests predictive of antidepressant effectiveness: reserpine antagonism, norepinephrine reuptake inhibition, REM sleep latency increase. In addition reboxetine has been found to be able to prevent clonidine effects in rodents after single oral administration, in contrast with what observed following tricyclic monoamine uptake inhibitors, which were found to be active only upon repeated doses: these results indicate that the compound is able to decrease the sensitivity of α2 noradrenergic receptors, one of the biochemical correlates of chronic antidepressant treatment, after single oral dose: therefore it may be expected to exert antidepressant effectiveness of faster onset with respect to available antidepressants in patients (1).

In phase I studies (2, 3) single doses of 0.5 - 5 mg of compound, were administered orally to healthy volunteers. After 5 mg orthostatic hypotension, accompanied by tachycardia and by subjective symptomatology consistent with the disturbed circulatory regulation was observed.

In these studies single doses of 1 & 3 mg of the compound showed dose-dependent CNS effects with EEG modifications (decreased power of theta and fast-beta waves in the fronto-central derivative), performance improvement (peg-board test) and growth hormone increase, the latter reportedly sensitive to hypothalamic noradrenergic stimulation by norepinephrine reuptake inhibitors.

The comparison with the positive control, imipramine 75 mg, associated to similar EEG modifications in the fronto-central derivative, to modifications indicative of sedative activity in the occipito-temporal derivative and to deterioration of the Pauli performance test, in the absence of growth hormone modifications, indicate that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties. After all treatment standing heart rate increase and salivation decrease was apparent. No other modifications of tolerability parameters were observed.

The pharmacokinetics of the compound were evaluated in the above mentioned studies as well as after administration of 2 mg 14C-FCE 20124 to 3 healthy volunteers (4). Most of the radioactivity circulating in plasma (73% in terms of AUC) was accounted for by unchanged reboxetine; the average peak levels were observed at 2 h, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 h, slightly lower than that of total radioactivity.

In addition the autonomic effects of the compound have been evaluated in a study carried out in 16 healthy volunteers according to a double-blind, latin square experimental design. Single doses of reboxetine 1, 2 & 4 mg, desipramine 25, 50 and 100 mg and placebo were administered at weekly intervals. Both reboxetine and desipramine were found to be similarly active in reducing salivation and antagonizing carbachol-evoked sweating, activities consistent with anticholinergic properties, and in increasing heart rate (consistent with muscarinic receptor blockade and/or noradrenergic stimulation); reboxetine, but not desipramine, was found to increase resting pupil diameter (consistent with muscarinic receptor blockade and/or α-stimulation) and to antagonize light evoked-miosis (consistent with anticholinergic activity).

Neither reboxetine nor desipramine were found to modify phenylephrine evoked sweating (no evidence of α-adrenoceptor blockade); following reboxetine a reduction of phenylephrine-evoked mydriasis was apparent, possibly due to a "ceiling effect" (due to the mydriatic effect of reboxetine) rather than α-adrenoceptor blockade. No evidence of noradrenaline-uptake blockade could be observed, since noradrenaline failed to evoke measurable pupillary response.
On the basis of the results of the phase I studies, a 6-center early phase II study was carried out aimed at assessing tolerability and activity of progressively increased doses of reboxetine, administered over a 4-week period to hospitalized patients suffering from Major Depressive Disorders (5).

Ninety-eight patients were admitted to the study to be treated with maximum reboxetine daily doses of 4 mg (29 pts), 6 mg (27 pts), 8 mg (18 pts), 10 mg (12 pts) and 12 mg (12 pts). Treatment was discontinued in 4 patients in the 4 mg group due to deterioration of the clinical picture (with a manic syndrome in one case); in 2 patients of the 6 mg group due to the development of a manic episode; in one patient of the 6 mg group due to a convulsive episode, under associated treatment with levomepromazine. Dosage decrease was almost only present in the 12 mg group where in 5/12 cases, due to hypotension and tachycardia, the daily dose was decreased to 10 mg until completion of the treatment period.

The rating scales applied showed dose related improvement of the clinical picture both as average changes vs basal conditions as well as frequencies of relevant modifications (defined as 50% decrease of HAMD) up to the 10 mg/day dose, whereas slight deterioration, concomitant to the intolerance signs/symptoms, was observed in the highest dose group.

The compound was well tolerated when administered at doses up to 10 mg/day, as shown by newly observed signs and symptoms, mainly of mild to moderate severity and transient, and by vital signs and lab tests assessments, ECG included.

A double blind parallel group study was subsequently carried out in 10 centers (Hungary, Italy, France and Latin America) in 258 patients hospitalized due to a Major DepressiveEpisode. The experimental treatment had to be administered for 4 weeks, with maximum doses of 8 mg reboxetine(RBX) or 200 mg desipramine(DMI). The experimental treatment was discontinued in 26 patients (10%): in 18 cases (5, 6 e 7 of the RBX, DMI and P group respectively) for inefficacy; in 3 cases for adverse events (2 of the RBX group due to deterioration of ventricular extrasystoles present before study start and hypertensive episodes respectively and 1 of the placebo group due to a cutaneous rash); in 5 cases (2, 1 and 2 in the RBX, DMI and P group respectively) for reasons unrelated to the experimental treatment.

Of the 80, 82 and 81 cases evaluable for efficacy in the RBX, DMI and P group (after exclusion of protocol violations, mainly related to associated treatments) 63%, 46% and 36% respectively showed a decrease >50% of the HAMD total score at the end of treatment; in 31%, 22% and 21% of these patients respectively the decrease was present within the 14th day of treatment. As to within-center results, the highest frequency of response was observed in the RBX group in all but 3 of the participating centers. After 2 and 4 weeks of treatment an average decrease of 23% and 34% of the HAMD was present in

the P group; the corresponding figures were 34% and 49% in the DMI group and 39% e 57% in the RBX group.

As to signs/symptoms, more frequent in the RBX group were headache, complained of by 33% of the patients (20% and 21% in the DMI e P group respectively), and urinary hesitancy/retention, present in 12% vs 4% vs 1% of the cases, RBX vs DMI vs P. More frequent in the DMI group were dry mouth (45% vs 26% vs 21%, DMI vs RBX vs P), sweating (28% vs 18% vs 22%), blurred vision (17% vs 4% in both RBX and P groups). Cardiovascular signs/symptoms were relatively rare, and appeared with slightly higher frequency in the DMI group: hypotension 13%, vs 6% in the RBX and 8% in the P group and tachycardia 19% vs 12% and 8% in the RBX and P group respectively.

3.0 RATIONALE

Phase II results obtained in controlled conditions in patients suffering from Major Depressive Episodes indicate that reboxetine is an effective antidepressant agent, with a favourable therapeutic index with respect to desipramine. Consistent information from further controlled studies is needed in order to properly document the activity and tolerability of the compound. In addition comparative evidence vs another tricyclic antidepressant is expected to allow a proper appraisal of the usefulness of the new molecule.

4.0 OBJECTIVES

To assess activity and tolerability of reboxetine in comparison with imipramine in patients suffering from Major Depressive Episodes.

5.0 DESIGN

5.1 Description

This phase III study will be carried out according to a double blind parallel group design, controlled vs imipramine, with random allocation of patients to one of the two treatments. The study will be organized on a multicenter, multinational basis.

5.2 Number of subjects proposed

Each center will recruit 20 patients, within a period of 12 months, for a total of 200 patients overall.

5.3 **Logistics**

The centers participating in the study are listed in enclosure 1.

6.0 **STUDY POPULATION**

6.1 **Source of subjects**

- Adult patients selected from the population under in-patient care or attending out-patient or day-hospital clinics of the participating centers will be studied.

6.2 **Inclusion criteria**

- Patients affected by Major Depressive Episodes (DSM-III-R see enclosure 2), not accompanied by psychotic features, with presence of illness for at least one month and not more than four.

- Patients of either sex, of any race, aged 18 to 65 years.

- A total score of 22 or above in the 21-HAMD.

- Patient's consent: informed consent will be obtained - see 15.2 (proposed form: enclosure 3).

6.3 **Exclusion criteria**

- Dysthymia, Cyclothymia

- History of Major Depressive Episodes associated with Endocrine Disorders: hypo and hyper-thyroidism tested by TSH and T4 at screening and defined as at least 10% abnormal values of the laboratory norms; adrenal insufficiency, etc.

- Pregnancy (tested by pregnancy test at the end of the wash-out period).

- Refusal by female patients in potential child bearing age of efficient contraceptivs use during the study period.

- Past history of any drug hypersensitivity.

- Participation in any clinical study with an investigational compound in the 4 weeks preceding the study.

- Evidence of Substance Use Disorder (DSM-III-R) within past 6 months or currently.

- Chronic respiratory insufficiency in the physical examination and X-ray.

- History or presence of gastrointestinal, liver, or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs.

- History of seizures or brain injury; current evidence of clinically important hematopoietic or cardiovascular diseases. Current evidence of urinary retention, or glaucoma.

- Symptoms of any other important clinical illness in the 4 weeks preceding the study.

- Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at screening.

- ECT in the previous 6 months.

- High risk of suicide

6.4 Identification of subjects

Patients will be identified by their initials and by the number in the trial.

7.0 RANDOMIZATION PROCEDURES

A randomization list balanced within center will be prepared for patient allocation to one of the 2 possible treatments (reboxetine, imipramine). On this basis the experimental treatments will be prepared and labelled with the corresponding patient number.

Patient allocation to treatment will be done at the end of the pre-treatment period by the main Investigator on the basis of the patient's temporal entry into the study.

8.0 EXPERIMENTAL TREATMENTS

8.1 Test preparation

Indistinguishable capsules containing reboxetine 2 mg (batch N°.....) or 4 mg (batch N°.....); or imipramine 50 mg (batch N°.....) plus excipients, or imipramine 100mg (batch N°.....) will be used. The experimental treatments will be administered according to fixed-flexible dose schedules as indicated under Study Conduct . Test preparations will consist of:

	morning	evening
-reboxetine	1 cps 4 mg	1 cps 4 mg
-reboxetine DOSE 2 (last 3 weeks)	as above	1 cps 6 mg
-imipramine day 1-3	1 cps 50 mg	1 cps 50 mg
day 4-42	1 cps 50 mg	1 cps 100 mg
-imipramine DOSE 2 (last 3 weeks)	1 cps 100 mg	1 cps 100 mg

8.2 Labelling

The experimental treatment will be labelled by using the labels in enclosure 4. Double labels will be used.

8.3 Packaging

For each patient 6 cartons labelled with the patient number and the indication "week 1" to "week 6" will be prepared. Each carton will contain the medication necessary for 1 week plus 2 cps for possible losses, prepared according to the b.i.d. regimen with 1 cps for the "morning" and 1 cps for the "evening" dose. In addition for each patient 3 cartons labelled with the patient number and the indication "week 4-dose 2", "week 5-dose 2" and "week 6-dose 2" will be provided, for the possible dosage increase during the last 3 weeks of treatment (see Study Conduct).

8.4 Drug supplies storage

Drug supplies will be stored at room temperature. All drug supplies will be handled under the direct responsibility of the Investigator and held by the Hospital Pharmacy. The study Monitor will check drug storage conditions during site visits.

The Investigator will be also responsible for drug accountability and will keep a record of the test compounds received from the Sponsor as well as of the dispensed drug.

8.5 Dispensing, use and disposition of test drugs during and at the end of the study

Medication will be dispensed to the patient on the occasion of each visit; the Investigator will detach the upper label from each of the weekly cartons he is dispensing to the patient and will attach them in the appropriate space in the Case Record Form. On the same occasion cartons of the possible previous supply will be returned by the patient.

Used cartons will be returned to the study Monitor during site visits.

All unused medication has to be returned to Farmitalia Carlo Erba at the end of the study.

9.0 STUDY CONDUCT

9.1 Pre-treatment period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 4-7 days (14 days in case of MAOI administration) will then be undertaken. During this period only chloral hydrate (0.5-1.0 9 night) as sleep inducer on p.r.n. basis will be allowed. Informed consent will be obtained from each patient (see 15.2).

Eligible patients will be then randomized to one of the two treatment groups and will undergo baseline assessments.

Information on patients screened for the study and found not to be eligible will be collected in the appropriate form (screening form, enclosure 5).

9.2 Treatment period

9.2.1 Dose/route of administration/treatment schedule

Patients will receive 1 capsule b.i.d. from day 1 to day 42. In case of inefficacy or unsatisfactory response (slight worsening or no change or minimal improvement at the CGI global improvement on day 21, see assessments), and in case of good tolerance, especially non-symptomatic hypotension, the dose will be increased to "dose 2" (see 8.0 Experimental Treatments) from day 22 to day 42, i.e. up to the end of treatment. In case of intolerance the

dose will be reduced to the previously well tolerated lower dosage level. The treatments will be administered in the morning and in the evening, at least 2 hours before or after meals.

9.2.2 Duration of treatment

The experimental treatment will be administered for 6 weeks.

9.2.3 Indications for early termination of test therapy

Termination of test therapy prior to completion of the 6 weeks treatment period may be considered under the following circumstances:

- Patient's request.

- Unacceptable toxicity: this is defined as the occurrence of serious (see Adverse Events) adverse events.

- Lack of efficacy: this will apply to patients who will show unacceptable deterioration of the clinical picture after at least two weeks of treatment (worsening at the CGI).

- Switch to mania.

In case of treatment discontinuation the complete final battery of assessments will be carried out.

9.2.4 Dropouts/replacement of subjects

Patients who drop out of the study for any reason will not be substituted.

For those patients who have been selected for the study who drop out at any time, even if it is before entrance to the treatment period, documentation will be provided.

9.2.5 Concomitant therapy

No concomitant medications other than hypnotic on p.r.n. basis are allowed at entry into the study. Concomitant medication should be avoided throughout the study.In case of events arising during the course of the study non-psychotropic medications which are considered necessary for the patient's welfare may be administered and will not be considered violation to the protocol. The drugs, dosage and frequency of administration will be recorded. Chloral

hydrate (0.5-1.0 g/night) as sleep inducer on p.r.n. basis at bed-time is allowed.

9.2.6 Indications for opening the code

The Investigator will be given individual sealed envelopes containing the information on patient's treatment. These latter may be opened only in case of emergency necessitating treatment identification; the Investigator will immediately (within 24 hours) inform the study Monitor at FICE Subsidiaries and will report full description of reasons for opening the code in the CRF (Adverse Event Form).

The sealed individual codes will be returned to Farmitalia Carlo Erba at the end of the study.

9.3 Follow-up

A follow-up visit will be carried out for each patient one month after treatment discontinuation, in order to monitor possible withdrawal reactions and collect information on interval events.

Patients willing to continue receiving the experimental treatment after completion of the 6 weeks treatment period will be maintained under the same medication in blind conditions until completion of the last patient of the center. Monthly visits will be carried out for efficacy and safety assessment and drug dispensing. The medications will be prepared as described for the initial double-blind treatment period, but in monthly units.

Afterwards, patients will be followed-up in open conditions. Reboxetine tablets will be provided by Farmitalia Carlo Erba while, for those patients who were receiving imipramine, Tofranil will be prescribed.

9.4 Study timetable

Foreseen start date: October-December 1990
Duration of accrual: 12 months
Foreseen end date (date of the last visit of the last patient, excluding follow up)): February 1992.

10.0 EFFICACY ASSESSMENTS

10.1 Variables to be measured for efficacy assessment

On days 0, 7, 14, 21, 28, 35, 42 :

- Hamilton Depression Rating Scale (21 items HAMD, enclosure 6); as above plus at screening for entry and monthly during the follow-up period.
- Clinical Global Impression (enclosure 7), as above plus monthly during the follow-up period.

- Montgomery-Asberg Depression Rating Scale (enclosure 8)

- Patient Global Impression (enclosure 9)

All psychiatric evaluations and ratings will be carried out by the same observer for a given patient, preferably in the same setting and at the same time of the day.

10.2 Efficacy definition

Decreases of at least 50 % in the total HAMD score vs day 0 will be considered index of response whereas total HAMD score of 10 or less will be considered index of remission.

10.3 Criteria for subject evaluability

Every randomized patient will be included in the analysis.

11.0 SAFETY ASSESSMENT

11.1 Variables to be measured for safety assessment

- Standard medical history: at screening

- Standard clinical examination: full physical examination: at screening.

- Blood pressure and pulse will be measured in the lying (after 5 minutes lying) and in the standing position (1 -2 minutes after standing up) in the morning: at screening and at each visit.

- ECG: at screening, day 21, day 42 and every three months during follow-up.

- Chest X-ray: at screening.

- Laboratory: TSH and T_4 at screening; full blood count, sodium, potassium, chlorine, BUN, creatinine, glucose, bilirubin, calcium, phosphorus, SGOT, SGPT, gamma, alkaline phosphatase, LDH, total proteins, albumin, cholesterol, uric acid, triglycerides, globulins - α_1, α_2, ß, gamma -, urinalysis: at screening, day 21, day 42,and every three months during follow-up.

- Adverse events: a check-list will be administered at each visit (Enclosure 10).

11.2 Criteria for subject evaluability

Every patient who has received at least one dose of the experimental treatment will be included in the safety evaluation.

12.0 ADVERSE EVENTS

Patients will be notified of possible adverse events they could experience and instructed to immediately report them to the Investigator.

Any newly observed sign or symptom, noticed by the Investigator or complained of by the patient, including clinically relevant lab abnormalities, will be recorded in the appropriate section of the CRF, regardless of presumed relationship to study medication.

For each event, the following information will be entered in the CRF: description, onset date, disappearance date, severity (1 = mild, awareness of sign or symptom, but easily tolerated; 2 = moderate, discomfort enough to cause interference with usual activity; 3 = severe, incapacitating with inability to work or do usual activity; 4 = unknown), drug cause-effect relationship (according to Karch and Lasagna modified criteria; see enclosure 11), outcome, dechallenge (what happened to the adverse event when the drug was stopped or the dose decreased?) rechallenge (what happened when the drug was restarted after the adverse event had disappeared?). The Investigator will also note if the double-blind code has been opened, the action taken regarding the test drug (none, discontinued, dosage reduced) and any treatment applied because of the adverse reactions.

All serious* ("any experience that is (potentially) fatal or life-threatening, disabling, incapacitating, requires inpatient hospitalization, or causes a congenital anomaly or cancer or is due to overdose") and/or unexpected* ("any adverse experience that is not identified in nature, severity or frequency in the current investigator's brochure for the study") adverse events must be immediately (within 24 hours) reported by telephone to FICE Subsidiaries Monitors (see Section 17.0) and the Adverse Event Report Form must be filled in immediately. FICE will notify the Regualtory Authority in accordance with statutory requirements. The same applies to all patients who die, irrespective of whether the event was judged as related to treatment, during the course of the study or within 30 days of completion of treatment.

In case of death, if an autopsy is performed, a copy of the pathological report should be sent to the FICE subsidiary monitor.

13.0 EVALUATION SCHEDULE

Is reported in table 1.

14.0 STATISTICAL CONSIDERATIONS

14.1 Sample size

The main evaluation of treatment effectiveness will be based on the comparison with respect to imipramine of the total score of the HAMD. The comparison will be performed on the difference between baseline and the last postbaseline score for each patient regardless the lenght of time in the study. This analysis will take into account all the available information, reducing the potential bias due to differential drop out rates between treatment groups. All randomized patients will be included in the analysis. A 95% confidence interval will be computed.

From the phase III and from the literature (6) it seems reasonable to assume that each treatment group will show a variability (expressed as standard deviation) of 9 points. Taking into account that 200 patients are planned to be recruited and assuming that 10% of patients will drop out before first postbaseline visit, we expect a lenght of 5.3 scores for the confidence interval.

---

* Code of Federal Regulation, Vol 21 Part 312. Revised as of April 1, 1987, pg. 75.
* J.L.Bem et al.: Review of yellow cards (1986): report to the Committe on the Safety of Medicines. Br.J. Clin. Pharmac. (1988), **26**, 679-689.

Refering to secondary efficacy analysis (see statistical analysis) based on proportions, the same sample size will allow for a maximum lenght of the confidence interval of 0.30. Maximum lenght is based on the hypothesis that both treatments will show a proportion of 0.5. Calculation is performed by the normal approximation method.

14.2 Statistical analysis

The main analysis of tretament effectiveness will be carried out on the variable 'total score of HAMD' considering the difference between baseline and the last postbaseline score for each patient regardless of lenght of time in the study. Reboxetine and imipramine will be compared by computing a 95% confidence interval of the difference between treatments mean decrements vs baseline in the two groups.

Evident unbalances between baseline values in the two groups will be taken into account by means of analysis of covariance. In this case the confidence interval will refer to the corrected menas.

In order to have a more complete picture of reboxetine effectiveness results obtained from the other administered scales (Montgomery-Asberg, CGI, PGI) as well as response/remission rates will be considered.

Response/remission rate is defined as the proportion of randomized patients experiencing response/remission (see 10.2) at a fixed time.

Explorative comparisons between groups will be performed. Confidence interval will be prefered to statistical test. Time course of the score of the administered rating scales will be described for the two groups. Time trend analysis will be performed on patients completing the six weeks treatment period. If judged to be informative, weekly analysis, including only those patients remaining in the study at a particular week, will be carried out.

Dropouts will be classified by reasons for study termination and proportions of patients dropped out compared between groups.

Frequencies of patients showing maximum decrease ≥20 mmHg in the standing systolic blood pressure will be compared between groups.

Adverse events will be presented by patient-by-patient listing and tabulated by treatment both on a patient basis and on an event basis. If clinically significant differences arise, they will be submitted to Chi-square test of the differences between teratment groups.

Descriptive statistics (mean, median, etc.) for laboratory data will be provided as well as frequency of abnormal values, with respect to normal range, after treatment in each group.

15.0 ETHICAL ASPECTS

The study will be carried out according to the Helsinki Declaration (Venice revision, Enclosure 12)

15.1 Ethical Committee

This study will not be undertaken until approval is obtained from the Ethical Committee or Institutional Review Board (IRB) of the participating centres. It is responsibility of the Investigator to submit the study protocol with its attachments to the Ethical Committee.

The written approval of the Ethical Committee or IRB will report the name and profession of all its members and a copy of it will be sent to the Sponsor before the study begins.

The Investigator is committed, in compliance with local requirements, to inform the Ethical Committee of any emergent problems, serious adverse reactions or protocol amendments.

15.2 Informed consent

Before entering the study each patient will be receive an explanation of the nature, duration, and purpose of the study and the action of the compounds in such a manner that the patient is aware of the potential risks, inconveniences or adverse effects that may occur and can express his/her informed consent to participate. The consent form (enclosure 2) will be signed by the patient or by the next of kin, and/or by the Investigator. In the latter case, the signature of a witness will testify that full information was given to the patient.

16.0 PROTOCOL AMENDMENTS

After the protocol has been signed, no changes will be made without the agreement of both the Investigator, the

Steering Committee and the Sponsor. Any change will be recorded on a written agreement which will be signed and dated by both parties and attached to the original protocol. No protocol change will be implemented without Regulatory approval, where required.

17.0 STUDY MONITORING

The monitors of the study are:

Dr. V. Bredenkamp
FICE South Africa
P.O.Box 41111 Craighall 2024
343 Kent Av. Ferndale
Randburg 2194
phone (27-11) 7879706

Dr. S. Dasseville
FICE Belgium
Rue de l'Industrie 8
1400 Nivelles
phone: (32-67) 2672925

Dr. I. Götz-Lee
FICE GmbH Germany
Merzhauser Str.122
Postfach 480
7800 Freiburg i.Br
phone: (49-761) 4013125

A pre-study visit will be made by the monitor to the Investigator in order to discuss problems, if any, and the obligations of both the Sponsor and the Investigator. During the trial monitoring visits will be paid to the site by the study monitor every four weeks. During the visits the monitor will assess the progress of the study, review the compliance with the study protocol, discuss any problem, check the CRFs for legibility, accuracy and completeness, validate CRFs content against source documents, assess the status of drug storage dispensing and retrieval.

Operating procedures for training on assessment instruments, study monitoring and coordination are described in attachment A.

18.0 SUPPLY AND INVENTORY

Test preparation will be supplied by Farmitalia Carlo Erba in the form described in 8.1. Records will be kept by the Investigator as to the disposition of study drug for each patient. A disposition form accounting for all study supplies will be signed by the Investigator - see enclosure 14.

19.0 ADMINISTRATIVE ASPECTS

19.1 Insurance policy

Farmitalia Carlo Erba Company declares to have a group insurance cover (policy N0. 4W8102 - Italia Assicurazioni - enclosure 13) which provides indemnity to the Investigator, to the co-Investigators and to the subjects participating in the trial.

19.2 Curriculum vitae

The Investigator will provide the Sponsor with signed copies of his/her and his/her co- Investigators CVs.

19.3 Data collection in the Case Record Form

All study data will be recorded in the CRF supplied by the Sponsor (Attachment B). A black ink ball point pen should be used for entering the data to ensure the good quality of the reproduced CRFs copies.

Only the Principal Investigator and the duly authorized co-Investigators can make entries in the CRF.

In case of errors corrections must be made by crossing out the incorrect entry (that must remain legible) and entering the correction followed by the Investigator's initials and the date of the correction.

On the occasion of the monitoring visits the monitor will take away the original and one copy of each page, while the Investigator will retain a copy for his files, together with the drug disposition records, for ten years after the discontinuation of the investigation.

19.4 Use and publication of the date obtained from the study

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure, given to the Investi-gator is confidential. These documents cannot be disclosed to a third party without the written consent of FICE R&D. The submission of these documents to the Ethical Committee is expressely permitted.

The Investigator agrees that FICE R&D maintains the right to utilize the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

20.0 STUDY REPORT

20.1 Clinical Study Final Report

The final Medical Study Report will be written by the Product Leader and will be submitted to the Investigator for approval and signature.

20.2 Use and publication of Study Results

The Investigators, whilst free to use the data resulting from this study, are asked to discuss any paper with Farmitalia Carlo Erba prior to publication; to this purpose copy of manuscript/abstract as to be available for FICE R&D Approval Procedure 30 days prior to publication. The results of the study may be submitted for a common publication, agreed upon between the Investigator and FICE R&D.

21.0 END OF THE STUDY

The Investigator or FICE R&D could terminate this study at any time for well documented reasons. In this event the other party will be immediately notified.

22.0 STUDY COORDINATION

A Steering Committee in charge of the coordination of the study will be formed, as described in Attachment A.

23.0 REFERENCES

1. Reboxetine Investigator Brochure, FICE, CNS Line, June 1988

2. /602i - Herrmann W.M. et al. (AFB - Berlin)
   Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study.
   June 15 1984.

3. /603i - Herrmann W.M. (AFB - Berlin)
   Reboxetine - Quantitative pharmaco EEG and pharmaco-psychological study.
   January 1985.

4. /604i - Dubini A. et al.
   Disposition and fate of ^{14}C-reboxetine administered orally to healthy volunteers.
   March 1985.

5. /701 - A. Dubini, T. Ban
Reboxetine: Open Dose Range Finding study in patients hospitalized for major depressive disorders
February 1989.

6. P. Stark, D. Hardison
J. Clin. Psychiat., 1985, 46:53-58

24.0 SIGNATURES

Signatures of the:

Investigator _____

Study Monitor _____

Product Leader _____

Line Medical Head _____

Biostatisticians _____

TABLE 1 **EVALUATION SCHEDULE**

DAY		SCREEN	0	4	7	14	21	28	35	42
TREATMENT	RBX mg		8----------							---->
								10----------		---->
	IMI mg		100-150----------							---->
								200----------		---->
DSM-III-R		■								
MEDICAL HISTORY		■								
PHYSICAL EXAMINATION		■								
X-RAY		■								
LABORATORY		■					■			■
ECG		■					■			■
VITAL SIGNS		■	■		■	■	■	■	■	■
21-ITEM HAMD		■	■		■	■	■	■	■	■
CGI			■		■	■	■	■	■	■
MONTGOMERY-ASBERG DEPRESSION RS			■		■	■	■	■	■	■
PATIENT GLOBAL IMPR.					■	■	■	■	■	■
COMPLIANCE					■	■	■	■	■	■
DISPENSING MED.					■	■	■	■	■	■
ADR					■	■	■	■	■	■

LIST OF ENCLOSURES

1) LIST OF INVESTIGATORS
2) DSM-III-R CRITERIA OF MAJOR DEPRESSIVE EPISODE
3) CONSENT FORM
4) EXPERIMENTAL TREATMENT LABELLING
5) SCREENING FORM
6) HAMD: HAMILTON DEPRESSION RATING SCALE
7) CLINICAL GLOBAL IMPRESSION (CGI)
8) MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE
9) PATIENT GLOBAL IMPRESSION
10) ADVERSE EVENTS: CHECK LIST
11) KARCH AND LASAGNA MODIFIED CRITERIA
12) DECLARATION OF HELSINKI
13) INSURANCE POLICY
14) DRUG ACCOUNTABILITY

ATTACHMENT A

PROTOCOL 20124/017: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COORDINATION

ATTACHMENT B

CASE RECORD FORM

Enclosure 1

LIST OF INVESTIGATORS

N°	Country	Name/Address	N° of patients
1.	Germany	Dr. Berzewski Department of Psychiatry University of Berlin	15
2.	"	Dr. Wolfersdorff Academic Teaching Hospital Ravensburg	25
3.	"	Dr. Täschner Academic Teaching Hospital Bürgerhospital, Stuttgart	10
4.	"	Dr. Uebehack Poliklinik der Charité Schumannstr. 20-21, 0-1040 Berlin	10
5.	"	Dr. Haüser Nervenklinik 0-1612 Teupitz	10
6.	"	Dr. König Weinsberg Psychiatric General Hospital, Weisenhof	10
7.	Belgium	Dr. Derely Clinique La Ramée Neuropsychiatric Hospital Brussels tel. (02) 3441894	20
8.	"	Dr. Wilmotte Hopital Civil et Hopital VVG Neuropsychiatric Hospital Charleroi tel. (071) 292911	20
9.	"	Dr. M. Van Moffaert Universitair Ziekenhuis Gent Psychiatrische Kliniek De Pintelaan 185, 9000 Gent tel. (091) 4043890	20
9/A	"	Dr. R. Spiers Gent	

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

10.	Belgium	Dr. J. Bollen Psychiatrisch Centrum Santa Maria Melverencentrum 111, 3800 Sint Truiden (011) 689911	20
11.	South Africa	Prof. C.A.Gagiano Department of Psychiatry University of Orange Free State P.O.Box 339, Bloemfontein 9300	20
12.	"	Prof. G. Hart, Dr. M. Berk Johannesburg Medical School Psychiatry Department 7 York Road Parktown 2193	20
13.	"	Dr. D.A.B. Wilson, Dr. M. Louw Department of Psychiatry Groote Schuur Hospital Observatory 7925 (Cape Town)	20
14.	Germany	Dr. Woelk Universitätsklinik Giessen	40
14.1	"	Dr. H. Hauer An der Aurach 8 8535 Emskirchen	
14.2	"	Dr. M. El Mallah Seltsamplatz 3 8550 Forchheim	
14.3	"	Dr. O' Connolly Haimendorfstr. 4 8540 Schwabach-Wolkersdorf	
14.4	"	Dr. Adler Nürnberg	
14.5	"	Dr. E. Samimi Heisterstr. 31 8500 Nürnberg	
14.6	"	Dr. E. Sarrafian Hauptstr. 28 8542 Roth	
14.7	"	Dr. K. Schröter Altdorfer Str. 11 8560 Lauf/Pegnitz	
14.8	"	Dr. G. Stumpf Volkacher Str. 31 8500 Nürnberg	

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

14.9	Germany	Dr. P. Weinholz Brauhofgasse 1 8520 Erlangen-Frauenaurach
14.10	"	Dr. H. Wiswedel Friedenstr. 12 8510 Fürth/Bay
15.	South Africa	Prof. A. Levin Psychiatric Hospital Grahamstown

9550085

Protocol 20124/ Enclosure 2

DSM-III-R
Diagnostic Criteria
of the MAJOR DEPRESSIVE EPISODE

Note: All A, B, C, and D must be "present"

A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.

1) depressed mood most of the day, nearly every day, as indicated by subjective account or observation by others
2) markedly diminished interest or pleasure in all, or allmost all, activities most of the day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time)
3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day
4) insomnia or hypersomnia nearly every day
5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)
6) fatigue or loss of energy nearly every day
7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)
8) diminished ability to think or concentrate, or indecisiveness, neraly every day (either by subjective account or as observed by others)
9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

B. 1) It cannot be established that an organic factor initiated and maintained the disturbance
2) The disturbance is not a normal reaction to the death of a loved one

C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)

D. Not superimposed on Schizophrenia, Schizophreniform Disorder, Delusional Disorder, or Psychotic Disorder NOS.

9550085

Enclosure 3

REBOXETINE PROTOCOL 20124/017

Multicenter, multinational double blind study of the activity and tolerability of reboxetine vs imipramine in patients suffering from Major Depressive Disorders.

CONSENT FORM

Principal Investigator: .....

EXPLANATION

Purpose of the study

Reboxetine, a new potential antidepressant agent, has effects in animals which suggest that it may exert therapeutic efficacy of faster onset, in comparison with established antidepressant drugs, in patients suffering from depressive disorders. The trial is proposed in order to learn about the antidepressant effectiveness of the compound and its tolerability.

Plan of the study

After an initial drug free wash out period of at least one week, patients will receive either reboxetine or imipramine, an antidepressant of established efficacy, available on the market in most countries. Neither patients nor doctors will know which treatment will be administered in individual cases untill after the study is completed. The identity of the treatments can anyhow be determined immediately if any medical problem will develop and it will become important to learn which of the two possible treatments is being given.

Treatment will be administered for six weeks. It will be discontinued in case of deterioration of psychiatric symptomatology or in case of significant side-effects. In addition patients participating in the study may withdraw their consent at any time without prejudice to their continued medical treatment.

During treatment, physical and psychiatric examinations will be done on frequent occasions, in order to determine

possible side-effects and benefits of treatments. Blood tests, urinalysis, ECG will be undertaken be-weekly. Blood pressure and pulse will be taken every week, on the occasion of each visit.

Possible discomforts and risks

Antidepressant drugs can cause dry mouth, blurred vision, dizziness, mild difficulty in voiding urine, postural hypotension and electrocardiographic changes.

Reboxétine has been so far administered for 28 days to about 180 patients and was well tolerated up to the dose of 5 mg twice daily. In the dose range of 3-5 mg twice daily clinically relevant improvement of depressive condition was present in the majority of patients; symptoms complained off by patients were mainly mild and transient and included most frequently headache, sweating, lassitude, nasal congestion, constipation and urinary hesitancy. At higher doses orthostatic hypotension, tachycardia, dizziness, blurred vision and nausea were reported.

Patients participating in the study will be carefully monitored to detect early signs of such side-effects.

Possible benefits

Other drugs are available for treatment of depressive disorders but none has been of proven value in all cases. This study will allow the evaluation of the antidepressant activity of reboxetine in comparison with imipramine, a compound of established efficacy.

Alternative treatment

Patients would receive alternative pharmacological therapy with an antidepressant drug chosen on the basis of response during previous episodes, if any. Risks and benefits of receiving treatment with any of the available antidepressant drugs can be explained by .....

Confidentiality

Participation in the study will be kept confidential to the extent permitted by law.

Problems and questions

Should any problem or question arise with regard to the study, patients can contact the Principal Investigator:

.....
or the other staff members also involved in the study:

.....

.....

.....

In addition any problem or question can be discussed with a member of the Institutional Review Board (..... .....), the Committee which has evaluated the potential risks and possible benefits of the study.

Payments and policy regarding research-related injuries.

Patients will not be paid for the participation in the study. The Clinical Center will provide short-term medical care for any physical injury resulting from participation in the study. No long-term medical care or financial compensation for such injuries will be provided except as it may be through whatever remedies are normally available under law. Insurance coverage is granted through the Sponsor Company.

PATIENTS CONSENT

I have read the explanation about this study and I have been given the opportunity to discuss it and to ask questions. I hereby consent to take part in this study.

Patient Signature _____ date _____

I have explained all the above indicated aspects of the study to the patient, who expressed his/her consent to the participation.

Investigator Signature _____ date _____

Wittness Signature _____ date _____

9550085

Enclosure 4

REBOXETINE PROTOCOL 20124/017

EXPERIMENTAL TREATMENT LABELLING

TREATMENT

reboxetine protocol 20124/017
patient No.....
week 1 - 6
batch No.....
expiry.....
drug for investigational use

HIGH DOSE TREATMENT

reboxetine protocol 20124/017
patient No.....
week 5 - 6
expiry.....
drug for investigational use

9550085

Enclosure 5

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|8

Centre No. ____ Pat. Initials ____ Visit/cycle S|C|R|E|E|N

Investigator's name _____ Monitor's name _____ Date ____ D M Y

PATIENT IDENTIFICATION

Hospital File/Out Pat. Register N° ____

Initials ____ Sex M F Age (years) ____ Weight (kg) ____ Height (cm) ____

Birth date ____ D M Y

Ethnic group: Caucasian ☐ Black ☐ Asian ☐ Other ☐, specify _____

Out-patient ☐ In patient ☐, hospitalized on ____ D M Y

DIAGNOSIS

– DSM-III-R AXIS I _____ ____

HISTORY OF THE MENTAL DISORDER: Unknown ☐ if known:

– Age of onset of disease years ____

– Number of previous episodes ____

– Approximate duration of last episode weeks ____ months ____ years ____

PRESENT EPISODE

– Approximate duration at the time of admission to the study days ____ weeks ____ months ____ years ____

THE PRESENT EPISODE IS BEST CHARACTERIZED AS:

– Exacerbation of chronic condition 1

– Recurrence of similar previous conditions 2

– Significantly different from any previous conditions 3

– First occurrence, no previous psychiatric diagnosis 4

ONSET OF PRESENT EPISODE WAS:

– Acute (<2 weeks) 1

– Subacute (≥ 2 weeks) 2

– Insidious (≥ 3 months) 3

PRECIPITATING EXTERNAL STRESS WAS:

– Absent 1

– Probably present 2

– Definitely present 3

477

1-scree

Investigator's signature _____

9550085 Cont'd Enclosure 5

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 7

Centre No. ____

Pat. Initials ____

Visit/cycle S C R E E N

Date ____ (D M Y)

ADMISSION EXAMINATION

CHEST X-RAY taken on ____ (D M Y) normal ☐ abnormal ☐

If abnormal, detail _____

VITAL SIGNS

- Body temperature (°C) ____
- Respiratory rate (breaths/min) ____
- 5 min lying arterial blood pressure (mmHg) systolic ____ diastolic ____
- 5 min lying heart rate (beats/min) ____
- 2 min standing arterial blood pressure (mmHg) systolic ____ diastolic ____
- 2 min standing heart rate (beats/min) ____

MEDICAL HISTORY

- Important previous diseases _____

7-scree

Investigator's signature _____

9550085 Cont'd Enclosure 5

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 8

Centre No. | | | |

Pat. Initials | | |

Visit/cycle S C R E E N

Date | | | | | | D M Y

HAMD: HAMILTON DEPRESSION RATING SCALE

1. Depressed mood ***(Sadness, hopeless, helpless, worthless)***

[0] Absent
[1] These feeling states indicated only on questioning
[2] These feeling states spontaneously reported verbally
[3] Communicates feeling states non-verbally - i.e., through facial expression, posture, voice, and tendency to weep
[4] Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2. Feelings of guilt

[0] Absent
[1] Self reproach, feels he has let people down
[2] Ideas of guilt or rumination over past errors or sinful deeds
[3] Present illness is a punishment. Delusions of guilt
[4] Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3. Suicide

[0] Absent
[1] Feels life is not worth living
[2] Wishes he were dead or any throughts of possible death to self
[3] Suicide ideas or gesture
[4] Attempts at suicide *(any serious attempt rates 4)*

4. Insomnia early

[0] No difficulty falling asleep
[1] Complains of occasional difficulty falling asleep - i.e., more than ½ hour
[2] Complains of nightly difficulty falling asleep

5. Insomnia middle

[0] No difficulty
[1] Patient complains of being restless and disturbed during the night
[2] Waking during the night - any getting out of bed rates 2 *(except for purposes of voiding)*

6. Insomnia late

[0] No difficulty
[1] Waking in early hours of the morning but goes back to slepp
[2] Unable to fall asleep again if he gets out of bed

7. Work and activities

[0] No difficulty
[1] Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies
[2] Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect in listlessness, indecision and vacillation *(feels he has to push self to work or activities)*
[3] Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if patient does not spend at least three hours a day in activities *(hospital job or hobbies)* exclusive of ward chores
[4] Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities except ward chores, or if patient fails to perform ward chores unassisted

Investigator's signature _____

8. Retardation ***(Slowness of thought and speech; impaired ability to concentrate; decreased motor activity)***

[0] Normal speech and thought
[1] Slight retardation at interview
[2] Obvious retardation at interview
[3] Interview difficult
[4] Complete stupor

9. Agitation

[0] None
[1] Fidgetiness
[2] Playing with hands, hair, etc.
[3] Moving about, can't sit still
[4] Hand wringing, nail biting, hair-pulling, biting of lips

10. Anxiety psychic

[0] No difficulty
[1] Subjective tension and irritability
[2] Worrying about mirror matters
[3] Apprehensive attitude apparent in face or speech
[4] Fears expressed without questioning

11. Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal *(dry mouth, wind, indigestion, diarrhea, cramps, belching)*; Cardio-vascular *(palpitations, headaches)*; Respiratory *(hyperventilation, sighing)*; Urinary frequency; Sweating

[0] Absent
[1] Mild
[2] Moderate
[3] Severe
[4] Incapacitating

12. Somatic symptoms gastrointestinal

[0] None
[1] Loss of appetite but eating without staff encouragement. Heavy feeelings in abdomen
[2] Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

13. Somatic symptoms general

[0] None
[1] Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability
[2] Any clear-cut symptoms rates 2

14. Genital symptoms (Such as: *Loss of libido; Menstrual disturbances)*

[0] Absent
[1] Mild
[2] Severe

15. Hypochondriasis

[0] Not present
[1] Self-absorption (bodily)
[2] Preoccupation with health
[3] Frequent complaints, requests for help, etc.
[4] Hypocondriacal delusions

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 7

Centre No. | | | | |

Pat. Initials | | |

Visit/cycle S C R E E N

Date | | | | | | (D M Y)

16. Loss of weight ***Rate either A or B***

A. *When Rating By History:*

[0] No weight loss
[1] Probable weight loss associated with present illness
[2] *Definite (according to patient)* weight loss
[3] Not assessed

B. On Weakly Ratings By Ward Psychiatrist, When Actual Weight Changes Are Measured:

[0] Less than 1 lb. weight loss in week
[1] Greater than 1 lb. weight loss in week
[2] Greater than 2 lb. weight loss in week
[3] Not assessed

17. Insight

[0] Acknowledges being depressed and ill
[1] Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest, etc.
[2] Denies being ill at all

18. Diurnal variation

A. Note Whether Symptoms Are Worse In Morning Or Evening. If NO Diurnal Variation, Mark "none":

[0] No variation [1] Worse in A.M. [2] Worse in P.M.

B. When Present, Mark The Severity Of The Variation. Mark "None" If NO Variation:

[0] None [1] Mild [2] Severe

19. Depersonalization and derealization (Such as: *Feelings of unreality, Nihilistic ideas)*

[0] Absent [1] Mild [2] Moderate
[3] Severe [4] Incapacitating

20. Paranoid symptoms

[0] None
[1] Suspicious
[2] Ideas of reference
[3] Delusions of reference and persecution

21. Obsessional and compulsive symptoms

[0] Absent [1] Mild [2] Severe

Total score | |

6-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 7

Centre No. _ _ _ _

Pat. Initials _ _ _

Visit/cycle S C R E E N

Date _ _ _ _ _ _ (D M Y)

ECG

HEART RATE _ _ _

- Normal ☐
- Abnormal ☐

if abnormal check one or more boxes as appropriate:

1 Sinus bradycardia (<60) ☐
2 Sinus tachycardia (>100) ☐
3 Sick Sinus Syndrome ☐

- Atrial ectopic beats:
  - Occasional ☐
  - Frequent (>6/mm) ☐
  - Couplets ☐
  - Supraventricular Tachycardia ☐
- Ventricular ectopic beats:
  - Occasional ☐
  - Frequent (>6/mm) ☐
  - Polymorphic ☐
  - Couplets ☐
  - Ventricular Tachycardia ☐
- Atrial fibrillation-flutter ☐
- A-V Block 1st degree ☐
  - 2nd degree - Mobitz 1 ☐
  - Mobitz 2 ☐
  - Complete ☐
- Left ventricular hypertrophy ☐
- Right ventricular hypertrophy ☐
- Myocardial ischemia ☐
- Previous Myocardial infarction ☐
- Acute Myocardial infarction ☐
- Right bundle branch block ☐
- Left bundle branch block ☐
- Left anterior hemiblock ☐
- Left posterior hemiblock ☐
- Bifascicular Block (specify) ☐
- Trifascicular Block (specify) ☐
- Other ☐

(specify) _____

8-scree

Investigator's signature _____

9550085 Cont'd Enclosure 5

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 8

Centre No. _ _ _ _

Pat. Initials _ _ _

Visit/cycle S C R E E N

Date _ _ / _ _ / _ _
D M Y

CONT' ECG

Please, add here the ORIGINAL TRACING AND MEDICAL REPORT

9-scree

Investigator's signature _____

9550085 Cont'd Enclosure 5

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 7

Centre No. ☐☐☐☐

Pat. Initials ☐☐☐

Visit/cycle S C R E E N

Date ☐☐ ☐☐ ☐☐ (D M Y)

LABORATORY TESTS

Tests	Value	Clinically Significant abnormality**	Tests	Value*	Clinically Significant abnormality**
BLOOD TESTS			BUN		☐
HB		☐	Creatinine		☐
HCT		☐	Uric acid		☐
RBC		☐	Total bilirubin		☐
WBC		☐	Direct bilirubin		☐
Neutrophils		☐	Total protein		☐
Lymphocytes		☐	Blood albumin		☐
Eosinophils		☐	Cholesterol*		☐
Monocytes		☐	Triglycerides*		☐
Basophils		☐	Globulins: α 1		☐
Platelets		☐	α 2		☐
Na^+		☐	β		☐
K^+		☐	γ		☐
CL		☐	TSH		
Ca^{++}		☐			
PO_4		☐	T_4		
SGOT		☐	**URINALYSIS**		
SGPT		☐	Specific gravity		☐
γ-GT		☐	Albumin		☐
LDH		☐	Sugar		☐
Alkaline phosphatase		☐	RBC		☐
Blood sugar*		☐	WBC		☐

* Fasting blood sample is required
** Cross in case of clinically significant abnormality

Observation: _____

484

10-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 7

Centre No. | | | | |

Pat. Initials | | |

Visit/cycle S C R E E N

Date | | | | | | (D M Y)

PREVIOUS TREATMENTS

NAME*	EFFICACY (Very poor, Poor, Fair, Good, Very good)	SIDE EFFECTS (if any)
	VP P F G VG	
	VP P F G VG	
	VP P F G VG	
	VP P F G VG	
	VP P F G VG	

Last treatment taken: name* _____ Last day of treatment | | | | | | (D M Y)

Drug free, Wash-Out Period: from | | | | | | (D M Y) to | | | | | | (D M Y)

CONCOMITANT DRUGS (during the drug free, wash-out period)

NAME*	Daily Dose (mg)	Started on (date)			Discontinued on (date)			Reason for the administration
		D	M	Y	D	M	Y	

* Whenever possible use non-proprietary name instead of trade name

Observations: _____

11-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|3

Centre No. | | | |

Pat. Initials | | |

Visit/cycle S|C|R|E|E|N

Date | | | | | | D M Y

PRE-STUDY CHECKLIST

IN THE PATIENT:

ARE THE FOLLOWING CONDITIONS PRESENT?	YES	NO
– Aged between 18 and 65 years inclusive?	☐	☐
– Affected by acute episodes of Major Depressive Episodes (DSM-III-R), not accompanied by psycothic features with presence of episode for at least one month and not for more than four?	☐	☐
– With a total score of 22 or above in the 21-HAMD?	☐	☐
– Able and willing (he/she or the next of kin) to give Informed Consent?	☐	☐
ARE THE FOLLOWING CONDITIONS ABSENT?		
– Dysthymia?	☐	☐
– History of Major Depressive Episodes, associated to Endocrine Disorders?	☐	☐
– Pregnancy? (if applicable)	☐	☐
– Refusal of contraceptive use during the study period? (if applicable)	☐	☐
– Clinically significant hematopoietic abnormality?	☐	☐
– Clinically significant lab values abnormality?	☐	☐
– Current evidence of urinary retention?	☐	☐
– Current evidence of glaucoma?	☐	☐
– Clinically significant physical abnormality?	☐	☐

If NO, please cross and detail:

– Hepatic function ☐: _____

– Renal function ☐: _____

– Gastrointestinal function ☐: _____

– Cardiovascular function ☐: _____

12-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 8

Centre No. ____

Pat. Initials ____

Visit/cycle S C R E E N

Date ____ D M Y

(CONT'D)

ARE THE FOLLOWING CONDITIONS ABSENT?	YES	NO
– Participation in a clinical trial with an investigational compound in the 4 weeks preceding the study?	☐	☐
– Evidence of substance use disorder within past 6 months or currently?	☐	☐
– Chronic respiratory insufficienty?	☐	☐
– History of drug hypersensitivity?	☐	☐
– Any history of seizures or brain injury?	☐	☐
– Any other important clinical illness in the 4 weeks preceding the study?	☐	☐
– ECT in the previous 3 months?	☐	☐
– MMS < 22?	☐	☐
– High risk of suicide?	☐	☐

If the answer to any of the above questions is NO the patient is unsuitable for entry into the study and should no proceed further.

CONCLUSION

I, dr. _____ confirm that the available informations on the patient agree with exclusion and inclusion criteria and that the patient is suitable to be included in this study and will receive the following patient number ____.

13-scree

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|7

Centre No. | | | | Patient No. | | | Initials | | | Visit/cycle | | | | |

Date | | | | | | | | D M Y

Enclosure 6

HAMD: HAMILTON DEPRESSION RATING SCALE

1. Depressed mood ***(Sadness, hopeless, helpless, worthless)***

[0] Absent
[1] These feeling states indicated only on questioning
[2] These feeling states spontaneously reported verbally
[3] Communicates feeling states non-verbally - i.e., through facial expression, posture, voice, and tendency to wee,
[4] Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2. Feelings of guilt

[0] Absent
[1] Self reproach, feels he has let people down
[2] Ideas of guilt or rumination over past errors or sinful deeds
[3] Present illness is a punishment. Delusions of guilt
[4] Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3. Suicide

[0] Absent
[1] Feels life is not worth living
[2] Wishes he were dead or any throughts of possible death to self
[3] Suicide ideas or gesture
[4] Attempts at suicide *(any serious attempt rates 4)*

4. Insomnia early

[0] No difficulty falling asleep
[1] Complains of occasional difficulty falling asleep - i.e., more than ½ hour
[2] Complains of nightly difficulty falling asleep

5. Insomnia middle

[0] No difficulty
[1] Patient complains of being restless and disturbed during the night
[2] Waking during the night - any getting out of bed rates 2 *(except for purposes of voiding)*

6. Insomnia late

[0] No difficulty
[1] Waking in early hours of the morning but goes back to slepp
[2] Unable to fall asleep again if he gets out of bed

7. Work and activities

[0] No difficulty
[1] Thoughts and feelings of incapacity, fatigue or weakness related to activities: work or hobbies
[2] Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect in listlessness, indecision and vacillation *(feels he has to push self to work or activities)*
[3] Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if patient does not spend at least three hours a day in activities *(hospital job or hobbies)* exclusive of ward chores
[4] Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities except ward chores, or if patient fails to perform ward chores unassisted

Investigator's signature _____

~~0550085~~

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1

Centre No. ___ Patient No. ___ Initials ___ Visit/cycle ___

Date ___ D M Y

Encl. 6 cont'd

8. Retardation ***(Slowness of thought and speech; impaired ability to concentrate; decreased motor activity)***

[0] Normal speech and thought
[1] Slight retardation at interview
[2] Obvious retardation at interview
[3] Interview difficult
[4] Complete stupor

9. Agitation

[0] None [1] Fidgetiness [2] Playing with hands, hair, etc.
[3] Moving about, can't sit still [4] Hand wringing, nail biting, hair-pulling, biting of lips

10. Anxiety psychic

[0] No difficulty [1] Subjective tension and irritability
[2] Worrying about mirror matters [3] Apprehensive attitude apparent in face or speech
[4] Fears expressed without questioning

11. Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal *(dry mouth, wind, indigestion, diarrhea, cramps, belching)*; Cardio-vascular *(palpitations, headaches)*; Respiratory *(hyperventilation, sighing)*; Urinary frequency: Sweating

[0] Absent [1] Mild [2] Moderate
[3] Severe [4] Incapacitating

12. Somatic symptoms gastrointestinal

[0] None
[1] Loss of appetite but eating without staff encouragement. Heavy feeelings in abdomen
[2] Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

13. Somatic symptoms general

[0] None
[1] Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability
[2] Any clear-cut symptoms rates 2

14. Genital symptoms (Such as: *Loss of libido; Menstrual disturbances)*

[0] Absent [1] Mild [2] Severe

15. Hypochondriasis

[0] Not present [1] Self-absorption (bodily)
[2] Preoccupation with health [3] Frequent complaints, requests for help, etc.
[4] Hypocondriacal delusions

Investigator's signature ___

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|

Centre No. | | | | Patient No. | | | Initials | | | Visit/cycle | | | | |

Date | | | | | | D M Y

Encl. 6 cont'd

16. Loss of weight ***Rate either A or B***

A. When Rating By History:

[0] No weight loss
[1] Probable weight loss associated with present illness
[2] Definite (according to patient) weight loss
[3] Not assessed

B. On Weekly Ratings By Ward Psychiatrist, When Actual Weight Changes Are Measured:

[0] Less than 1 lb. weight loss in week
[1] Greater than 1 lb. weight loss in week
[2] Greater than 2 lb. weight loss in week
[3] Not assessed

17. Insight

[0] Acknowledges being depressed and ill
[1] Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest, etc.
[2] Denies being ill at all

18. Diurnal variation

A. Note Whether Symptoms Are Worse In Morning Or Evening. If NO Diurnal Variation, Mark "none":

[0] No variation [1] Worse in A.M. [2] Worse in P.M.

B. When Present, Mark The Severity Of The Variation. Mark "None" If NO Variation:

[0] None [1] Mild [2] Severe

19. Depersonalization and derealization (Such as: *Feelings of unreality, Nihilistic ideas)*

[0] Absent [1] Mild [2] Moderate
[3] Severe [4] Incapacitating

20. Paranoid symptoms

[0] None
[1] Suspicious
[2] Ideas of reference
[3] Delusions of reference and persecution

21. Obsessional and compulsive symptoms

[0] Absent [1] Mild [2] Severe

Total score |__|

Investigator's signature _____

Enclosure 7

FARMITALIA CARLO ERBA
Erbamont Group

9550085
Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 1 7

Centre No. | | | | Patient No. _____ Initials _____ Visit cycle _____

Date _____ D M Y

CLINICAL GLOBAL IMPRESSION (CGI)

A. SEVERITY OF ILLNESS

Considering your clinical experience with this particular population, how mentally ill is the patient at this time?

1 Normal, not at all ill
2 Borderline mentally ill
3 Mildly ill
4 Moderately ill
5 Markedly ill
7 Severily ill
8 Among the most extremely ill patients

B. GLOBAL IMPROVEMENT (rate total improvement whether or not, in your judgement, it is due entirely to drug treatment)
Compared to this condition at admission to the study, how much has he changed?

1 Very much improved
2 Much improved
3 Minimally improved
4 No change
5 Minimally worse
6 Much worse
7 Very much worse

C. EFFICACY INDEX (rate this item on the basis of drug effect only)

	Tolerability: side effects			
Activity	None	Do not significantly Interfere with patient's functioning	Significantly interfere with patient's functioning	Outweigh therapeutic effect
MARKED Vast improvememt, complete or nearly complete remission of all symptoms	1	2	3	4
MODERATE Decided improvement, partial remission of symptoms	5	6	7	8
MINIMAL Slight improvement which does not alter status of care of patient	9	10	11	12
UNCHANGED OR WORSE	13	14	15	16

Investigator's signature _____

ARMITALIA CARLO ERBA Compound REBOXETINE 9550085 Protocol No [2|0|1|2|4|0|1|7]
Sanofi Group

Centre No. [| | |] Patient No. [| |] Initials [| |] Visit/cycle [| |]

Date [| | | | | |]
D M Y

ENCLOSURE N° 8

MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE

1. Reported sadness
- Representing subjectively experienced mood, regardless of whether it is reflected in appearance or not. Includes depressed mood, low spirits, despondency, and the feeling of being beyond help and without hope.
- Rate according to intensity, duration and the extent to which the mood is influenced by events.
- Elated mood is scored zero on this item.

Occasional sadness may occur in the circumstances [0]; Predominant feelings of sadness, but brighter moments occur [1]; Pervasive feelings of sadness or gloominess, the mood is hardly influenced by external circumstances [2]; Continuous experience of misery or extreme despondency [3]. [ ]

2. Inner tension
- Representing feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to panic, dread and anguish.
- Rate according to intensity, frequency, duration and the extent of reassurance called for.
- Distinguish from sadness, worrying and muscular tension.

Placid, only fleeting inner tension [0]; Occasional feelings of edginess and ill-defined discomfort [1]; Continuous feelings of inner tension, or intermittent panic which the patient can only master with some difficulty [2]; Unrelenting dread or anguish, overwhelming panic [3]. [ ]

3. Apparent sadness
- Representing despondency, gloom, and despair (more than just ordinary transient low spirits) reflected in speech, facial expression, and posture, rate by depth and inability to brighten up.

No sadness [0]; Looks dispirited but brightens up occasionally [1]; Appears sad and unhappy all of the time [2]; Extreme and continuous gloom and despondency [3]. [ ]

4. Suicidal thoughts
- Representing the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.
- Suicidal attempts should not in themselves influence the rating.

Enjoys life or takes it as it comes [0]; Weary of life, only fleeting suicidal thoughts [1]; Much better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without specific plans or intention [2]; Explicit plans for suicide when there is an opportunity, active preparation for suicide [3]. [ ]

5. Inertia
- Representing a difficulty getting started or slowness initiating and performing everyday activities
- Distinguish from indecision and fatiguability.

No difficulty in getting started. No sluggishness [0]; Difficulties in starting new activities [1]; Difficulties in starting very simple routine activities, which are carried out only with effort [2]; Complete inertia, unable to start any activity without help [3]. [ ]

6. Inability to feel
- Representing the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is produced.
- Distinguish from inertia

Normal interest in the surroundings and in other people [0]; Reduced ability to enjoy usual interests. Reduced ability to feel anger [1]; loss of interest in the surroundings. Loss of feelings for friends and acquaintances [2]; The experience of being emotionally paralyzed, inability to feel anger or grief, and a complete or even painful failure to feel for close relatives and friends [3]. [ ]

Investigator's signature _____

FARMITALIA CARLO ERBA Erbamont Group | Compound REBOXETINE 9550085 | Protocol No 2|0|1|2|4|0|1|7|

Centre No. | | | | Patient No. | | | Initials | | | Visit/cycle | | | | | Date | | | | | | D M Y

CONT. ENCLOSURE N°: 8

7. Pessimistic thoughts
- Representing thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.

No pessimistic thoughts [0]; fluctuating ideas of failure, self-reproach or self-depreciation [1]; Persistent self-accusations, or definite but still rational ideas of guilt or sin. Increasingly pessimistic about the future [2]; Delusions of ruin, remorse and unredeemable sin. Absurd self-accusations [3]. |_|

8. Concentration difficulties
- Representing difficulties in collecting one's thoughts mounting to incapacitating lack of concentration.
- Rate according to intensity, frequency, and degree of incapacity recorded.
- Distinguish from failing memory and disrupted thought.

No difficulties in concentrating [0]; Occasional difficulties in collecting one's thoughts [1]; Difficulties in concentrating and sustaining thoughts which interfere with reading or conversation [2]; Incapacitating lack of concentration [3] |_|

9. Reduced sleep
- Representing a subjective experience of reduced duration or depth of sleep compared to the subject's own fitful sleep.

Sleep as usual [0]; Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep [1]; sleep reduced or broken by at least 2 hours [2]; Less than two or three hours sleep [3]. |_|

10. Reduced appetite
- Representing the feeling of a loss of appetite compared with when well.

Normal or increased appetite [0]; Slightly reduced appetite [1]; No appetite. Food is tasteless. Need to force oneself to eat [2]; Must be forced to eat. Food refusal [3]. |_|

Total score |_|_|

Investigator's signature _____

9550685

ARMITALIA CARLO ERBA
ERBAMONT GROUP
NS LINE

Enclosure 9

PATIENT GLOBAL IMPRESSION

FROM STUDY START MY GENERAL CONDITIONS ARE:



using this visual-analogue scale, please
ite the number corresponding to your actual
tuation.

23 24

9550085

ARMITALIA CARLO ERBA
rbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1,7

Centre No. | | | |

Patient No. | | |

Initials | | |

Visit/cycle | | | | |

Date | | | | | |
D M Y

NEWLY ADVERSE EVENTS: CHECK-LIST

Enclosure 10

1. AUTONOMIC

- Dry mouth
- Nasal congestion
- Blurred vision
- Constipation
- Urinary hesitancy
- Urinary retention
- Increased salivation
- Sweating
- Vomiting
- Diarrhoea
- Sexual disturbances

2. BEHAVIORAL TOXICITY

- Confusional reaction
- Excitement/agitation
- Increased motor activity
- Decreased motor activity
- Insomnia
- Drowsiness
- Lassitude

3. CARDIOVASCULAR

- Hypotension
- Dizziness
- Circulatory collapse
- Tachycardia
- Hypertension

4. NEUROLOGICAL

- Rigidity
- Tremor
- Akathisia
- Dystonia
- Paresthesias
- Seizures
- Myoclonus

5. OTHER

- Skin-rash
- Urticaria
- Decreased appetite
- Headache

30 Investigator's signature _____

ADVERSE DRUG REACTION - A CRITICAL REVIEW

CAUSE-EFFECT RELATIONSHIP

F.E.KARCH, L.LASAGNA
(JAMA Dec. 22, 1975-Vol.234)

1. DEFINITE (or CERTAIN)
A reaction that follows a reasonable temporal sequence from administration of the drug or in which the drug level has been established in body fluids or tissues; that follows a known response pattern to the suspected drug; and that is confirmed by improvement on stopping the drug (dechallenge), and reappearance of the reaction on repeated exposure (rechallenge).

2. PROBABLE
A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; that is confirmed by dechallenge; and that could not be reasonably explained by the known characteristics of the patient's clinical state.

3. POSSIBLE
A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; but that could have been produced by the patient's clinical state or other modes of therapy administered to the patient.

4. DOUBTFUL
Any reaction that does not meet the criteria above.

5. UNKNOWN
Relationship for which no evaluation can be made.

6.NOT RELATED
A reaction for which sufficient information exists to indicate tha the aetiology is unrelated to the study drug.

Enclosure 1-2

DECLARATION OF HELSINKI

RECOMMENDATIONS GUIDING PHYSICIANS IN BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS

ADOPTED BY THE 18TH WORLD MEDICAL ASSEMBLY, HELSINKI, FINLAND, 1964,
AMENDED BY THE 29TH WORLD MEDICAL ASSEMBLY, TOKYO, JAPAN, 1975,
AND
THE 35TH WORLD MEDICAL ASSEMBLY, VENICE, ITALY, OCTOBER 1983.

INTRODUCTION

It is the mission of the medical doctor to safeguard the health of the people. His or her knowledge and conscience are dedicated to the fulfillment of this mission.

The Declaration of Geneva of the World Medical Association binds the doctor with the words, "The health of my patient will be my first consideration", and the International Code of Medical Ethics declares that, "A physician shall act only in the patient's interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient".

The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures and the understanding of the aetiology and pathogenesis of disease.

In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies especially to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medical research in which the aim is essentially diagnostic or therapeutic for a patient, and medical research, the essential object of which is purely scientific and without direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity, the World Medical Association has prepared the following recommendations as a guide to every physician in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the laws of their own countries.

I. BASIC PRINCIPLES

1. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.

2. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted to a specially appointed independent committee for consideration, comment and guidance.

3. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given his or her consent.

4. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.

5. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.

6. The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.

7. Physicians should abstain from engaging in research projects involving human subjects unless they are satisfied that the hazards involved are believed to be predictable. Physicians should cease any investigation if the hazards are found to outweigh the potential benefits.

8. In publication of the results of his or her research, the physician is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

9. In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The physician should then obtain the subject's freely-given informed consent, preferably in writing.

10. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.

11. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with national legislation.

12. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with.

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (CLINICAL RESEARCH)

1. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating suffering.

2. The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.

3. In any medical study, every patient - including those of a control group, if any - should be assured of the best proven diagnostic and therapeutic method.

4. The refusal of the patient to participate in a study must never interfere with the physician-patient relationship.

5. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (I.2).

6. The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the patient.

III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (NON-CLINICAL BIOMEDICAL RESEARCH)

1. In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out.

2. The subjects should be volunteers - either healthy persons or patients for whom the experimental design is not related to the patient's illness.

3. The investigator or the investigating team should discontinue the research if in his/Her judgement it may, if continued, be harmful to the individual.

4. In research on man, the interest of science and society should never take precedence over considerations related to the well-being of the subject.

9550085 Enclosure 13

ITALIA ASSICURAZIONI

Milano 11/01/90/GF

Spett.Le
FARMITALIA CARLO
ERBA S.R.L.
Via C. Imbonati 24

20159 MILANO

D I C H I A R A Z I O N E
D E C L A R A T I O N
To whom it may concern

La sottoscritta ITALIA Assicurazioni S.p.A. con sede in Genova -Via Fieschi 9 -
THE UNDERSIGNED ITALIA Assicurazioni S.p.A., with head office in Genoa,Via Fieschi 9,

dichiara a tutti gli effetti che la Spett.le FARMITALIA CARLO ERBA SRL
hereby declares to all intents and purposes that the firma FARMITALIA CARLO ERBA SRL

con sede in Milano - Via C. Imbonati 24 e' assicurata contro la
with head office in Milan - Via C. Imbonati 24, is insured against

responsabilita' civile verso terzi per danni derivanti dalla sua attivita' (ivi compresa "produzione"
third party liability for damage deriving from their activities (including "production"

e "smercio") e dalle sue proprieta' con polizza n.4W8102, scadente il 31.12.1990
and "sales") and its properties, under policy No.4W8102, expiring on 31.12.90

e tacitamente rinnovabile di anno in anno, per il massimale unico
di L. 10.000.000.000.=(diecimiliardi) per sinistro
automatically renewable for one year at a time, to cover up
to L.10.000.000.000 (ten thausand million Lire) as a single anyone claim,

nei termini tutti di cui alla polizza stessa.
in all terms concerning the policy itself.

La garanzia e'valida per il mondo intero e prevede, tra l'altro, anche l'estensione della copertura ai seguenti:
This coverage is applicable through out the world, and includes the following:

- danni causati da specialita' medicinali e prodotti medicinali che secondo la
- damage arising from medicinal specialities and products which, according to

comune prassi, prima della loro registrazione sanitaria e della loro
normal practice, before they are officially registered and

immissione in commercio, vengono consegnati a cliniche, ospedali,
put on the market, are giving to clinics, hospitals

case di cura ed esercenti professioni sanitarie per sperimentazioni e
nursing homes and professional healt workers for clinical trials and

Mod. 90/083 P - 7/88 - CRESTA-STAGNI

9550085

ITALIA ASSICURAZIONI

Enclosure 13 cont'd

prove cliniche, nonche'ai danni causati a seguito di somministrazione
tests and damage arising following administration for pharmacological tests

per ricerche di farmacologia ed esperimenti con farmaci e preparazioni gia' registrate in Italia
experiments of drugs or preparations already registered in Italy

e/o all'estero, ma con posologie diverse da quelle
and/or in other countries but using dosages different from these

indicate dalle case produttrici e con nuovi farmaci in fase di studio;
indicated by the manufacturer and of new drugs in the study stage;

comprese tutte le attivita' inerenti e connesse alle sperimentazioni stesse,
including all activities connected with and inherent to tests and trials

quali la tecnica di somministrazione dei farmaci ed il prelievo del
such as the methods of administering drugs and withdrawing

sangue dai soggetti per studio; il tutto con prodotti
blood samples from subjects under study; all with products

sia ad uso umano che non, propri e/o di terzi:
for human use or not, own and/or of the third party.

- connessi a responsabilita' civile che possa derivare personalmente
- damage relating to third party liability which may result personally

agli esperimentatori sia nel paese dell'Assicurata che all'estero
to the experimenters both in the country of Insured and/or in other countries

in ragione degli esperimenti effettuati su richiesta e/o per conto dell'Assicurata stessa.
because of the experiments effected at request and/or for account of the Insured.

La presente viene rilasciata a richiesta della Spett.le FARMITALIA CARLO ERBA SRL
This declaration is issued in response to a request by FARMITALIA CARLO ERBA SRL

Relativamente alla presente dichiarazione redatta sia in lingua italiana che in
Relatively to the present declaration drawn up both in italian language and

lingua inglese, viene convenuto che, in caso di divergenza tra i due testi,
English language, it is agreed that, in case of divergence between the two texts,

Mod. 90/182 P - 7/86 - CRESTA-GENOVA

Italia assicurazioni spa sede legale 16121 Genova via Fieschi 9 capitale sociale L. 30.000.000.000 trib. Genova 101 cciaa 30488
autorizzata all'esercizio delle assicurazioni (art. 65 r.d.l. 966/29-4-23) c.f. 00432690105

9550085

ITALIA ASSICURAZIONI

Enclosure L3 cont'd

prevarra', ai fini interpretativi, il testo in lingua italiana.
the one in Italian language will prevail for the purpose of interpretation.

In fede

ITALIA Assicurazioni S.p.A.
UPD Grandi [illegible]

9550085

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS LINE

Enclosure 14

DRUG ACCOUNTABILITY

Compound: REBOXETINE

Protocol N°: 20124/017

Title: Multicenter, multinational double-blind study of the activity and tolerability of Reboxetine vs Imipramine in patients suffering from Major Depressive Episodes

Centre N°/City__________

Investigator:__________

Treatment received: |__|__|__| (d m y) for patient N°____ to patient N°___ Receipt N°__________

Bottles per patient received: 14 + 6 (dose 2)

Pat N°	Pat. Init.	Date Start	Weekly treatment given (Please check:_✓_)	N° of remaining bottles per pat.	N° of remaining caps. per pat.
			1___ 2___ 3___ 4___ 5___ 6___ Dose 2: 4___ 5___ 6___	⊔ + ⊔ (dose 2)	⊔⊔ + ⊔⊔ (dose 2)
			1___ 2___ 3___ 4___ 5___ 6___ Dose 2: 4___ 5___ 6___	⊔ + ⊔ (dose 2)	⊔⊔ + ⊔⊔ (dose 2)
			1___ 2___ 3___ 4___ 5___ 6___ Dose 2: 4___ 5___ 6___	⊔ + ⊔ (dose 2)	⊔⊔ + ⊔⊔ (dose 2)
			1___ 2___ 3___ 4___ 5___ 6___ Dose 2: 4___ 5___ 6___	⊔ + ⊔ (dose 2)	⊔⊔ + ⊔⊔ (dose 2)
			1___ 2___ 3___ 4___ 5___ 6___ Dose 2: 4___ 5___ 6___	⊔ + ⊔ (dose 2)	⊔⊔ + ⊔⊔ (dose 2)
			1___ 2___ 3___ 4___ 5___ 6___ Dose 2: 4___ 5___ 6___	⊔ + ⊔ (dose 2)	⊔⊔ + ⊔⊔ (dose 2)

N° of total caps. to be returned: ________

N° of total bottles to be returned: _______

Date:__________

Investigator's signature __________

- The present form, duly filled out, should be kept as record by the investigator, together with his/her copy of CRFs.
- A photocopy of the present form should be given to the monitor of Farmitalia Carlo Erba, together with the unused drug at the end of the study.

Attachment A

REBOXETINE PROTOCOL 20124/017: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COORDINATION.

Aim

The purpose of these procedures is to provide standardization of the study conduct in the different clinical centers and to assure data uniformity and compatibility by appropriate interventions during data gathering.

Inter-rater reliability

During the clinical trial:

- inter-rater agreement for the instruments used in the assessment of change (HAMD, RDRS) will be tested on the occasion of the first Investigator Meeting (2 videotaped interviews) and of the monitoring visits (2 videotaped interviews).

Study monitoring

During the course of the study (14-months) monthly monitoring visits will be conducted by Study Monitors from Farmitalia Carlo Erba.

The start-up visit will take place after approval of the protocol by the Institutional Review Board (IRB) or Ethical Committee. On this visit the following documents will be collected:

- copy of the protocol signed by the Principal Investigator;
- CV of Principal Investigator and Co-Investigators;
- the written approval of the study (typed on the Institute's letter head) by the Hospital or University Center Review Board and the IRB members list;
- an IRB approved blank copy of the consent form;
- the list of the laboratory normal values or ranges of the lab. tests.
- an IRB approved blank copy of the consent form;
- the list of the laboratory normal values or ranges of the lab tests.

These documents will be sent to FICE-Milan. On the occasion of this visit the monitor will also check that the CRFs and the drug supply have been delivered to the Clinical Investigator and the accompanying letter, signed by the Clinical Investigator, will be collected. In addition the Monitor will identify the staff members who will be involved in the study conduct and the monitoring visits schedule will be agreed.

Following the start-up visit the form A (enclosed) will be filled in. Copy of it will be sent to FICE in Milan.

The first monitoring visit will be done immediately after the recruitment of the first two, three patients.

The periodic monitoring visits are carried out in order to:

1 verify protocol adherence: patient eligibility (page 1 of the CRF), times of assessments, completeness of data, pill count;

2 verify data consistency looking for inconsistencies or errors in the data recorded on the CRF;

3 verify the accuracy of data collection in CRFs against the original clinic or hospital records for:

- pt initials and hospital record no
- signed informed consent
- study medication administration and concomitant medications
- physician notes on adverse events
- 20% of data for laboratory tests, patient history and vital signs; in case of an error rate > 15% all data need to be monitored;
- total Hamilton score reported in the hospital record.

Source-verified data can be initialled by the study monitor in the CRF.

4 review all adverse events including laboratory abnormalities, occurred since the previous visit. Should the information of a serious, or unexpected adverse event newly emerge, the local study Monitor must immediately (within two working days) inform the Product Leader in Milan;

5 evaluate patient recruitment rate and treatment discontinuations;

6 verify study medication storage and accountability and collect bottles of completed treatments;

7 ensure continued acceptability of the facilities and of the staff.

CRFs will be completed in black ink and corrections, if needed, made only by the Clinical Investigator with a single line throughout; the corrections will be initialled by Clinical Investigator and dated. Each page of each completed CRF will be signed by Clinical Investigator.

After review for accuracy and completeness, the original and first copy of each page of the CRF will be removed (leaving the second copy with the Investigator). The first copy will be sent to Milan by Special Delivery Service for review and data processing while the original will be retained by the Monitor in the subsidiary until completion of the whole treatment period of the individual patient.

After each monitoring visit the periodic site visit report and the patients progress report form (form B and C enclosed) will be filled in. Copy of them will be sent to FICE Milan.

<u>The study termination</u> visit will be performed upon Investigator's completion of all CRFs of treated patients. During this visit:

1 the monitor will check and collect the remaining completed CRFs and will perform a final data review;

2 a final check and review of drug accounting, inventorying of remaining drug supplies and arrangement to send them to FICE will be done;

3 a time frame for study reporting will be discussed;

4 appropriate follow-up of patients under long-term treatment will be assured and monitoring and collection of data from these patients discussed and agreed

The study termination visit from (form D) will be filled in and copy of it sent to FICE Milan.

Prot. N° 20124/017 **Cont. Attachment A**

Study coordination

In order to obtain uniformity and standardization in the carrying out of the study a Steering Committee is established. All questions arising during the conduct of the study will be submitted to the Committee for advice and action taking.

In particular the Committee will take care of:

- **queries about patients acceptability**
- **possible need of protocol amendments**
- **possible need of premature termination of the study**
- **acceptability of particular cases of protocol violations**
- **evaluation of clinically relevant adverse events and their scientific and ethical consequences in terms of issues raised or study discontinuation.**

Members of the Committee will be: Prof. M. Van Moffaert and Dr. Berzewski.

Any problem or issue arising during the conduct of the study will be submitted to the Committee in writing by the Clinical Investigators or by the study Monitors. "Ad hoc" meetings of the Committee will be organized when needed. File note of the meeting with conclusions about action taking will be circulated to Clinical Investigators and study Monitors.

12.1.2 CRF sample

A complete CRF sample is filed in the Study Master File

12.1.3 ETHICS COMMITTEES OR INVESTIGATIONAL REVIEW BOARDS: APPROVALS, LIST OF MEMBERS, PATIENT INFORMATION AND CONSENT FORMS

Investigational Review Boards and Ethics Committees approvals were obtained according to local regulations and laws: copy of the approval documents and, in case of Ethics Committees, list of members is filed in the Study Master File.

The proposed consent form is enclosed (Enclosure 3 of Appendix 12.1.1). Copy of forms approved by Ethics Committees and local translations are filed in the Study Master File.

12.1.4 CLINICAL INVESTIGATOR LIST, SIGNATURES AND CURRICULA VITAE

PRINCIPAL INVESTIGATORS AND AFFILIATIONS

Centre 1: Dr H Berzewski
Universitätsklinikum Steglitz, Freie Universität Berlin, Berlin, Germany

Centre 2: Dr M Wolfersdorf
Abt. Psychiatrie I - Univ Ulm, Ravensburg-Weissenau, Germany

Centre 3: Dr J Fischer
Bürgerhospital, Psychiatrische Klinik, Stuttgart, Germany

Centre 4: Dr R Uebelhack
Poliklinik der Charité Nervenklinik, Berlin, Germany

Centre 6: Dr W Konig
Psychiatrisches Landeskrankenhaus Weissenhof, Weinsberg, Germany

Centre 7: Dr M Derely
Clinique La Raméc, Neuropsychiatric Hospital, Brussels, Belgium

Centre 8: Dr J Wilmotte
Hôpital Civil Vincent Van Gogh, Marchienne-au-Pont, Belgium

Centre 9: Dr M Van Moffaert
Universitair Ziekenhuis Gent, Psychiatrische Kliniek, Gent, Belgium

Centre 9/a: Dr R Spiers
St Camillus Ziekenhuis, St Denijs-Westrem, Belgium

Centre 10: Dr J Bollen
Sancta Maria Psychiatr Ziekenhuis, Sint Truiden, Belgium

Centre 11: Prof CA Gagiano
Department of Psychiatry, University of Orange Free State, Bloemfontein, South Africa

Centre 12:	Dr M Berk Johannesburg Medical School, Psychiatry Department, Parktown, South Africa
Centre 13:	Dr DAB Wilson Department of Psychiatry, Groote Schuur Hospital, Cape Town, South Africa
Centre 14:	Dr P Weinholz Brauhofgasse 1, Erlangen-Frauenaurach, Germany
Centre 14/1:	Dr H Hauer An der Aurach 8, Emskirchen, Germany
Centre 14/2:	Dr M El Mallah Seltsamplatz 3, Forchheim, Germany
Centre 14/3:	Dr M O'Connolly Haimendorfstrasse 4, Schwabach-Wolkersdorf, Germany
Centre 14/4:	Dr P Adler Schnieglingerstrasse 36a, Nürnberg, Germany
Centre 14/7:	Dr K Schroter Altdorfer Strasse 11, Lauf/Pegnitz, Germany
Centre 14/8:	Dr G Stumpf Volkacher Strasse 31, Nürnberg, Germany
Centre 14/10:	Dr H Wiswedel Friedenstrasse 12, Fürth/Bay, Germany
Centre 15:	Prof A Levin Fort England Hospital, Grahamstown, South Africa

Investigators' Signatures and Curricula Vitae are filed in the Study Master File.

12.1.5 CERTIFICATES OF ANALYSIS

9550085

CENTRO RICERCHE
VIA GIOVANNI XXIII, 23
20014 NERVIANO

TELEFONO (0331) 587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASELLA POSTALE 5
TELEX 310679 MONTED PER FARMITALIA NERVIANO

FARMITALIA CARLO ERBA

DATA December 9th, 1992

CERTIFICATE OF ANALYSIS

REBOXETINE 4 mg capsules

Batch SF 1131

Manufacturing date	: September, 1990
Expiry date	: June, 1993
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1105)
Identification	: positive
Average weight	: mg 202.01
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 3.998 of Reboxetine/capsule
Related substances	: 1.04%
Disintegration	: 6 minutes
Microbial contamination	: total viabl aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Reanalysis date	: December 9th, 1992

Note : this certificate replaces the previous one, edited on March 11th, 1992, owing to the extension of the shelf-life

Approved by : V. Busnelli

S.P.L. SEDE LEGALE IN MILANO
CAPITALE SOC. L. 528.732.127.000 I.V.
TRIBUNALE MILANO REG. N. 238346
VOL. 6366 - FASC. 46 - C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N. 07608890156

GRUPPO ERBAMONT

9550085

Pharmacia
Farmitalia Carlo Erba

Data January 24th, 1994
Vs. Rif.
Ns. Rif.
Tel. Diretto

CERTIFICATE OF ANALYSIS No. PC/267

REBOXETINE 4 mg capsules

Batch SF 1264

Manufacturing date	: October, 1991
Expiry date	: September, 1994
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1249)
Identification	: positive
Average weight	: mg 201.10
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 3.95 of Reboxetine/capsule
Dissolution	: 93.9% of the L.A. after 15 minutes
Disintegration	: 6 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent

Note : this certificate replaces the previous one edited on May 14th, 1992, vis-a-vis the extension of shelf-life

Approved by : V. Busnelli

515

Centro Ricerche
Farmitalia Carlo Erba srl
Via Giovanni XXIII, 23
20014 Nerviano (MI) Italy

Telef. (0331) 58.3111 (Centralino)
Casella Postale 2

Sede Legale Milano
Capit. L. 528.732.127.000 I.V.
Trib. Milano R.S. N. 238246
Vol. 6366 - Fasc. 46

C.C.I.A.A. N. 1171077
Cod. Fisc. e Part. IVA
N. 07608290156

9550085

CENTRO RICERCHE
VIA GIOVANNI XXIII, 23
20014 NERVIANO

TELEFONO (0331) 587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASELLA POSTALE 2
TELEX 310679 MONTED PER FARMITALIA NERVIANO

FARMITALIA CARLO ERBA

DATA December 9th, 1992

CERTIFICATE OF ANALYSIS

REBOXETINE 6 mg capsules

Batch SF 1132

Manufacturing date	: September, 1990
Expiry date	: June, 1993
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing three 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1105)
Identification	: positive
Average weight	: mg 302.97
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 5.993 of Reboxetine/capsule
Related substances	: 0.74%
Disintegration	: 6 minutes
Microbial contamination	: total viabl aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Reanalysis date	: December 9th, 1992

Note : this certificate replaces the previous one, edited on March 11th, 1992, owing to the extension of the shelf-life

Approved by : V. Busnelli

516

GRUPPO ERBAMONT

9550085

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6095.1 (CENTRALINO)
TELEGRAMMI ERBACAR MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA I-

FARMITALIA CARLO ERBA

DATA May 7th, 1992

VS. RIF.

NS. RIF.

TEL DIRETTO

CERTIFICATE OF ANALYSIS

REBOXETINE 6 mg capsules

Batch SF 1291

Manufacturing date	: March, 1992
Expiry date	: September, 1994
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing three 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1249)
Identification	: positive
Average weight	: mg 303.66
Uniformity of content	: within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay	: mg 6.08 of Reboxetine/capsule
Related substances	: 0.19%
Disintegration	: 6 minutes
Microbial contamination	: total viable aerobic counts < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by	: V. Busnelli

GRUPPO ERBAMONT

517

9550085

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA I-

FARMITALIA CARLO ERBA

DATA October 19, 1990

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 50 mg capsules

Batch SF 1130

Manufacturing date	: September 1990
Expiry date	: October 1994
Description	: hard-gelatin capsule, opaque red-brown, size No. 0, containing two 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No.153)
Average weight	: mg 149.443
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 13 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonella : absent
Approved by	: Virginio Busnelli

9550085

FARMITALIA CARLO ERBA

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6985.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA I-

DATA March 24th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 50 mg capsules

Batch SF 1265

Manufacturing date	: December 1990
Expiry date	: December 1995
Description	: hard-gelatin capsule, opaque red-brown, size No.0, containing two 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 178)
Average weight	: mg 151.49
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Identification	: positive, according to B.P. 1988 monograph texts A, B and C, page 956
Assay	: 48.41 mg/capsule (B.P. 1988 monograph, page 956)
Related substances	: within the limits, according to B.P.1988 monograph, page 956
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Approved by	: V. Busnelli

S.R.L. SEDE LEGALE IN MILANO
CAPITALE L. 528.732.127.000 I.V.
TRIBUNALE DI MILANO R.S. N. 238246
VOL. 6366 - FASC. 46 - C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N. 07608290156

519

GRUPPO ERBAMONT

9550085

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

FARMITALIA CARLO ERBA

DATA October 22, 1990

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 100 mg capsules

Batch SF 1129

Manufacturing date	: September 1990
Expiry date	: October 1994
Description	: hard-gelatin capsule, opaque red-brown, size No. 0, containing four 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No.156)
Average weight	: mg 301.251
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonella : absent
Approved by	: Virginio Busnelli

9550085

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 319205
TELEX 333314 ERBA-I-

FARMITALIA CARLO ERBA

DATA October 25, 1990

VS. RIF.

NS. RIF.

TEL. DIRETTO

ANALISYS CERTIFICATE

Imipramine hydrochloride 100 mg capsules

Batch SF 1151

Manufacturing date	: October 1990
Expiry date	: October 1994
Description	: hard-gelatin capsule, opaque red-brown, size No.0, containing four 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 153)
Average weight	: mg 300.63
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. coli and Salmonella : absent
APPROVED BY	: Virginio Busnelli

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 6995.1 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I-

9550085

FARMITALIA CARLO ERBA

DATA March 24th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 100 mg capsules

Batch SF 1263

Manufacturing date	: December 1990
Expiry date	: December 1995
Description	: hard-gelatin capsule, opaque red-brown, size No.0, containing four 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 178)
Average weight	: mg 299.87
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Identification	: positive, according to B.P. 1988 monograph texts A, B and C, page 956
Assay	: 95.43 mg/capsule (B.P. 1988 monograph, page 956)
Related substances	: within the limits, according to B.P.1988 monograph, page 956
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent

Approved by : V. Busnelli

S.R.L. - SEDE LEGALE IN MILANO
CAPITALE L. 528.732.127.000 I.V.
TRIBUNALE DI MILANO R.S. N. 238246
VOL. 6366 - FASC. 46 - C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N 07608290156

522 GRUPPO ERBAMONT

12.1.6 AUDIT CERTIFICATE

9550085

Pharmacia
Pharmaceuticals Milan R&D/GCP-QA

R&D/Q.A. AUDIT CERTIFICATE

Product **REBOXETINE**

Protocol N°: **FCE 20124/017** **N° GCP: 56**

Study title: **Multicenter, multinational double-blind study of the activity and tolerability of Reboxetine vs Imipramine in patients suffering from Major Depressive Disorders.**

Type of Audit	Site	Audit date(s)	Reporting date
Draft Protocol	FICE - Milan	08.1990	28.08.1990
Final Protocol	FICE - Milan	05-09.10.1990	09.10.1990
Study Master File	Pharmacia - Milan	03-29.04.1995	02.06.1995
Data Listings vs CRFs	Pharmacia - Milan	09-17.11.1995	23.11.1995
Draft Final Report	Pharmacia - Milan	28.11-01.12.1995	04.12.1995
Final Report	Pharmacia - Milan	17.01.1996	18.01.1996

Signature of the Head of R&D/GCP-Q.A. [signature]

Date: 18 Jan, 1996

12.1.7 RANDOMIZATION LIST

Randomization List 9550085

Center=1

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
1	1	1	reboxetine
2	1	2	reboxetine
3	1	3	imipramine
4	1	4	imipramine
5	1	5	reboxetine
6	1	6	imipramine
7	1	7	reboxetine
8	1	8	imipramine
9	1	9	imipramine
10	1	10	imipramine
11	1	11	reboxetine
12	1	12	reboxetine
13	1	13	reboxetine
14	1	14	reboxetine
15	1	15	imipramine
16	1	16	imipramine
17	1	17	imipramine
18	1	18	reboxetine
19	1	19	imipramine
20	1	20	reboxetine
21	1	21	reboxetine
22	1	22	imipramine
23	1	23	reboxetine
24	1	24	imipramine
25	1	25	imipramine
26	1	26	reboxetine
27	1	27	reboxetine
28	1	28	imipramine
29	1	29	reboxetine
30	1	30	imipramine
31	1	31	reboxetine
32	1	32	imipramine

Center=2

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
33	2	1	reboxetine
34	2	2	imipramine
35	2	3	reboxetine
36	2	4	imipramine
37	2	5	reboxetine
38	2	6	imipramine
39	2	7	reboxetine
40	2	8	imipramine
41	2	9	reboxetine
42	2	10	imipramine
43	2	11	reboxetine
44	2	12	imipramine
45	2	13	imipramine
46	2	14	reboxetine
47	2	15	reboxetine
48	2	16	imipramine
49	2	17	imipramine
50	2	18	reboxetine
51	2	19	reboxetine
52	2	20	imipramine
53	2	21	reboxetine
54	2	22	imipramine
55	2	23	reboxetine
56	2	24	imipramine
57	2	25	reboxetine
58	2	26	imipramine
59	2	27	imipramine
60	2	28	reboxetine
61	2	29	reboxetine
62	2	30	reboxetine
63	2	31	imipramine
64	2	32	imipramine

Randomization 9550085

Center=3

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
65	3	1	reboxetine
66	3	2	imipramine
67	3	3	reboxetine
68	3	4	imipramine
69	3	5	imipramine
70	3	6	reboxetine
71	3	7	imipramine
72	3	8	reboxetine
73	3	9	reboxetine
74	3	10	imipramine
75	3	11	imipramine
76	3	12	reboxetine
77	3	13	imipramine
78	3	14	reboxetine
79	3	15	reboxetine
80	3	16	imipramine
81	3	17	reboxetine
82	3	18	imipramine
83	3	19	imipramine
84	3	20	reboxetine
85	3	21	imipramine
86	3	22	imipramine
87	3	23	reboxetine
88	3	24	reboxetine
89	3	25	imipramine
90	3	26	reboxetine
91	3	27	reboxetine
92	3	28	imipramine
93	3	29	imipramine
94	3	30	reboxetine
95	3	31	reboxetine
96	3	32	imipramine

Center=4

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
97	4	1	imipramine
98	4	2	imipramine
99	4	3	reboxetine
100	4	4	reboxetine
101	4	5	imipramine
102	4	6	reboxetine
103	4	7	imipramine
104	4	8	reboxetine
105	4	9	imipramine
106	4	10	reboxetine
107	4	11	imipramine
108	4	12	reboxetine
109	4	13	imipramine
110	4	14	reboxetine
111	4	15	reboxetine
112	4	16	imipramine
113	4	17	imipramine
114	4	18	imipramine
115	4	19	reboxetine
116	4	20	reboxetine
117	4	21	imipramine
118	4	22	reboxetine
119	4	23	reboxetine
120	4	24	imipramine
121	4	25	imipramine
122	4	26	reboxetine
123	4	27	imipramine
124	4	28	reboxetine
125	4	29	reboxetine
126	4	30	imipramine
127	4	31	imipramine
128	4	32	reboxetine

Randomization 9550085

Center=5

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
129	5	1	reboxetine
130	5	2	reboxetine
131	5	3	imipramine
132	5	4	imipramine
133	5	5	imipramine
134	5	6	reboxetine
135	5	7	reboxetine
136	5	8	imipramine
137	5	9	reboxetine
138	5	10	imipramine
139	5	11	reboxetine
140	5	12	imipramine
141	5	13	reboxetine
142	5	14	imipramine
143	5	15	reboxetine
144	5	16	imipramine
145	5	17	imipramine
146	5	18	reboxetine
147	5	19	reboxetine
148	5	20	imipramine
149	5	21	imipramine
150	5	22	imipramine
151	5	23	reboxetine
152	5	24	reboxetine
153	5	25	reboxetine
154	5	26	imipramine
155	5	27	imipramine
156	5	28	reboxetine
157	5	29	imipramine
158	5	30	reboxetine
159	5	31	reboxetine
160	5	32	imipramine

Center=6

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
161	6	1	reboxetine
162	6	2	reboxetine
163	6	3	imipramine
164	6	4	imipramine
165	6	5	reboxetine
166	6	6	reboxetine
167	6	7	imipramine
168	6	8	imipramine
169	6	9	imipramine
170	6	10	reboxetine
171	6	11	reboxetine
172	6	12	imipramine
173	6	13	imipramine
174	6	14	reboxetine
175	6	15	imipramine
176	6	16	reboxetine
177	6	17	imipramine
178	6	18	reboxetine
179	6	19	reboxetine
180	6	20	imipramine
181	6	21	reboxetine
182	6	22	imipramine
183	6	23	reboxetine
184	6	24	imipramine
185	6	25	reboxetine
186	6	26	imipramine
187	6	27	imipramine
188	6	28	reboxetine
189	6	29	reboxetine
190	6	30	reboxetine
191	6	31	imipramine
192	6	32	imipramine

Center=7

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
193	7	1	reboxetine
194	7	2	reboxetine
195	7	3	imipramine
196	7	4	imipramine
197	7	5	reboxetine
198	7	6	imipramine
199	7	7	imipramine
200	7	8	reboxetine
201	7	9	imipramine
202	7	10	imipramine
203	7	11	reboxetine
204	7	12	reboxetine
205	7	13	imipramine
206	7	14	imipramine
207	7	15	reboxetine
208	7	16	reboxetine
209	7	17	imipramine
210	7	18	reboxetine
211	7	19	reboxetine
212	7	20	imipramine
213	7	21	imipramine
214	7	22	reboxetine
215	7	23	reboxetine
216	7	24	imipramine
217	7	25	imipramine
218	7	26	reboxetine
219	7	27	imipramine
220	7	28	reboxetine
221	7	29	imipramine
222	7	30	imipramine
223	7	31	reboxetine
224	7	32	reboxetine

Center=8

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
225	8	1	imipramine
226	8	2	reboxetine
227	8	3	imipramine
228	8	4	reboxetine
229	8	5	imipramine
230	8	6	imipramine
231	8	7	reboxetine
232	8	8	reboxetine
233	8	9	imipramine
234	8	10	reboxetine
235	8	11	reboxetine
236	8	12	imipramine
237	8	13	reboxetine
238	8	14	imipramine
239	8	15	imipramine
240	8	16	reboxetine
241	8	17	imipramine
242	8	18	reboxetine
243	8	19	imipramine
244	8	20	reboxetine
245	8	21	imipramine
246	8	22	reboxetine
247	8	23	reboxetine
248	8	24	imipramine
249	8	25	reboxetine
250	8	26	imipramine
251	8	27	imipramine
252	8	28	reboxetine
253	8	29	imipramine
254	8	30	imipramine
255	8	31	reboxetine
256	8	32	reboxetine

Randoniza 9550985

Center=9

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
257	9	1	reboxetine
258	9	2	reboxetine
259	9	3	imipramine
260	9	4	imipramine
261	9	5	imipramine
262	9	6	reboxetine
263	9	7	reboxetine
264	9	8	imipramine
265	9	9	reboxetine
266	9	10	reboxetine
267	9	11	imipramine
268	9	12	imipramine
269	9	13	reboxetine
270	9	14	imipramine
271	9	15	reboxetine
272	9	16	imipramine
273	9	17	imipramine
274	9	18	reboxetine
275	9	19	reboxetine
276	9	20	imipramine
277	9	21	reboxetine
278	9	22	imipramine
279	9	23	imipramine
280	9	24	reboxetine
281	9	25	reboxetine
282	9	26	reboxetine
283	9	27	imipramine
284	9	28	imipramine
285	9	29	reboxetine
286	9	30	reboxetine
287	9	31	imipramine
288	9	32	imipramine

Center=10

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
289	10	1	imipramine
290	10	2	reboxetine
291	10	3	imipramine
292	10	4	reboxetine
293	10	5	reboxetine
294	10	6	imipramine
295	10	7	imipramine
296	10	8	reboxetine
297	10	9	reboxetine
298	10	10	reboxetine
299	10	11	imipramine
300	10	12	imipramine
301	10	13	imipramine
302	10	14	imipramine
303	10	15	reboxetine
304	10	16	reboxetine
305	10	17	reboxetine
306	10	18	reboxetine
307	10	19	imipramine
308	10	20	imipramine
309	10	21	reboxetine
310	10	22	imipramine
311	10	23	imipramine
312	10	24	reboxetine
313	10	25	imipramine
314	10	26	reboxetine
315	10	27	imipramine
316	10	28	reboxetine
317	10	29	reboxetine
318	10	30	reboxetine
319	10	31	imipramine
320	10	32	imipramine

Center=11

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
321	11	1	reboxetine
322	11	2	reboxetine
323	11	3	imipramine
324	11	4	imipramine
325	11	5	reboxetine
326	11	6	imipramine
327	11	7	reboxetine
328	11	8	imipramine
329	11	9	imipramine
330	11	10	reboxetine
331	11	11	reboxetine
332	11	12	imipramine
333	11	13	imipramine
334	11	14	imipramine
335	11	15	reboxetine
336	11	16	reboxetine
337	11	17	imipramine
338	11	18	reboxetine
339	11	19	imipramine
340	11	20	reboxetine
341	11	21	reboxetine
342	11	22	imipramine
343	11	23	reboxetine
344	11	24	imipramine
345	11	25	imipramine
346	11	26	reboxetine
347	11	27	imipramine
348	11	28	reboxetine
349	11	29	imipramine
350	11	30	reboxetine
351	11	31	reboxetine
352	11	32	imipramine

Center=12

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
353	12	1	reboxetine
354	12	2	imipramine
355	12	3	reboxetine
356	12	4	imipramine
357	12	5	imipramine
358	12	6	reboxetine
359	12	7	reboxetine
360	12	8	imipramine
361	12	9	reboxetine
362	12	10	imipramine
363	12	11	reboxetine
364	12	12	imipramine
365	12	13	imipramine
366	12	14	reboxetine
367	12	15	imipramine
368	12	16	reboxetine
369	12	17	reboxetine
370	12	18	imipramine
371	12	19	reboxetine
372	12	20	imipramine
373	12	21	imipramine
374	12	22	reboxetine
375	12	23	reboxetine
376	12	24	imipramine
377	12	25	reboxetine
378	12	26	reboxetine
379	12	27	imipramine
380	12	28	imipramine
381	12	29	reboxetine
382	12	30	imipramine
383	12	31	imipramine
384	12	32	reboxetine

Center=13

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
385	13	1	reboxetine
386	13	2	reboxetine
387	13	3	imipramine
388	13	4	imipramine
389	13	5	imipramine
390	13	6	imipramine
391	13	7	reboxetine
392	13	8	reboxetine
393	13	9	imipramine
394	13	10	reboxetine
395	13	11	reboxetine
396	13	12	imipramine
397	13	13	reboxetine
398	13	14	imipramine
399	13	15	reboxetine
400	13	16	imipramine
401	13	17	imipramine
402	13	18	reboxetine
403	13	19	reboxetine
404	13	20	imipramine
405	13	21	reboxetine
406	13	22	imipramine
407	13	23	reboxetine
408	13	24	imipramine
409	13	25	imipramine
410	13	26	reboxetine
411	13	27	imipramine
412	13	28	reboxetine
413	13	29	reboxetine
414	13	30	imipramine
415	13	31	reboxetine
416	13	32	imipramine

Center=14

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
417	14	1	reboxetine
418	14	2	imipramine
419	14	3	reboxetine
420	14	4	imipramine
421	14	5	reboxetine
422	14	6	imipramine
423	14	7	imipramine
424	14	8	reboxetine
425	14	9	reboxetine
426	14	10	reboxetine
427	14	11	imipramine
428	14	12	imipramine
429	14	13	imipramine
430	14	14	reboxetine
431	14	15	reboxetine
432	14	16	imipramine
433	14	17	imipramine
434	14	18	reboxetine
435	14	19	imipramine
436	14	20	reboxetine
437	14	21	reboxetine
438	14	22	imipramine
439	14	23	reboxetine
440	14	24	imipramine
441	14	25	imipramine
442	14	26	imipramine
443	14	27	reboxetine
444	14	28	reboxetine
445	14	29	imipramine
446	14	30	reboxetine
447	14	31	reboxetine
448	14	32	imipramine

REBOXETINE - PROT. 017
Randomiza 0550085

------------------------------ Center=14 bis ------------------------------

Nr Patient in the Study	Center	Nr Patient in the Center	Treatment
449	14 bis	449	reboxetine
450	14 bis	450	imipramine
451	14 bis	451	imipramine
452	14 bis	452	reboxetine
453	14 bis	453	imipramine
454	14 bis	454	reboxetine
455	14 bis	455	reboxetine
456	14 bis	456	imipramine
457	14 bis	457	reboxetine
458	14 bis	458	imipramine
459	14 bis	459	reboxetine
460	14 bis	460	imipramine
461	14 bis	461	imipramine
462	14 bis	462	reboxetine
463	14 bis	463	imipramine
464	14 bis	464	reboxetine
465	14 bis	465	reboxetine
466	14 bis	466	imipramine
467	14 bis	467	reboxetine
468	14 bis	468	imipramine
469	14 bis	469	imipramine
470	14 bis	470	reboxetine
471	14 bis	471	reboxetine
472	14 bis	472	imipramine
473	14 bis	473	reboxetine
474	14 bis	474	reboxetine
475	14 bis	475	imipramine
476	14 bis	476	imipramine
477	14 bis	477	imipramine
478	14 bis	478	imipramine
479	14 bis	479	reboxetine
480	14 bis	480	reboxetine

12.1.8 LABORATORY REFERENCE VALUES AND CRITERIA USED TO JUDGE LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.8
LABORATORY REFERENCE VALUES

		Range values			
		Female		Male	
		Min	Max	Min	Max
Laboratory test	Units				
HB	g/dl	12.00	16.00	13.50	17.50
HT	%	36.00	46.00	41.00	53.00
RBC	10-6/mm-3	4.00	5.20	4.50	5.90
PLATELETS	10-3/mm-3	150.00	400.00	150.00	400.00
ESR/SEDIMENT. RATE 1st h	mm	0.00	10.00	0.00	10.00
ESR/SEDIMENT. RATE 2nd h	mm	0.00	20.00	0.00	20.00
WBC	10-3/mm-3	4.50	11.00	4.50	11.00
WBC: N	%	57.00	67.00	57.00	67.00
WBC: E	%	1.00	3.00	1.00	3.00
WBC: B	%	0.00	0.75	0.00	0.75
WBC: L	%	23.00	33.00	23.00	33.00
WBC: M	%	3.00	7.00	3.00	7.00
CREATININE	mg/dl	0.50	1.10	0.60	1.20
CREATININE CLEARANCE	ml/min	88.00	128.00	97.00	137.00
UREA	mg/dl	15.00	35.00	15.00	35.00
BUN	mg/dl	7.00	18.00	7.00	18.00
URIC ACID	mg/dl	2.60	6.00	3.50	7.20
TOT. PROTEINS	g/dl	6.40	8.30	6.40	8.30
ALBUMINE	g/dl	3.50	5.00	3.50	5.00
TOT BILIRUBIN	mg/dl	0.20	1.00	0.20	1.00
DIR BILIRUBIN	mg/dl	0.00	0.20	0.00	0.20
SGOT	U/l	10.00	30.00	10.00	30.00
SGPT	U/l	5.00	30.00	5.00	30.00
GAMMA GT	U/l	8.00	40.00	9.00	50.00
LDH	U/l	210.00	420.00	210.00	420.00
ALK. PHOSPH.	U/l	56.00	155.00	62.00	176.00
GLOBULINS ALPHA 1	g/dl	0.10	0.30	0.10	0.30
GLOBULINS ALPHA 2	g/dl	0.60	1.00	0.60	1.00
GLOBULINS BETA	g/dl	0.70	1.10	0.70	1.10
GLOBULINS GAMMA	g/dl	0.80	1.60	0.80	1.60
SEDIMENT.	mm/h	0.00	20.00	0.00	15.00
TOT. CHOLEST.	mg/dl	152.00	268.00	158.00	276.00
HDL	mg/dl	35.00	65.00	29.00	60.00
TRIGLYCERIDES	mg/dl	38.00	160.00	49.00	284.00
GLUCOSE	mg/dl	70.00	105.00	70.00	105.00
NA+	mEq/l	136.00	146.00	136.00	146.00
CL-	mEq/l	98.00	106.00	98.00	106.00
K+	mEq/l	3.50	5.10	3.50	5.10
Ca++	mEq/l	4.50	5.50	4.50	5.50
PO4--	mEq/l	1.00	1.50	1.00	1.50
T4	ug/dl	5.00	12.00	5.00	12.00
TSH	mU/l	2.00	10.00	2.00	10.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
APPENDIX No.: 12.1.5

CRITERIA USED TO JUDGE LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT

Laboratory test	Percent variation above or below normal range (*)
HB	- 15
HT	- - 15
RBC	- - 15
PLATELETS	-+ 30
WBC	-+ 30
WBC: N	+ - 30
WBC: E	+ + 30
WBC: B	-+ 30
WBC: L	+ + + 30
WBC: M	+ + + 50
CREATININE	+ + + + 50
UREA	+ + + + 50
BUN	-+ 30
URIC ACID	+ + + 100
TOT. PROTEINS	+ + + 100
ALBUMINE	+ + + 100
TOT BILIRUBIN	+ + + 100
DIR BILIRUBIN	+ + + 100
SGOT	+ + + 100
SGPT	+ + + 100
GAMMA GT	+ + + 100
LDH	-+ 30
ALK. PHOSPH.	-+ 30
GLOBULINS ALPHA 1	-+ 30
GLOBULINS ALPHA 2	-+ 30
GLOBULINS BETA	+ - 20
GLOBULINS GAMMA	-+ 30
TOT. CHOLEST.	-+ 10
HDL	-+ 10
TRIGLYCERIDES	-+ 15
GLUCOSE	-+ 15
Na+	-+ 15
Cl-	not defined
K+	not defined
Ca++	-+ 10
PO4--	not defined
RTS	
TS	
TA	
TBH	
ERS/SEDIMENT. RATE	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

12.1.9 ADVERSE EVENTS GROUPED IN CLUSTERS

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Appendix No.: 12.1.9

ADVERSE EVENTS GROUPED IN CLUSTERS

Body System	Cluster	Adverse event	Treatment	No of AE	No of Pt with AE
BODY AS A WHOLE-GENERAL DISORDERS	ASTHENIA / FATIGUE	ASTHENIA	Imipramine	2	2
		ASTHENIA	Reboxetine	1	1
		FATIGUE	Imipramine	5	5
		FATIGUE	Reboxetine	5	4
CARDIOVASCULAR DISORDERS, GENERAL	FLUSHING / HOT FLASHING	FLUSHING	Imipramine	1	1
		FLUSHING	Reboxetine	2	2
		HOT FLUSHES	Imipramine	2	2
	HYPOTENSION AND RELATED SYMPTOMS	DIZZINESS	Imipramine	19	18
		DIZZINESS	Reboxetine	13	12
		HYPOTENSION	Imipramine	6	5
		HYPOTENSION POSTURAL	Imipramine	2	2
		HYPOTENSION POSTURAL	Reboxetine	1	1
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	HEADACHE / MIGRAINE	HEADACHE	Imipramine	21	18
		HEADACHE	Reboxetine	27	21
GASTRO-INTESTINAL SYSTEM DISORDERS	NAUSEA AND RELATED SYMPTOMS	VOMITING	Imipramine	1	1
		VOMITING	Reboxetine	1	1
		DYSPEPSIA	Reboxetine	3	3
		NAUSEA	Imipramine	13	13
		NAUSEA	Reboxetine	16	16
LIVER AND BILIAR SYSTEM DISORDERS	INCREASED LIVER ENZYMES	SGPT INCREASED	Reboxetine	1	1
		GAMMA-GT INCREASED	Imipramine	2	2
		GAMMA-GT INCREASED	Reboxetine	1	1
		HEPATIC ENZYMES INCREASED	Imipramine	2	1
		HEPATIC ENZYMES INCREASED	Reboxetine	1	1
PSYCHIATRIC DISORDERS	AGITATION / ANXIETY / NERVOUSNESS	AGITATION	Imipramine	9	9
		AGITATION	Reboxetine	8	6
		ANXIETY	Imipramine	1	1
		NERVOUSNESS	Reboxetine	3	3
SKIN AND APPENDAGES DISORDERS	ERYTHEMA / RASH	RASH	Imipramine	2	2
		RASH	Reboxetine	3	3
URINARY SYSTEM DISORDERS	URINARY HESITANCY / RETENTION	URINARY RETENTION	Imipramine	4	4
		URINARY RETENTION	Reboxetine	3	2
		MICTURITION DISORDER	Imipramine	3	3
		MICTURITION DISORDER	Reboxetine	8	8
VISION DISORDERS	BLURRED VISION	ACCOMMODATION ABNORMAL	Imipramine	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Appendix No.: 12.1.9

ADVERSE EVENTS GROUPED IN CLUSTERS

Body System	Cluster	Adverse event	Treatment	No of AE	No of Pt with AE
VISION DISORDERS	BLURRED VISION	VISION ABNORMAL	Imipramine	4	4
		VISION ABNORMAL	Reboxetine	4	4

12.1.10 ECG CODES

APPENDIX No.: 12.1.10

ECG CODES

0 Normal

1 Rhythm disorders

10 Sinus bradycardia (<60)

20 Sinus tachycardia (>100)

30 Sick Sinus Syndrome

40 • Atrial ectopic beats:
- 41 - Occasional
- 42 - Frequent (>6/mm)
- 43 - Couplets
- 44 - Supraventricular Tachycardia

50 • Ventricular ectopic beats:
- 51 - Occasional
- 52 - Frequent (>6/mm)
- 53 - Polymorphic
- 54 - Couplets
- 55 - Ventricular Tachycardia

60 • Atrial fibrillation/flutter

105 • Vagotonia

108 • Atrial-ventricular dissociation

2 Conduction disorders

70 • A-V Block 1st degree
- 71 - 2nd degree - Mobitz 1
- 72 - - Mobitz 2
- 73 - Complete

85 • Right bundle branch block

86 • Left bundle branch block

87 • Left anterior hemiblock

88 • Left posterior hemiblock

89 • Bifascicular Block (specify)

90 • Trifascicular Block (specify)

91 • Conduction disorders

103 • Left axial deviation

106 • Right incomplete bundle branch block

3 Ischemic signs

102 • Ripolarization disturbances

107 • Non specific ST-T changes

82 • Myocardial Ischemia

84 • Acute Myocardial Infarction

4 Other

80 • Left ventricular hypertrophy

81 • Right ventricular hypertrophy

83 • Previous Myocardial Infarction

93 • Other (specify)_____

104 • Right axial deviation

12.1.11 STATISTICAL ANALYSIS PROGRAMS LISTINGS

```
*                                                                       ;
*                      PHARMACIA CNS R&D       9550085                  ;
*                    APPENDIX No.: 12.1.11                              ;
*                                                                       ;
 *---------------------------------------------------------------------*
 *  PGM NAME: perul95                                                  *
 *  CREATED:  15.02.94                                                 *
 *  AIM     :  95% exact confidence interval for a proportion          *
 *---------------------------------------------------------------------*
    *------------------------------------------------------------------*
    *  INPUT  :                                                        *
    *                                                                  *
    *  _pop_ -> total number of patients                               *
    *  _nr_  -> number of events                                       *
    *           % : pct=(_nr_/_pop_)*100                               *
    *                                                                  *
    *  OUTPUT  :                                                       *
    *  l95 -> % LOWER LIMIT                                            *
    *  u95 -> % UPPER LIMIT                                            *
    *------------------------------------------------------------------*;

   if pct = 0 then do;
                    l95=0;
                    u95 = (1-exp(log(0.05)/_pop_)) * 100;
                  end;
   else
   if pct = 100 then do;
                    u95=100;
                    l95 = exp(log(0.05)/_pop_) * 100;
                  end;
   else if pct ne . then do;

    li=pct/100;  * lower limit     ;
    ls=1;   * upper limit      ;

    do k =1 to 100;
      z =((ls - li) / 2) + li;
      a = probbnml(z,_pop_,_nr_);
      if .02501 > a > .02499 then leave;
      else
      if a > .02501 then li = z;
      else ls=z;
    end;
    u95 = z * 100;
    if k > 100 then put '**1** convergence was not attained in 100 '
                        'iterations ' k= z= pct= ls= li= ;


    ls=pct/100;  * limite superiore;
    li=0;   * limite inferiore ;

    do k =1 to 100;
      z=((ls - li) / 2) + li;
      a =1 - probbnml((1 - z),_pop_,(_pop_ - _nr_));
     if .97501 > a > .97499 then leave;
     else
     if a > .97501 then li = z;
     else ls=z;
   end;
   l95 = z * 100;
   if k > 100 then put '**1** convergence was not attained in 100 '
                       'iterations ' k= z= pct= ls= li= ;
end;
```

```
*                                                              ;
*                   PHARMACIA CNS R&D       ` 9550085          ;
*                   APPENDIX No.: 12.1.11                      ;
*                                                              ;

 *-------------------------------------------------------------*
 *                                                             *
 *  PGM NAME: LAB003                                           *
 *  CREATED:  07.12.93                                         *
 *  AIM    :  Stuart-Maxwell test                              *
 *                                                             *
 *                                                             *
 *  BY CORTESI - PANSID MI                                     *
 *-------------------------------------------------------------*;

%macro labstat(var= );

proc sort data = labst;
 by centre patient lab_par day;

data stat(keep = lab_par  day  lab_ind  lab_dif  &var
                 cod_trt  bas  nr_paz   nvis     num_ord)

     shift(keep = lab_par  day      &var  cod_trt   num_ord
                  lab_bas  lab_now  k     up   down  same  nvis)

     maxw  (keep = lab_par  day     &var   cod_trt
                   indice   k       nvis   num_ord);

 set labst;
 by centre patient lab_par day ;
 retain bas lab_bas 0;

 if first.patient then nr_paz = 1;
 else nr_paz = 0;

 if first.lab_par then do;
                    bas = lab_ind;
                    lab_bas = lab_uid;
                    lab_dif = .;
                 end;
 else do;
        k = 1;
        lab_now = lab_uid;
        lab_dif =lab_ind - bas;
        up = 0;
        down = 0;
        same = 0;
        if lab_dif > 0 then up = 1;
        else if lab_dif < 0 then down = 1;
        else same = 1;
        output shift;
        indice = (lab_bas-1) * 3 + (lab_now);
        output maxw;
      end;
 output stat;

              * proc univariate * ;

proc sort data = stat;
 by &var cod_trt lab_par day;

proc univariate data = stat noprint;
 by &var cod_trt lab_par  day;
 var lab_ind lab_dif bas;
 id num_ord;
 output out   =stat (drop=x2-x8 y1-y5)
        mean  =lab_mean x2        bas_mean
        median=lab_medi dif_medi  bas_medi
        std   =lab_std  x3        bas_std
        min   =lab_min  x4        y1
        max   =lab_max  x5        y2
        n     =lab_frq  x6        y3
        probt =x7       t_prob    y4
        probs =x8       s_prob    y5;

proc sort data = shift ;
 by &var cod_trt lab_par day lab_bas lab_now;

proc means data = shift noprint;
 by  &var cod_trt lab_par day;
 var up down same;
 id num_ord;
 output out=shifts
        sum=up down same;
```

```
data stat  ;                                                    9550085
 merge stat (in=a) shifts(in=b);
 by  &var cod_trt lab_par day;
 if a = 1 or b = 1;
 if b=1 then do;
        if up = down then p_value = 1;
        else p_value = 2. * (probbnml(.5,sum(up,down),min(up,down)));
 end;

 p_test = s_prob;


          *--------------------------------------*
          * MAXWELL TEST                         *
          *--------------------------------------*;

proc sort data = maxw  ;
 by  &var cod_trt lab_par  day indice;

proc means data = maxw noprint;
 by  &var cod_trt lab_par  day indice;
 var k;
 id num_ord;
 output out=maxw
        sum=k;

 data maxw(keep = &var cod_trt lab_par  day  p_maxw num_ord);
  set maxw;
 by  &var cod_trt lab_par  day indice;
  retain  a11 a12 a13 a21 a22 a23 a31 a32 a33;
  array _a_ (9) a11 a12 a13 a21 a22 a23 a31 a32 a33;

  if first.day then do i=1 to 9; _a_(i) = 0 ; end;

  _a_(indice)=k;
  if last.day then do;
       n12=(a12+a21)/2;
       n13=(a13+a31)/2;
       n23=(a23+a32)/2;

       d1=a12+a13-a21-a31;
       d2=a21+a23-a12-a32;
       d3=a31+a32-a13-a23;

       d1=d1*d1;
       d2=d2*d2;
       d3=d3*d3;

       numx2=n23*d1+n13*d2+n12*d3;
       denx2=(n12*(n13+n23)+n13*n23)*2;
       if denx2 > 0 then do;
                          x2=numx2/denx2;
                          p_maxw = 1 - probchi(x2,2);
                         end;
        else do;
              if a32 > 0 or a23 > 0 then do;
                    if a32 = a23 then p_maxw = 1;
                         else do;
                               denx2=a32+a23;
                               numx2=min(a32,a23);
                               p_maxw = 2. * probbnml(0.5,denx2,numx2);
                              end;
                   end; * if a32 > 0 ..... ;
              else if a21 > 0 or a12 > 0 then do;
                    if a21 = a12 then p_maxw = 1;
                         else do;
                               denx2=a21+a12;
                               numx2=min(a21,a12);
                               p_maxw = 2. * probbnml(0.5,denx2,numx2);
                              end;
                   end; * if a21 > 0 ..... ;
              else if a31 > 0 or a13 > 0 then do;
                    if a31 = a13 then p_maxw = 1;
                         else do;
                               denx2=a31+a13;
                               numx2=min(a31,a13);
                               p_maxw = 2. * probbnml(0.5,denx2,numx2);
                              end;
                   end; * if a31 > 0 ..... ;
             else p_maxw = 1;  * tutti gli elementi no su diag.;
        end; * if denx2 <= 0 ..... ;
        output;
        end; * if last day ..... ;

proc means data = shift noprint;
 by &var cod_trt lab_par day lab_bas lab_now;
 var k ;
 id num_ord;
 output out=shift
        sum=k;
```

```
                                                                    9550085
data maxw (keep = &var cod_trt lab_par  day  p_maxw maxw_p  num_ord
                  dw sm up k lab_bas);;
 merge shift(in=a) maxw(in=b);
 by &var cod_trt lab_par day ;
 retain maxw_p;
 if first.day then maxw_p = .;
 dw = .; sm = .; up = . ;
 array now (3) dw sm up;
 now(lab_now) = k;
 output;
 if last.day then do;
    * generazione di tutti i possibili incroci (con valori a zero);
    dw = .; sm = .; up = . ; k = .;
    lab_bas = 1; output;
    lab_bas = 2; output;
    lab_bas = 3;
    maxw_p = p_maxw;
    output;
 end;
run;

 %mend labstat;
```

```
                PHARMACIA CNS R&D                9550085

              APPENDIX NO. : 12.1.11
  *-------------------------------------------------------------------*
  *                                                                   *
  *  PGM NAME: tav50var                                               *
  *  CREATED:  16.05.95                                               *
  *  AIM     :  MEAN DECREASE OF HAMILTON TOTAL SCORE                 *
  *             AT LAST ASSESSMENT WITH RESPECT TO BASELINE           *
  *             AND 95% CONFIDENCE INTERVAL                           *
  *             USING OUTPUT OF ANOVA                                 *
  *                                                                   *
  *                                                                   *
  *  BY CORTESI - PANSID MI                                           *
  *-------------------------------------------------------------------*;

  options pageno=1;

  options pageno=1;
  proc glm data=last outstat=sta noprint;
 TITLE7 'ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE'
        ' AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE';
  class cod_trt;
  model diffn=cod_trt;
  lsmeans cod_trt /out=med;
  run;


data sta;
 set sta;
where _source_='ERROR';
tt=abs(tinv(0.025,df));

proc sort data=sta;
 by _name_;

proc sort data=med;
 by _name_;

data tot;
  merge sta med;
 by _name_;

limi=lsmean-tt*stderr;
lims=lsmean+tt*stderr;

 proc print data = tot;
 var cod_trt lsmean tt limi lims;

 proc sort data=tot;
  by cod_trt;

%let gmaxlev = 0.5;
%let gmaxval= 5;
%let gminval= 25;
%let gbyval =  5;

data graf(keep=cod_trt level value);
 set tot end=fine;
  by cod_trt;
retain level 0 maxv_ minv_ difval_;
array dati (3) limi lsmean lims;

 if limi < minv_ or minv_ = . then minv_ = limi;
 if lims > maxv_ then maxv_ = lims;
 x_ = lims - limi;
 if x_ > difval_ then difval_ = x_;

 level=level + 0.1;
 do _i_ = 1 to 3;
      value = dati(_i_);
      output;
 end;
 if fine then do;
              difval_ =abs(difval_)+1;
              minv_ = minv_ - difval_ ;
              if minv_ < 0 then minv_ = 0;
              maxv_ = maxv_ + difval_ ;
              gby_ = abs((maxv_ - minv_)* 0.1);
        *     if gby_ < 1 then gby_ = 1;
              call symput('gmaxlev',put(level+0.1,4.1));
              call symput('gminval',put(minv_,4.));
              call symput('gmaxval',put(maxv_,4.));
              call symput('gbyval',put(gby_,4.));
             end;

proc sort data = graf;
  by level;
RUN;

goptions reset=global gunit=pct  /*rotate=landscape */
```

```
          rotate=portrait                                    9550085
          device=gddmfam4 gddmtoken=fine240 gddmnickname=p3820
          vsize=      hsize= 7  in    hpos=   vpos=
          vorigin=1.25 in horigin=2.25 in
          ftext=swiss  htitle=3 htext=2 display;
RUN;


%include pgmgen(gtitle);
%include pgmgen(gsymb4);

title5 f=swiss  h=2.5
       'MEAN DECREASES OF HAMILTON TOTAL SCORE AT LAST ASSESSMENT';
TITLE6 F=SWISS  H=2.5  'POINT ESTIMATES AND CONFIDENCE INTERVALS';
title7 ' ' ;

data b;
 set graf;
 format function $8. text $8. x y 8.4 ;
   function='label';
   position='3';
   size=3  ;
   style='swiss';
   hsys = '1';
   xsys ='2';
   ysys = '2' ;
   when= 'a';

   x=value;
   y=level;
   text=put(value,4.1);
RUN;

axis1 label =(a=90 '          ')
      style=0
      offset=(2  )
      order=0 to &gmaxlev by 0.1
      value=none
      minor=none
      major=none;

axis2 label =(f=swiss h=1.8 '   ')
      value=(f=swiss h=1.5)
      minor=none
      order=&gminval to &gmaxval by &gbyval;

legend1 label =none
        frame
        value=(f=swiss h=2.0)
        position=(bottom center outside);

* legend1 label =(position=top  f=swiss h=1.8 'Treatments:')
        down=5
        value=(f=swiss h=2.0);

proc gplot data=graf;
plot level*value=cod_trt /
    annotate=b
    vaxis=axis1
    haxis=axis2
    legend=legend1;
format cod_trt $ftrt.;
run;


proc sort data = med;
 by descending cod_trt;

data med1(keep=trt_con dif ls li er);
 set med end=fine;
 retain m1-m10 st1-st10 i 0 ;
 format trt1-trt10 $8. trt_con $30.;
 retain trt1-trt10;
 array tmean (10) m1-m10;
 array tstd (10) st1-st10;
 array ttrt (10) trt1-trt10;
 i = i + 1;
 file print;
 if i > 10 then
    put 'MORE THAN 10 TREATMENTS  '
        ' delle array ' i= trt1= trt2= trt3= trt4= trt5= trt6=
         trt7= trt8= trt9= trt10=;

 else do;
       ttrt(i) = cod_trt;
       tmean(i) = lsmean;
       tstd(i) = stderr;                                  548
      end;
 if fine=1 then do;
    da = 0;
    DO K = 1 TO I - 1; *        MAX NUMBER OF TREATMENTS     ;
```

```
                                                                  9550085
      do da = k + 1 to i;
         trt_con = trim(put(ttrt(k),$ftrt.))||' - '||
                   trim(put(ttrt(da),$ftrt.));
         dif = tmean(k) - tmean(da);
         er=sqrt(tstd(k)**2+tstd(da)**2);
         ls=dif+1.96*er;
         li=dif-1.96*er;
         output;
      end;
   end;
end;
label trt_con='Treatments'
      dif='means difference'
       li='lower confidence limit'
       ls='upper confidence limit';
```

```
TITLE1  'PHARMACIA CNS R&D';
TITLE3  'REBOXETINE - PROTOCOL 20124/17';          9550085
TITLE5  'APPENDIX NO. 12.1.11';
FOOTNOTE;

      ************************************************
      *-  PROGRAM .. : Y00.REBOX.PGM(CONF17)         -*
      *-  GOAL ..... : CONFIDENCE INTERVAL           -*
      *-  AUTHOR ... : N.O.                          -*
      *-  REFERENCE  : DESIGN AND ANALYSIS OF EXPERIM.-*
      *-  JOHN L.GILL, 1978 PG 51-56                 -*
      *-                                            -*
      *-note : for each protocol introduce the requested-*
      *        data  ( supplied by ANOVA)           -*
      ************************************************ ;


*********************************************;
* MC=MEAN (CAMPION)                          ;
* MS=MEAN (STANDARD)                         ;
* NC=NUMBER OF OBSERVATION (CAMPION)         ;
* NS=NUMBER OF OBSERVATION (STANDARD)        ;
* S2E=MEAN SQUARE ERROR                      ;
* DF =DEGREE OF FREADOM OF ERROR             ;
*********************************************;

DATA PIPPO;INPUT
 TIT $ MC  MS  NC NS S2E  DF ;
CARDS;
LASTTOT   15.8 14.3  127 121 101.9 246
LASTMEL   16.9 15.25  51 44   131.7 93
LASTSEV   16.5 14.5   99 87  105.3 184
;
RUN;
DATA PIPPO;SET PIPPO;
tt=abs(tinv(0.025,df));
ERR2=(1/NC+1/NS);
ERR=SQRT(ERR2*S2E);
DIFF=MC-MS;
INF=DIFF-TT*ERR;
SUP=DIFF+TT*ERR;

LABEL DIFF='BETWEEN TREATM. DIFFERENCE '  TIT='POPULATION ANALYSED'
      INF='LOWER LIMIT'  SUP='UPPER LIMIT'
      MC= 'MEAN REBOXETINE ' MS='MEAN IMIPRAMINE';

PROC FORMAT ;VALUE $TIT  'LASTTOT'='TOTAL POPULATION'
                         'LASTMEL'='MELANCHOLIC PTS '
                         'LASTSEV'='SEVERE PTS ';

 PROC PRINT LABEL NOOBS;
 TITLE9 'BETWEEN TREATMENT DIFFERENCE AND 95% CONFIDENCE INTERVAL ';
 VAR TIT MC MS DIFF INF SUP;
 format tit $tit.;
 RUN;
```

12.1.12 SELECTION OF STATISTICAL ANALYSIS OUTPUTS

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/017

Appendix No.: 12.1.12

SELECTION OF STATISTICAL ANALYSIS OUTPUTS

Efficacy analyses

Study end point : HAMD decrease

- ANOVA on baseline values for comparison between treatments

The following analyses have been carried out on three sets of patients: all patients, severe and melancholic patients.
- Tables showing descriptive statistics (n, mean, standard deviation S.D.)
- ANOVA according to the model : HAMD decrease = treatment
- 95% confidence interval of the between treatments difference.

Response : 50% HAMD decrease

- Log-rank test on time to response (comparison between treatments).

Analysis of Adverse events

- Log-rank test on the time to the first occurrence of either any event and selected signs-symptoms (comparison between treatments).

PHARMACIA PHARMACEUTICAL MILANO - CNS

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON AT BASELINE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
CDD_TRT	2	INI REX

Number of observations in data set = 248

PHARMACIA PHARMACEUTICAL MILANO - CHE

REDUCTYNE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON AT BASELINE

General Linear Models Procedure

Dependent Variable: HAM0

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	34.59951073	34.59951073	1.36	0.2412
Error	246	6166.80032798	25.06841922		
Corrected Total	247	6201.47983871			

R-Square	C.V.	Root MSE	HAM0 Mean
0.005579	17.63028	5.00683722	28.39919355

Source	DF	Type I SS	Mean Square	F Value	Pr > F
CEO_TRT	1	34.59951073	34.59951073	1.36	0.2412

Source	DF	Type III SS	Mean Square	F Value	Pr > F
CEO_TRT	1	34.59951073	34.59951073	1.36	0.2412

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX NO.:12.1.12
HAMILTON DEPRESSION RATING SCALE
DESCRIPTIVE STATISTICS ON LAST ASSESSEMENT

TOTAL SCORE HAMILTON		BASELINE	LAST ASSESS.	DECREASE
TREATME-NT				
Imipram-ine	N	121	121	121
	MEAN	28.02	13.68	14.34
	S.D.	5.16	10.31	9.55
Reboxet-ine	N	127	127	127
	MEAN	28.76	12.98	15.78
	S.D.	4.84	10.24	10.59

9550085

PHARMACIA PHARMACEUTICAL RTLAND - CHE

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DEGREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
CEN_TRT	2	ZEI REX

Number of observations in data set = 248

PHARMACIA PHARMACEUTICAL MILANO - CHS

REBOXETINE - PROTOCOL 28124/017
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFN

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	128.61014517	128.61014517	1.26	0.2624
Error	246	25068.89430947	101.90624662		
Corrected Total	247	25197.50445464			

R-Square	C.V.	Root MSE	DIFFN Mean
0.005104	66.95709	10.09455189	15.07661290

Source	DF	Type I SS	Mean Square	F Value	Pr > F
CSD_TRT	1	128.61014517	128.61014517	1.26	0.2624

Source	DF	Type III SS	Mean Square	F Value	Pr > F
CSD_TRT	1	128.61014517	128.61014517	1.26	0.2624

9550085

PHARMACIA PHARMACEUTICAL MILANO - CMS

REBOXETINE - PROTOCOL 2012A/017
APPENDIX No.: 12.1.12

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DEPRESS AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Least Squares Means

	CHD_TRT	DIFFN LSMEAN
	1	14.3388430
	2	15.7795276

9550085

PHARMACIA CNS R&D

ESCITALOPRAM - PROTOCOL 20124/017
APPENDIX NO.: 12.1.12
HAMILTON DEPRESSION RATING SCALE
DESCRIPTIVE STATISTICS ON LAST ASSESSMENT
SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE

TOTAL SCORE HAMILTON			BASELINE	LAST ASSESS.	DECREASE
SEVERE	TREATMENT				
NO	Escitalopram	N	34	34	34
		MEAN	25.24	11.29	13.94
		S.D.	3.05	9.49	10.01
	Paroxetine	N	25	25	25
		MEAN	26.21	13.00	13.21
		S.D.	4.11	8.43	8.92
YES	Escitalopram	N	67	67	67
		MEAN	29.10	14.61	14.49
		S.D.	5.44	10.52	9.42
	Paroxetine	N	99	99	99
		MEAN	29.46	12.96	16.51
		S.D.	4.81	10.73	10.94

9550085

1

PHARMACIA PHARMACEUTICAL MILANO - CNS

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
COD_TRT	2	IMI REB

Number of observations in data set = 191

NOTE: Due to missing values, only 186 observations can be used in this analysis.

PHARMACIA PHARMACEUTICAL MILANO - CMS

RESONATINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

SEVERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFH

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	157.23120527	157.23120527	1.78	0.1840
Error	184	19268.42468115	105.26557762		
Corrected Total	185	19555.72588645			

R-Square	C.V.	Root MSE	DIFFH Mean
0.008074	65.91791	10.25960300	15.56451613

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	1	157.23120527	157.23120527	1.78	0.1840

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	1	157.23120527	157.23120527	1.78	0.1840

PHARMACIA PHARMACEUTICAL MILANO - CHS

REMOXITINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

ENTERE PATIENTS JUDGED BY CGI SEVERITY AT BASELINE
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DEGREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Least Squares Means

CGD_TRT	DIFFN LSMEAN
IMI	14.4942359
REM	16.8080305

9550085

PHARMACIA CRS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX NO.: 12.1.12
HAMILTON DEPRESSION RATING SCALE
DESCRIPTIVE STATISTICS ON LAST ASSESSMENT
MELANCHOLIC PATIENTS

TOTAL SCORE HAMILTON			BASELINE	LAST ASSESS.	DECREASE
MELANCHOLIC	TREATMENT				
NO	Reboxetine	N	64	64	64
		MEAN	26.00	12.27	13.73
		S.D.	3.29	9.19	9.24
	Reboxetine	N	60	60	60
		MEAN	27.00	12.38	14.62
		S.D.	3.76	9.70	9.95
YES	Reboxetine	N	44	44	44
		MEAN	31.50	16.25	15.25
		S.D.	5.94	11.58	10.33
	Reboxetine	N	51	51	51
		MEAN	31.16	14.22	16.94
		S.D.	5.97	11.56	12.38

PHARMACIA PHARMACEUTICAL MILANO - CMS

REMOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12
MELANCHOLIC PATIENTS
ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DEPRESSION AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Class Level Information

Class	Levels	Values
CUR_TRT	2	TRX PBO

Number of observations in data set = 97

NOTE: Due to missing values, only 95 observations can be used in this analysis.

2

PHARMACIA PHARMACEUTICAL MILANO - CMS

MOMENTINE - PROTOCOL 2012A/017
APPENDIX No.: 12.1.12
MELANCHOLIC PATIENTS

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENTS WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure

Dependent Variable: DIFFH

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	67.55804954	67.55804954	0.51	0.4756
Error	93	12245.07853941	131.66745731		
Corrected Total	94	12312.63657895			

R-Square	C.V.	Root MSE	DIFFH Mean
0.005487	71.01571	11.47464410	16.15789474

Source	DF	Type I SS	Mean Square	F Value	Pr > F
COD_TRT	1	67.55804954	67.55804954	0.51	0.4756

Source	DF	Type III SS	Mean Square	F Value	Pr > F
COD_TRT	1	67.55804954	67.55804954	0.51	0.4756

PHARMACIA PHARMACEUTICAL MILANO - CMS

REBOXETINE - PROTOCOL 28124/017
APPENDIX No.: 12.1.12

MELANCHOLIC PATIENTS

ANALYSIS OF VARIANCE ON TOTAL SCORE HAMILTON DEPRESSION AT LAST ASSESSMENTW WITH RESPECT TO BASELINE VALUE

General Linear Models Procedure
Least Squares Means

CUR_TRT	HAMTOT LSMEAN
REX	15.2500000
PBO	16.9411765

9550085

PHARMACIA - PHARMACEUTICAL MILANO - CNS

BROMOCRIPTINE - PROTOCOL 20124/17

APPENDIX NO. 12.1.12

BETWEEN TREATMENT DIFFERENCE AND 95% CONFIDENCE INTERVAL

POPULATION ANALYSED	MEAN REBOXETINE	MEAN IMIPRAMINE	BETWEEN TREATM. DIFFERENCE	LOWER LIMIT	UPPER LIMIT
TOTAL POPULATION	15.8	14.30	1.50	-1.02585	4.02585
MELANCHOLIC PTS	14.9	15.25	1.65	-3.03899	6.33899
SEVERE PTS	16.5	14.50	2.00	-0.97514	4.97514

PHARMACIA CNS R&D

BIOMARKERS - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

EFFICACY: KAPLAN / MEIER ANALYSIS - TIME TO ONSET OF RESPONSE (50 % HAMILTON DECREASE)

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IXI	121	68	53	43.8017
HBX	127	87	40	31.4961
Total	248	155	93	37.5000

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IXI	-14.517	-2351.0
HBX	14.517	2351.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IXI	HBX
IXI	33.8555	-33.8555
HBX	-33.8555	33.8555

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IXI	HBX
IXI	806223	-806223
HBX	-806223	806223

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	6.2251	1	0.0126
Wilcoxon	6.8557	1	0.0088
-2Log(LR)	3.4176	1	0.0645

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IRI	126	103	23	18.2540
RBX	130	106	24	18.4615
Total	256	209	47	18.3594

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IRI	3.6710	765.00
RBX	-3.6710	-765.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IRI	RBX
IRI	45.1117	-45.1117
RBX	-45.1117	45.1117

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IRI	RBX
IRI	1340262	-1340262
RBX	-1340262	1340262

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.2987	1	0.5847
Wilcoxon	0.4366	1	0.5087
-2Log(LR)	0.7945	1	0.3728

PHARMACIA CNS R&D

HEDONETINE - PROTOCOL 28124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IKI	126	9	117	92.8571
HEK	130	9	121	93.0769
Total	256	18	238	92.9688

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IKI	0.22194	7.0000
HEK	-0.22194	-7.0000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IKI	HEK
IKI	4.47473	-4.47473
HEK	-4.47473	4.47473

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IKI	HEK
IKI	249446	-249446
HEK	-249446	249446

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0199	1	0.9167
Wilcoxon	0.0002	1	0.9887
-2Log(LR)	0.0250	1	0.8744

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	126	6	120	95.2381
RBX	130	5	125	96.1538
Total	256	11	245	95.7031

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.63398	160.00
RBX	-0.63398	-160.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.72643	-2.72643
RBX	-2.72643	2.72643

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	156746	-156746
RBX	-156746	156746

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.1474	1	0.7010
Wilcoxon	0.1633	1	0.6861
-2Log(LR)	0.1745	1	0.6762

PHARMACIA CHS R&D

REMODULIN - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING BRONCHITIS

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	2Censored
IKI	126	1	125	99.2063
NEK	130	6	124	95.3846
Total	256	7	249	97.2656

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IKI	-2.3389	-474.00
NEK	2.3389	474.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IKI	NEK
IKI	1.74846	-1.74846
NEK	-1.74846	1.74846

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IKI	NEK
IKI	75295.0	-75295.0
NEK	-75295.0	75295.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.2313	1	0.0696
Wilcoxon	2.9339	1	0.0841
-2Log(LR)	3.6502	1	0.0561

PHARMACIA CRS R&D

REBOXETINE - PROTOCOL 2012A/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
INI	126	13	113	89.6825
NRX	130	13	117	90.0000
Total	256	26	230	89.8438

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
INI	0.44940	132.00
NRX	-0.44940	-132.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	INI	NRX
INI	6.45751	-6.45751
NRX	-6.45751	6.45751

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	INI	NRX
INI	322829	-322829
NRX	-322829	322829

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0313	1	0.8596
Wilcoxon	0.0540	1	0.8163
-2Log(LR)	0.0554	1	0.8172

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	126	18	108	85.7143
RBX	130	21	109	83.8462
Total	256	39	217	84.7656

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-0.84889	-113.00
RBX	0.84889	113.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	9.66366	-9.66366
RBX	-9.66366	9.66366

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	454320	-454320
RBX	-454320	454320

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0746	1	0.7848
Wilcoxon	0.0281	1	0.8669
-2Log(LR)	0.0548	1	0.8149

PHARMACIA CRS R&D

BENDAMUSTINE - PROTOCOL 2012A/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IKI	126	23	103	81.7460
BEK	130	13	117	90.0000
Total	256	36	220	85.9375

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IKI	5.8754	1325.0
BEK	-5.8754	-1325.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IKI	BEK
IKI	6.85942	-6.85942
BEK	-6.85942	6.85942

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IKI	BEK
IKI	443668	-443668
BEK	-443668	443668

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	3.8965	1	0.0484
Wilcoxon	3.9571	1	0.0467
-2Log(LR)	4.7494	1	0.0293

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING INSOMNIA

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
INI	126	14	112	88.8889
RBX	130	10	120	92.3077
Total	256	24	232	90.6250

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
INI	2.3366	403.00
RBX	-2.3366	-403.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	INI	RBX
INI	5.90078	-5.90078
RBX	-5.90078	5.90078

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	INI	RBX
INI	312388	-312388
RBX	-312388	312388

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.9252	1	0.3361
Wilcoxon	0.5199	1	0.4709
-2Log(LR)	1.1012	1	0.2940

PHARMACIA CNS R&D

HEMOSPATINE - PROTOCOL 2012A/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING MONTH DAY

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
INX	126	45	81	64.2857
HEX	130	32	98	75.3846
Total	256	77	179	69.9219

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
INX	9.1592	2117.0
HEX	-9.1592	-2117.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	INX	HEX
INX	18.2117	-18.2117
HEX	-18.2117	18.2117

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	INX	HEX
INX	834262	-834262
HEX	-834262	834262

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	4.6064	1	0.0319
Wilcoxon	5.3726	1	0.0205
-2Log(LR)	6.1999	1	0.0128

PHARMACIA CNS R&D

REDONDSTIME - PROTOCOL 20124/017
APPENDIX No.1 12.1.12

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IKI	126	14	112	88.8889
HBK	130	19	111	85.3846
Total	256	33	223	87.1094

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IKI	-2.1412	-459.00
HBK	2.1412	459.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IKI	HBK
IKI	7.96700	-7.96700
HBK	-7.96700	7.96700

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IKI	HBK
IKI	427566	-427566
HBK	-427566	427566

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.5735	1	0.4491
Wilcoxon	0.5684	1	0.4509
-2Log(LR)	0.4655	1	0.4951

PHARMACIA CHD R&D

REGRESSION - PROTOCOL 2012A/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SHINGLENCE

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IRI	126	9	117	92.8571
ERX	130	4	126	96.9231
Total	256	13	243	94.9219

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IRI	2.7537	610.00
ERX	-2.7537	-610.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IRI	ERX
IRI	3.23296	-3.23296
ERX	-3.23296	3.23296

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IRI	ERX
IRI	171282	-171282
ERX	-171282	171282

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.3541	1	0.1250
Wilcoxon	2.1724	1	0.1405
-2Log(LR)	2.5436	1	0.1107

PHARMACIA CNS R&D

REMOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IRX	126	18	108	85.7143
SER	130	18	112	86.1538
Total	256	36	220	85.9375

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IRX	0.83530	110.00
SER	-0.83530	-110.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IRX	SER
IRX	0.86047	-0.86047
SER	-0.86047	0.86047

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IRX	SER
IRX	445980	-445980
SER	-445980	445980

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.8323	1	0.3573
Wilcoxon	0.6271	1	0.4282
-2Log(LR)	0.0743	1	0.7851

PHARMACIA CMS R&D

REMODULINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TACHYCARDIA

The LIFETEST Procedure

Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IKI	126	13	113	89.6825
REM	130	8	122	93.8462
Total	256	21	235	91.7969

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IKI	3.4861	804.00
REM	-3.4861	-804.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IKI	REM
IKI	4.96120	-4.96120
REM	-4.96120	4.96120

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IKI	REM
IKI	231968	-231968
REM	-231968	231968

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	2.4496	1	0.1176
Wilcoxon	2.7867	1	0.0951
-2Log(LR)	1.8871	1	0.1695

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING TREMOR

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	126	13	113	89.6825
RBX	130	2	128	98.4615
Total	256	15	241	94.1406

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	5.8493	1319.0
RBX	-5.8493	-1319.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	3.72372	-3.72372
RBX	-3.72372	3.72372

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	190303	-190303
RBX	-190303	190303

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	9.1882	1	0.0024
Wilcoxon	9.1420	1	0.0025
-2Log(LR)	10.4602	1	0.0012

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
APPENDIX No.: 12.1.12

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
INI	126	6	120	95.2381
RBX	130	10	120	92.3077
Total	256	16	240	93.7500

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
INI	-1.8492	-511.00
RBX	1.8492	511.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	INI	RBX
INI	3.98554	-3.98554
RBX	-3.98554	3.98554

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	INI	RBX
INI	205568	-205568
RBX	-205568	205568

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.8580	1	0.3543
Wilcoxon	1.2702	1	0.2597
-2Log(LR)	0.8521	1	0.3559

12.2 Patient Information

Pharmacia Document 9550085

12.2.1 SERIOUS ADVERSE EVENTS - CASE HISTORIES

Narratives of serious adverse events reported on reboxetine treatment and case summaries of serious adverse events reported on reference treatment.

Pharmacia . Document 9550085

Narrative of Event No. SA 0025 **Protocol No. 20124/017** **Patient No. 353**

Center: Cape Town (South Africa) **Investigator: Wilson**

Adverse event: parasuicide by overdose (date of the event: 7 July 1992).

Patient's history: the patient was a 40 years old female and was suffering from a Major Depressive Episode for 9 weeks when she entered in the 20124/017 study on 5 June 1992. She had had the onset of depressive disorder at the age of 40 years.

Baseline ECG and chest X-ray were normal. Laboratory tests did not show any clinical relevant abnormalities.

Experimental period: the patient entered the 20124/017 study on 5 June 1992 and received the experimental treatment as follows:

Treatment		Days	Dose (mg/Day)
From	To		
5 June 1992	11 June 1992	7	8
12 June 1992	14 June 1992	3	0
15 June 1992	20 June 1992	6	8
21 June 1992	21 June 1992	1	0
22 June 1992	7 July 1992	16	8

From 13 June 1992 to 15 June 1992, she was treated with mefenamic acid (250 mg/day) because of urinary pain and from 22 June 1992 to 26 June 1992 with trimethoprim/sulfamethoxazol for a urinary tract infection. The experimental treatment was temporarily interrupted for the period of the urinary tract disorder.

At the baseline visit, the Hamilton Depression Rating Scale (HAMD) was performed and the total score was of 23 points. While she was on therapy, there was a progressive improvement in the severity of the depressive syndrome until 6 July 1992 when the HAMD total score of 7 points was reported.

Suicide ideas were present at the baseline visit but they disappear during the study.

On 7 July 1992, the patient took an overdose of reboxetine following a domestic argument. She asked her sister to contact the Investigator and she was advised to come to the hospital for examination and blood sample but she refused.

On 9 July 1992, she went to the hospital and during the medical visit she was found to be depressed, having unresolved domestic conflicts, but was not found to be suicidal. The patient claimed to have taken all tablets of the experimental treatment in her possession (a maximum of 13 tbs, equivalent to 52 mg) and was reported to be conscious at all times, able to communicate and to continue her normal tasks. The patient was definitively withdrawn from the study.

At the time of the event, the patient had been under the experimental treatment for 33 days and had received a cumulative amount of 232 mg of reboxetine, while being treated with 8 mg/day of the compound.

Comments: the Investigator judged the adverse event as drug related. However the reliability of the patient seems to be very poor because the complete absence of symptoms after a single intake of 52 mg of reboxetine which is quite unbelievable. Furthermore, on 13 July 1992 the patient's psychopathological condition was no worse (HAMD total score = 10) and no suicide feeling was present (HAMD item 3 = 0). The whole situation (family troubles, absence of suicidal thoughts, a domestic argument just before overdose was taken, refusal to attend medical care after the ingestion of the drug , no side effects after a single intake of 52 mg of reboxetine) could be interpreted as a demonstrative gesture.

Pharmacia Document 9550085

Narrative of Event No. DD 0192 **Protocol No. 20124/017** **Patient No. 50**

Center: Ravensburg (Germany) **Investigator: Wolfersdorf**

Adverse event: suicide by shooting (date of the event:15 December 1991)

Patient's history: the patient was a 54 years old male and was suffering from a Major Depressive Episode for 1 month when he entered in the 20124/017 study on 31 October 1991. He had had the onset of depressive disorder at the age of 53 years.

His previous antidepressive treatment was mianserin which had shown poor efficacy.

Baseline ECG and chest X-ray were normal. Laboratory tests did not show any clinical relevant abnormalities.

Experimental period: the patient entered the 20124/017 study on 31 October 1991 and received the experimental treatment as follows:

Treatment		Days	Dose (mg/Day)
From	To		
6 November 1991	14 December 1991	39	8
15 December 1991	15 December 1991	1	4

From 5 November 1991 to 12 November 1991 he was treated with clomethiazole (384 mg/day) for insomnia. From 13 November 1991 to 19 November 1991, he took the above mentioned drug at the dosage of 768 mg/day. On 20 November 1991, he started treatment with chloral hydrate (2000 mg/day) for the same problem.

At the baseline visit the Hamilton Depression Rating Scale (HAMD) was performed and the total score was 24 points. While he was on therapy there was an initial deterioration in his psychopathological conditions as seen by HAMD total score of 30 points (19 November 1991). It was followed by a progressive improvement in the severity of the depressive syndrome until 10 December 1991 when the HAMD total score of 17 points was reported. At the same time no suicidal intent was detected.

On 15 December 1991, he committed suicide by shooting outside the hospital.

At the time of the event, the patient had been under the experimental treatment for 40 days and he had received a cumulative amount of reboxetine of 316 mg, while being treated with 4 mg/day of the compound.

Comments: the Investigator judged the adverse event as not drug related.

Pharmacia Document 9550085

CASE SUMMARY OF EVENT	BE 0038
PROTOCOL N°	20124/017
PT. N°	270
SEX	F
AGE AT ENTRY	43
EXPERIMENTAL TREATMENT	IMIPRAMINE
DAILY DOSE	150 MG.
TREATMENT PERIOD	11.10.91 - 17.10.91
AFTER DAYS	7
ADE (DATE OF THE EVENT)	SUPRAVENTRICULAR TACHYCARDIA (17.10.91)
DISCONTINUED	YES
COURSE	RECOVERED
RELEVANT HISTORY	EPISODES OF TACHYCARDIA
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER
PREVIOUS ANTIDEPRESSIVE TREATMENTS	DOSULEPIN, MIANSERIN
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	NONE

Pharmacia Document 9550085

CASE SUMMARY OF EVENT	**DD 0223**
PROTOCOL N°	20124/017
PT. N°	451
SEX	M
AGE AT ENTRY	56
EXPERIMENTAL TREATMENT	IMIPRAMINE
DAILY DOSE	150 MG.
TREATMENT PERIOD	28.11.91 - 7.01.92
AFTER DAYS	22
ADE (DATE OF THE EVENT)	A-V BLOCK 1ST DEGREE (19.12.91)
DISCONTINUED	NO
COURSE	RECOVERED
RELEVANT HISTORY	A-V BLOCK 1ST DEGREE
RELEVANT BASELINE CONDIT.	MAJOR DEPRESSIVE DISORDER, HYPERTENSION, PERIPHERAL ARTERIAL PERFUSION DISORDER, DIABETES MELLITUS, POLYARTHROSIS
PREVIOUS ANTIDEPRESSIVE TREATMENTS	NO
RELEVANT EVENTS	NO
CONCOMITANT MEDICATIONS	DIPYRIDAMOLE/ACETYLSALICILIC ACID, ENALAPRIL

12.2.2 INDIVIDUAL DATA LISTINGS

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status: In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)
1	1	Reboxetine	DMD	OUT		Male	52	83.0	172.0	Caucasian	296.3
	2	Reboxetine	UKL	OUT		Female	55	70.0	170.0	Caucasian	296.3
	3	Imipramine	CFI	IN	10/04/91	Female	41	63.0	171.0	Caucasian	296.2
	4	Imipramine	JLO	OUT		Male	53	123.0	180.0	Caucasian	296.3
	5	Reboxetine	HNE	IN	15/07/91	Female	57	70.0	173.0	Caucasian	296.3
	6	Imipramine	NRR	IN	06/08/91	Male	62	67.0	168.0	Caucasian	296.2
	7	Reboxetine	GGO	OUT		Male	54	85.0	186.0	Caucasian	296.3
	8	Imipramine	ALE	IN	26/10/91	Male	50	88.5	174.0	Caucasian	296.3
	9	Imipramine	IGR	OUT		Female	65	53.0	156.0	Caucasian	296.3
	10	Imipramine	SSC	OUT		Female	46	71.0	168.0	Caucasian	296.3
	11	Reboxetine	MCA	IN	02/04/92	Male	50	71.0	159.0	Caucasian	296.3
	12	Reboxetine	J K	IN	09/04/92	Male	27	84.0	176.0	Caucasian	296.3
2	33	Reboxetine	VOK	IN	18/12/90	Male	48	83.0	174.0	Caucasian	296.3
	34	Imipramine	OTH	IN	27/12/90	Male	43	108.0	183.0	Caucasian	296.2
	35	Reboxetine	HEA	IN	27/12/90	Male	34	80.0	180.0	Caucasian	296.3
	36	Imipramine	BER	IN	09/01/91	Female	29	49.0	159.0	Caucasian	296.3
	37	Reboxetine	CHA	IN	17/01/91	Male	42	80.6	177.0	Caucasian	296.3
	38	Imipramine	SCP	IN	06/12/90	Female	54	51.0	159.0	Caucasian	296.3
	39	Reboxetine	SCP	IN	24/01/91	Female	46	65.0	161.0	Caucasian	296.2
	40	Imipramine	BMP	IN	18/02/91	Male	42	73.0	182.0	Caucasian	296.2
	41	Reboxetine	WAE	IN	30/01/91	Male	50	80.0	168.0	Caucasian	296.3
	42	Imipramine	WAH	IN	06/02/91	Male	55	75.5	178.0	Caucasian	296.2
	43	Reboxetine	WAH	IN	20/03/91	Female	40	56.0	152.0	Caucasian	296.3
	44	Imipramine	PIB	IN	08/04/91	Male	54	67.0	173.0	Caucasian	296.3
	45	Imipramine	J R	IN	26/04/91	Female	36	62.0	175.0	Caucasian	296.3
	46	Reboxetine	GOJ	IN	14/05/91	Female	53	66.0	160.0	Caucasian	296.3
	47	Reboxetine	SAR	IN	17/05/91	Female	56	74.4	168.0	Caucasian	296.3
	48	Imipramine	TBS	IN	23/08/91	Female	61	80.5	159.0	Caucasian	296.3
	49	Imipramine	HEN	IN	27/08/91	Female	52	53.3	162.0	Caucasian	296.3
	50	Reboxetine	HON	IN	31/10/91	Male	54	78.0	173.0	Caucasian	296.3
	51	Reboxetine	VOA	IN	30/10/91	Female	39	70.4	164.0	Caucasian	296.3
	52	Imipramine	SEK	IN	13/11/91	Male	25	77.0	182.0	Caucasian	296.2
3	65	Reboxetine	RK	IN	28/03/91	Male	46	87.0	173.0	Caucasian	296.3
	66	Imipramine	H U	IN	26/04/91	Female	39	52.0	155.0	Caucasian	296.2
	67	Reboxetine	V H	IN	04/04/91	Female	56	65.0	161.0	Caucasian	296.3
	68	Imipramine	E S	IN	01/08/91	Female	52	60.8	160.0	Caucasian	296.3
	69	Imipramine	P J	IN	28/02/91	Female	22	58.5	170.0	Caucasian	296.3
	70	Reboxetine	GB	IN	21/10/91	Female	60	78.0	165.0	Caucasian	296.3
	71	Imipramine	M B	IN	11/11/91	Female	27	55.4	164.0	Caucasian	296.2
	72	Reboxetine	R L	IN	24/01/92	Female	48	55.8	160.0	Caucasian	296.3
	73	Reboxetine	H P	IN	11/02/92	Female	52	80.0	159.0	Caucasian	296.3

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS BRD

HEDONSTONE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)
4	97	Indpramine	H H	IN	23/04/92	Male	22	60.0	175.0	Caucasian	296.3
	100	Reboxetine	K N	IN	27/04/92	Female	34	59.0	168.0	Caucasian	296.3
	101	Indpramine	B K	IN	22/01/91	Female	54	65.0	159.0	Caucasian	296.3
6	161	Reboxetine	A S	IN	26/03/91	Male	30	73.0	176.0	Caucasian	296.2
	162	Reboxetine	D S	IN	31/10/91	Female	56	64.0	163.0	Caucasian	296.2
7	193	Reboxetine	DC	IN	03/05/91	Female	56	73.0	156.0	Caucasian	296.3
	194	Reboxetine	K G	IN	30/05/91	Male	43	120.0	174.0	Caucasian	296.2
	196	Indpramine	CJ	IN	15/03/91	Female	25	51.0	153.0	Caucasian	296.3
8	225	Indpramine	S D	IN	26/02/91	Female	24	75.0	161.0	Caucasian	296.3
	226	Reboxetine	D G	IN	26/04/91	Female	51	60.0	168.0	Caucasian	296.3
	227	Indpramine	L R	IN	27/04/91	Male	27	97.0	180.0	Caucasian	296.2
	228	Reboxetine	V B	IN	06/05/91	Male	36	82.0	171.0	Caucasian	296.3
	229	Indpramine	B C	IN	05/10/91	Female	39	70.0	167.0	Caucasian	296.3
	230	Indpramine	A C	IN	30/10/91	Female	25	64.0	162.0	Caucasian	296.2
	231	Reboxetine	H R	IN	25/10/91	Female	41	57.5		Caucasian	296.3
	232	Reboxetine	B H	IN	22/11/91	Male	41	75.0	170.0	Caucasian	296.2
9	197	Reboxetine	VEA	OUT		Male	51	89.0	173.0	Caucasian	296.3
	198	Indpramine	VDB	OUT		Female	26	63.0	175.0	Caucasian	296.2
	199	Indpramine	T G	OUT		Male	47	84.0	174.0	Caucasian	296.3
	200	Reboxetine	S N	OUT		Male	52	84.0	186.0	Caucasian	296.2
	201	Indpramine	DVG	OUT		Female	52	75.0	158.0	Caucasian	296.2
	202	Indpramine	DCA	OUT		Male	65	67.0	160.0	Caucasian	296.3
	203	Reboxetine	B C	OUT		Female	34	76.0	167.0	Caucasian	296.3
	204	Reboxetine	V A	OUT		Male	45	87.5	189.0	Caucasian	296.3
	205	Indpramine	U K	OUT		Female	41	51.0	159.0	Caucasian	296.2
	206	Indpramine	V L	OUT		Female	58	68.0	168.0	Caucasian	296.3
	207	Reboxetine	S G	OUT		Female	64	72.0	156.0	Caucasian	296.3
	208	Reboxetine	U H	OUT		Male	42	84.0	169.0	Caucasian	296.3
	209	Indpramine	VBL	OUT		Male	32	65.0	168.0	Caucasian	296.3
	210	Reboxetine	VDS	OUT		Female	64	71.0	155.0	Caucasian	296.2
	211	Reboxetine	DPH	IN	11/02/92	Female	37	68.0	166.0	Caucasian	296.3
	212	Indpramine	D I	OUT		Female	25	61.0	163.0	Caucasian	296.2
	237	Reboxetine	M E	OUT		Male	45	75.0	170.0	Caucasian	296.2
	238	Indpramine	M A	OUT		Female	54	77.0	165.0	Caucasian	296.2
	239	Indpramine	L J	OUT		Male	29	100.0	194.0	Caucasian	296.2

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

DESMOXETINE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	HAM-D17-2 (*)
9	240	Reboxetine	V A	OUT		Female	26	62.0	174.0	Caucasian	296.2
	241	Imipramine	DEK	IN	05/05/92	Female	49	81.5	169.0	Caucasian	296.3
	242	Reboxetine	DL	OUT		Male	50	59.0	162.0	Caucasian	296.2
	243	Imipramine	P K	IN	07/05/92	Female	29	55.5	169.0	Caucasian	296.3
	244	Reboxetine	I D	OUT		Male	26	90.0	183.0	Caucasian	296.2
	257	Reboxetine	K K	OUT		Female	25		164.0	Caucasian	296.2
	258	Reboxetine	DMD	OUT		Male	24	79.0	178.0	Caucasian	296.2
	259	Imipramine	DED	OUT		Female	59	65.0	160.0	Caucasian	296.2
	260	Imipramine	DBA	OUT		Female	50	49.0	150.0	Caucasian	296.2
	261	Imipramine	B H	IN	18/07/91	Female	34	94.0	181.0	Caucasian	296.3
	262	Reboxetine	D H	OUT		Male	48	94.0	183.0	Caucasian	296.3
	263	Reboxetine	K V	OUT		Female	36	53.0	165.0	Caucasian	296.2
	264	Imipramine	H L	OUT		Female	46	74.0	169.0	Caucasian	296.3
	265	Reboxetine	SHR	OUT		Female	41	60.0	172.0	Caucasian	296.2
	266	Reboxetine	A H	OUT		Female	42	60.0	162.0	Caucasian	296.2
	267	Imipramine	G A	IN	19/08/91	Male	49	71.5	181.0	Caucasian	296.2
	268	Reboxetine	LMP	OUT		Female	41	92.0	159.0	Caucasian	296.3
	269	Reboxetine	VBK	OUT		Male	57	80.0	173.0	Caucasian	296.2
	270	Imipramine	S K	OUT		Female	48	56.0	160.0	Caucasian	296.2
	271	Reboxetine	VDD	OUT	29/10/91	Female	55	65.0	161.0	Caucasian	296.2
	272	Imipramine	B Y	OUT	29/10/91	Male	62	84.0	168.0	Caucasian	296.3
	273	Imipramine	H K	OUT	29/10/91	Female	35	74.0	163.0	Caucasian	296.2
	274	Reboxetine	UMJ	OUT		Female	47	62.0	160.0	Caucasian	296.3
	274/A	Reboxetine	V K	OUT		Female	46	53.0	163.0	Caucasian	296.2
	275	Reboxetine	DGD	IN	06/08/91	Female	59	69.0	170.0	Caucasian	296.2
	276	Imipramine	H H	OUT		Female	61	71.0	154.0	Caucasian	296.3
	276/A	Imipramine	S H	OUT		Male	41	88.0	182.0	Caucasian	296.3
	253	Imipramine	DMR	OUT		Male	57	72.0	173.0	Caucasian	296.3
9/A	254	Reboxetine	C A	IN	25/03/92	Female	51	49.5	159.0	Caucasian	296.3
	255	Reboxetine	S H	IN	22/05/92	Male	49	63.0	167.0	ARABIAN	296.2
	256	Imipramine	H D	IN	11/05/92	Male	38	78.0	175.0	Caucasian	296.3
	277	Reboxetine	P M	OUT		Female	36	77.0	176.0	Caucasian	296.3
	278	Imipramine	K Y	IN	10/06/92	Female	50	56.3	162.0	Caucasian	296.3
	279	Imipramine	DMJ	IN	21/07/92	Male	26	78.0	184.0	Caucasian	296.3
	280	Reboxetine	UTK	OUT		Female	44	70.0	169.0	Caucasian	296.3
	281	Reboxetine	MA	IN	25/08/92	Female	64	66.0	175.0	Caucasian	296.3
	282	Reboxetine	VJP	IN	09/07/92	Male	33	80.0	178.0	Caucasian	296.3
	283	Imipramine	S D	OUT		Female	58	73.0	163.0	Caucasian	296.3
	284	Imipramine	CJP	IN	16/09/92	Male	35	78.0	180.0	Caucasian	296.3
	301	Imipramine	H C	OUT		Female	44	60.0	165.0	Caucasian	296.2
	302	Imipramine	P H	IN	26/02/92	Male	26	76.0	175.0	Caucasian	296.2
	303	Reboxetine	DCH	IN	07/03/92	Female	29	78.0	175.0	Caucasian	296.3
	304	Reboxetine	D K	IN	10/03/92	Female	41	65.0	161.0	Caucasian	296.2

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-out patient	Patient status Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)
9/A	305	Reboxetine	H H	IN	10/12/91	Male	35	70.0	178.0	Caucasian	296.3
	306	Reboxetine	H A	IN	24/04/92	Female	38	47.7	163.0	Caucasian	296.3
	307	Imipramine	B C	OUT		Female	26	80.0	175.0	Caucasian	296.2
	308	Imipramine	VKD	IN	07/05/92	Female	46	62.0	168.0	Caucasian	296.3
10	289	Imipramine	M J	IN	16/09/91	Female	56	80.0	160.0	Caucasian	296.3
	290	Reboxetine	LM	IN	06/10/91	Male	19	76.2	179.0	Caucasian	296.3
	291	Imipramine	SD	IN	13/02/92	Male	39	84.0	186.0	Caucasian	296.3
	292	Reboxetine	EM	IN	05/12/91	Female	34	69.5	161.0	Caucasian	296.3
	293	Reboxetine	SM	IN	07/11/91	Female	62	59.0	162.0	Caucasian	296.3
	294	Imipramine	LV	IN	20/11/91	Female	63	55.0	154.0	Caucasian	296.3
	295	Imipramine	Y O	IN	16/12/91	Male	43	87.0	180.0	Caucasian	296.2
	296	Reboxetine	S R	IN	14/02/92	Female	48	65.0	161.0	Caucasian	296.3
	297	Reboxetine	E V	IN	18/03/92	Male	28	68.5	178.0	Caucasian	296.2
	298	Reboxetine	M M	IN	18/03/92	Female	58	66.3	153.0	Caucasian	296.3
	299	Imipramine	K L	OUT		Male	23	81.0	174.0	Caucasian	296.2
	300	Imipramine	T B	OUT		Female	34	103.0	158.0	Caucasian	296.3
11	321	Reboxetine	GDP	OUT		Female	43	76.0	170.0	Caucasian	296.2
	322	Reboxetine	SDP	OUT		Female	35	64.0	158.0	Caucasian	296.2
	323	Imipramine	JCY	OUT		Female	26	59.0	153.0	Caucasian	296.2
	324	Imipramine	FPS	OUT		Male	22	70.8	180.0	Caucasian	296.2
	325	Reboxetine	CBB	OUT		Female	18	60.9	168.0	Caucasian	296.2
	326	Imipramine	JCK	OUT		Male	29	83.7	182.0	Caucasian	296.2
	327	Reboxetine	LEP	OUT		Female	38	74.0	168.0	Caucasian	296.2
	328	Imipramine	FAG	OUT		Male	21	79.5	176.0	Caucasian	296.2
	329	Imipramine	EAM	OUT		Female	20	77.5	164.0	Caucasian	296.2
	330	Reboxetine	JJB	OUT		Female	23	75.5	176.0	Caucasian	296.2
	331	Reboxetine	JGO	OUT		Male	43	74.0	180.0	Caucasian	296.3
	332	Imipramine	M T	OUT		Female	27	55.0	165.0	Caucasian	296.2
	333	Imipramine	AMB	OUT		Female	47	74.0	161.0	Caucasian	296.3
12	337	Imipramine	AEB	IN	02/04/92	Female	54	72.5	164.0	Caucasian	296.3
	338	Reboxetine	MAV	IN	01/06/92	Female	65	55.0	147.0	Caucasian	296.3
	339	Imipramine	LK	IN	09/06/92	Male	64	78.0	188.0	Caucasian	296.3
	340	Reboxetine	LCB	IN	23/02/92	Female	44	64.0	161.0	Caucasian	296.3
	341	Reboxetine	AVZ	IN	13/08/92	Female	41	55.0	165.0	Caucasian	296.3
13	353	Reboxetine	LC	OUT		Female	40	73.5	166.0	Black	296.2
	354	Imipramine	L H	OUT		Female	34	47.0	162.0	Black	296.2
	355	Reboxetine	J S	OUT		Female	38	54.5	162.0	Black	296.2

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REMOXETINE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-/out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)
13	356	Imipramine	M M	OUT		Male	36	57.0		Black	296.2
	357	Imipramine	G P	OUT		Female	28	56.5	170.0	Black	296.2
	358	Reboxetine	V S	OUT		Male	50	67.0	168.0	Black	296.2
	359	Reboxetine	A R	OUT		Female	46	58.0	159.0	Black	296.2
	360	Imipramine	C S	OUT		Female	31	67.5	167.0	Black	296.2
	361	Reboxetine	E L	OUT		Female	25	51.0	159.0	Black	296.3
14	457	Reboxetine	A C	OUT		Female	59	62.0	168.0	Caucasian	296.2
	458	Imipramine	D E	OUT		Female	60	57.0	168.0	Caucasian	296.3
	459	Reboxetine	G T	OUT		Male	49	68.0	180.0	Caucasian	296.3
	460	Imipramine	C T	OUT		Male	49	66.0	174.0	Caucasian	296.3
	461	Imipramine	S M	OUT		Female	57	59.0	171.0	Caucasian	296.3
	462	Reboxetine	R M	OUT		Female	55	52.0	164.0	Caucasian	296.3
	463	Imipramine	U R	OUT		Female	62	69.0	176.0	Caucasian	296.3
	464	Reboxetine	B S	OUT		Male	64	51.0	183.0	Caucasian	296.3
	465	Reboxetine	T K	OUT		Female	51	64.0	172.0	Caucasian	296.2
	466	Imipramine	K L	OUT		Female	40	52.0	164.0	Caucasian	296.3
14/1	129	Reboxetine	N M	OUT		Male	59	74.8	169.0	Caucasian	296.2
	426	Reboxetine	M B	OUT		Female	55	61.4	176.0	Caucasian	296.3
	429	Imipramine	S E	OUT		Female	54	64.0	165.0	Caucasian	296.3
	451	Imipramine	SH	OUT		Male	56	90.2	178.0	Caucasian	296.2
	452	Reboxetine	MC	OUT		Female	47	78.0	154.0	Caucasian	296.2
14/2	136	Imipramine	MSD	OUT		Female	29	56.0	165.0	Caucasian	296.3
	456	Imipramine	AKM	OUT		Male	45	89.0	174.0	Caucasian	296.2
14/3	417	Reboxetine	D A	OUT		Female	27	56.0	165.0	Caucasian	296.3
	418	Imipramine	E P	OUT		Female	49	62.0	158.0	Caucasian	296.3
	419	Reboxetine	E K	OUT		Female	54	71.0	163.0	Caucasian	296.3
	420	Imipramine	K K	OUT		Female	36	59.0	160.0	Caucasian	296.3
	421	Reboxetine	K C	OUT		Female	27	64.0	170.0	Caucasian	296.3
	427	Imipramine	G K	OUT		Female	55	85.0	165.0	Caucasian	296.2
	428	Imipramine	K J	OUT		Female	28	54.0	160.0	Caucasian	296.3
14/4	131	Imipramine	PE	OUT		Female	60	72.0	164.0	Caucasian	296.3
	132	Imipramine	S K	OUT		Female	32	64.0	165.0	Caucasian	296.2
	133	Imipramine	K K	OUT		Female	38	70.0	164.0	Caucasian	296.2
	134	Reboxetine	K S	OUT		Female	26	58.0	162.0	Caucasian	296.3
	135	Reboxetine	B A	OUT		Male	58	85.0	179.0	Caucasian	296.2

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CHS BRD

REBOXETINE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status In-or-out patient	Hospital date	Sex	Age (years)	Height (kg)	Weight (cm)	Race	DSM-III-R (*)
14/7	422	Indpramine	D B	OUT		Female	51	72.4	171.0	Caucasian	296.3
	425	Indpramine	S C	OUT		Female	46	68.7	178.0	Caucasian	296.3
	424	Reboxetine	K H	OUT		Male	62	63.0	167.0	Caucasian	296.3
	430	Reboxetine	K J	OUT		Female	55	70.0	165.0	Caucasian	296.2
	431	Reboxetine	K A	OUT		Male	49	68.0	185.0	Caucasian	296.2
	432	Indpramine	K H	OUT		Male	42	81.5	178.0	Caucasian	296.2
	433	Indpramine	G D	OUT		Female	51	53.0	162.0	Caucasian	296.3
	434	Reboxetine	K H	OUT		Male	40	79.0	165.0	Caucasian	296.2
	439	Reboxetine	K K	OUT		Male	64	64.0	161.0	Caucasian	296.3
	440	Indpramine	K E	OUT		Female	23	56.0	158.0	Caucasian	296.2
	441	Indpramine	S D	OUT		Male	35	76.0	180.0	Caucasian	296.2
	442	Indpramine	K H	OUT		Male	38	78.0	172.0	Caucasian	296.2
	449	Reboxetine	K G	OUT		Female	48	63.0	160.0	Caucasian	296.2
	450	Indpramine	J D	OUT		Male	54	80.0	176.0	Caucasian	296.2
14/8	130	Reboxetine	F H	OUT		Male	54	81.0	178.0	Caucasian	296.3
	435	Reboxetine	L K	OUT		Female	57	70.0	168.0	Caucasian	296.3
	407	Reboxetine	H S	OUT		Male	63	80.0	178.0	Caucasian	296.3
14/10	53	Reboxetine	L F	OUT		Male	58	68.2	169.0	Caucasian	296.3
	54	Indpramine	E P	OUT		Female	63	73.8	165.0	Caucasian	296.2
	55	Reboxetine	AF	OUT		Female	57	57.0	167.0	Caucasian	296.3
	56	Indpramine	H H	OUT		Female	62	67.2	164.0	Caucasian	296.2
	57	Reboxetine	O U	OUT		Female	58	62.3	162.0	Caucasian	296.2
	58	Indpramine	E K	OUT		Female	56	59.2	163.0	Caucasian	296.2
	59	Indpramine	J E	OUT		Female	52	62.5	164.0	Caucasian	296.2
	60	Reboxetine	U H	OUT		Female	47	72.5	169.0	Caucasian	296.3
	137	Reboxetine	H O	OUT		Female	58	62.2	165.0	Caucasian	296.3
	138	Indpramine	S S	OUT		Female	51	59.2	164.0	Caucasian	296.2
	139	Reboxetine	B B	OUT		Female	44	67.2	168.0	Caucasian	296.2
	140	Indpramine	H E	OUT		Female	63	67.2	162.0	Caucasian	296.3
	435	Indpramine	H P	OUT		Female	61	77.2	169.0	Caucasian	296.3
	436	Reboxetine	E K	OUT		Female	49	68.2	171.0	Caucasian	296.2
	437	Reboxetine	S A	OUT		Female	44	71.3	163.0	Asian	296.2
	438	Indpramine	H K	OUT		Female	51	67.2	172.0	Caucasian	296.2
	443	Reboxetine	H S	OUT		Female	58	63.7	164.0	Caucasian	296.3
	444	Reboxetine	A R	OUT		Male	43	64.2	165.0	Caucasian	296.2
	445	Indpramine	H H	OUT		Female	63	72.2	169.0	Caucasian	296.3
	446	Reboxetine	E K	OUT		Female	64	63.2	166.0	Caucasian	296.2
	447	Reboxetine	HK	OUT		Male	60	69.2	167.0	Caucasian	296.3
	448	Indpramine	A K	OUT		Female	55	65.2	168.0	Caucasian	296.2

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Treatment	Initials	Patient status: In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)
14/10	453	Imipramine	J G	OUT		Female	55	67.2	167.0	Caucasian	296.2
	454	Reboxetine	M Z	OUT		Female	56	62.2	173.0	Caucasian	296.2
	455	Reboxetine	H H	OUT		Female	62	58.2	172.0	Caucasian	296.2
15	349	Imipramine	MS	OUT		Male	21	62.0	175.0	Caucasian	296.2
	351	Reboxetine	AO	IN	02/09/92	Male	58	60.0	165.5	Asian	296.3
	352	Imipramine	BQA	OUT		Male	24	75.0	185.0	Black	296.3
	364	Imipramine	AJJ	IN	29/07/92	Female	36	55.0	157.0	Caucasian	296.3
	366	Reboxetine	SK	IN	20/08/92	Male	28	49.8	169.0	Black	296.2
	367	Imipramine	MRK	OUT		Male	32	81.0	166.0	Black	296.3
	368	Reboxetine	VH	IN	24/07/92	Female	50	80.0	168.0	Black	296.3
	369	Reboxetine	ZS	OUT		Female	26	63.0	164.0	Black	296.3
	370	Imipramine	LAS	IN	16/07/92	Female	30	96.0	168.0	Caucasian	296.3
	371	Reboxetine	XO	OUT		Female	22	65.0	147.0	Black	296.3
	372	Imipramine	N S	IN	13/08/92	Male	36	37.5	167.0	Black	296.2
	373	Imipramine	BJT	IN	25/06/92	Female	28	68.0	167.0	Caucasian	296.2
	374	Reboxetine	SLN	IN	08/04/92	Female	48	49.0	155.0	Caucasian	296.3
	375	Reboxetine	CVB	IN	04/06/92	Female	35	60.0	161.0	Black	296.2
	376	Imipramine	GRN	IN	13/04/92	Female	66	59.0	150.0	Caucasian	296.3
	377	Reboxetine	DAK	IN	08/05/92	Female	37	63.5	160.5	Caucasian	296.3
	378	Reboxetine	KBC	IN	10/06/92	Female	34	62.0	166.0	Caucasian	296.3
	379	Imipramine	CL	OUT		Female	23	55.0	166.0	Caucasian	296.3
	380	Imipramine	VLC	IN	29/06/92	Female	49	53.0	159.0	Black	296.3
	381	Reboxetine	MLS	IN	21/05/92	Female	21	65.0	164.0	Caucasian	296.3
	382	Imipramine	A M	OUT		Male	19	66.0	169.0	Caucasian	296.3
	383	Imipramine	JAH	OUT		Female	36	63.0	148.0	Caucasian	296.3
	384	Reboxetine	PJE	IN	27/07/92	Female	65	47.0	165.0	Caucasian	296.3

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder			Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
1	1		36	9	3 months	2 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	2		45	4	4 months	7 days	Similar prev. cond.	Acute (< 2 weeks)	Absent
	3		41	0		4 months	First occurence	Insidious (>= 3 months)	Definitely present
	4		28	2	5 months	3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	5		40	1	5 months	3 months	Chronic condition	Insidious (>= 3 months)	Absent
	6		61	0		9 weeks	Different prev. cond.	Insidious (>= 3 months)	Definitely present
	7		39	9	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	8		30	10	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	9		64	1	4 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	10		38	2	3 months	4 weeks	Chronic condition	Subacute (>= 2 weeks)	Probably present
	11		45	3	7 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	12		25	2	4 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
2	33		48	1	2 months	3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	34		40	0		4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	35		20	2	3 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	36		27	1	6 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	37		37	1	3 months	4 weeks	Similar prev. cond.	Insidious (>= 3 months)	Absent
	38		40	6	6 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	39		46	0		3 months and 2 weeks	First occurence	Acute (< 2 weeks)	Probably present
	40		41	0		4 weeks	First occurence	Insidious (>= 3 months)	Definitely present
	41		30	1	2 years and 6 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	42		54	0		4 months	First occurence	Insidious (>= 3 months)	Absent
	43		39	1	1 year	3 months	Chronic condition	Insidious (>= 3 months)	Absent
	44		53	1	8 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	45		31	1	1 year	3 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	46		30	4	6 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	47		50	1		1 month	Chronic condition	Subacute (>= 2 weeks)	Definitely present
	48		51	1	4 months	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	49		50	1	4 weeks	3 months and 2 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	50		53	1	7 months	1 month	Similar prev. cond.	Acute (< 2 weeks)	Absent
	51		25	2	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	52		25	0		2 months	First occurence	Subacute (>= 2 weeks)	Absent
3	65		41	2	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	66		38			4 months	First occurence	Insidious (>= 3 months)	Absent
	67		46	5	4 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	68		50	2	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	69		20	3	4 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	70		54	15	2 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	71		27			6 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	72		38	1	6 months	8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	73		35	5	2 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
4	97		17	1	2 months	3 months	Different prev. cond.	Insidious (>= 3 months)	Probably present
	100		30	1	4 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	101		50	1	1 year	4 months	Similar prev. cond.	Acute (< 2 weeks)	Definitely present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
6	161		30	0		7 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	162		56	0		5 weeks	First occurence	Subacute (>= 2 weeks)	Absent
7	193	Yes				1 month	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	194	Yes				1 month	First occurence	Subacute (>= 2 weeks)	Definitely present
	196	Yes				6 weeks	Different prev. cond.	Insidious (>= 3 months)	Definitely present
8	225		22	5	2 months	5 weeks	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
	226		49	2	3 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	227		27	0		1 month	Different prev. cond.	Acute (< 2 weeks)	Definitely present
	228		22	5	6 weeks	30 days	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
	229		25	2	6 months	3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	230		24	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	231		35	1	2 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	232	Yes				1 month	First occurence	Acute (< 2 weeks)	Definitely present
9	197		45	1	2 months	12 weeks	Chronic condition	Insidious (>= 3 months)	Absent
	198		26	0		5 weeks	First occurence	Acute (< 2 weeks)	Probably present
	199		35	1	4 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	200	Yes		0		2 months	First occurence	Subacute (>= 2 weeks)	Probably present
	201		52	0		2 months	First occurence	Subacute (>= 2 weeks)	Absent
	202		51	2	6 months	6 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	203		29	3	4 months	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	204		36	1	24 weeks	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	205		41	0		14 weeks	First occurence	Insidious (>= 3 months)	Absent
	206		30	1	6 months	10 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	207		61	2	2 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	208		40	1	1 year	8 weeks	Chronic condition	Insidious (>= 3 months)	Probably present
	209		28	1	4 months	8 weeks	Different prev. cond.	Insidious (>= 3 months)	Probably present
	210		64	0		6 weeks	First occurence	Insidious (>= 3 months)	Probably present
	211		30	2	7 weeks	10 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	212		25	0		10 weeks	First occurence	Insidious (>= 3 months)	Probably present
	237	Yes				8 weeks	First occurence	Insidious (>= 3 months)	Absent
	238	Yes				8 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	239	Yes				2 months and 2 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	240	Yes				5 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	241		42	1	4 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	242	Yes				3 months	First occurence	Subacute (>= 2 weeks)	Probably present
	243		25	2	1 year	3 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	244	Yes				2 months	First occurence	Insidious (>= 3 months)	Absent
	257	Yes				5 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	258		24	0		13 weeks	First occurence	Insidious (>= 3 months)	Probably present
	259	Yes				6 weeks	First occurence	Insidious (>= 3 months)	Absent
	260	Yes				8 weeks	First occurence	Acute (< 2 weeks)	Absent
	261		22	2	4 months	6 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
9	262		41	1	5 weeks	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	263	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	264		38	2	4 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	265	Yes				3 months	First occurence	Insidious (>= 3 months)	Absent
	266	Yes					First occurence		Absent
	267		46	0		3 months	First occurence	Insidious (>= 3 months)	Definitely present
	268		21	3	4 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	269	Yes				3 months	First occurence	Insidious (>= 3 months)	Probably present
	270	Yes				8 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	271	Yes				2 months	Chronic condition	Insidious (>= 3 months)	Probably present
	272		54	1	2 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	273		35			4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	274		45	1	3 weeks	8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	274/A		45	0		3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	275	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Absent
	276		60	1	4 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	276/A		27	3	1 year and 2 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
9/A	233		56	3	12 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	234		25	4	4 months	4 weeks	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	235		49	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	236		21	8	4 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	277		33	4	3 months	2 months and 3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	278		40	3	4 months	4 weeks	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	279		25	2	2 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	280		43	3	8 weeks	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	281		57	3	6 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	282		25	10	5 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	283		56	2	2 months	4 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	284		35	0		6 weeks	First occurence	Acute (< 2 weeks)	Probably present
	301		44	0		3 months	First occurence	Subacute (>= 2 weeks)	Probably present
	302		23	2	3 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	303		29			4 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	304		20	4	3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	305		22	5	6 months	6 weeks	Similar prev. cond.	Insidious (>= 3 months)	Absent
	306		35	3	2 months	5 weeks	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	307		26	0		10 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	308		35	1	1 year	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
10	289		46	2	1 month	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	290		15		2 months	2 months	Chronic condition	Subacute (>= 2 weeks)	Probably present
	291		30		2 months	4 months	Chronic condition	Insidious (>= 3 months)	Probably present
	292		25	5	3 weeks	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	293		58			3 months	Chronic condition	Subacute (>= 2 weeks)	Absent
	294		52	3	4 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	295	Yes		0		2 months	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
	296		47	2	2 months	6 weeks	Similar prev. cond.	Insidious (>= 3 months)	Absent
	297	Yes				1 month	First occurence	Acute (< 2 weeks)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
10	298	Yes				1 month and 2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	299		21	0		2 months	Chronic condition	Insidious (>= 3 months)	Probably present
	300		29	3	4 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
11	321		43	0		4 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Probably present
	322	Yes				1 month	First occurence	Subacute (>= 2 weeks)	Definitely present
	323		26	0		3 months	First occurence	Insidious (>= 3 months)	Definitely present
	324		22	0		2 months	First occurence	Insidious (>= 3 months)	Probably present
	325		18			3 months	First occurence	Insidious (>= 3 months)	Probably present
	326		29			3 months	First occurence	Insidious (>= 3 months)	Probably present
	327	Yes				3 months	First occurence	Insidious (>= 3 months)	Definitely present
	328	Yes				3 months	First occurence	Insidious (>= 3 months)	Probably present
	329	Yes				3 months	First occurence	Insidious (>= 3 months)	Probably present
	330	Yes	23	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	331		41	2	3 months	2 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	332		27	0		3 months	First occurence	Insidious (>= 3 months)	Definitely present
	333	Yes			1 year	4 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
12	337		52	1	7 months	3 months	Similar prev. cond.	Acute (< 2 weeks)	Definitely present
	338		40	15	5 months	3 months and 2 weeks	Chronic condition	Acute (< 2 weeks)	Absent
	339		46	2	1 year	1 month	Chronic condition	Acute (< 2 weeks)	Definitely present
	340		34	12	6 months	7 weeks	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	341		30	4	6 months	2 months and 3 weeks	Chronic condition	Insidious (>= 3 months)	Absent
13	353		40	0		9 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	354	Yes				4 months	First occurence	Insidious (>= 3 months)	Probably present
	355		38	0		4 months	Different prev. cond.	Insidious (>= 3 months)	Definitely present
	356	Yes		0		4 months	First occurence	Acute (< 2 weeks)	Definitely present
	357	Yes				4 months	First occurence	Insidious (>= 3 months)	Probably present
	358	Yes				3 months	First occurence	Insidious (>= 3 months)	Probably present
	359	Yes				12 months	Chronic condition	Insidious (>= 3 months)	Probably present
	360	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	361		20	1	1 year	4 months	Different prev. cond.	Insidious (>= 3 months)	Absent
14	457		59	0		2 months	First occurence	Subacute (>= 2 weeks)	Absent
	458		54	5	2 months	34 days	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	459		48	1	3 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	460		46	3	10 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	461		54	4	8 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	462	Yes				7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	463		58	3	6 weeks	8 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	464		62	6	2 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	465		50	0		2 months	First occurence	Subacute (>= 2 weeks)	Absent
	466		39	2	2 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
14/1	129		58	0		6 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	426		54	1	10 weeks	10 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	429		50	1	14 months	10 weeks	Chronic condition	Subacute (>= 2 weeks)	Definitely present
	451		56	0		13 weeks	Chronic condition	Insidious (>= 3 months)	Probably present
	452		45	0		8 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
14/2	136		27	1	6 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	456	Yes				3 months	First occurence	Subacute (>= 2 weeks)	Probably present
14/3	417		25	1	7 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	418		45	2	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	419		25	4		8 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Absent
	420		25	10	6 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	421		24	1	6 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	427	Yes				3 months	Chronic condition	Insidious (>= 3 months)	Absent
	428		20	2	10 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
14/4	131		52	4	4 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	132	Yes				8 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	133	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	134		23	2	4 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	135	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
14/7	422	Yes	39	2	2 weeks	1 month and 3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	423	Yes	46	1	2 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	424		61	1	8 weeks	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	430	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Absent
	431	Yes				2 months and 2 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	432	Yes				1 month	First occurence	Subacute (>= 2 weeks)	Definitely present
	433		51	1	4 weeks	1 month and 8 days	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	434	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	439		64	1	3 months	1 month and 1 week	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	440	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Probably present
	441	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	442	Yes				2 months	First occurence	Subacute (>= 2 weeks)	Definitely present
	449	Yes				2 months and 2 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	450	Yes				1 month and 2 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
14/8	130		45	3	3 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	425	Yes				5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	467	Yes				5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
14/10	53		52	2	5 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	54		63	0		7 weeks	First occurence	Subacute (>= 2 weeks)	Probably present

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 2.0

HISTORY OF MENTAL DISORDER AND PRESENT EPISODE

		History of mental disorder				Present episode			
Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Onset was	External stress
14/10	55		54	1	5 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	56		61	0		7 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	57		58	0		8 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	58		56	0		6 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	59		51	0		5 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	60		42	1	4 months	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	137		55	1	4 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	138		51	0		7 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	139		44	0		8 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	140		61	1	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	435		56	2	6 months	4 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	436		49	0		6 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	437		44	0		4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	438		51	0		5 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	443		49	3	11 weeks	5 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	444		43	0		4 weeks	First occurence	Subacute (>= 2 weeks)	Probably present
	445		60	1	4 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	446		64	0		5 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	447		59	1	5 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	448		55	0		5 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	453		55	0		7 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	454	Yes				6 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
	455		62			7 weeks	First occurence	Subacute (>= 2 weeks)	Definitely present
15	349		21	0		2 months	First occurence	Subacute (>= 2 weeks)	Absent
	351		32	40	1 month	3 weeks	Different prev. cond.	Acute (< 2 weeks)	Definitely present
	352		23	1	5 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	364		32	1	5 months	2 months and 2 weeks	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	366		28	0		2 months	First occurence	Insidious (>= 3 months)	Definitely present
	367		26	11	5 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	368		39	8	3 weeks	3 months and 2 weeks	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	369		16	8	2 months and 2 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	370		20	10	3 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	371		16	4	3 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	372	Yes				3 months and 2 weeks	First occurence	Insidious (>= 3 months)	Absent
	373		28	0		3 months	First occurence	Insidious (>= 3 months)	Definitely present
	374		40	3	4 weeks	4 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Definitely present
	375		34	0		3 months	First occurence	Insidious (>= 3 months)	Probably present
	376		64	9	5 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	377		20	6	2 months	2 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	378		25	6	5 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	379		18	2	4 months	2 weeks	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	380		20	3	13 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	381		20	1	2 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	382			10	1 month	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	383		22	4	2 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	384		57	2	3 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/017
Listing No.: 3.0

DSM-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.

1) depressed mood most of day, nearly every day, as indicated by subjective account or observation by others

2) markedly diminished interest or pleasure in all, or almost all, activities most of day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time

3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day

4) insomnia or hypersomnia nearly every day

5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)

6) fatigue or loss of energy nearly every day

7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)

8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)

9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

B. 1) it cannot be established that an organic factor initiated and maintained the disturbance

2) the disturbance is not a normal reaction to the death of a loved one

C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)

D. Not superimposed on Schizophrenia, Schizophreniform, Disorder, Delusional Disorder, or Psychotic Disorder NOS.

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

						A items								B items		C	D
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
1	1	Male	52	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	2	Female	55	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	3	Female	41	296.2	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	4	Male	53	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	5	Female	57	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	6	Male	62	296.2	x	x	x		x	x	x	x	x		x	x	x	x	x
	7	Male	54	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	8	Male	50	296.3	x	x	x		x	x	x	x	x	x	x	x	x	x	x
	9	Female	65	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	10	Female	46	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	11	Male	50	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	12	Male	27	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
2	33	Male	48	296.3	x	x	x		x	x	x	x		x	x	x	x	x	x
	34	Male	43	296.2	x	x	x			x	x	x	x		x	x	x	x	x
	35	Male	34	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	36	Female	29	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	37	Male	42	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	38	Female	54	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	39	Female	46	296.2	x	x	x		x	x	x	x	x		x	x	x	x	x
	40	Male	42	296.2	x	x	x		x	x	x	x	x		x	x	x	x	x
	41	Male	50	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	42	Male	55	296.2	x	x	x			x	x	x	x		x	x	x	x	x
	43	Female	40	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	44	Male	54	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	45	Female	36	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	46	Female	53	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	47	Female	56	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	48	Female	61	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	49	Female	52	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	50	Male	54	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	51	Female	39	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	52	Male	25	296.2	x	x	x			x	x	x	x		x	x	x	x	x
3	65	Male	46	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	66	Female	39	296.2	x	x		x		x	x	x	x		x	x	x	x	x
	67	Female	56	296.3	x		x		x		x		x	x	x	x	x	x	x
	68	Female	52	296.3	x		x	x	x	x	x	x	x		x	x	x	x	x
	69	Female	22	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	70	Female	60	296.3	x	x	x		x	x	x	x			x	x	x	x	x
	71	Female	27	296.2	x	x	x		x	x	x	x	x		x	x	x	x	x
	72	Female	48	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	73	Female	52	296.3	x	x	x			x	x	x	x		x	x	x	x	x
4	97	Male	22	296.3	x	x	x		x		x		x	x	x	x	x	x	x
	100	Female	34	296.3	x	x	x	x	x	x	x	x	x		x	x	x	x	x
	101	Female	54	296.3	x	x	x	x	x	x	x		x		x	x	x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A Present	A 1)	A 2)	A 3)	A 4)	A 5)	A 6)	A 7)	A 8)	A 9)	B Present	B items 1)	B items 2)	C Present	D Present
6	161	Male	30	296.2	x	x	x	x	x	x	x		x		x	x	x	x	x
	162	Female	56	296.2	x	x	x	x	x	x	x		x		x	x	x	x	x
7	193	Female	56	296.3	x	x	x		x	x	x		x	x	x	x	x	x	x
	194	Male	43	296.2	x	x	x				x		x	x	x	x	x	x	x
	196	Female	23	296.3	x	x	x		x		x	x	x	x	x	x	x	x	x
8	225	Female	24	296.3	x	x	x	x	x		x	x		x	x			x	x
	226	Female	51	296.3	x	x	x	x	x		x			x	x			x	x
	227	Male	27	296.2	x	x	x		x		x	x		x	x			x	x
	228	Male	36	296.3	x	x	x			x	x	x	x	x	x	x	x	x	x
	229	Female	39	296.3	x	x	x		x	x	x		x	x	x	x	x	x	x
	230	Female	25	296.2	x	x	x				x	x	x	x	x	x	x	x	x
	231	Female	41	296.3	x	x	x		x		x	x	x	x	x	x	x	x	x
	232	Male	41	296.2	x	x	x		x	x	x	x		x	x	x	x	x	x
9	197	Male	51	296.3	x	x	x	x			x	x	x	x	x	x	x	x	x
	198	Female	26	296.2	x	x	x		x		x	x			x	x	x	x	x
	199	Male	47	296.3	x	x	x		x	x	x	x	x		x	x	x	x	x
	200	Male	32	296.2	x	x	x		x	x	x				x	x	x	x	x
	201	Female	52	296.2	x	x	x			x	x	x			x	x	x	x	x
	202	Male	65	296.3	x	x	x			x	x	x			x	x	x	x	x
	203	Female	34	296.3	x	x	x		x	x	x	x			x	x	x	x	x
	204	Male	45	296.3	x	x	x			x	x	x	x		x	x	x	x	x
	205	Female	41	296.2	x	x	x		x	x	x				x	x	x	x	x
	206	Female	50	296.3	x	x	x		x	x	x				x	x	x	x	x
	207	Female	64	296.3	x	x	x	x		x	x		x		x	x	x	x	x
	208	Male	42	296.3	x	x	x		x	x	x				x	x	x	x	x
	209	Male	32	296.3	x	x	x		x	x	x	x			x	x	x	x	x
	210	Female	64	296.2	x	x	x		x	x	x				x	x	x	x	x
	211	Female	37	296.3	x	x	x		x		x	x			x	x	x	x	x
	212	Female	25	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	237	Male	45	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	238	Female	54	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	239	Male	29	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	240	Female	26	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	241	Female	49	296.3	x	x	x		x	x	x	x			x	x	x	x	x
	242	Male	50	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	243	Female	29	296.3	x	x	x		x	x	x	x			x	x	x	x	x
	244	Male	26	296.2	x	x	x			x	x	x			x	x	x	x	x
	257	Female	25	296.2	x	x	x				x	x			x	x	x	x	x
	258	Male	24	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	259	Female	59	296.2	x	x	x		x	x	x	x			x	x	x	x	x
	260	Female	30	296.2	x	x	x		x	x	x				x	x	x	x	x
	261	Female	34	296.3	x	x	x		x	x	x	x			x	x	x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
9	262	Male	48	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	263	Female	36	296.2	X	X	X		X	X	X	X			X			X	X
	264	Female	46	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	265	Female	41	296.2	X	X	X	X	X	X	X		X		X			X	X
	266	Female	42	296.2	X	X	X		X	X	X	X	X		X	X	X	X	X
	267	Male	49	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	268	Female	41	296.3	X	X	X		X	X	X	X	X		X			X	X
	269	Male	57	296.2	X	X	X		X	X	X	X	X		X			X	X
	270	Female	43	296.2	X	X	X			X	X	X			X			X	X
	271	Female	55	296.2	X	X	X		X	X	X	X	X		X			X	X
	272	Male	62	296.3	X	X	X		X	X	X	X	X		X			X	X
	273	Female	35	296.2	X	X	X	X	X	X	X		X		X			X	X
	274	Female	47	296.3	X	X	X		X	X	X	X	X		X			X	X
	274/A	Female	46	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	275	Female	59	296.2	X	X	X		X		X		X		X			X	X
	276	Female	61	296.3	X	X	X		X		X		X		X	X	X	X	X
	276/A	Male	41	296.3	X		X			X	X	X	X		X	X	X	X	X
9/A	233	Male	57	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	234	Female	31	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	235	Male	49	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	236	Male	38	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	277	Female	36	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	278	Female	50	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	279	Male	26	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	280	Female	44	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	281	Female	64	296.3	X	X	X		X	X	X	X		X	X	X	X	X	X
	282	Male	35	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	283	Female	58	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	284	Male	35	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	301	Female	44	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	302	Male	26	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	303	Female	29	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	304	Female	41	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	305	Male	35	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	306	Female	38	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	307	Female	26	296.2	X	X	X			X	X	X	X		X	X	X	X	X
	308	Female	46	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
10	289	Female	56	296.3	X	X	X		X		X		X		X	X	X	X	X
	290	Male	19	296.3	X	X	X		X			X	X	X	X	X	X	X	X
	291	Male	39	296.3	X	X	X		X		X		X	X	X	X	X	X	X
	292	Female	34	296.3	X	X	X	X	X	X	X	X		X	X			X	X
	293	Female	62	296.3	X	X	X	X			X		X		X	X	X	X	X
	294	Female	63	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	295	Male	43	296.2	X	X	X	X	X		X	X	X		X	X	X	X	X
	296	Female	48	296.3	X	X	X	X	X		X	X	X	X	X	X	X	X	X
	297	Male	28	296.2	X	X	X	X	X	X	X		X		X	X	X	X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A items 1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	B items 1)	2)	Present	C	D Present
10	298	Female	58	296.3	x	x	x		x	x		x		x	x	x	x	x	x
	299	Male	23	296.2	x	x	x		x	x		x		x	x	x	x	x	x
	300	Female	34	296.3	x	x	x		x	x		x		x	x	x	x	x	x
11	321	Female	43	296.2	x	x	x	x	x	x		x	x	x	x	x	x	x	x
	322	Female	35	296.2	x	x	x	x	x	x	x	x		x	x	x	x	x	x
	323	Female	26	296.2	x	x	x	x	x	x		x	x	x	x	x	x	x	x
	324	Male	22	296.2	x	x	x	x	x	x	x	x		x	x	x	x	x	x
	325	Female	18	296.2	x	x	x	x		x		x	x	x	x	x	x	x	x
	326	Male	29	296.2	x	x	x	x		x		x	x	x	x	x	x	x	x
	327	Female	38	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	328	Male	21	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	329	Female	20	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	330	Female	23	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	331	Male	43	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	332	Female	27	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	333	Female	47	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
12	337	Female	54	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	338	Female	65	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	339	Male	64	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	340	Female	44	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	341	Female	41	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
13	353	Female	40	296.2	x	x	x	x			x			x	x	x	x	x	x
	354	Female	34	296.2	x	x	x			x				x	x	x	x	x	x
	355	Female	38	296.2	x	x	x	x	x		x			x	x		x	x	x
	356	Male	36	296.2	x	x	x	x	x			x		x	x	x	x	x	x
	357	Female	20	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	358	Male	50	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	359	Female	46	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	360	Female	31	296.2	x	x	x	x	x	x		x		x	x	x	x	x	x
	361	Female	25	296.3	x	x	x												
14	457	Female	59	296.2	x	x	x	x	x	x	x	x		x	x	x	x	x	x
	458	Female	60	296.3	x	x	x		x	x		x		x	x	x	x	x	x
	459	Male	49	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	460	Male	49	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	461	Female	57	296.3	x	x	x	x	x	x	x	x		x	x	x	x	x	x
	462	Female	55	296.3	x	x	x	x	x	x	x	x		x	x	x	x	x	x
	463	Male	62	296.3	x	x	x	x	x	x		x		x	x	x	x	x	x
	464	Female	64	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	465	Male	51	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	466	Female	40	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

					A										B			C	D
						items										items			
Centre	Patient	Sex	Age	DSM-III-R	Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
14/1	129	Male	59	296.2	X	X	X		X	X	X		X		X	X	X	X	X
	426	Female	55	296.3	X	X	X		X	X	X		X	X	X	X	X	X	X
	429	Female	54	296.3	X	X	X		X	X			X	X	X	X	X	X	X
	451	Male	56	296.2	X	X	X		X	X	X		X		X	X	X	X	X
	452	Female	47	296.2	X	X	X		X	X	X		X		X	X	X	X	X
14/2	136	Female	29	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	456	Male	45	296.2	X	X	X		X	X	X		X	X	X	X	X	X	X
14/3	417	Female	27	296.3	X	X	X		X	X	X		X	X	X	X	X	X	X
	418	Female	49	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	419	Female	54	296.3	X	X	X			X	X	X	X	X	X	X	X	X	X
	420	Female	38	296.3	X	X	X	X		X	X	X	X	X	X	X	X	X	X
	421	Female	27	296.3	X	X	X		X	X	X	X	X		X			X	X
	427	Female	55	296.2	X	X	X		X		X		X	X	X			X	X
	428	Female	28	296.3	X	X	X		X	X	X	X	X	X	X	X	X	X	X
14/4	131	Female	60	296.3	X	X	X	X	X		X		X		X	X	X	X	X
	132	Female	32	296.2	X	X	X	X	X		X		X		X	X	X	X	X
	133	Female	38	296.2	X	X	X	X	X	X	X		X		X	X	X	X	X
	134	Female	26	296.3	X	X	X	X	X	X	X	X	X		X	X	X	X	X
	135	Male	58	296.2	X	X	X	X	X	X	X	X	X		X	X	X	X	X
14/7	422	Female	51	296.3	X		X	X		X	X	X	X		X	X	X	X	X
	423	Female	46	296.3	X	X	X	X		X	X		X		X	X	X	X	X
	424	Male	62	296.3	X	X	X	X		X	X	X	X		X	X	X	X	X
	430	Female	55	296.2	X		X	X		X	X	X	X		X	X	X	X	X
	431	Male	43	296.2	X	X	X			X	X	X	X		X	X	X	X	X
	432	Male	42	296.2	X	X	X			X	X	X	X	X	X	X	X	X	X
	433	Female	51	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	434	Male	40	296.2	X	X	X	X			X	X	X	X	X	X	X	X	X
	439	Male	64	296.3	X	X	X			X	X	X	X		X	X	X	X	X
	440	Female	23	296.2	X	X	X			X	X	X	X		X	X	X	X	X
	441	Male	33	296.2	X	X	X			X	X	X	X		X	X	X	X	X
	442	Male	38	296.2	X	X	X			X	X	X	X		X	X	X	X	X
	449	Female	48	296.2	X	X	X			X	X	X	X	X	X	X	X	X	X
	450	Male	54	296.2	X	X	X			X	X	X	X	X	X	X	X	X	X
14/8	130	Male	54	296.3	X	X	X			X	X		X		X	X	X	X	X
	425	Female	57	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
	467	Male	63	296.3	X	X	X		X	X	X	X	X		X	X	X	X	X
14/10	53	Male	58	296.3	X	X	X	X	X	X	X	X	X		X			X	X
	54	Female	63	296.2	X	X	X		X	X	X	X	X	X	X			X	X

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A items 1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	B items 1)	2)	C Present	D Present
14/10	55	Female	57	296.3	x	x	x	x	x	x	x	x	x	x			x	x
	56	Female	62	296.2	x	x	x	x	x	x		x	x	x			x	x
	57	Female	58	296.2	x	x	x	x	x	x	x	x	x	x			x	x
	58	Female	56	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	59	Female	52	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	60	Female	47	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	137	Female	58	296.3	x	x	x	x	x	x	x	x	x	x			x	x
	138	Female	51	296.2	x	x	x	x	x	x	x	x	x	x			x	x
	139	Female	44	296.2	x	x	x	x	x	x	x	x	x	x			x	x
	140	Female	63	296.3	x	x	x	x	x	x	x	x	x	x			x	x
	435	Female	61	296.3	x	x	x	x	x	x	x	x	x	x			x	x
	436	Female	49	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	437	Female	44	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	438	Female	51	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	443	Female	58	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	444	Male	43	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	445	Female	63	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	446	Female	64	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	447	Male	60	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	448	Female	55	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	453	Female	55	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	454	Female	56	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	455	Female	62	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
15	349	Male	21	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	351	Male	58	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	352	Male	24	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	364	Female	36	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	366	Male	28	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	367	Male	32	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	368	Female	50	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	369	Female	26	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	370	Female	30	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	371	Female	22	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	372	Male	36	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	373	Female	28	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	374	Female	48	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	375	Female	35	296.2	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	376	Female	66	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	377	Female	37	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	378	Female	34	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	379	Female	23	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	380	Female	49	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	381	Female	21	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	382	Male	19	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	383	Female	36	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	384	Female	65	296.3	x	x	x	x	x	x	x	x	x	x	x	x	x	x

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
1	4	Male	53	ESSENTIAL HYPERTENSION CHR LIVER DIS/CIRRHOSIS	
	8	Male	50	SCIATIC NERVE LESION	
	9	Female	65	MALIGN NEOPL OVARY ACUTE PANCREATITIS TRANSIENT CEREB ISCHEMIA	
	10	Female	46	DIABETES MELLITUS DUODENAL ULCER NOS	
2	33	Male	48	ACUTE APPENDICITIS ACUTE TONSILLITIS	
	34	Male	43	OTH MUSCULOSKELET ANOMAL	
	35	Male	34	CHRONIC TONSILLITIS OTH SALMONELLA INFECTION	
	39	Female	46	NONTOXIC NODULAR GOITER	
3	65	Male	46	INGUINAL HERNIA	
	67	Female	56	OTHER BRAIN INJURY NONINFLAM DIS OVAR/ADNEX	
	68	Female	52	THYROTOXICOSIS UTERINE LEIOMYOMA	
6	162	Female	56	MAL NEO CERVIX UTERI NOS	
7	193	Female	56	PSYCHOGENIC SKIN DISEASE	
8	226	Female	51	PNEUMONIA, ORGANISM NOS	
	231	Female	41	DUODENAL ULCER NOS OTHER GU NEOPLASM NOS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
8	232	Male	41	ASTHMA NOS OTHER PSORIASIS	
9	201	Female	52	EXCESSIVE MENSTRUATION	
	202	Male	65	OBSTRUCT CHR BRONCHITIS	
	203	Female	34	UTERINE LEIOMYOMA	
	207	Female	64	MENIERE DISEASE	
	208	Male	42	AUTOIMMUNE DISEASE NEC	
	209	Male	32	UNC BEHAV NEO BONE	
	211	Female	37	UTERINE LEIOMYOMA	
	237	Male	45	DUODENAL ULCER NOS	
	243	Female	29	CHOLELITHIASIS NOS	
	258	Male	24	ASTHMA	
	261	Female	34	CONTACT DERMATITIS	
	264	Female	46	URINARY SYSTEM SYMPTOMS	
	276	Female	61	PROLAPSE OF VAGINAL WALL	
9/A	234	Female	31	OTOSCLEROSIS NOS	
	235	Male	49	STOMACH ULCER NOS DIABETES MELLITUS UNCOMP GOUT NOS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
9/A	282	Male	35	HYPERTENSION NOS	
10	296	Female	48	GASTRITIS/DUODENITIS NOS ANEMIA NOS VARICOSE VEIN OF LEG NOS	
	300	Female	34	IRRITABLE COLON NONINFL DIS OVA/ADNX NOS ANAL FISTULA	
11	321	Female	43	BRAIN INJURY NEC OTHER GU NEOPLASM NOS	
	322	Female	35	ACUTE TONSILLITIS OTHER GU NEOPLASM NOS CESAREAN DELIVERY NOS ACUTE IRIDOCYCLITIS	
	323	Female	26	CESAREAN DELIVERY NOS	
	324	Male	22	ASTHMA NOS OTITIS MEDIA NOS	
	328	Male	21	DIAPHRAGMATIC HERNIA	
	331	Male	43	OTHER GU NEOPLASM NOS PURE HYPERCHOLESTEROLEM	
	333	Female	47	OTHER GU NEOPLASM NOS PURE HYPERCHOLESTEROLEM	
12	337	Female	54	DIAPHRAGMATIC HERNIA RECTAL PROLAPSE	
	338	Female	65	URIN TRACT INFECTION NOS OTHER GU NEOPLASM NOS ATONY OF BLADDER	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
12	339	Male	64	ANGINA PECTORIS	
	341	Female	41	STOMACH ULCER NOS IRON DEFICIENCY ANEMIAS	
13	353	Female	40	METRORRHAGIA	
	354	Female	34	PEPTIC ULCER NOS	
	361	Female	25	ANEMIA NOS	
14	457	Female	59	ARTHROPATHY NOS DIARRHEA OF INFECT ORIG SPONDYLOSIS NOS	
	458	Female	60	ATROPHIC GASTRITIS PHOBIC DISORDERS SPONDYLOSIS NOS	
	459	Male	49	NONTOX NODUL GOITER NOS	
	460	Male	49	STOMACH FUNCTION DIS NOS MONOARTHRITIS NOS	
	462	Female	55	THORAC/LUMB DISC DISPLAC	
	463	Male	62	CIRCULATORY DISEASE NOS DIZZINESS AND GIDDINESS ALLERGIC RHINITIS NOS ATROPHIC GASTRITIS	
	464	Female	64	LUMBAGO ARTHROPATHY NOS INTESTINAL DISORDER NOS	
	465	Male	51	CERVICAL SYNDROME NEC AUTONOMIC NERVE DIS NEC ENTHESOPATHY OF ELBOW	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
14/1	429	Female	54	BRONCHITIS NOS LUMBAGO	
	451	Male	56	ATHEROSCLEROSIS NOS DIABETES MELLITUS POLYARTHRITIS NOS HYPERTENSION NOS	
	452	Female	47	DISC DISPLACEMENT NOS HEPATITIS NOS	
14/2	136	Female	29	UNSPECIFIED ABORTION	
	456	Male	45	CHOLELITHIASIS NOS	
14/3	418	Female	49	UTERINE LEIOMYOMA INTERVERTEBRAL DISC DIS	
	420	Female	38	FEMALE PELVIC INFLAM DIS	
14/4	131	Female	60	CHOLEDOCHOLITHIASIS NOS	
	135	Male	58	ACUTE MYOCARDIAL INFARCT	
14/7	422	Female	51	OTHER GU NEOPLASM NOS OSTEOPOROSIS OSTEOCHONDROPATHY NOS	
	424	Male	62	SPINAL CORD INJURY NOS OSTEOARTHROSIS NOS PSYCHOSEXUAL DYSFUNCTION	
	430	Female	55	CERVICOCRANIAL SYNDROME LUMBOSACRAL NEURITIS NOS	
	431	Male	43	MALE INFERTILITY	
	432	Male	42	NEURALGIA/NEURITIS NOS ANGINA PECTORIS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
14/7	433	Female	51	HYPERTENSION NOS	
	434	Male	40	SHOULDER REGION DIS NEC LUMBAGO	
	439	Male	64	BACKACHE NOS BREAST NEOPLASM NOS	
	441	Male	33	CHRONIC PROSTATITIS	
14/8	130	Male	54	APPENDICITIS NOS FX ANKLE NOS-CLOSED	
14/10	53	Male	58	CHRONIC PROSTATITIS THORAC/LUMB DISC DISPLAC CHOLELITHIASIS NOS TINNITUS	
	54	Female	63	HYPERTENSION NOS	
	55	Female	57	HYPOTENSION NOS SPONDYLOSIS NOS GASTRITIS/DUODENITIS NOS	
	56	Female	62	SPONDYLOSIS NOS HYPOTENSION NOS DIVERTICULA OF COLON PURE HYPERCHOLESTEROLEM	
	57	Female	58	CARPAL TUNNEL SYNDROME HYPERTENSION NOS	
	58	Female	56	SPONDYLOSIS NOS	
	60	Female	47	HYPERTENSION NOS	
	137	Female	58	NEOPLASM NOS, SITE NEC CHOLELITHIASIS NOS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
14/10	137	Female	58	HYPOTENSION NOS	
	138	Female	51	ASTHMA NOS	
	435	Female	61	HYPERTENSION NOS	
	438	Female	51	VARICOSE VEINS, LEG ORTHOSTATIC HYPOTENSION	
	443	Female	58	CERVICAL DISC DEGEN	
	444	Male	43	NONTOX NODUL GOITER NOS HYPERTENSION NOS	
	445	Female	63	MALIGN NEOPL BREAST NOS HYPERLIPIDEMIA NEC/NOS HYPERTENSION NOS	
	446	Female	64	HYPERLIPIDEMIA NEC/NOS DISC DEGENERATION NOS	
	447	Male	60	OLD MYOCARDIAL INFARCT DIABETES MELLITUS UNCOMP ABN BLOOD CHEMISTRY NEC	
	448	Female	55	TINNITUS SPONDYLOSIS NOS UTERINE LEIOMYOMA	
	454	Female	56	PURE HYPERCHOLESTEROLEM	
	455	Female	62	VARICOSE VEIN OF LEG NOS HYPOTENSION NOS	
15	351	Male	58	HYPERTENSION NOS	
	368	Female	50		ALCOHOL DEPENDENCE SYNDR

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 4.0

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history	Admission examination
15	374	Female	48	RHEUM FEV W/O HRT INVOLV SCARLET FEVER JAUNDICE NOS OTHER GU NEOPLASM NOS CHOLELITHIASIS NOS DIS TYMPANIC MEMB NEC URIN TRACT INFECTION NOS	
	380	Female	49	UTERINE LEIOMYOMA	
	384	Female	65	HYPOTHYROIDISM NOS	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
1	1	Male	Screen	08/02/91	Abnormal	AORTIC ATHEROSCLEROSIS
	2	Female	Screen	05/03/91	Normal	
	3	Female	Screen	13/04/91	Normal	
	4	Male	Screen	15/04/91	Normal	
	5	Female	Screen	17/07/91	Normal	
	6	Male	Screen	06/08/91	Normal	
	7	Male	Screen		Normal	
	8	Male	Screen	29/10/91	Normal	
	9	Female	Screen	14/11/91	Normal	
	10	Female	Screen		Normal	
	11	Male	Screen	03/04/92	Normal	
	12	Male	Screen	14/04/92	Normal	
2	33	Male	Screen	27/12/90	Abnormal	BRONCHITIS NOS
	34	Male	Screen	12/90	Normal	
	35	Male	Screen	28/12/90	Normal	
	36	Female	Screen	10/01/91	Normal	
	37	Male	Screen	17/01/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
2	38	Female	Screen	24/01/91	Abnormal	EMPHYSEMA
	39	Female	Screen	24/01/91	Normal	
	40	Male	Screen	19/02/91	Normal	
	41	Male	Screen	31/01/91	Normal	
	42	Male	Screen	08/02/91	Normal	
	43	Female	Screen	25/03/91	Normal	
	44	Male	Screen	10/04/91	Normal	
	45	Female	Screen	29/05/91	Normal	
	46	Female	Screen	15/05/91	Normal	
	47	Female	Screen	17/05/91	Normal	
	48	Female	Screen	26/08/91	Normal	
	49	Female	Screen	28/08/91	Normal	
	50	Male	Screen	04/11/91	Normal	
	51	Female	Screen	04/11/91	Normal	
	52	Male	Screen	13/11/91	Normal	
3	65	Male	Screen	08/03/91	Abnormal	CORONARY ATHEROSCLEROSIS
	66	Female	Screen	02/05/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
3	67	Female	Screen	10/04/91	Normal	
	68	Female	Screen	05/08/91	Normal	
	69	Female	Screen	19/03/91	Normal	
	70	Female	Screen	22/10/91	Normal	
	71	Female	Screen	13/11/91	Normal	
	72	Female	Screen	30/01/92	Normal	
	73	Female	Screen	12/02/92	Normal	
4	97	Male	Screen	26/05/92	Normal	
	100	Female	Screen	01/06/92	Normal	
	101	Female	Screen	06/05/91	Normal	
6	161	Male	Screen	27/03/91	Normal	
	162	Female	Screen	04/11/91	Normal	
7	193	Female	Screen		Not done	
	194	Male	Screen		Not done	
	196	Female	Screen		Not done	
8	225	Female	Screen	26/10/90	Normal	
	226	Female	Screen	03/05/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
8	227	Male	Screen	03/05/91	Normal	
	228	Male	Screen	08/05/91	Normal	
	229	Female	Screen	18/10/91	Normal	
	230	Female	Screen	04/11/91	Normal	
	231	Female	Screen		Not done	
	232	Male	Screen	21/10/91	Normal	
9	197	Male	Screen		Not done	
	198	Female	Screen		Not done	
	199	Male	Screen		Not done	
	200	Male	Screen		Not done	
	201	Female	Screen		Not done	
	202	Male	Screen		Not done	
	203	Female	Screen		Not done	
	204	Male	Screen		Not done	
	205	Female	Screen		Not done	
	206	Female	Screen		Not done	
	207	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
9	208	Male	Screen		Not done	
	209	Male	Screen		Not done	
	210	Female	Screen		Not done	
	211	Female	Screen		Not done	
	212	Female	Screen		Not done	
	237	Male	Screen		Not done	
	238	Female	Screen		Not done	
	239	Male	Screen		Not done	
	240	Female	Screen		Not done	
	241	Female	Screen	07/05/92	Normal	
	242	Male	Screen		Not done	
	243	Female	Screen	12/05/92	Normal	
	244	Male	Screen		Not done	
	257	Female	Screen		Not done	
	258	Male	Screen		Not done	
	259	Female	Screen		Not done	
	260	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Date	Value	Abnormality
9	261	Female	Screen		Not done	
	262	Male	Screen		Not done	
	263	Female	Screen		Not done	
	264	Female	Screen		Not done	
	265	Female	Screen		Not done	
	266	Female	Screen		Not done	
	267	Male	Screen	19/09/91	Normal	
	268	Female	Screen		Not done	
	269	Male	Screen		Not done	
	270	Female	Screen		Not done	
	271	Female	Screen		Not done	
	272	Male	Screen		Not done	
	273	Female	Screen		Not done	
	274	Female	Screen		Not done	
	274/A	Female	Screen		Not done	
	275	Female	Screen		Not done	
	276	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
9	276/A	Male	Screen		Not done	
9/A	233	Male	Screen		Not done	
	234	Female	Screen		Not done	
	235	Male	Screen		Not done	
	236	Male	Screen		Not done	
	277	Female	Screen		Not done	
	278	Female	Screen		Not done	
	279	Male	Screen		Not done	
	280	Female	Screen		Not done	
	281	Female	Screen		Not done	
	282	Male	Screen		Not done	
	283	Female	Screen		Not done	
	284	Male	Screen		Not done	
	301	Female	Screen		Not done	
	302	Male	Screen		Not done	
	303	Female	Screen		Not done	
	304	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
9/A	305	Male	Screen		Not done	
	306	Female	Screen		Not done	
	307	Female	Screen		Not done	
	308	Female	Screen		Not done	
10	289	Female	Screen	17/09/91	Normal	
	290	Male	Screen		Not done	
	291	Male	Screen	20/02/92	Abnormal	CHR AIRWAY OBSTRUCT NEC
	292	Female	Screen	12/12/91	Normal	
	293	Female	Screen	27/12/91	Normal	
	294	Female	Screen	06/01/92	Normal	
	295	Male	Screen	08/01/92	Normal	
	296	Female	Screen	24/02/92	Normal	
	297	Male	Screen	25/03/92	Normal	
	298	Female	Screen	25/03/92	Normal	
	299	Male	Screen	03/04/92	Normal	
	300	Female	Screen	07/04/92	Normal	
11	321	Female	Screen	10/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function Abnormality Date	Value
11	322	Female	Screen	08/06/92	Normal
	323	Female	Screen	23/06/92	Normal
	324	Male	Screen	16/07/92	Normal
	325	Female	Screen	24/07/92	Normal
	326	Male	Screen	30/07/92	Normal
	327	Female	Screen	17/08/92	Normal
	328	Male	Screen	11/08/92	Normal
	329	Female	Screen	18/08/92	Normal
	330	Female	Screen	21/08/92	Normal
	331	Male	Screen	01/09/92	Normal
	332	Female	Screen	31/08/92	Normal
	333	Female	Screen	04/09/92	Normal
12	337	Female	Screen		Normal
	338	Female	Screen		Not done
	339	Male	Screen		Not done
	340	Female	Screen		Not done
	341	Female	Screen		Not done

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function Assessment	Date	Value	Abnormality
13	353	Female	Screen	05/06/92	Normal	
	354	Female	Screen	24/06/92	Normal	
	355	Female	Screen	11/06/92	Normal	
	356	Male	Screen	22/07/92	Normal	
	357	Female	Screen	05/08/92	Normal	
	358	Male	Screen	13/07/92	Normal	
	359	Female	Screen	19/08/92	Normal	
	360	Female	Screen	19/08/92	Normal	
	361	Female	Screen	26/08/92	Normal	
14	457	Female	Screen	26/06/92	Normal	
	458	Female	Screen	24/06/92	Normal	
	459	Male	Screen	15/07/92	Normal	
	460	Male	Screen		Not done	
	461	Female	Screen		Not done	
	462	Female	Screen		Not done	
	463	Male	Screen		Not done	
	464	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
14	465	Male	Screen		Not done	
	466	Female	Screen		Not done	
14/1	129	Male	Screen	16/12/91	Normal	
	426	Female	Screen	04/91	Normal	
	429	Female	Screen	17/09/91	Abnormal	CHR AIRWAY OBSTRUCT NEC
	451	Male	Screen	03/12/91	Normal	
	452	Female	Screen	26/11/91	Normal	
14/2	136	Female	Screen	09/01/92	Normal	
	456	Male	Screen	17/04/91	Normal	
14/3	417	Female	Screen	12/90	Normal	
	418	Female	Screen	05/91	Normal	
	419	Female	Screen	03/07/91	Normal	
	420	Female	Screen	05/07/91	Normal	
	421	Female	Screen	11/07/91	Normal	
	427	Female	Screen	06/03/91	Abnormal	EMPHYSEMA
	428	Female	Screen	25/10/91	Normal	
14/4	131	Female	Screen	09/01/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
14/4	132	Female	Screen	19/12/91	Normal	
	133	Female	Screen	10/01/92	Normal	
	134	Female	Screen	26/11/91	Normal	
	135	Male	Screen	04/11/91	Normal	
14/7	422	Female	Screen	19/04/91	Abnormal	Not relevant
	423	Female	Screen	06/11/90	Normal	
	424	Male	Screen	03/07/91	Normal	
	430	Female	Screen	07/01/91	Normal	
	431	Male	Screen	08/11/90	Normal	
	432	Male	Screen	12/04/90	Normal	
	433	Female	Screen	08/10/91	Abnormal	OSTEOCHONDROPATHY NEC
	434	Male	Screen	27/03/91	Abnormal	OSTEOCHONDROPATHY NOS
	439	Male	Screen	03/09/91	Normal	
	440	Female	Screen	06/05/91	Normal	
	441	Male	Screen	26/06/91	Normal	
	442	Male	Screen	12/06/91	Normal	
	449	Female	Screen	30/12/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
14/7	450	Male	Screen	17/12/90	Normal	
14/8	130	Male	Screen	10/01/92	Normal	
	425	Female	Screen	06/09/91	Normal	
	467	Male	Screen	02/07/92	Normal	
14/10	53	Male	Screen	17/01/92	Normal	
	54	Female	Screen	28/01/92	Normal	
	55	Female	Screen	27/01/92	Normal	
	56	Female	Screen	03/02/92	Normal	
	57	Female	Screen	04/02/92	Normal	
	58	Female	Screen	27/03/92	Normal	
	59	Female	Screen	13/04/92	Normal	
	60	Female	Screen	06/05/92	Normal	
	137	Female	Screen	25/01/92	Normal	
	138	Female	Screen	07/01/92	Normal	
	139	Female	Screen	13/01/92	Normal	
	140	Female	Screen	15/01/92	Normal	
	435	Female	Screen	24/10/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
14/10	436	Female	Screen	22/10/91	Normal	
	437	Female	Screen	16/10/91	Normal	
	438	Female	Screen	08/10/91	Normal	
	443	Female	Screen	07/10/91	Normal	
	444	Male	Screen	18/11/91	Normal	
	445	Female	Screen	07/10/91	Normal	
	446	Female	Screen	15/11/91	Normal	
	447	Male	Screen	28/11/91	Normal	
	448	Female	Screen	26/11/91	Normal	
	453	Female	Screen	21/05/92	Normal	
	454	Female	Screen	04/06/92	Normal	
	455	Female	Screen	15/06/92	Normal	
15	349	Male	Screen		Not done	
	351	Male	Screen		Not done	
	352	Male	Screen		Not done	
	364	Female	Screen		Not done	
	366	Male	Screen		Not done	

15

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Chest X-Ray - Pulmonary Function			
			Assessment	Date	Value	Abnormality
15	367	Male	Screen		Not done	
	368	Female	Screen		Not done	
	369	Female	Screen		Not done	
	370	Female	Screen		Not done	
	371	Female	Screen		Not done	
	372	Male	Screen		Not done	
	373	Female	Screen		Not done	
	374	Female	Screen		Not done	
	375	Female	Screen	06/06/92	Normal	
	376	Female	Screen		Not done	
	377	Female	Screen		Not done	
	378	Female	Screen		Not done	
	379	Female	Screen		Not done	
	380	Female	Screen		Not done	
	381	Female	Screen		Not done	
	382	Male	Screen		Not done	
	383	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
15	384	Female	Screen		Not done	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
1	1	Male	52	CLOMIPRAMINE	Very good	Y	***	07/89
				MAPROTILINE	Good			
	2	Female	55	LUDIOMIL	Fair		***	07/90
				PAROXETIN	Good			
				LITHIUM	Poor	Y		
				AMITRIPTYLINE	Good			
				NORTRIPTYLINE	Good			
	4	Male	53	TOFRANIL	Good			
	5	Female	57	LUDIOMIL	Poor			
				ANAFRANIL	Poor			
	6	Male	62	AMITRIPTYLINE	Poor	Y	***	28/07/91
				NORTRIPTYLINE	Poor	Y		
	7	Male	54	IMIPRAMINE	Good	Y		
	9	Female	65	MOCLOBEMIDE	Poor		***	28/10/91
				TRANYLCYPROMINE	Very good			
	10	Female	46	FLUOXETINE	Fair		***	09/91
				DOXEPIN	Poor	Y		
				AMITRIPTYLINE	Poor	Y		
	11	Male	50	AMITRIPTYLINE	Fair	Y	***	01/04/92
	12	Male	27	CLOMIPRAMINE	Very good	Y	***	10/91
				MIANSERIN	Poor	Y		
				TRANYLCYPROMINE	Fair			
2	33	Male	48	DOXEPIN	Good		***	07/90
	34	Male	43	CLOMIPRAMINE	Very poor	Y	***	18/12/90
				MAPROTILINE	Poor			
	35	Male	34	AMITRIPTYLINOXIDE	Fair	Y	***	24/12/90

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
2	38	Female	54	MAPROTILINE	Poor		***	22/01/91
	39	Female	46	AMITRIPTYLINOXIDE	Poor	Y	***	28/12/90
	41	Male	50	AMITRIPTYLINOXIDE	Poor		***	29/01/91
	42	Male	55	AMITRIPTYLINE	Poor	Y	***	05/02/91
	43	Female	40	MAPROTILINE	Poor		***	20/03/91
	44	Male	54	FLUOXETINE	Poor		***	07/04/91
	45	Female	36	DOXEPIN	Very poor		***	26/04/91
	48	Female	61	MAPROTILINE	Fair	Y	***	22/08/91
	50	Male	54	MIANSERIN	Good			
	51	Female	39	MAPROTILINE LITHIUM CARBONATE	Poor Poor		***	29/10/91
	52	Male	25	MOCLOBEMIDE	Very poor	Y	***	12/11/91
3	65	Male	46	APONAL LUDIOMIL	Very poor Fair	 Y	***	28/03/91
	66	Female	39	SAROTEN EQUILIBRIN	Poor Poor	Y	***	25/04/91
	67	Female	56	APONAL SAROTEN	Fair Good		***	03/04/91
	68	Female	52	ANAFRANIL STANGYL	Poor Poor	Y Y	*** ***	29/07/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
3	70	Female	60	SAROTEN	Poor		***	01/91
	72	Female	48	SAROTEN	Poor	Y	***	28/01/92
	73	Female	52	AMITRIPTYLINE	Fair			
				LUDIOMIL	Good			
4	97	Male	22	MAPROTILINE	Very poor		***	22/04/92
	100	Female	34	AMITRIPTYLINE	Poor			
	101	Female	54	MAPROTILINE	Fair	Y	***	29/04/91
				DESIPRAMINE	Poor	Y		
6	162	Female	56	AMITRIPTYLINE	Poor	Y	***	30/10/91
7	193	Female	56	ANAFRANIL	Fair			
	196	Female	23	TRAZOLAN	Poor		***	15/03/91
8	225	Female	24	REDOMEX	Fair		***	22/02/91
				TRAZOLAN	Very poor	Y		
				PROTHIADEN	Poor			
	226	Female	51	AMITRIPTYLINE	Good		***	89
				DOSULEPIN	Good			
	229	Female	39	PHENELZINE	Good	Y	***	01/10/91
				ANAFRANIL - SLOW RELEASE	Good			
9	197	Male	51	DOSULEPIN	Fair		***	01/02/92
				MOCLOBEMIDE	Fair			
				AMITRIPTYLINE	Poor			
				MELITRACEN	Poor			
				MIANSERIN	Good			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment: Name	Efficacy	Side effects	Last taken	Last day of treat.
9	199	Male	47	AMITRIPTYLINE	Fair		***	24/03/92
				MIANSERIN	Fair			
				DOSULEPIN	Fair			
				DOXEPIN	Fair			
				VILOXAZINE	Fair			
	202	Male	65	DOSULEPIN	Very good		***	08/01/92
				MIANSERIN	Very good			
				CLOMIPRAMINE	Very poor			
	203	Female	34	MIANSERIN	Good			
				TRAZODONE	Fair			
	204	Male	45	DOSULEPIN	Poor		***	15/12/91
				CLOMIPRAMINE	Fair			
				TRAZODONE	Fair			
				TRIPT-OH	Very poor			
	205	Female	41	DOSULEPIN	Good			
				LERIVON	Good			
	207	Female	64	MIANSERIN	Poor		***	24/01/92
				CLOMIPRAMINE	Very poor	Y		
				AMITRIPTYLINE	Good			
				MAPROTILINE	Very good	Y		
	208	Male	42	AMITRIPTYLINE	Poor		***	01/12/91
	237	Male	45	AMITRIPTYLINE	Good		***	91
	239	Male	29	IMIPRAMINE	Good		***	10/04/92
	241	Female	49	IMIPRAMINE	Good		***	05/91
	243	Female	29	DOSULEPIN	Poor		***	10/05/92
				MIANSERIN	Poor			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
9	257	Female	25	MIANSERIN	Very poor		***	01/07/91
	260	Female	30	DOSULEPIN	Fair			
	261	Female	34	MIANSERIN	Poor			
				DOXEPIN	Fair			
	263	Female	36	MIANSERIN	Very poor	Y	***	23/07/91
	264	Female	46	MELITRACEN	Fair		***	24/07/91
				DOXEPIN	Fair			
				TRAZODONE	Good			
	268	Female	41	INSIDON	Good			
				AMITRIPTYLINE	Good			
	270	Female	43	DOSULEPIN	Very poor	Y	***	11/09/91
				MIANSERIN	Poor	Y		
	272	Male	62	DOSULEPIN	Very poor		***	10/10/91
				MIANSERIN	Fair			
				AMITRIPTYLINE	Good			
	273	Female	35	CLOMIPRAMINE	Good			
				DOSULEPIN	Good			
	274	Female	47	MIANSERIN	Very poor		***	15/09/91
	274/A	Female	46	TRAZODONE	Poor		***	21/04/92
				MIANSERIN	Fair			
				IMIPRAMINE	Good			
				DESIPRAMINE	Poor			
	275	Female	59	FLUVOXAMINE	Poor			
				TRAZODONE	Fair			
	276	Female	61	MIANSERIN	Poor		***	15/12/91
				DOSULEPIN	Good			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment: Name	Efficacy	Side effects	Last taken	Last day of treat.
9	276/A	Male	41	FLOXYFRAL	Very good			
9/A	233	Male	57	CITALOPRAM TRAZODONE VILOXAZINE FLUOXETINE	Very poor Fair Good Poor	Y	***	20/04/92
	234	Female	31	FLUOXETINE	Poor		***	08/03/92
	236	Male	38	CITALOPRAM	Very poor		***	01/05/92
	277	Female	36	CITALOPRAM FLUOXETINE VILOXAZINE	Very poor Poor Poor		***	23/04/92
	280	Female	44	MIANSERIN	Fair	Y	***	30/03/92
	281	Female	64	TRAZODONE	Very poor	Y	***	10/08/92
	282	Male	35	DOSULEPIN DOXEPIN FLUOXETINE	Poor Poor Poor		***	14/08/92
	283	Female	58	DOSULEPIN CITALOPRAM AMITRIPTYLINE	Very good Poor Good	Y	***	01/09/92
	302	Male	26	FLUOXETINE	Poor	Y	***	11/12/91
	303	Female	29	FLUVOXAMINE	Poor		***	10/02/92
	304	Female	41	PROTHIADEN	Poor			
	306	Female	38	FLUVOXAMINE	Good		***	30/09/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
9/A	307	Female	26	CIPRAMIL	Very poor		***	14/04/92
				FLUOXETINE	Very poor			
10	293	Female	62	ANAFRANIL - SLOW RELEASE	Fair			
	294	Female	63	DESIPRAMINE	Fair		***	29/12/91
	299	Male	23	CIPRAMIL	Poor		***	02/04/92
	300	Female	34	ANAFRANIL - SLOW RELEASE	Poor		***	10/04/92
11	323	Female	26	FLUOXETINE	Fair	Y	***	30/04/92
	325	Female	18	FLUOXETINE	Fair		***	15/11/91
	331	Male	43	TRAZODONE	Fair	Y	***	15/08/92
				MOCLOBEMIDE	Fair			
	333	Female	47	CLOMIPRAMINE	Fair	Y	***	21/08/92
				DOTHIEPIN	Fair	Y		
12	337	Female	54	CLOMIPRAMINE	Good			
	338	Female	65	DOTHIEPIN	Fair		***	12/06/92
	339	Male	64	IMIPRAMINE	Very poor			
	340	Female	44	FLUOXETINE	Poor	Y		
				IMIPRAMINE	Good			
				LITHIUM	Poor	Y		
	341	Female	41	CLOMIPRAMINE	Poor			
				DOTHIEPIN	Fair			
14	458	Female	60	AMITRIPTYLINE	Fair		***	09/91

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
14	459	Male	49	AMITRIPTYLINE	Good		***	04/91
	460	Male	49	AMITRIPTYLINE	Fair		***	04/91
	461	Female	57	OPIPRAMOL HYDROCHLORIDE	Poor		***	21/07/92
	462	Female	55	MIANSERIN	Fair		***	24/07/92
	463	Male	62	MAPROTILINE	Fair		***	26/07/92
	464	Female	64	NOCLOBEMIDE	Fair		***	28/07/92
	465	Male	51	MIANSERIN	Fair		***	29/07/92
	466	Female	40	AMITRIPTYLINE	Fair		***	30/07/92
14/1	129	Male	59	EQUILIBRIN	Fair		***	10/12/91
	426	Female	55	FLUOXETINE			***	25/08/91
14/2	136	Female	29	LUDIOMIL	Good	Y	***	02/91
14/3	417	Female	27	FLUOXETINE	Fair		***	01/91
14/4	131	Female	60	MAPROTILINE	Good		***	20/08/88
	134	Female	26	MIANSERIN	Good		***	15/02/91
14/10	53	Male	58	MAPROTILINE IMIPRAMIN	Fair Good		***	09/90
	55	Female	57	TRIMIPRAMINE	Fair		***	05/90

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

				Previous antidepressive treatment				
Centre	Patient	Sex	Age	Name	Efficacy	Side effects	Last taken	Last day of treat.
14/10	60	Female	47	IMIPRAMINE	Fair		***	04/87
	137	Female	58	MIANSERIN HYDROCHLORIDE	Fair		***	04/89
	140	Female	63	MAPROTILINE HYDROCHLORIDE			***	09/09/89
	435	Female	61	AMITRIPTYLINE HYDROCHLORIDE	Fair		***	07/89
	443	Female	58	TRIMIPRAMINE MESILATE	Fair		***	04/89
	445	Female	63	MAPROTILINE HYDROCHLORIDE	Fair		***	01/06/89
	447	Male	60	TRIMIPRAMINE MALEATE	Fair		***	23/04/90
15	364	Female	36	DOTHIEPIN MAPROTILINE	Fair Poor	Y	***	20/07/92
	367	Male	32	DOTHIEPIN MAPROTILINE	Fair Poor			
	371	Female	22	DOTHIEPIN AMITRIPTYLINE	Fair Poor	Y	***	30/06/92
	372	Male	36	MIANSERIN AMITRIPTYLINE	Very poor Very poor		*** ***	07/06/92
	374	Female	48	FLUOXETINE AMITRIPTYLINE	Fair Good		***	28/03/92
	376	Female	66	AMITRIPTYLINE LITHIUM	Good Good		*** ***	01/04/91
	377	Female	37	MIANSERIN IMIPRAMIN AMITRIPTYLINE	Very poor Very good Very good		***	04/05/92

10

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.0

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Previous antidepressive treatment Name	Efficacy	Side effects	Last taken	Last day of treat.
15	380	Female	49	AMITRIPTYLINE	Good		***	01/06/92
	382	Male	19	MIANSERIN	Poor		***	15/03/92
				DOTHIEPIN	Poor			
	384	Female	65	DOTHIEPIN	Poor		***	20/07/92
				FLUOXETINE	Poor			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
1	1	07/89	02/07/89	04/02/91	584	05/02/91	Reboxetine
	2	07/90	02/07/90	25/02/91	240	26/02/91	Reboxetine
	3			15/04/91		16/04/91	Imipramine
	4			16/04/91		17/04/91	Imipramine
	5		03/07/91	16/07/91	14	17/07/91	Reboxetine
	6	28/07/91	29/07/91	06/08/91	9	07/08/91	Imipramine
	7			08/10/91		09/10/91	Reboxetine
	8			28/10/91		29/10/91	Imipramine
	9	28/10/91	29/10/91	07/11/91	11	08/11/91	Imipramine
	10	09/91	02/09/91	18/11/91	79	19/11/91	Imipramine
	11	01/04/92	02/04/92	05/04/92	5	06/04/92	Reboxetine
	12	10/91	02/10/91	14/04/92	197	15/04/92	Reboxetine
2	33	07/90	02/07/90	18/12/90	171	19/12/90	Reboxetine
	34	18/12/90	19/12/90	27/12/90	10	28/12/90	Imipramine
	35	24/12/90	25/12/90	27/12/90	3	28/12/90	Reboxetine
	36		28/12/90	09/01/91	13	10/01/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
2	37		15/01/91	17/01/91	3	18/01/91	Reboxetine
	38	22/01/91	23/01/91	24/01/91	3	25/01/91	Imipramine
	39	28/12/90	29/12/90	24/01/91	27	25/01/91	Reboxetine
	40			19/02/91		20/02/91	Imipramine
	41	29/01/91	30/01/91	04/02/91	6	05/02/91	Reboxetine
	42	05/02/91	06/02/91	08/02/91	3	09/02/91	Imipramine
	43	20/03/91	21/03/91	25/03/91	5	26/03/91	Reboxetine
	44	07/04/91	08/04/91	10/04/91	3	11/04/91	Imipramine
	45	26/04/91	27/04/91	29/04/91	3	30/04/91	Imipramine
	46		13/05/91	15/05/91	3	16/05/91	Reboxetine
	47		17/05/91	21/05/91	5	22/05/91	Reboxetine
	48	22/08/91	23/08/91	26/08/91	4	27/08/91	Imipramine
	49		25/08/91	28/08/91	4	29/08/91	Imipramine
	50		31/10/91	05/11/91	6	06/11/91	Reboxetine
	51	29/10/91	30/10/91	05/11/91	7	06/11/91	Reboxetine
	52	12/11/91	13/11/91	26/11/91	14	27/11/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
3	65	28/03/91	29/03/91	01/04/91	5	02/04/91	Reboxetine
	66	25/04/91	26/04/91	30/04/91	5	01/05/91	Imipramine
	67	03/04/91	04/04/91	09/04/91	6	10/04/91	Reboxetine
	68	29/07/91	30/07/91	02/08/91	5	03/08/91	Imipramine
	69			28/02/91		01/03/91	Imipramine
	70	01/91	17/10/91	22/10/91	6	23/10/91	Reboxetine
	71		08/11/91	13/11/91	6	14/11/91	Imipramine
	72	28/01/92	29/01/92	30/01/92	3	31/01/92	Reboxetine
	73		07/02/92	14/02/92	8	15/02/92	Reboxetine
4	97	22/04/92	23/04/92	06/05/92	14	07/05/92	Imipramine
	100		01/05/92	06/05/92	6	07/05/92	Reboxetine
	101	29/04/91	30/04/91	05/05/91	6	06/05/91	Imipramine
6	161		26/03/91	28/03/91	3	29/03/91	Reboxetine
	162	30/10/91	31/10/91	04/11/91	5	05/11/91	Reboxetine
7	193		07/06/91	10/06/91	4	11/06/91	Reboxetine
	194			02/06/91		03/06/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
7	196	15/03/91	16/03/91	18/03/91	4	19/03/91	Imipramine
8	225	22/02/91	15/03/91	21/03/91	7	22/03/91	Imipramine
	226	89	26/04/91	02/05/91	7	03/05/91	Reboxetine
	227		28/04/91	06/05/91	9	07/05/91	Imipramine
	228		05/05/91	09/05/91	5	10/05/91	Reboxetine
	229	01/10/91	20/10/91	21/10/91	2	22/10/91	Imipramine
	230		30/10/91	04/11/91	6	05/11/91	Imipramine
	231			04/11/91		05/11/91	Reboxetine
	232		26/11/91	28/11/91	3	29/11/91	Reboxetine
9	197	01/02/92	02/02/92	06/03/92	35	07/03/92	Reboxetine
	198			17/03/92		18/03/92	Imipramine
	199	24/03/92	25/03/92	01/04/92	9	02/04/92	Imipramine
	200			27/04/92		28/04/92	Reboxetine
	201		01/01/92	15/01/92	15	16/01/92	Imipramine
	202	08/01/92	09/01/92	16/01/92	9	17/01/92	Imipramine
	203		11/91	14/01/92	75	15/01/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
9	204	15/12/91	16/12/91	16/01/92	33	17/01/92	Reboxetine
	205		15/01/92	04/02/92	21	05/02/92	Imipramine
	206		21/01/92	04/02/92	15	05/02/92	Imipramine
	207	24/01/92	25/01/92	05/02/92	13	06/02/92	Reboxetine
	208	01/12/91	02/12/91	14/02/92	76	15/02/92	Reboxetine
	209			11/02/92		12/02/92	Imipramine
	210		15/01/92	19/02/92	36	20/02/92	Reboxetine
	211		13/01/92	13/02/92	32	14/02/92	Reboxetine
	212			03/03/92		04/03/92	Imipramine
	237	91	02/01/91	22/04/92	478	23/04/92	Reboxetine
	238			19/05/92		20/05/92	Imipramine
	239	10/04/92	11/04/92	29/04/92	20	30/04/92	Imipramine
	240			27/04/92		28/04/92	Reboxetine
	241	05/91	05/05/92	08/05/92	4	09/05/92	Imipramine
	242			06/05/92		07/05/92	Reboxetine
	243	10/05/92	11/05/92	17/05/92	7	18/05/92	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period From (*)	Wash out period To (a)	Days	Treatment Start date	Treatment Randonized
9	244			05/06/92		06/06/92	Reboxetine
	257	01/07/91	02/07/91	16/07/91	16	17/07/91	Reboxetine
	258		10/07/91	16/07/91	7	17/07/91	Reboxetine
	259		10/06/91	16/07/91	37	17/07/91	Imipramine
	260		90	23/07/91	569	24/07/91	Imipramine
	261		10/07/91	22/07/91	13	23/07/91	Imipramine
	262		29/06/91	22/07/91	24	23/07/91	Reboxetine
	263	23/07/91	24/07/91	30/07/91	8	31/07/91	Reboxetine
	264	24/07/91	25/07/91	30/07/91	7	31/07/91	Imipramine
	265			22/08/91		23/08/91	Reboxetine
	266		15/08/91	17/09/91	34	18/09/91	Reboxetine
	267			01/09/91		02/09/91	Imipramine
	268		17/09/91	24/09/91	8	25/09/91	Imipramine
	269		19/09/91	24/09/91	6	25/09/91	Reboxetine
	270	11/09/91	12/09/91	10/10/91	30	11/10/91	Imipramine
	271		04/10/91	29/10/91	26	30/10/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
9	272	10/10/91	11/10/91	29/10/91	20	30/10/91	Imipramine
	273		15/10/91	29/10/91	15	30/10/91	Imipramine
	274	15/09/91	16/09/91	30/10/91	46	31/10/91	Reboxetine
	274/A	21/04/92	22/04/92	12/05/92	22	13/05/92	Reboxetine
	275		01/11/91	05/11/91	5	06/11/91	Reboxetine
	276	15/12/91	16/12/91	13/01/92	30	14/01/92	Imipramine
	276/A		10/01/92	03/03/92	54	04/03/92	Imipramine
9/A	233	20/04/92	21/04/92	13/05/92	24	14/05/92	Imipramine
	234	08/03/92	09/03/92	21/05/92	74	22/05/92	Reboxetine
	235		04/05/92	25/05/92	22	26/05/92	Reboxetine
	236	01/05/92	02/05/92	26/05/92	26	27/05/92	Imipramine
	277	23/04/92	24/04/92	09/06/92	48	10/06/92	Reboxetine
	278		01/01/90	12/06/92	894	13/06/92	Imipramine
	279		15/03/92	06/08/92	145	07/08/92	Imipramine
	280	30/03/92	31/03/92	07/08/92	131	08/08/92	Reboxetine
	281	10/08/92	24/08/92	31/08/92	8	01/09/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
9/A	282	14/08/92	15/08/92	01/09/92	19	02/09/92	Reboxetine
	283	01/09/92	02/09/92	15/09/92	15	16/09/92	Imipramine
	284			18/09/92		19/09/92	Imipramine
	301			04/03/92		05/03/92	Imipramine
	302	11/12/91	21/02/92	05/03/92	14	06/03/92	Imipramine
	303	10/02/92	11/02/92	11/03/92	31	12/03/92	Reboxetine
	304		10/03/92	25/03/92	16	26/03/92	Reboxetine
	305		25/02/92	30/03/92	35	31/03/92	Reboxetine
	306	30/09/91	01/10/91	28/04/92	212	29/04/92	Reboxetine
	307	14/04/92	15/04/92	04/05/92	21	05/05/92	Imipramine
	308			08/05/92		09/05/92	Imipramine
10	289		16/09/91	20/09/91	5	21/09/91	Imipramine
	290		07/10/91	13/10/91	7	14/10/91	Reboxetine
	291		13/02/92	16/02/92	4	17/02/92	Imipramine
	292		05/12/91	12/12/91	8	13/12/91	Reboxetine
	293		19/12/91	23/12/91	5	24/12/91	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
10	294	29/12/91	30/12/91	02/01/92	4	03/01/92	Imipramine
	295		02/01/92	06/01/92	5	07/01/92	Imipramine
	296		14/02/92	19/02/92	6	20/02/92	Reboxetine
	297			20/03/92		21/03/92	Reboxetine
	298		21/03/92	26/03/92	6	27/03/92	Reboxetine
	299	02/04/92	03/04/92	06/04/92	5	07/04/92	Imipramine
	300	10/04/92	11/04/92	13/04/92	4	14/04/92	Imipramine
11	321			10/06/92		11/06/92	Reboxetine
	322		03/06/92	10/06/92	8	11/06/92	Reboxetine
	323	30/04/92	01/05/92	23/06/92	54	24/06/92	Imipramine
	324			16/07/92		17/07/92	Imipramine
	325	15/11/91	16/11/91	29/07/92	257	30/07/92	Reboxetine
	326			29/07/92		30/07/92	Imipramine
	327			19/08/92		20/08/92	Reboxetine
	328			19/08/92		20/08/92	Imipramine
	329			20/08/92		21/08/92	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
11	330		14/08/92	23/08/92	10	24/08/92	Reboxetine
	331	15/08/92	16/08/92	02/09/92	19	03/09/92	Reboxetine
	332			04/09/92		05/09/92	Imipramine
	333	21/08/92	22/08/92	03/09/92	14	04/09/92	Imipramine
12	337		21/05/92	25/05/92	5	26/05/92	Imipramine
	338	12/06/92	13/06/92	19/06/92	7	20/06/92	Reboxetine
	339		16/06/92	22/06/92	7	23/06/92	Imipramine
	340		01/08/92	06/08/92	6	07/08/92	Reboxetine
	341		17/08/92	20/08/92	4	21/08/92	Reboxetine
13	353			04/06/92		05/06/92	Reboxetine
	354			23/06/92		24/06/92	Imipramine
	355		12/06/92	24/06/92	13	25/06/92	Reboxetine
	356			21/07/92		22/07/92	Imipramine
	357			04/08/92		05/08/92	Imipramine
	358			05/08/92		06/08/92	Reboxetine
	359			18/08/92		19/08/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
13	360			18/08/92		19/08/92	Imipramine
	361			25/08/92		26/08/92	Reboxetine
14	457			06/07/92		07/07/92	Reboxetine
	458	09/91	02/09/91	13/07/92	317	14/07/92	Imipramine
	459	04/91	02/04/91	15/07/92	472	16/07/92	Reboxetine
	460	04/91	02/04/91	22/07/92	479	23/07/92	Imipramine
	461	21/07/92	22/07/92	28/07/92	7	29/07/92	Imipramine
	462	24/07/92	25/07/92	30/07/92	7	31/07/92	Reboxetine
	463	26/07/92	27/07/92	02/08/92	7	03/08/92	Imipramine
	464	28/07/92	29/07/92	04/08/92	7	05/08/92	Reboxetine
	465	29/07/92	30/07/92	05/08/92	7	06/08/92	Reboxetine
	466	30/07/92	31/07/92	06/08/92	7	07/08/92	Imipramine
14/1	129	10/12/91	11/12/91	18/12/91	8	19/12/91	Reboxetine
	426	25/08/91	26/08/91	04/09/91	10	05/09/91	Reboxetine
	429			25/09/91		26/09/91	Imipramine
	451			27/11/91		28/11/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
14/1	452			27/11/91		28/11/91	Reboxetine
14/2	136	02/91	02/02/91	14/01/92	348	15/01/92	Imipramine
	456			14/04/92		15/04/92	Imipramine
14/3	417	01/91	07/06/91	13/06/91	7	14/06/91	Reboxetine
	418			17/06/91		18/06/91	Imipramine
	419			04/07/91		05/07/91	Reboxetine
	420			04/07/91		05/07/91	Imipramine
	421			18/07/91		19/07/91	Reboxetine
	427			17/09/91		18/09/91	Imipramine
	428			24/10/91		25/10/91	Imipramine
14/4	131	20/08/88	21/08/88	13/01/92	1242	14/01/92	Imipramine
	132			13/01/92		14/01/92	Imipramine
	133			15/01/92		16/01/92	Imipramine
	134	15/02/91	16/02/91	15/01/92	335	16/01/92	Reboxetine
	135			16/01/92		17/01/92	Reboxetine
14/7	422		02/91	03/09/91	215	04/09/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
14/7	423		03/03/90	16/09/91	563	17/09/91	Imipramine
	424		20/11/90	18/09/91	303	19/09/91	Reboxetine
	430			06/10/91		07/10/91	Reboxetine
	431			07/10/91		08/10/91	Reboxetine
	432			07/10/91		08/10/91	Imipramine
	433		23/07/91	07/10/91	77	08/10/91	Imipramine
	434			13/10/91		14/10/91	Reboxetine
	439		04/10/91	10/11/91	38	11/11/91	Reboxetine
	440			10/11/91		11/11/91	Imipramine
	441			10/11/91		11/11/91	Imipramine
	442			10/11/91		11/11/91	Imipramine
	449			19/12/91		20/12/91	Reboxetine
	450			22/12/91		23/12/91	Imipramine
14/8	130			09/01/92		10/01/92	Reboxetine
	425			08/09/91		09/09/91	Reboxetine
	467			05/07/92		06/07/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (@)	Days	Start date	Randomized
14/10	53	09/90	17/02/92	24/02/92	8	25/02/92	Reboxetine
	54		18/02/92	25/02/92	8	26/02/92	Imipramine
	55	05/90	20/02/92	27/02/92	8	28/02/92	Reboxetine
	56		24/02/92	02/03/92	8	03/03/92	Imipramine
	57		25/02/92	03/03/92	8	04/03/92	Reboxetine
	58		02/04/92	13/04/92	12	14/04/92	Imipramine
	59		15/04/92	23/04/92	9	24/04/92	Imipramine
	60	04/87	04/05/92	12/05/92	9	13/05/92	Reboxetine
	137	04/89	20/01/92	27/01/92	8	28/01/92	Reboxetine
	138		21/01/92	28/01/92	8	29/01/92	Imipramine
	139		27/01/92	03/02/92	8	04/02/92	Reboxetine
	140	09/09/89	28/01/92	04/02/92	8	05/02/92	Imipramine
	435	07/89	04/11/91	11/11/91	8	12/11/91	Imipramine
	436		05/11/91	12/11/91	8	13/11/91	Reboxetine
	437			13/11/91		14/11/91	Reboxetine
	438		07/11/91	14/11/91	8	15/11/91	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(@) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
14/10	443	04/89	14/11/91	18/11/91	5	19/11/91	Reboxetine
	444		07/11/91	15/11/91	9	16/11/91	Reboxetine
	445	01/06/89	12/11/91	19/11/91	8	20/11/91	Imipramine
	446		15/11/91	25/11/91	11	26/11/91	Reboxetine
	447	23/04/90	19/11/91	26/11/91	8	27/11/91	Reboxetine
	448		22/11/91	27/11/91	6	28/11/91	Imipramine
	453		18/05/92	27/05/92	10	28/05/92	Imipramine
	454		03/06/92	11/06/92	9	12/06/92	Reboxetine
	455		11/06/92	19/06/92	9	20/06/92	Reboxetine
15	349			19/08/92		20/08/92	Imipramine
	351			01/09/92		02/09/92	Reboxetine
	352			05/08/92		06/08/92	Imipramine
	364	20/07/92	21/07/92	28/07/92	8	29/07/92	Imipramine
	366		21/08/92	26/08/92	6	27/08/92	Reboxetine
	367		23/08/92	30/08/92	8	31/08/92	Imipramine
	368			03/09/92		04/09/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 6.1

DURATION OF DRUG-FREE WASH-OUT-PERIOD

Centre	Patient	Last day of previous treatment	Wash out period			Treatment	
			From (*)	To (a)	Days	Start date	Randomized
15	369			09/07/92		10/07/92	Reboxetine
	370			15/07/92		16/07/92	Imipramine
	371	30/06/92	17/07/92	19/07/92	3	20/07/92	Reboxetine
	372	07/06/92	08/06/92	16/06/92	9	17/06/92	Imipramine
	373			24/06/92		25/06/92	Imipramine
	374	28/03/92	29/03/92	08/04/92	11	09/04/92	Reboxetine
	375			05/06/92		06/06/92	Reboxetine
	376	01/04/91	02/04/91	12/04/92	377	13/04/92	Imipramine
	377	04/05/92	05/05/92	12/05/92	8	13/05/92	Reboxetine
	378			14/06/92		15/06/92	Reboxetine
	379			15/04/92		16/04/92	Imipramine
	380	01/06/92	02/06/92	29/06/92	28	30/06/92	Imipramine
	381			20/05/92		21/05/92	Reboxetine
	382	15/03/92	16/03/92	08/04/92	24	09/04/92	Imipramine
	383			06/07/92		07/07/92	Imipramine
	384	20/07/92	21/07/92	27/07/92	8	28/07/92	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

PHARMACIA CNS 9850085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 1

	Patient											
	1	2	3	4	5	6	7	8	9	10	11	12
	Male	Fem.	Fem.	Male	Fem.	Male	Male	Male	Fem.	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CNS 95 0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2

	Patient												
	33	34	35	36	37	38	39	40	41	42	43	44	45
	Male	Male	Male	Fem.	Male	Fem.	Fem.	Male	Male	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	NO	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA CR[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 2

	Patient						
	46	47	48	49	50	51	52
	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?							
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 or above 21HAMD	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?							
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	N/A	YES	YES	YES
Refusal of contraceptive use during	N/A	N/A	YES	N/A	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C9650085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 3

	Patient								
	65	66	67	68	69	70	71	72	73
	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?									
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 or above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?									
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorm.	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 4

	Patient		
	97	100	101
	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?			
Aged between 18 and 65 years inclusive	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?			
Dysthymia, Cyclothymia	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES
Pregnancy	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES
High risk of suicide	YES	YES	YES

PHARMACIA C9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 6

	Patient	
	161	162
	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?		
Aged between 18 and 65 years inclusive	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES
With a total score of 22 of above 21HAMD	YES	YES
Able and willing to give Informed Cons..	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?		
Dysthymia, Cyclothymia	YES	YES
History of DSM-III-R, associated to	YES	YES
Pregnancy	YES	YES
Refusal of contraceptive use during	YES	YES
Clinically significant hematopoietic ...	YES	YES
Clinically significant lab values abnor.	YES	YES
Current evidence of urinary retention	YES	YES
Current evidence of glaucoma	YES	YES
Clinically significant physical abnorma.	YES	YES
Participation in a clinical trial with .	YES	YES
Evidence of substance use disorder	YES	YES
Chronic respiratory insufficiency	YES	YES
History of drug hypersensitivity	YES	YES
Any history of seizures of brain injury	YES	YES
Any other important clinical illness ...	YES	YES
ECT in the previous 6 months	YES	YES
High risk of suicide	YES	YES

PHARMACIA 0558085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 7

	Patient		
	193	194	196
	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?			
Aged between 18 and 65 years inclusive	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES
With a total score of 22 or above 21HAMD	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?			
Dysthymia, Cyclothymia	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES
Pregnancy	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES
Clinically significant haematopoietic ...	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES
High risk of suicide	YES	YES	YES

PHARMACIA C[illegible]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 8

	Patient							
	225	226	227	228	229	230	231	232
	Fem.	Fem.	Male	Male	Fem.	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?								
Aged between 18 and 65,years inclusive	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?								
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant haematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient												
	197	198	199	200	201	202	203	204	205	206	207	208	209
	Male	Fem.	Male	Male	Fem.	Male	Fem.	Male	Fem.	Fem.	Fem.	Male	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient												
	210	211	212	237	238	239	240	241	242	243	244	257	258
	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Fem.	Male	Fem.	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient												
	259	260	261	262	263	264	265	266	267	268	269	270	271
	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient						
	272	273	274	274/A	275	276	276/A
	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?							
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?							
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CORP 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9/A

	Patient												
	233	234	235	236	277	278	279	280	281	282	283	284	301
	Male	Fem.	Male	Male	Fem.	Fem.	Male	Fem.	Fem.	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	NO	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 9/A

	Patient						
	302	303	304	305	306	307	308
	Male	Fem.	Fem.	Male	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?							
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?							
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorms.	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 10

	Patient											
	289	290	291	292	293	294	295	296	297	298	299	300
	Fem.	Male	Male	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	N/A	YES	YES
Refusal of contraceptive use during	N/A	YES	YES	NO	YES	YES	YES	YES	YES	N/A	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CN9500085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 11

	Patient												
	321	322	323	324	325	326	327	328	329	330	331	332	333
	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Male	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0 '

INCLUSION / EXCLUSION CRITERIA

Centre: 12

	Patient				
	337	338	339	340	341
	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	N/A	YES	N/A	YES
Refusal of contraceptive use during	N/A	N/A	YES	N/A	YES
Clinically significant haematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA 0590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 13

	Patient								
	353	354	355	356	357	358	359	360	361
	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?									
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?									
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	N/A	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant haematopoietic ...	YES	YES	YES	N/A	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C@5@@085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.8

INCLUSION / EXCLUSION CRITERIA

Centre: 14

	Patient									
	457	458	459	460	461	462	463	464	465	466
	Fem.	Fem.	Male	Male	Fem.	Fem.	Male	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?										
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?										
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA CN9980085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.8

INCLUSION / EXCLUSION CRITERIA

Centre: 14/1

	Patient				
	129	426	429	451	452
	Male	Fem.	Fem.	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 or above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA 0050085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/2

	Patient	
	136	456
	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?		
Aged between 18 and 65 years inclusive	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES
With a total score of 22 of above 21HAMD	YES	YES
Able and willing to give Informed Cons..	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?		
Dysthymia, Cyclothymia	YES	YES
History of DSM-III-R, associated to	YES	YES
Pregnancy	YES	YES
Refusal of contraceptive use during	YES	YES
Clinically significant hematopoietic ...	YES	YES
Clinically significant lab values abnor.	YES	YES
Current evidence of urinary retention	YES	YES
Current evidence of glaucoma	YES	YES
Clinically significant physical abnorma.	YES	YES
Participation in a clinical trial with .	YES	YES
Evidence of substance use disorder	YES	YES
Chronic respiratory insufficiency	YES	YES
History of drug hypersensitivity	YES	YES
Any history of seizures of brain injury	YES	YES
Any other important clinical illness ...	YES	YES
ECT in the previous 6 months	YES	YES
High risk of suicide	YES	YES

PHARMACIA C[illegible]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/3

	Patient						
	417	418	419	420	421	427	428
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?							
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?							
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C[illegible]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/4

	Patient				
	131	132	133	134	135
	Fem.	Fem.	Fem.	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?					
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES
With a total score of 22 or above 21HAMD	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?					
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES

PHARMACIA 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/7

	Patient												
	422	423	424	430	431	432	433	434	439	440	441	442	449
	Fem.	Fem.	Male	Fem.	Male	Male	Fem.	Male	Male	Fem.	Male	Male	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA C9600085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/7

	Patient
	450
	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?	
Aged between 18 and 65 years inclusive	YES
Affected by acute episodes of DSM-III-R.	YES
With a total score of 22 of above 21HAMD	YES
Able and willing to give Informed Cons..	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?	
Dysthymia, Cyclothymia	YES
History of DSM-III-R, associated to	YES
Pregnancy	YES
Refusal of contraceptive use during	YES
Clinically significant haematopoietic ...	YES
Clinically significant lab values abnor.	YES
Current evidence of urinary retention	YES
Current evidence of glaucoma	YES
Clinically significant physical abnorma.	YES
Participation in a clinical trial with .	YES
Evidence of substance use disorder	YES
Chronic respiratory insufficienty	YES
History of drug hypersensitivity	YES
Any history of seizures of brain injury	YES
Any other important clinical illness ...	YES
ECT in the previous 6 months	YES
High risk of suicide	YES

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/8

	Patient		
	130	425	467
	Male	Fem.	Male
ARE THE FOLLOWING CONDITIONS PRESENT ?			
Aged between 18 and 65 years inclusive	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES
With a total score of 22 or above 21HAMD	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?			
Dysthymia, Cyclothymia	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES
Pregnancy	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES
Any history of seizures or brain injury	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES
High risk of suicide	YES	YES	YES

PHARMACIA 0[illegible]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/10

	Patient												
	53	54	55	56	57	58	59	60	137	138	139	140	435
	Male	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	N/A	N/A	YES	YES	YES	N/A	N/A	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA 0[illegible]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 14/10

	Patient											
	436	437	438	443	444	445	446	447	448	453	454	455
	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?												
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?												
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	N/A	N/A	N/A
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	N/A	N/A	N/A
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

PHARMACIA C[illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 15

	Patient												
	349	351	352	364	366	367	368	369	370	371	372	373	374
	Male	Male	Male	Fem.	Male	Male	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?													
Aged between 18 and 65 years inclusive	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?													
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficienty	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES

(CONTINUED)

PHARMACIA C0580085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 7.0

INCLUSION / EXCLUSION CRITERIA

Centre: 15

	Patient									
	375	376	377	378	379	380	381	382	383	384
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.
ARE THE FOLLOWING CONDITIONS PRESENT ?										
Aged between 18 and 65 years inclusive	YES	NO	YES	YES	YES	YES	YES	YES	YES	YES
Affected by acute episodes of DSM-III-R.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
With a total score of 22 of above 21HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing to give Informed Cons..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ARE THE FOLLOWING CONDITIONS ABSENT ?										
Dysthymia, Cyclothymia	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of DSM-III-R, associated to	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Pregnancy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Refusal of contraceptive use during	YES	N/A	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant hematopoietic ...	YES	N/A	YES	YES	N/A	NO	YES	YES	YES	YES
Clinically significant lab values abnor.	YES	N/A	YES	YES	N/A	NO	YES	YES	YES	YES
Current evidence of urinary retention	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Current evidence of glaucoma	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Clinically significant physical abnorma.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Participation in a clinical trial with .	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Evidence of substance use disorder	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Chronic respiratory insufficiency	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
History of drug hypersensitivity	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any history of seizures of brain injury	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Any other important clinical illness ...	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
ECT in the previous 6 months	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
High risk of suicide	YES	YES	YES	YES	YES	YES	NO	YES	YES	YES

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
1	1	Male	Reboxetine	YES	DISTRANEURIN	05/02/91	Day 7	08/02/91	Day 7
					NOCTAMID	03/02/91	Screen	05/02/91	Screen
	2	Female	Reboxetine	YES	CHLORALDURAT	26/02/91	Day 7	28/02/91	Day 7
	3	Female	Imipramine	YES	MELLERIL	10/04/91	Screen	10/04/91	Screen
					NOCTAMID	15/04/91	Day 7	21/05/91	Day 35
	4	Male	Imipramine	YES	DYTIDE H	15/04/91($)	Screen	28/05/91(*)	Day 42
					XANEF	15/04/91($)	Screen	28/05/91(*)	Day 42
	6	Male	Imipramine	YES	CHLORALDURAT	29/07/91	Day 7	09/09/91	Day 35
					DIAZEPAM	16/08/91	Day 14	18/08/91	Day 14
					METOPROLOL	06/08/91($)	Day 7	17/09/91(*)	Day 42
	7	Male	Reboxetine	YES	CHLORALDURAT	08/10/91	Screen	20/11/91(*)	Day 42
					DIAZEPAM	14/10/91 17/10/91	Day 7 Day 14	14/10/91 19/10/91	Day 7 Day 14
	8	Male	Imipramine	NO	CHLORALDURAT	25/10/91	Screen	31/10/91(*)	Day 7
	9	Female	Imipramine	YES	ACETYLSALICYLIC ACID	10/89	Screen	19/12/91(*)	Day 42
	10	Female	Imipramine	YES	CHLORALDURAT	15/11/91	Screen	01/12/91	Day 14
					CHLORMETHIAZOLE	10/12/91	Day 21	30/12/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
1	10	Female	Imipramine	YES	EUGLUCON	79	Screen	30/12/91(*)	Day 42
					OMEPRAZOLE	79	Screen	30/12/91(*)	Day 42
	11	Male	Reboxetine	NO	DIAZEPAM	10/04/92	Day 7	12/04/92	Day 7
						19/04/92	Day 14	20/04/92	Day 14
						22/04/92	Day 21	22/04/92	Day 21
						24/04/92	Day 21	24/04/92	Day 21
					NOCTAMID	04/04/92	Screen	04/04/92	Screen
	12	Male	Reboxetine	NO	NOCTAMID	14/04/92	Day 7	05/05/92(*)	Day 21
2	33	Male	Reboxetine	YES	CHLORAL HYDRATE	18/12/90	Day 7	20/12/90	Day 7
	34	Male	Imipramine	NO	CHLORAL HYDRATE	27/12/90	Screen	27/12/90	Screen
					NEDOLON P	27/12/90($)	Screen	03/02/91	Day 42
					PARACETAMOL	06/02/91	Day 42	06/02/91	Day 42
	35	Male	Reboxetine	YES	CHLORAL HYDRATE	27/12/90	Screen	09/01/91	Day 14
					PARACETAMOL	07/02/91	Day 42	07/02/91	Day 42
					SODIUM PICOSULFATE	03/01/91	Day 7	03/01/91	Day 7
	36	Female	Imipramine	NO	CHLORAL HYDRATE	09/01/91	Day 7	30/01/91	Day 21
	37	Male	Reboxetine	YES	CHLORALDURAT	17/01/91	Screen	07/02/91	Day 21
	38	Female	Imipramine	YES	CHLORALDURAT	22/01/91	Screen	28/01/91	Day 7

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2	38	Female	Imipramine	YES	DIHYDROERGOTAMINE MESILAT	28/01/91	Day 14	13/02/91	Day 21
					DISTRANEURIN	25/01/91	Day 7	07/03/91(*)	Day 7
					DISTRANEURINE	25/01/91	Day 14	07/03/91(*)	Day 42
					GYNODIAN-DEPOT	12/90	Screen	07/03/91(*)	Day 14
	39	Female	Reboxetine	YES	CHLORAL HYDRATE	24/01/91	Screen	11/02/91	Day 21
					CYCLO-MENORETTE	25/01/91	Screen	07/03/91(*)	Day 42
					THYROXIN	25/01/91	Screen	07/03/91(*)	Day 42
	40	Male	Imipramine	YES	CHLORAL HYDRATE	19/02/91	Screen	02/04/91(*)	Screen
					CHLORALDURAT	19/02/91	Day 7	05/03/91	Day 14
					DISTRANEURIN	18/03/91 27/03/91	Day 28 Day 42	19/03/91 02/04/91	Day 28 Day 42
	41	Male	Reboxetine	YES	ASPIRINE	08/02/91	Day 7	08/02/91	Day 7
					CHLORAL HYDRATE	30/01/91	Screen	01/02/91	Screen
					CHLORALDURAT	05/02/91	Day 7	11/02/91	Day 7
					CHLORMETHIAZOLE	01/02/91 14/02/91 19/02/91	Screen Day 14 Day 21	11/02/91 15/02/91 08/03/91	Day 7 Day 14 Day 35
					DIHYDROERGOTAMIN	11/02/91	Day 7	18/03/91	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2	41	Male	Reboxetine	YES	MAGALDRATE	08/03/91	Day 35	18/03/91	Day 42
					THYROXIN	30/01/91	Screen	18/03/91	Day 42
	42	Male	Imipramine	YES	CHLORAL HYDRATE	06/02/91	Screen	15/02/91	Day 7
					DISTRANEURIN	16/02/91	Day 14	22/03/91	Day 42
	43	Female	Reboxetine	YES	CHLORAL HYDRATE	26/03/91	Day 7	15/04/91	Day 21
	44	Male	Imipramine	NO	CHLORAL HYDRATE	08/04/91	Day 7	11/04/91	Day 7
					DISTRANEURIN	08/04/91	Screen	11/04/91(*)	Screen
					IODINE	08/04/91	Screen	11/04/91(*)	Day 7
	45	Female	Imipramine	NO	CHLORAL HYDRATE	26/04/91	Screen	29/04/91	Screen
	46	Female	Reboxetine	YES	CHLORAL HYDRATE	14/05/91	Screen	26/06/91	Day 42
	47	Female	Reboxetine	YES	CHLORAL HYDRATE	17/05/91 27/05/91	Screen Day 7	21/05/91 18/06/91	Screen Day 28
					DISTRANEURIN	21/05/91	Day 7	02/07/91	Day 42
	48	Female	Imipramine	YES	CHLORAL HYDRATE	23/08/91	Screen	02/09/91	Day 7
	49	Female	Imipramine	YES	CHLORAL HYDRATE	27/08/91 20/09/91 26/09/91	Screen Day 28 Day 35	08/09/91 20/09/91 02/10/91	Day 14 Day 28 Day 35
	50	Male	Reboxetine	NO	CHLORAL HYDRATE	31/10/91	Screen	05/11/91	Screen

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
2	50	Male	Reboxetine	NO	CHLORAL HYDRATE	20/11/91	Day 21	15/12/91	Day 42
					DISTRANEURIN	05/11/91	Day 7	19/11/91	Day 14
	51	Female	Reboxetine	NO	CHLORAL HYDRATE	30/10/91	Screen	04/11/91	Screen
					DISTRANEURIN	06/11/91	Day 7	18/11/91	Day 14
					THYROXIN	80	Screen	17/11/91(*)	Day 14
	52	Male	Imipramine	YES	CHLORAL HYDRATE	27/11/91	Day 7	24/12/91	Day 28
3	65	Male	Reboxetine	YES	CHLORALDURAT	28/03/91 02/04/91	Screen Day 7	28/03/91 13/05/91(*)	Screen Day 42
					DIGITOXIN	26/04/91	Day 28	13/05/91(*)	Day 42
					VERAPAMIL HYDROCHLORIDE	26/04/91	Day 28	13/05/91(*)	Day 42
	66	Female	Imipramine	NO	CHLORALDURAT	27/04/91	Screen	15/05/91	Day 21
					DISTRANEURIN	02/06/91 05/06/91	Day 35 Day 42	02/06/91 05/06/91	Day 35 Day 42
					TAVOR	03/06/91	Day 35	03/06/91	Day 35
	67	Female	Reboxetine	YES	ADALAT	17/04/91	Day 14	17/04/91	Day 14
					CHLORAL HYDRATE	01/05/91	Day 28	21/05/91	Day 42
					CHLORALDURAT	04/04/91	Screen	30/04/91	Day 21
					CONCOR	24/04/91	Day 21	21/05/91	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
3	68	Female	Imipramine	YES	CHLORALDURAT	02/08/91	Screen	14/08/91	Day 14
						17/08/91	Day 21	13/09/91	Day 42
					DISTRANEURIN	01/08/91	Screen	14/08/91	Day 14
						17/08/91	Day 21	02/09/91	Day 35
						04/09/91	Day 35	13/09/91	Day 42
					EUGALAC	17/08/91	Day 21	30/08/91	Day 28
						07/09/91	Day 42	13/09/91	Day 42
	69	Female	Imipramine	YES	CHLORALDURAT	01/03/91	Day 7	05/03/91	Day 7
					DISTRANEURIN	03/03/91	Day 7	24/03/91	Day 28
	70	Female	Reboxetine	NO	CHLORALDURAT	21/10/91	Screen	12/11/91	Day 21
					DISTRANEURIN	23/10/91	Day 7	27/10/91	Day 7
						30/10/91	Day 14	19/11/91(*)	Day 28
					TAVOR	27/10/91	Day 7	27/10/91	Day 7
					TRENTAL	05/11/91	Day 28	19/11/91(*)	Day 28
	71	Female	Imipramine	YES	DISTRANEURINE	11/11/91	Screen	11/11/91	Screen
						14/11/91	Day 7	14/11/91	Day 7
						09/12/91	Day 28	09/12/91	Day 28
	72	Female	Reboxetine	YES	CHLORALDURAT	28/01/92	Screen	12/03/92(*)	Day 42
					HEMINEURIN	13/02/92	Day 14	13/02/92	Day 14
	73	Female	Reboxetine	YES	CHLORAL HYDRATE	18/02/92	Day 7	18/02/92	Day 7
						25/02/92	Day 14	25/02/92	Day 14
						16/03/92	Day 35	16/03/92	Day 35

(@) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
3	73	Female	Reboxetine	YES	CHLORAL HYDRATE	19/03/92	Day 35	19/03/92	Day 35
						22/03/92	Day 42	22/03/92	Day 42
4	97	Male	Imipramine	YES	CHLORALDURAT	12/05/92	Day 7	14/05/92	Day 14
						17/05/92	Day 14	19/05/92	Day 14
						24/05/92	Day 21	26/05/92	Day 21
						28/05/92	Day 28	28/05/92	Day 28
						31/05/92	Day 28	31/05/92	Day 28
						12/06/92	Day 42	14/06/92	Day 42
					NITRAZEPAM	24/04/92	Screen	01/05/92	Screen
	100	Female	Reboxetine	YES	CHLORALDURAT	05/05/92	Screen	24/06/92(*)	Day 42
	101	Female	Imipramine	NO	CHLORAL HYDRATE	07/05/91	Day 7	23/05/91	Day 14
					NITRAZEPAM	15/04/91	Screen	05/05/91	Screen
6	161	Male	Reboxetine	YES	CHLORAL HYDRATE	26/03/91	Screen	26/03/91	Screen
					CHLORALDURAT	29/03/91	Day 7	29/03/91	Day 7
						12/04/91	Day 21	12/04/91	Day 21
	162	Female	Reboxetine	YES	CHLORAL HYDRATE	31/10/91	Screen	29/11/91	Day 28
						02/12/91	Day 28	02/12/91	Day 28
7	193	Female	Reboxetine	NO	TRANXENE	11/06/91	Screen	17/06/91(*)	Day 7
	196	Female	Imipramine	NO	CHLORAL HYDRATE	15/03/91	Screen	18/03/91	Screen
					LORAZEPAM	16/04/91	Day 35	16/04/91	Day 35
					RINOMAR	05/04/91	Day 21	08/04/91	Day 21
8	226	Female	Reboxetine	YES	CHLORAL HYDRATE	26/04/91	Screen	13/06/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
8	227	Male	Imipramine	YES	CHLORAL HYDRATE	28/04/91	Screen	07/05/91	Screen
	228	Male	Reboxetine	NO	CHLORAL HYDRATE	06/05/91	Screen	17/05/91	Day 7
	229	Female	Imipramine	YES	CLAMOXYL	15/10/91	Screen	24/10/91	Day 7
					LORMETAZEPAM	18/10/91($)	Screen	19/10/91	Screen
	230	Female	Imipramine	YES	CHLORAL HYDRATE	30/10/91	Screen	21/11/91	Day 21
	231	Female	Reboxetine	NO	BROMAZEPAM	07/91	Screen	13/11/91(*)	Day 14
					FLUPENTIXOL	07/91	Screen	13/11/91(*)	Day 14
					MELITRACEN	07/91	Screen	13/11/91(*)	Day 14
	232	Male	Reboxetine	YES	CHLORAL HYDRATE	26/11/91	Screen	09/01/92(*)	Day 42
					SURBRONC	26/11/91	Screen	30/11/91	Day 7
9	198	Female	Imipramine	YES	MARVELON	89	Screen	28/04/92(*)	Screen
	202	Male	Imipramine	YES	AMOXICILLIN	12/02/92	Day 28	26/02/92	Day 28
					BECOTIDE	23/12/88	Screen	27/02/92(*)	Screen
					THEOPHYLLINE	23/12/88	Screen	27/02/92(*)	Screen
	206	Female	Imipramine	YES	CLOTIAZEPAM	16/02/92	Day 14	16/02/92	Day 14
	207	Female	Reboxetine	NO	FELDENE	12/91	Screen	12/02/92(*)	Screen

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
9	208	Male	Reboxetine	YES	BISOXATIN	02/03/92	Day 21	05/03/92	Day 21
	212	Female	Imipramine	YES	MERCILON	89	Screen	14/04/92(*)	Screen
	237	Male	Reboxetine	NO	BUSCOPAN	24/04/92	Day 7	24/04/92	Day 7
					MAGNESIUM HYDROXIDE	92	Screen	02/05/92(*)	Screen
	241	Female	Imipramine	YES	PREPULSID	15/05/92	Day 7	19/06/92(*)	Day 42
	243	Female	Imipramine	YES	INDERAL	25/05/92	Day 7	25/05/92	Day 7
	257	Female	Reboxetine	YES	DIANE	90	Screen	27/08/91(*)	Screen
	263	Female	Reboxetine	NO	MARVELON	90	Screen	13/08/91(*)	Screen
	266	Female	Reboxetine	YES	BECONASE	05/08/91	Screen	01/10/91	Day 14
					BROMAZEPAM	16/08/91	Screen	06/10/91	Day 21
	268	Female	Imipramine	YES	ACETYLSALICYLIC ACID	26/09/91	Day 7	27/09/91	Day 7
	271	Female	Reboxetine	NO	ADALAT	13/11/91 19/11/91	Day 21 Day 21	15/11/91 21/11/91	Day 21 Day 28
					BRUFEN	07/11/91 13/11/91	Day 14 Day 21	10/11/91 21/11/91	Day 14 Day 28
					EPHEDRINE SULFATE	05/11/91	Day 7	15/11/91	Day 21
					LORATADINE	05/11/91	Day 7	15/11/91	Day 21

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
9	272	Male	Imipramine	YES	LAXOBERON	13/11/91	Day 21	10/12/91	Day 42
	273	Female	Imipramine	NO	SULFARLEM-CHOLINE	01/11/91	Day 7	21/11/91	Day 28
	275	Female	Reboxetine	YES	ASPEGIC	07/11/91 13/11/91	Day 7 Day 14	08/11/91 15/11/91	Day 7 Day 14
					DAFALGAN	18/11/91	Day 14	20/11/91	Day 21
					SIBELIUM	10/90	Screen	17/12/91(*)	Screen
	276	Female	Imipramine	NO	DIMENFORMON	90	Screen	14/01/92(*)	Screen
9/A	233	Male	Imipramine	YES	CHLORAL HYDRATE	14/05/92	Day 7	24/06/92	Day 42
	235	Male	Reboxetine	NO	ALLOPURINOL	01/01/89	Screen	29/06/92(*)	Day 35
					CHLORAL HYDRATE	26/05/92	Day 7	29/06/92(*)	Day 35
					GLIPIZIDE	01/01/89	Screen	29/06/92(*)	Day 35
	281	Female	Reboxetine	YES	CHLORAL HYDRATE	25/08/92	Screen	14/09/92	Day 14
	282	Male	Reboxetine	YES	CHLORAL HYDRATE	14/08/92	Screen	13/10/92	Day 42
					ENALAPRIL	87	Screen	13/10/92(*)	Day 42
	302	Male	Imipramine	NO	CHLORAL HYDRATE	15/03/92	Day 14	23/03/92	Day 21
	304	Female	Reboxetine	YES	MARVELON	01/01/88	Screen	06/05/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
9/A	308	Female	Imipramine	NO	CHLORAL HYDRATE	09/05/92	Day 7	02/06/92	Day 28
					DICLOFENAC	01/01/92	Screen	09/05/92	Screen
10	289	Female	Imipramine	NO	CHLORAL HYDRATE	20/09/91	Screen	27/09/91(*)	Day 7
	291	Male	Imipramine	YES	CHLORAL HYDRATE	12/02/92	Screen	29/03/92	Day 42
					EFFORTIL	03/03/92	Day 14	29/03/92(*)	Day 42
					TREMBLEX	06/03/92	Day 21	29/03/92(*)	Day 42
	293	Female	Reboxetine	YES	BUFLOMEDIL HYDROCHLORIDE	07/11/91	Screen	15/11/91	Screen
					CHLORAL HYDRATE	21/12/91	Screen	01/02/92(*)	Day 42
					URFADYN	10/01/92	Day 21	17/01/92	Day 28
	294	Female	Imipramine	NO	CHLORAL HYDRATE	09/01/92	Day 14	23/01/92(*)	Day 21
					DOMPERIDONE	27/12/91	Screen	23/01/92(*)	Day 21
					LACTULOSE	09/01/92	Day 14	23/01/92(*)	Day 21
					SELECTOL	20/11/91	Screen	12/91	Day 7
	295	Male	Imipramine	YES	PARACETAMOL	02/01/92	Screen	04/01/92	Screen
	296	Female	Reboxetine	YES	ASCORBIN	24/02/92	Day 7	01/04/92(*)	Day 42
					CHLORAL HYDRATE	14/02/92	Screen	01/04/92(*)	Day 42

(*) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	*First report visit	End date	Last report visit
10	296	Female	Reboxetine	YES	DUPHALAC	24/02/92	Day 7	01/04/92(*)	Day 42
					FERRUM-HAUSMANN	14/02/92	Day 7	01/04/92(*)	Day 42
					SUPRADYN	23/02/92	Day 7	06/03/92	Day 14
					TAGAMET	14/02/92	Day 7	01/04/92(*)	Day 42
					VENORUTON	91	Screen	01/04/92(*)	Day 42
	298	Female	Reboxetine	YES	CHLORAL HYDRATE	19/03/92	Screen	07/05/92(*)	Day 42
					PARACETAMOL	20/04/92	Day 28	28/04/92	Day 42
	299	Male	Imipramine	YES	CHLORAL HYDRATE	07/04/92	Day 7	18/05/92(*)	Day 42
	300	Female	Imipramine	YES	CORDIUM	07/04/92($)	Screen	25/05/92(*)	Day 42
					DICETEL	07/04/92($)	Screen	25/05/92(*)	Day 42
					HYDERGINE	07/04/92($)	Screen	25/05/92(*)	Day 42
					MERCILON	07/04/92($)	Screen	25/05/92(*)	Day 42
11	321	Female	Reboxetine	YES	AMOXICILLIN	23/06/92	Day 14	27/06/92	Day 21
					CARBOCISTEINE	23/06/92	Day 14	27/06/92	Day 21
					LOPERAMIDE	29/06/92	Day 21	30/06/92	Day 21
	322	Female	Reboxetine	YES	PARACETAMOL	15/07/92	Day 35	15/07/92	Day 35

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
11	323	Female	Imipramine	YES	COLD CAPSULES	06/07/92	Day 14	07/07/92	Day 14
	324	Male	Imipramine	YES	BROMHEXINE	11/07/92	Screen	17/07/92	Screen
					OXITETRACYCLIN	11/07/92	Screen	17/07/92	Screen
					VENTOLINE INHALATOR	04/08/92	Day 21	04/08/92	Day 21
	326	Male	Imipramine	YES	DISPRIN	15/08/92	Day 21	16/08/92	Day 21
					ERYTHROMYCIN	15/08/92	Day 21	16/08/92	Day 21
	327	Female	Reboxetine	YES	ASPIRINE	28/08/92 18/09/92	Day 14 Day 35	01/09/92 20/09/92	Day 14 Day 35
					DISPRIN	26/09/92	Day 42	27/09/92	Day 42
	329	Female	Imipramine	YES	HYDROXYPROGESTERONE	90	Screen	02/10/92(*)	Screen
					PARACETAMOL	23/09/92	Day 35	23/09/92	Day 35
	330	Female	Reboxetine	NO	NORDETTE	01/08/92	Screen	26/08/92(*)	Screen
	331	Male	Reboxetine	YES	CAFERGOT	22/09/92	Day 21	23/09/92	Day 21
					CODIS	30/09/92	Day 28	01/10/92	Day 28
12	337	Female	Imipramine	YES	CHLORAL HYDRATE	25/05/92 02/06/92 09/06/92 12/06/92 19/06/92 24/06/92	Screen Day 14 Day 21 Day 21 Day 28 Day 35	31/05/92 07/06/92 10/06/92 17/06/92 22/06/92 05/07/92	Day 7 Day 14 Day 21 Day 28 Day 28 Day 35

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
12	337	Female	Imipramine	YES	LORAZEPAM	11/06/92	Day 21	11/06/92	Day 21
					METOCLOPRAMIDE HYDROCHLOR	23/06/92	Day 35	23/06/92	Day 35
					PARACETAMOL	26/05/92	Day 7	26/05/92	Day 7
						01/07/92	Day 42	02/07/92	Day 42
						04/07/92	Day 42	05/07/92	Day 42
	338	Female	Reboxetine	YES	ACTIFED	07/07/92	Day 21	12/07/92	Day 21
					CEPACOL	25/07/92	Day 42	26/07/92	Day 42
					CHLORAL HYDRATE	20/06/92	Day 7	30/07/92	Day 42
					DUPHALAC	25/07/92	Day 42	25/07/92	Day 42
					FLAVOXATE HYDROCHLORIDE	06/91	Screen	31/07/92(*)	Day 7
					PARACETAMOL	30/06/92	Day 14	30/06/92	Day 14
						04/07/92	Day 21	05/07/92	Day 21
						20/07/92	Day 35	20/07/92	Day 35
						24/07/92	Day 35	26/07/92	Day 35
					SENNA	10/07/92	Day 21	10/07/92	Day 21
						13/07/92	Day 28	13/07/92	Day 28
	339	Male	Imipramine	YES	PARACETAMOL	04/07/92	Day 14	05/07/92	Day 14
						28/07/92	Day 42	28/07/92	Day 42
					SENNA	29/06/92	Day 7	29/06/92	Day 7
						12/07/92	Day 21	13/07/92	Day 21
						17/07/92	Day 28	17/07/92	Day 28
	340	Female	Reboxetine	YES	BACTRIM	24/08/92	Day 21	31/08/92	Day 21

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
12	340	Female	Reboxetine	YES	CHLORAL HYDRATE	11/08/92	Day 7	11/08/92	Day 7
						16/08/92	Day 14	16/08/92	Day 14
						18/08/92	Day 14	19/08/92	Day 14
					GLYCERIN	12/08/92	Day 7	12/08/92	Day 7
					PARACETAMOL	05/08/92	Screen	06/08/92	Screen
					VITAMIN C	05/08/92	Screen	05/08/92	Screen
	341	Female	Reboxetine	NO	CHLORAL HYDRATE	17/08/92	Screen	24/09/92	Day 35
					PARACETAMOL	16/09/92	Day 28	16/09/92	Day 28
13	353	Female	Reboxetine	NO	BACTRIM	22/06/92	Day 14	26/06/92	Day 21
					MEFENAMIC ACID	13/06/92	Day 7	15/06/92	Day 7
	354	Female	Imipramine	YES	DICLOFENAC SODIUM	23/07/92	Day 35	25/07/92	Day 35
					PARACETAMOL	23/07/92	Day 35	25/07/92	Day 35
	355	Female	Reboxetine	NO	CODEINE PHOSPHATE	28/06/92	Day 7	29/06/92	Day 7
					PARACETAMOL	28/06/92	Day 7	29/06/92	Day 7
	356	Male	Imipramine	YES	PARACETAMOL	29/07/92	Day 14	01/09/92(*)	Day 14
	361	Female	Reboxetine	YES	ASPIRINE	05/10/92	Day 42	06/10/92	Day 42
					C-VITAMIN	20/09/92	Day 28	21/09/92	Day 28
					CALCIUM CARBONATE	20/09/92	Day 28	21/09/92	Day 28

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
13	361	Female	Reboxetine	YES	CITRIC ACID	20/09/92	Day 28	21/09/92	Day 28
14	460	Male	Imipramine	YES	PANKREATAN COMP.	90	Screen	06/08/92	Day 14
	464	Female	Reboxetine	YES	NOVADRAL RETARD	86	Screen	27/07/92	Screen
	465	Male	Reboxetine	YES	PANKREATAN COMP.	59	Screen	30/07/92	Screen
14/1	129	Male	Reboxetine	NO	CHLORALDURAT	11/12/91	Screen	19/12/91(*)	Screen
	426	Female	Reboxetine	YES	BACTOREDUCT	05/09/91	Day 7	10/09/91	Day 7
					DISTRANEURIN	25/09/91	Day 21	01/10/91	Day 28
	429	Female	Imipramine	NO	SALBUTAMOL SULFATE	87	Screen	29/09/91(*)	Day 7
					TERBUTALINE	87	Screen	29/09/91(*)	Screen
	451	Male	Imipramine	YES	ASASANTIN	89	Screen	07/01/92(*)	Day 42
					VALORON	02/01/92	Day 42	07/01/92(*)	Day 42
					XANEF	90	Screen	07/01/92(*)	Day 42
	452	Female	Reboxetine	YES	AZUDOXAT	03/01/92	Day 42	09/01/92	Day 42
					CHLORAL HYDRATE	21/11/91	Screen	26/11/91	Screen
					ISOPTIN	23/12/91	Day 28	09/01/92(*)	Day 42
					MEVINACOR	23/12/91	Day 28	09/01/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
14/1	452	Female	Reboxetine	YES	PARACETAMOL	03/01/92	Day 42	09/01/92	Day 42
14/2	456	Male	Imipramine	YES	ISOPTIN	91	Screen	26/05/92(*)	Day 42
14/3	421	Female	Reboxetine	NO	GASTROSIL	27/07/91	Day 14	28/07/91	Day 14
14/4	131	Female	Imipramine	YES	SODIUM FLUORIDE	08/90	Screen	13/01/92	Screen
	132	Female	Imipramine	YES	OVIOL	06/86	Screen	24/02/92	Day 42
	133	Female	Imipramine	YES	MARVELON	84	Screen	12/06/92	Day 28
	134	Female	Reboxetine	YES	OVIOL	10/86	Screen	26/02/92	Day 42
14/7	422	Female	Imipramine	YES	BERBERINE HYDROCHLORIDE	20/05/88	Screen	15/10/91(*)	Day 42
					CALCIUM	24/08/89	Screen	15/10/91(*)	Day 42
					COLCHICINE	20/05/88	Screen	15/10/91(*)	Day 42
	424	Male	Reboxetine	YES	HARZOL	01/08/88	Screen	30/10/91(*)	Day 42
					SERENOA REPENS	03/10/91	Day 14	30/10/91(*)	Day 42
	430	Female	Reboxetine	YES	DURAVOLTEN - SLOW RELEASE	20/08/91	Screen	17/11/91(*)	Day 42
					SINUPRET	06/11/91	Day 35	10/11/91	Day 35
	431	Male	Reboxetine	YES	SERENOA REPENS	13/03/91	Screen	18/11/91(*)	Day 42
	432	Male	Imipramine	YES	SERENOA REPENS	06/11/91	Day 35	18/11/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
14/7	434	Male	Reboxetine	YES	SERENOA REPENS	05/11/91	Day 28	24/11/91(*)	Day 42
	439	Male	Reboxetine	YES	MAGNESIUM VERLA DRAGEES	13/08/87	Screen	22/12/91(*)	Day 42
14/10	53	Male	Reboxetine	YES	PROSTATIN	88	Screen	06/04/92(*)	Day 42
	54	Female	Imipramine	YES	BAYOTENSIN	12/01/88	Screen	07/04/92(*)	Day 42
	55	Female	Reboxetine	YES	CARNIGEN	14/07/88	Screen	09/04/92(*)	Day 42
					METEOZYM	17/01/92	Screen	09/04/92(*)	Day 42
					PIROXICAM	27/03/92	Day 35	31/03/92	Day 35
14/9	56	Female	Imipramine	YES	DICLOFENAC	18/03/92	Day 21	22/03/92	Day 21
					LOPERAMIDE	01/04/92	Day 35	06/04/92	Day 35
					REGULTON	18/04/84	Screen	13/04/92(*)	Day 42
	57	Female	Reboxetine	YES	BRISERIN	07/11/86	Screen	25/02/92	Screen
					LOPERAMIDE HYDROCHLORIDE	02/04/92	Day 35	06/04/92	Day 35
			-		NITRENDIPINE	25/02/92	Screen	14/04/92(*)	Day 42
	60	Female	Reboxetine	YES	DIURSAN	04/88	Screen	23/06/92(*)	Day 7
	137	Female	Reboxetine	YES	DIHYDROERGOTAMIN	22/07/91	Screen	09/03/92(*)	Day 42
	138	Female	Imipramine	YES	AARANE	10/90	Screen	10/03/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
14/10	139	Female	Reboxetine	YES	ACETYLCYSTEINE	03/03/92	Day 35	09/03/92	Day 35
					CODIPRONT	03/03/92	Day 35	09/03/92	Day 35
					NORFENEFRINE	20/07/89	Screen	16/03/92(*)	Day 42
	435	Female	Imipramine	YES	BAYOTENSIN	04/90	Screen	23/12/91(*)	Day 42
	436	Female	Reboxetine	YES	CODIPRONT	23/12/91	Day 42	27/12/91	Day 42
					DOXYHEXAL TABS	22/12/91	Day 42	27/12/91	Day 42
	438	Female	Imipramine	YES	ACETYLCYSTEINE	22/11/91 13/12/91	Day 14 Day 35	27/11/91 19/12/91	Day 14 Day 35
					CODEINE PHOSPHATE	22/11/91	Day 14	27/11/91	Day 14
					CODIPRONT	13/12/91	Day 35	19/12/91	Day 35
					DIHYDERGOT PLUS	05/87	Screen	27/12/91(*)	Day 42
	443	Female	Reboxetine	YES	DICLOFENAC	05/87	Screen	30/12/91(*)	Day 42
	444	Male	Reboxetine	YES	ACETYLCYSTEINE	06/12/91	Day 21	13/12/91	Day 28
					CODEINE	06/12/91	Day 21	13/12/91	Day 28
					PRAZOSIN	03/91	Screen	27/12/91(*)	Day 42
					THYROXIN	02/88	Screen	27/12/91(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
14/10	445	Female	Imipramine	YES	BETAHISTINE MESILATE	15/08/89	Screen	30/12/91(*)	Day 42
					BEZAFIBRATE	31/01/89	Screen	30/12/91(*)	Day 42
					RAMIPRIL	30/10/91	Screen	30/12/91(*)	Day 42
	446	Female	Reboxetine	YES	CODIPRONT	11/12/91	Day 21	16/12/91	Day 21
					PRAVASTATIN	29/01/91	Screen	07/01/92(*)	Day 42
					RULID	11/12/91	Day 21	16/12/91	Day 21
	447	Male	Reboxetine	YES	ALLOPURINOL	07/11/88	Screen	07/01/92(*)	Day 42
					CIPROBAY	31/12/91	Day 42	06/01/92	Day 42
					DEPOT-H-INSULIN 'HOECHST'	08/03/91	Screen	07/01/92(*)	Day 42
					DIGOTAB	26/09/89	Screen	07/01/92(*)	Day 42
	448	Female	Imipramine	YES	GINKGO TREE LEAVES EXTRAC	25/10/91	Screen	07/01/92(*)	Day 42
					OXACEPROL	07/91	Screen	07/01/92(*)	Day 42
					PIROXICAM	23/12/91	Day 35	29/12/91	Day 35
	455	Female	Reboxetine	YES	VENALOT - SLOW RELEASE	04/86	Screen	31/07/92(*)	Day 42
15	349	Male	Imipramine	YES	SENNA	03/09/92	Day 14	01/10/92(*)	Day 14
	351	Male	Reboxetine	YES	AMILORETIK	02/09/92	Day 7	14/10/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
15	351	Male	Reboxetine	YES	ATENOLOL	02/09/92	Day 7	14/10/92(*)	Day 42
	352	Male	Imipramine	NO	AZIDOTHYMIDINE	12/08/92	Day 7	27/08/92(*)	Day 21
					IBUPROFEN	12/08/92	Day 7	27/08/92(*)	Day 21
					PARACETAMOL	12/08/92	Day 7	27/08/92(*)	Day 21
					VALOID	12/08/92	Day 7	27/08/92(*)	Day 21
	364	Female	Imipramine	NO	DIAZEPAM	24/08/92	Day 28	26/08/92(*)	Day 28
					PREMARIN	25/08/92	Day 28	26/08/92(*)	Day 28
	366	Male	Reboxetine	YES	CHLORAL HYDRATE	23/08/92	Screen	08/10/92(*)	Screen
15	367	Male	Imipramine	YES	CAPTOPRIL	05/10/92	Day 42	11/10/92(*)	Day 42
					CHLORAL HYDRATE	27/08/92	Screen	30/08/92	Screen
	371	Female	Reboxetine	YES	CHLORAL HYDRATE	17/07/92	Screen	19/08/92	Day 35
	372	Male	Imipramine	YES	CHLORAL HYDRATE	12/06/92	Screen	29/07/92(*)	Day 42
	374	Female	Reboxetine	YES	CHLORAL HYDRATE	14/04/92	Day 7	20/05/92(*)	Day 42
	376	Female	Imipramine	NO	TRICLORYL	14/04/92	Day 7	21/04/92(*)	Day 7
	377	Female	Reboxetine	YES	CHLORAL HYDRATE	12/05/92	Screen	25/06/92(*)	Screen
					GLYCERIN	15/05/92	Day 7	25/06/92(*)	Day 42

($) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
15	377	Female	Reboxetine	YES	SENNA	13/05/92	Screen	25/06/92(*)	Day 42
	380	Female	Imipramine	YES	CHLORAL HYDRATE	29/06/92	Screen	10/08/92(*)	Day 42
					PREDNISOLONE	31/07/92	Day 35	10/08/92(*)	Day 42
	381	Female	Reboxetine	YES	CHLORAL HYDRATE	09/06/92	Day 21	01/07/92	Day 42
	382	Male	Imipramine	NO	PARACETAMOL	10/04/92	Day 7	10/04/92(*)	Day 7
	383	Female	Imipramine	YES	CHLORAL HYDRATE	07/07/92	Day 7	18/08/92	Day 42

(*) - start date missing = screening date
(*) - end date missing = last dose taken date

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
1	1	Reboxetine	05/02/91	04/03/91	28	8	8	100.0	100.0		4	4	
			05/03/91	11/03/91	7	8	18	100.0	100.0		8	10	(3 - m) (3 - e)
			12/03/91	18/03/91	7	8	8	100.0	100.0		4	4	
					42								
	2	Reboxetine	26/02/91	03/04/91	37	8	8	100.0	100.0		4	4	
			04/04/91	08/04/91	5	8	4	50.0	94.0	4m		4	
					42								
	3	Imipramine	16/04/91	18/04/91	3	100	100	100.0	100.0		50	50	
			19/04/91	27/05/91	39	150	150	100.0	100.0		50	100	
					42								
	4	Imipramine	17/04/91	19/04/91	3	100	100	100.0	100.0		50	50	
			20/04/91	07/05/91	18	150	150	100.0	100.0		50	100	
			08/05/91	14/05/91	7	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			15/05/91	28/05/91	14	150	150	100.0	100.0		50	100	
					42								
	5	Reboxetine	17/07/91	13/08/91	28	8	8	100.0	100.0		4	4	
			14/08/91	27/08/91	14	10	10	100.0	100.0		4	6	
					42								
	6	Imipramine	07/08/91	09/08/91	3	100	100	100.0	100.0		50	50	
			10/08/91	17/09/91	39	150	150	100.0	100.0		50	100	
					42								
	7	Reboxetine	09/10/91	29/10/91	21	8	8	100.0	100.0		4	4	
			30/10/91	12/11/91	14	10	10	100.0	100.0		4	6	
			13/11/91	20/11/91	8	8	8	100.0	100.0		4	4	
					43								
	8	Imipramine	29/10/91	31/10/91	3	100	100	100.0	100.0		50	50	
					3								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
1	9	Imipramine	08/11/91	10/11/91	3	100	100	100.0	100.0		50	50	
			11/11/91	19/12/91	39	150	150	100.0	100.0		50	100	
					42								
	10	Imipramine	19/11/91	21/11/91	3	100	100	100.0	100.0		50	50	
			22/11/91	30/12/91	39	150	150	100.0	100.0		50	100	
					42								
	11	Reboxetine	06/04/92	03/05/92	28	8	8	100.0	100.0		4	4	
					28								
	12	Reboxetine	15/04/92	04/05/92	20	8	8	100.0	100.0		4	4	
			05/05/92	05/05/92	1	8	4	100.0	100.0	6e	4		
					21								
2	33	Reboxetine	19/12/90	29/01/91	42	8	8	100.0	100.0		4	4	
					42								
	34	Imipramine	28/12/90	30/12/90	3	100	100	100.0	100.0		50	50	
			31/12/90	02/02/91	34	150	150	100.0	100.0		50	100	
			03/02/91	03/02/91	1	150	50	100.0	100.0	6e	50		
					38								
	35	Reboxetine	28/12/90	07/02/91	42	8	8	100.0	100.0		4	4	
					42								
	36	Imipramine	10/01/91	12/01/91	3	100	100	100.0	100.0		50	50	
			13/01/91	30/01/91	18	150	150	100.0	100.0		50	100	
			31/01/91	31/01/91	1	150	50	100.0	100.0	6e	50		
					22								
	37	Reboxetine	18/01/91	28/02/91	42	8	8	100.0	100.0		4	4	
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
2	38	Imipramine	25/01/91	27/01/91	3	100	100	100.0	100.0		50	50	
			28/01/91	14/02/91	18	150	150	100.0	100.0		50	100	
			15/02/91	07/03/91	21	200	200	100.0	100.0		100	100	
					42								
	39	Reboxetine	25/01/91	07/03/91	42	8	8	100.0	100.0		4	4	
					42								
	40	Imipramine	20/02/91	22/02/91	3	100	100	100.0	100.0		50	50	
			23/02/91	02/04/91	39	150	150	100.0	100.0		50	100	
					42								
	41	Reboxetine	05/02/91	18/03/91	42	8	8	100.0	100.0		4	4	
					42								
	42	Imipramine	09/02/91	11/02/91	3	100	100	100.0	100.0		50	50	
			12/02/91	08/03/91	25	150	150	100.0	100.0		50	100	
			09/03/91	22/03/91	14	200	200	100.0	100.0		100	100	
					42								
	43	Reboxetine	26/03/91	06/05/91	42	8	8	100.0	100.0		4	4	
					42								
	44	Imipramine	11/04/91	11/04/91	1	100	50	100.0	100.0	3e	50		
					1								
	45	Imipramine	30/04/91	02/05/91	3	100	100	100.0	100.0		50	50	
			03/05/91	03/05/91	1	150	150	100.0	100.0		50	100	
					4								
	46	Reboxetine	16/05/91	26/06/91	42	8	8	100.0	100.0		4	4	
					42								
	47	Reboxetine	22/05/91	02/07/91	42	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
2	48	Imipramine	27/08/91	29/08/91	3	100	100	100.0	100.0		50	50	
			30/08/91	07/10/91	39	150	150	100.0	100.0		50	100	
					42								
	49	Imipramine	29/08/91	31/08/91	3	100	100	100.0	100.0		50	50	
			01/09/91	09/10/91	39	150	150	100.0	100.0		50	100	
					42								
	50	Reboxetine	06/11/91	14/12/91	39	8	8	100.0	100.0		4	4	
			15/12/91	15/12/91	1	8	4	100.0	100.0	6e	4		
					40								
	51	Reboxetine	06/11/91	17/11/91	12	8	8	100.0	100.0		4	4	
					12								
	52	Imipramine	27/11/91	29/11/91	3	100	100	100.0	100.0		50	50	
			30/11/91	07/01/92	39	150	150	100.0	100.0		50	100	
					42								
3	65	Reboxetine	02/04/91	13/05/91	42	8	8	100.0	100.0		4	4	
					42								
	66	Imipramine	01/05/91	03/05/91	3	100	100	100.0	100.0		50	50	
			04/05/91	03/06/91	31	150	150	100.0	100.0		50	100	
			04/06/91	04/06/91	1	150	250	100.0	100.0		50	200	(B - e)
			05/06/91	05/06/91	1	200	100	100.0	100.0	6e	100		
					36								
	67	Reboxetine	10/04/91	30/04/91	21	8	8	100.0	100.0		4	4	
			01/05/91	21/05/91	21	10	10	100.0	100.0		4	6	
					42								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
3	68	Imipramine	03/08/91	05/08/91	3	100	100	100.0	100.0		50	50	
			06/08/91	23/08/91	18	150	150	100.0	100.0		50	100	
			24/08/91	13/09/91	21	200	200	100.0	100.0		100	100	
					42								
	69	Imipramine	01/03/91	03/03/91	3	100	100	100.0	100.0		50	50	
			04/03/91	11/04/91	39	150	150	100.0	100.0		50	100	
					42								
	70	Reboxetine	23/10/91	12/11/91	21	8	8	100.0	100.0		4	4	
			13/11/91	19/11/91	7	10	10	100.0	100.0		4	6	
					28								
	71	Imipramine	14/11/91	16/11/91	3	100	100	100.0	100.0		50	50	
			17/11/91	25/12/91	39	150	150	100.0	100.0		50	100	
					42								
	72	Reboxetine	31/01/92	12/03/92	42	8	8	100.0	100.0		4	4	
					42								
	73	Reboxetine	15/02/92	27/03/92	42	8	8	100.0	100.0		4	4	
					42								
4	97	Imipramine	07/05/92	09/05/92	3	100	100	100.0	100.0		50	50	
			10/05/92	18/06/92	40	150	150	100.0	100.0		50	100	
					43								
	100	Reboxetine	07/05/92	17/06/92	42	8	8	100.0	100.0		4	4	
					42								
	101	Imipramine	06/05/91	08/05/91	3	100	100	100.0	100.0		50	50	
			09/05/91	22/05/91	14	150	150	100.0	100.0		50	100	
					17								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

718

9550085

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
6	161	Reboxetine	29/03/91	09/05/91	42	8	8	100.0	100.0		4	4	
					42								
	162	Reboxetine	05/11/91	16/12/91	42	8	8	100.0	100.0		4	4	
					42								
7	193	Reboxetine	11/06/91	17/06/91	7	8	8	100.0	100.0		4	4	
					7								
	194	Reboxetine	03/06/91	06/06/91	4	8	8	100.0	100.0		4	4	
			07/06/91	08/06/91	2	8		100.0	100.0	3n 3e			
					6								
	196	Imipramine	19/03/91	21/03/91	3	100	100	100.0	100.0		50	50	
			22/03/91	26/04/91	36	150	150	100.0	100.0		50	100	
					39								
8	225	Imipramine	22/03/91	22/03/91	1	100	50	100.0	100.0	9m		50	
			23/03/91	24/03/91	2	100	100	100.0	100.0		50	50	
			25/03/91	08/04/91	15	150	150	100.0	100.0		50	100	
			09/04/91	09/04/91	1	150	50	100.0	100.0	6e	50		
					19								
	226	Reboxetine	03/05/91	30/05/91	28	8	8	100.0	100.0		4	4	
			31/05/91	06/06/91	7	8	10	100.0	100.0		4	6	
			07/06/91	08/06/91	2	10	10	100.0	100.0		4	6	
			09/06/91	09/06/91	1	10	4	40.0	98.4	1e	4		
			10/06/91	13/06/91	4	10	10	100.0	98.6		4	6	
					42								
	227	Imipramine	07/05/91	09/05/91	3	100	100	100.0	100.0		50	50	
			10/05/91	17/06/91	39	150	150	100.0	100.0		50	100	
					42								
	228	Reboxetine	10/05/91	17/05/91	8	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					8								
8	229	Imipramine	22/10/91	24/10/91	3	100	100	100.0	100.0		50	50	
			25/10/91	02/12/91	39	150	150	100.0	100.0		50	100	
					42								
	230	Imipramine	05/11/91	07/11/91	3	100	100	100.0	100.0		50	50	
			08/11/91	03/12/91	26	150	150	100.0	100.0		50	100	
			04/12/91	04/12/91	1	150	50	33.3	97.8	1e	50		
			05/12/91	06/12/91	2	150	150	100.0	97.9		50	100	
			07/12/91	07/12/91	1	150	50	33.3	96.0	1e	50		
			08/12/91	10/12/91	3	150	150	100.0	96.3		50	100	
			11/12/91	11/12/91	1	150	50	33.3	94.6	1e	50		
			12/12/91	16/12/91	5	150	150	100.0	95.2		50	100	
					42								
	231	Reboxetine	05/11/91	12/11/91	8	8	8	100.0	100.0		4	4	
			13/11/91	13/11/91	1	8	4	100.0	100.0	6e	4		
					9								
	232	Reboxetine	29/11/91	09/01/92	42	8	8	100.0	100.0		4	4	
					42								
9	197	Reboxetine	07/03/92	10/03/92	4	8	8	100.0	100.0		4	4	
					4								
	198	Imipramine	18/03/92	20/03/92	3	100	100	100.0	100.0		50	50	
			21/03/92	28/04/92	39	150	150	100.0	100.0		50	100	
					42								
	199	Imipramine	02/04/92	04/04/92	3	100	100	100.0	100.0		50	50	
			05/04/92	23/04/92	19	150	150	100.0	100.0		50	100	
			24/04/92	24/04/92	1	150	100	66.7	98.6	1m		100	
			25/04/92	13/05/92	19	150	150	100.0	99.2		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
9	200	Reboxetine	28/04/92	08/06/92	42	8	8	100.0	100.0		4	4	
					42								
	201	Imipramine	16/01/92	16/01/92	1	100	50	50.0	50.0	1m		50	
			17/01/92	18/01/92	2	100	100	100.0	83.3		50	50	
			19/01/92	20/01/92	2	150	150	100.0	90.0		50	100	
			21/01/92	21/01/92	1	150	150	100.0	91.7	1m		150	(D - e)
			22/01/92	09/02/92	19	150	150	100.0	98.0		50	100	
			10/02/92	12/02/92	3	150		100.0	98.2	5m 5e			
			13/02/92	26/02/92	14	150	150	100.0	98.8		50	100	
					42								
	202	Imipramine	17/01/92	19/01/92	3	100	100	100.0	100.0		50	50	
			20/01/92	20/01/92	1	150	50	33.3	83.3	1e	50		
			21/01/92	21/01/92	1	150	150	100.0	86.7		50	100	
			22/01/92	22/01/92	1	150	100	66.7	83.3	1m		100	
			23/01/92	27/02/92	36	150	150	100.0	97.6		50	100	
					42								
	203	Reboxetine	15/01/92	18/01/92	4	8	8	100.0	100.0		4	4	
					4								
	204	Reboxetine	17/01/92	28/02/92	43	8	8	100.0	100.0		4	4	
					43								
	205	Imipramine	05/02/92	07/02/92	3	100	100	100.0	100.0		50	50	
					3								
	206	Imipramine	05/02/92	07/02/92	3	100	100	100.0	100.0		50	50	
			08/02/92	16/02/92	9	150	150	100.0	100.0		50	100	
			17/02/92	17/02/92	1	150		0.0	92.3	1m 1e			
			18/02/92	24/02/92	7	150	150	100.0	95.0		50	100	
			25/02/92	25/02/92	1	150	100	66.7	93.7	1m		100	
			26/02/92	18/03/92	22	150	150	100.0	96.9		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
9	207	Reboxetine	06/02/92	07/02/92	2	8	8	100.0	100.0		4	4	
			08/02/92	08/02/92	1	8	4	50.0	83.3	1e	4		
			09/02/92	12/02/92	4	8	8	100.0	92.9		4	4	
					7								
	208	Reboxetine	15/02/92	27/03/92	42	8	8	100.0	100.0		4	4	
					42								
	209	Imipramine	12/02/92	14/02/92	3	100	100	100.0	100.0		50	50	
			15/02/92	15/02/92	1	150	150	100.0	100.0		50	100	
					4								
	210	Reboxetine	20/02/92	12/03/92	22	8	8	100.0	100.0		4	4	
			13/03/92	13/03/92	1	8	4	50.0	97.8	1m		4	
			14/03/92	01/04/92	19	8	8	100.0	98.8		4	4	
					42								
	211	Reboxetine	14/02/92	01/03/92	17	8	8	100.0	100.0		4	4	
			02/03/92	02/03/92	1	8	4	100.0	100.0	6e	4		
					18								
	212	Imipramine	04/03/92	06/03/92	3	100	100	100.0	100.0		50	50	
			07/03/92	14/04/92	39	150	150	100.0	100.0		50	100	
					42								
	237	Reboxetine	23/04/92	26/04/92	4	8	8	100.0	100.0		4	4	
			27/04/92	27/04/92	1	8	4	100.0	100.0	3e	4		
			28/04/92	29/04/92	2	8		100.0	100.0	3m 3e			
			30/04/92	02/05/92	3	8	8	100.0	100.0		4	4	
					10								
	238	Imipramine	20/05/92	22/05/92	3	100	100	100.0	100.0		50	50	
			23/05/92	30/06/92	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
9	239	Imipramine	30/04/92	02/05/92	3	100	100	100.0	100.0		50	50	
			03/05/92	10/06/92	39	150	150	100.0	100.0		50	100	
					42								
	240	Reboxetine	28/04/92	16/05/92	19	8	8	100.0	100.0		4	4	
					19								
	241	Imipramine	09/05/92	11/05/92	3	100	100	100.0	100.0		50	50	
			12/05/92	22/05/92	11	150	150	100.0	100.0		50	100	
			23/05/92	23/05/92	1	150	100	100.0	100.0	3m		100	
			24/05/92	19/06/92	27	150	150	100.0	100.0		50	100	
					42								
	242	Reboxetine	07/05/92	17/06/92	42	8	8	100.0	100.0		4	4	
					42								
	243	Imipramine	18/05/92	20/05/92	3	100	100	100.0	100.0		50	50	
			21/05/92	28/06/92	39	150	150	100.0	100.0		50	100	
					42								
	244	Reboxetine	06/06/92	03/07/92	28	8	8	100.0	100.0		4	4	
			04/07/92	12/07/92	9	10	10	100.0	100.0		4	6	
			13/07/92	13/07/92	1	10		0.0	97.4	1m 1e			
			14/07/92	17/07/92	4	10	10	100.0	97.6		4	6	
					42								
	257	Reboxetine	17/07/91	27/08/91	42	8	8	100.0	100.0		4	4	
					42								
	258	Reboxetine	17/07/91	06/08/91	21	8	8	100.0	100.0		4	4	
					21								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
9	259	Imipramine	17/07/91	19/07/91	3	100	100	100.0	100.0		50	50	
			20/07/91	27/08/91	39	150	150	100.0	100.0		50	100	
					42								
	260	Imipramine	24/07/91	26/07/91	3	100	100	100.0	100.0		50	50	
			27/07/91	29/07/91	3	150	150	100.0	100.0		50	100	
			30/07/91	30/07/91	1	150		0.0	85.7	1m 1e			
			31/07/91	05/08/91	6	150	150	100.0	92.3		50	100	
			06/08/91	06/08/91	1	150		0.0	85.7	1m 1e			
			07/08/91	12/08/91	6	150	150	100.0	90.0		50	100	
			13/08/91	13/08/91	1	150		0.0	85.7	1m 1e			
					21								
	261	Imipramine	23/07/91	24/07/91	2	100	100	100.0	100.0		50	50	
			25/07/91	25/07/91	1	100	50	50.0	83.3	1e	50		
			26/07/91	29/07/91	4	150	150	100.0	92.9		50	100	
					7								
	262	Reboxetine	23/07/91	29/07/91	7	8	8	100.0	100.0		4	4	
			30/07/91	30/07/91	1	8		0.0	87.5				
			31/07/91	09/08/91	10	8	8	100.0	94.4		4	4	
			10/08/91	10/08/91	1	8	4	50.0	92.1	1m		4	
			11/08/91	15/08/91	5	8	8	100.0	93.8		4	4	
			16/08/91	16/08/91	1	8	4	50.0	92.0	1m		4	
			17/08/91	17/08/91	1	8	8	100.0	92.3		4	4	
			18/08/91	18/08/91	1	8	4	50.0	90.7	1e	4		
			19/08/91	30/08/91	12	8	8	100.0	93.6		4	4	
			31/08/91	31/08/91	1	8	4	50.0	92.5	1e	4		
			01/09/91	03/09/91	3	8	8	100.0	93.0		4	4	
					43								
	263	Reboxetine	31/07/91	03/08/91	4	8	8	100.0	100.0		4	4	
			04/08/91	04/08/91	1	8	4	50.0	90.0	1m		4	
			05/08/91	13/08/91	9	8	8	100.0	96.4		4	4	
					14								
	264	Imipramine	31/07/91	02/08/91	3	100	100	100.0	100.0		50	50	
			03/08/91	10/09/91	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

721

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
9	265	Reboxetine	23/08/91	07/09/91	16	8	8	100.0	100.0		4	4	
			08/09/91	08/09/91	1	8	4	50.0	97.1	1e	4		
			09/09/91	10/09/91	2	8	8	100.0	97.4		4	4	
			11/09/91	11/09/91	1	8	4	50.0	95.0	1e	4		
			12/09/91	29/09/91	18	8	8	100.0	97.4		4	4	
			30/09/91	30/09/91	1	8	4	50.0	96.2	1m		4	
			01/10/91	03/10/91	3	8	8	100.0	96.4		4	4	
					42								
	266	Reboxetine	18/09/91	29/10/91	42	8	8	100.0	100.0		4	4	
					42								
	267	Imipramine	02/09/91	04/09/91	3	100	100	100.0	100.0		50	50	
			05/09/91	05/09/91	1	150	300	100.0	100.0		100	200	(B - m) (B - e)
			06/09/91	28/09/91	23	150	150	100.0	100.0		50	100	
			29/09/91	29/09/91	1	150	150	100.0	100.0	1m		150	(D - e)
			30/09/91	13/10/91	14	150	150	100.0	100.0		50	100	
					42								
	268	Imipramine	25/09/91	27/09/91	3	100	100	100.0	100.0		50	50	
			28/09/91	29/10/91	32	150	150	100.0	100.0		50	100	
			30/10/91	05/11/91	7	200	200	100.0	100.0		100	100	
					42								
	269	Reboxetine	25/09/91	05/11/91	42	8	8	100.0	100.0		4	4	
					42								
	270	Imipramine	11/10/91	13/10/91	3	100	100	100.0	100.0		50	50	
			14/10/91	14/10/91	1	150	150	100.0	100.0		50	100	
			15/10/91	15/10/91	1	150	50	33.3	86.7	1e	50		
			16/10/91	17/10/91	2	150	150	100.0	90.5		50	100	
					7								
	271	Reboxetine	30/10/91	12/11/91	14	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
9	271	Reboxetine	13/11/91	13/11/91	1	8	4	100.0	100.0	3e	4		
			14/11/91	17/11/91	4	8		100.0	100.0	3m 3e			
			18/11/91	20/11/91	3	8	8	100.0	100.0		4	4	
					22								
	272	Imipramine	30/10/91	01/11/91	3	100	100	100.0	100.0		50	50	
			02/11/91	10/12/91	39	150	150	100.0	100.0		50	100	
					42								
	273	Imipramine	30/10/91	01/11/91	3	100	100	100.0	100.0		50	50	
			02/11/91	20/11/91	19	150	150	100.0	100.0		50	100	
			21/11/91	21/11/91	1	150		100.0	100.0	3m 6e			
					23								
	274	Reboxetine	31/10/91	31/10/91	1	8	4	100.0	100.0	6e	4		
					1								
	274/A	Reboxetine	13/05/92	26/05/92	14	8	8	100.0	100.0		4	4	
			27/05/92	27/05/92	1	8	4	50.0	96.7	1m		4	
			28/05/92	08/06/92	12	8	8	100.0	98.1		4	4	
			09/06/92	09/06/92	1	8	4	50.0	96.4	4e	4		
			10/06/92	23/06/92	14	8	8	100.0	97.6		4	4	
					42								
	275	Reboxetine	06/11/91	16/11/91	11	8	8	100.0	100.0		4	4	
			17/11/91	17/11/91	1	8	4	50.0	95.8	4m		4	
			18/11/91	07/12/91	20	8	8	100.0	98.4		4	4	
			08/12/91	08/12/91	1	8		0.0	95.5	1m 1e			
			09/12/91	17/12/91	9	8	8	100.0	96.4		4	4	
					42								
	276	Imipramine	14/01/92	14/01/92	1	100	50	100.0	100.0	6e	50		
					1								
	276/A	Imipramine	04/03/92	06/03/92	3	100	100	100.0	100.0		50	50	
			07/03/92	24/03/92	18	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
9	276/A	Imipramine	25/03/92	14/04/92	21	200	200	100.0	100.0		100	100	
					42								
9/A	233	Imipramine	14/05/92	16/05/92	3	100	100	100.0	100.0		50	50	
			17/05/92	26/05/92	10	150	150	100.0	100.0		50	100	
			27/05/92	27/05/92	1	150	50	33.3	95.2	1e	50		
			28/05/92	24/06/92	28	150	150	100.0	98.4		50	100	
					42								
	234	Reboxetine	22/05/92	02/07/92	42	8	8	100.0	100.0		4	4	
					42								
	235	Reboxetine	26/05/92	28/06/92	34	8	8	100.0	100.0		4	4	
			29/06/92	29/06/92	1	8	4	100.0	100.0	6e	4		
					35								
	236	Imipramine	27/05/92	29/05/92	3	100	100	100.0	100.0		50	50	
			30/05/92	07/07/92	39	150	150	100.0	100.0		50	100	
					42								
	277	Reboxetine	10/06/92	14/06/92	5	8	8	100.0	100.0		4	4	
					5								
	278	Imipramine	13/06/92	15/06/92	3	100	100	100.0	100.0		50	50	
			16/06/92	02/07/92	17	150	150	100.0	100.0		50	100	
			03/07/92	03/07/92	1	150	50	100.0	100.0	6e	50		
					21								
	279	Imipramine	07/08/92	09/08/92	3	100	100	100.0	100.0		50	50	
			10/08/92	21/08/92	12	150	150	100.0	100.0		50	100	
					15								
	280	Reboxetine	08/08/92	13/08/92	6	8	8	100.0	100.0		4	4	
			14/08/92	14/08/92	1	8	4	100.0	100.0	6e	4		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					7								
9/A	281	Reboxetine	01/09/92	12/10/92	42	8	8	100.0	100.0		4	4	
					42								
	282	Reboxetine	02/09/92	13/10/92	42	8	8	100.0	100.0		4	4	
					42								
	283	Imipramine	16/09/92	16/09/92	1	100	50	100.0	100.0	9m		50	
			17/09/92	18/09/92	2	100	100	100.0	100.0		50	50	
			19/09/92	28/10/92	40	150	150	100.0	100.0		50	100	
					43								
	284	Imipramine	19/09/92	21/09/92	3	100	100	100.0	100.0		50	50	
			22/09/92	09/10/92	18	150	150	100.0	100.0		50	100	
					21								
	301	Imipramine	05/03/92	07/03/92	3	100	100	100.0	100.0		50	50	
			08/03/92	15/04/92	39	150	150	100.0	100.0		50	100	
					42								
	302	Imipramine	06/03/92	08/03/92	3	100	100	100.0	100.0		50	50	
			09/03/92	22/03/92	14	150	150	100.0	100.0		50	100	
					17								
	303	Reboxetine	12/03/92	30/03/92	19	8	8	100.0	100.0		4	4	
			31/03/92	31/03/92	1	8	4	100.0	100.0	6e	4		
					20								
	304	Reboxetine	26/03/92	06/05/92	42	8	8	100.0	100.0		4	4	
					42								
	305	Reboxetine	31/03/92	11/05/92	42	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
9/A	306	Reboxetine	29/04/92	09/06/92	42	8	8	100.0	100.0		4	4	
					42								
	307	Imipramine	05/05/92	07/05/92	3	100	100	100.0	100.0		50	50	
			08/05/92	08/05/92	1	150	50	100.0	100.0	6e	50		
					4								
	308	Imipramine	09/05/92	11/05/92	3	100	100	100.0	100.0		50	50	
			12/05/92	01/06/92	21	150	150	100.0	100.0		50	100	
			02/06/92	02/06/92	1	150	50	100.0	100.0	6e	50		
					25								
10	289	Imipramine	21/09/91	23/09/91	3	100	100	100.0	100.0		50	50	
			24/09/91	25/09/91	2	150	150	100.0	100.0		50	100	
			26/09/91	26/09/91	1	150	50	33.3	88.9	10e	50		
			27/09/91	27/09/91	1	150	150	100.0	90.5		50	100	
					7								
	290	Reboxetine	14/10/91	25/10/91	12	8	8	100.0	100.0		4	4	
			26/10/91	26/10/91	1	8	12	100.0	100.0		4	8	(B - e)
			27/10/91	01/11/91	6	8	8	100.0	100.0		4	4	
			02/11/91	02/11/91	1	8	12	100.0	100.0		8	4	(B - m)
			03/11/91	13/11/91	11	8	8	100.0	100.0		4	4	
			14/11/91	14/11/91	1	8	4	50.0	98.4	1e	4		
			15/11/91	24/11/91	10	8	8	100.0	98.8		4	4	
					42								
	291	Imipramine	17/02/92	19/02/92	3	100	100	100.0	100.0		50	50	
			20/02/92	29/03/92	39	150	150	100.0	100.0		50	100	
					42								
	292	Reboxetine	13/12/91	20/12/91	8	8	8	100.0	100.0		4	4	
			21/12/91	21/12/91	1	8	4	50.0	94.4	10m		4	
			22/12/91	23/01/92	33	8	8	100.0	98.8		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
10	293	Reboxetine	24/12/91	29/12/91	6	8	8	100.0	100.0		4	4	
			30/12/91	30/12/91	1	8	4	50.0	92.9	1e	4		
			31/12/91	04/01/92	5	8	8	100.0	95.8		4	4	
			05/01/92	05/01/92	1	8	4	50.0	92.3	1e	4		
			06/01/92	14/01/92	9	8	8	100.0	95.5		4	4	
			15/01/92	15/01/92	1	8	14	100.0	95.7		4	10	(3 - e)
			16/01/92	01/02/92	17	8	18	100.0	97.5		8	10	(3 - m) (3 - e)
					40								
	294	Imipramine	03/01/92	05/01/92	3	100	100	100.0	100.0		50	50	
			06/01/92	23/01/92	18	150	150	100.0	100.0		50	100	
					21								
	295	Imipramine	07/01/92	07/01/92	1	100	100	100.0	100.0		50	50	
			08/01/92	08/01/92	1	100	50	50.0	75.0	2e	50		
			09/01/92	09/01/92	1	100	100	100.0	83.3		50	50	
			10/01/92	31/01/92	22	150	150	100.0	98.0		50	100	
			01/02/92	02/02/92	2	150		100.0	98.1	3m 3e			
			03/02/92	03/02/92	1	150	150	100.0	98.2		50	100	
			04/02/92	04/02/92	1	150		0.0	94.8	4m 4e			
			05/02/92	07/02/92	3	150	150	100.0	95.3		50	100	
			08/02/92	08/02/92	1	150	100	66.7	94.4	4m		100	
			09/02/92	17/02/92	9	150	150	100.0	95.6		50	100	
					42								
	296	Reboxetine	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4	
					42								
	297	Reboxetine	21/03/92	21/03/92	1	8	4	100.0	100.0	9m		4	
			22/03/92	01/05/92	41	8	8	100.0	100.0		4	4	
			02/05/92	02/05/92	1	8	4	100.0	100.0	9e	4		
					43								
	298	Reboxetine	27/03/92	07/05/92	42	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
10	299	Imipramine	07/04/92	09/04/92	3	100	100	100.0	100.0		50	50	
			10/04/92	18/05/92	39	150	150	100.0	100.0		50	100	
					42								
	300	Imipramine	14/04/92	16/04/92	3	100	100	100.0	100.0		50	50	
			17/04/92	17/04/92	1	150	150	100.0	100.0		50	100	
			18/04/92	18/04/92	1	150	250	100.0	100.0		50	200	(B - e)
			19/04/92	19/04/92	1	150	200	100.0	100.0		100	100	(B - m)
			20/04/92	25/05/92	36	150	150	100.0	100.0		50	100	
					42								
11	321	Reboxetine	11/06/92	22/07/92	42	8	8	100.0	100.0		4	4	
			23/07/92	23/07/92	1	8	4	100.0	100.0	9e	4		
					43								
	322	Reboxetine	11/06/92	23/07/92	43	8	8	100.0	100.0		4	4	
			24/07/92	24/07/92	1	8	4	100.0	100.0	9e	4		
					44								
	323	Imipramine	24/06/92	24/06/92	1	100	50	100.0	100.0	9m		50	
			25/06/92	26/06/92	2	100	100	100.0	100.0		50	50	
			27/06/92	28/07/92	32	150	150	100.0	100.0		50	100	
			29/07/92	29/07/92	1	150	50	33.3	98.1	1e	50		
			30/07/92	30/07/92	1	150	100	66.7	97.3	1m 9e		100	
			31/07/92	05/08/92	6	150	150	100.0	97.7		50	100	
			06/08/92	06/08/92	1	150	50	100.0	97.7	9e	50		
					44								
	324	Imipramine	17/07/92	17/07/92	1	100	50	100.0	100.0	9m		50	
			18/07/92	19/07/92	2	100	100	100.0	100.0		50	50	
			20/07/92	27/08/92	39	150	150	100.0	100.0		50	100	
			28/08/92	28/08/92	1	150	50	100.0	100.0	9e	50		
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
11	325	Reboxetine	30/07/92	30/07/92	1	8	4	100.0	100.0	9m		4	
			31/07/92	09/09/92	41	8	8	100.0	100.0		4	4	
			10/09/92	10/09/92	1	8	4	100.0	100.0	9e	4		
					43								
	326	Imipramine	30/07/92	30/07/92	1	100	50	100.0	100.0	9m		50	
			31/07/92	01/08/92	2	100	100	100.0	100.0		50	50	
			02/08/92	10/09/92	40	150	150	100.0	100.0		50	100	
					43								
	327	Reboxetine	20/08/92	20/08/92	1	8	4	100.0	100.0	9m		4	
			21/08/92	30/09/92	41	8	8	100.0	100.0		4	4	
			01/10/92	01/10/92	1	8	4	100.0	100.0	9e	4		
					43								
	328	Imipramine	20/08/92	20/08/92	1	100	50	100.0	100.0	9m		50	
			21/08/92	22/08/92	2	100	100	100.0	100.0		50	50	
			23/08/92	16/09/92	25	150	150	100.0	100.0		50	100	
			17/09/92	17/09/92	1	150	50	100.0	100.0	9e	50		
					29								
	329	Imipramine	21/08/92	23/08/92	3	100	100	100.0	100.0		50	50	
			24/08/92	01/10/92	39	150	150	100.0	100.0		50	100	
			02/10/92	02/10/92	1	150	50	100.0	100.0	9e	50		
					43								
	330	Reboxetine	24/08/92	25/08/92	2	8	8	100.0	100.0		4	4	
			26/08/92	26/08/92	1	8	4	100.0	100.0	6e	4		
					3								
	331	Reboxetine	03/09/92	20/09/92	18	8	8	100.0	100.0		4	4	
			21/09/92	21/09/92	1	8	4	100.0	100.0	3m		4	
			22/09/92	14/10/92	23	8	8	100.0	100.0		4	4	
			15/10/92	15/10/92	1	8	4	50.0	98.8	4e	4		
					43								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
11	332	Imipramine	05/09/92	05/09/92	1	100	50	100.0	100.0	9m		50	
			06/09/92	07/09/92	2	100	100	100.0	100.0		50	50	
			08/09/92	13/09/92	6	150	150	100.0	100.0		50	100	
			14/09/92	14/09/92	1	150	100	100.0	100.0	9m		100	
			15/09/92	19/10/92	35	150	150	100.0	100.0		50	100	
			20/10/92	20/10/92	1	150	50	100.0	100.0	9e	50		
					46								
	333	Imipramine	04/09/92	04/09/92	1	100	50	100.0	100.0	9m		50	
			05/09/92	06/09/92	2	100	100	100.0	100.0		50	50	
			07/09/92	24/09/92	18	150	150	100.0	100.0		50	100	
			25/09/92	25/09/92	1	150	250	100.0	100.0		50	200	(3 - e)
			26/09/92	01/10/92	6	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			02/10/92	02/10/92	1	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			03/10/92	08/10/92	6	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			09/10/92	09/10/92	1	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			10/10/92	15/10/92	6	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			16/10/92	16/10/92	1	150	150	100.0	100.0	9e	150		(3 - m)
					43								
12	337	Imipramine	26/05/92	28/05/92	3	100	100	100.0	100.0		50	50	
			29/05/92	11/06/92	14	150	150	100.0	100.0		50	100	
			12/06/92	12/06/92	1	150	100	66.7	98.1	4m		100	
			13/06/92	22/06/92	10	150	150	100.0	98.8		50	100	
			23/06/92	23/06/92	1	150	150	100.0	98.9	3e	150		(3 - m)
			24/06/92	24/06/92	1	150	250	100.0	98.9		150	100	(3 - m)
			25/06/92	06/07/92	12	150	150	100.0	99.2		50	100	
					42								
	338	Reboxetine	20/06/92	09/07/92	20	8	8	100.0	100.0		4	4	
			10/07/92	10/07/92	1	8	4	50.0	97.6	1m		4	
			11/07/92	30/07/92	20	10	10	100.0	98.8		4	6	
			31/07/92	31/07/92	1	10	4	40.0	97.4	1e	4		
					42								
	339	Imipramine	23/06/92	25/06/92	3	100	100	100.0	100.0		50	50	
			26/06/92	03/08/92	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
12	340	Reboxetine	07/08/92	10/09/92	35	8	8	100.0	100.0		4	4	
			11/09/92	17/09/92	7	10	10	100.0	100.0		4	6	
					42								
	341	Reboxetine	21/08/92	26/08/92	6	8	8	100.0	100.0		4	4	
			27/08/92	27/08/92	1	8	4	50.0	92.9	4e	4		
			28/08/92	02/09/92	6	8	8	100.0	96.2		4	4	
			03/09/92	03/09/92	1	8	4	50.0	92.9	4e	4		
			04/09/92	10/09/92	7	8	8	100.0	95.2		4	4	
			11/09/92	13/09/92	3	8	20	100.0	95.8		8	12	(A - m) (A - e)
			14/09/92	14/09/92	1	8	14	100.0	96.0		8	6	(A - m)
			15/09/92	17/09/92	3	8	10	100.0	96.4		4	6	
			18/09/92	24/09/92	7	10	10	100.0	97.1		4	6	
					35								
13	353	Reboxetine	05/06/92	11/06/92	7	8	8	100.0	100.0		4	4	
			12/06/92	14/06/92	3	8		0.0	70.0				
			15/06/92	20/06/92	6	8	8	100.0	81.3		4	4	
			21/06/92	21/06/92	1	8		100.0	82.4	3m 3e			
			22/06/92	06/07/92	15	8	8	100.0	90.6		4	4	
			07/07/92	07/07/92	1	8	8	100.0	90.9	7e	4	4	
					33								
	354	Imipramine	24/06/92	24/06/92	1	100	50	100.0	100.0	9m		50	
			25/06/92	26/06/92	2	100	100	100.0	100.0		50	50	
			27/06/92	20/07/92	24	150	150	100.0	100.0		50	100	
			21/07/92	21/07/92	1	150	50	33.3	97.6	4e	50		
			22/07/92	04/08/92	14	150	150	100.0	98.4		50	100	
					42								
	355	Reboxetine	25/06/92	26/06/92	2	8	8	100.0	100.0		4	4	
			27/06/92	27/06/92	1	8	4	100.0	100.0	6e	4		
					3								
	356	Imipramine	22/07/92	24/07/92	3	100	100	100.0	100.0		50	50	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
13	356	Imipramine	25/07/92	01/09/92	39	150	150	100.0	100.0		50	100	
					42								
	357	Imipramine	05/08/92	07/08/92	3	100	100	100.0	100.0		50	50	
			08/08/92	09/08/92	2	150	150	100.0	100.0		50	100	
			10/08/92	10/08/92	1	150		100.0	100.0	3m 3e			
					6								
	358	Reboxetine	06/08/92	27/08/92	22	8	8	100.0	100.0		4	4	
			28/08/92	29/08/92	2	8	8	100.0	100.0	4m		8	(D - e)
			30/08/92	31/08/92	2	8		100.0	100.0	3m 3e			
			01/09/92	05/09/92	5	8	8	100.0	100.0		4	4	
					31								
	359	Reboxetine	19/08/92	22/09/92	35	8	8	100.0	100.0		4	4	
			23/09/92	29/09/92	7	8	14	100.0	100.0		4	10	(3 - e)
					42								
	360	Imipramine	19/08/92	20/08/92	2	100	100	100.0	100.0		50	50	
			21/08/92	21/08/92	1	100	50	100.0	100.0	6e	50		
					3								
	361	Reboxetine	26/08/92	26/08/92	1	8	4	100.0	100.0	9m		4	
			27/08/92	06/10/92	41	8	8	100.0	100.0		4	4	
					42								
14	457	Reboxetine	07/07/92	26/07/92	20	8	8	100.0	100.0		4	4	
			27/07/92	27/07/92	1	8	4	50.0	97.6	1e	4		
			28/07/92	17/08/92	21	8	8	100.0	98.8		4	4	
					42								
	458	Imipramine	14/07/92	16/07/92	3	100	100	100.0	100.0		50	50	
			17/07/92	20/07/92	4	150	150	100.0	100.0		50	100	
			21/07/92	27/07/92	7	200	200	100.0	100.0		100	100	
			28/07/92	17/08/92	21	150	150	100.0	100.0		50	100	
			18/08/92	24/08/92	7	150	50	33.3	88.9	4e	50		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14	459	Reboxetine	16/07/92	26/08/92	42	8	8	100.0	100.0		4	4	
					42								
	460	Imipramine	23/07/92	25/07/92	3	100	100	100.0	100.0		50	50	
			26/07/92	02/09/92	39	150	150	100.0	100.0		50	100	
					42								
	461	Imipramine	29/07/92	31/07/92	3	100	100	100.0	100.0		50	50	
			01/08/92	04/08/92	4	150	50	33.3	61.9	4e	50		
			05/08/92	25/08/92	21	150	150	100.0	90.5		50	100	
			26/08/92	01/09/92	7	150	350	100.0	92.4		150	200	(3 - m) (3 - e)
			02/09/92	08/09/92	7	150	150	100.0	93.7		50	100	
					42								
	462	Reboxetine	31/07/92	10/09/92	42	8	8	100.0	100.0		4	4	
					42								
	463	Imipramine	03/08/92	05/08/92	3	100	100	100.0	100.0		50	50	
			06/08/92	13/09/92	39	150	150	100.0	100.0		50	100	
					42								
	464	Reboxetine	05/08/92	26/08/92	22	8	8	100.0	100.0		4	4	
			27/08/92	02/09/92	7	8	18	100.0	100.0		8	10	(3 - m) (3 - e)
			03/09/92	16/09/92	14	8	8	100.0	100.0		4	4	
					43								
	465	Reboxetine	06/08/92	16/09/92	42	8	8	100.0	100.0		4	4	
					42								
	466	Imipramine	07/08/92	09/08/92	3	100	100	100.0	100.0		50	50	
			10/08/92	17/09/92	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017 -
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14/1	129	Reboxetine	19/12/91	19/12/91	1	8	4	100.0	100.0	6e	4		
					1								
	426	Reboxetine	05/09/91	17/10/91	43	8	8	100.0	100.0		4	4	
					43								
	429	Imipramine	26/09/91	28/09/91	3	100	100	100.0	100.0		50	50	
			29/09/91	29/09/91	1	150	150	100.0	100.0		50	100	
					4								
	451	Imipramine	28/11/91	30/11/91	3	100	100	100.0	100.0		50	50	
			01/12/91	22/12/91	22	150	150	100.0	100.0		50	100	
			23/12/91	23/12/91	1	150	50	100.0	100.0	5e	50		
			24/12/91	07/01/92	15	150	150	100.0	100.0		50	100	
					41								
	452	Reboxetine	28/11/91	09/01/92	43	8	8	100.0	100.0		4	4	
					43								
14/2	136	Imipramine	15/01/92	17/01/92	3	100	100	100.0	100.0		50	50	
			18/01/92	25/02/92	39	150	150	100.0	100.0		50	100	
					42								
	456	Imipramine	15/04/92	17/04/92	3	100	100	100.0	100.0		50	50	
			18/04/92	05/05/92	18	150	150	100.0	100.0		50	100	
			06/05/92	26/05/92	21	200	200	100.0	100.0		100	100	
					42								
14/3	417	Reboxetine	14/06/91	15/07/91	32	8	8	100.0	100.0		4	4	
			16/07/91	18/07/91	3	8	4	50.0	95.7	1e	4		
			19/07/91	26/07/91	8	10	10	100.0	96.5		4	6	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					43								
14/3	418	Imipramine	18/06/91	20/06/91	3	100	100	100.0	100.0		50	50	
			21/06/91	08/07/91	18	150	150	100.0	100.0		50	100	
			09/07/91	29/07/91	21	200	200	100.0	100.0		100	100	
					42								
	419	Reboxetine	05/07/91	15/08/91	42	8	8	100.0	100.0		4	4	
					42								
	420	Imipramine	05/07/91	07/07/91	3	100	100	100.0	100.0		50	50	
			08/07/91	25/07/91	18	150	150	100.0	100.0		50	100	
					21								
	421	Reboxetine	19/07/91	22/08/91	35	8	8	100.0	100.0		4	4	
			23/08/91	29/08/91	7	10	10	100.0	100.0		4	6	
					42								
	427	Imipramine	18/09/91	20/09/91	3	100	100	100.0	100.0		50	50	
			21/09/91	08/10/91	18	150	150	100.0	100.0		50	100	
			09/10/91	15/10/91	7	200	200	100.0	100.0		100	100	
					28								
	428	Imipramine	25/10/91	27/10/91	3	100	100	100.0	100.0		50	50	
			28/10/91	08/11/91	12	150	150	100.0	100.0		50	100	
			09/11/91	09/11/91	1	150	100	66.7	97.9	1m		100	
			10/11/91	14/11/91	5	150	150	100.0	98.4		50	100	
			15/11/91	20/11/91	6	200	200	100.0	98.8		100	100	
			21/11/91	21/11/91	1	200	100	50.0	97.0	1m		100	
			22/11/91	05/12/91	14	200	200	100.0	98.0		100	100	
					42								
14/4	131	Imipramine	14/01/92	16/01/92	3	100	100	100.0	100.0		50	50	
			17/01/92	24/02/92	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14/4	132	Imipramine	14/01/92	16/01/92	3	100	100	100.0	100.0		50	50	
			17/01/92	24/02/92	39	150	150	100.0	100.0		50	100	
					42								
	133	Imipramine	16/01/92	18/01/92	3	100	100	100.0	100.0		50	50	
			19/01/92	22/01/92	4	150	150	100.0	100.0		50	100	
			23/01/92	23/01/92	1	150	200	100.0	100.0		100	100	(B - m)
			24/01/92	26/02/92	34	150	150	100.0	100.0		50	100	
					42								
	134	Reboxetine	16/01/92	26/02/92	42	8	8	100.0	100.0		4	4	
					42								
	135	Reboxetine	17/01/92	27/02/92	42	8	8	100.0	100.0		4	4	
					42								
14/7	422	Imipramine	04/09/91	06/09/91	3	100	100	100.0	100.0		50	50	
			07/09/91	15/10/91	39	150	150	100.0	100.0		50	100	
					42								
	423	Imipramine	17/09/91	19/09/91	3	100	100	100.0	100.0		50	50	
			20/09/91	28/10/91	39	150	150	100.0	100.0		50	100	
					42								
	424	Reboxetine	19/09/91	30/10/91	42	8	8	100.0	100.0		4	4	
					42								
	430	Reboxetine	07/10/91	17/11/91	42	8	8	100.0	100.0		4	4	
					42								
	431	Reboxetine	08/10/91	28/10/91	21	8	8	100.0	100.0		4	4	
			29/10/91	18/11/91	21	10	10	100.0	100.0		4	6	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14/7	432	Imipramine	08/10/91	10/10/91	3	100	100	100.0	100.0		50	50	
			11/10/91	18/11/91	39	150	150	100.0	100.0		50	100	
					42								
	433	Imipramine	08/10/91	10/10/91	3	100	100	100.0	100.0		50	50	
			11/10/91	18/11/91	39	150	150	100.0	100.0		50	100	
					42								
	434	Reboxetine	14/10/91	24/11/91	42	8	8	100.0	100.0		4	4	
					42								
	439	Reboxetine	11/11/91	22/12/91	42	8	8	100.0	100.0		4	4	
					42								
	440	Imipramine	11/11/91	13/11/91	3	100	100	100.0	100.0		50	50	
			14/11/91	22/12/91	39	150	150	100.0	100.0		50	100	
					42								
	441	Imipramine	11/11/91	13/11/91	3	100	100	100.0	100.0		50	50	
			14/11/91	22/12/91	39	150	150	100.0	100.0		50	100	
					42								
	442	Imipramine	11/11/91	13/11/91	3	100	100	100.0	100.0		50	50	
			14/11/91	22/12/91	39	150	150	100.0	100.0		50	100	
					42								
	449	Reboxetine	20/12/91	30/01/92	42	8	8	100.0	100.0		4	4	
					42								
	450	Imipramine	23/12/91	25/12/91	3	100	100	100.0	100.0		50	50	
			26/12/91	02/02/92	39	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14/8	130	Reboxetine	10/01/92	20/02/92	42	8	8	100.0	100.0		4	4	
					42								
	425	Reboxetine	09/09/91	20/10/91	42	8	8	100.0	100.0		4	4	
					42								
	467	Reboxetine	06/07/92	16/08/92	42	8	8	100.0	100.0		4	4	
					42								
14/10	53	Reboxetine	25/02/92	11/03/92	16	8	8	100.0	100.0		4	4	
			12/03/92	12/03/92	1	8	4	50.0	97.1	1m		4	
			13/03/92	25/03/92	13	8	8	100.0	98.3		4	4	
			26/03/92	26/03/92	1	8	4	50.0	96.8	1m		4	
			27/03/92	06/04/92	11	8	8	100.0	97.6		4	4	
					42								
	54	Imipramine	26/02/92	26/02/92	1	100	50	50.0	50.0	1e	50		
			27/02/92	28/02/92	2	100	100	100.0	83.3		50	50	
			29/02/92	17/03/92	18	150	150	100.0	97.6		50	100	
			18/03/92	07/04/92	21	200	200	100.0	98.8		100	100	
					42								
	55	Reboxetine	28/02/92	03/03/92	5	8	8	100.0	100.0		4	4	
			04/03/92	04/03/92	1	8	4	50.0	91.7	1e	4		
			05/03/92	12/03/92	8	8	8	100.0	96.4		4	4	
			13/03/92	13/03/92	1	8	4	50.0	93.3	1e	4		
			14/03/92	04/04/92	22	8	8	100.0	97.3		4	4	
			05/04/92	05/04/92	1	8	4	50.0	96.1	1e	4		
			06/04/92	09/04/92	4	8	8	100.0	96.4		4	4	
					42								
	56	Imipramine	03/03/92	05/03/92	3	100	100	100.0	100.0		50	50	
			06/03/92	20/03/92	15	150	150	100.0	100.0		50	100	
			21/03/92	21/03/92	1	150	100	66.7	98.2	1m		100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
14/10	56	Imipramine	22/03/92	07/04/92	17	150	150	100.0	99.1		50	100	
			08/04/92	08/04/92	1	150	100	66.7	98.2	1m		100	
			09/04/92	13/04/92	5	150	150	100.0	98.4		50	100	
					42								
	57	Reboxetine	04/03/92	24/03/92	21	8	8	100.0	100.0		4	4	
			25/03/92	31/03/92	7	10	10	100.0	100.0		4	6	
			01/04/92	01/04/92	1	8	8	100.0	100.0		4	4	
			02/04/92	02/04/92	1	8	4	50.0	98.3	1e	4		
			03/04/92	07/04/92	5	8	8	100.0	98.6		4	4	
			08/04/92	14/04/92	7	10	10	100.0	98.8		4	6	
					42								
	58	Imipramine	14/04/92	16/04/92	3	100	100	100.0	100.0		50	50	
			17/04/92	04/05/92	18	150	150	100.0	100.0		50	100	
			05/05/92	07/05/92	3	200	200	100.0	100.0		100	100	
			08/05/92	08/05/92	1	200	100	50.0	98.0	1e	100		
			09/05/92	25/05/92	17	200	200	100.0	98.8		100	100	
					42								
	59	Imipramine	24/04/92	26/04/92	3	100	100	100.0	100.0		50	50	
			27/04/92	13/05/92	17	150	150	100.0	100.0		50	100	
			14/05/92	14/05/92	1	150	50	33.3	96.8	1e	50		
			15/05/92	04/06/92	21	150	150	100.0	98.4		50	100	
					42								
	60	Reboxetine	13/05/92	27/05/92	15	8	8	100.0	100.0		4	4	
			28/05/92	28/05/92	1	8	4	50.0	96.9	1m		4	
			29/05/92	23/06/92	26	8	8	100.0	98.8		4	4	
					42								
	137	Reboxetine	28/01/92	06/02/92	10	8	8	100.0	100.0		4	4	
			07/02/92	07/02/92	1	8	4	50.0	95.5	1m		4	
			08/02/92	18/02/92	11	8	8	100.0	97.7		4	4	
			19/02/92	19/02/92	1	8	4	50.0	95.7	1e	4		
			20/02/92	06/03/92	16	8	8	100.0	97.4		4	4	
			07/03/92	07/03/92	1	8	4	50.0	96.3	1m		4	
			08/03/92	09/03/92	2	8	8	100.0	96.4		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14/10	138	Imipramine	29/01/92	31/01/92	3	100	100	100.0	100.0		50	50	
			01/02/92	07/02/92	7	150	150	100.0	100.0		50	100	
			08/02/92	08/02/92	1	150	50	33.3	93.9	1e	50		
			09/02/92	18/02/92	10	150	150	100.0	96.8		50	100	
			19/02/92	21/02/92	3	200	200	100.0	97.2		100	100	
			22/02/92	22/02/92	1	200	100	50.0	95.3	1e	100		
			23/02/92	04/03/92	11	200	200	100.0	96.8		100	100	
			05/03/92	05/03/92	1	200	100	50.0	95.5	1e	100		
			06/03/92	10/03/92	5	200	200	100.0	96.0		100	100	
					42								
	139	Reboxetine	04/02/92	06/02/92	3	8	8	100.0	100.0		4	4	
			07/02/92	07/02/92	1	8	4	50.0	87.5	1m		4	
			08/02/92	18/02/92	11	8	8	100.0	96.7		4	4	
			19/02/92	19/02/92	1	8	4	50.0	93.8	1m		4	
			20/02/92	12/03/92	22	8	8	100.0	97.4		4	4	
			13/03/92	13/03/92	1	8	4	50.0	96.2	1m		4	
			14/03/92	16/03/92	3	8	8	100.0	96.4		4	4	
					42								
	140	Imipramine	05/02/92	07/02/92	3	100	100	100.0	100.0		50	50	
			08/02/92	12/02/92	5	150	150	100.0	100.0		50	100	
			13/02/92	13/02/92	1	150	50	33.3	92.6	1e	50		
			14/02/92	25/02/92	12	150	150	100.0	96.8		50	100	
			26/02/92	09/03/92	13	200	200	100.0	98.0		100	100	
			10/03/92	10/03/92	1	200	100	50.0	96.7	1m		100	
			11/03/92	17/03/92	7	200	200	100.0	97.2		100	100	
					42								
	435	Imipramine	12/11/91	14/11/91	3	100	100	100.0	100.0		50	50	
			15/11/91	18/12/91	34	150	150	100.0	100.0		50	100	
			19/12/91	19/12/91	1	150	100	66.7	99.1	1m		100	
			20/12/91	23/12/91	4	150	150	100.0	99.2		50	100	
					42								
	436	Reboxetine	13/11/91	28/11/91	16	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
14/10	436	Reboxetine	29/11/91	29/11/91	1	8	4	50.0	97.1	1e	4		
			30/11/91	18/12/91	19	8	8	100.0	98.6		4	4	
			19/12/91	19/12/91	1	8	4	50.0	97.3	1m		4	
			20/12/91	20/12/91	1	8	8	100.0	97.4		4	4	
			21/12/91	21/12/91	1	8	4	50.0	96.2	1e	4		
			22/12/91	23/12/91	2	8	8	100.0	96.3		4	4	
					41								
	437	Reboxetine	14/11/91	20/11/91	7	8	8	100.0	100.0		4	4	
			21/11/91	21/11/91	1	8	4	50.0	93.8	1e	4		
			22/11/91	08/12/91	17	8	8	100.0	98.0		4	4	
			09/12/91	09/12/91	1	8	4	50.0	96.2	1m		4	
			10/12/91	23/12/91	14	8	8	100.0	97.5		4	4	
					40								
	438	Imipramine	15/11/91	17/11/91	3	100	100	100.0	100.0		50	50	
			18/11/91	02/12/91	15	150	150	100.0	100.0		50	100	
			03/12/91	03/12/91	1	150	100	66.7	98.2	1m		100	
			04/12/91	14/12/91	11	150	150	100.0	98.9		50	100	
			15/12/91	15/12/91	1	150	50	33.3	96.8	1e	50		
			16/12/91	27/12/91	12	150	150	100.0	97.7		50	100	
					43								
	443	Reboxetine	19/11/91	04/12/91	16	8	8	100.0	100.0		4	4	
			05/12/91	05/12/91	1	8	4	50.0	97.1	1m		4	
			06/12/91	17/12/91	12	8	8	100.0	98.3		4	4	
			18/12/91	18/12/91	1	8	4	50.0	96.7	1m		4	
			19/12/91	19/12/91	1	8	8	100.0	96.8		4	4	
			20/12/91	20/12/91	1	8	4	50.0	95.3	1e	4		
			21/12/91	24/12/91	4	8	8	100.0	95.8		4	4	
			25/12/91	25/12/91	1	8	4	50.0	94.6	1e	4		
			26/12/91	30/12/91	5	8	8	100.0	95.2		4	4	
					42								
	444	Reboxetine	16/11/91	06/12/91	21	8	8	100.0	100.0		4	4	
			07/12/91	21/12/91	15	10	10	100.0	100.0		4	6	
			22/12/91	22/12/91	1	10	6	60.0	98.9	1m		6	
			23/12/91	27/12/91	5	10	10	100.0	99.0		4	6	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
					42								
14/10	445	Imipramine	20/11/91	22/11/91	3	100	100	100.0	100.0		50	50	
			23/11/91	27/11/91	5	150	150	100.0	100.0		50	100	
			28/11/91	28/11/91	1	150	50	33.3	92.6	1e	50		
			29/11/91	10/12/91	12	150	150	100.0	96.8		50	100	
			11/12/91	12/12/91	2	200	200	100.0	97.1		100	100	
			13/12/91	13/12/91	1	200	100	50.0	95.1	1e	100		
			14/12/91	27/12/91	14	200	200	100.0	96.9		100	100	
			28/12/91	28/12/91	1	200	100	50.0	95.7	1m		100	
			29/12/91	30/12/91	2	200	200	100.0	95.9		100	100	
					41								
	446	Reboxetine	26/11/91	27/11/91	2	8	8	100.0	100.0		4	4	
			28/11/91	28/11/91	1	8	4	50.0	83.3	1m		4	
			29/11/91	12/12/91	14	8	8	100.0	97.1		4	4	
			13/12/91	13/12/91	1	8	4	50.0	94.4	1e	4		
			14/12/91	24/12/91	11	8	8	100.0	96.6		4	4	
			25/12/91	25/12/91	1	8	4	50.0	95.0	1e	4		
			26/12/91	07/01/92	13	8	8	100.0	96.5		4	4	
					43								
	447	Reboxetine	27/11/91	08/12/91	12	8	8	100.0	100.0		4	4	
			09/12/91	09/12/91	1	8	4	50.0	96.2	1m		4	
			10/12/91	17/12/91	8	8	8	100.0	97.6		4	4	
			18/12/91	28/12/91	11	10	10	100.0	98.4		4	6	
			29/12/91	29/12/91	1	10	6	60.0	97.3	1m		6	
			30/12/91	07/01/92	9	10	10	100.0	97.9		4	6	
					42								
	448	Imipramine	28/11/91	30/11/91	3	100	100	100.0	100.0		50	50	
			01/12/91	17/12/91	17	150	150	100.0	100.0		50	100	
			18/12/91	07/01/92	21	200	200	100.0	100.0		100	100	
					41								
	453	Imipramine	28/05/92	30/05/92	3	100	100	100.0	100.0		50	50	
			31/05/92	11/06/92	12	150	150	100.0	100.0		50	100	
			12/06/92	12/06/92	1	150	50	33.3	95.8	4e	50		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
14/10	453	Imipramine	13/06/92	08/07/92	26	150	150	100.0	98.4		50	100	
					42								
	454	Reboxetine	12/06/92	02/07/92	21	8	8	100.0	100.0		4	4	
			03/07/92	04/07/92	2	10	10	100.0	100.0		4	6	
			05/07/92	05/07/92	1	10	4	40.0	97.5	1e	4		
			06/07/92	23/07/92	18	10	10	100.0	98.6		4	6	
					42								
	455	Reboxetine	20/06/92	31/07/92	42	8	8	100.0	100.0		4	4	
					42								
15	349	Imipramine	20/08/92	20/08/92	1	100	50	100.0	100.0	9m		50	
			21/08/92	22/08/92	2	100	100	100.0	100.0		50	50	
			23/08/92	30/09/92	39	150	150	100.0	100.0		50	100	
			01/10/92	01/10/92	1	150	50	100.0	100.0	9e	50		
					43								
	351	Reboxetine	02/09/92	02/09/92	1	8	4	100.0	100.0	9m		4	
			03/09/92	13/10/92	41	8	8	100.0	100.0		4	4	
			14/10/92	14/10/92	1	8	4	100.0	100.0	9e	4		
					43								
	352	Imipramine	06/08/92	08/08/92	3	100	100	100.0	100.0		50	50	
			09/08/92	26/08/92	18	150	150	100.0	100.0		50	100	
			27/08/92	27/08/92	1	150	50	100.0	100.0	6e	50		
					22								
	364	Imipramine	29/07/92	29/07/92	1	100	50	100.0	100.0	9m		50	
			30/07/92	31/07/92	2	100	100	100.0	100.0		50	50	
			01/08/92	25/08/92	25	150	150	100.0	100.0		50	100	
			26/08/92	26/08/92	1	150	50	100.0	100.0	9e	50		
					29								
	366	Reboxetine	27/08/92	27/08/92	1	8	4	100.0	100.0	9m		4	
			28/08/92	07/10/92	41	8	8	100.0	100.0		4	4	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

746

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
15	366	Reboxetine	08/10/92	08/10/92	1	8	4	100.0	100.0	9e	4		
					43								
	367	Imipramine	31/08/92	02/09/92	3	100	100	100.0	100.0		50	50	
			03/09/92	11/10/92	39	150	150	100.0	100.0		50	100	
					42								
	368	Reboxetine	04/09/92	01/10/92	28	8	8	100.0	100.0		4	4	
			02/10/92	15/10/92	14	10	10	100.0	100.0		4	6	
					42								
	369	Reboxetine	10/07/92	20/08/92	42	8	8	100.0	100.0		4	4	
					42								
	370	Imipramine	16/07/92	16/07/92	1	100	50	100.0	100.0	9m		50	
			17/07/92	18/07/92	2	100	100	100.0	100.0		50	50	
			19/07/92	04/08/92	17	150	150	100.0	100.0		50	100	
			05/08/92	05/08/92	1	150	250	100.0	100.0		50	200	(B - e)
			06/08/92	06/08/92	1	150	300	100.0	100.0		100	200	(B - m) (3 - e)
			07/08/92	09/08/92	3	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			10/08/92	10/08/92	1	150	250	100.0	100.0		150	100	(3 - m)
			11/08/92	26/08/92	16	150	150	100.0	100.0		50	100	
			27/08/92	27/08/92	1	150	50	100.0	100.0	9e	50		
					43								
	371	Reboxetine	20/07/92	26/07/92	7	8	8	100.0	100.0		4	4	
			27/07/92	27/07/92	1	8		0.0	87.5	4m 4e			
			28/07/92	10/08/92	14	8	8	100.0	95.5		4	4	
			11/08/92	12/08/92	2	8		0.0	87.5	1m 1e			
			13/08/92	13/08/92	1	8	10	100.0	88.0	1m		10	(3 - e)
			14/08/92	30/08/92	17	8	18	100.0	92.9		8	10	(3 - m) (3 - e)
			31/08/92	31/08/92	1	8	8	100.0	93.0	9e	8		(3 - m)
					43								
	372	Imipramine	17/06/92	17/06/92	1	100	50	100.0	100.0	9m		50	
			18/06/92	19/06/92	2	100	100	100.0	100.0		50	50	
			20/06/92	15/07/92	26	150	150	100.0	100.0		50	100	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
15	372	Imipramine	16/07/92	16/07/92	1	150	250	100.0	100.0		50	200	(3 - e)
			17/07/92	21/07/92	5	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			22/07/92	22/07/92	1	150	250	100.0	100.0		150	100	(3 - m)
			23/07/92	28/07/92	6	150	150	100.0	100.0		50	100	
			29/07/92	29/07/92	1	150	50	100.0	100.0	9e	50		
					43								
	373	Imipramine	25/06/92	25/06/92	1	100	50	100.0	100.0	9m		50	
			26/06/92	26/06/92	1	100	50	100.0	100.0	6e	50		
					2								
	374	Reboxetine	09/04/92	20/05/92	42	8	8	100.0	100.0		4	4	
					42								
	375	Reboxetine	06/06/92	25/06/92	20	8	8	100.0	100.0		4	4	
					20								
	376	Imipramine	13/04/92	15/04/92	3	100	100	100.0	100.0		50	50	
			16/04/92	20/04/92	5	150	150	100.0	100.0		50	100	
			21/04/92	21/04/92	1	150	50	100.0	100.0	6e	50		
					9								
	377	Reboxetine	13/05/92	13/05/92	1	8	4	100.0	100.0	9m		4	
			14/05/92	02/06/92	20	8	8	100.0	100.0		4	4	
			03/06/92	03/06/92	1	8	4	100.0	100.0	9e	4		
			04/06/92	04/06/92	1	8	4	100.0	100.0	9m		4	
			05/06/92	24/06/92	20	8	8	100.0	100.0		4	4	
			25/06/92	25/06/92	1	8	4	100.0	100.0	9e	4		
					44								
	378	Reboxetine	15/06/92	15/06/92	1	8	4	100.0	100.0	9m		4	
			16/06/92	26/07/92	41	8	8	100.0	100.0		4	4	
			27/07/92	27/07/92	1	8	4	100.0	100.0	9e	4		
					43								
	379	Imipramine	16/04/92	16/04/92	1	100	100	100.0	100.0		50	50	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
15	379	Imipramine	17/04/92	17/04/92	1	100	50	100.0	100.0	6e	50		
					2								
	380	Imipramine	30/06/92	02/07/92	3	100	100	100.0	100.0		50	50	
			03/07/92	19/07/92	17	150	150	100.0	100.0		50	100	
			20/07/92	28/07/92	9	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			29/07/92	29/07/92	1	150	250	100.0	100.0		150	100	(3 - m)
			30/07/92	10/08/92	12	150	150	100.0	100.0		50	100	
					42								
	381	Reboxetine	21/05/92	01/07/92	42	8	8	100.0	100.0		4	4	
					42								
	382	Imipramine	09/04/92	09/04/92	1	100	50	100.0	100.0	9m		50	
			10/04/92	10/04/92	1	100	50	100.0	100.0	6e	50		
					2								
	383	Imipramine	07/07/92	07/07/92	1	100	50	100.0	100.0	9m		50	
			08/07/92	09/07/92	2	100	100	100.0	100.0		50	50	
			10/07/92	20/07/92	11	150	150	100.0	100.0		50	100	
			21/07/92	21/07/92	1	150	250	100.0	100.0		50	200	(3 - e)
			22/07/92	27/07/92	6	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			28/07/92	28/07/92	1	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			29/07/92	03/08/92	6	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			04/08/92	04/08/92	1	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			05/08/92	10/08/92	6	150	350	100.0	100.0		150	200	(3 - m) (3 - e)
			11/08/92	11/08/92	1	150	250	100.0	100.0		150	100	(3 - m)
			12/08/92	17/08/92	6	150	150	100.0	100.0		50	100	
			18/08/92	18/08/92	1	150	50	100.0	100.0	9e	50		
					43								
	384	Reboxetine	28/07/92	28/07/92	1	8	4	100.0	100.0	9m		4	
			29/07/92	04/08/92	7	8	8	100.0	100.0		4	4	
			05/08/92	05/08/92	1	8	4	100.0	100.0	6e	4		
					9								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient,
5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening,
10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose,
C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
1	1	Reboxetine	05/02/91	1	1	Reboxetine	1	
	1	Reboxetine	26/02/91	2	2	Reboxetine	1	
	1	Imipramine	16/04/91	3	3	Imipramine	1	
	1	Imipramine	17/04/91	4	4	Imipramine	1	
	2	Reboxetine	17/07/91	5	5	Reboxetine	2	
	2	Imipramine	07/08/91	6	6	Imipramine	2	
	2	Reboxetine	09/10/91	7	7	Reboxetine	2	
	2	Imipramine	29/10/91	8	8	Imipramine	2	
	3	Imipramine	08/11/91	9	9	Imipramine	3	
	3	Imipramine	19/11/91	10	10	Imipramine	3	
	3	Reboxetine	06/04/92	11	11	Reboxetine	3	
	3	Reboxetine	15/04/92	12	12	Reboxetine	3	
2	1	Reboxetine	19/12/90	33	33	Reboxetine	1	
	1	Imipramine	28/12/90	34	34	Imipramine	1	
	1	Reboxetine	28/12/90	35	35	Reboxetine	1	
	1	Imipramine	10/01/91	36	36	Imipramine	1	
	2	Reboxetine	18/01/91	37	37	Reboxetine	2	
	2	Imipramine	25/01/91	38	38	Imipramine	2	
	2	Reboxetine	25/01/91	39	39	Reboxetine	2	
	3	Reboxetine	05/02/91	41	40	Imipramine	2	*
	3	Imipramine	09/02/91	42	41	Reboxetine	3	*
	2	Imipramine	20/02/91	40	42	Imipramine	3	
	3	Reboxetine	26/03/91	43	43	Reboxetine	3	
	3	Imipramine	11/04/91	44	44	Imipramine	3	
	4	Imipramine	30/04/91	45	45	Imipramine	4	
	4	Reboxetine	16/05/91	46	46	Reboxetine	4	
	4	Reboxetine	22/05/91	47	47	Reboxetine	4	
	4	Imipramine	27/08/91	48	48	Imipramine	4	
	5	Imipramine	29/08/91	49	49	Imipramine	5	
	5	Reboxetine	06/11/91	50	50	Reboxetine	5	
	5	Reboxetine	06/11/91	51	51	Reboxetine	5	
	5	Imipramine	27/11/91	52	52	Imipramine	5	
3	1	Imipramine	01/03/91	69	69	Imipramine	1	
	2	Reboxetine	02/04/91	65	70	Reboxetine	1	
	2	Reboxetine	10/04/91	67	71	Imipramine	1	*
	2	Imipramine	01/05/91	66	72	Reboxetine	1	*
	2	Imipramine	03/08/91	68	65	Reboxetine	2	*
	1	Reboxetine	23/10/91	70	66	Imipramine	2	*
	1	Imipramine	14/11/91	71	67	Reboxetine	2	*
	1	Reboxetine	31/01/92	72	68	Imipramine	2	*
	3	Reboxetine	15/02/92	73	73	Reboxetine	3	
4	1	Imipramine	06/05/91	101	101	Imipramine	1	
	2	Imipramine	07/05/92	97	102	Reboxetine	1	*

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
4	2	Reboxetine	07/05/92	100	103	Imipramine	1	*
6	1	Reboxetine	29/03/91	161	161	Reboxetine	1	
	1	Reboxetine	05/11/91	162	162	Reboxetine	1	
7	1	Imipramine	19/03/91	196	193	Reboxetine	1	*
	1	Reboxetine	03/06/91	194	194	Reboxetine	1	
	1	Reboxetine	11/06/91	193	195	Imipramine	1	*
8	1	Imipramine	22/03/91	225	225	Imipramine	1	
	1	Reboxetine	03/05/91	226	226	Reboxetine	1	
	1	Imipramine	07/05/91	227	227	Imipramine	1	
	1	Reboxetine	10/05/91	228	228	Reboxetine	1	
	2	Imipramine	22/10/91	229	229	Imipramine	2	
	2	Imipramine	05/11/91	230	230	Imipramine	2	
	2	Reboxetine	05/11/91	231	231	Reboxetine	2	
	2	Reboxetine	29/11/91	232	232	Reboxetine	2	
9	1	Reboxetine	17/07/91	257	257	Reboxetine	1	
	1	Reboxetine	17/07/91	258	258	Reboxetine	1	
	1	Imipramine	17/07/91	259	259	Imipramine	1	
	2	Imipramine	23/07/91	261	260	Imipramine	1	
	2	Reboxetine	23/07/91	262	261	Imipramine	2	*
	1	Imipramine	24/07/91	260	262	Reboxetine	2	*
	2	Reboxetine	31/07/91	263	263	Reboxetine	2	
	2	Imipramine	31/07/91	264	264	Imipramine	2	
	3	Reboxetine	23/08/91	265	265	Reboxetine	3	
	3	Imipramine	02/09/91	267	266	Reboxetine	3	*
	3	Reboxetine	18/09/91	266	267	Imipramine	3	*
	3	Imipramine	25/09/91	268	268	Imipramine	3	
	4	Reboxetine	25/09/91	269	269	Reboxetine	4	
	4	Imipramine	11/10/91	270	270	Imipramine	4	
	4	Reboxetine	30/10/91	271	271	Reboxetine	4	
	4	Imipramine	30/10/91	272	272	Imipramine	4	
	5	Imipramine	30/10/91	273	273	Imipramine	5	
	5	Reboxetine	31/10/91	274	274	Reboxetine	5	
	5	Reboxetine	06/11/91	275	275	Reboxetine	5	
	5	Imipramine	14/01/92	276	276	Imipramine	5	
	6	Reboxetine	15/01/92	203	201	Imipramine	6	*
	6	Imipramine	16/01/92	201	202	Imipramine	6	
	6	Imipramine	17/01/92	202	203	Reboxetine	6	*
	6	Reboxetine	17/01/92	204	204	Reboxetine	6	
	7	Imipramine	05/02/92	205	205	Imipramine	7	
	7	Imipramine	05/02/92	206	206	Imipramine	7	
	7	Reboxetine	06/02/92	207	207	Reboxetine	7	

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given				Randomized			Error
	Sequen. block	Treatment	Start treat. date	Patient	Patient	Treatment	Sequen. block	(*)
9	8	Imipramine	12/02/92	209	208	Reboxetine	7	*
	8	Reboxetine	14/02/92	211	209	Imipramine	8	*
	7	Reboxetine	15/02/92	208	210	Reboxetine	8	
	8	Reboxetine	20/02/92	210	211	Reboxetine	8	
	8	Imipramine	04/03/92	212	212	Imipramine	8	
	9	Reboxetine	07/03/92	197	197	Reboxetine	9	
	9	Imipramine	18/03/92	198	198	Imipramine	9	
	9	Imipramine	02/04/92	199	199	Imipramine	9	
	10	Reboxetine	23/04/92	237	200	Reboxetine	9	
	9	Reboxetine	28/04/92	200	237	Reboxetine	10	
	10	Reboxetine	28/04/92	240	238	Imipramine	10	*
	10	Imipramine	30/04/92	239	239	Imipramine	10	
	11	Reboxetine	07/05/92	242	240	Reboxetine	10	
	11	Imipramine	09/05/92	241	241	Imipramine	11	
	11	Imipramine	18/05/92	243	242	Reboxetine	11	*
	10	Imipramine	20/05/92	238	243	Imipramine	11	
	11	Reboxetine	06/06/92	244	244	Reboxetine	11	
	5	Reboxetine	13/05/92	274/A	274	Reboxetine	5	
	5	Imipramine	04/03/92	276/A	276	Imipramine	5	
9/A	1	Imipramine	05/03/92	301	301	Imipramine	1	
	1	Imipramine	06/03/92	302	302	Imipramine	1	
	1	Reboxetine	12/03/92	303	303	Reboxetine	1	
	1	Reboxetine	26/03/92	304	304	Reboxetine	1	
	2	Reboxetine	31/03/92	305	305	Reboxetine	2	
	2	Reboxetine	29/04/92	306	306	Reboxetine	2	
	2	Imipramine	05/05/92	307	307	Imipramine	2	
	2	Imipramine	09/05/92	308	308	Imipramine	2	
	3	Imipramine	14/05/92	233	233	Imipramine	3	
	3	Reboxetine	22/05/92	234	234	Reboxetine	3	
	3	Reboxetine	26/05/92	235	235	Reboxetine	3	
	3	Imipramine	27/05/92	236	236	Imipramine	3	
	4	Reboxetine	10/06/92	277	277	Reboxetine	4	
	4	Imipramine	13/06/92	278	278	Imipramine	4	
	4	Imipramine	07/08/92	279	279	Imipramine	4	
	4	Reboxetine	08/08/92	280	280	Reboxetine	4	
	5	Reboxetine	01/09/92	281	281	Reboxetine	5	
	5	Reboxetine	02/09/92	282	282	Reboxetine	5	
	5	Imipramine	16/09/92	283	283	Imipramine	5	
	5	Imipramine	19/09/92	284	284	Imipramine	5	
10	1	Imipramine	21/09/91	289	289	Imipramine	1	
	1	Reboxetine	14/10/91	290	290	Reboxetine	1	
	1	Reboxetine	13/12/91	292	291	Imipramine	1	*
	2	Reboxetine	24/12/91	293	292	Reboxetine	1	
	2	Imipramine	03/01/92	294	293	Reboxetine	2	*
	2	Imipramine	07/01/92	295	294	Imipramine	2	

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
. Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
10	1	Imipramine	17/02/92	291	295	Imipramine	2	
	2	Reboxetine	20/02/92	296	296	Reboxetine	2	
	3	Reboxetine	21/03/92	297	297	Reboxetine	3	
	3	Reboxetine	27/03/92	298	298	Reboxetine	3	
	3	Imipramine	07/04/92	299	299	Imipramine	3	
	3	Imipramine	14/04/92	300	300	Imipramine	3	
11	1	Reboxetine	11/06/92	321	321	Reboxetine	1	
	1	Reboxetine	11/06/92	322	322	Reboxetine	1	
	1	Imipramine	24/06/92	323	323	Imipramine	1	
	1	Imipramine	17/07/92	324	324	Imipramine	1	
	2	Reboxetine	30/07/92	325	325	Reboxetine	2	
	2	Imipramine	30/07/92	326	326	Imipramine	2	
	2	Reboxetine	20/08/92	327	327	Reboxetine	2	
	2	Imipramine	20/08/92	328	328	Imipramine	2	
	3	Imipramine	21/08/92	329	329	Imipramine	3	
	3	Reboxetine	24/08/92	330	330	Reboxetine	3	
	3	Reboxetine	03/09/92	331	331	Reboxetine	3	
	4	Imipramine	04/09/92	333	332	Imipramine	3	
	3	Imipramine	05/09/92	332	333	Imipramine	4	
12	1	Imipramine	26/05/92	337	337	Imipramine	1	
	1	Reboxetine	20/06/92	338	338	Reboxetine	1	
	1	Imipramine	23/06/92	339	339	Imipramine	1	
	1	Reboxetine	07/08/92	340	340	Reboxetine	1	
	2	Reboxetine	21/08/92	341	341	Reboxetine	2	
13	1	Reboxetine	05/06/92	353	353	Reboxetine	1	
	1	Imipramine	24/06/92	354	354	Imipramine	1	
	1	Reboxetine	25/06/92	355	355	Reboxetine	1	
	1	Imipramine	22/07/92	356	356	Imipramine	1	
	2	Imipramine	05/08/92	357	357	Imipramine	2	
	2	Reboxetine	06/08/92	358	358	Reboxetine	2	
	2	Reboxetine	19/08/92	359	359	Reboxetine	2	
	2	Imipramine	19/08/92	360	360	Imipramine	2	
	3	Reboxetine	26/08/92	361	361	Reboxetine	3	
14	1	Reboxetine	07/07/92	457	457	Reboxetine	1	
	1	Imipramine	14/07/92	458	458	Imipramine	1	
	1	Reboxetine	16/07/92	459	459	Reboxetine	1	
	1	Imipramine	23/07/92	460	460	Imipramine	1	
	2	Imipramine	29/07/92	461	461	Imipramine	2	
	2	Reboxetine	31/07/92	462	462	Reboxetine	2	
	2	Imipramine	03/08/92	463	463	Imipramine	2	
	2	Reboxetine	05/08/92	464	464	Reboxetine	2	

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given: Sequen. block	Given: Treatment	Given: Start treat. date	Given: Patient	Randomized: Patient	Randomized: Treatment	Randomized: Sequen. block	Error (*)
14	3	Reboxetine	06/08/92	465	465	Reboxetine	3	
	3	Imipramine	07/08/92	466	466	Imipramine	3	
14/1	1	Reboxetine	05/09/91	426	426	Reboxetine	1	
	2	Imipramine	26/09/91	429	427	Imipramine	1	
	3	Imipramine	28/11/91	451	428	Imipramine	1	
	3	Reboxetine	28/11/91	452	429	Imipramine	2	*
	4	Reboxetine	19/12/91	129	430	Reboxetine	2	
14/2	1	Imipramine	15/01/92	136	136	Imipramine	1	
	2	Imipramine	15/04/92	456	456	Imipramine	2	
14/3	1	Reboxetine	14/06/91	417	417	Reboxetine	1	
	1	Imipramine	18/06/91	418	418	Imipramine	1	
	1	Reboxetine	05/07/91	419	419	Reboxetine	1	
	1	Imipramine	05/07/91	420	420	Imipramine	1	
	2	Reboxetine	19/07/91	421	421	Reboxetine	2	
	3	Imipramine	18/09/91	427	422	Imipramine	2	
	3	Imipramine	25/10/91	428	423	Imipramine	2	
14/4	1	Imipramine	14/01/92	131	131	Imipramine	1	
	1	Imipramine	14/01/92	132	132	Imipramine	1	
	2	Imipramine	16/01/92	133	133	Imipramine	2	
	2	Reboxetine	16/01/92	134	134	Reboxetine	2	
	2	Reboxetine	17/01/92	135	135	Reboxetine	2	
14/7	1	Imipramine	04/09/91	422	422	Imipramine	1	
	1	Imipramine	17/09/91	423	423	Imipramine	1	
	1	Reboxetine	19/09/91	424	424	Reboxetine	1	
	2	Reboxetine	07/10/91	430	430	Reboxetine	2	
	2	Reboxetine	08/10/91	431	431	Reboxetine	2	
	2	Imipramine	08/10/91	432	432	Imipramine	2	
	3	Imipramine	08/10/91	433	433	Imipramine	3	
	3	Reboxetine	14/10/91	434	434	Reboxetine	3	
	4	Reboxetine	11/11/91	439	435	Imipramine	3	*
	4	Imipramine	11/11/91	440	436	Reboxetine	3	*
	5	Imipramine	11/11/91	441	439	Reboxetine	4	*
	5	Imipramine	11/11/91	442	440	Imipramine	4	
	6	Reboxetine	20/12/91	449	441	Imipramine	5	*
	6	Imipramine	23/12/91	450	442	Imipramine	5	
14/8	1	Reboxetine	09/09/91	425	425	Reboxetine	1	
	2	Reboxetine	10/01/92	130	426	Reboxetine	1	

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

	Given				Randomized			Error
Centre	Sequen. block	Treatment	Start treat. date	Patient	Patient	Treatment	Sequen. block	(*)
14/8	3	Reboxetine	06/07/92	467	427	Imipramine	1	*
14/10	1	Imipramine	12/11/91	435	435	Imipramine	1	
	1	Reboxetine	13/11/91	436	436	Reboxetine	1	
	2	Reboxetine	14/11/91	437	437	Reboxetine	2	
	2	Imipramine	15/11/91	438	438	Imipramine	2	
	3	Reboxetine	16/11/91	444	439	Reboxetine	2	
	3	Reboxetine	19/11/91	443	440	Imipramine	2	*
	4	Imipramine	20/11/91	445	443	Reboxetine	3	*
	4	Reboxetine	26/11/91	446	444	Reboxetine	3	
	4	Reboxetine	27/11/91	447	445	Imipramine	4	*
	4	Imipramine	28/11/91	448	446	Reboxetine	4	*
	5	Reboxetine	28/01/92	137	447	Reboxetine	4	
	5	Imipramine	29/01/92	138	448	Imipramine	4	
	5	Reboxetine	04/02/92	139	137	Reboxetine	5	
	5	Imipramine	05/02/92	140	138	Imipramine	5	
	6	Reboxetine	25/02/92	53	139	Reboxetine	5	
	6	Imipramine	26/02/92	54	140	Imipramine	5	
	6	Reboxetine	28/02/92	55	53	Reboxetine	6	
	6	Imipramine	03/03/92	56	54	Imipramine	6	
	7	Reboxetine	04/03/92	57	55	Reboxetine	6	
	7	Imipramine	14/04/92	58	56	Imipramine	6	
	7	Imipramine	24/04/92	59	57	Reboxetine	7	*
	7	Reboxetine	13/05/92	60	58	Imipramine	7	*
	8	Imipramine	28/05/92	453	59	Imipramine	7	
	8	Reboxetine	12/06/92	454	60	Reboxetine	7	
	8	Reboxetine	20/06/92	455	453	Imipramine	8	*
15	1	Reboxetine	09/04/92	374	373	Imipramine	1	*
	2	Imipramine	09/04/92	382	374	Reboxetine	1	*
	1	Imipramine	13/04/92	376	375	Reboxetine	1	*
	3	Imipramine	16/04/92	379	376	Imipramine	1	
	3	Reboxetine	13/05/92	377	381	Reboxetine	2	
	2	Reboxetine	21/05/92	381	382	Imipramine	2	*
	1	Reboxetine	06/06/92	375	383	Imipramine	2	*
	3	Reboxetine	15/06/92	378	384	Reboxetine	2	
	4	Imipramine	17/06/92	372	377	Reboxetine	3	*
	1	Imipramine	25/06/92	373	378	Reboxetine	3	*
	3	Imipramine	30/06/92	380	379	Imipramine	3	
	2	Imipramine	07/07/92	383	380	Imipramine	3	
	4	Reboxetine	10/07/92	369	369	Reboxetine	4	
	4	Imipramine	16/07/92	370	370	Imipramine	4	
	4	Reboxetine	20/07/92	371	371	Reboxetine	4	
	2	Reboxetine	28/07/92	384	372	Imipramine	4	*
	5	Imipramine	29/07/92	364	364	Imipramine	5	
	6	Imipramine	06/08/92	352	349	Imipramine	6	
	6	Imipramine	20/08/92	349	350	Reboxetine	6	*

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 10.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given Sequen. block	Given Treatment	Given Start treat. date	Given Patient	Randomized Patient	Randomized Treatment	Randomized Sequen. block	Error (*)
15	7	Reboxetine	27/08/92	366	351	Reboxetine	6	
	7	Imipramine	31/08/92	367	352	Imipramine	6	
	6	Reboxetine	02/09/92	351	366	Reboxetine	7	
	7	Reboxetine	04/09/92	368	367	Imipramine	7	*

(*) Assigned treatment different from randomized

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
1	1	Male	Day 42	18/03/91	YES			Confirmed irregularities
	2	Female	Day 42	08/04/91	YES			As prescribed
	3	Female	Day 42	27/05/91	YES			As prescribed
	4	Male	Day 42	28/05/91	YES			As prescribed
	5	Female	Day 42	27/08/91	YES			As prescribed
	6	Male	Day 42	17/09/91	YES			As prescribed
	7	Male	Day 42	20/11/91	YES			As prescribed
	8	Male	Day 7	31/10/91	NO	Adverse event Patient uncooperative	Patient	As prescribed
	9	Female	Day 42	19/12/91	YES			As prescribed
	10	Female	Day 42	30/12/91	YES			As prescribed
	11	Male	Day 28	03/05/92	NO	Deterioration	Physician	As prescribed
	12	Male	Day 21	05/05/92	NO	Deterioration	Physician	As prescribed
2	33	Male	Day 42	29/01/91	YES			As prescribed
	34	Male	Day 42	03/02/91	NO	Intercurrent medical problem	Physician	As prescribed
	35	Male	Day 42	07/02/91	YES			As prescribed
	36	Female	Day 28	31/01/91	NO	Adverse event Deterioration	Physician	As prescribed
	37	Male	Day 42	28/02/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
2	38	Female	Day 42	07/03/91	YES			As prescribed
	39	Female	Day 42	07/03/91	YES			As prescribed
	40	Male	Day 42	02/04/91	YES			As prescribed
	41	Male	Day 42	18/03/91	YES			As prescribed
	42	Male	Day 42	22/03/91	YES			As prescribed
	43	Female	Day 42	06/05/91	YES			As prescribed
	44	Male	Day 7	11/04/91	NO	Adverse event	Physician	As prescribed
	45	Female	Day 7	03/05/91	NO	Adverse event Deterioration	Patient	As prescribed
	46	Female	Day 42	26/06/91	YES			As prescribed
	47	Female	Day 42	02/07/91	YES			As prescribed
	48	Female	Day 42	07/10/91	YES			As prescribed
	49	Female	Day 42	09/10/91	YES		Patient	As prescribed
	50	Male	Day 42	15/12/91	NO	Death	Patient	As prescribed
	51	Female	Day 14	17/11/91	NO	Adverse event Deterioration	Physician	As prescribed
	52	Male	Day 42	07/01/92	YES			As prescribed
3	65	Male	Day 42	13/05/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
3	66	Female	Day 42	05/06/91	NO	Deterioration	Physician	As prescribed
	67	Female	Day 42	21/05/91	YES			As prescribed
	68	Female	Day 42	13/09/91	YES			As prescribed
	69	Female	Day 42	11/04/91	YES			As prescribed
	70	Female	Day 28	19/11/91	NO	Patient uncooperative	Patient	As prescribed
	71	Female	Day 42	25/12/91	YES		Physician Patient	As prescribed
	72	Female	Day 42	12/03/92	YES			As prescribed
	73	Female	Day 42	27/03/92	YES			As prescribed
4	97	Male	Day 42	18/06/92	YES			As prescribed
	100	Female	Day 42	24/06/92	YES			As prescribed
	101	Female	Day 21	22/05/91	NO	Deterioration	Physician Patient	As prescribed
6	161	Male	Day 42	09/05/91	YES			As prescribed
	162	Female	Day 42	16/12/91	YES			As prescribed
7	193	Female	Day 7	17/06/91	NO	Protocol violation Patient uncooperative	Patient	Unknown
	194	Male	Day 7	06/06/91	NO	Adverse event	Physician	As prescribed
	196	Female	Day 42	26/04/91	NO	Adverse event	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
8	225	Female	Day 21	09/04/91	NO	Lost to follow up	Patient	As prescribed
	226	Female	Day 42	13/06/91	YES			As prescribed
	227	Male	Day 42	17/06/91	YES			Suspected irregularities
	228	Male	Day 14	17/05/91	NO	Patient uncooperative	Patient	As prescribed
	229	Female	Day 42	02/12/91	YES			As prescribed
	230	Female	Day 42	16/12/91	YES			As prescribed
	231	Female	Day 14	13/11/91	NO	Protocol violation	Physician	As prescribed
	232	Male	Day 42	09/01/92	YES			As prescribed
9	197	Male	Day 7	10/03/92	NO	Adverse event Patient uncooperative	Patient	Confirmed irregularities
	198	Female	Day 42	28/04/92	YES			As prescribed
	199	Male	Day 42	13/05/92	YES			As prescribed
	200	Male	Day 42	08/06/92	YES			As prescribed
	201	Female	Day 42	26/02/92	YES			As prescribed
	202	Male	Day 42	27/02/92	YES			As prescribed
	203	Female	Day 7	18/01/92	NO	Deterioration	Patient	Suspected irregularities
	204	Male	Day 42	28/02/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
9	205	Female	Day 7	07/02/92	NO	Lost to follow up Patient uncooperative	Patient	Confirmed irregularities
	206	Female	Day 42	18/03/92	YES			As prescribed
	207	Female	Day 7	12/02/92	NO	Deterioration Patient uncooperative	Physician	As prescribed
	208	Male	Day 42	27/03/92	YES			As prescribed
	209	Male	Day 7	15/02/92	NO	Adverse event Patient uncooperative	Patient	As prescribed
	210	Female	Day 42	01/04/92	YES			As prescribed
	211	Female	Day 21	02/03/92	NO	Deterioration	Physician	As prescribed
	212	Female	Day 42	14/04/92	YES			As prescribed
	237	Male	Day 14	02/05/92	NO	Adverse event	Physician	As prescribed
	238	Female	Day 42	30/06/92	YES			As prescribed
	239	Male	Day 42	10/06/92	YES			As prescribed
	240	Female	Day 21	16/05/92	NO	Patient uncooperative	Patient	Suspected irregularities
	241	Female	Day 42	19/06/92	YES			As prescribed
	242	Male	Day 42	17/06/92	YES			As prescribed
	243	Female	Day 42	28/06/92	YES			As prescribed
	244	Male	Day 42	17/07/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
9	257	Female	Day 42	27/08/91	YES			As prescribed
	258	Male	Day 21	06/08/91	NO	Deterioration	Physician	As prescribed
	259	Female	Day 42	27/08/91	YES			As prescribed
	260	Female	Day 21	12/08/91	NO	Deterioration	Physician	As prescribed
	261	Female	Day 7	29/07/91	NO	Adverse event	Physician	As prescribed
	262	Male	Day 42	03/09/91	YES			As prescribed
	263	Female	Day 14	13/08/91	NO	Patient uncooperative	Physician	As prescribed
	264	Female	Day 42	10/09/91	YES			As prescribed
	265	Female	Day 42	03/10/91	YES			As prescribed
	266	Female	Day 42	29/10/91	YES			As prescribed
	267	Male	Day 42	13/10/91	YES			As prescribed
	268	Female	Day 42	05/11/91	YES			As prescribed
	269	Male	Day 42	05/11/91	YES			As prescribed
	270	Female	Day 7	17/10/91	NO	Adverse event	Physician	As prescribed
	271	Female	Day 28	20/11/91	NO	Adverse event	Physician	As prescribed
	272	Male	Day 42	10/12/91	YES			As prescribed
	273	Female	Day 28	20/11/91	NO	Adverse event	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
9	274	Female	Day 7	31/10/91	NO	Patient uncooperative	Physician	As prescribed
	274/A	Female	Day 42	23/06/92	YES			As prescribed
	275	Female	Day 42	17/12/91	YES			As prescribed
	276	Female	Day 7	14/01/92	NO	Intercurrent medical problem Deterioration	Patient	As prescribed
	276/A	Male	Day 42	14/04/92	YES			As prescribed
9/A	233	Male	Day 42	24/06/92	YES			As prescribed
	234	Female	Day 42	02/07/92	YES			As prescribed
	235	Male	Day 35	29/06/92	NO	Deterioration	Patient	As prescribed
	236	Male	Day 42	07/07/92	YES			As prescribed
	277	Female	Day 7	14/06/92	NO	Adverse event	Patient	Confirmed irregularities
	278	Female	Day 21	03/07/92	NO	Deterioration	Patient	As prescribed
	279	Male	Day 14	21/08/92	NO	Deterioration	Patient	As prescribed
	280	Female	Day 7	14/08/92	NO	Adverse event	Patient	As prescribed
	281	Female	Day 42	12/10/92	YES			As prescribed
	282	Male	Day 42	13/10/92	YES			As prescribed
	283	Female	Day 42	28/10/92	YES			As prescribed
	284	Male	Day 21	09/10/92	NO	Deterioration	Patient	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
9/A	301	Female	Day 42	15/04/92	YES			As prescribed
	302	Male	Day 21	22/03/92	NO	Patient uncooperative	Patient	As prescribed
	303	Female	Day 21	31/03/92	NO	Patient uncooperative	Patient	As prescribed
	304	Female	Day 42	06/05/92	YES			As prescribed
	305	Male	Day 42	11/05/92	YES			As prescribed
	306	Female	Day 42	09/06/92	YES			As prescribed
	307	Female	Day 7	08/05/92	NO	Adverse event	Patient	As prescribed
	308	Female	Day 28	02/06/92	NO	Adverse event Deterioration	Patient	As prescribed
10	289	Female	Day 7	27/09/91	NO	Deterioration Patient uncooperative	Physician	As prescribed
	290	Male	Day 42	24/11/91	YES			As prescribed
	291	Male	Day 42	29/03/92	YES			As prescribed
	292	Female	Day 42	23/01/92	YES			As prescribed
	293	Female	Day 42	01/02/92	YES			Confirmed irregularities
	294	Female	Day 21	23/01/92	NO	Patient uncooperative	Patient Others	As prescribed
	295	Male	Day 42	17/02/92	YES			As prescribed
	296	Female	Day 42	01/04/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
10	297	Male	Day 42	02/05/92	YES			As prescribed
	298	Female	Day 42	07/05/92	YES			As prescribed
	299	Male	Day 42	18/05/92	YES			As prescribed
	300	Female	Day 42	25/05/92	YES			As prescribed
11	321	Female	Day 42	23/07/92	YES			As prescribed
	322	Female	Day 42	24/07/92	YES			As prescribed
	323	Female	Day 42	06/08/92	YES			As prescribed
	324	Male	Day 42	28/08/92	YES			As prescribed
	325	Female	Day 42	10/09/92	YES			As prescribed
	326	Male	Day 42	10/09/92	YES			As prescribed
	327	Female	Day 42	01/10/92	YES			As prescribed
	328	Male	Day 28	17/09/92	NO	Other	Physician Patient	As prescribed
	329	Female	Day 42	02/10/92	YES			As prescribed
	330	Female	Day 7	26/08/92	NO	Adverse event	Patient	As prescribed
	331	Male	Day 42	15/10/92	YES			As prescribed
	332	Female	Day 42	20/10/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
11	333	Female	Day 42	16/10/92	YES			As prescribed
12	337	Female	Day 42	06/07/92	YES			As prescribed
	338	Female	Day 42	31/07/92	YES			As prescribed
	339	Male	Day 42	03/08/92	YES			As prescribed
	340	Female	Day 42	17/09/92	YES			As prescribed
	341	Female	Day 35	24/09/92	NO	Protocol violation Deterioration	Physician	Confirmed irregularities
13	353	Female	Day 35	07/07/92	NO	Adverse event	Physician Patient	As prescribed
	354	Female	Day 42	04/08/92	YES			As prescribed
	355	Female	Day 7	27/06/92	NO	Adverse event	Physician Patient	As prescribed
	356	Male	Day 42	01/09/92	YES			As prescribed
	357	Female	Day 7	09/08/92	NO	Adverse event	Patient	As prescribed
	358	Male	Day 35	05/09/92	NO	Adverse event	Patient	As prescribed
	359	Female	Day 42	29/09/92	YES			As prescribed
	360	Female	Day 7	21/08/92	NO	Adverse event	Patient	As prescribed
	361	Female	Day 42	06/10/92	YES			As prescribed
14	457	Female	Day 42	17/08/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
14	458	Female	Day 42	24/08/92	YES			As prescribed
	459	Male	Day 42	26/08/92	YES			As prescribed
	460	Male	Day 42	02/09/92	YES			As prescribed
	461	Female	Day 42	08/09/92	YES			Confirmed irregularities
	462	Female	Day 42	10/09/92	YES			As prescribed
	463	Male	Day 42	13/09/92	YES			As prescribed
	464	Female	Day 42	16/09/92	YES			Confirmed irregularities
	465	Male	Day 42	16/09/92	YES			As prescribed
	466	Female	Day 42	17/09/92	YES			As prescribed
14/1	129	Male	Day 7	19/12/91	NO	Adverse event	Physician	As prescribed
	426	Female	Day 42	17/10/91	YES			As prescribed
	429	Female	Day 7	29/09/91	NO	Adverse event	Patient	Suspected irregularities
	451	Male	Day 42	07/01/92	YES			As prescribed
	452	Female	Day 42	09/01/92	YES			As prescribed
14/2	136	Female	Day 42	25/02/92	YES			As prescribed
	456	Male	Day 42	26/05/92	YES			As prescribed
14/3	417	Female	Day 42	26/07/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
14/3	418	Female	Day 42	29/07/91	YES			As prescribed
	419	Female	Day 42	15/08/91	YES			As prescribed
	420	Female	Day 21	25/07/91	NO	Patient uncooperative	Patient	As prescribed
	421	Female	Day 42	12/09/91	NO	Other		As prescribed
	427	Female	Day 28	15/10/91	NO	Adverse event Patient uncooperative	Patient	As prescribed
	428	Female	Day 42	05/12/91	YES			As prescribed
14/4	131	Female	Day 42	24/02/92	YES			As prescribed
	132	Female	Day 42	24/02/92	YES			As prescribed
	133	Female	Day 42	26/02/92	YES			As prescribed
	134	Female	Day 42	26/02/92	YES			As prescribed
	135	Male	Day 42	27/02/92	YES			As prescribed
14/7	422	Female	Day 42	15/10/91	YES			As prescribed
	423	Female	Day 42	28/10/91	YES			As prescribed
	424	Male	Day 42	30/10/91	YES			As prescribed
	430	Female	Day 42	17/11/91	YES			As prescribed
	431	Male	Day 42	18/11/91	YES			As prescribed
	432	Male	Day 42	18/11/91	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
14/7	433	Female	Day 42	18/11/91	YES			As prescribed
	434	Male	Day 42	24/11/91	YES			As prescribed
	439	Male	Day 42	22/12/91	YES			As prescribed
	440	Female	Day 42	22/12/91	YES			As prescribed
	441	Male	Day 42	22/12/91	YES			As prescribed
	442	Male	Day 42	22/12/91	YES			As prescribed
	449	Female	Day 42	30/01/92	YES			As prescribed
	450	Male	Day 42	02/02/92	YES			As prescribed
14/8	130	Male	Day 42	20/02/92	YES			As prescribed
	425	Female	Day 42	20/10/91	YES			As prescribed
	467	Male	Day 42	16/08/92	YES			As prescribed
14/10	53	Male	Day 42	06/04/92	YES			Confirmed irregularities
	54	Female	Day 42	07/04/92	YES			Confirmed irregularities
	55	Female	Day 42	09/04/92	YES			Confirmed irregularities
	56	Female	Day 42	13/04/92	YES			Confirmed irregularities
	57	Female	Day 42	14/04/92	YES			Suspected irregularities
	58	Female	Day 42	25/05/92	YES			Confirmed irregularities

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
14/10	59	Female	Day 42	04/06/92	YES			As prescribed
	60	Female	Day 42	23/06/92	YES			As prescribed
	137	Female	Day 42	09/03/92	YES			As prescribed
	138	Female	Day 42	10/03/92	YES			Confirmed irregularities
	139	Female	Day 42	16/03/92	YES			Confirmed irregularities
	140	Female	Day 42	17/03/92	YES			As prescribed
	435	Female	Day 42	23/12/91	YES			As prescribed
	436	Female	Day 42	23/12/91	YES			As prescribed
	437	Female	Day 42	23/12/91	YES			As prescribed
	438	Female	Day 42	27/12/91	YES			As prescribed
	443	Female	Day 42	30/12/91	YES			As prescribed
	444	Male	Day 42	27/12/91	YES			Confirmed irregularities
	445	Female	Day 42	30/12/91	YES			As prescribed
	446	Female	Day 42	07/01/92	YES			Confirmed irregularities
	447	Male	Day 42	07/01/92	YES			Confirmed irregularities
	448	Female	Day 42	07/01/92	YES			As prescribed
	453	Female	Day 42	08/07/92	YES			As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
14/10	454	Female	Day 42	23/07/92	YES			As prescribed
	455	Female	Day 42	31/07/92	YES			As prescribed
15	349	Male	Day 42	01/10/92	YES			As prescribed
	351	Male	Day 42	14/10/92	YES			As prescribed
	352	Male	Day 21	27/08/92	NO	Lost to follow up	Patient	As prescribed
	364	Female	Day 28	26/08/92	NO	Patient uncooperative	Physician	As prescribed
	366	Male	Day 42	08/10/92	YES			As prescribed
	367	Male	Day 42	11/10/92	YES			As prescribed
	368	Female	Day 42	15/10/92	YES			As prescribed
	369	Female	Day 42	20/08/92	YES			As prescribed
	370	Female	Day 42	27/08/92	YES			As prescribed
	371	Female	Day 42	31/08/92	YES			As prescribed
	372	Male	Day 42	29/07/92	YES			As prescribed
	373	Female	Day 7	26/06/92	NO	Protocol violation	Physician	As prescribed
	374	Female	Day 42	20/05/92	YES			As prescribed
	375	Female	Day 21	25/06/92	NO	Protocol violation	Physician	As prescribed
	376	Female	Day 14	21/04/92	NO	Adverse event	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
15	376	Female	Day 14	21/04/92	NO	Deterioration		
	377	Female	Day 42	25/06/92	YES			As prescribed
	378	Female	Day 42	27/07/92	YES			As prescribed
	379	Female	Day 7	17/04/92	NO	Adverse event	Patient	As prescribed
	380	Female	Day 42	10/08/92	YES			As prescribed
	381	Female	Day 42	01/07/92	YES			As prescribed
	382	Male	Day 7	10/04/92	NO	Adverse event	Patient	As prescribed
	383	Female	Day 42	18/08/92	YES			As prescribed
	384	Female	Day 14	05/08/92	NO	Protocol violation	Physician	As prescribed

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	1	Reboxetine	Male	01.DEPRESSED MOOD	3	3	4	3	2	3	2	2
				02.GUILT	1	1	2	0	0	1	1	1
				03.SUICIDE	1	0	1	0	0	1	1	0
				04.INSOMNIA EARLY	0	0	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	0	1
				06.INSOMNIA LATE	2	2	2	2	1	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	4	4	3
				08.RETARDATION	2	2	2	1	0	2	2	1
				09.AGITATION	0	0	0	0	0	1	1	1
				10.ANXIETY PSYCHIC	2	1	2	1	1	2	1	1
				11.ANXIETY SOMATIC	1	2	1	1	0	2	2	0
				12.SOMATIC GASTROINTESTINAL	1	2	2	1	1	1	1	0
				13.SOMATIC GENERAL	2	1	2	0	1	2	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	2	0	0
				15.HYPOCHONDRIASIS	1	2	1	0	0	1	1	0
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	2	0	0	2	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	0
				22.Total score	27	27	34	18	14	27	19	13
	2	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	0	0	0
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	2	2	1	1	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	0	0
				06.INSOMNIA LATE	1	1	2	2	2	0	1	0
				07.WORK AND ACTIVITIES	4	4	4	4	3	1	1	0
				08.RETARDATION	2	2	2	2	1	0	0	0
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	1	0	2	0
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	0	0	0
				19.DEPERSONALIZATION	3	3	1	1	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	32	26	26	19	4	6	1
	3	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	0	0	0
				02.GUILT	2	2	0	1	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	2	0	0	0	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	3	Imipramine	Female	05.INSOMNIA MIDDLE	2	2	1	0	0	1	0	0
				06.INSOMNIA LATE	2	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	1	1
				08.RETARDATION	2	1	1	1	0	0	0	0
				09.AGITATION	1	0	2	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	3	2	2	2	1	1	1
				11.ANXIETY SOMATIC	3	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	1	1	0	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	30	25	20	13	9	5	3
	4	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3	2	2	0
				02.GUILT	1	1	1	2	1	0	0	0
				03.SUICIDE	1	1	1	0	1	0	0	0
				04.INSOMNIA EARLY	0	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	2	2	2	1	1	0	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	3	3	0
				08.RETARDATION	1	2	2	1	0	0	0	0
				09.AGITATION	0	0	2	2	0	0	0	0
				10.ANXIETY PSYCHIC	3	2	3	1	2	2	1	0
				11.ANXIETY SOMATIC	1	2	2	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	2	2	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	2	2	2	0	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	0
				19.DEPERSONALIZATION	1	1	2	1	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	26	33	28	24	13	10	2
	5	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	2	2	2	2	2
				02.GUILT	1	2	0	1	0	1	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	2	0	0	1	0	0
				05.INSOMNIA MIDDLE	2	2	0	1	1	0	1	2
				06.INSOMNIA LATE	2	2	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	4	4	2	4	3	4	3	3
				08.RETARDATION	2	2	0	2	0	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	5	Reboxetine	Female	09.AGITATION	1	2	2	1	2	2	0	0
				10.ANXIETY PSYCHIC	1	1	0	1	0	1	1	1
				11.ANXIETY SOMATIC	1	1	0	0	0	0	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	2	2	2
				14.GENITAL SYMPTOMS	2	2	1	1	2	2	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	2	2	2	1	1
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	30	12	20	16	21	14	14
	6	Imipramine	Male	01.DEPRESSED MOOD	4	4	3	2	3	2	1	1
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	2	1	1	1
				08.RETARDATION	0	0	0	0	1	1	0	0
				09.AGITATION	3	2	2	3	1	1	1	1
				10.ANXIETY PSYCHIC	3	2	1	2	1	1	1	1
				11.ANXIETY SOMATIC	3	2	2	1	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	2	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	33	30	26	22	18	17	13	13
	7	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	2	3	3	2
				02.GUILT	1	1	2	2	1	0	1	1
				03.SUICIDE	2	2	2	2	1	1	1	1
				04.INSOMNIA EARLY	1	1	2	0	0	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	0	1
				06.INSOMNIA LATE	2	2	2	2	2	1	2	2
				07.WORK AND ACTIVITIES	4	4	4	4	4	3	4	4
				08.RETARDATION	1	1	0	1	0	0	0	0
				09.AGITATION	0	0	2	1	1	1	2	2
				10.ANXIETY PSYCHIC	3	3	3	2	1	2	2	2
				11.ANXIETY SOMATIC	3	3	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	7	Reboxetine	Male	13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	2	0	0	2	2	2
				17.INSIGHT	0	0	0	0	0	0	1	1
				18.DIURNAL VARIATION	2	2	2	2	1	1	2	2
				19.DEPERSONALIZATION	2	2	2	0	0	0	0	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	31	31	34	24	19	21	26	27
	8	Imipramine	Male	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	1	2	1					
				03.SUICIDE	3	3	3					
				04.INSOMNIA EARLY	1	1	0					
				05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	0	1	1					
				09.AGITATION	2	1	0					
				10.ANXIETY PSYCHIC	1	2	2					
				11.ANXIETY SOMATIC	1	1	2					
				12.SOMATIC GASTROINTESTINAL	0	0	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	1	1	2					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	27	29	29					
	9	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	0	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	1	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	3	2	2	1	0
				08.RETARDATION	2	2	2	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	0	0
				11.ANXIETY SOMATIC	2	2	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	0	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	9	Imipramine	Female	17.INSIGHT	1	1	1	1	1	1	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	0	0
				19.DEPERSONALIZATION	2	2	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	24	15	11	10	3	1
	10	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	2	1
				02.GUILT	1	1	1	0	0	1	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	2	2	0	0
				05.INSOMNIA MIDDLE	1	2	1	1	2	2	2	2
				06.INSOMNIA LATE	2	2	1	0	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	2	2	1	0	0	0	0	0
				09.AGITATION	0	0	0	0	1	2	1	0
				10.ANXIETY PSYCHIC	3	3	1	3	2	3	2	2
				11.ANXIETY SOMATIC	3	3	2	2	2	2	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	19	16	20	24	18	13
	11	Reboxetine	Male	01.DEPRESSED MOOD	4	4	4	3	3	3		
				02.GUILT	2	2	1	2	1	2		
				03.SUICIDE	1	1	1	1	0	2		
				04.INSOMNIA EARLY	2	2	1	2	0	2		
				05.INSOMNIA MIDDLE	1	1	2	2	2	2		
				06.INSOMNIA LATE	2	2	2	2	2	2		
				07.WORK AND ACTIVITIES	4	4	4	4	4	4		
				08.RETARDATION	2	2	1	0	0	0		
				09.AGITATION	0	0	2	3	2	3		
				10.ANXIETY PSYCHIC	2	2	2	2	1	3		
				11.ANXIETY SOMATIC	2	2	2	1	1	2		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1		
				13.SOMATIC GENERAL	2	2	2	2	2	2		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	2	1	2	1	1	3		
				16.LOSS OF WEIGHT	2	2	2	0	0	0		
				17.INSIGHT	1	0	0	1	1	1		
				18.DIURNAL VARIATION	2	2	2	2	2	2		
				19.DEPERSONALIZATION	2	1	1	2	1	3		
				20.PARANOID	0	0	0	0	0	0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	11	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	36	33	34	33	26	39		
	12	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	3	3			
				02.GUILT	1	0	2	1	2			
				03.SUICIDE	0	0	1	0	1			
				04.INSOMNIA EARLY	2	2	2	1	1			
				05.INSOMNIA MIDDLE	2	2	1	1	1			
				06.INSOMNIA LATE	2	2	2	2	2			
				07.WORK AND ACTIVITIES	4	4	4	4	4			
				08.RETARDATION	1	1	1	0	2			
				09.AGITATION	0	0	1	1	0			
				10.ANXIETY PSYCHIC	2	2	1	0	2			
				11.ANXIETY SOMATIC	2	1	2	1	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1			
				13.SOMATIC GENERAL	2	2	1	1	2			
				14.GENITAL SYMPTOMS	1	2	1	1	2			
				15.HYPOCHONDRIASIS	0	0	2	0	2			
				16.LOSS OF WEIGHT	2	2	0	0	0			
				17.INSIGHT	0	1	0	0	1			
				18.DIURNAL VARIATION	1	1	1	1	1			
				19.DEPERSONALIZATION	1	0	1	0	2			
				20.PARANOID	0	0	1	0	1			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	27	26	27	18	32			
2	33	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	1	0	2	1	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	4	4	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	1	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	1	0
				07.WORK AND ACTIVITIES	2	2	1	0	0	1	1	0
				08.RETARDATION	2	2	0	0	0	0	0	0
				09.AGITATION	0	0	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	2	2	1
				11.ANXIETY SOMATIC	2	2	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	1	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	1	0	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	1
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	1	0	0
				17.INSIGHT	1	1	1	1	1	1	1	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	11	6	5	12	8	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	34	Imipramine	Male	01.DEPRESSED MOOD	3	3	1	3	0	2	2	2
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	3	3	0	1	0	0	1	1
				04.INSOMNIA EARLY	1	1	0	0	0	0	1	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	1	1
				06.INSOMNIA LATE	1	1	2	0	0	0	1	0
				07.WORK AND ACTIVITIES	3	3	1	1	1	1	2	1
				08.RETARDATION	1	1	0	1	0	1	1	0
				09.AGITATION	0	0	0	0	0	0	0	1
				10.ANXIETY PSYCHIC	1	1	1	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	2	0	0	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	2	0	0	1	1
				13.SOMATIC GENERAL	2	2	1	1	0	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	1	1	0	1	1
				15.HYPOCHONDRIASIS	3	3	1	2	1	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	25	25	9	17	5	9	17	13
	35	Reboxetine	Male	01.DEPRESSED MOOD	4	4	2	0	1	0	1	1
				02.GUILT	2	2	1	0	0	1	1	1
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	1	0	0	1
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	1	1
				06.INSOMNIA LATE	1	1	2	0	0	1	0	0
				07.WORK AND ACTIVITIES	4	4	1	0	1	0	0	0
				08.RETARDATION	1	1	0	0	0	0	0	1
				09.AGITATION	1	1	2	1	1	0	1	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	0
				11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	11	3	5	3	5	6
	36	Imipramine	Female	01.DEPRESSED MOOD	3	3	4	0	0			
				02.GUILT	2	2	2	0	1			
				03.SUICIDE	0	0	1	0	0			
				04.INSOMNIA EARLY	2	2	1	1	0			

779

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	36	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	0	0			
				06.INSOMNIA LATE	1	1	1	0	2			
				07.WORK AND ACTIVITIES	3	3	3	1	0			
				08.RETARDATION	2	2	2	0	0			
				09.AGITATION	1	1	1	0	1			
				10.ANXIETY PSYCHIC	2	2	2	0	0			
				11.ANXIETY SOMATIC	1	1	1	0	0			
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0			
				13.SOMATIC GENERAL	1	1	1	1	0			
				14.GENITAL SYMPTOMS	2	2	2	1	1			
				15.HYPOCHONDRIASIS	0	0	0	0	0			
				16.LOSS OF WEIGHT	2	2	0	0	2			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	1	1	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	25	25	23	4	7			
	37	Reboxetine	Male	01.DEPRESSED MOOD	4	3	2	3	2	3	2	1
				02.GUILT	1	1	0	1	0	0	0	0
				03.SUICIDE	3	3	0	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	2
				06.INSOMNIA LATE	1	1	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	4	4	2	1	1	1	2	1
				08.RETARDATION	1	1	1	1	1	2	1	1
				09.AGITATION	0	0	0	0	1	1	1	1
				10.ANXIETY PSYCHIC	4	4	2	3	2	2	2	1
				11.ANXIETY SOMATIC	3	3	2	2	3	2	2	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	1	0	0
				13.SOMATIC GENERAL	2	2	2	1	2	2	2	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	1	0	0	1
				19.DEPERSONALIZATION	1	1	0	0	1	1	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	34	33	19	21	23	22	18	13
	38	Imipramine	Female	01.DEPRESSED MOOD	2	2	1	2	3	3	3	2
				02.GUILT	2	1	0	1	1	2	2	2
				03.SUICIDE	1	1	0	1	2	3	2	1
				04.INSOMNIA EARLY	1	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	2	2	2	2	2	2	1
				06.INSOMNIA LATE	1	2	1	1	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	2
				08.RETARDATION	1	2	2	2	3	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	38	Imipramine	Female	09.AGITATION	1	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	25	20	23	27	28	27	24
	39	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	2	2	1	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	2	1	1	1	1	1
				06.INSOMNIA LATE	2	2	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	20	19	14	13	12	13
	40	Imipramine	Male	01.DEPRESSED MOOD	4	4	1	2	2	3	3	1
				02.GUILT	2	1	1	0	0	1	1	1
				03.SUICIDE	4	4	3	3	2	3	1	0
				04.INSOMNIA EARLY	2	1	0	0	0	2	1	1
				05.INSOMNIA MIDDLE	0	1	0	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	0
				07.WORK AND ACTIVITIES	1	2	1	2	1	2	2	0
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	1	1	0	1	1	2	2	1
				10.ANXIETY PSYCHIC	1	2	1	2	1	2	1	1
				11.ANXIETY SOMATIC	1	1	0	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	40	Imipramine	Male	13.SOMATIC GENERAL	1	1	0	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	1	0	1
				18.DIURNAL VARIATION	0	0	1	0	0	2	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	26	13	19	15	25	18	8
	41	Reboxetine	Male	01.DEPRESSED MOOD	3	4	3	3	2	2	2	3
				02.GUILT	1	2	1	2	1	1	1	1
				03.SUICIDE	0	2	2	2	1	1	1	2
				04.INSOMNIA EARLY	2	2	2	1	1	0	0	2
				05.INSOMNIA MIDDLE	2	0	2	1	1	2	1	2
				06.INSOMNIA LATE	2	2	2	1	1	2	2	2
				07.WORK AND ACTIVITIES	4	3	2	3	2	2	2	2
				08.RETARDATION	2	1	2	2	1	2	1	1
				09.AGITATION	0	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	3	3	3	2	2	2	3
				11.ANXIETY SOMATIC	1	2	3	3	2	2	3	3
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	1	3	2	2	2	3	2
				16.LOSS OF WEIGHT	2	0	0	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	1	1	2	2
				19.DEPERSONALIZATION	0	0	1	1	0	0	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	29	32	30	21	24	26	31
	42	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	4	4	3	3	1
				02.GUILT	1	1	2	1	2	2	1	2
				03.SUICIDE	0	0	0	0	0	0	2	0
				04.INSOMNIA EARLY	2	2	2	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	2	2	1	1	2
				06.INSOMNIA LATE	1	1	1	2	1	1	1	0
				07.WORK AND ACTIVITIES	4	4	3	4	4	2	2	0
				08.RETARDATION	2	1	1	2	2	1	1	1
				09.AGITATION	2	2	1	1	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	3	2	3	2	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	1
				16.LOSS OF WEIGHT	0	0	0	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	42	Imipramine	Male	17.INSIGHT	0	0	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	1	1	2	2	2	1	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	1	0	0	1	1	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	1	0	1
				22.Total score	27	27	29	29	30	23	19	15
	43	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	0	0	0	0	1
				02.GUILT	2	2	1	1	0	1	0	1
				03.SUICIDE	0	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	2	0	1	1	0	0
				05.INSOMNIA MIDDLE	1	0	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	2	0	0	0	0	0	0
				08.RETARDATION	2	0	0	0	0	0	0	0
				09.AGITATION	1	2	1	1	0	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	0	1	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0
				22.Total score	23	23	17	5	3	4	2	4
	44	Imipramine	Male	01.DEPRESSED MOOD	4	3	4					
				02.GUILT	2	2	2					
				03.SUICIDE	3	1	2					
				04.INSOMNIA EARLY	1	1	0					
				05.INSOMNIA MIDDLE	2	1	0					
				06.INSOMNIA LATE	2	1	0					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	2	0	2					
				09.AGITATION	1	2	2					
				10.ANXIETY PSYCHIC	3	2	2					
				11.ANXIETY SOMATIC	1	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	1	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	1	2					
				16.LOSS OF WEIGHT	0	1	0					
				17.INSIGHT	1	1	2					
				18.DIURNAL VARIATION	0	2	2					
				19.DEPERSONALIZATION	2	1	2					
				20.PARANOID	1	0	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	44	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	2	2	1					
				22.Total score	37	31	35					
	45	Imipramine	Female	01.DEPRESSED MOOD	4	4	1					
				02.GUILT	1	1	1					
				03.SUICIDE	1	0	0					
				04.INSOMNIA EARLY	1	0	1					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	1	1	1					
				07.WORK AND ACTIVITIES	4	4	1					
				08.RETARDATION	2	2	0					
				09.AGITATION	1	1	1					
				10.ANXIETY PSYCHIC	1	2	1					
				11.ANXIETY SOMATIC	2	2	1					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	1					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	1					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	25	24	15					
	46	Reboxetine	Female	01.DEPRESSED MOOD	4	3	3	3	2	2	2	2
				02.GUILT	2	1	1	0	1	1	1	1
				03.SUICIDE	2	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	0	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	0
				06.INSOMNIA LATE	2	1	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	3	2	1	2	1	1	1	1
				08.RETARDATION	1	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	2	1	1	1
				11.ANXIETY SOMATIC	0	0	0	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	2	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	0	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	0	2
				19.DEPERSONALIZATION	0	1	1	0	1	0	0	0
				20.PARANOID	0	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	1	0	0	0	0	0	0
				22.Total score	27	22	22	19	18	11	11	10

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	47	Reboxetine	Female	01.DEPRESSED MOOD	4	2	4	2	1	0	0	0
				02.GUILT	2	2	1	1	1	0	0	0
				03.SUICIDE	1	0	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	1	1	1
				05.INSOMNIA MIDDLE	2	1	2	2	2	0	0	0
				06.INSOMNIA LATE	0	0	2	2	2	1	0	1
				07.WORK AND ACTIVITIES	3	3	2	2	1	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	4	3	3	1	1	1	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	0	1	0	0
				15.HYPOCHONDRIASIS	2	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	23	26	19	9	5	2	3
	48	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	1	1	1	1	1
				02.GUILT	1	1	2	1	1	0	0	1
				03.SUICIDE	2	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	0	1	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	0	0	1	1	0	0
				06.INSOMNIA LATE	2	2	0	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	1	1	1
				08.RETARDATION	2	1	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	0	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	25	17	13	8	7	6	8
	49	Imipramine	Female	01.DEPRESSED MOOD	4	3	2	1	1	1	2	1
				02.GUILT	2	2	0	0	1	1	0	1
				03.SUICIDE	2	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	0	1	2	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	49	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	0	0	1	0	0
				06.INSOMNIA LATE	2	2	1	2	0	2	2	2
				07.WORK AND ACTIVITIES	3	3	2	1	1	0	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	1	2	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	1	1	1	1	0	1	1
				11.ANXIETY SOMATIC	2	2	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	1	0
				13.SOMATIC GENERAL	1	1	1	0	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	0	2	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	23	17	11	10	8	10	7
	50	Reboxetine	Male	01.DEPRESSED MOOD	4	4	4	3	3	3	4	
				02.GUILT	2	1	1	1	1	0	0	
				03.SUICIDE	2	1	2	2	2	1	0	
				04.INSOMNIA EARLY	2	1	2	2	1	2	1	
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	
				06.INSOMNIA LATE	2	1	1	1	1	1	1	
				07.WORK AND ACTIVITIES	4	3	3	2	3	2	1	
				08.RETARDATION	1	1	0	0	0	0	0	
				09.AGITATION	1	1	2	2	2	1	1	
				10.ANXIETY PSYCHIC	1	1	2	2	2	1	1	
				11.ANXIETY SOMATIC	0	1	2	2	2	1	1	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	
				13.SOMATIC GENERAL	1	1	1	2	1	1	1	
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	
				15.HYPOCHONDRIASIS	0	0	1	2	2	1	1	
				16.LOSS OF WEIGHT	1	1	0	0	0	1	0	
				17.INSIGHT	0	1	1	1	1	1	1	
				18.DIURNAL VARIATION	2	1	0	1	1	1	1	
				19.DEPERSONALIZATION	0	0	0	1	0	0	0	
				20.PARANOID	0	0	0	1	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	28	24	27	30	26	20	17	
	51	Reboxetine	Female	01.DEPRESSED MOOD	4	3	3	4				
				02.GUILT	2	2	2	3				
				03.SUICIDE	2	1	0	3				
				04.INSOMNIA EARLY	1	2	2	2				
				05.INSOMNIA MIDDLE	1	1	2	2				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	3	4				
				08.RETARDATION	2	0	0	2				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	51	Reboxetine	Female	09.AGITATION	1	2	1	1				
				10.ANXIETY PSYCHIC	2	1	1	3				
				11.ANXIETY SOMATIC	2	0	1	0				
				12.SOMATIC GASTROINTESTINAL	1	1	1	2				
				13.SOMATIC GENERAL	1	1	1	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	0	1	0	0				
				16.LOSS OF WEIGHT	1	0	0	0				
				17.INSIGHT	0	0	0	2				
				18.DIURNAL VARIATION	1	2	1	2				
				19.DEPERSONALIZATION	0	1	1	2				
				20.PARANOID	0	0	0	2				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	28	25	23	40				
	52	Imipramine	Male	01.DEPRESSED MOOD	4	3	2	0	0	1	1	0
				02.GUILT	2	1	1	0	0	0	0	0
				03.SUICIDE	3	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	2	2	0	0	0	0	0
				08.RETARDATION	2	0	0	0	0	0	0	0
				09.AGITATION	2	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	0	1	1	0	0	0
				11.ANXIETY SOMATIC	0	1	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	23	12	4	2	2	2	0
3	65	Reboxetine	Male	01.DEPRESSED MOOD	3	3	1	0	0	0	0	0
				02.GUILT	0	1	0	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	2	0	1	0	2	2	1
				06.INSOMNIA LATE	1	1	1	0	0	2	1	1
				07.WORK AND ACTIVITIES	4	4	4	2	1	1	0	0
				08.RETARDATION	1	2	1	0	0	1	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	0	1	0	0	0
				11.ANXIETY SOMATIC	3	1	1	1	2	0	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3	65	Reboxetine	Male	13.SOMATIC GENERAL	2	2	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	0	0
				15.HYPOCHONDRIASIS	3	3	1	0	1	0	0	0
				16.LOSS OF WEIGHT	0	2	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	2	2	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPUESIVE	2	1	1	0	0	0	0	0
				22.Total score	31	34	20	8	9	8	5	3
	66	Imipramine	Female	01.DEPRESSED MOOD	3	1	0	0	0	1	4	
				02.GUILT	3	2	2	1	0	1	3	
				03.SUICIDE	4	3	0	0	0	0	3	
				04.INSOMNIA EARLY	1	2	0	0	0	0	0	
				05.INSOMNIA MIDDLE	1	2	0	1	0	0	1	
				06.INSOMNIA LATE	0	2	2	0	0	0	2	
				07.WORK AND ACTIVITIES	3	2	1	1	1	1	4	
				08.RETARDATION	1	1	0	0	0	0	3	
				09.AGITATION	4	2	1	0	0	1	1	
				10.ANXIETY PSYCHIC	2	3	1	0	0	1	3	
				11.ANXIETY SOMATIC	1	1	2	0	1	1	0	
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	2	
				13.SOMATIC GENERAL	1	1	0	0	0	0	2	
				14.GENITAL SYMPTOMS	2	2	0	0	0	0	2	
				15.HYPOCHONDRIASIS	2	2	1	0	0	1	0	
				16.LOSS OF WEIGHT	2	2	0	0	0	1	0	
				17.INSIGHT	1	1	0	0	1	0	2	
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	
				19.DEPERSONALIZATION	0	3	0	0	0	0	3	
				20.PARANOID	2	1	0	0	0	0	1	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	35	35	10	3	3	8	36	
	67	Reboxetine	Female	01.DEPRESSED MOOD	1	1	2	2	1	1	2	3
				02.GUILT	1	1	2	2	1	3	2	2
				03.SUICIDE	4	4	1	0	0	1	1	2
				04.INSOMNIA EARLY	2	2	1	0	0	0	0	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	2
				06.INSOMNIA LATE	2	2	2	1	2	1	1	2
				07.WORK AND ACTIVITIES	3	2	1	1	1	1	1	1
				08.RETARDATION	1	1	0	0	1	1	1	0
				09.AGITATION	2	1	1	2	2	2	1	2
				10.ANXIETY PSYCHIC	4	4	2	1	1	2	2	2
				11.ANXIETY SOMATIC	3	2	2	2	1	3	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	1	0	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	0	1	1	1	3	3
				16.LOSS OF WEIGHT	1	1	0	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3	67	Reboxetine	Female	17.INSIGHT	0	0	1	1	0	1	1	1
				18.DIURNAL VARIATION	0	0	1	1	0	1	1	1
				19.DEPERSONALIZATION	2	2	1	2	2	1	1	2
				20.PARANOID	1	1	1	1	1	0	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	2	2	1	0	0	1
				22.Total score	36	32	22	22	17	21	21	27
	68	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	2	3	2	3	2	2	2	2
				03.SUICIDE	2	2	3	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	1	2	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	1	1	0	1
				07.WORK AND ACTIVITIES	4	4	4	4	4	4	4	4
				08.RETARDATION	3	2	3	2	3	3	3	3
				09.AGITATION	2	3	1	1	3	2	2	2
				10.ANXIETY PSYCHIC	3	3	2	2	3	3	3	3
				11.ANXIETY SOMATIC	3	3	2	3	2	3	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	1	1	0	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	3	2	2	3	1	2	1	2
				20.PARANOID	1	0	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	1	0
				22.Total score	42	41	34	33	33	33	30	32
	69	Imipramine	Female	01.DEPRESSED MOOD	3	3	4	1	1	0	2	1
				02.GUILT	2	2	3	2	0	0	1	0
				03.SUICIDE	4	2	2	2	0	0	1	0
				04.INSOMNIA EARLY	1	2	0	0	2	1	0	0
				05.INSOMNIA MIDDLE	1	2	0	1	0	0	0	0
				06.INSOMNIA LATE	1	2	2	2	0	0	0	0
				07.WORK AND ACTIVITIES	2	3	3	1	1	1	1	1
				08.RETARDATION	2	2	2	1	0	0	0	0
				09.AGITATION	2	2	1	1	0	1	1	1
				10.ANXIETY PSYCHIC	4	3	4	2	1	1	1	1
				11.ANXIETY SOMATIC	3	3	1	1	1	0	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	1	0
				13.SOMATIC GENERAL	1	1	2	1	1	0	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	1	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	1
				19.DEPERSONALIZATION	3	3	1	1	0	0	2	1
				20.PARANOID	1	1	1	1	0	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3	69	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	37	38	31	23	9	5	14	8
	70	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2		
				02.GUILT	2	2	2	2	2	2		
				03.SUICIDE	1	1	2	1	1	1		
				04.INSOMNIA EARLY	2	2	2	2	2	1		
				05.INSOMNIA MIDDLE	2	2	2	2	2	2		
				06.INSOMNIA LATE	1	2	2	2	2	2		
				07.WORK AND ACTIVITIES	3	3	4	3	3	2		
				08.RETARDATION	1	1	3	1	1	1		
				09.AGITATION	1	1	2	2	2	1		
				10.ANXIETY PSYCHIC	1	2	3	3	1	2		
				11.ANXIETY SOMATIC	3	3	3	2	4	3		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1		
				13.SOMATIC GENERAL	1	1	2	1	1	1		
				14.GENITAL SYMPTOMS	1	1	1	1	1	1		
				15.HYPOCHONDRIASIS	2	2	2	3	2	2		
				16.LOSS OF WEIGHT	0	0	0	1	0	1		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	1	1	1	1	0	0		
				19.DEPERSONALIZATION	3	3	3	3	3	2		
				20.PARANOID	0	1	1	1	0	1		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	29	32	39	34	30	28		
	71	Imipramine	Female	01.DEPRESSED MOOD	3	2	0	0	2	0	0	0
				02.GUILT	2	1	1	0	1	0	0	0
				03.SUICIDE	2	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	1	0	0	0	0	0	0
				06.INSOMNIA LATE	2	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	2	2	1	1	0	0	1
				08.RETARDATION	1	2	1	0	0	0	0	0
				09.AGITATION	2	2	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	2	0	1	0	0	0
				11.ANXIETY SOMATIC	1	1	2	0	2	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	1	1	0	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	2	0	0	0	1	0	0
				16.LOSS OF WEIGHT	2	2	0	1	0	0	0	0
				17.INSIGHT	2	2	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	2	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	33	29	10	3	8	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3	72	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	3	2	2	2	1
				02.GUILT	3	2	2	2	2	1	1	1
				03.SUICIDE	3	1	1	1	1	1	1	0
				04.INSOMNIA EARLY	0	0	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	0	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	2	3	3	1	2	2
				08.RETARDATION	2	1	0	0	0	1	1	1
				09.AGITATION	2	2	2	1	1	1	0	1
				10.ANXIETY PSYCHIC	3	3	2	2	3	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	2	1	0
				12.SOMATIC GASTROINTESTINAL	2	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	1	0	0
				15.HYPOCHONDRIASIS	2	2	1	0	0	2	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	1	1	1	0	1	1	1
				19.DEPERSONALIZATION	1	1	1	2	0	0	1	0
				20.PARANOID	1	1	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	1	0	0
				22.Total score	36	30	22	21	18	19	14	11
	73	Reboxetine	Female	01.DEPRESSED MOOD	2	3	2	0	0	1	1	0
				02.GUILT	2	2	2	1	0	1	0	0
				03.SUICIDE	1	0	0	0	0	1	0	0
				04.INSOMNIA EARLY	1	0	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	1	0	0
				06.INSOMNIA LATE	1	1	0	1	0	1	0	0
				07.WORK AND ACTIVITIES	4	3	2	0	1	0	1	0
				08.RETARDATION	1	2	0	0	0	0	0	0
				09.AGITATION	2	1	2	0	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	0	0	0	0
				11.ANXIETY SOMATIC	3	3	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	1	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	1	0	0	0
				19.DEPERSONALIZATION	1	0	1	0	0	0	0	0
				20.PARANOID	1	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	22	13	5	5	6	2	0
4	97	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	4	2	2	1	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	2	2	2	1	1	2	1	2
				04.INSOMNIA EARLY	2	2	2	1	2	2	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.8

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4	97	Imipramine	Male	05.INSOMNIA MIDDLE	2	2	2	2	2	2	1	2
				06.INSOMNIA LATE	2	2	2	2	1	2	0	1
				07.WORK AND ACTIVITIES	4	4	4	3	4	3	2	2
				08.RETARDATION	1	1	1	0	0	1	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	0	2
				11.ANXIETY SOMATIC	2	2	2	2	1	2	0	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	2
				15.HYPOCHONDRIASIS	1	1	1	1	0	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	2	1
				19.DEPERSONALIZATION	3	3	3	3	3	2	3	3
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	1	1	1
				22.Total score	34	34	30	26	23	25	15	21
	100	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	3	2	1	1	1
				02.GUILT	2	2	3	2	1	0	0	0
				03.SUICIDE	3	3	3	3	2	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	2	2	2	2	1	2	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	3	1	0	0
				08.RETARDATION	3	3	3	3	0	0	0	0
				09.AGITATION	3	3	4	2	2	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	0	1
				11.ANXIETY SOMATIC	3	3	3	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	1	1	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	2	2	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	39	38	41	34	22	10	5	7
	101	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3			
				02.GUILT	0	0	0	0	0			
				03.SUICIDE	2	2	1	3	3			
				04.INSOMNIA EARLY	2	2	0	1	2			
				05.INSOMNIA MIDDLE	2	2	1	0	0			
				06.INSOMNIA LATE	2	2	2	2	2			
				07.WORK AND ACTIVITIES	2	2	1	3	3			
				08.RETARDATION	1	1	1	0	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
4	101	Imipramine	Female	09.AGITATION	0	0	1	0	0			
				10.ANXIETY PSYCHIC	2	2	3	1	3			
				11.ANXIETY SOMATIC	1	1	2	1	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2			
				13.SOMATIC GENERAL	0	0	1	2	2			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	2	2	2	2	2			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	1	1	0	0	0			
				18.DIURNAL VARIATION	1	1	2	2	1			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	24	24	23	23	28			
6	161	Reboxetine	Male	01.DEPRESSED MOOD	3	3	0	1	1	0	3	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	3	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	2	1	0	2
				05.INSOMNIA MIDDLE	2	2	1	1	2	2	2	2
				06.INSOMNIA LATE	1	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	1	0	0	0	2	1
				08.RETARDATION	2	2	1	1	1	0	1	1
				09.AGITATION	1	1	0	0	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	0	0	0	0	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	2	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	1	0	1	1
				13.SOMATIC GENERAL	2	2	0	0	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	1
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	0	0	0	0	0	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	28	9	8	13	7	13	14
	162	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	1	1	0	0	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	1	0	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	0	0	1	1
				05.INSOMNIA MIDDLE	2	1	2	1	1	1	1	1
				06.INSOMNIA LATE	2	1	1	1	0	0	1	1
				07.WORK AND ACTIVITIES	4	4	2	2	1	1	1	1
				08.RETARDATION	2	2	1	1	0	0	0	0
				09.AGITATION	2	2	2	2	1	0	0	1
				10.ANXIETY PSYCHIC	3	3	1	1	1	0	0	0
				11.ANXIETY SOMATIC	2	2	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
6	162	Reboxetine	Female	13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	1
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	0	2	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	31	28	22	18	12	3	7	8
7	193	Reboxetine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	2	2						
				03.SUICIDE	3	3						
				04.INSOMNIA EARLY	1	1						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	0	0						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	1	1						
				09.AGITATION	3	3						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	3	3						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	0	0						
				15.HYPOCHONDRIASIS	2	2						
				16.LOSS OF WEIGHT	0	0						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	0	0						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	28	28						
	194	Reboxetine	Male	01.DEPRESSED MOOD	3	2						
				02.GUILT	2	2						
				03.SUICIDE	3	3						
				04.INSOMNIA EARLY	1	0						
				05.INSOMNIA MIDDLE	1	2						
				06.INSOMNIA LATE	0	0						
				07.WORK AND ACTIVITIES	4	4						
				08.RETARDATION	1	0						
				09.AGITATION	2	0						
				10.ANXIETY PSYCHIC	1	1						
				11.ANXIETY SOMATIC	2	1						
				12.SOMATIC GASTROINTESTINAL	0	0						
				13.SOMATIC GENERAL	1	1						
				14.GENITAL SYMPTOMS	1	0						
				15.HYPOCHONDRIASIS	0	0						
				16.LOSS OF WEIGHT	0	0						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7	194	Reboxetine	Male	17.INSIGHT	0	0						
				18.DIURNAL VARIATION	1	0						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	23	16						
	196	Imipramine	Female	01.DEPRESSED MOOD	4	4	2	1	2	2	2	2
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	2	2	0	0	0	1	0	2
				04.INSOMNIA EARLY	0	0	2	0	0	1	2	1
				05.INSOMNIA MIDDLE	1	1	2	0	0	1	1	1
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	1	1	1	1
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	1	0	0	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	1	0	0
				13.SOMATIC GENERAL	1	1	2	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	1	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	1	0	0	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	16	7	5	10	10	9
8	225	Imipramine	Female	01.DEPRESSED MOOD	2	2	3	0				
				02.GUILT	1	1	1	0				
				03.SUICIDE	1	1	2	0				
				04.INSOMNIA EARLY	2	2	1	0				
				05.INSOMNIA MIDDLE	1	1	0	0				
				06.INSOMNIA LATE	1	1	0	0				
				07.WORK AND ACTIVITIES	2	2	2	1				
				08.RETARDATION	1	1	1	0				
				09.AGITATION	0	0	0	0				
				10.ANXIETY PSYCHIC	2	2	2	1				
				11.ANXIETY SOMATIC	2	2	2	1				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	1	1	2	1				
				14.GENITAL SYMPTOMS	1	1	1	0				
				15.HYPOCHONDRIASIS	0	0	2	0				
				16.LOSS OF WEIGHT	2	2	2	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	1	1	2	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	225	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1	1				
				22.Total score	22	22	25	6				
	226	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	3	2	3	3
				02.GUILT	0	0	0	0	0	0	2	1
				03.SUICIDE	1	1	1	0	1	2	2	1
				04.INSOMNIA EARLY	2	2	2	1	2	2	1	2
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	2	1	2	1	1	2	1	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	1	2
				08.RETARDATION	2	2	1	1	1	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	1
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	3
				11.ANXIETY SOMATIC	3	2	2	1	2	1	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	2	1	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	1	1	0	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	1	1	1	0	0
				22.Total score	27	25	20	16	17	18	17	17
	227	Imipramine	Male	01.DEPRESSED MOOD	4	4	2	1	2	2	1	1
				02.GUILT	2	2	1	1	2	1	0	0
				03.SUICIDE	2	2	1	1	2	1	0	0
				04.INSOMNIA EARLY	1	1	1	1	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	2	1	1	0
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	4	4	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	4	3	2	1	3	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	1	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	2	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	30	19	16	23	17	11	7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	228	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2				
				02.GUILT	2	2	1	1				
				03.SUICIDE	2	1	1	1				
				04.INSOMNIA EARLY	2	2	2	2				
				05.INSOMNIA MIDDLE	2	1	1	1				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	2	2				
				08.RETARDATION	2	2	1	1				
				09.AGITATION	2	2	2	2				
				10.ANXIETY PSYCHIC	2	2	3	3				
				11.ANXIETY SOMATIC	2	2	2	2				
				12.SOMATIC GASTROINTESTINAL	1	1	1	1				
				13.SOMATIC GENERAL	1	1	2	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	1	1	3	3				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	0	0	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	1	1	1	1				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	30	28	28	28				
	229	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	1	2	1	2	1
				02.GUILT	3	2	2	1	1	1	1	1
				03.SUICIDE	3	3	0	0	1	0	1	0
				04.INSOMNIA EARLY	1	2	1	0	2	1	0	0
				05.INSOMNIA MIDDLE	0	0	1	1	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	1	2	2	1	1	1
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	1	0	0	1	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	1	2	1	1	2
				11.ANXIETY SOMATIC	2	2	1	0	2	1	1	2
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	1	1	0	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	1	0	0	0
				22.Total score	26	24	13	8	16	8	8	11
	230	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	0	1
				02.GUILT	0	0	0	1	1	1	0	1
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	230	Imipramine	Female	05.INSOMNIA MIDDLE	0	1	0	0	0	1	1	0
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	1	0	1	1
				08.RETARDATION	3	3	2	1	1	0	0	0
				09.AGITATION	1	1	0	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	2	1	1	1
				11.ANXIETY SOMATIC	0	0	0	0	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	2	0	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	0	0	0
				15.HYPOCHONDRIASIS	1	2	0	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	2	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	25	12	13	12	5	4	5
	231	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1					
				02.GUILT	2	2	1					
				03.SUICIDE	2	1	0					
				04.INSOMNIA EARLY	2	1	1					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	1	1	1					
				07.WORK AND ACTIVITIES	3	2	2					
				08.RETARDATION	1	1	0					
				09.AGITATION	0	0	0					
				10.ANXIETY PSYCHIC	2	2	1					
				11.ANXIETY SOMATIC	2	2	1					
				12.SOMATIC GASTROINTESTINAL	0	1	0					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	2	1					
				19.DEPERSONALIZATION	0	1	0					
				20.PARANOID	0	1	0					
				21.OBSESSIONAL/COMPULSIVE	0	1	0					
				22.Total score	25	26	14					
	232	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	2	3	1	1	1
				02.GUILT	3	2	0	0	0	0	0	0
				03.SUICIDE	1	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	0	0	1	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	4	3	3	3	3	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	232	Reboxetine	Male	09.AGITATION	2	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	3	4	2	3	3	2	1	1
				11.ANXIETY SOMATIC	3	3	3	1	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	2	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	1	0
				15.HYPOCHONDRIASIS	1	2	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	2	0	0	2	0	0	0
				17.INSIGHT	0	0	0	0	0	0	1	0
				18.DIURNAL VARIATION	1	1	2	1	1	1	1	1
				19.DEPERSONALIZATION	0	1	0	0	0	0	0	0
				20.PARANOID	1	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	1	0	1	1	0	0	0
				22.Total score	28	34	22	23	25	16	15	11
9	197	Reboxetine	Male	01.DEPRESSED MOOD	2	3	3					
				02.GUILT	2	2	2					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	0	0	0					
				05.INSOMNIA MIDDLE	0	0	0					
				06.INSOMNIA LATE	0	0	0					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	0	2	2					
				09.AGITATION	3	2	0					
				10.ANXIETY PSYCHIC	1	2	2					
				11.ANXIETY SOMATIC	2	1	3					
				12.SOMATIC GASTROINTESTINAL	0	1	0					
				13.SOMATIC GENERAL	1	1	2					
				14.GENITAL SYMPTOMS	2	1	1					
				15.HYPOCHONDRIASIS	3	3	3					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	2	0	0					
				19.DEPERSONALIZATION	0	1	1					
				20.PARANOID	0	0	1					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	22	23	24					
	198	Imipramine	Female	01.DEPRESSED MOOD	3	2	2	3	2	0	0	0
				02.GUILT	2	2	2	2	2	0	0	0
				03.SUICIDE	0	2	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	1	2	2	2	0	0	0
				05.INSOMNIA MIDDLE	0	2	2	0	1	0	0	0
				06.INSOMNIA LATE	2	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	3	2	0	0	0	1	0	0
				10.ANXIETY PSYCHIC	3	2	2	2	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	2	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	198	Imipramine	Female	13.SOMATIC GENERAL	2	2	2	2	2	0	0	0
				14.GENITAL SYMPTOMS	2	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	2	2	2	2	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	2	2	2	2	0	0	0
				19.DEPERSONALIZATION	1	2	1	1	0	0	0	0
				20.PARANOID	0	1	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	2	0	2	2	0	0	0
				22.Total score	27	29	24	25	22	1	0	0
	199	Imipramine	Male	01.DEPRESSED MOOD	4	3	3	3	3	1	3	2
				02.GUILT	2	1	1	1	1	1	1	1
				03.SUICIDE	1	2	2	2	2	0	0	1
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	1
				05.INSOMNIA MIDDLE	1	0	0	0	1	0	0	0
				06.INSOMNIA LATE	1	0	2	2	0	0	0	0
				07.WORK AND ACTIVITIES	1	4	4	4	4	4	4	4
				08.RETARDATION	2	1	1	1	1	1	1	0
				09.AGITATION	1	2	1	2	2	2	2	2
				10.ANXIETY PSYCHIC	3	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	3	3	3	3	3	4	3
				12.SOMATIC GASTROINTESTINAL	2	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	1	0
				15.HYPOCHONDRIASIS	3	3	3	3	3	2	3	2
				16.LOSS OF WEIGHT	0	0	1	0	1	0	0	0
				17.INSIGHT	2	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	29	25	27	27	27	19	24	21
	200	Reboxetine	Male	01.DEPRESSED MOOD	2	3	3	2	2	0	0	0
				02.GUILT	3	3	3	1	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	1	1
				11.ANXIETY SOMATIC	3	3	3	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	200	Reboxetine	Male	17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0
				22.Total score	29	30	30	18	9	6	6	5
	201	Imipramine	Female	01.DEPRESSED MOOD	3	3	0	0	0	0	0	0
				02.GUILT	3	2	0	0	0	0	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	2	2	0	0	0	1	0
				05.INSOMNIA MIDDLE	2	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	1	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	4	2	3	3	2	2	0
				08.RETARDATION	1	2	0	0	1	0	1	1
				09.AGITATION	2	2	1	0	0	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	1	1	0
				11.ANXIETY SOMATIC	4	3	4	2	2	0	0	2
				12.SOMATIC GASTROINTESTINAL	1	0	0	1	1	0	2	0
				13.SOMATIC GENERAL	1	0	1	0	1	2	2	0
				14.GENITAL SYMPTOMS	0	0	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	1	1	1	0	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	1	0	0	2	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	18	11	13	9	11	6
	202	Imipramine	Male	01.DEPRESSED MOOD	3	4	3	0	1	3	2	2
				02.GUILT	2	1	0	0	1	2	2	2
				03.SUICIDE	0	0	2	0	1	1	1	1
				04.INSOMNIA EARLY	2	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	1	0	1	0	0	0	0
				06.INSOMNIA LATE	1	1	2	0	2	0	0	1
				07.WORK AND ACTIVITIES	3	3	3	3	1	3	2	2
				08.RETARDATION	1	2	1	1	0	0	0	0
				09.AGITATION	3	1	2	1	0	2	2	2
				10.ANXIETY PSYCHIC	3	1	1	2	1	2	1	2
				11.ANXIETY SOMATIC	2	1	1	1	1	1	2	3
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	0	1	1	1
				13.SOMATIC GENERAL	2	1	1	1	1	1	1	2
				14.GENITAL SYMPTOMS	2	0	2	2	0	1	1	2
				15.HYPOCHONDRIASIS	3	3	3	3	1	2	2	3
				16.LOSS OF WEIGHT	0	0	0	0	0	2	2	1
				17.INSIGHT	1	1	1	1	1	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	0	0	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	1	2
				20.PARANOID	0	0	0	1	0	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	202	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0
				22.Total score	30	24	26	19	11	21	22	28
	203	Reboxetine	Female	01.DEPRESSED MOOD	3	4	4					
				02.GUILT	2	0	2					
				03.SUICIDE	1	0	2					
				04.INSOMNIA EARLY	1	2	1					
				05.INSOMNIA MIDDLE	2	0	1					
				06.INSOMNIA LATE	2	0	1					
				07.WORK AND ACTIVITIES	2	4	3					
				08.RETARDATION	1	1	1					
				09.AGITATION	1	3	3					
				10.ANXIETY PSYCHIC	3	4	1					
				11.ANXIETY SOMATIC	4	4	1					
				12.SOMATIC GASTROINTESTINAL	0	0	1					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	0	1	0					
				15.HYPOCHONDRIASIS	2	3	0					
				16.LOSS OF WEIGHT	0	0	1					
				17.INSIGHT	0	1	2					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	2	0	2					
				20.PARANOID	1	0	1					
				21.OBSESSIONAL/COMPULSIVE	1	0	0					
				22.Total score	29	28	28					
	204	Reboxetine	Male	01.DEPRESSED MOOD	3	4	2	0	0	0	0	0
				02.GUILT	2	1	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	1	0	0	0	0	0
				06.INSOMNIA LATE	0	1	0	0	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	2	0	0	0	0	0
				08.RETARDATION	2	1	0	0	0	0	0	0
				09.AGITATION	1	1	0	0	0	1	0	0
				10.ANXIETY PSYCHIC	4	1	1	0	0	0	0	0
				11.ANXIETY SOMATIC	1	2	1	0	0	0	0	1
				12.SOMATIC GASTROINTESTINAL	0	1	0	1	0	0	0	1
				13.SOMATIC GENERAL	1	1	0	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	1
				17.INSIGHT	1	2	0	0	2	0	0	0
				18.DIURNAL VARIATION	0	2	0	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	0	0	0	0	0	0	0
				22.Total score	22	22	8	4	3	2	1	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	205	Imipramine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	0	3						
				03.SUICIDE	0	0						
				04.INSOMNIA EARLY	2	1						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	2	0						
				07.WORK AND ACTIVITIES	3	1						
				08.RETARDATION	0	0						
				09.AGITATION	4	3						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	3	3						
				12.SOMATIC GASTROINTESTINAL	1	2						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	1	1						
				15.HYPOCHONDRIASIS	3	3						
				16.LOSS OF WEIGHT	0	0						
				17.INSIGHT	1	2						
				18.DIURNAL VARIATION	0	0						
				19.DEPERSONALIZATION	0	1						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	1	1						
				22.Total score	30	30						
	206	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	4	0	2	0	0
				02.GUILT	2	2	2	2	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	1	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	1	1	1	1	0	0	0	0
				08.RETARDATION	3	2	1	0	0	0	0	0
				09.AGITATION	1	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	3	3	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	0	0	1	1	0	0	0
				18.DIURNAL VARIATION	0	1	1	0	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	1	0	0	0
				22.Total score	29	28	26	25	13	6	4	4
	207	Reboxetine	Female	01.DEPRESSED MOOD	3	3	4					
				02.GUILT	1	0	1					
				03.SUICIDE	0	0	1					
				04.INSOMNIA EARLY	2	2	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	207	Reboxetine	Female	05.INSOMNIA MIDDLE	0	2	0					
				06.INSOMNIA LATE	2	1	0					
				07.WORK AND ACTIVITIES	1	3	2					
				08.RETARDATION	1	2	0					
				09.AGITATION	1	2	1					
				10.ANXIETY PSYCHIC	1	3	2					
				11.ANXIETY SOMATIC	3	3	3					
				12.SOMATIC GASTROINTESTINAL	2	1	1					
				13.SOMATIC GENERAL	0	2	1					
				14.GENITAL SYMPTOMS	1	0	0					
				15.HYPOCHONDRIASIS	2	1	3					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	2	0	0					
				18.DIURNAL VARIATION	0	1	2					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	22	26	22					
	208	Reboxetine	Male	01.DEPRESSED MOOD	4	3	0	0	0	3	2	2
				02.GUILT	0	2	2	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	0	2	0
				05.INSOMNIA MIDDLE	1	0	2	0	0	0	0	0
				06.INSOMNIA LATE	1	2	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	1	2	1	0	1	3	2
				08.RETARDATION	0	1	0	2	0	1	1	0
				09.AGITATION	2	2	1	1	1	0	0	1
				10.ANXIETY PSYCHIC	1	2	3	2	1	2	1	3
				11.ANXIETY SOMATIC	3	2	4	2	1	0	1	2
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	2
				14.GENITAL SYMPTOMS	1	1	1	2	2	2	1	0
				15.HYPOCHONDRIASIS	2	1	3	3	2	4	0	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	2
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	1
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	2	0	0	1	0	0	1
				22.Total score	25	26	23	15	10	15	13	18
	209	Imipramine	Male	01.DEPRESSED MOOD	2	2	2					
				02.GUILT	3	2	2					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	0	0	0					
				05.INSOMNIA MIDDLE	0	0	0					
				06.INSOMNIA LATE	2	2	0					
				07.WORK AND ACTIVITIES	2	2	2					
				08.RETARDATION	0	0	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	209	Imipramine	Male	09.AGITATION	2	2	1					
				10.ANXIETY PSYCHIC	2	4	2					
				11.ANXIETY SOMATIC	2	2	0					
				12.SOMATIC GASTROINTESTINAL	0	0	0					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	1	1	0					
				15.HYPOCHONDRIASIS	3	2	1					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	1	0					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	22	23	14					
	210	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	3	0	1	0	1
				02.GUILT	0	2	2	1	1	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	1	0	1	1	1	1	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	1	1	0
				06.INSOMNIA LATE	1	2	0	2	0	0	1	0
				07.WORK AND ACTIVITIES	3	2	2	1	0	1	0	1
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	0	0	2	2	1	1	1	0
				10.ANXIETY PSYCHIC	3	2	1	3	3	2	2	1
				11.ANXIETY SOMATIC	4	2	2	2	2	1	2	1
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	0	0	0	0	1	0	0
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	3	3	3	2	3	1	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	1
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	1	1	1	1	0	0
				19.DEPERSONALIZATION	0	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	2	1	1	0	1	0
				22.Total score	28	25	20	21	12	13	10	7
	211	Reboxetine	Female	01.DEPRESSED MOOD	2	3	3	3	3			
				02.GUILT	3	3	3	3	0			
				03.SUICIDE	3	3	3	3	1			
				04.INSOMNIA EARLY	2	2	2	0	2			
				05.INSOMNIA MIDDLE	2	1	1	1	2			
				06.INSOMNIA LATE	1	1	2	1	2			
				07.WORK AND ACTIVITIES	3	2	2	3	3			
				08.RETARDATION	2	0	0	0	1			
				09.AGITATION	2	2	2	2	2			
				10.ANXIETY PSYCHIC	3	2	3	3	2			
				11.ANXIETY SOMATIC	3	2	3	3	2			
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	211	Reboxetine	Female	13.SOMATIC GENERAL	1	1	2	2	1			
				14.GENITAL SYMPTOMS	2	0	1	1	1			
				15.HYPOCHONDRIASIS	2	1	2	2	1			
				16.LOSS OF WEIGHT	1	0	1	1	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	2	1	2	0			
				19.DEPERSONALIZATION	2	3	3	3	1			
				20.PARANOID	1	1	1	1	0			
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	1			
				22.Total score	38	30	37	35	26			
	212	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	3	2	1	1	0
				02.GUILT	2	0	1	3	1	1	1	1
				03.SUICIDE	3	0	1	0	1	1	1	0
				04.INSOMNIA EARLY	0	1	0	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	1	1	0	1	0	0	0
				06.INSOMNIA LATE	2	1	1	0	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	0
				08.RETARDATION	0	1	0	0	0	0	0	0
				09.AGITATION	2	3	3	0	2	1	1	0
				10.ANXIETY PSYCHIC	1	1	1	2	1	2	1	1
				11.ANXIETY SOMATIC	2	1	2	0	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	1	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	0	1	1	0
				14.GENITAL SYMPTOMS	0	1	0	0	1	0	0	0
				15.HYPOCHONDRIASIS	1	3	3	1	2	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	1	0
				17.INSIGHT	0	0	0	2	0	0	0	0
				18.DIURNAL VARIATION	0	1	2	0	2	0	0	0
				19.DEPERSONALIZATION	2	0	0	1	0	0	0	0
				20.PARANOID	0	1	1	0	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	1	0	2	0	0	0	0
				22.Total score	25	25	23	17	18	10	10	2
	237	Reboxetine	Male	01.DEPRESSED MOOD	2	3	2	3				
				02.GUILT	2	0	0	0				
				03.SUICIDE	0	0	0	0				
				04.INSOMNIA EARLY	2	2	2	2				
				05.INSOMNIA MIDDLE	2	2	2	2				
				06.INSOMNIA LATE	2	2	1	2				
				07.WORK AND ACTIVITIES	3	3	2	4				
				08.RETARDATION	2	3	3	3				
				09.AGITATION	1	0	0	3				
				10.ANXIETY PSYCHIC	3	3	2	4				
				11.ANXIETY SOMATIC	3	2	2	2				
				12.SOMATIC GASTROINTESTINAL	2	2	2	2				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	2	2	2	2				
				15.HYPOCHONDRIASIS	3	3	3	3				
				16.LOSS OF WEIGHT	0	0	0	0				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	237	Reboxetine	Male	17.INSIGHT	1	1	1	1				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	1	1	1	1				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	33	31	27	36				
	238	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	0	0
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	2	2	0	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	2	2	2	2	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	2	1	0	0
				11.ANXIETY SOMATIC	3	3	3	3	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	0	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	28	19	10	2	2
	239	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	1	1
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	2	2	1	1
				08.RETARDATION	2	2	1	1	0	1	1	0
				09.AGITATION	1	1	1	2	2	2	2	1
				10.ANXIETY PSYCHIC	3	3	2	1	1	2	2	2
				11.ANXIETY SOMATIC	3	3	3	3	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	239	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	25	23	13	17	14	11
	240	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	0	0	0	0				
				03.SUICIDE	2	2	1	1				
				04.INSOMNIA EARLY	0	0	1	1				
				05.INSOMNIA MIDDLE	0	0	1	1				
				06.INSOMNIA LATE	2	2	2	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	1	1	1	1				
				09.AGITATION	2	2	1	1				
				10.ANXIETY PSYCHIC	4	4	3	3				
				11.ANXIETY SOMATIC	2	2	2	2				
				12.SOMATIC GASTROINTESTINAL	2	2	1	1				
				13.SOMATIC GENERAL	2	2	1	1				
				14.GENITAL SYMPTOMS	1	1	1	1				
				15.HYPOCHONDRIASIS	2	2	2	1				
				16.LOSS OF WEIGHT	2	1	0	0				
				17.INSIGHT	1	2	1	1				
				18.DIURNAL VARIATION	1	1	1	1				
				19.DEPERSONALIZATION	0	2	2	2				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	30	32	27	26				
	241	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	1	1	1	1	0	0	0	0
				03.SUICIDE	1	1	1	1	1	1	1	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	2	2	1	1	1	1	1
				08.RETARDATION	0	3	3	2	2	2	2	2
				09.AGITATION	3	3	3	3	3	3	3	3
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	1
				11.ANXIETY SOMATIC	3	3	3	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	0	1	2	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	26	27	20	18	18	18	15

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	242	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	2	1	0	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	2	2	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	1	0	0
				07.WORK AND ACTIVITIES	4	3	3	3	2	2	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	2	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	0	0
				11.ANXIETY SOMATIC	3	3	3	2	2	2	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	23	21	19	18	11	0	0
	243	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	1
				02.GUILT	0	0	0	0	0	1	1	0
				03.SUICIDE	3	3	2	2	1	1	1	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	0
				08.RETARDATION	2	2	2	1	1	1	0	0
				09.AGITATION	0	0	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	0
				11.ANXIETY SOMATIC	3	3	3	3	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	2	2	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	21	18	12	13	12	5
	244	Reboxetine	Male	01.DEPRESSED MOOD	4	4	2	2	2	4	1	1
				02.GUILT	3	3	1	1	1	2	1	1
				03.SUICIDE	0	0	0	0	0	1	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	2	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	244	Reboxetine	Male	05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	2	2	0	0	1
				08.RETARDATION	3	3	1	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	1	1	1	2	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	0	0	0	2	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	16	14	14	21	14	12
	257	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	0	1	0	0
				02.GUILT	1	3	0	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	1	0	0	0	0
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	1	0	0	1	1	0
				08.RETARDATION	3	2	1	1	0	1	0	0
				09.AGITATION	3	3	0	0	0	1	0	0
				10.ANXIETY PSYCHIC	2	2	1	0	0	2	0	1
				11.ANXIETY SOMATIC	3	1	1	1	0	2	3	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	2	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	0	1	1	1
				14.GENITAL SYMPTOMS	2	1	2	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	1	0	0	0	1	0	2
				16.LOSS OF WEIGHT	0	0	0	2	0	0	0	2
				17.INSIGHT	1	1	1	1	0	1	1	1
				18.DIURNAL VARIATION	2	1	1	1	0	2	2	0
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	36	30	14	12	1	13	8	7
	258	Reboxetine	Male	01.DEPRESSED MOOD	2	3	2	3	3			
				02.GUILT	2	2	2	2	2			
				03.SUICIDE	1	1	2	0	2			
				04.INSOMNIA EARLY	2	1	2	2	2			
				05.INSOMNIA MIDDLE	2	1	0	1	2			
				06.INSOMNIA LATE	2	1	0	1	2			
				07.WORK AND ACTIVITIES	1	2	2	3	3			
				08.RETARDATION	1	1	3	2	3			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	258	Reboxetine	Male	09.AGITATION	2	3	0	2	1			
				10.ANXIETY PSYCHIC	3	4	4	1	2			
				11.ANXIETY SOMATIC	4	3	4	2	2			
				12.SOMATIC GASTROINTESTINAL	1	2	1	2	2			
				13.SOMATIC GENERAL	2	1	2	1	2			
				14.GENITAL SYMPTOMS	1	0	2	1	1			
				15.HYPOCHONDRIASIS	2	2	0	2	2			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	1	1	0	0	0			
				18.DIURNAL VARIATION	0	0	1	0	1			
				19.DEPERSONALIZATION	0	1	0	1	1			
				20.PARANOID	0	1	1	0	1			
				21.OBSESSIONAL/COMPULSIVE	0	1	1	2	1			
				22.Total score	29	31	29	28	35			
	259	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	2	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	2	1	0	0	0
				09.AGITATION	2	2	2	2	1	2	3	2
				10.ANXIETY PSYCHIC	3	3	3	3	2	2	2	2
				11.ANXIETY SOMATIC	3	3	3	3	1	1	2	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	0	1	0	1
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	0	0	1	1
				16.LOSS OF WEIGHT	1	1	1	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	29	29	13	14	15	12
	260	Imipramine	Female	01.DEPRESSED MOOD	4	1	1	2	4			
				02.GUILT	2	2	2	1	1			
				03.SUICIDE	0	0	0	0	3			
				04.INSOMNIA EARLY	2	2	1	2	1			
				05.INSOMNIA MIDDLE	0	0	0	0	0			
				06.INSOMNIA LATE	0	0	1	0	0			
				07.WORK AND ACTIVITIES	3	2	0	3	2			
				08.RETARDATION	0	0	0	1	0			
				09.AGITATION	4	4	4	4	4			
				10.ANXIETY PSYCHIC	4	3	3	3	2			
				11.ANXIETY SOMATIC	4	2	2	1	1			
				12.SOMATIC GASTROINTESTINAL	1	0	0	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	260	Imipramine	Female	13.SOMATIC GENERAL	1	1	0	1	1			
				14.GENITAL SYMPTOMS	1	1	0	1	1			
				15.HYPOCHONDRIASIS	2	3	3	1	1			
				16.LOSS OF WEIGHT	0	0	1	0	0			
				17.INSIGHT	2	0	2	2	0			
				18.DIURNAL VARIATION	0	2	2	0	0			
				19.DEPERSONALIZATION	1	1	0	1	1			
				20.PARANOID	2	2	2	2	1			
				21.OBSESSIONAL/COMPULSIVE	2	0	0	1	1			
				22.Total score	35	26	24	27	25			
	261	Imipramine	Female	01.DEPRESSED MOOD	4	4	4					
				02.GUILT	3	2	3					
				03.SUICIDE	0	0	2					
				04.INSOMNIA EARLY	1	1	2					
				05.INSOMNIA MIDDLE	2	2	1					
				06.INSOMNIA LATE	2	2	1					
				07.WORK AND ACTIVITIES	1	2	3					
				08.RETARDATION	2	2	1					
				09.AGITATION	2	2	3					
				10.ANXIETY PSYCHIC	3	2	2					
				11.ANXIETY SOMATIC	1	2	2					
				12.SOMATIC GASTROINTESTINAL	0	2	2					
				13.SOMATIC GENERAL	2	2	1					
				14.GENITAL SYMPTOMS	1	1	2					
				15.HYPOCHONDRIASIS	1	2	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	2	1	0					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	1	1	0					
				20.PARANOID	2	1	1					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	32	33	34					
	262	Reboxetine	Male	01.DEPRESSED MOOD	4	4	2	1	2	2	3	1
				02.GUILT	2	3	2	1	3	1	1	1
				03.SUICIDE	1	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	2	2	1	3	0	1	1
				08.RETARDATION	0	1	0	0	0	0	0	0
				09.AGITATION	2	1	1	1	0	1	0	1
				10.ANXIETY PSYCHIC	3	1	1	1	0	1	1	1
				11.ANXIETY SOMATIC	2	2	2	0	0	2	0	0
				12.SOMATIC GASTROINTESTINAL	1	2	0	0	0	0	1	1
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	1	2	0	0	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	2	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	262	Reboxetine	Male	17.INSIGHT	0	1	0	1	0	0	0	0
				18.DIURNAL VARIATION	2	0	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	30	20	12	12	8	8	7
	263	Reboxetine	Female	01.DEPRESSED MOOD	4	1	3	3				
				02.GUILT	2	0	2	1				
				03.SUICIDE	2	0	1	0				
				04.INSOMNIA EARLY	1	0	1	1				
				05.INSOMNIA MIDDLE	2	1	2	0				
				06.INSOMNIA LATE	2	0	1	0				
				07.WORK AND ACTIVITIES	3	4	2	2				
				08.RETARDATION	0	0	3	0				
				09.AGITATION	1	0	1	1				
				10.ANXIETY PSYCHIC	2	0	2	2				
				11.ANXIETY SOMATIC	3	1	1	2				
				12.SOMATIC GASTROINTESTINAL	0	1	1	0				
				13.SOMATIC GENERAL	2	1	1	2				
				14.GENITAL SYMPTOMS	1	0	1	1				
				15.HYPOCHONDRIASIS	0	2	1	1				
				16.LOSS OF WEIGHT	2	2	0	0				
				17.INSIGHT	0	1	0	0				
				18.DIURNAL VARIATION	1	1	0	0				
				19.DEPERSONALIZATION	0	0	0	0				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	1	0	0				
				22.Total score	28	16	23	16				
	264	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	0	0	0	1
				02.GUILT	2	3	1	0	0	0	0	0
				03.SUICIDE	0	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	1	1	2	2	2	1
				05.INSOMNIA MIDDLE	1	0	0	0	1	1	1	1
				06.INSOMNIA LATE	0	0	1	0	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	2	0	0	0	2
				08.RETARDATION	3	3	1	0	0	0	0	0
				09.AGITATION	2	1	1	1	0	0	0	1
				10.ANXIETY PSYCHIC	3	2	2	1	0	0	0	2
				11.ANXIETY SOMATIC	2	2	2	0	0	0	0	2
				12.SOMATIC GASTROINTESTINAL	2	2	1	2	2	2	2	2
				13.SOMATIC GENERAL	2	1	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	1	2	0	0	0	0	1
				15.HYPOCHONDRIASIS	2	1	3	0	0	0	0	2
				16.LOSS OF WEIGHT	2	0	0	0	1	1	1	0
				17.INSIGHT	2	1	0	0	1	0	0	0
				18.DIURNAL VARIATION	0	0	1	0	2	2	2	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	264	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	2	2	1	0	0	0	0	0
				22.Total score	32	27	25	10	11	10	11	16
	265	Reboxetine	Female	01.DEPRESSED MOOD	3	2	3	1	0	3	2	1
				02.GUILT	0	0	0	0	0	0	1	0
				03.SUICIDE	0	3	3	1	0	3	1	0
				04.INSOMNIA EARLY	2	1	1	1	0	2	2	1
				05.INSOMNIA MIDDLE	1	1	1	2	1	2	2	0
				06.INSOMNIA LATE	1	1	1	1	0	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	3	1	2	3	2
				08.RETARDATION	1	1	1	1	0	1	1	1
				09.AGITATION	1	1	1	3	1	2	2	0
				10.ANXIETY PSYCHIC	2	3	4	3	1	2	2	1
				11.ANXIETY SOMATIC	3	3	3	0	1	2	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	1	1	1	0
				13.SOMATIC GENERAL	2	1	1	0	1	1	0	1
				14.GENITAL SYMPTOMS	0	1	1	1	0	1	0	0
				15.HYPOCHONDRIASIS	1	2	0	1	0	1	1	0
				16.LOSS OF WEIGHT	1	1	0	0	0	2	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	2	2	2	1	0	0	0
				19.DEPERSONALIZATION	0	1	1	0	1	1	0	1
				20.PARANOID	0	2	1	2	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	1
				22.Total score	22	30	29	22	10	28	20	9
	266	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	0	0	0	0	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	0	2	1
				06.INSOMNIA LATE	1	2	2	2	2	1	1	2
				07.WORK AND ACTIVITIES	3	3	2	1	0	0	1	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	3	3	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	2	0
				11.ANXIETY SOMATIC	3	3	3	2	1	1	2	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	2	2	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	2	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	27	23	18	14	10	14	8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	267	Imipramine	Male	01.DEPRESSED MOOD	3	3	1	0	0	0	0	0
				02.GUILT	2	2	1	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	0	0	0	0	0
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	2	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	2
				11.ANXIETY SOMATIC	3	3	2	2	2	1	1	2
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	19	12	6	4	4	6
	268	Imipramine	Female	01.DEPRESSED MOOD	4	4	0	0	1	1	3	2
				02.GUILT	1	2	0	1	2	2	2	1
				03.SUICIDE	0	1	0	1	1	0	0	2
				04.INSOMNIA EARLY	0	0	0	0	0	1	0	0
				05.INSOMNIA MIDDLE	0	0	0	1	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	1	0
				07.WORK AND ACTIVITIES	4	4	2	1	2	1	3	1
				08.RETARDATION	3	2	2	1	1	1	2	1
				09.AGITATION	1	1	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	1	2	2	1	4	3
				11.ANXIETY SOMATIC	4	4	1	1	0	0	1	2
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	0	1	1	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	2
				14.GENITAL SYMPTOMS	2	2	1	1	1	1	2	2
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	1	0
				18.DIURNAL VARIATION	1	0	1	1	1	1	2	2
				19.DEPERSONALIZATION	1	1	0	1	0	0	0	0
				20.PARANOID	1	1	0	1	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	1	0	0	0
				22.Total score	31	32	14	16	16	14	25	19
	269	Reboxetine	Male	01.DEPRESSED MOOD	3	3	0	0	0	0	0	0
				02.GUILT	1	0	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	269	Reboxetine	Male	05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	3	2	2	1	1	1	1
				08.RETARDATION	2	2	1	0	0	0	1	0
				09.AGITATION	2	2	1	1	1	1	0	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	0	0	0
				11.ANXIETY SOMATIC	1	1	1	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	1	1	1	0	1	1	1
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	1	0
				15.HYPOCHONDRIASIS	3	3	1	1	0	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	1	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	0	0	1	0	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	2
				22.Total score	25	23	13	8	4	6	4	6
	270	Imipramine	Female	01.DEPRESSED MOOD	4	4	3					
				02.GUILT	1	0	0					
				03.SUICIDE	0	0	1					
				04.INSOMNIA EARLY	0	0	0					
				05.INSOMNIA MIDDLE	1	0	0					
				06.INSOMNIA LATE	0	1	0					
				07.WORK AND ACTIVITIES	4	4	3					
				08.RETARDATION	2	3	0					
				09.AGITATION	0	0	2					
				10.ANXIETY PSYCHIC	3	2	1					
				11.ANXIETY SOMATIC	2	1	2					
				12.SOMATIC GASTROINTESTINAL	1	1	2					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	2	1	0					
				15.HYPOCHONDRIASIS	2	1	1					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	1	0					
				20.PARANOID	0	1	0					
				21.OBSESSIONAL/COMPULSIVE	0	1	0					
				22.Total score	24	23	17					
	271	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2		
				02.GUILT	2	2	2	2	2	2		
				03.SUICIDE	1	0	0	0	0	0		
				04.INSOMNIA EARLY	1	2	2	2	2	2		
				05.INSOMNIA MIDDLE	2	2	2	2	2	2		
				06.INSOMNIA LATE	2	1	1	1	0	1		
				07.WORK AND ACTIVITIES	4	3	3	3	3	3		
				08.RETARDATION	3	3	3	1	1	1		

45

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	271	Reboxetine	Female	09.AGITATION	1	3	1	1	1	1	1	
				10.ANXIETY PSYCHIC	4	3	3	1	1	1	1	
				11.ANXIETY SOMATIC	1	2	2	1	1	1	1	
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	0	0	0	
				13.SOMATIC GENERAL	1	2	1	2	2	2	2	
				14.GENITAL SYMPTOMS	1	2	2	1	1	1	1	
				15.HYPOCHONDRIASIS	0	2	0	0	0	0	0	
				16.LOSS OF WEIGHT	0	1	1	1	1	1	1	
				17.INSIGHT	1	1	1	0	0	0	0	
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	1	1	1	1	1	1	
				22.Total score	31	35	31	24	23	24	24	
	272	Imipramine	Male	01.DEPRESSED MOOD	4	4	3	0	0	0	0	0
				02.GUILT	1	2	2	0	0	0	0	0
				03.SUICIDE	0	2	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	2	2	1	1	0	0	0
				06.INSOMNIA LATE	1	2	4	1	0	1	0	0
				07.WORK AND ACTIVITIES	3	4	4	3	3	3	2	1
				08.RETARDATION	2	2	1	1	1	1	1	0
				09.AGITATION	1	2	3	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	3	2	0	0	0	0	0
				11.ANXIETY SOMATIC	1	4	2	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	1	3	3	2	2	2	2	2
				16.LOSS OF WEIGHT	0	2	2	1	0	0	0	0
				17.INSIGHT	2	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	2	2	1	1	1	1
				19.DEPERSONALIZATION	1	2	2	0	0	0	0	0
				20.PARANOID	1	2	2	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	29	45	37	17	15	12	11	9
	273	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	4	3	3	3	
				02.GUILT	1	3	3	3	3	3	3	
				03.SUICIDE	1	3	3	3	3	3	3	
				04.INSOMNIA EARLY	1	1	2	2	2	2	2	
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	
				06.INSOMNIA LATE	0	2	1	1	1	1	1	
				07.WORK AND ACTIVITIES	4	4	3	3	3	3	3	
				08.RETARDATION	3	2	1	1	1	1	1	
				09.AGITATION	1	2	2	1	0	0	0	
				10.ANXIETY PSYCHIC	1	4	4	3	3	3	3	
				11.ANXIETY SOMATIC	1	2	2	1	1	1	1	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	273	Imipramine	Female	13.SOMATIC GENERAL	2	2	2	2	2	2		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	2	2	2	2	2	2		
				16.LOSS OF WEIGHT	1	0	0	0	0	0		
				17.INSIGHT	1	1	1	1	1	1		
				18.DIURNAL VARIATION	1	2	2	0	2	2		
				19.DEPERSONALIZATION	1	1	2	0	0	0		
				20.PARANOID	1	1	1	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1		
				22.Total score	32	42	41	33	31	34		
	274	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1					
				02.GUILT	2	1	1					
				03.SUICIDE	0	1	0					
				04.INSOMNIA EARLY	1	2	1					
				05.INSOMNIA MIDDLE	1	0	2					
				06.INSOMNIA LATE	1	2	1					
				07.WORK AND ACTIVITIES	3	1	0					
				08.RETARDATION	3	3	2					
				09.AGITATION	2	1	1					
				10.ANXIETY PSYCHIC	1	1	1					
				11.ANXIETY SOMATIC	1	2	1					
				12.SOMATIC GASTROINTESTINAL	1	2	1					
				13.SOMATIC GENERAL	2	2	1					
				14.GENITAL SYMPTOMS	2	2	1					
				15.HYPOCHONDRIASIS	2	1	1					
				16.LOSS OF WEIGHT	0	2	0					
				17.INSIGHT	1	2	0					
				18.DIURNAL VARIATION	1	0	0					
				19.DEPERSONALIZATION	0	0	2					
				20.PARANOID	0	1	2					
				21.OBSESSIONAL/COMPULSIVE	0	0	2					
				22.Total score	27	29	21					
	274/A	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	2
				02.GUILT	3	3	1	0	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	1	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	2	1	1	2
				08.RETARDATION	1	1	2	2	1	0	0	0
				09.AGITATION	1	1	0	1	1	2	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	3	3	2	2	1	1	1	1
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	274/A	Reboxetine	Female	17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	0
				22.Total score	31	30	24	22	15	13	11	13
	275	Reboxetine	Female	01.DEPRESSED MOOD	3	4	3	3	2	2	1	1
				02.GUILT	0	2	2	2	2	2	1	1
				03.SUICIDE	0	2	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	1	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	2	2
				08.RETARDATION	2	2	2	2	1	1	1	0
				09.AGITATION	1	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	3	3	3	0	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	1	2	2	2	2	2	1	1
				16.LOSS OF WEIGHT	0	2	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	2	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	1	0	0	0	0	0	0
				20.PARANOID	0	1	1	1	1	1	1	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0
				22.Total score	23	38	28	26	15	15	10	8
	276	Imipramine	Female	01.DEPRESSED MOOD	4	3	3					
				02.GUILT	1	1	3					
				03.SUICIDE	0	0	1					
				04.INSOMNIA EARLY	1	1	2					
				05.INSOMNIA MIDDLE	1	0	0					
				06.INSOMNIA LATE	1	2	1					
				07.WORK AND ACTIVITIES	3	4	3					
				08.RETARDATION	2	1	1					
				09.AGITATION	0	1	1					
				10.ANXIETY PSYCHIC	0	2	1					
				11.ANXIETY SOMATIC	3	1	1					
				12.SOMATIC GASTROINTESTINAL	2	1	1					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	0	0	1					
				17.INSIGHT	1	2	1					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	1	0	0					
				20.PARANOID	0	0	0					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	276	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	1	0					
				22.Total score	23	23	23					
	276/A	Imipramine	Male	01.DEPRESSED MOOD	2	2	3	4	3	0	0	0
				02.GUILT	2	2	0	3	2	0	0	0
				03.SUICIDE	1	1	0	2	1	0	0	0
				04.INSOMNIA EARLY	0	1	2	1	1	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	1	0	0	0	0
				06.INSOMNIA LATE	0	0	2	0	1	1	1	0
				07.WORK AND ACTIVITIES	1	0	3	3	1	1	1	1
				08.RETARDATION	0	0	0	1	1	0	0	0
				09.AGITATION	4	3	3	3	3	1	1	0
				10.ANXIETY PSYCHIC	3	3	3	3	2	2	2	1
				11.ANXIETY SOMATIC	4	4	3	2	3	2	2	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	3	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	2	0	1	1	0	0	0
				22.Total score	22	23	25	30	23	8	8	4
9/A	283	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2
				02.GUILT	1	1	1	1	1	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	1
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	2	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	4	4	3	2	2	3
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	2
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	1	2	1	2
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	0	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	30	29	28	17	16	15	19

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day
9/A	234	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	3	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	2	1	1	0	0	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	1	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	1	2	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	30	29	28	22	16	15	13	13
	235	Reboxetine	Male	01.DEPRESSED MOOD	4	4	3	2	1	1	3	
				02.GUILT	1	1	1	0	0	0	1	
				03.SUICIDE	1	1	1	0	0	0	1	
				04.INSOMNIA EARLY	2	2	1	1	1	1	2	
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	2	
				06.INSOMNIA LATE	2	2	1	1	1	1	2	
				07.WORK AND ACTIVITIES	4	3	2	2	2	2	2	
				08.RETARDATION	1	1	1	1	0	1	0	
				09.AGITATION	2	2	1	0	1	1	2	
				10.ANXIETY PSYCHIC	2	1	1	1	1	1	2	
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	1	
				13.SOMATIC GENERAL	2	2	1	1	1	2	2	
				14.GENITAL SYMPTOMS	2	2	1	1	1	2	2	
				15.HYPOCHONDRIASIS	2	3	2	1	1	1	2	
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	
				17.INSIGHT	1	1	1	0	0	0	1	
				18.DIURNAL VARIATION	0	1	0	0	0	0	0	
				19.DEPERSONALIZATION	1	1	0	0	0	0	1	
				20.PARANOID	0	0	0	0	0	0	1	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	33	33	20	13	12	15	- 28	
	236	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	1	1	1	1
				02.GUILT	2	2	2	2	1	1	1	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	236	Imipramine	Male	05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	1	0	0
				07.WORK AND ACTIVITIES	4	3	3	2	1	2	1	1
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	2	2	2	2	2	2	2	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	1	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	0
				19.DEPERSONALIZATION	1	1	2	1	1	1	1	0
				20.PARANOID	1	1	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	30	29	29	26	16	18	17	6
	277	Reboxetine	Female	01.DEPRESSED MOOD	3	3	4					
				02.GUILT	1	1	2					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	1	1	2					
				05.INSOMNIA MIDDLE	0	0	2					
				06.INSOMNIA LATE	1	1	2					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	1	1	1					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	0	1					
				18.DIURNAL VARIATION	1	0	0					
				19.DEPERSONALIZATION	1	2	2					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	29	28	35					
	278	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	3			
				02.GUILT	1	2	1	0	0			
				03.SUICIDE	1	1	1	0	1			
				04.INSOMNIA EARLY	1	1	1	1	1			
				05.INSOMNIA MIDDLE	1	1	0	0	1			
				06.INSOMNIA LATE	1	1	1	0	1			
				07.WORK AND ACTIVITIES	4	4	2	1	2			
				08.RETARDATION	0	0	0	0	0			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	278	Imipramine	Female	09.AGITATION	3	2	2	1	2			
				10.ANXIETY PSYCHIC	2	2	2	1	2			
				11.ANXIETY SOMATIC	1	2	1	1	2			
				12.SOMATIC GASTROINTESTINAL	0	1	0	0	1			
				13.SOMATIC GENERAL	2	2	2	1	2			
				14.GENITAL SYMPTOMS	2	2	2	1	2			
				15.HYPOCHONDRIASIS	2	2	1	1	2			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	1	1	1	0	0			
				19.DEPERSONALIZATION	2	2	1	0	1			
				20.PARANOID	1	1	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	1			
				22.Total score	29	31	21	9	24			
	279	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3				
				02.GUILT	2	2	2	1				
				03.SUICIDE	1	1	1	1				
				04.INSOMNIA EARLY	1	1	1	1				
				05.INSOMNIA MIDDLE	1	1	2	2				
				06.INSOMNIA LATE	1	1	1	2				
				07.WORK AND ACTIVITIES	3	3	3	3				
				08.RETARDATION	1	1	0	0				
				09.AGITATION	1	1	2	3				
				10.ANXIETY PSYCHIC	2	2	2	2				
				11.ANXIETY SOMATIC	1	1	2	2				
				12.SOMATIC GASTROINTESTINAL	0	0	1	1				
				13.SOMATIC GENERAL	2	2	2	2				
				14.GENITAL SYMPTOMS	1	1	1	2				
				15.HYPOCHONDRIASIS	1	1	1	3				
				16.LOSS OF WEIGHT	0	0	0	0				
				17.INSIGHT	1	1	0	0				
				18.DIURNAL VARIATION	0	0	0	0				
				19.DEPERSONALIZATION	1	1	2	2				
				20.PARANOID	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0				
				22.Total score	23	23	26	30				
	280	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	2	2	2					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	1	1	1					
				05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	1	1	2					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	1	0	0					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	280	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	2	3					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	1	1	1					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	29	28	30					
	281	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	0	0	0	0
				02.GUILT	1	2	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	0
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	0	0	0	0
				11.ANXIETY SOMATIC	2	2	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	27	15	7	4	3	3	2
	282	Reboxetine	Male	01.DEPRESSED MOOD	4	3	3	2	2	2	1	1
				02.GUILT	2	1	1	1	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	1	1
				06.INSOMNIA LATE	1	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	3	3	2	2	1	1
				08.RETARDATION	2	1	1	1	0	0	1	1
				09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	2	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	1	2	2	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	282	Reboxetine	Male	17.INSIGHT	0	0	0	1	1	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	1	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	34	33	29	22	18	15	15	12
	283	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	1	1	1	1	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	1	0	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	1	1	0	1
				05.INSOMNIA MIDDLE	0	1	1	1	1	0	1	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	1
				07.WORK AND ACTIVITIES	2	3	2	1	1	1	1	1
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	0
				11.ANXIETY SOMATIC	2	2	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	25	26	24	8	9	8	7	5
	284	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	3	3			
				02.GUILT	1	1	1	1	1			
				03.SUICIDE	1	1	1	1	1			
				04.INSOMNIA EARLY	2	2	2	2	2			
				05.INSOMNIA MIDDLE	2	1	1	1	1			
				06.INSOMNIA LATE	2	1	1	1	1			
				07.WORK AND ACTIVITIES	4	4	4	3	4			
				08.RETARDATION	0	0	0	0	0			
				09.AGITATION	2	2	2	2	2			
				10.ANXIETY PSYCHIC	2	2	2	1	2			
				11.ANXIETY SOMATIC	2	2	2	2	2			
				12.SOMATIC GASTROINTESTINAL	2	1	1	1	1			
				13.SOMATIC GENERAL	2	2	2	2	2			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	2	2	2	2	2			
				16.LOSS OF WEIGHT	2	2	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	1	1	1	0	1			
				20.PARANOID	0	0	0	0	0			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	284	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	1			
				22.Total score	33	30	28	24	28			
	301	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	0	0	0	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	1
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	0	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	2	1	1	1	0	0	0
				11.ANXIETY SOMATIC	1	2	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	0
				15.HYPOCHONDRIASIS	1	2	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	25	20	8	5	3	2	3
	302	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3			
				02.GUILT	2	2	2	1	1			
				03.SUICIDE	1	1	1	1	1			
				04.INSOMNIA EARLY	0	0	1	0	1			
				05.INSOMNIA MIDDLE	1	1	1	1	1			
				06.INSOMNIA LATE	1	1	1	1	1			
				07.WORK AND ACTIVITIES	3	3	3	3	3			
				08.RETARDATION	1	1	1	1	0			
				09.AGITATION	2	3	3	3	4			
				10.ANXIETY PSYCHIC	2	2	2	3	2			
				11.ANXIETY SOMATIC	2	2	2	2	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1			
				13.SOMATIC GENERAL	2	2	2	2	2			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	2	2	2	2	2			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	1	1	1	1	1			
				20.PARANOID	0	0	1	1	1			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	1			
				22.Total score	26	27	29	28	29			

826

9550085

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	303	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	3	3			
				02.GUILT	1	2	1	2	2			
				03.SUICIDE	1	1	1	1	1			
				04.INSOMNIA EARLY	1	1	1	1	1			
				05.INSOMNIA MIDDLE	1	1	1	1	1			
				06.INSOMNIA LATE	1	1	0	0	1			
				07.WORK AND ACTIVITIES	4	3	3	3	3			
				08.RETARDATION	1	1	0	0	0			
				09.AGITATION	2	2	1	2	3			
				10.ANXIETY PSYCHIC	2	2	1	3	3			
				11.ANXIETY SOMATIC	2	2	1	2	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1			
				13.SOMATIC GENERAL	2	2	1	2	2			
				14.GENITAL SYMPTOMS	2	2	2	2	2			
				15.HYPOCHONDRIASIS	1	2	1	2	2			
				16.LOSS OF WEIGHT	2	0	0	0	0			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	1	1	0	0	1			
				20.PARANOID	1	1	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	1			
				22.Total score	30	29	18	26	29			
	304	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	0	0
				02.GUILT	1	1	1	1	1	1	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	0	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	1	1	0	1	1	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	2	2	1	1
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	3	2	2	2	1	1	0
				10.ANXIETY PSYCHIC	2	3	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	2	2	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	0	0
				15.HYPOCHONDRIASIS	2	2	2	1	2	2	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	1	1	1	1	0	0	0
				22.Total score	26	29	18	14	17	14	7	5
	305	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1

827

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	305	Reboxetine	Male	05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	0	1
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	3	3	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	3	1	1	1	1	0	0
				11.ANXIETY SOMATIC	2	2	1	1	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	1	1	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	32	31	18	10	8	9	4	5
	306	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	1	1	1	1	1
				02.GUILT	2	2	2	0	0	0	0	0
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	1	1	1	1	1
				08.RETARDATION	1	1	2	1	0	0	0	0
				09.AGITATION	1	1	2	1	0	1	1	1
				10.ANXIETY PSYCHIC	1	2	2	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	0	1	0	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	28	29	30	10	3	5	4	5
	307	Imipramine	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	2	2	2					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	0	0	0					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	0	0	0					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	1	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	307	Imipramine	Female	09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	2	2	2					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	0	0	0					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	2	2	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	1	1	1					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	25	25	25					
	308	Imipramine	Female	01.DEPRESSED MOOD	4	4	3	3	2	4		
				02.GUILT	2	2	1	1	1	1		
				03.SUICIDE	1	1	1	1	0	1		
				04.INSOMNIA EARLY	2	2	2	2	1	2		
				05.INSOMNIA MIDDLE	2	2	2	2	1	2		
				06.INSOMNIA LATE	2	2	2	2	0	2		
				07.WORK AND ACTIVITIES	3	3	3	3	2	3		
				08.RETARDATION	2	2	2	1	1	1		
				09.AGITATION	2	2	2	2	1	2		
				10.ANXIETY PSYCHIC	2	2	2	2	1	2		
				11.ANXIETY SOMATIC	2	2	1	1	1	2		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1		
				13.SOMATIC GENERAL	2	2	2	2	1	2		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	2	2	1	2	1	2		
				16.LOSS OF WEIGHT	2	2	0	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	0	0	0	0	0	0		
				19.DEPERSONALIZATION	1	1	0	0	0	1		
				20.PARANOID	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	1		
				22.Total score	35	35	28	27	15	31		
10	289	Imipramine	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	0	0	0					
				03.SUICIDE	0	0	0					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	0	1	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	3	3	3					
				08.RETARDATION	1	1	1					
				09.AGITATION	0	1	2					
				10.ANXIETY PSYCHIC	0	1	2					
				11.ANXIETY SOMATIC	1	1	1					
				12.SOMATIC GASTROINTESTINAL	2	0	2					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	289	Imipramine	Female	13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	2	2	0					
				16.LOSS OF WEIGHT	2	2	2					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	2	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	1					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	22	22	26					
	290	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	0
				02.GUILT	4	4	2	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	1	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	2	1	1	1	1
				08.RETARDATION	3	2	2	1	1	1	0	0
				09.AGITATION	0	0	2	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	1	0	0	0	0
				11.ANXIETY SOMATIC	0	0	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	0	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	2	2	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	17	9	6	5	4	3
	291	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	0
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	0	0	0
				08.RETARDATION	2	2	1	0	0	0	0	0
				09.AGITATION	2	2	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	0
				11.ANXIETY SOMATIC	1	1	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	291	Imipramine	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	16	5	5	2	2	0
	292	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	2	2	1	1	1
				03.SUICIDE	3	3	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	0	0	0	0	0
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	2	2	2	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	0	0	0	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	22	9	9	5	5	4
	293	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	3	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	4	4	4	4	4	4	4	4
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	1	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	293	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	22	23	22	22	22	19	19
	294	Imipramine	Female	01.DEPRESSED MOOD	4	2	4	4	3			
				02.GUILT	1	1	1	1	1			
				03.SUICIDE	2	1	2	2	1			
				04.INSOMNIA EARLY	2	1	2	2	2			
				05.INSOMNIA MIDDLE	2	1	2	2	2			
				06.INSOMNIA LATE	2	1	2	2	2			
				07.WORK AND ACTIVITIES	3	2	4	3	3			
				08.RETARDATION	1	1	1	1	1			
				09.AGITATION	2	1	2	1	1			
				10.ANXIETY PSYCHIC	2	1	2	2	2			
				11.ANXIETY SOMATIC	1	2	3	3	2			
				12.SOMATIC GASTROINTESTINAL	2	1	2	2	2			
				13.SOMATIC GENERAL	1	1	1	1	1			
				14.GENITAL SYMPTOMS	0	0	0	0	0			
				15.HYPOCHONDRIASIS	1	2	2	2	2			
				16.LOSS OF WEIGHT	1	2	2	2	2			
				17.INSIGHT	0	0	0	0	0			
				18.DIURNAL VARIATION	2	2	2	2	2			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	1	1	1	1	1			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	30	23	35	33	30			
	295	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	2	1	1	1
				02.GUILT	2	2	2	1	1	0	0	0
				03.SUICIDE	2	2	2	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	2	2	1	1	0	0
				06.INSOMNIA LATE	1	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	0
				09.AGITATION	1	3	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	0	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	24	22	19	16	12	11	10

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	296	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	1	1	1	1
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	23	17	12	11	11	11
	297	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	3	2	1	0
				02.GUILT	2	2	2	1	1	1	1	0
				03.SUICIDE	2	2	1	1	1	1	1	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	0
				09.AGITATION	2	2	2	2	1	1	0	0
				10.ANXIETY PSYCHIC	2	1	1	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	1	1	1	1	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	2	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	28	25	23	19	15	10	8	4
	298	Reboxetine	Female	01.DEPRESSED MOOD	3	4	4	3	3	2	1	1
				02.GUILT	1	2	2	1	1	1	1	0
				03.SUICIDE	1	2	2	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	298	Reboxetine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	3	3	3	3	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	1	1	1	1	1	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	2	2	2	2	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	32	32	29	26	21	15	10
	299	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	2	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	1	1	1	3	1	1	1	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	3	1
				08.RETARDATION	3	3	3	3	3	3	3	2
				09.AGITATION	3	3	2	3	2	2	2	1
				10.ANXIETY PSYCHIC	3	3	3	3	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	28	31	24	24	23	11
	300	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	2
				02.GUILT	1	1	1	1	1	0	0	2
				03.SUICIDE	1	1	1	1	0	0	0	2
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	2	1	1	2
				08.RETARDATION	2	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	300	Imipramine	Female	09.AGITATION	2	2	1	1	1	0	0	2
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	0	0	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	22	21	16	12	12	19
11	321	Reboxetine	Female	01.DEPRESSED MOOD	2	3	1	1	1	1	0	0
				02.GUILT	1	0	0	0	0	1	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	1	0	0	1	1	2
				06.INSOMNIA LATE	2	1	1	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	0	1	0	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	1	0
				10.ANXIETY PSYCHIC	3	3	1	1	1	1	1	1
				11.ANXIETY SOMATIC	3	2	2	2	3	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	2	0	0	0
				14.GENITAL SYMPTOMS	1	1	0	1	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	2	2	0	2	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	1	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0
				22.Total score	28	26	16	15	13	13	8	8
	322	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	0	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	0	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	2
				05.INSOMNIA MIDDLE	2	2	2	2	0	0	2	1
				06.INSOMNIA LATE	0	0	2	0	2	1	0	1
				07.WORK AND ACTIVITIES	2	2	1	1	1	0	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	0	1	1	0	0
				11.ANXIETY SOMATIC	2	2	0	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	322	Reboxetine	Female	13.SOMATIC GENERAL	2	2	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	2	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	1	2	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	1	0	0	0	0	0
				22.Total score	22	22	15	7	9	3	4	6
	323	Imipramine	Female	01.DEPRESSED MOOD	2	2	1	2	0	0	0	0
				02.GUILT	0	1	0	0	0	0	1	0
				03.SUICIDE	2	1	0	1	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	2	2	1	1	1	1
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	1	1	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	2
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	1	0	0	0	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	0	1	1	1
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	1	1	1	1	0	0
				22.Total score	24	23	17	18	10	8	7	8
	324	Imipramine	Male	01.DEPRESSED MOOD	3	3	2	1	2	1	1	1
				02.GUILT	1	1	0	0	1	0	1	0
				03.SUICIDE	2	1	1	0	1	1	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	1	1
				06.INSOMNIA LATE	0	0	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	2	1	1	1
				08.RETARDATION	1	1	0	0	1	0	0	0
				09.AGITATION	2	1	1	0	0	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	3	1	2	1
				11.ANXIETY SOMATIC	1	1	0	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	1	0
				14.GENITAL SYMPTOMS	0	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	0	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	324	Imipramine	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	1	1	2	1	1	1
				19.DEPERSONALIZATION	1	1	1	0	0	0	1	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	23	22	16	9	16	10	11	6
	325	Reboxetine	Female	01.DEPRESSED MOOD	3	2	2	1	1	0	0	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	0	0	0	0	1
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	1	0	0	0
				19.DEPERSONALIZATION	0	1	1	0	0	0	0	0
				20.PARANOID	1	0	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	1	0	0
				22.Total score	22	21	19	8	6	1	0	1
	326	Imipramine	Male	01.DEPRESSED MOOD	3	3	2	1	1	1	0	1
				02.GUILT	1	1	1	1	0	0	0	1
				03.SUICIDE	2	2	0	0	0	0	0	1
				04.INSOMNIA EARLY	1	2	2	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	2	1	1	0
				07.WORK AND ACTIVITIES	2	2	2	1	0	0	0	0
				08.RETARDATION	2	1	1	0	0	0	0	0
				09.AGITATION	0	0	0	0	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	0	1
				11.ANXIETY SOMATIC	2	2	1	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	1	1	0	1
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	1	1	1	1	1	0	2
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	326	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	21	14	6	9	6	1	8
	327	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	1	1	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	1	1	0	0
				05.INSOMNIA MIDDLE	1	2	2	1	1	1	1	1
				06.INSOMNIA LATE	2	1	1	2	1	0	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	1	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	2	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	2	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	1	2	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	0	0	0
				20.PARANOID	1	1	0	1	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	0	0	0	0
				22.Total score	26	25	25	24	18	10	13	8
	328	Imipramine	Male	01.DEPRESSED MOOD	2	2	1	2	0	0		
				02.GUILT	1	1	0	1	0	0		
				03.SUICIDE	1	1	0	0	0	0		
				04.INSOMNIA EARLY	2	2	0	0	0	0		
				05.INSOMNIA MIDDLE	2	1	0	0	0	0		
				06.INSOMNIA LATE	1	1	2	0	1	0		
				07.WORK AND ACTIVITIES	2	2	2	1	1	1		
				08.RETARDATION	0	0	0	0	0	0		
				09.AGITATION	2	1	0	0	0	0		
				10.ANXIETY PSYCHIC	3	3	1	2	2	1		
				11.ANXIETY SOMATIC	3	3	1	2	1	2		
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	0	0		
				13.SOMATIC GENERAL	1	2	2	2	0	0		
				14.GENITAL SYMPTOMS	0	0	0	0	0	0		
				15.HYPOCHONDRIASIS	0	0	0	0	0	0		
				16.LOSS OF WEIGHT	0	0	2	0	0	0		
				17.INSIGHT	0	0	0	0	0	0		
				18.DIURNAL VARIATION	2	2	1	2	1	1		
				19.DEPERSONALIZATION	1	1	0	0	0	0		
				20.PARANOID	1	1	1	1	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	1	0	0	0	0		
				22.Total score	24	24	13	14	6	5		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	329	Imipramine	Female	01.DEPRESSED MOOD	3	2	2	1	1	1	1	1
				02.GUILT	2	2	1	1	1	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	1	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	2	1	1	0	0	0	0
				06.INSOMNIA LATE	1	2	2	0	1	1	0	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	1	1	0	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	3	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	0	1	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	1	0	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	0	0	1
				20.PARANOID	1	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0
				22.Total score	25	22	19	11	10	5	6	9
	330	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3					
				02.GUILT	1	2	1					
				03.SUICIDE	2	2	1					
				04.INSOMNIA EARLY	0	0	1					
				05.INSOMNIA MIDDLE	1	1	2					
				06.INSOMNIA LATE	0	0	2					
				07.WORK AND ACTIVITIES	3	2	2					
				08.RETARDATION	1	1	1					
				09.AGITATION	0	0	0					
				10.ANXIETY PSYCHIC	3	2	1					
				11.ANXIETY SOMATIC	1	2	2					
				12.SOMATIC GASTROINTESTINAL	0	0	2					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	1	1	0					
				15.HYPOCHONDRIASIS	0	0	1					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	0	0					
				18.DIURNAL VARIATION	2	2	1					
				19.DEPERSONALIZATION	1	1	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	1	0	0					
				22.Total score	23	21	22					
	331	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	1	1	3	0	0
				02.GUILT	1	2	1	1	1	1	1	0
				03.SUICIDE	2	1	0	0	0	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	0	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	331	Reboxetine	Male	05.INSOMNIA MIDDLE	1	0	1	2	1	1	1	0
				06.INSOMNIA LATE	2	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	2	1	1
				08.RETARDATION	1	1	0	0	0	1	0	0
				09.AGITATION	0	0	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	1	2	1	1
				11.ANXIETY SOMATIC	2	2	2	1	3	2	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	1	1	0	1
				13.SOMATIC GENERAL	2	2	1	0	2	2	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	2	1	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	1	0	0
				16.LOSS OF WEIGHT	1	0	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	0	1	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	29	28	21	12	12	21	7	4
	332	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	0	0	0	0	0
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	1	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	0	0	0	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	0	0	0	0	0	0
				11.ANXIETY SOMATIC	2	2	0	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	22	22	3	1	1	0	0	0
	333	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	3	2	1	0
				02.GUILT	2	2	2	2	2	1	0	0
				03.SUICIDE	1	1	0	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	2	1	0	0	0
				06.INSOMNIA LATE	0	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	0
				08.RETARDATION	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	333	Imipramine	Female	09.AGITATION	2	2	2	2	1	1	1	0
				10.ANXIETY PSYCHIC	3	3	3	3	3	1	2	0
				11.ANXIETY SOMATIC	1	1	1	1	0	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	2	2	2	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	1
				19.DEPERSONALIZATION	0	0	0	0	1	1	1	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	24	26	25	25	22	11	9	1
12	337	Imipramine	Female	01.DEPRESSED MOOD	2	4	1	0	3	2	2	0
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	2	2	0	0	0	3	2	0
				04.INSOMNIA EARLY	0	2	2	0	0	1	0	0
				05.INSOMNIA MIDDLE	0	2	1	0	1	0	1	1
				06.INSOMNIA LATE	2	2	1	1	2	1	1	0
				07.WORK AND ACTIVITIES	2	3	0	0	0	0	0	0
				08.RETARDATION	0	0	0	0	0	0	1	0
				09.AGITATION	0	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	4	0	0	0	1	2	0
				11.ANXIETY SOMATIC	2	1	0	0	0	0	1	0
				12.SOMATIC GASTROINTESTINAL	2	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	3	0	0	0	0	2	0
				16.LOSS OF WEIGHT	1	1	2	2	0	0	2	0
				17.INSIGHT	1	0	0	0	1	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	32	12	6	10	11	17	3
	338	Reboxetine	Female	01.DEPRESSED MOOD	2	4	3	0	1	1	2	1
				02.GUILT	2	2	1	1	0	0	0	0
				03.SUICIDE	3	3	2	0	0	1	0	1
				04.INSOMNIA EARLY	2	2	2	1	2	2	2	2
				05.INSOMNIA MIDDLE	0	1	1	1	0	0	0	2
				06.INSOMNIA LATE	0	2	1	1	1	0	0	2
				07.WORK AND ACTIVITIES	3	3	2	1	0	1	1	0
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	4	4	3	1	2	1	2	1
				11.ANXIETY SOMATIC	3	2	1	1	2	1	2	2
				12.SOMATIC GASTROINTESTINAL	0	0	1	1	0	0	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	338	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	1	0	0	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	3	3	3	3	3	2	3	2
				16.LOSS OF WEIGHT	2	0	2	0	0	0	0	2
				17.INSIGHT	0	0	0	1	0	0	0	0
				18.DIURNAL VARIATION	2	1	1	2	1	1	0	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	33	32	28	18	15	13	17	20
	339	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	1	1	1	1	0
				02.GUILT	2	2	1	2	1	1	1	0
				03.SUICIDE	2	2	1	2	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	1	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	0	2	1	1	1
				06.INSOMNIA LATE	1	1	1	0	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	1	1	0	0	0	1
				08.RETARDATION	2	2	1	0	1	1	1	1
				09.AGITATION	2	1	0	2	1	2	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	1	3	1	1
				11.ANXIETY SOMATIC	2	2	0	0	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	2	1	0	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	1	2	1	2	2	1	1
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0
				22.Total score	33	30	16	16	14	16	10	5
	340	Reboxetine	Female	01.DEPRESSED MOOD	2	3	3	0	0	0	2	2
				02.GUILT	1	1	1	0	0	0	1	0
				03.SUICIDE	2	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	2	1
				06.INSOMNIA LATE	1	2	2	1	1	1	1	2
				07.WORK AND ACTIVITIES	2	2	2	0	0	0	1	0
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	1	2	0	0	0	0	0	1
				10.ANXIETY PSYCHIC	2	2	2	0	0	0	1	2
				11.ANXIETY SOMATIC	1	2	1	0	1	0	1	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	0	1	0	1	1
				13.SOMATIC GENERAL	1	2	1	0	0	0	1	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	0	1	2
				15.HYPOCHONDRIASIS	0	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	0	0	2	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	340	Reboxetine	Female	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	3	3	1	1	0	0	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	32	23	5	7	4	13	14
	341	Reboxetine	Female	01.DEPRESSED MOOD	3	2	2	2	3	0	3	
				02.GUILT	2	2	2	2	2	1	1	
				03.SUICIDE	3	0	1	1	2	0	2	
				04.INSOMNIA EARLY	2	2	2	0	2	0	0	
				05.INSOMNIA MIDDLE	2	2	2	2	2	0	2	
				06.INSOMNIA LATE	2	2	2	1	0	2	2	
				07.WORK AND ACTIVITIES	4	2	2	2	3	1	2	
				08.RETARDATION	2	2	1	1	2	0	2	
				09.AGITATION	0	0	1	1	1	0	0	
				10.ANXIETY PSYCHIC	3	2	3	2	3	1	3	
				11.ANXIETY SOMATIC	3	2	2	2	2	0	3	
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	1	1	1	
				13.SOMATIC GENERAL	1	2	2	2	2	1	2	
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	
				15.HYPOCHONDRIASIS	2	0	0	0	0	0	1	
				16.LOSS OF WEIGHT	2	2	0	0	2	0	0	
				17.INSIGHT	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	2	2	2	2	0	1	2	
				19.DEPERSONALIZATION	2	2	2	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	2	1	1	1	1	0	1	
				22.Total score	40	30	31	24	30	10	29	
13	353	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	0	3	
				02.GUILT	2	2	0	1	0	1	0	
				03.SUICIDE	3	3	2	0	0	0	0	
				04.INSOMNIA EARLY	2	2	0	1	1	0	1	
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	1	
				06.INSOMNIA LATE	0	0	1	1	1	0	0	
				07.WORK AND ACTIVITIES	1	1	2	1	1	1	1	
				08.RETARDATION	1	1	1	0	0	0	1	
				09.AGITATION	2	2	0	0	0	0	0	
				10.ANXIETY PSYCHIC	0	0	2	2	1	1	0	
				11.ANXIETY SOMATIC	1	1	1	1	1	0	1	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	
				13.SOMATIC GENERAL	0	0	1	1	1	1	1	
				14.GENITAL SYMPTOMS	2	2	0	0	0	0	0	
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	
				16.LOSS OF WEIGHT	2	2	2	0	0	2	0	
				17.INSIGHT	1	1	0	0	0	0	0	
				18.DIURNAL VARIATION	1	1	1	0	1	1	1	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	353	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	23	23	17	11	9	7	10	
	354	Imipramine	Female	01.DEPRESSED MOOD	2	2	1	1	0	0	0	0
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	1
				06.INSOMNIA LATE	0	0	0	0	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	1	1	1	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	1	2	0	2	0	2
				11.ANXIETY SOMATIC	3	3	2	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	2	1	1	0	1	1
				14.GENITAL SYMPTOMS	1	1	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	1	1	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	2	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	15	11	5	4	3	4
	355	Reboxetine	Female	01.DEPRESSED MOOD	2	2	1					
				02.GUILT	2	2	0					
				03.SUICIDE	3	2	1					
				04.INSOMNIA EARLY	2	2	1					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	0	0	0					
				07.WORK AND ACTIVITIES	0	1	0					
				08.RETARDATION	0	0	0					
				09.AGITATION	3	2	1					
				10.ANXIETY PSYCHIC	2	2	1					
				11.ANXIETY SOMATIC	3	3	1					
				12.SOMATIC GASTROINTESTINAL	1	1	1					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	2	2	0					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	1	1	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	1	1	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	25	24	10					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	356	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	0	0	2
				05.INSOMNIA MIDDLE	2	2	1	1	0	1	1	0
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	1	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	2	1	1
				10.ANXIETY PSYCHIC	4	4	3	2	1	1	1	2
				11.ANXIETY SOMATIC	3	3	3	2	1	1	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	2	2	2	2	2
				16.LOSS OF WEIGHT	1	1	1	0	0	1	0	0
				17.INSIGHT	1	1	1	1	1	0	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	2	2	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	32	26	17	14	15	15	16
13	357	Imipramine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	0	0						
				03.SUICIDE	1	1						
				04.INSOMNIA EARLY	0	0						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	0	0						
				07.WORK AND ACTIVITIES	2	2						
				08.RETARDATION	0	0						
				09.AGITATION	2	2						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	1	3						
				12.SOMATIC GASTROINTESTINAL	2	1						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	0	0						
				15.HYPOCHONDRIASIS	1	1						
				16.LOSS OF WEIGHT	2	2						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	2	2						
				19.DEPERSONALIZATION	0	0						
				20.PARANOID	2	2						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	24	25						
	358	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	1	1		
				02.GUILT	1	1	1	0	0	2		
				03.SUICIDE	2	2	2	0	0	0		
				04.INSOMNIA EARLY	2	2	0	2	2	0		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	358	Reboxetine	Male	05.INSOMNIA MIDDLE	0	0	2	2	1	2		
				06.INSOMNIA LATE	1	1	0	0	0	0		
				07.WORK AND ACTIVITIES	2	2	2	0	0	0		
				08.RETARDATION	0	0	0	0	0	0		
				09.AGITATION	1	1	1	1	0	1		
				10.ANXIETY PSYCHIC	3	3	2	2	2	2		
				11.ANXIETY SOMATIC	3	3	1	2	1	1		
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1		
				13.SOMATIC GENERAL	2	2	1	1	0	1		
				14.GENITAL SYMPTOMS	0	0	0	0	0	0		
				15.HYPOCHONDRIASIS	1	1	1	1	0	1		
				16.LOSS OF WEIGHT	2	2	0	2	0	0		
				17.INSIGHT	1	1	0	0	0	0		
				18.DIURNAL VARIATION	2	2	1	1	1	1		
				19.DEPERSONALIZATION	0	0	0	0	0	0		
				20.PARANOID	2	2	2	0	1	1		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0		
				22.Total score	29	29	19	17	9	14		
	359	Reboxetine	Female	01.DEPRESSED MOOD	2	2	1	1	0	0	0	0
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	2	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	1	1	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	3	2	1	2	0	2
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	2	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	1	0	0	1	0
				16.LOSS OF WEIGHT	0	0	0	1	0	0	2	0
				17.INSIGHT	1	1	1	0	0	1	1	0
				18.DIURNAL VARIATION	0	0	1	1	1	1	0	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	26	26	26	19	11	12	9	7
	360	Imipramine	Female	01.DEPRESSED MOOD	2	2	2					
				02.GUILT	2	2	1					
				03.SUICIDE	1	1	1					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	1	1	1					
				06.INSOMNIA LATE	0	0	0					
				07.WORK AND ACTIVITIES	2	2	0					
				08.RETARDATION	0	0	0					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	360	Imipramine	Female	09.AGITATION	2	2	1					
				10.ANXIETY PSYCHIC	3	3	2					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	1	1	0					
				13.SOMATIC GENERAL	1	1	1					
				14.GENITAL SYMPTOMS	2	2	1					
				15.HYPOCHONDRIASIS	0	0	0					
				16.LOSS OF WEIGHT	1	1	2					
				17.INSIGHT	0	0	0					
				18.DIURNAL VARIATION	0	0	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	2	2	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	24	24	16					
	361	Reboxetine	Female	01.DEPRESSED MOOD	2	2	1	0	0	0	0	0
				02.GUILT	2	2	0	0	0	0	0	0
				03.SUICIDE	3	3	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	2	1	1	0	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	0	0	0	0	0	1
				10.ANXIETY PSYCHIC	2	2	1	0	1	2	0	0
				11.ANXIETY SOMATIC	2	2	1	1	0	1	0	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	2	0	0	0	1	0
				17.INSIGHT	1	1	1	1	1	1	1	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	17	5	3	4	3	4
14	457	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	3	3	2	1
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	2	2
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	2	2	2	1	1
				09.AGITATION	3	3	3	3	2	2	2	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	457	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	2	1	1	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	0	0
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	38	36	36	36	32	32	29	25
	458	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	2	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	2	2	2	2	1
				09.AGITATION	2	2	1	1	1	1	2	1
				10.ANXIETY PSYCHIC	3	3	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	1	1	1	0	0	1	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	2	2	2	2	2	1	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	37	37	34	30	27	28	26	23
	459	Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	459	Reboxetine	Male	17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	29	29	29	25	22	22	21	20
	460	Imipramine	Male	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	35	33	32	31	30	29	27	22
	461	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	3	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	3	3	3	3	3	2	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	2	0	0	1	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2
				20.PARANOID	2	2	2	2	2	2	1	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	461	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2
				22.Total score	39	40	39	40	39	39	37	40
	462	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2
				22.Total score	36	36	35	35	35	35	34	34
	463	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	1	1
				08.RETARDATION	2	2	2	2	2	2	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	1	1	1	1	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	1	1	1	1
				22.Total score	35	34	33	30	29	29	23	21

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	464	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	2
				02.GUILT	2	2	2	2	2	2	2	2
				03.SUICIDE	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	3	3	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	2	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2
				20.PARANOID	2	2	2	2	2	1	1	2
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2
				22.Total score	40	40	39	39	38	36	37	36
	465	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	2	2	2	2	1	1	0	0
				03.SUICIDE	2	2	2	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	0
				08.RETARDATION	2	3	2	1	1	1	1	1
				09.AGITATION	2	3	2	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	1	1
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	1	1	1	0
				20.PARANOID	1	1	1	1	1	1	1	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	1	1	1	0
				22.Total score	38	40	36	32	26	24	16	7
	466	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	2	2	1	1	1
				03.SUICIDE	2	2	2	2	1	1	1	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	466	Imipramine	Female	05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	2	2	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	1	1
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	1	1	1	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	1	1	1	1
				22.Total score	38	38	34	30	22	20	20	14
14/1	129	Reboxetine	Male	01.DEPRESSED MOOD	3	3						
				02.GUILT	0	0						
				03.SUICIDE	1	1						
				04.INSOMNIA EARLY	0	0						
				05.INSOMNIA MIDDLE	2	2						
				06.INSOMNIA LATE	1	1						
				07.WORK AND ACTIVITIES	2	2						
				08.RETARDATION	1	1						
				09.AGITATION	0	0						
				10.ANXIETY PSYCHIC	3	1						
				11.ANXIETY SOMATIC	2	3						
				12.SOMATIC GASTROINTESTINAL	0	0						
				13.SOMATIC GENERAL	2	0						
				14.GENITAL SYMPTOMS	1	1						
				15.HYPOCHONDRIASIS	3	4						
				16.LOSS OF WEIGHT	0	0						
				17.INSIGHT	0	1						
				18.DIURNAL VARIATION	2	2						
				19.DEPERSONALIZATION	2	1						
				20.PARANOID	0	0						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	25	23						
	426	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	1	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	0	0
				06.INSOMNIA LATE	2	0	2	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	0	1	0	0	0
				08.RETARDATION	0	1	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/1	426	Reboxetine	Female	09.AGITATION	3	0	0	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	3	2	1	2	1	1	1
				11.ANXIETY SOMATIC	3	3	2	1	2	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	0	0	1	0	0
				14.GENITAL SYMPTOMS	1	2	1	0	0	1	1	1
				15.HYPOCHONDRIASIS	0	1	1	0	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	25	23	8	13	6	4	3
	429	Imipramine	Female	01.DEPRESSED MOOD	1	2	2					
				02.GUILT	0	1	1					
				03.SUICIDE	2	2	1					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	2	1	2					
				07.WORK AND ACTIVITIES	1	2	1					
				08.RETARDATION	1	0	0					
				09.AGITATION	2	2	1					
				10.ANXIETY PSYCHIC	2	3	2					
				11.ANXIETY SOMATIC	2	2	2					
				12.SOMATIC GASTROINTESTINAL	0	2	2					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	1	1	1					
				15.HYPOCHONDRIASIS	3	3	2					
				16.LOSS OF WEIGHT	0	0	0					
				17.INSIGHT	1	1	1					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	0					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	25	29	25					
	451	Imipramine	Male	01.DEPRESSED MOOD	3	3	1	1	2	3	3	3
				02.GUILT	1	1	1	1	1	1	0	0
				03.SUICIDE	0	0	1	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	1	1	0	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	2	0	2	1	1
				06.INSOMNIA LATE	1	1	0	0	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	2	1	2	2
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	0	1	0	1	1
				11.ANXIETY SOMATIC	1	0	2	1	2	1	2	3
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/1	451	Imipramine	Male	13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	2
				15.HYPOCHONDRIASIS	3	3	3	2	2	2	3	3
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	0	0
				19.DEPERSONALIZATION	0	0	1	2	1	2	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	24	20	18	19	20	19	20
	452	Reboxetine	Female	01.DEPRESSED MOOD	4	4	2	3	3	2	2	3
				02.GUILT	2	2	0	0	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	1
				04.INSOMNIA EARLY	2	2	2	0	1	1	1	0
				05.INSOMNIA MIDDLE	0	0	0	1	2	0	0	0
				06.INSOMNIA LATE	0	0	2	2	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	1	2	1
				08.RETARDATION	2	2	2	1	1	1	0	1
				09.AGITATION	0	0	0	0	0	0	0	1
				10.ANXIETY PSYCHIC	0	0	0	0	0	1	1	0
				11.ANXIETY SOMATIC	1	1	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	1	1	0
				19.DEPERSONALIZATION	1	1	0	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	14	12	10	7	7	7
14/2	136	Imipramine	Female	01.DEPRESSED MOOD	3	2	3	3	2	2	1	1
				02.GUILT	2	2	1	2	2	1	1	0
				03.SUICIDE	2	1	2	1	1	1	1	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	1	0	0
				06.INSOMNIA LATE	1	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	2	2	1
				08.RETARDATION	1	0	1	1	1	0	0	0
				09.AGITATION	0	4	0	2	2	2	1	2
				10.ANXIETY PSYCHIC	2	3	2	3	1	2	2	1
				11.ANXIETY SOMATIC	1	1	2	1	1	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1.	0	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/2	136	Imipramine	Female	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	25	19	21	15	13	11	7
	456	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	1	1	1	1	1
				02.GUILT	2	2	2	1	1	0	0	0
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	1	1	0	0	0
				06.INSOMNIA LATE	0	0	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	1	0	0
				08.RETARDATION	3	2	2	2	1	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	1	1	1	0	1	1	1
				11.ANXIETY SOMATIC	1	0	0	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	1	1	1	0	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	1	1	1	0	1	1	1
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	22	19	17	14	11	9	7	6
14/3	417	Reboxetine	Female	01.DEPRESSED MOOD	4	4	2	2	1	1	2	1
				02.GUILT	3	3	0	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	1	0
				04.INSOMNIA EARLY	1	1	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	0	1
				06.INSOMNIA LATE	1	1	0	0	1	1	0	1
				07.WORK AND ACTIVITIES	4	4	3	2	1	1	1	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	3	3	3	3	1	1	1	1
				10.ANXIETY PSYCHIC	4	4	3	3	1	0	1	1
				11.ANXIETY SOMATIC	2	2	1	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	1	1
				15.HYPOCHONDRIASIS	2	2	1	1	0	1	1	1
				16.LOSS OF WEIGHT	1	1	0	1	0	1	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/3	417	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	30	17	17	7	6	8	9
	418	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	1	1	3	3	3
				02.GUILT	2	2	2	1	1	3	3	3
				03.SUICIDE	1	1	1	1	1	2	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	1
				06.INSOMNIA LATE	2	2	0	0	0	0	0	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	3	3	3
				08.RETARDATION	1	1	0	0	0	1	1	1
				09.AGITATION	3	3	3	2	2	2	1	1
				10.ANXIETY PSYCHIC	4	4	1	3	2	3	2	2
				11.ANXIETY SOMATIC	3	3	1	1	1	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	0	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	2	3	2	1	0	2
				16.LOSS OF WEIGHT	2	2	0	0	0	0	2	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	17	14	13	21	18	20
	419	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	2	1	1	1	1
				02.GUILT	2	2	2	2	1	1	1	0
				03.SUICIDE	2	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	1	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	1	0
				06.INSOMNIA LATE	0	0	0	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	1	2	1
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	3	3	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	2	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	1	1
				13.SOMATIC GENERAL	1	1	0	1	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	2	0	0	0	2
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	24	21	20	11	9	12	9

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/3	420	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	2			
				02.GUILT	2	2	2	1	1			
				03.SUICIDE	3	3	3	0	0			
				04.INSOMNIA EARLY	0	0	0	0	0			
				05.INSOMNIA MIDDLE	2	2	1	0	1			
				06.INSOMNIA LATE	1	1	1	0	0			
				07.WORK AND ACTIVITIES	4	4	4	3	2			
				08.RETARDATION	0	0	0	0	0			
				09.AGITATION	3	3	3	2	1			
				10.ANXIETY PSYCHIC	4	4	4	2	3			
				11.ANXIETY SOMATIC	3	3	3	2	2			
				12.SOMATIC GASTROINTESTINAL	1	1	1	0	2			
				13.SOMATIC GENERAL	1	1	1	0	1			
				14.GENITAL SYMPTOMS	1	1	1	1	1			
				15.HYPOCHONDRIASIS	3	3	3	2	3			
				16.LOSS OF WEIGHT	3	3	1	0	2			
				17.INSIGHT	1	1	1	1	1			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	35	35	31	15	22			
	421	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	2	2	2	1	
				02.GUILT	2	2	1	1	1	1	1	
				03.SUICIDE	0	0	0	0	0	0	0	
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	0	
				06.INSOMNIA LATE	2	2	1	0	0	0	0	
				07.WORK AND ACTIVITIES	3	3	2	1	1	1	1	
				08.RETARDATION	0	0	0	0	0	0	0	
				09.AGITATION	4	3	2	1	1	1	1	
				10.ANXIETY PSYCHIC	4	3	2	1	1	1	1	
				11.ANXIETY SOMATIC	3	3	3	2	1	1	1	
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	
				13.SOMATIC GENERAL	1	1	1	0	0	1	1	
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	
				15.HYPOCHONDRIASIS	3	3	3	1	1	1	1	
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	
				17.INSIGHT	1	1	1	1	1	1	1	
				18.DIURNAL VARIATION	2	2	1	1	0	0	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	
				22.Total score	33	31	22	11	9	10	9	
	427	Imipramine	Female	01.DEPRESSED MOOD	3	3	2		2	2		
				02.GUILT	1	1	1		2	2		
				03.SUICIDE	1	1	1		1	1		
				04.INSOMNIA EARLY	1	1	1		1	1		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/3	427	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1		1	1		
				06.INSOMNIA LATE	1	1	0		0	0		
				07.WORK AND ACTIVITIES	4	4	2		2	2		
				08.RETARDATION	1	1	0		0	0		
				09.AGITATION	1	1	1		1	1		
				10.ANXIETY PSYCHIC	3	3	2		2	2		
				11.ANXIETY SOMATIC	2	2	2		2	2		
				12.SOMATIC GASTROINTESTINAL	0	0	0		1	1		
				13.SOMATIC GENERAL	1	1	1		2	1		
				14.GENITAL SYMPTOMS	0	0	0		0	0		
				15.HYPOCHONDRIASIS	3	3	2		3	3		
				16.LOSS OF WEIGHT	0	0	0		0	0		
				17.INSIGHT	1	1	1		1	1		
				18.DIURNAL VARIATION	0	0	0		0	0		
				19.DEPERSONALIZATION	0	0	0		0	0		
				20.PARANOID	0	0	0		0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0		0	0		
				22.Total score	24	24	17		21	20		
	428	Imipramine	Female	01.DEPRESSED MOOD	4	4	3	1	2	2	1	1
				02.GUILT	2	2	2	0	2	1	1	1
				03.SUICIDE	2	2	1	0	1	1	0	0
				04.INSOMNIA EARLY	2	2	1	0	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0
				06.INSOMNIA LATE	2	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	3	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	0	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	3	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	21	16	16	14	11	11
14/4	131	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	3	2	1	1	0
				08.RETARDATION	1	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/4	131	Imipramine	Female	09.AGITATION	0	0	0	0	0	1	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	1	0
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	21	21	17	10	9	5
	132	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	1
				02.GUILT	2	2	2	2	1	1	1	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	0
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	1	2	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	25	25	17	14	11	10	5
	133	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	2	1
				02.GUILT	0	0	0	1	0	0	0	0
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	0
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	3	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/4	133	Imipramine	Female	13.SOMATIC GENERAL	2	2	2	2	1	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	0	1	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	1	1	0
				20.PARANOID	1	1	1	1	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	28	29	24	16	15	10	5
	134	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	2	2	2	2	1	1	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	0
				08.RETARDATION	1	1	1	1	1	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	1	1	0	1	0
				11.ANXIETY SOMATIC	3	3	3	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	1	1	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	2	0	1	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	1	1	1	1	1	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	34	32	33	23	18	9	9	7
	135	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	1	1	0	0
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	1	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	0
				08.RETARDATION	2	2	2	1	1	1	0	0
				09.AGITATION	2	2	2	1	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	1	1	0	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/4	135	Reboxetine	Male	17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	1	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	32	32	32	24	16	13	7	5
14/7	422	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	2	1	0
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	0
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	1	1	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	4	4	4	3	2	2	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	0	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	25	23	21	17	9	6
	423	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	2	0
				02.GUILT	2	2	2	2	2	2	2	0
				03.SUICIDE	1	1	1	1	2	2	2	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	1
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	2	2	2	2	2	2	2	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	0
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	1	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	2	2	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	1	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	423	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	23	23	21	21	20	18	17	2
	424	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	1	3	1	0
				02.GUILT	3	3	3	3	2	2	1	0
				03.SUICIDE	1	1	1	1	1	1	1	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	1	0
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	3	3	3	3	2	2	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	27	27	21	19	13	4
	430	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	1	0	0
				02.GUILT	3	3	3	3	2	1	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	0
				06.INSOMNIA LATE	2	2	2	1	1	1	1	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	0	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	3	3	3	3	2	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	27	24	15	8	3	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	431	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	4	4	2	1
				02.GUILT	3	3	3	3	3	3	1	0
				03.SUICIDE	1	1	1	3	3	3	1	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	2	2	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	1	0
				07.WORK AND ACTIVITIES	2	2	2	2	3	3	1	0
				08.RETARDATION	1	1	1	1	2	2	1	0
				09.AGITATION	3	3	3	3	3	3	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	4	4	2	1
				11.ANXIETY SOMATIC	2	2	2	2	3	3	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2	2	1	0
				13.SOMATIC GENERAL	1	1	1	2	1	1	1	0
				14.GENITAL SYMPTOMS	1	1	1	2	2	2	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	2	2	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	2	2	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	27	31	40	40	17	5
862	432	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	2	1	0	0
				02.GUILT	3	3	3	3	2	1	0	0
				03.SUICIDE	2	2	2	1	1	1	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	0
				06.INSOMNIA LATE	1	1	1	1	1	1	1	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	1	0	0
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	3	3	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	0	0
				11.ANXIETY SOMATIC	2	2	1	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	26	23	20	12	5	1
	433	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	1	1	0	0
				02.GUILT	3	3	3	2	1	1	1	0
				03.SUICIDE	2	2	2	1	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	433	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	1	1	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	3	3	2	2	2	1	1	0
				10.ANXIETY PSYCHIC	2	2	3	2	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	28	24	15	8	6	1
	434	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	0	0	0	0
				02.GUILT	3	3	3	2	1	0	0	0
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	1	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	1	1	1	0	0
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	3	3	3	1	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	0	0	0	0
				11.ANXIETY SOMATIC	2	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	1	1	0
				13.SOMATIC GENERAL	1	1	1	1	0	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	1	2	1	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	27	16	8	6	3	0
	439	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	2	1	1	0
				02.GUILT	3	3	3	2	2	1	1	0
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	0
				06.INSOMNIA LATE	1	1	1	1	1	1	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	1	1	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	439	Reboxetine	Male	09.AGITATION	2	2	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	2	2	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	27	27	24	19	15	9	4
	440	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	0	0	0	0
				02.GUILT	3	3	3	3	1	0	0	0
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	0	0	0	0
				08.RETARDATION	1	1	1	1	0	0	0	0
				09.AGITATION	2	2	2	2	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	0	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	26	3	0	0	0
	441	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	1	0	0	0
				02.GUILT	2	2	2	2	1	0	0	0
				03.SUICIDE	2	2	2	2	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	0	1	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	0	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	2	2	2	2	1	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	441	Imipramine	Male	13.SOMATIC GENERAL	1	1	1	1	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	26	7	1	0	0
	442	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	1	1	0	0	0
				02.GUILT	3	3	3	2	1	1	0	0
				03.SUICIDE	2	2	2	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0
				06.INSOMNIA LATE	2	2	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	2	0	0	0
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	1	1	1	1	0	0
				11.ANXIETY SOMATIC	1	1	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	28	26	17	15	6	2	1
	449	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	1	0	0	0	0
				02.GUILT	3	3	2	1	1	0	0	0
				03.SUICIDE	2	2	2	1	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	0	1	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	1	1	0	0	0
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	1	1	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	0
				11.ANXIETY SOMATIC	1	1	2	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	1	1	0	0	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	0	0
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	449	Reboxetine	Female	17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	1	1	1	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	0	0	0	0
				22.Total score	24	24	23	14	7	2	0	0
	450	Imipramine	Male	01.DEPRESSED MOOD	2	2	2	2	2	1	0	0
				02.GUILT	3	3	3	2	2	1	0	0
				03.SUICIDE	2	2	2	2	1	1	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	0	0
				06.INSOMNIA LATE	1	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	2	1	0	0	0
				08.RETARDATION	1	1	1	1	1	1	0	0
				09.AGITATION	2	2	2	2	1	1	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	26	26	22	19	10	0	0
14/8	130	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	2	2	1	0
				02.GUILT	2	2	2	2	2	2	2	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	1	1	1	0	0	0
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	1	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/8	130	Reboxetine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	22	17	15	13	10	8
	425	Reboxetine	Female	01.DEPRESSED MOOD	1	1	1	1	1	1	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	3	3	3	3	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	25	25	25	23	22	22	22	22
	467	Reboxetine	Male	01.DEPRESSED MOOD	2	1	1	1	1	1	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1
				08.RETARDATION	3	1	1	1	1	1	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	2	2	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	3	3	2	1	3	3	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2
				20.PARANOID	1	1	1	1	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1
				22.Total score	27	24	24	21	20	23	22	19

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	53	Reboxetine	Male	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	0	0	1	1	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	0	0
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	1	1
				08.RETARDATION	2	2	1	1	1	1	1	1
				09.AGITATION	2	2	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	3	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	1	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	2	0	1	0	0	0	0	0
				17.INSIGHT	0	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	28	28	22	16	11	8	8
	54	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	2	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	2	2	2
				05.INSOMNIA MIDDLE	2	2	1	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	2	3	2	2	2	2	2
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	1	2	2	2	2	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	1	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	1	0
				18.DIURNAL VARIATION	2	2	2	2	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	30	29	26	22	22	20	16
	55	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	1	1	1
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	55	Reboxetine	Female	05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	2	2	2	1	2	2	1	1
				07.WORK AND ACTIVITIES	3	2	2	2	2	2	2	1
				08.RETARDATION	2	2	2	1	1	1	1	0
				09.AGITATION	3	2	2	2	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	0	0
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	1	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	1	1	1	0	0
				19.DEPERSONALIZATION	0	0	0	1	0	0	0	0
				20.PARANOID	0	0	0	1	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	0	0	0	0
				22.Total score	30	27	24	23	20	15	11	8
	56	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	0	1	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	2
				05.INSOMNIA MIDDLE	1	1	2	1	1	1	2	1
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	2	2	2	2	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	25	22	19	17	14	14	13
	57	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	2	1
				05.INSOMNIA MIDDLE	1	1	1	1	2	2	1	2
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	57	Reboxetine	Female	09.AGITATION	2	1	1	1	1	1	0	1
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	1	1	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	26	23	20	20	17	15	15
	58	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	2	2	1	1	1	1	2
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	0	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	28	26	22	20	15	15	15
	59	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	1	1	1	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	3	3	2	2	2	1	1
				08.RETARDATION	2	2	2	2	1	1	1	0
				09.AGITATION	3	2	2	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	59	Imipramine	Female	13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	27	27	21	16	13	12	10
	60	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1
				02.GUILT	2	3	2	1	1	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	2	2	2	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	1	1
				06.INSOMNIA LATE	1	1	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	2	1	0	0	0
				09.AGITATION	2	2	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	2	2	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	1	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	2	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	24	31	28	23	18	14	11	10
	137	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	2	3	3	2	2	2	2
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	1	1	2	1	1	1	2	1
				10.ANXIETY PSYCHIC	3	3	3	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	137	Reboxetine	Female	17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	28	29	25	20	17	18	18
	138	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	1	2	2	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	2	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	2	2	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	0	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	28	26	21	20	17	14	13
	139	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	1	1
				02.GUILT	2	2	2	1	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	2	3	2	2	1	1	1	1
				08.RETARDATION	2	2	2	1	1	0	0	0
				09.AGITATION	2	2	2	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	0	0	0
				15.HYPOCHONDRIASIS	1	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	139	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	26	28	24	18	11	8	8	8
	140	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	1	1
				02.GUILT	2	2	3	2	1	1	2	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	1	1	1	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	2	2
				06.INSOMNIA LATE	1	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	1	1	2	2	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	1	1	1	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	2	2	2	2	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	1	1	1	1	1
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	28	29	26	23	19	21	19
	435	Imipramine	Female	01.DEPRESSED MOOD	4	4	3	2	2	2	2	2
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	2	1	1
				06.INSOMNIA LATE	1	1	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	1	1	1
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	2	2	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	27	28	28	23	19	18	16	15

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	436	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	1	1	1	1
				02.GUILT	2	2	2	2	1	1	1	1
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	1	2	1	1	1	1	1
				09.AGITATION	2	2	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	0	0	0	0	0
				17.INSIGHT	1	0	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	28	28	22	16	14	12	12
	437	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	2	2	2	1	1	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	1	0	0	0
				06.INSOMNIA LATE	2	2	2	2	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	1	1	1	1
				08.RETARDATION	2	1	2	1	1	1	1	1
				09.AGITATION	2	2	1	1	1	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	1	0	0	0
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	1	2	1	1	1	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	0	0
				16.LOSS OF WEIGHT	0	0	1	0	0	0	0	0
				17.INSIGHT	0	0	0	1	1	1	1	1
				18.DIURNAL VARIATION	1	2	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	27	26	22	16	12	9	9
	438	Imipramine	Female	01.DEPRESSED MOOD	2	3	2	2	2	1	1	1
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	1	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	438	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	1	2	1	1	1	1	1
				09.AGITATION	1	2	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	1	2	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	1	2	1	1	1	0	0
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	1	2	2	2	1	1	1
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	0	0	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	25	25	26	23	21	18	17	15
	443	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	3	2	1	1	1
				02.GUILT	2	2	2	2	2	1	1	1
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	2	1	0	0
				06.INSOMNIA LATE	1	1	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	2	2	1	1	1
				08.RETARDATION	2	2	2	2	2	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	0
				10.ANXIETY PSYCHIC	2	3	2	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	0	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	30	29	27	23	15	13	12
	444	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	2	2	1	1
				02.GUILT	2	2	2	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	1	2	2	2	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	444	Reboxetine	Male	09.AGITATION	2	2	1	1	1	1	1	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	2	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	29	27	26	19	15	14
	445	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	2	2	2	1	1
				02.GUILT	3	3	2	2	2	1	1	1
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	2	1	1	1	1	0
				10.ANXIETY PSYCHIC	4	4	3	3	3	2	1	1
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	1
				16.LOSS OF WEIGHT	2	2	2	1	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	33	33	31	26	25	21	18	16
	446	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	1	1	1	1
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	1	2	2	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	1	0	0	0	0	0
				09.AGITATION	1	1	1	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	2	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	446	Reboxetine	Female	13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	2	2	0	0	0	1	1	1
				18.DIURNAL VARIATION	2	2	2	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	31	27	19	16	16	15	15
	447	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	2	2	2	1	1
				02.GUILT	1	2	2	2	2	1	1	0
				03.SUICIDE	1	1	1	1	1	1	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	0
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	1	1	1	1	1
				09.AGITATION	2	2	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	2	2	2	2	1	1
				11.ANXIETY SOMATIC	2	2	2	2	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	1	1	1	1
				18.DIURNAL VARIATION	1	2	2	2	2	2	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	28	30	28	23	23	19	13	11
	448	Imipramine	Female	01.DEPRESSED MOOD	4	4	3	3	3	2	1	1
				02.GUILT	2	2	2	2	2	2	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	1	1
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	2	2	2	2	2
				08.RETARDATION	3	3	2	2	2	2	1	1
				09.AGITATION	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	3	3	3	3	2	2	2	2
				11.ANXIETY SOMATIC	3	2	3	3	3	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	2	2	2	2	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	448	Imipramine	Female	17.INSIGHT	0	0	0	0	0	0	1	1
				18.DIURNAL VARIATION	2	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	36	33	32	30	27	25	22	22
	453	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	0
				02.GUILT	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	0	1	0	1
				05.INSOMNIA MIDDLE	2	1	2	1	1	1	1	0
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	2	1
				08.RETARDATION	2	2	2	1	1	1	1	0
				09.AGITATION	2	2	2	1	0	1	0	1
				10.ANXIETY PSYCHIC	3	2	2	1	1	1	1	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	2	1	0	0	1	0	1
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	0	1
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	0	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	30	24	17	14	17	13	12
	454	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	1	1	1
				02.GUILT	1	1	1	1	1	1	1	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	2	1	2	1	1	1	0
				06.INSOMNIA LATE	2	2	2	2	2	2	1	1
				07.WORK AND ACTIVITIES	3	2	2	2	2	2	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	3	3	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	1	0
				11.ANXIETY SOMATIC	2	2	2	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	2	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	2	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	454	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	30	28	25	21	19	18	14	11
	455	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	2	2	1	1	1
				02.GUILT	0	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	2	2	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	1	0	0
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	1	1
				08.RETARDATION	2	2	2	2	1	1	1	1
				09.AGITATION	2	3	2	1	1	1	0	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	2	2	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	2	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	2	2	2	2	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	29	29	28	24	19	16	13	14
15	349	Imipramine	Male	01.DEPRESSED MOOD	2	2	1	0	0	0	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	1	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	1	1	0	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	1	1	1	2	1
				11.ANXIETY SOMATIC	2	2	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	0	1	0	0
				13.SOMATIC GENERAL	1	1	1	1	0	0	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	1	1
				15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	2	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	3	3	1	0	0	0	0	0
				20.PARANOID	2	2	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	31	31	15	6	4	5	5	3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	351	Reboxetine	Male	01.DEPRESSED MOOD	4	4	1	0	1	0	0	0
				02.GUILT	1	1	0	0	2	0	0	0
				03.SUICIDE	3	3	0	0	2	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	2	1	0	0
				05.INSOMNIA MIDDLE	2	2	2	0	2	1	0	0
				06.INSOMNIA LATE	2	2	2	0	2	0	0	0
				07.WORK AND ACTIVITIES	4	4	1	0	3	1	0	0
				08.RETARDATION	3	3	1	0	1	1	1	0
				09.AGITATION	2	2	1	0	1	0	0	0
				10.ANXIETY PSYCHIC	3	3	1	0	2	0	0	0
				11.ANXIETY SOMATIC	2	2	0	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	1	0	1	0	0	0
				13.SOMATIC GENERAL	2	2	0	0	2	1	0	0
				14.GENITAL SYMPTOMS	2	2	2	1	2	1	1	0
				15.HYPOCHONDRIASIS	1	1	0	0	2	1	0	0
				16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	0	2	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	2	1	0	0
				20.PARANOID	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	0	0	2	1	0	0
				22.Total score	41	41	17	1	32	9	2	0
	352	Imipramine	Male	01.DEPRESSED MOOD	3	3	1	0	1			
				02.GUILT	2	2	2	2	2			
				03.SUICIDE	2	2	1	0	0			
				04.INSOMNIA EARLY	0	0	0	0	0			
				05.INSOMNIA MIDDLE	1	1	1	0	0			
				06.INSOMNIA LATE	1	1	1	1	0			
				07.WORK AND ACTIVITIES	2	2	2	2	1			
				08.RETARDATION	1	1	2	1	0			
				09.AGITATION	0	0	0	1	1			
				10.ANXIETY PSYCHIC	3	3	1	0	3			
				11.ANXIETY SOMATIC	2	2	3	1	0			
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1			
				13.SOMATIC GENERAL	2	2	2	1	2			
				14.GENITAL SYMPTOMS	2	2	1	1	1			
				15.HYPOCHONDRIASIS	1	1	2	2	2			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	1	1	1	0	0			
				18.DIURNAL VARIATION	2	1	1	1	0			
				19.DEPERSONALIZATION	0	0	1	1	0			
				20.PARANOID	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0			
				22.Total score	26	25	23	15	14			
	364	Imipramine	Female	01.DEPRESSED MOOD	4	4	1	1	2	3		
				02.GUILT	3	3	2	1	2	2		
				03.SUICIDE	3	3	1	1	2	3		
				04.INSOMNIA EARLY	2	2	0	2	0	2		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	364	Imipramine	Female	05.INSOMNIA MIDDLE	2	2	1	2	0	2		
				06.INSOMNIA LATE	2	2	1	1	1	2		
				07.WORK AND ACTIVITIES	4	4	3	0	0	1		
				08.RETARDATION	2	2	1	0	0	0		
				09.AGITATION	0	0	1	1	0	1		
				10.ANXIETY PSYCHIC	3	3	3	2	1	3		
				11.ANXIETY SOMATIC	2	2	1	0	1	1		
				12.SOMATIC GASTROINTESTINAL	2	2	2	0	1	1		
				13.SOMATIC GENERAL	2	2	1	0	1	2		
				14.GENITAL SYMPTOMS	2	2	2	2	2	2		
				15.HYPOCHONDRIASIS	0	0	0	0	0	2		
				16.LOSS OF WEIGHT	2	2	2	0	0	0		
				17.INSIGHT	1	1	1	0	0	0		
				18.DIURNAL VARIATION	2	2	2	1	0	0		
				19.DEPERSONALIZATION	0	0	0	0	1	3		
				20.PARANOID	2	2	1	1	1	2		
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	2		
				22.Total score	41	41	27	16	16	34		
	366	Reboxetine	Male	01.DEPRESSED MOOD	3	3	0	0	0	0	0	0
				02.GUILT	3	3	0	0	0	0	0	0
				03.SUICIDE	4	4	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	1	0	1
				06.INSOMNIA LATE	2	2	1	0	0	0	0	0
				07.WORK AND ACTIVITIES	2	2	0	0	1	1	1	0
				08.RETARDATION	1	1	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	0	0	0	1	2	0
				11.ANXIETY SOMATIC	2	2	0	0	0	1	1	0
				12.SOMATIC GASTROINTESTINAL	2	2	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	0	0	0	1	2	0
				14.GENITAL SYMPTOMS	2	2	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	2	2	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0
				22.Total score	36	36	1	0	1	5	6	1
	367	Imipramine	Male	01.DEPRESSED MOOD	4	4	4	3	2	2	2	3
				02.GUILT	1	1	1	2	1	1	1	1
				03.SUICIDE	2	2	2	2	2	1	1	2
				04.INSOMNIA EARLY	0	0	0	1	2	1	1	2
				05.INSOMNIA MIDDLE	1	1	1	0	2	1	1	1
				06.INSOMNIA LATE	1	1	1	1	2	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	3	3	4
				08.RETARDATION	2	2	2	1	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	367	Imipramine	Male	09.AGITATION	1	1	0	3	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	2	3	3	0	1	3
				11.ANXIETY SOMATIC	2	2	1	1	3	2	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	1	0	1	1
				13.SOMATIC GENERAL	2	2	2	1	2	2	1	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	2	2	2	1	1	0	0
				16.LOSS OF WEIGHT	0	0	0	2	0	0	1	2
				17.INSIGHT	1	1	1	0	1	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	1	0	0
				19.DEPERSONALIZATION	2	2	1	3	2	0	0	0
				20.PARANOID	0	0	0	0	3	1	1	1
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	1	1
				22.Total score	32	32	28	32	35	19	19	27
	368	Reboxetine	Female	01.DEPRESSED MOOD	4	4	1	0	0	0	1	1
				02.GUILT	0	0	0	0	0	0	0	0
				03.SUICIDE	3	3	2	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	1	1	1	0	0
				05.INSOMNIA MIDDLE	2	2	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	1	1	1	1	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	0	0	1	0	2	2	0	1
				11.ANXIETY SOMATIC	3	3	2	0	1	0	2	2
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	0	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	1	1	2	2	0	0
				15.HYPOCHONDRIASIS	3	3	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	2	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	0	1	0
				19.DEPERSONALIZATION	2	2	1	0	0	0	0	0
				20.PARANOID	0	0	1	0	1	1	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	1	1	1	0
				22.Total score	31	31	15	4	11	10	9	8
	369	Reboxetine	Female	01.DEPRESSED MOOD	3	3	0	0	0	0	0	0
				02.GUILT	3	3	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	0	0	0	0	0	0
				06.INSOMNIA LATE	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	1	0	0	0	0	0
				08.RETARDATION	1	1	1	0	0	0	0	0
				09.AGITATION	1	1	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	0	0	0	0	0	0
				11.ANXIETY SOMATIC	2	2	0	1	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	369	Reboxetine	Female	13.SOMATIC GENERAL	2	2	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	2	0	0	2	0
				17.INSIGHT	1	1	1	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	3	3	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	0	0	0	0	0	0
				22.Total score	34	34	4	3	0	0	2	0
	370	Imipramine	Female	01.DEPRESSED MOOD	2	2	1	1	2	0	1	1
				02.GUILT	0	0	0	0	0	0	1	1
				03.SUICIDE	3	3	1	0	2	0	1	0
				04.INSOMNIA EARLY	2	2	2	1	2	1	0	0
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	0	1
				06.INSOMNIA LATE	1	1	1	1	1	1	0	1
				07.WORK AND ACTIVITIES	2	2	2	1	1	0	0	0
				08.RETARDATION	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	2	1	2	1	1	2
				10.ANXIETY PSYCHIC	1	1	1	1	2	1	2	2
				11.ANXIETY SOMATIC	0	0	0	1	0	0	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	0	0	0	0
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	0	0	0	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	1	1	1	1	0	0
				17.INSIGHT	0	0	1	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	0	1	1	0	0
				19.DEPERSONALIZATION	2	2	2	0	0	0	0	0
				20.PARANOID	1	1	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	1	1
				22.Total score	22	22	20	10	15	7	10	11
	371	Reboxetine	Female	01.DEPRESSED MOOD	2	2	0	0	1	0	0	0
				02.GUILT	1	1	0	0	0	0	0	0
				03.SUICIDE	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	2	0	0	1
				06.INSOMNIA LATE	2	2	1	2	2	1	2	2
				07.WORK AND ACTIVITIES	2	2	0	0	0	0	0	0
				08.RETARDATION	1	1	0	0	1	0	0	0
				09.AGITATION	1	1	1	2	2	1	1	0
				10.ANXIETY PSYCHIC	3	3	1	1	1	0	0	0
				11.ANXIETY SOMATIC	2	2	1	2	0	1	2	1
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	0	2	1	1	2	0
				14.GENITAL SYMPTOMS	2	2	1	1	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	0	0	1	0	0	0
				16.LOSS OF WEIGHT	0	0	2	0	2	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	371	Reboxetine	Female	17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	2	1	0	1	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	2	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	0	1	0	0	0	0
				22.Total score	30	30	12	18	15	4	8	4
	372	Imipramine	Male	01.DEPRESSED MOOD	4	4	3	3	3	3	1	2
				02.GUILT	3	3	3	1	2	2	3	2
				03.SUICIDE	4	4	2	3	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	1	0	2	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	2
				06.INSOMNIA LATE	2	2	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	3	4	3	3	3	2
				08.RETARDATION	3	3	3	2	2	2	1	1
				09.AGITATION	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	0	0	0	0	0	0	0	3
				11.ANXIETY SOMATIC	0	0	0	0	1	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	0	2	1
				13.SOMATIC GENERAL	0	0	0	2	1	2	2	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	1	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	2	2	0
				17.INSIGHT	2	2	1	2	2	2	2	1
				18.DIURNAL VARIATION	0	0	0	0	0	2	2	1
				19.DEPERSONALIZATION	0	0	0	0	2	0	0	0
				20.PARANOID	2	2	2	1	2	2	2	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	1	0	0	0
				22.Total score	34	34	25	25	27	28	27	23
	373	Imipramine	Female	01.DEPRESSED MOOD	3	3						
				02.GUILT	3	3						
				03.SUICIDE	2	2						
				04.INSOMNIA EARLY	1	1						
				05.INSOMNIA MIDDLE	2	2						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	4	4						
				08.RETARDATION	1	1						
				09.AGITATION	1	1						
				10.ANXIETY PSYCHIC	2	2						
				11.ANXIETY SOMATIC	1	1						
				12.SOMATIC GASTROINTESTINAL	1	1						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	2	2						
				15.HYPOCHONDRIASIS	0	1						
				16.LOSS OF WEIGHT	2	2						
				17.INSIGHT	1	1						
				18.DIURNAL VARIATION	1	1						
				19.DEPERSONALIZATION	1	1						
				20.PARANOID	1	1						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	373	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	1	1						
				22.Total score	34	35						
	374	Reboxetine	Female	01.DEPRESSED MOOD	3	3	1	1	0	0	0	0
				02.GUILT	2	2	1	0	0	0	0	0
				03.SUICIDE	2	2	1	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	1	2	1	1	0	0
				05.INSOMNIA MIDDLE	0	0	2	1	2	0	1	1
				06.INSOMNIA LATE	0	0	2	1	2	1	0	0
				07.WORK AND ACTIVITIES	4	4	1	0	0	1	0	0
				08.RETARDATION	2	2	1	1	1	1	0	0
				09.AGITATION	2	2	2	1	1	1	0	0
				10.ANXIETY PSYCHIC	3	3	2	1	1	0	0	2
				11.ANXIETY SOMATIC	3	3	2	1	1	0	0	1
				12.SOMATIC GASTROINTESTINAL	2	2	0	0	1	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	0	0	0	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	1	0
				15.HYPOCHONDRIASIS	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	2	0
				17.INSIGHT	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	1	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	0	0	0	0	0	0
				20.PARANOID	2	2	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	0	0	0	0	0	1
				22.Total score	36	36	20	12	12	7	4	6
	375	Reboxetine	Female	01.DEPRESSED MOOD	4	4	0	0	0			
				02.GUILT	0	0	0	0	0			
				03.SUICIDE	3	3	0	0	0			
				04.INSOMNIA EARLY	2	2	1	0	0			
				05.INSOMNIA MIDDLE	2	2	0	0	0			
				06.INSOMNIA LATE	1	1	0	0	0			
				07.WORK AND ACTIVITIES	4	4	2	0	0			
				08.RETARDATION	3	3	1	0	0			
				09.AGITATION	0	0	0	0	0			
				10.ANXIETY PSYCHIC	1	1	2	0	0			
				11.ANXIETY SOMATIC	1	2	0	0	0			
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0			
				13.SOMATIC GENERAL	0	1	1	0	0			
				14.GENITAL SYMPTOMS	0	0	0	0	0			
				15.HYPOCHONDRIASIS	1	1	0	0	0			
				16.LOSS OF WEIGHT	0	0	0	0	0			
				17.INSIGHT	2	2	0	0	0			
				18.DIURNAL VARIATION	0	0	0	0	0			
				19.DEPERSONALIZATION	2	2	0	0	0			
				20.PARANOID	2	2	1	0	0			
				21.OBSESSIONAL/COMPULSIVE	2	2	1	0	0			
				22.Total score	30	32	9	0	0			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	376	Imipramine	Female	01.DEPRESSED MOOD	4	4	4					
				02.GUILT	3	3	3					
				03.SUICIDE	2	2	2					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	1	1	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	3	3	3					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	3	3	3					
				11.ANXIETY SOMATIC	1	1	3					
				12.SOMATIC GASTROINTESTINAL	2	2	2					
				13.SOMATIC GENERAL	2	2	2					
				14.GENITAL SYMPTOMS	0	0	0					
				15.HYPOCHONDRIASIS	2	2	3					
				16.LOSS OF WEIGHT	1	1	2					
				17.INSIGHT	1	1	0					
				18.DIURNAL VARIATION	1	1	0					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	0	0	1					
				21.OBSESSIONAL/COMPULSIVE	0	0	0					
				22.Total score	36	36	40					
	377	Reboxetine	Female	01.DEPRESSED MOOD	4	4	2	1	0	0	1	0
				02.GUILT	3	3	2	1	1	1	0	0
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	0	0	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	0	0
				06.INSOMNIA LATE	2	2	1	1	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	1	1	1	1	0	0
				08.RETARDATION	3	3	1	1	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	0	0
				10.ANXIETY PSYCHIC	4	4	2	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	2	2	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	1	1	2	1	0	0	0	0
				13.SOMATIC GENERAL	2	2	1	1	1	1	0	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	1	1	1	1	1
				16.LOSS OF WEIGHT	2	2	2	0	0	0	0	0
				17.INSIGHT	2	2	1	1	0	0	0	0
				18.DIURNAL VARIATION	2	2	0	0	0	0	0	0
				19.DEPERSONALIZATION	3	3	2	0	0	0	0	0
				20.PARANOID	2	2	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	0	0	0	0	0	1
				22.Total score	50	50	25	15	8	8	5	4
	378	Reboxetine	Female	01.DEPRESSED MOOD	4	4	1	0	0	0	0	0
				02.GUILT	3	3	2	1	0	0	0	0
				03.SUICIDE	3	3	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	378	Reboxetine	Female	05.INSOMNIA MIDDLE	2	2	2	2	0	2	0	0
				06.INSOMNIA LATE	1	1	1	2	1	1	1	1
				07.WORK AND ACTIVITIES	4	4	2	1	0	0	0	1
				08.RETARDATION	2	2	1	1	1	0	0	0
				09.AGITATION	0	0	1	1	1	0	1	0
				10.ANXIETY PSYCHIC	0	0	1	1	0	0	0	0
				11.ANXIETY SOMATIC	1	1	0	0	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	1	1	0	0	0	1	0	0
				13.SOMATIC GENERAL	1	1	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	0	0	0
				15.HYPOCHONDRIASIS	0	0	1	0	0	0	1	0
				16.LOSS OF WEIGHT	0	0	0	0	0	1	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	1	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	1	0	0	0	0	0
				20.PARANOID	1	1	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	1	1	0	0	0
				22.Total score	28	28	19	13	5	5	3	2
	379	Imipramine	Female	01.DEPRESSED MOOD	4	4						
				02.GUILT	1	1						
				03.SUICIDE	3	3						
				04.INSOMNIA EARLY	2	2						
				05.INSOMNIA MIDDLE	2	2						
				06.INSOMNIA LATE	2	2						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	2	2						
				09.AGITATION	0	0						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	1	1						
				12.SOMATIC GASTROINTESTINAL	2	2						
				13.SOMATIC GENERAL	2	2						
				14.GENITAL SYMPTOMS	0	0						
				15.HYPOCHONDRIASIS	2	2						
				16.LOSS OF WEIGHT	2	2						
				17.INSIGHT	0	0						
				18.DIURNAL VARIATION	1	1						
				19.DEPERSONALIZATION	3	3						
				20.PARANOID	1	1						
				21.OBSESSIONAL/COMPULSIVE	0	0						
				22.Total score	36	36						
	380	Imipramine	Female	01.DEPRESSED MOOD	4	4	3	2	3	0	1	1
				02.GUILT	3	3	3	3	3	0	0	0
				03.SUICIDE	3	3	2	2	3	0	0	0
				04.INSOMNIA EARLY	2	2	0	0	2	0	0	1
				05.INSOMNIA MIDDLE	2	2	0	1	2	0	0	0
				06.INSOMNIA LATE	1	0	2	2	2	0	0	0
				07.WORK AND ACTIVITIES	4	4	2	2	4	1	1	1
				08.RETARDATION	2	2	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	380	Imipramine	Female	09.AGITATION	3	3	1	1	0	0	0	0
				10.ANXIETY PSYCHIC	4	4	2	3	3	0	1	1
				11.ANXIETY SOMATIC	1	1	1	1	3	0	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	2	0	1	0
				13.SOMATIC GENERAL	1	1	1	2	2	1	0	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	0	0	1
				15.HYPOCHONDRIASIS	2	2	1	2	1	0	2	2
				16.LOSS OF WEIGHT	2	2	2	0	2	0	0	0
				17.INSIGHT	0	0	1	0	1	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	2	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	2	1	1	0	0	0
				22.Total score	40	39	29	26	39	3	8	10
	381	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	3	1	1	1	2
				02.GUILT	1	1	1	0	0	0	0	2
				03.SUICIDE	4	4	2	2	0	1	0	1
				04.INSOMNIA EARLY	2	2	2	0	1	0	1	0
				05.INSOMNIA MIDDLE	1	1	1	2	2	2	1	1
				06.INSOMNIA LATE	2	2	2	2	1	2	1	1
				07.WORK AND ACTIVITIES	4	4	2	3	3	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1
				09.AGITATION	1	1	1	0	1	1	2	1
				10.ANXIETY PSYCHIC	2	2	3	2	2	2	1	2
				11.ANXIETY SOMATIC	1	1	2	2	0	1	0	0
				12.SOMATIC GASTROINTESTINAL	0	0	2	2	2	1	1	1
				13.SOMATIC GENERAL	2	2	2	0	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	0	2	1	0	2
				15.HYPOCHONDRIASIS	0	0	2	0	2	2	2	2
				16.LOSS OF WEIGHT	0	0	2	0	1	0	0	0
				17.INSIGHT	1	1	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	1	2	0	1	1
				20.PARANOID	0	0	1	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	1	1	1	1	1	1
				22.Total score	32	32	34	21	23	19	16	21
	382	Imipramine	Male	01.DEPRESSED MOOD	3	3						
				02.GUILT	1	1						
				03.SUICIDE	1	1						
				04.INSOMNIA EARLY	1	1						
				05.INSOMNIA MIDDLE	1	1						
				06.INSOMNIA LATE	1	1						
				07.WORK AND ACTIVITIES	3	3						
				08.RETARDATION	2	2						
				09.AGITATION	3	3						
				10.ANXIETY PSYCHIC	3	3						
				11.ANXIETY SOMATIC	0	0						
				12.SOMATIC GASTROINTESTINAL	1	1						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	382	Imipramine	Male	13.SOMATIC GENERAL	1	1						
				14.GENITAL SYMPTOMS	2	2						
				15.HYPOCHONDRIASIS	1	1						
				16.LOSS OF WEIGHT	0	0						
				17.INSIGHT	1	1						
				18.DIURNAL VARIATION	0	0						
				19.DEPERSONALIZATION	2	2						
				20.PARANOID	1	1						
				21.OBSESSIONAL/COMPULSIVE	2	2						
				22.Total score	30	30						
	383	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	1	1	0	0
				02.GUILT	3	3	2	2	1	0	0	0
				03.SUICIDE	3	3	3	1	1	0	0	0
				04.INSOMNIA EARLY	2	2	2	0	0	2	1	0
				05.INSOMNIA MIDDLE	2	2	2	2	0	1	1	1
				06.INSOMNIA LATE	2	2	2	2	0	2	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	0	0
				08.RETARDATION	1	1	1	2	1	0	0	0
				09.AGITATION	2	2	0	3	2	1	0	2
				10.ANXIETY PSYCHIC	3	3	2	3	1	1	1	2
				11.ANXIETY SOMATIC	2	2	2	3	1	0	0	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	2	1	1	1	0
				13.SOMATIC GENERAL	2	2	2	2	1	2	1	0
				14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	0
				15.HYPOCHONDRIASIS	2	2	1	1	1	0	0	1
				16.LOSS OF WEIGHT	2	2	1	2	0	0	0	0
				17.INSIGHT	1	1	0	1	0	0	0	0
				18.DIURNAL VARIATION	1	1	0	0	0	0	0	0
				19.DEPERSONALIZATION	3	3	2	0	0	1	0	0
				20.PARANOID	2	2	2	0	1	1	1	0
				21.OBSESSIONAL/COMPULSIVE	2	2	1	1	0	1	0	0
				22.Total score	43	43	33	34	15	17	8	9
	384	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3					
				02.GUILT	3	3	3					
				03.SUICIDE	4	4	2					
				04.INSOMNIA EARLY	2	2	2					
				05.INSOMNIA MIDDLE	2	2	2					
				06.INSOMNIA LATE	2	2	2					
				07.WORK AND ACTIVITIES	4	4	4					
				08.RETARDATION	3	3	3					
				09.AGITATION	2	2	2					
				10.ANXIETY PSYCHIC	4	4	4					
				11.ANXIETY SOMATIC	0	0	1					
				12.SOMATIC GASTROINTESTINAL	2	2	2					
				13.SOMATIC GENERAL	0	0	0					
				14.GENITAL SYMPTOMS	2	2	2					
				15.HYPOCHONDRIASIS	1	1	1					
				16.LOSS OF WEIGHT	2	2	1					

890

9550085

PHARMACIA CNS R&D

REMOXETINE - PROTOCOL 2012A/017
Listing No.: 12.8

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	304	Reboxetine	Female	17.INSIGHT	2	2	1					
				18.DIURNAL VARIATION	1	1	1					
				19.DEPERSONALIZATION	0	0	0					
				20.PARANOID	1	1	0					
				21.OBSESSIONAL/COMPULSIVE	1	1	1					
				22.Total score	42	42	37					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day
1	1	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.50	0.50	0.50	1.33	1.00	0.33
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	1.00	0.17	0.17	1.00	0.67	0.50
				4.DIURNAL VARIATION	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.75	2.25	1.75	2.75	2.00	1.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	1.33	0.67	0.33	0.00	0.33
				7.Total score	7.67	7.67	9.92	5.25	4.08	6.42	4.67	3.67
	2	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	1.00	0.83	0.17	0.50	0.00
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.67	0.67	0.50	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.75	2.75	1.75	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.00	1.00	0.33	0.33	0.00
				7.Total score	9.92	9.92	7.42	7.42	5.08	1.00	1.33	0.25
	3	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.17	0.67	0.33	0.33	0.17
				2.WEIGHT	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.67	0.50	0.33	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.25	2.25	2.00	1.50	1.00	0.25	0.25
				6.SLEEP DISTURBANCE	1.33	2.00	1.00	0.33	0.00	0.67	0.33	0.00
				7.Total score	8.17	9.25	7.92	5.83	3.50	3.00	1.92	1.42
	4	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.33	1.00	1.00	0.67	0.33	0.00
				2.WEIGHT	0.00	0.00	2.00	2.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	1.00	0.83	0.50	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	2.50	2.75	2.75	2.50	2.25	1.50	1.50	0.25
				6.SLEEP DISTURBANCE	1.00	1.67	1.67	1.33	1.00	0.67	0.33	0.33
				7.Total score	6.00	6.92	9.75	8.67	7.75	3.83	3.17	0.58
	5	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.17	0.50	0.33	0.67	0.83	0.67
				2.WEIGHT	1.00	1.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.17	0.33	0.33	0.33	0.50	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.75	2.75	1.00	2.25	1.75	2.25	1.50	1.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	1.00	0.67	1.00
				7.Total score	8.75	9.08	3.83	7.08	5.42	6.42	4.00	4.17
	6	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.33	1.33	1.00	0.67	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.00	0.67	0.83	0.50	0.33	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	2.00	2.00	1.75	1.50	1.50	1.00	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.00	1.00	1.33	1.00	1.00
				7.Total score	8.83	8.33	7.42	6.33	5.67	5.50	4.50	4.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
1	7	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	0.83	0.83	1.00	1.17	1.17
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	2.00	2.00	2.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.33	0.83	0.50	0.33	0.67	0.83
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	2.00	2.00
				5.RETARDATION	2.50	2.50	2.00	2.25	1.75	1.75	2.25	2.00
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	1.00	1.00	1.00	0.67	1.00
				7.Total score	8.50	8.50	10.67	6.92	5.08	7.08	8.75	9.00
	8	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	1.00	1.33					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	2.25	2.50	2.50					
				6.SLEEP DISTURBANCE	1.67	1.67	1.33					
				7.Total score	6.92	7.33	7.17					
	9	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.17	0.83	0.50	0.50	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00
				5.RETARDATION	2.75	2.75	2.75	1.75	1.50	1.50	0.75	0.25
				6.SLEEP DISTURBANCE	0.33	0.00	0.33	0.00	0.00	0.00	0.00	0.00
				7.Total score	7.08	6.92	6.75	4.75	4.00	3.00	0.75	0.25
	10	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.00	1.33	1.00	1.33	1.00	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.33	0.17	0.00	0.33	0.50	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.25	1.50	1.25	1.50	1.50	1.25
				6.SLEEP DISTURBANCE	1.67	2.00	0.67	0.33	2.00	2.00	1.33	1.33
				7.Total score	7.17	7.33	5.08	4.17	5.58	6.33	5.00	4.08
	11	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.33	1.50	1.33	1.17	2.00		
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.83	1.33	0.67	1.67		
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00		
				5.RETARDATION	3.00	3.00	2.75	2.25	2.25	2.25		
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	2.00	1.33	2.00		
				7.Total score	11.17	10.67	10.75	8.92	7.42	9.92		
	12	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	0.50	1.67			
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.33	0.00	1.00	0.33	1.00			
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00			
				5.RETARDATION	2.25	2.50	2.00	2.00	2.75			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day
1	12	Reboxetine	Male	6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.33	1.33			
				7.Total score	8.75	8.67	6.83	5.17	7.75			
2	33	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	0.33	0.33	0.83	0.50	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	0.75	0.25	0.00	0.75	0.50	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	0.33	0.67	0.67	0.67	0.67	0.00
				7.Total score	6.25	6.25	2.25	1.42	1.17	3.42	1.83	0.75
	34	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	0.83	1.67	0.50	0.83	1.17	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.00	0.17	0.00	0.00	0.17	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	0.50	1.50	0.50	1.00	1.50	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.00	0.00	0.00	1.00	0.33
				7.Total score	5.33	5.33	2.00	3.33	1.00	1.83	3.83	2.67
	35	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.67	0.67	0.50	0.33	0.17	0.17	0.17	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.17	0.17	0.17	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	0.75	0.00	0.50	0.00	0.25	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.00	0.33	0.33	0.33	0.67
				7.Total score	9.17	9.17	2.42	0.50	1.17	0.67	1.08	1.50
	36	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.17	0.00			
				2.WEIGHT	2.00	2.00	0.00	0.00	2.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.00	0.33			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.50	2.50	2.75	0.50	0.25			
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.33	0.67			
				7.Total score	7.33	7.33	5.25	1.00	3.25			
	37	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	1.17	1.17	1.33	1.50	1.33	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.00	0.33	0.50	0.33	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00
				5.RETARDATION	2.50	2.25	1.50	1.50	1.25	1.75	1.50	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	2.00	2.00	1.33	1.00	1.00
				7.Total score	8.17	7.92	4.67	5.00	6.08	4.92	4.00	3.83
	38	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.17	1.00	1.17	1.17	1.17	1.17	1.17
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.33	0.00	0.33	0.50	0.83	0.67	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.4

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	38	Imipramine	Female	4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00
				5.RETARDATION	2.00	2.25	2.00	2.25	2.75	2.50	2.50	2.00
				6.SLEEP DISTURBANCE	1.00	2.00	1.33	1.33	1.67	1.67	1.67	1.33
				7.Total score	5.67	6.75	6.33	6.08	7.08	7.17	7.00	7.00
	39	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.83	0.83	0.83	0.83	0.83
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.50	0.33	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00
				5.RETARDATION	2.00	2.00	1.50	1.50	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.33	0.33	0.33	0.33
				7.Total score	8.17	8.17	5.17	4.83	3.67	3.50	3.33	4.33
	40	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	1.00	0.33	0.83	0.67	1.00	0.67	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.00	0.67	0.67	0.50	1.00	0.67	0.33
				4.DIURNAL VARIATION	0.00	0.00	1.00	0.00	0.00	2.00	0.00	0.00
				5.RETARDATION	2.00	2.25	1.00	1.50	1.25	1.75	1.75	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	1.33	1.00	1.33	1.00	0.67
				7.Total score	6.33	6.58	3.67	4.33	3.42	7.08	4.08	1.75
	41	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	1.50	2.00	1.83	1.33	1.50	1.83	1.83
				2.WEIGHT	2.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	1.00	1.00	1.00	0.50	0.50	0.67	0.83
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	1.00	1.00	2.00	2.00
				5.RETARDATION	2.75	2.25	2.00	2.25	1.50	1.75	1.50	1.75
				6.SLEEP DISTURBANCE	2.00	1.33	2.00	1.00	1.00	1.33	1.00	2.00
				7.Total score	8.92	7.08	7.00	7.08	5.33	6.08	7.00	8.42
	42	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.50	1.17	1.33	1.00	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	0.33	0.67	0.83	0.83	0.67
				4.DIURNAL VARIATION	0.00	1.00	1.00	2.00	2.00	2.00	1.00	2.00
				5.RETARDATION	3.00	2.75	2.50	3.00	3.00	2.00	2.00	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.67	1.33	0.67	0.67	0.67
				7.Total score	6.17	6.92	7.17	9.17	8.33	6.50	5.00	4.83
	43	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.83	0.17	0.17	0.17	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	1.17	0.67	0.33	0.00	0.33	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	1.75	0.50	0.00	0.00	0.00	0.00	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.67	0.67	0.67	0.33	0.00	0.00
				7.Total score	6.92	6.58	4.67	1.17	0.83	0.83	0.33	0.75
	44	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.33	1.83					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	44	Imipramine	Male	2.WEIGHT	0.00	1.00	0.00					
				3.COGNITIVE DISTURBANCE	1.83	1.33	1.67					
				4.DIURNAL VARIATION	0.00	2.00	2.00					
				5.RETARDATION	3.00	2.25	3.00					
				6.SLEEP DISTURBANCE	1.67	1.00	0.00					
				7.Total score	8.00	8.92	8.50					
	45	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	0.83					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.50	0.33	0.50					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	3.00	3.00	1.00					
				6.SLEEP DISTURBANCE	1.00	0.67	1.00					
				7.Total score	5.67	5.33	3.33					
	46	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.50	0.50	0.83	0.83	0.83	0.33	0.33	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.67	0.17	0.50	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	0.00	2.00
				5.RETARDATION	2.50	1.75	1.50	1.75	1.25	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	1.67	1.33	1.67	1.33	1.00	0.67	1.00	0.67
				7.Total score	9.50	8.25	6.67	6.08	5.58	3.42	2.75	4.00
	47	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.33	1.33	1.17	0.17	0.17	0.17	0.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	0.83	1.00	0.33	0.33	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	1.75	2.00	1.50	0.50	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	0.67	1.33	1.33	1.33	0.67	0.33	0.67
				7.Total score	7.08	5.58	5.67	4.33	2.33	1.25	0.50	0.83
	48	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.50	0.17	0.17	0.17	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.33	0.17	0.17	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.50	2.00	1.25	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.33	0.33	0.67	0.33	0.33	0.00	0.00
				7.Total score	8.75	8.17	4.50	3.75	2.67	1.67	1.33	1.67
	49	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	0.83	0.67	0.33	0.50	0.00	0.33	0.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.50	0.50	0.33	0.33	0.33	0.17	0.17
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	1.50	1.00	1.00	0.25	1.25	0.75
				6.SLEEP DISTURBANCE	1.67	1.33	1.00	0.67	0.33	1.67	0.67	0.67
				7.Total score	7.92	7.67	4.67	3.33	2.17	2.25	2.42	1.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
2	50	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.50	0.83	1.33	1.67	1.50	1.00	1.00	
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	1.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	0.50	0.83	1.17	0.83	0.33	0.17	
				4.DIURNAL VARIATION	2.00	1.00	0.00	1.00	1.00	1.00	1.00	
				5.RETARDATION	2.75	2.50	2.25	1.75	1.75	1.50	1.50	
				6.SLEEP DISTURBANCE	2.00	1.33	1.67	1.67	1.33	1.33	1.00	
				7.Total score	9.08	7.17	6.08	7.25	6.42	6.17	4.67	
	51	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	0.67	0.67	1.50				
				2.WEIGHT	1.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.67	1.83				
				4.DIURNAL VARIATION	1.00	2.00	1.00	2.00				
				5.RETARDATION	2.75	2.00	2.00	3.00				
				6.SLEEP DISTURBANCE	1.33	1.67	2.00	2.00				
				7.Total score	7.92	7.33	6.33	10.33				
	52	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.50	0.83	0.17	0.33	0.17	0.00	0.00	0.00
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.00	0.50	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	1.75	1.25	0.25	0.00	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	1.33	1.00	1.00	0.33	0.33	0.33	0.33	0.00
				7.Total score	10.33	6.58	2.92	0.92	0.50	0.58	0.58	0.00
3	65	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.50	0.83	0.33	0.83	0.00	0.17	0.00
				2.WEIGHT	0.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.75	1.75	0.75	0.50	0.75	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	1.67	0.67	0.67	0.33	1.33	1.00	0.67
				7.Total score	8.17	10.75	6.75	2.75	2.67	3.08	2.17	1.67
	66	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	0.67	0.00	0.33	0.50	1.50	
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	1.00	0.00	
				3.COGNITIVE DISTURBANCE	2.17	1.83	0.50	0.17	0.00	0.33	1.83	
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.25	1.50	0.25	0.25	0.25	0.50	3.25	
				6.SLEEP DISTURBANCE	0.67	2.00	0.67	0.33	0.00	0.00	1.00	
				7.Total score	9.42	9.83	2.08	0.75	0.58	2.33	7.58	
	67	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.17	1.83	0.83	1.00	0.67	1.33	1.33	1.17
				2.WEIGHT	1.00	1.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	1.67	1.33	1.50	1.17	1.17	1.00	1.67
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	0.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.00	0.75	0.75	0.75	0.75	1.00	1.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3	67	Reboxetine	Female	6.SLEEP DISTURBANCE	2.00	2.00	1.67	0.67	1.00	0.67	0.67	1.67
				7.Total score	8.25	7.50	5.58	5.92	3.58	4.92	5.00	6.50
	68	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	1.50	1.17	1.67	1.67	1.33	1.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	1.50	1.50	1.33	1.33	1.33	1.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	2.75	3.00	2.75	3.00	3.00	3.00	3.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	2.00	1.00	1.00	0.67	1.00
				7.Total score	10.67	10.42	7.33	7.42	7.00	7.00	6.33	6.83
	69	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.00	0.50	0.17	0.67	0.33
				2.WEIGHT	2.00	2.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	1.67	1.33	1.17	0.00	0.17	1.00	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00
				5.RETARDATION	2.25	2.50	2.75	1.25	0.75	0.25	1.00	0.50
				6.SLEEP DISTURBANCE	1.00	2.00	0.67	1.00	0.67	0.33	0.00	0.00
				7.Total score	9.92	10.67	7.25	6.42	2.92	1.92	2.67	2.33
	70	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.83	1.67	1.50	1.50		
				2.WEIGHT	0.00	0.00	0.00	1.00	0.00	1.00		
				3.COGNITIVE DISTURBANCE	1.17	1.33	1.67	1.50	1.33	1.17		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00		
				5.RETARDATION	2.00	2.00	2.75	1.75	1.75	1.50		
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	2.00	2.00	1.67		
				7.Total score	7.17	7.83	9.25	8.92	6.58	6.83		
	71	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.00	0.67	0.33	0.17	0.00
				2.WEIGHT	2.00	2.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.33	0.33	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	1.75	0.75	0.25	0.75	0.00	0.00	0.25
				6.SLEEP DISTURBANCE	1.33	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	10.17	8.42	1.92	1.42	1.58	0.33	0.17	0.25
	72	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.50	1.17	0.83	1.00	1.00	0.50	0.33
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.17	1.17	1.17	0.67	0.67	0.50	0.33
				4.DIURNAL VARIATION	2.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.25	1.00	1.50	1.25	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	0.67	1.00	1.00	0.67	0.67
				7.Total score	10.50	8.58	5.33	5.17	3.92	4.92	3.92	3.33
	73	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	0.17	0.17	0.17	0.17	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	0.50	1.00	0.17	0.17	0.33	0.00	0.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
3	73	Reboxetine	Female	4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	2.00	1.00	0.00	0.25	0.25	0.50	0.00
				6.SLEEP DISTURBANCE	1.00	0.67	0.67	1.00	0.33	0.67	0.00	0.00
				7.Total score	6.08	5.50	2.83	1.33	1.92	1.42	0.50	0.00
4	97	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.83	0.83	0.50	0.83	0.17	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	1.00	1.00	0.83	0.83	1.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	2.00	1.00
				5.RETARDATION	2.75	2.75	2.75	2.25	2.00	2.00	1.00	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	2.00	1.00	1.33
				7.Total score	9.25	9.25	7.75	6.75	6.17	6.67	5.00	5.42
	100	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.17	0.67	0.17	0.00	0.17
				2.WEIGHT	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.67	1.17	0.83	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	3.00	3.00	3.25	3.00	1.50	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.67	1.67	1.00	1.33
				7.Total score	11.00	10.00	11.42	9.33	6.67	3.50	2.25	2.75
	101	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.50	1.17	1.83			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.50	0.50			
				4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	1.00			
				5.RETARDATION	2.00	2.00	1.75	2.00	2.25			
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.00	1.33			
				7.Total score	6.50	6.50	6.58	6.67	6.92			
6	161	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.67	0.50	0.83	0.50	0.67	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	0.67	0.33	0.00	0.00	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	2.00
				5.RETARDATION	2.25	2.25	0.50	0.50	0.50	0.00	1.50	0.75
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	1.00	1.67	1.33	1.00	1.67
				7.Total score	8.75	8.75	2.17	2.00	3.17	1.83	3.17	5.92
	162	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.00	1.00	0.83	0.17	0.17	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	0.50	0.33	0.50	0.33	0.17	0.00	0.00	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	0.00	2.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.25	0.75	0.25	0.25	0.50
				6.SLEEP DISTURBANCE	1.67	1.00	1.33	1.00	0.33	0.33	1.00	1.00
				7.Total score	10.17	9.33	6.58	5.58	4.08	0.75	3.42	2.83
7	193	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
7	193	Reboxetine	Female	2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	1.33	1.33						
				4.DIURNAL VARIATION	0.00	0.00						
				5.RETARDATION	1.75	1.75						
				6.SLEEP DISTURBANCE	0.67	0.67						
				7.Total score	5.58	5.58						
	194	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.67	0.50						
				2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	1.17	0.83						
				4.DIURNAL VARIATION	1.00	0.00						
				5.RETARDATION	2.25	1.50						
				6.SLEEP DISTURBANCE	0.67	0.67						
				7.Total score	5.75	3.50						
	196	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.17	0.17	0.50	0.33	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.17	0.17	0.17	0.33	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	0.00	1.00	0.00	0.00	1.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.00	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	0.33	0.33	1.33	0.00	0.00	0.67	1.00	0.67
				7.Total score	7.42	7.42	3.83	2.33	1.08	2.25	3.25	2.08
8	225	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.50	0.67				
				2.WEIGHT	2.00	2.00	2.00	0.00				
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.17				
				4.DIURNAL VARIATION	1.00	1.00	2.00	0.00				
				5.RETARDATION	1.50	1.50	1.75	0.25				
				6.SLEEP DISTURBANCE	1.33	1.33	0.33	0.00				
				7.Total score	7.33	7.33	8.25	1.08				
	226	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.33	1.17	1.00	0.83	0.83	0.83	1.00
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.33	0.50	0.67	0.50
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	0.00	1.00	1.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.50	1.75	1.25	1.25	1.50
				6.SLEEP DISTURBANCE	1.67	1.33	1.33	0.67	1.00	1.33	0.67	0.67
				7.Total score	7.75	7.25	5.42	4.33	3.92	4.92	4.42	3.67
	227	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.33	0.83	0.50	0.83	0.67	0.33	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	0.67	0.67	1.17	0.50	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.50	1.75	1.50	1.25	0.75
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.33	1.00	1.00	0.67
				7.Total score	6.67	6.33	4.25	3.67	5.08	4.67	2.75	1.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
8	228	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.83	1.83				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	1.17	1.00	0.83	0.83				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.50	2.50	1.75	1.75				
				6.SLEEP DISTURBANCE	2.00	1.67	1.67	1.67				
				7.Total score	6.83	6.33	6.08	6.08				
	229	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.67	0.33	1.00	0.67	0.50	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	1.33	0.83	0.33	0.33	0.50	0.17	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.25	0.75	1.00	0.50	0.75	0.50
				6.SLEEP DISTURBANCE	0.33	0.67	0.67	0.33	0.67	0.33	0.00	0.00
				7.Total score	6.00	5.83	2.92	1.75	4.17	1.67	1.58	2.83
	230	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.50	0.83	0.17	0.50	0.83	0.33	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.00	0.33	0.17	0.17	0.00	0.17
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	3.00	3.00	2.50	1.50	1.25	0.25	0.25	0.50
				6.SLEEP DISTURBANCE	1.33	1.67	0.33	0.00	0.00	0.33	0.33	0.00
				7.Total score	6.17	6.83	3.00	4.33	3.25	1.08	0.92	1.00
	231	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	0.83					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	1.00	0.17					
				4.DIURNAL VARIATION	2.00	2.00	1.00					
				5.RETARDATION	2.00	1.75	1.00					
				6.SLEEP DISTURBANCE	1.33	1.00	1.00					
				7.Total score	7.17	7.08	4.00					
	232	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.83	1.17	1.17	1.17	1.00	0.83	0.33
				2.WEIGHT	1.00	2.00	0.00	0.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.33	0.33	0.50	0.50	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.50	2.00	1.50	1.50	1.75	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	2.00	1.67	1.00	1.00	1.00
				7.Total score	7.50	9.50	6.67	6.17	8.08	4.42	4.25	3.50
9	197	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83					
				4.DIURNAL VARIATION	2.00	0.00	0.00					
				5.RETARDATION	1.75	2.25	2.25					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	197	Reboxetine	Male	6.SLEEP DISTURBANCE	0.00	0.00	0.00					
				7.Total score	5.92	4.58	4.75					
	198	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.50	1.50	1.50	1.33	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.83	0.83	1.17	0.83	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00
				5.RETARDATION	1.50	0.75	0.75	1.00	0.75	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	1.00	1.33	0.00	0.00	0.00
				7.Total score	5.67	7.42	6.75	6.67	6.25	0.17	0.00	0.00
	199	Imipramine	Male	1.ANXIETY/SOMATIZATION	2.00	1.83	1.83	1.83	1.83	1.67	2.00	1.67
				2.WEIGHT	0.00	0.00	1.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67	0.83	0.83	0.50	0.50	0.67
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	1.50	2.25	1.50
				6.SLEEP DISTURBANCE	1.00	0.33	1.00	1.00	0.67	0.00	0.00	0.33
				7.Total score	6.00	5.00	6.50	5.67	6.33	3.67	4.75	4.17
	200	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.17	2.17	2.00	1.67	1.00	0.67	0.67	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.33	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.75	1.75	1.25	0.75	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.00	0.33	0.33	0.00
				7.Total score	6.67	6.92	6.08	3.75	1.75	1.25	1.25	0.92
	201	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.00	1.50	1.17	1.33	1.00	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.33	0.00	0.00	0.17	0.33	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	2.25	0.75	1.00	1.25	0.50	0.75	0.25
				6.SLEEP DISTURBANCE	0.67	1.00	1.33	0.00	0.00	0.00	0.33	0.00
				7.Total score	4.50	4.92	3.92	2.17	2.58	1.67	2.25	1.08
	202	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.83	1.33	1.33	1.50	0.83	1.17	1.17	1.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	2.00	2.00	1.00
				3.COGNITIVE DISTURBANCE	0.83	0.33	0.83	0.33	0.33	0.83	1.17	1.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	0.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	1.50	0.50	1.75	1.25	1.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.67	0.00	0.00	0.33
				7.Total score	7.92	6.92	6.42	4.67	2.33	5.75	6.58	7.00
	203	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	2.17	1.00					
				2.WEIGHT	0.00	0.00	1.00					
				3.COGNITIVE DISTURBANCE	1.33	0.50	1.67					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	203	Reboxetine	Female	4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	1.50	2.50	2.00					
				6.SLEEP DISTURBANCE	1.67	0.67	1.00					
				7.Total score	6.17	5.83	6.67					
	204	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.33	0.33	0.33	0.00	0.00	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	0.83	0.33	0.17	0.00	0.00	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	2.00	0.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.00	0.25	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	0.33	0.67	0.33	0.00	0.33	0.33	0.33	0.00
				7.Total score	4.58	6.42	1.83	1.58	0.67	0.50	0.33	1.33
	205	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.17	2.50						
				2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	0.83	1.33						
				4.DIURNAL VARIATION	0.00	0.00						
				5.RETARDATION	1.75	1.25						
				6.SLEEP DISTURBANCE	1.67	0.67						
				7.Total score	6.42	5.75						
	206	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	1.67	1.67	1.67	0.67	0.33	0.33	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.00	1.00	1.00	0.67	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	1.00	1.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	1.75	1.50	1.25	0.00	0.50	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	1.33	1.33	0.33	0.33	0.33
				7.Total score	6.17	6.75	6.17	5.25	3.67	1.33	0.83	0.83
	207	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.50					
				4.DIURNAL VARIATION	0.00	1.00	2.00					
				5.RETARDATION	1.50	2.00	1.50					
				6.SLEEP DISTURBANCE	1.33	1.67	0.33					
				7.Total score	4.83	6.67	6.00					
	208	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	2.17	1.50	1.00	1.33	0.67	1.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.33	0.50	0.17	0.33	0.00	0.00	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.00
				5.RETARDATION	1.75	1.50	0.75	1.25	0.50	1.75	1.75	1.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	0.00	0.00	0.00	0.67	0.00
				7.Total score	5.25	5.33	4.75	2.92	1.83	3.08	3.08	5.00
	209	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.83	0.83					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	209	Imipramine	Male	2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	1.25	1.25	1.25					
				6.SLEEP DISTURBANCE	0.67	0.67	0.00					
				7.Total score	4.42	4.58	2.75					
	210	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.17	1.33	1.17	1.33	1.17	1.17	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	0.33	0.83	1.17	0.83	0.50	0.17	0.33	0.00
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.25	1.75	1.25	1.00	0.00	0.50	0.00	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	0.00	1.00	0.33	0.67	1.00	0.00
				7.Total score	6.75	6.92	4.58	5.17	3.00	3.50	2.17	2.17
	211	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.17	2.00	1.83	1.17			
				2.WEIGHT	1.00	0.00	1.00	1.00	0.00			
				3.COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	0.83			
				4.DIURNAL VARIATION	1.00	2.00	1.00	2.00	0.00			
				5.RETARDATION	2.25	1.25	1.50	1.75	2.00			
				6.SLEEP DISTURBANCE	1.67	1.33	1.67	0.67	2.00			
				7.Total score	9.58	7.75	9.17	9.25	6.00			
	212	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.33	1.33	0.83	0.83	0.83	0.67	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	0.83	1.00	1.00	0.83	0.50	0.50	0.17
				4.DIURNAL VARIATION	0.00	1.00	2.00	0.00	2.00	0.00	0.00	0.00
				5.RETARDATION	1.50	2.00	1.25	1.25	1.00	0.50	0.50	0.00
				6.SLEEP DISTURBANCE	1.33	1.00	0.67	0.33	0.67	0.00	0.00	0.00
				7.Total score	5.33	6.17	6.25	3.42	5.33	1.83	2.67	0.33
	237	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.33	2.17	2.00	2.33				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	0.17	0.17	0.67				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.25	2.75	2.25	3.00				
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	2.00				
				7.Total score	7.25	7.08	6.08	8.00				
	238	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.33	0.33	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.33	0.33	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.00	0.75	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	0.33	0.33	0.33
				7.Total score	7.50	7.50	7.50	7.50	5.67	3.75	0.50	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	239	Imipramine	Male	1.ANXIETY/SOMATIZATION	2.17	2.17	2.00	1.67	0.83	1.00	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.33	0.33	0.33	0.33	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.00	1.75	0.75	1.00	0.75	0.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	1.33	1.00	1.00
				7.Total score	6.25	6.25	5.50	5.08	2.92	4.67	3.92	3.33
	240	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.17	2.33	1.67	1.50				
				2.WEIGHT	2.00	1.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.67	1.00	0.67	0.67				
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00				
				5.RETARDATION	2.00	2.00	2.00	2.00				
				6.SLEEP DISTURBANCE	0.67	0.67	1.33	1.33				
				7.Total score	8.50	8.00	6.67	6.50				
	241	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.00	1.00	1.00	1.00	0.67
				2.WEIGHT	1.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.67	0.67	0.67	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	2.25	2.25	1.50	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				7.Total score	6.42	7.08	8.08	5.00	4.58	4.58	4.58	4.08
	242	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.00	1.00	1.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.50	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.50	1.50	1.25	1.00	0.75	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.67	0.33	0.00	0.00
				7.Total score	5.58	5.33	4.83	4.42	4.17	2.25	0.00	0.00
	243	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.17	1.17	0.83	0.83	0.83	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.50	0.50	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	1.25	1.00	1.00	0.75	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	0.33	0.33	0.33	0.33
				7.Total score	7.83	7.83	4.75	3.92	2.50	2.67	2.42	1.08
	244	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	1.33	1.00	1.00	1.17	1.00	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.17	0.17	0.83	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00
				5.RETARDATION	3.25	3.25	1.50	1.50	1.50	1.75	0.75	1.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	244	Reboxetine	Male	6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.67	0.33	0.00
				7.Total score	6.08	6.08	3.33	3.00	3.00	4.42	3.58	2.33
	257	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	1.33	1.17	1.00	0.17	1.17	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	1.00	1.17	0.00	0.00	0.00	0.17	0.00	0.00
				4.DIURNAL VARIATION	2.00	1.00	1.00	1.00	0.00	2.00	2.00	0.00
				5.RETARDATION	2.75	2.25	1.50	0.50	0.00	0.75	0.25	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	0.00	0.33	0.00	0.00	0.00	0.00
				7.Total score	9.42	7.42	3.67	4.83	0.17	4.08	3.08	2.83
	258	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.17	2.17	1.83	1.33	1.67			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.83	1.50	1.00	1.17	1.33			
				4.DIURNAL VARIATION	0.00	0.00	1.00	0.00	1.00			
				5.RETARDATION	1.25	1.50	2.25	2.25	2.50			
				6.SLEEP DISTURBANCE	2.00	1.00	0.67	1.33	2.00			
				7.Total score	6.25	6.17	6.75	6.08	8.50			
	259	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	2.00	2.00	0.67	0.83	1.00	0.67
				2.WEIGHT	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.17	0.33	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.75	0.75	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.33	1.67	1.33	1.33
				7.Total score	8.08	8.08	8.08	8.08	3.92	3.33	3.33	2.83
	260	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.33	1.50	1.67	1.50	1.00			
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.83	1.50	1.33	1.50	1.83			
				4.DIURNAL VARIATION	0.00	2.00	2.00	0.00	0.00			
				5.RETARDATION	2.00	1.00	0.25	1.75	1.75			
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.33			
				7.Total score	6.83	6.67	6.92	5.42	4.92			
	261	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.83	1.50					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.50	1.17	1.67					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	2.00	2.25	2.50					
				6.SLEEP DISTURBANCE	1.67	1.67	1.33					
				7.Total score	7.67	7.92	8.00					
	262	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.67	0.50	0.00	0.50	0.33	0.33
				2.WEIGHT	2.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.83	0.50	0.50	0.33	0.17	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	262	Reboxetine	Male	4.DIURNAL VARIATION	2.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.25	1.00	0.50	1.50	0.50	1.00	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	1.33	1.00	0.33	0.33	0.33
				7.Total score	10.33	6.75	6.83	2.83	3.00	1.67	1.83	1.50
	263	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.00	1.17				
				2.WEIGHT	2.00	2.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.83	0.17	0.67	0.33				
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00				
				5.RETARDATION	2.00	1.25	2.25	1.50				
				6.SLEEP DISTURBANCE	1.67	0.33	1.33	0.33				
				7.Total score	8.67	5.75	5.25	3.33				
	264	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.17	1.50	1.67	0.83	0.67	0.50	0.50	1.50
				2.WEIGHT	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.33	0.67	0.17	0.00	0.00	0.33	0.17
				4.DIURNAL VARIATION	0.00	0.00	1.00	0.00	2.00	2.00	2.00	0.00
				5.RETARDATION	2.75	2.50	2.00	0.75	0.00	0.00	0.00	1.00
				6.SLEEP DISTURBANCE	0.33	0.00	0.67	0.33	1.33	1.33	1.00	0.67
				7.Total score	6.42	5.33	6.00	2.08	5.00	4.83	4.83	3.33
	265	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.67	1.67	0.67	0.67	1.17	0.83	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	1.17	1.00	1.00	0.50	1.17	0.67	0.33
				4.DIURNAL VARIATION	0.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	2.00	1.50	0.25	1.75	1.50	1.00
				6.SLEEP DISTURBANCE	1.33	1.00	1.00	1.33	0.33	1.67	1.67	0.33
				7.Total score	5.75	8.58	7.67	6.50	2.75	7.75	4.67	2.00
	266	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.17	0.67	0.67	1.00	0.17
				2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.00	0.25	0.50	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	2.00	2.00	1.00	1.67	1.67
				7.Total score	6.50	6.83	6.83	6.58	4.33	2.33	3.33	2.25
	267	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.83	0.67	0.50	0.50	0.83
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	0.50	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	0.33	0.33	0.33	0.33
				7.Total score	8.50	8.50	6.83	3.67	2.00	0.83	0.83	1.17
	268	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	2.17	0.83	1.00	0.67	0.67	1.50	1.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	268	Imipramine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.17	0.50	0.83	1.00	0.67	0.50	0.67
				4.DIURNAL VARIATION	1.00	0.00	1.00	1.00	1.00	1.00	2.00	2.00
				5.RETARDATION	3.25	3.00	1.25	0.75	1.25	1.00	2.50	1.50
				6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.33	0.00	0.33	0.33	0.00
				7.Total score	7.08	6.33	3.58	3.92	3.92	3.67	6.83	5.33
	269	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	0.83	0.33	0.50	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.33	0.33	0.17	0.17	0.17	0.00	0.50
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	1.00	0.00	1.00
				5.RETARDATION	2.50	2.00	0.75	0.50	0.25	0.25	0.75	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	5.50	5.83	2.92	1.50	0.75	1.92	0.92	1.92
	270	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.17	1.33					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.17	0.50	0.50					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	3.00	3.00	1.50					
				6.SLEEP DISTURBANCE	0.33	0.33	0.00					
				7.Total score	5.17	5.00	3.33					
	271	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.83	1.83	1.17	1.17	1.17		
				2.WEIGHT	0.00	2.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.17	1.00	0.67	0.67	0.67	0.67		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	2.75	2.50	2.50	1.75	1.75	1.75		
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.33	1.67		
				7.Total score	7.75	10.00	7.67	6.25	5.92	6.25		
	272	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	2.33	1.83	0.67	0.67	0.50	0.67	0.67
				2.WEIGHT	0.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	2.00	1.33	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	1.00	2.00	2.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.75	3.00	2.50	1.50	1.50	1.50	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.33	0.33	0.33	0.00
				7.Total score	6.42	11.67	11.00	6.33	3.67	3.50	2.42	1.83
	273	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	2.00	2.00	1.67	1.50	1.67		
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	1.83	2.00	1.33	1.17	1.17		
				4.DIURNAL VARIATION	1.00	2.00	2.00	0.00	2.00	2.00		
				5.RETARDATION	3.25	3.00	2.50	2.50	2.25	2.25		
				6.SLEEP DISTURBANCE	1.00	1.67	1.67	1.67	1.33	2.00		
				7.Total score	8.58	10.50	10.17	7.17	8.25	9.08		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9	274	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.67	0.83					
				2.WEIGHT	0.00	2.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	0.67	1.33					
				4.DIURNAL VARIATION	1.00	0.00	0.00					
				5.RETARDATION	2.75	2.25	1.00					
				6.SLEEP DISTURBANCE	1.00	1.33	1.33					
				7.Total score	6.75	7.92	4.50					
	274/A	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.50	0.67	0.83	1.00	1.00
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.33	0.33	0.50	0.67	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.50	2.25	1.50	0.75	0.75	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	0.67	0.67	0.67	0.33	0.00	0.00
				7.Total score	7.58	6.58	5.17	4.75	3.33	2.58	2.08	2.58
	275	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.83	1.67	1.67	0.33	0.33	0.17	0.17
				2.WEIGHT	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	1.33	1.00	0.67	0.67	0.67	0.50	0.33
				4.DIURNAL VARIATION	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.75	2.50	2.50	2.00	2.00	1.25	1.00
				6.SLEEP DISTURBANCE	1.00	1.33	0.67	0.67	0.33	0.33	0.33	0.33
				7.Total score	5.17	11.25	5.83	5.50	3.33	3.33	2.25	1.83
	276	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00					
				2.WEIGHT	0.00	0.00	1.00					
				3.COGNITIVE DISTURBANCE	0.33	0.50	0.83					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	2.50	2.25	2.00					
				6.SLEEP DISTURBANCE	1.00	1.00	1.00					
				7.Total score	5.17	5.08	5.83					
	276/A	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.83	1.67	1.33	0.83	0.83	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.50	0.50	1.50	1.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	0.75	0.50	1.75	2.25	1.50	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	0.00	0.33	1.33	0.67	0.67	0.33	0.33	0.00
				7.Total score	4.75	5.00	5.42	6.08	4.67	1.58	1.58	0.75
9/A	233	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.50	0.67	0.83	0.67	1.00
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.83	0.67	0.33	0.17	0.17	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	2.50	2.00	1.75	1.75	2.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day
9/A	233	Imipramine	Male	6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.00	1.00	1.00	1.00
				7.Total score	8.67	8.33	6.50	6.33	4.00	3.75	3.58	4.33
	234	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.67	1.17	0.83	1.00	0.83	0.67
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.67	0.50	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	2.25	1.50	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.67	1.33	1.00	1.00	0.33	0.33	0.67
				7.Total score	8.17	6.50	6.17	4.92	3.67	3.17	2.75	2.92
	235	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	0.67	0.67	0.83	1.50	
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.00	0.17	0.17	1.00	
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.75	2.50	1.75	1.50	1.00	1.50	1.75	
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.00	1.00	1.00	2.00	
				7.Total score	9.08	9.83	4.42	3.17	2.83	3.50	6.25	
	236	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.33	1.00	1.00	1.17	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.50	1.33	0.67	0.67	0.67	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	2.50	2.25	2.25	2.00	1.00	1.25	1.00	0.75
				6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.33	0.33	0.67	0.33	0.00
				7.Total score	7.00	6.75	6.58	6.00	4.00	4.58	4.17	1.25
	277	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.50	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.00	1.17	1.33					
				4.DIURNAL VARIATION	1.00	0.00	0.00					
				5.RETARDATION	2.50	2.50	2.75					
				6.SLEEP DISTURBANCE	0.67	0.67	2.00					
				7.Total score	6.83	5.83	7.75					
	278	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.50	1.00	0.67	1.50			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.00	0.17	0.83			
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00			
				5.RETARDATION	2.25	2.25	1.50	0.75	1.75			
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	1.00			
				7.Total score	6.92	7.25	5.17	1.92	5.08			
	279	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.67				
				2.WEIGHT	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	0.83	0.83	1.17	1.17				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	279	Imipramine	Male	4.DIURNAL VARIATION	0.00	0.00	0.00	0.00				
				5.RETARDATION	2.00	2.00	1.75	2.00				
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	1.67				
				7.Total score	5.00	5.00	5.58	6.50				
	280	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.67					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	2.25	2.00	2.00					
				6.SLEEP DISTURBANCE	1.33	1.33	1.67					
				7.Total score	6.25	6.00	6.50					
	281	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	0.67	0.50	0.17	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.33	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	0.75	0.50	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	5.58	6.08	3.50	1.42	0.83	0.67	0.67	0.42
	282	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.17	1.00	0.83	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	1.00	2.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.17	0.83	0.50	0.17	0.17	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	2.50	2.25	2.00	1.50	1.25	1.25	1.00
				6.SLEEP DISTURBANCE	1.33	2.00	2.00	1.00	1.00	0.67	1.00	1.00
				7.Total score	8.17	8.17	7.42	5.67	5.67	4.92	3.42	2.83
	283	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	0.50	0.50	0.50	0.33	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	1.00	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.25	2.00	0.75	0.75	0.75	0.75	0.50
				6.SLEEP DISTURBANCE	0.67	1.00	1.00	0.33	0.67	0.33	0.33	0.67
				7.Total score	5.17	5.58	5.17	1.75	2.08	1.75	1.58	1.33
	284	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.33	1.50			
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	1.00			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.50	2.50	2.50	2.00	2.25			
				6.SLEEP DISTURBANCE	2.00	1.33	1.33	1.33	1.33			
				7.Total score	9.00	8.17	6.17	5.33	6.08			
	301	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.50	1.00	0.50	0.33	0.00	0.00	0.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	301	Imipramine	Female	2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.17	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.50	0.75	0.50	0.50	0.25	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.33	0.33	0.33	0.67
				7.Total score	6.83	5.33	4.33	1.75	1.17	0.83	0.58	0.92
	302	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.67	1.50			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.00	1.17	1.33	1.17	1.50			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.25	2.25	2.25	2.25	2.00			
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	0.67	1.00			
				7.Total score	5.42	5.58	6.08	5.75	6.00			
	303	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	0.83	1.67	1.67			
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.00	1.17	0.50	1.00	1.33			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.75	2.50	2.00	2.00	2.00			
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	1.00			
				7.Total score	8.08	6.17	4.00	5.33	6.00			
	304	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.00	0.83	1.00	0.83	0.50	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.17	0.67	0.67	0.67	0.33	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.00	1.25	1.25	0.50	0.50
				6.SLEEP DISTURBANCE	0.67	1.00	0.33	0.33	0.67	0.67	0.33	0.33
				7.Total score	5.42	6.08	3.75	2.83	3.58	3.08	1.50	1.17
	305	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.83	0.83	0.67	0.50	0.67	0.17	0.17
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	0.67	0.33	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	0.75	0.75	0.75	0.25	0.50
				6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33
				7.Total score	8.92	7.08	5.33	2.08	1.75	1.92	0.92	1.17
	306	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.50	0.67	0.00	0.17	0.00	0.17
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.17	0.00	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	1.00	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.00	0.00	0.00	0.00
				7.Total score	7.67	7.83	8.00	2.17	0.75	1.08	0.92	1.08

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
9/A	307	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	2.25	2.25	2.25					
				6.SLEEP DISTURBANCE	0.33	0.33	0.33					
				7.Total score	5.08	5.08	5.08					
	308	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	1.33	0.67	1.50		
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.67	0.33	1.00		
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	2.75	2.75	2.50	2.25	1.75	2.50		
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	0.67	2.00		
				7.Total score	9.42	9.42	6.50	6.25	3.42	7.00		
10	289	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.17					
				2.WEIGHT	2.00	2.00	2.00					
				3.COGNITIVE DISTURBANCE	0.00	0.17	0.50					
				4.DIURNAL VARIATION	2.00	1.00	1.00					
				5.RETARDATION	1.75	1.75	1.75					
				6.SLEEP DISTURBANCE	1.33	1.67	2.00					
				7.Total score	8.25	7.58	8.42					
	290	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.67	0.83	0.50	0.17	0.00	0.00	0.00	0.00
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.17	0.67	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	1.50	1.00	0.75	0.75	0.50	0.25
				6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.00	0.00	0.00	0.00	0.00
				7.Total score	5.58	5.50	3.50	1.83	1.25	1.08	0.83	0.58
	291	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.50	0.50	0.50	0.17	0.17	0.00	0.00	0.00
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.33	0.33	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.00	0.50	0.50	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.67	6.67	4.67	1.00	1.00	0.42	0.42	0.00
	292	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.50	0.50	0.50	0.33	0.33	0.17	0.17	0.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.33	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	0.50	0.50	0.50	0.50	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	292	Reboxetine	Female	6.SLEEP DISTURBANCE	1.67	1.67	1.67	0.67	0.67	0.33	0.33	0.00
				7.Total score	8.08	8.08	6.75	2.83	2.83	1.17	1.17	0.83
	293	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.25	1.50	1.25	1.25	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	6.75	6.75	7.00	6.75	6.75	6.75	5.33	5.33
	294	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.67	1.67	1.50			
				2.WEIGHT	1.00	2.00	2.00	2.00	2.00			
				3.COGNITIVE DISTURBANCE	1.00	0.67	1.00	0.83	0.67			
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00			
				5.RETARDATION	2.00	1.25	2.25	2.00	1.75			
				6.SLEEP DISTURBANCE	2.00	1.00	2.00	2.00	2.00			
				7.Total score	9.17	8.08	10.92	10.50	9.92			
	295	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.50	0.50	0.33	0.33	0.33	0.33
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.17	1.00	0.50	0.50	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00
				5.RETARDATION	1.75	1.50	1.50	1.25	1.00	0.75	0.75	0.50
				6.SLEEP DISTURBANCE	1.33	1.67	2.00	2.00	1.67	1.00	0.67	0.67
				7.Total score	6.75	6.17	6.00	6.25	5.50	4.42	4.08	3.83
	296	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.50	0.33	0.33	0.33	0.33
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.00	1.00	1.00	1.00
				7.Total score	6.08	6.08	6.08	4.17	2.83	2.58	2.58	2.58
	297	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	0.50	0.50	0.50	0.17	0.00	0.00	0.00
				2.WEIGHT	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	0.67	0.50	0.50	0.33	0.00
				4.DIURNAL VARIATION	1.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.25	1.00	0.75	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.33	1.33	1.00	1.00	1.00
				7.Total score	8.58	8.08	7.58	6.00	5.25	2.50	2.08	1.25
	298	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33	1.00	0.67	0.50
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.17	1.17	0.83	0.67	0.50	0.33	0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
10	298	Reboxetine	Female	4.DIURNAL VARIATION	1.00	2.00	2.00	2.00	2.00	2.00	1.00	0.00
				5.RETARDATION	2.00	2.25	2.25	2.00	1.50	1.25	1.00	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.33	1.33	1.00
				7.Total score	7.83	9.42	9.42	8.83	8.17	7.08	4.33	2.42
	299	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	0.83	0.83	0.83	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	1.00	0.50	0.50	0.50	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	2.50	2.50	2.50	2.50	2.25	2.25	2.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	7.50	7.50	7.33	7.83	6.58	6.58	6.33	3.17
	300	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.67	0.50	0.33	0.33	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.50	0.33	0.00	0.00	1.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.75	1.00	0.75	0.75	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	6.25	6.25	6.08	5.92	4.83	4.08	4.08	5.42
11	321	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.33	1.00	0.83	1.17	0.67	0.50	0.50
				2.WEIGHT	1.00	1.00	2.00	2.00	0.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.50	0.17	0.17	0.33	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.50	0.25	0.75	0.25	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	1.67	1.00	1.33	1.00	1.33	1.33	1.67
				7.Total score	7.75	7.33	5.75	5.08	3.58	4.58	2.00	2.17
	322	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.17	0.50	0.17	0.33	0.33	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	2.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	1.00	2.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	0.75	0.50	0.50	0.00	0.25	0.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.67	0.33	0.67	1.33
				7.Total score	6.42	5.58	5.08	2.50	3.67	0.67	1.08	2.58
	323	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	1.00	0.67	0.50	0.50	0.67
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.50	0.67	0.50	0.33	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.00	0.75	1.00	0.25	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.67	0.33	0.33	0.33
				7.Total score	6.58	7.17	5.25	4.67	2.08	2.42	2.25	3.25
	324	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.00	1.17	0.83	0.83	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	324	Imipramine	Male	2.WEIGHT	1.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	0.83	0.50	0.00	0.33	0.33	0.33	0.00
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	2.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.75	1.00	0.50	1.25	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.00	0.00	0.00	0.33	0.33
				7.Total score	6.17	6.08	4.83	2.50	4.75	2.67	3.00	2.17
	325	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.17	1.00	0.67	0.50	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.17	0.00	0.17	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.00	1.00	0.50	0.50	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.33	6.00	6.33	2.33	2.00	0.17	0.00	1.00
	326	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.33	0.67	0.33	0.00	0.33
				2.WEIGHT	2.00	1.00	1.00	1.00	1.00	1.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.33	0.17	0.17	0.17	0.00	0.50
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.50	1.25	0.50	0.25	0.25	0.00	0.25
				6.SLEEP DISTURBANCE	0.33	0.67	0.67	0.00	0.67	0.33	0.33	0.00
				7.Total score	6.08	5.17	3.92	2.00	2.75	2.08	0.33	3.08
	327	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.00	1.00	0.50	1.00	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.83	1.00	1.17	0.67	0.33	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.50	1.50	1.00	1.00	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.67	1.00	0.67	0.67	0.67
				7.Total score	7.33	7.17	7.00	6.83	4.67	3.00	3.50	2.58
	328	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.33	0.67	1.17	0.50	0.50		
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.17	0.33	0.00	0.00		
				4.DIURNAL VARIATION	2.00	2.00	1.00	2.00	1.00	1.00		
				5.RETARDATION	1.00	1.00	0.75	0.75	0.25	0.25		
				6.SLEEP DISTURBANCE	1.67	1.33	0.67	0.00	0.33	0.00		
				7.Total score	6.83	6.67	5.25	4.25	2.08	1.75		
	329	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.17	0.67	0.50	0.33	0.50	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	0.83	0.67	0.50	0.50	0.00	0.00	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	1.00	0.00	1.00	1.00
				5.RETARDATION	1.50	1.25	1.00	0.75	0.50	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.00	1.33	1.00	0.33	0.33	0.33	0.00	0.33
				7.Total score	6.83	6.42	4.83	2.25	2.83	1.17	2.00	2.67

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
11	330	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.33					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.33					
				4.DIURNAL VARIATION	2.00	2.00	1.00					
				5.RETARDATION	2.00	1.75	1.50					
				6.SLEEP DISTURBANCE	0.33	0.33	1.67					
				7.Total score	6.33	5.92	5.83					
	331	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.50	1.17	1.33	0.33	0.33
				2.WEIGHT	1.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.33	0.17	0.17	0.33	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	1.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.25	0.75	0.75	2.00	0.50	0.25
				6.SLEEP DISTURBANCE	1.67	1.33	1.33	1.33	0.33	0.67	0.67	0.33
				7.Total score	8.83	7.67	7.08	3.75	2.42	5.33	1.67	0.92
	332	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	0.00	0.00	0.17	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.17	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.25	0.50	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	0.67	0.67	0.00	0.33	0.00	0.00	0.00	0.00
				7.Total score	5.33	5.25	0.67	0.33	0.17	0.00	0.00	0.00
	333	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.00	0.33	0.50	0.00
				2.WEIGHT	0.00	0.00	2.00	2.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	1.00	0.83	0.67	0.33	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
				5.RETARDATION	1.50	1.50	1.50	1.25	1.50	0.75	0.50	0.00
				6.SLEEP DISTURBANCE	1.00	1.67	1.00	1.00	0.33	0.00	0.00	0.00
				7.Total score	6.67	7.33	8.50	8.42	7.67	3.75	3.33	1.00
12	337	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.67	0.17	0.00	0.17	0.17	0.83	0.00
				2.WEIGHT	1.00	1.00	2.00	2.00	0.00	0.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.17	0.00	0.00	0.50	0.33	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	1.50	2.25	0.75	0.50	1.25	1.00	1.25	0.50
				6.SLEEP DISTURBANCE	0.67	2.00	1.33	0.33	1.00	0.67	0.67	0.33
				7.Total score	7.17	9.58	5.42	3.83	3.42	3.33	6.08	0.83
	338	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	1.83	1.67	1.33	1.17	0.67	1.50	1.00
				2.WEIGHT	2.00	0.00	2.00	0.00	0.00	0.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	1.17	0.83	0.50	0.17	0.00	0.17	0.00	0.17
				4.DIURNAL VARIATION	2.00	1.00	1.00	2.00	1.00	1.00	0.00	1.00
				5.RETARDATION	2.00	2.50	2.00	1.00	1.00	1.25	1.50	1.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
12	338	Reboxetine	Female	6.SLEEP DISTURBANCE	0.67	1.67	1.33	1.00	1.00	0.67	0.67	2.00
				7.Total score	9.83	7.83	8.50	5.50	4.17	3.75	3.67	7.17
	339	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.17	0.50	0.67	0.50	0.83	0.50	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.17	0.33	1.00	0.33	0.50	0.17	0.00
				4.DIURNAL VARIATION	2.00	1.00	2.00	1.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.50	2.50	1.75	1.00	1.00	1.00	1.00	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	1.00	0.67	0.33	0.33
				7.Total score	10.17	8.83	5.25	4.00	4.83	5.00	3.00	2.00
	340	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.67	1.33	0.83	0.00	0.33	0.00	0.67	0.50
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	2.00	0.00	1.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.17	0.17	0.00	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	2.00	2.00	0.25	0.25	0.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	2.00	1.00	0.67	0.67	0.33	1.00	1.00
				7.Total score	9.08	10.33	7.50	2.08	2.42	3.33	3.83	4.83
	341	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.17	1.50	1.17	1.33	0.50	1.67	
				2.WEIGHT	2.00	2.00	0.00	0.00	2.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.50	0.83	1.17	0.83	1.00	0.17	0.67	
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	0.00	1.00	2.00	
				5.RETARDATION	2.75	2.00	1.75	1.75	2.50	0.75	2.25	
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.00	1.33	0.67	1.33	
				7.Total score	11.92	10.00	8.42	6.75	8.17	3.08	7.92	
13	353	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.50	0.50	0.83	0.83	0.50	0.33	0.33	
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	2.00	0.00	
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.33	0.17	0.00	0.17	0.00	
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	1.00	1.00	1.00	
				5.RETARDATION	1.75	1.75	1.25	0.50	0.50	0.25	1.25	
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	1.00	1.00	0.00	0.67	
				7.Total score	7.42	7.42	6.08	2.50	3.00	3.75	3.25	
	354	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.00	0.50	0.50	0.33	0.50
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.33	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	2.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	0.50	0.50	0.25	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	0.33	0.33	0.00	0.00	0.33	0.00	0.00	0.33
				7.Total score	7.08	7.08	4.33	2.83	1.08	0.75	0.58	0.83
	355	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83					
				2.WEIGHT	2.00	2.00	0.00					
				3.COGNITIVE DISTURBANCE	1.50	1.17	0.33					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	355	Reboxetine	Female	4.DIURNAL VARIATION	1.00	1.00	0.00					
				5.RETARDATION	0.50	0.75	0.25					
				6.SLEEP DISTURBANCE	1.00	1.00	0.67					
				7.Total score	7.33	7.25	2.08					
	356	Imipramine	Male	1.ANXIETY/SOMATIZATION	2.33	2.33	2.17	1.50	1.17	1.00	1.33	1.50
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.50	0.50	0.67	0.50	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	1.25	0.50	0.50	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.00	0.67	0.67	0.67	1.00
				7.Total score	7.58	7.58	6.08	3.50	2.83	3.83	3.00	3.33
	357	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.67						
				2.WEIGHT	2.00	2.00						
				3.COGNITIVE DISTURBANCE	0.83	0.83						
				4.DIURNAL VARIATION	2.00	2.00						
				5.RETARDATION	1.25	1.25						
				6.SLEEP DISTURBANCE	0.33	0.33						
				7.Total score	7.92	8.08						
	358	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.00	1.17	0.50	1.00		
				2.WEIGHT	2.00	2.00	0.00	2.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.17	0.17	0.67		
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	1.25	1.25	1.00	0.50	0.25	0.25		
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	1.33	1.00	0.67		
				7.Total score	9.08	9.08	4.67	6.17	2.92	3.58		
	359	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.83	1.00	0.50	0.83	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	1.00	0.00	0.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	0.67	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	1.00	1.00	0.00	1.00
				5.RETARDATION	1.00	1.00	0.75	0.50	0.25	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.33	1.33	1.00
				7.Total score	5.50	5.50	6.25	5.83	3.58	3.58	3.83	2.50
	360	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.83					
				2.WEIGHT	1.00	1.00	2.00					
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.50					
				4.DIURNAL VARIATION	0.00	0.00	0.00					
				5.RETARDATION	1.50	1.50	0.75					
				6.SLEEP DISTURBANCE	1.00	1.00	1.00					
				7.Total score	5.83	5.83	5.08					
	361	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.50	0.33	0.67	0.17	0.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
13	361	Reboxetine	Female	2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	1.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.17	0.00	0.00	0.00	0.00	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	0.75	0.25	0.25	0.00	0.25	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	0.33	0.00	0.00	0.00	0.00
				7.Total score	5.58	5.58	5.75	1.08	0.58	0.67	1.42	0.75
14	457	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.50	1.50	1.67	1.50
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	1.67	1.67	1.50	1.50	1.33	1.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.50	2.50	2.25	2.25	1.50	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.33	1.33	1.67	1.67
				7.Total score	10.50	8.50	8.50	8.50	7.58	7.58	6.17	5.42
	458	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.67	1.50	1.50	1.33	1.33
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.33	1.00	1.00	1.00	1.00	0.83
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	2.00	1.75	1.75	1.75	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.33	1.33	1.33	1.33
				7.Total score	9.58	9.58	9.08	7.33	6.58	7.58	6.42	5.75
	459	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.50	1.17	1.17	1.17	1.17
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33	1.33	1.33	1.00
				7.Total score	7.17	7.17	7.17	5.42	4.83	4.83	4.58	4.25
	460	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.50	1.50	1.50	1.50	1.33
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.33	1.33	1.17	1.17	1.00	1.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.25	2.00	2.00	1.75	1.50	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
				7.Total score	8.50	7.33	7.08	6.83	6.67	6.42	6.00	4.58
	461	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	2.00	2.00	2.00	2.00	2.00	1.83	2.00
				2.WEIGHT	2.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	2.00	1.83	1.83	1.83	1.83	1.67	2.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	2.50	2.50	2.50	2.50	2.50	2.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	9.92	8.50	8.33	9.33	8.33	8.33	8.00	8.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14	462	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	1.83	1.83	1.83	1.83	1.83	1.67	1.67
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	8.50	8.50	7.50	7.50	7.50	7.50	7.33	7.33
	463	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	1.67	1.50	1.33
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.50	1.17	1.00	1.00	1.00	1.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.75	1.75	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	1.33	1.00
				7.Total score	9.17	8.17	7.17	6.58	6.42	6.42	4.83	4.33
	464	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	2.00	2.00	1.83	1.67	1.83	1.67
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.83	1.83	2.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	10.08	10.08	8.25	8.25	8.08	7.75	7.92	7.67
	465	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.67	1.67	1.50	0.83	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	2.00	1.83	1.50	1.00	1.00	0.67	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.50	2.00	1.75	1.50	1.25	1.00	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.33	1.33	1.00	0.33
				7.Total score	8.92	9.33	7.67	6.92	5.50	5.08	3.50	1.58
	466	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.67	1.50	1.33	1.17	1.17	0.67
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	1.83	1.67	1.67	1.17	1.00	1.00	0.67
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.00	1.75	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	1.00	1.00	1.00	0.67
				7.Total score	8.92	8.92	7.33	6.25	4.50	4.17	4.17	3.00
14/1	129	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50						
				2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	0.50	0.33						
				4.DIURNAL VARIATION	2.00	2.00						
				5.RETARDATION	1.75	1.75						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day
14/1	129	Reboxetine	Male	6.SLEEP DISTURBANCE	1.00	1.00						
				7.Total score	6.92	6.58						
	426	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.17	0.33	0.83	0.33	0.17	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	0.50	0.33	0.33	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	1.00	0.00	0.00	0.00
				5.RETARDATION	1.50	2.00	1.75	0.50	0.50	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	2.00	1.33	2.00	0.67	1.00	0.67	0.33	0.33
				7.Total score	6.83	6.33	6.25	1.83	3.67	1.50	1.00	0.75
	429	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	2.17	1.83					
				2.WEIGHT	0.00	0.00	0.00					
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.50					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	1.00	1.25	1.00					
				6.SLEEP DISTURBANCE	2.00	1.67	2.00					
				7.Total score	6.33	6.92	6.33					
	451	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.50	1.33	0.83	1.17	0.83	1.50	1.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	0.17	0.50	0.67	0.50	0.67	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.25	1.00	1.50	1.50	1.75	2.00
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	1.00	0.33	1.00	0.67	0.67
				7.Total score	7.17	7.00	5.75	5.50	5.50	6.00	4.08	4.33
	452	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.33	0.17	0.00	0.17	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.00	0.17	0.17	0.00	0.00	0.33
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	1.00	1.00	0.00
				5.RETARDATION	3.00	3.00	2.00	1.75	1.50	1.00	1.00	1.25
				6.SLEEP DISTURBANCE	0.67	0.67	1.33	1.00	1.00	0.33	0.33	0.00
				7.Total score	6.17	6.17	3.67	3.08	2.67	2.50	2.50	1.58
14/2	136	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	1.33	0.83	0.67	0.83	0.50
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	1.17	0.50	0.83	0.83	0.67	0.50	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	1.75	2.25	2.00	1.25	1.00	0.75	0.50
				6.SLEEP DISTURBANCE	1.00	0.67	0.00	0.00	0.00	0.33	0.00	0.00
				7.Total score	6.08	5.92	3.92	4.17	2.92	2.67	2.08	1.33
	456	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	0.83	0.83	0.83	0.50	0.67	0.50	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.33	0.17	0.17	0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/2	456	Imipramine	Male	4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.00	2.00	1.25	1.00	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.67	0.67	0.00	0.00	0.00
				7.Total score	5.58	5.00	3.67	3.08	2.50	1.83	1.42	1.25
14/3	417	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	0.83	0.83	0.17	0.17	0.33	0.50
				2.WEIGHT	1.00	1.00	0.00	1.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.50	0.50	0.17	0.17	0.33	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.25	1.00	0.50	0.50	1.00	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	0.33	0.00	0.67
				7.Total score	7.17	7.17	3.92	4.67	1.83	2.17	1.67	2.08
	418	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	1.00	1.17	1.00	1.17	0.83	1.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.67	0.67	1.17	0.67	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	1.00	0.75	0.75	1.75	1.75	1.75
				6.SLEEP DISTURBANCE	0.67	0.67	0.00	0.00	0.00	0.00	0.00	0.67
				7.Total score	7.92	7.92	4.00	2.58	2.42	4.08	5.25	4.25
	419	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.67	0.67	0.67	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	0.00	2.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.67	0.33	0.33	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	1.50	1.00	0.75	0.75	0.50
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	1.00	0.33	0.00	0.67	0.00
				7.Total score	6.67	6.67	6.08	6.83	2.33	1.75	2.58	3.33
	420	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.17	2.17	2.17	1.17	2.00			
				2.WEIGHT	3.00	3.00	1.00	0.00	2.00			
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.33	0.50	0.33			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.00	2.00	1.75	1.25	1.25			
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.00	0.33			
				7.Total score	9.50	9.50	6.92	2.92	5.92			
	421	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.33	2.17	1.83	0.83	0.67	0.83	0.83	
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.00	0.83	0.50	0.33	0.33	0.33	0.33	
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	0.00	0.00	0.00	
				5.RETARDATION	1.75	1.75	1.25	0.75	0.75	0.75	0.50	
				6.SLEEP DISTURBANCE	1.33	1.33	0.67	0.00	0.00	0.00	0.00	
				7.Total score	8.42	8.08	5.25	2.92	1.75	1.92	1.67	
	427	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33		1.83	1.67		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/3	427	Imipramine	Female	2.WEIGHT	0.00	0.00	0.00		0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50		0.67	0.67		
				4.DIURNAL VARIATION	0.00	0.00	0.00		0.00	0.00		
				5.RETARDATION	2.00	2.00	1.00		1.00	1.00		
				6.SLEEP DISTURBANCE	1.00	1.00	0.67		0.67	0.67		
				7.Total score	5.17	5.17	3.50		4.17	4.00		
	428	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.33	0.83	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.17	0.67	0.50	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	0.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.75	1.25	1.00	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	0.33	0.33	0.00	0.00	0.00
				7.Total score	6.83	6.83	4.58	4.08	4.83	2.83	2.17	2.17
14/4	131	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	0.83	0.33	0.50	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.25	1.75	1.50	1.25	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	0.33	0.33	0.33
				7.Total score	7.67	7.67	5.67	5.75	4.75	2.33	2.08	1.25
	132	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.00	0.83	0.67	0.67	0.33
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.50	1.00	1.25	1.00	0.75	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.00	1.00	0.67	0.67	0.33
				7.Total score	8.50	6.50	6.50	3.67	3.25	2.50	2.25	1.17
	133	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.17	0.83	0.83	0.50	0.33
				2.WEIGHT	2.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83	0.33	0.50	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50	1.25	1.00	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	1.00	0.67	0.67	0.33
				7.Total score	9.17	7.17	8.17	6.08	3.67	3.25	2.33	1.17
	134	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.17	2.17	2.17	1.50	1.17	0.67	0.83	0.67
				2.WEIGHT	2.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.50	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.50	1.25	0.50	0.50	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.00	1.00	0.67	0.67	0.67
				7.Total score	9.00	7.00	8.00	4.83	3.92	2.00	2.00	1.58

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/4	135	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.00	0.83	0.50	0.33
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.50	0.33	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.75	1.00	1.00	0.50	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	1.00	1.00	0.33	0.33
				7.Total score	8.75	8.75	8.75	6.08	4.33	3.00	1.50	1.08
14/7	422	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.17	1.00	0.67	0.33	0.33
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.33	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	1.75	0.75	0.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.33	1.00	0.67	0.67
				7.Total score	6.83	6.83	5.83	5.33	4.83	3.92	2.08	1.42
	423	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.33	0.33	0.33	0.33	0.50	0.00
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	1.00	1.00	1.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	1.75	1.75	1.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.33	1.00	1.00	0.33
				7.Total score	6.17	6.17	5.83	5.83	5.42	4.08	3.75	0.58
	424	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	0.83	0.67	0.67	0.17
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.17	0.83	0.83	0.50	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.25	1.50	1.75	0.75	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.00	1.00	0.67
				7.Total score	7.08	7.08	6.08	6.08	4.83	4.25	2.92	1.08
	430	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.00	0.50	0.33	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.17	0.83	0.33	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.00	0.50	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	1.00	0.67	0.67	0.00
				7.Total score	6.33	6.33	6.17	5.25	3.33	1.83	0.83	0.00
	431	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.50	2.33	2.33	1.00	0.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.50	1.50	1.50	0.50	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	2.00	2.75	2.75	1.25	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	431	Reboxetine	Male	6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	2.00	2.00	1.00	0.67
				7.Total score	5.92	5.92	5.92	6.67	8.58	8.58	3.75	1.33
	432	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.00	0.83	0.50	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	1.00	0.83	0.50	0.17	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.00	1.75	0.75	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				7.Total score	5.92	5.92	5.58	5.00	4.42	2.75	1.33	0.17
	433	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.50	1.33	0.83	0.33	0.33	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	0.83	0.67	0.33	0.33	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	2.00	0.75	0.75	0.50	0.25
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	0.33	0.00	0.00
				7.Total score	5.92	5.92	5.92	5.17	3.25	1.75	1.17	0.25
	434	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	0.83	0.17	0.33	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	0.67	0.50	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.00	0.50	0.75	0.25	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.67	0.33	0.33	0.00
				7.Total score	5.92	5.92	5.92	3.50	1.83	1.42	0.75	0.00
	439	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.33	1.00	0.83	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.00	0.67	0.50	0.33	0.17
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50	1.00	1.00	0.50
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	0.67	0.33
				7.Total score	5.67	5.67	5.67	5.08	4.17	3.33	2.17	1.00
	440	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	0.17	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.17	0.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.50	1.50	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	0.33	0.00	0.00	0.00
				7.Total score	5.67	5.67	5.67	5.67	0.67	0.00	0.00	0.00
	441	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	0.33	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	0.33	0.00	0.00	0.00

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/7	441	Imipramine	Male	4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	0.50	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	0.33	0.33	0.00	0.00
				7.Total score	5.83	5.83	5.83	5.83	1.50	0.33	0.00	0.00
	442	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.67	0.33	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.33	0.67	0.50	0.33	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	2.25	1.25	1.25	0.25	0.25	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.00	1.00	0.33	0.33	0.00
				7.Total score	6.25	6.25	5.58	3.75	3.42	1.25	0.58	0.25
	449	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	1.00	0.67	0.17	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.33	0.83	0.50	0.17	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.00	0.50	0.25	0.00	0.00
				6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33	0.00	0.00	0.00
				7.Total score	5.08	5.08	4.75	2.83	1.50	0.42	0.00	0.00
	450	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.00	1.00	0.33	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.00	0.67	0.50	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.75	1.50	0.75	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	0.67	0.00	0.00
				7.Total score	5.67	5.67	5.67	4.75	4.17	2.25	0.00	0.00
14/8	130	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.00	0.83	0.67	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.67	0.67	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.50	1.25	1.00	0.75	0.75	0.50	0.25
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.33	0.33	0.33
				7.Total score	5.83	5.83	5.25	4.33	3.92	3.42	2.83	2.42
	425	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.67	1.67	1.67	1.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.25	1.25	1.00	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	1.00	1.00	1.00
				7.Total score	6.08	6.08	6.08	5.50	5.33	5.33	5.33	5.33
	467	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.83	1.83	1.33	1.17	1.67	1.67	1.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/8	467	Reboxetine	Male	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.67	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.00
				7.Total score	6.58	5.75	5.75	5.25	5.08	5.58	5.42	4.75
14/10	53	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.50	0.83	0.50	0.33	0.33
				2.WEIGHT	2.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.75	1.50	1.25	1.25	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.33	1.00	0.67	0.67
				7.Total score	8.42	6.42	7.92	5.00	3.75	2.75	2.00	2.00
	54	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.33	1.33	1.17	1.17	1.17	1.17	0.67
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.83	0.83	0.67	0.50	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	0.00	0.00
				5.RETARDATION	2.25	2.00	2.25	1.75	1.50	1.50	1.50	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.33	1.67	1.67	1.67
				7.Total score	8.42	9.17	8.08	7.42	5.67	5.83	4.67	3.92
	55	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.33	0.83	0.67	0.67
				2.WEIGHT	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.67	0.50	0.83	0.17	0.17	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00
				5.RETARDATION	1.75	1.50	1.50	1.25	1.25	1.00	1.00	0.50
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.67	1.33	1.00	0.67
				7.Total score	9.75	8.33	7.00	5.75	5.42	4.33	2.67	1.83
	56	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	1.00	1.00	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.50	0.33	0.33	0.17	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	2.25	1.75	1.75	1.25	1.25	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.00	1.00	1.33	1.33
				7.Total score	7.58	7.25	6.75	5.92	5.42	4.00	4.08	3.92
	57	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.33	1.17	0.83	1.00	0.83	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.33	0.33	0.33	0.33	0.33	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.00	1.75	1.50	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.33	1.33	1.33	1.33	1.33
				7.Total score	7.92	7.58	6.83	6.25	6.17	5.50	4.33	4.33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	58	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33	0.83	1.00	1.00
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00
				5.RETARDATION	2.00	1.75	1.75	1.50	1.25	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	2.00	1.67	1.33	1.00	1.00	1.00	1.33
				7.Total score	7.67	8.75	7.42	6.50	5.92	4.17	4.08	3.42
	59	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.33	1.17	0.83	0.83	0.83
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.50	0.17	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.75	2.00	1.50	1.00	1.00	0.75	0.50
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.33	1.00	0.67	0.67	0.33
				7.Total score	9.83	7.75	7.67	6.33	4.33	3.67	3.42	2.83
	60	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.83	1.83	1.33	1.00	1.00	0.83	0.83
				2.WEIGHT	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.50	0.33	0.33	0.17	0.17	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.75	1.75	1.75	1.25	0.75	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	1.67	2.00	1.67	1.33	1.00	0.67	0.67
				7.Total score	6.00	9.08	7.08	6.08	4.92	3.92	3.17	3.00
	137	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.50	1.00	1.00	1.00	1.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.50	0.33	0.33	0.50	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	2.00
				5.RETARDATION	2.25	2.00	2.25	2.00	1.75	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	1.00	1.00	1.00	1.00
				7.Total score	8.08	7.83	7.92	7.00	6.08	4.58	4.75	5.58
	138	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.17	1.17	0.83	0.83	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.50	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.00	2.00	1.75	1.75	1.25	1.25	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.33	1.00	1.00	1.00
				7.Total score	7.50	7.67	7.25	6.25	6.08	5.42	3.92	3.75
	139	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.17	1.00	0.67	0.50	0.50	0.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.25	1.75	1.25	1.00	0.50	0.50	0.50

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	139	Reboxetine	Female	6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.67	0.67	0.67	0.67
				7.Total score	7.33	7.75	6.92	5.58	3.33	2.67	2.67	2.67
	140	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.33	1.33	1.17	1.33	1.17
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	0.67	0.33	0.33	0.50	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.25	2.00	2.00	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.33	1.00	1.33	1.33
				7.Total score	9.17	7.17	7.25	6.67	6.00	5.00	5.42	5.08
	435	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.50	1.17	1.17	1.00	1.00	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	1.75	1.50	1.50	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.67	1.33	1.00	1.33	0.67	0.67
				7.Total score	7.50	7.67	7.75	5.83	5.00	4.92	4.25	4.08
	436	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.00	1.17	1.00	1.00	1.00	0.83	0.83
				2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.50	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.00	2.25	1.75	1.00	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.33	1.00	0.67	0.67
				7.Total score	9.25	8.83	8.92	5.92	4.50	3.92	3.42	3.42
	437	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.17	1.33	1.33	1.00	0.83	0.50	0.50
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.33	0.33	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	1.75	1.75	1.50	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.00	0.67	0.33	0.33
				7.Total score	7.17	7.75	7.58	5.83	4.33	3.50	2.83	2.83
	438	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.67	1.33	1.17	1.00	0.83	0.83
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.50	0.50	0.50	0.50	0.50	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.50	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	1.33	1.67	1.67	1.33	1.00	1.00	1.00
				7.Total score	7.25	7.08	6.58	6.00	5.50	4.75	4.58	4.25
	443	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.17	1.33	1.17	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.67	0.50	0.33	0.17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	443	Reboxetine	Female	4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	1.75	1.50	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	2.00	1.67	1.00	0.67	0.67
				7.Total score	8.08	8.25	8.25	7.75	6.00	4.08	3.58	3.42
	444	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33	0.83	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.33	0.33	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	2.00	1.75	1.75	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	1.67	2.00	2.00	2.00	1.00	1.00	1.00
				7.Total score	8.08	8.08	8.25	7.83	7.58	5.92	4.17	4.00
	445	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.67	1.50	1.50	1.17	1.17	1.00
				2.WEIGHT	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.67	0.67	0.50	0.33	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.50	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.33	1.00	1.00
				7.Total score	9.58	9.58	9.25	7.33	6.33	5.50	4.75	4.42
	446	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.17	2.17	1.83	1.33	1.00	1.17	1.17	1.17
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.33	0.33	0.17	0.17
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.25	1.00	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	1.33	1.33	1.00	1.00	1.00
				7.Total score	8.08	8.42	7.58	5.00	4.42	4.25	4.08	4.08
	447	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.33	1.33	1.00	0.83	0.83
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.83	0.83	0.67	0.67	0.50	0.17	0.00
				4.DIURNAL VARIATION	1.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.75	1.25	1.25	1.25	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.33	1.33	1.00	1.00	0.67
				7.Total score	7.08	8.25	7.75	6.58	6.58	5.75	3.75	3.25
	448	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	1.83	2.00	2.00	1.83	1.67	1.83	1.83
				2.WEIGHT	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.50	0.50
				4.DIURNAL VARIATION	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	2.00	1.75	1.75	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.67	1.33	1.33
				7.Total score	11.17	9.00	8.67	8.08	5.92	5.50	4.67	4.67
	453	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.00	1.00	1.00	0.83	0.83

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
14/10	453	Imipramine	Female	2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.17	0.33	0.17	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.25	1.75	1.25	1.00	1.25	1.00	0.50
				6.SLEEP DISTURBANCE	2.00	1.67	1.33	1.00	0.67	1.00	0.67	0.67
				7.Total score	9.17	9.08	6.08	4.58	3.83	4.58	3.67	3.33
	454	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.00	1.00	1.17	0.83	0.67
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.33	0.33	0.33	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
				5.RETARDATION	2.00	1.75	1.50	1.50	1.25	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.67	2.00	1.67	1.67	1.33	1.33	1.00	0.67
				7.Total score	9.83	7.92	7.17	6.50	5.92	4.83	4.00	3.33
	455	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.50	1.33	1.17	1.00	1.00	1.00
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.67	0.50	0.33	0.33	0.33	0.17	0.33
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.00	1.75	1.25	1.00	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.33	1.00	0.67	0.67
				7.Total score	9.92	8.25	8.00	7.08	5.08	4.33	3.58	3.75
15	349	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	0.33	0.17	0.33	0.50	0.17
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	2.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	0.50	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.00	0.75	0.25	0.00	0.25	0.25
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.33	0.67	0.33	0.33	0.33
				7.Total score	9.33	9.33	4.00	1.42	1.08	2.67	1.08	0.75
	351	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	0.50	0.00	1.33	0.33	0.00	0.00
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	0.17	0.00	1.50	0.33	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	2.00	0.00	0.00	0.00
				5.RETARDATION	3.25	3.25	1.25	0.25	1.75	0.75	0.50	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	0.00	2.00	0.67	0.00	0.00
				7.Total score	11.42	11.42	5.92	0.25	8.58	2.08	0.50	0.00
	352	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	0.83	1.33			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50			
				4.DIURNAL VARIATION	2.00	1.00	1.00	1.00	0.00			
				5.RETARDATION	2.00	2.00	1.50	1.00	0.75			
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.33	0.00			
				7.Total score	7.00	6.00	5.50	3.83	2.58			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	364	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	0.33	0.67	1.50		
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.00	0.83	1.17	2.17		
				4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	0.00		
				5.RETARDATION	3.00	3.00	1.75	0.75	1.00	1.50		
				6.SLEEP DISTURBANCE	2.00	2.00	0.67	1.67	0.33	2.00		
				7.Total score	12.17	12.17	8.75	4.58	3.17	7.17		
	366	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	0.00	0.00	0.00	0.50	0.83	0.00
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	1.83	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	0.00	0.00	0.25	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.00	0.00	0.33	0.00	0.33
				7.Total score	9.50	9.50	0.33	0.00	0.25	1.08	1.08	0.33
	367	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	1.33	1.83	0.83	0.67	1.17
				2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	1.00	2.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	1.67	1.33	0.50	0.67	0.83
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	1.00	0.00	0.00
				5.RETARDATION	3.00	3.00	3.00	2.50	2.50	2.00	2.00	2.50
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	2.00	0.67	0.67	1.00
				7.Total score	7.50	7.50	6.83	8.17	7.67	5.00	5.00	7.50
	368	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.67	0.17	0.83	0.67	0.67	0.83
				2.WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.00	0.33	0.33	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	1.00	0.00
				5.RETARDATION	2.50	2.50	0.75	0.50	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	0.33	0.33	0.33	0.33	0.00	0.00
				7.Total score	8.67	8.67	5.42	1.00	2.25	2.08	2.58	1.58
	369	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	0.17	0.17	0.00	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	0.75	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.67	1.67	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	9.00	9.00	0.92	2.17	0.00	0.00	2.00	0.00
	370	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.17	0.17	0.33	0.50	0.33	0.17	0.50	0.33
				2.WEIGHT	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	0.17	0.67	0.17	0.67	0.67
				4.DIURNAL VARIATION	2.00	2.00	2.00	0.00	1.00	1.00	0.00	0.00
				5.RETARDATION	1.50	1.50	1.00	0.50	0.75	0.00	0.75	0.75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	370	Imipramine	Female	6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	1.33	1.00	0.00	0.67
				7.Total score	6.67	6.67	6.83	3.17	5.08	3.33	1.92	2.42
	371	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	0.33	0.83	0.50	0.33	0.67	0.17
				2.WEIGHT	0.00	0.00	2.00	0.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.17	0.83	0.33	0.17	0.17	0.00
				4.DIURNAL VARIATION	2.00	2.00	1.00	2.00	1.00	0.00	1.00	0.00
				5.RETARDATION	1.75	1.75	0.25	0.25	0.50	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.67	0.33	0.67	1.00
				7.Total score	8.25	8.25	5.42	5.58	6.00	0.83	2.50	1.17
	372	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.67	0.67	0.50	0.83	1.00	0.67	1.00	1.00
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	2.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.17	1.00	1.50	1.00	1.17	0.83
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	2.00	2.00	1.00
				5.RETARDATION	3.25	3.25	2.75	2.75	2.50	2.50	1.75	1.75
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	1.00	0.67	1.33	1.00	1.33
				7.Total score	9.42	9.42	5.75	5.58	5.67	9.50	8.92	5.92
	373	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33						
				2.WEIGHT	2.00	2.00						
				3.COGNITIVE DISTURBANCE	1.50	1.50						
				4.DIURNAL VARIATION	1.00	1.00						
				5.RETARDATION	2.50	2.50						
				6.SLEEP DISTURBANCE	1.67	1.67						
				7.Total score	9.83	10.00						
	374	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	0.83	0.50	0.50	0.00	0.00	0.67
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	2.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	2.00	0.67	0.17	0.17	0.17	0.00	0.17
				4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	1.25	1.00	0.75	1.00	0.25	0.00
				6.SLEEP DISTURBANCE	0.00	0.00	1.67	1.33	1.67	0.67	0.33	0.33
				7.Total score	8.58	8.58	5.42	3.00	3.08	1.83	2.58	1.17
	375	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	1.17	0.50	0.00	0.00			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	1.50	1.50	0.33	0.00	0.00			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.75	2.75	0.75	0.00	0.00			
				6.SLEEP DISTURBANCE	1.67	1.67	0.33	0.00	0.00			
				7.Total score	6.75	7.08	1.92	0.00	0.00			
	376	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	2.17					
				2.WEIGHT	1.00	1.00	2.00					
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.33					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	376	Imipramine	Female	4.DIURNAL VARIATION	1.00	1.00	0.00					
				5.RETARDATION	2.75	2.75	2.75					
				6.SLEEP DISTURBANCE	1.67	1.67	2.00					
				7.Total score	9.42	9.42	10.25					
	377	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.50	2.50	1.83	1.17	0.67	0.67	0.50	0.33
				2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.33	2.33	0.83	0.33	0.33	0.33	0.00	0.17
				4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.75	2.75	1.00	0.75	0.25	0.25	0.25	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	1.00	0.33	0.33	0.33	0.33
				7.Total score	13.58	13.58	6.67	3.25	1.58	1.58	1.08	0.83
	378	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.33	0.17	0.00	0.17	0.17	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.50	0.33	0.00	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	3.00	3.00	1.50	1.00	0.50	0.00	0.00	0.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	0.33	1.00	0.33	0.33
				7.Total score	6.50	6.50	5.33	3.33	1.17	2.17	0.67	0.58
	379	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67						
				2.WEIGHT	2.00	2.00						
				3.COGNITIVE DISTURBANCE	1.33	1.33						
				4.DIURNAL VARIATION	1.00	1.00						
				5.RETARDATION	2.25	2.25						
				6.SLEEP DISTURBANCE	2.00	2.00						
				7.Total score	10.25	10.25						
	380	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	1.50	2.00	0.17	0.83	0.83
				2.WEIGHT	2.00	2.00	2.00	0.00	2.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.83	1.83	1.50	1.17	1.17	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	2.00	0.00	0.00	0.00
				5.RETARDATION	3.00	3.00	2.00	1.75	2.50	0.50	0.75	1.00
				6.SLEEP DISTURBANCE	1.67	1.33	0.67	1.00	2.00	0.00	0.00	0.33
				7.Total score	11.00	10.67	8.33	5.42	11.67	0.67	1.58	2.17
	381	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.83	1.00	1.17	1.17	0.83	1.00
				2.WEIGHT	0.00	0.00	2.00	0.00	1.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.67	1.67	1.33	0.67	0.67	0.50	0.67	1.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.50	2.50	1.75	1.75	1.75	1.25	1.00	1.75
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33	1.33	1.00	0.67
				7.Total score	7.83	7.83	9.58	4.75	5.92	4.25	3.50	4.42
	382	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42
15	382	Imipramine	Male	2.WEIGHT	0.00	0.00						
				3.COGNITIVE DISTURBANCE	1.67	1.67						
				4.DIURNAL VARIATION	0.00	0.00						
				5.RETARDATION	2.50	2.50						
				6.SLEEP DISTURBANCE	1.00	1.00						
				7.Total score	6.33	6.33						
	383	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.33	2.00	0.83	0.67	0.50	0.83
				2.WEIGHT	2.00	2.00	1.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.50	2.50	1.67	1.17	0.83	0.67	0.17	0.33
				4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.25	1.25	1.00	0.25	0.00
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.33	0.00	1.67	1.00	0.67
				7.Total score	11.33	11.33	8.00	8.75	2.92	4.00	1.92	1.83
	384	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50					
				2.WEIGHT	2.00	2.00	1.00					
				3.COGNITIVE DISTURBANCE	1.83	1.83	1.33					
				4.DIURNAL VARIATION	1.00	1.00	1.00					
				5.RETARDATION	3.25	3.25	3.00					
				6.SLEEP DISTURBANCE	2.00	2.00	2.00					
				7.Total score	11.58	11.58	9.83					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	1	Reboxetine	Male	01.REPORTED SADNESS	2	3	2	1	2	2	1
				02.INNER TENSION	1	2	1	1	2	1	1
				03.APPARENT SADNESS	2	2	2	1	3	2	1
				04.SUICIDAL THOUGHTS	1	1	0	0	1	1	1
				05.INERTIA	2	2	2	2	3	2	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	1	3	2	1	1	1	1
				10.REDUCED APPETITE	1	2	1	1	2	1	0
				11.Total score	16	20	15	12	19	15	10
	2	Reboxetine	Female	01.REPORTED SADNESS	3	2	2	1	0	0	0
				02.INNER TENSION	2	1	1	1	0	0	0
				03.APPARENT SADNESS	2	2	2	1	0	0	0
				04.SUICIDAL THOUGHTS	2	1	1	1	0	0	0
				05.INERTIA	3	2	2	1	0	0	0
				06.INABILITY TO FEEL	2	2	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	2	2
				09.REDUCED SLEEP	1	1	1	1	1	1	0
				10.REDUCED APPETITE	2	1	1	1	0	0	0
				11.Total score	21	15	15	10	2	3	2
	3	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	0	0	0
				02.INNER TENSION	1	1	1	1	1	0	0
				03.APPARENT SADNESS	2	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	2	1	0
				06.INABILITY TO FEEL	2	1	2	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	3	1	1	1	1	1	0
				10.REDUCED APPETITE	2	1	1	0	0	0	0
				11.Total score	19	12	13	8	7	4	2
	4	Imipramine	Male	01.REPORTED SADNESS	2	2	3	2	2	1	0
				02.INNER TENSION	2	2	1	1	1	1	0
				03.APPARENT SADNESS	2	2	2	2	1	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	2	3	2	2	2	0
				06.INABILITY TO FEEL	2	2	2	2	1	2	0
				07.PESSIMISTIC THOUGHTS	2	1	2	2	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	0	0	0
				11.Total score	19	18	18	15	11	10	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	5	Reboxetine	Female	01.REPORTED SADNESS	2	1	2	1	2	2	2
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	1	2	1	2	2	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	3	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	1	1	2	2	1	0
				07.PESSIMISTIC THOUGHTS	1	0	1	0	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	1	2	1	2	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	0	1	1	1	1	1
				11.Total score	19	10	14	11	15	13	11
	6	Imipramine	Male	01.REPORTED SADNESS	3	2	2	2	1	0	0
				02.INNER TENSION	2	2	1	2	2	1	1
				03.APPARENT SADNESS	2	2	2	2	2	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	1	1	0	1
				06.INABILITY TO FEEL	2	1	2	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	3	2	2	2	2	1	1
				10.REDUCED APPETITE	1	1	1	0	1	1	1
				11.Total score	19	16	16	13	12	5	6
	7	Reboxetine	Male	01.REPORTED SADNESS	2	3	2	1	2	2	2
				02.INNER TENSION	2	2	2	1	1	1	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	2	2	2	2	1	1	1
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	1	1	2	2
				07.PESSIMISTIC THOUGHTS	1	2	2	1	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	2	3	2	2	1	2	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	18	21	19	15	15	17	17
	8	Imipramine	Male	01.REPORTED SADNESS	3	2					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	2	2					
				05.INERTIA	3	2					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	1	2					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	2	2					
				10.REDUCED APPETITE	0	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	8	Imipramine	Male	11.Total score	19	17					
	9	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	0	0
				02.INNER TENSION	1	1	1	1	1	0	0
				03.APPARENT SADNESS	2	2	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	2	2	2	2	0	0
				06.INABILITY TO FEEL	2	1	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	2	2	0
				09.REDUCED SLEEP	0	1	0	0	0	0	0
				10.REDUCED APPETITE	1	1	1	0	0	0	0
				11.Total score	14	14	11	6	6	2	0
	10	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	2	2	1
				02.INNER TENSION	1	0	1	1	2	1	0
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	1	2	1	1	1	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	3	2	1	3	3	2	2
				10.REDUCED APPETITE	1	1	1	0	1	1	0
				11.Total score	17	13	12	11	15	12	8
	11	Reboxetine	Male	01.REPORTED SADNESS	3	3	3	2	3		
				02.INNER TENSION	1	2	2	1	2		
				03.APPARENT SADNESS	3	2	2	2	3		
				04.SUICIDAL THOUGHTS	1	1	1	0	2		
				05.INERTIA	2	2	2	2	3		
				06.INABILITY TO FEEL	2	2	2	1	2		
				07.PESSIMISTIC THOUGHTS	1	1	2	1	3		
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
				09.REDUCED SLEEP	3	2	3	2	3		
				10.REDUCED APPETITE	2	1	1	1	1		
				11.Total score	20	18	20	14	24		
	12	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	2			
				02.INNER TENSION	1	1	1	1			
				03.APPARENT SADNESS	2	2	2	2			
				04.SUICIDAL THOUGHTS	0	1	1	1			
				05.INERTIA	2	2	2	2			
				06.INABILITY TO FEEL	1	1	1	2			
				07.PESSIMISTIC THOUGHTS	0	1	1	2			
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
				09.REDUCED SLEEP	3	2	2	2			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	12	Reboxetine	Male	10.REDUCED APPETITE	1	1	1	1			
				11.Total score	14	15	14	17			
2	33	Reboxetine	Male	01.REPORTED SADNESS	1	1	0	0	1	1	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	2	1	0
				04.SUICIDAL THOUGHTS	3	0	0	0	0	0	0
				05.INERTIA	1	0	0	0	0	1	0
				06.INABILITY TO FEEL	2	1	0	0	1	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0
				09.REDUCED SLEEP	2	1	1	0	1	1	0
				10.REDUCED APPETITE	1	1	0	0	1	0	0
				11.Total score	15	7	4	3	8	6	2
	34	Imipramine	Male	01.REPORTED SADNESS	2	0	1	0	1	1	1
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	1	1	1	0	1	1	1
				04.SUICIDAL THOUGHTS	2	0	0	0	0	1	1
				05.INERTIA	2	1	0	0	1	1	1
				06.INABILITY TO FEEL	1	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	2	1
				08.CONCENTRATIONS DIFFICULTIES	1	0	1	0	0	0	0
				09.REDUCED SLEEP	1	1	0	0	0	1	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	14	5	5	2	5	8	7
	35	Reboxetine	Male	01.REPORTED SADNESS	3	1	0	0	0	0	1
				02.INNER TENSION	2	1	1	1	1	1	0
				03.APPARENT SADNESS	2	1	0	1	1	1	1
				04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
				05.INERTIA	2	1	0	0	0	0	0
				06.INABILITY TO FEEL	2	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	0	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0
				09.REDUCED SLEEP	1	0	0	1	0	1	1
				10.REDUCED APPETITE	2	0	0	0	0	0	0
				11.Total score	20	7	1	4	3	4	3
	36	Imipramine	Female	01.REPORTED SADNESS	2	2	0	0			
				02.INNER TENSION	2	2	0	1			
				03.APPARENT SADNESS	2	2	1	1			
				04.SUICIDAL THOUGHTS	0	1	0	0			
				05.INERTIA	2	2	1	0			
				06.INABILITY TO FEEL	1	1	0	0			
				07.PESSIMISTIC THOUGHTS	1	1	0	0			
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	36	Imipramine	Female	09.REDUCED SLEEP	2	1	1	1			
				10.REDUCED APPETITE	2	2	0	0			
				11.Total score	16	16	4	4			
	37	Reboxetine	Male	01.REPORTED SADNESS	2	1	2	1	2	1	1
				02.INNER TENSION	3	2	2	2	1	1	1
				03.APPARENT SADNESS	2	1	1	1	2	1	1
				04.SUICIDAL THOUGHTS	3	0	1	1	0	1	0
				05.INERTIA	2	0	0	1	1	1	0
				06.INABILITY TO FEEL	2	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	0	1	0	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	2	1	1	2	1	1
				09.REDUCED SLEEP	2	3	2	2	1	1	1
				10.REDUCED APPETITE	1	1	0	0	1	1	0
				11.Total score	19	11	11	10	12	10	7
	38	Imipramine	Female	01.REPORTED SADNESS	1	1	2	2	3	3	2
				02.INNER TENSION	2	1	2	2	2	2	2
				03.APPARENT SADNESS	1	1	2	2	2	2	1
				04.SUICIDAL THOUGHTS	1	1	1	2	2	1	1
				05.INERTIA	2	1	1	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	3	2	2	2	2	2	2
				10.REDUCED APPETITE	1	1	2	2	2	2	2
				11.Total score	16	13	17	19	20	19	16
	39	Reboxetine	Female	01.REPORTED SADNESS	3	2	2	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	3	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	1	1	1	1	1	1
				11.Total score	23	17	15	10	9	9	8
	40	Imipramine	Male	01.REPORTED SADNESS	2	1	2	1	3	2	1
				02.INNER TENSION	1	1	1	1	2	2	1
				03.APPARENT SADNESS	2	1	1	1	3	2	1
				04.SUICIDAL THOUGHTS	2	2	2	2	2	2	0
				05.INERTIA	2	1	1	1	1	1	0
				06.INABILITY TO FEEL	1	1	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	1	2	2	3	2	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	40	Imipramine	Male	08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
				09.REDUCED SLEEP	2	1	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	0
				11.Total score	16	11	13	12	18	15	5
	41	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	1	1	2	1
				02.INNER TENSION	2	2	2	2	2	1	2
				03.APPARENT SADNESS	2	2	1	1	1	1	2
				04.SUICIDAL THOUGHTS	1	1	2	1	1	1	1
				05.INERTIA	1	2	2	1	1	2	1
				06.INABILITY TO FEEL	2	2	1	1	1	2	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	2	2	1	2	2	1
				09.REDUCED SLEEP	2	1	2	1	1	1	3
				10.REDUCED APPETITE	1	1	1	0	1	1	2
				11.Total score	16	17	16	10	12	14	15
	42	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	2	2	1
				02.INNER TENSION	2	2	2	2	2	1	1
				03.APPARENT SADNESS	2	2	2	2	2	1	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	1	0
				05.INERTIA	2	2	1	1	2	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	1	2	1	2	2	2	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	0	1	0
				09.REDUCED SLEEP	2	3	2	2	1	1	1
				10.REDUCED APPETITE	1	1	1	2	1	0	0
				11.Total score	16	18	15	17	14	11	6
	43	Reboxetine	Female	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	0	0	0	0	1
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	1	0	0	0	0	0	0
				06.INABILITY TO FEEL	1	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	0	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	0	0	0	0	0
				09.REDUCED SLEEP	1	2	1	1	1	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	13	9	3	3	2	2	3
	44	Imipramine	Male	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	1	2					
				05.INERTIA	1	2					
				06.INABILITY TO FEEL	2	2					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	44	Imipramine	Male	07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	2	1					
				10.REDUCED APPETITE	1	2					
				11.Total score	17	18					
	45	Imipramine	Female	01.REPORTED SADNESS	2	1					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	2	1					
				04.SUICIDAL THOUGHTS	1	0					
				05.INERTIA	1	1					
				06.INABILITY TO FEEL	1	0					
				07.PESSIMISTIC THOUGHTS	2	1					
				08.CONCENTRATIONS DIFFICULTIES	1	1					
				09.REDUCED SLEEP	1	1					
				10.REDUCED APPETITE	1	1					
				11.Total score	14	8					
	46	Reboxetine	Female	01.REPORTED SADNESS	2	1	2	1	1	1	1
				02.INNER TENSION	1	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	1	2	2	1	0	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	0	0
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	1	1	1	1	0	0	0
				11.Total score	12	13	13	10	7	6	6
	47	Reboxetine	Female	01.REPORTED SADNESS	2	3	1	1	0	0	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	0	0	0
				04.SUICIDAL THOUGHTS	0	1	0	0	0	0	0
				05.INERTIA	1	1	1	0	0	0	0
				06.INABILITY TO FEEL	1	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
				09.REDUCED SLEEP	2	3	2	2	2	1	1
				10.REDUCED APPETITE	1	1	1	0	0	0	0
				11.Total score	14	17	9	6	3	2	2
	48	Imipramine	Female	01.REPORTED SADNESS	2	2	1	1	0	0	1
				02.INNER TENSION	1	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	0	0	1	1
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	48	Imipramine	Female	06.INABILITY TO FEEL	2	2	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0	0	0
				09.REDUCED SLEEP	2	0	1	1	0	0	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	16	13	7	4	2	4	5
	49	Imipramine	Female	01.REPORTED SADNESS	2	1	1	0	1	1	1
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	0	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	0	1	0
				06.INABILITY TO FEEL	2	1	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	1	0	1	0	0
				09.REDUCED SLEEP	2	1	1	1	2	2	1
				10.REDUCED APPETITE	1	1	1	1	0	1	0
				11.Total score	16	8	9	7	6	8	4
	50	Reboxetine	Male	01.REPORTED SADNESS	2	3	3	2	2	2	
				02.INNER TENSION	1	2	2	1	2	2	
				03.APPARENT SADNESS	2	2	2	2	2	2	
				04.SUICIDAL THOUGHTS	1	1	2	1	1	1	
				05.INERTIA	2	1	1	1	1	1	
				06.INABILITY TO FEEL	2	1	2	1	1	1	
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	
				08.CONCENTRATIONS DIFFICULTIES	2	1	2	1	1	0	
				09.REDUCED SLEEP	2	3	3	3	2	2	
				10.REDUCED APPETITE	1	1	1	1	1	1	
				11.Total score	17	17	20	15	14	13	
	51	Reboxetine	Female	01.REPORTED SADNESS	2	2	3				
				02.INNER TENSION	2	1	2				
				03.APPARENT SADNESS	2	2	3				
				04.SUICIDAL THOUGHTS	1	1	3				
				05.INERTIA	2	2	3				
				06.INABILITY TO FEEL	3	2	3				
				07.PESSIMISTIC THOUGHTS	2	2	3				
				08.CONCENTRATIONS DIFFICULTIES	2	1	2				
				09.REDUCED SLEEP	2	3	3				
				10.REDUCED APPETITE	1	1	2				
				11.Total score	19	17	27				
	52	Imipramine	Male	01.REPORTED SADNESS	2	1	0	0	0	1	0
				02.INNER TENSION	1	1	1	1	0	0	0
				03.APPARENT SADNESS	2	1	0	0	0	1	0
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	52	Imipramine	Male	05.INERTIA	2	1	1	0	0	0	0
				06.INABILITY TO FEEL	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	0	0	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	0	0	0	0	0
				09.REDUCED SLEEP	2	1	1	1	1	0	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	17	8	3	2	2	2	0
3	65	Reboxetine	Male	01.REPORTED SADNESS	2	1	0	0	1	0	0
				02.INNER TENSION	0	2	0	1	0	0	0
				03.APPARENT SADNESS	2	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	1	1	0	1	0	0	0
				06.INABILITY TO FEEL	1	1	0	0	1	0	0
				07.PESSIMISTIC THOUGHTS	1	0	0	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
				09.REDUCED SLEEP	2	1	2	1	2	2	1
				10.REDUCED APPETITE	1	2	0	0	0	0	0
				11.Total score	12	10	3	4	4	2	1
	66	Imipramine	Female	01.REPORTED SADNESS	1	0	0	0	1	3	
				02.INNER TENSION	1	0	1	0	1	3	
				03.APPARENT SADNESS	1	0	0	0	1	3	
				04.SUICIDAL THOUGHTS	2	0	0	0	0	2	
				05.INERTIA	2	1	0	0	0	3	
				06.INABILITY TO FEEL	2	0	0	0	0	3	
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	3	
				08.CONCENTRATIONS DIFFICULTIES	1	0	0	0	1	2	
				09.REDUCED SLEEP	2	2	0	0	0	1	
				10.REDUCED APPETITE	1	0	0	0	0	3	
				11.Total score	14	4	1	0	4	26	
	67	Reboxetine	Female	01.REPORTED SADNESS	1	0	2	1	2	1	2
				02.INNER TENSION	3	1	1	1	1	2	2
				03.APPARENT SADNESS	1	2	1	1	1	1	2
				04.SUICIDAL THOUGHTS	1	1	1	0	0	1	2
				05.INERTIA	2	1	1	1	1	2	2
				06.INABILITY TO FEEL	3	2	2	1	1	2	1
				07.PESSIMISTIC THOUGHTS	1	2	1	1	1	1	2
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
				09.REDUCED SLEEP	3	2	1	2	1	2	1
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	18	12	11	9	9	13	15
	68	Imipramine	Female	01.REPORTED SADNESS	3	2	3	2	2	2	2
				02.INNER TENSION	3	1	2	2	3	3	3
				03.APPARENT SADNESS	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3	68	Imipramine	Female	04.SUICIDAL THOUGHTS	1	2	1	1	1	1	1
				05.INERTIA	2	3	3	3	3	3	3
				06.INABILITY TO FEEL	3	3	3	3	3	2	3
				07.PESSIMISTIC THOUGHTS	3	2	2	1	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	3	2	3	2	1	1	1
				10.REDUCED APPETITE	3	2	0	2	1	2	2
				11.Total score	25	21	21	20	20	20	21
	69	Imipramine	Female	01.REPORTED SADNESS	2	3	1	1	0	1	0
				02.INNER TENSION	2	3	2	1	0	1	1
				03.APPARENT SADNESS	2	2	1	1	0	1	1
				04.SUICIDAL THOUGHTS	2	1	1	0	0	1	0
				05.INERTIA	2	2	1	1	0	1	1
				06.INABILITY TO FEEL	3	2	2	1	1	2	0
				07.PESSIMISTIC THOUGHTS	2	2	1	0	0	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	0	2	0
				09.REDUCED SLEEP	3	2	2	1	0	0	0
				10.REDUCED APPETITE	2	2	2	1	0	1	0
				11.Total score	22	21	15	8	1	11	4
	70	Reboxetine	Female	01.REPORTED SADNESS	2	3	2	2	2		
				02.INNER TENSION	2	3	2	2	2		
				03.APPARENT SADNESS	2	2	2	1	1		
				04.SUICIDAL THOUGHTS	1	2	1	1	1		
				05.INERTIA	2	3	2	2	2		
				06.INABILITY TO FEEL	2	3	3	2	2		
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2		
				08.CONCENTRATIONS DIFFICULTIES	1	2	1	1	1		
				09.REDUCED SLEEP	2	3	3	3	2		
				10.REDUCED APPETITE	1	2	2	1	2		
				11.Total score	17	25	20	17	17		
	71	Imipramine	Female	01.REPORTED SADNESS	1	0	0	1	0	0	0
				02.INNER TENSION	2	1	0	0	0	0	0
				03.APPARENT SADNESS	1	1	0	1	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	0	1	0	0	0
				06.INABILITY TO FEEL	2	1	0	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	0	0	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0
				09.REDUCED SLEEP	1	0	0	0	0	0	0
				10.REDUCED APPETITE	2	0	0	1	0	0	0
				11.Total score	15	5	0	6	0	0	0
	72	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	1	1	2	1
				02.INNER TENSION	2	2	2	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3	72	Reboxetine	Female	03.APPARENT SADNESS	2	1	1	1	1	2	1
				04.SUICIDAL THOUGHTS	1	1	1	1	2	1	0
				05.INERTIA	2	2	2	1	1	2	1
				06.INABILITY TO FEEL	1	2	2	2	1	0	1
				07.PESSIMISTIC THOUGHTS	2	1	1	1	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	0	1	0	1	0	0
				09.REDUCED SLEEP	1	2	2	1	1	1	1
				10.REDUCED APPETITE	2	1	2	2	1	0	1
				11.Total score	16	13	15	12	13	10	8
	73	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	0	0	0	0
				02.INNER TENSION	1	1	1	1	0	0	0
				03.APPARENT SADNESS	1	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	0	1	0
				06.INABILITY TO FEEL	3	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	1	1	1	0	0
				09.REDUCED SLEEP	1	1	1	1	1	0	0
				10.REDUCED APPETITE	0	0	0	1	0	0	0
				11.Total score	14	8	6	6	3	2	0
4	97	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	1	1	1	2	1	2	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	2	1	2	2	2	2
				06.INABILITY TO FEEL	3	3	2	3	2	3	3
				07.PESSIMISTIC THOUGHTS	1	2	1	2	2	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	3	3
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	1	1	0	1	2	2
				11.Total score	18	18	15	18	17	16	18
	100	Reboxetine	Female	01.REPORTED SADNESS	3	3	2	2	0	0	0
				02.INNER TENSION	2	3	2	1	1	1	0
				03.APPARENT SADNESS	2	2	2	1	1	0	0
				04.SUICIDAL THOUGHTS	2	2	2	2	1	1	1
				05.INERTIA	3	3	3	1	1	0	0
				06.INABILITY TO FEEL	3	3	3	3	1	0	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	0	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	0
				09.REDUCED SLEEP	3	3	2	2	2	2	2
				10.REDUCED APPETITE	3	3	3	0	0	0	0
				11.Total score	25	26	23	14	9	5	5
	101	Imipramine	Female	01.REPORTED SADNESS	2	2	2	3			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
4	101	Imipramine	Female	02.INNER TENSION	1	2	2	2			
				03.APPARENT SADNESS	1	1	2	3			
				04.SUICIDAL THOUGHTS	2	2	2	3			
				05.INERTIA	2	2	1	1			
				06.INABILITY TO FEEL	1	1	2	2			
				07.PESSIMISTIC THOUGHTS	1	1	0	0			
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1			
				09.REDUCED SLEEP	2	2	2	2			
				10.REDUCED APPETITE	1	2	2	2			
				11.Total score	14	16	16	19			
6	161	Reboxetine	Male	01.REPORTED SADNESS	2	0	0	0	0	2	1
				02.INNER TENSION	2	1	1	1	0	2	1
				03.APPARENT SADNESS	2	1	0	1	0	1	1
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	0	0	0	1	1
				06.INABILITY TO FEEL	2	0	0	0	0	1	0
				07.PESSIMISTIC THOUGHTS	1	0	1	1	0	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0
				09.REDUCED SLEEP	3	2	2	2	2	1	2
				10.REDUCED APPETITE	3	1	1	1	0	1	2
				11.Total score	20	7	5	6	2	10	9
	162	Reboxetine	Female	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	2	2	1	0	0	0	1
				03.APPARENT SADNESS	2	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	1	1	1	0	1	1
				06.INABILITY TO FEEL	2	2	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	0	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	1	1	1	0	0	0
				11.Total score	18	13	8	5	2	2	4
7	193	Reboxetine	Female	01.REPORTED SADNESS	0						
				02.INNER TENSION	3						
				03.APPARENT SADNESS	1						
				04.SUICIDAL THOUGHTS	2						
				05.INERTIA	2						
				06.INABILITY TO FEEL	2						
				07.PESSIMISTIC THOUGHTS	1						
				08.CONCENTRATIONS DIFFICULTIES	2						
				09.REDUCED SLEEP	0						
				10.REDUCED APPETITE	0						
				11.Total score	13						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7	194	Reboxetine	Male	01.REPORTED SADNESS	1						
				02.INNER TENSION	1						
				03.APPARENT SADNESS	1						
				04.SUICIDAL THOUGHTS	2						
				05.INERTIA	2						
				06.INABILITY TO FEEL	1						
				07.PESSIMISTIC THOUGHTS	1						
				08.CONCENTRATIONS DIFFICULTIES	1						
				09.REDUCED SLEEP	1						
				10.REDUCED APPETITE	0						
				11.Total score	11						
	196	Imipramine	Female	01.REPORTED SADNESS	2	1	0	1	1	1	1
				02.INNER TENSION	1	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	1	0	0
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	0	0	1	1
				07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0	1	1
				09.REDUCED SLEEP	1	0	0	0	0	1	1
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	16	6	5	4	4	6	6
8	225	Imipramine	Female	01.REPORTED SADNESS	2	2	0				
				02.INNER TENSION	2	2	1				
				03.APPARENT SADNESS	2	2	0				
				04.SUICIDAL THOUGHTS	1	2	0				
				05.INERTIA	2	1	1				
				06.INABILITY TO FEEL	2	2	1				
				07.PESSIMISTIC THOUGHTS	1	1	0				
				08.CONCENTRATIONS DIFFICULTIES	1	2	0				
				09.REDUCED SLEEP	2	0	0				
				10.REDUCED APPETITE	2	1	1				
				11.Total score	17	15	4				
	226	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	2	1	2	2
				02.INNER TENSION	2	2	2	2	1	2	1
				03.APPARENT SADNESS	2	2	1	2	2	2	2
				04.SUICIDAL THOUGHTS	1	1	0	1	1	2	1
				05.INERTIA	2	2	2	2	2	1	1
				06.INABILITY TO FEEL	2	2	1	2	1	1	2
				07.PESSIMISTIC THOUGHTS	2	2	0	2	1	2	2
				08.CONCENTRATIONS DIFFICULTIES	0	1	1	1	1	0	0
				09.REDUCED SLEEP	2	2	1	2	2	2	1
				10.REDUCED APPETITE	1	1	1	1	1	1	0
				11.Total score	16	17	10	17	13	15	12

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	227	Imipramine	Male	01.REPORTED SADNESS	2	1	1	2	1	1	1
				02.INNER TENSION	3	1	1	2	1	1	1
				03.APPARENT SADNESS	3	1	1	2	1	1	0
				04.SUICIDAL THOUGHTS	1	1	1	2	1	0	0
				05.INERTIA	1	1	1	1	1	1	0
				06.INABILITY TO FEEL	1	1	1	2	1	1	0
				07.PESSIMISTIC THOUGHTS	2	1	1	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	0
				09.REDUCED SLEEP	1	1	1	2	1	1	1
				10.REDUCED APPETITE	1	1	0	0	1	1	1
				11.Total score	17	11	9	16	10	9	5
	228	Reboxetine	Male	01.REPORTED SADNESS	2	2	2				
				02.INNER TENSION	2	3	3				
				03.APPARENT SADNESS	2	1	1				
				04.SUICIDAL THOUGHTS	2	1	1				
				05.INERTIA	2	1	1				
				06.INABILITY TO FEEL	1	1	1				
				07.PESSIMISTIC THOUGHTS	2	2	2				
				08.CONCENTRATIONS DIFFICULTIES	2	2	2				
				09.REDUCED SLEEP	3	3	3				
				10.REDUCED APPETITE	1	2	2				
				11.Total score	19	18	18				
	229	Imipramine	Female	01.REPORTED SADNESS	2	2	1	2	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	2	1	1	1
				04.SUICIDAL THOUGHTS	3	1	0	1	0	1	0
				05.INERTIA	2	2	1	1	1	0	1
				06.INABILITY TO FEEL	1	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	1
				09.REDUCED SLEEP	1	1	0	1	1	0	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	17	12	7	9	6	5	6
	230	Imipramine	Female	01.REPORTED SADNESS	3	2	1	1	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	3	2	1	1	0	0	0
				06.INABILITY TO FEEL	2	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	0	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0	0	0
				09.REDUCED SLEEP	2	1	0	0	1	1	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	230	Imipramine	Female	11.Total score	19	11	7	5	3	2	2
	231	Reboxetine	Female	01.REPORTED SADNESS	2	1					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	2	1					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	2	1					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	2	1					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	2	2					
				10.REDUCED APPETITE	0	0					
				11.Total score	16	10					
	232	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	2	1	1	1
				02.INNER TENSION	2	1	2	1	1	1	1
				03.APPARENT SADNESS	2	1	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	1	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	2	2	2	1
				09.REDUCED SLEEP	3	3	2	2	1	1	2
				10.REDUCED APPETITE	2	1	1	2	1	1	1
				11.Total score	18	14	14	14	10	10	9
9	197	Reboxetine	Male	01.REPORTED SADNESS	3	2					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	0	1					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	0	1					
				08.CONCENTRATIONS DIFFICULTIES	1	2					
				09.REDUCED SLEEP	0	0					
				10.REDUCED APPETITE	0	1					
				11.Total score	12	14					
	198	Imipramine	Female	01.REPORTED SADNESS	1	1	1	1	0	0	0
				02.INNER TENSION	2	1	1	1	0	0	0
				03.APPARENT SADNESS	1	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	2	1	2	1	0	0	0
				05.INERTIA	2	1	1	1	0	0	0
				06.INABILITY TO FEEL	1	2	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	2	0	0	0
				09.REDUCED SLEEP	2	2	1	2	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	198	Imipramine	Female	10.REDUCED APPETITE	0	1	2	0	0	0	0
				11.Total score	15	13	13	11	0	0	0
	199	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	1	2	1
				02.INNER TENSION	2	2	2	2	1	2	2
				03.APPARENT SADNESS	2	2	2	2	1	2	2
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	2	2	2	1	2	2
				06.INABILITY TO FEEL	2	2	2	2	1	2	2
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	2	2
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
				09.REDUCED SLEEP	1	2	1	1	1	1	1
				10.REDUCED APPETITE	0	1	0	0	0	0	0
				11.Total score	16	18	16	15	10	16	14
	200	Reboxetine	Male	01.REPORTED SADNESS	3	3	2	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	1	1	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	3	3	2	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
				09.REDUCED SLEEP	2	2	2	0	0	0	0
				10.REDUCED APPETITE	1	1	1	1	0	0	0
				11.Total score	19	18	11	5	2	2	2
	201	Imipramine	Female	01.REPORTED SADNESS	1	2	0	0	0	1	0
				02.INNER TENSION	1	2	2	2	1	1	0
				03.APPARENT SADNESS	1	1	0	0	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	1	2	1	1	1	0
				06.INABILITY TO FEEL	0	0	0	0	1	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	0	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	1	1	1
				09.REDUCED SLEEP	1	1	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	8	9	5	3	6	4	1
	202	Imipramine	Male	01.REPORTED SADNESS	2	3	0	0	2	2	1
				02.INNER TENSION	2	1	1	1	2	2	1
				03.APPARENT SADNESS	2	2	0	0	1	1	1
				04.SUICIDAL THOUGHTS	0	1	0	1	1	1	1
				05.INERTIA	1	1	1	0	1	2	2
				06.INABILITY TO FEEL	1	2	0	0	1	1	2
				07.PESSIMISTIC THOUGHTS	3	2	1	1	1	2	1
				08.CONCENTRATIONS DIFFICULTIES	3	1	1	0	0	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	202	Imipramine	Male	09.REDUCED SLEEP	2	1	1	1	0	0	0
				10.REDUCED APPETITE	0	0	0	0	1	1	0
				11.Total score	16	14	5	4	10	13	10
	203	Reboxetine	Female	01.REPORTED SADNESS	2	3					
				02.INNER TENSION	2	3					
				03.APPARENT SADNESS	2	3					
				04.SUICIDAL THOUGHTS	0	1					
				05.INERTIA	1	1					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	1	2					
				08.CONCENTRATIONS DIFFICULTIES	1	1					
				09.REDUCED SLEEP	1	1					
				10.REDUCED APPETITE	0	1					
				11.Total score	11	17					
	204	Reboxetine	Male	01.REPORTED SADNESS	1	1	0	0	0	0	0
				02.INNER TENSION	2	1	0	0	0	0	0
				03.APPARENT SADNESS	1	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	1	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	0	2	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	0	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
				09.REDUCED SLEEP	1	1	0	1	1	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	11	5	4	1	1	0	0
	205	Imipramine	Female	01.REPORTED SADNESS	2						
				02.INNER TENSION	2						
				03.APPARENT SADNESS	1						
				04.SUICIDAL THOUGHTS	0						
				05.INERTIA	0						
				06.INABILITY TO FEEL	0						
				07.PESSIMISTIC THOUGHTS	1						
				08.CONCENTRATIONS DIFFICULTIES	0						
				09.REDUCED SLEEP	1						
				10.REDUCED APPETITE	0						
				11.Total score	7						
	206	Imipramine	Female	01.REPORTED SADNESS	2	2	2	0	0	0	0
				02.INNER TENSION	2	2	2	0	1	1	1
				03.APPARENT SADNESS	1	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	0	0
				06.INABILITY TO FEEL	1	1	0	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	206	Imipramine	Female	08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	1	1	1	1	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	13	13	10	5	4	2	2
	207	Reboxetine	Female	01.REPORTED SADNESS	2	1					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	2	1					
				04.SUICIDAL THOUGHTS	0	1					
				05.INERTIA	2	1					
				06.INABILITY TO FEEL	2	1					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	2	1					
				10.REDUCED APPETITE	1	0					
				11.Total score	17	10					
	208	Reboxetine	Male	01.REPORTED SADNESS	2	2	0	0	1	1	1
				02.INNER TENSION	2	1	1	1	2	1	1
				03.APPARENT SADNESS	2	1	0	0	0	1	2
				04.SUICIDAL THOUGHTS	0	0	0	0	1	0	0
				05.INERTIA	0	1	1	0	0	2	1
				06.INABILITY TO FEEL	0	0	0	0	0	1	2
				07.PESSIMISTIC THOUGHTS	1	1	1	0	1	3	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	1	1
				09.REDUCED SLEEP	1	1	0	0	0	1	0
				10.REDUCED APPETITE	0	0	0	0	1	0	0
				11.Total score	9	8	4	1	6	11	9
	209	Imipramine	Male	01.REPORTED SADNESS	1	1					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	1	1					
				04.SUICIDAL THOUGHTS	0	0					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	2					
				09.REDUCED SLEEP	2	0					
				10.REDUCED APPETITE	0	0					
				11.Total score	14	12					
	210	Reboxetine	Female	01.REPORTED SADNESS	1	1	1	0	1	0	0
				02.INNER TENSION	1	1	1	1	2	1	1
				03.APPARENT SADNESS	2	1	1	0	1	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	1	1	0	1	0	0
				06.INABILITY TO FEEL	2	1	1	0	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	210	Reboxetine	Female	07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	1	0	0	0	1	1	1
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	13	9	8	3	9	3	3
	211	Reboxetine	Female	01.REPORTED SADNESS	2	3	3	1			
				02.INNER TENSION	2	2	2	2			
				03.APPARENT SADNESS	2	2	2	1			
				04.SUICIDAL THOUGHTS	2	2	2	1			
				05.INERTIA	1	2	2	1			
				06.INABILITY TO FEEL	2	2	2	1			
				07.PESSIMISTIC THOUGHTS	2	2	2	1			
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1			
				09.REDUCED SLEEP	1	2	1	0			
				10.REDUCED APPETITE	1	2	2	0			
				11.Total score	17	21	20	9			
	212	Imipramine	Female	01.REPORTED SADNESS	2	1	2	1	1	1	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	1	1	1	0
				05.INERTIA	1	2	1	0	0	0	0
				06.INABILITY TO FEEL	1	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
				09.REDUCED SLEEP	1	1	0	1	0	0	0
				10.REDUCED APPETITE	1	1	0	1	0	0	0
				11.Total score	13	11	6	6	4	4	2
	237	Reboxetine	Male	01.REPORTED SADNESS	2	2	3				
				02.INNER TENSION	2	2	2				
				03.APPARENT SADNESS	1	1	1				
				04.SUICIDAL THOUGHTS	0	0	0				
				05.INERTIA	2	2	2				
				06.INABILITY TO FEEL	1	1	2				
				07.PESSIMISTIC THOUGHTS	1	1	1				
				08.CONCENTRATIONS DIFFICULTIES	1	1	1				
				09.REDUCED SLEEP	2	2	2				
				10.REDUCED APPETITE	0	0	1				
				11.Total score	12	12	15				
	238	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	0	0
				02.INNER TENSION	2	2	2	1	1	0	0
				03.APPARENT SADNESS	2	2	2	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	1	1	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	238	Imipramine	Female	06.INABILITY TO FEEL	2	2	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	1	1	1	1	0	0	0
				11.Total score	17	17	17	10	6	1	1
	239	Imipramine	Male	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	3	2	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	2	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	0
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	0	1	1	0	0	0	0
				11.Total score	17	19	15	7	7	7	5
	240	Reboxetine	Female	01.REPORTED SADNESS	2	2	2				
				02.INNER TENSION	3	2	2				
				03.APPARENT SADNESS	2	2	2				
				04.SUICIDAL THOUGHTS	1	1	1				
				05.INERTIA	2	2	2				
				06.INABILITY TO FEEL	2	2	2				
				07.PESSIMISTIC THOUGHTS	1	1	1				
				08.CONCENTRATIONS DIFFICULTIES	3	3	3				
				09.REDUCED SLEEP	2	2	2				
				10.REDUCED APPETITE	1	1	1				
				11.Total score	19	18	18				
	241	Imipramine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	2	2	2	2	2	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
				09.REDUCED SLEEP	1	2	2	2	2	2	2
				10.REDUCED APPETITE	1	2	2	2	2	2	1
				11.Total score	17	19	15	15	15	15	10
	242	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	2	1	0	0
				02.INNER TENSION	2	2	2	2	1	0	0
				03.APPARENT SADNESS	2	2	2	2	1	0	0
				04.SUICIDAL THOUGHTS	2	1	1	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	242	Reboxetine	Male	05.INERTIA	2	2	2	2	2	0	0
				06.INABILITY TO FEEL	2	1	1	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	2	1	0	0
				10.REDUCED APPETITE	1	1	1	1	1	0	0
				11.Total score	19	17	16	16	11	1	1
	243	Imipramine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	0
				02.INNER TENSION	2	2	2	2	2	2	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	2	1	1	1	1	1	0
				05.INERTIA	2	2	1	1	1	0	0
				06.INABILITY TO FEEL	2	2	2	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	0
				09.REDUCED SLEEP	2	2	2	1	1	1	0
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	19	18	15	11	11	10	4
	244	Reboxetine	Male	01.REPORTED SADNESS	3	2	2	2	1	1	1
				02.INNER TENSION	2	1	1	1	2	2	1
				03.APPARENT SADNESS	2	2	2	2	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	1	0	0
				05.INERTIA	2	1	1	1	2	1	1
				06.INABILITY TO FEEL	2	1	1	1	2	1	1
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	0	0
				09.REDUCED SLEEP	1	1	1	1	2	1	1
				10.REDUCED APPETITE	0	0	0	0	1	0	0
				11.Total score	16	11	11	11	14	8	7
	257	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	0	1	0	0
				02.INNER TENSION	2	1	0	0	1	0	1
				03.APPARENT SADNESS	2	2	1	0	1	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	0	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	0	0
				09.REDUCED SLEEP	2	0	0	0	0	0	0
				10.REDUCED APPETITE	1	2	2	1	0	0	0
				11.Total score	18	13	6	3	5	1	2
	258	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	3			
				02.INNER TENSION	2	3	3	3			
				03.APPARENT SADNESS	2	2	2	2			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	258	Reboxetine	Male	04.SUICIDAL THOUGHTS	1	2	1	1			
				05.INERTIA	1	2	2	2			
				06.INABILITY TO FEEL	1	2	2	3			
				07.PESSIMISTIC THOUGHTS	1	2	2	1			
				08.CONCENTRATIONS DIFFICULTIES	1	3	2	2			
				09.REDUCED SLEEP	2	2	1	2			
				10.REDUCED APPETITE	0	1	0	0			
				11.Total score	13	21	17	19			
	259	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	0	0	0
				02.INNER TENSION	2	2	2	1	2	1	1
				03.APPARENT SADNESS	2	2	2	0	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0
				09.REDUCED SLEEP	3	3	3	2	2	2	2
				10.REDUCED APPETITE	2	2	2	0	0	0	0
				11.Total score	18	18	18	7	6	4	4
	260	Imipramine	Female	01.REPORTED SADNESS	2	1	2	3			
				02.INNER TENSION	2	3	1	2			
				03.APPARENT SADNESS	2	1	2	2			
				04.SUICIDAL THOUGHTS	1	0	1	2			
				05.INERTIA	2	0	2	1			
				06.INABILITY TO FEEL	2	0	1	2			
				07.PESSIMISTIC THOUGHTS	2	3	1	2			
				08.CONCENTRATIONS DIFFICULTIES	1	0	2	3			
				09.REDUCED SLEEP	1	1	1	1			
				10.REDUCED APPETITE	1	0	0	0			
				11.Total score	16	9	13	18			
	261	Imipramine	Female	01.REPORTED SADNESS	3	1					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	1	2					
				04.SUICIDAL THOUGHTS	0	1					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	2					
				09.REDUCED SLEEP	2	2					
				10.REDUCED APPETITE	0	0					
				11.Total score	16	15					
	262	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	2	0	1	1
				02.INNER TENSION	2	1	1	0	2	0	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	262	Reboxetine	Male	03.APPARENT SADNESS	1	2	2	1	0	1	0
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	1	2	1	0	0	0	0
				06.INABILITY TO FEEL	1	2	1	0	0	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	0	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	2	1	1	0	0
				09.REDUCED SLEEP	2	1	1	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	14	14	12	4	4	4	4
	263	Reboxetine	Female	01.REPORTED SADNESS	1	2	3				
				02.INNER TENSION	0	2	3				
				03.APPARENT SADNESS	0	2	2				
				04.SUICIDAL THOUGHTS	0	1	0				
				05.INERTIA	0	1	1				
				06.INABILITY TO FEEL	1	1	1				
				07.PESSIMISTIC THOUGHTS	0	1	1				
				08.CONCENTRATIONS DIFFICULTIES	0	1	1				
				09.REDUCED SLEEP	1	1	1				
				10.REDUCED APPETITE	1	0	0				
				11.Total score	4	12	13				
	264	Imipramine	Female	01.REPORTED SADNESS	2	2	0	0	0	0	1
				02.INNER TENSION	2	1	1	0	0	0	1
				03.APPARENT SADNESS	2	2	1	0	0	0	1
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	1	0	0	0	1
				06.INABILITY TO FEEL	2	2	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	2
				08.CONCENTRATIONS DIFFICULTIES	1	2	1	0	0	0	1
				09.REDUCED SLEEP	0	0	1	1	1	1	1
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	13	12	6	1	1	1	8
	265	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	3	2	1
				02.INNER TENSION	3	3	1	1	2	2	1
				03.APPARENT SADNESS	3	3	1	0	2	1	1
				04.SUICIDAL THOUGHTS	2	2	1	0	3	1	0
				05.INERTIA	2	3	0	0	2	2	0
				06.INABILITY TO FEEL	3	3	1	1	1	2	1
				07.PESSIMISTIC THOUGHTS	1	1	0	0	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	2	2	2	1	1
				09.REDUCED SLEEP	1	1	1	0	3	2	1
				10.REDUCED APPETITE	0	0	1	0	2	2	0
				11.Total score	18	19	10	5	21	16	7
	266	Reboxetine	Female	01.REPORTED SADNESS	1	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	266	Reboxetine	Female	02.INNER TENSION	2	2	1	1	1	2	1
				03.APPARENT SADNESS	1	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	0
				06.INABILITY TO FEEL	1	1	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
				09.REDUCED SLEEP	3	3	3	3	1	2	2
				10.REDUCED APPETITE	2	1	0	0	0	0	0
				11.Total score	16	12	8	7	4	6	4
	267	Imipramine	Male	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	2
				03.APPARENT SADNESS	2	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	1	0	0	0	0	0
				06.INABILITY TO FEEL	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
				09.REDUCED SLEEP	3	3	2	1	1	1	1
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	18	11	5	3	3	3	4
	268	Imipramine	Female	01.REPORTED SADNESS	3	0	2	1	1	2	2
				02.INNER TENSION	2	1	1	1	1	2	2
				03.APPARENT SADNESS	3	0	1	1	2	2	1
				04.SUICIDAL THOUGHTS	1	0	1	1	0	0	0
				05.INERTIA	2	1	1	1	1	2	2
				06.INABILITY TO FEEL	2	1	0	1	1	1	1
				07.PESSIMISTIC THOUGHTS	3	0	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	0	1	1	1	1	1
				09.REDUCED SLEEP	0	0	1	0	1	1	0
				10.REDUCED APPETITE	1	0	1	0	1	0	0
				11.Total score	19	3	10	8	10	12	10
	269	Reboxetine	Male	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	1	1	1	1	0	0	0
				03.APPARENT SADNESS	1	0	1	0	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	1	1	0	0	0	1	1
				06.INABILITY TO FEEL	2	1	0	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
				09.REDUCED SLEEP	1	1	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	10	7	3	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	270	Imipramine	Female	01.REPORTED SADNESS	3	2					
				02.INNER TENSION	3	2					
				03.APPARENT SADNESS	3	0					
				04.SUICIDAL THOUGHTS	0	0					
				05.INERTIA	2	1					
				06.INABILITY TO FEEL	2	1					
				07.PESSIMISTIC THOUGHTS	2	1					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	1	0					
				10.REDUCED APPETITE	0	0					
				11.Total score	18	8					
	271	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	1	1		
				02.INNER TENSION	2	2	1	1	1		
				03.APPARENT SADNESS	1	1	1	1	1		
				04.SUICIDAL THOUGHTS	1	0	0	0	0		
				05.INERTIA	2	1	1	1	1		
				06.INABILITY TO FEEL	2	2	1	1	1		
				07.PESSIMISTIC THOUGHTS	1	1	2	2	2		
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
				09.REDUCED SLEEP	2	2	2	2	2		
				10.REDUCED APPETITE	2	2	0	0	0		
				11.Total score	17	14	11	11	11		
	272	Imipramine	Male	01.REPORTED SADNESS	2	1	1	0	0	0	0
				02.INNER TENSION	2	1	1	1	0	0	0
				03.APPARENT SADNESS	3	2	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	3	1	1	0	0	0
				09.REDUCED SLEEP	3	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	0	0	0	0	0
				11.Total score	22	16	6	4	2	2	2
	273	Imipramine	Female	01.REPORTED SADNESS	2	3	2	1	1		
				02.INNER TENSION	2	2	1	1	1		
				03.APPARENT SADNESS	2	2	1	1	1		
				04.SUICIDAL THOUGHTS	2	2	2	2	2		
				05.INERTIA	2	2	1	1	1		
				06.INABILITY TO FEEL	2	2	1	1	1		
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2		
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2		
				09.REDUCED SLEEP	2	2	2	2	2		
				10.REDUCED APPETITE	2	2	2	1	1		
				11.Total score	20	21	16	14	14		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	274	Reboxetine	Female	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	1	1					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	1	0					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	1	1					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	2	1					
				10.REDUCED APPETITE	0	0					
				11.Total score	13	9					
	274/A	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	0	0	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	3	3	3	1	1	1	1
				06.INABILITY TO FEEL	2	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	2	1	1	1	1
				09.REDUCED SLEEP	2	1	1	1	1	1	1
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	18	11	11	7	6	6	7
	275	Reboxetine	Female	01.REPORTED SADNESS	3	1	1	1	1	1	1
				02.INNER TENSION	2	1	1	0	0	0	0
				03.APPARENT SADNESS	2	1	1	1	1	1	1
				04.SUICIDAL THOUGHTS	2	2	2	1	1	0	0
				05.INERTIA	2	2	2	1	1	1	0
				06.INABILITY TO FEEL	2	2	2	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0
				09.REDUCED SLEEP	2	2	2	1	0	0	0
				10.REDUCED APPETITE	2	1	1	0	0	0	0
				11.Total score	21	16	16	8	7	4	3
	276	Imipramine	Female	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	1	2					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	0	1					
				05.INERTIA	1	3					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	1	2					
				08.CONCENTRATIONS DIFFICULTIES	1	2					
				09.REDUCED SLEEP	1	1					
				10.REDUCED APPETITE	1	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	276	Imipramine	Female	11.Total score	11	17					
	276/A	Imipramine	Male	01.REPORTED SADNESS	2	2	3	2	0	0	0
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	1	2	2	2	0	0	0
				04.SUICIDAL THOUGHTS	0	0	1	1	0	0	0
				05.INERTIA	1	1	0	1	0	0	0
				06.INABILITY TO FEEL	1	1	1	2	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	0	0
				09.REDUCED SLEEP	1	1	1	1	1	1	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	11	11	12	13	3	3	2
9/A	233	Imipramine	Male	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	3	3	3	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	2	1	1	0	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	2	0	0	0	0
				11.Total score	19	19	20	10	10	9	10
	234	Reboxetine	Female	01.REPORTED SADNESS	3	2	2	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	2	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	1
				11.Total score	18	17	15	9	10	9	8
	235	Reboxetine	Male	01.REPORTED SADNESS	3	2	1	1	1	2	
				02.INNER TENSION	1	1	1	1	1	1	
				03.APPARENT SADNESS	3	1	1	1	1	2	
				04.SUICIDAL THOUGHTS	1	1	0	0	0	1	
				05.INERTIA	2	2	1	1	2	2	
				06.INABILITY TO FEEL	2	1	1	0	1	2	
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	1	
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	
				09.REDUCED SLEEP	3	2	2	2	2	2	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	235	Reboxetine	Male	10.REDUCED APPETITE	2	1	0	0	0	1	
				11.Total score	19	13	9	7	9	15	
	236	Imipramine	Male	01.REPORTED SADNESS	2	2	2	1	1	1	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	0
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	2	2	1	2	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	0
				09.REDUCED SLEEP	1	1	1	1	1	1	0
				10.REDUCED APPETITE	0	0	0	0	0	1	0
				11.Total score	16	15	13	8	9	9	3
	277	Reboxetine	Female	01.REPORTED SADNESS	3	3					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	3	3					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	2					
				09.REDUCED SLEEP	1	3					
				10.REDUCED APPETITE	1	1					
				11.Total score	19	21					
	278	Imipramine	Female	01.REPORTED SADNESS	2	1	1	2			
				02.INNER TENSION	2	1	1	2			
				03.APPARENT SADNESS	2	1	1	2			
				04.SUICIDAL THOUGHTS	1	1	0	0			
				05.INERTIA	2	2	1	2			
				06.INABILITY TO FEEL	2	2	0	2			
				07.PESSIMISTIC THOUGHTS	2	1	0	0			
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	1			
				09.REDUCED SLEEP	1	1	1	2			
				10.REDUCED APPETITE	1	0	0	1			
				11.Total score	17	11	5	14			
	279	Imipramine	Male	01.REPORTED SADNESS	2	2	2				
				02.INNER TENSION	2	2	2				
				03.APPARENT SADNESS	2	2	2				
				04.SUICIDAL THOUGHTS	1	1	1				
				05.INERTIA	2	2	2				
				06.INABILITY TO FEEL	2	2	2				
				07.PESSIMISTIC THOUGHTS	1	1	2				
				08.CONCENTRATIONS DIFFICULTIES	1	1	2				

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	279	Imipramine	Male	09.REDUCED SLEEP	1	2	2				
				10.REDUCED APPETITE	0	1	1				
				11.Total score	14	16	18				
	280	Reboxetine	Female	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	2					
				09.REDUCED SLEEP	2	2					
				10.REDUCED APPETITE	1	1					
				11.Total score	18	18					
	281	Reboxetine	Female	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	1	1	1	1	0	0	1
				03.APPARENT SADNESS	2	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	0
				06.INABILITY TO FEEL	2	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	0	0	0	0	0
				09.REDUCED SLEEP	2	1	0	0	0	0	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	14	7	4	2	1	1	1
	282	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	3	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	0
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	0
				11.Total score	19	18	13	10	9	9	6
	283	Imipramine	Female	01.REPORTED SADNESS	2	2	1	1	0	0	0
				02.INNER TENSION	1	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	1	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	283	Imipramine	Female	08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
				09.REDUCED SLEEP	1	1	1	1	1	1	1
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	14	14	6	6	3	3	3
	284	Imipramine	Male	01.REPORTED SADNESS	3	2	2	2			
				02.INNER TENSION	2	2	2	2			
				03.APPARENT SADNESS	2	2	2	2			
				04.SUICIDAL THOUGHTS	1	1	1	1			
				05.INERTIA	2	2	1	2			
				06.INABILITY TO FEEL	2	2	2	2			
				07.PESSIMISTIC THOUGHTS	1	1	1	1			
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1			
				09.REDUCED SLEEP	2	2	2	2			
				10.REDUCED APPETITE	2	1	1	1			
				11.Total score	19	16	15	16			
	301	Imipramine	Female	01.REPORTED SADNESS	2	1	1	0	0	0	0
				02.INNER TENSION	1	1	1	1	1	0	0
				03.APPARENT SADNESS	2	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
				09.REDUCED SLEEP	1	1	1	1	1	1	1
				10.REDUCED APPETITE	2	1	1	0	0	0	0
				11.Total score	16	10	9	3	3	2	2
	302	Imipramine	Male	01.REPORTED SADNESS	2	2	2	3			
				02.INNER TENSION	2	2	2	2			
				03.APPARENT SADNESS	2	2	2	2			
				04.SUICIDAL THOUGHTS	1	1	1	1			
				05.INERTIA	2	2	2	2			
				06.INABILITY TO FEEL	2	2	2	2			
				07.PESSIMISTIC THOUGHTS	2	2	1	1			
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1			
				09.REDUCED SLEEP	1	1	1	2			
				10.REDUCED APPETITE	1	1	1	1			
				11.Total score	17	17	16	17			
	303	Reboxetine	Female	01.REPORTED SADNESS	3	2	2	2			
				02.INNER TENSION	1	1	2	2			
				03.APPARENT SADNESS	3	2	2	2			
				04.SUICIDAL THOUGHTS	1	1	1	1			
				05.INERTIA	3	2	2	2			
				06.INABILITY TO FEEL	2	2	2	2			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	303	Reboxetine	Female	07.PESSIMISTIC THOUGHTS	2	1	1	2			
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
				09.REDUCED SLEEP	1	1	1	2			
				10.REDUCED APPETITE	2	1	1	1			
				11.Total score	20	15	16	18			
	304	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	1	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	1	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	0	0
				09.REDUCED SLEEP	1	1	1	1	1	0	1
				10.REDUCED APPETITE	1	1	1	0	0	0	0
				11.Total score	15	9	8	7	6	2	3
	305	Reboxetine	Male	01.REPORTED SADNESS	2	1	1	0	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	0	0
				09.REDUCED SLEEP	1	1	1	1	1	1	1
				10.REDUCED APPETITE	2	1	0	0	0	0	0
				11.Total score	18	9	7	6	5	3	3
	306	Reboxetine	Female	01.REPORTED SADNESS	3	3	1	1	0	0	0
				02.INNER TENSION	2	2	1	0	1	1	1
				03.APPARENT SADNESS	2	3	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	0	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
				09.REDUCED SLEEP	2	1	1	0	0	0	0
				10.REDUCED APPETITE	2	2	0	0	0	0	0
				11.Total score	20	20	7	4	3	3	3
	307	Imipramine	Female	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	2	2					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	307	Imipramine	Female	06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	1	2					
				08.CONCENTRATIONS DIFFICULTIES	1	1					
				09.REDUCED SLEEP	1	1					
				10.REDUCED APPETITE	0	0					
				11.Total score	14	15					
	308	Imipramine	Female	01.REPORTED SADNESS	3	3	2	1	3		
				02.INNER TENSION	2	2	2	1	2		
				03.APPARENT SADNESS	3	2	2	1	2		
				04.SUICIDAL THOUGHTS	1	1	1	1	1		
				05.INERTIA	2	2	2	2	2		
				06.INABILITY TO FEEL	2	2	2	2	2		
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1		
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1		
				09.REDUCED SLEEP	2	2	2	1	3		
				10.REDUCED APPETITE	2	1	1	1	1		
				11.Total score	21	17	16	12	18		
10	289	Imipramine	Female	01.REPORTED SADNESS	1	1					
				02.INNER TENSION	0	1					
				03.APPARENT SADNESS	1	1					
				04.SUICIDAL THOUGHTS	0	0					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	1	1					
				08.CONCENTRATIONS DIFFICULTIES	1	2					
				09.REDUCED SLEEP	1	2					
				10.REDUCED APPETITE	1	2					
				11.Total score	9	13					
	290	Reboxetine	Male	01.REPORTED SADNESS	3	1	1	1	1	0	0
				02.INNER TENSION	1	1	1	0	0	0	0
				03.APPARENT SADNESS	2	2	1	0	0	0	0
				04.SUICIDAL THOUGHTS	2	2	1	1	1	0	0
				05.INERTIA	0	0	0	0	0	0	1
				06.INABILITY TO FEEL	3	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
				09.REDUCED SLEEP	1	1	0	0	0	0	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	17	14	7	5	5	2	3
	291	Imipramine	Male	01.REPORTED SADNESS	3	1	0	0	0	0	0
				02.INNER TENSION	1	1	1	1	0	0	0
				03.APPARENT SADNESS	3	2	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
10	291	Imipramine	Male	05.INERTIA	2	1	0	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
				09.REDUCED SLEEP	2	2	0	0	0	0	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	18	13	4	4	2	2	0
	292	Reboxetine	Female	01.REPORTED SADNESS	1	1	1	1	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
				05.INERTIA	1	1	0	0	0	0	0
				06.INABILITY TO FEEL	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	0
				09.REDUCED SLEEP	2	2	1	1	1	1	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	17	13	6	6	4	4	2
	293	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	17	17	17	17	17	15	15
	294	Imipramine	Female	01.REPORTED SADNESS	1	3	3	2			
				02.INNER TENSION	1	2	2	2			
				03.APPARENT SADNESS	2	3	2	1			
				04.SUICIDAL THOUGHTS	1	1	1	1			
				05.INERTIA	2	2	2	2			
				06.INABILITY TO FEEL	2	2	2	2			
				07.PESSIMISTIC THOUGHTS	1	1	1	1			
				08.CONCENTRATIONS DIFFICULTIES	1	2	2	2			
				09.REDUCED SLEEP	2	3	2	2			
				10.REDUCED APPETITE	1	2	2	2			
				11.Total score	14	21	19	17			
	295	Imipramine	Male	01.REPORTED SADNESS	2	2	1	1	1	1	0
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
10	295	Imipramine	Male	04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	2	2	1	0	0	0
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	0	0
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	17	15	13	10	7	7	5
	296	Reboxetine	Female	01.REPORTED SADNESS	3	3	3	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	3	3	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	1
				11.Total score	20	20	15	9	9	9	9
	297	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	1	0	0	0
				02.INNER TENSION	1	1	1	1	1	1	0
				03.APPARENT SADNESS	2	2	2	1	0	0	0
				04.SUICIDAL THOUGHTS	2	2	1	1	1	1	0
				05.INERTIA	2	2	1	0	0	0	0
				06.INABILITY TO FEEL	1	1	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	0	0
				11.Total score	17	17	12	9	5	4	2
	298	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	2	2	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	2	2	2	2	1	1	0
				06.INABILITY TO FEEL	2	2	1	1	1	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
				09.REDUCED SLEEP	2	2	2	2	2	2	1
				10.REDUCED APPETITE	1	1	1	1	1	0	0
				11.Total score	16	16	15	13	10	7	5
	299	Imipramine	Male	01.REPORTED SADNESS	3	3	3	3	3	3	1
				02.INNER TENSION	2	2	3	2	2	2	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
10	299	Imipramine	Male	03.APPARENT SADNESS	3	3	2	2	2	2	1
				04.SUICIDAL THOUGHTS	1	1	3	1	1	1	0
				05.INERTIA	2	2	3	3	3	2	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	0
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	0	0	1	0	0	0	0
				11.Total score	19	19	23	19	19	16	7
	300	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	2
				02.INNER TENSION	1	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	2
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	1
				05.INERTIA	3	3	3	2	1	1	2
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	16	16	14	10	9	9	13
11	321	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	1	0	0	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	0	0	0	1	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	1	0	1	0	0	0	0
				06.INABILITY TO FEEL	1	0	0	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	0	0	0	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	0	1	1	0	0	0
				09.REDUCED SLEEP	3	2	2	2	2	2	2
				10.REDUCED APPETITE	2	1	2	1	1	1	1
				11.Total score	18	5	8	7	6	4	4
	322	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	0	0	0	0
				02.INNER TENSION	2	1	0	1	1	1	0
				03.APPARENT SADNESS	1	2	0	1	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	0	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	0	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	1	1	0	1	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	0	1	0	0	0	0	1
				11.Total score	14	9	5	7	4	5	5
	323	Imipramine	Female	01.REPORTED SADNESS	2	1	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	323	Imipramine	Female	02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	1	0	1	0	0	0	0
				04.SUICIDAL THOUGHTS	2	0	1	0	0	0	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	0	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	0	0	0	0	0	0
				11.Total score	18	12	12	7	6	5	5
	324	Imipramine	Male	01.REPORTED SADNESS	2	2	1	2	1	1	0
				02.INNER TENSION	1	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	2	1	1	1
				04.SUICIDAL THOUGHTS	1	1	0	1	1	0	0
				05.INERTIA	2	1	1	2	1	1	1
				06.INABILITY TO FEEL	2	1	1	1	0	1	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	1	1	0	1
				09.REDUCED SLEEP	1	1	0	0	0	0	0
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	15	13	8	12	8	7	5
	325	Reboxetine	Female	01.REPORTED SADNESS	1	1	1	0	0	0	0
				02.INNER TENSION	2	2	1	1	0	0	0
				03.APPARENT SADNESS	1	1	0	1	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	0	0	0
				06.INABILITY TO FEEL	1	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
				09.REDUCED SLEEP	1	1	0	0	0	0	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	13	11	4	4	1	0	0
	326	Imipramine	Male	01.REPORTED SADNESS	2	2	1	1	0	0	1
				02.INNER TENSION	2	1	1	1	1	0	1
				03.APPARENT SADNESS	2	2	1	1	1	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	2	1	1	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	1	0	0	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	1
				08.CONCENTRATIONS DIFFICULTIES	1	2	1	1	0	1	1
				09.REDUCED SLEEP	1	1	0	2	0	0	0
				10.REDUCED APPETITE	1	0	0	1	1	0	1
				11.Total score	15	12	7	9	4	1	6

37

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	327	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	0
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	1
				05.INERTIA	2	2	1	1	1	1	0
				06.INABILITY TO FEEL	2	2	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	0	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	16	16	12	8	7	8	6
	328	Imipramine	Male	01.REPORTED SADNESS	2	1	1	0	0		
				02.INNER TENSION	2	1	1	1	1		
				03.APPARENT SADNESS	1	1	1	0	1		
				04.SUICIDAL THOUGHTS	1	0	0	0	0		
				05.INERTIA	2	1	1	1	1		
				06.INABILITY TO FEEL	2	1	1	0	0		
				07.PESSIMISTIC THOUGHTS	1	0	1	0	1		
				08.CONCENTRATIONS DIFFICULTIES	2	1	2	1	1		
				09.REDUCED SLEEP	2	1	0	1	0		
				10.REDUCED APPETITE	0	0	1	0	0		
				11.Total score	15	7	9	4	5		
	329	Imipramine	Female	01.REPORTED SADNESS	1	2	1	1	0	1	1
				02.INNER TENSION	1	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	14	14	9	7	5	5	5
	330	Reboxetine	Female	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	1	1					
				03.APPARENT SADNESS	2	2					
				04.SUICIDAL THOUGHTS	2	1					
				05.INERTIA	2	2					
				06.INABILITY TO FEEL	2	1					
				07.PESSIMISTIC THOUGHTS	1	1					
				08.CONCENTRATIONS DIFFICULTIES	1	2					
				09.REDUCED SLEEP	0	2					
				10.REDUCED APPETITE	0	2					
				11.Total score	13	16					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	331	Reboxetine	Male	01.REPORTED SADNESS	2	1	0	0	2	0	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	2	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	1	0	0
				05.INERTIA	2	1	1	1	2	0	1
				06.INABILITY TO FEEL	2	1	1	1	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	1	1	0	1	1	0	1
				11.Total score	18	13	9	8	14	5	6
	332	Imipramine	Female	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	2	0	0	0	0	0	0
				03.APPARENT SADNESS	1	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0
				09.REDUCED SLEEP	1	0	1	0	0	0	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0
				11.Total score	13	3	1	0	0	0	0
	333	Imipramine	Female	01.REPORTED SADNESS	2	2	1	2	1	1	0
				02.INNER TENSION	2	2	2	2	1	1	0
				03.APPARENT SADNESS	2	2	2	2	1	1	0
				04.SUICIDAL THOUGHTS	1	0	1	1	1	0	0
				05.INERTIA	2	2	2	2	1	1	0
				06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	2	1	1	1	0	0	0
				10.REDUCED APPETITE	0	2	1	1	0	0	0
				11.Total score	16	16	15	16	8	7	2
12	337	Imipramine	Female	01.REPORTED SADNESS	2	0	0	2	1	1	0
				02.INNER TENSION	2	0	0	0	1	1	1
				03.APPARENT SADNESS	2	1	0	2	1	1	0
				04.SUICIDAL THOUGHTS	2	0	0	0	1	1	0
				05.INERTIA	1	0	0	0	0	0	0
				06.INABILITY TO FEEL	0	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0
				09.REDUCED SLEEP	2	1	0	2	1	1	1
				10.REDUCED APPETITE	2	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	337	Imipramine	Female	11.Total score	14	3	0	7	5	5	2
	338	Reboxetine	Female	01.REPORTED SADNESS	3	2	1	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	2	1
				03.APPARENT SADNESS	2	1	1	1	1	1	1
				04.SUICIDAL THOUGHTS	2	1	1	1	1	0	1
				05.INERTIA	2	2	1	0	1	2	1
				06.INABILITY TO FEEL	1	2	1	0	1	1	1
				07.PESSIMISTIC THOUGHTS	2	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	0	0	1	1	1	1	1
				09.REDUCED SLEEP	2	1	1	2	2	2	3
				10.REDUCED APPETITE	0	1	1	0	0	1	0
				11.Total score	16	13	11	7	9	11	10
	339	Imipramine	Male	01.REPORTED SADNESS	2	1	1	1	0	0	0
				02.INNER TENSION	2	2	2	1	2	1	1
				03.APPARENT SADNESS	1	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	1	1	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
				09.REDUCED SLEEP	1	1	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	2	2	1	0
				11.Total score	15	13	11	8	7	5	2
	340	Reboxetine	Female	01.REPORTED SADNESS	2	2	0	0	0	0	1
				02.INNER TENSION	2	2	0	0	0	1	1
				03.APPARENT SADNESS	1	1	0	0	0	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	0	0	0	1	1
				06.INABILITY TO FEEL	1	1	0	0	0	1	1
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	0	1	0	1	1
				09.REDUCED SLEEP	2	2	1	2	1	1	2
				10.REDUCED APPETITE	2	2	1	1	0	1	1
				11.Total score	15	15	2	4	1	8	10
	341	Reboxetine	Female	01.REPORTED SADNESS	1	2	1	2	0	1	
				02.INNER TENSION	2	2	2	2	1	2	
				03.APPARENT SADNESS	1	1	1	2	0	1	
				04.SUICIDAL THOUGHTS	0	1	1	2	0	2	
				05.INERTIA	2	1	1	2	1	1	
				06.INABILITY TO FEEL	2	2	2	1	0	2	
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	2	
				09.REDUCED SLEEP	3	3	2	2	2	2	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	341	Reboxetine	Female	10.REDUCED APPETITE	1	2	1	2	1	2	
				11.Total score	16	18	15	19	7	16	
13	353	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	1	0	1	
				02.INNER TENSION	1	1	1	1	1	1	
				03.APPARENT SADNESS	2	2	1	1	1	2	
				04.SUICIDAL THOUGHTS	2	2	0	0	0	1	
				05.INERTIA	2	1	1	1	1	1	
				06.INABILITY TO FEEL	1	1	1	0	0	1	
				07.PESSIMISTIC THOUGHTS	2	1	1	0	0	1	
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	
				09.REDUCED SLEEP	2	2	1	1	0	1	
				10.REDUCED APPETITE	2	2	2	0	0	1	
				11.Total score	17	14	10	6	4	11	
	354	Imipramine	Female	01.REPORTED SADNESS	2	1	1	0	0	0	0
				02.INNER TENSION	2	1	1	0	1	0	1
				03.APPARENT SADNESS	1	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	0	0
				06.INABILITY TO FEEL	1	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	0	1	0
				09.REDUCED SLEEP	1	0	0	1	0	0	1
				10.REDUCED APPETITE	2	1	0	0	0	0	0
				11.Total score	15	7	5	3	2	1	2
	355	Reboxetine	Female	01.REPORTED SADNESS	1	1					
				02.INNER TENSION	2	1					
				03.APPARENT SADNESS	1	1					
				04.SUICIDAL THOUGHTS	2	1					
				05.INERTIA	1	1					
				06.INABILITY TO FEEL	2	1					
				07.PESSIMISTIC THOUGHTS	2	1					
				08.CONCENTRATIONS DIFFICULTIES	1	0					
				09.REDUCED SLEEP	1	1					
				10.REDUCED APPETITE	2	1					
				11.Total score	15	9					
	356	Imipramine	Male	01.REPORTED SADNESS	2	2	1	0	1	0	1
				02.INNER TENSION	2	2	2	1	1	1	2
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	0	0	1	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	0	1	1
				07.PESSIMISTIC THOUGHTS	2	1	1	1	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	356	Imipramine	Male	09.REDUCED SLEEP	2	1	1	1	1	1	2
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	18	15	10	6	8	8	10
	357	Imipramine	Female	01.REPORTED SADNESS	2						
				02.INNER TENSION	2						
				03.APPARENT SADNESS	2						
				04.SUICIDAL THOUGHTS	1						
				05.INERTIA	2						
				06.INABILITY TO FEEL	1						
				07.PESSIMISTIC THOUGHTS	0						
				08.CONCENTRATIONS DIFFICULTIES	2						
				09.REDUCED SLEEP	2						
				10.REDUCED APPETITE	1						
				11.Total score	15						
	358	Reboxetine	Male	01.REPORTED SADNESS	2	1	2	0	1		
				02.INNER TENSION	2	2	2	1	2		
				03.APPARENT SADNESS	2	1	1	1	1		
				04.SUICIDAL THOUGHTS	1	2	0	0	0		
				05.INERTIA	2	1	0	0	0		
				06.INABILITY TO FEEL	2	0	1	1	0		
				07.PESSIMISTIC THOUGHTS	1	1	1	1	2		
				08.CONCENTRATIONS DIFFICULTIES	0	0	0	1	0		
				09.REDUCED SLEEP	2	2	2	2	2		
				10.REDUCED APPETITE	1	1	1	0	1		
				11.Total score	15	11	10	7	9		
	359	Reboxetine	Female	01.REPORTED SADNESS	1	1	1	0	0	0	0
				02.INNER TENSION	2	2	2	1	1	0	1
				03.APPARENT SADNESS	1	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	2	1	0	0	0	0
				05.INERTIA	2	2	0	1	1	0	0
				06.INABILITY TO FEEL	1	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	2	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	1	0	0
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	0	0	0	0	0
				11.Total score	15	16	10	5	5	2	3
	360	Imipramine	Female	01.REPORTED SADNESS	2	1					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	1	1					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	2	1					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	2	1					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	360	Imipramine	Female	08.CONCENTRATIONS DIFFICULTIES	1	1					
				09.REDUCED SLEEP	2	2					
				10.REDUCED APPETITE	1	1					
				11.Total score	15	12					
	361	Reboxetine	Female	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	1	1	0	0	1	0	1
				03.APPARENT SADNESS	2	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
				05.INERTIA	2	2	0	0	0	0	1
				06.INABILITY TO FEEL	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	0	0	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	0	1	0
				09.REDUCED SLEEP	2	2	1	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	17	11	2	1	2	1	2
14	457	Reboxetine	Female	01.REPORTED SADNESS	3	3	3	2	2	1	1
				02.INNER TENSION	2	2	2	2	2	2	1
				03.APPARENT SADNESS	2	2	2	2	2	2	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	1	1	1	1	1	2	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	3	2	2	2
				10.REDUCED APPETITE	2	2	2	2	2	2	1
				11.Total score	18	18	18	18	17	15	11
	458	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	1
				02.INNER TENSION	2	2	2	2	2	2	1
				03.APPARENT SADNESS	3	3	3	3	2	2	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	2	1	1	1	1
				11.Total score	20	20	20	17	16	16	12
	459	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	2	2	2	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14	459	Reboxetine	Male	07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	18	18	14	11	11	10	10
	460	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	2	2	2	2	1
				03.APPARENT SADNESS	2	2	2	2	2	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
				09.REDUCED SLEEP	2	2	2	2	2	2	1
				10.REDUCED APPETITE	2	2	2	2	2	1	1
				11.Total score	18	18	18	18	16	13	10
	461	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	2	2	2	2	2
				11.Total score	21	21	21	21	21	20	20
	462	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	2	2	2	2	2
				11.Total score	20	20	20	20	20	20	20
	463	Imipramine	Male	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	2	1	1	1	1	1	1
				05.INERTIA	1	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14	463	Imipramine	Male	06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	2	2	2	2	2	1
				10.REDUCED APPETITE	2	2	1	1	1	1	1
				11.Total score	19	18	14	12	11	11	10
	464	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	2	2	2	2	2
				11.Total score	20	20	20	20	20	20	20
	465	Reboxetine	Male	01.REPORTED SADNESS	3	2	1	1	1	1	0
				02.INNER TENSION	3	2	1	1	1	1	0
				03.APPARENT SADNESS	2	2	1	1	1	1	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	1	1	1	0
				06.INABILITY TO FEEL	2	2	2	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	0	0
				11.Total score	21	19	14	11	10	8	2
	466	Imipramine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	2	2	1	1	1	1	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	1	0
				11.Total score	20	20	13	11	11	10	6
14/1	129	Reboxetine	Male	01.REPORTED SADNESS	1						
				02.INNER TENSION	1						
				03.APPARENT SADNESS	2						
				04.SUICIDAL THOUGHTS	1						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/1	129	Reboxetine	Male	05.INERTIA	1						
				06.INABILITY TO FEEL	1						
				07.PESSIMISTIC THOUGHTS	1						
				08.CONCENTRATIONS DIFFICULTIES	2						
				09.REDUCED SLEEP	2						
				10.REDUCED APPETITE	0						
				11.Total score	12						
	426	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	0
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	2	1	0	0	0	0	0
				06.INABILITY TO FEEL	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	1	2	0	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	1	1	1	1
				09.REDUCED SLEEP	2	3	2	2	1	1	1
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	16	14	6	8	5	4	3
	429	Imipramine	Female	01.REPORTED SADNESS	2	2					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	1	1					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	1	1					
				06.INABILITY TO FEEL	1	1					
				07.PESSIMISTIC THOUGHTS	1	1					
				08.CONCENTRATIONS DIFFICULTIES	2	1					
				09.REDUCED SLEEP	2	3					
				10.REDUCED APPETITE	2	1					
				11.Total score	15	14					
	451	Imipramine	Male	01.REPORTED SADNESS	2	1	1	1	2	1	2
				02.INNER TENSION	1	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	2	2	2	2	2
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	1	1	1	2	1	1	2
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	2	1	0	1	2	2
				09.REDUCED SLEEP	2	2	2	1	2	1	2
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	13	11	11	10	12	11	14
	452	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2
				02.INNER TENSION	1	1	0	0	1	1	0
				03.APPARENT SADNESS	3	2	2	2	1	0	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/1	452	Reboxetine	Female	04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	2	2	2	0	2	2	1
				06.INABILITY TO FEEL	3	3	3	2	2	2	1
				07.PESSIMISTIC THOUGHTS	2	1	0	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	1	2
				09.REDUCED SLEEP	2	1	2	2	1	1	0
				10.REDUCED APPETITE	2	1	1	0	0	0	0
				11.Total score	22	15	14	11	12	10	9
14/2	136	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	1	2	2	1	2	1	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	1	0
				05.INERTIA	2	2	2	1	1	1	0
				06.INABILITY TO FEEL	2	2	2	1	2	1	1
				07.PESSIMISTIC THOUGHTS	1	1	2	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
				09.REDUCED SLEEP	1	0	0	0	1	0	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	15	14	14	10	12	8	5
	456	Imipramine	Male	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	1	1	1	0	1	1	1
				03.APPARENT SADNESS	2	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	0	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
				09.REDUCED SLEEP	1	1	1	1	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	13	11	9	8	5	4	4
14/3	417	Reboxetine	Female	01.REPORTED SADNESS	3	1	1	1	0	1	1
				02.INNER TENSION	2	1	1	1	1	1	1
				03.APPARENT SADNESS	2	1	1	1	0	1	1
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	1	0	0	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	2	1	0	0	0	0
				09.REDUCED SLEEP	1	1	1	1	0	1	1
				10.REDUCED APPETITE	1	1	1	0	0	1	0
				11.Total score	18	11	8	6	4	8	7
	418	Imipramine	Female	01.REPORTED SADNESS	3	2	1	1	2	2	2
				02.INNER TENSION	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/3	418	Imipramine	Female	03.APPARENT SADNESS	2	2	2	1	2	2	2
				04.SUICIDAL THOUGHTS	1	2	1	1	1	1	1
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	1	3	1	1	2	2	2
				09.REDUCED SLEEP	0	0	0	0	0	0	0
				10.REDUCED APPETITE	0	1	0	0	0	1	1
				11.Total score	15	17	12	10	13	14	14
	419	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	0
				09.REDUCED SLEEP	0	1	2	2	0	1	0
				10.REDUCED APPETITE	1	0	0	0	0	0	1
				11.Total score	15	15	11	9	7	7	6
	420	Imipramine	Female	01.REPORTED SADNESS	3	3	2	2			
				02.INNER TENSION	2	2	2	2			
				03.APPARENT SADNESS	2	2	1	2			
				04.SUICIDAL THOUGHTS	1	1	0	0			
				05.INERTIA	3	3	2	2			
				06.INABILITY TO FEEL	2	2	1	1			
				07.PESSIMISTIC THOUGHTS	3	3	1	2			
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2			
				09.REDUCED SLEEP	1	1	0	1			
				10.REDUCED APPETITE	1	2	0	2			
				11.Total score	20	21	11	16			
	421	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	
				02.INNER TENSION	2	1	1	1	1	1	
				03.APPARENT SADNESS	3	2	1	1	1	1	
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	
				05.INERTIA	2	2	1	1	1	1	
				06.INABILITY TO FEEL	1	1	1	1	1	1	
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	
				09.REDUCED SLEEP	2	1	0	0	0	0	
				10.REDUCED APPETITE	0	0	0	0	0	0	
				11.Total score	16	12	7	7	7	7	
	427	Imipramine	Female	01.REPORTED SADNESS	2	1		1	1		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/3	427	Imipramine	Female	02.INNER TENSION	2	1		1	1		
				03.APPARENT SADNESS	2	2		2	2		
				04.SUICIDAL THOUGHTS	1	0		1	1		
				05.INERTIA	2	1		1	1		
				06.INABILITY TO FEEL	2	1		1	0		
				07.PESSIMISTIC THOUGHTS	2	2		2	2		
				08.CONCENTRATIONS DIFFICULTIES	2	1		1	1		
				09.REDUCED SLEEP	1	0		0	0		
				10.REDUCED APPETITE	1	0		1	1		
				11.Total score	17	9		11	10		
	428	Imipramine	Female	01.REPORTED SADNESS	3	2	1	2	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	2	1	1	1
				04.SUICIDAL THOUGHTS	2	2	0	1	1	1	0
				05.INERTIA	2	2	2	2	2	2	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	1	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	1
				09.REDUCED SLEEP	1	1	1	1	0	0	0
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	19	17	13	14	11	10	8
14/4	131	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	1	1	1	1	1	1	0
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	1	1	1	1	1	1	0
				06.INABILITY TO FEEL	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	1	0
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	13	13	12	9	7	7	4
	132	Imipramine	Female	01.REPORTED SADNESS	3	3	2	1	1	0	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	0	0
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	0	0
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	0	0
				11.Total score	18	18	11	9	9	5	4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/4	133	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	2	1	1	0	0
				03.APPARENT SADNESS	2	2	1	1	1	1	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	1	1	1	1
				06.INABILITY TO FEEL	1	1	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	0
				09.REDUCED SLEEP	2	2	2	2	2	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	0
				11.Total score	16	16	15	12	12	7	3
	134	Reboxetine	Female	01.REPORTED SADNESS	3	3	2	1	1	1	0
				02.INNER TENSION	2	2	2	2	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	0
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	2	2	2	1	1	1	0
				06.INABILITY TO FEEL	2	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	0	0	0
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	1
				11.Total score	19	19	16	11	8	7	4
	135	Reboxetine	Male	01.REPORTED SADNESS	3	3	2	1	1	0	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	3	3	2	1	1	0	0
				04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	0
				06.INABILITY TO FEEL	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	0	0
				11.Total score	19	19	13	10	9	5	4
14/7	422	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	2	2	1	1	0
				03.APPARENT SADNESS	1	1	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	0	0	0	0
				06.INABILITY TO FEEL	2	2	2	2	2	0	0
				07.PESSIMISTIC THOUGHTS	1	2	2	2	2	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	1	0
				09.REDUCED SLEEP	2	2	2	2	1	1	0
				10.REDUCED APPETITE	1	1	1	0	0	0	0
				11.Total score	15	16	14	12	10	6	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/7	423	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	0
				02.INNER TENSION	2	2	2	2	2	2	0
				03.APPARENT SADNESS	2	2	2	2	1	1	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	0
				09.REDUCED SLEEP	2	2	2	2	1	1	0
				10.REDUCED APPETITE	3	2	2	1	1	0	0
				11.Total score	18	16	16	14	11	9	2
	424	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	1	2	0	0
				02.INNER TENSION	2	2	2	1	1	0	1
				03.APPARENT SADNESS	1	1	1	1	1	2	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	2	2	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	0	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	0	0
				09.REDUCED SLEEP	2	1	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	0
				11.Total score	18	17	17	14	13	6	4
	430	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	1	0	0
				02.INNER TENSION	2	2	2	1	1	0	0
				03.APPARENT SADNESS	2	2	2	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	2	2	2	1	1	1	0
				06.INABILITY TO FEEL	2	2	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	2	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	0
				09.REDUCED SLEEP	2	1	1	1	0	0	0
				10.REDUCED APPETITE	1	1	0	0	0	0	0
				11.Total score	18	17	15	9	5	3	0
	431	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	3	3	1	0
				02.INNER TENSION	2	2	2	2	2	1	0
				03.APPARENT SADNESS	2	2	2	2	2	1	1
				04.SUICIDAL THOUGHTS	1	2	3	2	2	1	0
				05.INERTIA	1	1	2	2	2	1	1
				06.INABILITY TO FEEL	2	2	2	3	3	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	2	2	1	0
				10.REDUCED APPETITE	1	1	2	2	2	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/7	431	Reboxetine	Male	11.Total score	17	18	21	22	22	10	5
	432	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	1	1	0
				02.INNER TENSION	2	2	2	2	1	0	0
				03.APPARENT SADNESS	2	2	2	2	1	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	1	1	0	0
				06.INABILITY TO FEEL	2	2	2	2	1	1	0
				07.PESSIMISTIC THOUGHTS	1	1	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	0	0	0
				09.REDUCED SLEEP	2	2	1	1	0	1	1
				10.REDUCED APPETITE	2	2	1	1	1	1	1
				11.Total score	18	18	16	14	7	4	2
	433	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	0
				02.INNER TENSION	3	2	2	1	1	1	0
				03.APPARENT SADNESS	2	3	2	1	1	1	0
				04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0
				05.INERTIA	2	2	1	1	1	0	0
				06.INABILITY TO FEEL	2	2	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	0	0
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	0	0
				11.Total score	20	20	15	9	6	4	1
	434	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	0	0	0	0
				02.INNER TENSION	2	2	1	1	0	0	0
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	2	2	1	0	0	0	0
				05.INERTIA	2	2	1	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	0	0
				09.REDUCED SLEEP	2	2	1	1	1	1	0
				10.REDUCED APPETITE	2	2	1	1	0	1	0
				11.Total score	20	20	9	6	2	3	0
	439	Reboxetine	Male	01.REPORTED SADNESS	3	3	2	2	1	1	0
				02.INNER TENSION	2	2	2	2	1	0	0
				03.APPARENT SADNESS	3	3	2	2	1	0	0
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
				09.REDUCED SLEEP	2	2	1	1	1	1	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1477	439	Reboxetine	Male	10.REDUCED APPETITE	3	3	2	1	1	1	0
				11.Total score	22	22	16	14	10	5	2
	440	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	0	0	0
				02.INNER TENSION	2	2	2	0	0	0	0
				03.APPARENT SADNESS	3	3	3	1	0	0	0
				04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0
				05.INERTIA	2	2	2	0	0	0	0
				06.INABILITY TO FEEL	2	2	2	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	2	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	0	0	0	0
				09.REDUCED SLEEP	2	2	2	1	1	1	0
				10.REDUCED APPETITE	2	2	2	0	0	0	0
				11.Total score	20	20	20	3	1	1	0
	441	Imipramine	Male	01.REPORTED SADNESS	2	2	2	0	0	0	0
				02.INNER TENSION	2	2	2	1	0	0	0
				03.APPARENT SADNESS	2	2	2	1	0	0	0
				04.SUICIDAL THOUGHTS	2	2	2	0	0	0	0
				05.INERTIA	2	2	2	0	0	0	0
				06.INABILITY TO FEEL	2	2	2	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	2	2	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	0	0	0	0
				09.REDUCED SLEEP	2	2	2	1	1	1	0
				10.REDUCED APPETITE	2	2	2	0	0	0	0
				11.Total score	20	20	20	4	2	1	0
	442	Imipramine	Male	01.REPORTED SADNESS	1	2	1	0	0	0	0
				02.INNER TENSION	2	2	1	0	0	0	0
				03.APPARENT SADNESS	1	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	1	2	1	0	0	0	0
				05.INERTIA	2	2	1	1	1	0	0
				06.INABILITY TO FEEL	2	1	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	2	1	1	0	0	0
				09.REDUCED SLEEP	2	2	1	1	1	1	0
				10.REDUCED APPETITE	2	1	0	0	0	0	0
				11.Total score	18	16	9	6	2	1	0
	449	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	0	0	0
				02.INNER TENSION	1	1	1	0	0	0	0
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	2	1	1	0	0	0	0
				05.INERTIA	1	2	0	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/7	449	Reboxetine	Female	09.REDUCED SLEEP	2	2	1	2	1	1	0
				10.REDUCED APPETITE	2	2	1	1	0	0	0
				11.Total score	18	18	9	5	1	1	0
	450	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	1	0	0
				02.INNER TENSION	2	2	2	2	1	0	0
				03.APPARENT SADNESS	2	2	2	1	1	0	0
				04.SUICIDAL THOUGHTS	2	1	1	1	0	0	0
				05.INERTIA	2	2	2	1	1	0	0
				06.INABILITY TO FEEL	2	2	2	1	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	2	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	3	2	1	1	0	0
				09.REDUCED SLEEP	2	3	2	1	0	0	0
				10.REDUCED APPETITE	1	3	2	2	0	0	0
				11.Total score	19	22	19	13	5	0	0
14/8	130	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	1	1	1	0
				02.INNER TENSION	1	1	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	1	1	1	1	0
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	1	1	1
				09.REDUCED SLEEP	1	1	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	0
				11.Total score	15	14	11	10	9	9	6
	425	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	3	3	3	2	2	2	2
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	18	18	18	16	16	16	16
	467	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	2	2	2	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	3	2	1	1	3	2	1
				06.INABILITY TO FEEL	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/8	467	Reboxetine	Male	08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	3	2	2
				09.REDUCED SLEEP	3	3	3	2	3	3	2
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	19	18	15	13	18	14	12
14/10	53	Reboxetine	Male	01.REPORTED SADNESS	2	1	1	1	0	0	0
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	1	1	0	0
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	0
				11.Total score	19	17	15	10	7	6	5
	54	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	1
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	1	2	2	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	1	1
				11.Total score	20	19	17	15	15	14	12
	55	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	0	0
				02.INNER TENSION	3	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	0	0
				10.REDUCED APPETITE	2	2	1	1	1	1	0
				11.Total score	20	18	14	13	9	6	5
	56	Imipramine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	56	Imipramine	Female	07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	2	1	1	1
				11.Total score	18	17	14	14	9	9	9
	57	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	2	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	3	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	19	17	15	14	13	10	9
	58	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	1	0
				11.Total score	18	18	15	13	11	9	8
	59	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	1	1	0	0	0
				03.APPARENT SADNESS	2	2	2	1	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	17	17	14	11	8	7	7
	60	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	1	1	1
				02.INNER TENSION	3	2	1	1	1	1	0
				03.APPARENT SADNESS	2	2	2	1	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	60	Reboxetine	Female	06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	3	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	1	1	0	0
				10.REDUCED APPETITE	2	2	2	1	1	1	0
				11.Total score	20	18	17	12	10	7	5
	137	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	2	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	2	2
				11.Total score	17	17	15	13	11	12	10
	138	Imipramine	Female	01.REPORTED SADNESS	1	1	1	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	1	1	1	2	2	1
				11.Total score	17	16	14	13	12	9	8
	139	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	0	0
				02.INNER TENSION	2	2	2	1	0	0	0
				03.APPARENT SADNESS	2	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	1	1	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	16	14	11	9	6	5	5
	140	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2
				02.INNER TENSION	2	2	2	2	2	1	1
				03.APPARENT SADNESS	2	2	2	2	1	2	2
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	140	Imipramine	Female	05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2
				09.REDUCED SLEEP	2	2	2	2	1	2	1
				10.REDUCED APPETITE	2	2	2	2	1	2	1
				11.Total score	18	18	17	17	14	16	14
	435	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	0
				04.SUICIDAL THOUGHTS	0	1	1	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	1	1	1	1	1	1	1
				11.Total score	16	17	16	11	11	11	8
	436	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	1
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	1	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	0	0
				11.Total score	16	17	14	10	9	8	8
	437	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	2	1	1	0	0	0
				03.APPARENT SADNESS	2	2	1	1	1	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	0	0
				11.Total score	17	16	11	9	8	6	6
	438	Imipramine	Female	01.REPORTED SADNESS	2	3	2	1	1	1	1
				02.INNER TENSION	2	2	2	2	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	438	Imipramine	Female	04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1
				05.INERTIA	2	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	1
				10.REDUCED APPETITE	2	2	1	1	1	1	1
				11.Total score	19	19	17	14	12	10	10
	443	Reboxetine	Female	01.REPORTED SADNESS	3	3	2	2	1	0	0
				02.INNER TENSION	2	2	2	2	1	1	1
				03.APPARENT SADNESS	3	3	2	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	3	3	3	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	1	1	1
				07.PESSIMISTIC THOUGHTS	3	3	3	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	3	2	2	1	1	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	1	1
				11.Total score	24	24	21	18	11	8	8
	444	Reboxetine	Male	01.REPORTED SADNESS	3	3	3	3	2	1	1
				02.INNER TENSION	2	2	2	1	1	1	1
				03.APPARENT SADNESS	2	2	2	2	2	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	1
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	2	2	2	1	1	1
				11.Total score	17	17	17	16	13	10	9
	445	Imipramine	Female	01.REPORTED SADNESS	3	3	2	2	1	1	1
				02.INNER TENSION	2	2	2	2	2	1	1
				03.APPARENT SADNESS	3	2	2	2	2	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	2	1
				11.Total score	20	19	18	18	15	11	10
	446	Reboxetine	Female	01.REPORTED SADNESS	2	2	1	1	1	1	1
				02.INNER TENSION	2	1	1	1	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	446	Reboxetine	Female	03.APPARENT SADNESS	2	2	1	1	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	2	2	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	1	1
				11.Total score	18	17	14	14	12	10	10
	447	Reboxetine	Male	01.REPORTED SADNESS	2	2	2	2	2	1	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	2	1	1	1
				04.SUICIDAL THOUGHTS	1	1	1	1	1	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	1	1
				11.Total score	19	19	16	16	14	9	8
	448	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	1	1	1
				02.INNER TENSION	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	2	2	2	1	1	1
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	3	3	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2
				09.REDUCED SLEEP	2	2	2	2	2	2	2
				10.REDUCED APPETITE	2	2	1	2	2	1	1
				11.Total score	19	19	17	18	16	15	15
	453	Imipramine	Female	01.REPORTED SADNESS	2	2	1	0	1	0	0
				02.INNER TENSION	3	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	1	0	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	0	1	1	0
				11.Total score	19	18	12	7	11	7	6
	454	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	2	1	1	1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	454	Reboxetine	Female	02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	1	1	1	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	2	2	2	2	2	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1
				09.REDUCED SLEEP	2	2	2	2	1	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	0
				11.Total score	18	18	16	14	11	10	7
	455	Reboxetine	Female	01.REPORTED SADNESS	2	2	2	1	1	1	0
				02.INNER TENSION	3	2	1	1	1	1	1
				03.APPARENT SADNESS	2	2	2	2	1	0	0
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0
				05.INERTIA	2	2	1	1	1	1	1
				06.INABILITY TO FEEL	3	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	3	2	2	1	1	1
				09.REDUCED SLEEP	2	2	2	1	1	1	0
				10.REDUCED APPETITE	1	2	2	1	0	0	0
				11.Total score	19	18	15	11	8	7	5
15	349	Imipramine	Male	01.REPORTED SADNESS	1	0	0	0	0	0	0
				02.INNER TENSION	1	1	0	1	1	1	1
				03.APPARENT SADNESS	1	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	1	1	1	0	0	0	0
				06.INABILITY TO FEEL	2	1	2	1	1	0	0
				07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0	0	0	0
				09.REDUCED SLEEP	1	1	1	1	1	1	1
				10.REDUCED APPETITE	1	0	0	0	1	1	0
				11.Total score	12	6	5	3	4	3	2
	351	Reboxetine	Male	01.REPORTED SADNESS	2	0	0	1	0	0	0
				02.INNER TENSION	2	1	0	1	0	0	0
				03.APPARENT SADNESS	2	0	0	1	0	0	0
				04.SUICIDAL THOUGHTS	2	0	0	1	0	0	0
				05.INERTIA	3	1	0	1	1	1	0
				06.INABILITY TO FEEL	2	2	0	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	0	0	1	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	1	0	2	1	1	0
				09.REDUCED SLEEP	3	2	0	2	1	0	0
				10.REDUCED APPETITE	3	1	0	1	0	0	0
				11.Total score	24	8	0	12	4	2	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	352	Imipramine	Male	01.REPORTED SADNESS	2	1	0	0			
				02.INNER TENSION	2	1	1	1			
				03.APPARENT SADNESS	2	1	0	1			
				04.SUICIDAL THOUGHTS	1	1	0	0			
				05.INERTIA	1	2	1	1			
				06.INABILITY TO FEEL	2	2	2	1			
				07.PESSIMISTIC THOUGHTS	2	0	1	1			
				08.CONCENTRATIONS DIFFICULTIES	1	1	1	0			
				09.REDUCED SLEEP	1	1	1	0			
				10.REDUCED APPETITE	1	2	1	1			
				11.Total score	15	12	8	6			
	364	Imipramine	Female	01.REPORTED SADNESS	3	1	0	0	2		
				02.INNER TENSION	2	1	1	1	2		
				03.APPARENT SADNESS	3	1	1	1	2		
				04.SUICIDAL THOUGHTS	2	1	1	1	2		
				05.INERTIA	3	2	0	1	1		
				06.INABILITY TO FEEL	3	2	1	1	1		
				07.PESSIMISTIC THOUGHTS	2	1	1	1	2		
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	1	0		
				09.REDUCED SLEEP	2	2	2	1	2		
				10.REDUCED APPETITE	2	2	0	1	1		
				11.Total score	24	14	7	9	15		
	366	Reboxetine	Male	01.REPORTED SADNESS	1	0	0	0	0	0	0
				02.INNER TENSION	2	0	0	0	1	1	0
				03.APPARENT SADNESS	1	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	2	0	0	1	1	1	0
				06.INABILITY TO FEEL	2	0	0	1	1	1	0
				07.PESSIMISTIC THOUGHTS	1	0	0	0	0	1	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	0	1	1	0	1
				09.REDUCED SLEEP	2	1	0	0	1	0	1
				10.REDUCED APPETITE	2	0	0	0	0	0	0
				11.Total score	16	1	0	3	5	4	2
	367	Imipramine	Male	01.REPORTED SADNESS	2	2	2	2	1	2	2
				02.INNER TENSION	1	0	2	1	0	1	1
				03.APPARENT SADNESS	2	2	3	2	2	2	2
				04.SUICIDAL THOUGHTS	1	1	1	2	1	1	1
				05.INERTIA	3	3	3	3	2	2	2
				06.INABILITY TO FEEL	3	3	3	2	1	2	1
				07.PESSIMISTIC THOUGHTS	1	1	2	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	1	2	2
				09.REDUCED SLEEP	1	1	1	3	1	1	1
				10.REDUCED APPETITE	0	0	0	2	0	1	1
				11.Total score	17	16	20	21	10	15	14

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	368	Reboxetine	Female	01.REPORTED SADNESS	3	1	0	0	0	0	0
				02.INNER TENSION	0	0	0	1	1	0	1
				03.APPARENT SADNESS	3	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
				05.INERTIA	3	1	1	1	1	1	1
				06.INABILITY TO FEEL	3	1	1	2	2	2	1
				07.PESSIMISTIC THOUGHTS	0	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	1	0
				09.REDUCED SLEEP	2	1	1	1	1	1	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	16	7	3	5	5	5	3
	369	Reboxetine	Female	01.REPORTED SADNESS	2	0	0	0	0	0	0
				02.INNER TENSION	1	0	1	0	0	0	0
				03.APPARENT SADNESS	3	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	3	1	1	0	0	0	0
				06.INABILITY TO FEEL	3	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	0	0	0	0
				09.REDUCED SLEEP	2	0	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0
				11.Total score	19	4	4	0	0	0	0
	370	Imipramine	Female	01.REPORTED SADNESS	1	1	0	1	0	0	0
				02.INNER TENSION	2	2	1	1	1	1	1
				03.APPARENT SADNESS	1	1	1	1	0	0	0
				04.SUICIDAL THOUGHTS	2	1	1	1	0	0	0
				05.INERTIA	1	2	1	1	0	0	0
				06.INABILITY TO FEEL	2	2	1	1	0	0	0
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	2	1
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	0	0	0
				09.REDUCED SLEEP	2	2	2	2	1	0	1
				10.REDUCED APPETITE	0	0	0	0	0	1	0
				11.Total score	14	13	9	9	2	4	3
	371	Reboxetine	Female	01.REPORTED SADNESS	1	0	0	0	0	0	0
				02.INNER TENSION	1	1	1	1	1	1	0
				03.APPARENT SADNESS	1	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	1	0	0	0	0	0	0
				06.INABILITY TO FEEL	1	0	0	1	1	0	0
				07.PESSIMISTIC THOUGHTS	1	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	0	1	1	0	0
				09.REDUCED SLEEP	3	2	2	2	1	2	2
				10.REDUCED APPETITE	2	0	0	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	371	Reboxetine	Female	11.Total score	13	3	3	5	4	3	2
	372	Imipramine	Male	01.REPORTED SADNESS	2	3	2	1	2	2	1
				02.INNER TENSION	0	0	0	0	0	0	1
				03.APPARENT SADNESS	3	3	2	1	2	2	1
				04.SUICIDAL THOUGHTS	2	3	2	2	2	1	2
				05.INERTIA	3	3	2	2	2	2	2
				06.INABILITY TO FEEL	3	3	3	3	3	2	2
				07.PESSIMISTIC THOUGHTS	3	3	2	2	2	2	1
				08.CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	1
				09.REDUCED SLEEP	3	2	1	1	2	2	2
				10.REDUCED APPETITE	3	3	2	2	3	3	2
				11.Total score	25	26	18	16	20	18	15
	373	Imipramine	Female	01.REPORTED SADNESS	2						
				02.INNER TENSION	1						
				03.APPARENT SADNESS	1						
				04.SUICIDAL THOUGHTS	1						
				05.INERTIA	2						
				06.INABILITY TO FEEL	2						
				07.PESSIMISTIC THOUGHTS	2						
				08.CONCENTRATIONS DIFFICULTIES	2						
				09.REDUCED SLEEP	2						
				10.REDUCED APPETITE	2						
				11.Total score	17						
	374	Reboxetine	Female	01.REPORTED SADNESS	2	0	0	0	0	0	0
				02.INNER TENSION	2	1	1	0	0	0	1
				03.APPARENT SADNESS	1	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	1	0	0	0	0	0	0
				05.INERTIA	3	1	0	1	1	0	0
				06.INABILITY TO FEEL	3	0	0	1	1	0	0
				07.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	1
				08.CONCENTRATIONS DIFFICULTIES	3	2	1	1	1	0	0
				09.REDUCED SLEEP	0	2	2	3	1	1	1
				10.REDUCED APPETITE	2	0	0	0	0	1	0
				11.Total score	19	8	4	6	4	2	3
	375	Reboxetine	Female	01.REPORTED SADNESS	2	0	0	0			
				02.INNER TENSION	1	1	0	0			
				03.APPARENT SADNESS	2	0	0	0			
				04.SUICIDAL THOUGHTS	2	0	0	0			
				05.INERTIA	3	1	0	0			
				06.INABILITY TO FEEL	2	1	0	0			
				07.PESSIMISTIC THOUGHTS	1	0	0	0			
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	0			
				09.REDUCED SLEEP	2	1	0	0			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	375	Reboxetine	Female	10.REDUCED APPETITE	0	0	0	0			
				11.Total score	17	5	0	0			
	376	Imipramine	Female	01.REPORTED SADNESS	3	3					
				02.INNER TENSION	2	2					
				03.APPARENT SADNESS	2	3					
				04.SUICIDAL THOUGHTS	1	1					
				05.INERTIA	3	3					
				06.INABILITY TO FEEL	2	2					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	3	3					
				09.REDUCED SLEEP	2	2					
				10.REDUCED APPETITE	2	3					
				11.Total score	22	24					
	377	Reboxetine	Female	01.REPORTED SADNESS	2	1	0	0	0	0	0
				02.INNER TENSION	2	2	1	1	1	0	1
				03.APPARENT SADNESS	2	1	1	0	0	0	0
				04.SUICIDAL THOUGHTS	2	0	0	0	0	0	0
				05.INERTIA	3	1	1	1	1	0	0
				06.INABILITY TO FEEL	2	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	0	0	0	1
				09.REDUCED SLEEP	3	1	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	0	0	0	0
				11.Total score	22	11	7	4	4	2	3
	378	Reboxetine	Female	01.REPORTED SADNESS	3	0	0	0	0	0	0
				02.INNER TENSION	0	1	1	1	0	0	0
				03.APPARENT SADNESS	3	1	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	1	0	0	0	0	0
				05.INERTIA	3	0	1	0	0	0	1
				06.INABILITY TO FEEL	3	2	2	0	1	0	0
				07.PESSIMISTIC THOUGHTS	2	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	1	1	0	0	0
				09.REDUCED SLEEP	2	2	2	1	2	1	1
				10.REDUCED APPETITE	1	0	0	0	1	0	0
				11.Total score	21	9	8	3	4	1	2
	379	Imipramine	Female	01.REPORTED SADNESS	2						
				02.INNER TENSION	2						
				03.APPARENT SADNESS	3						
				04.SUICIDAL THOUGHTS	2						
				05.INERTIA	2						
				06.INABILITY TO FEEL	3						
				07.PESSIMISTIC THOUGHTS	1						
				08.CONCENTRATIONS DIFFICULTIES	2						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	379	Imipramine	Female	09.REDUCED SLEEP	2						
				10.REDUCED APPETITE	2						
				11.Total score	21						
	380	Imipramine	Female	01.REPORTED SADNESS	3	2	1	3	0	0	0
				02.INNER TENSION	2	1	1	1	0	1	1
				03.APPARENT SADNESS	3	2	1	3	0	0	0
				04.SUICIDAL THOUGHTS	2	2	2	2	0	0	0
				05.INERTIA	3	2	1	2	1	0	1
				06.INABILITY TO FEEL	1	3	2	3	0	1	1
				07.PESSIMISTIC THOUGHTS	2	2	2	2	1	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	1	1	0	1	1	1
				09.REDUCED SLEEP	2	2	2	2	0	0	1
				10.REDUCED APPETITE	2	2	1	2	0	1	1
				11.Total score	23	19	14	20	3	4	6
	381	Reboxetine	Female	01.REPORTED SADNESS	2	1	2	0	0	0	1
				02.INNER TENSION	2	1	2	2	1	1	1
				03.APPARENT SADNESS	2	1	1	0	0	1	1
				04.SUICIDAL THOUGHTS	3	1	1	0	1	1	2
				05.INERTIA	3	2	2	2	1	1	2
				06.INABILITY TO FEEL	3	2	2	2	1	1	2
				07.PESSIMISTIC THOUGHTS	1	1	1	2	2	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	2
				09.REDUCED SLEEP	3	1	3	2	2	2	2
				10.REDUCED APPETITE	0	2	2	2	1	1	2
				11.Total score	21	14	18	14	10	10	16
	382	Imipramine	Male	01.REPORTED SADNESS	3						
				02.INNER TENSION	2						
				03.APPARENT SADNESS	3						
				04.SUICIDAL THOUGHTS	1						
				05.INERTIA	2						
				06.INABILITY TO FEEL	2						
				07.PESSIMISTIC THOUGHTS	2						
				08.CONCENTRATIONS DIFFICULTIES	2						
				09.REDUCED SLEEP	2						
				10.REDUCED APPETITE	1						
				11.Total score	20						
	383	Imipramine	Female	01.REPORTED SADNESS	2	2	2	1	0	0	0
				02.INNER TENSION	2	1	2	1	1	2	2
				03.APPARENT SADNESS	3	1	2	0	0	0	0
				04.SUICIDAL THOUGHTS	2	2	2	1	0	0	0
				05.INERTIA	2	2	1	1	1	0	0
				06.INABILITY TO FEEL	3	2	2	2	1	1	0
				07.PESSIMISTIC THOUGHTS	3	2	1	0	0	0	0

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	383	Imipramine	Female	08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	1	0	0
				09.REDUCED SLEEP	3	3	2	0	2	1	1
				10.REDUCED APPETITE	2	2	2	1	1	1	0
				11.Total score	24	19	17	8	7	5	3
	384	Reboxetine	Female	01.REPORTED SADNESS	3	2					
				02.INNER TENSION	3	2					
				03.APPARENT SADNESS	3	2					
				04.SUICIDAL THOUGHTS	3	2					
				05.INERTIA	3	3					
				06.INABILITY TO FEEL	3	2					
				07.PESSIMISTIC THOUGHTS	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	2					
				09.REDUCED SLEEP	3	2					
				10.REDUCED APPETITE	3	2					
				11.Total score	28	21					

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	1	Reboxetine	Male	Severity of illness	5.00	6.00	4.00	4.00	6.00	4.00	3.00
				Global improvement		5.00	3.00	2.00	4.00	3.00	2.00
				Efficacy index		14.00	6.00	6.00	14.00	10.00	6.00
				Efficacy index (*)		0.50	1.50	1.50	0.50	1.00	1.50
	2	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	4.00	1.00	2.00	1.00
				Global improvement		3.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		10.00	10.00	6.00	2.00	2.00	3.00
				Efficacy index (*)		1.00	1.00	1.50	2.00	2.00	1.33
	3	Imipramine	Female	Severity of illness	6.00	5.00	5.00	4.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	10.00	6.00	6.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	4.00	4.00
	4	Imipramine	Male	Severity of illness	6.00	6.00	6.00	6.00	4.00	3.00	2.00
				Global improvement		5.00	4.00	3.00	3.00	2.00	1.00
				Efficacy index		14.00	14.00	10.00	6.00	6.00	2.00
				Efficacy index (*)		0.50	0.50	1.00	1.50	1.50	2.00
	5	Reboxetine	Female	Severity of illness	6.00	3.00	5.00	4.00	5.00	4.00	4.00
				Global improvement		2.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		2.00	10.00	6.00	10.00	6.00	5.00
				Efficacy index (*)		2.00	1.00	1.50	1.00	1.50	3.00
	6	Imipramine	Male	Severity of illness	6.00	6.00	6.00	5.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	10.00	10.00	10.00	6.00	6.00
				Efficacy index (*)		0.50	1.00	1.00	1.00	1.50	1.50
	7	Reboxetine	Male	Severity of illness	6.00	6.00	6.00	5.00	5.00	6.00	6.00
				Global improvement		5.00	4.00	3.00	3.00	3.00	4.00
				Efficacy index		14.00	14.00	10.00	10.00	11.00	14.00
				Efficacy index (*)		0.50	0.50	1.00	1.00	0.67	0.50
	8	Imipramine	Male	Severity of illness	6.00	6.00					
				Global improvement		4.00					
				Efficacy index		15.00					
				Efficacy index (*)		0.33					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
1	9	Imipramine	Female	Severity of illness	6.00	6.00	4.00	3.00	3.00	2.00	1.00
				Global improvement		4.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		14.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		0.50	1.50	2.00	2.00	2.00	2.00
	10	Imipramine	Female	Severity of illness	6.00	5.00	4.00	5.00	6.00	5.00	4.00
				Global improvement		3.00	3.00	3.00	4.00	3.00	2.00
				Efficacy index		11.00	6.00	11.00	15.00	10.00	6.00
				Efficacy index (*)		0.67	1.50	0.67	0.33	1.00	1.50
	11	Reboxetine	Male	Severity of illness	7.00	7.00	6.00	6.00	7.00		
				Global improvement		4.00	5.00	3.00	6.00		
				Efficacy index		14.00	14.00	10.00	13.00		
				Efficacy index (*)		0.50	0.50	1.00	1.00		
	12	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	6.00			
				Global improvement		4.00	3.00	5.00			
				Efficacy index		14.00	10.00	14.00			
				Efficacy index (*)		0.50	1.00	0.50			
2	33	Reboxetine	Male	Severity of illness	5.00	4.00	2.00	2.00	4.00	3.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	1.00	1.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	4.00	4.00	3.00	3.00	4.00
	34	Imipramine	Male	Severity of illness	5.00	3.00	4.00	2.00	4.00	3.00	4.00
				Global improvement		2.00	5.00	2.00	2.00	2.00	3.00
				Efficacy index		6.00	6.00	2.00	5.00	7.00	6.00
				Efficacy index (*)		1.50	1.50	2.00	3.00	1.00	1.50
	35	Reboxetine	Male	Severity of illness	6.00	4.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	1.00	1.00	2.00	2.00
				Efficacy index		5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	4.00	4.00	4.00	4.00	4.00
	36	Imipramine	Female	Severity of illness	6.00	5.00	4.00	2.00	6.00		
				Global improvement		3.00	1.00	2.00	6.00		
				Efficacy index		10.00	2.00	1.00	16.00		
				Efficacy index (*)		1.00	2.00	4.00	0.25		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	37	Reboxetine	Male	Severity of illness	6.00	4.00	4.00	4.00	4.00	4.00	3.00
				Global improvement		2.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		6.00	9.00	10.00	6.00	6.00	5.00
				Efficacy index (*)		1.50	2.00	1.00	1.50	1.50	3.00
	38	Imipramine	Female	Severity of illness	5.00	5.00	5.00	6.00	6.00	6.00	5.00
				Global improvement		3.00	3.00	4.00	6.00	6.00	3.00
				Efficacy index		9.00	10.00	14.00	14.00	14.00	9.00
				Efficacy index (*)		2.00	1.00	0.50	0.50	0.50	2.00
	39	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	4.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	3.00	4.00
	40	Imipramine	Male	Severity of illness	5.00	3.00	4.00	3.00	5.00	4.00	3.00
				Global improvement		2.00	2.00	2.00	3.00	2.00	2.00
				Efficacy index		5.00	5.00	5.00	9.00	5.00	5.00
				Efficacy index (*)		3.00	3.00	3.00	2.00	3.00	3.00
	41	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	5.00	5.00	5.00
				Global improvement		5.00	5.00	3.00	3.00	4.00	4.00
				Efficacy index		15.00	16.00	7.00	10.00	10.00	13.00
				Efficacy index (*)		0.33	0.25	1.00	1.00	1.00	1.00
	42	Imipramine	Male	Severity of illness	6.00	5.00	5.00	5.00	5.00	5.00	3.00
				Global improvement		5.00	4.00	4.00	3.00	3.00	2.00
				Efficacy index		14.00	10.00	14.00	6.00	9.00	5.00
				Efficacy index (*)		0.50	1.00	0.50	1.50	2.00	3.00
	43	Reboxetine	Female	Severity of illness	5.00	4.00	2.00	2.00	2.00	1.00	2.00
				Global improvement		2.00	1.00	2.00	2.00	1.00	2.00
				Efficacy index		6.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index (*)		1.50	2.00	2.00	4.00	4.00	4.00
	44	Imipramine	Male	Severity of illness	6.00	6.00					
				Global improvement		6.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
2	45	Imipramine	Female	Severity of illness	5.00	4.00					
				Global improvement		3.00					
				Efficacy index		12.00					
				Efficacy index (*)		0.50					
	46	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		11.00	10.00	6.00	6.00	6.00	6.00
				Efficacy index (*)		0.67	1.00	1.50	1.50	1.50	1.50
	47	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	2.00	1.00	1.00
				Global improvement		5.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		15.00	7.00	6.00	6.00	2.00	2.00
				Efficacy index (*)		0.33	1.00	1.50	1.50	2.00	2.00
	48	Imipramine	Female	Severity of illness	6.00	5.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	5.00	6.00	1.00	1.00	6.00
				Efficacy index (*)		1.00	3.00	1.50	4.00	4.00	1.50
	49	Imipramine	Female	Severity of illness	6.00	5.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	3.00	2.00	6.00
				Efficacy index (*)		1.00	1.50	1.50	1.33	2.00	1.50
	50	Reboxetine	Male	Severity of illness	6.00	6.00	6.00	5.00	5.00	5.00	
				Global improvement		4.00	6.00	4.00	3.00	3.00	
				Efficacy index		14.00	15.00	15.00	11.00	11.00	
				Efficacy index (*)		0.50	0.33	0.33	0.67	0.67	
	51	Reboxetine	Female	Severity of illness	6.00	6.00	7.00				
				Global improvement		4.00	7.00				
				Efficacy index		14.00	15.00				
				Efficacy index (*)		0.50	0.33				
	52	Imipramine	Male	Severity of illness	6.00	4.00	3.00	2.00	1.00	2.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index (*)		1.50	2.00	2.00	2.00	2.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3	65	Reboxetine	Male	Severity of illness	5.00	3.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		6.00	6.00	7.00	2.00	3.00	3.00
				Efficacy index (*)		1.50	1.50	1.00	2.00	1.33	1.33
	66	Imipramine	Female	Severity of illness	6.00	2.00	1.00	1.00	2.00	7.00	
				Global improvement		2.00	2.00	1.00	2.00	7.00	
				Efficacy index		2.00	2.00	2.00	2.00	14.00	
				Efficacy index (*)		2.00	2.00	2.00	2.00	0.50	
	67	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	4.00
				Efficacy index		10.00	10.00	10.00	11.00	10.00	14.00
				Efficacy index (*)		1.00	1.00	1.00	0.67	1.00	0.50
	68	Imipramine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		10.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00
	69	Imipramine	Female	Severity of illness	6.00	6.00	5.00	3.00	2.00	4.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	3.00	2.00
				Efficacy index		14.00	10.00	2.00	1.00	5.00	1.00
				Efficacy index (*)		0.50	1.00	2.00	4.00	3.00	4.00
	70	Reboxetine	Female	Severity of illness	6.00	7.00	5.00	5.00	5.00		
				Global improvement		6.00	3.00	3.00	3.00		
				Efficacy index		15.00	11.00	11.00	11.00		
				Efficacy index (*)		0.33	0.67	0.67	0.67		
	71	Imipramine	Female	Severity of illness	5.00	2.00	1.00	2.00	1.00	1.00	1.00
				Global improvement		2.00	1.00	2.00	1.00	1.00	1.00
				Efficacy index		2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00
	72	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		10.00	10.00	10.00	10.00	10.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
3	73	Reboxetine	Female	Severity of illness	5.00	3.00	2.00	2.00	2.00	2.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00
4	97	Imipramine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	9.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	2.00	1.00	1.00	1.00	1.00
	100	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	4.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00
	101	Imipramine	Female	Severity of illness	4.00	4.00	5.00	5.00			
				Global improvement		4.00	6.00	6.00			
				Efficacy index		15.00	14.00	14.00			
				Efficacy index (*)		0.33	0.50	0.50			
6	161	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	4.00	2.00	4.00	3.00
				Global improvement		2.00	1.00	2.00	1.00	3.00	3.00
				Efficacy index		6.00	1.00	6.00	2.00	6.00	6.00
				Efficacy index (*)		1.50	4.00	1.50	2.00	1.50	1.50
	162	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	1.00	1.00	2.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	2.00
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00
7	193	Reboxetine	Female	Severity of illness	5.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	194	Reboxetine	Male	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
7	196	Imipramine	Female	Severity of illness	5.00	3.00	3.00	3.00	3.00	3.00	4.00
				Global improvement		2.00	2.00	2.00	2.00	2.00	3.00
				Efficacy index		7.00	7.00	7.00	7.00	7.00	8.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	0.75
8	225	Imipramine	Female	Severity of illness	4.00	4.00	2.00				
				Global improvement		5.00	1.00				
				Efficacy index		15.00	2.00				
				Efficacy index (*)		0.33	2.00				
	226	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	5.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	5.00	3.00	5.00	3.00
				Efficacy index		13.00	9.00	10.00	9.00	13.00	9.00
				Efficacy index (*)		1.00	2.00	1.00	2.00	1.00	2.00
	227	Imipramine	Male	Severity of illness	5.00	3.00	3.00	4.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	3.00	2.00	2.00	2.00
				Efficacy index		2.00	2.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	2.00	1.50	2.00	2.00	2.00
	228	Reboxetine	Male	Severity of illness	5.00	4.00	4.00				
				Global improvement		3.00	3.00				
				Efficacy index		11.00	12.00				
				Efficacy index (*)		0.67	0.50				
	229	Imipramine	Female	Severity of illness	5.00	4.00	3.00	4.00	3.00	3.00	3.00
				Global improvement		2.00	2.00	3.00	2.00	2.00	2.00
				Efficacy index		6.00	2.00	10.00	6.00	6.00	6.00
				Efficacy index (*)		1.50	2.00	1.00	1.50	1.50	1.50
	230	Imipramine	Female	Severity of illness	5.00	4.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		5.00	5.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	3.00	4.00	4.00	4.00
	231	Reboxetine	Female	Severity of illness	4.00	3.00					
				Global improvement		2.00					
				Efficacy index		5.00					
				Efficacy index (*)		3.00					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
8	232	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	3.00	3.00	2.00
				Global improvement		3.00	4.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	13.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	1.00	2.00	3.00	3.00	3.00
9	197	Reboxetine	Male	Severity of illness	4.00	4.00					
				Global improvement		5.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	198	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	1.00	1.00	1.00
				Global improvement		4.00	4.00	3.00	1.00	1.00	1.00
				Efficacy index		14.00	14.00	6.00	2.00	2.00	1.00
				Efficacy index (*)		0.50	0.50	1.50	2.00	2.00	4.00
	199	Imipramine	Male	Severity of illness	4.00	4.00	5.00	5.00	4.00	5.00	4.00
				Global improvement		5.00	5.00	5.00	3.00	6.00	3.00
				Efficacy index		14.00	14.00	14.00	10.00	14.00	10.00
				Efficacy index (*)		0.50	0.50	0.50	1.00	0.50	1.00
	200	Reboxetine	Male	Severity of illness	5.00	5.00	3.00	2.00	1.00	1.00	1.00
				Global improvement		4.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		14.00	6.00	2.00	1.00	1.00	1.00
				Efficacy index (*)		0.50	1.50	2.00	4.00	4.00	4.00
	201	Imipramine	Female	Severity of illness	6.00	5.00	2.00	2.00	2.00	2.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		9.00	3.00	1.00	1.00	1.00	2.00
				Efficacy index (*)		2.00	1.33	4.00	4.00	4.00	2.00
	202	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	2.00	5.00	3.00	4.00
				Efficacy index		15.00	10.00	2.00	15.00	10.00	14.00
				Efficacy index (*)		0.33	1.00	2.00	0.33	1.00	0.50
	203	Reboxetine	Female	Severity of illness	6.00	6.00					
				Global improvement		6.00					
				Efficacy index		15.00					
				Efficacy index (*)		0.33					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	204	Reboxetine	Male	Severity of illness	5.00	2.00	2.00	1.00	2.00	2.00	1.00
				Global improvement		2.00	2.00	1.00	2.00	2.00	1.00
				Efficacy index		2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	4.00	4.00	4.00	4.00	4.00
	205	Imipramine	Female	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	206	Imipramine	Female	Severity of illness	4.00	4.00	3.00	3.00	2.00	1.00	1.00
				Global improvement		4.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	6.00	2.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	1.50	2.00	4.00	4.00
	207	Reboxetine	Female	Severity of illness	4.00	4.00					
				Global improvement		3.00					
				Efficacy index		11.00					
				Efficacy index (*)		0.67					
	208	Reboxetine	Male	Severity of illness	4.00	5.00	2.00	2.00	2.00	2.00	4.00
				Global improvement		4.00	2.00	1.00	2.00	2.00	3.00
				Efficacy index		14.00	2.00	3.00	1.00	1.00	6.00
				Efficacy index (*)		0.50	2.00	1.33	4.00	4.00	1.50
	209	Imipramine	Male	Severity of illness	3.00	3.00					
				Global improvement		4.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	210	Reboxetine	Female	Severity of illness	3.00	3.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	10.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	1.00	1.50	3.00	3.00	3.00
	211	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00			
				Global improvement		4.00	4.00	3.00			
				Efficacy index		14.00	14.00	10.00			
				Efficacy index (*)		0.50	0.50	1.00			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	212	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	2.00	2.00	1.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		11.00	6.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		0.67	1.50	1.50	2.00	2.00	2.00
	237	Reboxetine	Male	Severity of illness	5.00	5.00	4.00				
				Global improvement		3.00	4.00				
				Efficacy index		11.00	15.00				
				Efficacy index (*)		0.67	0.33				
	238	Imipramine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	1.00	1.00
				Global improvement		4.00	4.00	3.00	3.00	1.00	1.00
				Efficacy index		13.00	13.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	2.00	3.00	4.00	4.00
	239	Imipramine	Male	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index (*)		0.50	1.50	1.50	1.50	1.50	1.50
	240	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00			
				Global improvement		4.00	4.00	4.00			
				Efficacy index		14.00	14.00	14.00			
				Efficacy index (*)		0.50	0.50	0.50			
	241	Imipramine	Female	Severity of illness	6.00	5.00	4.00	4.00	4.00	4.00	3.00
				Global improvement		5.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		14.00	10.00	10.00	10.00	10.00	6.00
				Efficacy index (*)		0.50	1.00	1.00	1.00	1.00	1.50
	242	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	1.00	1.00
				Global improvement		4.00	3.00	3.00	3.00	1.00	1.00
				Efficacy index		14.00	10.00	10.00	10.00	1.00	1.00
				Efficacy index (*)		0.50	1.00	1.00	1.00	4.00	4.00
	243	Imipramine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		11.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		0.67	2.00	3.00	3.00	3.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	244	Reboxetine	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		6.00	10.00	10.00	6.00	9.00	9.00
				Efficacy index (*)		1.50	1.00	1.00	1.50	2.00	2.00
	257	Reboxetine	Female	Severity of illness	5.00	3.00	3.00	2.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	1.00	2.00	2.00	2.00
				Efficacy index		5.00	5.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		3.00	3.00	2.00	2.00	2.00	2.00
	258	Reboxetine	Male	Severity of illness	4.00	5.00	5.00	6.00			
				Global improvement		5.00	4.00	6.00			
				Efficacy index		15.00	13.00	13.00			
				Efficacy index (*)		0.33	1.00	1.00			
	259	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	2.00	2.00	2.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	14.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		0.50	0.50	1.50	2.00	2.00	2.00
	260	Imipramine	Female	Severity of illness	4.00	4.00	4.00	5.00			
				Global improvement		3.00	3.00	5.00			
				Efficacy index		9.00	9.00	13.00			
				Efficacy index (*)		2.00	2.00	1.00			
	261	Imipramine	Female	Severity of illness	5.00	5.00					
				Global improvement		5.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	262	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		9.00	5.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	4.00	4.00	4.00
	263	Reboxetine	Female	Severity of illness	4.00	4.00	4.00				
				Global improvement		4.00	5.00				
				Efficacy index		13.00	13.00				
				Efficacy index (*)		1.00	1.00				

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	264	Imipramine	Female	Severity of illness	5.00	5.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	7.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00
	265	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	5.00	3.00	2.00
				Efficacy index		13.00	9.00	5.00	13.00	9.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	1.00	2.00	4.00
	266	Reboxetine	Female	Severity of illness	4.00	3.00	2.00	2.00	2.00	3.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	6.00	6.00	6.00	6.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	1.50	1.50	2.00
	267	Imipramine	Male	Severity of illness	5.00	4.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	1.50	2.00	2.00	2.00	2.00
	268	Imipramine	Female	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		2.00	2.00	2.00	2.00	4.00	3.00
				Efficacy index		6.00	6.00	6.00	6.00	13.00	7.00
				Efficacy index (*)		1.50	1.50	1.50	1.50	1.00	1.00
	269	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	1.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		6.00	6.00	6.00	5.00	1.00	1.00
				Efficacy index (*)		1.50	1.50	1.50	3.00	4.00	4.00
	270	Imipramine	Female	Severity of illness	5.00	5.00					
				Global improvement		5.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	271	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00		
				Global improvement		3.00	3.00	3.00	3.00		
				Efficacy index		11.00	11.00	12.00	12.00		
				Efficacy index (*)		0.67	0.67	0.50	0.50		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9	272	Imipramine	Male	Severity of illness	6.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	2.00	2.00	2.00
	273	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00		
				Global improvement		4.00	3.00	3.00	3.00		
				Efficacy index		15.00	11.00	12.00	12.00		
				Efficacy index (*)		0.33	0.67	0.50	0.50		
	274	Reboxetine	Female	Severity of illness	4.00	4.00					
				Global improvement		4.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	274/A	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	5.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		10.00	10.00	10.00	10.00	6.00	10.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.50	1.00
	275	Reboxetine	Female	Severity of illness	5.00	3.00	3.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		6.00	6.00	2.00	1.00	1.00	1.00
				Efficacy index (*)		1.50	1.50	2.00	4.00	4.00	4.00
	276	Imipramine	Female	Severity of illness	4.00	5.00					
				Global improvement		5.00					
				Efficacy index		13.00					
				Efficacy index (*)		1.00					
	276/A	Imipramine	Male	Severity of illness	4.00	5.00	5.00	5.00	2.00	2.00	2.00
				Global improvement		5.00	5.00	5.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	1.00	4.00	4.00	4.00
9/A	233	Imipramine	Male	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	6.00	6.00	6.00	6.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	1.50	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	234	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	10.00	6.00	6.00	6.00	6.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	1.50	1.50
	235	Reboxetine	Male	Severity of illness	6.00	4.00	3.00	3.00	3.00	5.00	
				Global improvement		2.00	2.00	2.00	2.00	4.00	
				Efficacy index		5.00	5.00	5.00	6.00	14.00	
				Efficacy index (*)		3.00	3.00	3.00	1.50	0.50	
	236	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	10.00	6.00	6.00	6.00	1.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	1.50	4.00
	277	Reboxetine	Female	Severity of illness	6.00	6.00					
				Global improvement		5.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	278	Imipramine	Female	Severity of illness	5.00	3.00	3.00	4.00			
				Global improvement		2.00	1.00	4.00			
				Efficacy index		6.00	1.00	13.00			
				Efficacy index (*)		1.50	4.00	1.00			
	279	Imipramine	Male	Severity of illness	4.00	4.00	5.00				
				Global improvement		4.00	5.00				
				Efficacy index		15.00	15.00				
				Efficacy index (*)		0.33	0.33				
	280	Reboxetine	Female	Severity of illness	5.00	5.00					
				Global improvement		5.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	281	Reboxetine	Female	Severity of illness	4.00	3.00	2.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	4.00	4.00	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	282	Reboxetine	Male	Severity of illness	6.00	6.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	6.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.50	1.50	3.00	3.00	3.00
	283	Imipramine	Female	Severity of illness	4.00	4.00	3.00	3.00	2.00	1.00	1.00
				Global improvement		4.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	4.00	4.00	4.00	4.00	4.00
	284	Imipramine	Male	Severity of illness	5.00	5.00	4.00	5.00			
				Global improvement		4.00	3.00	4.00			
				Efficacy index		14.00	10.00	13.00			
				Efficacy index (*)		0.50	1.00	1.00			
	301	Imipramine	Female	Severity of illness	4.00	3.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		10.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	2.00	2.00	2.00	2.00
	302	Imipramine	Male	Severity of illness	4.00	4.00	4.00	4.00			
				Global improvement		4.00	4.00	4.00			
				Efficacy index		14.00	14.00	14.00			
				Efficacy index (*)		0.50	0.50	0.50			
	303	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	4.00			
				Global improvement		3.00	4.00	4.00			
				Efficacy index		10.00	14.00	14.00			
				Efficacy index (*)		1.00	0.50	0.50			
	304	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00	1.00	1.00
				Global improvement		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		6.00	6.00	6.00	6.00	2.00	1.00
				Efficacy index (*)		1.50	1.50	1.50	1.50	2.00	4.00
	305	Reboxetine	Male	Severity of illness	5.00	3.00	2.00	2.00	2.00	1.00	1.00
				Global improvement		2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.50	4.00	4.00	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
9/A	306	Reboxetine	Female	Severity of illness	5.00	5.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		4.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		15.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		0.33	2.00	4.00	4.00	4.00	4.00
	307	Imipramine	Female	Severity of illness	4.00	4.00					
				Global improvement		4.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	308	Imipramine	Female	Severity of illness	6.00	5.00	5.00	4.00	6.00		
				Global improvement		3.00	3.00	2.00	4.00		
				Efficacy index		10.00	10.00	6.00	15.00		
				Efficacy index (*)		1.00	1.00	1.50	0.33		
10	289	Imipramine	Female	Severity of illness	5.00	5.00					
				Global improvement		6.00					
				Efficacy index		14.00					
				Efficacy index (*)		0.50					
	290	Reboxetine	Male	Severity of illness	6.00	4.00	4.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.50	1.50	3.00	3.00	3.00
	291	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	2.00	2.00	1.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	7.00	7.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00
	292	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	4.00	4.00	4.00	4.00	4.00
	293	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
10	294	Imipramine	Female	Severity of illness	5.00	6.00	6.00	5.00			
				Global improvement		7.00	7.00	6.00			
				Efficacy index		15.00	13.00	13.00			
				Efficacy index (*)		0.33	1.00	1.00			
	295	Imipramine	Male	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	6.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	1.50	3.00	3.00
	296	Reboxetine	Female	Severity of illness	6.00	6.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	7.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	3.00	3.00	3.00	3.00
	297	Reboxetine	Male	Severity of illness	6.00	6.00	4.00	3.00	2.00	2.00	1.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	4.00
	298	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	10.00	6.00	6.00	6.00
				Efficacy index (*)		1.00	2.00	1.00	1.50	1.50	1.50
	299	Imipramine	Male	Severity of illness	5.00	5.00	6.00	6.00	5.00	5.00	3.00
				Global improvement		4.00	6.00	4.00	3.00	3.00	3.00
				Efficacy index		14.00	14.00	14.00	10.00	10.00	10.00
				Efficacy index (*)		0.50	0.50	0.50	1.00	1.00	1.00
	300	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	3.00	2.00	2.00	3.00
				Efficacy index		13.00	13.00	9.00	6.00	6.00	10.00
				Efficacy index (*)		1.00	1.00	2.00	1.50	1.50	1.00
11	321	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		6.00	5.00	6.00	5.00	1.00	1.00
				Efficacy index (*)		1.50	3.00	1.50	3.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	322	Reboxetine	Female	Severity of illness	4.00	4.00	3.00	3.00	2.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		9.00	6.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	1.50	3.00	4.00	4.00	4.00
	323	Imipramine	Female	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	1.00	2.00	1.00
				Efficacy index		10.00	10.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00
	324	Imipramine	Male	Severity of illness	4.00	4.00	3.00	4.00	2.00	2.00	2.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	10.00	6.00	6.00	2.00
				Efficacy index (*)		1.00	1.50	1.00	1.50	1.50	2.00
	325	Reboxetine	Female	Severity of illness	4.00	4.00	2.00	2.00	2.00	1.00	1.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		10.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	4.00	4.00	4.00
	326	Imipramine	Male	Severity of illness	4.00	4.00	3.00	3.00	2.00	1.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	1.00	2.00
				Efficacy index		10.00	6.00	6.00	2.00	2.00	1.00
				Efficacy index (*)		1.00	1.50	1.50	2.00	2.00	4.00
	327	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	3.00	3.00	3.00	2.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	6.00	6.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	1.50	1.50	2.00
	328	Imipramine	Male	Severity of illness	4.00	3.00	3.00	2.00	2.00		
				Global improvement		2.00	2.00	2.00	1.00		
				Efficacy index		6.00	6.00	2.00	2.00		
				Efficacy index (*)		1.50	1.50	2.00	2.00		
	329	Imipramine	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	1.00	2.00
				Efficacy index		10.00	6.00	6.00	6.00	1.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	1.50	4.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
11	330	Reboxetine	Female	Severity of illness	4.00	4.00					
				Global improvement		4.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	331	Reboxetine	Male	Severity of illness	4.00	4.00	3.00	3.00	4.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	3.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	10.00	6.00	6.00
				Efficacy index (*)		1.00	1.50	1.50	1.00	1.50	1.50
	332	Imipramine	Female	Severity of illness	4.00	2.00		1.00	1.00	1.00	1.00
				Global improvement		1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	2.00	4.00	4.00	4.00
	333	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	3.00	3.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	9.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	2.00	2.00	1.50	2.00	2.00
12	337	Imipramine	Female	Severity of illness	4.00	3.00	2.00	3.00	3.00	4.00	1.00
				Global improvement		2.00	1.00	3.00	3.00	5.00	1.00
				Efficacy index		6.00	2.00	6.00	6.00	15.00	2.00
				Efficacy index (*)		1.50	2.00	1.50	1.50	0.33	2.00
	338	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	4.00	4.00
				Global improvement		4.00	3.00	2.00	2.00	3.00	3.00
				Efficacy index		14.00	10.00	6.00	6.00	10.00	10.00
				Efficacy index (*)		0.50	1.00	1.50	1.50	1.00	1.00
	339	Imipramine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	2.00	1.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	10.00	6.00	6.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	2.00	2.00
	340	Reboxetine	Female	Severity of illness	5.00	5.00	2.00	2.00	1.00	3.00	4.00
				Global improvement		4.00	1.00	1.00	1.00	2.00	3.00
				Efficacy index		14.00	2.00	2.00	1.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	4.00	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
12	341	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	5.00	
				Global improvement		4.00	3.00	4.00	3.00	4.00	
				Efficacy index		14.00	10.00	14.00	11.00	14.00	
				Efficacy index (*)		0.50	1.00	0.50	0.67	0.50	
13	353	Reboxetine	Female	Severity of illness	3.00	3.00	3.00	2.00	2.00	4.00	
				Global improvement		3.00	2.00	2.00	2.00	5.00	
				Efficacy index		9.00	6.00	5.00	6.00	13.00	
				Efficacy index (*)		2.00	1.50	3.00	1.50	1.00	
	354	Imipramine	Female	Severity of illness	4.00	3.00	3.00	1.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	2.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	355	Reboxetine	Female	Severity of illness	4.00	3.00					
				Global improvement		2.00					
				Efficacy index		3.00					
				Efficacy index (*)		1.33					
	356	Imipramine	Male	Severity of illness	5.00	4.00	3.00	3.00	3.00	4.00	4.00
				Global improvement		3.00	2.00	2.00	3.00	2.00	3.00
				Efficacy index		10.00	6.00	6.00	10.00	6.00	6.00
				Efficacy index (*)		1.00	1.50	1.50	1.00	1.50	1.50
	357	Imipramine	Female	Severity of illness	4.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	358	Reboxetine	Male	Severity of illness	5.00	4.00	4.00	3.00	3.00		
				Global improvement		3.00	5.00	2.00	5.00		
				Efficacy index		10.00	14.00	6.00	15.00		
				Efficacy index (*)		1.00	0.50	1.50	0.33		
	359	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	2.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
13	360	Imipramine	Female	Severity of illness	4.00	4.00					
				Global improvement		3.00					
				Efficacy index		12.00					
				Efficacy index (*)		0.50					
	361	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	3.00	2.00	1.00
				Global improvement		2.00	1.00	1.00	2.00	1.00	1.00
				Efficacy index		6.00	1.00	1.00	5.00	1.00	1.00
				Efficacy index (*)		1.50	4.00	4.00	3.00	4.00	4.00
14	457	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	4.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	14.00	10.00	10.00	6.00	6.00
				Efficacy index (*)		1.00	0.50	1.00	1.00	1.50	1.50
	458	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	2.00
				Efficacy index		14.00	14.00	10.00	10.00	10.00	6.00
				Efficacy index (*)		0.50	0.50	1.00	1.00	1.00	1.50
	459	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00
	460	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	4.00	4.00	3.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	3.00	3.00
	461	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	3.00	5.00
				Efficacy index		13.00	14.00	14.00	14.00	11.00	14.00
				Efficacy index (*)		1.00	0.50	0.50	0.50	0.67	0.50
	462	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)		1.00	0.50	0.50	0.50	0.50	0.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14	463	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	3.00	3.00
	464	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	13.00	13.00	14.00	14.00	14.00
				Efficacy index (*)		1.00	1.00	1.00	0.50	0.50	0.50
	465	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	1.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		10.00	10.00	6.00	6.00	5.00	1.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	3.00	4.00
	466	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
14/1	129	Reboxetine	Male	Severity of illness	5.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	426	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	3.00	1.00	1.00	1.00
				Efficacy index		13.00	10.00	10.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00
	429	Imipramine	Female	Severity of illness	5.00	4.00					
				Global improvement		5.00					
				Efficacy index		16.00					
				Efficacy index (*)		0.25					
	451	Imipramine	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	5.00	2.00	3.00	4.00	4.00
				Efficacy index		10.00	13.00	7.00	9.00	14.00	14.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	0.50	0.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/1	452	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	4.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	3.00
				Efficacy index		9.00	10.00	10.00	6.00	6.00	10.00
				Efficacy index (*)		2.00	1.00	1.00	1.50	1.50	1.00
14/2	136	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	2.00
				Global improvement		5.00	4.00	3.00	3.00	2.00	1.00
				Efficacy index		14.00	13.00	9.00	9.00	5.00	1.00
				Efficacy index (*)		0.50	1.00	2.00	2.00	3.00	4.00
	456	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	2.00	2.00
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	5.00	2.00	1.00	1.00
				Efficacy index (*)		1.00	1.50	3.00	2.00	4.00	4.00
14/3	417	Reboxetine	Female	Severity of illness	5.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		2.00	2.00	2.00	1.00	2.00	2.00
				Efficacy index		1.00	1.00	6.00	1.00	1.00	1.00
				Efficacy index (*)		4.00	4.00	1.50	4.00	4.00	4.00
	418	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	5.00	5.00	5.00
				Global improvement		3.00	3.00	3.00	4.00	3.00	5.00
				Efficacy index		9.00	9.00	9.00	13.00	9.00	13.00
				Efficacy index (*)		2.00	2.00	2.00	1.00	2.00	1.00
	419	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	4.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	13.00	6.00	2.00	6.00	1.00
				Efficacy index (*)		2.00	1.00	1.50	2.00	1.50	4.00
	420	Imipramine	Female	Severity of illness	5.00	5.00	4.00	5.00			
				Global improvement		3.00	2.00	6.00			
				Efficacy index		9.00	1.00	13.00			
				Efficacy index (*)		2.00	4.00	1.00			
	421	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	3.00	
				Global improvement		2.00	2.00	2.00	2.00	2.00	
				Efficacy index		5.00	2.00	1.00	1.00	1.00	
				Efficacy index (*)		3.00	2.00	4.00	4.00	4.00	

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/3	427	Imipramine	Female	Severity of illness	4.00	4.00		4.00	4.00		
				Global improvement		3.00		4.00	4.00		
				Efficacy index		10.00		13.00	15.00		
				Efficacy index (*)		1.00		1.00	0.33		
	428	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	2.00	3.00	3.00	2.00	2.00
				Efficacy index		9.00	6.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	1.50	3.00	3.00	3.00	3.00
14/4	131	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		14.00	10.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		0.50	1.00	3.00	3.00	3.00	4.00
	132	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	3.00	3.00	3.00	3.00	4.00
	133	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	5.00	6.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	1.50	3.00	4.00
	134	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	4.00
	135	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	2.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		14.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		0.50	3.00	3.00	3.00	3.00	4.00
14/7	422	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	10.00	10.00	6.00	6.00	2.00
				Efficacy index (*)		1.00	1.00	1.00	1.50	1.50	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/7	423	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	1.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	10.00	10.00	10.00	9.00	2.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	2.00	2.00
	424	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	1.00
				Global improvement		3.00	5.00	3.00	3.00	3.00	1.00
				Efficacy index		9.00	10.00	10.00	6.00	6.00	2.00
				Efficacy index (*)		2.00	1.00	1.00	1.50	1.50	2.00
	430	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	6.00	5.00	6.00	2.00
				Efficacy index (*)		1.00	2.00	1.50	3.00	1.50	2.00
	431	Reboxetine	Male	Severity of illness	6.00	6.00	6.00	6.00	6.00	5.00	3.00
				Global improvement		4.00	5.00	6.00	4.00	3.00	2.00
				Efficacy index		13.00	13.00	15.00	14.00	10.00	6.00
				Efficacy index (*)		1.00	1.00	0.33	0.50	1.00	1.50
	432	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	3.00	3.00	3.00
				Global improvement		4.00	4.00	4.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	6.00	6.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.50	1.50	1.50
	433	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	1.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	1.00
				Efficacy index		13.00	9.00	10.00	10.00	6.00	2.00
				Efficacy index (*)		1.00	2.00	1.00	1.00	1.50	2.00
	434	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	10.00	6.00	6.00	6.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	1.50	1.50	2.00
	439	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	10.00	10.00	10.00	6.00	2.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.50	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/7	440	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	1.00	1.00
				Global improvement		4.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		13.00	9.00	6.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	1.50	4.00	4.00	4.00
	441	Imipramine	Male	Severity of illness	5.00	5.00	5.00	4.00	1.00	1.00	1.00
				Global improvement		4.00	3.00	2.00	1.00	1.00	1.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00
	442	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	3.00	3.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	5.00	6.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	1.50	4.00	4.00
	449	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	1.00	1.00
				Global improvement		4.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00
	450	Imipramine	Male	Severity of illness	4.00	5.00	5.00	5.00	3.00	1.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	4.00	4.00
14/8	130	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	6.00	2.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	1.50	2.00
	425	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00
	467	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		13.00	10.00	10.00	10.00	10.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.50

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	53	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	3.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	5.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	3.00	4.00	4.00	4.00
	54	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	13.00	9.00	9.00	9.00	5.00
				Efficacy index (*)		0.50	1.00	2.00	2.00	2.00	3.00
	55	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	2.00	2.00
				Global improvement		4.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	5.00	6.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	3.00	1.50	3.00	4.00	4.00
	56	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	3.00	3.00	3.00	3.00
	57	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		9.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	3.00	3.00
	58	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	2.00	3.00	3.00	3.00
	59	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	2.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	1.00	1.00	2.00
				Efficacy index		14.00	10.00	6.00	1.00	1.00	1.00
				Efficacy index (*)		0.50	1.00	1.50	4.00	4.00	4.00
	60	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	2.00	2.00
				Global improvement		4.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	137	Reboxetine	Female	Severity of illness	5.00	6.00	5.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	1.50	3.00	3.00	3.00
	138	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	2.00	3.00	3.00
	139	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		10.00	5.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	3.00	3.00	4.00	4.00	4.00
	140	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	3.00	3.00	4.00	3.00
				Efficacy index		14.00	13.00	9.00	9.00	13.00	9.00
				Efficacy index (*)		0.50	1.00	2.00	2.00	1.00	2.00
	435	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00
	436	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	10.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	3.00	3.00	3.00	3.00
	437	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	2.00	2.00
				Global improvement		3.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	9.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	3.00	3.00	4.00	4.00
	438	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	3.00	3.00	3.00	3.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	443	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	5.00	4.00	3.00	3.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	3.00	3.00	3.00
	444	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	3.00
				Global improvement		4.00	4.00	3.00	2.00	2.00	2.00
				Efficacy index		14.00	13.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	2.00	3.00	3.00	3.00
	445	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	2.00	3.00	3.00
	446	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	3.00	3.00	3.00	3.00	3.00
	447	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		14.00	9.00	9.00	9.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	2.00	3.00	3.00
	448	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00
	453	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	4.00	3.00	2.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		14.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		0.50	3.00	3.00	3.00	3.00	4.00
	454	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	2.00
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
14/10	455	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	9.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	3.00	3.00	3.00	3.00
15	349	Imipramine	Male	Severity of illness	4.00	3.00	2.00	2.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	4.00	4.00
	351	Reboxetine	Male	Severity of illness	6.00	4.00	1.00	5.00	2.00	1.00	1.00
				Global improvement		2.00	1.00	3.00	2.00	1.00	1.00
				Efficacy index		5.00	1.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	4.00	3.00	4.00	4.00	4.00
	352	Imipramine	Male	Severity of illness	4.00	4.00	3.00	3.00			
				Global improvement		3.00	2.00	3.00			
				Efficacy index		10.00	5.00	5.00			
				Efficacy index (*)		1.00	3.00	3.00			
	364	Imipramine	Female	Severity of illness	6.00	5.00	3.00	4.00	5.00		
				Global improvement		3.00	2.00	3.00	3.00		
				Efficacy index			5.00	5.00	9.00		
				Efficacy index (*)			3.00	3.00	2.00		
	366	Reboxetine	Male	Severity of illness	5.00	1.00	1.00	1.00	1.00	2.00	1.00
				Global improvement		1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	2.00	4.00	4.00	4.00	4.00
	367	Imipramine	Male	Severity of illness	5.00	5.00	5.00	6.00	4.00	4.00	5.00
				Global improvement		4.00	5.00	5.00	3.00	3.00	4.00
				Efficacy index		13.00	13.00	14.00	6.00	5.00	13.00
				Efficacy index (*)		1.00	1.00	0.50	1.50	3.00	1.00
	368	Reboxetine	Female	Severity of illness	5.00	3.00	2.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	1.00	1.00	2.00	2.00	2.00
				Efficacy index		5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	4.00	4.00	4.00	4.00	4.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	369	Reboxetine	Female	Severity of illness	5.00	2.00	2.00	1.00	1.00	1.00	1.00
				Global improvement		1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		4.00	4.00	4.00	4.00	4.00	4.00
	370	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	3.00	4.00	3.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00
				Efficacy index		9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	3.00
	371	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	2.00	2.00	1.00
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00
				Efficacy index		1.00	2.00	6.00	1.00	1.00	2.00
				Efficacy index (*)		4.00	2.00	1.50	4.00	4.00	2.00
	372	Imipramine	Male	Severity of illness	7.00	6.00	5.00	5.00	5.00	5.00	4.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		9.00	9.00	5.00	9.00	10.00	5.00
				Efficacy index (*)		2.00	2.00	3.00	2.00	1.00	3.00
	373	Imipramine	Female	Severity of illness	5.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	374	Reboxetine	Female	Severity of illness	6.00	3.00	3.00	2.00	1.00	1.00	1.00
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		6.00	6.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		1.50	1.50	1.50	2.00	2.00	2.00
	375	Reboxetine	Female	Severity of illness	5.00	3.00	1.00	1.00			
				Global improvement		2.00	1.00	1.00			
				Efficacy index		5.00	1.00	1.00			
				Efficacy index (*)		3.00	4.00	4.00			
	376	Imipramine	Female	Severity of illness	6.00	7.00					
				Global improvement		6.00					
				Efficacy index		14.00					
				Efficacy index (*)		0.50					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
15	377	Reboxetine	Female	Severity of illness	6.00	4.00	3.00	2.00	2.00	2.00	2.00
				Global improvement		2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00
	378	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	1.00	1.00	1.00
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		5.00	1.00	1.00	2.00	2.00	2.00
				Efficacy index (*)		3.00	4.00	4.00	2.00	2.00	2.00
	379	Imipramine	Female	Severity of illness	6.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	380	Imipramine	Female	Severity of illness	6.00	5.00	4.00	5.00	2.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	1.00	2.00	2.00
				Efficacy index		9.00	9.00	9.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00
	381	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	4.00
				Global improvement		3.00	3.00	3.00	2.00	2.00	3.00
				Efficacy index		10.00	11.00	11.00	7.00	2.00	7.00
				Efficacy index (*)		1.00	0.67	0.67	1.00	2.00	1.00
	382	Imipramine	Male	Severity of illness	5.00						
				Global improvement							
				Efficacy index							
				Efficacy index (*)							
	383	Imipramine	Female	Severity of illness	7.00	5.00	5.00	3.00	3.00	2.00	2.00
				Global improvement		3.00	4.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	13.00	1.00	5.00	1.00	1.00
				Efficacy index (*)		2.00	1.00	4.00	3.00	4.00	4.00
	384	Reboxetine	Female	Severity of illness	6.00	5.00					
				Global improvement		4.00					
				Efficacy index		9.00					
				Efficacy index (*)		2.00					

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severily ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present (c)	
1	1	Reboxetine	05/02/91	18/03/91	CONSTIPATION	25/01/91	Detail	0			2										
							Detail	42											3	Y	
							Summary		19/03/91(*)	42	2								3	Y	NO
					SWEATING INCREASED	08/02/91	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			3	2	3	1		3	3	3	3		
							Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		19/03/91(*)	42	3	2	2	1		2	3	3	3	Y	YES
	2	Reboxetine	26/02/91	08/04/91	CONSTIPATION	28/02/91	Detail	7			1	2	4	1		2	3	3	3		
							Detail	14			1	2	4	1		3	3	3	3		
							Detail	21			2	2	4	1		3	3	3	3		
							Detail	28			3	2	4	1		3	3	3	3		
							Detail	35			1	1	4	1		3	3	3	3		
							Detail	42			3	2	2	2		2	1	3	3	Y	
							Summary		09/04/91(*)	42	3	1	2	2		2	1	3	3	Y	YES
					INSOMNIA	26/02/91	Detail	7	28/02/91		2	1	4	1	YES	3	3	3	1		
							Summary		28/02/91	7	2	1	4	1	YES	3	3	3	1		YES
					MOUTH DRY	21/02/91	Detail	0			2										
							Detail	7			2	1	2	1		3	3	3	3		
							Detail	14			2	2	2	1		3	3	3	3		
							Detail	28			2	2	2	1		3	3		3		
							Detail	35			1	1	3	1		3	3	3	3		
							Detail	42			3	2	1	2		2	1	3	3	Y	
							Summary		09/04/91(*)	42	3	1	1	2		2	1	3	3	Y	YES
					RASH	14/03/91	Detail	21	19/03/91		1	2	4	1		3	3	3	1		
							Summary		19/03/91	21	1	2	4	1		3	3	3	1		YES
					VISION ABNORMAL	01/03/91	Detail	7			1	2	2	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present	(c)
1	2	Reboxetine	26/02/91	08/04/91	VISION ABNORMAL	01/03/91	Detail	14			1	2	2	1	3	3	3	3		
							Detail	21			1	2	2	1	3	3	3	3		
							Detail	28			1	2	2	1	3	3	3	3		
							Detail	35			1	1	3	1	3	3	3	3		
							Detail	42			2	2	1	2	2	1	3	3	Y	
							Summary		09/04/91(*)	42	2	1	1	2	2	1	3	3	Y	YES
	3	Imipramine	16/04/91	27/05/91	HEADACHE		Detail	0			2									
							Detail	7	22/04/91		2	1	4	1	3	3	3	1		
						11/04/91(@)	Summary		22/04/91	7	2	1	4	1	3	3	3	1		NO
					PARAESTHESIA	28/04/91	Detail	7			1	2	4	1	3	3	3	3		
							Detail	14			1	2	4	1	3	3	3	3		
							Detail	21			1	2	4	1	3	3	3	3		
							Detail	28			1	2	4	1	3	3	3	3		
							Detail	35	18/05/91		1	2	4	1	3	3	3	1		
							Summary		18/05/91	35	1	2	4	1	3	3	3	1		YES
					TACHYCARDIA	19/04/91	Detail	7			2	2	3	1	3	3	3	3		
							Detail	14			1	2	3	1	3	3	3	3		
							Detail	21			2	2	3	1	3	3	3	3		
							Detail	28			1	2	3	1	3	3	3	3		
							Detail	35	18/05/91		1	2	3	1	3	3	3	1		
							Summary		18/05/91	35	2	2	3	1	3	3	3	1		YES
	4	Imipramine	17/04/91	28/05/91	AGITATION	21/04/91	Detail	7			1	2	4	1	3	3	3	3		
							Detail	14	28/04/91		1	1	3	1	3	3	3	1		
							Summary		28/04/91	14	1	1	3	1	3	3	3	1		YES
					SWEATING INCREASED	28/04/91	Detail	7			1	2	4	1	3	3	3	3		
							Detail	14			2	2	3	1	3	3	3	3		
							Detail	21			2	2	3	1	3	3	3	3		
							Detail	28			1	2	3	1	3	3	3	3		
							Detail	35			1	2	3	1	3	3	3	3		
							Detail	42			1	2	3	1	3	3	3	3	Y	
							Summary		29/05/91(*)	42	2	2	3	1	3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe; -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Disapp.	Reapp.	Outcome	Still present (¢)
1	4	Imipramine	17/04/91	28/05/91	WEIGHT DECREASE	16/04/91	Detail	7			3	2	4	1		3	3	3	3	
							Detail	14			2	1	4	1		3	3	3	3	
							Detail	21	02/05/91		1	1	4	1		3	3	3	1	
							Summary		02/05/91	21	3	1	4	1		3	3	3	1	NO
	5	Reboxetine	17/07/91	27/08/91	CONSTIPATION	18/07/91	Detail	7			1	2	3	1		3	3	3	3	
							Detail	14			1	2	3	1		3	3	3	3	
							Detail	21			1	2	3	1		3	3	3	3	
							Detail	28			1	2	3	1		3	3	3	3	
							Detail	35	18/08/91		1	2	4	1		3	3	3	1	
							Summary		18/08/91	35	1	2	3	1		3	3	3	1	YES
					INSOMNIA	20/07/91	Detail	7			2	2	3	1		3	3	3	3	
							Detail	14	27/07/91		2	2	3	1		3	3	3	1	
							Summary		27/07/91	14	2	2	3	1		3	3	3	1	YES
	6	Imipramine	07/08/91	17/09/91	AGITATION	16/08/91	Detail	14	18/08/91		3	2	3	1	YES	3	3	3	1	
							Summary		18/08/91	14	3	2	3	1	YES	3	3	3	1	YES
					DIZZINESS	09/08/91	Detail	7			1	2	4	1		3	3	3	3	
							Detail	14			1	2	3	1		3	3	3	3	
							Detail	21			1	2	3	1		3	3	3	3	
							Detail	28			1	2	3	1		3	3	3	3	
							Detail	35	08/09/91		1	2	3	1		3	3	3	1	
							Summary		08/09/91	35	1	2	3	1		3	3	3	1	YES
					INSOMNIA		Detail	0			3									
						05/08/91(@)	Summary		16/09/91(*)	0	3									NO
					SWEATING INCREASED		Detail	0			2									
						05/08/91(@)	Summary		18/09/91(*)	0	2									NO
						10/08/91	Detail	7			2	1	4	1		3	3	3	3	
							Detail	14			2	1	4	1		3	3	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe; -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(¢) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
1	6	Imipramine	07/08/91	17/09/91	SWEATING INCREASED	10/08/91	Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	1	3	1		3	3	3	3	Y	
							Summary		18/09/91(*)	42	2	1	3	1		3	3	3	3	Y	YES
	7	Reboxetine	09/10/91	20/11/91	AGITATION	14/10/91	Detail	7	14/10/91		3	2	3	1	YES	3	3	3	1		
							Summary		14/10/91	7	3	2	3	1	YES	3	3	3	1		YES
						17/10/91	Detail	14	19/10/91		3	2	3	1	YES	3	3	3	1		
							Summary		19/10/91	14	3	2	3	1	YES	3	3	3	1		YES
					MICTURITION DISORDER	13/10/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	2		3	1	3	3	Y	
							Summary		21/11/91(*)	42	1	2	3	2		3	1	3	3	Y	YES
					SWEATING INCREASED		Detail	0			2										
						07/10/91(2)	Summary		21/11/91(*)	0	2										NO
					VISION ABNORMAL	14/10/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			3	2	2	1		3	3	3	3		
							Detail	42			1	2	3	2		3	1	3	3	Y	
							Summary		21/11/91(*)	42	3	2	2	2		3	1	3	3	Y	YES
	8	Imipramine	29/10/91	31/10/91	CHEST PAIN	30/10/91	Detail	7	31/10/91		2	2	4	1		3	3	3	1		
							Summary		31/10/91	7	2	2	4	1		3	3	3	1		YES
					DIZZINESS	30/10/91	Detail	7	01/11/91		1	2	3	3		3	2	3	1	Y	
							Summary		01/11/91	7	1	2	3	3		3	2	3	1	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(8) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Dis app.	Re app.	Out come	Still present	(c)
1	8	Imipramine	29/10/91	31/10/91	HEADACHE	30/10/91	Detail	7	01/11/91		2	2	3	3		3	2	3	1	Y	
							Summary		01/11/91	7	2	2	3	3		3	2	3	1	Y	YES
					MOUTH DRY	29/10/91	Detail	7	01/11/91		2	2	3	3		3	2	3	1	Y	
							Summary		01/11/91	7	2	2	3	3		3	2	3	1	Y	YES
					SOMNOLENCE	30/10/91	Detail	7	01/11/91		1	2	3	3		3	2	3	1	Y	
							Summary		01/11/91	7	1	2	3	3		3	2	3	1	Y	YES
					SWEATING INCREASED	30/10/91	Detail	7	01/11/91		1	2	3	3		3	2	3	1	Y	
							Summary		01/11/91	7	1	2	3	3		3	2	3	1	Y	YES
					TREMOR	30/10/91	Detail	7	01/11/91		1	2	3	3		3	2	3	1	Y	
							Summary		01/11/91	7	1	2	3	3		3	2	3	1	Y	YES
					VISION ABNORMAL	30/10/91	Detail	7	01/11/91		2	2	2	3		3	2	3	1	Y	
							Summary		01/11/91	7	2	2	2	3		3	2	3	1	Y	YES
	9	Imipramine	08/11/91	19/12/91	CONSTIPATION	12/11/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	1	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		19/12/91(*)	42	2	1	3	1		3	3	3	3	Y	YES
					DIARRHOEA	09/12/91	Detail	35	09/12/91		3	1	6	1		3	3	3	1		
							Summary		09/12/91	35	3	1	6	1		3	3	3	1		YES
					SWEATING INCREASED		Detail	8			2										
							Detail	7			2	1	6	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Dismpp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
1	9	Imipramine	08/11/91	19/12/91	SWEATING INCREASED		Detail	14			1	1	6	1		3	3	3	3		
							Detail	21			1	1	6	1		3	3	3	3		
							Detail	28			1	1	6	1		3	3	3	3		
							Detail	35			1	1	6	1		3	3	3	3		
							Detail	42			1	1	6	1		3	3	3	3		
						05/11/91(2)	Summary		19/12/91(*)	42	2	1	6	1		3	3	3	3		NO
	10	Imipramine	19/11/91	30/12/91	INSOMNIA	15/11/91	Detail	0			3										
							Summary		30/12/91(*)	0	3										NO
						08/12/91	Detail	21			3	1	3	1	YES	3	3	3	3		
							Detail	28			2	1	4	1	YES	3	3	3	3		
							Detail	35			1	1	4	1	YES	3	3	3	3		
							Detail	42			1	1	4	1	YES	3	3	3	3	Y	
							Summary		30/12/91(*)	42	3	1	3	1	YES	3	3	3	3	Y	YES
					MOUTH DRY	22/11/91	Detail	7			3	2	2	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35	28/12/91		1	2	3	1		3	3	3	1		
							Summary		28/12/91	35	3	2	2	1		3	3	3	1		YES
					SOMNOLENCE	27/11/91	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21	09/12/91		1	2	3	1		3	3	3	1		
							Summary		09/12/91	21	1	2	3	1		3	3	3	1		YES
					TINNITUS	23/11/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14	29/11/91		2	2	3	1		3	3	3	1		
							Summary		29/11/91	14	2	2	3	1		3	3	3	1		YES
						06/12/91	Detail	21			1	2	4	1		3	3	3	3		
							Detail	28			1	2	4	1		3	3	3	3		
							Detail	35	22/12/91		1	2	4	1		3	3	3	1		
							Summary		22/12/91	35	1	2	4	1		3	3	3	1		YES
	11	Reboxetine	06/04/92	03/05/92	AGITATION	18/04/92	Detail	7	12/04/92		2	2	3	1	YES	3	3	3	1		
							Summary		12/04/92	7	2	2	3	1	YES	3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Study drug	Symptom treat	Hosp	Disapp.	Reapp.	Outcome	Still present	(C)
1	11	Reboxetine	06/04/92	03/05/92	AGITATION	19/04/92	Detail	14			2	2	4	1	YES	3	3	3	3		
							Detail	21	24/04/92		2	2	4	1	YES	3	3	3	1		
							Summary		24/04/92	21	2	2	4	1	YES	3	3	3	1		YES
	12	Reboxetine	15/04/92	05/05/92	INSOMNIA	14/04/92	Detail	7			2	1	4	1	YES	3	3	3	3		
							Detail	14			2	1	4	1	YES	3	3	3	3		
							Detail	21			1	1	4	1	YES	3	3	3	3	Y	
							Summary		05/05/92(*)	21	2	1	4	1	YES	3	3	3	3	Y	NO
					MOUTH DRY	17/04/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3	Y	
							Summary		05/05/92(*)	21	1	2	3	1		3	3	3	3	Y	YES
					SWEATING INCREASED	17/04/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3	Y	
							Summary		05/05/92(*)	21	1	2	3	1		3	3	3	3	Y	YES
2	55	Reboxetine	19/12/90	29/01/91	ECG ABNORMAL	29/01/91	Detail	42			1	2	3	1		3	3	3		Y	
							Summary		29/01/91(*)	42	1	2	3	1		3	3	3		Y	YES
					INSOMNIA		Detail	0			2										
							Detail	42	29/01/91		1	1	6	1		3	3	3	1		
						17/12/90(D)	Summary		29/01/91	42	2	1	6	1		3	3	3	1		NO
					MOUTH DRY	20/12/90	Detail	7	25/12/90		2	2	1	1		3	3	3	1		
							Summary		25/12/90	7	2	2	1	1		3	3	3	1		YES
					VOMITING	25/12/90	Detail	7	25/12/90		2	2	3	1		3	3	3	1		
							Summary		25/12/90	7	2	2	3	1		3	3	3	1		YES
	34	Imipramine	28/12/90	03/02/91	ACCOMMODATION ABNORMAL	29/12/90	Detail	7	02/01/91		1	2	3	1		3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2	54	Imipramine	28/12/90	03/02/91	ACCOMMODATION ABNORMAL	29/12/90	Summary		02/01/91	7	1	2	3	1		3	3	3	1		YES
					BACK PAIN	31/12/90	Detail	7	31/12/90		2	1	6	1	YES	3	3	3	1		
							Summary		31/12/90	7	2	1	6	1	YES	3	3	3	1		YES
						02/02/91	Detail	42	02/02/91		3	1	6	3	YES	3	2	3	1		
							Summary		02/02/91	42	3	1	6	3	YES	3	2	3	1		YES
					DIZZINESS	31/12/90	Detail	7	02/01/91		1	2	3	1		3	3	3	1		
							Summary		02/01/91	7	1	2	3	1		3	3	3	1		YES
						09/01/91	Detail	14	10/01/91		2	2	3	1		3	3	3	1		
							Summary		10/01/91	14	2	2	3	1		3	3	3	1		YES
					HEADACHE	31/12/90	Detail	7	31/12/90		2	1	6	1	YES	3	3	3	1		
							Summary		31/12/90	7	2	1	6	1	YES	3	3	3	1		YES
						28/01/91	Detail	35	31/01/91		1	2	2	1		3	3	3	1		
							Summary		31/01/91	35	1	2	2	1		3	3	3	1		YES
						02/02/91	Detail	42	02/02/91		2	1	6	3		3	2	3	1		
							Summary		02/02/91	42	2	1	6	3		3	2	3	1		YES
					HYPOTENSION	31/12/90	Detail	7	02/01/91		2	2	1	1		3	3	3	1		
							Summary		02/01/91	7	2	2	1	1		3	3	3	1		YES
						09/01/91	Detail	14	10/01/91		2	2	3	1		3	3	3	1		
							Summary		10/01/91	14	2	2	3	1		3	3	3	1		YES
					MOUTH DRY	28/12/90	Detail	7			2	2	1	1		3	3	3	3		
							Detail	14			1	2	1	1		3	3	3	3		
							Detail	21	17/01/91		1	2	1	1		3	3	3	1		
							Summary		17/01/91	21	2	2	1	1		3	3	3	1		YES
					PARAESTHESIA	31/12/90	Detail	7	02/01/91		1	2	6	1		3	3	3	1		
							Summary		02/01/91	7	1	2	6	1		3	3	3	1		YES
					SOMNOLENCE	28/01/91	Detail	35	30/01/91		2	2	2	1		3	3	3	1		
							Summary		30/01/91	35	2	2	2	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
2	34	Imipramine	28/12/90	03/02/91	VISION ABNORMAL	29/12/90	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14	08/01/91		1	2	3	1		3	3	3	1		
							Summary		08/01/91	14	1	2	2	1		3	3	3	1		YES
	35	Reboxetine	28/12/90	07/02/91	ECG ABNORMAL	07/02/91	Detail	42	07/02/91		1	2	4	1		3	3	3			
							Summary		07/02/91	42	1	2	4	1		3	3	3			YES
					INFLUENZA-LIKE SYMPTOMS	06/02/91	Detail	42	08/02/91		2	2	5	1	YES	3	3	3	1		
							Summary		08/02/91	42	2	2	5	1	YES	3	3	3	1		YES
	36	Imipramine	10/01/91	31/01/91	CONSTIPATION	15/01/91	Detail	7			2	2	1	1		3	3	3	3		
							Detail	14	22/01/91		1	2	3	1		3	3	3	1		
							Summary		22/01/91	14	2	2	1	1		3	3	3	1		YES
					INSOMNIA	09/01/91	Detail	0			1										
							Summary		31/01/91(*)	0	1										NO
					MANIC REACTION	24/01/91	Detail	21			2	2	1	1		3	3	3	3		
							Detail	28			3	2	1	3		3	2	3	3	Y	
							Summary		31/01/91(*)	28	3	2	1	3		3	2	3	3	Y	YES
					MOUTH DRY	10/01/91	Detail	7			2	2	1	1		3	3	3	3		
							Detail	14	22/01/91		1	2	3	1		3	3	3	1		
							Summary		22/01/91	14	2	2	1	1		3	3	3	1		YES
					TACHYCARDIA	30/01/91	Detail	21			2	3	3	1		3	3	3	3	Y	
							Summary		31/01/91(*)	21	2	3	3	1		3	3	3	3	Y	YES
	37	Reboxetine	18/01/91	26/02/91	HEADACHE	19/02/91	Detail	28			2	1	3	1		3	3	3	3		
							Detail	35	21/02/91		1	1	3	1		3	3	3	1		
							Summary		21/02/91	35	2	1	3	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
2	37	Reboxetine	18/01/91	28/02/91	INSOMNIA	17/01/91	Detail	0			1										
							Detail	21	07/02/91		1	2	3	1		3	3	3	1		
							Summary		07/02/91	21	1	2	3	1		3	3	3	1		NO
	38	Imipramine	25/01/91	07/03/91	HYPERCHOLESTERDLAEMIA	25/01/91	Detail	42			2	1	3	1		3	3	3	3	Y	
							Summary		07/03/91(*)	42	2	1	3	1		3	3	3	3	Y	YES
					HYPERLIPAEMIA	10/02/91	Detail	21	14/02/91		1	2	5	1		3	3	3	1		
							Summary		14/02/91	21	1	2	5	1		3	3	3	1		YES
					HYPOTENSION	25/01/91	Detail	14	03/02/91		2	2	5	1	YES	3	3	3	1		
							Summary		03/02/91	14	2	2	5	1	YES	3	3	3	1		YES
					INSOMNIA	22/01/91	Detail	0			2										
							Detail	14			3	1	3	1	YES	3	3	3	3		
							Detail	21			2	1	3	1	YES	3	3	3	3		
							Detail	28			2	1	3	1	YES	3	3	3	3		
							Detail	35			2	1	3	1	YES	3	3	3	3	Y	
							Summary		07/03/91(*)	35	3	1	3	1	YES	3	3	3	3	Y	YES
	40	Imipramine	20/02/91	02/04/91	INSOMNIA	19/02/91	Detail	0			2										
							Detail	28			2	2	1	1	YES	3	3	3	3	Y	
							Summary		02/04/91(*)	28	2	2	1	1	YES	3	3	3	3	Y	NO
	41	Reboxetine	05/02/91	18/03/91	ABDOMINAL PAIN	08/03/91	Detail	35			2	2	6	1	YES	3	3	3	3		
							Detail	42			2	2	6	1		3	3	3	3	Y	
							Summary		18/03/91(*)	42	2	2	6	1	YES	3	3	3	3	Y	YES
					HEADACHE	07/02/91	Detail	7			3	1	3	1	YES	2	3	3	3		
							Detail	14			3	1	3	1	YES	3	3	3	3		
							Detail	21			2	1	3	1	YES	3	3	3	3		
							Detail	28			2	1	3	1	YES	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Sever ity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
2	41	Reboxetine	05/02/91	18/03/91	HEADACHE	07/02/91	Detail	35			2	1	3	1	YES	3	3	3	3		
							Detail	42			2	1	3	1	YES	3	3	3	3	Y	
							Summary		18/03/91(*)	42	3	1	3	1	YES	2	3	3	3	Y	YES
					MICTURITION DISORDER	07/02/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35	08/03/91		1	2	3	1		3	3	3	1		
							Summary		08/03/91	35	1	2	3	1		2	3	3	1		YES
					MOUTH DRY	05/02/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		18/03/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
					TACHYCARDIA	18/03/91	Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		18/03/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
	42	Imipramine	09/02/91	22/03/91	INSOMNIA	02/03/91	Detail	28			2	2	4	1		3	3	3	3	Y	
							Summary		22/03/91(*)	28	2	2	4	1		3	3	3	3	Y	YES
					MOUTH DRY	09/02/91	Detail	7	13/02/91		1	2	3	1		3	3	3	1		
							Summary		13/02/91	7	1	2	3	1		3	3	3	1		YES
						22/02/91	Detail	14			1	2	2	1		3	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35	15/03/91		1	2	1	1		3	3	3	1		
							Summary		15/03/91	35	1	2	1	1		3	3	3	1		YES
					TACHYCARDIA	01/03/91	Detail	21			2	2	2	1		3	3	3	3	Y	
							Summary		22/03/91(*)	21	2	2	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2	45	Reboxetine	26/03/91	06/05/91	INSOMNIA	25/03/91	Detail	7			2	1	6	1	YES	3	3	3	3		
							Detail	14			2	1	6	1	YES	3	3	3	3		
							Detail	21			2	1	6	1	YES	3	3	3	3		
							Detail	28	21/04/91		2	1	6	1	YES	3	3	3	1		
							Summary		21/04/91	28	2	1	6	1	YES	3	3	3	1		NO
					MOUTH DRY	26/03/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	08/04/91		1	2	3	1		3	3	3	1		
							Summary		08/04/91	14	1	2	3	1		3	3	3	1		YES
	44	Imipramine	11/04/91	11/04/91	DELUSION	11/04/91	Detail	7			3	2	4	3		3	3	3	3		
							Summary		11/04/91(*)	7	3	2	4	3		3	3	3	3		YES
					INSOMNIA	08/04/91	Detail	7	11/04/91		2	1	3	1	YES	3	3	3	1		
							Summary		11/04/91	7	2	1	3	1	YES	3	3	3	1		NO
	45	Imipramine	30/04/91	05/05/91	SOMNOLENCE	29/04/91	Detail	7			3	2	1	3		3	1	3	3	Y	
							Summary		05/05/91(*)	7	3	2	1	3		3	1	3	3	Y	NO
	46	Reboxetine	16/05/91	26/06/91	INSOMNIA	14/05/91	Detail	0			2										
							Detail	7			3	2	3	1	YES	3	3	3	3		
							Detail	14			2	2	3	1	YES	3	3	3	3		
							Detail	21			2	2	3	1	YES	3	3	3	3		
							Detail	28			2	2	1	1	YES	3	3	3	3		
							Detail	35			2	2	3	1	YES	3	3	3	3		
							Detail	42			2	2	1	1	YES	3	3	3	3	Y	
							Summary		26/06/91(*)	42	3	2	1	1	YES	3	3	3	3	Y	YES
					NERVOUSNESS	18/05/91	Detail	7	21/05/91		3	2	1	1		3	3	3	1		
							Summary		21/05/91	7	3	2	1	1		3	3	3	1		YES
					TACHYCARDIA		Detail	42	26/06/91		1	2	2	1		3	2	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
2	46	Reboxetine	15/05/91	26/06/91	TACHYCARDIA	20/06/91(@)	Summary		26/06/91	42	1	2	2	1		3	2	3	1		YES
	47	Reboxetine	22/05/91	02/07/91	INSOMNIA	17/05/91	Detail	0			2										
							Detail	7	27/05/91		3	1	3	1	YES	3	3	3	1		
							Summary		27/05/91	7	3	1	3	1	YES	3	3	3	1		YES
						29/05/91	Detail	14			3	2	3	1	YES	3	3	3	3		
							Detail	21			2	2	1	1	YES	3	3	3	3		
							Detail	28			2	2	3	1	YES	3	3	3	3		
							Detail	35			1	2	3	1	YES	3	3	3	3		
							Detail	42			2	2	3	1	YES	3	3	3	3	Y	
							Summary		02/07/91(*)	42	3	2	1	1	YES	3	3	3	3	Y	YES
					NERVOUSNESS	22/05/91	Detail	7	28/05/91		2	2	3	1		3	3	3	1		
							Summary		28/05/91	7	2	2	3	1		3	3	3	1		YES
	48	Imipramine	27/08/91	07/10/91	EXTRASYSTOLES	07/10/91	Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		07/10/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
					GAMMA-GT INCREASED	16/09/91	Detail	21			2	1	3	1		3	3	3	3	Y	
							Summary		07/10/91(*)	21	2	1	3	1		3	3	3	3	Y	YES
					HYPERURICAEMIA	16/09/91	Detail	21	07/10/91		2	2	3	1		3	3	3	3		
							Summary		07/10/91	21	2	2	3	1		3	3	3	3		YES
					INSOMNIA	23/08/91	Detail	0			2										
							Detail	7	02/09/91		1	1	6	1	YES	3	3	3	1		
							Summary		02/09/91	7	2	1	6	1	YES	3	3	3	1		NO
					TACHYCARDIA	16/09/91	Detail	21	16/09/91		2	1	4	1		3	3	3	1		
							Summary		16/09/91	21	2	1	4	1		3	3	3	1		YES
						07/10/91	Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		07/10/91(*)	42	1	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
2	49	Imipramine	29/08/91	09/10/91	AGITATION	26/09/91	Detail	35	02/10/91		2	2	1	1		3	3	3	1		
							Summary		02/10/91	35	2	2	1	1		3	3	3	1		YES
					ANXIETY	28/09/91	Detail	28	25/09/91		2	2	1	1		3	3	3	1		
							Summary		25/09/91	28	2	2	1	1		3	3	3	1		YES
					INSOMNIA		Detail	0			2										
						26/08/91(D)	Summary		09/10/91(*)	8	2										NO
						27/08/91	Detail	7			1	1	6	1	YES	3	3	3	3		
							Detail	14	08/09/91		1	1	6	1	YES	3	3	3	1		
							Summary		08/09/91	14	1	1	6	1	YES	3	3	3	1		NO
						20/09/91	Detail	28			2	2	1	1	YES	3	3	3	3		
							Detail	35			2	1	1	1	YES	3	3	3	3		
							Detail	42			2	2	1	1	YES	3	3	3	3	Y	
							Summary		09/10/91(*)	42	2	1	1	1	YES	3	3	3	3	Y	YES
					SWEATING INCREASED	12/09/91	Detail	21	18/09/91		1	2	2	1		3	3	3	1		
							Summary		18/09/91	21	1	2	2	1		3	3	3	1		YES
					TACHYCARDIA SUPRAVENTRICU	11/09/91	Detail	14	11/09/91		2	2	3	1		3	3	3	1		
							Summary		11/09/91	14	2	2	3	1		3	3	3	1		YES
	50	Reboxetine	05/11/91	15/12/91	BUNDLE BRANCH BLOCK	26/11/91	Detail	21			2		3	1		3	3	3	3	Y	
							Summary		17/12/91(*)	21	2		3	1		3	3	3	3	Y	YES
					HYPERURICAEMIA	26/11/91	Detail	21			2	2	3	1		3	3	3	3	Y	
							Summary		17/12/91(*)	21	2	2	3	1		3	3	3	3	Y	YES
					INSOMNIA	31/10/91	Detail	0			2										
							Detail	7			2	1	3	1	YES	3	3	3	3		
							Detail	14			3	2	2	1	YES	3	3	3	3		
							Detail	21			2	2	2	1	YES	3	3	3	3		
							Detail	28			2	2	2	1	YES	3	3	3	3		
							Detail	35			2	2	2	1	YES	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknowa
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2	50	Reboxetine	06/11/91	15/12/91	INSOMNIA	31/10/91	Summary		18/12/91(*)	35	3	1	2	1	YES	3	3	3	3		YES
					SUICIDE ATTEMPT	15/12/91	Detail	42	15/12/91		3		6	1		3	3	3	4		
							Summary		15/12/91	42	3		6	1		3	3	3	4		YES
					SWEATING INCREASED	10/11/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	18/11/91		1	2	3	1		3	3	3	1		
							Summary		18/11/91	14	1	2	3	1		3	3	3	1		YES
					TACHYCARDIA	10/12/91	Detail	35	10/12/91		1	2	3	1		3	3	3	1		
							Summary		10/12/91	35	1	2	3	1		3	3	3	1		YES
	51	Reboxetine	06/11/91	17/11/91	CONSTIPATION	06/11/91	Detail	7	12/11/91		2	2	3	1		3	3	3	1		
							Summary		12/11/91	7	2	2	3	1		3	3	3	1		YES
					DELUSION	16/11/91	Detail	14			3	2	2	3		3	1	3	3		
							Summary		19/11/91(*)	14	3	2	2	3		3	1	3	3		YES
					INSOMNIA	30/10/91	Detail	0			2										
							Detail	7			2	1	3	1	YES	3	3	3	3		
							Detail	14			3	2	2	1	YES	3	3	3	3	Y	
							Summary		19/11/91(*)	14	3	1	2	1	YES	3	3	3	3	Y	YES
	52	Imipramine	27/11/91	07/01/92	ACCOMMODATION ABNORMAL	27/11/91	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14	10/12/91		1	2	2	1		3	3	3	1		
							Summary		10/12/91	14	1	2	2	1		3	3	3	1		YES
					INSOMNIA	27/11/91	Detail	7			1	2	3	1	YES	3	3	3	3		
							Detail	14			1	2	2	1	YES	3	3	3	3		
							Detail	21			1	2	2	1	YES	3	3	3	3		
							Detail	28			1	2	2	1	YES	3	3	3	3		
							Detail	35	30/12/91		1	2	2	1	YES	3	3	3	1		
							Summary		30/12/91	35	1	2	2	1	YES	3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Treatment Drug	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
2	52	Imipramine	27/11/91	07/01/92	SOMNOLENCE	27/11/91	Detail	7	30/11/91		1	2	2	1		3	3	3	1		
							Summary		30/11/91	7	1	2	2	1		3	3	3	1		YES
					SPUTUM INCREASED	20/12/91	Detail	28	25/12/91		1	2	6	1		3	3	3	1		
							Summary		25/12/91	28	1	2	6	1		3	3	3	1		YES
					TACHYCARDIA	03/12/91	Detail	14			1	2	2	1		3	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35	31/12/91		1	2	2	1		3	3	3	1		
							Summary		31/12/91	35	1	2	2	1		3	3	3	1		YES
3	65	Reboxetine	02/04/91	13/05/91	ANOREXIA	05/04/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	11/04/91		2	2	4	1		3	3	3	1		
							Summary		11/04/91	14	2	2	3	1		3	3	3	1		YES
					CONSTIPATION	01/05/91	Detail	35			1	1	4	1		3	3	3	3		
							Detail	42	10/05/91		1	1	4	1		3	3	3	1		
							Summary		10/05/91	42	1	1	4	1		3	3	3	1		YES
					HYPERTENSION	15/04/91	Detail	21			3	1	3	1		3	3	3	3		
							Detail	28			2	1	2	1	YES	3	3	3	3		
							Detail	35	05/05/91		2	1	3	1	YES	3	3	3	1		
							Summary		05/05/91	35	3	1	2	1	YES	3	3	3	1		YES
						09/05/91	Detail	42			2	1	2	1	YES	3	3	3	3	Y	
							Summary		13/05/91(*)	42	2	1	2	1	YES	3	3	3	3	Y	YES
					MOUTH DRY		Detail	0			2										
						27/03/91(D)	Summary		13/05/91(*)	0	2										NO
					SGPT INCREASED	13/05/91	Detail	42			1	2	2	1		3	3	3	3	Y	
							Summary		13/05/91(*)	42	1	2	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observa bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
[illegible] first treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
3	65	Reboxetine	02/04/91	13/05/91	SWEATING INCREASED	04/04/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	1	3	1		3	3	3	3		
							Detail	28			2	2	4	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	2	2	1		3	3	3	3	Y	
							Summary		13/05/91(*)	42	2	1	2	1		3	3	3	3	Y	YES
					TACHYCARDIA	15/04/91	Detail	14	15/04/91		1	1	3	1		3	3	3	1		
							Detail	21			1	1	3	1		3	3	3	3		
							Detail	28			1	1	3	1		3	3	3	3		
							Detail	35			2	1	3	1	YES	3	3	3	3		
							Detail	42			2	1	4	1		3	3	3	3	Y	
							Summary		13/05/91(*)	42	2	1	3	1	YES	3	3	3	3	Y	YES
					VISION ABNORMAL		Detail	0			1										
							Detail	7	05/04/91		1	1	6	1		3	3	3	1		
						27/03/91(2)	Summary		05/04/91	7	1	1	6	1		3	3	3	1		NO
	66	Imipramine	01/05/91	05/06/91	HYPOKINESIA	02/06/91	Detail	35	04/06/91		3	2	4	1	YES	3	3	3	1		
							Summary		04/06/91	35	3	2	4	1	YES	3	3	3	1		YES
					INSOMNIA		Detail	0			3										
							Detail	7			3	1	6	1	YES	3	3	3	3		
							Detail	14	14/05/91		1	1	6	1		3	3	3	1		
						26/04/91(2)	Summary		14/05/91	14	3	1	6	1	YES	3	3	3	1		NO
					MOUTH DRY		Detail	0			1										
						01/04/91	Detail	7			2	1	2	1		3	3	3	3		
							Detail	14	11/05/91		1	1	2	1		3	3	3	1		
							Summary		11/05/91	14	2	1	2	1		3	3	3	1		NO
						26/04/91(2)	Summary		05/06/91(*)	0	1										NO
						18/05/91	Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	2	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
3	66	Imipramine	01/05/91	05/06/91	MOUTH DRY	18/05/91	Detail	35			1	2	3	1		3	3	3	3	Y	
							Summary		05/06/91(*)	35	1	2	2	1		3	3	3	3	Y	YES
					TACHYCARDIA	07/05/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	21/05/91		1	2	3	1		3	3	3	3		
							Summary		21/05/91	14	1	2	3	1		3	3	3	3		YES
						22/05/91	Detail	28			1	2	2	1		3	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3	Y	
							Summary		05/06/91(*)	35	1	2	2	1		3	3	3	3	Y	YES
					TREMOR	07/05/91	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	2	1		3	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3	Y	
							Summary		05/06/91(*)	35	1	2	2	1		3	3	3	3	Y	YES
	67	Reboxetine	18/04/91	21/05/91	HYPERTENSION	16/04/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	1	3	1	YES	3	3	3	3		
							Detail	21			2	1	3	1	YES	3	3	3	3		
							Detail	28			2	1	3	1	YES	3	3	3	3		
							Detail	35	15/05/91		2	1	3	1	YES	3	3	3	1		
							Summary		15/05/91	35	2	1	3	1	YES	3	3	3	1		YES
						18/05/91	Detail	42			1	1	3	1	YES	3	3	3	3	Y	
							Summary		21/05/91(*)	42	1	1	3	1	YES	3	3	3	3	Y	YES
					LEUKOCYTOSIS	25/05/91	Detail	42	23/05/91		1	2	3	1		3	3	3	3	Y	
							Summary		23/05/91	42	1	2	3	1		3	3	3	3	Y	YES
					MOUTH DRY	12/04/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			3	2	3	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	2	2	1		3	3	3	3	Y	
							Summary		21/05/91(*)	42	3	2	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present (*)	(C)
3	67	Reboxetine	10/04/91	21/05/91	TACHYCARDIA	10/04/91	Detail	7			2	2	2	1		3	3	3	3		
							Detail	14			2	2	2	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28	02/05/91		1	2	3	1	YES	3	3	3	2		
							Summary		02/05/91	28	2	2	2	1	YES	3	3	3	2		YES
						10/05/91	Detail	35	12/05/91		1	2	3	1	YES	3	3	3	1		
							Summary		12/05/91	35	1	2	3	1	YES	3	3	3	1		YES
						12/05/91	Detail	42			1	2	3	1	YES	3	3	3	3	Y	
							Summary		21/05/91(*)	42	1	2	3	1	YES	3	3	3	3	Y	YES
	68	Imipramine	03/08/91	13/09/91	CONSTIPATION	17/08/91	Detail	21			3	2	3	1	YES	3	3	3	3		
							Detail	28			2	2	3	1	YES	3	3	3	3		
							Detail	35			2	2	3	1	YES	3	3	3	3		
							Detail	42			1	2	2	1	YES	3	3	3	3	Y	
							Summary		13/09/91(*)	42	3	2	2	1	YES	3	3	3	3	Y	YES
					GAMMA-GT INCREASED	23/08/91	Detail	21			1	2	3	1		3	3	3	3	Y	
							Summary		13/09/91(*)	21	1	2	3	1		3	3	3	3	Y	YES
					HEPATIC ENZYMES INCREASED	23/08/91	Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		13/09/91(*)	42	2	2	3	1		3	3	3	3	Y	YES
						13/09/91	Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		13/09/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
					HYPERLIPAEMIA	02/08/91	Detail	42			3	1	4	1		3	3	3	3	Y	
							Summary		13/09/91(*)	42	3	1	4	1		3	3	3	3	Y	ND
					HYPOTENSION POSTURAL	09/08/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28	30/08/91		1	2	3	1		3	3	3	2		
							Summary		30/08/91	28	2	2	3	1		3	3	3	2		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=preseat before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
[illegible] = end of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
3	68	Imipramine	03/08/91	13/09/91	INSOMNIA		Detail	0			3										
						31/07/91(@)	Summary		13/09/91(*)	0	3										NO
					MOUTH DRY		Detail	0			2										
						31/07/91(@)	Summary		13/09/91(*)	0	2										NO
	69	Imipramine	01/03/91	11/04/91	HYPOTENSION POSTURAL	05/03/91	Detail	7			1	2	5	1		3	3	3	3		
							Detail	14			1	2	2	1		3	3	3	3		
							Detail	21	28/03/91		2	2	2	1		3	3	3	2		
							Summary		28/03/91	21	2	2	2	1		3	3	3	2		YES
					INSOMNIA	10/02/91	Detail	0			2										
							Detail	28	24/03/91		1	1	6	1	YES	3	3	3	1		
							Summary		24/03/91	28	2	1	6	1	YES	3	3	3	1		NO
					MOUTH DRY		Detail	0			2										
							Detail	7			2	1	4	1		3	3	3	3		
							Detail	14			1	1	4	1		3	3	3	3		
							Detail	21			1	1	4	1		3	3	3	3		
							Detail	28			1	1	4	1		3	3	3	3		
							Detail	35			1	1	4	1		3	3	3	3		
							Detail	42	05/04/91		1	1	4	1		3	3	3	2		
						27/02/91(@)	Summary		05/04/91	42	2	1	4	1		3	3	3	2		NO
	70	Reboxetine	25/10/91	19/11/91	FLUSHING	08/11/91	Detail	21			3	1	5	1		3	3	3	3		
							Detail	28			3	1	5	1		3	3	3	3	Y	
							Summary		19/11/91(*)	28	3	1	5	1		3	3	3	3	Y	YES
					HEADACHE	04/11/91	Detail	14	04/11/91		3	2	3	1	YES	3	3	3	1		
							Summary		04/11/91	14	3	2	3	1	YES	3	3	3	1		YES
					HEPATIC ENZYMES INCREASED	12/11/91	Detail	21			1	2	3	1		3	3	3	3	Y	
							Summary		19/11/91(*)	21	1	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(c)
3	70	Reboxetine	23/10/91	19/11/91	PAIN	28/10/91	Detail	7			3	1	5	1		3	3	3	3		
							Detail	14	31/10/91		2	1	5	1		3	3	3	1		
							Summary		31/10/91	14	3	1	5	1		3	3	3	1		YES
					PALPITATION	19/10/91	Detail	7			3	1	5	1		3	3	3	3		
							Detail	14			2	1	5	1		3	3	3	3		
							Detail	21			3	1	5	1		3	3	3	3		
							Detail	28			3	1	5	1		3	3	3	3	Y	
							Summary		19/11/91(*)	28	3	1	5	1		3	3	3	3	Y	NO
					TACHYCARDIA	29/10/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3	Y	
							Summary		19/11/91(*)	14	2	2	3	1		3	3	3	3	Y	YES
					TINNITUS		Detail	0			3										
							Detail	7			3	1	6	1		3	3	3	3		
							Detail	28			3	1	6	1	YES	3	3	3	3	Y	
						28/10/91(@)	Summary		19/11/91(*)	28	3	1	5	1	YES	3	3	3	3	Y	NO
	71	Imipramine	14/11/91	25/12/91	CONSTIPATION	11/11/91	Detail	0			2										
							Detail	7	15/11/91		2	2	5	1		3	3	3	1		
							Summary		15/11/91	7	2	2	5	1		3	3	3	1		NO
					DIZZINESS	03/12/91	Detail	21			2	1	4	1		3	3	3	3		
							Detail	28			1	1	4	1		3	3	3	3		
							Detail	35	12/12/91		1	1	4	1		3	3	3	1		
							Summary		12/12/91	35	2	1	4	1		3	3	3	1		YES
					INSOMNIA		Detail	0			2										
						11/11/91(@)	Summary		25/12/91(*)	0	2										NO
					MOUTH DRY	15/11/91	Detail	7			2	2	3	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
[illegible] = present date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
3	71	Imipramine	14/11/91	25/12/91	MOUTH DRY	15/11/91	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42	19/12/91		1	2	5	1		3	3	3	1		
							Summary		19/12/91	42	2	2	3	1		3	3	3	1		YES
					TACHYCARDIA	14/11/91	Detail	0			1										
							Detail	7			1	1	3	1		3	3	3	3		
							Detail	14			1	1	3	1		3	3	3	3		
							Detail	21			1	1	3	1		3	3	3	3		
							Detail	28			1	1	3	1		3	3	3	3		
							Detail	35			1	1	3	1		3	3	3	3		
							Detail	42			2	1	3	1		2	3	3	3	Y	
							Summary		25/12/91(*)	42	2	1	3	1		2	3	3	3	Y	YES
					TREMOR	11/11/91	Detail	0			3										
							Detail	7	15/11/91		2	1	5	1		3	3	3	1		
							Summary		15/11/91	7	3	1	5	1		3	3	3	1		NO
	72	Reboxetine	31/01/92	12/03/92	AGITATION	05/02/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			1	2	2	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	1		
							Summary		06/03/92(*)	35	2	2	2	1		3	3	3	1		YES
					CONSTIPATION	26/02/92	Detail	28	28/02/92		2	1	4	1		3	3	3	1		
							Summary		28/02/92	28	2	1	4	1		3	3	3	1		YES
					DIZZINESS	09/03/92	Detail	42			1	1	4	1		3	3	3	3	Y	
							Summary		13/03/92(*)	42	1	1	4	1		3	3	3	3	Y	YES
					INSOMNIA		Detail	0			2										
							Detail	7			2	1	5	1	YES	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
3	72	Reboxetine	31/01/92	12/03/92	INSOMNIA		Detail	14			3	1	5	1	YES	3	3	3	3		
							Detail	21			3	1	5	1		3	3	3	3		
							Detail	28			1	1	4	1		3	3	3	3		
							Detail	35			1	1	4	1	YES	3	3	3	3	Y	
						27/01/92(@)	Summary		13/03/92(*)	35	3	1	4	1	YES	3	3	3	3	Y	YES
					MOUTH DRY		Detail	0			2										
							Detail	7			1	1	5	1		3	3	3	3		
							Detail	14			1	1	5	1		3	3	3	3		
							Detail	21	16/02/92		1	1	5	1		3	3	3	1		
						27/01/92(@)	Summary		16/02/92	21	2	1	5	1		3	3	3	1		NO
						22/02/92	Detail	28	25/02/92		1	1	6	1		3	3	3	1		
							Summary		25/02/92	28	1	1	6	1		3	3	3	1		YES
					NAUSEA	06/03/92	Detail	35			2	2	5	1		3	3	3	3		
							Detail	42	08/03/92		1	1	4	1		3	3	3	1		
							Summary		08/03/92	42	2	1	4	1		3	3	3	1		YES
	73	Reboxetine	15/02/92	27/03/92	CONSTIPATION	18/02/92	Detail	7	18/02/92		2	2	4	1		3	3	3	2		
							Summary		18/02/92	7	2	2	4	1		3	3	3	2		YES
					DIZZINESS	13/03/92	Detail	28	13/03/92		1	1	4	1		3	3	3	1		
							Summary		13/03/92	28	1	1	4	1		3	3	3	1		YES
					HYPERTENSION	27/02/92	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28	29/02/92		1	2	3	1		3	3	3	1		
							Summary		29/02/92	28	2	2	3	1		3	3	3	1		YES
					INSOMNIA		Detail	0			1										
							Detail	7			1	1	4	1		3	3	3	3		
							Detail	14	26/02/92		1	1	4	1	YES	3	3	3	2		
						10/02/92(@)	Summary		26/02/92	14	1	1	4	1	YES	3	3	3	2		NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
3	73	Reboxetine	15/02/92	27/03/92	TASTE PERVERSION	07/03/92	Detail	28			1	2	4	1		3	3	3	3		
							Detail	35			1	2	4	1		3	3	3	3		
							Detail	42	28/03/92		1	2	4	1		3	3	3	1		
							Summary		28/03/92	42	1	2	4	1		3	3	3	1		YES
4	97	Imipramine	07/05/92	18/06/92	DIZZINESS	23/04/92	Detail	0			1										
							Detail	42			1	1	6	1		3	3	3	3	Y	
							Summary		18/06/92(*)	42	1	1	6	1		3	3	3	3	Y	NO
					HEADACHE	23/04/92	Detail	0			2										
							Detail	42			1	1	6	1		3	3	3	3	Y	
							Summary		18/06/92(*)	42	2	1	6	1		3	3	3	3	Y	NO
					INSOMNIA	23/04/92	Detail	0			2										
							Detail	7			1	1	6	1	YES	3	3	3	3		
							Detail	14	19/05/92		1	1	6	1	YES	3	3	3	2		
							Summary		19/05/92	14	2	1	6	1	YES	3	3	3	2		NO
						24/05/92	Detail	21	26/05/92		1	1	6	1	YES	3	3	3	2		
							Summary		26/05/92	21	1	1	6	1	YES	3	3	3	2		YES
						28/05/92	Detail	28	31/05/92		1	1	6	1	YES	3	3	3	1		
							Summary		31/05/92	28	1	1	6	1	YES	3	3	3	1		YES
						12/06/92	Detail	42	14/06/92		1	1	6	1	YES	3	3	3	2		
							Summary		14/06/92	42	1	1	6	1	YES	3	3	3	2		YES
	100	Reboxetine	07/05/92	24/06/92	HEADACHE	27/04/92	Detail	0			2										
							Detail	42			2	1	6	1		3	3	3	3	Y	
							Summary		17/06/92(*)	42	2	1	6	1		3	3	3	3	Y	NO
					INSOMNIA	27/04/92	Detail	0			3										
							Detail	42			3	1	6	1		3	3	3	3	Y	
							Summary		17/06/92(*)	42	3	1	6	1		3	3	3	3	Y	NO
	101	Imipramine	06/05/91	22/05/91	FLATULENCE	13/05/91	Detail	14			2	2	3	1		3	1	1	3		
							Detail	21			2	2	3	3		3	1	3	3	Y	
							Summary		23/05/91(*)	21	2	2	3	3		3	1	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
4	101	Imipramine	06/05/91	22/05/91	HEADACHE		Detail	0			1										
							Detail	7			2	1	4	1		3	3	3	3	Y	
						05/05/91(D)	Summary		23/05/91(*)	7	2	1	4	1		3	3	3	3	Y	YES
					MICTURITION DISORDER	11/05/91	Detail	7			1	2	3	1		3	3	3	3	Y	
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	3		3	1	3	3	Y	
							Summary		23/05/91(*)	21	1	2	3	3		3	1	3	3	Y	YES
					NAUSEA	30/04/91	Detail	0			1										
							Detail	21			1	1	4	3		3	1	3	3	Y	
							Summary		23/05/91(*)	21	1	1	4	3		3	1	3	3	Y	NO
					RASH	14/05/91	Detail	14	15/05/91		1	2	5	1		3	3	3	1		
							Summary		15/05/91	14	1	2	5	1		3	3	3	1		YES
					TACHYCARDIA		Detail	0			2										
							Detail	7			2	1	5	1		3	3	3	3	Y	
						05/05/91(D)	Summary		23/05/91(*)	7	2	1	5	1		3	3	3	3	Y	NO
6	161	Reboxetine	29/03/91	09/05/91	CONSTIPATION	18/04/91	Detail	21			2	2	3	1		3	3	3	3		
							Detail	28	28/04/91		2	2	3	1		3	3	3	1		
							Summary		28/04/91	28	2	2	3	1		3	3	3	1		YES
					HEADACHE	03/04/91	Detail	7	03/04/91		2	1	4	1		3	3	3	1		
							Summary		03/04/91	7	2	1	4	1		3	3	3	1		YES
						14/04/91	Detail	21	18/04/91		1	1	4	1		3	3	3	1		
							Summary		18/04/91	21	1	1	4	1		3	3	3	1		YES
						25/04/91	Detail	28			2	1	4	1		3	3	3	3		
							Detail	35	26/04/91		2	1	4	1		3	3	3	1		
							Summary		26/04/91	35	2	1	4	1		3	3	3	1		YES
						28/04/91	Detail	35	29/04/91		2	1	4	1		3	3	3	1		
							Summary		29/04/91	35	2	1	4	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=Probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(c)
6	161	Reboxetine	29/03/91	09/05/91	INSOMNIA	26/03/91	Detail	0			3										
							Detail	7			2	1	4	1	YES	3	3	3	3		
							Detail	14			2	1	4	1		3	3	3	3		
							Detail	21			2	1	4	1		3	3	3	3		
							Detail	28			2	1	4	1		3	3	3	3		
							Detail	35			1	1	4	1		3	3	3	3		
							Detail	42			2	1	4	1		3	3	3	3	Y	
							Summary		09/05/91(*)	42	3	1	4	1	YES	3	3	3	3	Y	ND
					SWEATING INCREASED	03/04/91	Detail	7	03/04/91		1	2	4	1		3	3	3	1		
							Summary		03/04/91	7	1	2	4	1		3	3	3	1		YES
	162	Reboxetine	05/11/91	16/12/91	HEADACHE	09/12/91	Detail	35	09/12/91		1	2	6	1		3	3	3	1		
							Summary		09/12/91	35	1	2	6	1		3	3	3	1		YES
					INSOMNIA	31/10/91	Detail	0			3										
							Detail	7			3	1	6	1	YES	3	3	3	3		
							Detail	14			2	1	6	1	YES	3	3	3	3		
							Detail	21			1	1	6	1	YES	3	3	3	3		
							Detail	28			1	1	6	1	YES	3	3	3	3		
							Detail	35			1	1	6	1	YES	3	3	3	3		
							Detail	42			2	1	6	1		3	3	3	3	Y	
							Summary		16/12/91(*)	42	3	1	6	1	YES	3	3	3	3	Y	ND
					SWEATING INCREASED	25/11/91	Detail	21	25/11/91		2	2	4	1		3	3	3	1		
							Summary		25/11/91	21	2	2	4	1		3	3	3	1		YES
7	194	Reboxetine	03/06/91	06/06/91	URINARY RETENTION	04/06/91	Detail	7	10/06/91		3	2	2	3		3	2	3	1		
							Summary		10/06/91	7	3	2	2	3		3	2	3	1		YES
	196	Imipramine	19/03/91	26/04/91	AGITATION	11/04/91	Detail	28			2	1	4	1		2	3	3	3		
							Detail	35			2	1	3	1	YES	2	3	3	3		
							Detail	42			2	1	3	1	YES	2	3	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
7	196	Imipramine	19/03/91	25/04/91	AGITATION	11/04/91	Summary		27/04/91(*)	42	2	1	3	1	YES	2	3	3	3	Y	YES
					HYPOTENSION	07/04/91	Detail	21	07/04/91		2	3	3	1		2	3	3	1		
							Summary		07/04/91	21	2	3	3	1		2	3	3	1		YES
					INSOMNIA	15/04/91	Detail	35			2	2	3	1		2	3	3	3		
							Detail	42			2		3	1		2	3	3	3	Y	
							Summary		27/04/91(*)	42	2	2	3	1		2	3	3	3	Y	YES
					MOUTH DRY	21/03/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			3	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35	16/04/91		1	2	3	1		2	3	3	1		
							Summary		16/04/91	35	3	2	3	1		2	3	3	1		YES
					RASH	24/04/91	Detail	42			3	2	2	3		2	1	3	3	Y	
							Summary		27/04/91(*)	42	3	2	2	3		2	1	3	3	Y	YES
					SOMNOLENCE	21/03/91	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			1	2	3	1		2	3	3	3		
							Detail	28	18/04/91		1	2	3	1		2	3	3	1		
							Summary		18/04/91	28	2	2	3	1		2	3	3	1		YES
					SPUTUM INCREASED	05/04/91	Detail	21			2	2	6	1	YES	2	3	3	3		
							Detail	28	08/04/91		2	2	6	1	YES	2	3	3	1		
							Summary		08/04/91	28	2	2	6	1	YES	2	3	3	1		YES
8	225	Imipramine	22/03/91	09/04/91	DIZZINESS	25/03/91	Detail	7			2	1	2	1		3	3	3	3		
							Detail	14	03/04/91		1	1	4	1		3	3	3	1		
							Summary		03/04/91	14	2	1	2	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
8	225	Imipramine	22/03/91	09/04/91	MOUTH DRY	23/03/91	Detail	7			1	1	2	1			3	3	3	3		
							Detail	14			1	1	3	1			3	3	3	3	Y	
							Summary		11/04/91(*)	14	1	1	2	1			3	3	3	3	Y	YES
					TREMOR	29/03/91	Detail	14			1	2	3	1			3	3	3	3	Y	
							Summary		11/04/91(*)	14	1	2	3	1			3	3	3	3	Y	YES
	226	Reboxetine	03/05/91	13/06/91	NERVOUSNESS	20/05/91	Detail	21	23/05/91		2	1	6	1			3	3	3	1		
							Summary		23/05/91	21	2	1	6	1			3	3	3	1		YES
					RASH	04/06/91	Detail	35			2	2	4	1			2	3	3	3		
							Detail	42			1	2	4	1			3	3	3	3	Y	
							Summary		14/06/91(*)	42	2	2	4	1			2	3	3	3	Y	YES
	227	Imipramine	07/05/91	17/06/91	MOUTH DRY	10/05/91	Detail	7			1	2	3	1			3	3	3	3		
							Detail	14			1	2	3	1			3	3	3	3		
							Detail	21			1	2	3	1			3	3	3	3		
							Detail	28			1	2	2	1			3	3	3	3		
							Detail	35			1	2	3	1			3	3	3	3		
							Detail	42			1	2	3	1			2	3	3	3	Y	
							Summary		18/06/91(*)	42	1	2	2	1			2	3	3	3	Y	YES
	228	Reboxetine	10/05/91	17/05/91	HEADACHE	12/05/91	Detail	7			2	1	3	1			3	3	3	3		
							Detail	14			3	1	3	3			3	1	3	3	Y	
							Summary		18/05/91(*)	14	3	1	3	3			3	1	3	3	Y	YES
	229	Imipramine	22/10/91	02/12/91	BRONCHITIS	14/10/91	Detail	7	22/10/91		2	1	6	1	YES		3	3	3	1		
							Summary		22/10/91	7	2	1	6	1	YES		3	3	3	1		NO
					SWEATING INCREASED	24/10/91	Detail	7			2	2	2	1			2	3	3	3		
							Detail	42			2	2	2	1			2	3	3	3	Y	
							Summary		03/12/91(*)	42	2	2	2	1			2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
[illegible] start treatment data of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Treatment Drug	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalisation	Disapp.	Reapp.	Outcome	Still present	(C)
8	251	Reboxetine	05/11/91	13/11/91	HEADACHE	07/11/91	Detail	7			1	1	4	1	2	3	3	3	Y	
							Summary		15/11/91(*)	7	1	1	4	1	2	3	3	3	Y	YES
					RASH	07/11/91	Detail	7			1	3	4	1	2	3	3	3	Y	
							Summary		15/11/91(*)	7	1	3	4	1	2	3	3	3	Y	YES
9	197	Reboxetine	07/03/92	10/03/92	ASTHENIA	08/03/92	Detail	7	11/03/92		2	2	4	3	2	2	3	1		
							Summary		11/03/92	7	2	2	4	3	2	2	3	1		YES
					HEADACHE	08/03/92	Detail	7	11/03/92		3	2	4	3	2	2	3	1		
							Summary		11/03/92	7	3	2	4	3	2	2	3	1		YES
	198	Imipramine	18/03/92	28/04/92	MOUTH DRY	17/03/92	Detail	7			3	2	3	1	3	3	3	3		
							Detail	14	27/03/92					1	2	3	3	1		
							Summary		27/03/92	14	3	2	3	1	2	3	3	1		NO
						31/03/92	Detail	21			2	2	3	1	3	3	3	3		
							Detail	28			1	2	3	1	3	3	3	3		
							Detail	35	15/04/92		1	2	3	1	3	3	3	1		
							Summary		15/04/92	35	2	2	3	1	3	3	3	1		YES
					NAUSEA	17/03/92	Detail	7			2	2	3	1	3	3	3	3		
							Detail	14	26/03/92							3	3	1		
							Summary		26/03/92	14	2	2	3	1	3	3	3	1		NO
						31/03/92	Detail	21			3	2	3	1	3	3	3	3		
							Detail	28	08/04/92		1					3	3	1		
							Summary		08/04/92	28	3	2	3	1	3	3	3	1		YES
					TREMOR	31/03/92	Detail	21			2	2	3	1	3	3	3	3		
							Detail	28	08/04/92							3	3	1		
							Summary		08/04/92	28	2	2	3	1	3	3	3	1		YES
	199	Imipramine	02/04/92	13/05/92	CONSTIPATION	05/04/92	Detail	7			1	2	3	1	3	3	3	3		
							Detail	14	11/04/92		1	2	3	1	3	3	3	1		
							Summary		11/04/92	14	1	2	3	1	3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
9	199	Imipramine	02/04/92	13/05/92	LIBIDO DECREASED	30/04/92	Detail	35	01/05/92		2	3	4	1		2	3	3	1		
							Summary		01/05/92	35	2	3	4	1		2	3	3	1		YES
					MICTURITION DISORDER	30/04/92	Detail	35	02/05/92		2	1	3	1		2	3	3	1		
							Summary		02/05/92	35	2	1	3	1		2	3	3	1		YES
					MOUTH DRY	06/04/92	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14			1	2	2	1		3	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	2	1		3	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3		
							Detail	42			1	2	2	1		3	3	3	3	Y	
							Summary		13/05/92(*)	42	1	2	2	1		3	3	3	3	Y	YES
	208	Reboxetine	28/04/92	08/06/92	MOUTH DRY	28/04/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28	19/05/92										1		
							Summary		19/05/92	28	1	2	3	1		3	3	3	1		YES
	201	Imipramine	16/01/92	26/02/92	ABDOMINAL PAIN	27/01/92	Detail	14	27/01/92		3	2	3	1		3	3	3	1		
							Summary		27/01/92	14	3	2	3	1		3	3	3	1		YES
					MENSTRUAL DISORDER		Detail	28	12/02/92				6						1		
						06/02/92(&)	Summary		12/02/92	28			6						1		YES
					SWEATING INCREASED	20/02/92	Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		26/02/92(*)	42	1	2	3	1		3	3	3	3	Y	YES
	202	Imipramine	17/01/92	27/02/92	COUGHING	11/02/92	Detail	28			2	2	4	1	YES	2	3	3	3		
							Detail	35	15/02/92		2	2	4	1	YES	2	3	3	1		
							Summary		15/02/92	35	2	2	4	1	YES	2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
9	282	Imipramine	17/01/92	27/02/92	FEVER	11/02/92	Detail	28			2	2	4	1	YES	2	3	3	3		
							Detail	35	15/02/92		2	2	4	1	YES	2	3	3	1		
							Summary		15/02/92	35	2	2	4	1	YES	2	3	3	1		YES
					MOUTH DRY	20/01/92	Detail	7			3	2	3	1		3	3	3	3		
							Detail	14			2	1	3	1		3	3	3	3		
							Detail	21			2	1	3	1		3	3	3	3		
							Detail	28			2	1	4	1		3	3	3	3		
							Detail	35			3	1	2	1		3	3	3	3		
							Detail	42			3	1	2	1		3	3	3	3	Y	
							Summary		27/02/92(*)	42	3	1	2	1		3	3	3	3	Y	YES
					SWEATING INCREASED	17/01/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14	29/01/92		2	2	3	1		3	3	3	1		
							Summary		29/01/92	14	2	2	3	1		3	3	3	1		YES
						05/02/92	Detail	21	05/02/92		1	2	3	1		3	3	3	1		
							Summary		05/02/92	21	1	2	3	1		3	3	3	1		YES
						18/02/92	Detail	28			3	2	3	1		3	3	3	3		
							Detail	35			2	2	4	1		3	3	3	3		
							Detail	42			2	2	4	1		3	3	3	3	Y	
							Summary		27/02/92(*)	42	3	2	3	1		3	3	3	3	Y	YES
	283	Reboxetine	15/01/92	18/01/92	AGITATION	16/01/92	Detail	7	17/01/92		3	2	3	4		3	2	3	1		
							Summary		17/01/92	7	3	2	3	4		3	2	3	1		YES
	284	Reboxetine	17/01/92	28/02/92	HERPES SIMPLEX	28/01/92	Detail	14	04/02/92		3	2	4	1		2	3	3	1		
							Summary		04/02/92	14	3	2	4	1		2	3	3	1		YES
					INFLUENZA-LIKE SYMPTOMS	27/01/92	Detail	14			2	2	4	1		2	3	3	3		
							Detail	21	03/02/92		2	2	4	1		2	3	3	1		
							Summary		03/02/92	21	2	2	4	1		2	3	3	1		YES
					MOUTH DRY	15/02/92	Detail	35	28/02/92		1	2	3	1		3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
[illegible] start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/917
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
9	204	Reboxetine	17/01/92	28/02/92	MOUTH DRY	15/02/92	Summary		20/02/92	35	1	2	3	1		3	3	3	1		YES
					SWEATING INCREASED	15/01/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28	11/02/92		1	2	3	1		3	3	3	1		
							Summary		11/02/92	28	2	2	3	1		3	3	3	1		NO
	206	Imipramine	05/02/92	18/03/92	HEADACHE	04/02/92	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21	24/02/92		1	2	3	1		3	3	3	1		
							Summary		24/02/92	21	1	2	3	1		3	3	3	1		NO
					PALPITATION	16/02/92	Detail	14	17/02/92		3	2	3	4		2	2	1	1		
							Summary		17/02/92	14	3	2	3	4		2	2	1	1		YES
					VERTIGO	02/03/92	Detail	28	02/03/92		1	2	3	1		2	3	3	1		
							Summary		02/03/92	28	1	2	3	1		2	3	3	1		YES
	207	Reboxetine	06/02/92	12/02/92	FATIGUE	06/02/92	Detail	7	11/02/92		2	2	3	1		3	3	3	1		
							Summary		11/02/92	7	2	2	3	1		3	3	3	1		YES
	208	Reboxetine	15/02/92	27/03/92	BACK PAIN	16/02/92	Detail	7			1	1	3	1		3	3	3	3		
							Detail	14	27/02/92		1	1	3	1		3	3	3	1		
							Summary		27/02/92	14	1	1	3	1		3	3	3	1		YES
					CONSTIPATION	01/03/92	Detail	21	05/03/92		2	2	3	1		3	3	3	1		
							Summary		05/03/92	21	2	2	3	1		3	3	3	1		YES
					MOUTH DRY	17/02/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14	24/02/92		1	1	3	1		3	3	3	1		
							Summary		24/02/92	14	2	1	3	1		3	3	3	1		YES
						24/03/92	Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		27/03/92(*)	42	2	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. interr.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
[illegible] report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
9	208	Reboxetine	15/02/92	27/03/92	SWEATING INCREASED	15/02/92	Detail	7			1	2	3	1	3	3	3	3			
							Detail	14	22/02/92		1	2	3	1	3	3	3	1			
							Summary		22/02/92	14	1	2	3	1	3	3	3	1			YES
						24/03/92	Detail	42			1	2	3	1	3	3	3	3	Y		
							Summary		27/03/92(*)	42	1	2	3	1	3	3	3	3	Y	Y	YES
	209	Imipramine	12/02/92	15/02/92	FATIGUE	12/02/92	Detail	7	16/02/92		3	2	2	3	2	2	3	1			
							Summary		16/02/92	7	3	2	2	3	2	2	3	1			YES
					HEADACHE	12/02/92	Detail	7			3	2	2	3	2	1	3	3	Y		
							Summary		18/02/92(*)	7	3	2	2	3	2	1	3	3	Y	Y	YES
					MOUTH DRY	12/02/92	Detail	7			2	2	3	3	2	1	3	3	Y		
							Summary		18/02/92(*)	7	2	2	3	3	2	1	3	3	Y	Y	YES
	210	Reboxetine	20/02/92	01/04/92	MOUTH DRY	27/02/92	Detail	14			1	2	3	1	3	3	3	3			
							Detail	21	09/03/92		1	2	3	1	3	3	3	1			
							Summary		09/05/92	21	1	2	3	1	3	3	3	1			YES
					NAUSEA	01/03/92	Detail	14	02/03/92		1	2	3	1	2	3	3	1			
							Summary		02/03/92	14	1	2	3	1	2	3	3	1			YES
	211	Reboxetine	14/02/92	02/03/92	MOUTH DRY	11/02/92	Detail	0			1										
							Detail	7			2	1	3	1	3	3	3	3			
							Detail	14			3	1	3	1	3	3	3	3			
							Detail	21			3	1	3	1	3	3	3	3	Y		
							Summary		03/03/92(*)	21	3	1	3	1	3	3	3	3	Y	Y	YES
					NAUSEA	22/02/92	Detail	14			2	2	3	1	3	3	3	3			
							Detail	21			2	2	3	1	3	3	3	3	Y		
							Summary		03/05/92(*)	21	2	2	3	1	3	3	3	3	Y	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End data	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
9	211	Reboxetine	14/02/92	02/03/92	TREMOR	19/02/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3	Y	
							Summary		03/03/92(*)	21	1	2	3	1		2	3	3	3	Y	YES
	212	Imipramine	04/03/92	14/04/92	MOUTH DRY	03/03/92	Detail	7			3	2	2	1		3	3	3	3		
							Detail	14			2	2	2	1		3	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	2	1		3	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3		
							Detail	42	08/04/92								3	3	1		
							Summary		08/04/92	42	3	2	2	1		3	3	3	1		NO
					SWEATING INCREASED	03/03/92	Detail	7			3	2	2	1		3	3	3	3		
							Detail	14			3	2	2	1		3	3	3	3		
							Detail	21			3	2	2	1		3	3	3	3		
							Detail	28	29/03/92		2	2	2	1		3	3	3	1		
							Summary		29/03/92	28	3	2	2	1		3	3	3	1		NO
	237	Reboxetine	23/04/92	02/05/92	MOUTH DRY	23/04/92	Detail	7	28/04/92		1	3	1	4		3	2	3	1		
							Summary		28/04/92	7	1	3	1	4		3	2	3	1		YES
					SWEATING INCREASED	23/04/92	Detail	7	29/04/92		2	3	1	4		2	1	3	1		
							Summary		29/04/92	7	2	3	1	4		2	1	3	1		YES
					URINARY RETENTION	23/04/92	Detail	7	28/04/92		3	2	2	4	YES	2	2	3	1		
							Summary		28/04/92	7	3	2	2	4	YES	2	2	3	1		YES
						03/05/92	Detail	14	05/05/92		2	2	3	3		2	2	3	1		
							Summary		05/05/92	14	2	2	3	3		2	2	3	1		YES
	239	Imipramine	30/04/92	10/06/92	MOUTH DRY	30/04/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	2	1		3	3	3	3		
							Detail	21			2	2	2	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 5=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset data missing: first report visit date used
(S) onset data missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
9	239	Imipramine	30/04/92	10/06/92	MOUTH DRY	30/04/92	Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		10/06/92(M)	42	2	2	2	1		3	3	3	3	Y	YES
					SWEATING INCREASED	01/05/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			3	2	2	1		3	3	3	3		
							Detail	21			3	2	2	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		10/06/92(M)	42	3	2	2	1		3	3	3	3	Y	YES
	240	Reboxetine	28/04/92	16/05/92	MOUTH DRY	28/04/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	16/05/92		1	2	3	1		3	3	3	1		
							Summary		16/05/92	14	1	2	3	1		3	3	3	1		YES
					NAUSEA	28/04/92	Detail	21	16/05/92		1	2	3	1		3	3	1	1		
							Summary		16/05/92	21	1	2	3	1		3	3	1	1		YES
					VISION ABNORMAL	30/04/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21	16/05/92		1	2	3	1		3	3	3	1		
							Summary		16/05/92	21	1	2	3	1		3	3	3	1		YES
	241	Imipramine	09/05/92	19/06/92	NAUSEA	15/05/92	Detail	7			2	2	4	4	YES	3	1	3	3		
							Detail	14			2	2	4	1	YES	3	3	3	3		
							Detail	21			2	2	4	1	YES	3	3	3	3		
							Detail	28			2	2	4	1	YES	3	3	3	3		
							Detail	35			2	2	4	1	YES	3	3	3	3		
							Detail	42	15/06/92		2	2	4	1	YES	3	3	3	1		
							Summary		15/06/92	42	2	2	4	4	YES	3	3	3	1		YES
					SWEATING INCREASED	13/05/92	Detail	7			2	2	2	1		3	3	3	3		
							Detail	14	19/05/92		2	2	2	1		3	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(M) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(E) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
9	241	Imipramine	09/05/92	19/06/92	SWEATING INCREASED	13/05/92	Summary		19/05/92	14	2	2	2	1		3	3	3	1		YES
	242	Reboxetine	07/05/92	17/06/92	SWEATING INCREASED	08/05/92	Detail	7			2	2	3	1		3	3	3	3		
							Detail	14			2	2	3	1		3	3	3	3		
							Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3		
							Detail	35	09/06/92		2	2	3	1		3	3	3	1		
							Summary		09/06/92	35	2	2	3	1		3	3	3	1		YES
	243	Imipramine	18/05/92	28/06/92	TACHYCARDIA	25/05/92	Detail	7	25/05/92		2	1	3	1	YES	3	3	3	1		
							Summary		25/05/92	7	2	1	3	1	YES	3	3	3	1		YES
	244	Reboxetine	06/06/92	17/07/92	MICTURITION DISORDER	06/06/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28	02/07/92		1	2	3	1		3	3	3	1		
							Summary		02/07/92	28	1	2	3	1		3	3	3	1		YES
					NAUSEA	06/06/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	13/06/92		1	2	3	1		3	1	3	1		
							Summary		13/06/92	14	1	2	3	1		3	1	3	1		YES
	257	Reboxetine	17/07/91	27/08/91	DIZZINESS	01/08/91	Detail	21			1	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		28/08/91(*)	42	1	2	3	1		2	3	3	3	Y	YES
	258	Reboxetine	17/07/91	06/08/91	SOMNOLENCE	19/07/91	Detail	7	23/07/91		2	2	3	1		2	3	3	1		
							Summary		23/07/91	7	2	2	3	1		2	3	3	1		YES
	259	Imipramine	17/07/91	27/08/91	MOUTH DRY	31/07/91	Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		
							Detail	28			2		3	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic trea	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
9	259	Imipramine	17/07/91	27/08/91	MOUTH DRY	31/07/91	Detail	35			2	2	3	1	2	3	3	3			
							Detail	42			2	2	3	1	2	3	3	3		Y	
							Summary		28/08/91(*)	42	2	2	3	1	2	3	3	3		Y	YES
					SWEATING INCREASED	18/07/91	Detail	7			1	2	3	1	2	3	3	3			
							Detail	14			1	2	3	1	2	3	3	3			
							Detail	21			1	2	3	1	2	3	3	3			
							Detail	28			1	2	3	1	2	3	3	3			
							Detail	35			1	2	3	1	2	3	3	3			
							Detail	42			1		3	1	2	3	3	3		Y	
							Summary		28/08/91(*)	42	1	2	3	1	2	3	3	3		Y	YES
					URINARY RETENTION	08/08/91	Detail	28			1	2	3	1	2	3	3	3			
							Detail	35	19/08/91		1		3	1	2	3	3	1			
							Summary		19/08/91	35	1	2	3	1	2	3	3	1			YES
	261	Imipramine	25/07/91	29/07/91	URINARY RETENTION	24/07/91	Detail	7	01/08/91		3	2	3	3	3	2	3	1			
							Summary		01/08/91	7	3	2	3	3	3	2	3	1			YES
	264	Imipramine	31/07/91	10/09/91	DIZZINESS	01/08/91	Detail	7			1	2	3	1	2	3	3	3			
							Detail	14	09/08/91		1	2	3	1	2	3	3	1			
							Summary		09/08/91	14	1	2	3	1	2	3	3	1			YES
					MOUTH DRY	03/08/91	Detail	7			2	2	3	1	3	3	3	3			
							Detail	14	12/08/91		2	2	3	1	2	3	3	1			
							Summary		12/08/91	14	2	2	3	1	2	3	3	1			YES
					SWEATING INCREASED	10/08/91	Detail	14			2	2	3	1	2	3	3	3			
							Detail	21			2	2	2	1	2	3	3	3			
							Detail	28			2	2	3	1	2	3	3	3			
							Detail	35			1	2	3	1	2	3	3	3			
							Detail	42	10/09/91		1	2	3	1	3	3	3	1			
							Summary		10/09/91	42	2	2	2	1	2	3	3	1			YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
9	266	Reboxetine	18/09/91	29/10/91	MENSTRUAL DISORDER	04/10/91	Detail	21			1	2	3	1		2	3	3	3		
							Detail	28	10/10/91		2	2	3	1		2	3	3	1		
							Summary		10/10/91	28	2	2	3	1		2	3	3	1		YES
					PALPITATION	18/09/91	Detail	7			2	1	6	1		2	3	3	3		
							Detail	14			1	1	3	1		2	3	3	3		
							Detail	21			1	1	3	1		2	3	3	3		
							Detail	28			1	1	3	1		2	3	3	3		
							Detail	35			1	1	3	1		2	3	3	3		
							Detail	42	25/10/91								3	3	1		
							Summary		25/10/91	42	2	1	3	1		2	3	3	1		YES
					RHINITIS	01/05/91	Detail	0			2										
							Detail	7			2	1	3	1		2	3	3	3		
							Detail	14			2	1	6	1	YES	2	3	3	3		
							Detail	21	08/10/91		2	1	6	1		2	3	3	1		
							Summary		08/10/91	21	2	1	3	1	YES	2	3	3	1		NO
	267	Imipramine	02/09/91	13/10/91	SALIVA INCREASED	03/09/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	5	1		3	3	3	3		
							Detail	21			1	2	5	1		3	3	3	3		
							Detail	28			1	2	5	1		3	3	3	3		
							Detail	35			1	2	5	1		3	3	3	3		
							Detail	42			1	2	5	1		3	3	3	3	Y	
							Summary		14/10/91(*)	42	1	2	3	1		3	3	3	3	Y	YES
					SWEATING INCREASED		Detail	0			3										
						29/08/91(D)	Summary		14/10/91(*)	0	3										NO
					TREMOR	03/09/91	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	5	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	5	1		3	3	3	3	Y	
							Summary		14/10/91(*)	42	1	2	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit data used
(D) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
9	267	Imipramine	02/09/91	13/10/91	VISION ABNORMAL	03/09/91	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14			1	2	5	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	5	1		3	3	3	3		
							Detail	35			1	2	5	1		3	3	3	3		
							Detail	42			1	2	5	1		3	3	3	3	Y	
							Summary		14/10/91(*)	42	1	2	2	1		3	3	3	3	Y	YES
	268	Imipramine	25/09/91	05/11/91	AGITATION	26/09/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3		
							Detail	21	10/10/91		1	2	3	1		2	3	3	1		
							Summary		10/10/91	21	1	2	3	1		2	3	3	1		YES
					HEADACHE	26/09/91	Detail	7	29/09/91		1	3	3	1	YES	2	3	3	1		
							Summary		29/09/91	7	1	3	3	1	YES	2	3	3	1		YES
					SWEATING INCREASED	25/09/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3		
							Detail	21			1	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		05/11/91(*)	42	1	2	3	1		2	3	3	3	Y	YES
					TREMOR	03/11/91	Detail	42	04/11/91		1	2	3	1		3	3	3	1		
							Summary		04/11/91	42	1	2	3	1		3	3	3	1		YES
	269	Reboxetine	25/09/91	05/11/91	MICTURITION DISORDER	02/10/91	Detail	14			2	2	3	1		2	3	3	3		
							Detail	21	10/10/91		2	2	3	1		2	3	3	1		
							Summary		10/10/91	21	2	2	3	1		2	3	3	1		YES
					SWEATING INCREASED	26/09/91	Detail	7	29/09/91		1	2	3	1		2	3	3	1		
							Summary		29/09/91	7	1	2	3	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with sse., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
9	270	Imipramine	11/10/91	17/10/91	TACHYCARDIA	17/10/91	Detail	7			3	1	5	1		2	3	3	3	Y	
							Summary		17/10/91(*)	7	3	1	5	1		2	3	3	3	Y	YES
	271	Reboxetine	30/10/91	20/11/91	BACK PAIN	07/11/91	Detail	14	10/11/91		1	2	3	1	YES	3	3	3	1		
							Summary		10/11/91	14	1	2	3	1	YES	3	3	3	1		YES
					EARACHE		Detail	0			2										
						21/10/91(D)	Summary		26/11/91(*)	0	2										NO
						27/10/91	Detail	7			2	1	3	1	YES	3	3	3	3		
							Detail	14			1	1	3	1	YES	3	3	3	3		
							Detail	21	15/11/91		1	1	3	4	YES	3	2	1	1		
							Summary		15/11/91	21	2	1	3	4	YES	3	2	1	1		NO
					HEADACHE	13/11/91	Detail	21			3	2	3	4	YES	3	1	3	3		
							Detail	28	21/11/91		3	2	3	3	YES	3	2	3	1		
							Summary		21/11/91	28	3	2	3	3	YES	3	2	3	1		YES
					HYPERTENSION	13/11/91	Detail	21			3	2	3	4	YES	3	2	2	3		
							Detail	28	21/11/91		3	2	3	3	YES	3	2	3	1		
							Summary		21/11/91	28	3	2	3	3	YES	3	2	3	1		YES
					MOUTH DRY	01/10/91	Detail	0			2										
							Detail	7			2	1	3	1		3	3	3	3		
							Detail	14			1	1	3	1		3	3	3	3		
							Detail	21			1	1	3	4		3	1	3	3		
							Detail	28			1	1	3	3		3	1	3	3	Y	
							Summary		26/11/91(*)	28	2	1	3	3		3	1	3	3	Y	NO
					PALPITATION	13/11/91	Detail	21	16/11/91		2	2	3	4		3	2	1	1		
							Summary		16/11/91	21	2	2	3	4		3	2	1	1		YES
					RHINITIS	27/10/91	Detail	0			3										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset data	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Resapp.	Outcome	Still Present	(C)
9	271	Reboxetine	30/10/91	20/11/91	RHINITIS	27/10/91	Detail	7			1	1	3	1	YES	3	3	3	3		
							Detail	14			1	1	3	1	YES	3	3	3	3		
							Detail	21	15/11/91		1	1	3	4	YES	3	2	1	1		
							Summary		15/11/91	21	3	1	3	4	YES	3	2	1	1		NO
					SWEATING INCREASED		Detail	0			3										
							Detail	7			2	1	3	1		3	3	3	3		
							Detail	14			2	1	3	1		3	3	3	3		
							Detail	21			2	1	3	4		3	1	3	3		
							Detail	28			2	1	3	3		3	1	3	3	Y	
						21/10/91(2)	Summary		26/11/91(*)	28	3	1	3	3		3	1	3	3	Y	NO
	272	Imipramine	30/10/91	10/12/91	CONSTIPATION	09/11/91	Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1	YES	3	3	3	3		
							Detail	28			1	2	3	1	YES	3	3	3	3		
							Detail	35			1	2	3	1	YES	3	3	3	3		
							Detail	42	05/12/91		1	2	3	1	YES	3	3	3	1		
							Summary		05/12/91	42	1	2	3	1	YES	3	3	3	1		YES
					HYPOTENSION	15/11/91	Detail	21	17/11/91		1	2	3	1		3	3	3	1		
							Summary		17/11/91	21	1	2	3	1		3	3	3	1		YES
					MOUTH DRY	17/10/91	Detail	0			2										
							Detail	7			2	1	3	1		3	3	3	3		
							Detail	14			2	1	3	1		3	3	3	3		
							Detail	21			2	1	3	1		3	3	3	3		
							Detail	28			2	1	3	1		3	3	3	3		
							Detail	35			2	1	3	1		3	3	3	3		
							Detail	42			2	1	3	1		3	3	3	3	Y	
							Summary		10/12/91(*)	42	2	1	3	1		3	3	3	3	Y	NO
	273	Imipramine	30/10/91	20/11/91	CONFUSION	14/11/91	Detail	21			2	2	3	1		3	3	3	3		
							Detail	28	20/11/91		2	2	3	3		3	2	3	1		
							Summary		20/11/91	28	2	2	3	3		3	2	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
9	273	Imipramine	30/10/91	20/11/91	MOUTH DRY	01/11/91	Detail	7			3	2	3	1	YES	3	3	3	3		
							Detail	14			3	2	3	1	YES	3	3	3	3		
							Detail	21			3	2	3	1	YES	3	3	3	3		
							Detail	28	21/11/91		3	2	3	3	YES	3	2	3	1		
							Summary		21/11/91	28	3	2	3	3	YES	3	2	3	1		YES
					TASTE LOSS	01/11/91	Detail	28	21/11/91		3	2	3	3	YES	3	2	3	1		
							Summary		21/11/91	28	3	2	3	3	YES	3	2	3	1		YES
					TREMOR	14/11/91	Detail	21			3	2	3	1		3	3	3	3		
							Detail	28	25/11/91		3	2	3	3		3	2	3	1		
							Summary		25/11/91	28	3	2	3	3		3	2	3	1		YES
					URINARY RETENTION	20/11/91	Detail	28	21/11/91		2	2	3	3		3	2	3	1		
							Summary		21/11/91	28	2	2	3	3		3	2	3	1		YES
	274	Reboxetine	31/10/91	31/10/91	NAUSEA	31/10/91	Detail	7	31/10/91		3	2	3	3		3	2	3	1		
							Summary		31/10/91	7	3	2	3	3		3	2	3	1		YES
	274/A	Reboxetine	13/05/92	25/06/92	MOUTH DRY	10/05/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	2	3	1		3	3	3	3		
							Detail	28			1	2	3	1		3	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		24/06/92(*)	42	1	2	3	1		3	3	3	3	Y	NO
					PALPITATION	16/05/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14	29/05/92								3	3	1		
							Summary		29/05/92	14	1	2	3	1		3	3	3	1		YES
	275	Reboxetine	06/11/91	17/12/91	HEADACHE		Detail	0			3										
							Detail	7			1	1	6	1	YES	3	3	3	3		
							Detail	14			2	1	3	1	YES	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
9	275	Reboxetine	06/11/91	17/12/91	HEADACHE		Detail	21	20/11/91		1	1	3	1	YES	3	3	3	1		
						30/10/91(@)	Summary		20/11/91	21	3	1	3	1	YES	3	3	3	1		NO
	276	Imipramine	14/01/92	14/01/92	INFLUENZA-LIKE SYMPTOMS	07/01/92	Detail	7	15/01/92		1	1	4	3		2	2	3	1		
							Summary		15/01/92	7	1	1	4	3		2	2	3	1		NO
					NAUSEA	10/01/92	Detail	7	15/01/92		2	2	3	3		3	2	3	1		
							Summary		15/01/92	7	2	2	3	3		3	2	3	1		NO
9/A	233	Imipramine	14/05/92	24/06/92	INSOMNIA	14/05/92	Detail	7			2	2	4	1	YES	2	3	3	3		
							Detail	42	24/06/92		2	2	4	1	YES	2	3	3	1		
							Summary		24/06/92	42	2	2	4	1	YES	2	3	3	1		YES
					SWEATING INCREASED	31/05/92	Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		24/06/92(*)	42	1	2	2	1		2	3	3	3	Y	YES
	234	Reboxetine	22/05/92	02/07/92	SWEATING INCREASED	01/06/92	Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42	04/07/92		1	2	2	3		2	2	3	1		
							Summary		04/07/92	42	1	2	2	3		2	2	3	1		YES
	235	Reboxetine	26/05/92	29/06/92	INSOMNIA	26/05/92	Detail	7			2	2	4	1	YES	2	3	3	3		
							Detail	35			2	2	4	1	YES	2	3	3	3	Y	
							Summary		29/06/92(*)	35	2	2	4	1	YES	2	3	3	3	Y	YES
					SWEATING INCREASED	20/06/92	Detail	28			1	2	2	1		2	3	3	3		
							Detail	35	01/07/92		1	2	2	3		2	2	3	1		
							Summary		01/07/92	35	1	2	2	3		2	2	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
9/A	236	Imipramine	27/05/92	07/07/92	MOUTH DRY	04/06/92	Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42	03/07/92		1		2	1		2	3	3	1		
							Summary		03/07/92	42	1	2	2	1		2	3	3	1		YES
	277	Reboxetine	10/06/92	14/06/92	AGITATION	11/06/92	Detail	7	16/06/92		3	2	2	3		2	2	3	1		
							Summary		16/06/92	7	3	2	2	3		2	2	3	1		YES
					HYPOTHYROIDISM		Detail	0			3										
						04/06/92(Q)	Summary		16/06/92(*)	0	3										ND
						11/06/92	Detail	7			3	1	6	3		2	1	3	3	Y	
							Summary		16/06/92(*)	7	3	1	6	3		2	1	3	3	Y	YES
					INSOMNIA	11/06/92	Detail	7	16/06/92		3	2	2	3		2	2	3	1		
							Summary		16/06/92	7	3	2	2	3		2	2	3	1		YES
					SWEATING INCREASED	11/06/92	Detail	7	16/06/92		3	2	2	3		2	2	3	1		
							Summary		16/06/92	7	3	2	2	3		2	2	3	1		YES
	278	Imipramine	13/06/92	03/07/92	HYPERKINESIA	17/06/92	Detail	7	17/06/92		2	2	3	1		2	3	3	1		
							Summary		17/06/92	7	2	2	3	1		2	3	3	1		YES
	279	Imipramine	07/08/92	21/08/92	NAUSEA	07/08/92	Detail	7	10/08/92		2	2	2	1		2	3	3	1		
							Summary		10/08/92	7	2	2	2	1		2	3	3	1		YES
					PALPITATION	10/08/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14			2	2	2	1		2	3	3	3	Y	
							Summary		21/08/92(*)	14	2	2	2	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(Q) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
9/A	280	Reboxetine	08/08/92	14/08/92	DIZZINESS	08/08/92	Detail	7			2	2	2	3		2	1	3	3	Y	
							Summary		14/08/92(*)	7	2	2	2	3		2	1	3	3	Y	YES
					MOUTH DRY	08/08/92	Detail	7			3	2	2	3		2	1	3	3	Y	
							Summary		14/08/92(*)	7	3	2	2	3		2	1	3	3	Y	YES
					SOMNOLENCE	08/08/92	Detail	7			2	2	2	3		2	1	3	3	Y	
							Summary		14/08/92(*)	7	2	2	2	3		2	1	3	3	Y	YES
	281	Reboxetine	01/09/92	12/10/92	INSOMNIA	25/08/92	Detail	7			2	2	4	1	YES	2	3	3	3		
							Detail	14	14/09/92		2	2	4	1	YES	2	3	3	1		
							Summary		14/09/92	14	2	2	4	1	YES	2	3	3	1		NO
	282	Reboxetine	02/09/92	13/10/92	MOUTH DRY	03/09/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21	20/09/92		1	2	2	1		2	3	3	1		
							Summary		20/09/92	21	1	2	2	1		2	3	3	1		YES
	284	Imipramine	19/09/92	09/10/92	MOUTH DRY	20/09/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14	30/09/92		1	2	2	1		2	3	3	1		
							Summary		30/09/92	14	1	2	2	1		2	3	3	1		YES
	301	Imipramine	05/03/92	15/04/92	MOUTH DRY	07/03/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		15/04/92(*)	42	1	2	2	1		2	3	3	3	Y	YES
					PALPITATION	14/03/92	Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28	27/03/92		1	2	2	1		2	3	3	1		
							Summary		27/03/92	28	1	2	2	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: [7.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
9/A	302	Imipramine	06/03/92	22/03/92	INSOMNIA	15/03/92	Detail	14			2	2	4	1	YES	2	3	3	3		
							Detail	21	23/03/92		2	2	4	1	YES	2	3	3	1		
							Summary		23/03/92	21	2	2	4	1	YES	2	3	3	1		YES
					MOUTH DRY	07/03/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3	Y	
							Summary		23/03/92(*)	21	1	2	2	1		2	3	3	3	Y	YES
					SWEATING INCREASED	07/03/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3	Y	
							Summary		23/03/92(*)	21	1	2	2	1		2	3	3	3	Y	YES
	303	Reboxetine	12/03/92	31/03/92	MOUTH DRY	14/03/92	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14			2	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3	Y	
							Summary		31/03/92(*)	21	2	2	2	1		2	3	3	3	Y	YES
					SWEATING INCREASED	14/03/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3	Y	
							Summary		31/03/92(*)	21	1	2	2	1		2	3	3	3	Y	YES
	304	Reboxetine	26/03/92	06/05/92	MOUTH DRY	28/03/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	35	27/04/92		1	2	2	1		2	3	3	1		
							Summary		27/04/92	35	1	2	2	1		2	3	3	1		YES
	305	Reboxetine	31/03/92	11/05/92	MOUTH DRY	02/04/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14	10/04/92		1	2	6	1		2	3	3	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
9/A	305	Reboxetine	31/03/92	11/05/92	MOUTH DRY	02/04/92	Summary		10/04/92	14	1	2	2	1		2	3	3	1		YES
	306	Reboxetine	29/04/92	09/06/92	FATIGUE	29/04/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14	08/05/92		2	2	2	1		2	3	3	1		
							Summary		08/05/92	14	2	2	2	1		2	3	3	1		YES
					MOUTH DRY	29/04/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14	08/05/92		2	2	2	1		2	3	3	1		
							Summary		08/05/92	14	2	2	2	1		2	3	3	1		YES
	307	Imipramine	05/05/92	08/05/92	AGITATION	06/05/92	Detail	7	10/05/92		3	2	2	3		2	2	3	1		
							Summary		10/05/92	7	3	2	2	3		2	2	3	1		YES
					TREMOR	06/05/92	Detail	7	10/05/92		3	2	2	3		2	2	3	1		
							Summary		10/05/92	7	3	2	2	3		2	2	3	1		YES
	308	Imipramine	09/05/92	02/06/92	FATIGUE	10/05/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14			2	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			3	2	2	3		2	1	3	3	Y	
							Summary		02/06/92(*)	28	3	2	2	3		2	1	3	3	Y	YES
					INSOMNIA	16/05/92	Detail	7			2	2	4	1	YES	2	3	3	3		
							Detail	28	02/06/92		2	2	4	1	YES	2	3	3	1		
							Summary		02/06/92	28	2	2	4	1	YES	2	3	3	1		YES
					NAUSEA	10/05/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			2	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			1	2	2	3		2	1	3	3	Y	
							Summary		02/06/92(*)	28	2	2	2	3		2	1	3	3	Y	YES
					SWEATING INCREASED	10/05/92	Detail	7			2	2	2	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
9/A	508	Imipramine	09/05/92	02/06/92	SWEATING INCREASED	10/05/92	Detail	14			2	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	28			3	2	2	3		2	1	3	3	Y	
							Summary		02/06/92(*)	28	3	2	2	3		2	1	3	3	Y	YES
					URINARY TRACT INFECTION	29/05/92	Detail	21			1	2	6	1		2	3	3	3		
							Detail	28	31/05/92		1	2	6	3		2	2	3	1		
							Summary		31/05/92	28	1	2	6	3		2	2	3	1		YES
10	289	Imipramine	21/09/91	27/09/91	ANOREXIA	22/09/91	Detail	7			2	2	4	1		3	3	3	3	Y	
							Summary		27/09/91(*)	7	2	2	4	1		3	3	3	3	Y	YES
					CONSTIPATION	20/09/91	Detail	7			2	3	3	1		3	3	3	3	Y	
							Summary		27/09/91(*)	7	2	3	3	1		3	3	3	3	Y	NO
	290	Reboxetine	14/10/91	24/11/91	FATIGUE	21/10/91	Detail	14			1	3	3	1		2	3	3	3		
							Detail	21	04/11/91		1	3	4	1		2	3	3	1		
							Summary		04/11/91	21	1	3	3	1		2	3	3	1		YES
					SOMNOLENCE	17/10/91	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14	28/10/91		1		3	1		3	3	3	1		
							Summary		28/10/91	14	1	2	3	1		2	3	3	1		YES
	291	Imipramine	17/02/92	29/03/92	DIZZINESS	29/02/92	Detail	14			1	2	3	1	YES	2	3	3	3		
							Detail	21			1	2	3	1	YES	2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		30/03/92(*)	42	1	2	3	1	YES	2	3	3	3	Y	YES
					HYPOTENSION	02/03/92	Detail	14			1	2	3	1	YES	3	3	3	3		
							Detail	42			1	2	3	1	YES	3	3	3	3	Y	
							Summary		30/03/92(*)	42	1	2	3	1	YES	3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
10	291	Imipramine	17/02/92	29/03/92	TREMOR	22/02/92	Detail	7			2	2	3	1		2	3	3	3		
							Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1	YES	2	3	3	3		
							Detail	28	14/03/92		2	2	3	1	YES	2	3	3	1		
							Summary		14/03/92	28	2	2	3	1	YES	2	3	3	1		YES
	292	Reboxetine	15/12/91	23/01/92	SWEATING INCREASED	13/12/91	Detail	7	15/12/91		1	2	3	1		3	3	3	1		
							Summary		15/12/91	7	1	2	3	1		3	3	3	1		YES
	293	Reboxetine	24/12/91	01/02/92	URINARY TRACT INFECTION	18/01/92	Detail	21			2		3	1	YES	3	3	3	3		
							Detail	28	17/01/92		2	2	3	1		3	3	3	1		
							Summary		17/01/92	28	2	2	3	1	YES	3	3	3	1		YES
	294	Imipramine	03/01/92	25/01/92	CONSTIPATION	09/01/92	Detail	14			2	2	3	1	YES	3	3	3	3		
							Detail	21			2	2	3	1	YES	3	3	3	3	Y	
							Summary		23/01/92(*)	21	2	2	3	1	YES	3	3	3	3	Y	YES
					INSOMNIA	09/01/92	Detail	14			2	2	3	1	YES	3	3	3	3		
							Detail	21			2	2	3	1	YES	3	3	3	3	Y	
							Summary		23/01/92(*)	21	2	2	3	1	YES	3	3	3	3	Y	YES
					NAUSEA	04/01/92	Detail	7			2	2	3	1	YES	3	3	3	3		
							Detail	14			2	2	3	1	YES	3	3	3	3		
							Detail	21			2	2	3	1	YES	3	3	3	3	Y	
							Summary		23/01/92(*)	21	2	2	3	1	YES	3	3	3	3	Y	YES
					TACHYCARDIA	05/01/92	Detail	7			2	1	4	1	YES	3	3	3	3		
							Detail	14	14/01/92		1	1	4	1		3	3	3	1		
							Summary		14/01/92	14	2	1	4	1	YES	3	3	3	1		YES
	295	Imipramine	07/01/92	17/02/92	DIZZINESS	29/01/92	Detail	28	01/02/92		3	2	2	4		3	2	3	1		
							Summary		01/02/92	28	3	2	2	4		3	2	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
10	296	Reboxetine	20/02/92	01/04/92	AGITATION	25/02/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14	05/03/92		1	2	3	1		2	3	3	1		
							Summary		05/03/92	14	1	2	3	1		2	3	3	1		YES
					CERVICITIS	25/02/92	Detail	7			1	3	5	1		2	3	3	3		
							Detail	14	05/03/92				5				3	3	1		
							Summary		05/03/92	14	1	3	5	1		2	3	3	1		YES
					CONSTIPATION	24/02/92	Detail	7			2	2	3	1	YES	3	3	3	3		
							Detail	42			2	2	3	1	YES	3	3	3	3	Y	
							Summary		02/04/92(*)	42	2	2	3	1	YES	3	3	3	3	Y	YES
	298	Reboxetine	27/03/92	07/05/92	HEADACHE	20/04/92	Detail	28			1	2	3	1	YES	3	3	3	3		
							Detail	35	28/04/92		1	2	3	1	YES	3	3	3	1		
							Summary		28/04/92	35	1	2	3	1	YES	3	3	3	1		YES
					SWEATING INCREASED	12/04/92	Detail	21			2	2	2	1		3	3	3	3		
							Detail	28			2	2	2	1		3	3	3	3		
							Detail	35			2	2	2	1		3	3	3	3		
							Detail	42			3	2	2	1		3	3	3	3	Y	
							Summary		07/05/92(*)	42	3	2	2	1		3	3	3	3	Y	YES
	299	Imipramine	07/04/92	18/05/92	INSOMNIA	07/04/92	Detail	7			2	3	5	1	YES	3	3	3	3		
							Detail	42			2	3	5	1	YES	3	3	3	3	Y	
							Summary		19/05/92(*)	42	2	3	5	1	YES	3	3	3	3	Y	YES
					MOUTH DRY	09/04/92	Detail	7			2	3	3	1		2	3	3	3		
							Detail	14			2	3	3	1		2	3	3	3		
							Detail	21			2	3	3	1		2	3	3	3		
							Detail	28			2	3	3	1		2	3	3	3		
							Detail	35			1		3				3	3	3		
							Detail	42			1	3	3	1		2	3	3	3	Y	
							Summary		19/05/92(*)	42	2	3	3	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalisation	Disapp.	Reapp.	Outcome	Still present (*)	(C)
10	299	Imipramine	07/04/92	18/05/92	NAUSEA	18/04/92	Detail	14			1	3	3	1		2	3	3	3		
							Detail	21			1	3	3	1		2	3	3	3		
							Detail	28			1	3	3	1		2	3	3	3		
							Detail	35			1	3	3	1		2	3	3	3		
							Detail	42	16/05/92		1	3	3	1		2	3	3	1		
							Summary		16/05/92	42	1	3	3	1		2	3	3	1		YES
					SWEATING INCREASED	12/05/92	Detail	42			1	3	3	1		2	3	3	3	Y	
							Summary		19/05/92(*)	42	1	3	3	1		2	3	3	3	Y	YES
	308	Imipramine	14/04/92	25/05/92	HEADACHE	05/05/92	Detail	28	11/05/92		2	3	3	1		2	3	3	1		
							Summary		11/05/92	28	2	3	3	1		2	3	3	1		YES
						13/05/92	Detail	35			2	3	3	1		2	3	3	3		
							Detail	42			2	3	3	1		2	3	3	3	Y	
							Summary		26/05/92(*)	42	2	3	3	1		2	3	3	3	Y	YES
					SWEATING INCREASED	13/05/92	Detail	35			1	3	3	1		2	3	3	3		
							Detail	42			1	3	3	1		2	3	3	3	Y	
							Summary		26/05/92(*)	42	1	3	3	1		2	3	3	3	Y	YES
11	321	Reboxetine	11/06/92	23/07/92	BRONCHITIS	21/06/92	Detail	14			2	2	6	1	YES	2			3		
							Detail	21	28/06/92		2	2	6	1	YES	2	3	3	1		
							Summary		28/06/92	21	2	2	6	1	YES	2	3	3	1		YES
					DIARRHOEA	15/06/92	Detail	7			2	2	3	1		2	3		3		
							Detail	21	30/06/92		3	2	3	1	YES	2	3	3	1		
							Summary		30/06/92	21	3	2	3	1	YES	2	3	3	1		YES
	322	Reboxetine	11/06/92	24/07/92	HEADACHE	15/07/92	Detail	35	15/07/92		2	1	4	1	YES	2	3	3	1		
							Summary		15/07/92	35	2	1	4	1	YES	2	3	3	1		YES
					MOUTH DRY	24/06/92	Detail	14	01/07/92		2	2	3	1		2			1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
11	322	Reboxetine	11/06/92	24/07/92	MOUTH DRY	24/06/92	Summary		01/07/92	14	2	2	3	1		2			1		YES
	323	Imipramine	24/06/92	06/08/92	APPETITE INCREASED	15/07/92	Detail	28			2	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		06/08/92(*)	42	2	2	3	1		2	3	3	3	Y	YES
					INFLUENZA-LIKE SYMPTOMS	06/07/92	Detail	14	09/07/92		1	1	4	1	YES	2	3	3	1		
							Summary		09/07/92	14	1	1	4	1	YES	2	3	3	1		YES
					MOUTH DRY	29/06/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	28			1	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		06/08/92(*)	42	2	2	2	1		2	3	3	3	Y	YES
					TREMOR	29/06/92	Detail	7			2	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	42	06/08/92		1	2	3	1		2	3	3	1		
							Summary		06/08/92	42	2	2	3	1		2	3	3	1		YES
	324	Imipramine	17/07/92	28/08/92	ASTHMA	04/08/92	Detail	21	04/08/92		1	1	4	1	YES	2	3	3	1		
							Summary		04/08/92	21	1	1	4	1	YES	2	3	3	1		YES
					DIZZINESS	17/07/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3		
							Detail	21			2	2	3	1		2	3	3	3		
							Detail	42	25/08/92		1	2	3	1		2	3	3	1		
							Summary		25/08/92	42	2	2	3	1		2	3	3	1		YES
					MOUTH DRY	17/07/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3	Y	
							Summary		28/08/92(M)	14	2	2	2	1		2	3	3	3	Y	YES
						17/08/92	Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		28/08/92(*)	42	1	2	2	1		2	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOKETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
11	325	Reboxetine	30/07/92	18/09/92	DIZZINESS	01/08/92	Detail	7			1	2	3	1		2	3	3	3		
							Detail	14	10/08/92		1	2	3	1		2	3	3	1		
							Detail	21	15/08/92		1	2	3	1		2	3	3	1		
							Summary		15/08/92	21	1	2	3	1		2	3	3	1		YES
					INFLUENZA-LIKE SYMPTOMS	15/08/92	Detail	21	18/08/92		1	1	4	1		2	3	3	1		
							Summary		18/08/92	21	1	1	4	1		2	3	3	1		YES
	326	Imipramine	30/07/92	10/09/92	HOT FLUSHES	31/07/92	Detail	7	05/08/92		1	2	3	1		2	3	3	1		
							Summary		05/08/92	7	1	2	3	1		2	3	3	1		YES
					INSOMNIA	17/08/92	Detail	21	18/08/92		2	2	2	1		2	3	3	1		
							Summary		18/08/92	21	2	2	2	1		2	3	3	1		YES
					MOUTH DRY	31/07/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		10/09/92(*)	42	2	2	2	1		2	3	3	3	Y	YES
					OTITIS MEDIA	15/08/92	Detail	21	16/08/92		1	2	4	1	YES	2	3	3	1		
							Summary		16/08/92	21	1	2	4	1	YES	2	3	3	1		YES
					PALPITATION	13/08/92	Detail	14	13/08/92		1	2	4	1		2	3	3	1		
							Summary		13/08/92	14	1	2	4	1		2	3	3	1		YES
					SWEATING INCREASED	31/07/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14			1	2	3	1		2	3	3	3		
							Detail	21	19/08/92		1	2	3	1		2	3	3	1		
							Summary		19/08/92	21	2	2	2	1		2	3	3	1		YES
	327	Reboxetine	20/08/92	01/10/92	CONSTIPATION	21/08/92	Detail	7			2	2	3	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 5=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(9) onset date missing: first report visit date used
(8) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
11	327	Reboxetine	20/08/92	01/10/92	CONSTIPATION	21/08/92	Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		01/10/92(*)	42	2	2	3	1		2	3	3	3	Y	YES
					DYSPEPSIA	04/09/92	Detail	21			2	1	3	1		2	3	3	3		
							Detail	42			1	1	3	1		2	3	3	3	Y	
							Summary		01/10/92(*)	42	2	1	3	1		2	3	3	3	Y	YES
					HEADACHE	01/09/92	Detail	14	01/09/92		2	1	4	1	YES	2	3	3	1		
							Summary		01/09/92	14	2	1	4	1	YES	2	3	3	1		YES
						18/09/92	Detail	35	18/09/92		2	1	4	1	YES	2	3	3	1		
							Summary		18/09/92	35	2	1	4	1	YES	2	3	3	1		YES
						26/09/92	Detail	42	26/09/92		2	1		1	YES	2					
							Summary		26/09/92	42	2	1		1	YES	2					YES
					MOUTH DRY	21/08/92	Detail	7			2	1	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	3	1		3	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		01/10/92(*)	42	2	1	3	1		2	3	3	3	Y	YES
	328	Imipramine	20/08/92	17/09/92	MOUTH DRY	22/08/92	Detail	7			2	1	2	1		2	3	3	3		
							Detail	21			1	1	3	1		2	3	3	3		
							Detail	28			1	1	3	1		2	3	3	3	Y	
							Summary		17/09/92(*)	28	2	1	2	1		2	3	3	3	Y	YES
	329	Imipramine	21/08/92	02/10/92	ABDOMINAL PAIN	30/09/92	Detail	42	01/10/92		2	1	4	1		2	3	3	1		
							Summary		01/10/92	42	2	1	4	1		2	3	3	1		YES
					CONSTIPATION	22/08/92	Detail	7	27/08/92		2	1	3	1		2	3	3	1		
							Summary		27/08/92	7	2	1	3	1		2	3	3	1		YES
					DIZZINESS	22/08/92	Detail	7			2	1	3	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalisation	Disapp.	Reapp.	Outcome	Still present	(C)
11	329	Imipramine	21/08/92	02/10/92	DIZZINESS	22/08/92	Detail	14			1	1	3	1		2	3	3	3		
							Detail	21			1	1	4	1		2	3	3	3		
							Detail	28	13/09/92		1	1	4	1		2	3	3	1		
							Summary		13/09/92	28	2	1	3	1		2	3	3	1		YES
					HEADACHE	23/09/92	Detail	42	25/09/92		2	1	4	1	YES	2	3	3	1		
							Summary		25/09/92	42	2	1	4	1	YES	2	3	3	1		YES
	330	Reboxetine	24/08/92	26/08/92	INSOMNIA	24/08/92	Detail	7	28/08/92		2	2	2	3		2	2	3	1		
							Summary		28/08/92	7	2	2	2	3		2	2	3	1		YES
					NAUSEA	24/08/92	Detail	7	27/08/92		3	2	2	3		2	2	3	1		
							Summary		27/08/92	7	3	2	2	3		2	2	3	1		YES
	331	Reboxetine	05/09/92	15/10/92	CONSTIPATION	11/09/92	Detail	14			2	2	3	1		2	3	3	3		
							Detail	21			1	2	3	1		2	3	3	3		
							Detail	28	30/09/92		1	2	3	1		2	3	3	1		
							Summary		30/09/92	28	2	2	3	1		2	3	3	1		YES
					HEADACHE	21/09/92	Detail	21			3	2	4	4	YES	2	1	3	3		
							Summary		24/09/92(*)	21	3	2	4	4	YES	2	1	3	3		YES
					PARAESTHESIA	04/09/92	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14	14/09/92		2	2	4	1		2	3	3	1		
							Summary		14/09/92	14	2	2	2	1		2	3	3	1		YES
						03/10/92	Detail	35			1	2	3	1		2	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		15/10/92(*)	42	1	2	3	1		2	3	3	3	Y	YES
					SINUSITIS	25/09/92	Detail	28	04/10/92		2	1	4	1	YES	2	3	3	1		
							Summary		04/10/92	28	2	1	4	1	YES	2	3	3	1		YES
	332	Imipramine	05/09/92	20/10/92	MOUTH DRY	05/09/92	Detail	7			1	2	2	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(S) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Dis app.	Re app.	Outcome	Still present	(c)
11	332	Imipramine	05/09/92	20/10/92	MOUTH DRY	05/09/92	Detail	21	23/09/92		1	2	3	1		2	3	3	1		
							Summary		23/09/92	21	1	2	2	1		2	3	3	1		YES
	333	Imipramine	04/09/92	16/10/92	DIZZINESS	26/09/92	Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42	10/10/92		1	2	3	1		2	3	3	1		
							Summary		10/10/92	42	1	2	2	1		2	3	3	1		YES
					MOUTH DRY	26/09/92	Detail	28			1	2	2	1		2	3	3	3		
							Detail	42			1	2	3	1		3	3	3	3	Y	
							Summary		16/10/92(*)	42	1	2	2	1		2	3	3	3	Y	YES
					VISION ABNORMAL	26/09/92	Detail	28			2	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		3	3	3	3	Y	
							Summary		16/10/92(*)	42	2	2	2	1		2	3	3	3	Y	YES
					AGITATION		Detail	8			3										
12	337	Imipramine	26/05/92	06/07/92		10/05/92(@)	Summary		06/07/92(*)	8	3										NO
					FATIGUE	25/06/92	Detail	35	23/06/92		3	2	1	2		3	2	1	1		
							Summary		25/06/92	35	3	2	1	2		3	2	1	1		YES
					FLATULENCE	26/05/92	Detail	7			1	2	2	1		3	3	3	3	Y	
							Summary		06/07/92(*)	7	1	2	2	1		3	3	3	3	Y	YES
					HEADACHE	24/05/92	Detail	8			2										
							Detail	7	26/05/92		2	1	4	1	YES	3	3	3	1		
							Summary		26/05/92	7	2	1	4	1	YES	3	3	3	1		NO
					INSOMNIA		Detail	8			2										
						10/05/92(@)	Summary		06/07/92(*)	8	2										NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
12	337	Imipramine	26/05/92	06/07/92	MICTURITION DISORDER	23/06/92	Detail	35	23/06/92		2	2	1	2		3	2	1	1		
							Summary		23/06/92	35	2	2	1	2		3	2	1	1		YES
					PALPITATION	20/06/92	Detail	28	28/06/92		1	2	3	1		3	3	3	1		
							Summary		28/06/92	28	1	2	3	1		3	3	3	1		YES
						23/06/92	Detail	35	23/06/92		1	2	2	2		3	2	1	1		
							Summary		23/06/92	35	1	2	2	2		3	2	1	1		YES
					SOMNOLENCE	26/05/92	Detail	7	04/06/92		1	2	2	1		3	3	3	1		
							Summary		04/06/92	7	1	2	2	1		3	3	3	1		YES
						23/06/92	Detail	35	23/06/92		3	2	1	2		3	2	1	1		
							Summary		23/06/92	35	3	2	1	2		3	2	1	1		YES
					TACHYCARDIA	23/06/92	Detail	35	23/06/92		1	2	2	2		3	2	1	1		
							Summary		23/06/92	35	1	2	2	2		3	2	1	1		YES
					UPPER RESP TRACT INFECTID	01/07/92	Detail	42	05/07/92		1	1	6	1	YES	3	3	3	1		
							Summary		05/07/92	42	1	1	6	1	YES	3	3	3	1		YES
					URINARY RETENTION	23/06/92	Detail	35	23/06/92		2	2	1	2		3	2	1	1		
							Summary		23/06/92	35	2	2	1	2		3	2	1	1		YES
					VOMITING	23/06/92	Detail	35	23/06/92		2	2	1	2	YES	2	2	1	1		
							Summary		23/06/92	35	2	2	1	2	YES	2	2	1	1		YES
	338	Reboxetine	28/06/92	31/07/92	CONSTIPATION	02/06/92	Detail	0			2										
							Summary		31/07/92(*)	0	2										NO
					FLATULENCE	25/06/92	Detail	7			2	2	3	1		3	3	3	3	Y	
							Summary		31/07/92(*)	7	2	2	3	1		3	3	3	3	Y	YES
					HEADACHE	17/06/92	Detail	0			1										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
12	336	Reboxetine	20/06/92	31/07/92	HEADACHE	17/06/92	Summary		31/07/92(*)	0	1										NO
					INSOMNIA		Detail	0			3										
							Detail	21			3	1	4	1	YES	3	3	3	3	Y	
						10/06/92(2)	Summary		31/07/92(*)	21	3	1	4	1	YES	3	3	3	3	Y	NO
					MOUTH DRY		Detail	0			1										
							Detail	21			1	1	4	1		3	3	3	3		
						10/06/92(2)	Summary		18/07/92(*)	21	1	1	4	1		3	3	3	3		NO
					PALPITATION		Detail	0			1										
						10/06/92(2)	Summary		31/07/92(*)	0	1										NO
					RHINITIS	04/07/92	Detail	21	09/07/92		1	1	6	1	YES	3	3	3	1		
							Summary		09/07/92	21	1	1	6	1	YES	3	3	3	1		YES
					UPPER RESP TRACT INFECTIO	28/07/92	Detail	35	26/07/92		1	1	6	1	YES	3	3	3	1		
							Summary		26/07/92	35	1	1	6	1	YES	3	3	3	1		YES
	339	Imipramine	23/06/92	03/08/92	CHEST PAIN	03/07/92	Detail	14	03/07/92		2	1	4	1		3	3	3	1		
							Summary		03/07/92	14	2	1	4	1		3	3	3	1		YES
					CONSTIPATION	23/06/92	Detail	7			1	1	2	1	YES	3	3	3	3	Y	
							Summary		03/08/92(*)	7	1	1	2	1	YES	3	3	3	3	Y	YES
					HEADACHE	04/07/92	Detail	14	16/07/92		1	2	3	1		3	3	3	1		
							Summary		16/07/92	14	1	2	3	1		3	3	3	1		YES
					MOUTH DRY	24/06/92	Detail	7			1	2	2	1		3	3	3	3	Y	
							Summary		03/08/92(*)	7	1	2	2	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observa baf., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
12	339	Imipramine	23/06/92	03/08/92	UPPER RESP TRACT INFECTID	03/07/92	Detail	14	06/07/92		1	1	6	1	YES	3	3	3	1		
							Summary		06/07/92	14	1	1	6	1	YES	3	3	3	1		YES
						30/07/92	Detail	42	04/08/92		1	1	6	1	YES	2	3	3	1		
							Summary		04/08/92	42	1	1	6	1	YES	2	3	3	1		YES
	340	Reboxetine	07/08/92	17/09/92	ABDOMINAL PAIN	10/08/92	Detail	7			1	2	3	1		3	3	3	3		
							Summary		15/08/92(*)	7	1	2	3	1		3	3	3	3		YES
					CONSTIPATION	11/08/92	Detail	7	12/08/92		2	2	2	1	YES	3	3	3	1		
							Summary		12/08/92	7	2	2	2	1	YES	3	3	3	1		YES
					FLATULENCE	10/08/92	Detail	7	13/08/92		2	2	2	1	YES	3	3	3	1		
							Summary		13/08/92	7	2	2	2	1	YES	3	3	3	1		YES
					INSOMNIA	02/07/92	Detail	0														
							Detail	28	28/08/92			1	6	1			3	3	1		
							Summary		28/08/92	28		1	6	1			3	3	1		NO
					NAUSEA	05/08/92	Detail	0														
							Detail	28	30/08/92			1	6	1			3	3	1		
							Summary		30/08/92	28		1	6	1			3	3	1		NO
					PARAESTHESIA	18/08/92	Detail	14	28/08/92		2	2	3	1		3	3	3	1		
							Summary		28/08/92	14	2	2	3	1		3	3	3	1		YES
					UPPER RESP TRACT INFECTID	23/08/92	Detail	21	31/08/92		1	1	6	1	YES	3	3	3	1		
							Summary		31/08/92	21	1	1	6	1	YES	3	3	3	1		YES
	341	Reboxetine	21/08/92	24/09/92	FLATULENCE	28/08/92	Detail	14	27/09/92		3	2	2	3		3	2	3	1		
							Summary		27/09/92	14	3	2	2	3		3	2	3	1		YES
					HEADACHE	14/09/92	Detail	28			2	1	5	1	YES	3	3	3	3	Y	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(C)
12	341	Reboxetine	21/08/92	24/09/92	HEADACHE	14/09/92	Summary		24/09/92(*)	28	2	1	5	1	YES	3	3	3	3	Y	YES
					NAUSEA	14/09/92	Detail	28	24/09/92		2	2	2	3		3	2	3	1		
							Summary		24/09/92	28	2	2	2	3		3	2	3	1		YES
					PALPITATION	07/09/92	Detail	21	30/09/92		2	2	3	3		3	2	3	1		
							Summary		30/09/92	21	2	2	3	3		3	2	3	1		YES
					PRURITUS	24/08/92	Detail	7	01/09/92		2	2	2	1		3	3	3	1		
							Summary		01/09/92	7	2	2	2	1		3	3	3	1		YES
					VISION ABNORMAL	23/08/92	Detail	7			1	2	3	1		3	3	3	3	Y	
							Summary		24/09/92(*)	7	1	2	3	1		3	3	3	3	Y	YES
13	353	Reboxetine	05/06/92	07/07/92	MICTURITION DISORDER	13/06/92	Detail	7			1	1	6	1	YES	2			3		
							Detail	14			1	1	2	1	YES	2	3	3	3		
							Detail	28	03/07/92										1		
							Summary		03/07/92	28	1	1	2	1	YES	2	3	3	1		YES
					SUICIDE ATTEMPT	07/07/92	Detail	35	07/07/92		2		1	3		2	2	3	1		
							Summary		07/07/92	35	2		1	3		2	2	3	1		YES
	354	Imipramine	24/06/92	04/08/92	BACK PAIN	23/07/92	Detail	35	25/07/92		2	1	6	1	YES	2	3	3	1		
							Summary		25/07/92	35	2	1	6	1	YES	2	3	3	1		YES
	355	Reboxetine	25/06/92	27/06/92	ABDOMINAL PAIN	25/06/92	Detail	7	29/06/92		2	1	2	3		2	2	3	1		
							Summary		29/06/92	7	2	1	2	3		2	2	3	1		YES
					DIZZINESS	25/06/92	Detail	7	29/06/92		2	2	2	3		2	2	3	1		
							Summary		29/06/92	7	2	2	2	3		2	2	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 5=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(c)
13	355	Reboxetine	25/06/92	27/06/92	DYSPEPSIA	25/06/92	Detail	7	29/06/92		2	1	2	3		2	2	3	1		
							Summary		29/06/92	7	2	1	2	3		2	2	3	1		YES
					HEADACHE	25/06/92	Detail	7			2	2	2	3		2	1	3	3	Y	
							Summary		01/07/92(*)	7	2	2	2	3		2	1	3	3	Y	YES
					NAUSEA	25/06/92	Detail	7			2	1	2	3		2	1	3	3	Y	
							Summary		01/07/92(*)	7	2	1	2	3		2	1	3	3	Y	YES
	356	Imipramine	22/07/92	01/09/92	HEADACHE	29/07/92	Detail	14			1	1	6	1	YES	2	3	3	3	Y	
							Summary		02/09/92(*)	14	1	1	6	1	YES	2	3	3	3	Y	YES
					TREMOR	28/07/92	Detail	7			2	2	2	1		2	3		3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	3	1		2	3	3	3		
							Detail	35			1	2	4	1		2	3	3	3		
							Detail	42			1	2	3	1		2	3	3	3	Y	
							Summary		02/09/92(*)	42	2	2	2	1		2	3	3	3	Y	YES
	357	Imipramine	05/08/92	09/08/92	ASTHENIA	10/08/92	Detail	7			3	1	2	3		2	1	3	3	Y	
							Summary		12/08/92(*)	7	3	1	2	3		2	1	3	3	Y	YES
					DIZZINESS	10/08/92	Detail	7			3	2	2	3		2	1		3	Y	
							Summary		12/08/92(*)	7	3	2	2	3		2	1		3	Y	YES
					SINUSITIS	05/08/92	Detail	7	08/08/92		1	2	3	3		2	2	3	1		
							Summary		08/08/92	7	1	2	3	3		2	2	3	1		YES
					SOMNOLENCE	10/08/92	Detail	7			3	2	2	3		2	1		3	Y	
							Summary		12/08/92(*)	7	3	2	2	3		2	1		3	Y	YES
	358	Reboxetine	06/08/92	05/09/92	DIZZINESS	28/08/92	Detail	28	30/08/92		2	2	2	4		2	2	1	1		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start data	Treatment End data	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
13	358	Reboxetine	06/08/92	05/09/92	DIZZINESS	28/08/92	Summary		30/08/92	28	2	2	2	4		2	2	1	1		YES
						05/09/92	Detail	35													
							Summary		06/09/92(*)	35											YES
					MOUTH DRY	05/08/92	Detail	7			1	2	2	1		2	3	3	3		
							Detail	14			1	2	2	1		2	3	3	3		
							Detail	21			1	2	2	1		2	3	3	3	Y	
							Summary		06/09/92(*)	21	1	2	2	1		2	3	3	3	Y	NO
					SWEATING INCREASED	28/08/92	Detail	28	30/08/92		2	2	2	4		2	2	1	1		
							Summary		30/08/92	28	2	2	2	4		2	2	1	1		YES
						05/09/92	Detail	35													
							Summary		06/09/92(*)	35											YES
	359	Reboxetine	19/08/92	29/09/92	HYPOAESTHESIA	16/09/92	Detail	35	22/09/92		1	2	4	1		2	3	1	1		
							Summary		22/09/92	35	1	2	4	1		2	3	1	1		YES
	360	Imipramine	19/08/92	21/08/92	AGITATION	19/08/92	Detail	7	24/08/92		3	2	2	3		2	2	3	1		
							Summary		24/08/92	7	3	2	2	3		2	2	3	1		YES
					HOT FLUSHES	19/08/92	Detail	7	24/08/92		3	2	2	3		2	2	3	1		
							Summary		24/08/92	7	3	2	2	3		2	2	3	1		YES
					INSOMNIA	19/08/92	Detail	7	24/08/92		3	2	2	3		2	2	3	1		
							Summary		24/08/92	7	3	2	2	3		2	2	3	1		YES
	361	Reboxetine	25/08/92	06/10/92	HEADACHE	05/10/92	Detail	42	06/10/92		2	3	4	1	YES	2	3	3	1		
							Summary		06/10/92	42	2	3	4	1	YES	2	3	3	1		YES
					HYPOTENSION POSTURAL	29/08/92	Detail	7			1	2	2	1		3	3	3	3		
							Detail	14	05/09/92		1	2	2	1		2	3	3	1		
							Summary		05/09/92	14	1	2	2	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with sequ., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(Q) onset date missing: first report visit date used

PHARMACIA CNS R&D

. REBOXETINE - PROTOCOL 29124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End data		Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
13	361	Reboxetine	26/08/92	06/10/92	RHINITIS	28/09/92	Detail	28	21/09/92			1	2	4	1		2	3	3	1		
							Summary		21/09/92		28	1	2	4	1		2	3	3	1		YES
14	457	Reboxetine	07/07/92	17/08/92	MOUTH DRY	15/07/92	Detail	14				1	2	2	1		2	3	3	3		
							Detail	28				1	2	2	1		2	3	3	3	Y	
							Summary		18/08/92(*)		28	1	2	2	1		2	3	3	3	Y	YES
	458	Imipramine	14/07/92	24/08/92	CONSTIPATION	17/07/92	Detail	7				1	3	3	1		2	3	3	3		
							Detail	14				1	3	3	1		2	3	3	3		
							Detail	21				1	3	3	1		3	3	3	3		
							Detail	28				1	3	3	1		3	3	3	3		
							Detail	35				1	3	3	1		3	3	3	3		
							Detail	42				1	3	3	1		3	3	3	3	Y	
							Summary		25/08/92(*)		42	1	3	3	1		2	3	3	3	Y	YES
	461	Imipramine	29/07/92	08/09/92	CONSTIPATION	07/08/92	Detail	14				1	3	3	1		3	3	3	3		
							Detail	21				1	3	3	1		3	3	3	3		
							Detail	28				1	3	3	1		3	3	3	3		
							Detail	35				2	3	3	1		3	3	3	3		
							Detail	42	04/09/92			1	3	1	2		3	2	3	1		
							Summary		04/09/92		42	2	3	1	2		3	2	3	1		YES
					MOUTH DRY	28/08/92	Detail	35				2	3	3	1		3	3	3	3		
							Detail	42				1	3	3	2		3	1	3	3	Y	
							Summary		09/09/92(*)		42	2	3	3	2		3	1	3	3	Y	YES
	462	Reboxetine	31/07/92	10/09/92	CONSTIPATION	18/08/92	Detail	14				1	3	3	1		3	3	3	3		
							Detail	21				1	3	3	1		3	3	3	3		
							Detail	28				1	3	3	1		3	3	3	3		
							Detail	35				1	3	3	1		3	3	3	3		
							Detail	42				1	3	3	1		3	3	3	3	Y	
							Summary		11/09/92(*)		42	1	3	3	1		3	3	3	3	Y	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
14	464	Reboxetine	05/08/92	16/09/92	FATIGUE	28/08/92	Detail	28			2	2	2	1		3	3	3	3		
							Detail	35	08/09/92		2	2	2	2		3	2	3	1		
							Summary		08/09/92	35	2	2	2	2		3	2	3	1		YES
						14/09/92	Detail	42			2	1	4	1		3	3	3	3	Y	
							Summary		17/09/92(*)	42	2	1	4	1		3	3	3	3	Y	YES
					NAUSEA	14/09/92	Detail	42			2	2	4	1		3	3	3	3	Y	
							Summary		17/09/92(*)	42	2	2	4	1		3	3	3	3	Y	YES
	465	Reboxetine	06/08/92	16/09/92	HEADACHE	08/08/92	Detail	7			1	2	3	1		3	3	3	3		
							Detail	14			1	2	3	1		3	3	3	3		
							Detail	21			1	3	3	1		3	3	3	3		
							Detail	28	30/08/92		1	3	3	1		3	3	3	1		
							Summary		30/08/92	28	1	2	3	1		3	3	3	1		YES
14/1	129	Reboxetine	19/12/91	19/12/91	MICTURITION DISORDER	19/12/91	Detail	7	19/12/91		3	2	2	3		2	2	3	1		
							Summary		19/12/91	7	3	2	2	3		2	2	3	1		YES
	426	Reboxetine	05/09/91	17/10/91	MOUTH DRY	14/09/91	Detail	14			2	2	2	1		3	3	3	3		
							Detail	21			1	2	2	1		3	3	3	3		
							Detail	28			1	2	2	1		3	3	3	3		
							Detail	35			1	2	2	1		3	3	3	3		
							Detail	42			1	2	2	1		3	3	3	3	Y	
							Summary		17/10/91(*)	42	2	2	2	1		3	3	3	3	Y	YES
					SWEATING INCREASED	12/09/91	Detail	14			2	2	2	1		3	3	3	3		
							Detail	21	24/09/91		2	1	4	1		3	3	3	1		
							Summary		24/09/91	21	2	1	2	1		3	3	3	1		YES
					URINARY TRACT INFECTION	05/09/91	Detail	7	10/09/91		2	1	6	1	YES	3	3	3	1		
							Summary		10/09/91	7	2	1	6	1	YES	3	3	3	1		YES
						08/09/91	Detail	28			1	1	6	1		3	3	3	3		
							Detail	35			1	1	6	1		3	3	3	3		
							Detail	42	11/10/91		1	1	6	1		3	3	3	1		
							Summary		11/10/91	42	1	1	6	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. interr.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
[illegible] = end of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(¢)
14/1	429	Imipramine	26/09/91	29/09/91	ANOREXIA	27/09/91	Detail	7	02/10/91		2	2	2	3		2	2	3	1		
							Summary		02/10/91	7	2	2	2	3		2	2	3	1		YES
					ASTHENIA	26/09/91	Detail	7	30/09/91		3	2	2	3		2	2	3	1		
							Summary		30/09/91	7	3	2	2	3		2	2	3	1		YES
					DIZZINESS	26/09/91	Detail	7	30/09/91		2	2	2	3		2	2	3	1		
							Summary		30/09/91	7	2	2	2	3		2	2	3	1		YES
					FATIGUE	26/09/91	Detail	7	30/09/91		3	2	2	3		2	2	3	1		
							Summary		30/09/91	7	3	2	2	3		2	2	3	1		YES
					HEADACHE	26/09/91	Detail	7	30/09/91		2	1	2	3		2	2	3	1		
							Summary		30/09/91	7	2	1	2	3		2	2	3	1		YES
					MOUTH DRY	26/09/91	Detail	7	30/09/91		2	2	2	3		2	2	3	1		
							Summary		30/09/91	7	2	2	2	3		2	2	3	1		YES
					NAUSEA	26/09/91	Detail	7	30/09/91		2	2	2	3		2	2	3	1		
							Summary		30/09/91	7	2	2	2	3		2	2	3	1		YES
	451	Imipramine	28/11/91	07/01/92	ARTHROSIS	01/01/92	Detail	42			3	1	6	1	YES	3	3	3	3	Y	
							Summary		08/01/92(*)	42	3	1	6	1	YES	3	3	3	3	Y	YES
					AV BLOCK	18/12/91	Detail	21			1	2	5	1		3	3	3	3		
							Detail	42			1	2	5	1		3	3	3	3	Y	
							Summary		08/01/92(*)	42	1	2	5	1		3	3	3	3	Y	YES
					CIRCULATORY FAILURE		Detail	0			2										
						24/11/91(Q)	Summary		08/01/92(*)	0	2										NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe baf., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(¢) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(Q) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalisation	Disapp.	Reapp.	Outcome	Still present	(C)
14/1	451	Imipramine	28/11/91	07/01/92	DIABETES MELLITUS		Detail	0			1										
						24/11/91(D)	Summary		08/01/92(*)	0	1										NO
					HYPERTENSION		Detail	0			2										
						24/11/91(D)	Summary		08/01/92(*)	0	2										NO
					MOUTH DRY	28/11/91	Detail	7	02/12/91		2	2	3	1		3	3	3	1		
							Summary		02/12/91	7	2	2	3	1		3	3	3	1		YES
						16/12/91	Detail	21			2	2	3	1		3	3	3	3		
							Detail	28			2	2	3	1		3	3	3	3		
							Detail	35			2	2	3	1		3	3	3	3		
							Detail	42			2	2	3	1		3	3	3	3	Y	
							Summary		08/01/92(*)	42	2	2	3	1		3	3	3	3	Y	YES
	452	Reboxetine	28/11/91	09/01/92	BRONCHITIS	03/01/92	Detail	42	09/01/92		2	3	6	1	YES	3	3	3	1		
							Summary		09/01/92	42	2	3	6	1	YES	3	3	3	1		YES
					HYPERCHOLESTEROLAEMIA	23/12/91	Detail	28			2	3	5	1	YES	3	3	3	3	Y	
							Summary		09/01/92(*)	28	2	3	5	1	YES	3	3	3	3	Y	YES
					HYPERTENSION	23/12/91	Detail	28	27/12/91		1	1	5	1	YES	3	3	3	1		
							Summary		27/12/91	28	1	1	5	1	YES	3	3	3	1		YES
					MOUTH DRY	21/12/91	Detail	28			2	1	3	1		3	3	3	3		
							Detail	35			2	1	3	1		3	3	3	3		
							Detail	42	06/01/92		2	1	3	1		3	3	3	1		
							Summary		06/01/92	42	2	1	3	1		3	3	3	1		YES
					PALPITATION	08/12/91	Detail	14			2	2	3	1		3	3	3	3		
							Detail	21	16/12/91		2	2	3	1		3	3	3	1		
							Summary		16/12/91	21	2	2	3	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present (¢)
14/1	452	Reboxetine	28/11/91	09/01/92	PARAESTHESIA	08/12/91	Detail	14			2	2	3	1	3	3	3	3		
							Detail	21	18/12/91		2	2	3	1	3	3	3	1		
							Summary		18/12/91	21	2	2	3	1	3	3	3	1		YES
14/2	136	Imipramine	15/01/92	25/02/92	AGITATION	15/01/92	Detail	7			1	2	3	1	2	3	3	3		
							Detail	14	19/01/92		1	2	3	1	2	3	3	1		
							Summary		19/01/92	14	1	2	3	1	2	3	3	1		YES
					CONSTIPATION	15/01/92	Detail	7			1	2	2	1	2	3	3	3		
							Detail	14	24/01/92		1	2	2	1	2	3	3	1		
							Summary		24/01/92	14	1	2	2	1	2	3	3	1		YES
					MOUTH DRY	15/01/92	Detail	7			1	2	2	1	2	3	3	3		
							Detail	14	24/01/92		1	2	2	1	2	3	3	1		
							Summary		24/01/92	14	1	2	2	1	2	3	3	1		YES
	456	Imipramine	15/04/92	26/05/92	CONSTIPATION	09/05/92	Detail	28	09/05/92		1	2	3	1	2	3	3	1		
							Summary		09/05/92	28	1	2	3	1	2	3	3	1		YES
					DIZZINESS	21/04/92	Detail	7	21/04/92		1	2	3	1	2	3	3	1		
							Summary		21/04/92	7	1	2	3	1	2	3	3	1		YES
					MOUTH DRY	16/04/92	Detail	7	19/04/92		1	2	3	1	2	3	3	1		
							Summary		19/04/92	7	1	2	3	1	2	3	3	1		YES
					NAUSEA	22/04/92	Detail	14	23/04/92		1	1	3	1	2	3	3	1		
							Summary		23/04/92	14	1	1	3	1	2	3	3	1		YES
14/3	417	Reboxetine	14/06/91	26/07/91	DERMATITIS FUNGAL	16/07/91	Detail	35			2	1	4	1	YES	3	3	3	3	
							Detail	42	20/07/91		2	1	4	1	YES	3	3	1	1	
							Summary		20/07/91	42	2	1	4	1	YES	3	3	1	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(¢) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(¢)
14/3	417	Reboxetine	14/06/91	26/07/91	DIZZINESS	30/06/91	Detail	21	04/07/91		2	2	3	1		3	3	3	1		
							Summary		04/07/91	21	2	2	3	1		3	3	3	1		YES
					BLOBULINS INCREASED	05/07/91	Detail	21			1	2	4	1		3	3	3	3	Y	
							Summary		26/07/91(*)	21	1	2	4	1		3	3	3	3	Y	YES
					TREMOR	30/06/91	Detail	21	04/07/91		2	2	3	1		2	3	3	1		
							Summary		04/07/91	21	2	2	3	1		2	3	3	1		YES
	419	Reboxetine	05/07/91	15/08/91	MOUTH DRY	19/07/91	Detail	21			2	2	2	1		3	3	3	3		
							Detail	28			2	2	2	1		3	3	3	3		
							Detail	35	03/08/91		2	2	2	1		3	3	3	1		
							Summary		03/08/91	35	2	2	2	1		3	3	3	1		YES
	421	Reboxetine	19/07/91	12/09/91	DYSPEPSIA	26/07/91	Detail	14	28/07/91		2	1	4	1	YES	3	3	1	1		
							Summary		28/07/91	14	2	1	4	1	YES	3	3	1	1		YES
	427	Imipramine	18/09/91	15/10/91	OESOPHAGITIS	10/10/91	Detail	28			3	2	3	3		2	2	3	3	Y	
							Summary		16/10/91(*)	28	3	2	3	3		2	2	3	3	Y	YES
					TASTE PERVERSION	19/09/91	Detail	7			2	2	2	1		2	3	3	3		
							Detail	14	27/09/91		2	2	2	1		2	3	3	1		
							Summary		27/09/91	14	2	2	2	1		2	3	3	1		YES
	428	Imipramine	25/10/91	05/12/91	HYPOAESTHESIA	04/11/91	Detail	14			1	2	5	1		2	3	3	3		
							Detail	21	12/11/91		1	2	5	1		2	3	3	1		
							Summary		12/11/91	21	1	2	5	1		2	3	3	1		YES
14/4	131	Imipramine	14/01/92	24/02/92	HEADACHE	16/01/92	Detail	7	20/01/92		2	2	3	1		3	3	3	1		
							Summary		20/01/92	7	2	2	3	1		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(¢) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start data	Treatment End data	Adverse event	Onset data	Type record	Visit No	End data	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
14/4	131	Imipramine	14/01/92	24/02/92	MOUTH DRY	15/01/92	Detail	7			1	2	2	1	3	3	3	3			
							Detail	14	25/01/92		1	2	2	1	3	3	3	1			
							Summary		25/01/92	14	1	2	2	1	3	3	3	1			YES
	133	Imipramine	16/01/92	26/02/92	HEADACHE	18/02/92	Detail	28	10/02/92		2	1	4	1	3	3	3	1			
							Summary		10/02/92	28	2	1	4	1	3	3	3	1			YES
	135	Reboxetine	17/01/92	27/02/92	DIZZINESS	18/01/92	Detail	7	22/01/92		2	2	3	1	3	3	3	1			
							Summary		22/01/92	7	2	2	3	1	3	3	3	1			YES
14/7	422	Imipramine	04/09/91	15/10/91	ARTHRALGIA		Detail	0			3										
						01/09/91(@)	Summary		16/10/91(*)	0	3										NO
					HEADACHE	15/09/91	Detail	14			1	2	3	1	2	3	3	3			
							Detail	21			1	2	3	1	2	3	3	3			
							Detail	28			1	2	3	1	2	3	3	3			
							Detail	35			1	2	3	1	2	3	3	3			
							Detail	42			2	2	3	1	2	3	3	3	Y		
							Summary		16/10/91(*)	42	2	2	3	1	2	3	3	3	Y		YES
					OSTEOPOROSIS		Detail	0			3										
						01/09/91(@)	Summary		16/10/91(*)	0	3										NO
	423	Imipramine	17/09/91	28/10/91	HEADACHE	27/09/91	Detail	14			2	2	3	1	2	3	3	3			
							Detail	21			1	2	3	1	2	3	3	3			
							Detail	28	12/10/91		1	2	3	1	2	3	3	1			
							Summary		12/10/91	28	2	2	3	1	2	3	3	1			YES
					MOUTH DRY	25/10/91	Detail	42			1	2	3	1	2	3	3	3	Y		
							Summary		29/10/91(*)	42	1	2	3	1	2	3	3	3	Y		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
14/7	424	Reboxetine	19/09/91	30/10/91	HEADACHE	22/10/91	Detail	35	23/10/91		1	2	4	1		2	3	3	1		
							Summary		23/10/91	35	1	2	4	1		2	3	3	1		YES
					LIBIDO DECREASED	22/09/91	Detail	0			1										
							Detail	7			2	1	6	1		2	3	3	3		
							Detail	14			2	1	3	1		2	3	3	3		
							Detail	21			2	1	3	1	YES	2	3	3	3	Y	
							Summary		31/10/91(*)	21	2	1	3	1	YES	2	3	3	3	Y	YES
					TACHYCARDIA	04/11/91	Detail	42	04/11/91		2	1	3	1		2	3	3	1		
							Summary		04/11/91	42	2	1	3	1		2	3	3	1		YES
	430	Reboxetine	07/10/91	17/11/91	INFLUENZA-LIKE SYMPTOMS	06/11/91	Detail	35	10/11/91		2	2	6	1		2	3	3	1		
							Summary		10/11/91	35	2	2	6	1		2	3	3	1		YES
					MOUTH DRY	25/10/91	Detail	21			1	2	1	1		2	3	3	3		
							Detail	28			2	2	1	1		2	3	3	3		
							Detail	35			2	2	1	1		2	3	3	3		
							Detail	42			1	2	1	1		2	3	3	3	Y	
							Summary		18/11/91(*)	42	2	2	1	1		2	3	3	3	Y	YES
					SINUSITIS	06/11/91	Detail	35	10/11/91		2	2	6	1	YES	2	3	3	1		
							Summary		10/11/91	35	2	2	6	1	YES	2	3	3	1		YES
	431	Reboxetine	08/10/91	18/11/91	FEVER	25/10/91	Detail	21	26/10/91		2	2	3	1		2	3	3	1		
							Summary		26/10/91	21	2	2	3	1		2	3	3	1		YES
					IMPOTENCE		Detail	0			1										
						07/10/91(@)	Summary		19/11/91(*)	0	1										NO
					LIBIDO DECREASED	23/10/91	Detail	21			2	3	3	1		2	3	3	3		
							Detail	28			1	3	3	1		2	3	3	3		
							Detail	35			1	3	3	1		2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
14/7	431	Reboxetine	08/10/91	18/11/91	LIBIDO DECREASED	23/10/91	Detail	42			1	3	3	1		2	3	3	3	Y	
							Summary		19/11/91(*)	42	2	3	3	1		2	3	3	3	Y	YES
					MOUTH DRY	01/11/91	Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			1	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1		2	3	3	3	Y	
							Summary		19/11/91(*)	42	1	2	2	1		2	3	3	3	Y	YES
					TACHYCARDIA	24/10/91	Detail	21			2	3	3	1		2	3	3	3		
							Detail	28	01/11/91		2	3	3	1		2	3	3	1		
							Summary		01/11/91	28	2	3	3	1		2	3	3	1		YES
	432	Imipramine	08/10/91	18/11/91	ABITATION	23/10/91	Detail	21			2	3	3	1		2	3	3	3		
							Detail	28	02/11/91		2	3	3	1		2	3	3	1		
							Summary		02/11/91	28	2	3	3	1		2	3	3	1		YES
					LIBIDO DECREASED	01/11/91	Detail	28			1	2	3	1		2	3	3	3		
							Detail	35			2	2	2	1		2	3	3	3		
							Detail	42			1	2	2	1	YES	2	3	3	3	Y	
							Summary		19/11/91(*)	42	2	2	2	1	YES	2	3	3	3	Y	YES
					MOUTH DRY	30/10/91	Detail	28			2	2	1	1		2	3	3	3		
							Detail	35			2	2	1	1		2	3	3	3		
							Detail	42			1	2	1	1		2	3	3	3	Y	
							Summary		19/11/91(*)	42	2	2	1	1		2	3	3	3	Y	YES
	433	Imipramine	08/10/91	18/11/91	DIZZINESS	24/10/91	Detail	21	28/10/91		1	2	3	1		2	3	3	1		
							Summary		28/10/91	21	1	2	3	1		2	3	3	1		YES
					HEADACHE	23/10/91	Detail	21			1	2	3	1		2	3	3	3		
							Detail	28			1	2	3	1		2	3	3	3		
							Detail	35	09/11/91		1	3	3	1		2	3	3	1		
							Summary		09/11/91	35	1	2	3	1		2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(Q) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
14/7	433	Imipramine	08/10/91	18/11/91	MOUTH DRY	06/11/91	Detail	35			2	2	1	1	2	3	3	3		
							Detail	42			1	2	1	1	2	3	3	3	Y	
							Summary		19/11/91(*)	42	2	2	1	1	2	3	3	3	Y	YES
	434	Reboxetine	14/10/91	24/11/91	HEADACHE	22/10/91	Detail	14			1	2	3	1	2	3	3	3		
							Detail	21			1	2	3	1	2	3	3	3		
							Detail	28			1	3	3	1	2	3	3	3		
							Detail	35	15/11/91		2	2	3	1	2	3	3	1		
							Summary		15/11/91	35	2	2	3	1	2	3	3	1		YES
					LIBIDO DECREASED	30/10/91	Detail	21			1	2	2	1	2	3	3	3		
							Detail	28			2	2	2	1	2	3	3	3		
							Detail	35			2	2	2	1	YES 2	3	3	3		
							Detail	42			1	2	2	1	YES 2	3	3	3	Y	
							Summary		25/11/91(*)	42	2	2	2	1	YES 2	3	3	3	Y	YES
	439	Reboxetine	11/11/91	22/12/91	MOUTH DRY	20/11/91	Detail	14			1	2	2	1	2	3	3	3		
							Detail	21			1	2	2	1	2	3	3	3		
							Detail	28			1	2	2	1	2	3	3	3		
							Detail	35			2	2	2	1	2	3	3	3		
							Detail	42			1	2	2	1	2	3	3	3	Y	
							Summary		23/12/91(*)	42	2	2	2	1	2	3	3	3	Y	YES
	440	Imipramine	11/11/91	22/12/91	TACHYCARDIA	02/12/91	Detail	21	02/12/91		2	1	3	1	2	3	3	1		
							Summary		02/12/91	21	2	1	3	1	2	3	3	1		YES
	442	Imipramine	11/11/91	22/12/91	HEADACHE	05/12/91	Detail	28	06/12/91		2	2	3	1	2	3	3	1		
							Summary		06/12/91	28	2	2	3	1	2	3	3	1		YES
					TACHYCARDIA	02/12/91	Detail	21	02/12/91		2	1	3	1	2	3	3	1		
							Summary		02/12/91	21	2	1	3	1	2	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Seve rity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(c)
14/8	139	Reboxetine	10/01/92	28/02/92	MICTURITION DISORDER	10/02/92	Detail	35			1	2	2	1			2	3	3	3	
							Detail	42			1	2	2	1			2	3	3	3	Y	
							Summary		21/02/92(*)	42	1	2	2	1			2	3	3	3	Y	YES
	467	Reboxetine	06/07/92	16/08/92	MICTURITION DISORDER	14/07/92	Detail	14			1	2	2	3			2	2	3	3		
							Detail	42	17/08/92		1	2	3	1			2	3	3	1		
							Summary		17/08/92	42	1	2	2	3			2	3	3	1		YES
14/10	53	Reboxetine	25/02/92	06/04/92	PROSTATIC DISORDER		Detail	0			2											
						16/02/92(@)	Summary		06/04/92(*)	0	2											NO
	54	Imipramine	26/02/92	07/04/92	HYPERTENSION		Detail	0			2											
						17/02/92(@)	Summary		07/04/92(*)	0	2											NO
					NAUSEA	26/02/92	Detail	7	02/03/92		1	2	1	1			3	3	3	1		
							Summary		02/03/92	7	1	2	1	1			3	3	3	1		YES
	55	Reboxetine	28/02/92	09/04/92	ARTHRALGIA	27/03/92	Detail	35	31/03/92		2	2	5	1	YES		3	3	3	1		
							Summary		31/03/92	35	2	2	5	1	YES		3	3	3	1		YES
					FLATULENCE	17/01/92	Detail	0			2											
							Summary		09/04/92(*)	0	2											NO
					GAMMA-GT INCREASED	19/03/92	Detail	21	09/04/92		1	2	4	1			3	3	3	1		
							Summary		09/04/92	21	1	2	4	1			3	3	3	1		YES
					HYPOTENSION	14/07/88	Detail	0			2											
							Summary		09/04/92(*)	0	2											NO
	56	Imipramine	03/03/92	15/04/92	ARTHRALGIA	18/03/92	Detail	21	22/03/92		2	2	5	1	YES		3	3	3	1		
							Summary		22/03/92	21	2	2	5	1	YES		3	3	3	1		YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=daf. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present (C)
14/10	56	Imipramine	03/03/92	13/04/92	DIZZINESS	03/03/92	Detail	7	08/03/92		1	2	1	1		2	3	3	1	
							Summary		08/03/92	7	1	2	1	1		2	3	3	1	YES
					GASTROENTERITIS	01/04/92	Detail	35	06/04/92		2	2	6	1	YES	3	3	3	1	
							Summary		06/04/92	35	2	2	6	1	YES	3	3	3	1	YES
					HYPOTENSION		Detail	0			1										
						23/02/92(D)	Summary		13/04/92(*)	0	1									NO
					MOUTH DRY	03/03/92	Detail	7	09/03/92		1	2	1	1		2	3	3	1	
							Summary		09/03/92	7	1	2	1	1		2	3	3	1	YES
	57	Reboxetine	04/03/92	14/04/92	GASTROENTERITIS	01/04/92	Detail	35	06/04/92		2	2	6	1	YES	3	3	3	1	
							Summary		06/04/92	35	2	2	6	1	YES	3	3	3	1	YES
					HYPERTENSION		Detail	0			2										
						24/02/92(D)	Summary		14/04/92(*)	0	2									NO
	58	Imipramine	14/04/92	25/05/92	MOUTH DRY	14/04/92	Detail	7			2	2	1	1		3	3	3	3	
							Detail	14	26/04/92		2	2	1	1		3	3	3	1	
							Summary		26/04/92	14	2	2	1	1		3	3	3	1	YES
					NAUSEA	14/04/92	Detail	7	19/04/92		2	2	1	1		3	3	3	1	
							Summary		19/04/92	7	2	2	1	1		3	3	3	1	YES
	59	Imipramine	24/04/92	04/06/92	MOUTH DRY	24/04/92	Detail	7			2	2	1	1		3	3	3	3	
							Detail	14			2	2	1	1		3	3	3	3	
							Detail	21	10/05/92		2	2	1	1		3	3	3	1	
							Summary		10/05/92	21	2	2	1	1		3	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present (C)
14/10	137	Reboxetine	28/01/92	09/03/92	MOUTH DRY	28/01/92	Detail	7			1	2	1	1		3	3	3	3	
							Detail	14			1	2	1	1		3	3	3	3	
							Detail	21	14/02/92		1	2	1	1		3	3	3	1	
							Summary		14/02/92	21	1	2	1	1		3	3	3	1	YES
					NAUSEA	28/01/92	Detail	7	30/01/92		2	2	1	1		3	3	3	1	
							Summary		30/01/92	7	2	2	1	1		3	3	3	1	YES
	138	Imipramine	29/01/92	10/03/92	SOMNOLENCE	28/01/92	Detail	7	02/02/92		1	2	1	1		3	3	3	1	
							Summary		02/02/92	7	1	2	1	1		3	3	3	1	NO
	139	Reboxetine	04/02/92	16/03/92	BRONCHITIS	03/03/92	Detail	35	09/03/92		2	2	6	1	YES	3	3	3	1	
							Summary		09/03/92	35	2	2	6	1	YES	3	3	3	1	YES
					NAUSEA	04/02/92	Detail	7	06/02/92		1	2	1	1		3	3	3	1	
							Summary		06/02/92	7	1	2	1	1		3	3	3	1	YES
	140	Imipramine	05/02/92	17/03/92	MOUTH DRY	05/02/92	Detail	7	11/02/92		1	2	1	1		3	3	3	1	
							Summary		11/02/92	7	1	2	1	1		3	3	3	1	YES
					NAUSEA	05/02/92	Detail	7	09/02/92		1	2	1	1		3	3	3	1	
							Summary		09/02/92	7	1	2	1	1		3	3	3	1	YES
	435	Imipramine	12/11/91	23/12/91	HYPERTENSION		Detail	0			2									
						03/11/91(D)	Summary		23/12/91(*)	0	2										NO
	436	Reboxetine	13/11/91	23/12/91	BRONCHITIS	21/12/91	Detail	42	27/12/91		2	2	6	1	YES	2	3	3	1	
							Summary		27/12/91	42	2	2	6	1	YES	2	3	3	1	YES
					DIZZINESS	13/11/91	Detail	7	16/11/91		1	2	1	1		3	3	3	1	
							Summary		16/11/91	7	1	2	1	1		3	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(D) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relship	Study drug	Symp treat	Hosp	Dis app.	Re app.	Out come	Still present (c)
14/10	438	Imipramine	15/11/91	27/12/91	BRONCHITIS	22/11/91	Detail	14	27/11/91		2	2	6	1		2	3	3	1	
							Summary		27/11/91	14	2	2	6	1		2	3	3	1	YES
						13/12/91	Detail	35	19/12/91		2	2	6	1	YES	2	3	3	1	
							Summary		19/12/91	35	2	2	6	1	YES	2	3	3	1	YES
					DIZZINESS	16/11/91	Detail	7	18/11/91		1	2	1	1		2	3	3	1	
							Summary		18/11/91	7	1	2	1	1		2	3	3	1	YES
					HYPOTENSION POSTURAL		Detail	0			1										
						05/11/91(2)	Summary		27/12/91(*)	0	1										NO
	443	Reboxetine	19/11/91	30/12/91	MOUTH DRY	18/11/91	Detail	7			2	2	1	1		2	3	3	3	
							Detail	14	01/12/91		2	2	1	1		2	3	3	1	
							Summary		01/12/91	14	2	2	1	1		2	3	3	1	NO
					NAUSEA	19/11/91	Detail	7	23/11/91		2	2	1	1		2	3	3	1	
							Summary		23/11/91	7	2	2	1	1		2	3	3	1	YES
	444	Reboxetine	16/11/91	27/12/91	BRONCHITIS	05/12/91	Detail	21			2	2	6	1	YES	2	3	3	3	
							Detail	28	13/12/91		2	2	6	1	YES	2	3	3	1	
							Summary		13/12/91	28	2	2	6	1	YES	2	3	3	1	YES
					DIZZINESS	16/11/91	Detail	7	21/11/91		1	2	1	1		2	3	3	1	
							Summary		21/11/91	7	1	2	1	1		2	3	3	1	YES
					HYPERTENSION		Detail	0			1										
						14/11/91(2)	Summary		27/12/91(*)	0	1										NO
					NAUSEA	16/11/91	Detail	7	21/11/91		1	2	1	1		2	3	3	1	
							Summary		21/11/91	7	1	2	1	1		2	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still Present (C)
14/10	445	Imipramine	20/11/91	30/12/91	HYPERLIPAEMIA		Detail	0	-		2									
						14/11/91(2)	Summary		30/12/91(*)	0	2									NO
					HYPERTENSION		Detail	0			2									
						14/11/91(2)	Summary		30/12/91(*)	0	2									NO
					NAUSEA	26/11/91	Detail	7	26/11/91		1	2	2	1		2	3	3	1	
							Summary		26/11/91	7	1	2	2	1		2	3	3	1	YES
					TINNITUS		Detail	0			2									
						14/11/91(2)	Summary		30/12/91(*)	0	2									NO
	446	Reboxetine	26/11/91	07/01/92	BRONCHITIS	11/12/91	Detail	21	16/12/91		2	2	6	1	YES	2	3	3	1	
							Summary		16/12/91	21	2	2	6	1	YES	2	3	3	1	YES
	447	Reboxetine	27/11/91	07/01/92	ATHEROSCLEROSIS		Detail	0			2									
						25/11/91(2)	Summary		07/01/92(*)	0	2									NO
					CYSTITIS HAEMORRHAGIC	31/12/91	Detail	42	06/01/92		2	2	6	1	YES	2	3	3	1	
							Summary		06/01/92	42	2	2	6	1	YES	2	3	3	1	YES
					DIABETES MELLITUS		Detail	0			2									
						25/11/91(2)	Summary		07/01/92(*)	0	2									NO
					HYPERURICAEMIA		Detail	0			1									
						25/11/91(2)	Summary		07/01/92(*)	0	1									NO
					NAUSEA	27/11/91	Detail	7	02/12/91		1	2	1	1		2	3	3	1	
							Summary		02/12/91	7	1	2	1	1		2	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
(2) onset date missing: first report visit date used
(8) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/817
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Rel ship	Study drug	Symp treat	Hosp	Disapp.	Reapp.	Outcome	Still present (C)
14/10	448	Imipramine	28/11/91	07/01/92	ARTHRALGIA	23/12/91	Detail	35	29/12/91		2	2	6	1	YES	2	3	3	1	
							Summary		29/12/91	35	2	2	6	1	YES	2	3	3	1	YES
	453	Imipramine	28/05/92	08/07/92	MOUTH DRY	28/05/92	Detail	7	02/06/92		1	2	1	1		3	3	3	1	
							Summary		02/06/92	7	1	2	1	1		3	3	3	1	YES
	455	Reboxetine	26/06/92	31/07/92	NAUSEA	28/06/92	Detail	7	25/06/92		2	2	1	1		3	3	3	1	
							Summary		25/06/92	7	2	2	1	1		3	3	3	1	YES
15	349	Imipramine	20/08/92	01/10/92	CONSTIPATION	01/09/92	Detail	14			1	1	3	1	YES	2	3	3	3	
							Detail	21			1		3	1		2	3	3	3	
							Detail	28			1	1	3	1		2	3	3	3	
							Detail	35	21/09/92		1		3	1		2	3	3	1	
							Summary		21/09/92	35	1	1	3	1	YES	2	3	3	1	YES
					NAUSEA	27/08/92	Detail	7	27/08/92		1	1	4	1		2	3	3	1	
							Detail	14	03/09/92		1	2	3	1		2	3	3	1	
							Summary		03/09/92	14	1	1	3	1		2	3	3	1	YES
	352	Imipramine	06/08/92	27/08/92	FATIGUE	06/08/92	Detail	7	06/08/92		1	2	3	1		2	3	3	1	
							Summary		06/08/92	7	1	2	3	1		2	3	3	1	YES
	366	Reboxetine	27/08/92	05/10/92	FLUSHING	01/09/92	Detail	7			1	2	2	1		3	3	3	3	
							Detail	14	04/09/92		1	2	2	1		3	3	3	1	
							Summary		04/09/92	14	1	2	2	1		3	3	3	1	YES
	367	Imipramine	31/08/92	11/10/92	DIZZINESS	09/09/92	Detail	28	24/09/92		1	1	4	1		2	3	3	1	
							Summary		24/09/92	28	1	1	4	1		2	3	3	1	YES
					FLUSHING	14/09/92	Detail	21			1	1	3	1		2	3	3	3	
							Detail	28	26/09/92		1		3	1		3	3	3	1	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(@) onset date missing: first report visit date used
(&) onset date missing: start treatment date of report visit

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospital	Disapp.	Reapp.	Outcome	Still present	(C)
15	367	Imipramine	31/08/92	11/10/92	FLUSHING	14/09/92	Summary		26/09/92	28	1	1	5	1		2	5	5	1		YES
					HYPERTENSION	05/10/92	Detail	55							YES					Y	
							Summary		12/10/92(*)	35					YES					Y	YES
	371	Reboxetine	20/07/92	31/08/92	HEADACHE	27/07/92	Detail	14			2	1	3	1		2	3	3	3		
							Detail	21	10/08/92		1		3	1		2	3	3	1		
							Summary		10/08/92	21	2	1	3	1		2	3	3	1		YES
						31/08/92	Detail	42			1	1	4	1		2	3	3	3	Y	
							Summary		31/08/92(*)	42	1	1	4	1		2	3	3	3	Y	YES
	372	Imipramine	17/06/92	29/07/92	HEADACHE	17/07/92	Detail	35			2	1	2	1		3	3	3	3		
							Detail	42	24/07/92		1	1	2	2		3	2	3	1		
							Summary		24/07/92	42	2	1	2	2		3	2	3	1		YES
					SOMNOLENCE	16/07/92	Detail	35			2	2	1	1		3	3	3	3		
							Detail	42	22/07/92		1		2	2		3	2	3	1		
							Summary		22/07/92	42	2	2	1	2		3	2	3	1		YES
					TREMOR	20/07/92	Detail	35			2	2	1	1		3	3	3	3		
							Detail	42	23/07/92		1	2	2	2		3	2	3	1		
							Summary		23/07/92	42	2	2	1	2		3	2	3	1		YES
	374	Reboxetine	09/04/92	20/05/92	DIZZINESS	23/04/92	Detail	14	23/04/92		1	1	5	1		3	3	3	1		
							Summary		23/04/92	14	1	1	5	1		3	3	3	1		YES
					HEADACHE	09/04/92	Detail	7			2	1	3	1		3	3	3	3		
							Detail	14			2	1	2	1		3	3	3	3		
							Detail	21	27/04/92		2	1	3	1		3	3	3	1		
							Summary		27/04/92	21	2	1	2	1		3	3	3	1		YES
					TASTE PERVERSION	15/04/92	Detail	7			2	2	2	1		3	3	3	3		
							Detail	14			1	2	2	1		3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	History	Relationship	Study drug	Symptomatic treatment	Hospitalization	Disapp.	Reapp.	Outcome	Still present	(c)
15	374	Reboxetine	09/04/92	20/05/92	TASTE PERVERSION	13/04/92	Detail	21			1	2	2	1	3	3	3	3			
							Detail	28			1	2	3	1	3	3	3	3			
							Detail	35			1		2	1	3	3	3	3			
							Detail	42			1	2	2	1	3	3	3	3	Y		
							Detail	99	16/06/92		1		2	3	3	2	3	1			
							Summary		16/06/92	99	2	2	2	3	3	2	3	1			YES
	375	Imipramine	13/04/92	21/04/92	DYSPHAGIA	20/04/92	Detail	14			2	2	2	1	3	3	3	3	Y		
							Summary		26/04/92(*)	14	2	2	2	1	3	3	3	3	Y		YES
					TREMOR	20/04/92	Detail	14			3	2	2	3	3	1	3	3	Y		
							Summary		26/04/92(*)	14	3	2	2	3	3	1	3	3	Y		YES
	377	Reboxetine	13/05/92	25/06/92	ANXIETY		Detail	0			3										
						12/05/92(2)	Summary		25/06/92(*)	0	3										NO
					TREMOR		Detail	0			3					3					
						12/05/92(2)	Summary		25/06/92(*)	0	3					3					NO
	378	Reboxetine	15/06/92	27/07/92	ALOPECIA	14/07/92	Detail	35			1	2	3	1	3	3	3	3			
							Detail	42	25/07/92		1	2	4	1	2	3	3	1			
							Summary		25/07/92	42	1	2	3	1	2	3	3	1			YES
					MOUTH DRY	08/07/92	Detail	28	17/07/92		1	2	1	1	2	3	3	1			
							Summary		17/07/92	28	1	2	1	1	2	3	3	1			YES
					SOMNOLENCE	13/07/92	Detail	42			1	2	2	1	2	3	3	3	Y		
							Summary		27/07/92(*)	42	1	2	2	1	2	3	3	3	Y		YES
					TINNITUS	15/05/92	Detail	35			1	1	4	1	3	3	3	3			
							Summary		20/07/92(*)	35	1	1	4	1	3	3	3	3			NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 28124/017
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	Treatment End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Severity	Hist ory	Rel ship	Stud drug	Symp trea	Hosp	Dis app.	Re app.	Out come	Still present	(C)
15	379	Imipramine	16/04/92	17/04/92	CONFUSION	17/04/92	Detail	7	18/04/92		3		2	3		2	2		1		
							Summary		18/04/92	7	3		2	3		2	2		1		YES
					MOUTH DRY	17/04/92	Detail	7	18/04/92		3	2	2	3		2	2	3	1		
							Summary		18/04/92	7	3	2	2	3		2	2	3	1		YES
					TASTE PERVERSION	17/04/92	Detail	7	18/04/92		3	2	2	3		2	2	3	1		
							Summary		18/04/92	7	3	2	2	3		2	2	3	1		YES
	380	Imipramine	30/06/92	10/08/92	SOMNOLENCE	21/07/92	Detail	28			1	2	3	2		2	1	3	3	Y	
							Summary		10/08/92(*)	28	1	2	3	2		2	1	3	3	Y	YES
	381	Reboxetine	21/05/92	01/07/92	MOUTH DRY	25/05/92	Detail	7			3	2	1	1		3	3	3	3		
							Detail	14			3	2	1	1		3	3	3	3		
							Detail	21			3		1	1		3	3	3	3		
							Detail	28			3		2	1		2	3	3	3		
							Detail	35			3		2	1		2	3	3	3		
							Detail	42			3		2	1		2	3	3	3	Y	
							Summary		02/07/92(*)	42	3	2	1	1		2	3	3	3	Y	YES
	382	Imipramine	09/04/92	10/04/92	HEADACHE	10/04/92	Detail	7	17/04/92		3	2	2	3	YES	2	2	3	1		
							Summary		17/04/92	7	3	2	2	3	YES	2	2	3	1		YES
	383	Imipramine	07/07/92	18/08/92	INFLUENZA-LIKE SYMPTOMS	14/07/92	Detail	14			2	1	6	1		2	3	3	3		
							Detail	21	26/07/92		1	1	6	1		2	3	3	1		
							Summary		26/07/92	21	2	1	6	1		2	3	3	1		YES
						12/08/92	Detail	42			1	1	6	1		2	3	3	3	Y	
							Summary		18/08/92(*)	42	1	1	6	1		2	3	3	3	Y	YES
					INSOMNIA	01/05/92	Detail	7			3	1	6	1	YES	2	3	3	3		
							Detail	42			1	1	6	1	YES	2	3	3	3	Y	
							Summary		18/08/92(*)	42	3	1	6	1	YES	2	3	3	3	Y	NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(2) onset date missing: first report visit date used
(3) onset date missin : start treatment date of report visit

PHARMACIA CNS [redacted]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 1 Patient: 1 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/02/91		26/02/91		19/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.4-18.5 (G/DL)	01/01/91	15.80		15.50		16.60	
HT	40-48 (%)	01/01/91	45.20		45.20		47.60	
RBC	4.15-5.9 (10¬6/MM3)	01/01/91	5.28		5.18		5.56	
WBC	4-10.7 (10¬3/MM3)	01/01/91	5.90		5.90		6.90	
WBC: N	40-75 (%)	01/01/91	59.00		53.00		70.00	
WBC: L	20-45 (%)	01/01/91	34.00		38.00		26.00	
WBC: E	1-6 (%)	01/01/91	2.00		4.00		3.00	
WBC: M	2-10 (%)	01/01/91	5.00		5.00		0.00	<
WBC: B	0-1 (%)	01/01/91	0.00		0.00		1.00	
PLATELETS	100-300 (10¬3/MM3)	01/01/91			203.00		195.00	
NA+	130-149 (MMOL/L)	01/01/91	139.00		143.00		143.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	5.70	>	5.10		4.10	
CL-	94-109 (MMOL/L)	01/01/91	111.00	>	102.00		101.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.35		2.15	<	2.48	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	1.09		0.60	<<	0.89	
SGOT	5-19 (U/L)	01/01/91	11.00		7.00		8.00	
SGPT	5-23 (U/L)	01/01/91	15.00		17.00		20.00	
GAMMA GT	6-28 (U/L)	01/01/91	4.00	<	9.00		13.00	
LDH	120-240 (U/L)	01/01/91	232.00		159.00		207.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	65.00		65.00		87.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	8.80	>>	8.65	>>	6.97	>
BUN	1.7-8.3 (MMOL/L)	01/01/91	3.90		4.00		4.40	
UREA	()	01/01/91						
CREATININE	58-110 (UMOL/L)	01/01/91	82.00		87.00		82.00	
URIC ACID	202-416 (UMOL/L)	01/01/91	292.00		299.00		328.00	
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	8.80		7.70		5.30	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	76.40		67.70		79.10	
ALBUMINE	58-70 (%)	01/01/91	67.00		66.20		67.00	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91			5.97	>	7.04	>>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91			1.27	<	1.68	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	2.60		2.80		2.70	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	7.00		7.50		6.90	
GLOBULINS BETA	7-13 (%)	01/01/91	9.00		9.60		9.70	
GLOBULINS GAMMA	10-19 (%)	01/01/91	14.40		13.90		13.70	
TSH	0.3-4 (MU/L)	01/01/91	1.20					
T4	50-115 (UG/L)	01/01/91	110.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 1 Patient: 11 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			03/04/92		28/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13.4-18.5 (G/DL)	01/01/91	16.30		16.20	
HT	40-48 (%)	01/01/91	49.60	>	49.40	>
RBC	4.15-5.9 (10-6/MM3)	01/01/91	5.31		5.25	
WBC	4-10.7 (10-3/MM3)	01/01/91	7.70		7.10	
WBC: N	40-75 (%)	01/01/91	56.00		50.00	
WBC: L	20-45 (%)	01/01/91	30.00		43.00	
WBC: E	1-6 (%)	01/01/91	5.00		3.00	
WBC: M	2-10 (%)	01/01/91	8.00		4.00	
WBC: B	0-1 (%)	01/01/91	1.00		0.00	
PLATELETS	100-300 (10-3/MM3)	01/01/91	244.00		237.00	
NA+	130-149 (MMOL/L)	01/01/91	142.00			
K+	3.66-5.35 (MMOL/L)	01/01/91	4.90			
CL-	94-109 (MMOL/L)	01/01/91	109.00			
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.38		2.48	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	1.21		1.10	
SGOT	5-19 (U/L)	01/01/91	6.00		6.00	
SGPT	5-23 (U/L)	01/01/91	9.00		12.00	
GAMMA GT	6-28 (U/L)	01/01/91	16.00		14.00	
LDH	120-240 (U/L)	01/01/91	118.00	<	118.00	<
ALK. PHOSPH.	60-170 (U/L)	01/01/91	134.00		120.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	5.02			
BUN	1.7-8.3 (MMOL/L)	01/01/91	4.70		7.10	
UREA	()	01/01/91				
CREATININE	58-110 (UMOL/L)	01/01/91	86.00		78.00	
URIC ACID	202-416 (UMOL/L)	01/01/91	2.74	<	311.00	
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	8.40		18.60	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91				
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	75.00		74.80	
ALBUMINE	58-70 (%)	01/01/91	60.90		64.30	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	5.51	>	5.38	>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	2.25		1.63	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	1.80		1.40	<
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	8.10		7.00	
GLOBULINS BETA	7-13 (%)	01/01/91	12.00		10.90	
GLOBULINS GAMMA	10-19 (%)	01/01/91	17.20		16.40	
TSH	0.3-4 (MU/L)	01/01/91	2.30			
T4	50-115 (UG/L)	01/01/91	98.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9350085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 1 Patient: 12 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			13/04/92		05/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13.4-18.5 (G/DL)	01/01/91	17.80		18.20	
HT	40-48 (%)	01/01/91	53.20	>	54.20	>
RBC	4.15-5.9 (10-6/MM3)	01/01/91	6.12	>	6.30	>
WBC	4-10.7 (10-3/MM3)	01/01/91	5.80		7.00	
WBC: N	40-75 (%)	01/01/91	62.00		68.00	
WBC: L	20-45 (%)	01/01/91	28.00		24.00	
WBC: E	1-6 (%)	01/01/91	2.00		1.00	
WBC: M	2-10 (%)	01/01/91	7.00		7.00	
WBC: B	0-1 (%)	01/01/91	1.00		0.00	
PLATELETS	100-300 (10-3/MM3)	01/01/91	145.00		226.00	
NA+	130-149 (MMOL/L)	01/01/91	144.00		140.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.10		3.80	
CL-	94-109 (MMOL/L)	01/01/91	119.00	>	95.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.34		2.53	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	0.91		0.93	
SGOT	5-19 (U/L)	01/01/91	8.00		7.00	
SGPT	5-23 (U/L)	01/01/91	15.00		16.00	
GAMMA GT	6-28 (U/L)	01/01/91	8.00		13.00	
LDH	120-240 (U/L)	01/01/91	150.00		146.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	105.00		102.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	5.51			
BUN	1.7-8.3 (MMOL/L)	01/01/91	7.50		6.30	
UREA	()	01/01/91				
CREATININE	58-110 (UMOL/L)	01/01/91	87.00		99.00	
URIC ACID	202-416 (UMOL/L)	01/01/91	258.00		267.00	
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	23.20	>	34.70	>
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91				
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	69.40		73.70	
ALBUMINE	58-70 (%)	01/01/91	71.90	>	71.00	>
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	4.34		4.60	
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	1.91		1.33	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	2.50		2.60	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	6.80		6.90	
GLOBULINS BETA	7-13 (%)	01/01/91	8.40		8.60	
GLOBULINS GAMMA	10-19 (%)	01/01/91	10.40		10.90	
TSH	0.3-4 (MU/L)	01/01/91	1.90			
T4	50-115 (UG/L)	01/01/91	101.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 1 Patient: 2 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/02/91		19/03/91		09/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.7-16.6 (G/DL)	01/01/91	15.00		14.10		14.90	
HT	36-42 (%)	01/01/91	42.70	>	39.70		42.30	>
RBC	3.6-5.3 (10-6/MM3)	01/01/91	4.63		4.31		4.56	
WBC	4-10.7 (10-3/MM3)	01/01/91	5.50		6.80		4.90	
WBC: N	40-75 (%)	01/01/91	68.00		69.00		65.00	
WBC: L	20-45 (%)	01/01/91	20.00		26.00		27.00	
WBC: E	1-6 (%)	01/01/91	1.00		1.00		2.00	
WBC: M	2-10 (%)	01/01/91	10.00		4.00		4.00	
WBC: B	0-1 (%)	01/01/91	1.00		0.00		2.00	>>
PLATELETS	100-300 (10-3/MM3)	01/01/91	358.00	>	328.00	>	337.00	>
NA+	130-149 (MMOL/L)	01/01/91	141.00		140.00		142.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.66		4.40		4.39	
CL-	94-109 (MMOL/L)	01/01/91	105.00		104.00		106.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.31		2.60		2.58	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	1.05		1.09		0.85	<
SGOT	5-18 (U/L)	01/01/91	4.00	<	7.00		10.00	
SGPT	5-18 (U/L)	01/01/91	10.00		11.00		17.00	
GAMMA GT	4-18 (U/L)	01/01/91	18.00		19.00	>	19.00	>
LDH	120-240 (U/L)	01/01/91	120.00		164.00		171.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	110.00		108.00		118.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	5.16		4.92		4.94	
BUN	1.7-8.3 (MMOL/L)	01/01/91	2.70		3.80		4.50	
UREA	()	01/01/91						
CREATININE	50-98 (UMOL/L)	01/01/91	75.00		69.00		77.00	
URIC ACID	142-339 (UMOL/L)	01/01/91	244.00		239.00		316.00	
TOT BILIRUBIN	3.6-21.5 (UMOL/L)	01/01/91	6.30		6.50		8.20	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	77.70		76.50		83.00	
ALBUMINE	58-70 (%)	01/01/91			66.10		66.10	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	8.46	>>	8.13	>>	8.48	>>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	2.89	>	2.06		1.50	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91			2.40		2.20	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91			7.50		7.40	
GLOBULINS BETA	7-13 (%)	01/01/91			10.90		10.60	
GLOBULINS GAMMA	10-19 (%)	01/01/91			13.10		13.70	
TSH	0.3-4 (MU/L)	01/01/91	1.10					
T4	50-115 (UG/L)	01/01/91	96.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 1 Patient: 5 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/07/91		07/08/91		28/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.7-16.6 (G/DL)	01/01/91	14.10		14.30		14.60	
HT	36-42 (%)	01/01/91	42.70	>	43.80	>	43.20	>
RBC	3.6-5.3 (10-6/MM3)	01/01/91	4.68		4.82		4.77	
WBC	4-10.7 (10-3/MM3)	01/01/91	6.60		8.50		7.00	
WBC: N	40-75 (%)	01/01/91	61.00		71.00		60.00	
WBC: L	20-45 (%)	01/01/91	34.00		25.00		32.00	
WBC: E	1-6 (%)	01/01/91	1.00		1.00		1.00	
WBC: M	2-10 (%)	01/01/91	4.00		3.00		6.00	
WBC: B	0-1 (%)	01/01/91	0.00		0.00		1.00	
PLATELETS	100-300 (10-3/MM3)	01/01/91	333.00	>	361.00	>	353.00	>
NA+	130-149 (MMOL/L)	01/01/91	146.00		148.00		142.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.23		4.80		4.49	
CL-	94-109 (MMOL/L)	01/01/91			105.00		101.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.16	<				
PO4--	0.87-1.45 (MMOL/L)	01/01/91	1.20		1.47	>	1.09	
SGOT	5-18 (U/L)	01/01/91	10.00		7.00		12.00	
SGPT	5-18 (U/L)	01/01/91	13.00		8.00		17.00	
GAMMA GT	4-18 (U/L)	01/01/91	11.00		10.00		11.00	
LDH	120-240 (U/L)	01/01/91	130.00		134.00		230.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	103.00		91.00		135.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91			5.92	>	5.02	
BUN	1.7-8.3 (MMOL/L)	01/01/91	5.10		4.70		8.70	>
UREA	()	01/01/91						
CREATININE	50-98 (UMOL/L)	01/01/91	78.00		86.00		86.00	
URIC ACID	142-339 (UMOL/L)	01/01/91	218.00		231.00		438.00	>
TOT BILIRUBIN	3.6-21.5 (UMOL/L)	01/01/91	8.10		6.80		6.90	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	67.80				69.40	
ALBUMINE	58-70 (%)	01/01/91	66.70				67.80	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	5.62	>	6.62	>	5.47	>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	1.37	<	1.45	<	0.95	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	2.50				2.90	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	6.50				4.90	<
GLOBULINS BETA	7-13 (%)	01/01/91	10.50				11.20	
GLOBULINS GAMMA	10-19 (%)	01/01/91	13.70				13.20	
TSH	0.3-4 (MU/L)	01/01/91	0.56					
T4	50-115 (UG/L)	01/01/91	111.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 1 Patient: 7 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/10/91		30/10/91		21/11/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13.4-18.5 (G/DL)	01/01/91	15.70		14.70		15.00	
HT	40-48 (%)	01/01/91	45.40		43.40		43.10	
RBC	4.15-5.9 (10-6/MM3)	01/01/91	4.93		4.70		4.71	
WBC	4-10.7 (10-3/MM3)	01/01/91	8.00		5.10		5.60	
WBC: N	40-75 (%)	01/01/91	75.00		54.00			
WBC: L	20-45 (%)	01/01/91	16.00	<	30.00			
WBC: E	1-6 (%)	01/01/91	1.00		5.00			
WBC: M	2-10 (%)	01/01/91	8.00		10.00			
WBC: B	0-1 (%)	01/01/91	0.00		1.00			
PLATELETS	100-300 (10-3/MM3)	01/01/91	289.00		262.00		263.00	
NA+	130-149 (MMOL/L)	01/01/91	145.00		142.00		146.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	5.00		4.50		4.61	
CL-	94-109 (MMOL/L)	01/01/91	104.00		102.00		105.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.33		2.46		2.36	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	0.64	<<	0.80	<	0.77	<
SGOT	5-19 (U/L)	01/01/91	9.00		8.00		13.00	
SGPT	5-23 (U/L)	01/01/91	10.00		8.00		11.00	
GAMMA GT	6-28 (U/L)	01/01/91	19.00		13.00		12.00	
LDH	120-240 (U/L)	01/01/91	164.00		164.00		207.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	138.00		124.00		120.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	6.41	>	5.35		5.56	
BUN	1.7-8.3 (MMOL/L)	01/01/91	5.00		6.20		4.60	
UREA	()	01/01/91						
CREATININE	58-110 (UMOL/L)	01/01/91	104.00		97.00		85.00	
URIC ACID	202-416 (UMOL/L)	01/01/91	315.00		350.00		374.00	
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	7.00		7.80		7.70	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	70.10		73.30		68.00	
ALBUMINE	58-70 (%)	01/01/91	67.50		69.70		70.50	>
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	6.50	>	4.60		5.07	
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	1.75		1.30	<	1.27	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	2.40		2.20		2.40	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	6.60		5.60		5.20	
GLOBULINS BETA	7-13 (%)	01/01/91	10.50		9.20		8.90	
GLOBULINS GAMMA	10-19 (%)	01/01/91	13.00		13.30		13.00	
TSH	0.3-4 (MU/L)	01/01/91	0.64					
T4	50-115 (UG/L)	01/01/91	110.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 33 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/12/90		08/01/91		29/01/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/11/90	15.70		16.10		16.20	
HT	0.38-0.57 (L/L)	01/11/90	0.47		0.47		0.47	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	5.00		4.91		5.10	
WBC	4000-9000 (/MM3)	01/11/90	7500.00		7100.00		8200.00	
WBC: N	55-60 (%)	01/11/90	56.00				59.00	
WBC: L	30-40 (%)	01/11/90	39.00				28.00	<
WBC: E	1-3 (%)	01/11/90	0.00	<			3.00	
WBC: M	3-7 (%)	01/11/90	5.00				10.00	>>
WBC: B	0-1 (%)	01/11/90	0.00				0.00	
PLATELETS	150000-300000 (/MM3)	01/11/90					196000	
NA+	136-147 (MMOL/L)	01/11/90	141.00		143.00		143.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.70		4.00		4.30	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.60		2.40		2.40	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	15.00		13.00		17.00	
SGPT	5-22 (U/L)	01/11/90	18.00		19.00		27.00	>
GAMMA GT	6-28 (U/L)	01/11/90	20.00		20.00		20.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90			114.00		122.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	81.00		96.00		94.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	0.90		0.90		0.80	
URIC ACID	0.4-7 (MG/DL)	01/11/90			4.80		4.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90			0.60		0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	6.90		6.90		6.70	
ALBUMINE	53-63 (%)	01/11/90	65.00	>	62.90		64.70	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	279.00	>	313.00	>>	325.00	>>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	166.00		102.00		104.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.00		2.90	<	3.10	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.70		8.10		7.00	
GLOBULINS BETA	10-13 (%)	01/11/90	10.20		11.30		10.90	
GLOBULINS GAMMA	14-20 (%)	01/11/90	14.10		14.80		14.30	
TSH	0.3-4 (UU/ML)	01/11/90	1.20				1.60	
T4	5-12 (UG/DL)	01/11/90	8.40		8.40		7.30	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CM[illegible]9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 35 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/12/90		17/01/91		07/02/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	15.20		15.70		16.30	
HT	0.38-0.57 (L/L)	01/11/90	0.45		0.50		0.48	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	5.00		4.87		5.30	
WBC	4000-9000 (/MM3)	01/11/90	7000.00		8700.00		5400.00	
WBC: N	55-60 (%)	01/11/90	64.00	>			72.90	>
WBC: L	30-40 (%)	01/11/90	26.00	<			21.00	<
WBC: E	1-3 (%)	01/11/90	1.00				1.00	
WBC: M	3-7 (%)	01/11/90	7.00				6.00	
WBC: B	0-1 (%)	01/11/90	0.00				0.00	
PLATELETS	150000-300000 (/MM3)	01/11/90			302000	>	302000	>
NA+	136-147 (MMOL/L)	01/11/90	141.00		144.00		145.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	3.80		4.20		4.90	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.50		2.70	>	2.70	>
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	24.00	>			22.00	>
SGPT	5-22 (U/L)	01/11/90	46.00	>>			35.00	>
GAMMA GT	6-28 (U/L)	01/11/90	22.00				19.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	79.00		81.00		79.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	88.00		84.00		73.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	0.80				1.00	
URIC ACID	0.4-7 (MG/DL)	01/11/90	4.30		4.10		5.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90			0.40		0.30	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.20		7.60		8.00	
ALBUMINE	53-63 (%)	01/11/90	64.30	>	62.10		62.70	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90			319.00	>>	319.00	>>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90			146.00		83.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.20	<	2.70	<	2.70	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	6.90	<	6.50	<	8.30	
GLOBULINS BETA	10-13 (%)	01/11/90	10.50		11.40		9.90	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	16.10		17.30		16.40	
TSH	0.3-4 (UU/ML)	01/11/90	1.80				1.50	
T4	5-12 (UG/DL)	01/11/90	1.80		8.20		8.90	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CM95000085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 37 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/01/91		07/02/91		28/02/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/11/90	16.40		15.20		15.40	
HT	0.38-0.57 (L/L)	01/11/90	0.48		0.44		0.45	
RBC	4.5-5.8 (10¬6/MM3)	01/11/90	5.60		5.10		5.30	
WBC	4000-9000 (/MM3)	01/11/90	6800.00		6700.00		6000.00	
WBC: N	55-60 (%)	01/11/90	62.00	>	63.00	>	69.00	>
WBC: L	30-40 (%)	01/11/90	30.00		21.00	<	23.00	<
WBC: E	1-3 (%)	01/11/90	1.00		3.00		1.00	
WBC: M	3-7 (%)	01/11/90	6.00		12.00	>>	7.00	
WBC: B	0-1 (%)	01/11/90	1.00		1.00		0.00	
PLATELETS	150000-300000 (/MM3)	01/11/90			260000		270000	
NA+	136-147 (MMOL/L)	01/11/90	144.00		143.00		142.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	3.90		4.30		4.30	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40		2.60			
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	9.00		16.00		10.00	
SGPT	5-22 (U/L)	01/11/90	25.00	>	40.00	>	17.00	
GAMMA GT	6-28 (U/L)	01/11/90	106.00	>>	159.00	>>	73.00	>>
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	90.00		126.00		104.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	81.00		75.00			
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	0.90				0.80	
URIC ACID	0.4-7 (MG/DL)	01/11/90	4.90		4.80		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.90		0.90		1.00	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.60		7.20		7.40	
ALBUMINE	53-63 (%)	01/11/90	64.60	>	63.20	>	62.60	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	200.00		242.00	>	197.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	821.00	>>	1010.00	>>	330.00	>>
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.70	<	2.70	<	2.70	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.70		7.30		7.10	
GLOBULINS BETA	10-13 (%)	01/11/90	10.10		10.80		11.30	
GLOBULINS GAMMA	14-20 (%)	01/11/90	14.90		16.00		16.30	
TSH	0.3-4 (UU/ML)	01/11/90	1.90					
T4	5-12 (UG/DL)	01/11/90	12.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 39 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/01/91		14/02/91		07/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	13.60		14.40		13.70	
HT	0.37-0.46 (L/L)	01/11/90	0.41		0.43		0.40	
RBC	4-5 (10¬6/MM3)	01/11/90	4.40		4.70		4.30	
WBC	4000-9000 (/MM3)	01/11/90	5700.00		7300.00		6000.00	
WBC: N	55-60 (%)	01/11/90	67.00	>	69.00	>	56.00	
WBC: L	30-40 (%)	01/11/90	23.00	<	18.00	<<	31.00	
WBC: E	1-3 (%)	01/11/90	4.00	>>	2.00		2.00	
WBC: M	3-7 (%)	01/11/90	5.00		9.00	>	10.00	>>
WBC: B	0-1 (%)	01/11/90	1.00		2.00	>>	2.00	>>
PLATELETS	150000-300000 (/MM3)	01/11/90	345000	>	331000	>	302000	>
NA+	136-147 (MMOL/L)	01/11/90	143.00		142.00		141.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.00		4.30		4.10	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40		2.40		2.40	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	6.00		6.00		7.00	
SGPT	5-22 (U/L)	01/11/90	11.00		8.00		9.00	
GAMMA GT	6-28 (U/L)	01/11/90	8.00		9.00		8.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	72.00		76.00		80.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	81.00		77.00		45.00	<<
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.80		0.80		0.80	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	4.20		3.30		3.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.90		0.60		0.60	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	6.70		7.30		6.80	
ALBUMINE	53-63 (%)	01/11/90	65.80	>	62.10		61.50	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	182.00		215.00		186.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	67.00	<	75.00		56.00	<
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.70	<	2.50	<	2.80	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	6.60	<	7.50		7.50	
GLOBULINS BETA	10-13 (%)	01/11/90	9.70	<	11.10		10.40	
GLOBULINS GAMMA	14-20 (%)	01/11/90	15.20		16.80		17.80	
TSH	0.3-4 (UU/ML)	01/11/90	0.60		0.30		0.50	
T4	5-12 (UG/DL)	01/11/90	12.10		10.00		7.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 41 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/02/91		25/02/91		18/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	17.00		17.00		17.10	
HT	0.38-0.57 (L/L)	01/11/90	0.49		0.50		0.49	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	5.20		5.30		5.20	
WBC	4000-9000 (/MM3)	01/11/90	7700.00		7600.00		8900.00	
WBC: N	55-60 (%)	01/11/90	67.00	>	72.00	>	84.00	>>
WBC: L	30-40 (%)	01/11/90	24.00	<	19.00	<<	12.00	<<
WBC: E	1-3 (%)	01/11/90	2.00		1.00		0.00	<
WBC: M	3-7 (%)	01/11/90	7.00		6.00		4.00	
WBC: B	0-1 (%)	01/11/90	0.00		2.00	>>	0.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	282000		313000	>	330000	>
NA+	136-147 (MMOL/L)	01/11/90	142.00		139.00		141.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	3.90		4.20		3.90	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40				2.30	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	7.00		7.00		7.00	
SGPT	5-22 (U/L)	01/11/90	14.00		18.00		22.00	
GAMMA GT	6-28 (U/L)	01/11/90	16.00		16.00		22.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	66.00		64.00		75.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	85.00		87.00		107.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	0.90		1.00		1.10	
URIC ACID	0.4-7 (MG/DL)	01/11/90	4.10		3.70		4.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.90		0.70		0.50	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90					0.20	
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	6.70		6.90		6.90	
ALBUMINE	53-63 (%)	01/11/90	65.10	>	63.50	>	68.30	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	190.00		195.00		186.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	62.00	<	56.00	<	53.00	<
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.10		3.00		2.60	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	6.30	<	8.30		6.50	<
GLOBULINS BETA	10-13 (%)	01/11/90	11.80		11.10		12.60	
GLOBULINS GAMMA	14-20 (%)	01/11/90	13.70	<	14.30		10.00	<
TSH	0.3-4 (UU/ML)	01/11/90	0.20					
T4	5-12 (UG/DL)	01/11/90	8.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 5550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 43 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/03/91		15/04/91		06/05/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/11/90	14.30		12.60		13.20	
HT	0.37-0.46 (L/L)	01/11/90	0.41		0.37		0.39	
RBC	4-5 (10¬6/MM3)	01/11/90	4.80		4.30		4.60	
WBC	4000-9000 (/MM3)	01/11/90	9400.00	>	7800.00		8700.00	
WBC: N	55-60 (%)	01/11/90	53.00	<	56.00		69.00	>
WBC: L	30-40 (%)	01/11/90	41.00	>	32.00		23.00	<
WBC: E	1-3 (%)	01/11/90	2.00		3.00		2.00	
WBC: M	3-7 (%)	01/11/90	4.00		8.00	>	5.00	
WBC: B	0-1 (%)	01/11/90	0.00		1.00		1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	419000	>>	411000	>>	444000	>>
NA+	136-147 (MMOL/L)	01/11/90	139.00		140.00		143.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.10		4.10		4.00	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40		2.30		2.30	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	10.00		7.00		16.00	
SGPT	5-22 (U/L)	01/11/90	10.00		12.00		34.00	>
GAMMA GT	6-28 (U/L)	01/11/90	7.00		9.00		14.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	84.00		82.00		89.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	72.00		79.00		80.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.70		0.60		0.50	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	0.60	<	3.60		4.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.60		0.40		0.50	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	6.70		6.30	<	6.90	
ALBUMINE	53-63 (%)	01/11/90	64.00	>	61.90		62.20	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	218.00		172.00		279.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	55.00	<	66.00	<	87.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.60		4.30		3.90	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	8.80		11.10	>	9.10	
GLOBULINS BETA	10-13 (%)	01/11/90	10.60		10.80		12.20	
GLOBULINS GAMMA	14-20 (%)	01/11/90	12.60	<	11.90	<	14.60	
TSH	0.3-4 (UU/ML)	01/11/90	0.10		0.10		0.10	
T4	5-12 (UG/DL)	01/11/90	12.40		9.90		8.40	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS-R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 46 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/05/91		05/06/91		26/06/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	14.30		14.30		14.50	
HT	0.37-0.46 (L/L)	01/11/90	0.42		0.42		0.43	
RBC	4-5 (10¬6/MM3)	01/11/90	4.70		4.60		4.83	
WBC	4000-9000 (/MM3)	01/11/90	5800.00		6400.00		5100.00	
WBC: N	55-60 (%)	01/11/90	54.00	<	76.00	>	52.00	<
WBC: L	30-40 (%)	01/11/90	41.00	>	18.00	<<	43.00	>
WBC: E	1-3 (%)	01/11/90	1.00		1.00		0.00	<
WBC: M	3-7 (%)	01/11/90	4.00		3.00		4.00	
WBC: B	0-1 (%)	01/11/90	0.00		2.00	>>	1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	322000	>	308000	>	339000	>
NA+	136-147 (MMOL/L)	01/11/90	144.00		145.00		142.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.30		4.10		4.10	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.50				2.39	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	10.00		14.00		13.00	
SGPT	5-22 (U/L)	01/11/90	13.00		18.00		15.00	
GAMMA GT	6-28 (U/L)	01/11/90	12.00		11.00		11.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	80.00		76.00		80.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	93.00		97.00		97.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.90		0.90		1.00	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	5.80	>	0.90	<	7.20	>
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.40		0.50		0.70	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	8.10		8.10		7.80	
ALBUMINE	53-63 (%)	01/11/90	64.70	>	64.10	>	64.90	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	271.00	>	252.00	>	268.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	252.00	>>	222.00	>	201.00	>
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.20	<	2.20	<	2.30	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	6.90	<	6.90	<	5.10	<
GLOBULINS BETA	10-13 (%)	01/11/90	9.40	<	9.40	<	10.00	
GLOBULINS GAMMA	14-20 (%)	01/11/90	16.80		16.80		17.70	
TSH	0.3-4 (UU/ML)	01/11/90	0.70		1.70		0.90	
T4	5-12 (UG/DL)	01/11/90			8.20		8.50	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA [illegible]0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 47 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/05/91		11/06/91		02/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	14.70		14.10		13.80	
HT	0.37-0.46 (L/L)	01/11/90	0.42		0.43		0.42	
RBC	4-5 (10¬6/MM3)	01/11/90	5.10	>	5.10	>	5.10	>
WBC	4000-9000 (/MM3)	01/11/90	6700.00		6300.00		5800.00	
WBC: N	55-60 (%)	01/11/90	72.00	>	70.00	>	67.00	>
WBC: L	30-40 (%)	01/11/90	22.00	<	22.00	<	27.00	<
WBC: E	1-3 (%)	01/11/90	2.00		0.00	<	0.00	<
WBC: M	3-7 (%)	01/11/90	3.00		7.00		5.00	
WBC: B	0-1 (%)	01/11/90	1.00		0.00		1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	322000	>	339000	>	379000	>
NA+	136-147 (MMOL/L)	01/11/90	145.00		142.00		142.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.40		4.20		4.31	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40				2.15	<
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	10.00		10.00		9.00	
SGPT	5-22 (U/L)	01/11/90	15.00		18.00		21.00	
GAMMA GT	6-28 (U/L)	01/11/90	20.00		12.00		17.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	138.00		123.00		135.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	85.00		91.00		91.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.90		1.10		1.10	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	5.30		5.00		5.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.50		0.50		0.60	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.60		7.20		7.00	
ALBUMINE	53-63 (%)	01/11/90	63.90	>	62.70		61.30	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	302.00	>>	320.00	>>	343.00	>>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	169.00		118.00		160.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.80	<	2.60	<	3.40	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	8.20		8.00		7.90	
GLOBULINS BETA	10-13 (%)	01/11/90	13.00		12.90		10.80	
GLOBULINS GAMMA	14-20 (%)	01/11/90	12.10	<	13.80	<	16.60	
TSH	0.3-4 (UU/ML)	01/11/90	0.10					
T4	5-12 (UG/DL)	01/11/90	11.30				9.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 50 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			04/11/91		26/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	16.00		15.60	
HT	0.38-0.57 (L/L)	01/11/90	0.48		0.47	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	5.00		4.90	
WBC	4000-9000 (/MM3)	01/11/90	10900.0	>	7900.00	
WBC: N	55-60 (%)	01/11/90	51.80	<	53.10	<
WBC: L	30-40 (%)	01/11/90	35.10		33.50	
WBC: E	1-3 (%)	01/11/90	2.10		2.90	
WBC: M	3-7 (%)	01/11/90	10.20	>>	9.60	>>
WBC: B	0-1 (%)	01/11/90	0.90		0.90	
PLATELETS	150000-300000 (/MM3)	01/11/90	193000		184000	
NA+	136-147 (MMOL/L)	01/11/90	140.00		138.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.33		4.50	
CL-	95-108 (MMOL/L)	01/11/90				
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40		2.41	
PO4--	()	01/11/90				
SGOT	5-18 (U/L)	01/11/90	11.00		14.00	
SGPT	5-22 (U/L)	01/11/90	24.00	>	25.00	>
GAMMA GT	6-28 (U/L)	01/11/90	24.00		22.00	
LDH	()	01/11/90				
ALK. PHOSPH.	60-170 (U/L)	01/11/90	94.00		88.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	81.00		89.00	
BUN	20-40 (MG/DL)	01/11/90			23.00	
UREA	()	01/11/90				
CREATININE	0.5-1.1 (MG/DL)	01/11/90	1.10		1.20	>
URIC ACID	0.4-7 (MG/DL)	01/11/90	5.80		10.00	>>
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.40		0.60	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90				
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.00		7.20	
ALBUMINE	53-63 (%)	01/11/90	61.50		65.60	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	215.00		205.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	143.00		134.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.10		3.00	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	8.30		7.20	
GLOBULINS BETA	10-13 (%)	01/11/90	10.90		10.10	
GLOBULINS GAMMA	14-20 (%)	01/11/90	16.20		14.10	
TSH	0.3-4 (UU/ML)	01/11/90	2.60			
T4	5-12 (UG/DL)	01/11/90	8.30			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

1130

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 51 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			04/11/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/11/90	13.10	
HT	0.37-0.46 (L/L)	01/11/90	0.40	
RBC	4-5 (10-6/MM3)	01/11/90	4.00	
WBC	4000-9000 (/MM3)	01/11/90	7100.00	
WBC: N	55-60 (%)	01/11/90	70.00	>
WBC: L	30-40 (%)	01/11/90	22.30	<
WBC: E	1-3 (%)	01/11/90	1.30	
WBC: M	3-7 (%)	01/11/90	5.10	
WBC: B	0-1 (%)	01/11/90	1.20	>
PLATELETS	150000-300000 (/MM3)	01/11/90	276000	
NA+	136-147 (MMOL/L)	01/11/90	139.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.05	
CL-	95-108 (MMOL/L)	01/11/90		
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.28	<
PO4--	()	01/11/90		
SGOT	5-18 (U/L)	01/11/90	7.00	
SGPT	5-22 (U/L)	01/11/90	10.00	
GAMMA GT	6-28 (U/L)	01/11/90	12.00	
LDH	()	01/11/90		
ALK. PHOSPH.	60-170 (U/L)	01/11/90	82.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	76.00	
BUN	20-40 (MG/DL)	01/11/90		
UREA	()	01/11/90		
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.80	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	2.20	<
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90		
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.40	
ALBUMINE	53-63 (%)	01/11/90	58.50	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	254.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	104.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.70	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	9.10	
GLOBULINS BETA	10-13 (%)	01/11/90	10.40	
GLOBULINS GAMMA	14-20 (%)	01/11/90	19.30	
TSH	0.3-4 (UU/ML)	01/11/90	0.50	
T4	5-12 (UG/DL)	01/11/90	8.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 65 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/03/91		22/04/91		13/05/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/02/91	16.80		17.20		16.80	
HT	42-52 (%)	01/02/91	48.00		49.50		47.00	
RBC	4.6-6.2 (10¬6/MM3)	01/02/91	5.42		5.47		5.34	
WBC	4.8-10.8 (10¬3/MM3)	01/02/91	7.40		9.40		10.80	
WBC: N	45-78 (%)	01/02/91	56.30		63.30		63.80	
WBC: L	18-45 (%)	01/02/91	31.30		24.80		24.50	
WBC: E	0-5 (%)	01/02/91	3.80		2.10		3.00	
WBC: M	2-12 (%)	01/02/91	4.80		5.40		5.30	
WBC: B	0-1 (%)	01/02/91	0.70		0.90		0.80	
PLATELETS	125-400 (10¬3/MM3)	01/02/91	265.00		301.00		283.00	
NA+	135-150 (MMOL/L)	01/02/91	142.00		151.00	>	147.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.60		4.50		4.30	
CL-	97-108 (MMOL/L)	01/02/91	97.00		100.00		95.00	<
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.40		2.60		2.50	
PO4--	2-4.9 (MG/DL)	01/02/91	4.00		3.90		4.00	
SGOT	5-18 (U/L)	01/02/91	12.00		9.00		10.00	
SGPT	5-22 (U/L)	01/02/91	32.00	>	23.00	>	31.00	>
GAMMA GT	0-28 (U/L)	01/02/91	13.00		15.00		14.00	
LDH	150-240 (U/L)	01/02/91	193.00		177.00		165.00	
ALK. PHOSPH.	40-200 (U/L)	01/02/91	91.00		102.00		109.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	114.00	>	140.00	>	197.00	>>
BUN	0-25 (MG/DL)	01/02/91	14.00		12.00		15.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	1.10		1.00		1.00	
URIC ACID	2.5-7 (MG/DL)	01/02/91	5.10		6.30		5.70	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	1.10		0.90		0.70	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.90		7.80		7.60	
ALBUMINE	58-72 (%)	01/02/91	62.10		54.40	<	62.10	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	310.00	>>	233.00	>	243.00	>
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	271.00	>>	165.00		364.00	>>
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	3.80		3.50		3.80	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	8.60		10.10		8.60	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	9.30		11.40	>	9.30	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	16.10		19.00		16.10	
TSH	0.1-4 (UU/ML)	01/02/91	2.00					
T4	0.92-1.82 (NG/DL)	01/02/91	1.18					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 67 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/04/91		30/04/91		23/05/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/02/91	14.30		15.20		14.60	
HT	37-47 (%)	01/02/91	43.10		45.30		43.80	
RBC	4.2-5.4 (10¬6/MM3)	01/02/91	4.54		4.82		4.73	
WBC	4.8-10.8 (10¬3/MM3)	01/02/91	7.60		8.00		11.80	>
WBC: N	45-76 (%)	01/02/91	63.80		63.80		73.80	
WBC: L	18-45 (%)	01/02/91	28.60		27.30		19.80	
WBC: E	0-5 (%)	01/02/91	1.10		1.06		1.20	
WBC: M	2-12 (%)	01/02/91	4.40		5.20		3.80	
WBC: B	0-1 (%)	01/02/91	0.50		0.60		0.40	
PLATELETS	125-400 (10¬3/MM3)	01/02/91	242.00		257.00		301.00	
NA+	135-150 (MMOL/L)	01/02/91	144.00		143.00		142.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.60		5.10		4.10	
CL-	97-108 (MMOL/L)	01/02/91	102.00		101.00		95.00	<
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.60		2.70		2.50	
PO4--	2-4.9 (MG/DL)	01/02/91	4.30		4.40		4.40	
SGOT	5-18 (U/L)	01/02/91	5.00		6.00		6.00	
SGPT	5-22 (U/L)	01/02/91	7.00		7.00		6.00	
GAMMA GT	0-18 (U/L)	01/02/91	10.00		9.00		8.00	
LDH	150-240 (U/L)	01/02/91	75.00	<	131.00	<	164.00	
ALK. PHOSPH.	40-200 (U/L)	01/02/91	72.00		75.00		78.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	119.00	>	105.00		168.00	>>
BUN	0-25 (MG/DL)	01/02/91	13.00		14.00		12.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	0.90		0.90		0.90	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	4.40		6.20	>	5.10	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.70		0.60		0.60	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.10		7.50		7.00	
ALBUMINE	58-72 (%)	01/02/91	62.60		63.40		59.60	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	270.00	>>	305.00	>>	288.00	>>
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	199.00		178.00		177.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	3.80		3.60		4.00	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	8.70		8.60		9.70	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	10.30		10.90		11.40	>
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	13.30		13.30		15.00	
TSH	0.1-4 (UU/ML)	01/02/91	5.20					
T4	0.92-1.82 (NG/DL)	01/02/91	1.36					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS PV0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 70 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			22/10/91		12/11/91	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/02/91	15.30		14.60	
HT	37-47 (%)	01/02/91	43.60		41.30	
RBC	4.2-5.4 (10¬6/MM3)	01/02/91	5.06		4.89	
WBC	4.8-10.8 (10¬3/MM3)	01/02/91	6.50		5.40	
WBC: N	45-78 (%)	01/02/91	59.40		64.10	
WBC: L	18-45 (%)	01/02/91	33.50		24.00	
WBC: E	0-5 (%)	01/02/91	1.40		3.70	
WBC: M	2-12 (%)	01/02/91	3.50		4.60	
WBC: B	0-1 (%)	01/02/91	0.70		1.10	>
PLATELETS	125-400 (10¬3/MM3)	01/02/91	268.00		230.00	
NA+	135-150 (MMOL/L)	01/02/91	141.00		142.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.60		4.40	
CL-	97-108 (MMOL/L)	01/02/91	99.00		103.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.50		2.50	
PO4--	2-4.9 (MG/DL)	01/02/91	3.60		4.30	
SGOT	5-18 (U/L)	01/02/91	11.00		13.00	
SGPT	5-22 (U/L)	01/02/91	15.00		31.00	>
GAMMA GT	0-18 (U/L)	01/02/91	25.00	>	37.00	>>
LDH	150-240 (U/L)	01/02/91	135.00	<	152.00	
ALK. PHOSPH.	40-200 (U/L)	01/02/91	109.00		118.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	159.00	>>	159.00	>>
BUN	0-25 (MG/DL)	01/02/91	16.00		13.00	
UREA	()	01/02/91				
CREATININE	0-1.3 (MG/DL)	01/02/91	0.80		0.80	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	4.10		3.50	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.80		0.70	
DIR BILIRUBIN	()	01/02/91				
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.30		7.20	
ALBUMINE	58-72 (%)	01/02/91	51.30	<	50.80	<
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	271.00	>>	238.00	>
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	220.00	>	168.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	4.10		5.10	>
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	9.60		10.50	>
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	15.20	>>	16.60	>>
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	19.60		16.70	
TSH	0.1-4 (UU/ML)	01/02/91	0.70			
T4	0.92-1.82 (NG/DL)	01/02/91	1.24			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 72 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/01/92		21/02/92		13/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/02/91	13.50		14.10		12.90	
HT	37-47 (%)	01/02/91	40.10		41.20		37.20	
RBC	4.2-5.4 (10-6/MM3)	01/02/91	4.63		4.89		4.53	
WBC	4.8-10.8 (10-3/MM3)	01/02/91	7.20		8.10		6.80	
WBC: N	45-78 (%)	01/02/91	61.10		67.10		66.30	
WBC: L	18-45 (%)	01/02/91	25.80		23.30		26.40	
WBC: E	0-5 (%)	01/02/91	1.00		1.50		0.80	
WBC: M	2-12 (%)	01/02/91	4.90		6.20		4.50	
WBC: B	0-1 (%)	01/02/91	0.50		0.60		0.60	
PLATELETS	125-400 (10-3/MM3)	01/02/91	332.00		303.00		296.00	
NA+	135-150 (MMOL/L)	01/02/91	141.00		140.00		139.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.50	<	3.80		3.30	<
CL-	97-108 (MMOL/L)	01/02/91	103.00		102.00		102.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.20		2.20		2.10	
PO4--	2-4.9 (MG/DL)	01/02/91	2.70		3.50		3.30	
SGOT	5-18 (U/L)	01/02/91	7.00		9.00		14.00	
SGPT	5-22 (U/L)	01/02/91	10.00		14.00		14.00	
GAMMA GT	0-18 (U/L)	01/02/91	16.00		12.00		10.00	
LDH	150-240 (U/L)	01/02/91	100.00	<	131.00	<	122.00	<
ALK. PHOSPH.	40-200 (U/L)	01/02/91	80.00		128.00		113.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	130.00	>	97.00			
BUN	0-25 (MG/DL)	01/02/91	15.00		15.00		11.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	1.00		0.80		0.80	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	3.50		4.90		4.30	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.40		0.50		0.50	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.20		7.10		7.40	
ALBUMINE	58-72 (%)	01/02/91	54.00	<	61.40		61.40	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	202.00	>	197.00		198.00	
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	230.00	>	154.00		134.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	5.10	>	3.40		3.40	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	9.60		7.90		7.90	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	10.60		10.10		10.10	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	16.70		16.70		16.70	
TSH	0.1-4 (UU/ML)	01/02/91	1.10					
T4	0.92-1.82 (NG/DL)	01/02/91	1.37					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 73 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/02/92		06/03/92		27/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/02/91	14.20		13.70		13.90	
HT	37-47 (%)	01/02/91	38.50		38.80		39.80	
RBC	4.2-5.4 (10-6/MM3)	01/02/91	4.57		4.52		4.62	
WBC	4.8-10.8 (10-3/MM3)	01/02/91	4.50	<	5.10		6.30	
WBC: N	45-78 (%)	01/02/91	61.90		65.60		67.70	
WBC: L	18-45 (%)	01/02/91	28.60		24.20		24.00	
WBC: E	0-5 (%)	01/02/91	1.50		2.80		1.50	
WBC: M	2-12 (%)	01/02/91	6.80		5.60		5.20	
WBC: B	0-1 (%)	01/02/91	0.20		0.30		0.30	
PLATELETS	125-400 (10-3/MM3)	01/02/91	199.00		211.00		242.00	
NA+	135-150 (MMOL/L)	01/02/91	141.00		143.00		141.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.70		5.10		4.60	
CL-	97-108 (MMOL/L)	01/02/91	107.00		105.00		106.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.30		2.40		2.40	
PO4--	2-4.9 (MG/DL)	01/02/91	3.70		3.90		3.50	
SGOT	5-18 (U/L)	01/02/91	13.00		17.00		13.00	
SGPT	5-22 (U/L)	01/02/91	14.00		24.00	>	17.00	
GAMMA GT	0-18 (U/L)	01/02/91	20.00	>	22.00	>	23.00	>
LDH	150-240 (U/L)	01/02/91	159.00		190.00		207.00	
ALK. PHOSPH.	40-200 (U/L)	01/02/91	88.00		109.00		106.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	87.00		108.00		101.00	
BUN	0-25 (MG/DL)	01/02/91	24.00		21.00		22.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	0.70		0.70		0.80	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	5.30		6.30	>	7.00	>
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.80		0.80		0.70	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.40		7.50		8.20	
ALBUMINE	58-72 (%)	01/02/91	56.30	<	62.40		62.40	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	154.00		179.00		164.00	
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	96.00		99.00		102.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	4.00		2.90		2.90	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	8.20		7.10		7.10	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	9.90		9.50		9.50	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	21.50	>	18.10		18.10	
TSH	0.1-4 (UU/ML)	01/02/91	0.40					
T4	0.92-1.82 (NG/DL)	01/02/91	1.54					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 4 Patient: 100 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/05/92		27/05/92		17/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	7.4-10.5 (MMOL/L)	01/04/91	7.90		7.60		8.00	
HT	0.36-0.45 (L/L)	01/04/91	0.39		0.41		0.37	
RBC	4.2-5.4 (10~6/MM3)	01/04/91	4.28		4.20		4.21	
WBC	3.8-9.8 (10~3/MM3)	01/04/91	5.25		6.00		7.17	
WBC: N	36-84 (%)	01/04/91	69.00		68.50		68.70	
WBC: L	20-42 (%)	01/04/91	21.20		21.70		24.00	
WBC: E	0-5 (%)	01/04/91	1.10		1.00		0.80	
WBC: M	0-9.5 (%)	01/04/91	7.20		7.40		6.00	
WBC: B	0-1 (%)	01/04/91	0.30		0.20		0.40	
PLATELETS	150-300 (10~3/MM3)	01/04/91	257.00		270.00		271.00	
NA+	136-152 (MMOL/L)	01/04/91	140.00		141.50		142.00	
K+	3.8-5.5 (MMOL/L)	01/04/91	4.04		4.20		4.10	
CL-	97-108 (MMOL/L)	01/04/91	93.00	<	96.00	<	94.00	<
Ca++	2.4-2.65 (MMOL/L)	01/04/91	2.20	<	2.16	<	2.41	
PO4--	0.8-1.3 (MMOL/L)	01/04/91	1.14		1.20		1.24	
SGOT	0.32-0.49 (MMOL/L/S)	01/04/91	0.20	<	0.24	<	0.39	
SGPT	0.17-0.4 (MMOL/L/S)	01/04/91	0.17		0.28		0.27	
GAMMA GT	0-0.4 (MMOL/L/S)	01/04/91	0.45	>	0.52	>	0.22	
LDH	0-6.6 (MMOL/L)	01/04/91	4.00		4.12		4.85	
ALK. PHOSPH.	1.45-3.65 (MMOL/L/S)	01/04/91	2.27		2.17		2.07	
GLUCOSE	3.33-5.55 (MMOL/L)	01/04/91	3.90		4.10		3.40	
BUN	3.6-7.1 (MMOL/L)	01/04/91						
UREA	()	01/04/91						
CREATININE	0-88 (UMOL/L)	01/04/91	53.00		61.00		63.00	
URIC ACID	140-340 (UMOL/L)	01/04/91	266.00		265.00		364.00	>
TOT BILIRUBIN	0-16 (UMOL/L)	01/04/91	12.00		11.80		16.50	>
DIR BILIRUBIN	()	01/04/91						
TOT. PROTEINS	65-85 (G/L)	01/04/91	72.00		71.80		76.30	
ALBUMINE	55-65 (%)	01/04/91	60.40		60.10		63.80	
TOT. CHOLEST.	3.5-6.6 (MMOL/L)	01/04/91	6.32		6.80	>	5.42	
TRIGLYCERIDES	1.75-2.1 (MMOL/L)	01/04/91	1.25	<	1.75		0.60	<
GLOBULINS ALPHA 1	3-6 (%)	01/04/91	2.50	<	2.50	<	2.40	<
GLOBULINS ALPHA 2	5-10 (%)	01/04/91	7.20		7.40		6.40	
GLOBULINS BETA	9-14 (%)	01/04/91	11.90		11.70		10.40	
GLOBULINS GAMMA	12-20 (%)	01/04/91	18.00		17.90		17.00	
TSH	0.24-2.9 (MU/L)	01/04/91	0.88					
T4	65-155 (NMOL/L)	01/04/91	74.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS [illegible] 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 6 Patient: 161 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/03/91		18/04/91		08/05/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	26/03/91	16.10		15.20		15.70	
HT	40-52 (%)	26/03/91	47.90		44.30		45.30	
RBC	4.5-5.9 (10-6/MM3)	26/03/91	5.30		4.93		5.06	
WBC	4000-10000 (/MM3)	26/03/91	5800.00		8100.00		9100.00	
WBC: N	45-80 (%)	26/03/91	65.00		50.00		62.00	
WBC: L	20-40 (%)	26/03/91	32.00		38.00		31.00	
WBC: E	0-4 (%)	26/03/91	0.00		5.00	>	4.00	
WBC: M	2-8 (%)	26/03/91	2.00		6.00		3.00	
WBC: B	0-1 (%)	26/03/91	0.00		0.00		0.00	
PLATELETS	150-400 (10-3/MM3)	26/03/91	278.00		242.00		291.00	
NA+	134-147 (MMOL/L)	26/03/91	141.00		143.00		144.00	
K+	3.6-5.5 (MMOL/L)	26/03/91	3.87		4.01		4.37	
CL-	98-109 (MMOL/L)	26/03/91	103.00		103.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	26/03/91	2.44		2.42		2.56	
PO4--	0.8-1.6 (MMOL/L)	26/03/91	1.10		1.20		1.20	
SGOT	5-18 (U/L)	26/03/91	8.00		8.00		8.00	
SGPT	5-22 (U/L)	26/03/91	14.00		12.00		12.00	
GAMMA GT	0-28 (U/L)	26/03/91	17.00		13.00		15.00	
LDH	120-140 (U/L)	26/03/91	101.00	<	107.00	<	110.00	<
ALK. PHOSPH.	50-170 (U/L)	26/03/91	97.00		88.00		96.00	
GLUCOSE	50-100 (MG/DL)	26/03/91	81.00		84.00		80.00	
BUN	10-50 (MG/DL)	26/03/91	26.00		24.00		36.00	
UREA	()	26/03/91						
CREATININE	0.6-1.2 (MG/DL)	26/03/91	1.30	>	0.99		1.07	
URIC ACID	3.4-7 (MG/DL)	26/03/91	4.70		4.95		5.30	
TOT BILIRUBIN	0-1 (MG/DL)	26/03/91	0.62		0.36		0.59	
DIR BILIRUBIN	0-0.3 (MG/DL)	26/03/91	0.20		0.10		0.10	
TOT. PROTEINS	6-8.2 (G/DL)	26/03/91	7.30		7.90		7.60	
ALBUMINE	58-70 (%)	26/03/91	67.00		71.80	>	69.00	
TOT. CHOLEST.	120-260 (MG/DL)	26/03/91	176.00		251.00		197.00	
TRIGLYCERIDES	74-172 (MG/DL)	26/03/91	195.00	>	173.00	>	116.00	
GLOBULINS ALPHA 1	1.5-4 (%)	26/03/91	2.00		2.30		4.00	
GLOBULINS ALPHA 2	5-10 (%)	26/03/91	9.00		5.90		7.00	
GLOBULINS BETA	8-13 (%)	26/03/91	8.00		9.10		9.00	
GLOBULINS GAMMA	10-19 (%)	26/03/91	14.00		10.90		11.00	
TSH	0.2-3.9 (MU/L)	26/03/91	0.70					
T4	4.5-12 (UG/DL)	26/03/91	10.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 5600085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 6 Patient: 162 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/11/91		25/11/91		16/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	02/02/91	13.80		14.00		13.30	
HT	36-46 (%)	02/02/91	41.50		42.00		39.80	
RBC	4-5.3 (10¬6/MM3)	02/02/91	4.40		4.54		4.33	
WBC	4000-10000 (/MM3)	02/02/91	6100.00		4600.00		4300.00	
WBC: N	45-80 (%)	02/02/91	68.00		73.00		71.00	
WBC: L	20-40 (%)	02/02/91	24.00		19.00	<	19.00	<
WBC: E	0-4 (%)	02/02/91	1.00		3.00		2.00	
WBC: M	2-8 (%)	02/02/91	7.00		5.00		7.00	
WBC: B	0-1 (%)	02/02/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	02/02/91	212.00		222.00		227.00	
NA+	134-147 (MMOL/L)	02/02/91	149.00	>	143.00		141.00	
K+	3.6-5.5 (MMOL/L)	02/02/91	4.40		3.90		3.70	
CL-	98-109 (MMOL/L)	02/02/91	107.00		106.00		104.00	
Ca++	2.1-2.6 (MMOL/L)	02/02/91	2.50		2.50		2.40	
PO4--	0.8-1.6 (MMOL/L)	02/02/91	0.90		1.20		1.10	
SGOT	5-15 (U/L)	02/02/91	7.00		9.00		9.00	
SGPT	5-17 (U/L)	02/02/91	8.00		11.00		9.00	
GAMMA GT	0-18 (U/L)	02/02/91	13.00		16.00		12.00	
LDH	120-140 (U/L)	02/02/91	100.00	<	124.00		121.00	
ALK. PHOSPH.	50-170 (U/L)	02/02/91	100.00		98.00		132.00	
GLUCOSE	50-100 (MG/DL)	02/02/91	91.00		77.00		82.00	
BUN	10-50 (MG/DL)	02/02/91	39.00		37.00		26.00	
UREA	()	02/02/91						
CREATININE	0.5-1 (MG/DL)	02/02/91	0.66		0.72		0.59	
URIC ACID	2.4-5.7 (MG/DL)	02/02/91	2.30	<	3.85		3.60	
TOT BILIRUBIN	0-1 (MG/DL)	02/02/91	0.30		0.30		0.50	
DIR BILIRUBIN	0-0.3 (MG/DL)	02/02/91	0.10		0.30		0.10	
TOT. PROTEINS	6-8.2 (G/DL)	02/02/91	7.30		7.70		7.40	
ALBUMINE	58-70 (%)	02/02/91	59.00		59.00		63.00	
TOT. CHOLEST.	120-260 (MG/DL)	02/02/91	252.00		257.00		253.00	
TRIGLYCERIDES	74-172 (MG/DL)	02/02/91	123.00		82.00		105.00	
GLOBULINS ALPHA 1	1.5-4 (%)	02/02/91	4.00		4.00		4.00	
GLOBULINS ALPHA 2	5-10 (%)	02/02/91	10.00		10.00		8.00	
GLOBULINS BETA	8-13 (%)	02/02/91	11.00		11.00		11.00	
GLOBULINS GAMMA	10-19 (%)	02/02/91	16.00		16.00		14.00	
TSH	0.2-3.9 (MU/L)	02/02/91	0.10					
T4	0.7-2 (NG/DL)	02/02/91	2.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 7 Patient: 193 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			04/04/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	03/02/91	13.70	
HT	37-56 (%)	03/02/91	41.90	
RBC	4200-6200 (10-3/MM3)	03/02/91	4590.00	
WBC	4000-10000 (/MM3)	03/02/91	5380.00	
WBC: N	50-70 (%)	03/02/91	58.40	
WBC: L	20-40 (%)	03/02/91	20.50	
WBC: E	0-5 (%)	03/02/91	11.10	>>
WBC: M	2-10 (%)	03/02/91	7.90	
WBC: B	0-2 (%)	03/02/91	0.70	
PLATELETS	150-400 (10-3/MM3)	03/02/91	211.00	
NA+	136-146 (MMOL/L)	03/02/91	147.00	>
K+	3.5-5 (MMOL/L)	03/02/91	5.10	>
CL-	95-105 (MMOL/L)	03/02/91	106.00	>
Ca++	2-2.6 (MMOL/L)	03/02/91	2.27	
PO4--	0.79-1.56 (MMOL/L)	03/02/91	1.49	
SGOT	5-25 (U/L)	03/02/91	43.00	>
SGPT	5-20 (U/L)	03/02/91	82.00	>>
GAMMA GT	0-38 (U/L)	03/02/91	561.00	>>
LDH	138-276 (U/L)	03/02/91		
ALK. PHOSPH.	0-207 (U/L)	03/02/91	400.00	>
GLUCOSE	0.6-1.2 (G/L)	03/02/91	0.76	
BUN	0.1-0.5 (G/L)	03/02/91	0.27	
UREA	()	03/02/91		
CREATININE	0-1.4 (MG/DL)	03/02/91	1.06	
URIC ACID	2.4-7 (MG/DL)	03/02/91	4.40	
TOT BILIRUBIN	0-1.5 (MG/DL)	03/02/91	0.27	
DIR BILIRUBIN	0-0.5 (MG/DL)	03/02/91	0.10	
TOT. PROTEINS	6.3-8.5 (G/DL)	03/02/91		
ALBUMINE	53-70 (%)	03/02/91		
TOT. CHOLEST.	1.5-2.5 (G/L)	03/02/91	3.07	>
TRIGLYCERIDES	0.4-1.72 (G/L)	03/02/91	1.23	
GLOBULINS ALPHA 1	1.5-5.5 (%)	03/02/91		
GLOBULINS ALPHA 2	8-12 (%)	03/02/91		
GLOBULINS BETA	8-14 (%)	03/02/91		
GLOBULINS GAMMA	9-18 (%)	03/02/91		
TSH	0.2-5 (MU/L)	03/02/91		
T4	0.8-1.9 (NG/DL)	03/02/91		

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 7 Patient: 194 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			31/05/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	03/02/91	14.90	
HT	37-56 (%)	03/02/91	43.00	
RBC	4200-6200 (10¬3/MM3)	03/02/91	5110.00	
WBC	4000-10000 (/MM3)	03/02/91	5970.00	
WBC: N	50-70 (%)	03/02/91	43.70	<
WBC: L	20-40 (%)	03/02/91	39.30	
WBC: E	0-5 (%)	03/02/91	4.00	
WBC: M	2-10 (%)	03/02/91	10.00	
WBC: B	0-2 (%)	03/02/91	1.00	
PLATELETS	150-400 (10¬3/MM3)	03/02/91	184.00	
NA+	136-146 (MMOL/L)	03/02/91	146.00	
K+	3.5-5 (MMOL/L)	03/02/91	3.90	
CL-	95-105 (MMOL/L)	03/02/91	106.00	>
Ca++	2-2.6 (MMOL/L)	03/02/91	2.20	
PO4--	0.79-1.56 (MMOL/L)	03/02/91	1.19	
SGOT	5-25 (U/L)	03/02/91	18.00	
SGPT	5-20 (U/L)	03/02/91	36.00	>
GAMMA GT	0-38 (U/L)	03/02/91	21.00	
LDH	138-276 (U/L)	03/02/91	261.00	
ALK. PHOSPH.	0-207 (U/L)	03/02/91	127.00	
GLUCOSE	0.6-1.2 (G/L)	03/02/91	0.87	
BUN	0.1-0.5 (G/L)	03/02/91	0.37	
UREA	()	03/02/91		
CREATININE	0-1.4 (MG/DL)	03/02/91	1.15	
URIC ACID	2.4-7 (MG/DL)	03/02/91	7.40	>
TOT BILIRUBIN	0-1.5 (MG/DL)	03/02/91	0.67	
DIR BILIRUBIN	0-0.5 (MG/DL)	03/02/91	0.10	
TOT. PROTEINS	6.3-8.5 (G/DL)	03/02/91	6.80	
ALBUMINE	53-70 (%)	03/02/91	69.90	
TOT. CHOLEST.	1.5-2.5 (G/L)	03/02/91	1.67	
TRIGLYCERIDES	0.4-1.72 (G/L)	03/02/91	1.16	
GLOBULINS ALPHA 1	1.5-5.5 (%)	03/02/91	4.40	
GLOBULINS ALPHA 2	8-12 (%)	03/02/91	6.40	<
GLOBULINS BETA	8-14 (%)	03/02/91	9.60	
GLOBULINS GAMMA	9-18 (%)	03/02/91	9.70	
TSH	0.2-5 (MU/L)	03/02/91	0.80	
T4	0.8-1.9 (NG/DL)	03/02/91	1.50	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 226 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/05/91		24/05/91		14/06/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	04/02/91	13.30		13.40		13.40	
HT	32-36 (%)	04/02/91	40.20	>	40.30	>	38.50	>
RBC	4-5 (10-6/MM3)	04/02/91	4.33		4.36		4.13	
WBC	4.5-9 (10-3/MM3)	04/02/91	4.30	<	4.00	<	4.60	
WBC: N	45-70 (%)	04/02/91	40.00	<	47.00		39.00	<
WBC: L	20-40 (%)	04/02/91	51.00	>	44.00	>	50.00	>
WBC: E	1-3 (%)	04/02/91	2.00		2.00		3.00	
WBC: M	3-7 (%)	04/02/91	5.00		4.00		7.00	
WBC: B	0-1 (%)	04/02/91	2.00	>>	3.00	>>	1.00	
PLATELETS	150-400 (10-3/MM3)	04/02/91	322.00		298.00		350.00	
NA+	135-146 (MEQ/L)	04/02/91	143.00		140.00		140.00	
K+	3.5-5 (MEQ/L)	04/02/91	4.50		4.20		4.20	
CL-	95-106 (MEQ/L)	04/02/91	97.00		98.00		92.00	<
Ca++	4.2-5.3 (MEQ/L)	04/02/91	4.80		4.80		5.20	
PO4--	2.7-4.5 (MG/DL)	04/02/91	4.30		4.10		4.40	
SGOT	5-21 (U/L)	04/02/91	13.00		13.00		13.00	
SGPT	5-22 (U/L)	04/02/91	14.00		14.00		14.00	
GAMMA GT	5-25 (U/L)	04/02/91	11.00		11.00		13.00	
LDH	160-320 (U/L)	04/02/91	217.00		212.00		217.00	
ALK. PHOSPH.	73-207 (U/L)	04/02/91	162.00		153.00		165.00	
GLUCOSE	80-110 (MG/DL)	04/02/91	80.00		89.00		73.00	<
BUN	10-50 (MG/DL)	04/02/91	42.00		50.00		38.00	
UREA	()	04/02/91						
CREATININE	0.5-0.9 (MG/DL)	04/02/91	0.90		0.80		0.80	
URIC ACID	2.4-5.7 (MG/DL)	04/02/91	3.10		1.90	<	3.20	
TOT BILIRUBIN	0-1 (MG/DL)	04/02/91			0.40		0.30	
DIR BILIRUBIN	0-0.3 (MG/DL)	04/02/91	0.30		0.20		0.20	
TOT. PROTEINS	66-70 (G/L)	04/02/91	71.90	>	74.90	>	75.80	>
ALBUMINE	56-70 (%)	04/02/91	64.10		72.30	>	70.30	>
TOT. CHOLEST.	150-250 (MG/DL)	04/02/91	240.00		291.00	>	299.00	>
TRIGLYCERIDES	35-185 (MG/DL)	04/02/91	135.00		75.00		108.00	
GLOBULINS ALPHA 1	1.8-4.5 (%)	04/02/91	6.60	>>	2.50		2.50	
GLOBULINS ALPHA 2	4-13 (%)	04/02/91	7.80		6.80		7.30	
GLOBULINS BETA	9-14 (%)	04/02/91	11.00		9.90		10.60	
GLOBULINS GAMMA	8-16 (%)	04/02/91	10.50		8.50		9.40	
TSH	0.4-3.7 (UUI/ML)	04/02/91	1.10					
T4	6.1-11.5 (UG/DL)	04/02/91	8.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 5550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 228 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			08/05/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-17 (G/DL)	02/04/91	14.60	
HT	35-50 (%)	02/04/91	41.00	
RBC	4-5.5 (10¬6/MM3)	02/04/91	4.70	
WBC	4-10 (10¬3/MM3)	02/04/91	8.30	
WBC: N	25-75 (%)	02/04/91	59.00	
WBC: L	10-40 (%)	02/04/91	30.00	
WBC: E	0-4 (%)	02/04/91	2.00	
WBC: M	2-10 (%)	02/04/91	8.00	
WBC: B	0-1 (%)	02/04/91	0.00	
PLATELETS	150-400 (10¬3/MM3)	02/04/91	212.00	
NA+	137-150 (MEQ/L)	02/04/91	139.00	
K+	3.5-5.2 (MEQ/L)	02/04/91	4.50	
CL-	90-110 (MEQ/L)	02/04/91	101.00	
Ca++	4.5-5.5 (MEQ/L)	02/04/91	4.70	
PO4--	25-45 (MG/L)	02/04/91	29.00	
SGOT	5-25 (U/L)	02/04/91	20.00	
SGPT	5-25 (U/L)	02/04/91	32.00	>
GAMMA GT	0-40 (U/L)	02/04/91	30.00	
LDH	160-320 (U/L)	02/04/91	198.00	
ALK. PHOSPH.	40-210 (U/L)	02/04/91	104.00	
GLUCOSE	0.6-1.1 (G/L)	02/04/91	1.07	
BUN	0.1-0.45 (G/L)	02/04/91	0.20	
UREA	()	02/04/91		
CREATININE	5-12 (MG/L)	02/04/91	10.60	
URIC ACID	30-65 (MG/L)	02/04/91	67.00	>
TOT BILIRUBIN	0-10 (MG/L)	02/04/91	5.20	
DIR BILIRUBIN	0-3 (MG/L)	02/04/91	1.70	
TOT. PROTEINS	65-80 (G/L)	02/04/91	65.00	
ALBUMINE	55-70 (%)	02/04/91	63.50	
TOT. CHOLEST.	1.5-2.5 (G/L)	02/04/91	2.16	
TRIGLYCERIDES	0.7-1.5 (G/L)	02/04/91	2.99	>>
GLOBULINS ALPHA 1	2-4 (%)	02/04/91	2.80	
GLOBULINS ALPHA 2	6-10 (%)	02/04/91	8.00	
GLOBULINS BETA	9-13 (%)	02/04/91	12.10	
GLOBULINS GAMMA	11-15 (%)	02/04/91	13.60	
TSH	0.1-4 (MU/L)	02/04/91	1.20	
T4	7.3-20.1 (PG/ML)	02/04/91	12.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 231 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			29/10/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	04/02/91	12.50	
HT	32-36 (%)	04/02/91	36.30	>
RBC	4-5 (10¬6/MM3)	04/02/91	3.87	<
WBC	4.5-9 (10¬3/MM3)	04/02/91	6.30	
WBC: N	45-70 (%)	04/02/91	33.00	<
WBC: L	20-40 (%)	04/02/91	60.00	>>
WBC: E	1-3 (%)	04/02/91	3.00	
WBC: M	3-7 (%)	04/02/91	4.00	
WBC: B	0-1 (%)	04/02/91	0.00	
PLATELETS	150-400 (10¬3/MM3)	04/02/91	197.00	
NA+	135-146 (MEQ/L)	04/02/91	148.00	>
K+	3.5-5 (MEQ/L)	04/02/91	4.40	
CL-	95-106 (MEQ/L)	04/02/91	99.00	
Ca++	4.2-5.3 (MEQ/L)	04/02/91	4.80	
PO4--	2.7-4.5 (MG/DL)	04/02/91	4.00	
SGOT	5-21 (U/L)	04/02/91	10.00	
SGPT	5-22 (U/L)	04/02/91	9.00	
GAMMA GT	5-25 (U/L)	04/02/91	7.00	
LDH	160-320 (U/L)	04/02/91	177.00	
ALK. PHOSPH.	73-207 (U/L)	04/02/91	75.00	
GLUCOSE	80-110 (MG/DL)	04/02/91	79.00	<
BUN	10-50 (MG/DL)	04/02/91	25.00	
UREA	()	04/02/91		
CREATININE	0.5-0.9 (MG/DL)	04/02/91	0.90	
URIC ACID	2.4-5.7 (MG/DL)	04/02/91	3.90	
TOT BILIRUBIN	0-1 (MG/DL)	04/02/91		
DIR BILIRUBIN	0-0.3 (MG/DL)	04/02/91		
TOT. PROTEINS	66-70 (G/L)	04/02/91	77.40	>
ALBUMINE	56-70 (%)	04/02/91	62.00	
TOT. CHOLEST.	150-250 (MG/DL)	04/02/91	278.00	>
TRIGLYCERIDES	35-185 (MG/DL)	04/02/91	150.00	
GLOBULINS ALPHA 1	1.8-4.5 (%)	04/02/91	2.70	
GLOBULINS ALPHA 2	4-13 (%)	04/02/91	7.80	
GLOBULINS BETA	9-14 (%)	04/02/91	12.00	
GLOBULINS GAMMA	8-16 (%)	04/02/91	14.60	
TSH	0.4-3.7 (UUI/ML)	04/02/91	9.10	
T4	6.1-11.5 (UG/DL)	04/02/91	11.90	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 232 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/11/91		20/12/91		08/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-17 (G/DL)	02/04/91	13.20		13.50		13.60	
HT	35-50 (%)	02/04/91	41.00		38.00		46.00	
RBC	4-5.5 (10¬6/MM3)	02/04/91	4.20		4.10		4.90	
WBC	4-10 (10¬3/MM3)	02/04/91	12.40	>	7.80		13.60	>>
WBC: N	25-75 (%)	02/04/91	72.00		51.00		72.00	
WBC: L	10-40 (%)	02/04/91	21.00		38.00		24.00	
WBC: E	0-4 (%)	02/04/91	2.00		5.00	>	1.00	
WBC: M	2-10 (%)	02/04/91	5.00		4.00		2.00	
WBC: B	0-1 (%)	02/04/91	0.00		1.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	02/04/91	346.00		379.00		491.00	>
NA+	137-150 (MEQ/L)	02/04/91	145.00		139.00		145.00	
K+	3.5-5.2 (MEQ/L)	02/04/91	4.70		4.90		4.30	
CL-	90-110 (MEQ/L)	02/04/91	110.00		104.00		108.00	
Ca++	4.5-5.5 (MEQ/L)	02/04/91	4.80		4.90		4.80	
PO4--	25-45 (MG/L)	02/04/91	34.00		31.00		28.00	
SGOT	5-25 (U/L)	02/04/91	23.00		11.00		13.00	
SGPT	5-25 (U/L)	02/04/91	20.00		10.00		11.00	
GAMMA GT	0-40 (U/L)	02/04/91	78.00	>	27.00		19.00	
LDH	160-320 (U/L)	02/04/91	193.00		197.00		231.00	
ALK. PHOSPH.	40-210 (U/L)	02/04/91	64.00		62.00		75.00	
GLUCOSE	0.6-1.1 (G/L)	02/04/91	1.09		1.05		0.97	
BUN	0.1-0.45 (G/L)	02/04/91	0.16		0.20		0.22	
UREA	()	02/04/91						
CREATININE	5-12 (MG/L)	02/04/91	10.40		9.70		10.50	
URIC ACID	30-65 (MG/L)	02/04/91	70.00	>			68.00	>
TOT BILIRUBIN	0-10 (MG/L)	02/04/91	5.40		5.80		3.90	
DIR BILIRUBIN	0-3 (MG/L)	02/04/91	2.20		2.40		1.50	
TOT. PROTEINS	65-80 (G/L)	02/04/91	74.00				78.00	
ALBUMINE	55-70 (%)	02/04/91					61.10	
TOT. CHOLEST.	1.5-2.5 (G/L)	02/04/91	1.78		2.13			
TRIGLYCERIDES	0.7-1.5 (G/L)	02/04/91	0.80		0.96			
GLOBULINS ALPHA 1	2-4 (%)	02/04/91					2.70	
GLOBULINS ALPHA 2	6-10 (%)	02/04/91					9.40	
GLOBULINS BETA	9-13 (%)	02/04/91					12.20	
GLOBULINS GAMMA	11-15 (%)	02/04/91					14.60	
TSH	0.1-4 (MU/L)	02/04/91	1.80					
T4	7.3-20.1 (PG/ML)	02/04/91	11.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 197 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 7	
			27/02/92		17/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	16.60		16.80	
HT	37-54 (%)	01/06/91	50.00		49.50	
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.40		5.44	
WBC	4-10 (10¬3/MM3)	01/06/91	9.80		11.00	>
WBC: N	40-70 (%)	01/06/91	62.10		65.00	
WBC: L	19-48 (%)	01/06/91	33.90		26.40	
WBC: E	0-7 (%)	01/06/91	0.70		0.62	
WBC: M	3.4-9 (%)	01/06/91	4.00		7.53	
WBC: B	0-1.5 (%)	01/06/91	0.20		0.43	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	223.00		214.00	
NA+	135-145 (MMOL/L)	01/06/91	140.00		143.00	
K+	3.5-5 (MMOL/L)	01/06/91			4.49	
CL-	98-108 (MMOL/L)	01/06/91	98.00		98.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	8.99		9.00	
PO4--	2.1-4 (MG/DL)	01/06/91	2.58		2.18	
SGOT	11-33 (U/L)	01/06/91	19.00		20.00	
SGPT	11-39 (U/L)	01/06/91	22.00		23.00	
GAMMA GT	15-85 (U/L)	01/06/91	28.00		27.00	
LDH	200-450 (U/L)	01/06/91	325.00		324.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	122.00		141.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.54	<	0.78	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.29		0.30	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.96		1.08	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.40		4.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.67		0.41	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.08		0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	6.80		7.20	
ALBUMINE	52-68 (%)	01/06/91	59.80		57.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	239.00		258.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	145.00		180.00	>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.80		3.10	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	7.60		9.50	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.90	>	13.80	
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.90		16.40	
TSH	1-5 (UU/ML)	01/06/91				
T4	4.5-13 (UG/DL)	01/06/91	8.90			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 200 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/04/92		18/05/92		08/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	10/04/92	15.10		14.90		15.40	
HT	37-54 (%)	10/04/92	45.10		43.40		45.30	
RBC	4-6.2 (10-6/MM3)	10/04/92	4.92		4.81		4.98	
WBC	4-10 (10-3/MM3)	10/04/92	4.65		5.37		4.74	
WBC: N	40-70 (%)	10/04/92	48.20		49.10		48.30	
WBC: L	19-48 (%)	10/04/92	34.00		34.70		34.20	
WBC: E	0-7 (%)	10/04/92	5.50		6.32		6.04	
WBC: M	3.4-9 (%)	10/04/92	11.60	>	9.07	>	10.07	>
WBC: B	0-1.5 (%)	10/04/92	0.59		0.86		0.86	
PLATELETS	150-350 (10-3/MM3)	10/04/92	276.00		316.00		318.00	
NA+	135-145 (MMOL/L)	10/04/92	143.00		140.00		139.00	
K+	3.5-5 (MMOL/L)	10/04/92	4.45		7.19	>>	4.52	
CL-	98-108 (MMOL/L)	10/04/92	103.00		98.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/04/92	10.10		9.51		10.10	
PO4--	2.1-4 (MG/DL)	10/04/92	2.67		3.29		2.24	
SGOT	11-33 (U/L)	10/04/92	21.00		21.00		28.00	
SGPT	11-39 (U/L)	10/04/92	25.00		31.00		42.00	>
GAMMA GT	15-85 (U/L)	10/04/92	44.00		29.00		60.00	
LDH	200-450 (U/L)	10/04/92	336.00		536.00	>	367.00	
ALK. PHOSPH.	34-154 (U/L)	10/04/92	92.00		86.00		113.00	
GLUCOSE	0.6-1 (G/L)	10/04/92	0.69		0.84		0.68	
BUN	()	10/04/92						
UREA	0.18-0.43 (G/L)	10/04/92	0.34		0.26		0.36	
CREATININE	0.7-1.3 (MG/DL)	10/04/92	0.97		1.01		0.99	
URIC ACID	3.4-7.3 (MG/DL)	10/04/92	4.60		3.90		4.20	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	10/04/92	0.72		0.69		0.62	
DIR BILIRUBIN	0-0.36 (MG/DL)	10/04/92	0.15				0.10	
TOT. PROTEINS	6.7-7.9 (G/DL)	10/04/92	7.70		7.70		7.50	
ALBUMINE	3.8-4.8 (G/DL)	10/04/92	4.70				4.40	
	52-68 (%)	10/05/92			58.50			
TOT. CHOLEST.	155-280 (MG/DL)	10/04/92	272.00		257.00		259.00	
TRIGLYCERIDES	62-162 (MG/DL)	10/04/92	74.00		121.00		119.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	10/04/92	2.50		2.00	<	4.00	
GLOBULINS ALPHA 2	6.2-11 (%)	10/04/92	8.80		12.30	>	11.30	>
GLOBULINS BETA	9.5-14 (%)	10/04/92	12.60		12.40		15.60	>
GLOBULINS GAMMA	12-21 (%)	10/04/92	14.90		14.90		10.10	<
TSH	1-5 (UU/ML)	10/04/92	1.05					
T4	4.5-13 (UG/DL)	10/04/92	62.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 203 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 7	
			10/01/92		28/01/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/06/91	15.60		15.90	
HT	37-54 (%)	01/06/91	46.50		47.10	
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.10		5.24	
WBC	4-10 (10¬3/MM3)	01/06/91	10.50	>	9.27	
WBC: N	40-70 (%)	01/06/91	63.00		59.60	
WBC: L	19-48 (%)	01/06/91	30.00		30.00	
WBC: E	0-7 (%)	01/06/91	3.00		3.05	
WBC: M	3.4-9 (%)	01/06/91	5.00		6.73	
WBC: B	0-1.5 (%)	01/06/91	0.00		0.62	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	352.00	>	315.00	
NA+	135-145 (MMOL/L)	01/06/91	142.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	6.06	>>	4.08	
CL-	98-108 (MMOL/L)	01/06/91	102.00		100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.68		9.33	
PO4--	2.1-4 (MG/DL)	01/06/91	4.04	>	3.33	
SGOT	11-33 (U/L)	01/06/91	38.00	>	39.00	>
SGPT	11-39 (U/L)	01/06/91	50.00	>	53.00	>
GAMMA GT	5-55 (U/L)	01/06/91	40.00		36.00	
LDH	200-450 (U/L)	01/06/91	357.00		333.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	70.00		78.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.87		0.89	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.20		0.25	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.95		0.95	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.20		5.80	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.52		0.40	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.06		0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.50		7.30	
ALBUMINE	52-68 (%)	01/06/91	58.60		59.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	273.00		228.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	281.00	>>	155.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.60		3.30	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.00		10.20	
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.80		12.50	
GLOBULINS GAMMA	12-21 (%)	01/06/91	13.00		14.50	
TSH	1-5 (UU/ML)	01/06/91	1.24			
T4	4.5-13 (UG/DL)	01/06/91	8.50			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN9350085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 204 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/01/92		06/02/92		28/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/06/91	15.10		13.90		13.40	
HT	37-54 (%)	01/06/91	45.90		40.90		39.90	
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.03		4.53		4.32	
WBC	4-10 (10¬3/MM3)	01/06/91	8.83		7.75		9.00	
WBC: N	40-70 (%)	01/06/91	62.90		59.60		44.90	
WBC: L	19-48 (%)	01/06/91	26.20		29.50		49.20	>
WBC: E	0-7 (%)	01/06/91	2.71		4.13		0.70	
WBC: M	3.4-9 (%)	01/06/91	7.77		6.60		5.90	
WBC: B	0-1.5 (%)	01/06/91	0.41		0.21		0.20	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	385.00	>	469.00	>>	459.00	>>
NA+	135-145 (MMOL/L)	01/06/91	141.00		143.00		143.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.19		4.75		3.85	
CL-	98-108 (MMOL/L)	01/06/91	98.00		101.00		100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.64		9.90		9.39	
PO4--	2.1-4 (MG/DL)	01/06/91	2.91		3.54		3.72	
SGOT	11-33 (U/L)	01/06/91	27.00		24.00		35.00	>
SGPT	11-39 (U/L)	01/06/91	33.00		26.00		36.00	
GAMMA GT	15-85 (U/L)	01/06/91	40.00		40.00		52.00	
LDH	200-450 (U/L)	01/06/91	367.00		359.00		338.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	127.00		111.00		121.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.91		0.53	<	0.81	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.28		0.34		0.26	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.94		1.14		0.92	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.40		5.40		3.70	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.70		0.65		0.56	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.15		0.14		0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.90		7.20		7.30	
ALBUMINE	52-68 (%)	01/06/91	55.50		52.60		57.10	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	227.00		210.00		202.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	78.00		93.00		75.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.20	<	2.90		2.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.70		10.50		8.10	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.00		11.70		13.30	
GLOBULINS GAMMA	12-21 (%)	01/06/91	19.60		22.30	>	18.70	
TSH	1-5 (UU/ML)	01/06/91	7.90					
T4	4.5-13 (UG/DL)	01/06/91	0.52					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 207 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			27/01/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	11-16 (G/DL)	01/06/91	12.90	
HT	37-54 (%)	01/06/91	39.40	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.43	
WBC	4-10 (10¬3/MM3)	01/06/91	4.76	
WBC: N	40-70 (%)	01/06/91		
WBC: L	19-48 (%)	01/06/91		
WBC: E	0-7 (%)	01/06/91		
WBC: M	3.4-9 (%)	01/06/91		
WBC: B	0-1.5 (%)	01/06/91		
PLATELETS	150-350 (10-3/MM3)	01/06/91	310.00	
NA+	135-145 (MMOL/L)	01/06/91	144.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.16	
CL-	98-108 (MMOL/L)	01/06/91	106.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.67	
PO4--	2.1-4 (MG/DL)	01/06/91	3.26	
SGOT	11-33 (U/L)	01/06/91	15.00	
SGPT	11-39 (U/L)	01/06/91	13.00	
GAMMA GT	5-55 (U/L)	01/06/91		
LDH	200-450 (U/L)	01/06/91		
ALK. PHOSPH.	34-154 (U/L)	01/06/91		
GLUCOSE	0.6-1 (G/L)	01/06/91	0.84	
BUN	()	01/06/91		
UREA	0.18-0.43 (G/L)	01/06/91	0.53	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.15	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.00	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.40	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91		
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	6.60	<
ALBUMINE	52-68 (%)	01/06/91	49.00	<
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	253.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	303.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.30	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.20	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.90	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	16.90	
TSH	1-5 (UU/ML)	01/06/91	0.50	
T4	4.5-13 (UG/DL)	01/06/91	8.60	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 208 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/02/92		06/03/92		30/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	15.30		14.50		15.10	
HT	37-54 (%)	01/06/91	43.90		41.40		43.80	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.51		4.29		4.53	
WBC	4-10 (10-3/MM3)	01/06/91	6.39		5.69		5.88	
WBC: N	40-70 (%)	01/06/91	64.00		40.50			
WBC: L	19-48 (%)	01/06/91	26.00		44.10			
WBC: E	0-7 (%)	01/06/91	2.00		3.08			
WBC: M	3.4-9 (%)	01/06/91	8.00		11.90	>>		
WBC: B	0-1.5 (%)	01/06/91	0.00		0.48			
PLATELETS	150-350 (10-3/MM3)	01/06/91	218.00		205.00		191.00	
NA+	135-145 (MMOL/L)	01/06/91			139.00			
K+	3.5-5 (MMOL/L)	01/06/91			3.86			
CL-	98-108 (MMOL/L)	01/06/91			98.00			
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.23		9.33		9.59	
PO4--	2.1-4 (MG/DL)	01/06/91	3.46		3.67		4.27	>
SGOT	11-33 (U/L)	01/06/91	37.00	>	40.00	>	45.00	>
SGPT	11-39 (U/L)	01/06/91	45.00	>	55.00	>	67.00	>
GAMMA GT	15-85 (U/L)	01/06/91	56.00		50.00		61.00	
LDH	200-450 (U/L)	01/06/91	377.00		318.00		367.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	72.00		65.00		67.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.71		0.85			
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.38		0.55	>	0.46	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.15		1.11		1.09	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	5.70		4.00		4.70	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.79		0.84		1.24	>
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.20		0.18		0.23	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.30		7.00		7.30	
ALBUMINE	52-68 (%)	01/06/91	60.10		61.80		51.40	<
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	244.00		240.00		263.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	78.00		74.00		80.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.00	<	2.20	<	2.30	<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.00		8.00		12.40	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.50		12.40		15.80	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.30		15.60		18.00	
TSH	1-5 (UU/ML)	01/06/91	6.20					
T4	4.5-13 (UG/DL)	01/06/91	1.61					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 0550085
Centre: 9 Patient: 210 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/02/92		11/03/92		01/04/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/06/91	12.80		13.10		12.70	
HT	37-54 (%)	01/06/91	36.70	<	37.90		37.80	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.21		4.35		4.34	
WBC	4-10 (10¬3/MM3)	01/06/91	7.32		7.61		7.41	
WBC: N	40-70 (%)	01/06/91	57.40		50.50		50.00	
WBC: L	19-48 (%)	01/06/91	28.70		37.30		36.70	
WBC: E	0-7 (%)	01/06/91	2.25		2.04		2.42	
WBC: M	3.4-9 (%)	01/06/91	9.49	>	9.68	>	10.20	>
WBC: B	0-1.5 (%)	01/06/91	2.20	>>	0.53		0.73	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	283.00		280.00		296.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		145.00		144.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.51		4.48		4.27	
CL-	98-108 (MMOL/L)	01/06/91	100.00		100.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.56		9.79		9.39	
PO4--	2.1-4 (MG/DL)	01/06/91	3.49		3.51		3.67	
SGOT	11-33 (U/L)	01/06/91	14.00		16.00		16.00	
SGPT	11-39 (U/L)	01/06/91	12.00		12.00		13.00	
GAMMA GT	5-55 (U/L)	01/06/91	14.00		13.00		13.00	
LDH	200-450 (U/L)	01/06/91	279.00		329.00		305.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	92.00		103.00		106.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	1.11	>	1.06	>	0.94	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.31		0.39		0.31	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.90		1.05		1.13	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.50		4.40		4.40	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.39		0.37		0.22	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.07		0.05		0.05	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.40		7.60		7.40	
ALBUMINE	52-68 (%)	01/06/91			57.80		63.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	241.00		250.00		250.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	158.00		109.00		139.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91			2.70		2.60	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91			8.60		7.50	
GLOBULINS BETA	9.5-14 (%)	01/06/91			14.40	>	12.50	
GLOBULINS GAMMA	12-21 (%)	01/06/91			16.60		14.20	
TSH	1-5 (UU/ML)	01/06/91	0.87					
T4	4.5-13 (UG/DL)	01/06/91	2.10					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 9 Patient: 211 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			11/02/92		03/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	14.40		13.80	
HT	37-54 (%)	01/06/91	42.00		39.60	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.18		4.09	
WBC	4-10 (10¬3/MM3)	01/06/91	6.70		6.67	
WBC: N	40-70 (%)	01/06/91			67.60	
WBC: L	19-48 (%)	01/06/91	33.70		22.20	
WBC: E	0-7 (%)	01/06/91			1.09	
WBC: M	3.4-9 (%)	01/06/91	5.10		8.90	
WBC: B	0-1.5 (%)	01/06/91			0.18	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	262.00		237.00	
NA+	135-145 (MMOL/L)	01/06/91	140.00		137.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.07		4.53	
CL-	98-108 (MMOL/L)	01/06/91	100.00		98.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.60		9.71	
PO4--	2.1-4 (MG/DL)	01/06/91	3.70		3.48	
SGOT	11-33 (U/L)	01/06/91	13.00		12.00	
SGPT	11-39 (U/L)	01/06/91	11.00		9.00	<
GAMMA GT	5-55 (U/L)	01/06/91	13.00		11.00	
LDH	200-450 (U/L)	01/06/91	279.00		282.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	58.00		57.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.82		0.79	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.30		0.23	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.96		0.92	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	2.65	<	2.90	<
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.37		0.76	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.09		0.15	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91			7.20	
ALBUMINE	52-68 (%)	01/06/91	54.10		59.90	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	219.00		187.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	110.00		68.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.30		2.70	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.10	>	9.50	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.30	>	12.20	
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.40		15.70	
TSH	1-5 (UU/ML)	01/06/91	0.61			
T4	4.5-13 (UG/DL)	01/06/91	7.80			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9 Patient: 237 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 14	
			15/04/92		06/05/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	13-18 (G/DL)	01/06/91	16.00		15.60	
HT	37-54 (%)	01/06/91	46.40		46.70	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.91		4.90	
WBC	4-10 (10-3/MM3)	01/06/91	6.88		7.76	
WBC: N	40-70 (%)	01/06/91	51.30		60.00	
WBC: L	19-48 (%)	01/06/91	37.50		30.20	
WBC: E	0-7 (%)	01/06/91	1.41		1.27	
WBC: M	3.4-9 (%)	01/06/91	9.08	>	7.89	
WBC: B	0-1.5 (%)	01/06/91	0.67		0.59	
PLATELETS	150-350 (10-3/MM3)	01/06/91	233.00		256.00	
NA+	135-145 (MMOL/L)	01/06/91	144.00		145.00	
K+	3.5-5 (MMOL/L)	01/06/91	5.03	>	5.04	>
CL-	98-108 (MMOL/L)	01/06/91	102.00		106.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.91		10.30	
PO4--	2.1-4 (MG/DL)	01/06/91	2.67		3.13	
SGOT	11-33 (U/L)	01/06/91	23.00		19.00	
SGPT	11-39 (U/L)	01/06/91	36.00		24.00	
GAMMA GT	15-85 (U/L)	01/06/91	20.00		20.00	
LDH	200-450 (U/L)	01/06/91	261.00		259.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	93.00		103.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.86		1.03	>
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.41		0.49	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.12		1.18	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.60		5.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.55		0.22	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.09		0.05	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.50		7.30	
ALBUMINE	52-68 (%)	01/06/91	54.70		56.60	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	267.00		206.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	77.00		123.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.80		2.40	<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.10		9.20	
GLOBULINS BETA	9.5-14 (%)	01/06/91	15.30	>	14.60	>
GLOBULINS GAMMA	12-21 (%)	01/06/91			17.20	
TSH	1-5 (UU/ML)	01/06/91	0.94			
T4	4.5-13 (UG/DL)	01/06/91	7.70			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 240 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			23/04/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11-16 (G/DL)	01/06/91	14.60	
HT	37-54 (%)	01/06/91	43.30	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.64	
WBC	4-10 (10-3/MM3)	01/06/91	5.81	
WBC: N	40-70 (%)	01/06/91	63.40	
WBC: L	19-48 (%)	01/06/91	27.30	
WBC: E	0-7 (%)	01/06/91	0.78	
WBC: M	3.4-9 (%)	01/06/91	8.23	
WBC: B	0-1.5 (%)	01/06/91	0.23	
PLATELETS	150-350 (10-3/MM3)	01/06/91	345.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.47	
CL-	98-108 (MMOL/L)	01/06/91	103.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.60	>
PO4--	2.1-4 (MG/DL)	01/06/91	1.86	<
SGOT	11-33 (U/L)	01/06/91	21.00	
SGPT	11-39 (U/L)	01/06/91	17.00	
GAMMA GT	5-55 (U/L)	01/06/91	29.00	
LDH	200-450 (U/L)	01/06/91	335.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	83.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.68	
BUN	()	01/06/91		
UREA	0.18-0.43 (G/L)	01/06/91	0.31	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.94	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.90	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.47	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	8.60	>
ALBUMINE	52-68 (%)	01/06/91	57.80	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	264.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	66.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.80	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.90	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.20	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.20	
TSH	1-5 (UU/ML)	01/06/91	1.26	
T4	4.5-13 (UG/DL)	01/06/91	13.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centro: 9 Patient: 242 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/04/92		27/05/92		17/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	01/06/91	15.20		14.70		13.80	
HT	37-54 (%)	01/06/91	45.30		44.20		40.70	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.80		4.71		4.41	
WBC	4-10 (10¬3/MM3)	01/06/91	9.04		4.53		4.21	
WBC: N	40-70 (%)	01/06/91	78.00	>	57.40		52.10	
WBC: L	19-48 (%)	01/06/91	13.00	<<	32.70		36.80	
WBC: E	0-7 (%)	01/06/91	0.00		0.79		1.10	
WBC: M	3.4-9 (%)	01/06/91	8.00		8.79		9.01	>
WBC: B	0-1.5 (%)	01/06/91	1.00		0.27		0.99	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	380.00	>	336.00		328.00	
NA+	135-145 (MMOL/L)	01/06/91	140.00		139.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.39		3.91		3.94	
CL-	98-108 (MMOL/L)	01/06/91	94.00	<	95.00	<	98.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.30		9.93		9.69	
PO4--	2.1-4 (MG/DL)	01/06/91	3.05		2.39		2.66	
SGOT	11-33 (U/L)	01/06/91	23.00		18.00		21.00	
SGPT	11-39 (U/L)	01/06/91	32.00		11.00		13.00	
GAMMA GT	15-85 (U/L)	01/06/91	60.00		30.00		24.00	
LDH	200-450 (U/L)	01/06/91	356.00		305.00		301.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	115.00		92.00		86.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	1.05	>	0.97		0.92	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.41		0.45	>	0.45	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.98		0.89		0.89	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.80		4.00		4.70	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.43		0.37		0.39	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.07		0.06		0.07	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.60		7.40		7.10	
ALBUMINE	52-68 (%)	01/06/91	53.50		53.80		52.60	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	290.00	>	245.00		229.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	144.00		160.00		75.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.10		2.50		2.80	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	13.50	>	11.50	>	11.80	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.70	>	15.00	>	15.40	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.30		17.20		17.40	
TSH	1-5 (UU/ML)	01/06/91	1.64					
T4	4.5-13 (UG/DL)	01/06/91	11.50					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 244 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/05/92		26/06/92		16/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	14.90		15.40		14.90	
HT	37-54 (%)	01/06/91	44.00		46.00		43.80	
RBC	4-6,2 (10¬6/MM3)	01/06/91	5.17		5.40		5.20	
WBC	4-10 (10¬3/MM3)	01/06/91	5.86		5.99		5.43	
WBC: N	40-70 (%)	01/06/91	50.00		43.10		55.60	
WBC: L	19-48 (%)	01/06/91	42.00		48.70	>	35.80	
WBC: E	0-7 (%)	01/06/91	0.00		2.49		1.55	
WBC: M	3,4-9 (%)	01/06/91	6.00		4.75		6.82	
WBC: B	0-1.5 (%)	01/06/91	0.00		1.00		0.21	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	244.00		328.00		350.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		138.00			
K+	3.5-5 (MMOL/L)	01/06/91						
CL-	98-108 (MMOL/L)	01/06/91	100.00		98.00			
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.40		10.40			
PO4--	2.1-4 (MG/DL)	01/06/91	2.87		4.01	>		
SGOT	11-33 (U/L)	01/06/91	24.00		23.00			
SGPT	11-39 (U/L)	01/06/91	41.00	>	29.00			
GAMMA GT	15-85 (U/L)	01/06/91	36.00		35.00			
LDH	200-450 (U/L)	01/06/91	322.00		327.00			
ALK. PHOSPH.	34-154 (U/L)	01/06/91	81.00		81.00			
GLUCOSE	0,6-1 (G/L)	01/06/91	0.57	<	0.82			
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.34		0.35			
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.19		1.24			
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	8.10	>	6.90			
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.44		0.44			
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.06		0.07			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	8.10	>	8.10	>		
ALBUMINE	52-68 (%)	01/06/91	59.10		60.70			
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	246.00		237.00			
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	284.00	>>	182.00	>		
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.70		1.60	<<		
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	9.10		7.60			
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.60		14.90	>		
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.50		15.20			
TSH	1-5 (UU/ML)	01/06/91	0.78					
T4	4.5-13 (UG/DL)	01/06/91	7.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9 Patient: 257 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/07/91		07/08/91		28/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.90		13.30		13.30	
HT	37-54 (%)	01/06/91	40.10		39.90		39.50	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.35		4.37		4.32	
WBC	4-10 (10-3/MM3)	01/06/91	9.65		9.11		8.08	
WBC: N	40-70 (%)	01/06/91	47.00		65.00		55.50	
WBC: L	19-48 (%)	01/06/91	38.10		28.10		34.90	
WBC: E	0-7 (%)	01/06/91			2.54		4.52	
WBC: M	3.4-9 (%)	01/06/91	8.00		4.01		3.58	
WBC: B	0-1.5 (%)	01/06/91			0.41		1.56	>
PLATELETS	150-350 (10-3/MM3)	01/06/91	275.00		288.00		312.00	
NA+	135-145 (MMOL/L)	01/06/91			140.00		143.00	
K+	3.5-5 (MMOL/L)	01/06/91			4.02		3.66	
CL-	98-108 (MMOL/L)	01/06/91			98.00		103.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.80		9.20		9.40	
PO4--	2.1-4 (MG/DL)	01/06/91	3.60		4.20	>	4.00	
SGOT	11-33 (U/L)	01/06/91	15.00		15.00		15.00	
SGPT	11-39 (U/L)	01/06/91	21.00		12.00		15.00	
GAMMA GT	5-55 (U/L)	01/06/91	41.00		38.00		31.00	
LDH	200-450 (U/L)	01/06/91	319.00		282.00		264.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	77.00		76.00		73.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.91		0.87		1.11	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.29					
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.77		0.86		0.84	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91			4.10		5.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.40		2.30	>>	0.20	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.08			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91			7.80		7.80	
ALBUMINE	52-68 (%)	01/06/91						
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91			226.00		258.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91			122.00		100.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91						
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91						
GLOBULINS BETA	9.5-14 (%)	01/06/91						
GLOBULINS GAMMA	12-21 (%)	01/06/91						
TSH	1-5 (UU/ML)	01/06/91	2.07					
T4	4.5-13 (UG/DL)	01/06/91	12.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9 Patient: 258 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			10/07/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	01/06/91	15.50	
HT	37-54 (%)	01/06/91	44.10	
RBC	4-6.2 (10-6/MM3)	01/06/91	5.03	
WBC	4-10 (10-3/MM3)	01/06/91	5.48	
WBC: N	40-70 (%)	01/06/91	56.10	
WBC: L	19-48 (%)	01/06/91	36.10	
WBC: E	0-7 (%)	01/06/91	0.96	
WBC: M	3.4-9 (%)	01/06/91	4.79	
WBC: B	0-1.5 (%)	01/06/91	2.09	>>
PLATELETS	150-350 (10-3/MM3)	01/06/91	211.00	
NA+	135-145 (MMOL/L)	01/06/91		
K+	3.5-5 (MMOL/L)	01/06/91		
CL-	98-108 (MMOL/L)	01/06/91		
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.20	
PO4--	2.1-4 (MG/DL)	01/06/91	2.70	
SGOT	11-33 (U/L)	01/06/91	20.00	
SGPT	11-39 (U/L)	01/06/91	18.00	
GAMMA GT	15-85 (U/L)	01/06/91	16.00	
LDH	200-450 (U/L)	01/06/91	306.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	84.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.88	
BUN	()	01/06/91		
UREA	0.18-0.43 (G/L)	01/06/91	0.39	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.88	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91		
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.76	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91		
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91		
ALBUMINE	52-68 (%)	01/06/91		
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91		
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91		
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91		
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91		
GLOBULINS BETA	9.5-14 (%)	01/06/91		
GLOBULINS GAMMA	12-21 (%)	01/06/91		
TSH	1-5 (UU/ML)	01/06/91	1.29	
T4	4.5-13 (UG/DL)	01/06/91	7.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 262 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/07/91		13/08/91		03/09/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/06/91	16.20		16.70		16.30	
HT	37-54 (%)	01/06/91	45.50		47.60		47.90	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.85		5.11		5.09	
WBC	4-10 (10¬3/MM3)	01/06/91	11.90	>	12.60	>	12.00	>
WBC: N	40-70 (%)	01/06/91	74.40	>	77.00	>	72.70	>
WBC: L	19-48 (%)	01/06/91	19.50		17.00	<	20.20	
WBC: E	0-7 (%)	01/06/91	1.88		1.00		2.30	
WBC: M	3.4-9 (%)	01/06/91	3.58		4.00		4.46	
WBC: B	0-1.5 (%)	01/06/91	0.64		1.00		0.36	
PLATELETS	150-350 (10-3/MM3)	01/06/91	226.00		213.00		211.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		140.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.25		4.17		3.59	
CL-	98-108 (MMOL/L)	01/06/91	107.00		97.00	<	98.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	8.80		9.10		9.10	
PO4--	2.1-4 (MG/DL)	01/06/91	2.90		2.20		2.80	
SGOT	11-33 (U/L)	01/06/91	32.00		33.00		24.00	
SGPT	11-39 (U/L)	01/06/91	37.00		27.00		43.00	>
GAMMA GT	15-85 (U/L)	01/06/91	37.00		33.00		28.00	
LDH	200-450 (U/L)	01/06/91	286.00		388.00		298.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	82.00		102.00		83.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.99		0.94		1.02	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.22		0.15	<	0.18	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.12		1.00		1.15	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.60		6.80		5.90	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.44		0.37		0.50	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.11		0.13	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.79		7.80		7.50	
ALBUMINE	52-68 (%)	01/06/91	59.80		49.90	<	64.30	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	220.00		214.00		230.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	349.00	>>	380.00	>>	384.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	1.50	<<	2.10	<	1.00	<<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.10		6.90		7.30	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.90	>	14.40	>	12.70	
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.70		17.20		14.70	
TSH	1-5 (UU/ML)	01/06/91	0.78					
T4	4.5-13 (UG/DL)	01/06/91	10.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 263 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 14	
			24/07/91		14/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.50		13.40	
HT	37-54 (%)	01/06/91	39.90		39.40	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.23		4.19	
WBC	4-10 (10¬3/MM3)	01/06/91	5.08		5.16	
WBC: N	40-70 (%)	01/06/91	62.00		54.80	
WBC: L	19-48 (%)	01/06/91	19.00		33.80	
WBC: E	0-7 (%)	01/06/91	5.00		4.46	
WBC: M	3.4-9 (%)	01/06/91	12.00	>>	6.46	
WBC: B	0-1.5 (%)	01/06/91			0.51	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	173.00		153.00	
NA+	135-145 (MMOL/L)	01/06/91	139.00		142.00	
K+	3.5-5 (MMOL/L)	01/06/91			4.35	
CL-	98-108 (MMOL/L)	01/06/91	100.00		100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.50		9.70	
PO4--	2.1-4 (MG/DL)	01/06/91	3.50		4.70	>>
SGOT	11-33 (U/L)	01/06/91	19.00		13.00	
SGPT	11-39 (U/L)	01/06/91	14.00		12.00	
GAMMA GT	5-55 (U/L)	01/06/91	14.00		11.00	
LDH	200-450 (U/L)	01/06/91	354.00		305.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	66.00		56.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.89		0.75	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.30			
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.16		0.85	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91			5.50	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.30		0.39	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.07	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.39		7.30	
ALBUMINE	52-68 (%)	01/06/91	62.20			
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	243.00		247.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	79.00		47.00	<
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.70			
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.10			
GLOBULINS BETA	9.5-14 (%)	01/06/91	9.40	<		
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.60			
TSH	1-5 (UU/ML)	01/06/91	0.52			
T4	4.5-13 (UG/DL)	01/06/91	7.20			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 265 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/08/91		12/09/91		03/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	14.10		14.60		15.50	
HT	37-54 (%)	01/06/91	42.00		42.80		45.90	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.42		4.59		4.92	
WBC	4-10 (10¬3/MM3)	01/06/91	6.68		6.05		7.48	
WBC: N	40-70 (%)	01/06/91	60.50		54.50		58.70	
WBC: L	19-48 (%)	01/06/91	31.00		36.70		32.50	
WBC: E	0-7 (%)	01/06/91	0.97		2.11		1.81	
WBC: M	3.4-9 (%)	01/06/91	6.40		6.24		6.42	
WBC: B	0-1.5 (%)	01/06/91	1.16		0.49		0.58	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	311.00		340.00		401.00	>
NA+	135-145 (MMOL/L)	01/06/91	142.00		142.00		137.00	
K+	3.5-5 (MMOL/L)	01/06/91	5.30	>	4.19		4.58	
CL-	98-108 (MMOL/L)	01/06/91	105.00		101.00		95.00	<
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.90		9.70		11.20	>
PO4--	2.1-4 (MG/DL)	01/06/91	2.20		3.10		2.70	
SGOT	11-33 (U/L)	01/06/91	20.00		16.00		23.00	
SGPT	11-39 (U/L)	01/06/91	9.00	<	13.00		6.00	<
GAMMA GT	5-55 (U/L)	01/06/91	10.00		12.00		14.00	
LDH	200-450 (U/L)	01/06/91	510.00	>	254.00		398.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	45.00		41.00		52.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.70		0.65		0.84	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.20		0.14	<	0.33	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.76		0.85		0.83	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.70		3.70		4.90	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.64		0.60		0.48	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.11			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.60		7.60		9.00	>
ALBUMINE	52-68 (%)	01/06/91	60.40		63.60		53.10	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	178.00		167.00		212.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	82.00		73.00		120.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	1.90	<	1.50	<<	1.70	<<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.20		7.70		11.10	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	10.70		10.90		12.80	
GLOBULINS GAMMA	12-21 (%)	01/06/91	16.80		16.40		19.60	
TSH	1-5 (UU/ML)	01/06/91	1.31					
T4	4.5-13 (UG/DL)	01/06/91	6.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9 Patient: 266 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/09/91		08/10/91		28/10/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/06/91	14.40		13.60		15.00	
HT	37-54 (%)	01/06/91	42.90		40.20		43.40	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.32		4.12		4.52	
WBC	4-10 (10-3/MM3)	01/06/91	7.57		7.15		9.63	
WBC: N	40-70 (%)	01/06/91	67.80		61.90		75.00	>
WBC: L	19-48 (%)	01/06/91	26.30		31.50		20.80	
WBC: E	0-7 (%)	01/06/91	0.66		0.68		0.81	
WBC: M	3.4-9 (%)	01/06/91	5.19		5.45		2.75	<
WBC: B	0-1.5 (%)	01/06/91	0.12		0.47		0.66	
PLATELETS	150-350 (10-3/MM3)	01/06/91	382.00	>	419.00	>	359.00	>
NA+	135-145 (MMOL/L)	01/06/91	140.00		139.00		141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.52		4.60		4.46	
CL-	98-108 (MMOL/L)	01/06/91	103.00		103.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.70		9.50		9.70	
PO4--	2.1-4 (MG/DL)	01/06/91	3.20		3.30		3.50	
SGOT	11-33 (U/L)	01/06/91	21.00		20.00		27.00	
SGPT	11-39 (U/L)	01/06/91	27.00		22.00		28.00	
GAMMA GT	5-55 (U/L)	01/06/91	39.00		32.00		29.00	
LDH	200-450 (U/L)	01/06/91	375.00		277.00		341.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	65.00		71.00		81.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.90		0.84		0.90	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.18		0.22		0.18	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.69	<	0.68	<	0.68	<
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.30		3.90		3.80	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.63		0.59		0.67	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.04		0.08			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.70		7.00		8.00	>
ALBUMINE	52-68 (%)	01/06/91	62.60		55.50		57.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	241.00		238.00		247.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	140.00		249.00	>>	225.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.40	<	3.10		3.10	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.70		12.20	>	12.10	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.30		14.30	>	13.10	
GLOBULINS GAMMA	12-21 (%)	01/06/91	11.00	<	14.80		14.20	
TSH	1-5 (UU/ML)	01/06/91	2.98					
T4	4.5-13 (UG/DL)	01/06/91	8.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 269 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/09/91		15/10/91		05/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	16.40		16.30		16.30	
HT	37-54 (%)	01/06/91	46.60		46.50		45.60	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.73		4.79		4.70	
WBC	4-10 (10¬3/MM3)	01/06/91	8.27		7.64		8.82	
WBC: N	40-70 (%)	01/06/91	62.40		46.00		52.00	
WBC: L	19-48 (%)	01/06/91	28.80		41.80		36.20	
WBC: E	0-7 (%)	01/06/91	1.45		3.33		2.94	
WBC: M	3.4-9 (%)	01/06/91	6.76		8.03		8.49	
WBC: B	0-1.5 (%)	01/06/91	0.64		0.85		0.45	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	62.40	<<	289.00		282.00	
NA+	135-145 (MMOL/L)	01/06/91	137.00		141.00		142.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.95		4.90		4.70	
CL-	98-108 (MMOL/L)	01/06/91	104.00		104.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.60		10.10		9.30	
PO4--	2.1-4 (MG/DL)	01/06/91	3.20		4.10	>	3.70	
SGOT	11-33 (U/L)	01/06/91	32.00		24.00		28.00	
SGPT	11-39 (U/L)	01/06/91	31.00		27.00		40.00	>
GAMMA GT	15-85 (U/L)	01/06/91	97.00	>	79.00		102.00	>
LDH	200-450 (U/L)	01/06/91	699.00	>	320.00		357.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	65.00		68.00		75.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.85		0.76		0.81	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.25		0.23		0.21	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.87		0.89		0.99	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	5.70		5.60		5.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.76		0.32		0.67	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.15		0.14	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.70		7.10		7.30	
ALBUMINE	52-68 (%)	01/06/91	55.00		57.60		53.70	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	315.00	>	330.00	>	364.00	>
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	404.00	>>	450.00	>>	588.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.70		2.70		2.50	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.30	>	12.00	>	10.60	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.60	>	12.30		18.10	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	16.40		15.50		14.90	
TSH	1-5 (UU/ML)	01/06/91	1.25					
T4	4.5-13 (UG/DL)	01/06/91	8.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 271 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			22/10/91		19/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	12.90		12.50	
HT	37-54 (%)	01/06/91	39.60		37.10	
RBC	4-6,2 (10¬6/MM3)	01/06/91	4.23		3.97	<
WBC	4-10 (10¬3/MM3)	01/06/91	5.81		6.75	
WBC: N	40-70 (%)	01/06/91	55.20		64.90	
WBC: L	19-48 (%)	01/06/91	35.20		26.90	
WBC: E	0-7 (%)	01/06/91	2.95		1.47	
WBC: M	3.4-9 (%)	01/06/91	5.91		6.19	
WBC: B	0-1.5 (%)	01/06/91	0.77		0.42	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	327.00		413.00	>
NA+	135-145 (MMOL/L)	01/06/91	138.00		138.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.81		4.32	
CL-	98-108 (MMOL/L)	01/06/91	94.00	<	96.00	<
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.40		10.40	
PO4--	2.1-4 (MG/DL)	01/06/91	3.30		3.70	
SGOT	11-33 (U/L)	01/06/91	25.00		26.00	
SGPT	11-39 (U/L)	01/06/91	26.00		14.00	
GAMMA GT	5-55 (U/L)	01/06/91	36.00		37.00	
LDH	200-450 (U/L)	01/06/91	344.00		363.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	88.00		100.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.83		0.71	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.38		0.58	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.15		1.27	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	5.60		6.00	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.40		0.32	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.12		0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	8.00	>	8.10	>
ALBUMINE	52-68 (%)	01/06/91	54.50		46.00	<
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	344.00	>	284.00	>
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	434.00	>>	309.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.80		2.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	13.10	>	11.40	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	12.50		12.60	
GLOBULINS GAMMA	12-21 (%)	01/06/91	17.10		16.40	
TSH	1-5 (UU/ML)	01/06/91	9.30			
T4	4.5-13 (UG/DL)	01/06/91	1.62			

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 274 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 7	
			23/10/91		06/11/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/06/91	14.40		32.30	>
HT	37-54 (%)	01/06/91	41.70		42.20	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.46		4.51	
WBC	4-10 (10¬3/MM3)	01/06/91	5.10		6.24	
WBC: N	40-70 (%)	01/06/91	54.50		55.40	
WBC: L	19-48 (%)	01/06/91	36.00		36.10	
WBC: E	0-7 (%)	01/06/91	3.73		2.24	
WBC: M	3.4-9 (%)	01/06/91	5.00		5.18	
WBC: B	0-1.5 (%)	01/06/91	0.87		1.16	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	242.00		254.00	
NA+	135-145 (MMOL/L)	01/06/91	139.00		144.00	
K+	3.5-5 (MMOL/L)	01/06/91	3.99		3.85	
CL-	98-108 (MMOL/L)	01/06/91	99.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.80		9.20	
PO4--	2.1-4 (MG/DL)	01/06/91	3.20		3.30	
SGOT	11-33 (U/L)	01/06/91	18.00		17.00	
SGPT	11-39 (U/L)	01/06/91	31.00		33.00	
GAMMA GT	5-55 (U/L)	01/06/91	36.00		36.00	
LDH	200-450 (U/L)	01/06/91	308.00		285.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	73.00		70.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	1.06	>	1.08	>
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.32		0.44	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.72		0.74	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	2.50	<	2.70	<
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.50		0.43	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.10		0.08	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.30		7.20	
ALBUMINE	52-68 (%)	01/06/91				
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	312.00	>	302.00	>
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	80.00		69.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91				
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91				
GLOBULINS BETA	9.5-14 (%)	01/06/91				
GLOBULINS GAMMA	12-21 (%)	01/06/91				
TSH	1-5 (UU/ML)	01/06/91				
T4	4.5-13 (UG/DL)	01/06/91				

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 274/A Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/04/92		02/06/92		24/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.50		13.90		13.90	
HT	37-54 (%)	01/06/91	40.20		41.20		41.60	
RBC	4-6.2 (10~6/MM3)	01/06/91	4.03		4.15		4.20	
WBC	4-10 (10~3/MM3)	01/06/91	9.33		8.59		10.10	>
WBC: N	40-70 (%)	01/06/91	58.20		58.10		61.60	
WBC: L	19-48 (%)	01/06/91	28.40		27.40		23.40	
WBC: E	0-7 (%)	01/06/91	1.30		1.74		1.51	
WBC: M	3,4-9 (%)	01/06/91	10.80	>	12.70	>>	12.80	>>
WBC: B	0-1.5 (%)	01/06/91	1.40		0.13		0.75	
PLATELETS	150-350 (10~3/MM3)	01/06/91	329.00		312.00		395.00	>
NA+	135-145 (MMOL/L)	01/06/91	140.00		141.00		139.00	
K+	3,5-5 (MMOL/L)	01/06/91	3.60		3.46	<	3.26	<
CL-	98-108 (MMOL/L)	01/06/91	99.00		95.00	<	96.00	<
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.60		9.50		9.13	
PO4--	2.1-4 (MG/DL)	01/06/91	3.83		2.64		2.71	
SGOT	11-33 (U/L)	01/06/91	21.00		22.00		20.00	
SGPT	11-39 (U/L)	01/06/91	11.00		11.00		10.00	<
GAMMA GT	5-55 (U/L)	01/06/91	9.00		9.00		8.00	
LDH	200-450 (U/L)	01/06/91	364.00		401.00		375.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	68.00		65.00		71.00	
GLUCOSE	0,6-1 (G/L)	01/06/91	0.77		0.88		0.86	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.24		0.25		0.30	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.87		0.83		0.85	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.50		4.10		5.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.40		0.28		0.29	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.08		0.07		0.06	
TOT. PROTEINS	6,7-7.9 (G/DL)	01/06/91	6.90		6.60	<	6.60	<
ALBUMINE	52-68 (%)	01/06/91	59.60		63.30		58.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	255.00		245.00		250.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	67.00		66.00		81.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.90		3.00		3.00	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.30	>	9.20		10.20	
GLOBULINS BETA	9.5-14 (%)	01/06/91	12.50		11.40		12.60	
GLOBULINS GAMMA	12-21 (%)	01/06/91	13.70		13.10		16.00	
TSH	1-5 (UU/ML)	01/06/91	1.57					
T4	4.5-13 (UG/DL)	01/06/91	8.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 275 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			31/10/91		26/11/91		18/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.30		12.80		12.60	
HT	37-54 (%)	01/06/91	38.30		38.40		36.30	<
RBC	4-6.2 (10-6/MM3)	01/06/91	4.48		4.44		4.21	
WBC	4-10 (10-3/MM3)	01/06/91	5.62		5.65		5.46	
WBC: N	40-70 (%)	01/06/91	56.80		54.10		63.40	
WBC: L	19-48 (%)	01/06/91	31.40		28.70		22.50	
WBC: E	0-7 (%)	01/06/91	5.09		8.03	>	5.15	
WBC: M	3.4-9 (%)	01/06/91	5.27		8.82		8.44	
WBC: B	0-1.5 (%)	01/06/91	1.47		0.44		0.52	
PLATELETS	150-350 (10-3/MM3)	01/06/91	273.00		328.00		298.00	
NA+	135-145 (MMOL/L)	01/06/91	142.00		145.00		142.00	
K+	3.5-5 (MMOL/L)	01/06/91	3.72		3.62		4.41	
CL-	98-108 (MMOL/L)	01/06/91	102.00		101.00		100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.90		10.00		9.80	
PO4--	2.1-4 (MG/DL)	01/06/91	3.20		3.40		3.20	
SGOT	11-33 (U/L)	01/06/91	35.00	>	17.00		24.00	
SGPT	11-39 (U/L)	01/06/91	24.00		14.00		22.00	
GAMMA GT	5-55 (U/L)	01/06/91	20.00		16.00		18.00	
LDH	200-450 (U/L)	01/06/91	315.00		269.00		289.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	158.00	>	152.00		151.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.79		0.89		0.83	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.45	>	0.50	>	0.44	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.84		0.86		0.73	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	1.80	<	2.60	<	2.30	<
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.47		0.43		0.51	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.07		0.09		0.08	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.10		7.00		7.10	
ALBUMINE	52-68 (%)	01/06/91	56.80		58.90		59.00	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	295.00	>	242.00		254.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	79.00		122.00		146.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.70		2.10	<	2.70	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.60	>	11.90	>	12.10	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	15.80	>	14.30	>	15.60	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	13.10		11.70	<	12.40	
TSH	1-5 (UU/ML)	01/06/91						
T4	4.5-13 (UG/DL)	01/06/91						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

1162

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9/A Patient: 234 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/05/92		11/06/92		02/07/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/92	13.10		14.50		14.20	
HT	37-47 (%)	01/01/92	37.60		40.50		42.30	
RBC	4-5.8 (10-6/MM3)	01/01/92	3.70	<	4.13		4.20	
WBC	4000-10000 (/MM3)	01/01/92	7900.00		8400.00		8900.00	
WBC: N	40-70 (%)	01/01/92	39.10	<	35.90	<	46.20	
WBC: L	20-50 (%)	01/01/92	50.50	>	50.90	>	46.40	
WBC: E	0-8 (%)	01/01/92	5.20		6.00		4.50	
WBC: M	0-13 (%)	01/01/92	4.70		6.70		2.00	
WBC: B	0-3 (%)	01/01/92	0.60		0.50		1.00	
PLATELETS	150-400 (10-3/MM3)	01/01/92			256.00		287.00	
NA+	136-147 (MMOL/L)	01/01/92	139.00		138.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.30				4.50	
CL-	95-110 (MMOL/L)	01/01/92	105.00		99.00		102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.58		9.94		10.15	
PO4--	2.4-4.8 (MG/DL)	01/01/92			4.10		4.00	
SGOT	5-40 (U/L)	01/01/92	15.00		27.00		22.00	
SGPT	5-40 (U/L)	01/01/92	16.00		30.00		18.00	
GAMMA GT	0-40 (U/L)	01/01/92	11.00		23.00		24.00	
LDH	150-460 (U/L)	01/01/92			339.00		282.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92			105.00		122.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	76.00		79.00		71.00	
BUN	()	01/01/92						
UREA	8-48 (MG/DL)	01/01/92	18.00		27.00		25.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	1.00		0.96		1.00	
URIC ACID	2-6.5 (MG/DL)	01/01/92						
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.53		0.43		0.60	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.15		0.09		0.17	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	6.62		7.39		7.19	
ALBUMINE	55-72 (%)	01/01/92	65.70		68.20		69.00	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	177.00		179.00		171.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	58.00		65.00		46.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	4.10		2.80		2.40	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.60		7.50		6.80	
GLOBULINS BETA	9-14 (%)	01/01/92	10.10		8.70	<	7.20	<
GLOBULINS GAMMA	10-20 (%)	01/01/92	12.50		12.80		14.60	
TSH	0.1-4 (UU/ML)	01/01/92	1.49					
T4	4.8-12.8 (UG/DL)	01/01/92	8.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 235 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			22/05/92		16/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/01/92	16.10		15.20	
HT	42-53 (%)	01/01/92	46.40		43.80	
RBC	4.5-6.2 (10-6/MM3)	01/01/92	5.32		5.08	
WBC	4000-10000 (/MM3)	01/01/92	6600.00		8000.00	
WBC: N	40-70 (%)	01/01/92	63.10		66.20	
WBC: L	20-50 (%)	01/01/92	27.50		26.60	
WBC: E	0-8 (%)	01/01/92	3.80		4.00	
WBC: M	0-13 (%)	01/01/92	5.00		2.80	
WBC: B	0-3 (%)	01/01/92	0.50		0.40	
PLATELETS	150-400 (10-3/MM3)	01/01/92	264.00		317.00	
NA+	136-147 (MMOL/L)	01/01/92	143.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.00		4.20	
CL-	95-110 (MMOL/L)	01/01/92	100.00		104.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.61		8.85	
PO4--	2-4.5 (MG/DL)	01/01/92	3.50		3.50	
SGOT	5-40 (U/L)	01/01/92	14.00		25.00	
SGPT	5-40 (U/L)	01/01/92	17.00		25.00	
GAMMA GT	0-40 (U/L)	01/01/92	14.00		18.00	
LDH	150-460 (U/L)	01/01/92			281.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	134.00		182.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	117.00		118.00	
BUN	()	01/01/92				
UREA	8-50 (MG/DL)	01/01/92	28.00		39.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	1.21		1.07	
URIC ACID	2-7.5 (MG/DL)	01/01/92	6.39			
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.64		0.43	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.17		0.12	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	6.70		6.74	
ALBUMINE	55-72 (%)	01/01/92	66.80		66.20	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	160.00		180.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	88.00		59.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.90		2.80	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	9.10		8.50	
GLOBULINS BETA	9-14 (%)	01/01/92	10.70		11.40	
GLOBULINS GAMMA	10-20 (%)	01/01/92	10.50		11.10	
TSH	0.1-4 (UU/ML)	01/01/92	1.20			
T4	4.8-12.8 (UG/DL)	01/01/92	8.20			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 277 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			11/06/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/01/92	15.10	
HT	37-47 (%)	01/01/92	44.30	
RBC	4-5.8 (10¬6/MM3)	01/01/92	4.87	
WBC	4000-10000 (/MM3)	01/01/92	6100.00	
WBC: N	40-70 (%)	01/01/92	71.60	>
WBC: L	20-50 (%)	01/01/92	24.00	
WBC: E	0-8 (%)	01/01/92	0.90	
WBC: M	0-13 (%)	01/01/92	2.60	
WBC: B	0-3 (%)	01/01/92	0.80	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	175.00	
NA+	136-147 (MMOL/L)	01/01/92	136.00	
K+	3.6-5.5 (MMOL/L)	01/01/92		
CL-	95-110 (MMOL/L)	01/01/92	104.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.84	
PO4--	2.4-4.8 (MG/DL)	01/01/92	4.10	
SGOT	5-40 (U/L)	01/01/92	21.00	
SGPT	5-40 (U/L)	01/01/92	18.00	
GAMMA GT	0-40 (U/L)	01/01/92	12.00	
LDH	150-460 (U/L)	01/01/92	339.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	101.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	78.00	
BUN	()	01/01/92		
UREA	8-48 (MG/DL)	01/01/92	41.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	1.10	
URIC ACID	2-6.5 (MG/DL)	01/01/92		
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.60	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.16	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.77	
ALBUMINE	55-72 (%)	01/01/92	63.60	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	202.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	64.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.30	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.00	
GLOBULINS BETA	9-14 (%)	01/01/92	9.60	
GLOBULINS GAMMA	10-20 (%)	01/01/92	17.50	
TSH	0.1-4 (UU/ML)	01/01/92	59.20	
T4	4.8-12.8 (UG/DL)	01/01/92	3.10	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 16.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 280 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			07/08/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/01/92	14.90	
HT	37-47 (%)	01/01/92	43.60	
RBC	4-5.8 (10¬6/MM3)	01/01/92	5.03	
WBC	4000-10000 (/MM3)	01/01/92	10800.0	>
WBC: N	40-70 (%)	01/01/92	78.70	>
WBC: L	20-50 (%)	01/01/92	19.00	<
WBC: E	0-8 (%)	01/01/92	0.70	
WBC: M	0-13 (%)	01/01/92	1.10	
WBC: B	0-3 (%)	01/01/92	0.60	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	230.00	
NA+	136-147 (MMOL/L)	01/01/92	131.00	<
K+	3.6-5.5 (MMOL/L)	01/01/92		
CL-	95-110 (MMOL/L)	01/01/92	89.00	<
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.91	
PO4--	2.4-4.8 (MG/DL)	01/01/92		
SGOT	5-40 (U/L)	01/01/92	20.00	
SGPT	5-40 (U/L)	01/01/92	14.00	
GAMMA GT	0-40 (U/L)	01/01/92	9.00	
LDH	150-460 (U/L)	01/01/92	356.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	167.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	79.00	
BUN	()	01/01/92		
UREA	8-48 (MG/DL)	01/01/92	35.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	1.03	
URIC ACID	2-6.5 (MG/DL)	01/01/92	2.45	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.61	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.09	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	8.24	>
ALBUMINE	55-72 (%)	01/01/92	64.30	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	327.00	>>
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	81.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.70	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.80	
GLOBULINS BETA	9-14 (%)	01/01/92	10.70	
GLOBULINS GAMMA	10-20 (%)	01/01/92	14.50	
TSH	0.1-4 (UU/ML)	01/01/92	2.40	
T4	4.8-12.8 (UG/DL)	01/01/92	11.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9/A Patient: 281 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/08/92		21/09/92		12/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/01/92	15.20		15.00		15.50	
HT	37-47 (%)	01/01/92	44.70		44.40		47.30	>
RBC	4-5.8 (10-6/MM3)	01/01/92	4.70		4.77		5.05	
WBC	4000-10000 (/MM3)	01/01/92	5900.00		6300.00		5500.00	
WBC: N	40-70 (%)	01/01/92	46.60		47.50		47.20	
WBC: L	20-50 (%)	01/01/92	44.30		42.30		41.60	
WBC: E	0-8 (%)	01/01/92	2.60		4.50		5.70	
WBC: M	0-13 (%)	01/01/92	6.10		5.40		5.20	
WBC: B	0-3 (%)	01/01/92	0.50		0.30		0.30	
PLATELETS	150-400 (10-3/MM3)	01/01/92	223.00		231.00		224.00	
NA+	136-147 (MMOL/L)	01/01/92	141.00		143.00		145.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.90		4.10		4.60	
CL-	95-110 (MMOL/L)	01/01/92	96.00		101.00		104.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.73		9.28		9.49	
PO4--	2.4-4.8 (MG/DL)	01/01/92			3.50		3.40	
SGOT	5-40 (U/L)	01/01/92	36.00		28.00		25.00	
SGPT	5-40 (U/L)	01/01/92	26.00		34.00		21.00	
GAMMA GT	0-40 (U/L)	01/01/92	29.00		37.00		33.00	
LDH	150-460 (U/L)	01/01/92	541.00	>	252.00		242.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	156.00		237.00		220.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	99.00		82.00		102.00	
BUN	()	01/01/92						
UREA	8-48 (MG/DL)	01/01/92	24.00		27.00		27.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.85		1.01		1.00	
URIC ACID	2-6.5 (MG/DL)	01/01/92	9.07	>>	8.01	>	7.83	>
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.84		0.50		0.61	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.05		0.17		0.20	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.53		7.62		7.39	
ALBUMINE	55-72 (%)	01/01/92	59.60		69.20		63.60	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	220.00		206.00		203.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	162.00		128.00		123.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.50		2.50		3.30	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	10.30		6.40		7.50	
GLOBULINS BETA	9-14 (%)	01/01/92	11.90		10.30		11.70	
GLOBULINS GAMMA	10-20 (%)	01/01/92	14.70		11.60		13.90	
TSH	0.1-4 (UU/ML)	01/01/92						
T4	4.8-12.8 (UG/DL)	01/01/92	9.50					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done

>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

1173

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9/A Patient: 282 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/09/92		22/09/92		13/10/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/01/92	12.10	<	14.60		14.80	
HT	42-53 (%)	01/01/92	39.50	<	45.30		46.30	
RBC	4.5-6.2 (10¬6/MM3)	01/01/92	4.70		5.25		5.33	
WBC	4000-10000 (/MM3)	01/01/92	8200.00		10900.0	>	11500.0	>
WBC: N	40-70 (%)	01/01/92	56.90		50.80		67.40	
WBC: L	20-50 (%)	01/01/92	35.80		39.30		26.50	
WBC: E	0-8 (%)	01/01/92	2.20		3.90		2.50	
WBC: M	0-13 (%)	01/01/92	4.80		5.60		3.50	
WBC: B	0-3 (%)	01/01/92	0.30		0.40		0.10	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	149.00	<	334.00		334.00	
NA+	136-147 (MMOL/L)	01/01/92	139.00		140.00		139.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.40		4.10		4.70	
CL-	95-110 (MMOL/L)	01/01/92	102.00		102.00		100.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.44		9.73		9.48	
PO4--	2-4.5 (MG/DL)	01/01/92	3.90		4.30		3.10	
SGOT	5-40 (U/L)	01/01/92	21.00		17.00		20.00	
SGPT	5-40 (U/L)	01/01/92	42.00	>	10.00		17.00	
GAMMA GT	0-40 (U/L)	01/01/92	26.00		17.00		17.00	
LDH	150-460 (U/L)	01/01/92	367.00		375.00		344.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	147.00		156.00		167.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	61.00		75.00		77.00	
BUN	()	01/01/92						
UREA	8-50 (MG/DL)	01/01/92	27.00		26.00		26.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	1.11		1.36		1.25	
URIC ACID	2-7.5 (MG/DL)	01/01/92	7.74	>	6.87		5.26	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.22		0.35		0.52	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.03		0.01		0.16	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.40		7.61		7.65	
ALBUMINE	55-72 (%)	01/01/92	65.90		62.60		68.80	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	265.00	>	218.00		206.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	266.00	>>	134.00		140.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.70		2.50		2.60	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	9.30		7.70		8.00	
GLOBULINS BETA	9-14 (%)	01/01/92	11.30		8.70	<	10.00	
GLOBULINS GAMMA	10-20 (%)	01/01/92	10.80		18.50		10.60	
TSH	0.1-4 (UU/ML)	01/01/92	0.96					
T4	4.8-12.8 (UG/DL)	01/01/92	6.90					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

1174

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 303 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			06/03/92		31/03/92	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/01/92	14.40		14.80	
HT	37-47 (%)	01/01/92	40.50		43.40	
RBC	4-5.8 (10¬6/MM3)	01/01/92	4.25		4.47	
WBC	4000-10000 (/MM3)	01/01/92	17400.0	>>	14000.0	>>
WBC: N	40-70 (%)	01/01/92	76.00	>	74.40	>
WBC: L	20-50 (%)	01/01/92	8.00	<<	15.60	<
WBC: E	0-8 (%)	01/01/92	0.00		1.20	
WBC: M	0-13 (%)	01/01/92	2.00		2.50	
WBC: B	0-3 (%)	01/01/92	0.00		0.30	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	372.00		426.00	>
NA+	136-147 (MMOL/L)	01/01/92	142.00		139.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.70		4.60	
CL-	95-110 (MMOL/L)	01/01/92	102.00		101.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.30		9.87	
PO4--	2.4-4.8 (MG/DL)	01/01/92	4.50		5.00	>
SGOT	5-40 (U/L)	01/01/92	19.00		25.00	
SGPT	5-40 (U/L)	01/01/92	21.00		34.00	
GAMMA GT	0-40 (U/L)	01/01/92	44.00	>	40.00	
LDH	150-460 (U/L)	01/01/92			265.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	70.00		76.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	76.00		76.00	
BUN	()	01/01/92				
UREA	8-48 (MG/DL)	01/01/92	22.00		36.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.92		0.95	
URIC ACID	2-6.5 (MG/DL)	01/01/92	3.06		3.17	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.24		0.78	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.07		0.05	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	6.85		7.42	
ALBUMINE	55-72 (%)	01/01/92	59.90		60.50	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	202.00		243.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	141.00		168.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	5.00		5.40	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	10.20		10.60	
GLOBULINS BETA	9-14 (%)	01/01/92	12.50		11.40	
GLOBULINS GAMMA	10-20 (%)	01/01/92	12.40		12.10	
TSH	0.1-4 (UU/ML)	01/01/92	2.19			
T4	4.8-12.8 (UG/DL)	01/01/92	8.40			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 304 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/03/92		15/04/92		06/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/01/92	13.80		13.20		15.40	
HT	37-47 (%)	01/01/92	39.10		39.40		43.80	
RBC	4-5.8 (10-6/MM3)	01/01/92	4.39		4.31		4.82	
WBC	4000-10000 (/MM3)	01/01/92	9400.00		6500.00		7200.00	
WBC: N	40-70 (%)	01/01/92	46.00		61.00		59.60	
WBC: L	20-50 (%)	01/01/92	48.00		31.70		32.00	
WBC: E	0-8 (%)	01/01/92	2.00		1.00		3.00	
WBC: M	0-13 (%)	01/01/92	4.00		5.70		4.90	
WBC: B	0-3 (%)	01/01/92	0.00		0.70		0.50	
PLATELETS	150-400 (10-3/MM3)	01/01/92	131.00	<	288.00		271.00	
NA+	136-147 (MMOL/L)	01/01/92	145.00		141.00		142.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.30		4.00		4.10	
CL-	95-110 (MMOL/L)	01/01/92	102.00		102.00		102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.59		8.65		9.42	
PO4--	2.4-4.8 (MG/DL)	01/01/92	3.50		3.40		2.80	
SGOT	5-40 (U/L)	01/01/92	27.00		15.00		18.00	
SGPT	5-40 (U/L)	01/01/92	29.00		14.00		13.00	
GAMMA GT	0-40 (U/L)	01/01/92	15.00		15.00		17.00	
LDH	150-460 (U/L)	01/01/92			322.00		392.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	138.00		144.00		165.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	90.00		87.00		83.00	
BUN	()	01/01/92						
UREA	8-48 (MG/DL)	01/01/92	36.00		25.00		32.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.94		0.91		1.00	
URIC ACID	2-6.5 (MG/DL)	01/01/92	6.09					
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.72		0.35		0.33	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.11		0.03		0.01	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.35		6.88		7.63	
ALBUMINE	55-72 (%)	01/01/92	67.10		66.10		65.40	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	300.00	>	308.00	>	307.00	>
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	128.00		126.00		87.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.00		3.40		3.60	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	6.90		7.00		7.30	
GLOBULINS BETA	9-14 (%)	01/01/92	10.90		11.50		11.70	
GLOBULINS GAMMA	10-20 (%)	01/01/92	12.10		12.00		12.00	
TSH	0,1-4 (UU/ML)	01/01/92	4.12					
T4	4.8-12.8 (UG/DL)	01/01/92	11.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085
Centre: 9/A Patient: 305 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/03/92		20/04/92		11/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/01/92	15.90		16.00		16.20	
HT	42-53 (%)	01/01/92	47.70		45.70		43.90	
RBC	4.5-6.2 (10-6/MM3)	01/01/92	4.87		4.71		4.56	
WBC	4000-10000 (/MM3)	01/01/92	7100.00		6900.00		7700.00	
WBC: N	40-70 (%)	01/01/92	47.80		53.90		56.30	
WBC: L	20-50 (%)	01/01/92	40.70		36.80		36.80	
WBC: E	0-8 (%)	01/01/92	7.00		5.40		4.60	
WBC: M	0-13 (%)	01/01/92	3.60		3.50		2.20	
WBC: B	0-3 (%)	01/01/92	0.90		0.30		0.20	
PLATELETS	150-400 (10-3/MM3)	01/01/92	295.00		284.00		303.00	
NA+	136-147 (MMOL/L)	01/01/92	138.00		142.00		143.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.90		4.40		4.30	
CL-	95-110 (MMOL/L)	01/01/92	98.00		98.00		103.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.77		9.83		9.40	
PO4--	2-4.5 (MG/DL)	01/01/92	3.20		3.80		3.90	
SGOT	5-40 (U/L)	01/01/92	17.00		20.00		15.00	
SGPT	5-40 (U/L)	01/01/92	12.00		20.00		11.00	
GAMMA GT	0-40 (U/L)	01/01/92	12.00		16.00		18.00	
LDH	150-460 (U/L)	01/01/92			378.00			
ALK. PHOSPH.	40-350 (U/L)	01/01/92	190.00		202.00		199.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	80.00		79.00		83.00	
BUN	()	01/01/92						
UREA	8-50 (MG/DL)	01/01/92	18.00		22.00		16.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	1.24		1.08		1.12	
URIC ACID	2-7.5 (MG/DL)	01/01/92	5.96				6.20	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.70		0.52		0.47	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.04		0.01		0.12	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.12		7.29		7.27	
ALBUMINE	55-72 (%)	01/01/92			68.70		69.50	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	206.00		217.00		190.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	123.00		118.00		115.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.90		2.90		3.10	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.00		7.00		7.10	
GLOBULINS BETA	9-14 (%)	01/01/92	10.40		10.40		10.30	
GLOBULINS GAMMA	10-20 (%)	01/01/92	11.00		11.00		10.00	
TSH	0.1-4 (UU/ML)	01/01/92	1.58					
T4	4.8-12.8 (UG/DL)	01/01/92	7.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 306 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data					
			Screen		Day 21		Day 42	
			28/04/92		19/05/92		09/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/01/92	14.40		15.90		15.40	
HT	37-47 (%)	01/01/92	39.80		45.80		43.90	
RBC	4-5.8 (10¬6/MM3)	01/01/92	4.38		5.09		4.91	
WBC	4000-10000 (/MM3)	01/01/92	12400.0	>	7600.00		9700.00	
WBC: N	40-70 (%)	01/01/92	64.20		51.30		66.10	
WBC: L	20-50 (%)	01/01/92	32.70		41.20		28.70	
WBC: E	0-8 (%)	01/01/92	1.10		3.00		1.60	
WBC: M	0-13 (%)	01/01/92	1.60		4.10		3.40	
WBC: B	0-3 (%)	01/01/92	0.40		0.50		0.20	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	105.00	<	225.00		248.00	
NA+	136-147 (MMOL/L)	01/01/92	140.00		140.00		139.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.40		4.90		4.10	
CL-	95-110 (MMOL/L)	01/01/92	106.00		105.00		102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	8.65		9.13		8.28	<
PO4--	2.4-4.8 (MG/DL)	01/01/92	3.50		4.30		3.70	
SGOT	5-40 (U/L)	01/01/92	18.00		19.00		21.00	
SGPT	5-40 (U/L)	01/01/92	12.00		15.00		12.00	
GAMMA GT	0-40 (U/L)	01/01/92	13.00		12.00		12.00	
LDH	150-460 (U/L)	01/01/92	496.00	>	411.00		453.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	144.00		154.00		165.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	71.00		74.00		85.00	
BUN	()	01/01/92						
UREA	8-48 (MG/DL)	01/01/92	30.00		31.00		37.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.84		0.91		0.91	
URIC ACID	2-6.5 (MG/DL)	01/01/92	2.96					
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.52		0.44		0.35	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.01		0.04		0.02	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	6.75		6.91		6.38	
ALBUMINE	55-72 (%)	01/01/92	63.80		63.90		67.30	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	186.00		213.00		183.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	72.00		80.00		120.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.30		3.30		3.40	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	10.60		8.50		7.70	
GLOBULINS BETA	9-14 (%)	01/01/92	11.10		11.50		9.90	
GLOBULINS GAMMA	10-20 (%)	01/01/92	11.20		12.80		11.70	
TSH	0.1-4 (UU/ML)	01/01/92			2.98			
T4	4.8-12.8 (UG/DL)	01/01/92			6.70			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

1178

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 10 Patient: 290 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/10/91		04/11/91		25/11/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	21/09/91	15.80		16.30		13.70	<
HT	36-54 (%)	21/09/91	48.10		51.70		44.20	
RBC	4-5 (10-6/MM3)	21/09/91	5.46	>	5.53	>	4.78	
WBC	4000-10000 (/MM3)	21/09/91	7700.00		6400.00		5500.00	
WBC: N	40-70 (%)	21/09/91	36.00	<	74.00	>	32.00	<
WBC: L	20-40 (%)	21/09/91	56.00	>>	20.00		56.00	>>
WBC: E	1-4 (%)	21/09/91	4.00		0.00	<	4.00	
WBC: M	4-8 (%)	21/09/91	4.00		6.00		6.00	
WBC: B	0-1 (%)	21/09/91	0.00		0.00		2.00	>>
PLATELETS	150000-400000 (/MM3)	21/09/91	193000		220000		199000	
NA+	135-155 (MEQ/L)	21/09/91	140.80		140.50		141.30	
K+	3.1-5.5 (MEQ/L)	21/09/91	3.77		4.47		4.58	
CL-	98-107 (MEQ/L)	21/09/91	103.00		100.00		100.00	
Ca++	88-102 (MG/L)	21/09/91	98.00		104.00	>	102.00	
PO4--	2.5-4.8 (MG/DL)	21/09/91	4.77		4.70		5.46	>
SGOT	5-18 (U/L)	21/09/91	8.00		10.00		9.00	
SGPT	5-22 (U/L)	21/09/91	7.00		11.00		8.00	
GAMMA GT	0-25 (U/L)	21/09/91	7.00		7.00		5.00	
LDH	150-240 (U/L)	21/09/91	119.00	<	197.00		128.00	<
ALK. PHOSPH.	40-90 (U/L)	21/09/91	107.00	>	101.00	>	69.00	
GLUCOSE	76-120 (MG/DL)	21/09/91	97.00		97.00		99.00	
BUN	10-50 (MG/DL)	21/09/91	18.00		22.80		29.00	
UREA	()	21/09/91						
CREATININE	0.7-1.35 (MG/DL)	21/09/91	0.83		0.82		0.83	
URIC ACID	2.5-7 (MG/DL)	21/09/91	2.92		3.41		2.89	
TOT BILIRUBIN	0-1 (MG/DL)	21/09/91	0.50		0.65		0.58	
DIR BILIRUBIN	0-0.25 (MG/DL)	21/09/91	0.08		0.02		0.01	
TOT. PROTEINS	6.6-8.7 (G/DL)	21/09/91	7.20		6.58	<	6.58	<
ALBUMINE	3.97-5.34 (G/DL)	21/09/91	4.25		4.01		4.28	
TOT. CHOLEST.	120-260 (MG/DL)	21/09/91	142.00		138.00		121.00	
TRIGLYCERIDES	65-172 (MG/DL)	21/09/91	62.00	<	68.00		55.00	<
GLOBULINS ALPHA 1	1.8-5 (%)	21/09/91	5.30	>				
	0.11-0.32 (G/DL)	03/11/91			0.28		0.37	>
GLOBULINS ALPHA 2	7-12 (%)	21/09/91	13.50	>				
	0.42-0.87 (G/DL)	03/11/91			0.92	>	0.92	>
GLOBULINS BETA	6-15 (%)	21/09/91	13.10					
	0.53-1.12 (G/DL)	03/11/91			0.81		0.87	
GLOBULINS GAMMA	7.8-18.2 (%)	21/09/91	9.80					
	0.53-1.97 (G/DL)	03/11/91			0.56		0.72	
TSH	0.15-5.5 (MU/L)	21/09/91	1.80					
T4	5-12 (UG/DL)	21/09/91	8.40					
	5-12 (MG/DL)	03/11/91						

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done

>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

1179

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 10 Patient: 292 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/12/91		03/01/92		25/01/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	22/09/91	14.20		14.60		13.70	
HT	36-54 (%)	22/09/91	39.90		42.60		40.20	
RBC	4-5 (10¬6/MM3)	22/09/91	4.48		4.40		4.60	
WBC	4000-10000 (/MM3)	22/09/91	5800.00		6900.00		6000.00	
WBC: N	40-70 (%)	22/09/91	64.00		70.00		46.00	
WBC: L	20-40 (%)	22/09/91	28.00		26.00		38.00	
WBC: E	1-4 (%)	22/09/91	6.00	>>	2.00		10.00	>>
WBC: M	4-8 (%)	22/09/91	2.00	<	2.00	<	4.00	
WBC: B	0-1 (%)	22/09/91	0.00		0.00		2.00	>>
PLATELETS	150000-400000 (/MM3)	22/09/91	321000		214000		361000	
NA+	135-155 (MEQ/L)	22/09/91	140.10		141.80		141.70	
K+	3.1-5.5 (MEQ/L)	22/09/91	4.20		3.78		4.25	
CL-	98-107 (MEQ/L)	22/09/91	105.00		112.00	>	93.00	<
Ca++	88-102 (MG/L)	22/09/91	100.00		93.00		93.00	
PO4--	2.5-4.8 (MG/DL)	22/09/91	4.40		3.83		3.77	
SGOT	5-15 (U/L)	22/09/91	6.00		7.00		7.00	
SGPT	5-17 (U/L)	22/09/91	15.00		3.00	<	11.00	
GAMMA GT	0-18 (U/L)	22/09/91	7.00		4.00		5.00	
LDH	150-240 (U/L)	22/09/91	176.00		132.00	<	181.00	
ALK. PHOSPH.	40-90 (U/L)	22/09/91	81.00		77.00		97.00	>
GLUCOSE	76-120 (MG/DL)	22/09/91	96.00		99.00		112.00	
BUN	10-50 (MG/DL)	22/09/91	30.80		25.00		29.20	
UREA	()	22/09/91						
CREATININE	0.55-1.1 (MG/DL)	22/09/91	0.76		0.72		0.55	
URIC ACID	2.5-5.7 (MG/DL)	22/09/91	2.31	<	2.57		1.79	<
TOT BILIRUBIN	0-1 (MG/DL)	22/09/91	1.03	>	0.71		0.30	
DIR BILIRUBIN	0-0.25 (MG/DL)	22/09/91	0.12		0.08		0.02	
TOT. PROTEINS	6.6-8.7 (G/DL)	22/09/91	7.62		7.50		7.60	
ALBUMINE	56-72 (%)	22/09/91	48.90	<				
	3.97-5.34 (G/DL)	02/01/92			4.10		4.80	
TOT. CHOLEST.	120-260 (MG/DL)	22/09/91	156.00		133.00		171.00	
TRIGLYCERIDES	65-172 (MG/DL)	22/09/91	108.00		73.00		60.00	<
GLOBULINS ALPHA 1	1.8-5 (%)	22/09/91	3.90					
	0.11-0.32 (G/DL)	02/01/92			0.30		0.20	
GLOBULINS ALPHA 2	7-12 (%)	22/09/91	12.20	>				
	0.42-0.87 (G/DL)	02/01/92			0.80		0.70	
GLOBULINS BETA	6-15 (%)	22/09/91	18.20	>				
	0.53-1.12 (G/DL)	02/01/92			1.10		0.90	
GLOBULINS GAMMA	7.8-18.2 (%)	22/09/91	17.30					
	0.53-1.97 (G/DL)	02/01/92			1.30		1.00	
TSH	0.15-5.5 (MU/L)	22/09/91	0.90					
T4	5-12 (UG/DL)	22/09/91						
	5-12 (MG/DL)	02/01/92						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 10 Patient: 293 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/12/91		14/01/92		04/02/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	22/09/91	13.60		12.90		12.20	
HT	36-54 (%)	22/09/91	44.90				39.50	
RBC	4-5 (10-6/MM3)	22/09/91	4.56		4.11		4.01	
WBC	4000-10000 (/MM3)	22/09/91	6500.00		5000.00		4900.00	
WBC: N	40-70 (%)	22/09/91	82.00	>	82.00	>	46.00	
WBC: L	20-40 (%)	22/09/91	14.00	<	14.00	<	42.00	>
WBC: E	1-4 (%)	22/09/91	2.00		2.00		2.00	
WBC: M	4-8 (%)	22/09/91	2.00	<	2.00	<	10.00	>
WBC: B	0-1 (%)	22/09/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	22/09/91	323000		396000		392000	
NA+	135-155 (MEQ/L)	22/09/91	140.90		141.40		142.20	
K+	3.1-5.5 (MEQ/L)	22/09/91	4.28		4.58		4.63	
CL-	98-107 (MEQ/L)	22/09/91	102.00		102.00		92.00	<
Ca++	88-102 (MG/L)	22/09/91	93.00		95.00		97.00	
PO4--	2.5-4.8 (MG/DL)	22/09/91	4.16		4.33		3.90	
SGOT	5-15 (U/L)	22/09/91	16.00	>	6.00		6.00	
SGPT	5-17 (U/L)	22/09/91	14.00		3.00	<	7.00	
GAMMA GT	0-18 (U/L)	22/09/91	17.00		11.00		7.00	
LDH	150-240 (U/L)	22/09/91	184.00		172.00		138.00	<
ALK. PHOSPH.	40-90 (U/L)	22/09/91	129.00	>	116.00	>	97.00	>
GLUCOSE	76-120 (MG/DL)	22/09/91	123.00	>	95.00		99.00	
BUN	10-50 (MG/DL)	22/09/91	40.00		39.00		52.00	>
UREA	()	22/09/91						
CREATININE	0.55-1.1 (MG/DL)	22/09/91	0.75		0.66		0.69	
URIC ACID	2.5-5.7 (MG/DL)	22/09/91	1.45	<	3.12		3.30	
TOT BILIRUBIN	0-1 (MG/DL)	22/09/91	0.57		0.49		0.49	
DIR BILIRUBIN	0-0.25 (MG/DL)	22/09/91	0.07		0.05		0.03	
TOT. PROTEINS	6.6-8.7 (G/DL)	22/09/91	7.13		7.10		7.55	
ALBUMINE	56-72 (%)	22/09/91	59.70					
	3.97-5.34 (G/DL)	13/01/92			3.80	<	4.30	
TOT. CHOLEST.	120-260 (MG/DL)	22/09/91	190.00		195.00		260.00	
TRIGLYCERIDES	65-172 (MG/DL)	22/09/91	75.00		105.00		104.00	
GLOBULINS ALPHA 1	1.8-5 (%)	22/09/91	3.80					
	0.11-0.32 (G/DL)	13/01/92			0.50	>>	0.20	
GLOBULINS ALPHA 2	7-12 (%)	22/09/91	12.90	>				
	0.42-0.87 (G/DL)	13/01/92			0.90	>	0.60	
GLOBULINS BETA	6-15 (%)	22/09/91	12.40					
	0.53-1.12 (G/DL)	13/01/92			1.20	>	0.80	
GLOBULINS GAMMA	7.8-18.2 (%)	22/09/91	11.20					
	0.53-1.97 (G/DL)	13/01/92			0.80		0.50	<
TSH	0.15-5.5 (MU/L)	22/09/91	0.50					
T4	5-12 (UG/DL)	22/09/91	7.20					
	5-12 (MG/DL)	13/01/92						

(◊) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max ran
> out of range (value higher than max ran
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 10 Patient: 296 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/02/92		12/03/92		02/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	31/12/91	12.00		15.30		11.70	<
HT	36-54 (%)	31/12/91	34.60	<	38.70		36.80	
RBC	4-5 (10¬6/MM3)	31/12/91	4.22		4.68		4.13	
WBC	4000-10000 (/MM3)	31/12/91	12700.0	>	11300.0	>	4300.00	
WBC: N	40-70 (%)	31/12/91	52.00		52.00		46.00	
WBC: L	20-40 (%)	31/12/91	40.00		36.00		32.00	
WBC: E	1-4 (%)	31/12/91	8.00	>>	0.00	<	12.00	>>
WBC: M	4-8 (%)	31/12/91	0.00	<	12.00	>>	8.00	
WBC: B	0-1 (%)	31/12/91	0.00		0.00		2.00	>>
PLATELETS	150000-400000 (/MM3)	31/12/91	276000		304000		249000	
NA+	135-155 (MEQ/L)	31/12/91	139.80		139.50		140.40	
K+	3.1-5.5 (MEQ/L)	31/12/91	4.48		4.30		4.12	
CL-	98-107 (MEQ/L)	31/12/91	100.00		98.00		97.00	<
Ca++	88-102 (MG/L)	31/12/91	90.00		97.00		100.00	
PO4--	2.5-4.8 (MG/DL)	31/12/91	3.90		4.10		5.09	>
SGOT	5-15 (U/L)	31/12/91	9.00		6.00		8.00	
SGPT	5-17 (U/L)	31/12/91	6.00		6.00		9.00	
GAMMA GT	0-18 (U/L)	31/12/91	5.00		4.00		5.00	
LDH	150-240 (U/L)	31/12/91	201.00		188.00		129.00	<
ALK. PHOSPH.	40-90 (U/L)	31/12/91	51.00		49.00		39.00	<
GLUCOSE	76-120 (MG/DL)	31/12/91	93.00		185.00	>>	98.00	
BUN	10-50 (MG/DL)	31/12/91	19.90		26.00		19.60	
UREA	()	31/12/91						
CREATININE	0.55-1.1 (MG/DL)	31/12/91	0.74		1.05		0.89	
URIC ACID	2.5-5.7 (MG/DL)	31/12/91	2.67		5.27		5.62	
TOT BILIRUBIN	0-1 (MG/DL)	31/12/91	0.36		0.24		0.23	
DIR BILIRUBIN	0-0.25 (MG/DL)	31/12/91	0.05		0.02		0.01	
TOT. PROTEINS	6.6-8.7 (G/DL)	31/12/91	8.06		6.80		7.00	
ALBUMINE	3.97-5.34 (G/DL)	31/12/91	4.30		4.30		4.50	
TOT. CHOLEST.	120-260 (MG/DL)	31/12/91	157.90		147.00		165.00	
TRIGLYCERIDES	65-172 (MG/DL)	31/12/91	101.00		85.00		86.00	
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	31/12/91	0.30		0.20		0.20	
GLOBULINS ALPHA 2	0.42-0.87 (G/DL)	31/12/91	0.70		0.60		0.60	
GLOBULINS BETA	0.53-1.12 (G/DL)	31/12/91	0.90		0.80		0.80	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	31/12/91	1.10		0.90		0.80	
TSH	0.2-6 (MUI/L)	31/12/91	2.20				3.70	
T4	45-135 (NG/ML)	31/12/91	76.00				76.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 10 Patient: 297 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/03/92		10/04/92		01/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	31/12/91	15.30		16.50		15.70	
HT	36-54 (%)	31/12/91	49.50		50.00		47.00	
RBC	4-5 (10¬6/MM3)	31/12/91	4.87		5.60	>	5.10	>
WBC	4000-10000 (/MM3)	31/12/91	8500.00		8700.00		7900.00	
WBC: N	40-70 (%)	31/12/91	56.00		65.00		64.00	
WBC: L	20-40 (%)	31/12/91	30.00		30.00		30.00	
WBC: E	1-4 (%)	31/12/91	8.00	>>	2.00		2.00	
WBC: M	4-8 (%)	31/12/91	6.00		3.00	<	4.00	
WBC: B	0-1 (%)	31/12/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	31/12/91	311000		288000		315000	
NA+	135-155 (MEQ/L)	31/12/91	139.60		143.00		141.00	
K+	3.1-5.5 (MEQ/L)	31/12/91	4.28		5.20		4.20	
CL-	98-107 (MEQ/L)	31/12/91	99.00		102.00		99.00	
Ca++	88-102 (MG/L)	31/12/91	102.00		95.00		93.00	
PO4--	2.5-4.8 (MG/DL)	31/12/91	4.85	>	3.70		3.50	
SGOT	5-18 (U/L)	31/12/91	6.00		8.00		21.00	>
SGPT	5-22 (U/L)	31/12/91	9.00		10.00		17.00	
GAMMA GT	0-25 (U/L)	31/12/91	8.00		12.00		21.00	
LDH	150-240 (U/L)	31/12/91	194.00		162.00		162.00	
ALK. PHOSPH.	40-90 (U/L)	31/12/91	47.00		91.00	>	120.00	>
GLUCOSE	76-120 (MG/DL)	31/12/91	90.00		105.00		77.00	
BUN	10-50 (MG/DL)	31/12/91	12.90		23.00		28.00	
UREA	()	31/12/91						
CREATININE	0.7-1.35 (MG/DL)	31/12/91	0.90		1.10		1.00	
URIC ACID	2.5-7 (MG/DL)	31/12/91	5.40		6.20		5.70	
TOT BILIRUBIN	0-1 (MG/DL)	31/12/91	0.49		0.60		1.10	>
DIR BILIRUBIN	0-0.25 (MG/DL)	31/12/91	0.10		0.20		0.20	
TOT. PROTEINS	6.6-8.7 (G/DL)	31/12/91	6.55	<	6.30	<	6.70	
ALBUMINE	3.97-5.34 (G/DL)	31/12/91	4.60		4.40		4.70	
TOT. CHOLEST.	120-260 (MG/DL)	31/12/91	196.00		211.00		226.00	
TRIGLYCERIDES	65-172 (MG/DL)	31/12/91	79.00		91.00		93.00	
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	31/12/91	0.20		0.20		0.10	<
GLOBULINS ALPHA 2	0.42-0.87 (G/DL)	31/12/91	0.60		0.70		0.70	
GLOBULINS BETA	0.53-1.12 (G/DL)	31/12/91	0.70		1.00		0.90	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	31/12/91	0.50	<	0.30	<<	0.30	<<
TSH	0.2-6 (MUI/L)	31/12/91	1.60					
T4	45-135 (NG/ML)	31/12/91	76.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 10 Patient: 298 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/03/92		16/04/92		11/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	31/12/91	14.50		15.90		13.60	
HT	36-54 (%)	31/12/91	48.40		51.00		48.50	
RBC	4-5 (10¬6/MM3)	31/12/91	4.81		5.20	>	4.37	
WBC	4000-10000 (/MM3)	31/12/91	7900.00		7300.00		9300.00	
WBC: N	40-70 (%)	31/12/91	51.00		69.00		58.00	
WBC: L	20-40 (%)	31/12/91	33.00		27.00		34.00	
WBC: E	1-4 (%)	31/12/91	5.00	>	1.00		1.00	
WBC: M	4-8 (%)	31/12/91	6.00		2.00	<	2.00	<
WBC: B	0-1 (%)	31/12/91	1.00		0.00		2.00	>>
PLATELETS	150000-400000 (/MM3)	31/12/91	313000		367000			
NA+	135-155 (MEQ/L)	31/12/91	141.10		141.00		138.70	
K+	3.1-5.5 (MEQ/L)	31/12/91	4.47		4.90		4.23	
CL-	98-107 (MEQ/L)	31/12/91	100.00		100.00		89.00	<
Ca++	88-102 (MG/L)	31/12/91	98.00		93.00		89.00	
PO4--	2.5-4.8 (MG/DL)	31/12/91	3.60		3.60			
SGOT	5-15 (U/L)	31/12/91	12.00		18.00	>	11.00	
SGPT	5-17 (U/L)	31/12/91	9.00		29.00	>	19.00	>
GAMMA GT	0-18 (U/L)	31/12/91	7.00		15.00		13.00	
LDH	150-240 (U/L)	31/12/91	203.00		238.00		201.00	
ALK. PHOSPH.	40-90 (U/L)	31/12/91	70.00		132.00	>	93.00	>
GLUCOSE	76-120 (MG/DL)	31/12/91	108.00		81.00		105.00	
BUN	10-50 (MG/DL)	31/12/91	29.70		30.00			
UREA	()	31/12/91						
CREATININE	0.55-1.1 (MG/DL)	31/12/91	0.99		0.80		0.66	
URIC ACID	2.5-5.7 (MG/DL)	31/12/91	4.80		5.80	>	6.31	>
TOT BILIRUBIN	0-1 (MG/DL)	31/12/91	0.55		0.56		0.79	
DIR BILIRUBIN	0-0.25 (MG/DL)	31/12/91	0.10		0.10		0.02	
TOT. PROTEINS	6.6-8.7 (G/DL)	31/12/91	7.21		7.70		7.36	
ALBUMINE	3.97-5.34 (G/DL)	31/12/91	4.60		4.60		4.90	
TOT. CHOLEST.	120-260 (MG/DL)	31/12/91	224.00		197.00		189.00	
TRIGLYCERIDES	65-172 (MG/DL)	31/12/91	116.00		168.00		86.00	
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	31/12/91	0.30		0.30		0.20	
GLOBULINS ALPHA 2	0.42-0.87 (G/DL)	31/12/91	0.70		0.70		0.80	
GLOBULINS BETA	0.53-1.12 (G/DL)	31/12/91	0.90		0.90		0.80	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	31/12/91	0.90		0.90		1.00	
TSH	0.2-6 (MUI/L)	31/12/91	1.80					
T4	45-135 (NG/ML)	31/12/91	83.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 11 Patient: 321 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/06/92		02/07/92		22/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.5-16.5 (G/DL)	01/05/92	14.50		14.90		14.60	
HT	0.37-0.49 (L/L)	01/05/92	0.42		0.44		0.43	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	4.80		4.90		4.72	
WBC	4-11 (10¬3/MM3)	01/05/92	6.60		8.10		7.50	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	3.70		4.50		4.40	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	2.30		3.10		2.60	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.10		0.10		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.30		0.40		0.50	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.10		0.10		0.10	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	244.00		326.00		258.00	
NA+	136-147 (MMOL/L)	01/05/92	139.00		136.00		138.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.80		4.20		5.10	
CL-	98-108 (MMOL/L)	01/05/92	107.00		102.00		107.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.37		2.28		2.31	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	0.85		1.30		0.98	
SGOT	5-40 (U/L)	01/05/92	18.00		27.00		21.00	
SGPT	5-35 (U/L)	01/05/92	28.00		20.00		19.00	
GAMMA GT	4-18 (U/L)	01/05/92	17.00		18.00		22.00	>
LDH	100-350 (U/L)	01/05/92	181.00		330.00		256.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	88.00		142.00		107.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	4.42		4.60		4.30	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	5.00		4.50		4.30	
CREATININE	47-88 (UMOL/L)	01/05/92	54.00		86.00		71.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.35		0.34		0.40	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	4.50		2.00	<	4.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92					2.00	
TOT. PROTEINS	65-80 (G/L)	01/05/92	75.00		78.00		72.00	
ALBUMINE	38-52 (G/L)	01/05/92	40.00		43.00		45.00	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	9.42	>>	9.90	>>	7.91	>
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	3.59	>>	2.50	>>	2.00	>
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.11		2.84		2.28	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	7.51		10.32	>	8.82	
GLOBULINS BETA	7-11 (G/L)	01/05/92	10.59		12.10	>	10.43	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	6.50	<	9.48		7.75	
TSH	0.4-5 (MUI/L)	01/05/92	1.60					
T4	9-20.9 (PMOL/L)	01/05/92	13.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 11 Patient: 322 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/06/92		03/07/92		27/07/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12.5-16.5 (G/DL)	01/05/92	14.20		15.60		14.20	
HT	0.37-0.49 (L/L)	01/05/92	0.43		0.46		0.43	
RBC	4.2-5.8 (10-6/MM3)	01/05/92	5.40		5.80		5.40	
WBC	4-11 (10-3/MM3)	01/05/92	6.50		4.70		4.40	
WBC: N	1.6-8 (10-3/MM3)	01/05/92	3.40		2.00		2.00	
WBC: L	1-4.5 (10-3/MM3)	01/05/92	2.20		2.10		1.60	
WBC: E	0-0.4 (10-3/MM3)	01/05/92	0.30		0.20		0.40	
WBC: M	0.2-0.8 (10-3/MM3)	01/05/92	0.40		0.40		0.40	
WBC: B	0-0.1 (10-3/MM3)	01/05/92	0.10		0.00		0.10	
PLATELETS	150-400 (10-3/MM3)	01/05/92	208.00		140.00	<	169.00	
NA+	136-147 (MMOL/L)	01/05/92	139.00		133.00	<	140.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.40		4.80		4.20	
CL-	98-108 (MMOL/L)	01/05/92	106.00		99.00		109.00	>
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.39		1.91	<	2.31	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.08		1.06		1.10	
SGOT	5-40 (U/L)	01/05/92	17.00		13.00		9.00	
SGPT	5-35 (U/L)	01/05/92	16.00		10.00		8.00	
GAMMA GT	4-18 (U/L)	01/05/92	7.00		8.00		6.00	
LDH	100-350 (U/L)	01/05/92	230.00		286.00		273.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	59.00		68.00		63.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	6.29		5.40		4.20	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	5.20		5.70		6.00	
CREATININE	47-88 (UMOL/L)	01/05/92	68.00		78.00		80.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.22		0.26		0.30	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	7.40		5.00		7.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	75.00		77.00		72.00	
ALBUMINE	38-52 (G/L)	01/05/92	43.60		43.00		39.00	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	5.62		5.60		5.20	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	1.03		0.60		0.40	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.27		2.40		2.55	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	7.26		5.15		7.97	
GLOBULINS BETA	7-11 (G/L)	01/05/92	9.72		14.21	>	9.41	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	12.11		11.89		12.65	
TSH	0.4-5 (MUI/L)	01/05/92	2.70					
T4	9-20.9 (PMOL/L)	01/05/92	14.80					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max r...
< out of range (value lower than min range) > out of range (value higher than max r...
** missing laboratory test value nd laboratory not done () missing range value

1186

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 11 Patient: 325 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/07/92		21/08/92		11/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.5-16.5 (G/DL)	01/05/92	15.00		15.40		14.50	
HT	0.37-0.49 (L/L)	01/05/92	0.46		0.49		0.45	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	4.90		5.20		4.80	
WBC	4-11 (10¬3/MM3)	01/05/92	4.30		10.10		4.50	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	2.20		7.10		2.10	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	1.40		1.80		1.50	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.40		0.50	>	0.70	>>
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.30		0.60		0.20	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.10		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	226.00		260.00		260.00	
NA+	136-147 (MMOL/L)	01/05/92	137.00		142.00		139.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.00		3.90		4.70	
CL-	98-108 (MMOL/L)	01/05/92	105.00		104.00		105.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.42		2.24		2.26	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.22		1.05		1.11	
SGOT	5-40 (U/L)	01/05/92	23.00		23.00		22.00	
SGPT	5-35 (U/L)	01/05/92	34.00		28.00		22.00	
GAMMA GT	4-18 (U/L)	01/05/92	7.00		15.00		8.00	
LDH	100-350 (U/L)	01/05/92	290.00		153.00		144.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	93.00		97.00		93.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	3.60		4.30		4.10	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	5.20		3.50		3.00	
CREATININE	47-88 (UMOL/L)	01/05/92	64.00		61.00		56.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.22		0.22		0.34	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	4.00		6.00		10.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	75.00		76.00		74.00	
ALBUMINE	38-52 (G/L)	01/05/92	43.15		42.50		49.80	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	3.90		4.90		4.40	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.60		0.50		0.70	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.91		2.82		2.10	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	7.39		8.09		5.60	
GLOBULINS BETA	7-11 (G/L)	01/05/92	9.23		10.21		7.00	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	12.33		12.29		9.50	
TSH	0.4-5 (MUI/L)	01/05/92	2.50					
T4	9-20.9 (PMOL/L)	01/05/92	11.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

1q4D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 11 Patient: 327 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/08/92		09/09/92		01/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.5-16.5 (G/DL)	01/05/92	13.70		13.20		13.10	
HT	0.37-0.49 (L/L)	01/05/92	0.42		0.40		0.43	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	4.70		4.50		4.60	
WBC	4-11 (10¬3/MM3)	01/05/92	4.30		3.60	<	4.10	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	2.10		2.00		1.90	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	1.90		1.30		1.80	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.10		0.10		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.20		0.20		0.30	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	247.00		231.00		235.00	
NA+	136-147 (MMOL/L)	01/05/92	141.00		137.00		136.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.80		4.60		3.60	
CL-	98-108 (MMOL/L)	01/05/92	107.00		106.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.60		2.21		2.20	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.00		0.87		0.92	
SGOT	5-40 (U/L)	01/05/92	14.00		15.00		19.00	
SGPT	5-35 (U/L)	01/05/92	11.00		12.00		16.00	
GAMMA GT	4-18 (U/L)	01/05/92	6.00		9.00		16.00	
LDH	100-350 (U/L)	01/05/92	122.00		128.00		140.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	35.00		40.00		48.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	4.10		4.10		4.60	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	4.90		3.30		4.00	
CREATININE	47-88 (UMOL/L)	01/05/92	85.00		73.00		77.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.17		0.13		0.20	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	12.00		13.00		8.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	75.00		71.00		71.00	
ALBUMINE	38-52 (G/L)	01/05/92	41.45		46.30		44.20	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	5.90		5.60		5.10	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.50		0.50		0.50	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.59		1.70	<	2.00	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.47		4.30	<	5.30	
GLOBULINS BETA	7-11 (G/L)	01/05/92	10.07		8.40		9.40	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	14.42		10.30		10.10	
TSH	0.4-5 (MUI/L)	01/05/92	2.50					
T4	9-20,9 (PMOL/L)	01/05/92	17.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 95550085

Centre: 11 Patient: 330 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 7	
			22/08/92		31/08/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	12.5-16.5 (G/DL)	01/05/92	14.30		14.20	
HT	0,37-0.49 (L/L)	01/05/92	0.45		0.43	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	5.00		4.80	
WBC	4-11 (10¬3/MM3)	01/05/92	9.70		8.30	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	5.90		4.80	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	3.10		3.10	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.10		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.40		0.30	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.10		0.10	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	228.00		218.00	
NA+	136-147 (MMOL/L)	01/05/92	137.00		134.00	<
K+	3.5-5.1 (MMOL/L)	01/05/92	3.60		3.60	
CL-	98-108 (MMOL/L)	01/05/92	108.00		107.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.22		2.20	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.07		1.03	
SGOT	5-40 (U/L)	01/05/92	17.00		17.00	
SGPT	5-35 (U/L)	01/05/92	15.00		13.00	
GAMMA GT	4-18 (U/L)	01/05/92	16.00		9.00	
LDH	100-350 (U/L)	01/05/92	191.00		163.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	49.00		50.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	4.40		5.50	
BUN	()	01/05/92				
UREA	2.6-6.7 (MMOL/L)	01/05/92	3.90		5.00	
CREATININE	47-88 (UMOL/L)	01/05/92	61.00		56.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.26		0.27	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	13.00		25.00	>
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92				
TOT. PROTEINS	65-80 (G/L)	01/05/92	70.00		71.00	
ALBUMINE	38-52 (G/L)	01/05/92	37.80	<	40.00	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	5.60		6.00	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	1.50		1.00	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.93		2.10	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.71		4.80	<
GLOBULINS BETA	7-11 (G/L)	01/05/92	9.30		7.90	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	13.20		11.30	
TSH	0.4-5 (MUI/L)	01/05/92	3.10			
T4	9-20.9 (PMOL/L)	01/05/92	13.00			

1180

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 11 Patient: 331 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/09/92		24/09/92		15/10/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	14.5-18.5 (G/DL)	01/05/92	15.00		14.60		14.30	<
HT	0.42-0.54 (L/L)	01/05/92	0.47		0.44		0.42	
RBC	4.8-6.4 (10¬6/MM3)	01/05/92	4.80		4.62	<	4.50	<
WBC	4-11 (10¬3/MM3)	01/05/92	5.00		7.30		6.30	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	2.40		4.40		3.60	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	1.90		2.10		2.10	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.20		0.20		0.20	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.60		0.60		0.40	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	291.00		298.00		250.00	
NA+	136-147 (MMOL/L)	01/05/92	139.00		141.00		136.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.30		4.80		4.00	
CL-	98-108 (MMOL/L)	01/05/92	105.00		105.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.31		2.47		2.27	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	0.79	<	0.94		0.97	
SGOT	5-40 (U/L)	01/05/92	19.00		14.00		15.00	
SGPT	5-35 (U/L)	01/05/92	21.00		16.00		14.00	
GAMMA GT	0-28 (U/L)	01/05/92	26.00		39.00	>	20.00	
LDH	100-350 (U/L)	01/05/92	141.00		158.00		120.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	38.00		43.00		36.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	3.50		4.00		4.00	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	5.50		5.60		5.40	
CREATININE	60-115 (UMOL/L)	01/05/92	90.00		77.00		92.00	
URIC ACID	0.18-0.45 (MMOL/L)	01/05/92	0.39		0.38		0.37	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	9.00		9.00		8.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	74.00		76.00		72.00	
ALBUMINE	38-52 (G/L)	01/05/92	48.70		47.10		48.40	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	8.00	>	7.40	>	6.70	>
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.80		1.30		1.50	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.40		2.70		2.10	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	7.40		9.30	>	6.80	
GLOBULINS BETA	7-11 (G/L)	01/05/92	8.80		10.10		8.20	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	6.70	<	6.70	<	6.60	<
TSH	0.4-5 (MUI/L)	01/05/92	1.50					
T4	9-20.9 (PMOL/L)	01/05/92	14.60					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 950085

LABORATORY DATA
Centre: 12 Patient: 338 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/06/92		10/07/92		31/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.3-16.7 (G/DL)	01/04/92	16.00		16.40		15.50	
HT	36-50 (%)	01/04/92	46.00		48.00		45.00	
RBC	3.7-5.7 (10-6/MM3)	01/04/92	5.00		5.40		5.00	
WBC	3.9-11.5 (10-3/MM3)	01/04/92	10.20		8.10		8.90	
WBC: N	2-7.5 (10-3/MM3)	01/04/92	5.92		4.37		4.46	
WBC: L	1-4 (10-3/MM3)	01/04/92	3.37		2.75		3.07	
WBC: E	0.2-0.45 (10-3/MM3)	01/04/92	0.10	<	0.16	<	0.18	<
WBC: M	0.2-0.8 (10-3/MM3)	01/04/92	0.82	>	0.81	>	1.01	>
WBC: B	0-0.1 (10-3/MM3)	01/04/92	0.00		0.00		0.19	>>
PLATELETS	150-400 (10-3/MM3)	01/04/92	363.00		355.00		327.00	
NA+	135-150 (MMOL/L)	01/04/92	142.00		138.00		141.00	
K+	3.6-5.7 (MMOL/L)	01/04/92	4.30		5.00		5.20	
CL-	99-110 (MMOL/L)	01/04/92	109.00		109.00		107.00	
Ca++	2.15-2.65 (MMOL/L)	01/04/92	2.35		2.40		2.47	
PO4--	0.8-1.5 (MMOL/L)	01/04/92	1.07		1.42		1.59	>
SGOT	5-45 (U/L)	01/04/92	24.00		19.00		21.00	
SGPT	5-50 (U/L)	01/04/92	18.00		15.00		14.00	
GAMMA GT	0-50 (U/L)	01/04/92	19.00		26.00		23.00	
LDH	120-230 (U/L)	01/04/92	161.00		205.00		171.00	
ALK. PHOSPH.	21-91 (IU/L)	01/04/92	78.00		63.00		45.00	
GLUCOSE	4.5-7.8 (MMOL/L)	01/04/92	4.10	<	4.00	<	4.60	
BUN	2.5-6.6 (MMOL/L)	01/04/92	4.40		3.20		3.80	
UREA	()	01/04/92						
CREATININE	62-115 (UMOL/L)	01/04/92	78.00		87.00		97.00	
URIC ACID	0.09-0.35 (MMOL/L)	01/04/92	0.16		0.29		0.22	
TOT BILIRUBIN	2-26 (UMOL/L)	01/04/92	15.00		12.00		7.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/04/92	2.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	01/04/92	80.00		77.00		70.00	
ALBUMINE	35-50 (G/L)	01/04/92	48.00		47.00		41.00	
TOT. CHOLEST.	3.5-5.1 (MMOL/L)	01/04/92	7.36	>>	7.84	>>	7.82	>>
TRIGLYCERIDES	0.28-2.3 (MMOL/L)	01/04/92	1.97		1.95		1.16	
GLOBULINS ALPHA 1	1-4 (G/L)	01/04/92	2.00		3.00		2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/04/92	8.00		8.00		7.00	
GLOBULINS BETA	5-10 (G/L)	01/04/92	9.00		9.00		9.00	
GLOBULINS GAMMA	6-15 (G/L)	01/04/92	13.00		10.00		11.00	
TSH	0.4-5 (UU/ML)	01/04/92	0.56					
T4	11-24 (PMOL/L)	01/04/92	19.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085

LABORATORY DATA
Centre: 12 Patient: 340 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/08/92		27/08/92		17/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.3-16.7 (G/DL)	01/04/92	13.50		14.50		14.60	
HT	36-50 (%)	01/04/92	40.00		42.00		44.00	
RBC	3.7-5.7 (10-6/MM3)	01/04/92	4.40		4.70		4.80	
WBC	3.9-11.5 (10-3/MM3)	01/04/92	4.50		4.10		5.00	
WBC: N	2-7.5 (10-3/MM3)	01/04/92	2.57		2.46		3.33	
WBC: L	1-4 (10-3/MM3)	01/04/92	1.36		1.19		1.12	
WBC: E	0.2-0.45 (10-3/MM3)	01/04/92	0.03	<	0.08	<	0.04	<
WBC: M	0.2-0.8 (10-3/MM3)	01/04/92	0.51		0.33		0.47	
WBC: B	0-0.1 (10-3/MM3)	01/04/92	0.03		0.04		0.05	
PLATELETS	150-400 (10-3/MM3)	01/04/92	325.00		308.00		275.00	
NA+	135-150 (MMOL/L)	01/04/92	143.00		139.00		138.00	
K+	3.6-5.7 (MMOL/L)	01/04/92	4.00		5.00		3.90	
CL-	99-110 (MMOL/L)	01/04/92	109.00		106.00		109.00	
Ca++	2.15-2.65 (MMOL/L)	01/04/92	2.32		2.38		2.29	
PO4--	0.8-1.5 (MMOL/L)	01/04/92	0.90		1.20		1.15	
SGOT	5-45 (U/L)	01/04/92	29.00		36.00		26.00	
SGPT	5-50 (U/L)	01/04/92	14.00		21.00		14.00	
GAMMA GT	0-50 (U/L)	01/04/92	38.00		12.00		15.00	
LDH	120-230 (U/L)	01/04/92	198.00		195.00		149.00	
ALK. PHOSPH.	21-91 (IU/L)	01/04/92	40.00		69.00		44.00	
GLUCOSE	4.5-7.8 (MMOL/L)	01/04/92	5.50		4.90		5.40	
BUN	2.5-6.6 (MMOL/L)	01/04/92	2.60		3.70		3.60	
UREA	()	01/04/92						
CREATININE	62-115 (UMOL/L)	01/04/92	75.00		78.00		98.00	
URIC ACID	0.09-0.35 (MMOL/L)	01/04/92	0.20		0.12		0.18	
TOT BILIRUBIN	2-26 (UMOL/L)	01/04/92	6.00		5.00		10.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/04/92	1.00		1.00		2.00	
TOT. PROTEINS	60-80 (G/L)	01/04/92	70.00		74.00		73.00	
ALBUMINE	35-50 (G/L)	01/04/92	44.00		44.00		37.00	
TOT. CHOLEST.	3.5-5.1 (MMOL/L)	01/04/92	5.89	>	5.41	>	4.96	
TRIGLYCERIDES	0.28-2.3 (MMOL/L)	01/04/92	0.86		0.79		0.93	
GLOBULINS ALPHA 1	1-4 (G/L)	01/04/92	2.00		2.00		3.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/04/92	5.00		7.00		8.00	
GLOBULINS BETA	5-10 (G/L)	01/04/92	8.00		9.00		10.00	
GLOBULINS GAMMA	6-15 (G/L)	01/04/92	11.00		12.00		15.00	
TSH	0.4-5 (UU/ML)	01/04/92	1.20					
T4	11-24 (PMOL/L)	01/04/92	11.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1192

PHARMACIA CNS R&D

*p920X

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085

LABORATORY DATA

Centre: 12 Patient: 341 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			18/08/92		10/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12.3-16.7 (G/DL)	01/04/92	11.90	<	11.50	<
HT	36-50 (%)	01/04/92	36.00		36.00	
RBC	3.7-5.7 (10¬6/MM3)	01/04/92	4.60		4.60	
WBC	3.9-11.5 (10¬3/MM3)	01/04/92	7.40		5.80	
WBC: N	2-7.5 (10¬3/MM3)	01/04/92	3.92		2.55	
WBC: L	1-4 (10¬3/MM3)	01/04/92	2.22		2.61	
WBC: E	0.2-0.45 (10¬3/MM3)	01/04/92	0.74	>>	0.41	
WBC: M	0.2-0.8 (10¬3/MM3)	01/04/92	0.52		0.17	<
WBC: B	0-0.1 (10¬3/MM3)	01/04/92	0.00		0.06	
PLATELETS	150-400 (10¬3/MM3)	01/04/92	477.00	>	368.00	
NA+	135-150 (MMOL/L)	01/04/92	142.00		140.00	
K+	3.6-5.7 (MMOL/L)	01/04/92	4.90		4.70	
CL-	99-110 (MMOL/L)	01/04/92	105.00		107.00	
Ca++	2.15-2.65 (MMOL/L)	01/04/92	2.37		2.19	
PO4--	0.8-1.5 (MMOL/L)	01/04/92	1.34		1.30	
SGOT	5-45 (U/L)	01/04/92	47.00	>	26.00	
SGPT	5-50 (U/L)	01/04/92	16.00		16.00	
GAMMA GT	0-50 (U/L)	01/04/92	9.00		9.00	
LDH	120-230 (U/L)	01/04/92	226.00		156.00	
ALK. PHOSPH.	21-91 (IU/L)	01/04/92	33.00		74.00	
GLUCOSE	4.5-7.8 (MMOL/L)	01/04/92	4.90		5.00	
BUN	2.5-6.6 (MMOL/L)	01/04/92	4.10		4.40	
UREA	()	01/04/92				
CREATININE	62-115 (UMOL/L)	01/04/92	79.00		114.00	
URIC ACID	0.09-0.35 (MMOL/L)	01/04/92	0.20		0.25	
TOT BILIRUBIN	2-26 (UMOL/L)	01/04/92	7.00		6.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/04/92	1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	01/04/92	71.00		60.00	
ALBUMINE	35-50 (G/L)	01/04/92	47.00		35.00	
TOT. CHOLEST.	3.5-5.1 (MMOL/L)	01/04/92	5.29	>	5.62	>
TRIGLYCERIDES	0.28-2.3 (MMOL/L)	01/04/92	0.60		0.70	
GLOBULINS ALPHA 1	1-4 (G/L)	01/04/92	2.00		2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/04/92	5.00		5.00	
GLOBULINS BETA	5-10 (G/L)	01/04/92	8.00		7.00	
GLOBULINS GAMMA	6-15 (G/L)	01/04/92	9.00		11.00	
TSH	0.4-5 (UU/ML)	01/04/92	0.85			
T4	11-24 (PMOL/L)	01/04/92	24.40			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA [redacted]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 13 Patient: 353 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			05/06/92		29/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	11.6-15.6 (G/DL)	01/06/92	13.50		13.90	
HT	0.35-0.45 (L/L)	01/06/92	0.43		0.44	
RBC	3.7-5.3 (10¬6/MM3)	01/06/92	5.31	>	5.65	>
WBC	4-11 (10¬3/MM3)	01/06/92	6.03		6.39	
WBC: N	40-75 (%)	01/06/92	52.00		68.00	
WBC: L	20-45 (%)	01/06/92	38.00		16.00	<
WBC: E	1-6 (%)	01/06/92	1.00		1.00	
WBC: M	2-10 (%)	01/06/92	7.00		12.00	>
WBC: B	0-1 (%)	01/06/92			1.00	
PLATELETS	140-420 (10¬3/MM3)	01/06/92	196.00		187.00	
NA+	135-145 (MMOL/L)	01/06/92	137.00		133.00	<
K+	3.5-5.5 (MMOL/L)	01/06/92	4.80		5.00	
CL-	97-107 (MMOL/L)	01/06/92			104.00	
Ca++	2.1-2.6 (MMOL/L)	01/06/92	2.28		2.38	
PO4--	0.8-1.3 (MMOL/L)	01/06/92	1.12		1.09	
SGOT	0-53 (U/L)	01/06/92	9.00		9.00	
SGPT	1-25 (U/L)	01/06/92	9.00		7.00	
GAMMA GT	0-40 (U/L)	01/06/92	10.00		5.00	
LDH	175-350 (U/L)	01/06/92	186.00		153.00	<
ALK. PHOSPH.	30-70 (U/L)	01/06/92	63.00		59.00	
GLUCOSE	3.7-5.6 (MMOL/L)	01/06/92	4.80		4.70	
BUN	1.7-6.7 (MMOL/L)	01/06/92	3.30		3.90	
UREA	()	01/06/92				
CREATININE	75-115 (UMOL/L)	01/06/92	79.00		85.00	
URIC ACID	0.09-0.36 (MMOL/L)	01/06/92	0.25		0.23	
TOT BILIRUBIN	1-17 (UMOL/L)	01/06/92	9.00		5.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	01/06/92	1.00	<	1.00	<
TOT. PROTEINS	60-80 (G/L)	01/06/92	69.00		72.00	
ALBUMINE	35-50 (G/L)	01/06/92	43.00		45.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	01/06/92	4.10		4.60	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	01/06/92				
GLOBULINS ALPHA 1	1-5 (%)	01/06/92	1.88		1.82	
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/06/92	7.88		10.74	>
GLOBULINS BETA	11-16 (%)	01/06/92	13.35		10.09	<
GLOBULINS GAMMA	12-22 (%)	01/06/92	11.55	<	13.04	
TSH	0.4-4 (MU/L)	01/06/92	0.76			
T4	6.3-22.8 (PMOL/L)	01/06/92				

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 13 Patient: 355 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			17/06/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.6-15.6 (G/DL)	02/05/92	13.50	
HT	0.35-0.45 (L/L)	02/05/92	0.46	>
RBC	3.7-5.3 (10¬6/MM3)	02/05/92	5.40	>
WBC	4-11 (10¬3/MM3)	02/05/92	3.42	<
WBC: N	40-75 (%)	02/05/92	49.00	
WBC: L	20-45 (%)	02/05/92	40.00	
WBC: E	1-6 (%)	02/05/92	2.00	
WBC: M	2-10 (%)	02/05/92	5.00	
WBC: B	0-1 (%)	02/05/92	1.00	
PLATELETS	140-420 (10¬3/MM3)	02/05/92	309.00	
NA+	135-145 (MMOL/L)	02/05/92	138.00	
K+	3.5-5.5 (MMOL/L)	02/05/92	4.70	
CL-	97-107 (MMOL/L)	02/05/92	107.00	
Ca++	2.1-2.6 (MMOL/L)	02/05/92	2.24	
PO4--	0.8-1.3 (MMOL/L)	02/05/92	1.09	
SGOT	0-53 (U/L)	02/05/92	16.00	
SGPT	1-25 (U/L)	02/05/92	17.00	
GAMMA GT	0-40 (U/L)	02/05/92	3.00	
LDH	175-350 (U/L)	02/05/92	191.00	
ALK. PHOSPH.	30-70 (U/L)	02/05/92	78.00	>
GLUCOSE	3.7-5.6 (MMOL/L)	02/05/92	4.40	
BUN	1.7-6.7 (MMOL/L)	02/05/92	4.60	
UREA	()	02/05/92		
CREATININE	75-115 (UMOL/L)	02/05/92	76.00	
URIC ACID	0.09-0.36 (MMOL/L)	02/05/92	0.14	
TOT BILIRUBIN	1-17 (UMOL/L)	02/05/92	7.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	02/05/92	1.00	<
TOT. PROTEINS	60-80 (G/L)	02/05/92	66.00	
ALBUMINE	35-50 (G/L)	02/05/92	45.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	02/05/92	6.10	>
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	02/05/92		
GLOBULINS ALPHA 1	1-3 (G/L)	02/05/92	4.07	>>
GLOBULINS ALPHA 2	5-9 (G/L)	02/05/92	8.83	
GLOBULINS BETA	4-10 (G/L)	02/05/92	11.66	>
GLOBULINS GAMMA	7-20 (G/L)	02/05/92	3.93	<<
TSH	0.4-4 (MU/L)	02/05/92		
T4	6.3-22.8 (PMOL/L)	02/05/92		

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 13 Patient: 358 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			06/08/92		27/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13.3-17.3 (G/DL)	01/08/92	17.40	>	17.60	>
HT	0.4-0.5 (L/L)	01/08/92	0.49		0.49	
RBC	4.5-5.9 (10¬6/MM3)	01/08/92	5.44		5.71	
WBC	4-11 (10¬3/MM3)	01/08/92	10.20		7.68	
WBC: N	40-75 (%)	01/08/92			64.00	
WBC: L	20-45 (%)	01/08/92			27.00	
WBC: E	1-6 (%)	01/08/92			1.00	
WBC: M	2-10 (%)	01/08/92			7.00	
WBC: B	0-1 (%)	01/08/92			1.00	
PLATELETS	140-420 (10¬3/MM3)	01/08/92	297.00		344.00	
NA+	135-145 (MMOL/L)	01/08/92	145.00		141.00	
K+	3.5-5.5 (MMOL/L)	01/08/92	5.00		4.20	
CL-	97-107 (MMOL/L)	01/08/92	109.00	>	104.00	
Ca++	2.1-2.6 (MMOL/L)	01/08/92	2.48		2.40	
PO4--	0.8-1.3 (MMOL/L)	01/08/92	1.28			
SGOT	0-53 (U/L)	01/08/92	17.00		21.00	
SGPT	1-25 (U/L)	01/08/92	19.00		18.00	
GAMMA GT	0-40 (U/L)	01/08/92	0.00		0.00	
LDH	175-350 (U/L)	01/08/92	151.00	<	188.00	
ALK. PHOSPH.	30-70 (U/L)	01/08/92	122.00	>	166.00	>>
GLUCOSE	3.7-5.6 (MMOL/L)	01/08/92	4.60		4.70	
BUN	1.7-6.7 (MMOL/L)	01/08/92	5.10			
UREA	()	01/08/92				
CREATININE	75-115 (UMOL/L)	01/08/92	89.00		86.00	
URIC ACID	0.15-0.48 (MMOL/L)	01/08/92	0.25		0.26	
TOT BILIRUBIN	1-17 (UMOL/L)	01/08/92	10.00		15.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	01/08/92	1.00	<	2.00	
TOT. PROTEINS	60-80 (G/L)	01/08/92	74.00		75.00	
ALBUMINE	35-50 (G/L)	01/08/92	44.00		45.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	01/08/92	4.10		4.00	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	01/08/92				
GLOBULINS ALPHA 1	1-5 (%)	01/08/92	2.84			
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/08/92	9.40			
GLOBULINS BETA	11-16 (%)	01/08/92	13.04			
GLOBULINS GAMMA	12-22 (%)	01/08/92	19.83			
TSH	0.4-4 (MU/L)	01/08/92	0.82			
T4	6.3-22.8 (PMOL/L)	01/08/92				

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 13 Patient: 359 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			19/08/92		09/09/92		30/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.6-15.6 (G/DL)	10/08/92	14.90		15.10		15.20	
HT	0.35-0.45 (L/L)	10/08/92	0.43		0.43		0.44	
RBC	3.7-5.3 (10-6/MM3)	10/08/92	4.86		4.72		4.72	
WBC	4-11 (10-3/MM3)	10/08/92	10.60		7.11		5.87	
WBC: N	40-75 (%)	10/08/92	75.00		76.00	>	70.00	
WBC: L	20-45 (%)	10/08/92	16.00	<	17.00	<	22.00	
WBC: E	1-6 (%)	10/08/92	1.00		1.00		1.00	
WBC: M	2-10 (%)	10/08/92	6.00		4.00		6.00	
WBC: B	0-1 (%)	10/08/92	1.00		1.00		1.00	
PLATELETS	140-420 (10-3/MM3)	10/08/92	278.00		220.00		233.00	
NA+	135-145 (MMOL/L)	10/08/92	141.00		139.00		141.00	
K+	3.5-5.5 (MMOL/L)	10/08/92	4.60		5.20			
CL-	97-107 (MMOL/L)	10/08/92	108.00	>	108.00	>	107.00	
Ca++	2.1-2.6 (MMOL/L)	10/08/92	2.63	>	2.48		2.42	
PO4--	0.8-1.3 (MMOL/L)	10/08/92	0.96		0.96			
SGOT	0-53 (U/L)	10/08/92	12.00		10.00		11.00	
SGPT	1-25 (U/L)	10/08/92	5.00		7.00		7.00	
GAMMA GT	0-40 (U/L)	10/08/92	0.00				0.00	
LDH	175-350 (U/L)	10/08/92	238.00		166.00	<	9.00	<
ALK. PHOSPH.	30-70 (U/L)	10/08/92	93.00	>	90.00	>	95.00	>
GLUCOSE	3.7-5.6 (MMOL/L)	10/08/92	5.10		4.60		4.40	
BUN	1.7-6.7 (MMOL/L)	10/08/92	4.00		3.90		3.00	
UREA	()	10/08/92						
CREATININE	75-115 (UMOL/L)	10/08/92	85.00		76.00		86.00	
URIC ACID	0.09-0.36 (MMOL/L)	10/08/92	0.30		0.28		0.27	
TOT BILIRUBIN	1-17 (UMOL/L)	10/08/92	10.00		5.00		5.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	10/08/92	2.00		2.00		1.00	<
TOT. PROTEINS	60-80 (G/L)	10/08/92	77.00		76.00		74.00	
ALBUMINE	35-50 (G/L)	10/08/92	44.00		48.00		46.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	10/08/92	5.70	>	4.80		4.70	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	10/08/92	1.00					
GLOBULINS ALPHA 1	1-5 (%)	10/08/92	3.32					
GLOBULINS ALPHA 2	4.5-9.5 (%)	10/08/92	10.98	>				
GLOBULINS BETA	11-16 (%)	10/08/92	10.51	<				
GLOBULINS GAMMA	12-22 (%)	10/08/92	14.85					
TSH	0.4-4 (MU/L)	10/08/92	1.11					
T4	6.3-22.8 (PMOL/L)	10/08/92						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 13 Patient: 361 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/08/92		16/09/92		07/10/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11.6-15.6 (G/DL)	15/08/92	11.50	<	12.60		12.60	
HT	0.35-0.45 (L/L)	15/08/92	0.38		0.37		0.38	
RBC	3.7-5.3 (10-6/MM3)	15/08/92	4.81		4.50		4.58	
WBC	4-11 (10-3/MM3)	15/08/92	8.27		6.12		4.22	
WBC: N	40-75 (%)	15/08/92	66.00		51.00		57.00	
WBC: L	20-45 (%)	15/08/92	23.00		35.00		35.00	
WBC: E	1-6 (%)	15/08/92	2.00		2.00		2.00	
WBC: M	2-10 (%)	15/08/92	7.00		8.00		4.00	
WBC: B	0-1 (%)	15/08/92	0.00		1.00		1.00	
PLATELETS	140-420 (10-3/MM3)	15/08/92	238.00		210.00		248.00	
NA+	135-145 (MMOL/L)	15/08/92	139.00		139.00		139.00	
K+	3.5-5.5 (MMOL/L)	15/08/92	4.40		4.80		5.30	
CL-	97-107 (MMOL/L)	15/08/92	106.00		106.00		102.00	
Ca++	2.1-2.6 (MMOL/L)	15/08/92	2.35		2.35		2.38	
PO4--	0.8-1.3 (MMOL/L)	15/08/92	1.28		1.28		1.38	>
SGOT	0-53 (U/L)	15/08/92	15.00		12.00		13.00	
SGPT	1-25 (U/L)	15/08/92	13.00		8.00		7.00	
GAMMA GT	0-40 (U/L)	15/08/92	0.00		0.00		12.00	
LDH	175-350 (U/L)	15/08/92	158.00	<	149.00	<	182.00	
ALK. PHOSPH.	30-70 (U/L)	15/08/92	57.00		50.00		39.00	
GLUCOSE	3.7-5.6 (MMOL/L)	15/08/92	4.80		4.20		5.60	
BUN	1.7-6.7 (MMOL/L)	15/08/92	5.60		6.20		3.70	
UREA	()	15/08/92						
CREATININE	75-115 (UMOL/L)	15/08/92	75.00		70.00	<	86.00	
URIC ACID	0.09-0.36 (MMOL/L)	15/08/92	0.23		0.25		0.24	
TOT BILIRUBIN	1-17 (UMOL/L)	15/08/92	5.00		3.00		4.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	15/08/92	2.00		2.00		0.00	<
TOT. PROTEINS	60-80 (G/L)	15/08/92	77.00		77.00		83.00	>
ALBUMINE	35-50 (G/L)	15/08/92	48.00		47.00		49.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	15/08/92	5.20	>	5.10		6.05	>
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	15/08/92	0.50		0.60			
GLOBULINS ALPHA 1	1-5 (%)	15/08/92	1.83				3.70	
GLOBULINS ALPHA 2	4.5-9.5 (%)	15/08/92	9.13				11.97	>
GLOBULINS BETA	11-16 (%)	15/08/92	13.90				13.20	
GLOBULINS GAMMA	12-22 (%)	15/08/92	20.67				17.42	
TSH	0.4-4 (MU/L)	15/08/92	0.63					
T4	6.3-22.8 (PMOL/L)	15/08/92						

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14 Patient: 457 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/07/92		28/07/92		18/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	13.80		13.90		13.80	
HT	42-54 (%)	01/06/92	41.00	<	40.80	<	40.60	<
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.10	<	4.20		4.10	<
WBC	4000-9000 (/MM3)	01/06/92	6800.00		6600.00		6800.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	38.00		39.00		38.00	
WBC: E	1-4 (%)	01/06/92	2.00		2.00		2.00	
WBC: M	4-8 (%)	01/06/92	5.00		5.00		4.00	
WBC: B	0-1 (%)	01/06/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	270000		270000		270000	
NA+	134-148 (MMOL/L)	01/06/92	140.00		141.00		140.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	3.90		4.00		4.00	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.10		2.10		2.20	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.10		2.30		2.30	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	8.00		8.00		10.00	
SGPT	5-22 (U/L)	01/06/92	8.00		8.00		10.00	
GAMMA GT	4-28 (U/L)	01/06/92	10.00		11.00		16.00	
LDH	120-240 (U/L)	01/06/92	164.00		161.00		156.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	119.00		104.00		111.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	92.00		96.00		89.00	
BUN	10-50 (MG/DL)	01/06/92	19.00		20.00		21.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	5.80		6.10		5.90	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.80		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.30		7.20		7.10	
ALBUMINE	57-68 (%)	01/06/92	62.00		61.00		62.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	256.00	>	281.00	>>	167.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	184.00	>	196.00	>	188.00	>
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.20		3.30		3.40	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.10		7.40		7.70	
GLOBULINS BETA	9-13 (%)	01/06/92	10.40		10.20		10.10	
GLOBULINS GAMMA	10-20 (%)	01/06/92	16.20		16.90		16.20	
TSH	0.2-3.1 (UU/ML)	01/06/92	0.20					
T4	5-11.5 (UG/DL)	01/06/92	7.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14 Patient: 459 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/07/92		06/08/92		27/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	14.40		14.20		14.30	
HT	42-54 (%)	01/06/92	41.00	<	41.00	<	40.00	<
RBC	4.2-5.8 (10¬6/MM3)	01/06/92	4.30		4.20		4.30	
WBC	4000-9000 (/MM3)	01/06/92	7400.00		7000.00		7200.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	36.00		35.00		37.00	
WBC: E	1-4 (%)	01/06/92	3.00		3.00		3.00	
WBC: M	4-8 (%)	01/06/92	6.00		5.00		4.00	
WBC: B	0-1 (%)	01/06/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	290000		290000		290000	
NA+	134-148 (MMOL/L)	01/06/92	140.00		140.00		141.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	3.90		4.10		4.00	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.10		2.00		2.00	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.30		2.20		2.10	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	16.00		16.00		16.00	
SGPT	5-22 (U/L)	01/06/92	18.00		19.00		18.00	
GAMMA GT	4-28 (U/L)	01/06/92	21.00		23.00		22.00	
LDH	120-240 (U/L)	01/06/92	211.00		209.00		212.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	158.00		156.00		161.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	101.00		99.00		96.00	
BUN	10-50 (MG/DL)	01/06/92	42.00		41.00		42.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	6.10		6.40		6.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.70		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.90		7.80		7.70	
ALBUMINE	57-68 (%)	01/06/92	62.00		61.00		62.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	216.00	>	236.00	>	216.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	211.00	>	198.00	>	192.00	>
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.60		3.70		3.90	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.80		7.60		7.40	
GLOBULINS BETA	9-13 (%)	01/06/92	11.20		11.30		11.80	
GLOBULINS GAMMA	10-20 (%)	01/06/92	18.90		18.70		17.90	
TSH	0.2-3.1 (UU/ML)	01/06/92	1.40					
T4	5-11.5 (UG/DL)	01/06/92	7.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1200

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14 Patient: 462 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/07/92		21/08/92		11/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	13.30		13.50		13.40	
HT	42-54 (%)	01/06/92	39.00	<	39.00	<	39.00	<
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.10	<	4.10	<	4.00	<
WBC	4000-9000 (/MM3)	01/06/92	7000.00		6800.00		7000.00	
WBC: N	50-70 (%)	01/06/92	37.00		38.00		39.00	
WBC: L	25-40 (%)	01/06/92	3.00		3.00		3.00	
WBC: E	1-4 (%)	01/06/92	3.00	<	2.00	<	2.00	<
WBC: M	4-8 (%)	01/06/92	0.00		0.00		0.00	
WBC: B	0-1 (%)	01/06/92						
PLATELETS	150000-400000 (/MM3)	01/06/92	270000		270000		270000	
NA+	134-148 (MMOL/L)	01/06/92	139.00		140.00		141.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	4.10		4.20		4.10	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.00		2.00		2.00	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.10		2.20		2.10	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	8.00		9.00		9.00	
SGPT	5-22 (U/L)	01/06/92	8.00		8.00		9.00	
GAMMA GT	4-28 (U/L)	01/06/92	12.00		13.00		12.00	
LDH	120-240 (U/L)	01/06/92	146.00		139.00		140.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	98.00		99.00		100.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	84.00		90.00		91.00	
BUN	10-50 (MG/DL)	01/06/92	29.00		31.00		31.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.70		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	4.90		5.20		5.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.80		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.40		7.60		7.40	
ALBUMINE	57-68 (%)	01/06/92	64.00		66.00		64.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	198.00		201.00	>	204.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	114.00		112.00		112.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.80		3.90		3.80	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.40		7.50		7.60	
GLOBULINS BETA	9-13 (%)	01/06/92	11.90		12.10		12.40	
GLOBULINS GAMMA	10-20 (%)	01/06/92	18.20		13.90		18.00	
TSH	0.2-3.1 (UU/ML)	01/06/92	1.80					
T4	5-11.5 (UG/DL)	01/06/92	6.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ran
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

1202

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14 Patient: 464 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/07/92		27/08/92		17/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	12.80		13.00		13.10	
HT	42-54 (%)	01/06/92	39.00	<	39.00	<	39.00	<
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.00	<	4.10	<	4.20	
WBC	4000-9000 (/MM3)	01/06/92	5600.00		6000.00		6600.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	39.00		38.00		38.00	
WBC: E	1-4 (%)	01/06/92	3.00		3.00		2.00	
WBC: M	4-8 (%)	01/06/92	6.00		5.00		5.00	
WBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	270000		270000		270000	
NA+	134-148 (MMOL/L)	01/06/92	138.00		137.00		139.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	3.90		3.70	<	3.80	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.00		1.90		1.90	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.30		2.10		2.10	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	12.00		12.00		12.00	
SGPT	5-22 (U/L)	01/06/92	12.00		12.00		12.00	
GAMMA GT	4-28 (U/L)	01/06/92	21.00		18.00		16.00	
LDH	120-240 (U/L)	01/06/92	194.00		190.00		189.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	98.00		100.00		99.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	112.00	>	109.00		104.00	
BUN	10-50 (MG/DL)	01/06/92	39.00		40.00		42.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	5.70		5.80		5.90	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.80		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.20		7.10		7.00	
ALBUMINE	57-68 (%)	01/06/92	61.00		62.00		60.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	246.00	>	251.00	>	247.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	118.00		121.00		119.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.60		3.70		3.80	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	11.80	>>	11.90	>>	12.00	>>
GLOBULINS BETA	9-13 (%)	01/06/92	10.60		10.20		10.40	
GLOBULINS GAMMA	10-20 (%)	01/06/92	18.40		18.70		18.60	
TSH	0.2-3.1 (UU/ML)	01/06/92	2.30					
T4	5-11.5 (UG/DL)	01/06/92	7.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14 Patient: 465 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/07/92		27/08/92		17/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	14.20		14.40		14.20	
HT	42-54 (%)	01/06/92	41.00	<	41.00	<	42.00	
RBC	4.2-5.8 (10¬6/MM3)	01/06/92	4.30		4.40		4.40	
WBC	4000-9000 (/MM3)	01/06/92	7200.00		7000.00		6800.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	40.00		39.00		38.00	
WBC: E	1-4 (%)	01/06/92	2.00		2.00		2.00	
WBC: M	4-8 (%)	01/06/92	7.00		6.00		5.00	
WBC: B	0-1 (%)	01/06/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	290000		290000		290000	
NA+	134-148 (MMOL/L)	01/06/92	142.00		140.00		139.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	4.20		4.10		2.00	<<
CL-	1.8-2.2 (MG/DL)	01/06/92	2.00		2.00		2.10	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.10		2.10		2.00	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	16.00		14.00		12.00	
SGPT	5-22 (U/L)	01/06/92	16.00		16.00		12.00	
GAMMA GT	4-28 (U/L)	01/06/92	28.00		26.00		20.00	
LDH	120-240 (U/L)	01/06/92	164.00		168.00		171.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	112.00		114.00		112.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	96.00		99.00		96.00	
BUN	10-50 (MG/DL)	01/06/92	36.00		38.00		39.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	6.20		6.60		6.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.70		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.60		7.50		7.40	
ALBUMINE	57-68 (%)	01/06/92	64.00		66.00		64.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	257.00	>	263.00	>>	246.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	173.00		191.00	>	174.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	4.20		4.20		4.10	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	8.60		7.80		7.90	
GLOBULINS BETA	9-13 (%)	01/06/92	12.20		13.10	>	13.60	>
GLOBULINS GAMMA	10-20 (%)	01/06/92	19.70		19.00		18.40	
TSH	0.2-3.1 (UU/ML)	01/06/92	2.60					
T4	5-11.5 (UG/DL)	01/06/92	8.20					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/1 Patient: 129 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			11/12/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	01/07/91	15.40	
HT	40-54 (%)	01/07/91	46.90	
RBC	4.1-6 (10¬6/MM3)	01/07/91	5.30	
WBC	4000-9000 (/MM3)	01/07/91	6200.00	
WBC: N	50-70 (%)	01/07/91	66.00	
WBC: L	20-40 (%)	01/07/91	31.00	
WBC: E	0-3 (%)	01/07/91	0.00	
WBC: M	0-8 (%)	01/07/91	3.00	
WBC: B	0-2 (%)	01/07/91	0.00	
PLATELETS	150-400 (10¬3/MM3)	01/07/91	282.00	
NA+	135-145 (MMOL/L)	01/07/91	139.00	
K+	3.7-5 (MMOL/L)	01/07/91	4.30	
CL-	()	01/07/91		
Ca++	4.5-5.2 (MEQ/L)	01/07/91	4.61	
PO4--	()	01/07/91		
SGOT	5-18 (U/L)	01/07/91	8.00	
SGPT	5-22 (U/L)	01/07/91	16.00	
GAMMA GT	0-28 (U/L)	01/07/91	12.00	
LDH	120-240 (U/L)	01/07/91	172.00	
ALK. PHOSPH.	40-190 (U/L)	01/07/91	92.00	
GLUCOSE	60-100 (MG/DL)	01/07/91	89.00	
BUN	10-50 (MG/DL)	01/07/91	30.00	
UREA	()	01/07/91		
CREATININE	0-1.2 (MG/DL)	01/07/91	1.09	
URIC ACID	2.5-7 (MG/DL)	01/07/91	5.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/07/91	0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/07/91	0.10	
TOT. PROTEINS	6.5-8 (G/DL)	01/07/91	6.93	
ALBUMINE	57-68 (%)	01/07/91	65.40	
TOT. CHOLEST.	130-200 (MG/DL)	01/07/91	208.00	>
TRIGLYCERIDES	65-170 (MG/DL)	01/07/91	69.00	
GLOBULINS ALPHA 1	2-4 (%)	01/07/91	2.30	
GLOBULINS ALPHA 2	5-9 (%)	01/07/91	5.10	
GLOBULINS BETA	8-12 (%)	01/07/91	12.10	>
GLOBULINS GAMMA	12-19 (%)	01/07/91	14.90	
TSH	0.2-4 (MU/L)	01/07/91	0.24	
T4	10-25 (PMOL/L)	01/07/91	31.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/1 Patient: 426 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			29/08/91		24/09/91		17/10/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	10/08/91	13.30		14.00		12.90	
HT	37-47 (%)	10/08/91	38.40		41.10		39.00	
RBC	3.9-5.3 (10¬6/MM3)	10/08/91	4.00		4.30		4.00	
WBC	4000-9000 (/MM3)	10/08/91	5100.00		5700.00		6000.00	
WBC: N	50-70 (%)	10/08/91	43.00	<	41.00	<	49.00	<
WBC: L	20-40 (%)	10/08/91	51.00	>	52.00	>	47.00	>
WBC: E	0-3 (%)	10/08/91	0.00		0.00		0.00	
WBC: M	0-8 (%)	10/08/91	6.00		7.00		4.00	
WBC: B	0-2 (%)	10/08/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	10/08/91	291.00		265.00		387.00	
NA+	135-145 (MMOL/L)	10/08/91	142.00		141.00		140.00	
K+	3.7-5 (MMOL/L)	10/08/91	4.40		3.89		5.19	>
CL-	()	10/08/91						
Ca++	2.2-2.6 (MMOL/L)	10/08/91	2.52					
	4.5-5.2 (MEQ/L)	10/09/91			4.66		4.32	<
PO4--	()	10/08/91						
SGOT	5-18 (U/L)	10/08/91	9.00		9.00		16.00	
SGPT	5-22 (U/L)	10/08/91	9.00		10.00		31.00	>
GAMMA GT	0-28 (U/L)	10/08/91	9.00		10.00		11.00	
LDH	120-240 (U/L)	10/08/91			198.00		258.00	>
ALK. PHOSPH.	40-190 (U/L)	10/08/91	147.00		128.00		123.00	
GLUCOSE	60-100 (MG/DL)	10/08/91	114.00	>	90.00		92.00	
BUN	10-50 (MG/DL)	10/08/91	28.00		33.00		4.10	<
UREA	()	10/08/91						
CREATININE	0-1.2 (MG/DL)	10/08/91	0.80		0.91		0.81	
URIC ACID	2.5-5.8 (MG/DL)	10/08/91	5.90	>	5.00			
TOT BILIRUBIN	0-1 (MG/DL)	10/08/91			0.50		0.50	
DIR BILIRUBIN	0-0.25 (MG/DL)	10/08/91	0.18		0.20		0.20	
TOT. PROTEINS	6.5-8 (G/DL)	10/08/91	7.10		7.20		7.02	
ALBUMINE	57-68 (%)	10/08/91	65.90		64.90		61.20	
TOT. CHOLEST.	130-200 (MG/DL)	10/08/91	233.00	>	226.00	>	177.00	
TRIGLYCERIDES	65-170 (MG/DL)	10/08/91	96.00		111.00			
GLOBULINS ALPHA 1	2-4 (%)	10/08/91	2.50		2.80		3.80	
GLOBULINS ALPHA 2	5-9 (%)	10/08/91	7.40		7.60		9.00	
GLOBULINS BETA	8-12 (%)	10/08/91	10.80		11.60		11.70	
GLOBULINS GAMMA	12-19 (%)	10/08/91	13.40		12.90		14.10	
TSH	0.2-4 (MU/L)	10/08/91	0.98					
T4	10-25 (PMOL/L)	10/08/91	8.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14/1 Patient: 452 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/11/91		19/12/91		09/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/07/91	12.50		12.80		12.70	
HT	37-47 (%)	01/07/91	34.30	<	35.80	<	34.90	<
RBC	3.9-5.3 (10¬6/MM3)	01/07/91	4.00		4.10		4.10	
WBC	4000-9000 (/MM3)	01/07/91	6300.00		6800.00		8100.00	
WBC: N	50-70 (%)	01/07/91	55.00		58.00		58.00	
WBC: L	20-40 (%)	01/07/91	41.00	>	40.00		41.00	>
WBC: E	0-3 (%)	01/07/91	0.00		0.00		0.00	
WBC: M	0-8 (%)	01/07/91	4.00		2.00		1.00	
WBC: B	0-2 (%)	01/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10-3/MM3)	01/07/91	345.00		349.00		344.00	
NA+	135-145 (MMOL/L)	01/07/91	142.00		139.00		139.00	
K+	3.7-5 (MMOL/L)	01/07/91	3.70		4.10		4.20	
CL-	()	01/07/91						
Ca++	4.5-5.2 (MEQ/L)	01/07/91	4.25	<	4.59		4.77	
PO4--	()	01/07/91						
SGOT	5-18 (U/L)	01/07/91	8.00		10.00		14.00	
SGPT	5-22 (U/L)	01/07/91	10.00		12.00		18.00	
GAMMA GT	0-28 (U/L)	01/07/91	24.00		15.00		15.00	
LDH	120-240 (U/L)	01/07/91	137.00		161.00		152.00	
ALK. PHOSPH.	40-190 (U/L)	01/07/91	103.00		132.00		108.00	
GLUCOSE	60-100 (MG/DL)	01/07/91	101.00	>	89.00		83.00	
BUN	10-50 (MG/DL)	01/07/91	17.00		24.00		29.00	
UREA	()	01/07/91						
CREATININE	0-1.2 (MG/DL)	01/07/91	0.70		0.66		0.78	
URIC ACID	2.5-5.8 (MG/DL)	01/07/91	3.80		3.90		2.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/07/91	0.40		0.40		0.30	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/07/91	0.10		0.10			
TOT. PROTEINS	6.5-8 (G/DL)	01/07/91	6.92		7.06		6.82	
ALBUMINE	57-68 (%)	01/07/91	61.10		60.80		63.60	
TOT. CHOLEST.	130-200 (MG/DL)	01/07/91	294.00	>>	160.00		196.00	
TRIGLYCERIDES	65-170 (MG/DL)	01/07/91	119.00		56.00	<	50.00	<
GLOBULINS ALPHA 1	2-4 (%)	01/07/91	2.40		2.80		1.90	<
GLOBULINS ALPHA 2	5-9 (%)	01/07/91	8.10		8.50		6.50	
GLOBULINS BETA	8-12 (%)	01/07/91	10.60		10.30		10.10	
GLOBULINS GAMMA	12-19 (%)	01/07/91	17.60		17.40		17.60	
TSH	0.2-4 (MU/L)	01/07/91	0.56					
T4	10-25 (PMOL/L)	01/07/91	24.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ran
< out of range (value lower than min range) > out of range (value higher than max ran
** missing laboratory test value nd laboratory not done () missing range value

1206

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/3 Patient: 417 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/06/91		05/07/91		26/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/05/91	14.00		12.80		12.50	
HT	36-48 (%)	01/05/91	42.70		39.70		39.20	
RBC	4.2-5.8 (10-6/MM3)	01/05/91	4.60		4.20		4.00	<
WBC	4000-9000 (/MM3)	01/05/91	7000.00		6900.00		8700.00	
WBC: N	50-70 (%)	01/05/91	55.00		52.00		46.00	<
WBC: L	25-40 (%)	01/05/91	41.00	>	40.00		40.00	
WBC: E	0-1 (%)	01/05/91	1.00		1.00		0.00	
WBC: M	4-8 (%)	01/05/91	1.00	<	2.00	<	6.00	
WBC: B	0-1 (%)	01/05/91	2.00	>>	1.00		0.00	
PLATELETS	150-400 (10-3/MM3)	01/05/91	270.00		290.00		275.00	
NA+	134-148 (MMOL/L)	01/05/91	140.10		144.50		139.80	
K+	3.8-5.2 (MMOL/L)	01/05/91	3.80		7.31	>>	4.00	
CL-	96-111 (MMOL/L)	01/05/91	103.00		104.20		103.10	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.50		2.50		2.50	
PO4--	0.8-1.6 (MMOL/L)	01/05/91	1.14		1.15		1.13	
SGOT	5-18 (U/L)	01/05/91	7.00		6.00		7.00	
SGPT	5-22 (U/L)	01/05/91	8.00		6.00		10.00	
GAMMA GT	4-28 (U/L)	01/05/91	9.00		8.00		13.00	
LDH	120-240 (U/L)	01/05/91	148.00		127.00		140.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	74.00		68.00		84.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	103.80		103.10		85.40	
BUN	10-50 (MG/DL)	01/05/91	36.00		36.00		31.00	
UREA	()	01/05/91						
CREATININE	0.3-1.2 (MG/DL)	01/05/91	0.80		1.10		0.90	
URIC ACID	2.4-7 (MG/DL)	01/05/91	5.10		5.40		5.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.20		0.30		0.20	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.10		0.10		0.10	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	7.70		8.20		7.70	
ALBUMINE	57-68 (%)	01/05/91	51.10	<	43.00	<	50.30	<
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	235.00	>	217.00	>	289.00	>>
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	115.00		119.00		161.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	5.60	>	3.30		4.20	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	11.00	>	8.10		8.70	
GLOBULINS BETA	9-13 (%)	01/05/91	14.00	>	11.80		14.80	>
GLOBULINS GAMMA	10-20 (%)	01/05/91	18.30		33.80	>>	22.00	>
TSH	0.2-3.1 (UU/ML)	01/05/91	0.61					
T4	5-11.5 (UG/DL)	01/05/91	12.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14/3 Patient: 419 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/07/91		25/07/91		15/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/05/91	13.70		13.50		13.80	
HT	36-48 (%)	01/05/91	39.70		39.00		41.80	
RBC	4.2-5.8 (10-6/MM3)	01/05/91	4.40		4.20		4.50	
WBC	4000-9000 (/MM3)	01/05/91	4000.00		5200.00		4000.00	
WBC: N	50-70 (%)	01/05/91	39.00	<	40.00	<	40.00	<
WBC: L	25-40 (%)	01/05/91	54.00	>>	50.00	>	56.00	>>
WBC: E	0-1 (%)	01/05/91	2.00	>>	1.00		2.00	>>
WBC: M	4-8 (%)	01/05/91	5.00		6.00		2.00	<
WBC: B	0-1 (%)	01/05/91	0.00		1.00		0.00	
PLATELETS	150-400 (10-3/MM3)	01/05/91	216.00		220.00		202.00	
NA+	134-148 (MMOL/L)	01/05/91	145.00		145.00		141.70	
K+	3.8-5.2 (MMOL/L)	01/05/91	4.00		4.40		4.10	
CL-	96-111 (MMOL/L)	01/05/91	103.80		105.40		103.60	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.40		2.50		2.50	
PO4--	0.8-1.6 (MMOL/L)	01/05/91	1.20		1.22		1.44	
SGOT	5-18 (U/L)	01/05/91	8.00		12.00		8.00	
SGPT	5-22 (U/L)	01/05/91	6.00		10.00		6.00	
GAMMA GT	4-28 (U/L)	01/05/91	8.00		9.00		6.00	
LDH	120-240 (U/L)	01/05/91	201.00		209.00		201.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	90.00		94.00		84.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	101.00		123.10	>	89.20	
BUN	10-50 (MG/DL)	01/05/91	36.00		34.00		33.00	
UREA	()	01/05/91						
CREATININE	0.3-1.2 (MG/DL)	01/05/91	0.90		1.00		1.00	
URIC ACID	2.4-7 (MG/DL)	01/05/91	5.70		5.10		5.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.60		0.30		0.30	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.30	>	0.10			
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	7.60		7.50		7.60	
ALBUMINE	57-68 (%)	01/05/91	66.70		60.50		68.50	>
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	264.00	>>	311.00	>>	246.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	93.00		110.00		124.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	2.90		2.80		3.40	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	8.00		7.80		7.20	
GLOBULINS BETA	9-13 (%)	01/05/91	9.30		9.80		10.80	
GLOBULINS GAMMA	10-20 (%)	01/05/91	13.10		19.10		9.70	<
TSH	0.2-3.1 (UU/ML)	01/05/91	1.37					
T4	5-11.5 (UG/DL)	01/05/91	7.94					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

1208

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14/3 Patient: 421 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/07/91		08/08/91		22/08/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/05/91	13.40		13.70		12.70	
HT	36-48 (%)	01/05/91	39.50		41.10		40.10	
RBC	4.2-5.8 (10-6/MM3)	01/05/91	4.60		4.50		4.10	<
WBC	4000-9000 (/MM3)	01/05/91	3600.00	<	5300.00		4500.00	
WBC: N	50-70 (%)	01/05/91	54.80		58.00		47.00	<
WBC: L	25-40 (%)	01/05/91	30.80		27.00		40.00	
WBC: E	0-1 (%)	01/05/91	3.20	>>	4.00	>>	1.00	
WBC: M	4-8 (%)	01/05/91	7.70		10.00	>	12.00	>>
WBC: B	0-1 (%)	01/05/91	1.20	>	1.00		0.00	
PLATELETS	150-400 (10-3/MM3)	01/05/91	263.00		228.00		242.00	
NA+	134-148 (MMOL/L)	01/05/91	141.00		140.10		138.40	
K+	3.8-5.2 (MMOL/L)	01/05/91	3.90		4.10		3.70	<
CL-	96-111 (MMOL/L)	01/05/91	102.40		102.00		103.00	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.20		2.40		2.30	
PO4--	0.8-1.6 (MMOL/L)	01/05/91	1.10		1.12		1.11	
SGOT	5-18 (U/L)	01/05/91	7.00		7.00		7.00	
SGPT	5-22 (U/L)	01/05/91	11.00		10.00		9.00	
GAMMA GT	4-28 (U/L)	01/05/91	5.00		5.00		4.00	
LDH	120-240 (U/L)	01/05/91	100.00	<	124.00		130.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	54.00	<	81.00		61.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	73.50		111.50	>	124.10	>
BUN	10-50 (MG/DL)	01/05/91	34.00		22.00		23.00	
UREA	()	01/05/91						
CREATININE	0.3-1.2 (MG/DL)	01/05/91	0.91		1.00		1.00	
URIC ACID	2.4-7 (MG/DL)	01/05/91	1.80	<	2.40		2.20	<
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.37		0.30		0.20	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.10		0.10		0.00	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	7.00		7.60		7.30	
ALBUMINE	57-68 (%)	01/05/91	63.30		66.50		56.90	<
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	140.00		170.00		154.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	34.00	<	68.00		52.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	2.50		1.50	<	4.40	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	5.50		5.50		7.30	
GLOBULINS BETA	9-13 (%)	01/05/91	10.10		10.10		11.40	
GLOBULINS GAMMA	10-20 (%)	01/05/91	18.60		16.40		20.00	
TSH	0.2-3.1 (UU/ML)	01/05/91	0.42					
T4	5-11.5 (UG/DL)	01/05/91	9.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14/4 Patient: 134 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/01/92		06/02/92		27/02/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	02/12/91	13.20		13.80		14.20	
HT	35.8-45.4 (%)	02/12/91	46.00	>	42.00		45.00	
RBC	3.9-5.6 (10¬6/MM3)	02/12/91	4.80		5.10		5.20	
WBC	5-9 (10¬3/MM3)	02/12/91	8.30		7.80		7.60	
WBC: N	50-70 (%)	02/12/91	62.00		57.00		57.00	
WBC: L	25-40 (%)	02/12/91	34.00		38.00		39.00	
WBC: E	2-4 (%)	02/12/91	3.00		4.00		2.00	
WBC: M	2-8 (%)	02/12/91	3.00		1.00	<	1.00	<
WBC: B	0-1 (%)	02/12/91	1.00		0.00		1.00	
PLATELETS	200-350 (10¬3/MM3)	02/12/91	240.00		270.00		265.00	
NA+	137-147 (MMOL/L)	02/12/91	144.00		140.00		139.00	
K+	3.6-5.5 (MMOL/L)	02/12/91	4.10		3.90		3.80	
CL-	101-111 (MMOL/L)	02/12/91	109.00		108.00		102.00	
Ca++	2.25-2.6 (MMOL/L)	02/12/91	2.46		2.32		2.48	
PO4--	0.8-1.6 (MMOL/L)	02/12/91	0.90		1.40		0.95	
SGOT	5-17 (U/L)	02/12/91	16.00		14.00		15.00	
SGPT	5-23 (U/L)	02/12/91	18.00		20.00		21.00	
GAMMA GT	6-28 (U/L)	02/12/91	24.00		21.00		24.00	
LDH	80-240 (U/L)	02/12/91	160.00		221.00		218.00	
ALK. PHOSPH.	40-190 (U/L)	02/12/91	140.00		113.00		160.00	
GLUCOSE	70-115 (MG/DL)	02/12/91	84.00		91.00		102.00	
BUN	20-40 (MG/DL)	02/12/91	36.00		32.00		39.00	
UREA	()	02/12/91						
CREATININE	0.6-1.1 (MG/DL)	02/12/91	0.90		0.90		0.80	
URIC ACID	2.4-5.7 (MG/DL)	02/12/91	3.60		3.50		5.60	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/12/91	0.80		0.90		0.90	
DIR BILIRUBIN	()	02/12/91						
TOT. PROTEINS	6.7-8.2 (G/DL)	02/12/91	6.90		6.70		7.40	
ALBUMINE	53-70 (%)	02/12/91	69.00		58.00		56.00	
TOT. CHOLEST.	140-240 (MG/DL)	02/12/91	201.00		233.00		240.00	
TRIGLYCERIDES	0-200 (MG/DL)	02/12/91	184.00		192.00		185.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	02/12/91	3.40		3.20		4.20	
GLOBULINS ALPHA 2	9-14 (%)	02/12/91	10.20		10.40		9.30	
GLOBULINS BETA	8-12 (%)	02/12/91	11.20		11.40		14.60	>
GLOBULINS GAMMA	10-18 (%)	02/12/91	11.80		10.90		11.20	
TSH	0.16-3.2 (MU/L)	02/12/91	2.41					
T4	48-120 (UG/L)	02/12/91	102.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1210

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14/4 Patient: 135 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/01/92		06/02/92		28/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	02/12/91	15.30		15.60		15.80	
HT	43.2-49.2 (%)	02/12/91	46.40		48.00		49.00	
RBC	4.6-6.2 (10¬6/MM3)	02/12/91	5.30		5.40		5.60	
WBC	5-9 (10¬3/MM3)	02/12/91	8.20		7.60		8.40	
WBC: N	50-70 (%)	02/12/91	59.00		55.00		64.00	
WBC: L	25-40 (%)	02/12/91	33.00		39.00		30.00	
WBC: E	2-4 (%)	02/12/91	3.00		4.00		2.00	
WBC: M	3-5 (%)	02/12/91	3.00		2.00	<	4.00	
WBC: B	0-1 (%)	02/12/91	1.00		0.00		0.00	
PLATELETS	200-350 (10¬3/MM3)	02/12/91	320.00		316.00		290.00	
NA+	137-142 (MMOL/L)	02/12/91	139.00		142.00		140.00	
K+	3.6-5.5 (MMOL/L)	02/12/91	3.90		4.90		4.70	
CL-	101-111 (MMOL/L)	02/12/91	109.00		109.00		109.00	
Ca++	2.25-2.6 (MMOL/L)	02/12/91	2.34		2.43		2.58	
PO4--	0.8-1.6 (MMOL/L)	02/12/91	0.91		1.30		1.40	
SGOT	5-17 (U/L)	02/12/91	19.00	>	20.00	>	21.00	>
SGPT	5-23 (U/L)	02/12/91	20.00		24.00	>	25.00	>
GAMMA GT	6-28 (U/L)	02/12/91	24.00		32.00	>	34.00	>
LDH	80-240 (U/L)	02/12/91	160.00		180.00		225.00	
ALK. PHOSPH.	50-190 (U/L)	02/12/91	154.00		144.00		165.00	
GLUCOSE	50-100 (MG/DL)	02/12/91	102.00	>	98.00		104.00	>
BUN	20-40 (MG/DL)	02/12/91	43.00	>	41.00	>	42.00	>
UREA	()	02/12/91						
CREATININE	0.7-1.3 (MG/DL)	02/12/91	1.12		1.20		0.91	
URIC ACID	3.7-7 (MG/DL)	02/12/91	6.50		6.20		6.50	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/12/91	1.00		0.90		1.00	
DIR BILIRUBIN	()	02/12/91						
TOT. PROTEINS	6.7-8.2 (G/DL)	02/12/91	7.20		7.40		7.60	
ALBUMINE	53-70 (%)	02/12/91	56.00		58.00		61.00	
TOT. CHOLEST.	140-250 (MG/DL)	02/12/91	246.00		233.00		248.00	
TRIGLYCERIDES	0-200 (MG/DL)	02/12/91	184.00		201.00	>	222.00	>
GLOBULINS ALPHA 1	2.5-4.5 (%)	02/12/91	3.30		3.60		4.20	
GLOBULINS ALPHA 2	9-14 (%)	02/12/91	9.20		9.80		11.20	
GLOBULINS BETA	8-12 (%)	02/12/91	10.40		12.20	>	11.80	
GLOBULINS GAMMA	10-18 (%)	02/12/91	14.60		15.20		14.80	
TSH	0.16-3.2 (MU/L)	02/12/91	2.28					
T4	48-120 (UG/L)	02/12/91	116.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1211

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/7 Patient: 424 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/09/91		10/10/91		31/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.00		13.50		15.40	
HT	37-47 (%)	01/08/91	45.00		47.00		37.80	
RBC	4.5-5 (10~6/MM3)	01/08/91	4.30	<	4.60		4.70	
WBC	3500-9000 (/MM3)	01/08/91	6500.00		7200.00		6200.00	
WBC: N	37-73 (%)	01/08/91	62.00		48.00		43.00	
WBC: L	20-55 (%)	01/08/91	32.00		32.00		25.00	
WBC: E	0.5-11 (%)	01/08/91	2.00		2.00		6.00	
WBC: M	2.5-10 (%)	01/08/91	2.00	<	2.00	<	3.50	
WBC: B	0-2 (%)	01/08/91	1.00		0.00		1.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	290000		325000		395000	
NA+	134-148 (MMOL/L)	01/08/91	140.00		142.00		148.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.20		4.40		3.70	<
CL-	84-110 (MMOL/L)	01/08/91	99.00		96.00		98.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.30		4.40		5.00	
PO4--	23.3-49.8 (MG/L)	01/08/91	42.00		38.00		28.50	
SGOT	5-18 (U/L)	01/08/91	12.00		13.00		16.00	
SGPT	5-22 (U/L)	01/08/91	10.00		11.00		20.00	
GAMMA GT	4-28 (U/L)	01/08/91	20.00		18.00		26.00	
LDH	120-240 (U/L)	01/08/91	180.00		184.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	140.00		145.00		160.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	69.30		72.40		115.00	>
BUN	10-50 (MG/DL)	01/08/91	46.00		42.00		25.80	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	0.90		0.80		1.00	
URIC ACID	2.4-7 (MG/DL)	01/08/91	5.40		5.20		6.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.80		0.80		0.40	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	6.90		6.80		8.00	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.30		5.20		5.10	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	222.00	>	254.00	>	254.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	162.00		148.00		190.00	>
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.30		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.60		0.50		0.70	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.80		0.70		0.80	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.20		0.90		1.20	
TSH	0.2-4 (UU/ML)	01/08/91	2.40					
T4	5-11.5 (UG/DL)	01/08/91	7.80					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 14/7 Patient: 430 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/10/91		28/10/91		18/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	05/10/91	14.30		14.50		15.20	
HT	37-47 (%)	05/10/91	44.80		45.20		42.80	
RBC	4.5-5 (10-6/MM3)	05/10/91	4.30	<	4.50		4.60	
WBC	3500-9000 (/MM3)	05/10/91	7800.00		8200.00		7400.00	
WBC: N	37-73 (%)	05/10/91	48.00		47.00		53.00	
WBC: L	20-55 (%)	05/10/91	32.00		33.00		32.00	
WBC: E	0.5-11 (%)	05/10/91	5.80		5.70		0.90	
WBC: M	2.5-10 (%)	05/10/91	8.40		8.20		7.40	
WBC: B	0-2 (%)	05/10/91	1.20		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	05/10/91	320000		400000		290000	
NA+	134-148 (MMOL/L)	05/10/91	140.00		145.00		143.00	
K+	3.8-5.2 (MMOL/L)	05/10/91	4.20		4.50		4.80	
CL-	84-110 (MMOL/L)	05/10/91	98.00		97.00		97.00	
Ca++	4.2-5.5 (MEQ/L)	05/10/91	4.30		4.50		4.80	
PO4--	2.5-4.5 (MG/DL)	05/10/91	3.20		3.30			
	23.3-49.8 (MG/L)	17/11/91					42.40	
SGOT	5-18 (U/L)	05/10/91	8.00		10.00		16.00	
SGPT	5-22 (U/L)	05/10/91	7.00		12.00		18.00	
GAMMA GT	4-28 (U/L)	05/10/91	7.00		8.00		12.00	
LDH	120-240 (U/L)	05/10/91	127.00		135.00		195.00	
ALK. PHOSPH.	60-170 (U/L)	05/10/91	140.00		142.00		136.00	
GLUCOSE	60-110 (MG/DL)	05/10/91	94.20		97.20		96.40	
BUN	10-50 (MG/DL)	05/10/91	39.80		35.20		21.40	
UREA	()	05/10/91						
CREATININE	0.3-1.2 (MG/DL)	05/10/91	1.00		0.90		1.00	
URIC ACID	2.4-7 (MG/DL)	05/10/91	4.50		4.70		6.20	
TOT BILIRUBIN	0-1 (MG/DL)	05/10/91	0.29		0.30		0.10	
DIR BILIRUBIN	()	05/10/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	05/10/91	7.52		8.20		7.40	
ALBUMINE	3.7-5.5 (G/DL)	05/10/91	3.90		4.10		5.20	
TOT. CHOLEST.	120-200 (MG/DL)	05/10/91	240.00	>	238.00	>	225.00	>
TRIGLYCERIDES	50-180 (MG/DL)	05/10/91	183.00	>	169.00		154.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	05/10/91	0.10		0.20		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	05/10/91	0.50		0.40		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	05/10/91	0.70		0.80		0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	05/10/91	0.90		1.20		1.20	
TSH	0.2-4 (UU/ML)	05/10/91	2.30					
T4	5-11.5 (UG/DL)	05/10/91	10.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14/7 Patient: 431 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/10/91		29/10/91		19/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	05/10/91	14.70		14.30		14.20	
HT	37-47 (%)	05/10/91	43.40		42.20		41.00	
RBC	4.5-5 (10~6/MM3)	05/10/91	4.30	<	4.10	<	4.20	<
WBC	3500-9000 (/MM3)	05/10/91	7500.00		8200.00		4900.00	
WBC: N	37-73 (%)	05/10/91	45.00		43.00		57.00	
WBC: L	20-55 (%)	05/10/91	32.00		30.00		35.00	
WBC: E	0.5-11 (%)	05/10/91	0.80		0.70		0.60	
WBC: M	2.5-10 (%)	05/10/91	3.40		3.40		7.20	
WBC: B	0-2 (%)	05/10/91	1.50		1.50		0.00	
PLATELETS	150000-400000 (/MM3)	05/10/91	420000	>	375000		325000	
NA+	134-148 (MMOL/L)	05/10/91	143.00		142.00		142.00	
K+	3.8-5.2 (MMOL/L)	05/10/91	4.20		3.80		4.20	
CL-	84-110 (MMOL/L)	05/10/91	101.00		100.00		98.00	
Ca++	4.2-5.5 (MEQ/L)	05/10/91	4.14	<	4.00	<	4.80	
PO4--	2.5-4.5 (MG/DL)	05/10/91	3.50		3.20			
	23.3-49.8 (MG/L)	18/11/91					37.20	
SGOT	5-18 (U/L)	05/10/91	8.00		12.00		12.00	
SGPT	5-22 (U/L)	05/10/91	10.00		14.00		21.00	
GAMMA GT	4-28 (U/L)	05/10/91	9.00		12.00		26.00	
LDH	120-240 (U/L)	05/10/91	146.00		152.00		186.00	
ALK. PHOSPH.	60-170 (U/L)	05/10/91	70.70		78.40		154.00	
GLUCOSE	60-110 (MG/DL)	05/10/91	78.60		72.40		78.40	
BUN	10-50 (MG/DL)	05/10/91	32.00		28.30		18.40	
UREA	()	05/10/91						
CREATININE	0.3-1.2 (MG/DL)	05/10/91	1.20		1.00		0.90	
URIC ACID	2.4-7 (MG/DL)	05/10/91	6.64		6.70		6.40	
TOT BILIRUBIN	0-1 (MG/DL)	05/10/91	0.24		0.10		0.20	
DIR BILIRUBIN	()	05/10/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	05/10/91	6.50	<	6.20	<	6.80	
ALBUMINE	3.7-5.5 (G/DL)	05/10/91	4.30		4.10		4.70	
TOT. CHOLEST.	120-200 (MG/DL)	05/10/91	195.00		182.00		202.00	>
TRIGLYCERIDES	50-180 (MG/DL)	05/10/91	98.60		82.40		84.30	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	05/10/91	0.20		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	05/10/91	0.70		0.50		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	05/10/91	0.60		0.60		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	05/10/91	1.10		1.30		1.20	
TSH	0.2-4 (UU/ML)	05/10/91	3.20					
T4	5-11.5 (UG/DL)	05/10/91	10.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 14/7 Patient: 434 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/10/91		04/11/91		25/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	05/10/91	14.80		14.20		13.40	
HT	37-47 (%)	05/10/91	44.00		43.00		42.00	
RBC	4.5-5 (10-6/MM3)	05/10/91	4.80		4.60		4.80	
WBC	3500-9000 (/MM3)	05/10/91	7800.00		8200.00		7600.00	
WBC: N	37-73 (%)	05/10/91	69.00		72.00		55.00	
WBC: L	20-55 (%)	05/10/91	35.00		36.00		32.00	
WBC: E	0.5-11 (%)	05/10/91	2.40		2.30		4.50	
WBC: M	2.5-10 (%)	05/10/91	6.80		6.40		4.20	
WBC: B	0-2 (%)	05/10/91	0.00		0.00		1.00	
PLATELETS	150000-400000 (/MM3)	05/10/91	240000		315000		295000	
NA+	134-148 (MMOL/L)	05/10/91	145.00		144.00		132.00	<
K+	3.8-5.2 (MMOL/L)	05/10/91	4.30		4.10		3.80	
CL-	84-110 (MMOL/L)	05/10/91	98.00		96.00		97.00	
Ca++	4.2-5.5 (MEQ/L)	05/10/91	4.80		4.60		4.40	
PO4--	2.5-4.5 (MG/DL)	05/10/91	3.70		3.60			
	23.3-49.8 (MG/L)	24/11/91					30.20	
SGOT	5-18 (U/L)	05/10/91	9.00		12.00		16.00	
SGPT	5-22 (U/L)	05/10/91	10.00		14.00		20.00	
GAMMA GT	4-28 (U/L)	05/10/91	18.00		22.00		28.00	
LDH	120-240 (U/L)	05/10/91	160.00		176.00		140.00	
ALK. PHOSPH.	60-170 (U/L)	05/10/91	130.00		145.00		125.00	
GLUCOSE	60-110 (MG/DL)	05/10/91	72.80		68.40		72.40	
BUN	10-50 (MG/DL)	05/10/91	22.00		21.40		23.20	
UREA	()	05/10/91						
CREATININE	0.3-1.2 (MG/DL)	05/10/91	0.90		0.70		0.80	
URIC ACID	2.4-7 (MG/DL)	05/10/91	6.20		6.00		6.80	
TOT BILIRUBIN	0-1 (MG/DL)	05/10/91	0.90		0.80		0.40	
DIR BILIRUBIN	()	05/10/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	05/10/91	6.80		6.40	<	6.90	
ALBUMINE	3.7-5.5 (G/DL)	05/10/91	4.90		4.80		4.70	
TOT. CHOLEST.	120-200 (MG/DL)	05/10/91	320.00	>>	310.00	>>	295.00	>>
TRIGLYCERIDES	50-180 (MG/DL)	05/10/91	175.00		105.00		128.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	05/10/91	0.20		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	05/10/91	0.80		0.60		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	05/10/91	0.70		0.70		0.40	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	05/10/91	1.30		1.20		1.00	
TSH	0.2-4 (UU/ML)	05/10/91	3.40					
T4	5-11.5 (UG/DL)	05/10/91	10.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/7 Patient: 439 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/11/91		02/12/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.50		14.70		15.20	
HT	37-47 (%)	01/08/91	42.00		45.00		42.00	
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.60		4.90		4.70	
WBC	3500-9000 (/MM3)	01/08/91	6400.00		7200.00		6800.00	
WBC: N	37-73 (%)	01/08/91	56.00		53.00		48.00	
WBC: L	20-55 (%)	01/08/91	35.00		40.00		32.00	
WBC: E	0.5-11 (%)	01/08/91	0.60		0.80		7.40	
WBC: M	2.5-10 (%)	01/08/91	8.00		8.50		6.20	
WBC: B	0-2 (%)	01/08/91	1.00		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	157000		232000		325000	
NA+	134-148 (MMOL/L)	01/08/91	141.40		140.20		141.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.53		4.40		4.30	
CL-	84-110 (MMOL/L)	01/08/91	96.00		103.00		97.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.30		4.20		4.90	
PO4--	23.3-49.8 (MG/L)	01/08/91	32.40		23.80		32.40	
SGOT	5-18 (U/L)	01/08/91	11.00		14.60		18.40	>
SGPT	5-22 (U/L)	01/08/91	8.00		20.30		20.60	>
GAMMA GT	4-28 (U/L)	01/08/91	3.00	<	24.80		32.40	>
LDH	120-240 (U/L)	01/08/91	184.00		192.00		204.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	106.00		112.00		152.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	90.50		79.40		92.00	
BUN	10-50 (MG/DL)	01/08/91	61.00	>	53.00	>	45.80	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	0.90		0.70		0.90	
URIC ACID	2.4-7 (MG/DL)	01/08/91	4.40		4.30		5.60	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.48		0.74		0.00	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	6.86		7.20		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.60		5.10		4.20	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	257.00	>	268.00	>>	254.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	51.00		78.00		68.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.20		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.60		0.80		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.80		0.80		0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.20		1.20		1.00	
TSH	0.2-4 (UU/ML)	01/08/91	2.80					
T4	5-11.5 (UG/DL)	01/08/91	8.40					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

1216

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14/7 Patient: 449 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/12/91		10/01/92		31/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.20		14.80		13.20	
HT	37-47 (%)	01/08/91	41.80		42.40		40.60	
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.80		4.90		4.90	
WBC	3500-9000 (/MM3)	01/08/91	7200.00		8400.00		8600.00	
WBC: N	37-73 (%)	01/08/91	45.00		52.00		50.00	
WBC: L	20-55 (%)	01/08/91	35.00		48.00		45.00	
WBC: E	0.5-11 (%)	01/08/91	4.50		5.70		7.40	
WBC: M	2.5-10 (%)	01/08/91	3.50		2.90		4.80	
WBC: B	0-2 (%)	01/08/91	0.00		0.00		0.80	
PLATELETS	150000-400000 (/MM3)	01/08/91	193000		232000		287000	
NA+	134-148 (MMOL/L)	01/08/91	138.00		135.00		142.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	3.90		4.80		4.20	
CL-	84-110 (MMOL/L)	01/08/91	98.00		96.00		97.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.50		4.80		4.90	
PO4--	23.3-49.8 (MG/L)	01/08/91	36.20		39.20		42.40	
SGOT	5-18 (U/L)	01/08/91	9.00		8.00		10.00	
SGPT	5-22 (U/L)	01/08/91	9.00		8.00		8.00	
GAMMA GT	4-28 (U/L)	01/08/91	9.00		9.00		8.00	
LDH	120-240 (U/L)	01/08/91	166.00		172.00		148.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	107.00		118.00		123.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	103.00		100.00		89.00	
BUN	10-50 (MG/DL)	01/08/91	31.00		30.80		29.40	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	0.80		0.70		0.80	
URIC ACID	2.4-7 (MG/DL)	01/08/91	5.90		6.20		4.90	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.28		0.42		0.62	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	6.62		6.84		7.02	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.80		5.10		5.00	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	216.00	>	220.00	>	214.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	121.00		112.00		98.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.20		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.40		0.50		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.50		0.60		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	0.80		0.70		0.80	
TSH	0.2-4 (UU/ML)	01/08/91	0.30					
T4	5-11.5 (UG/DL)	01/08/91	7.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/8 Patient: 130 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/01/92		31/01/92		21/02/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	02/08/91	12.90	<	12.80	<	12.90	<
HT	38-52 (%)	02/08/91	43.00		44.00		43.00	
RBC	4.5-6 (10-6/MM3)	02/08/91	4.10	<	4.20	<	4.20	<
WBC	4000-10000 (/MM3)	02/08/91	7600.00		8400.00		7600.00	
WBC: N	63-73 (%)	02/08/91	63.00		67.00		63.00	
WBC: L	19-52 (%)	02/08/91	31.00		32.00		33.00	
WBC: E	0-4 (%)	02/08/91	2.00		0.00		1.00	
WBC: M	0-8 (%)	02/08/91	3.00		1.00		2.00	
WBC: B	0-2 (%)	02/08/91	1.00		0.00		1.00	
PLATELETS	140000-440000 (/MM3)	02/08/91	225000		220000		175000	
NA+	135-145 (MMOL/L)	02/08/91	149.00	>	145.00		141.00	
K+	3.8-5 (MMOL/L)	02/08/91	3.90		4.10		4.00	
CL-	()	02/08/91						
Ca++	2.2-2.75 (MMOL/L)	02/08/91	2.59		2.61		2.49	
PO4--	()	02/08/91						
SGOT	5-18 (U/L)	02/08/91	11.00		10.00		9.00	
SGPT	5-22 (U/L)	02/08/91	9.00		11.00		13.00	
GAMMA GT	0-28 (U/L)	02/08/91	13.00		15.00		14.00	
LDH	120-240 (U/L)	02/08/91	126.00		131.00		129.00	
ALK. PHOSPH.	60-170 (U/L)	02/08/91	154.00		156.00		154.00	
GLUCOSE	60-110 (MG/DL)	02/08/91	96.00		102.00		107.00	
BUN	10-50 (MG/DL)	02/08/91	36.00		40.00		40.00	
UREA	()	02/08/91						
CREATININE	0.6-1.1 (MG/DL)	02/08/91	1.00		0.90		1.00	
URIC ACID	3.4-7 (MG/DL)	02/08/91	5.40		5.60		5.40	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/08/91	0.70		0.70		0.70	
DIR BILIRUBIN	()	02/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	02/08/91	6.80		6.70		6.70	
ALBUMINE	55-70 (%)	02/08/91	63.00		63.00		64.00	
TOT. CHOLEST.	120-200 (MG/DL)	02/08/91	205.00	>	209.00	>	212.00	>
TRIGLYCERIDES	65-200 (MG/DL)	02/08/91	174.00		170.00		181.00	
GLOBULINS ALPHA 1	1.5-4 (%)	02/08/91	5.00	>	6.00	>>	5.00	>
GLOBULINS ALPHA 2	5-10 (%)	02/08/91	7.00		7.00		7.00	
GLOBULINS BETA	8-13 (%)	02/08/91	12.00		11.00		11.00	
GLOBULINS GAMMA	10-19 (%)	02/08/91	13.00		13.00		13.00	
TSH	0.25-3.1 (UU/ML)	02/08/91	2.90					
T4	5-11.5 (UG/DL)	02/08/91	9.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

1218

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14/8 Patient: 425 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/09/91		30/09/91		21/10/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/08/91	13.10		13.20		12.90	
HT	36-46 (%)	02/08/91	43.00		42.00		41.00	
RBC	4.1-5.4 (10-6/MM3)	02/08/91	3.90	<	3.80	<	3.80	<
WBC	4000-10000 (/MM3)	02/08/91	8400.00		7600.00		7800.00	
WBC: N	63-73 (%)	02/08/91	67.00		62.00	<	62.00	<
WBC: L	19-52 (%)	02/08/91	30.00		32.00		34.00	
WBC: E	0-4 (%)	02/08/91	1.00		4.00		1.00	
WBC: M	0-8 (%)	02/08/91	2.00		1.00		2.00	
WBC: B	0-2 (%)	02/08/91	0.00		1.00		0.00	
PLATELETS	140000-440000 (/MM3)	02/08/91	325000		330000		350000	
NA+	135-145 (MMOL/L)	02/08/91	141.00		144.00		142.00	
K+	3.8-5 (MMOL/L)	02/08/91	3.90		3.90		3.90	
CL-	()	02/08/91						
Ca++	2.2-2.75 (MMOL/L)	02/08/91	2.61		2.56		2.62	
PO4--	()	02/08/91						
SGOT	5-15 (U/L)	02/08/91	12.00		14.00		13.00	
SGPT	5-17 (U/L)	02/08/91	14.00		11.00		12.00	
GAMMA GT	0-18 (U/L)	02/08/91	17.00		16.00		15.00	
LDH	120-240 (U/L)	02/08/91	125.00		127.00		137.00	
ALK. PHOSPH.	60-170 (U/L)	02/08/91	154.00		157.00		156.00	
GLUCOSE	60-110 (MG/DL)	02/08/91	94.00		88.00		78.00	
BUN	10-50 (MG/DL)	02/08/91	40.00		40.00		40.00	
UREA	()	02/08/91						
CREATININE	0.5-1 (MG/DL)	02/08/91	1.00		1.00		0.90	
URIC ACID	2.4-5.7 (MG/DL)	02/08/91	5.20		5.40		5.60	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/08/91	0.70		0.70		0.60	
DIR BILIRUBIN	()	02/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	02/08/91	7.30		7.40		7.40	
ALBUMINE	53-68 (%)	02/08/91	62.00		65.00		63.00	
TOT. CHOLEST.	120-200 (MG/DL)	02/08/91	207.00	>	211.00	>	219.00	>
TRIGLYCERIDES	65-200 (MG/DL)	02/08/91	169.00		161.00		174.00	
GLOBULINS ALPHA 1	1.5-4 (%)	02/08/91	5.00	>	6.00	>>	5.00	>
GLOBULINS ALPHA 2	5-10 (%)	02/08/91	8.00		8.00		9.00	
GLOBULINS BETA	8-13 (%)	02/08/91	10.00		9.00		10.00	
GLOBULINS GAMMA	10-19 (%)	02/08/91	15.00		12.00		13.00	
TSH	0.25-3.1 (UU/ML)	02/08/91	2.70					
T4	5-11.5 (UG/DL)	02/08/91	8.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/8 Patient: 467 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/07/92		27/07/92		17/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	02/08/91	13.00	<	12.90	<	12.80	<
HT	38-52 (%)	02/08/91	41.00		41.00		42.00	
RBC	4.5-6 (10-6/MM3)	02/08/91	3.80	<<	3.70	<<	3.80	<<
WBC	4000-10000 (/MM3)	02/08/91	7600.00		8400.00		7600.00	
WBC: N	63-73 (%)	02/08/91	62.00	<	60.00	<	64.00	
WBC: L	19-52 (%)	02/08/91	30.00		29.00		26.00	
WBC: E	0-4 (%)	02/08/91	3.00		5.00	>	4.00	
WBC: M	0-8 (%)	02/08/91	4.00		4.00		6.00	
WBC: B	0-2 (%)	02/08/91	1.00		2.00		0.00	
PLATELETS	140000-440000 (/MM3)	02/08/91	275000		225000		250000	
NA+	135-145 (MMOL/L)	02/08/91	139.00		134.00	<	131.00	<
K+	3.8-5 (MMOL/L)	02/08/91	4.00		3.80		3.90	
CL-	()	02/08/91						
Ca++	2.2-2.75 (MMOL/L)	02/08/91	2.48		2.51		2.54	
PO4--	()	02/08/91						
SGOT	5-18 (U/L)	02/08/91	11.00		12.00		13.00	
SGPT	5-22 (U/L)	02/08/91	13.00		13.00		11.00	
GAMMA GT	0-28 (U/L)	02/08/91	9.00		17.00		16.00	
LDH	120-240 (U/L)	02/08/91	122.00		124.00		127.00	
ALK. PHOSPH.	60-170 (U/L)	02/08/91	151.00		154.00		150.00	
GLUCOSE	60-110 (MG/DL)	02/08/91	88.00		92.00		101.00	
BUN	10-50 (MG/DL)	02/08/91	36.00		40.00		40.00	
UREA	()	02/08/91						
CREATININE	0.6-1.1 (MG/DL)	02/08/91	1.00		1.00		0.90	
URIC ACID	3.4-7 (MG/DL)	02/08/91	5.60		5.70		5.90	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/08/91	0.60		0.70		0.70	
DIR BILIRUBIN	()	02/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	02/08/91	7.20		7.10		7.00	
ALBUMINE	55-70 (%)	02/08/91	63.00		62.00		61.00	
TOT. CHOLEST.	120-200 (MG/DL)	02/08/91	211.00	>	217.00	>	229.00	>
TRIGLYCERIDES	65-200 (MG/DL)	02/08/91	181.00		192.00		174.00	
GLOBULINS ALPHA 1	1.5-4 (%)	02/08/91	5.00	>	6.00	>>	7.00	>>
GLOBULINS ALPHA 2	5-10 (%)	02/08/91	7.00		8.00		9.00	
GLOBULINS BETA	8-13 (%)	02/08/91	11.00		10.00		11.00	
GLOBULINS GAMMA	10-19 (%)	02/08/91	14.00		14.00		12.00	
TSH	0.25-3.1 (UU/ML)	02/08/91	2.60					
T4	5-11.5 (UG/DL)	02/08/91	9.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1220

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 53 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/02/92		16/03/92		06/04/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13-18 (G/DL)	01/10/91	15.20		13.10		14.10	
HT	40-54 (%)	01/10/91	44.20		37.60	<	40.50	
RBC	4.6-6.2 (10-6/MM3)	01/10/91	4.85		4.95		4.25	<
WBC	5000-9000 (/MM3)	01/10/91	12700.0	>>	7200.00		6400.00	
WBC: N	50-70 (%)	01/10/91	72.00	>	68.00		58.00	
WBC: L	25-40 (%)	01/10/91	18.00	<	20.00	<	33.00	
WBC: E	2-4 (%)	01/10/91	2.00		0.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	7.00		12.00	>>	8.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	316.00	>	299.00		236.00	
NA+	137-147 (MMOL/L)	01/10/91	144.00		142.00		141.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		5.10		4.10	
CL-	85-120 (MMOL/L)	01/10/91	111.00		101.00		99.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.26		2.31		2.39	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.05		0.73	<	1.07	
SGOT	4-20 (U/L)	01/10/91	7.00		6.60		5.80	
SGPT	4-20 (U/L)	01/10/91	7.00		4.60		8.00	
GAMMA GT	4-18 (U/L)	01/10/91	7.50		5.90		9.40	
LDH	55-150 (U/L)	01/10/91	140.00		124.00		149.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	99.00		70.00		76.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	73.00		89.00		109.00	
BUN	20-40 (MG/DL)	01/10/91	25.00		21.00		48.00	>
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.84		0.81		1.07	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	2.86		2.06	<	5.59	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.55		0.12		0.47	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.08		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	6.33	<	7.36		7.76	
ALBUMINE	56-66 (%)	01/10/91	58.50		58.20		69.80	>
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	228.00		220.00		258.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	94.00		114.00		100.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	4.40		4.10		5.20	>
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	10.10	>	8.90		10.80	>
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.20	>	15.50	>	10.40	
GLOBULINS GAMMA	11-19 (%)	01/10/91	10.80	<	13.30		17.80	
TSH	0.16-3.2 (MU/L)	01/10/91	0.73					
T4	48-120 (UG/L)	01/10/91	73.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14/10 Patient: 55 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/02/92		19/03/92		07/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	17.30	>	16.40	>	15.20	
HT	36-47 (%)	01/10/91	47.10	>	45.20		43.80	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	5.10		5.07		4.25	
WBC	5000-9000 (/MM3)	01/10/91	8800.00		7500.00		7300.00	
WBC: N	50-70 (%)	01/10/91	62.00		66.00		62.00	
WBC: L	25-40 (%)	01/10/91	22.00	<	26.00		31.00	
WBC: E	2-4 (%)	01/10/91	2.00		3.00		1.00	<
WBC: M	2-8 (%)	01/10/91	13.00	>>	4.00		6.00	
WBC: B	0-1 (%)	01/10/91	1.00		1.00		0.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	250.00		249.00		177.00	
NA+	137-147 (MMOL/L)	01/10/91	145.00		145.00		142.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		5.00		3.90	
CL-	85-120 (MMOL/L)	01/10/91	105.00		106.00		102.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.40		2.49		2.30	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.01		1.05		1.02	
SGOT	4-20 (U/L)	01/10/91	7.20		12.00		7.90	
SGPT	4-20 (U/L)	01/10/91	10.20		28.00	>	4.90	
GAMMA GT	4-18 (U/L)	01/10/91	22.60	>	60.00	>>	5.00	
LDH	55-150 (U/L)	01/10/91	142.00		117.00		117.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	137.00		82.00		49.00	<
GLUCOSE	70-120 (MG/DL)	01/10/91	109.00		100.00		123.00	>
BUN	20-40 (MG/DL)	01/10/91	33.00		28.00		22.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.96		1.07		0.87	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	5.13		7.22	>	5.01	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.29		0.61		0.39	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.06		0.05		0.14	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.37		7.10		6.58	<
ALBUMINE	56-66 (%)	01/10/91	68.90	>	62.80		70.40	>
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	276.00	>	278.00	>	244.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	167.00		222.00	>	144.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.60		2.90		2.60	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	5.40	<	6.60		6.30	<
GLOBULINS BETA	8.5-14 (%)	01/10/91	14.30	>	14.70	>	11.30	
GLOBULINS GAMMA	11-19 (%)	01/10/91	8.70	<	13.00		9.30	<
TSH	0.16-3.2 (MU/L)	01/10/91	0.47					
T4	48-120 (UG/L)	01/10/91	91.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 57 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/02/92		24/03/92		14/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	15.80		15.60		13.30	
HT	36-47 (%)	01/10/91	43.80		43.90		38.90	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.69		4.44		4.02	
WBC	5000-9000 (/MM3)	01/10/91	4900.00	<	8100.00		4900.00	<
WBC: N	50-70 (%)	01/10/91	61.00		62.00		54.00	
WBC: L	25-40 (%)	01/10/91	53.00	>>	30.00		33.00	
WBC: E	2-4 (%)	01/10/91	0.00	<	1.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	6.00		6.00		11.00	>>
WBC: B	0-1 (%)	01/10/91	0.00		1.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	261.00		367.00	>	322.00	>
NA+	137-147 (MMOL/L)	01/10/91	138.00		141.00		137.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.10		4.70		4.40	
CL-	85-120 (MMOL/L)	01/10/91	106.00		111.00		104.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.32		2.43		2.56	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	2.16	>>	1.21		1.16	
SGOT	4-20 (U/L)	01/10/91	6.00		9.40		8.80	
SGPT	4-20 (U/L)	01/10/91	4.90		7.70		7.30	
GAMMA GT	4-18 (U/L)	01/10/91	7.80		12.80		8.30	
LDH	55-150 (U/L)	01/10/91	88.00		70.00		188.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	95.00		137.00		87.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	87.00		97.00		99.00	
BUN	20-40 (MG/DL)	01/10/91	32.00		36.00		25.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	1.08		0.97		0.80	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	3.42		5.40		4.34	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.17		0.42		0.22	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.06		0.08		0.27	>
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.38		8.33	>	7.08	
ALBUMINE	56-66 (%)	01/10/91	58.90		52.50	<	58.50	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	148.00		226.00		191.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	50.00		122.00		89.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.30		4.90	>	4.10	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	9.40		15.20	>>	9.50	
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.10	>	15.60	>	12.40	
GLOBULINS GAMMA	11-19 (%)	01/10/91	12.40		11.80		15.20	
TSH	0.16-3.2 (MU/L)	01/10/91	0.72					
T4	48-120 (UG/L)	01/10/91	88.00					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 60 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/05/92		02/06/92		23/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	13.40		14.10		13.50	
HT	36-47 (%)	01/10/91	39.00		41.50		37.90	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	3.96		4.52		4.39	
WBC	5000-9000 (/MM3)	01/10/91	10200.0	>	10400.0	>	5200.00	
WBC: N	50-70 (%)	01/10/91	60.00		51.00		39.00	<
WBC: L	25-40 (%)	01/10/91	34.00		44.00	>	52.00	>
WBC: E	2-4 (%)	01/10/91	3.00		0.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	3.00		5.00		8.00	
WBC: B	0-1 (%)	01/10/91	0.00		0.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	246.00		171.00		318.00	>
NA+	137-147 (MMOL/L)	01/10/91	145.00		141.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.20		3.90		4.30	
CL-	85-120 (MMOL/L)	01/10/91	101.00		104.00		107.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.42		2.34		2.37	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.43		1.01		1.26	
SGOT	4-20 (U/L)	01/10/91	4.30		57.00	>>	7.80	
SGPT	4-20 (U/L)	01/10/91	3.80	<	6.20		8.20	
GAMMA GT	4-18 (U/L)	01/10/91	8.20		11.10		5.70	
LDH	55-150 (U/L)	01/10/91	123.00		153.00	>	124.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	71.00		67.00		58.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	89.00		94.00		99.00	
BUN	20-40 (MG/DL)	01/10/91	29.00		15.00	<	32.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.80		0.75		0.76	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.17		3.29		4.53	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.25		0.44		0.31	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.21		0.14		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.04		7.17		7.55	
ALBUMINE	56-66 (%)	01/10/91	59.10		63.90		58.40	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	252.00	>	207.00		289.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	147.00		149.00		161.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	5.40	>	2.90		4.30	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	10.30	>	7.90		8.50	
GLOBULINS BETA	8.5-14 (%)	01/10/91	13.40		10.70		12.30	
GLOBULINS GAMMA	11-19 (%)	01/10/91	11.80		14.60		16.50	
TSH	0.16-3.2 (MU/L)	01/10/91	1.58					
T4	48-120 (UG/L)	01/10/91	95.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 137 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/01/92		17/02/92		09/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	12.80		13.20		13.60	
HT	36-47 (%)	01/10/91	37.80		36.40		38.20	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	3.93		4.53		4.51	
WBC	5000-9000 (/MM3)	01/10/91	6000.00		8800.00		4000.00	<
WBC: N	50-70 (%)	01/10/91	51.00		58.00		59.00	
WBC: L	25-40 (%)	01/10/91	40.00		33.00		30.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	0.00	<	2.00	
WBC: M	2-8 (%)	01/10/91	7.00		8.00		7.00	
WBC: B	0-1 (%)	01/10/91	1.00		1.00		2.00	>>
PLATELETS	150-300 (10-3/MM3)	01/10/91	200.00		246.00		270.00	
NA+	137-147 (MMOL/L)	01/10/91	144.00		152.00	>	146.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		5.30		4.10	
CL-	85-120 (MMOL/L)	01/10/91	95.00		99.00		101.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.34		2.78	>	2.40	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	0.96		1.45		1.07	
SGOT	4-20 (U/L)	01/10/91	11.30		6.50		5.20	
SGPT	4-20 (U/L)	01/10/91	18.20		8.20		6.90	
GAMMA GT	4-18 (U/L)	01/10/91	11.30		12.60		10.00	
LDH	55-150 (U/L)	01/10/91	175.00	>	185.00	>	206.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	61.00		104.00		71.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	90.00		114.00		100.00	
BUN	20-40 (MG/DL)	01/10/91	33.00		13.00	<	21.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.82		0.97		0.94	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	2.81		2.74		3.92	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.29		0.49		0.57	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.07		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.00		6.96		7.41	
ALBUMINE	56-66 (%)	01/10/91	58.50	>	60.80		63.60	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	279.00	>	279.00	>	277.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	120.00		153.00		118.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.50		3.00		3.10	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	6.80		11.60	>	8.40	
GLOBULINS BETA	8.5-14 (%)	01/10/91	11.20		16.80	>	11.90	
GLOBULINS GAMMA	11-19 (%)	01/10/91	11.00		7.90	<	12.80	
TSH	0.16-3.2 (MU/L)	01/10/91	1.08					
T4	48-120 (UG/L)	01/10/91	77.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14/10 Patient: 139 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/01/92		24/02/92		16/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	13.50		14.00		14.00	
HT	36-47 (%)	01/10/91	38.40		39.80		40.30	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.42		4.45		5.21	
WBC	5000-9000 (/MM3)	01/10/91	5400.00		6200.00		6400.00	
WBC: N	50-70 (%)	01/10/91	45.00	<	55.00		58.00	
WBC: L	25-40 (%)	01/10/91	48.00	>	40.00		34.00	
WBC: E	2-4 (%)	01/10/91	2.00		1.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	5.00		3.00		6.00	
WBC: B	0-1 (%)	01/10/91	1.00		1.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	236.00		184.00		296.00	
NA+	137-147 (MMOL/L)	01/10/91	145.00		142.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.30		4.30		3.60	
CL-	85-120 (MMOL/L)	01/10/91	105.00		100.00		93.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.45		3.00	>>	2.36	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.11		1.26		2.00	>>
SGOT	4-20 (U/L)	01/10/91	9.90		11.70		12.10	
SGPT	4-20 (U/L)	01/10/91	7.20		22.70	>	14.00	
GAMMA GT	4-18 (U/L)	01/10/91	8.80		31.70	>	4.90	
LDH	55-150 (U/L)	01/10/91	206.00	>	246.00	>	285.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	104.00		191.00	>	122.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	102.00		106.00		128.00	>
BUN	20-40 (MG/DL)	01/10/91			33.00		40.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.87		0.89		0.31	<
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	3.59		3.93		6.03	>
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.48		0.40		0.53	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.05		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.02		6.98		7.51	
ALBUMINE	56-66 (%)	01/10/91	61.10		60.40		55.40	<
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	228.00		285.00	>	261.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	233.00	>	145.00		242.00	>
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.70		1.50	<<	3.60	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	9.90		10.30	>	8.50	
GLOBULINS BETA	8.5-14 (%)	01/10/91	9.70		13.90		15.10	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	16.60		13.90		17.50	
TSH	0.16-3.2 (MU/L)	01/10/91	0.55					
T4	48-120 (UG/L)	01/10/91	103.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 436 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/11/91		03/12/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	14.10		13.90		13.60	
HT	36-47 (%)	01/10/91	40.90		39.60		38.20	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.36		5.06		4.29	
WBC	5000-9000 (/MM3)	01/10/91	7100.00		5800.00		7200.00	
WBC: N	50-70 (%)	01/10/91	60.00		70.00		68.00	
WBC: L	25-40 (%)	01/10/91	34.00		23.00	<	23.00	<
WBC: E	2-4 (%)	01/10/91	0.00	<	2.00		2.00	
WBC: M	2-8 (%)	01/10/91	5.00		3.00		5.00	
WBC: B	0-1 (%)	01/10/91	0.00		1.00		2.00	>>
PLATELETS	150-300 (10-3/MM3)	01/10/91	128.00	<	333.00	>	216.00	
NA+	137-147 (MMOL/L)	01/10/91	145.00		142.00		141.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.60		4.40		4.30	
CL-	85-120 (MMOL/L)	01/10/91	112.00		100.00		103.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.41		2.35		2.43	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.21		1.01		1.96	>>
SGOT	4-20 (U/L)	01/10/91	6.10		8.20		5.00	
SGPT	4-20 (U/L)	01/10/91	5.70		16.10		8.00	
GAMMA GT	4-18 (U/L)	01/10/91	14.80		15.00		9.20	
LDH	55-150 (U/L)	01/10/91	194.00	>	154.00	>	116.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	67.00		108.00		121.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	98.00		128.00	>	109.00	
BUN	20-40 (MG/DL)	01/10/91	70.00	>>	34.00		34.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.95		1.00		0.66	<
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	7.08	>	7.43	>>	5.23	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.23		0.46		0.37	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.08		0.13		0.10	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.43		7.58		6.68	
ALBUMINE	56-66 (%)	01/10/91	59.00		61.50		58.30	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	253.00	>	290.00	>	201.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	145.00		451.00	>>	139.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.90		3.00		5.40	>
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	7.40		6.80		10.20	>
GLOBULINS BETA	8.5-14 (%)	01/10/91	14.20	>	14.20	>	14.00	
GLOBULINS GAMMA	11-19 (%)	01/10/91	16.50		14.40		12.20	
TSH	0.16-3.2 (MU/L)	01/10/91	0.33					
T4	48-120 (UG/L)	01/10/91	63.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1227

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 437 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/11/91		03/12/91		23/12/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	15.70		15.30		14.20	
HT	36-47 (%)	01/10/91	43.50		42.70		38.60	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.46		4.73		4.78	
WBC	5000-9000 (/MM3)	01/10/91	7500.00		4600.00	<	7700.00	
WBC: N	50-70 (%)	01/10/91	55.00		51.00		54.00	
WBC: L	25-40 (%)	01/10/91	42.00	>	31.00		38.00	
WBC: E	2-4 (%)	01/10/91	0.00	<	3.00		0.00	<
WBC: M	2-8 (%)	01/10/91	0.00	<	6.00		6.00	
WBC: B	0-1 (%)	01/10/91	3.00	>>	3.00	>>	2.00	>>
PLATELETS	150-300 (10¬3/MM3)	01/10/91	183.00		231.00		257.00	
NA+	137-147 (MMOL/L)	01/10/91	143.00		139.00		145.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.00		4.70		4.40	
CL-	85-120 (MMOL/L)	01/10/91	105.00		99.00		103.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.26		2.33		2.31	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	0.90		1.04		0.83	
SGOT	4-20 (U/L)	01/10/91	8.60		16.00		11.50	
SGPT	4-20 (U/L)	01/10/91	18.70		34.80	>	14.70	
GAMMA GT	4-18 (U/L)	01/10/91	29.00	>	25.80	>	11.40	
LDH	55-150 (U/L)	01/10/91	189.00	>	150.00		206.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	76.00		70.00		133.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	101.00		112.00		123.00	>
BUN	20-40 (MG/DL)	01/10/91	31.00		39.00		27.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.83		1.01		1.02	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	3.38		4.22		5.27	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.37		0.73		0.24	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.08				0.06	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.89		7.60		7.53	
ALBUMINE	56-66 (%)	01/10/91	59.20		63.10		57.90	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	238.00		218.00		259.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	141.00		133.00		212.00	>
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.80		3.10		2.60	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	7.40		8.90		7.60	
GLOBULINS BETA	8.5-14 (%)	01/10/91	14.10	>	12.90		19.00	>>
GLOBULINS GAMMA	11-19 (%)	01/10/91	16.50		12.00		12.90	
TSH	0.16-3.2 (MU/L)	01/10/91	1.09					
T4	48-120 (UG/L)	01/10/91	124.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 14/10 Patient: 443 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/11/91		09/12/91		30/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	14.40		14.20		14.00	
HT	36-47 (%)	01/10/91	40.50		40.60		42.10	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.61		4.49		4.42	
WBC	5000-9000 (/MM3)	01/10/91	10500.0	>	5700.00		4900.00	<
WBC: N	50-70 (%)	01/10/91	60.00		62.00		75.00	>
WBC: L	25-40 (%)	01/10/91	32.00		32.00		21.00	<
WBC: E	2-4 (%)	01/10/91	1.00	<	0.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	7.00		6.00		2.00	
WBC: B	0-1 (%)	01/10/91	0.00		0.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	333.00	>	355.00	>	270.00	
NA+	137-147 (MMOL/L)	01/10/91	143.00		140.00		146.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	3.90		4.00		4.10	
CL-	85-120 (MMOL/L)	01/10/91	99.00		98.00		96.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.47		2.38		2.29	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.43		1.26		1.11	
SGOT	4-20 (U/L)	01/10/91	10.70		8.50		7.80	
SGPT	4-20 (U/L)	01/10/91	18.90		13.30		7.70	
GAMMA GT	4-18 (U/L)	01/10/91	7.30		8.70		6.40	
LDH	55-150 (U/L)	01/10/91	148.00		160.00	>	209.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	98.00		106.00		69.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	97.00		96.00		106.00	
BUN	20-40 (MG/DL)	01/10/91	42.00	>	37.00		24.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	1.15		1.05		0.84	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.90		4.93		4.34	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.52		0.80		0.66	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.13		0.08		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.18		7.51		7.31	
ALBUMINE	56-66 (%)	01/10/91	53.50	<	58.70		64.00	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	324.00	>	268.00	>	233.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	82.00		90.00		64.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	5.80	>	2.20	<	3.50	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	9.60		8.80		8.10	
GLOBULINS BETA	8.5-14 (%)	01/10/91	18.60	>>	11.10		10.60	
GLOBULINS GAMMA	11-19 (%)	01/10/91	12.50		19.30	>	13.80	
TSH	0.16-3.2 (MU/L)	01/10/91	2.34					
T4	48-120 (UG/L)	01/10/91	87.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 14/10 Patient: 444 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/11/91		06/12/91		27/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/10/91	14.00		14.50		13.60	
HT	40-54 (%)	01/10/91	39.80	<	41.00		37.80	<
RBC	4.6-6.2 (10-6/MM3)	01/10/91	4.34	<	4.83		4.89	
WBC	5000-9000 (/MM3)	01/10/91	7000.00		6900.00		5800.00	
WBC: N	50-70 (%)	01/10/91	60.00		67.00		64.00	
WBC: L	25-40 (%)	01/10/91	36.00		26.00		30.00	
WBC: E	2-4 (%)	01/10/91	0.00	<	2.00		2.00	
WBC: M	2-8 (%)	01/10/91	4.00		2.00		3.00	
WBC: B	0-1 (%)	01/10/91	0.00		3.00	>>	1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	253.00		319.00	>	350.00	>
NA+	137-147 (MMOL/L)	01/10/91	144.00		143.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.50		4.80		4.00	
CL-	85-120 (MMOL/L)	01/10/91	109.00		93.00		99.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.35		2.45		2.30	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.27		1.09		1.32	
SGOT	4-20 (U/L)	01/10/91	7.30		9.00		5.10	
SGPT	4-20 (U/L)	01/10/91	8.10		9.20		6.60	
GAMMA GT	4-18 (U/L)	01/10/91	18.90	>	12.20		8.80	
LDH	55-150 (U/L)	01/10/91	168.00	>	169.00	>	150.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	94.00		136.00		65.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	104.00		112.00		107.00	
BUN	20-40 (MG/DL)	01/10/91	79.00	>>	43.00	>	14.00	<
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	1.02		0.90		1.03	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.15		4.40		3.11	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.49		0.60		0.56	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.14		0.14		0.08	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.44		7.23		6.90	
ALBUMINE	56-66 (%)	01/10/91	52.90	<	54.80	<	62.70	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	206.00		229.00		195.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	147.00		81.00		127.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.90		4.00		2.80	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	9.10		9.00		7.60	
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.90	>	10.30		15.10	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	17.10		17.90		12.00	
TSH	0.16-3.2 (MU/L)	01/10/91	3.18					
T4	48-120 (UG/L)	01/10/91	89.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 14/10 Patient: 446 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/11/91		16/12/91		07/01/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	12.30		14.20		17.40	>
HT	36-47 (%)	01/10/91	34.00	<	39.40		47.10	>
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	3.50	<	4.52		4.98	
WBC	5000-9000 (/MM3)	01/10/91	2700.00	<<	10700.0	>	5300.00	
WBC: N	50-70 (%)	01/10/91	64.00		49.00	<	62.00	
WBC: L	25-40 (%)	01/10/91	28.00		44.00	>	28.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	2.00		1.00	<
WBC: M	2-8 (%)	01/10/91	7.00		4.00		9.00	>
WBC: B	0-1 (%)	01/10/91	0.00		1.00		0.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	170.00		231.00		197.00	
NA+	137-147 (MMOL/L)	01/10/91	141.00		145.00		145.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	5.10		5.00		4.90	
CL-	85-120 (MMOL/L)	01/10/91	104.00		102.00		102.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.48		2.59		2.46	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	0.99		1.04		1.06	
SGOT	4-20 (U/L)	01/10/91	8.10		6.90		9.50	
SGPT	4-20 (U/L)	01/10/91	11.60		5.90		12.10	
GAMMA GT	4-18 (U/L)	01/10/91	15.90		8.80		22.60	>
LDH	55-150 (U/L)	01/10/91	246.00	>	137.00		168.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	68.00		78.00		103.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	114.00		111.00		114.00	
BUN	20-40 (MG/DL)	01/10/91	69.00	>>	31.00		33.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	1.11		1.00		0.99	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.60		4.79		4.92	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.44		0.85		0.73	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.10		0.07		0.10	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.89		7.45		7.21	
ALBUMINE	56-66 (%)	01/10/91	55.00	<	55.40	<	62.00	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	262.00	>	191.00		234.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	74.00		73.00		76.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.40		4.20		3.60	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	8.50		9.80		8.00	
GLOBULINS BETA	8.5-14 (%)	01/10/91	13.50		17.10	>	17.70	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	19.70	>	13.50		8.20	<
TSH	0.16-3.2 (MU/L)	01/10/91	1.19					
T4	48-120 (UG/L)	01/10/91	80.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 14/10 Patient: 447 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/11/91		17/12/91		07/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/10/91	14.60		15.40		14.90	
HT	40-54 (%)	01/10/91	40.70		42.60		40.20	
RBC	4.6-6.2 (10¬6/MM3)	01/10/91	4.60		4.45	<	4.91	
WBC	5000-9000 (/MM3)	01/10/91	5100.00		5400.00		5500.00	
WBC: N	50-70 (%)	01/10/91	54.00		66.00		71.00	>
WBC: L	25-40 (%)	01/10/91	38.00		30.00		22.00	<
WBC: E	2-4 (%)	01/10/91	2.00		1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	4.00		2.00		7.00	
WBC: B	0-1 (%)	01/10/91	2.00	>>	1.00		0.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	276.00		229.00		210.00	
NA+	137-147 (MMOL/L)	01/10/91	141.00		147.00		139.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	3.70		4.20		4.50	
CL-	85-120 (MMOL/L)	01/10/91	96.00		106.00		97.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.38		2.26		2.26	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.09		1.13		1.00	
SGOT	4-20 (U/L)	01/10/91	9.20		8.60		8.60	
SGPT	4-20 (U/L)	01/10/91	10.90		8.50		12.90	
GAMMA GT	4-18 (U/L)	01/10/91	6.70		8.50		8.70	
LDH	55-150 (U/L)	01/10/91	175.00	>	194.00	>	135.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	90.00		118.00		93.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	106.00		99.00		101.00	
BUN	20-40 (MG/DL)	01/10/91	32.00		42.00	>	32.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.79		0.79		0.95	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	5.63		3.52		4.82	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.93		0.49		0.18	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.06		0.10	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.64		7.70		6.84	
ALBUMINE	56-66 (%)	01/10/91	61.50		63.30		58.60	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	210.00		236.00		181.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	69.00		81.00		54.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.80		2.80		4.60	>
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	11.00	>	8.50		9.80	
GLOBULINS BETA	8.5-14 (%)	01/10/91	12.00		12.30		15.70	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	12.70		13.10		11.30	
TSH	0.16-3.2 (MU/L)	01/10/91	1.00					
T4	48-120 (UG/L)	01/10/91	97.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1232

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 454 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/06/92		02/07/92		23/07/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	14.60		14.60		14.80	
HT	36-47 (%)	01/10/91	41.40		42.50		44.40	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.20		5.07		4.79	
WBC	5000-9000 (/MM3)	01/10/91	6700.00		7700.00		5300.00	
WBC: N	50-70 (%)	01/10/91	56.00		76.00	>	55.00	
WBC: L	25-40 (%)	01/10/91	37.00		24.00	<	33.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	0.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	6.00		5.00		10.00	>
WBC: B	0-1 (%)	01/10/91	0.00		1.00		2.00	>>
PLATELETS	150-300 (10-3/MM3)	01/10/91	269.00		306.00	>	277.00	
NA+	137-147 (MMOL/L)	01/10/91	135.00	<	143.00		142.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.50		5.00		4.40	
CL-	85-120 (MMOL/L)	01/10/91	107.00		102.00		104.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.32		2.44		2.26	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.08		1.32		1.09	
SGOT	4-20 (U/L)	01/10/91	6.00		5.50		7.60	
SGPT	4-20 (U/L)	01/10/91	7.00		4.70		8.40	
GAMMA GT	4-18 (U/L)	01/10/91	12.80		6.70		9.10	
LDH	55-150 (U/L)	01/10/91	138.00		79.00		138.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	73.00		97.00		66.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	126.00	>	98.00		98.00	
BUN	20-40 (MG/DL)	01/10/91	38.00		20.00		35.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.82		0.80		1.10	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	3.99		3.31		4.68	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.39		0.32		0.35	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.10		0.14		0.15	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.50		6.63		7.81	
ALBUMINE	56-66 (%)	01/10/91	59.90		70.60	>	52.70	<
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	218.00		199.00		230.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	45.00		94.00		61.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.20		2.80		3.80	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	8.70		7.10		10.50	>
GLOBULINS BETA	8.5-14 (%)	01/10/91	13.30		11.30		13.90	
GLOBULINS GAMMA	11-19 (%)	01/10/91	15.00		8.30	<	19.10	>
TSH	0.16-3.2 (MU/L)	01/10/91	1.21					
T4	48-120 (UG/L)	01/10/91	82.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang-
< out of range (value lower than min range) > out of range (value higher than max rang-
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 14/10 Patient: 455 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/06/92		10/07/92		31/07/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	14.80		14.40		14.50	
HT	36-47 (%)	01/10/91	44.20		41.80		41.80	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.71		4.82		4.96	
WBC	5000-9000 (/MM3)	01/10/91	5100.00		5300.00		6600.00	
WBC: N	50-70 (%)	01/10/91	44.00	<	43.00	<	63.00	
WBC: L	25-40 (%)	01/10/91	48.00	>	46.00	>	32.00	
WBC: E	2-4 (%)	01/10/91	0.00	<	1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	7.00		10.00	>	5.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		0.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	204.00		351.00	>	250.00	
NA+	137-147 (MMOL/L)	01/10/91	142.00		136.00	<	143.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.30		4.10		4.20	
CL-	85-120 (MMOL/L)	01/10/91	104.00		104.00		106.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.45		2.41		2.41	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.10		1.09		0.85	
SGOT	4-20 (U/L)	01/10/91	8.20		7.80		7.10	
SGPT	4-20 (U/L)	01/10/91	8.70		10.30		15.50	
GAMMA GT	4-18 (U/L)	01/10/91	10.50		7.70		22.70	>
LDH	55-150 (U/L)	01/10/91	166.00	>	112.00		112.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	94.00		104.00		111.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	101.00		110.00		101.00	
BUN	20-40 (MG/DL)	01/10/91	33.00		19.00	<	36.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.85		0.75		0.74	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	6.01	>	3.19		6.41	>
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.56		0.51		0.95	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.14		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.62		7.50		6.72	
ALBUMINE	56-66 (%)	01/10/91	59.70		57.60		63.00	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	248.00		177.00		176.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	72.00		60.00		81.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	4.10		3.60		3.90	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	7.20		7.50		8.70	
GLOBULINS BETA	8.5-14 (%)	01/10/91	12.10		12.70		12.40	
GLOBULINS GAMMA	11-19 (%)	01/10/91	16.90		18.70		12.10	
TSH	0.16-3.2 (MU/L)	01/10/91	0.51					
T4	48-120 (UG/L)	01/10/91	72.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 15 Patient: 351 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/09/92		23/09/92		14/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.5-18 (G/DL)	01/03/92	18.60	>	16.70		17.00	
HT	0.4-0.54 (L/L)	01/03/92	0.56	>	0.49		0.49	
RBC	4.4-6 (10¬6/MM3)	01/03/92	6.68	>	5.77		5.87	
WBC	4-11 (10¬3/MM3)	01/03/92	7.80		6.30		9.40	
WBC: N	20-75 (%)	01/03/92	52.00		50.00		45.00	
WBC: L	10-40 (%)	01/03/92	35.00		46.00	>	38.00	
WBC: E	1-6 (%)	01/03/92	6.00		1.00		4.00	
WBC: M	2-10 (%)	01/03/92	7.00		3.00		12.00	>
WBC: B	0-2 (%)	01/03/92	0.00		0.00		1.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92	245.00		250.00		285.00	
NA+	136-148 (MMOL/L)	01/03/92	143.00		139.00		145.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.50		4.40		5.00	
CL-	97-106 (MMOL/L)	01/03/92	94.00	<	91.00	<	94.00	<
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.54		2.58		2.57	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.33		0.66		1.24	
SGOT	5-37 (U/L)	01/03/92	19.00		27.00		28.00	
SGPT	5-40 (U/L)	01/03/92	20.00		41.00	>	31.00	
GAMMA GT	11-50 (U/L)	01/03/92	22.00		19.00		19.00	
LDH	230-460 (U/L)	01/03/92	291.00		274.00		271.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	82.00		72.00		69.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	10.30	>>	17.10	>>	11.30	>>
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.50		4.80		4.90	
CREATININE	44-120 (UMOL/L)	01/03/92	162.70	>	139.00	>	163.90	>
URIC ACID	0.19-0.43 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	10.00		9.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	3.00		5.00		5.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	92.00	>	85.00	>	80.00	
ALBUMINE	35-57 (G/L)	01/03/92	39.00		39.00		45.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.90	>	7.30	>	8.00	>
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	4.37	>>	3.58	>>	3.13	>>
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92					4.20	
T4	8-25 (PMOL/L)	01/03/92					15.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 15 Patient: 366 Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/08/92		17/09/92		08/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.5-18 (G/DL)	01/03/92	15.10		13.40	<	15.60	
HT	0.4-0.54 (L/L)	01/03/92	0.47		0.41		0.45	
RBC	4.4-6 (10¬6/MM3)	01/03/92	5.24		4.61		5.06	
WBC	4-11 (10¬3/MM3)	01/03/92	4.70		9.60		5.50	
WBC: N	20-75 (%)	01/03/92	38.00		43.00		43.00	
WBC: L	10-40 (%)	01/03/92	57.00	>>	51.00	>	47.00	>
WBC: E	1-6 (%)	01/03/92	0.00	<	4.00		2.00	
WBC: M	2-10 (%)	01/03/92	5.00		1.00	<	8.00	
WBC: B	0-2 (%)	01/03/92	0.00		1.00		0.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92	237.00				340.00	
NA+	136-148 (MMOL/L)	01/03/92	141.00		145.00		148.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.10		3.90		4.20	
CL-	97-106 (MMOL/L)	01/03/92	101.00		101.00		100.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.69		2.18	<	2.20	<
PO4--	0.6-1.8 (MMOL/L)	01/03/92	0.55	<	1.14		1.14	
SGOT	5-37 (U/L)	01/03/92	27.00		23.00		30.00	
SGPT	5-40 (U/L)	01/03/92	43.00	>	36.00		38.00	
GAMMA GT	11-50 (U/L)	01/03/92	30.00		29.00		73.00	>
LDH	230-460 (U/L)	01/03/92	320.00		360.00		309.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	72.00		76.00		81.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	5.90		4.30		5.00	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.70		3.60		3.00	
CREATININE	44-120 (UMOL/L)	01/03/92	75.00		81.40		68.70	
URIC ACID	0.19-0.43 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	3.00	<	5.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		5.00		5.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	78.00		82.00		82.00	
ALBUMINE	35-57 (G/L)	01/03/92	39.00		39.00		44.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	3.50		3.40		4.60	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.04		0.87		1.03	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	0.90		1.50		1.00	
T4	8-25 (PMOL/L)	01/03/92	15.40		15.30		15.40	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 15 Patient: 368 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/09/92		24/09/92		15/10/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11.5-16.5 (G/DL)	01/03/92	12.60				12.60	
HT	0.35-0.49 (L/L)	01/03/92	0.41				0.36	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.75				4.35	
WBC	4-11 (10-3/MM3)	01/03/92	6.00				6.70	
WBC: N	20-75 (%)	01/03/92	46.00				51.00	
WBC: L	10-40 (%)	01/03/92	45.00	>			43.00	>
WBC: E	1-6 (%)	01/03/92	1.00				2.00	
WBC: M	2-10 (%)	01/03/92	8.00				4.00	
WBC: B	0-2 (%)	01/03/92	0.00				0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	510.00	>			453.00	>
NA+	136-148 (MMOL/L)	01/03/92	143.00		144.00		144.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.40		4.50		4.30	
CL-	97-106 (MMOL/L)	01/03/92	99.00		99.00		100.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.31		2.25		2.34	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.09		0.88		0.97	
SGOT	5-31 (U/L)	01/03/92	16.00				16.00	
SGPT	5-31 (U/L)	01/03/92	17.00				21.00	
GAMMA GT	7-32 (U/L)	01/03/92	21.00				19.00	
LDH	230-460 (U/L)	01/03/92	372.00				358.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	68.00				65.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	6.40	>	7.80	>	6.40	>
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.30		3.60		2.90	
CREATININE	44-120 (UMOL/L)	01/03/92	90.20		88.00		70.70	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92			0.24			
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	3.00	<			6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00				5.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92			81.00		83.00	>
ALBUMINE	35-57 (G/L)	01/03/92	40.00		50.00		45.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.50				6.40	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	3.09	>>			2.25	>
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92			1.90		1.50	
T4	8-25 (PMOL/L)	01/03/92			25.10		16.40	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 15 Patient: 369 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/07/92		30/07/92		20/08/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/03/92	14.00		13.80		14.50	
HT	0.35-0.49 (L/L)	01/03/92	0.42		0.41		0.45	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.43		4.48		4.96	
WBC	4-11 (10-3/MM3)	01/03/92	9.30		8.20		7.80	
WBC: N	20-75 (%)	01/03/92	58.00		65.00		50.00	
WBC: L	10-40 (%)	01/03/92	38.00		31.00		46.00	>
WBC: E	1-6 (%)	01/03/92	0.00	<	0.00	<	1.00	
WBC: M	2-10 (%)	01/03/92	3.00		3.00		3.00	
WBC: B	0-2 (%)	01/03/92	1.00		1.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	363.00		347.00		478.00	>
NA+	136-148 (MMOL/L)	01/03/92	146.00		146.00		139.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.50		4.30		4.50	
CL-	97-106 (MMOL/L)	01/03/92	99.00		102.00		94.00	<
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.44		2.29		2.63	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.70		1.37		1.11	
SGOT	5-31 (U/L)	01/03/92	22.00		24.00		22.00	
SGPT	5-31 (U/L)	01/03/92	21.00		16.00		18.00	
GAMMA GT	7-32 (U/L)	01/03/92	21.00		16.00		23.00	
LDH	230-460 (U/L)	01/03/92	325.00		269.00			
ALK. PHOSPH.	40-120 (U/L)	01/03/92	37.00	<	36.00	<	36.00	<
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	4.60		4.90		4.70	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	5.00		5.80		4.10	
CREATININE	44-120 (UMOL/L)	01/03/92	82.00		89.00		89.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	6.00		5.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		1.80		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	89.00	>	85.00	>	90.00	>
ALBUMINE	35-57 (G/L)	01/03/92	40.00		41.00		39.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	5.70				5.90	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.02				1.52	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	1.10		1.30			
T4	8-25 (PMOL/L)	01/03/92	11.70		12.70			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 15 Patient: 371 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/07/92		10/08/92		31/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	01/03/92	13.40		14.50		13.30	
HT	0.35-0.49 (L/L)	01/03/92	0.40		0.44		0.39	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.36		4.83		4.34	
WBC	4-11 (10-3/MM3)	01/03/92	9.00		6.60		6.30	
WBC: N	20-75 (%)	01/03/92	56.00		55.00		51.00	
WBC: L	10-40 (%)	01/03/92	39.00		40.00		40.00	
WBC: E	1-6 (%)	01/03/92	0.00	<	2.00		1.00	
WBC: M	2-10 (%)	01/03/92	5.00		3.00		8.00	
WBC: B	0-2 (%)	01/03/92	0.00		0.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	325.00		342.00		397.00	
NA+	136-148 (MMOL/L)	01/03/92	143.00		144.00		143.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.20		4.50		4.10	
CL-	97-106 (MMOL/L)	01/03/92	104.00		102.00		108.00	>
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.20	<	2.15	<	2.31	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	0.80		1.12		0.49	<<
SGOT	5-31 (U/L)	01/03/92	28.00		28.00		19.00	
SGPT	5-31 (U/L)	01/03/92	18.00		30.00		13.00	
GAMMA GT	7-32 (U/L)	01/03/92	26.00		22.00		21.00	
LDH	230-460 (U/L)	01/03/92	432.00		341.00		366.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	81.00		96.00		86.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	4.80		4.60		5.10	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	2.30	<	2.00	<	3.10	
CREATININE	44-120 (UMOL/L)	01/03/92	67.00		69.00		82.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	11.00		5.00		1.00	<
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		2.00		1.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	76.00		78.00		77.00	
ALBUMINE	35-57 (G/L)	01/03/92	38.00		37.00		39.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	4.20		3.60		3.70	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	0.82	<	0.76	<	0.78	<
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	0.90		0.60		0.40	
T4	8-25 (PMOL/L)	01/03/92	15.40		17.30		16.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 15 Patient: 374 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Day 21		Day 42	
			24/04/92		20/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	01/03/92	14.30		13.70	
HT	0.35-0.49 (L/L)	01/03/92	0.41		0.40	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.55		4.45	
WBC	4-11 (10-3/MM3)	01/03/92	4.80		6.60	
WBC: N	20-75 (%)	01/03/92	62.00		55.00	
WBC: L	10-40 (%)	01/03/92	27.00		36.00	
WBC: E	1-6 (%)	01/03/92	4.00		6.00	
WBC: M	2-10 (%)	01/03/92	6.00		3.00	
WBC: B	0-2 (%)	01/03/92	1.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	275.00		393.00	
NA+	136-148 (MMOL/L)	01/03/92	139.00		142.00	
K+	3.8-5 (MMOL/L)	01/03/92	5.00		3.70	<
CL-	97-106 (MMOL/L)	01/03/92	99.00		100.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.45		2.33	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.30		1.20	
SGOT	5-31 (U/L)	01/03/92	26.00		24.00	
SGPT	5-31 (U/L)	01/03/92	22.00		26.00	
GAMMA GT	7-32 (U/L)	01/03/92	36.00	>	23.00	
LDH	230-460 (U/L)	01/03/92	409.00			
ALK. PHOSPH.	40-120 (U/L)	01/03/92	57.00		49.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	5.10		4.70	
BUN	()	01/03/92				
UREA	2.5-6.6 (MMOL/L)	01/03/92	4.60		4.50	
CREATININE	44-120 (UMOL/L)	01/03/92	79.00		65.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92				
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	6.00		6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		1.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	79.00		80.00	
ALBUMINE	35-57 (G/L)	01/03/92	38.00		40.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	5.20		5.90	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	0.77	<	1.03	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92				
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92				
GLOBULINS BETA	11-16 (%)	01/03/92				
GLOBULINS GAMMA	()	01/03/92				
TSH	0.4-4 (MU/L)	01/03/92				
T4	8-25 (PMOL/L)	01/03/92				

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max ran
< out of range (value lower than min range) > out of range (value higher than max r
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 15 Patient: 375 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Day 21	
			25/06/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/03/92	13.70	
HT	0.35-0.49 (L/L)	01/03/92	0.40	
RBC	3.9-5.6 (10¬6/MM3)	01/03/92	4.49	
WBC	4-11 (10¬3/MM3)	01/03/92	8.00	
WBC: N	20-75 (%)	01/03/92	50.00	
WBC: L	10-40 (%)	01/03/92	42.00	>
WBC: E	1-6 (%)	01/03/92	1.00	
WBC: M	2-10 (%)	01/03/92	6.00	
WBC: B	0-2 (%)	01/03/92	1.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92	377.00	
NA+	136-148 (MMOL/L)	01/03/92	134.00	<
K+	3.8-5 (MMOL/L)	01/03/92	4.60	
CL-	97-106 (MMOL/L)	01/03/92	103.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.26	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.20	
SGOT	5-31 (U/L)	01/03/92	26.00	
SGPT	5-31 (U/L)	01/03/92	18.00	
GAMMA GT	7-32 (U/L)	01/03/92	9.00	
LDH	230-460 (U/L)	01/03/92	612.00	>
ALK. PHOSPH.	40-120 (U/L)	01/03/92	31.00	<
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	7.30	>
BUN	()	01/03/92		
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.20	
CREATININE	44-120 (UMOL/L)	01/03/92	59.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92		
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	4.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	77.00	
ALBUMINE	35-57 (G/L)	01/03/92	38.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.00	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.00	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92		
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92		
GLOBULINS BETA	11-16 (%)	01/03/92		
GLOBULINS GAMMA	()	01/03/92		
TSH	0.4-4 (MU/L)	01/03/92	0.80	
T4	8-25 (PMOL/L)	01/03/92	16.10	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 15 Patient: 377 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/05/92		03/06/92		24/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/03/92	15.60		15.90		14.40	
HT	0.35-0.49 (L/L)	01/03/92	0.48		0.46		0.43	
RBC	3.9-5.6 (10¬6/MM3)	01/03/92	5.43		5.33		5.04	
WBC	4-11 (10¬3/MM3)	01/03/92	9.60		8.10		6.80	
WBC: N	20-75 (%)	01/03/92	65.00		52.00		57.00	
WBC: L	10-40 (%)	01/03/92	26.00		36.00		37.00	
WBC: E	1-6 (%)	01/03/92	3.00		1.00		1.00	
WBC: M	2-10 (%)	01/03/92	6.00		10.00		4.00	
WBC: B	0-2 (%)	01/03/92	0.00		1.00		1.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92	358.00		346.00		297.00	
NA+	136-148 (MMOL/L)	01/03/92	140.00		140.00		138.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.60		4.50		4.30	
CL-	97-106 (MMOL/L)	01/03/92	103.00		100.00		103.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.29		2.18	<	2.18	<
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.10		0.90		0.80	
SGOT	5-31 (U/L)	01/03/92	30.00		17.00		19.00	
SGPT	5-31 (U/L)	01/03/92	31.00		24.00		25.00	
GAMMA GT	7-32 (U/L)	01/03/92	66.00	>>	38.00	>	28.00	
LDH	230-460 (U/L)	01/03/92	424.00		328.00		321.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	67.00		73.00		64.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	5.10		5.60		5.30	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	2.70		2.10	<	2.70	
CREATININE	44-120 (UMOL/L)	01/03/92	77.00		54.00		57.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	6.00		6.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	1.00		1.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	68.00		79.00		77.00	
ALBUMINE	35-57 (G/L)	01/03/92	43.00		40.00		40.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.40		6.90	>	5.40	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.81		1.43		1.05	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	0.60		1.10		0.60	
T4	8-25 (PMOL/L)	01/03/92	16.90		21.00		31.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 15 Patient: 378 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/06/92		06/07/92		27/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	01/03/92	13.90		13.90		14.60	
HT	0.35-0.49 (L/L)	01/03/92	0.42		0.42		0.41	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.36		4.40		4.37	
HBC	4-11 (10-3/MM3)	01/03/92	7.40		7.10		9.40	
WBC: N	20-75 (%)	01/03/92	51.00		70.00		48.00	
WBC: L	10-40 (%)	01/03/92	36.00		22.00		41.00	>
WBC: E	1-6 (%)	01/03/92	4.00		1.00		5.00	
WBC: M	2-10 (%)	01/03/92	9.00		6.00		6.00	
WBC: B	0-2 (%)	01/03/92	0.00		1.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	240.00		300.00		277.00	
NA+	136-148 (MMOL/L)	01/03/92	138.00		141.00		145.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.70		3.80		6.00	>>
CL-	97-106 (MMOL/L)	01/03/92	99.00		96.00	<	100.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.22	<	2.20	<	2.56	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.10		1.10		0.90	
SGOT	5-31 (U/L)	01/03/92	18.00		23.00		38.00	>
SGPT	5-31 (U/L)	01/03/92	12.00		24.00		33.00	>
GAMMA GT	7-32 (U/L)	01/03/92	11.00		14.00			
LDH	230-460 (U/L)	01/03/92	288.00		235.00		786.00	>
ALK. PHOSPH.	40-120 (U/L)	01/03/92	79.00		92.00		72.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	6.90	>	5.80		4.90	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	2.80		4.10		4.40	
CREATININE	44-120 (UMOL/L)	01/03/92	86.00		77.00		49.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	5.00		3.00	<	5.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		1.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	76.00		81.00		95.00	>
ALBUMINE	35-57 (G/L)	01/03/92	39.00		38.00		40.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	5.10		5.90		6.00	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.84		0.89		0.67	<
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	2.00					
T4	8-25 (PMOL/L)	01/03/92	16.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 15 Patient: 381 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/05/92		11/06/92		02/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	01/03/92	13.00		12.60		12.30	
HT	0.35-0.49 (L/L)	01/03/92	0.39		0.37		0.38	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.29		4.09		4.14	
WBC	4-11 (10-3/MM3)	01/03/92	7.30		6.20		8.10	
WBC: N	20-75 (%)	01/03/92	63.00		48.00		60.00	
WBC: L	10-40 (%)	01/03/92	34.00		44.00	>	34.00	
WBC: E	1-6 (%)	01/03/92	0.00	<	2.00		1.00	
WBC: M	2-10 (%)	01/03/92	3.00		4.00		5.00	
WBC: B	0-2 (%)	01/03/92	0.00		2.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	377.00		324.00		400.00	
NA+	136-148 (MMOL/L)	01/03/92	137.00		138.00		143.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.20		3.90		4.30	
CL-	97-106 (MMOL/L)	01/03/92	102.00		98.00		103.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.29		2.16	<	2.26	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.10		1.10		1.00	
SGOT	5-31 (U/L)	01/03/92	11.00		20.00		15.00	
SGPT	5-31 (U/L)	01/03/92	12.00		21.00		12.00	
GAMMA GT	7-32 (U/L)	01/03/92	13.00		11.00		7.00	
LDH	230-460 (U/L)	01/03/92	188.00	<	233.00		270.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	39.00	<	47.00		34.00	<
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	4.80		5.20		5.90	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.60		3.20		3.50	
CREATININE	44-120 (UMOL/L)	01/03/92	58.00		46.00		56.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	14.00		13.00		12.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		3.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	77.00		77.00		77.00	
ALBUMINE	35-57 (G/L)	01/03/92	40.00		41.00		37.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.00		5.80		5.60	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.04		1.01		0.70	<
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92			0.40			
T4	8-25 (PMOL/L)	01/03/92			17.20			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 15 Patient: 384 Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			28/07/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/03/92	13.10	
HT	0.35-0.49 (L/L)	01/03/92	0.38	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.28	
WBC	4-11 (10-3/MM3)	01/03/92	13.10	>
WBC: N	20-75 (%)	01/03/92	75.00	
WBC: L	10-40 (%)	01/03/92	20.00	
WBC: E	1-6 (%)	01/03/92	0.00	<
WBC: M	2-10 (%)	01/03/92	5.00	
WBC: B	0-2 (%)	01/03/92	0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	275.00	
NA+	136-148 (MMOL/L)	01/03/92	138.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.60	
CL-	97-106 (MMOL/L)	01/03/92	96.00	<
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.05	<
PO4--	0.6-1.8 (MMOL/L)	01/03/92	0.40	<<
SGOT	5-31 (U/L)	01/03/92	20.00	
SGPT	5-31 (U/L)	01/03/92	21.00	
GAMMA GT	7-32 (U/L)	01/03/92	72.00	>>
LDH	230-460 (U/L)	01/03/92	330.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	116.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	8.00	>>
BUN	()	01/03/92		
UREA	2.5-6.6 (MMOL/L)	01/03/92	4.80	
CREATININE	44-120 (UMOL/L)	01/03/92	61.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92		
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	11.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	4.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	82.00	
ALBUMINE	35-57 (G/L)	01/03/92	37.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	4.40	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	0.75	<
GLOBULINS ALPHA 1	1-5 (%)	01/03/92		
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92		
GLOBULINS BETA	11-16 (%)	01/03/92		
GLOBULINS GAMMA	()	01/03/92		
TSH	0.4-4 (MU/L)	01/03/92	4.50	
T4	8-25 (PMOL/L)	01/03/92	16.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 1 Patient: 3 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/04/91		07/05/91		28/05/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.7-16.6 (G/DL)	01/01/91	14.50		14.20		13.50	
HT	36-42 (%)	01/01/91	42.00		41.80		37.80	
RBC	3.6-5.3 (10-6/MM3)	01/01/91	4.58		4.58		4.28	
WBC	4-10.7 (10-3/MM3)	01/01/91	7.80		6.90		7.00	
WBC: N	40-75 (%)	01/01/91	79.00	>	56.00		55.00	
WBC: L	20-45 (%)	01/01/91	14.00	<	35.00		33.00	
WBC: E	1-6 (%)	01/01/91	2.00		3.00		3.00	
WBC: M	2-10 (%)	01/01/91	4.00		5.00		6.00	
WBC: B	0-1 (%)	01/01/91	1.00		1.00		0.00	
PLATELETS	100-300 (10-3/MM3)	01/01/91	369.00	>	365.00	>	350.00	>
NA+	130-149 (MMOL/L)	01/01/91	139.00		142.00		141.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.10		5.60	>	4.30	
CL-	94-109 (MMOL/L)	01/01/91	109.00		100.00			
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.72		2.50			
PO4--	0.87-1.45 (MMOL/L)	01/01/91	1.05		1.03		1.06	
SGOT	5-18 (U/L)	01/01/91	8.00		7.00		7.00	
SGPT	5-18 (U/L)	01/01/91	11.00		8.00		10.00	
GAMMA GT	4-18 (U/L)	01/01/91	17.00		11.00		13.00	
LDH	120-240 (U/L)	01/01/91	134.00		121.00		141.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	126.00		121.00		124.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	7.09	>	5.08		5.42	
BUN	1.7-8.3 (MMOL/L)	01/01/91	3.90		3.40		5.30	
UREA	()	01/01/91						
CREATININE	50-98 (UMOL/L)	01/01/91	67.00		77.00		77.00	
URIC ACID	142-339 (UMOL/L)	01/01/91	256.00		221.00		259.00	
TOT BILIRUBIN	3.6-21.5 (UMOL/L)	01/01/91	4.60		8.90		7.90	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91			78.60		77.80	
ALBUMINE	58-70 (%)	01/01/91			65.80		66.30	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91			5.74	>	5.49	>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91			0.95	<	1.17	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91			2.20		2.30	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91			7.10		6.90	
GLOBULINS BETA	7-13 (%)	01/01/91			10.50		10.30	
GLOBULINS GAMMA	10-19 (%)	01/01/91			14.40		14.20	
TSH	0.3-4 (MU/L)	01/01/91	1.20					
T4	50-115 (UG/L)	01/01/91	124.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 1 Patient: 4 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/04/91		07/05/91		29/05/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	13.4-18.5 (G/DL)	01/01/91	16.80		16.50		16.00	
HT	40-48 (%)	01/01/91	48.60	>	47.50		46.30	
RBC	4.15-5.9 (10~6/MM3)	01/01/91	5.33		5.13		5.10	
WBC	4-10.7 (10~3/MM3)	01/01/91	7.80		6.50		6.40	
WBC: N	40-75 (%)	01/01/91	67.00		64.00		59.00	
WBC: L	20-45 (%)	01/01/91	28.00		29.00		33.00	
WBC: E	1-6 (%)	01/01/91	1.00		2.00		1.00	
WBC: M	2-10 (%)	01/01/91	4.00		5.00		7.00	
WBC: B	0-1 (%)	01/01/91	0.00		0.00		0.00	
PLATELETS	100-300 (10~3/MM3)	01/01/91	270.00		257.00		281.00	
NA+	130-149 (MMOL/L)	01/01/91	145.00		141.00		142.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.00		4.10		3.90	
CL-	94-109 (MMOL/L)	01/01/91			103.00		102.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.45		2.13	<	2.11	<
PO4--	0.87-1.45 (MMOL/L)	01/01/91	0.98		1.01		0.88	
SGOT	5-19 (U/L)	01/01/91	7.00		7.00		9.00	
SGPT	5-23 (U/L)	01/01/91	12.00		12.00		16.00	
GAMMA GT	6-28 (U/L)	01/01/91	30.00	>	30.00	>	36.00	>
LDH	120-240 (U/L)	01/01/91	134.00		112.00	<	127.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	124.00		98.00		96.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	5.83	>	4.83		6.15	>
BUN	1.7-8.3 (MMOL/L)	01/01/91	7.20		7.40		6.30	
UREA	()	01/01/91						
CREATININE	58-110 (UMOL/L)	01/01/91	84.00		82.00		82.00	
URIC ACID	202-416 (UMOL/L)	01/01/91	325.00		278.00		322.00	
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	9.10		5.70		7.20	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	73.80		70.10		77.00	
ALBUMINE	58-70 (%)	01/01/91	65.60		65.00		56.60	<
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	5.76	>	5.16		5.98	>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	2.49	>	2.68	>		
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	1.60		1.60		3.00	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	6.80		7.60		7.40	
GLOBULINS BETA	7-13 (%)	01/01/91	12.00		11.80		10.00	
GLOBULINS GAMMA	10-19 (%)	01/01/91	14.00		14.00		23.00	>
TSH	0.3-4 (MU/L)	01/01/91	0.69					
T4	50-115 (UG/L)	01/01/91	133.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 1 Patient: 6 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/08/91		28/08/91		18/09/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.4-18.5 (G/DL)	01/01/91	14.80		14.40		14.40	
HT	40-48 (%)	01/01/91	44.70		42.00		42.80	
RBC	4.15-5.9 (10-6/MM3)	01/01/91	4.73		4.55		4.57	
WBC	4-10.7 (10-3/MM3)	01/01/91	7.20		8.60		8.00	
WBC: N	40-75 (%)	01/01/91	60.00		53.00			
WBC: L	20-45 (%)	01/01/91	31.00		33.00			
WBC: E	1-6 (%)	01/01/91	3.00		4.00			
WBC: M	2-10 (%)	01/01/91	6.00		10.00			
WBC: B	0-1 (%)	01/01/91	0.00		0.00			
PLATELETS	100-300 (10-3/MM3)	01/01/91	290.00		284.00		286.00	
NA+	130-149 (MMOL/L)	01/01/91	143.00		143.00		132.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.20		5.15		4.77	
CL-	94-109 (MMOL/L)	01/01/91			103.00			
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.16	<	2.49		2.48	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	0.72	<<	1.17		0.80	<
SGOT	5-19 (U/L)	01/01/91	9.00		8.00		12.00	
SGPT	5-23 (U/L)	01/01/91	10.00		9.00		10.00	
GAMMA GT	6-28 (U/L)	01/01/91	13.00		9.00		13.00	
LDH	120-240 (U/L)	01/01/91	264.00	>	123.00		284.00	>
ALK. PHOSPH.	60-170 (U/L)	01/01/91	151.00		100.00		152.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91			4.35		4.82	
BUN	1.7-8.3 (MMOL/L)	01/01/91	4.30		3.80		7.40	
UREA	()	01/01/91						
CREATININE	58-110 (UMOL/L)	01/01/91	76.00		78.00		76.00	
URIC ACID	202-416 (UMOL/L)	01/01/91	281.00		215.00		356.00	
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	7.90		6.30		9.20	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	74.50		69.40		74.10	
ALBUMINE	58-70 (%)	01/01/91	66.80		67.80		68.20	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	5.01		6.03	>	4.80	
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	0.80	<	2.25			
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	2.80		2.90		2.80	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	5.00		4.90	<	4.90	<
GLOBULINS BETA	7-13 (%)	01/01/91	11.80		11.20		11.20	
GLOBULINS GAMMA	10-19 (%)	01/01/91	13.60		13.20		12.90	
TSH	0.3-4 (MU/L)	01/01/91	0.28					
T4	50-115 (UG/L)	01/01/91	118.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 1 Patient: 8 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			29/10/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	13.4-18.5 (G/DL)	01/01/91	17.20	
HT	40-48 (%)	01/01/91	48.70	>
RBC	4.15-5.9 (10¬6/MM3)	01/01/91	5.26	
WBC	4-10.7 (10¬3/MM3)	01/01/91	9.60	
WBC: N	40-75 (%)	01/01/91	68.00	
WBC: L	20-45 (%)	01/01/91	23.00	
WBC: E	1-6 (%)	01/01/91	4.00	
WBC: M	2-10 (%)	01/01/91	5.00	
WBC: B	0-1 (%)	01/01/91	0.00	
PLATELETS	100-300 (10¬3/MM3)	01/01/91	288.00	
NA+	130-149 (MMOL/L)	01/01/91	143.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.70	
CL-	94-109 (MMOL/L)	01/01/91	83.00	<<
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.53	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	0.81	<
SGOT	5-19 (U/L)	01/01/91	8.00	
SGPT	5-23 (U/L)	01/01/91	12.00	
GAMMA GT	6-28 (U/L)	01/01/91	15.00	
LDH	120-240 (U/L)	01/01/91	165.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	94.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	7.44	>>
BUN	1.7-8.3 (MMOL/L)	01/01/91	6.30	
UREA	()	01/01/91		
CREATININE	58-110 (UMOL/L)	01/01/91	133.00	>
URIC ACID	202-416 (UMOL/L)	01/01/91	426.00	>
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	01/01/91	17.00	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91		
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	73.90	
ALBUMINE	58-70 (%)	01/01/91	67.10	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	4.81	
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	0.93	<
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	2.60	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	7.50	
GLOBULINS BETA	7-13 (%)	01/01/91	11.50	
GLOBULINS GAMMA	10-19 (%)	01/01/91	11.30	
TSH	0.3-4 (MU/L)	01/01/91	1.30	
T4	50-115 (UG/L)	01/01/91	143.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 1 Patient: 9 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/11/91		28/11/91		19/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11.7-16.6 (G/DL)	01/01/91	14.60		13.80		13.70	
HT	36-42 (%)	01/01/91	42.80	>	41.20		40.60	
RBC	3.6-5.3 (10¬6/MM3)	01/01/91	4.67		4.42		4.36	
HBC	4-10.7 (10¬3/MM3)	01/01/91	9.10		7.30		7.80	
HBC: N	40-75 (%)	01/01/91	64.00		68.00		70.00	
HBC: L	20-45 (%)	01/01/91	27.00		23.00		20.00	
HBC: E	1-6 (%)	01/01/91	1.00		1.00		1.00	
HBC: M	2-10 (%)	01/01/91	6.00		7.00		8.00	
HBC: B	0-1 (%)	01/01/91	2.00	>>	1.00		1.00	
PLATELETS	100-300 (10¬3/MM3)	01/01/91	322.00	>	336.00	>	366.00	>
NA+	130-149 (MMOL/L)	01/01/91	142.00		142.00		142.00	
K+	3.66-5.35 (MMOL/L)	01/01/91	4.90		4.80		5.20	
CL-	94-109 (MMOL/L)	01/01/91	100.00		96.00		98.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.65		2.45		2.35	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	1.22		1.44		1.13	
SGOT	5-18 (U/L)	01/01/91	7.00		6.00		7.00	
SGPT	5-18 (U/L)	01/01/91	7.00		9.00		12.00	
GAMMA GT	4-18 (U/L)	01/01/91	15.00		14.00		24.00	>
LDH	120-240 (U/L)	01/01/91	207.00		137.00		141.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	107.00		110.00		126.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	5.50		4.87		4.32	
BUN	1.7-8.3 (MMOL/L)	01/01/91	6.20		7.30		3.80	
UREA	()	01/01/91						
CREATININE	50-98 (UMOL/L)	01/01/91	73.00		75.00		78.00	
URIC ACID	142-339 (UMOL/L)	01/01/91	271.00		251.00		248.00	
TOT BILIRUBIN	3.6-21.5 (UMOL/L)	01/01/91	9.70		8.60		8.10	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	74.00				69.00	
ALBUMINE	58-70 (%)	01/01/91	63.80				62.30	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	6.46	>	6.05	>	6.04	>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	2.44	>	2.76	>	2.66	>
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	3.00				3.40	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	7.60				8.20	
GLOBULINS BETA	7-13 (%)	01/01/91	11.50				12.20	
GLOBULINS GAMMA	10-19 (%)	01/01/91	14.10				13.90	
TSH	0.3-4 (MU/L)	01/01/91	0.60					
T4	50-115 (UG/L)	01/01/91	157.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 1 Patient: 10 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/11/91		10/12/91		30/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11.7-16.6 (G/DL)	01/01/91	15.70		15.80			
HT	36-42 (%)	01/01/91	45.00	>	45.20	>		
RBC	3.6-5.3 (10¬6/MM3)	01/01/91	4.75		4.76			
WBC	4-10.7 (10¬3/MM3)	01/01/91	9.80		6.90			
WBC: N	40-75 (%)	01/01/91	81.00	>				
WBC: L	20-45 (%)	01/01/91	13.00	<<				
WBC: E	1-6 (%)	01/01/91	1.00					
WBC: M	2-10 (%)	01/01/91	3.00					
WBC: B	0-1 (%)	01/01/91						
PLATELETS	100-300 (10¬3/MM3)	01/01/91	283.00		258.00			
NA+	130-149 (MMOL/L)	01/01/91			141.00		146.00	
K+	3.66-5.35 (MMOL/L)	01/01/91			3.70		3.90	
CL-	94-109 (MMOL/L)	01/01/91			99.00		99.00	
Ca++	2.24-2.78 (MMOL/L)	01/01/91	2.50		2.29		2.37	
PO4--	0.87-1.45 (MMOL/L)	01/01/91	0.65	<<	0.79	<	0.69	<<
SGOT	5-18 (U/L)	01/01/91	8.00		7.00		9.00	
SGPT	5-18 (U/L)	01/01/91	8.00		7.00		11.00	
GAMMA GT	4-18 (U/L)	01/01/91	20.00	>	18.00		26.00	>
LDH	120-240 (U/L)	01/01/91	179.00		121.00		152.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/91	149.00		122.00		116.00	
GLUCOSE	3.54-5.68 (MMOL/L)	01/01/91	7.53	>>	9.80	>>	12.80	>>
BUN	1.7-8.3 (MMOL/L)	01/01/91	3.90		4.60		4.90	
UREA	()	01/01/91						
CREATININE	50-98 (UMOL/L)	01/01/91	75.00		74.00		70.00	
URIC ACID	142-339 (UMOL/L)	01/01/91	460.00	>>	374.00	>	365.00	>
TOT BILIRUBIN	3.6-21.5 (UMOL/L)	01/01/91	6.90		6.00		7.30	
DIR BILIRUBIN	0-4.3 (UMOL/L)	01/01/91						
TOT. PROTEINS	65.6-86.5 (G/L)	01/01/91	78.00		78.00		77.00	
ALBUMINE	58-70 (%)	01/01/91	62.90		64.00		62.00	
TOT. CHOLEST.	4-5.2 (MMOL/L)	01/01/91	5.68	>	5.90	>	6.37	>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	01/01/91	2.81	>	3.62	>>	4.33	>>
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/91	3.40		2.80		3.30	
GLOBULINS ALPHA 2	5-10 (%)	01/01/91	9.00		8.70		9.50	
GLOBULINS BETA	7-13 (%)	01/01/91	10.50		9.50		10.10	
GLOBULINS GAMMA	10-19 (%)	01/01/91	14.20		15.00		15.10	
TSH	0.3-4 (MU/L)	01/01/91	0.45					
T4	50-115 (UG/L)	01/01/91	138.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 2 Patient: 34 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/12/90		17/01/91		07/02/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	15.80		15.90		16.30	
HT	0.38-0.57 (L/L)	01/11/90	0.48		0.47		0.48	
RBC	4.5-5.8 (10¬6/MM3)	01/11/90	5.30		5.14		5.20	
WBC	4000-9000 (/MM3)	01/11/90	8400.00		5900.00		6700.00	
WBC: N	55-60 (%)	01/11/90	65.00	>			66.00	>
WBC: L	30-40 (%)	01/11/90	20.00	<<			20.00	<<
WBC: E	1-3 (%)	01/11/90	5.00	>>			5.00	>>
WBC: M	3-7 (%)	01/11/90	10.00	>>			8.00	>
WBC: B	0-1 (%)	01/11/90	0.00				1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90					307000	>
NA+	136-147 (MMOL/L)	01/11/90	143.00		150.00	>	146.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.40		4.70		4.70	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.50		2.60		2.60	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	26.00	>	18.00		21.00	>
SGPT	5-22 (U/L)	01/11/90	46.00	>>	38.00	>	58.00	>>
GAMMA GT	6-28 (U/L)	01/11/90	17.00		17.00		21.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	84.00		76.00		81.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	100.00				90.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	1.20	>	1.20	>	1.10	
URIC ACID	0.4-7 (MG/DL)	01/11/90	6.60		5.90		7.50	>
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90			1.00		0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.40		6.90		7.20	
ALBUMINE	53-63 (%)	01/11/90	63.60	>	64.40	>	64.80	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	179.00		157.00		230.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	156.00		116.00		193.00	>
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.80	<	2.70	<	2.50	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	6.90	<	6.70	<	6.30	<
GLOBULINS BETA	10-13 (%)	01/11/90	12.00		11.70		11.40	
GLOBULINS GAMMA	14-20 (%)	01/11/90	14.70		14.50		15.00	
TSH	0.3-4 (UU/ML)	01/11/90	1.00				1.50	
T4	5-12 (UG/DL)	01/11/90	9.20		8.40		9.30	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA
Centre: 2 Patient: 36 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			09/01/91		30/01/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	12.70		14.10	
HT	0.37-0.46 (L/L)	01/11/90	0.37		0.41	
RBC	4-5 (10-6/MM3)	01/11/90	4.20		4.60	
WBC	4000-9000 (/MM3)	01/11/90	7100.00		6300.00	
WBC: N	55-60 (%)	01/11/90	41.00	<	42.00	<
WBC: L	30-40 (%)	01/11/90	48.00	>	42.00	>
WBC: E	1-3 (%)	01/11/90	4.00	>>	8.00	>>
WBC: M	3-7 (%)	01/11/90	6.00		4.00	
WBC: B	0-1 (%)	01/11/90	1.00		4.00	>>
PLATELETS	150000-300000 (/MM3)	01/11/90			275000	
NA+	136-147 (MMOL/L)	01/11/90	140.00		140.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.30		4.40	
CL-	95-108 (MMOL/L)	01/11/90				
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.50		2.30	
PO4--	()	01/11/90				
SGOT	5-18 (U/L)	01/11/90	7.00		8.00	
SGPT	5-22 (U/L)	01/11/90	3.00	<	5.00	
GAMMA GT	6-28 (U/L)	01/11/90	10.00		8.00	
LDH	()	01/11/90				
ALK. PHOSPH.	60-170 (U/L)	01/11/90	104.00		115.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	72.00		89.00	
BUN	20-40 (MG/DL)	01/11/90				
UREA	()	01/11/90				
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.90		0.90	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	4.00		5.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90			0.60	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90				
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.10		7.60	
ALBUMINE	53-63 (%)	01/11/90	61.70		65.80	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	221.00	>	261.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	89.00		49.00	<
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.10		2.40	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.80		6.10	<
GLOBULINS BETA	10-13 (%)	01/11/90	9.80	<	9.00	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	17.60		16.70	
TSH	0.3-4 (UU/ML)	01/11/90	0.40		1.30	
T4	5-12 (UG/DL)	01/11/90	9.40		7.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 38 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/01/91		14/02/91		07/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	13.40		13.70		12.90	
HT	0.37-0.46 (L/L)	01/11/90	0.39		0.40		0.38	
RBC	4-5 (10-6/MM3)	01/11/90	3.92	<	4.10		3.80	<
WBC	4000-9000 (/MM3)	01/11/90	6400.00		5600.00		5600.00	
WBC: N	55-60 (%)	01/11/90			66.00	>	68.00	>
WBC: L	30-40 (%)	01/11/90			24.00	<	21.00	<
WBC: E	1-3 (%)	01/11/90			1.00		1.00	
WBC: M	3-7 (%)	01/11/90			9.00	>	10.00	>>
WBC: B	0-1 (%)	01/11/90			0.00		0.00	
PLATELETS	150000-300000 (/MM3)	01/11/90			276000		272000	
NA+	136-147 (MMOL/L)	01/11/90	142.00		139.00		141.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.20		3.70		4.60	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.20	<	2.20	<	2.30	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	14.00		8.00		7.00	
SGPT	5-22 (U/L)	01/11/90	21.00		10.00		7.00	
GAMMA GT	6-28 (U/L)	01/11/90	7.00		7.00		8.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	81.00		72.00		74.00	
GLUCOSE	70-110 (MG/DL)	01/11/90			144.00	>>	92.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90			1.00		1.00	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	3.50		4.10		3.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.50		0.50		0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.00		7.00		6.70	
ALBUMINE	53-63 (%)	01/11/90	63.30	>	60.80		61.20	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	333.00	>>	356.00	>>	308.00	>>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	114.00		131.00		93.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.30	<	2.70	<	2.70	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.80		7.80		8.10	
GLOBULINS BETA	10-13 (%)	01/11/90	9.30	<	10.40		9.60	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	17.30		18.30		18.40	
TSH	0.3-4 (UU/ML)	01/11/90			0.30		0.20	
T4	5-12 (UG/DL)	01/11/90	9.20		8.40		5.90	

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 40 Treatment: Imipramine Sex: Male

			Visit number / Laboratory data					
			Screen		Day 21		Day 42	
			20/02/91		19/03/91		02/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	15.70		16.70		15.40	
HT	0.38-0.57 (L/L)	01/11/90	0.46		0.49		0.45	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	4.47	<	4.90		4.60	
WBC	4000-9000 (/MM3)	01/11/90	9400.00	>	10200.0	>	9600.00	>
WBC: N	55-60 (%)	01/11/90			59.00		50.00	<
WBC: L	30-40 (%)	01/11/90			28.00	<	37.00	
WBC: E	1-3 (%)	01/11/90			4.00	>>	4.00	>>
WBC: M	3-7 (%)	01/11/90			9.00	>	8.00	>
WBC: B	0-1 (%)	01/11/90			0.00		1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90			376000	>	353000	>
NA+	136-147 (MMOL/L)	01/11/90	145.00		143.00		140.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.70		4.60		3.90	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.20	<	2.60			
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	7.00		7.00		10.00	
SGPT	5-22 (U/L)	01/11/90	9.00		8.00		14.00	
GAMMA GT	6-28 (U/L)	01/11/90	11.00		9.00		12.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	94.00		111.00		86.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	83.00		86.00		68.00	<
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	1.10		1.40	>	1.10	
URIC ACID	0.4-7 (MG/DL)	01/11/90	7.10	>	8.60	>	7.80	>
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.70		0.40		0.50	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.60		7.30		7.20	
ALBUMINE	53-63 (%)	01/11/90	59.30		63.70	>	62.70	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	251.00	>	209.00		261.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	233.00	>>	156.00		305.00	>>
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.70		2.90	<	3.10	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	9.10		8.10		8.50	
GLOBULINS BETA	10-13 (%)	01/11/90	13.00		10.50		11.70	
GLOBULINS GAMMA	14-20 (%)	01/11/90	14.90		14.80		14.00	
TSH	0.3-4 (UU/ML)	01/11/90	0.30		1.30		1.70	
T4	5-12 (UG/DL)	01/11/90	9.90		7.20		9.40	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 42 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/02/91		01/03/91		22/03/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	15.70		15.30		14.70	
HT	0.38-0.57 (L/L)	01/11/90	0.46		0.46		0.43	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	5.00		4.90		4.60	
WBC	4000-9000 (/MM3)	01/11/90	5900.00		6300.00		5600.00	
WBC: N	55-60 (%)	01/11/90	58.00		64.00	>	56.00	
WBC: L	30-40 (%)	01/11/90	36.00		28.00	<	37.00	
WBC: E	1-3 (%)	01/11/90	2.00		2.00		3.00	
WBC: M	3-7 (%)	01/11/90	4.00		6.00		3.00	
WBC: B	0-1 (%)	01/11/90	0.00		0.00		1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	184000		212000		229000	
NA+	136-147 (MMOL/L)	01/11/90	141.00		141.00		142.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	3.90		4.10		4.00	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.50				2.40	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	8.00		6.00		7.00	
SGPT	5-22 (U/L)	01/11/90	12.00		12.00		8.00	
GAMMA GT	6-28 (U/L)	01/11/90	37.00	>	27.00		26.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	85.00		104.00		95.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	88.00		90.00		78.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	0.90		0.90		0.90	
URIC ACID	0.4-7 (MG/DL)	01/11/90	4.10		3.60		4.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.50		0.60		0.80	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.00		8.00		7.10	
ALBUMINE	53-63 (%)	01/11/90	65.50	>	63.70	>	66.00	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	328.00	>>	300.00	>>	337.00	>>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	214.00	>	97.00		174.00	>
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.30	<	2.50	<	2.40	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	8.00		8.50		8.70	
GLOBULINS BETA	10-13 (%)	01/11/90	10.20		11.30		11.40	
GLOBULINS GAMMA	14-20 (%)	01/11/90	14.00		14.00		11.50	<
TSH	0.3-4 (UU/ML)	01/11/90	0.60		1.00			
T4	5-12 (UG/DL)	01/11/90	8.70		8.30			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 44 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			10/04/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/11/90	16.00	
HT	0.38-0.57 (L/L)	01/11/90	0.47	
RBC	4.5-5.8 (10~6/MM3)	01/11/90	4.90	
WBC	4000-9000 (/MM3)	01/11/90	6500.00	
WBC: N	55-60 (%)	01/11/90	68.00	>
WBC: L	30-40 (%)	01/11/90	20.00	<<
WBC: E	1-3 (%)	01/11/90	1.00	
WBC: M	3-7 (%)	01/11/90	11.00	>>
WBC: B	0-1 (%)	01/11/90	0.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	268000	
NA+	136-147 (MMOL/L)	01/11/90	135.00	<
K+	3.6-5.1 (MMOL/L)	01/11/90	4.30	
CL-	95-108 (MMOL/L)	01/11/90		
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.60	
PO4--	()	01/11/90		
SGOT	5-18 (U/L)	01/11/90	12.00	
SGPT	5-22 (U/L)	01/11/90	18.00	
GAMMA GT	6-28 (U/L)	01/11/90	12.00	
LDH	()	01/11/90		
ALK. PHOSPH.	60-170 (U/L)	01/11/90	72.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	100.00	
BUN	20-40 (MG/DL)	01/11/90		
UREA	()	01/11/90		
CREATININE	0.5-1.1 (MG/DL)	01/11/90	0.80	
URIC ACID	0.4-7 (MG/DL)	01/11/90	3.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	1.10	>
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90		
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.10	
ALBUMINE	53-63 (%)	01/11/90	67.40	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	266.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	99.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.70	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.60	
GLOBULINS BETA	10-13 (%)	01/11/90	9.10	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	13.20	<
TSH	0.3-4 (UU/ML)	01/11/90	0.90	
T4	5-12 (UG/DL)	01/11/90	7.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 45 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			29/04/91	
Laboratory test	Range value	Range date	value	(¢)
HB	12-16 (G/DL)	01/11/90	12.80	
HT	0.37-0.46 (L/L)	01/11/90	0.39	
RBC	4-5 (10¬6/MM3)	01/11/90	4.40	
WBC	4000-9000 (/MM3)	01/11/90	4600.00	
WBC: N	55-60 (%)	01/11/90	57.00	
WBC: L	30-40 (%)	01/11/90	36.00	
WBC: E	1-3 (%)	01/11/90	2.00	
WBC: M	3-7 (%)	01/11/90	4.00	
WBC: B	0-1 (%)	01/11/90	1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	189000	
NA+	136-147 (MMOL/L)	01/11/90	145.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.40	
CL-	95-108 (MMOL/L)	01/11/90		
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.40	
PO4--	()	01/11/90		
SGOT	5-18 (U/L)	01/11/90	8.00	
SGPT	5-22 (U/L)	01/11/90	12.00	
GAMMA GT	6-28 (U/L)	01/11/90	7.00	
LDH	()	01/11/90		
ALK. PHOSPH.	60-170 (U/L)	01/11/90	65.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	89.00	
BUN	20-40 (MG/DL)	01/11/90		
UREA	()	01/11/90		
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.60	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	3.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.50	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90		
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.30	
ALBUMINE	53-63 (%)	01/11/90	65.00	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	181.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	75.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.20	<
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	5.60	<
GLOBULINS BETA	10-13 (%)	01/11/90	8.80	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	18.40	
TSH	0.3-4 (UU/ML)	01/11/90	1.30	
T4	5-12 (UG/DL)	01/11/90	7.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 48 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			26/08/91		16/09/91		07/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	14.90		14.80		14.40	
HT	0.37-0.46 (L/L)	01/11/90	0.45		0.45		0.44	
RBC	4-5 (10-6/MM3)	01/11/90	5.14	>	5.00		4.90	
WBC	4000-9000 (/MM3)	01/11/90	5600.00		5300.00		5400.00	
WBC: N	55-60 (%)	01/11/90	58.00		47.00	<	50.00	<
WBC: L	30-40 (%)	01/11/90	34.00		41.00	>	40.00	
WBC: E	1-3 (%)	01/11/90	1.00		2.00		2.00	
WBC: M	3-7 (%)	01/11/90	6.00		8.00	>	7.00	
WBC: B	0-1 (%)	01/11/90	1.00		2.00	>>	1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	177000		177000		241000	
NA+	136-147 (MMOL/L)	01/11/90	143.00		140.00		146.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	3.98		4.34		4.90	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.20	<	2.20	<	2.27	<
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	15.00		19.00	>	17.00	
SGPT	5-22 (U/L)	01/11/90	15.00		18.00		15.00	
GAMMA GT	6-28 (U/L)	01/11/90	32.00	>	38.00	>	31.00	>
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	136.00		147.00		145.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	99.00		85.00		85.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90			1.10		1.00	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	5.60		6.40	>	5.80	>
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.70		0.80		0.70	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.10		7.20		7.20	
ALBUMINE	53-63 (%)	01/11/90	57.90		58.80		57.80	
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	201.00		222.00	>	214.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	124.00		149.00		160.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.40		3.20		3.40	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.90		8.80		9.00	
GLOBULINS BETA	10-13 (%)	01/11/90	10.70		10.00		10.80	
GLOBULINS GAMMA	14-20 (%)	01/11/90	20.10	>	19.20		18.80	
TSH	0.3-4 (UU/ML)	01/11/90			2.50			
T4	5-12 (UG/DL)	01/11/90	10.50		10.10			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: 49 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/08/91		18/09/91		09/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/11/90	13.80		13.20		13.30	
HT	0.37-0.46 (L/L)	01/11/90	0.39		0.41		0.40	
RBC	4-5 (10-6/MM3)	01/11/90	4.40		4.30		4.20	
WBC	4000-9000 (/MM3)	01/11/90	7600.00		7100.00		10400.0	>
WBC: N	55-60 (%)	01/11/90	49.90	<	65.70	>	72.00	>
WBC: L	30-40 (%)	01/11/90	40.80	>	26.20	<	22.00	<
WBC: E	1-3 (%)	01/11/90	1.10		0.80	<	0.00	<
WBC: M	3-7 (%)	01/11/90	7.20	>	6.80		5.00	
WBC: B	0-1 (%)	01/11/90	1.00		0.50		1.00	
PLATELETS	150000-300000 (/MM3)	01/11/90	232000		231000		227000	
NA+	136-147 (MMOL/L)	01/11/90	144.00		139.00		143.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.67		4.35		4.49	
CL-	95-108 (MMOL/L)	01/11/90					109.00	>
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.30		2.31		2.39	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	20.00	>	12.00		12.00	
SGPT	5-22 (U/L)	01/11/90	28.00	>	18.00		15.00	
GAMMA GT	6-28 (U/L)	01/11/90	35.00	>	30.00	>	17.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	71.00		106.00			
GLUCOSE	70-110 (MG/DL)	01/11/90	80.00		81.00		74.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.3 (MG/DL)	01/11/90	0.90		0.90		0.80	
URIC ACID	2.4-5.7 (MG/DL)	01/11/90	3.50		3.70		4.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.50		0.30		0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.10		7.20		7.10	
ALBUMINE	53-63 (%)	01/11/90	65.60	>	62.20		70.70	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	223.00	>	262.00	>	257.00	>
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	74.00		78.00		89.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	3.20		2.20	<	3.70	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	7.60		7.80		8.30	
GLOBULINS BETA	10-13 (%)	01/11/90	10.40		11.00		8.20	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	13.20	<	13.80	<	9.10	<<
TSH	0.3-4 (UU/ML)	01/11/90	0.60		1.00		0.70	
T4	5-12 (UG/DL)	01/11/90	9.00		6.60		9.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 2 Patient: S2 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			15/11/91		17/12/91		07/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/11/90	14.40		14.50		15.10	
HT	0.38-0.57 (L/L)	01/11/90	0.44		0.44		0.46	
RBC	4.5-5.8 (10-6/MM3)	01/11/90	4.80		4.80		5.10	
WBC	4000-9000 (/MM3)	01/11/90	7600.00		6500.00		7000.00	
WBC: N	55-60 (%)	01/11/90	58.20		51.10	<	50.00	<
WBC: L	30-40 (%)	01/11/90	30.10		36.70		35.00	
WBC: E	1-3 (%)	01/11/90	3.40	>	4.40	>>	5.00	>>
WBC: M	3-7 (%)	01/11/90	7.30	>	6.70		8.00	>
WBC: B	0-1 (%)	01/11/90	1.00		1.10	>	2.00	>>
PLATELETS	150000-300000 (/MM3)	01/11/90	200000		206000		212000	
NA+	136-147 (MMOL/L)	01/11/90	142.00		140.00		138.00	
K+	3.6-5.1 (MMOL/L)	01/11/90	4.40		4.33		4.08	
CL-	95-108 (MMOL/L)	01/11/90						
Ca++	2.3-2.6 (MMOL/L)	01/11/90	2.47		2.48		2.52	
PO4--	()	01/11/90						
SGOT	5-18 (U/L)	01/11/90	11.00		13.00		14.00	
SGPT	5-22 (U/L)	01/11/90	14.00		10.00		11.00	
GAMMA GT	6-28 (U/L)	01/11/90	8.00		7.00		8.00	
LDH	()	01/11/90						
ALK. PHOSPH.	60-170 (U/L)	01/11/90	88.00		99.00		108.00	
GLUCOSE	70-110 (MG/DL)	01/11/90	70.00		76.00		88.00	
BUN	20-40 (MG/DL)	01/11/90						
UREA	()	01/11/90						
CREATININE	0.5-1.1 (MG/DL)	01/11/90	1.10		1.10		1.00	
URIC ACID	0.4-7 (MG/DL)	01/11/90	4.90		5.80		4.90	
TOT BILIRUBIN	0-1 (MG/DL)	01/11/90	0.60		0.60		0.80	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/11/90						
TOT. PROTEINS	6.5-8.5 (G/DL)	01/11/90	7.10		7.10		7.70	
ALBUMINE	53-63 (%)	01/11/90	69.00	>	67.30	>	65.30	>
TOT. CHOLEST.	140-220 (MG/DL)	01/11/90	201.00		185.00		210.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/11/90	78.00		93.00		97.00	
GLOBULINS ALPHA 1	3-5 (%)	01/11/90	2.70	<	2.70	<	3.20	
GLOBULINS ALPHA 2	7-10 (%)	01/11/90	6.50	<	6.70	<	7.60	
GLOBULINS BETA	10-13 (%)	01/11/90	10.10		8.20	<	9.60	<
GLOBULINS GAMMA	14-20 (%)	01/11/90	11.70	<	15.10		14.30	
TSH	0.3-4 (UU/ML)	01/11/90	0.80		1.60		2.80	
T4	5-12 (UG/DL)	01/11/90	8.10		5.80		7.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 66 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			27/04/91		23/05/91	
Laboratory test	Range value	Range date	value	(ϕ)	value	(ϕ)
HB	12-16 (G/DL)	01/02/91	12.90		14.00	
HT	37-47 (%)	01/02/91	38.60		40.50	
RBC	4.2-5.4 (10¬6/MM3)	01/02/91	4.14	<	4.41	
WBC	4.8-10.8 (10¬3/MM3)	01/02/91	6.50		5.70	
WBC: N	45-78 (%)	01/02/91	62.80		67.10	
WBC: L	18-45 (%)	01/02/91	26.70		24.10	
WBC: E	0-5 (%)	01/02/91	2.50		2.70	
WBC: M	2-12 (%)	01/02/91	4.50		3.90	
WBC: B	0-1 (%)	01/02/91	0.60		0.90	
PLATELETS	125-400 (10¬3/MM3)	01/02/91	330.00		390.00	
NA+	135-150 (MMOL/L)	01/02/91	140.00		138.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	4.40		4.00	
CL-	97-108 (MMOL/L)	01/02/91	97.00		98.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.50		2.40	
PO4--	2-4.9 (MG/DL)	01/02/91	3.70		4.30	
SGOT	5-18 (U/L)	01/02/91	7.00		9.00	
SGPT	5-22 (U/L)	01/02/91	7.00		11.00	
GAMMA GT	0-18 (U/L)	01/02/91	13.00		13.00	
LDH	150-240 (U/L)	01/02/91	161.00		152.00	
ALK. PHOSPH.	40-200 (U/L)	01/02/91	88.00		95.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	94.00		123.00	>
BUN	0-25 (MG/DL)	01/02/91	21.00		21.00	
UREA	()	01/02/91				
CREATININE	0-1.3 (MG/DL)	01/02/91	0.90		0.90	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	5.50		5.10	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.70		0.50	
DIR BILIRUBIN	()	01/02/91				
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	8.10		7.20	
ALBUMINE	58-72 (%)	01/02/91	63.70		62.90	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	253.00	>	228.00	>
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	114.00		116.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	3.30		2.80	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	8.50		7.30	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	9.30		9.10	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	14.80		17.00	
TSH	0.1-4 (UU/ML)	01/02/91	0.60			
T4	0.92-1.82 (NG/DL)	01/02/91	1.52			

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 68 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/08/91		23/08/91		13/09/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/02/91	13.60		13.70		12.90	
HT	37-47 (%)	01/02/91	39.50		38.90		38.40	
RBC	4.2-5.4 (10-6/MM3)	01/02/91	4.92		4.68		4.51	
WBC	4.8-10.8 (10-3/MM3)	01/02/91	6.60		7.10		6.90	
WBC: N	45-78 (%)	01/02/91	65.90		63.90		60.50	
WBC: L	18-45 (%)	01/02/91	27.80		28.20		32.30	
WBC: E	0-5 (%)	01/02/91	0.90		0.70		1.00	
WBC: M	2-12 (%)	01/02/91	3.90		5.30		4.90	
WBC: B	0-1 (%)	01/02/91	0.20		0.30		0.30	
PLATELETS	125-400 (10-3/MM3)	01/02/91	218.00		276.00		261.00	
NA+	135-150 (MMOL/L)	01/02/91	143.00		145.00		144.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.60		3.70		3.80	
CL-	97-108 (MMOL/L)	01/02/91	105.00		98.00		98.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.40		2.50		2.40	
PO4--	2-4.9 (MG/DL)	01/02/91	4.40		3.70		4.10	
SGOT	5-18 (U/L)	01/02/91	6.00		7.00		28.00	>
SGPT	5-22 (U/L)	01/02/91	4.00	<	11.00		79.00	>>
GAMMA GT	0-18 (U/L)	01/02/91	10.00		25.00	>	57.00	>>
LDH	150-240 (U/L)	01/02/91	131.00	<	157.00		165.00	
ALK. PHOSPH.	40-200 (U/L)	01/02/91	141.00		162.00		185.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	61.00	<	101.00		129.00	>
BUN	0-25 (MG/DL)	01/02/91	24.00		19.00		17.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	0.80		1.00		0.80	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	4.60		4.40		4.90	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.80		0.60		0.40	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.20		7.80		7.50	
ALBUMINE	58-72 (%)	01/02/91	57.90	<	57.90	<	64.10	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	247.00	>	236.00	>	270.00	>>
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	251.00	>	231.00	>	612.00	>>
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	3.60		3.60		3.40	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	9.50		9.50		8.40	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	9.10		9.10		8.40	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	19.60		19.60		15.50	
TSH	0.1-4 (UU/ML)	01/02/91	1.40					
T4	0.92-1.82 (NG/DL)	01/02/91	0.81					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 69 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			01/03/91		22/03/91		11/04/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/02/91	14.50		14.90		13.50	
HT	37-47 (%)	01/02/91	42.70		44.30		37.50	
RBC	4.2-5.4 (10-6/MM3)	01/02/91	4.28		4.40		3.92	<
WBC	4.8-10.8 (10-3/MM3)	01/02/91	8.10		6.20		7.00	
WBC: N	45-78 (%)	01/02/91	65.10		56.80		64.10	
WBC: L	18-45 (%)	01/02/91	23.40		32.30		21.90	
WBC: E	0-5 (%)	01/02/91	3.00		4.50		3.40	
WBC: M	2-12 (%)	01/02/91	6.00		4.60		7.60	
WBC: B	0-1 (%)	01/02/91	0.70		1.10	>	0.40	
PLATELETS	125-400 (10-3/MM3)	01/02/91	281.00		313.00		300.00	
NA+	135-150 (MMOL/L)	01/02/91	145.00		143.00		143.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.80		4.50		4.30	
CL-	97-108 (MMOL/L)	01/02/91	103.00		98.00		102.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.50		2.60		2.50	
PO4--	2-4.9 (MG/DL)	01/02/91	4.30		3.80		4.50	
SGOT	5-18 (U/L)	01/02/91	6.00		6.00		5.00	
SGPT	5-22 (U/L)	01/02/91	8.00		6.00		6.00	
GAMMA GT	0-18 (U/L)	01/02/91	7.00		7.00		7.00	
LDH	150-240 (U/L)	01/02/91	115.00	<	121.00	<	88.00	<
ALK. PHOSPH.	40-200 (U/L)	01/02/91	80.00		88.00		81.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	81.00		80.00		94.00	
BUN	0-25 (MG/DL)	01/02/91	8.00		7.00		6.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	0.80		0.70		0.80	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	2.20	<	2.20	<	2.30	<
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.60		0.80		0.40	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.20		7.30		6.40	
ALBUMINE	58-72 (%)	01/02/91	64.60		68.40		68.30	
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	231.00	>	186.00		179.00	
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	76.00		84.00		44.00	<
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	4.20		4.10		4.30	>
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	8.20		6.50		6.30	<
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	8.80		8.10		7.90	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	14.00		12.90		12.40	
TSH	0.1-4 (UU/ML)	01/02/91	1.47					
T4	0.92-1.82 (NG/DL)	01/02/91	1.31					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 3 Patient: 71 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/11/91		04/12/91		25/12/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	12-16 (G/DL)	01/02/91	13.70		14.60		13.40	
HT	37-47 (%)	01/02/91	38.60		42.10		37.70	
RBC	4.2-5.4 (10¬6/MM3)	01/02/91	4.21		4.55		4.03	<
WBC	4.8-10.8 (10¬3/MM3)	01/02/91	6.60		6.70		6.50	
WBC: N	45-78 (%)	01/02/91	69.60		64.80		59.80	
WBC: L	18-45 (%)	01/02/91	21.60		22.50		26.20	
WBC: E	0-5 (%)	01/02/91	1.90		2.50		3.30	
WBC: M	2-12 (%)	01/02/91	4.80		6.30		6.60	
WBC: B	0-1 (%)	01/02/91	0.60		1.30	>	0.70	
PLATELETS	125-400 (10¬3/MM3)	01/02/91	235.00		198.00		179.00	
NA+	135-150 (MMOL/L)	01/02/91	140.00		141.00		140.00	
K+	3.6-5.3 (MMOL/L)	01/02/91	3.20	<	3.60		3.20	<
CL-	97-108 (MMOL/L)	01/02/91	102.00		99.00		104.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/91	2.40		2.30		2.30	
PO4--	2-4.9 (MG/DL)	01/02/91	3.30		3.70		3.00	
SGOT	5-18 (U/L)	01/02/91	10.00		9.00		10.00	
SGPT	5-22 (U/L)	01/02/91	6.00		10.00		16.00	
GAMMA GT	0-18 (U/L)	01/02/91	6.00		6.00		9.00	
LDH	150-240 (U/L)	01/02/91	125.00	<	102.00	<	112.00	<
ALK. PHOSPH.	40-200 (U/L)	01/02/91	62.00		68.00		81.00	
GLUCOSE	70-110 (MG/DL)	01/02/91	76.00		77.00			
BUN	0-25 (MG/DL)	01/02/91	11.00		10.00		9.00	
UREA	()	01/02/91						
CREATININE	0-1.3 (MG/DL)	01/02/91	0.80		0.80		0.70	
URIC ACID	2.5-5.7 (MG/DL)	01/02/91	2.60		2.60		4.20	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/02/91	0.60		0.60		0.60	
DIR BILIRUBIN	()	01/02/91						
TOT. PROTEINS	6.2-8.2 (G/DL)	01/02/91	7.10		6.90		6.70	
ALBUMINE	58-72 (%)	01/02/91	52.20	<	58.90		56.00	<
TOT. CHOLEST.	120-200 (MG/DL)	01/02/91	180.00		160.00		192.00	
TRIGLYCERIDES	75-200 (MG/DL)	01/02/91	72.00	<	52.00	<	78.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/02/91	6.70	>>	3.70		5.30	>
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/02/91	10.80	>	10.10		9.90	
GLOBULINS BETA	6.7-11.2 (%)	01/02/91	11.10		10.40		10.10	
GLOBULINS GAMMA	11.8-20.5 (%)	01/02/91	18.90		16.30		18.40	
TSH	0.1-4 (UU/ML)	01/02/91	1.50					
T4	0.92-1.82 (NG/DL)	01/02/91	1.26					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 4 Patient: 97 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/05/92		27/05/92		17/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	8.6-12 (MMOL/L)	01/04/91	10.30		10.70		10.00	
HT	0.43-0.49 (L/L)	01/04/91	0.49		0.49		0.45	
RBC	4.6-6.2 (10¬6/MM3)	01/04/91	5.21		5.30		4.90	
WBC	3.8-9.8 (10¬3/MM3)	01/04/91	5.80		5.70		5.52	
WBC: N	36-84 (%)	01/04/91	60.60		61.00		53.20	
WBC: L	20-42 (%)	01/04/91	29.40		28.80		34.80	
WBC: E	0-5 (%)	01/04/91	3.30		3.10		5.00	
WBC: M	0-9.5 (%)	01/04/91	3.50		3.70		4.50	
WBC: B	0-1 (%)	01/04/91	1.00		1.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/04/91	212.00		205.00		227.00	
NA+	136-152 (MMOL/L)	01/04/91	141.00		142.00		141.00	
K+	3.8-5.5 (MMOL/L)	01/04/91	4.59		4.57		4.86	
CL-	97-108 (MMOL/L)	01/04/91	98.00		98.00		100.00	
Ca++	2.4-2.65 (MMOL/L)	01/04/91	2.29	<	2.28	<	2.60	
PO4--	0.8-1.3 (MMOL/L)	01/04/91	1.03		1.03		1.08	
SGOT	0.32-0.49 (MMOL/L/S)	01/04/91	0.17	<	0.17	<	0.31	<
SGPT	0.22-0.57 (MMOL/L/S)	01/04/91	0.18	<	0.18	<	0.19	<
GAMMA GT	0-0.57 (MMOL/L/S)	01/04/91	0.19		0.19		0.19	
LDH	0-6.6 (MMOL/L)	01/04/91	3.73		3.73		4.48	
ALK. PHOSPH.	3.7-4.85 (MMOL/L/S)	01/04/91	3.25	<	3.23	<	2.91	<
GLUCOSE	3.33-5.55 (MMOL/L)	01/04/91	3.70		4.10		3.70	
BUN	5.3-8.9 (MMOL/L)	01/04/91						
UREA	()	01/04/91						
CREATININE	0-102 (UMOL/L)	01/04/91	75.00		69.00		76.00	
URIC ACID	140-340 (UMOL/L)	01/04/91	349.00	>	349.00	>	504.00	>>
TOT BILIRUBIN	0-16 (UMOL/L)	01/04/91	11.00		11.00		12.00	
DIR BILIRUBIN	()	01/04/91						
TOT. PROTEINS	65-85 (G/L)	01/04/91	71.60		71.60		70.80	
ALBUMINE	55-65 (%)	01/04/91	65.70	>	65.50	>	65.70	>
TOT. CHOLEST.	3.5-6.6 (MMOL/L)	01/04/91	5.70		5.69		6.99	>
TRIGLYCERIDES	1.75-2.1 (MMOL/L)	01/04/91	0.94	<	0.94	<	1.38	<
GLOBULINS ALPHA 1	3-6 (%)	01/04/91	3.30		3.50		3.30	
GLOBULINS ALPHA 2	5-10 (%)	01/04/91	8.60		8.50		8.60	
GLOBULINS BETA	9-14 (%)	01/04/91	10.20		10.20		10.20	
GLOBULINS GAMMA	12-20 (%)	01/04/91	12.20		12.30		12.20	
TSH	0.24-2.9 (MU/L)	01/04/91	0.59					
T4	65-155 (NMOL/L)	01/04/91	83.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS REG 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 4 Patient: 101 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			06/05/91		23/05/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	7.4-10.5 (MMOL/L)	01/04/91	8.70		8.80	
HT	0.36-0.45 (L/L)	01/04/91	0.40		0.40	
RBC	4.2-5.4 (10-6/MM3)	01/04/91	4.36		4.26	
WBC	3.8-9.8 (10-3/MM3)	01/04/91	6.90		6.83	
WBC: N	36-84 (%)	01/04/91			62.20	
WBC: L	20-42 (%)	01/04/91			27.60	
WBC: E	0-5 (%)	01/04/91			1.70	
WBC: M	0-9.5 (%)	01/04/91			5.10	
WBC: B	0-1 (%)	01/04/91			1.20	>
PLATELETS	150-300 (10-3/MM3)	01/04/91			293.00	
NA+	136-152 (MMOL/L)	01/04/91	143.00		140.00	
K+	3.8-5.5 (MMOL/L)	01/04/91	4.71		4.25	
CL-	97-108 (MMOL/L)	01/04/91	108.00		110.00	>
Ca++	2.4-2.65 (MMOL/L)	01/04/91	2.47			
PO4--	0.8-1.3 (MMOL/L)	01/04/91				
SGOT	0.32-0.49 (MMOL/L/S)	01/04/91	0.35		0.27	<
SGPT	0.17-0.4 (MMOL/L/S)	01/04/91	0.33		0.33	
GAMMA GT	0-0.4 (MMOL/L/S)	01/04/91	0.57	>	0.50	>
LDH	0-6.6 (MMOL/L)	01/04/91			4.95	
ALK. PHOSPH.	1.45-3.65 (MMOL/L/S)	01/04/91				
GLUCOSE	3.33-5.55 (MMOL/L)	01/04/91	4.20		4.30	
BUN	3.6-7.1 (MMOL/L)	01/04/91	5.50		7.40	>
UREA	()	01/04/91				
CREATININE	0-88 (UMOL/L)	01/04/91	83.00		90.00	>
URIC ACID	140-340 (UMOL/L)	01/04/91	333.00		341.00	>
TOT BILIRUBIN	0-16 (UMOL/L)	01/04/91	9.00		9.00	
DIR BILIRUBIN	()	01/04/91				
TOT. PROTEINS	65-85 (G/L)	01/04/91				
ALBUMINE	55-65 (%)	01/04/91				
TOT. CHOLEST.	3.5-6.6 (MMOL/L)	01/04/91				
TRIGLYCERIDES	1.75-2.1 (MMOL/L)	01/04/91				
GLOBULINS ALPHA 1	3-6 (%)	01/04/91				
GLOBULINS ALPHA 2	5-10 (%)	01/04/91				
GLOBULINS BETA	9-14 (%)	01/04/91				
GLOBULINS GAMMA	12-20 (%)	01/04/91				
TSH	0.24-2.9 (MU/L)	01/04/91	0.30			
T4	65-155 (NMOL/L)	01/04/91	64.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 7 Patient: 196 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/03/91		06/04/91		04/05/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-18 (G/DL)	03/02/91	14.90		13.80		14.70	
HT	37-56 (%)	03/02/91	43.20		39.40		43.00	
RBC	4200-6200 (10-3/MM3)	03/02/91	4850.00		4500.00		4730.00	
WBC	4000-10000 (/MM3)	03/02/91	7320.00		7920.00		6970.00	
WBC: N	50-70 (%)	03/02/91	54.10		52.40		56.40	
WBC: L	20-40 (%)	03/02/91	36.10		31.20		31.80	
WBC: E	0-5 (%)	03/02/91	3.50		2.20		3.50	
WBC: M	2-10 (%)	03/02/91	4.00		2.00		4.70	
WBC: B	0-2 (%)	03/02/91	0.60		0.50		0.90	
PLATELETS	150-400 (10-3/MM3)	03/02/91	284.00		346.00		364.00	
NA+	136-146 (MMOL/L)	03/02/91	141.00		139.00		145.00	
K+	3.5-5 (MMOL/L)	03/02/91	4.40		3.80		3.70	
CL-	95-105 (MMOL/L)	03/02/91	105.00		102.00		103.00	
Ca++	2-2.6 (MMOL/L)	03/02/91	2.31		2.40		2.35	
PO4--	0.79-1.56 (MMOL/L)	03/02/91	1.19		1.03		0.92	
SGOT	5-25 (U/L)	03/02/91	13.00		14.00		14.00	
SGPT	5-20 (U/L)	03/02/91	21.00	>	23.00	>	13.00	
GAMMA GT	0-38 (U/L)	03/02/91	27.00		38.00		22.00	
LDH	138-276 (U/L)	03/02/91			236.00		291.00	>
ALK. PHOSPH.	0-207 (U/L)	03/02/91	114.00		141.00		139.00	
GLUCOSE	0.6-1.2 (G/L)	03/02/91	0.82		1.01		1.11	
BUN	0.1-0.5 (G/L)	03/02/91	0.26		0.31		0.29	
UREA	()	03/02/91						
CREATININE	0-1.4 (MG/DL)	03/02/91	0.79		0.94		0.85	
URIC ACID	2.4-7 (MG/DL)	03/02/91	4.30		4.40		4.30	
TOT BILIRUBIN	0-1.5 (MG/DL)	03/02/91	0.18		0.16		0.27	
DIR BILIRUBIN	0-0.5 (MG/DL)	03/02/91	0.08		0.08		0.06	
TOT. PROTEINS	6.3-8.5 (G/DL)	03/02/91	7.80		8.10		7.90	
ALBUMINE	53-70 (%)	03/02/91	65.80		63.80		59.30	
TOT. CHOLEST.	1.5-2.5 (G/L)	03/02/91	2.57	>	2.52	>	2.44	
TRIGLYCERIDES	0.4-1.72 (G/L)	03/02/91	2.71	>>	2.09	>	1.40	
GLOBULINS ALPHA 1	1.5-5.5 (%)	03/02/91	5.00		4.60		3.80	
GLOBULINS ALPHA 2	8-12 (%)	03/02/91	7.90	<	8.40		12.70	>
GLOBULINS BETA	8-14 (%)	03/02/91	7.70	<	8.90		8.80	
GLOBULINS GAMMA	9-18 (%)	03/02/91	13.60		14.30		15.30	
TSH	0.2-5 (MU/L)	03/02/91						
T4	0.8-1.9 (NG/DL)	03/02/91	1.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 225 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			22/03/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	04/02/91	15.40	
HT	32-36 (%)	04/02/91	44.50	>
RBC	4-5 (10-6/MM3)	04/02/91	5.17	>
WBC	4.5-9 (10-3/MM3)	04/02/91	9.60	>
WBC: N	45-70 (%)	04/02/91	49.00	
WBC: L	20-40 (%)	04/02/91	37.00	
WBC: E	1-3 (%)	04/02/91	4.00	>>
WBC: M	3-7 (%)	04/02/91	10.00	>>
WBC: B	0-1 (%)	04/02/91	0.00	
PLATELETS	150-400 (10-3/MM3)	04/02/91	318.00	
NA+	135-146 (MEQ/L)	04/02/91		
K+	3.5-5 (MEQ/L)	04/02/91		
CL-	95-106 (MEQ/L)	04/02/91		
Ca++	4.2-5.3 (MEQ/L)	04/02/91		
PO4--	2.7-4.5 (MG/DL)	04/02/91		
SGOT	5-21 (U/L)	04/02/91	17.00	
SGPT	5-22 (U/L)	04/02/91	33.00	>
GAMMA GT	5-25 (U/L)	04/02/91	21.00	
LDH	160-320 (U/L)	04/02/91		
ALK. PHOSPH.	73-207 (U/L)	04/02/91		
GLUCOSE	80-110 (MG/DL)	04/02/91		
BUN	10-50 (MG/DL)	04/02/91		
UREA	()	04/02/91		
CREATININE	0.5-0.9 (MG/DL)	04/02/91		
URIC ACID	2.4-5.7 (MG/DL)	04/02/91		
TOT BILIRUBIN	0-1 (MG/DL)	04/02/91		
DIR BILIRUBIN	0-0.3 (MG/DL)	04/02/91		
TOT. PROTEINS	66-70 (G/L)	04/02/91		
ALBUMINE	56-70 (%)	04/02/91		
TOT. CHOLEST.	150-250 (MG/DL)	04/02/91		
TRIGLYCERIDES	35-185 (MG/DL)	04/02/91		
GLOBULINS ALPHA 1	1.8-4.5 (%)	04/02/91		
GLOBULINS ALPHA 2	4-13 (%)	04/02/91		
GLOBULINS BETA	9-14 (%)	04/02/91		
GLOBULINS GAMMA	8-16 (%)	04/02/91		
TSH	0.4-3.7 (UUI/ML)	04/02/91		
T4	6.1-11.5 (UG/DL)	04/02/91		

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 227 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/05/91		29/05/91		18/06/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-17 (G/DL)	02/04/91	15.40		16.40		16.40	
HT	35-50 (%)	02/04/91	45.00		48.00		49.00	
RBC	4-5.5 (10¬6/MM3)	02/04/91	4.50		4.90		5.00	
WBC	4-10 (10¬3/MM3)	02/04/91	9.70		10.30	>	9.70	
WBC: N	25-75 (%)	02/04/91	52.00		60.00		82.00	>
WBC: L	10-40 (%)	02/04/91	39.00		33.00		17.00	
WBC: E	0-4 (%)	02/04/91	1.00		2.00		0.00	
WBC: M	2-10 (%)	02/04/91	8.00		5.00		1.00	<
WBC: B	0-1 (%)	02/04/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	02/04/91	247.00		284.00		305.00	
NA+	137-150 (MEQ/L)	02/04/91	140.00		147.00		143.00	
K+	3.5-5.2 (MEQ/L)	02/04/91	4.80		5.20		5.20	
CL-	90-110 (MEQ/L)	02/04/91	112.00	>	104.00		104.00	
Ca++	4.5-5.5 (MEQ/L)	02/04/91	4.90		5.20		5.10	
PO4--	25-45 (MG/L)	02/04/91	39.00		32.00		33.00	
SGOT	5-25 (U/L)	02/04/91	13.00		15.00		12.00	
SGPT	5-25 (U/L)	02/04/91	14.00		19.00		12.00	
GAMMA GT	0-40 (U/L)	02/04/91	103.00	>>	29.00			
LDH	160-320 (U/L)	02/04/91	202.00					
ALK. PHOSPH.	40-210 (U/L)	02/04/91	103.00				125.00	
GLUCOSE	0.6-1.1 (G/L)	02/04/91	0.95				0.92	
BUN	0.1-0.45 (G/L)	02/04/91	0.17		0.17		0.15	
UREA	()	02/04/91						
CREATININE	5-12 (MG/L)	02/04/91	9.70		12.10	>	12.10	>
URIC ACID	30-65 (MG/L)	02/04/91	47.00		54.00		47.00	
TOT BILIRUBIN	0-10 (MG/L)	02/04/91	4.50		6.60		5.70	
DIR BILIRUBIN	0-3 (MG/L)	02/04/91	1.80		2.10		1.90	
TOT. PROTEINS	65-80 (G/L)	02/04/91	64.00	<	80.00		75.00	
ALBUMINE	55-70 (%)	02/04/91	65.10		62.40		65.90	
TOT. CHOLEST.	1.5-2.5 (G/L)	02/04/91	1.88		2.62	>	2.48	
TRIGLYCERIDES	0.7-1.5 (G/L)	02/04/91	1.17		0.85		1.26	
GLOBULINS ALPHA 1	2-4 (%)	02/04/91	3.10		3.60		3.30	
GLOBULINS ALPHA 2	6-10 (%)	02/04/91	8.80		9.80		8.30	
GLOBULINS BETA	9-13 (%)	02/04/91	12.10		12.60		11.10	
GLOBULINS GAMMA	11-15 (%)	02/04/91	11.00		11.50		11.40	
TSH	0.1-4 (MU/L)	02/04/91	1.20					
T4	7.3-20.1 (PG/ML)	02/04/91	9.30		14.80			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1270

PHARMACIA CME SRO 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 229 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/10/91		12/11/91		03/12/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	04/02/91	14.00		14.00		13.80	
HT	32-36 (%)	04/02/91	40.60	>	40.90	>	40.60	>
RBC	4-5 (10~6/MM3)	04/02/91	4.36		4.40		4.38	
WBC	4.5-9 (10~3/MM3)	04/02/91	8.30		8.90		7.00	
WBC: N	45-70 (%)	04/02/91	60.00		72.00	>	55.00	
WBC: L	20-40 (%)	04/02/91	30.00		19.00	<	34.00	
WBC: E	1-3 (%)	04/02/91	2.00		0.00	<	2.00	
WBC: M	3-7 (%)	04/02/91	6.00		9.00	>	6.00	
WBC: B	0-1 (%)	04/02/91	2.00	>>	0.00		3.00	>>
PLATELETS	150-400 (10~3/MM3)	04/02/91	298.00		274.00		298.00	
NA+	135-146 (MEQ/L)	04/02/91	141.00		141.00		141.00	
K+	3.5-5 (MEQ/L)	04/02/91	4.60		4.60		4.10	
CL-	95-106 (MEQ/L)	04/02/91	102.00		103.00		99.00	
Ca++	4.2-5.3 (MEQ/L)	04/02/91	4.60		4.60		4.40	
PO4--	2.7-4.5 (MG/DL)	04/02/91	4.70	>	3.70		3.90	
SGOT	5-21 (U/L)	04/02/91	13.00		10.00		11.00	
SGPT	5-22 (U/L)	04/02/91	14.00		10.00		11.00	
GAMMA GT	5-25 (U/L)	04/02/91	13.00		6.00		11.00	
LDH	160-320 (U/L)	04/02/91	199.00		176.00		173.00	
ALK. PHOSPH.	73-207 (U/L)	04/02/91	135.00		120.00		124.00	
GLUCOSE	80-110 (MG/DL)	04/02/91	90.00		95.00		93.00	
BUN	10-50 (MG/DL)	04/02/91	24.00		28.00		32.00	
UREA	()	04/02/91						
CREATININE	0.5-0.9 (MG/DL)	04/02/91	0.80		0.90		0.90	
URIC ACID	2.4-5.7 (MG/DL)	04/02/91	3.60		3.60		3.10	
TOT BILIRUBIN	0-1 (MG/DL)	04/02/91	0.30		0.30		0.40	
DIR BILIRUBIN	0-0.3 (MG/DL)	04/02/91	0.10				0.20	
TOT. PROTEINS	66-70 (G/L)	04/02/91	66.70		71.60	>	70.30	>
ALBUMINE	56-70 (%)	04/02/91	62.50		71.50	>	66.70	
TOT. CHOLEST.	150-250 (MG/DL)	04/02/91	238.00		249.00		269.00	>
TRIGLYCERIDES	35-185 (MG/DL)	04/02/91	109.00		136.00		133.00	
GLOBULINS ALPHA 1	1.8-4.5 (%)	04/02/91	3.90		2.60		2.80	
GLOBULINS ALPHA 2	4-13 (%)	04/02/91	10.10		7.20		8.10	
GLOBULINS BETA	9-14 (%)	04/02/91	12.20		10.30		12.70	
GLOBULINS GAMMA	8-16 (%)	04/02/91	11.30		8.40		9.80	
TSH	0.4-3.7 (UUI/ML)	04/02/91	1.60					
T4	6.1-11.5 (UG/DL)	04/02/91	7.60					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 8 Patient: 230 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/11/91		26/11/91		17/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	04/02/91	14.60		14.50		13.70	
HT	32-36 (%)	04/02/91	42.20	>	42.30	>	40.40	>
RBC	4-5 (10-6/MM3)	04/02/91	4.59		4.58		4.32	
WBC	4.5-9 (10-3/MM3)	04/02/91	6.40		7.30		5.70	
WBC: N	45-70 (%)	04/02/91	54.00		48.00		52.00	
WBC: L	20-40 (%)	04/02/91	39.00		44.00	>	39.00	
WBC: E	1-3 (%)	04/02/91	2.00		2.00		2.00	
WBC: M	3-7 (%)	04/02/91	5.00		6.00		5.00	
WBC: B	0-1 (%)	04/02/91	0.00		0.00		1.00	
PLATELETS	150-400 (10-3/MM3)	04/02/91	327.00		380.00		349.00	
NA+	135-146 (MEQ/L)	04/02/91	142.00		138.00		144.00	
K+	3.5-5 (MEQ/L)	04/02/91	4.40		4.30		4.50	
CL-	95-106 (MEQ/L)	04/02/91	102.00		98.00		106.00	
Ca++	4.2-5.3 (MEQ/L)	04/02/91	4.60		4.70		4.80	
PO4--	2.7-4.5 (MG/DL)	04/02/91	3.40		3.70		3.60	
SGOT	5-21 (U/L)	04/02/91	12.00		11.00		9.00	
SGPT	5-22 (U/L)	04/02/91	25.00	>	20.00		19.00	
GAMMA GT	5-25 (U/L)	04/02/91	14.00		12.00		12.00	
LDH	160-320 (U/L)	04/02/91	190.00		196.00		231.00	
ALK. PHOSPH.	73-207 (U/L)	04/02/91	89.00		95.00		89.00	
GLUCOSE	80-110 (MG/DL)	04/02/91	82.00		87.00		93.00	
BUN	10-50 (MG/DL)	04/02/91	25.00		32.00		32.00	
UREA	()	04/02/91						
CREATININE	0.5-0.9 (MG/DL)	04/02/91	0.90		0.90		1.00	>
URIC ACID	2.4-5.7 (MG/DL)	04/02/91	4.60		4.30		3.90	
TOT BILIRUBIN	0-1 (MG/DL)	04/02/91	1.10	>	0.70		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	04/02/91			0.30		0.20	
TOT. PROTEINS	66-70 (G/L)	04/02/91	71.90	>	71.30	>	71.40	>
ALBUMINE	56-70 (%)	04/02/91	66.00		63.40		64.20	
TOT. CHOLEST.	150-250 (MG/DL)	04/02/91	250.00		228.00		247.00	
TRIGLYCERIDES	35-185 (MG/DL)	04/02/91	217.00	>	224.00	>	189.00	>
GLOBULINS ALPHA 1	1.8-4.5 (%)	04/02/91	3.40		4.30		3.30	
GLOBULINS ALPHA 2	4-13 (%)	04/02/91	9.10		10.50		8.80	
GLOBULINS BETA	9-14 (%)	04/02/91	12.60		12.00		12.50	
GLOBULINS GAMMA	8-16 (%)	04/02/91	8.90		9.90		11.10	
TSH	0.4-3.7 (UUI/ML)	04/02/91	3.10					
T4	6.1-11.5 (UG/DL)	04/02/91	11.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1272

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 198 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/03/92		07/04/92		28/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	15.00		14.00		14.90	
HT	37-54 (%)	01/06/91	43.80		41.30		43.30	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.60		4.40		4.60	
WBC	4-10 (10¬3/MM3)	01/06/91	8.13		7.00		5.61	
WBC: N	40-70 (%)	01/06/91	69.50		54.60		35.30	<
WBC: L	19-48 (%)	01/06/91	23.50		35.90		50.40	>
WBC: E	0-7 (%)	01/06/91	0.71		1.90		2.47	
WBC: M	3.4-9 (%)	01/06/91	6.26		6.22		10.50	>
WBC: B	0-1.5 (%)	01/06/91	0.02		1.38		1.08	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	274.00		283.00		291.00	
NA+	135-145 (MMOL/L)	01/06/91	141.00		135.00			
K+	3.5-5 (MMOL/L)	01/06/91	4.00		6.80	>>		
CL-	98-108 (MMOL/L)	01/06/91	98.00		96.00	<		
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.31		9.50		9.38	
PO4--	2.1-4 (MG/DL)	01/06/91	3.09		3.85		3.91	
SGOT	11-33 (U/L)	01/06/91	16.00		17.00		16.00	
SGPT	11-39 (U/L)	01/06/91	13.00		13.00		12.00	
GAMMA GT	5-55 (U/L)	01/06/91	11.00		11.00		13.00	
LDH	200-450 (U/L)	01/06/91	336.00		347.00		345.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	62.00		67.00		70.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.85		1.06	>	0.74	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.36		0.38		0.30	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.73		0.83		0.82	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	2.70	<	3.50		2.60	<
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.35		0.19		0.46	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.05		0.05		0.05	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.50		7.30		7.20	
ALBUMINE	52-68 (%)	01/06/91	56.60		54.80		56.50	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	179.00		169.00		230.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	58.00	<	59.00	<	52.00	<
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.10		3.20		2.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	9.90		11.00		9.90	
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.20		16.10	>	14.50	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	17.20		14.90		16.40	
TSH	1-5 (UU/ML)	01/06/91	1.01					
T4	4.5-13 (UG/DL)	01/06/91	10.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 199 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			30/03/92		22/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	15.10		15.60	
HT	37-54 (%)	01/06/91	45.40		46.50	
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.05		5.30	
WBC	4-10 (10¬3/MM3)	01/06/91	6.28		8.01	
WBC: N	40-70 (%)	01/06/91			47.70	
WBC: L	19-48 (%)	01/06/91			40.60	
WBC: E	0-7 (%)	01/06/91			2.91	
WBC: M	3.4-9 (%)	01/06/91			10.30	>
WBC: B	0-1.5 (%)	01/06/91			0.56	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	341.00		364.00	>
NA+	135-145 (MMOL/L)	01/06/91			141.00	
K+	3.5-5 (MMOL/L)	01/06/91			4.62	
CL-	98-108 (MMOL/L)	01/06/91			102.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.10		9.48	
PO4--	2.1-4 (MG/DL)	01/06/91	5.92	>>	2.19	
SGOT	11-33 (U/L)	01/06/91	23.00		25.00	
SGPT	11-39 (U/L)	01/06/91	37.00		35.00	
GAMMA GT	15-85 (U/L)	01/06/91	23.00		21.00	
LDH	200-450 (U/L)	01/06/91	333.00		312.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	116.00		104.00	
GLUCOSE	0.6-1 (G/L)	01/06/91			0.81	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.29		0.28	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.99		0.98	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.50		5.20	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.35		0.59	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.06		0.12	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.80		7.70	
ALBUMINE	52-68 (%)	01/06/91	54.40		61.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	305.00	>	285.00	>
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	314.00	>>	201.00	>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.60		1.70	<<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.50	>	9.40	
GLOBULINS BETA	9.5-14 (%)	01/06/91	16.50	>	14.40	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.10		13.20	
TSH	1-5 (UU/ML)	01/06/91	4.88			
T4	4.5-13 (UG/DL)	01/06/91	9.50			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CVS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 201 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/01/92		05/02/92		26/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/06/91	14.70		14.80		14.40	
HT	37-54 (%)	01/06/91	45.70		44.70		42.90	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.95		4.72		4.71	
WBC	4-10 (10¬3/MM3)	01/06/91	8.12		5.70		7.08	
WBC: N	40-70 (%)	01/06/91					65.10	
WBC: L	19-48 (%)	01/06/91			36.30		23.50	
WBC: E	0-7 (%)	01/06/91	2.83				2.32	
WBC: M	3.4-9 (%)	01/06/91			5.10		8.22	
WBC: B	0-1.5 (%)	01/06/91					0.90	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	113.00	<	244.00		321.00	
NA+	135-145 (MMOL/L)	01/06/91	137.00		142.00		142.00	
K+	3.5-5 (MMOL/L)	01/06/91			4.24		4.73	
CL-	98-108 (MMOL/L)	01/06/91	101.00		103.00		97.00	<
Ca++	8.5-10.5 (MG/DL)	01/06/91	8.69		9.50		9.86	
PO4--	2.1-4 (MG/DL)	01/06/91	3.37		3.63		3.54	
SGOT	11-33 (U/L)	01/06/91	33.00		13.00		19.00	
SGPT	11-39 (U/L)	01/06/91	14.00		14.00		23.00	
GAMMA GT	5-55 (U/L)	01/06/91	6.00		15.00		24.00	
LDH	200-450 (U/L)	01/06/91	741.00	>	258.00		315.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	72.00		81.00		82.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.67		1.01	>	0.76	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.26		0.21		0.29	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.83		1.05		1.01	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	5.20		3.57		5.20	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91			0.30		0.13	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.07			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	6.80		6.74		7.20	
ALBUMINE	52-68 (%)	01/06/91	54.70				58.70	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	245.00				258.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	191.00	>	228.00	>>	280.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.20				3.20	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	12.90	>			12.20	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	15.90	>			14.90	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	13.20				11.00	<
TSH	1-5 (UU/ML)	01/06/91	1.46					
T4	4.5-13 (UG/DL)	01/06/91	5.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 202 Treatment: Imipramine Sex: Male

			Visit number / Laboratory data					
			Screen		Day 21		Day 42	
			09/01/92		06/02/92		27/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/06/91	15.90		15.40		16.10	
HT	37-54 (%)	01/06/91	47.60		43.60		47.40	
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.10		4.73		5.05	
WBC	4-10 (10¬3/MM3)	01/06/91	6.24		7.09		5.50	
WBC: N	40-70 (%)	01/06/91	79.30	>	75.00	>	67.00	
WBC: L	19-48 (%)	01/06/91	11.80	<<	13.00	<<	16.00	<
WBC: E	0-7 (%)	01/06/91	0.92		1.00		1.00	
WBC: M	3.4-9 (%)	01/06/91	7.70		11.00	>	15.00	>>
WBC: B	0-1.5 (%)	01/06/91	0.23		0.00			
PLATELETS	150-350 (10¬3/MM3)	01/06/91	178.00		150.00		199.00	
NA+	135-145 (MMOL/L)	01/06/91	140.00		141.00		143.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.42		4.43			
CL-	98-108 (MMOL/L)	01/06/91	100.00		100.00		98.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.71		9.28		9.42	
PO4--	2.1-4 (MG/DL)	01/06/91	1.75	<<	2.87		2.15	
SGOT	11-33 (U/L)	01/06/91	21.00		33.00		21.00	
SGPT	11-39 (U/L)	01/06/91	26.00		26.00		15.00	
GAMMA GT	15-85 (U/L)	01/06/91	25.00		14.00	<	21.00	
LDH	200-450 (U/L)	01/06/91	358.00		644.00	>	344.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	119.00		91.00		97.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.97		0.77		0.57	<
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.41		0.45	>	0.43	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.98		1.10		0.95	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.30		6.80		6.60	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.48		0.62		0.62	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.09				0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	6.50	<	6.40	<	6.30	<
ALBUMINE	52-68 (%)	01/06/91	57.90		55.80		64.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	172.00		190.00		205.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	66.00		59.00	<	54.00	<
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.70		3.40		2.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	7.40		14.10	>	7.20	
GLOBULINS BETA	9.5-14 (%)	01/06/91	12.70		13.40		14.00	
GLOBULINS GAMMA	12-21 (%)	01/06/91	19.30		13.30		11.40	<
TSH	1-5 (UU/ML)	01/06/91	0.79					
T4	4.5-13 (UG/DL)	01/06/91	9.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 205 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			27/01/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	11-16 (G/DL)	01/06/91	14.20	
HT	37-54 (%)	01/06/91	43.60	
RBC	4-6.2 (10~6/MM3)	01/06/91	4.73	
WBC	4-10 (10~3/MM3)	01/06/91	8.34	
WBC: N	40-70 (%)	01/06/91	67.00	
WBC: L	19-48 (%)	01/06/91	24.00	
WBC: E	0-7 (%)	01/06/91	2.00	
WBC: M	3.4-9 (%)	01/06/91	7.00	
WBC: B	0-1.5 (%)	01/06/91	0.00	
PLATELETS	150-350 (10~3/MM3)	01/06/91	250.00	
NA+	135-145 (MMOL/L)	01/06/91	139.00	
K+	3.5-5 (MMOL/L)	01/06/91		
CL-	98-108 (MMOL/L)	01/06/91	99.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.68	
PO4--	2.1-4 (MG/DL)	01/06/91	2.73	
SGOT	11-33 (U/L)	01/06/91	16.00	
SGPT	11-39 (U/L)	01/06/91	14.00	
GAMMA GT	5-55 (U/L)	01/06/91	14.00	
LDH	200-450 (U/L)	01/06/91	350.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	67.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.79	
BUN	()	01/06/91		
UREA	0.18-0.43 (G/L)	01/06/91	0.31	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.85	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	3.50	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.22	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.04	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	8.00	>
ALBUMINE	52-68 (%)	01/06/91	55.80	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	262.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	113.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.60	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.90	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.80	
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.80	
TSH	1-5 (UU/ML)	01/06/91		
T4	4.5-13 (UG/DL)	01/06/91		

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CVS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 206 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/01/92		26/02/92		18/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	10.70	<	8.86	<<	8.86	<<
HT	37-54 (%)	01/06/91	34.30	<	32.20	<	27.20	<<
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.14		4.20		4.18	
WBC	4-10 (10¬3/MM3)	01/06/91	8.40		6.52		6.52	
WBC: N	40-70 (%)	01/06/91	66.30					
WBC: L	19-48 (%)	01/06/91	27.20					
WBC: E	0-7 (%)	01/06/91	0.37					
WBC: M	3.4-9 (%)	01/06/91	5.77					
WBC: B	0-1.5 (%)	01/06/91	0.36					
PLATELETS	150-350 (10¬3/MM3)	01/06/91	369.00	>	313.00		313.00	
NA+	135-145 (MMOL/L)	01/06/91	141.00		141.00		141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.00		5.10	>	5.69	>
CL-	98-108 (MMOL/L)	01/06/91	100.00		101.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.06		8.80		8.80	
PO4--	2.1-4 (MG/DL)	01/06/91	3.40		2.84		2.84	
SGOT	11-33 (U/L)	01/06/91	14.00		14.00		14.00	
SGPT	11-39 (U/L)	01/06/91	14.00		13.00		13.00	
GAMMA GT	5-55 (U/L)	01/06/91	10.00		11.00		9.00	
LDH	200-450 (U/L)	01/06/91	265.00		269.00		44.00	<
ALK. PHOSPH.	34-154 (U/L)	01/06/91	70.00		67.00		67.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.94		0.78		0.78	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.38		0.28		0.28	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.98		1.00		1.00	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	2.50	<	2.60	<	2.60	<
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.37		0.16		0.16	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.09		0.04		0.04	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.50		6.40	<	6.40	<
ALBUMINE	52-68 (%)	01/06/91	53.40		60.00		60.00	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	213.00		183.00		183.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	100.00		97.00		97.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.00		2.90		2.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.20	>	8.70		8.70	
GLOBULINS BETA	9.5-14 (%)	01/06/91	15.50	>	13.20		13.20	
GLOBULINS GAMMA	12-21 (%)	01/06/91	17.00		16.20		15.20	
TSH	1-5 (UU/ML)	01/06/91	0.26					
T4	4.5-13 (UG/DL)	01/06/91	6.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 209 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			04/02/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	13-18 (G/DL)	01/06/91	15.40	
HT	37-54 (%)	01/06/91	44.60	
RBC	4-6.2 (10-6/MM3)	01/06/91	5.16	
WBC	4-10 (10-3/MM3)	01/06/91	5.09	
WBC: N	40-70 (%)	01/06/91	57.30	
WBC: L	19-48 (%)	01/06/91	29.90	
WBC: E	0-7 (%)	01/06/91	1.92	
WBC: M	3.4-9 (%)	01/06/91	10.80	>
WBC: B	0-1.5 (%)	01/06/91	0.09	
PLATELETS	150-350 (10-3/MM3)	01/06/91	281.00	
NA+	135-145 (MMOL/L)	01/06/91	145.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.30	
CL-	98-108 (MMOL/L)	01/06/91	103.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.36	
PO4--	2.1-4 (MG/DL)	01/06/91	2.66	
SGOT	11-33 (U/L)	01/06/91	27.00	
SGPT	11-39 (U/L)	01/06/91	36.00	
GAMMA GT	15-85 (U/L)	01/06/91	42.00	
LDH	200-450 (U/L)	01/06/91	285.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	103.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.80	
BUN	()	01/06/91		
UREA	0.18-0.43 (G/L)	01/06/91	0.31	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.11	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.00	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.94	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.19	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.50	
ALBUMINE	52-68 (%)	01/06/91	63.70	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	187.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	86.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	1.90	<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	7.40	
GLOBULINS BETA	9.5-14 (%)	01/06/91	11.30	
GLOBULINS GAMMA	12-21 (%)	01/06/91	15.80	
TSH	1-5 (UU/ML)	01/06/91	0.58	
T4	4.5-13 (UG/DL)	01/06/91	8.10	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 212 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/02/92		24/03/92		14/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.40		13.70		14.10	
HT	37-54 (%)	01/06/91	38.80		40.00		41.80	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.35		4.53		4.71	
WBC	4-10 (10-3/MM3)	01/06/91	8.56		8.64		8.62	
WBC: N	40-70 (%)	01/06/91	52.30		52.60		55.60	
WBC: L	19-48 (%)	01/06/91	35.20		37.20		34.60	
WBC: E	0-7 (%)	01/06/91	1.03		0.85		1.36	
WBC: M	3.4-9 (%)	01/06/91	9.95	>	6.47		6.60	
WBC: B	0-1.5 (%)	01/06/91	1.47		2.94	>>	1.87	>
PLATELETS	150-350 (10-3/MM3)	01/06/91	255.00		307.00		260.00	
NA+	135-145 (MMOL/L)	01/06/91	141.00		135.00		139.00	
K+	3.5-5 (MMOL/L)	01/06/91			3.56		4.59	
CL-	98-108 (MMOL/L)	01/06/91	98.00		90.00	<	99.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.00		9.64		9.71	
PO4--	2.1-4 (MG/DL)	01/06/91	2.91		2.88		2.80	
SGOT	11-33 (U/L)	01/06/91	17.00		21.00		23.00	
SGPT	11-39 (U/L)	01/06/91	12.00		16.00		16.00	
GAMMA GT	5-55 (U/L)	01/06/91	11.00		15.00		13.00	
LDH	200-450 (U/L)	01/06/91	327.00		328.00		432.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	64.00		70.00		74.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.84		0.82		0.71	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.22		0.16	<	0.20	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.88		0.90		0.98	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	3.60		3.60		3.60	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.27		0.31		0.28	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.06		0.06			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.80		7.90		7.60	
ALBUMINE	52-68 (%)	01/06/91	57.70		53.40		50.00	<
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	240.00		263.00		259.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	112.00		115.00		208.00	>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.20		3.20		3.60	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	12.10	>	13.60	>	13.90	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	12.80		15.20	>	14.60	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.20		14.70		18.00	
TSH	1-5 (UU/ML)	01/06/91	0.55					
T4	4.5-13 (UG/DL)	01/06/91	13.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA ~~ONE R&D~~ 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 238 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/05/92		09/06/92		30/06/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/06/91	15.10		14.80		14.40	
HT	37-54 (%)	01/06/91	44.70		43.60		43.20	
RBC	4-6.2 (10~6/MM3)	01/06/91	4.65		4.56		4.38	
WBC	4-10 (10~3/MM3)	01/06/91	9.27		9.82		12.90	>
WBC: N	40-70 (%)	01/06/91	64.70		64.30		77.00	>
WBC: L	19-48 (%)	01/06/91	23.60		27.70		16.00	<
WBC: E	0-7 (%)	01/06/91	0.94		1.17		1.00	
WBC: M	3.4-9 (%)	01/06/91	10.40	>	6.15		5.00	
WBC: B	0-1.5 (%)	01/06/91	0.41		0.63		1.00	
PLATELETS	150-350 (10~3/MM3)	01/06/91	231.00		359.00	>	290.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		138.00		142.00	
K+	3.5-5 (MMOL/L)	01/06/91	3.75		4.28		4.17	
CL-	98-108 (MMOL/L)	01/06/91	102.00		101.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.70		10.60	>	10.10	
PO4--	2.1-4 (MG/DL)	01/06/91	2.99		4.01	>	3.96	
SGOT	11-33 (U/L)	01/06/91	20.00		21.00		18.00	
SGPT	11-39 (U/L)	01/06/91	25.00		34.00		16.00	
GAMMA GT	5-55 (U/L)	01/06/91	36.00		48.00		40.00	
LDH	200-450 (U/L)	01/06/91	367.00		355.00		375.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	54.00		52.00		46.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.65		0.86		1.03	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.34		0.35		0.45	>
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.09		1.27		1.05	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.60		4.20		4.60	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.26		0.48		0.61	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.05		0.10		0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	6.90		7.40		7.20	
ALBUMINE	52-68 (%)	01/06/91	51.10	<	54.40		52.60	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	293.00	>	307.00	>	278.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	150.00		133.00		112.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	4.20		3.50		3.50	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	13.30	>	12.90	>	13.40	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	15.20	>	14.50	>	14.60	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	16.20		14.70		15.90	
TSH	1-5 (UU/ML)	01/06/91	1.37					
T4	4.5-13 (UG/DL)	01/06/91	9.80					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS BSD 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 239 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/04/92		20/05/92		10/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/06/91	14.50		14.90		14.60	
HT	37-54 (%)	01/06/91	43.20		45.30		43.60	
RBC	4-6.2 (10-6/MM3)	01/06/91	5.16		5.34		5.50	
WBC	4-10 (10-3/MM3)	01/06/91	6.43		6.75		6.53	
WBC: N	40-70 (%)	01/06/91	49.50		55.20		47.90	
WBC: L	19-48 (%)	01/06/91	40.00		35.20		41.70	
WBC: E	0-7 (%)	01/06/91	2.14		3.21		3.19	
WBC: M	3.4-9 (%)	01/06/91	7.51		6.35		7.13	
WBC: B	0-1.5 (%)	01/06/91	0.84				0.16	
PLATELETS	150-350 (10-3/MM3)	01/06/91	252.00		216.00		210.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		144.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.34		4.06		4.27	
CL-	98-108 (MMOL/L)	01/06/91	104.00		101.00		101.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.54		9.33		9.31	
PO4--	2.1-4 (MG/DL)	01/06/91	4.08	>	3.39		3.70	
SGOT	11-33 (U/L)	01/06/91	33.00		36.00	>	32.00	
SGPT	11-39 (U/L)	01/06/91	30.00		55.00	>	43.00	>
GAMMA GT	15-85 (U/L)	01/06/91	21.00		26.00		28.00	
LDH	200-450 (U/L)	01/06/91	328.00		313.00		325.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	102.00		109.00		93.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	1.02	>	1.04	>	0.99	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.32		0.29		0.30	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.04		1.15		1.07	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	8.10	>	8.20	>	8.20	>
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.47		0.29		0.97	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.08		0.12		0.12	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.60		7.50		7.20	
ALBUMINE	52-68 (%)	01/06/91	59.90		61.80		58.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	193.00		207.00		203.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	195.00	>	317.00	>>	187.00	>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.90		2.40	<	2.10	<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.90		6.20		8.10	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.10	>	12.80		19.70	>>
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.20		16.80		10.60	<
TSH	1-5 (UU/ML)	01/06/91	1.31					
T4	4.5-13 (UG/DL)	01/06/91	8.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9 Patient: 241 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/05/92		29/05/92		17/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	14.10		12.40		14.10	
HT	37-54 (%)	01/06/91	42.60		37.40		42.50	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.62		4.04		4.60	
WBC	4-10 (10¬3/MM3)	01/06/91	6.91		6.28		6.06	
WBC: N	40-70 (%)	01/06/91	64.00		67.10		66.70	
WBC: L	19-48 (%)	01/06/91	24.00		23.10		22.10	
WBC: E	0-7 (%)	01/06/91	1.00		1.83		2.87	
WBC: M	3.4-9 (%)	01/06/91	5.00		7.53		7.46	
WBC: B	0-1.5 (%)	01/06/91	3.00	>>	0.42		0.85	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	54.60	<<	173.00		146.00	<
NA+	135-145 (MMOL/L)	01/06/91	142.00		142.00		142.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.37		3.98		3.92	
CL-	98-108 (MMOL/L)	01/06/91	102.00		103.00		103.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.61		8.43	<	9.08	
PO4--	2.1-4 (MG/DL)	01/06/91	2.30		2.07	<	3.11	
SGOT	11-33 (U/L)	01/06/91	15.00		11.00		13.00	
SGPT	11-39 (U/L)	01/06/91	17.00		13.00		18.00	
GAMMA GT	5-55 (U/L)	01/06/91	25.00		25.00		40.00	
LDH	200-450 (U/L)	01/06/91	272.00		218.00		242.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	59.00		53.00		63.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.91		0.87		1.01	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.34		0.27		0.37	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.92		0.97		1.00	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	3.90		4.90		4.70	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.83		0.30		0.79	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.08			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	6.90		5.70	<	6.50	<
ALBUMINE	52-68 (%)	01/06/91	62.70		61.00		63.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	261.00		184.00		285.00	>
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	72.00		91.00		99.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.10	<	2.50		2.20	<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.50		12.60	>	8.80	
GLOBULINS BETA	9.5-14 (%)	01/06/91	12.90		12.60		14.60	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	13.90		11.20	<	11.20	<
TSH	1-5 (UU/ML)	01/06/91	0.22					
T4	4.5-13 (UG/DL)	01/06/91	7.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 0550085

Centre: 9 Patient: 243 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/05/92		08/06/92		29/06/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.70		14.00		14.20	
HT	37-54 (%)	01/06/91	40.40		41.10		42.10	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.52		4.58		4.69	
WBC	4-10 (10-3/MM3)	01/06/91	8.99		8.47		9.31	
WBC: N	40-70 (%)	01/06/91	74.50	>	74.00	>	68.00	
WBC: L	19-48 (%)	01/06/91	16.80	<	16.00	<	21.50	
WBC: E	0-7 (%)	01/06/91	1.22		3.57		4.87	
WBC: M	3.4-9 (%)	01/06/91	6.96		5.82		4.90	
WBC: B	0-1.5 (%)	01/06/91	0.47		0.56		0.77	
PLATELETS	150-350 (10-3/MM3)	01/06/91	376.00	>	397.00	>	456.00	>>
NA+	135-145 (MMOL/L)	01/06/91	138.00		139.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.72		4.47		4.43	
CL-	98-108 (MMOL/L)	01/06/91	96.00	<	96.00	<	100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.53		9.67		9.45	
PO4--	2.1-4 (MG/DL)	01/06/91	2.85		3.52		3.88	
SGOT	11-33 (U/L)	01/06/91	15.00		13.00		17.00	
SGPT	11-39 (U/L)	01/06/91	16.00		15.00		16.00	
GAMMA GT	5-55 (U/L)	01/06/91	45.00		32.00		40.00	
LDH	200-450 (U/L)	01/06/91	275.00		257.00		295.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	82.00		84.00		114.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.76		0.82		1.29	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.17	<	0.17	<	0.19	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.77		0.77		0.84	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	3.20	<	3.60		3.60	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.59		0.76		0.40	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.13		0.16		0.08	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.70		7.40		7.40	
ALBUMINE	52-68 (%)	01/06/91	53.30		55.50		50.20	<
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	201.00		263.00		247.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	187.00	>	182.00	>	308.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.70		6.70	>>	3.20	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.10		8.60		11.80	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.50	>	11.70		16.30	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	18.40		17.50		18.50	
TSH	1-5 (UU/ML)	01/06/91	0.84					
T4	4.5-13 (UG/DL)	01/06/91	13.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9 Patient: 259 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			05/07/91		07/08/91		28/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	13.90		16.00		13.90	
HT	37-54 (%)	01/06/91	37.30		38.20		38.10	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.12		4.18		4.19	
WBC	4-10 (10¬3/MM3)	01/06/91	6.91		7.15		8.14	
WBC: N	40-70 (%)	01/06/91	66.70		58.80		57.20	
WBC: L	19-48 (%)	01/06/91	28.40		34.80		36.80	
WBC: E	0-7 (%)	01/06/91	0.25		0.91		1.02	
WBC: M	3.4-9 (%)	01/06/91	4.47		5.07		3.63	
WBC: B	0-1.5 (%)	01/06/91	0.19		0.41		1.30	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	297.00		340.00		349.00	
NA+	135-145 (MMOL/L)	01/06/91	147.00	>	142.00		145.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.13		4.05		4.25	
CL-	98-108 (MMOL/L)	01/06/91	104.00		99.00		105.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.00		8.80		9.40	
PO4--	2.1-4 (MG/DL)	01/06/91	2.60		3.60		3.60	
SGOT	11-33 (U/L)	01/06/91	22.00		20.00		25.00	
SGPT	11-39 (U/L)	01/06/91	8.00	<	11.00		18.00	
GAMMA GT	5-55 (U/L)	01/06/91	27.00		26.00		59.00	>
LDH	200-450 (U/L)	01/06/91	306.00		315.00		323.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	60.00		72.00		87.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.91		0.88		1.01	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.38					
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.94		1.07		1.31	>
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.30		3.10	<	3.50	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.69		0.19		0.33	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.11		0.09			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.90		6.80		7.20	
ALBUMINE	52-68 (%)	01/06/91	58.50					
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	147.00	<	154.00	<	170.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	68.00		253.00	>>	230.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.50					
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	9.60					
GLOBULINS BETA	9.5-14 (%)	01/06/91	12.10					
GLOBULINS GAMMA	12-21 (%)	01/06/91	17.30					
TSH	1-5 (UU/ML)	01/06/91						
T4	4.5-13 (UG/DL)	01/06/91						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 9 Patient: 260 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			17/07/91		14/08/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	14.70		15.90	
HT	37-54 (%)	01/06/91	42.10		43.70	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.59		4.78	
WBC	4-10 (10¬3/MM3)	01/06/91	10.10	>	9.83	
WBC: N	40-70 (%)	01/06/91	73.00	>	66.00	
WBC: L	19-48 (%)	01/06/91	10.00	<<	18.00	<
WBC: E	0-7 (%)	01/06/91	3.00		2.00	
WBC: M	3.4-9 (%)	01/06/91	12.00	>>	9.00	
WBC: B	0-1.5 (%)	01/06/91	2.00	>>	1.00	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	270.00		279.00	
NA+	135-145 (MMOL/L)	01/06/91			143.00	
K+	3.5-5 (MMOL/L)	01/06/91			3.84	
CL-	98-108 (MMOL/L)	01/06/91			99.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91			9.40	
PO4--	2.1-4 (MG/DL)	01/06/91			4.40	>
SGOT	11-33 (U/L)	01/06/91			47.00	>
SGPT	11-39 (U/L)	01/06/91			54.00	>
GAMMA GT	5-55 (U/L)	01/06/91			33.00	
LDH	200-450 (U/L)	01/06/91			509.00	>
ALK. PHOSPH.	34-154 (U/L)	01/06/91			75.00	
GLUCOSE	0.6-1 (G/L)	01/06/91			1.09	>
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91				
CREATININE	0.7-1.3 (MG/DL)	01/06/91			0.85	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91			6.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91			0.43	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.03	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91			7.90	
ALBUMINE	52-68 (%)	01/06/91				
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	157.00		185.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	76.00		98.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91				
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91				
GLOBULINS BETA	9.5-14 (%)	01/06/91				
GLOBULINS GAMMA	12-21 (%)	01/06/91				
TSH	1-5 (UU/ML)	01/06/91	0.91			
T4	4.5-13 (UG/DL)	01/06/91	9.40			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 261 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 7	
			19/07/91		30/07/91	
			value	(¢)	value	(¢)
Laboratory test	Range value	Range date				
HB	11-16 (G/DL)	01/06/91	14.40		14.30	
HT	37-54 (%)	01/06/91	41.80		42.10	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.61		4.57	
WBC	4-10 (10¬3/MM3)	01/06/91	6.98		5.70	
WBC: N	40-70 (%)	01/06/91	46.20		39.70	<
WBC: L	19-48 (%)	01/06/91	40.80		47.00	
WBC: E	0-7 (%)	01/06/91	5.09		4.60	
WBC: M	3.4-9 (%)	01/06/91	7.28		8.04	
WBC: B	0-1.5 (%)	01/06/91	0.71		0.74	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	241.00		279.00	
NA+	135-145 (MMOL/L)	01/06/91	138.00		141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.37		4.42	
CL-	98-108 (MMOL/L)	01/06/91	104.00		102.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.10		9.40	
PO4--	2.1-4 (MG/DL)	01/06/91	3.60			
SGOT	11-33 (U/L)	01/06/91	31.00		17.00	
SGPT	11-39 (U/L)	01/06/91	39.00		18.00	
GAMMA GT	5-55 (U/L)	01/06/91	60.00	>	35.00	
LDH	200-450 (U/L)	01/06/91	432.00		355.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	96.00		81.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.96		0.88	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.22		0.26	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.98		0.86	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.30		4.30	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.68		0.58	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91			0.14	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.49		7.10	
ALBUMINE	52-68 (%)	01/06/91	51.50	<	52.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	200.00		179.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	181.00	>		
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.20	<	2.30	<
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.20		7.90	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.40	>	13.00	
GLOBULINS GAMMA	12-21 (%)	01/06/91	23.70	>	24.50	>
TSH	1-5 (UU/ML)	01/06/91	3.13			
T4	4.5-13 (UG/DL)	01/06/91	8.60			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 264 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/07/91		21/08/91		11/09/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	12.60		12.20		12.40	
HT	37-54 (%)	01/06/91	37.10		36.00	<	36.60	<
RBC	4-6.2 (10-6/MM3)	01/06/91	4.21		4.14		4.19	
WBC	4-10 (10-3/MM3)	01/06/91	5.23		7.55		4.69	
WBC: N	40-70 (%)	01/06/91	52.80		66.70		63.80	
WBC: L	19-48 (%)	01/06/91	38.80		24.70		28.90	
WBC: E	0-7 (%)	01/06/91	1.93		1.57		0.84	
WBC: M	3.4-9 (%)	01/06/91	5.23		6.49		5.41	
WBC: B	0-1.5 (%)	01/06/91	1.96	>>	0.55		1.06	
PLATELETS	150-350 (10-3/MM3)	01/06/91	201.00		211.00		217.00	
NA+	135-145 (MMOL/L)	01/06/91	142.00		143.00		146.00	>
K+	3.5-5 (MMOL/L)	01/06/91	4.22		3.86		4.49	
CL-	98-108 (MMOL/L)	01/06/91	102.00		101.00		106.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.70		9.30		9.50	
PO4--	2.1-4 (MG/DL)	01/06/91	3.10		3.50		3.30	
SGOT	11-33 (U/L)	01/06/91	14.00		13.00		11.00	
SGPT	11-39 (U/L)	01/06/91	15.00		5.00	<	9.00	<
GAMMA GT	5-55 (U/L)	01/06/91	21.00		18.00		18.00	
LDH	200-450 (U/L)	01/06/91	333.00		268.00		269.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	40.00		56.00		57.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.97		1.19	>	0.88	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91					0.36	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.93		0.92		0.87	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91			4.00		3.40	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.60		0.33		0.43	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.05		0.09		0.10	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.60		7.90		6.90	
ALBUMINE	52-68 (%)	01/06/91						
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	215.00		195.00		232.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	81.00		74.00		75.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91						
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91						
GLOBULINS BETA	9.5-14 (%)	01/06/91						
GLOBULINS GAMMA	12-21 (%)	01/06/91						
TSH	1-5 (UU/ML)	01/06/91	1.60					
T4	4.5-13 (UG/DL)	01/06/91	10.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 267 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/08/91		23/09/91		14/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	16.40		16.00		16.70	
HT	37-54 (%)	01/06/91	47.40		49.50		49.30	
RBC	4-6.2 (10¬6/MM3)	01/06/91	5.04		5.26		5.29	
WBC	4-10 (10¬3/MM3)	01/06/91	6.93		8.22		7.28	
WBC: N	40-70 (%)	01/06/91	61.10		60.70		62.20	
WBC: L	19-48 (%)	01/06/91	31.10		29.10		28.20	
WBC: E	0-7 (%)	01/06/91	2.48		2.87		3.02	
WBC: M	3.4-9 (%)	01/06/91	5.04		6.53		4.94	
WBC: B	0-1.5 (%)	01/06/91	1.32		0.82		1.71	>
PLATELETS	150-350 (10¬3/MM3)	01/06/91	343.00		266.00		284.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		144.00		144.00	
K+	3.5-5 (MMOL/L)	01/06/91	3.91		3.82		4.31	
CL-	98-108 (MMOL/L)	01/06/91	105.00		103.00		100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.80		10.20		10.60	>
PO4--	2.1-4 (MG/DL)	01/06/91	3.90		4.80	>>	4.20	>
SGOT	11-33 (U/L)	01/06/91	27.00		33.00		26.00	
SGPT	11-39 (U/L)	01/06/91	53.00	>	37.00		27.00	
GAMMA GT	15-85 (U/L)	01/06/91	77.00		53.00		28.00	
LDH	200-450 (U/L)	01/06/91	330.00				348.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	69.00		79.00		73.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	1.43	>>	0.93		0.97	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.58	>	0.29		0.39	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.80		1.02		0.92	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.10		4.00		5.40	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.63		0.58		0.76	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.16		0.10		0.02	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.00		7.30		7.20	
ALBUMINE	52-68 (%)	01/06/91	66.20		63.40		63.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	179.00		125.00	<	224.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	106.00		115.00		95.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.20	<	2.60		3.00	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	8.30		9.30		8.80	
GLOBULINS BETA	9.5-14 (%)	01/06/91	11.00		10.90		11.60	
GLOBULINS GAMMA	12-21 (%)	01/06/91	12.20		13.90		13.40	
TSH	1-5 (UU/ML)	01/06/91	1.35					
T4	4.5-13 (UG/DL)	01/06/91	9.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 268 Treatment: Imipramine Sex: Female

			Visit number / Laboratory data					
			Screen		Day 21		Day 42	
			17/09/91		15/10/91		05/11/91	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/06/91	14.70		14.90		14.40	
HT	37-54 (%)	01/06/91	43.00		43.00		42.40	
RBC	4-6.2 (10-6/MM3)	01/06/91	4.74		4.79		4.66	
WBC	4-10 (10-3/MM3)	01/06/91	6.56		8.69		6.32	
WBC: N	40-70 (%)	01/06/91	61.00		58.80		50.70	
WBC: L	19-48 (%)	01/06/91	31.10		34.10		41.30	
WBC: E	0-7 (%)	01/06/91	1.82		1.16		2.02	
WBC: M	3.4-9 (%)	01/06/91	5.08		4.48		5.06	
WBC: B	0-1.5 (%)	01/06/91	1.07		1.56	>	0.88	
PLATELETS	150-350 (10-3/MM3)	01/06/91	321.00		342.00		378.00	>
NA+	135-145 (MMOL/L)	01/06/91	140.00		141.00		140.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.49		3.86		4.77	
CL-	98-108 (MMOL/L)	01/06/91	103.00		100.00		99.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.70		9.70		9.30	
PO4--	2.1-4 (MG/DL)	01/06/91	2.80		3.30		3.40	
SGOT	11-33 (U/L)	01/06/91	22.00		18.00		20.00	
SGPT	11-39 (U/L)	01/06/91	33.00		22.00		27.00	
GAMMA GT	5-55 (U/L)	01/06/91	17.00		18.00		26.00	
LDH	200-450 (U/L)	01/06/91	349.00		327.00		381.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	66.00		72.00		82.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.89		0.75		0.64	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.29		0.30		0.34	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.89		0.98		0.93	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.40		5.60		5.30	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.35		0.33		0.43	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.04		0.08		0.05	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.70		7.80		7.90	
ALBUMINE	52-68 (%)	01/06/91	54.20		62.80		52.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	183.00		215.00		218.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	53.00	<	179.00	>	123.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.30		1.80	<	2.50	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.10		6.10	<	10.20	
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.90	>	14.20	>	16.40	>
GLOBULINS GAMMA	12-21 (%)	01/06/91	17.60		15.10		18.40	
TSH	1-5 (UU/ML)	01/06/91	1.48					
T4	4.5-13 (UG/DL)	01/06/91	8.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 9 Patient: 270 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			02/10/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11-16 (G/DL)	01/06/91	13.30	
HT	37-54 (%)	01/06/91	39.40	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.35	
WBC	4-10 (10¬3/MM3)	01/06/91	5.12	
WBC: N	40-70 (%)	01/06/91	34.20	<
WBC: L	19-48 (%)	01/06/91	57.90	>
WBC: E	0-7 (%)	01/06/91	0.85	
WBC: M	3.4-9 (%)	01/06/91	6.47	
WBC: B	0-1.5 (%)	01/06/91	0.56	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	272.00	
NA+	135-145 (MMOL/L)	01/06/91	141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.23	
CL-	98-108 (MMOL/L)	01/06/91	100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.20	
PO4--	2.1-4 (MG/DL)	01/06/91	3.20	
SGOT	11-33 (U/L)	01/06/91	18.00	
SGPT	11-39 (U/L)	01/06/91	15.00	
GAMMA GT	5-55 (U/L)	01/06/91	22.00	
LDH	200-450 (U/L)	01/06/91	192.00	<
ALK. PHOSPH.	34-154 (U/L)	01/06/91	36.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	1.29	>
BUN	()	01/06/91		
UREA	0.18-0.43 (G/L)	01/06/91	0.26	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.02	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	3.20	<
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.36	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.11	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.30	
ALBUMINE	52-68 (%)	01/06/91		
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91		
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91		
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91		
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91		
GLOBULINS BETA	9.5-14 (%)	01/06/91		
GLOBULINS GAMMA	12-21 (%)	01/06/91		
TSH	1-5 (UU/ML)	01/06/91	10.60	
T4	4.5-13 (UG/DL)	01/06/91	1.09	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

9550085

LABORATORY DATA

Centre: 9 Patient: 272 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/10/91		19/11/91		10/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	16.10		16.30		16.70	
HT	37-54 (%)	01/06/91	48.80		47.70		51.30	
RBC	4-6,2 (10-6/MM3)	01/06/91	5.26		5.21		5.47	
WBC	4-10 (10-3/MM3)	01/06/91	7.63		7.76		7.01	
WBC: N	40-70 (%)	01/06/91	64.10		65.40		69.00	
WBC: L	19-48 (%)	01/06/91	24.50		20.90		18.00	<
WBC: E	0-7 (%)	01/06/91	3.55		7.90	>	6.00	
WBC: M	3.4-9 (%)	01/06/91	4.43		4.67		7.00	
WBC: B	0-1.5 (%)	01/06/91	3.51	>>	1.17		0.00	
PLATELETS	150-350 (10-3/MM3)	01/06/91	279.00		259.00		266.00	
NA+	135-145 (MMOL/L)	01/06/91	143.00		140.00		143.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.84		4.49		3.88	
CL-	98-108 (MMOL/L)	01/06/91	100.00		98.00		95.00	<
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.50		9.80		10.00	
PO4--	2.1-4 (MG/DL)	01/06/91	1.20	<<	1.60	<<	2.30	
SGOT	11-33 (U/L)	01/06/91	22.00		17.00		24.00	
SGPT	11-39 (U/L)	01/06/91	16.00		14.00		21.00	
GAMMA GT	15-85 (U/L)	01/06/91	30.00		19.00		23.00	
LDH	200-450 (U/L)	01/06/91	343.00		296.00		308.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	78.00		68.00		83.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.84		0.81		1.14	>
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.34		0.67	>>	0.37	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	1.23		1.37	>	1.41	>
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.60		5.40		5.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.44		0.60		0.56	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.11		0.10		0.12	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.60		7.10		7.80	
ALBUMINE	52-68 (%)	01/06/91	56.30		63.80		52.50	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	232.00		174.00		246.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	228.00	>>	142.00		162.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.50		2.50		2.50	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.60	>	8.60		12.10	>
GLOBULINS BETA	9.5-14 (%)	01/06/91	14.30	>	13.00		18.40	>>
GLOBULINS GAMMA	12-21 (%)	01/06/91	14.30		12.10		14.40	
TSH	1-5 (UU/ML)	01/06/91	7.70					
T4	4.5-13 (UG/DL)	01/06/91	3.28					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 273 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			24/10/91		19/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/06/91	14.90		14.70	
HT	37-54 (%)	01/06/91	42.60		43.10	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.60		4.65	
WBC	4-10 (10¬3/MM3)	01/06/91	6.87		8.46	
WBC: N	40-70 (%)	01/06/91	65.00		63.80	
WBC: L	19-48 (%)	01/06/91	28.10		25.40	
WBC: E	0-7 (%)	01/06/91	2.00		4.58	
WBC: M	3.4-9 (%)	01/06/91	4.44		4.97	
WBC: B	0-1.5 (%)	01/06/91	0.42		1.28	
PLATELETS	150-350 (10¬3/MM3)	01/06/91	322.00		318.00	
NA+	135-145 (MMOL/L)	01/06/91	140.00		141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.60		4.23	
CL-	98-108 (MMOL/L)	01/06/91	101.00		100.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.20		9.70	
PO4--	2.1-4 (MG/DL)	01/06/91	3.00		2.50	
SGOT	11-33 (U/L)	01/06/91	17.00		16.00	
SGPT	11-39 (U/L)	01/06/91	21.00		14.00	
GAMMA GT	5-55 (U/L)	01/06/91	14.00		13.00	
LDH	200-450 (U/L)	01/06/91	353.00		334.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	55.00		60.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.85		0.65	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.36		0.28	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.83		0.89	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	3.10	<	3.70	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.57		0.42	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.11		0.08	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.90		7.90	
ALBUMINE	52-68 (%)	01/06/91	55.00		53.10	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	232.00		205.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	52.00	<	93.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.00		3.30	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	10.80		9.60	
GLOBULINS BETA	9.5-14 (%)	01/06/91	13.80		11.50	
GLOBULINS GAMMA	12-21 (%)	01/06/91	17.40		14.20	
TSH	1-5 (UU/ML)	01/06/91	1.72			
T4	4.5-13 (UG/DL)	01/06/91	7.60			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9 Patient: 276 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 7	
			24/12/91		16/01/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/06/91	13.70		11.80	
HT	37-54 (%)	01/06/91	42.10		35.60	<
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.38		3.74	<
WBC	4-10 (10¬3/MM3)	01/06/91	8.17		7.11	
WBC: N	40-70 (%)	01/06/91	69.90		61.50	
WBC: L	19-48 (%)	01/06/91	24.00		30.10	
WBC: E	0-7 (%)	01/06/91	0.06		1.73	
WBC: M	3.4-9 (%)	01/06/91	5.13		5.62	
WBC: B	0-1.5 (%)	01/06/91	0.06		1.73	>
PLATELETS	150-350 (10¬3/MM3)	01/06/91	275.00		278.00	
NA+	135-145 (MMOL/L)	01/06/91	140.00		141.00	
K+	3.5-5 (MMOL/L)	01/06/91	4.25		4.63	
CL-	98-108 (MMOL/L)	01/06/91	95.00	<	102.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	10.00		8.48	<
PO4--	2.1-4 (MG/DL)	01/06/91	4.20	>	3.71	
SGOT	11-33 (U/L)	01/06/91	18.00		16.00	
SGPT	11-39 (U/L)	01/06/91	16.00		12.00	
GAMMA GT	5-55 (U/L)	01/06/91	14.00		11.00	
LDH	200-450 (U/L)	01/06/91	281.00		282.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	48.00		53.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.81		0.82	
BUN	()	01/06/91				
UREA	0.18-0.43 (G/L)	01/06/91	0.20		0.19	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.64	<	0.73	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	4.20		3.80	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.49		0.39	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.10			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.30		6.50	<
ALBUMINE	52-68 (%)	01/06/91	58.10		60.90	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	243.00		186.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	111.00		125.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	3.30		3.00	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	11.30	>	8.70	
GLOBULINS BETA	9.5-14 (%)	01/06/91	11.20		11.50	
GLOBULINS GAMMA	12-21 (%)	01/06/91	16.10		15.90	
TSH	1-5 (UU/ML)	01/06/91	0.69			
T4	4.5-13 (UG/DL)	01/06/91	11.90			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085
Centre: 9 Patient: 276/A Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/02/92		24/03/92		14/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/06/91	14.60		14.60		14.10	
HT	37-54 (%)	01/06/91	42.70		43.10		40.70	
RBC	4-6.2 (10¬6/MM3)	01/06/91	4.80		4.76		4.64	
WBC	4-10 (10¬3/MM3)	01/06/91	9.95		7.89		6.22	
WBC: N	40-70 (%)	01/06/91	57.00				53.70	
WBC: L	19-48 (%)	01/06/91	34.00				32.70	
WBC: E	0-7 (%)	01/06/91	5.00				4.12	
WBC: M	3.4-9 (%)	01/06/91	3.00	<			5.76	
WBC: B	0-1.5 (%)	01/06/91	1.00				3.70	>>
PLATELETS	150-350 (10¬3/MM3)	01/06/91	205.00		151.00		226.00	
NA+	135-145 (MMOL/L)	01/06/91	144.00				138.00	
K+	3.5-5 (MMOL/L)	01/06/91	6.26	>>				
CL-	98-108 (MMOL/L)	01/06/91	99.00				102.00	
Ca++	8.5-10.5 (MG/DL)	01/06/91	9.56		9.59		9.13	
PO4--	2.1-4 (MG/DL)	01/06/91	3.93		8.42	>>	3.12	
SGOT	11-33 (U/L)	01/06/91	18.00		17.00		20.00	
SGPT	11-39 (U/L)	01/06/91	20.00		19.00		19.00	
GAMMA GT	15-85 (U/L)	01/06/91	16.00		17.00		14.00	<
LDH	200-450 (U/L)	01/06/91	407.00		442.00		383.00	
ALK. PHOSPH.	34-154 (U/L)	01/06/91	80.00		102.00		93.00	
GLUCOSE	0.6-1 (G/L)	01/06/91	0.95				0.64	
BUN	()	01/06/91						
UREA	0.18-0.43 (G/L)	01/06/91	0.31		0.25		0.21	
CREATININE	0.7-1.3 (MG/DL)	01/06/91	0.88		1.12		1.00	
URIC ACID	3.4-7.3 (MG/DL)	01/06/91	6.50		5.40		6.20	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/06/91	0.39		0.18		0.21	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/06/91	0.08		0.03		0.04	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/06/91	7.10		7.10		7.00	
ALBUMINE	52-68 (%)	01/06/91	68.40	>	55.90		65.70	
TOT. CHOLEST.	155-280 (MG/DL)	01/06/91	181.00		203.00		175.00	
TRIGLYCERIDES	62-162 (MG/DL)	01/06/91	242.00	>>	370.00	>>	237.00	>>
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/06/91	2.30	<	2.70		3.30	
GLOBULINS ALPHA 2	6.2-11 (%)	01/06/91	6.70		10.40		5.60	<
GLOBULINS BETA	9.5-14 (%)	01/06/91	10.90		14.90	>	11.90	
GLOBULINS GAMMA	12-21 (%)	01/06/91	11.80	<	16.10		13.50	
TSH	1-5 (UU/ML)	01/06/91	0.57					
T4	4.5-13 (UG/DL)	01/06/91	6.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 9/A Patient: 233 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/05/92		03/06/92		24/06/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/01/92	16.70		17.70		17.70	
HT	42-53 (%)	01/01/92	49.70		49.10		53.10	>
RBC	4.5-6.2 (10~6/MM3)	01/01/92	5.21		5.22		5.43	
WBC	4000-10000 (/MM3)	01/01/92	10100.0	>	8400.00		8200.00	
WBC: N	40-70 (%)	01/01/92	70.30	>	66.40		79.90	>
WBC: L	20-50 (%)	01/01/92	25.20		23.50		15.10	<
WBC: E	0-8 (%)	01/01/92	1.50		3.60		1.30	
WBC: M	0-13 (%)	01/01/92	2.70		5.40		3.60	
WBC: B	0-3 (%)	01/01/92	0.30		1.10		0.00	
PLATELETS	150-400 (10~3/MM3)	01/01/92	403.00	>	386.00		350.00	
NA+	136-147 (MMOL/L)	01/01/92	135.00	<	135.00	<	136.00	
K+	3.6-5.5 (MMOL/L)	01/01/92						
CL-	95-110 (MMOL/L)	01/01/92	100.00		100.00		102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.32		8.94		9.45	
PO4--	2-4.5 (MG/DL)	01/01/92	3.10		3.40		3.20	
SGOT	5-40 (U/L)	01/01/92	22.00		27.00		28.00	
SGPT	5-40 (U/L)	01/01/92	26.00		34.00		48.00	>
GAMMA GT	0-40 (U/L)	01/01/92	36.00		42.00	>	39.00	
LDH	150-460 (U/L)	01/01/92	254.00		293.00		268.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	279.00		309.00		261.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	97.00		95.00		107.00	
BUN	()	01/01/92						
UREA	8-50 (MG/DL)	01/01/92	33.00		34.00		34.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	0.95		0.89		0.89	
URIC ACID	2-7.5 (MG/DL)	01/01/92						
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.30		0.23		0.22	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.11		0.01		0.09	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.90		7.33		6.93	
ALBUMINE	55-72 (%)	01/01/92	59.50		62.60		65.70	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	209.00		208.00		225.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	124.00		228.00	>>	259.00	>>
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.20		2.50		2.60	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	9.00		7.90		7.40	
GLOBULINS BETA	9-14 (%)	01/01/92	11.60		9.50		10.60	
GLOBULINS GAMMA	10-20 (%)	01/01/92	16.70		17.50		13.70	
TSH	0.1-4 (UU/ML)	01/01/92	0.42					
T4	4.6-12.8 (UG/DL)	01/01/92	7.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 236 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			12/05/92		16/06/92		07/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/01/92	15.50		15.30		15.20	
HT	42-53 (%)	01/01/92	42.80		45.50		44.10	
RBC	4.5-6.2 (10-6/MM3)	01/01/92	4.82		5.13		5.04	
WBC	4000-10000 (/MM3)	01/01/92	8200.00		7700.00		6500.00	
WBC: N	40-70 (%)	01/01/92	58.80		63.30		61.30	
WBC: L	20-50 (%)	01/01/92	31.00		30.80		31.60	
WBC: E	0-8 (%)	01/01/92	2.50		2.00		1.90	
WBC: M	0-13 (%)	01/01/92	7.50		3.60		5.10	
WBC: B	0-3 (%)	01/01/92	0.30		0.30		0.20	
PLATELETS	150-400 (10-3/MM3)	01/01/92	288.00		324.00		295.00	
NA+	136-147 (MMOL/L)	01/01/92	138.00		140.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	3.80		3.80		4.40	
CL-	95-110 (MMOL/L)	01/01/92	100.00		98.00		103.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	8.90				9.10	
PO4--	2-4.5 (MG/DL)	01/01/92	3.40				2.80	
SGOT	5-40 (U/L)	01/01/92	51.00	>	28.00		29.00	
SGPT	5-40 (U/L)	01/01/92	61.00	>	48.00	>	44.00	>
GAMMA GT	0-40 (U/L)	01/01/92	30.00		30.00		31.00	
LDH	150-460 (U/L)	01/01/92	419.00		333.00		360.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	174.00		191.00		199.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	79.00		73.00		76.00	
BUN	()	01/01/92						
UREA	8-50 (MG/DL)	01/01/92	31.00		32.00		18.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	0.98		1.04		1.02	
URIC ACID	2-7.5 (MG/DL)	01/01/92	4.99		4.13		3.83	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.68		0.55		0.33	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.14		0.16		0.04	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.02		7.10		6.85	
ALBUMINE	55-72 (%)	01/01/92	65.10		63.50		62.70	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	222.00		203.00		203.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	113.00		119.00		116.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.00		2.30		2.50	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	6.40		6.60		7.10	
GLOBULINS BETA	9-14 (%)	01/01/92	12.70		12.20		12.70	
GLOBULINS GAMMA	10-20 (%)	01/01/92	12.80		15.40		15.00	
TSH	0.1-4 (UU/ML)	01/01/92	1.51					
T4	4.8-12.8 (UG/DL)	01/01/92	1.16					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 278 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			12/06/92		03/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/01/92	13.90		13.10	
HT	37-47 (%)	01/01/92	40.80		40.80	
RBC	4-5.8 (10-6/MM3)	01/01/92	4.77		4.78	
WBC	4000-10000 (/MM3)	01/01/92	8300.00		7400.00	
WBC: N	40-70 (%)	01/01/92	71.60	>	75.90	>
WBC: L	20-50 (%)	01/01/92	22.40		20.30	
WBC: E	0-8 (%)	01/01/92	1.50		1.10	
WBC: M	0-13 (%)	01/01/92	3.90		2.20	
WBC: B	0-3 (%)	01/01/92	0.60		0.60	
PLATELETS	150-400 (10-3/MM3)	01/01/92	410.00	>	339.00	
NA+	136-147 (MMOL/L)	01/01/92	139.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.50		4.90	
CL-	95-110 (MMOL/L)	01/01/92	99.00		102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.30		9.57	
PO4--	2.4-4.8 (MG/DL)	01/01/92	3.40		3.00	
SGOT	5-40 (U/L)	01/01/92	30.00		23.00	
SGPT	5-40 (U/L)	01/01/92	15.00		12.00	
GAMMA GT	0-40 (U/L)	01/01/92	10.00		10.00	
LDH	150-460 (U/L)	01/01/92	337.00		279.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	147.00		131.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	80.00		87.00	
BUN	()	01/01/92				
UREA	8-48 (MG/DL)	01/01/92	30.00		35.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	1.09		0.89	
URIC ACID	2-6.5 (MG/DL)	01/01/92			3.62	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.40		0.44	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.14		0.14	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.60		7.76	
ALBUMINE	55-72 (%)	01/01/92	64.60		66.70	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	220.00		182.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	68.00		48.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.40		3.00	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.20		5.90	<
GLOBULINS BETA	9-14 (%)	01/01/92	11.20		9.90	
GLOBULINS GAMMA	10-20 (%)	01/01/92	13.60		14.50	
TSH	0.1-4 (UU/ML)	01/01/92	0.76			
T4	4.8-12.8 (UG/DL)	01/01/92	12.60			

(¢) << clinically relevant (value lower than min range) 1298 >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 279 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			05/08/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/01/92	17.10	
HT	42-53 (%)	01/01/92	48.80	
RBC	4.5-6.2 (10¬6/MM3)	01/01/92	5.06	
WBC	4000-10000 (/MM3)	01/01/92	8300.00	
WBC: N	40-70 (%)	01/01/92	58.10	
WBC: L	20-50 (%)	01/01/92	34.50	
WBC: E	0-8 (%)	01/01/92	1.50	
WBC: M	0-13 (%)	01/01/92	5.60	
WBC: B	0-3 (%)	01/01/92	0.30	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	280.00	
NA+	136-147 (MMOL/L)	01/01/92	142.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	3.90	
CL-	95-110 (MMOL/L)	01/01/92	101.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.21	
PO4--	2-4.5 (MG/DL)	01/01/92	3.60	
SGOT	5-40 (U/L)	01/01/92	19.00	
SGPT	5-40 (U/L)	01/01/92	18.00	
GAMMA GT	0-40 (U/L)	01/01/92	18.00	
LDH	150-460 (U/L)	01/01/92	273.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	146.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	75.00	
BUN	()	01/01/92		
UREA	8-50 (MG/DL)	01/01/92	29.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	1.21	
URIC ACID	2-7.5 (MG/DL)	01/01/92	4.37	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.50	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.11	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.42	
ALBUMINE	55-72 (%)	01/01/92	65.80	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	205.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	94.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.70	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.00	
GLOBULINS BETA	9-14 (%)	01/01/92	10.40	
GLOBULINS GAMMA	10-20 (%)	01/01/92	14.10	
TSH	0.1-4 (UU/ML)	01/01/92	1.20	
T4	4.8-12.8 (UG/DL)	01/01/92	7.50	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 283 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/09/92		07/10/92		28/10/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/92	13.80		14.40		15.20	
HT	37-47 (%)	01/01/92	41.60		44.00		44.10	
RBC	4-5.8 (10-6/MM3)	01/01/92	4.45		4.77		4.83	
WBC	4000-10000 (/MM3)	01/01/92	5400.00		6500.00		6300.00	
WBC: N	40-70 (%)	01/01/92	51.80		66.80		53.00	
WBC: L	20-50 (%)	01/01/92	41.70		29.30		40.80	
WBC: E	0-8 (%)	01/01/92	1.50		1.00		0.40	
WBC: M	0-13 (%)	01/01/92	4.50		2.70		5.70	
WBC: B	0-3 (%)	01/01/92	0.60		0.30		0.10	
PLATELETS	150-400 (10-3/MM3)	01/01/92	236.00		210.00		201.00	
NA+	136-147 (MMOL/L)	01/01/92	143.00		141.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.50		4.20		4.60	
CL-	95-110 (MMOL/L)	01/01/92	105.00		107.00		101.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.23		9.20		9.00	
PO4--	2.4-4.8 (MG/DL)	01/01/92	2.70		2.60			
SGOT	5-40 (U/L)	01/01/92	24.00		22.00		21.00	
SGPT	5-40 (U/L)	01/01/92	30.00		23.00		22.00	
GAMMA GT	0-40 (U/L)	01/01/92	20.00		20.00		19.00	
LDH	150-460 (U/L)	01/01/92	234.00		296.00		205.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	208.00		232.00		230.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	83.00		78.00		71.00	
BUN	()	01/01/92						
UREA	8-48 (MG/DL)	01/01/92	24.00		28.00		31.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	1.03		1.01		1.04	
URIC ACID	2-6.5 (MG/DL)	01/01/92	5.48		4.95		4.77	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.31		0.47		0.53	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.10		0.12		0.13	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	6.99		7.42		7.52	
ALBUMINE	55-72 (%)	01/01/92	68.10		59.00		62.50	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	210.00		219.00		216.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	67.00		100.00		88.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.10		2.80		2.80	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	6.40		7.20		8.60	
GLOBULINS BETA	9-14 (%)	01/01/92	11.20		14.20	>	11.90	
GLOBULINS GAMMA	10-20 (%)	01/01/92	11.20		16.80		14.20	
TSH	0.1-4 (UU/ML)	01/01/92	3.64					
T4	4.8-12.8 (UG/DL)	01/01/92	6.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

1300

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0
9550085
LABORATORY DATA
Centre: 9/A Patient: 284 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			16/09/92		09/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/01/92	16.90		16.80	
HT	42-53 (%)	01/01/92	52.00		50.60	
RBC	4.5-6.2 (10¬6/MM3)	01/01/92	5.26		5.11	
WBC	4000-10000 (/MM3)	01/01/92	9600.00		11300.0	>
WBC: N	40-70 (%)	01/01/92	71.20	>	77.10	>
WBC: L	20-50 (%)	01/01/92	22.80		19.60	<
WBC: E	0-8 (%)	01/01/92	1.70		0.80	
WBC: M	0-13 (%)	01/01/92	4.10		2.40	
WBC: B	0-3 (%)	01/01/92	0.30		0.10	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	215.00		300.00	
NA+	136-147 (MMOL/L)	01/01/92	140.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.00		4.30	
CL-	95-110 (MMOL/L)	01/01/92	100.00		101.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.88		9.39	
PO4--	2-4.5 (MG/DL)	01/01/92	4.00		3.60	
SGOT	5-40 (U/L)	01/01/92	37.00		21.00	
SGPT	5-40 (U/L)	01/01/92	34.00		23.00	
GAMMA GT	0-40 (U/L)	01/01/92	20.00		13.00	
LDH	150-460 (U/L)	01/01/92	307.00		385.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	191.00		177.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	75.00		74.00	
BUN	()	01/01/92				
UREA	8-50 (MG/DL)	01/01/92	23.00		25.00	
CREATININE	0.3-1.38 (MG/DL)	01/01/92	0.95		0.95	
URIC ACID	2-7.5 (MG/DL)	01/01/92	4.47		4.43	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.65		0.59	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.25			
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.17		7.43	
ALBUMINE	55-72 (%)	01/01/92	68.00		67.80	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	209.00		154.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	177.00	>	129.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.50		3.70	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	6.60		8.50	
GLOBULINS BETA	9-14 (%)	01/01/92	9.80		10.00	
GLOBULINS GAMMA	10-20 (%)	01/01/92	12.10		10.00	
TSH	0.1-4 (UU/ML)	01/01/92	3.45			
T4	4.8-12.8 (UG/DL)	01/01/92	5.70			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 301 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/02/92		25/03/92		15/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/01/92	13.50		14.40		14.20	
HT	37-47 (%)	01/01/92	40.90		43.20		42.20	
RBC	4-5.8 (10¬6/MM3)	01/01/92	4.32		4.58		4.44	
WBC	4000-10000 (/MM3)	01/01/92	6100.00		6400.00		4900.00	
WBC: N	40-70 (%)	01/01/92	38.80	<	63.80		59.10	
WBC: L	20-50 (%)	01/01/92	54.90	>	30.90		33.70	
WBC: E	0-8 (%)	01/01/92	0.40		1.20		0.60	
WBC: M	0-13 (%)	01/01/92	5.30		3.30		5.90	
WBC: B	0-3 (%)	01/01/92	0.50		0.80		0.60	
PLATELETS	150-400 (10¬3/MM3)	01/01/92			233.00		239.00	
NA+	136-147 (MMOL/L)	01/01/92	146.00		140.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.40		3.80		4.10	
CL-	95-110 (MMOL/L)	01/01/92	108.00		100.00		101.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	7.98	<	9.20		8.97	
PO4--	2.4-4.8 (MG/DL)	01/01/92			3.30		3.70	
SGOT	5-40 (U/L)	01/01/92	21.00		19.00		19.00	
SGPT	5-40 (U/L)	01/01/92	15.00		12.00		15.00	
GAMMA GT	0-40 (U/L)	01/01/92	12.00		11.00		13.00	
LDH	150-460 (U/L)	01/01/92			276.00		282.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	83.00		91.00		101.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	81.00		127.00	>	83.00	
BUN	()	01/01/92						
UREA	8-48 (MG/DL)	01/01/92	31.00		34.00		38.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.89		0.95		0.90	
URIC ACID	2-6.5 (MG/DL)	01/01/92	4.84		4.02		4.36	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.38		0.91		0.79	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.07		0.19		0.20	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	6.66		7.53		7.51	
ALBUMINE	55-72 (%)	01/01/92			61.00		64.50	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	164.00		202.00		210.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	230.00	>>	196.00	>	142.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92			4.50		4.20	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92			10.60		7.40	
GLOBULINS BETA	9-14 (%)	01/01/92			10.90		9.10	
GLOBULINS GAMMA	10-20 (%)	01/01/92			20.00		14.80	
TSH	0.1-4 (UU/ML)	01/01/92	2.09					
T4	4.8-12.8 (UG/DL)	01/01/92	6.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang·
< out of range (value lower than min range) > out of range (value higher than max rang·
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 302 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			02/03/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/01/92	17.00	
HT	42-53 (%)	01/01/92	50.60	
RBC	4.5-6.2 (10-6/MM3)	01/01/92	5.73	
WBC	4000-10000 (/MM3)	01/01/92	6100.00	
WBC: N	40-70 (%)	01/01/92	50.40	
WBC: L	20-50 (%)	01/01/92	37.30	
WBC: E	0-8 (%)	01/01/92	6.00	
WBC: M	0-13 (%)	01/01/92	5.50	
WBC: B	0-3 (%)	01/01/92	0.80	
PLATELETS	150-400 (10-3/MM3)	01/01/92	315.00	
NA+	136-147 (MMOL/L)	01/01/92	140.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.80	
CL-	95-110 (MMOL/L)	01/01/92	99.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	10.34	
PO4--	2-4.5 (MG/DL)	01/01/92	3.60	
SGOT	5-40 (U/L)	01/01/92	23.00	
SGPT	5-40 (U/L)	01/01/92	26.00	
GAMMA GT	0-40 (U/L)	01/01/92	14.00	
LDH	150-460 (U/L)	01/01/92	279.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	147.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	69.00	
BUN	()	01/01/92		
UREA	8-50 (MG/DL)	01/01/92		
CREATININE	0.3-1.38 (MG/DL)	01/01/92	1.11	
URIC ACID	2-7.5 (MG/DL)	01/01/92	4.33	
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.64	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.12	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	8.71	>
ALBUMINE	55-72 (%)	01/01/92	57.90	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	149.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	59.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	2.60	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.50	
GLOBULINS BETA	9-14 (%)	01/01/92	9.60	
GLOBULINS GAMMA	10-20 (%)	01/01/92	22.40	>
TSH	0.1-4 (UU/ML)	01/01/92	1.49	
T4	4.8-12.8 (UG/DL)	01/01/92	8.80	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA 9550085

Centre: 9/A Patient: 307 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			05/05/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/01/92	15.70	
HT	37-47 (%)	01/01/92	45.20	
RBC	4-5.8 (10¬6/MM3)	01/01/92	4.64	
WBC	4000-10000 (/MM3)	01/01/92	6200.00	
WBC: N	40-70 (%)	01/01/92	49.80	
WBC: L	20-50 (%)	01/01/92	39.20	
WBC: E	0-8 (%)	01/01/92	5.30	
WBC: M	0-13 (%)	01/01/92	5.20	
WBC: B	0-3 (%)	01/01/92	0.50	
PLATELETS	150-400 (10¬3/MM3)	01/01/92	253.00	
NA+	136-147 (MMOL/L)	01/01/92	141.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	4.80	
CL-	95-110 (MMOL/L)	01/01/92	102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.21	
PO4--	2.4-4.8 (MG/DL)	01/01/92	3.80	
SGOT	5-40 (U/L)	01/01/92	21.00	
SGPT	5-40 (U/L)	01/01/92	17.00	
GAMMA GT	0-40 (U/L)	01/01/92	11.00	
LDH	150-460 (U/L)	01/01/92	284.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	174.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	77.00	
BUN	()	01/01/92		
UREA	8-48 (MG/DL)	01/01/92	27.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.95	
URIC ACID	2-6.5 (MG/DL)	01/01/92		
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.26	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.08	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.28	
ALBUMINE	55-72 (%)	01/01/92	66.20	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	236.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	74.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	4.00	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	6.00	
GLOBULINS BETA	9-14 (%)	01/01/92	10.60	
GLOBULINS GAMMA	10-20 (%)	01/01/92	13.20	
TSH	0.1-4 (UU/ML)	01/01/92	0.48	
T4	4.8-12.8 (UG/DL)	01/01/92	9.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 9/A Patient: 308 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			09/05/92		29/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/01/92	14.50		14.20	
HT	37-47 (%)	01/01/92	41.60		41.30	
RBC	4-5.8 (10-6/MM3)	01/01/92	4.46		4.53	
WBC	4000-10000 (/MM3)	01/01/92	4000.00		4200.00	
WBC: N	40-70 (%)	01/01/92	50.40		59.10	
WBC: L	20-50 (%)	01/01/92	39.40		34.90	
WBC: E	0-8 (%)	01/01/92	6.40		1.90	
WBC: M	0-13 (%)	01/01/92	3.50		3.70	
WBC: B	0-3 (%)	01/01/92	0.30		0.30	
PLATELETS	150-400 (10-3/MM3)	01/01/92	264.00		262.00	
NA+	136-147 (MMOL/L)	01/01/92	142.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/01/92	5.10		4.40	
CL-	95-110 (MMOL/L)	01/01/92	97.00		102.00	
Ca++	8.3-10.5 (MG/DL)	01/01/92	9.77		9.36	
PO4--	2.4-4.8 (MG/DL)	01/01/92	3.60		3.60	
SGOT	5-40 (U/L)	01/01/92	21.00		18.00	
SGPT	5-40 (U/L)	01/01/92	15.00		10.00	
GAMMA GT	0-40 (U/L)	01/01/92	12.00		11.00	
LDH	150-460 (U/L)	01/01/92	419.00		342.00	
ALK. PHOSPH.	40-350 (U/L)	01/01/92	188.00		171.00	
GLUCOSE	50-120 (MG/DL)	01/01/92	75.00		67.00	
BUN	()	01/01/92				
UREA	8-48 (MG/DL)	01/01/92	27.00		23.00	
CREATININE	0.3-1.25 (MG/DL)	01/01/92	0.97		0.94	
URIC ACID	2-6.5 (MG/DL)	01/01/92	3.98			
TOT BILIRUBIN	0.1-1 (MG/DL)	01/01/92	0.57		0.46	
DIR BILIRUBIN	0-0.9 (MG/DL)	01/01/92	0.01		0.01	
TOT. PROTEINS	6.1-8 (G/DL)	01/01/92	7.89		6.72	
ALBUMINE	55-72 (%)	01/01/92	63.10		65.50	
TOT. CHOLEST.	120-250 (MG/DL)	01/01/92	281.00	>	232.00	
TRIGLYCERIDES	40-170 (MG/DL)	01/01/92	99.00		71.00	
GLOBULINS ALPHA 1	2-6 (%)	01/01/92	3.90		3.70	
GLOBULINS ALPHA 2	6-11 (%)	01/01/92	7.80		6.90	
GLOBULINS BETA	9-14 (%)	01/01/92	11.40		11.00	
GLOBULINS GAMMA	10-20 (%)	01/01/92	13.80		12.90	
TSH	0.1-4 (UU/ML)	01/01/92	1.39			
T4	4.8-12.8 (UG/DL)	01/01/92	9.70			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 10 Patient: 289 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			23/09/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	22/09/91	12.80	
HT	36-54 (%)	22/09/91	48.10	
RBC	4-5 (10-6/MM3)	22/09/91	4.35	
WBC	4000-10000 (/MM3)	22/09/91	4500.00	
WBC: N	40-70 (%)	22/09/91		
WBC: L	20-40 (%)	22/09/91	35.00	
WBC: E	1-4 (%)	22/09/91	2.00	
WBC: M	4-8 (%)	22/09/91	2.00	<
WBC: B	0-1 (%)	22/09/91	0.00	
PLATELETS	150000-400000 (/MM3)	22/09/91	159000	
NA+	135-155 (MEQ/L)	22/09/91	140.30	
K+	3.1-5.5 (MEQ/L)	22/09/91	3.77	
CL-	98-107 (MEQ/L)	22/09/91	103.00	
Ca++	88-102 (MG/L)	22/09/91	98.00	
PO4--	2.5-4.8 (MG/DL)	22/09/91	4.77	
SGOT	5-15 (U/L)	22/09/91	8.00	
SGPT	5-17 (U/L)	22/09/91	7.00	
GAMMA GT	0-18 (U/L)	22/09/91	7.00	
LDH	150-240 (U/L)	22/09/91	119.00	<
ALK. PHOSPH.	40-90 (U/L)	22/09/91	101.00	>
GLUCOSE	76-120 (MG/DL)	22/09/91	108.00	
BUN	10-50 (MG/DL)	22/09/91	18.00	
UREA	()	22/09/91		
CREATININE	0.55-1.1 (MG/DL)	22/09/91	0.83	
URIC ACID	2.5-5.7 (MG/DL)	22/09/91	2.92	
TOT BILIRUBIN	0-1 (MG/DL)	22/09/91	0.54	
DIR BILIRUBIN	0-0.25 (MG/DL)	22/09/91	0.12	
TOT. PROTEINS	6.6-8.7 (G/DL)	22/09/91	7.30	
ALBUMINE	56-72 (%)	22/09/91	62.90	
TOT. CHOLEST.	120-260 (MG/DL)	22/09/91	148.00	
TRIGLYCERIDES	65-172 (MG/DL)	22/09/91		
GLOBULINS ALPHA 1	1.8-5 (%)	22/09/91	3.00	
GLOBULINS ALPHA 2	7-12 (%)	22/09/91	6.80	<
GLOBULINS BETA	6-15 (%)	22/09/91	13.10	
GLOBULINS GAMMA	7.8-18.2 (%)	22/09/91	14.20	
TSH	0.15-5.5 (MU/L)	22/09/91	1.20	
T4	5-12 (UG/DL)	22/09/91	8.60	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 10 Patient: 291 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			13/02/92		09/03/92		30/03/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	12/02/92	15.10		15.40		14.80	
HT	36-54 (%)	12/02/92	45.50		49.10		47.20	
RBC	4-5 (10-6/MM3)	12/02/92	5.01	>	5.40	>	4.95	
WBC	4000-10000 (/MM3)	12/02/92	7300.00		6300.00		10100.0	>
WBC: N	40-70 (%)	12/02/92	40.00		66.00		74.00	>
WBC: L	20-40 (%)	12/02/92	48.00	>	24.00		20.00	
WBC: E	1-4 (%)	12/02/92	4.00		4.00		4.00	
WBC: M	4-8 (%)	12/02/92	4.00		6.00		2.00	<
WBC: B	0-1 (%)	12/02/92	4.00	>>	0.00		0.00	
PLATELETS	150000-400000 (/MM3)	12/02/92	318000		235000		259000	
NA+	135-155 (MEQ/L)	12/02/92	134.70	<	139.10		139.80	
K+	3.1-5.5 (MEQ/L)	12/02/92	4.23		4.69		4.25	
CL-	98-107 (MEQ/L)	12/02/92	98.00		102.00		100.00	
Ca++	88-102 (MG/L)	12/02/92	99.00		79.00	<	108.00	>
PO4--	2.5-4.8 (MG/DL)	12/02/92	4.20		3.96		3.22	
SGOT	5-18 (U/L)	12/02/92	10.00		11.00		11.00	
SGPT	5-22 (U/L)	12/02/92	15.00		20.00		22.00	
GAMMA GT	0-25 (U/L)	12/02/92	28.00	>	17.00		27.00	>
LDH	150-240 (U/L)	12/02/92	120.00	<	201.00		176.00	
ALK. PHOSPH.	40-90 (U/L)	12/02/92	63.00		63.00		70.00	
GLUCOSE	76-120 (MG/DL)	12/02/92	102.00		80.00		114.00	
BUN	10-50 (MG/DL)	12/02/92	31.20		9.60	<	34.90	
UREA	()	12/02/92						
CREATININE	0.7-1.35 (MG/DL)	12/02/92	0.79		0.76		0.90	
URIC ACID	2.5-7 (MG/DL)	12/02/92	5.10		4.74		6.90	
TOT BILIRUBIN	0-1 (MG/DL)	12/02/92	0.33		0.26		0.47	
DIR BILIRUBIN	0-0.25 (MG/DL)	12/02/92	0.09		0.02		0.05	
TOT. PROTEINS	6.6-8.7 (G/DL)	12/02/92	7.70		7.50		7.60	
ALBUMINE	3.97-5.34 (G/DL)	12/02/92	4.80		5.00			
TOT. CHOLEST.	120-260 (MG/DL)	12/02/92	190.00		169.00		258.00	
TRIGLYCERIDES	65-172 (MG/DL)	12/02/92	139.00		139.00		170.00	
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	12/02/92	0.20		0.20			
GLOBULINS ALPHA 2	0.42-0.87 (G/DL)	12/02/92	0.90	>	0.70			
GLOBULINS BETA	0.53-1.12 (G/DL)	12/02/92	1.00		1.10			
GLOBULINS GAMMA	0.53-1.97 (G/DL)	12/02/92	0.80		0.70			
TSH	0.15-5.5 (MU/L)	12/02/92						
T4	5-12 (MG/DL)	12/02/92						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS-RSD 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 10 Patient: 294 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			07/01/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	06/01/92	14.30	
HT	36-54 (%)	06/01/92	40.90	
RBC	4-5 (10-6/MM3)	06/01/92	4.57	
WBC	4000-10000 (/MM3)	06/01/92	8800.00	
WBC: N	40-70 (%)	06/01/92	68.00	
WBC: L	20-40 (%)	06/01/92	20.00	
WBC: E	1-4 (%)	06/01/92	8.00	>>
WBC: M	4-8 (%)	06/01/92	4.00	
WBC: B	0-1 (%)	06/01/92	0.00	
PLATELETS	150000-400000 (/MM3)	06/01/92	380000	
NA+	135-155 (MEQ/L)	06/01/92	141.80	
K+	3.1-5.5 (MEQ/L)	06/01/92	4.94	
CL-	98-107 (MEQ/L)	06/01/92	101.00	
Ca++	88-102 (MG/L)	06/01/92	104.00	>
PO4--	2.5-4.8 (MG/DL)	06/01/92	4.70	
SGOT	5-15 (U/L)	06/01/92	17.00	>
SGPT	5-17 (U/L)	06/01/92	9.00	
GAMMA GT	0-18 (U/L)	06/01/92	9.00	
LDH	150-240 (U/L)	06/01/92	172.00	
ALK. PHOSPH.	40-90 (U/L)	06/01/92	79.00	
GLUCOSE	76-120 (MG/DL)	06/01/92	113.00	
BUN	10-50 (MG/DL)	06/01/92	40.50	
UREA	()	06/01/92		
CREATININE	0.55-1.1 (MG/DL)	06/01/92	0.91	
URIC ACID	2.5-5.7 (MG/DL)	06/01/92	5.52	
TOT BILIRUBIN	0-1 (MG/DL)	06/01/92	0.66	
DIR BILIRUBIN	0-0.25 (MG/DL)	06/01/92	0.06	
TOT. PROTEINS	6.6-8.7 (G/DL)	06/01/92	8.01	
ALBUMINE	56-72 (%)	06/01/92	52.40	<
TOT. CHOLEST.	120-260 (MG/DL)	06/01/92	191.20	
TRIGLYCERIDES	65-172 (MG/DL)	06/01/92	200.00	>
GLOBULINS ALPHA 1	1.8-5 (%)	06/01/92	3.70	
GLOBULINS ALPHA 2	7-12 (%)	06/01/92	11.10	
GLOBULINS BETA	6-15 (%)	06/01/92	19.00	>
GLOBULINS GAMMA	7.8-18.2 (%)	06/01/92	17.90	
TSH	0.2-6 (MUI/L)	06/01/92	2.30	
T4	45-135 (NG/ML)	06/01/92	92.00	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 10 Patient: 295 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/01/92		27/01/92		24/02/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	31/12/91	14.70		14.70		12.60	<
HT	36-54 (%)	31/12/91	43.40		43.40		43.60	
RBC	4-5 (10¬6/MM3)	31/12/91	4.66		4.66		4.26	
WBC	4000-10000 (/MM3)	31/12/91	11500.0	>	11000.0	>	4300.00	
WBC: N	40-70 (%)	31/12/91	66.00		66.00		56.00	
WBC: L	20-40 (%)	31/12/91	30.00		30.00		24.00	
WBC: E	1-4 (%)	31/12/91	2.00		2.00		12.00	>>
WBC: M	4-8 (%)	31/12/91	2.00	<	2.00	<	8.00	
WBC: B	0-1 (%)	31/12/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	31/12/91	305000		305000		263000	
NA+	135-155 (MEQ/L)	31/12/91	141.90		141.90		140.40	
K+	3.1-5.5 (MEQ/L)	31/12/91	4.58		4.58		4.68	
CL-	98-107 (MEQ/L)	31/12/91	101.00		101.00		97.00	<
Ca++	88-102 (MG/L)	31/12/91	98.00		98.00		102.00	
PO4--	2.5-4.8 (MG/DL)	31/12/91	3.52		3.52		3.06	
SGOT	5-18 (U/L)	31/12/91	10.00		10.00		12.00	
SGPT	5-22 (U/L)	31/12/91	15.00		15.00		22.00	
GAMMA GT	0-25 (U/L)	31/12/91	21.00		21.00		10.00	
LDH	150-240 (U/L)	31/12/91	159.00		159.00		160.00	
ALK. PHOSPH.	40-90 (U/L)	31/12/91	38.00	<	38.00	<	52.00	
GLUCOSE	76-120 (MG/DL)	31/12/91	94.00		94.00		92.00	
BUN	10-50 (MG/DL)	31/12/91	25.60		25.60		20.60	
UREA	()	31/12/91						
CREATININE	0.7-1.35 (MG/DL)	31/12/91	1.06		1.06		1.07	
URIC ACID	2.5-7 (MG/DL)	31/12/91	6.63		6.63		6.16	
TOT BILIRUBIN	0-1 (MG/DL)	31/12/91	0.52		0.52		0.02	
DIR BILIRUBIN	0-0.25 (MG/DL)	31/12/91	0.07		0.07		0.34	>
TOT. PROTEINS	6.6-8.7 (G/DL)	31/12/91	7.20		7.20		7.98	
ALBUMINE	3.97-5.34 (G/DL)	31/12/91	4.40		4.40		4.20	
TOT. CHOLEST.	120-260 (MG/DL)	31/12/91	138.00		138.00		122.00	
TRIGLYCERIDES	65-172 (MG/DL)	31/12/91	247.00	>>	247.00	>>	232.00	>>
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	31/12/91	0.30		0.30		0.20	
GLOBULINS ALPHA 2	0.42-0.87 (G/DL)	31/12/91	0.60		0.60		0.50	
GLOBULINS BETA	0.53-1.12 (G/DL)	31/12/91	1.10		0.90		0.70	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	31/12/91	0.90		2.20	>	0.60	
TSH	0.2-6 (MUI/L)	31/12/91	2.20				2.30	
T4	45-135 (NG/ML)	31/12/91	71.00				57.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN5590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 10 Patient: 299 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/04/92		28/04/92		19/05/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	14-18 (G/DL)	31/12/91	15.00		15.70		14.80	
HT	36-54 (%)	31/12/91	47.20		53.40		46.20	
RBC	4-5 (10¬6/MM3)	31/12/91	4.89		5.17	>	4.52	
WBC	4000-10000 (/MM3)	31/12/91	6100.00		10500.0	>	4800.00	
WBC: N	40-70 (%)	31/12/91	61.00		72.00	>	42.00	
WBC: L	20-40 (%)	31/12/91	30.00		24.00		46.00	>
WBC: E	1-4 (%)	31/12/91	7.00	>>	0.00	<	2.00	
WBC: M	4-8 (%)	31/12/91	2.00	<	4.00		10.00	>
WBC: B	0-1 (%)	31/12/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	31/12/91	359000		368000		368000	
NA+	135-155 (MEQ/L)	31/12/91	140.50		139.70		135.60	
K+	3.1-5.5 (MEQ/L)	31/12/91	4.47		4.65		4.96	
CL-	98-107 (MEQ/L)	31/12/91	100.00		103.00		100.00	
Ca++	88-102 (MG/L)	31/12/91	101.00		101.00		96.00	
PO4--	2.5-4.8 (MG/DL)	31/12/91	4.02		4.08		3.34	
SGOT	5-18 (U/L)	31/12/91	13.00		14.00		14.00	
SGPT	5-22 (U/L)	31/12/91	5.00		21.00		24.00	>
GAMMA GT	0-25 (U/L)	31/12/91	51.00	>>	68.00	>>	14.00	
LDH	150-240 (U/L)	31/12/91	216.00		151.00		153.00	
ALK. PHOSPH.	40-90 (U/L)	31/12/91	88.00		85.00		87.00	
GLUCOSE	76-120 (MG/DL)	31/12/91	110.00		118.00		82.00	
BUN	10-50 (MG/DL)	31/12/91	20.40		33.70		18.20	
UREA	()	31/12/91						
CREATININE	0.7-1.35 (MG/DL)	31/12/91	0.82		0.96		0.84	
URIC ACID	2.5-7 (MG/DL)	31/12/91	5.72		5.17		6.63	
TOT BILIRUBIN	0-1 (MG/DL)	31/12/91	0.61		0.18		0.19	
DIR BILIRUBIN	0-0.25 (MG/DL)	31/12/91	0.03		0.01		0.06	
TOT. PROTEINS	6.6-8.7 (G/DL)	31/12/91	7.40		7.33		8.17	
ALBUMINE	3.97-5.34 (G/DL)	31/12/91	5.50	>	5.30			
	56-72 (%)	18/05/92					69.50	
TOT. CHOLEST.	120-260 (MG/DL)	31/12/91	161.00		214.00		241.00	
TRIGLYCERIDES	65-172 (MG/DL)	31/12/91	107.00		151.00		264.00	>>
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	31/12/91	0.20		0.10	<		
	1.8-5 (%)	18/05/92					2.60	
GLOBULINS ALPHA 2	0.42-0.87 (G/DL)	31/12/91	0.50		0.70			
	7-12 (%)	18/05/92					9.60	
GLOBULINS BETA	0.53-1.12 (G/DL)	31/12/91	0.70		0.60			
	6-15 (%)	18/05/92					9.10	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	31/12/91	0.50	<	0.70			
	7.8-18.2 (%)	18/05/92					9.10	
TSH	0.2-6 (MUI/L)	31/12/91	1.10					
	0.2-6 (IE)	18/05/92						
T4	45-135 (NG/ML)	31/12/91	195.00					
	45-135 (NG/NL)	18/05/92						

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 10 Patient: 300 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/04/92		05/05/92		26/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	06/04/92	13.20		12.90		13.90	
HT	36-54 (%)	06/04/92	45.00		43.90		47.50	
RBC	4-5 (10¬6/MM3)	06/04/92	4.80		4.51		4.66	
WBC	4000-10000 (/MM3)	06/04/92	4900.00		8100.00		5000.00	
WBC: N	40-70 (%)	06/04/92	64.00		68.00		48.00	
WBC: L	20-40 (%)	06/04/92	32.00		20.00		44.00	>
WBC: E	1-4 (%)	06/04/92	2.00		0.00	<	0.00	<
WBC: M	4-8 (%)	06/04/92	2.00	<	12.00	>>	8.00	
WBC: B	0-1 (%)	06/04/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	06/04/92	259000		265000		268000	
NA+	135-155 (MEQ/L)	06/04/92	142.10		141.00		140.70	
K+	3.1-5.5 (MEQ/L)	06/04/92	3.90		4.03		3.61	
CL-	98-107 (MEQ/L)	06/04/92	110.00	>	103.00		105.00	
Ca++	88-102 (MG/L)	06/04/92	100.00		102.00		100.00	
PO4--	2.5-4.8 (MG/DL)	06/04/92	4.08		3.96		3.97	
SGOT	5-15 (U/L)	06/04/92	7.00		7.00		9.00	
SGPT	5-17 (U/L)	06/04/92	9.00		10.00		12.00	
GAMMA GT	0-18 (U/L)	06/04/92	5.00		13.00		11.00	
LDH	150-240 (U/L)	06/04/92	201.00		203.00		200.00	
ALK. PHOSPH.	40-90 (U/L)	06/04/92	45.00		59.00		40.00	
GLUCOSE	76-120 (MG/DL)	06/04/92	91.00		121.00	>	94.00	
BUN	10-50 (MG/DL)	06/04/92	22.80		19.50		15.20	
UREA	()	06/04/92						
CREATININE	0.55-1.1 (MG/DL)	06/04/92	0.67		0.89		0.62	
URIC ACID	2.5-5.7 (MG/DL)	06/04/92	2.60		5.19		2.33	<
TOT BILIRUBIN	0-1 (MG/DL)	06/04/92	0.46		0.30		0.19	
DIR BILIRUBIN	0-0.25 (MG/DL)	06/04/92	0.01		0.01		0.03	
TOT. PROTEINS	6.6-8.7 (G/DL)	06/04/92	7.60		7.50		7.71	
ALBUMINE	56-72 (%)	06/04/92	64.80				50.00	<
	3.97-5.34 (G/DL)	04/05/92			5.10			
TOT. CHOLEST.	120-260 (MG/DL)	06/04/92	245.00		266.00	>	225.00	
TRIGLYCERIDES	65-172 (MG/DL)	06/04/92	224.00	>>			196.00	>
GLOBULINS ALPHA 1	1.8-5 (%)	06/04/92	3.70				5.00	
	0.11-0.32 (G/DL)	04/05/92			0.30			
GLOBULINS ALPHA 2	7-12 (%)	06/04/92	9.50				17.10	>>
	0.42-0.87 (G/DL)	04/05/92			0.70			
GLOBULINS BETA	6-15 (%)	06/04/92	14.10				16.70	>
	0.53-1.12 (G/DL)	04/05/92			0.90			
GLOBULINS GAMMA	7.8-18.2 (%)	06/04/92	7.90				11.20	
	0.53-1.97 (G/DL)	04/05/92			0.60			
TSH	0.2-6 (MUI/L)	06/04/92	1.30					
T4	45-135 (NG/ML)	06/04/92	105.00					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

1311

PHARMACIA CNS [illegible] 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 323 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/06/92		15/07/92		06/08/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12.5-16.5 (G/DL)	01/05/92	14.60		14.60		15.10	
HT	0.37-0.49 (L/L)	01/05/92	0.43		0.45		0.47	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	4.90		5.00		5.10	
WBC	4-11 (10¬3/MM3)	01/05/92	4.90		5.10		6.00	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	2.80		3.00		3.80	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	1.70		1.60		1.60	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.00		0.10		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.30		0.50		0.50	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	269.00		314.00		265.00	
NA+	136-147 (MMOL/L)	01/05/92	141.00		138.00		143.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.40		4.40		4.90	
CL-	98-108 (MMOL/L)	01/05/92	107.00		105.00		106.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.27		2.36		2.26	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	0.88		0.95		1.21	
SGOT	5-40 (U/L)	01/05/92	20.00		21.00		19.00	
SGPT	5-35 (U/L)	01/05/92	17.00		13.00		19.00	
GAMMA GT	4-18 (U/L)	01/05/92	6.00		11.00		17.00	
LDH	100-350 (U/L)	01/05/92	216.00		416.00	>	203.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	44.00		56.00		51.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	3.67		4.00		3.90	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	5.60		5.10		5.40	
CREATININE	47-88 (UMOL/L)	01/05/92	65.00		78.00		73.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.16		0.20		0.17	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	11.00		6.00		8.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	75.00		75.00		79.00	
ALBUMINE	38-52 (G/L)	01/05/92	45.00		45.00		49.55	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	5.59		5.40		4.50	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.89		1.30		1.10	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	3.30		3.30		2.61	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.97		6.97		6.59	
GLOBULINS BETA	7-11 (G/L)	01/05/92	10.20		10.20		9.69	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	9.05		9.05		10.56	
TSH	0.4-5 (MUI/L)	01/05/92	4.10					
T4	9-20.9 (PMOL/L)	01/05/92	13.70					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done

>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CMS 5590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 324 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/07/92		07/08/92		28/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14.5-18.5 (G/DL)	01/05/92	14.90		15.60		15.50	
HT	0.42-0.54 (L/L)	01/05/92	0.45		0.46		0.47	
RBC	4.8-6.4 (10¬6/MM3)	01/05/92	4.70	<	4.80		4.84	
WBC	4-11 (10¬3/MM3)	01/05/92	6.60		6.50		9.15	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	3.30		3.50		6.22	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	2.50		2.30		1.92	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.30		0.30		0.46	>
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.60		0.30		0.46	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.09	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	283.00		259.00		290.00	
NA+	136-147 (MMOL/L)	01/05/92	139.00		137.00		136.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	3.90		3.70		4.10	
CL-	98-108 (MMOL/L)	01/05/92	106.00		104.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.30		2.46		2.15	<
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.03		1.06		0.88	
SGOT	5-40 (U/L)	01/05/92	20.00		20.00		20.00	
SGPT	5-35 (U/L)	01/05/92	42.00	>	29.00		30.00	
GAMMA GT	0-28 (U/L)	01/05/92	21.00		10.00		29.00	>
LDH	100-350 (U/L)	01/05/92	285.00		122.00		142.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	52.00		55.00		20.00	<
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	3.60		4.60		3.30	<
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	3.40		3.80		3.10	
CREATININE	60-115 (UMOL/L)	01/05/92	79.00		76.00		65.00	
URIC ACID	0.18-0.45 (MMOL/L)	01/05/92	0.34		0.28		0.31	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	13.00		16.00		12.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	77.00		77.00		77.00	
ALBUMINE	38-52 (G/L)	01/05/92	46.18		41.20		51.30	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	3.20		3.90		4.00	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.50		0.70		0.50	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.46		2.66		2.00	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.48		5.67		4.30	<
GLOBULINS BETA	7-11 (G/L)	01/05/92	7.60		9.83		12.60	>
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	14.28		17.63	>	17.20	>
TSH	0.4-5 (MUI/L)	01/05/92	2.30					
T4	9-20.9 (PMOL/L)	01/05/92	17.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 0558085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 326 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			30/07/92		20/08/92		10/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14.5-18.5 (G/DL)	01/05/92	16.00		15.60		15.90	
HT	0.42-0.54 (L/L)	01/05/92	0.50		0.49		0.49	
RBC	4.8-6.4 (10¬6/MM3)	01/05/92	5.60		5.40		5.40	
WBC	4-11 (10¬3/MM3)	01/05/92	6.90		5.50		6.80	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	4.40		3.40		4.50	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	2.10		1.60		1.90	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.10		0.10		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.30		0.40		0.30	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	199.00		156.00		183.00	
NA+	136-147 (MMOL/L)	01/05/92	139.00		142.00		141.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.20		4.00		4.30	
CL-	98-108 (MMOL/L)	01/05/92	104.00		106.00		105.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.54		2.21		2.24	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.08		0.73	<	0.86	
SGOT	5-40 (U/L)	01/05/92	23.00		32.00		16.00	
SGPT	5-35 (U/L)	01/05/92	23.00		57.00	>	18.00	
GAMMA GT	0-28 (U/L)	01/05/92	13.00		26.00		15.00	
LDH	100-350 (U/L)	01/05/92	315.00		137.00		144.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	47.00		52.00		53.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	4.30		3.20	<	3.50	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	4.90		3.80		4.10	
CREATININE	60-115 (UMOL/L)	01/05/92	96.00		100.00		93.00	
URIC ACID	0.18-0.45 (MMOL/L)	01/05/92	0.39		0.49	>	0.33	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	13.00		10.00		15.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	72.00		73.00		72.00	
ALBUMINE	38-52 (G/L)	01/05/92	43.00		43.30		54.70	>
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	4.30		4.10		4.60	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.80		0.50		0.60	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.38		2.86		1.70	<
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	7.07		8.52		4.50	<
GLOBULINS BETA	7-11 (G/L)	01/05/92	9.88		9.48		6.30	<
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	8.77		8.76		4.80	<<
TSH	0.4-5 (MUI/L)	01/05/92	1.60					
T4	9-20.9 (PMOL/L)	01/05/92	14.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS SRL 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 328 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 28	
			19/08/92		10/09/92		18/09/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	14.5-18.5 (G/DL)	01/05/92	14.10	<	17.00		16.50	
HT	0.42-0.54 (L/L)	01/05/92	0.44		0.51		0.52	
RBC	4.8-6.4 (10¬6/MM3)	01/05/92	5.10		5.70		5.60	
WBC	4-11 (10¬3/MM3)	01/05/92	4.80		5.50		6.60	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	0.91	<<	3.10		4.00	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	2.40		1.90		2.10	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.38		0.10		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.62		0.40		0.40	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	260.00		233.00		257.00	
NA+	136-147 (MMOL/L)	01/05/92	140.00		137.00		137.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	3.80		3.90		3.40	<
CL-	98-108 (MMOL/L)	01/05/92	102.00		100.00		99.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.37		2.31		2.35	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.06		0.71	<	1.06	
SGOT	5-40 (U/L)	01/05/92	23.00		18.00		19.00	
SGPT	5-35 (U/L)	01/05/92	26.00		18.00		21.00	
GAMMA GT	0-28 (U/L)	01/05/92	24.00		21.00		22.00	
LDH	100-350 (U/L)	01/05/92	126.00		139.00		135.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	69.00		71.00		77.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	4.90		4.30		3.80	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	4.70		4.30		4.20	
CREATININE	60-115 (UMOL/L)	01/05/92	83.00		85.00		72.00	
URIC ACID	0.18-0.45 (MMOL/L)	01/05/92	0.38		0.34		0.32	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	11.00		11.00		12.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	80.00		72.00		79.00	
ALBUMINE	38-52 (G/L)	01/05/92	47.90		50.10		57.00	>
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	5.40		4.70		5.50	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	1.40		1.20		1.80	>
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.54		1.80	<	1.70	<
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.90		4.50	<	4.40	<
GLOBULINS BETA	7-11 (G/L)	01/05/92	11.26	>	7.70		7.90	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	11.51		7.80		8.00	
TSH	0.4-5 (MUI/L)	01/05/92	1.60					
T4	9-20.9 (PMOL/L)	01/05/92	16.60					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 329 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/08/92		11/09/92		02/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.5-16.5 (G/DL)	01/05/92	13.60		12.60		13.20	
HT	0.37-0.49 (L/L)	01/05/92	0.41		0.39		0.43	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	4.80		4.40		4.70	
WBC	4-11 (10¬3/MM3)	01/05/92	4.80		4.70		5.30	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	0.82	<<	2.00		2.20	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	2.83		2.00		2.30	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.43	>	0.30		0.30	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.43		0.30		0.40	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.10		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	215.00		257.00		308.00	
NA+	136-147 (MMOL/L)	01/05/92	143.00		140.00		141.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.10		4.60		4.20	
CL-	98-108 (MMOL/L)	01/05/92	108.00		108.00		108.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.21		2.29		2.10	<
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.00		1.09		1.05	
SGOT	5-40 (U/L)	01/05/92	30.00		28.00		23.00	
SGPT	5-35 (U/L)	01/05/92	43.00	>	35.00		21.00	
GAMMA GT	4-18 (U/L)	01/05/92	49.00	>>	26.00	>	38.00	>>
LDH	100-350 (U/L)	01/05/92	203.00		177.00		165.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	106.00		113.00		97.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	3.40	<	3.80		3.80	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	3.30		3.60		2.30	<
CREATININE	47-88 (UMOL/L)	01/05/92	74.00		68.00		60.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.29		0.31		0.26	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	23.00	>	5.00		18.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	79.00		73.00		73.00	
ALBUMINE	38-52 (G/L)	01/05/92	47.30		46.00		44.60	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	4.90		4.70		4.80	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92			1.30		1.00	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.46		2.10		2.10	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.97		5.90		6.80	
GLOBULINS BETA	7-11 (G/L)	01/05/92	9.66		8.20		8.80	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	12.58		10.70		10.70	
TSH	0.4-5 (MUI/L)	01/05/92	2.00					
T4	9-20.9 (PMOL/L)	01/05/92	14.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 332 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			03/09/92		28/09/92		15/10/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12.5-16.5 (G/DL)	01/05/92	12.00	<	11.30	<	11.40	<
HT	0.37-0.49 (L/L)	01/05/92	0.38		0.36	<	0.35	<
RBC	4.2-5.8 (10~6/MM3)	01/05/92	4.30		4.10	<	4.00	<
WBC	4-11 (10~3/MM3)	01/05/92	9.50		7.80		6.90	
WBC: N	1.6-8 (10~3/MM3)	01/05/92	7.30		5.30		4.10	
WBC: L	1-4.5 (10~3/MM3)	01/05/92	1.80		1.70		2.20	
WBC: E	0-0.4 (10~3/MM3)	01/05/92	0.10		0.40		0.30	
WBC: M	0.2-0.8 (10~3/MM3)	01/05/92	0.30		0.40		0.40	
WBC: B	0-0.1 (10~3/MM3)	01/05/92	0.10		0.10		0.00	
PLATELETS	150-400 (10~3/MM3)	01/05/92	372.00		361.00		360.00	
NA+	136-147 (MMOL/L)	01/05/92	138.00		141.00		133.00	<
K+	3.5-5.1 (MMOL/L)	01/05/92	4.00		4.20		4.00	
CL-	98-108 (MMOL/L)	01/05/92	105.00		107.00		106.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.38		2.26		2.22	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.24		1.13		1.06	
SGOT	5-40 (U/L)	01/05/92	19.00		26.00		22.00	
SGPT	5-35 (U/L)	01/05/92	14.00		13.00		20.00	
GAMMA GT	4-18 (U/L)	01/05/92	19.00	>	11.00		16.00	
LDH	100-350 (U/L)	01/05/92	156.00		144.00		146.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	77.00		74.00		72.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	3.80		2.90	<	2.80	<
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	2.70		3.80		3.80	
CREATININE	47-88 (UMOL/L)	01/05/92	81.00		67.00		99.00	>
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.29		0.17		0.18	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	8.00		6.00		6.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	76.00		77.00		75.00	
ALBUMINE	38-52 (G/L)	01/05/92	49.40		46.30		48.10	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	4.60		4.60		4.40	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	1.00		1.30		1.10	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.40		2.70		2.10	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	5.60		6.90		5.40	
GLOBULINS BETA	7-11 (G/L)	01/05/92	7.40		8.30		8.00	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	11.20		12.90		11.30	
TSH	0.4-5 (MUI/L)	01/05/92	2.20					
T4	9-20.9 (PMOL/L)	01/05/92	15.80					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9950085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 11 Patient: 333 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/09/92		25/09/92		16/10/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12.5-16.5 (G/DL)	01/05/92	13.60		13.70		13.10	
HT	0.37-0.49 (L/L)	01/05/92	0.42		0.42		0.41	
RBC	4.2-5.8 (10¬6/MM3)	01/05/92	4.32		4.40		4.12	<
WBC	4-11 (10¬3/MM3)	01/05/92	4.60		6.90		4.50	
WBC: N	1.6-8 (10¬3/MM3)	01/05/92	1.80		5.00		2.20	
WBC: L	1-4.5 (10¬3/MM3)	01/05/92	2.30		1.50		1.80	
WBC: E	0-0.4 (10¬3/MM3)	01/05/92	0.10		0.00		0.10	
WBC: M	0.2-0.8 (10¬3/MM3)	01/05/92	0.30		0.30		0.30	
WBC: B	0-0.1 (10¬3/MM3)	01/05/92	0.00		0.00		0.10	
PLATELETS	150-400 (10¬3/MM3)	01/05/92	329.00		261.00		296.00	
NA+	136-147 (MMOL/L)	01/05/92	138.00		141.00		138.00	
K+	3.5-5.1 (MMOL/L)	01/05/92	4.50		3.80		4.20	
CL-	98-108 (MMOL/L)	01/05/92	103.00		104.00		105.00	
Ca++	2.2-2.6 (MMOL/L)	01/05/92	2.31		2.20		2.26	
PO4--	0.8-1.45 (MMOL/L)	01/05/92	1.32		0.91		1.01	
SGOT	5-40 (U/L)	01/05/92	22.00		21.00		17.00	
SGPT	5-35 (U/L)	01/05/92	23.00		18.00		19.00	
GAMMA GT	4-18 (U/L)	01/05/92	19.00	>	7.00		17.00	
LDH	100-350 (U/L)	01/05/92	155.00		142.00		132.00	
ALK. PHOSPH.	25-160 (U/L)	01/05/92	57.00		49.00		59.00	
GLUCOSE	3.5-6.8 (MMOL/L)	01/05/92	4.40		4.60		3.80	
BUN	()	01/05/92						
UREA	2.6-6.7 (MMOL/L)	01/05/92	3.00		2.30	<	3.40	
CREATININE	47-88 (UMOL/L)	01/05/92	82.00		71.00		69.00	
URIC ACID	0.12-0.4 (MMOL/L)	01/05/92	0.13		0.23		0.19	
TOT BILIRUBIN	4-21 (UMOL/L)	01/05/92	5.00		6.00		7.00	
DIR BILIRUBIN	0-4 (UMOL/L)	01/05/92						
TOT. PROTEINS	65-80 (G/L)	01/05/92	75.00		69.00		70.00	
ALBUMINE	38-52 (G/L)	01/05/92	51.20		47.30		47.20	
TOT. CHOLEST.	2-6.5 (MMOL/L)	01/05/92	7.90	>	4.80		6.40	
TRIGLYCERIDES	0-1.7 (MMOL/L)	01/05/92	0.70		0.90		0.70	
GLOBULINS ALPHA 1	2-4 (G/L)	01/05/92	2.60		2.10		2.00	
GLOBULINS ALPHA 2	5-9 (G/L)	01/05/92	6.70		6.10		7.10	
GLOBULINS BETA	7-11 (G/L)	01/05/92	8.10		7.00		7.30	
GLOBULINS GAMMA	7-16 (G/L)	01/05/92	6.50	<	6.30	<	6.40	<
TSH	0.4-5 (MUI/L)	01/05/92	2.90					
T4	9-20.9 (PMOL/L)	01/05/92	9.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 12 Patient: 337 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			11/05/92		15/06/92		06/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.3-16.7 (G/DL)	01/04/92	15.30		14.20		14.90	
HT	36-50 (%)	01/04/92	45.00		42.00		44.00	
RBC	3.7-5.7 (10-6/MM3)	01/04/92	5.00		4.60		5.00	
WBC	3.9-11.5 (10-3/MM3)	01/04/92	8.80		8.00		5.60	
WBC: N	2-7.5 (10-3/MM3)	01/04/92	5.96		4.80		2.58	
WBC: L	1-4 (10-3/MM3)	01/04/92	2.02		2.40		2.31	
WBC: E	0.2-0.45 (10-3/MM3)	01/04/92	0.08	<	0.08	<	0.08	<
WBC: M	0.2-0.8 (10-3/MM3)	01/04/92	0.68		0.72		0.54	
WBC: B	0-0.1 (10-3/MM3)	01/04/92	0.06		0.00		0.08	
PLATELETS	150-400 (10-3/MM3)	01/04/92	416.00	>	386.00		384.00	
NA+	135-150 (MMOL/L)	01/04/92	141.00		141.00		138.00	
K+	3.6-5.7 (MMOL/L)	01/04/92	5.10		4.50		4.90	
CL-	99-110 (MMOL/L)	01/04/92	105.00		106.00		104.00	
Ca++	2.15-2.65 (MMOL/L)	01/04/92	2.42		2.34		2.48	
PO4--	0.8-1.5 (MMOL/L)	01/04/92	1.04		1.02		1.27	
SGOT	5-45 (U/L)	01/04/92	24.00		24.00		46.00	>
SGPT	5-50 (U/L)	01/04/92	18.00		17.00		36.00	
GAMMA GT	0-50 (U/L)	01/04/92	15.00		17.00		7.00	
LDH	120-230 (U/L)	01/04/92	188.00		162.00		184.00	
ALK. PHOSPH.	21-91 (IU/L)	01/04/92	81.00		78.00		59.00	
GLUCOSE	4.5-7.8 (MMOL/L)	01/04/92	3.20	<	2.70	<<	4.00	<
BUN	2.5-6.6 (MMOL/L)	01/04/92	4.50		4.30		4.00	
UREA	()	01/04/92						
CREATININE	62-115 (UMOL/L)	01/04/92	101.00		88.00		112.00	
URIC ACID	0.09-0.35 (MMOL/L)	01/04/92	0.23		0.26		0.34	
TOT BILIRUBIN	2-26 (UMOL/L)	01/04/92	5.00		6.00		4.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/04/92	1.00		2.00		1.00	
TOT. PROTEINS	60-80 (G/L)	01/04/92	73.00		79.00		71.00	
ALBUMINE	35-50 (G/L)	01/04/92	43.00		48.00		46.00	
TOT. CHOLEST.	3.5-5.1 (MMOL/L)	01/04/92	6.30	>	6.52	>	5.86	>
TRIGLYCERIDES	0.28-2.3 (MMOL/L)	01/04/92	2.55	>	2.57	>	1.16	
GLOBULINS ALPHA 1	1-4 (G/L)	01/04/92	3.00		3.00		3.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/04/92	7.00		7.00		7.00	
GLOBULINS BETA	5-10 (G/L)	01/04/92	11.00	>	11.00	>	8.00	
GLOBULINS GAMMA	6-15 (G/L)	01/04/92	9.00		10.00		7.00	
TSH	0.4-5 (UU/ML)	01/04/92	1.46					
T4	11-24 (PMOL/L)	01/04/92	15.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 12 Patient: 339 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/06/92		13/07/92		03/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14.1-18.5 (G/DL)	01/04/92	14.70		15.30		15.00	
HT	41-56 (%)	01/04/92	43.00		44.00		44.00	
RBC	4-6.5 (10¬6/MM3)	01/04/92	4.50		4.80		4.80	
WBC	3.9-11.5 (10¬3/MM3)	01/04/92	8.90		11.60	>	8.90	
WBC: N	2-7.5 (10¬3/MM3)	01/04/92	4.68		6.24		3.77	
WBC: L	1-4 (10¬3/MM3)	01/04/92	3.07		3.48		3.75	
WBC: E	0.2-0.45 (10¬3/MM3)	01/04/92	0.27		0.15	<	0.43	
WBC: M	0.2-0.8 (10¬3/MM3)	01/04/92	0.76		1.02	>	0.86	>
WBC: B	0-0.1 (10¬3/MM3)	01/04/92	0.12	>	0.10		0.09	
PLATELETS	150-400 (10¬3/MM3)	01/04/92	398.00		409.00	>	389.00	
NA+	135-150 (MMOL/L)	01/04/92	142.00		141.00		140.00	
K+	3.6-5.7 (MMOL/L)	01/04/92	4.40		5.30		4.20	
CL-	99-110 (MMOL/L)	01/04/92	109.00		105.00		103.00	
Ca++	2.15-2.65 (MMOL/L)	01/04/92	2.44		2.38		2.25	
PO4--	0.8-1.5 (MMOL/L)	01/04/92	1.15		1.13		1.03	
SGOT	5-45 (U/L)	01/04/92	20.00		37.00		22.00	
SGPT	5-50 (U/L)	01/04/92	9.00		17.00		10.00	
GAMMA GT	0-50 (U/L)	01/04/92	24.00		24.00		18.00	
LDH	120-230 (U/L)	01/04/92	156.00		182.00		152.00	
ALK. PHOSPH.	21-91 (IU/L)	01/04/92	62.00		70.00		48.00	
GLUCOSE	4.5-7.8 (MMOL/L)	01/04/92	4.00	<	3.90	<	4.20	<
BUN	2.5-6.6 (MMOL/L)	01/04/92	6.60		6.10		3.90	
UREA	()	01/04/92						
CREATININE	62-115 (UMOL/L)	01/04/92	109.00		113.00		98.00	
URIC ACID	0.15-0.41 (MMOL/L)	01/04/92	0.30		0.30		0.23	
TOT BILIRUBIN	2-26 (UMOL/L)	01/04/92	10.00		12.00		3.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/04/92	1.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	01/04/92	70.00		71.00		61.00	
ALBUMINE	35-50 (G/L)	01/04/92	38.00		44.00		37.00	
TOT. CHOLEST.	3.5-5.1 (MMOL/L)	01/04/92	3.81		3.94		3.73	
TRIGLYCERIDES	0.28-2.3 (MMOL/L)	01/04/92	0.66		0.79		1.57	
GLOBULINS ALPHA 1	1-4 (G/L)	01/04/92	3.00		2.00		2.00	
GLOBULINS ALPHA 2	4-9 (G/L)	01/04/92	7.00		6.00		6.00	
GLOBULINS BETA	5-10 (G/L)	01/04/92	10.00		8.00		8.00	
GLOBULINS GAMMA	6-15 (G/L)	01/04/92	12.00		11.00		8.00	
TSH	0.4-5 (UU/ML)	01/04/92	1.89					
T4	11-24 (PMOL/L)	01/04/92	14.50					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 13 Patient: 354 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/06/92		15/07/92		12/08/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11.6-15.6 (G/DL)	02/05/92	12.70		12.70		13.40	
HT	0.35-0.45 (L/L)	02/05/92	0.36		0.39		0.38	
RBC	3.7-5.3 (10¬6/MM3)	02/05/92	4.02		4.44		4.37	
WBC	4-11 (10¬3/MM3)	02/05/92	6.99		6.86		5.44	
WBC: N	40-75 (%)	02/05/92	54.00		52.00		48.00	
WBC: L	20-45 (%)	02/05/92	38.00		36.00		35.00	
WBC: E	1-6 (%)	02/05/92	1.00		3.00		5.00	
WBC: M	2-10 (%)	02/05/92	6.00		7.00		9.00	
WBC: B	0-1 (%)	02/05/92	0.00		0.00		1.00	
PLATELETS	140-420 (10¬3/MM3)	02/05/92	250.00		299.00		293.00	
NA+	135-145 (MMOL/L)	02/05/92	140.00		142.00		140.00	
K+	3.5-5.5 (MMOL/L)	02/05/92	3.90		4.20		4.30	
CL-	97-107 (MMOL/L)	02/05/92	106.00		111.00	>	109.00	>
Ca++	2.1-2.6 (MMOL/L)	02/05/92	2.29		2.32		2.34	
PO4--	0.8-1.3 (MMOL/L)	02/05/92	1.28		1.12		1.09	
SGOT	0-53 (U/L)	02/05/92	12.00		25.00		78.00	>
SGPT	1-25 (U/L)	02/05/92	7.00		29.00	>	19.00	
GAMMA GT	0-40 (U/L)	02/05/92	21.00		25.00		27.00	
LDH	175-350 (U/L)	02/05/92	195.00		207.00		206.00	
ALK. PHOSPH.	30-70 (U/L)	02/05/92	91.00	>	86.00	>	129.00	>
GLUCOSE	3.7-5.6 (MMOL/L)	02/05/92	4.80		3.70			
BUN	1.7-6.7 (MMOL/L)	02/05/92	3.70		4.00		4.00	
UREA	()	02/05/92						
CREATININE	75-115 (UMOL/L)	02/05/92	72.00	<	71.00	<	72.00	<
URIC ACID	0.09-0.36 (MMOL/L)	02/05/92	0.19		0.20		0.25	
TOT BILIRUBIN	1-17 (UMOL/L)	02/05/92	5.00		7.00		5.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	02/05/92	1.00	<	2.00		1.00	<
TOT. PROTEINS	60-80 (G/L)	02/05/92	71.00		72.00		76.00	
ALBUMINE	35-50 (G/L)	02/05/92	43.00		41.00		44.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	02/05/92	4.40		5.20	>	5.00	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	02/05/92						
GLOBULINS ALPHA 1	1-3 (G/L)	02/05/92			1.66			
GLOBULINS ALPHA 2	5-9 (G/L)	02/05/92			5.62			
GLOBULINS BETA	4-10 (G/L)	02/05/92			7.96			
GLOBULINS GAMMA	7-20 (G/L)	02/05/92			12.84			
TSH	0.4-4 (MU/L)	02/05/92	1.07					
T4	6.3-22.8 (PMOL/L)	02/05/92						

(◊) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max rang
> out of range (value higher than max rang
() missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 13 Patient: 356 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/07/92		12/08/92		02/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.3-17.3 (G/DL)	10/07/92			15.20		15.70	
HT	0.4-0.5 (L/L)	10/07/92			0.46		0.46	
RBC	4.5-5.9 (10¬6/MM3)	10/07/92			5.24		5.24	
WBC	4-11 (10¬3/MM3)	10/07/92			7.40		11.82	>
WBC: N	40-75 (%)	10/07/92			66.00		71.00	
WBC: L	20-45 (%)	10/07/92			21.00		14.00	<
WBC: E	1-6 (%)	10/07/92			5.00		7.00	>
WBC: M	2-10 (%)	10/07/92			7.00		6.00	
WBC: B	0-1 (%)	10/07/92			1.00		1.00	
PLATELETS	140-420 (10¬3/MM3)	10/07/92			343.00		385.00	
NA+	135-145 (MMOL/L)	10/07/92	139.00		139.00		137.00	
K+	3.5-5.5 (MMOL/L)	10/07/92	4.80		4.90		4.40	
CL-	97-107 (MMOL/L)	10/07/92	105.00		105.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	10/07/92	2.32		2.41		2.35	
PO4--	0.8-1.3 (MMOL/L)	10/07/92	1.04		0.77	<	1.06	
SGOT	0-53 (U/L)	10/07/92	29.00		26.00		31.00	
SGPT	1-25 (U/L)	10/07/92	17.00		31.00	>	39.00	>
GAMMA GT	0-40 (U/L)	10/07/92	0.00		0.00		11.00	
LDH	175-350 (U/L)	10/07/92	233.00		171.00	<	211.00	
ALK. PHOSPH.	30-70 (U/L)	10/07/92	106.00	>	103.00	>	120.00	>
GLUCOSE	3.7-5.6 (MMOL/L)	10/07/92	4.50		3.20	<	4.30	
BUN	1.7-6.7 (MMOL/L)	10/07/92	4.30		3.50		3.80	
UREA	()	10/07/92						
CREATININE	75-115 (UMOL/L)	10/07/92	83.00		80.00		87.00	
URIC ACID	0.15-0.48 (MMOL/L)	10/07/92	0.23		0.25		0.25	
TOT BILIRUBIN	1-17 (UMOL/L)	10/07/92	9.00		7.00		5.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	10/07/92	1.00	<	1.00	<	2.00	
TOT. PROTEINS	60-80 (G/L)	10/07/92	74.00		72.00		71.00	
ALBUMINE	35-50 (G/L)	10/07/92	46.00		44.00		41.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	10/07/92	5.50	>	5.00		5.10	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	10/07/92	0.90		1.10		1.20	
GLOBULINS ALPHA 1	1-5 (%)	10/07/92			2.11			
GLOBULINS ALPHA 2	4.5-9.5 (%)	10/07/92			12.32	>		
GLOBULINS BETA	11-16 (%)	10/07/92			11.93			
GLOBULINS GAMMA	12-22 (%)	10/07/92			13.34			
TSH	0.4-4 (MU/L)	10/07/92	1.47					
T4	6.3-22.8 (PMOL/L)	10/07/92						

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 13 Patient: 357 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			05/08/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.6-15.6 (G/DL)	03/08/92	11.40	<
HT	0.35-0.45 (L/L)	03/08/92	0.33	<
RBC	3.7-5.3 (10¬6/MM3)	03/08/92	4.24	
WBC	4-11 (10¬3/MM3)	03/08/92	5.51	
WBC: N	40-75 (%)	03/08/92	59.00	
WBC: L	20-45 (%)	03/08/92	33.00	
WBC: E	1-6 (%)	03/08/92	0.00	<
WBC: M	2-10 (%)	03/08/92	6.00	
WBC: B	0-1 (%)	03/08/92	0.00	
PLATELETS	140-420 (10¬3/MM3)	03/08/92	348.00	
NA+	135-145 (MMOL/L)	03/08/92	140.00	
K+	3.5-5.5 (MMOL/L)	03/08/92	4.30	
CL-	97-107 (MMOL/L)	03/08/92	103.00	
Ca++	2.1-2.6 (MMOL/L)	03/08/92	2.35	
PO4--	0.8-1.3 (MMOL/L)	03/08/92	1.27	
SGOT	0-53 (U/L)	03/08/92	13.00	
SGPT	1-25 (U/L)	03/08/92	12.00	
GAMMA GT	0-40 (U/L)	03/08/92	11.00	
LDH	175-350 (U/L)	03/08/92	198.00	
ALK. PHOSPH.	30-70 (U/L)	03/08/92		
GLUCOSE	3.7-5.6 (MMOL/L)	03/08/92	4.40	
BUN	1.7-6.7 (MMOL/L)	03/08/92	6.10	
UREA	()	03/08/92		
CREATININE	75-115 (UMOL/L)	03/08/92	64.00	<
URIC ACID	0.09-0.36 (MMOL/L)	03/08/92	0.19	
TOT BILIRUBIN	1-17 (UMOL/L)	03/08/92	8.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	03/08/92	2.00	
TOT. PROTEINS	60-80 (G/L)	03/08/92	83.00	>
ALBUMINE	55-75 (%)	03/08/92	51.00	<
TOT. CHOLEST.	0-5.1 (MMOL/L)	03/08/92	4.10	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	03/08/92		
GLOBULINS ALPHA 1	1-5 (%)	03/08/92	1.87	
GLOBULINS ALPHA 2	4.5-9.5 (%)	03/08/92	7.88	
GLOBULINS BETA	11-16 (%)	03/08/92	15.44	
GLOBULINS GAMMA	12-22 (%)	03/08/92	23.32	>
TSH	0.4-4 (MU/L)	03/08/92	0.78	
T4	6.3-22.8 (PMOL/L)	03/08/92		

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 5590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 13 Patient: 360 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			19/08/92	
			value	(¢)
Laboratory test	Range value	Range date		
HB	11.6-15.6 (G/DL)	02/05/92	13.00	
HT	0.35-0.45 (L/L)	02/05/92	0.39	
RBC	3.7-5.3 (10¬6/MM3)	02/05/92	4.59	
WBC	4-11 (10¬3/MM3)	02/05/92	5.30	
WBC: N	40-75 (%)	02/05/92	57.00	
WBC: L	20-45 (%)	02/05/92	32.00	
WBC: E	1-6 (%)	02/05/92	1.00	
WBC: M	2-10 (%)	02/05/92	7.00	
WBC: B	0-1 (%)	02/05/92		
PLATELETS	140-420 (10¬3/MM3)	02/05/92	184.00	
NA+	135-145 (MMOL/L)	02/05/92	140.00	
K+	3.5-5.5 (MMOL/L)	02/05/92	4.00	
CL-	97-107 (MMOL/L)	02/05/92	108.00	>
Ca++	2.1-2.6 (MMOL/L)	02/05/92	2.33	
PO4--	0.8-1.3 (MMOL/L)	02/05/92	0.96	
SGOT	0-53 (U/L)	02/05/92	10.00	
SGPT	1-25 (U/L)	02/05/92	17.00	
GAMMA GT	0-40 (U/L)	02/05/92	2.00	
LDH	175-350 (U/L)	02/05/92	171.00	<
ALK. PHOSPH.	30-70 (U/L)	02/05/92	77.00	>
GLUCOSE	3.7-5.6 (MMOL/L)	02/05/92	4.10	
BUN	1.7-6.7 (MMOL/L)	02/05/92	2.70	
UREA	()	02/05/92		
CREATININE	75-115 (UMOL/L)	02/05/92	68.00	<
URIC ACID	0.09-0.36 (MMOL/L)	02/05/92	0.14	
TOT BILIRUBIN	1-17 (UMOL/L)	02/05/92	3.00	
DIR BILIRUBIN	1.7-5.1 (UMOL/L)	02/05/92	1.00	<
TOT. PROTEINS	60-80 (G/L)	02/05/92	69.00	
ALBUMINE	35-50 (G/L)	02/05/92	43.00	
TOT. CHOLEST.	0-5.1 (MMOL/L)	02/05/92	4.90	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	02/05/92		
GLOBULINS ALPHA 1	1-3 (G/L)	02/05/92		
GLOBULINS ALPHA 2	5-9 (G/L)	02/05/92		
GLOBULINS BETA	4-10 (G/L)	02/05/92		
GLOBULINS GAMMA	7-20 (G/L)	02/05/92		
TSH	0.4-4 (MU/L)	02/05/92	0.57	
T4	6.3-22.8 (PMOL/L)	02/05/92		

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14 Patient: 458 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/07/92		04/08/92		25/08/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/06/92	13.10		13.20		13.30	
HT	42-54 (%)	01/06/92	39.00	<	39.00	<	40.00	<
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.00	<	4.10	<	4.20	
WBC	4000-9000 (/MM3)	01/06/92	7200.00		7000.00		6800.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	39.00		39.00		38.00	
WBC: E	1-4 (%)	01/06/92	3.00		4.00		3.00	
WBC: M	4-8 (%)	01/06/92	4.00		3.00	<	2.00	<
WBC: B	0-1 (%)	01/06/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	280000		280000		280000	
NA+	134-148 (MMOL/L)	01/06/92	136.00		139.00		138.00	
K+	3,8-5.2 (MMOL/L)	01/06/92	3.80		3.70	<	3.60	<
CL-	1.8-2.2 (MG/DL)	01/06/92	2.10		2.00		1.90	
Ca++	2-2.6 (MMOL/L)	01/06/92	1.90	<	1.90	<	2.00	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	10.00		10.00		11.00	
SGPT	5-22 (U/L)	01/06/92	10.00		10.00		15.00	
GAMMA GT	4-28 (U/L)	01/06/92	12.00		14.00		19.00	
LDH	120-240 (U/L)	01/06/92	171.00		170.00		172.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	134.00		126.00		131.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	88.00		94.00		96.00	
BUN	10-50 (MG/DL)	01/06/92	21.00		22.00		26.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	5.20		5.10		5.60	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.70		0.70		0.70	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	8.00		7.00		7.10	
ALBUMINE	57-68 (%)	01/06/92	61.00		62.00		64.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	241.00	>	236.00	>	251.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	116.00		120.00		141.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	2.90		2.80		3.00	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	6.80		6.70		6.80	
GLOBULINS BETA	9-13 (%)	01/06/92	11.70		11.90		12.40	
GLOBULINS GAMMA	10-20 (%)	01/06/92	12.30		12.80		16.60	
TSH	0.2-3.1 (UU/ML)	01/06/92	1.10					
T4	5-11.5 (UG/DL)	01/06/92	7.20					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 95000085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14 Patient: 460 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/07/92		13/08/92		03/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	14.20		14.20		14.10	
HT	42-54 (%)	01/06/92	39.00	<	39.00	<	39.00	<
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.40		4.30		4.40	
WBC	4000-9000 (/MM3)	01/06/92	6800.00		6600.00		6900.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	36.00		38.00		38.00	
WBC: E	1-4 (%)	01/06/92	3.00		3.00		2.00	
WBC: M	4-8 (%)	01/06/92	2.00	<	2.00	<	2.00	<
WBC: B	0-1 (%)	01/06/92	1.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	260000		260000		260000	
NA+	134-148 (MMOL/L)	01/06/92	141.00		140.00		139.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	3.90		3.80		3.80	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.00		1.90		2.00	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.40		2.30		2.10	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	10.00		10.00		10.00	
SGPT	5-22 (U/L)	01/06/92	11.00		10.00		10.00	
GAMMA GT	4-28 (U/L)	01/06/92	14.00		12.00		14.00	
LDH	120-240 (U/L)	01/06/92	161.00		158.00		156.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	102.00		101.00		102.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	84.00		92.00		94.00	
BUN	10-50 (MG/DL)	01/06/92	42.00		40.00		41.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.90		0.90		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	6.40		6.20		6.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.80		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	8.40		7.20		7.10	
ALBUMINE	57-68 (%)	01/06/92	62.00		63.00		64.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	207.00	>	113.00		202.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	113.00		119.00		176.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.80		3.90		3.80	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.40		7.60		7.40	
GLOBULINS BETA	9-13 (%)	01/06/92	12.10		12.40		12.90	
GLOBULINS GAMMA	10-20 (%)	01/06/92	16.40		16.80		16.60	
TSH	0.2-3.1 (UU/ML)	01/06/92	2.20					
T4	5-11.5 (UG/DL)	01/06/92	8.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
xx missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14 Patient: 461 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/07/92		19/08/92		09/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	12.80		13.00		13.10	
HT	42-54 (%)	01/06/92	39.00	<	39.00	<	39.00	<
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.00	<	4.10	<	4.10	<
WBC	4000-9000 (/MM3)	01/06/92	6800.00		6600.00		6800.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	35.00		36.00		35.00	
WBC: E	1-4 (%)	01/06/92	2.00		2.00		2.00	
WBC: M	4-8 (%)	01/06/92	4.00		4.00		4.00	
WBC: B	0-1 (%)	01/06/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	260000		260000		260000	
NA+	134-148 (MMOL/L)	01/06/92	141.00		138.00		139.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	3.90		4.00		4.10	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.00		2.10		2.00	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.10		2.00		2.10	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	12.00		12.00		12.00	
SGPT	5-22 (U/L)	01/06/92	12.00		12.00		12.00	
GAMMA GT	4-28 (U/L)	01/06/92	16.00		17.00		16.00	
LDH	120-240 (U/L)	01/06/92	198.00		196.00		194.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	112.00		116.00		121.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	108.00		98.00		94.00	
BUN	10-50 (MG/DL)	01/06/92	41.00		42.00		41.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.70		0.70		0.70	
URIC ACID	2.4-7 (MG/DL)	01/06/92	5.80		5.90		6.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.70		0.70		0.70	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.60		7.40		7.20	
ALBUMINE	57-68 (%)	01/06/92	61.00		62.00		61.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	212.00	>	216.00	>	198.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	108.00		112.00		107.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.70		3.80		3.90	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.90		7.60		7.50	
GLOBULINS BETA	9-13 (%)	01/06/92	11.70		12.40		12.70	
GLOBULINS GAMMA	10-20 (%)	01/06/92	17.60		17.90		19.00	
TSH	0.2-3.1 (UU/ML)	01/06/92	1.30					
T4	5-11.5 (UG/DL)	01/06/92	7.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14 Patient: 463 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			27/07/92		24/08/92		14/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	14.80		14.90		14.70	
HT	42-54 (%)	01/06/92	42.00		42.00		42.00	
RBC	4.2-5.8 (10-6/MM3)	01/06/92	4.40		4.40		4.40	
WBC	4000-9000 (/MM3)	01/06/92	6900.00		7000.00		6900.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	38.00		39.00		39.00	
WBC: E	1-4 (%)	01/06/92	4.00		4.00		4.00	
WBC: M	4-8 (%)	01/06/92	2.00	<	2.00	<	2.00	<
WBC: B	0-1 (%)	01/06/92	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	290000		290000		290000	
NA+	134-148 (MMOL/L)	01/06/92	142.00		140.00		141.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	4.10		4.00		3.90	
CL-	1.8-2.2 (MG/DL)	01/06/92	2.00		2.00		2.10	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.20		2.00		1.90	<
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	12.00		10.00		10.00	
SGPT	5-22 (U/L)	01/06/92	12.00		11.00		11.00	
GAMMA GT	4-28 (U/L)	01/06/92	19.00		17.00		16.00	
LDH	120-240 (U/L)	01/06/92	152.00		156.00		154.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	101.00		102.00		100.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	103.00		99.00		106.00	
BUN	10-50 (MG/DL)	01/06/92	39.00		40.00		41.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	6.20		6.10		6.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.80		0.80		0.80	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	6.80		7.00		7.10	
ALBUMINE	57-68 (%)	01/06/92	62.00		61.00		62.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	221.00	>	213.00	>	41.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	198.00	>	180.00		182.00	>
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.90		3.80		3.90	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.60		7.40		7.60	
GLOBULINS BETA	9-13 (%)	01/06/92	12.80		12.90		13.10	>
GLOBULINS GAMMA	10-20 (%)	01/06/92	17.90		18.20		18.40	
TSH	0.2-3.1 (UU/ML)	01/06/92	1.70					
T4	5-11.5 (UG/DL)	01/06/92	6.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

1328

PHARMACIA CNS R&D 3590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14 Patient: 466 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			31/07/92		28/08/92		18/09/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/06/92	12.20		12.40		12.50	
HT	42-54 (%)	01/06/92	38.00	<	38.00	<	38.00	<
RBC	4.2-5.8 (10¬6/MM3)	01/06/92	4.00	<	4.10	<	4.10	<
WBC	4000-9000 (/MM3)	01/06/92	6800.00		7000.00		6900.00	
WBC: N	50-70 (%)	01/06/92						
WBC: L	25-40 (%)	01/06/92	37.00		38.00		39.00	
WBC: E	1-4 (%)	01/06/92	3.00		3.00		2.00	
WBC: M	4-8 (%)	01/06/92	4.00		5.00		5.00	
WBC: B	0-1 (%)	01/06/92	1.00		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/06/92	280000		280000		280000	
NA+	134-148 (MMOL/L)	01/06/92	136.00		138.00		139.00	
K+	3.8-5.2 (MMOL/L)	01/06/92	3.80		3.80		3.80	
CL-	1.8-2.2 (MG/DL)	01/06/92	1.90		2.00		2.00	
Ca++	2-2.6 (MMOL/L)	01/06/92	2.10		2.00		2.00	
PO4--	()	01/06/92						
SGOT	5-18 (U/L)	01/06/92	12.00		12.00		12.00	
SGPT	5-22 (U/L)	01/06/92	12.00		12.00		12.00	
GAMMA GT	4-28 (U/L)	01/06/92	16.00		17.00		16.00	
LDH	120-240 (U/L)	01/06/92	172.00		174.00		176.00	
ALK. PHOSPH.	60-170 (U/L)	01/06/92	102.00		100.00		96.00	
GLUCOSE	60-110 (MG/DL)	01/06/92	89.00		93.00		92.00	
BUN	10-50 (MG/DL)	01/06/92	41.00		40.00		41.00	
UREA	()	01/06/92						
CREATININE	0.3-1.2 (MG/DL)	01/06/92	0.80		0.80		0.80	
URIC ACID	2.4-7 (MG/DL)	01/06/92	5.80		5.90		6.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/06/92	0.70		0.70		0.70	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/06/92						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/06/92	7.20		7.10		7.00	
ALBUMINE	57-68 (%)	01/06/92	62.00		63.00		64.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/06/92	212.00	>	232.00	>	221.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/06/92	134.00		156.00		119.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/06/92	3.70		3.80		3.90	
GLOBULINS ALPHA 2	5-9 (%)	01/06/92	7.80		8.00		7.80	
GLOBULINS BETA	9-13 (%)	01/06/92	12.10		12.30		11.90	
GLOBULINS GAMMA	10-20 (%)	01/06/92	16.60		16.80		16.70	
TSH	0.2-3.1 (UU/ML)	01/06/92	1.70					
T4	5-11.5 (UG/DL)	01/06/92	8.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/1 Patient: 429 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			18/09/91	
			value	(¢)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/07/91	13.50	
HT	37-47 (%)	01/07/91	38.10	
RBC	3.9-5.3 (10¬6/MM3)	01/07/91	4.50	
WBC	4000-9000 (/MM3)	01/07/91	11600.0	>
WBC: N	50-70 (%)	01/07/91	63.00	
WBC: L	20-40 (%)	01/07/91	36.00	
WBC: E	0-3 (%)	01/07/91	0.00	
WBC: M	0-8 (%)	01/07/91	1.00	
WBC: B	0-2 (%)	01/07/91	0.00	
PLATELETS	150-400 (10¬3/MM3)	01/07/91	387.00	
NA+	135-145 (MMOL/L)	01/07/91	141.00	
K+	3.7-5 (MMOL/L)	01/07/91	4.12	
CL-	()	01/07/91		
Ca++	4.5-5.2 (MEQ/L)	01/07/91	4.62	
PO4--	()	01/07/91		
SGOT	5-18 (U/L)	01/07/91	4.00	<
SGPT	5-22 (U/L)	01/07/91	6.00	
GAMMA GT	0-28 (U/L)	01/07/91	15.00	
LDH	120-240 (U/L)	01/07/91	120.00	
ALK. PHOSPH.	40-190 (U/L)	01/07/91	112.00	
GLUCOSE	60-100 (MG/DL)	01/07/91	100.00	
BUN	10-50 (MG/DL)	01/07/91	3.60	<
UREA	()	01/07/91		
CREATININE	0-1.2 (MG/DL)	01/07/91	0.76	
URIC ACID	2.5-5.8 (MG/DL)	01/07/91	3.60	
TOT BILIRUBIN	0-1 (MG/DL)	01/07/91	0.30	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/07/91		
TOT. PROTEINS	6.5-8 (G/DL)	01/07/91	7.09	
ALBUMINE	57-68 (%)	01/07/91	67.80	
TOT. CHOLEST.	130-200 (MG/DL)	01/07/91	245.00	>
TRIGLYCERIDES	65-170 (MG/DL)	01/07/91		
GLOBULINS ALPHA 1	2-4 (%)	01/07/91	1.90	<
GLOBULINS ALPHA 2	5-9 (%)	01/07/91	4.30	<
GLOBULINS BETA	8-12 (%)	01/07/91	7.70	<
GLOBULINS GAMMA	12-19 (%)	01/07/91	22.90	>
TSH	0.2-4 (MU/L)	01/07/91	1.38	
T4	10-25 (PMOL/L)	01/07/91	14.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

1330

PHARMACIA CNS 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/1 Patient: 451 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			14/11/91		19/12/91		08/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13-18 (G/DL)	01/07/91	15.60		15.20		14.80	
HT	40-54 (%)	01/07/91	46.60		42.40		41.90	
RBC	4.1-6 (10¬6/MM3)	01/07/91	5.20		5.00		5.00	
WBC	4000-9000 (/MM3)	01/07/91	7900.00		7400.00		9100.00	>
WBC: N	50-70 (%)	01/07/91	73.00	>	79.00	>	76.00	>
WBC: L	20-40 (%)	01/07/91	22.00		20.00		20.00	
WBC: E	0-3 (%)	01/07/91	0.00		0.00		0.00	
WBC: M	0-8 (%)	01/07/91	5.00		1.00		4.00	
WBC: B	0-2 (%)	01/07/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/07/91	283.00		298.00		328.00	
NA+	135-145 (MMOL/L)	01/07/91	138.00		136.00		134.00	<
K+	3.7-5 (MMOL/L)	01/07/91	5.00		4.90		4.50	
CL-	()	01/07/91						
Ca++	4.5-5.2 (MEQ/L)	01/07/91	4.67		4.80		4.75	
PO4--	()	01/07/91						
SGOT	5-18 (U/L)	01/07/91	5.00		5.00		6.00	
SGPT	5-22 (U/L)	01/07/91	6.00		6.00		10.00	
GAMMA GT	0-28 (U/L)	01/07/91	22.00		22.00		26.00	
LDH	120-240 (U/L)	01/07/91					128.00	
ALK. PHOSPH.	40-190 (U/L)	01/07/91	125.00		132.00		123.00	
GLUCOSE	60-100 (MG/DL)	01/07/91	113.00	>	155.00	>>	161.00	>>
BUN	10-50 (MG/DL)	01/07/91	41.00		48.00		39.00	
UREA	()	01/07/91						
CREATININE	0-1.2 (MG/DL)	01/07/91	1.13		1.01		1.11	
URIC ACID	2.5-7 (MG/DL)	01/07/91	4.10		4.80		4.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/07/91	0.40		0.40		0.50	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/07/91	0.10		0.10		0.10	
TOT. PROTEINS	6.5-8 (G/DL)	01/07/91	7.23		7.35		7.36	
ALBUMINE	57-68 (%)	01/07/91					65.30	
TOT. CHOLEST.	130-200 (MG/DL)	01/07/91	285.00	>>	305.00	>>	342.00	>>
TRIGLYCERIDES	65-170 (MG/DL)	01/07/91	404.00	>>	309.00	>>	440.00	>>
GLOBULINS ALPHA 1	2-4 (%)	01/07/91					2.50	
GLOBULINS ALPHA 2	5-9 (%)	01/07/91					8.90	
GLOBULINS BETA	8-12 (%)	01/07/91					10.30	
GLOBULINS GAMMA	12-19 (%)	01/07/91					12.80	
TSH	0.2-4 (MU/L)	01/07/91						
T4	10-25 (PMOL/L)	01/07/91	6.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 0085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/2 Patient: 136 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/01/92		11/02/92		25/02/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/12/91	13.00		12.50			
HT	36-46 (%)	01/12/91	38.60		36.50			
RBC	4.2-5.4 (10¬6/MM3)	01/12/91	4.23		4.09	<		
WBC	4-9.4 (10¬3/MM3)	01/12/91	8.00		9.40			
WBC: N	50-70 (%)	01/12/91	67.80		69.60			
WBC: L	25-40 (%)	01/12/91	25.50		24.10	<		
WBC: E	0-4 (%)	01/12/91	1.30		0.50			
WBC: M	2-13 (%)	01/12/91	4.70		4.80			
WBC: B	0-1 (%)	01/12/91	0.70		0.90			
PLATELETS	150-440 (10¬3/MM3)	01/12/91	299.00		282.00			
NA+	134-150 (MMOL/L)	01/12/91	138.00		139.00		139.00	
K+	3.5-5.6 (MMOL/L)	01/12/91	4.29		4.00		4.00	
CL-	94-111 (MMOL/L)	01/12/91	94.00		105.00		106.00	
Ca++	2.05-2.55 (MMOL/L)	01/12/91	2.51		2.30		2.20	
PO4--	2.5-4.8 (MG/DL)	01/12/91	2.50		3.02			
SGOT	5-15 (U/L)	01/12/91	10.00		10.00		9.00	
SGPT	5-22 (U/L)	01/12/91	16.00		15.00		8.00	
GAMMA GT	0-18 (U/L)	01/12/91	12.00		8.00		8.00	
LDH	120-240 (U/L)	01/12/91	153.00		148.00		153.00	
ALK. PHOSPH.	50-170 (U/L)	01/12/91	101.00		120.00		87.00	
GLUCOSE	60-110 (MG/DL)	01/12/91	57.00	<	103.00		82.00	
BUN	10-50 (MG/DL)	01/12/91	25.00		38.00		22.00	
UREA	()	01/12/91						
CREATININE	0-1.2 (MG/DL)	01/12/91	0.79		0.73		0.80	
URIC ACID	2.5-5.7 (MG/DL)	01/12/91	3.70		3.60		3.60	
TOT BILIRUBIN	0-1 (MG/DL)	01/12/91	0.69		0.73		0.71	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/12/91	0.21		0.38	>	0.21	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/12/91	6.80					
ALBUMINE	3500-5500 (MG/DL)	01/12/91	3740.00		4090.00			
TOT. CHOLEST.	120-200 (MG/DL)	01/12/91	229.00	>	210.00	>	183.00	
TRIGLYCERIDES	65-175 (MG/DL)	01/12/91	92.20		94.80		94.20	
GLOBULINS ALPHA 1	1.5-4 (%)	01/12/91	3.20				3.80	
GLOBULINS ALPHA 2	5-12 (%)	01/12/91	6.20				6.80	
GLOBULINS BETA	7-13 (%)	01/12/91	9.80				10.40	
GLOBULINS GAMMA	10-19 (%)	01/12/91	13.40				13.80	
TSH	0.16-3.2 (UU/ML)	01/12/91	0.48					
T4	5-13 (UG/DL)	01/12/91	7.80					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 5890085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/2 Patient: 456 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/04/92		07/05/92		29/05/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	14-18 (G/DL)	01/12/91	15.80		16.00		16.20	
HT	38-52 (%)	01/12/91	45.60		48.20		48.10	
RBC	4.5-6.3 (10¬6/MM3)	01/12/91	5.39		5.44		5.53	
WBC	4-9.4 (10¬3/MM3)	01/12/91	7.70		5.70		8.70	
WBC: N	50-70 (%)	01/12/91	53.10		52.80		52.30	
WBC: L	25-40 (%)	01/12/91	39.70		37.40		39.30	
WBC: E	0-4 (%)	01/12/91	1.00		1.50		1.30	
WBC: M	2-13 (%)	01/12/91	5.20		8.20		6.70	
WBC: B	0-1 (%)	01/12/91	1.10	>	0.10		0.40	
PLATELETS	150-440 (10¬3/MM3)	01/12/91	258.00		252.00		272.00	
NA+	134-150 (MMOL/L)	01/12/91	138.00		143.00		167.00	>>
K+	3.5-5.6 (MMOL/L)	01/12/91	3.60		4.30		4.69	
CL-	94-111 (MMOL/L)	01/12/91			111.00		121.00	>
Ca++	2.05-2.55 (MMOL/L)	01/12/91	2.20		2.20		2.43	
PO4--	2.5-4.8 (MG/DL)	01/12/91			3.49			
SGOT	5-18 (U/L)	01/12/91	10.00		9.00		12.00	
SGPT	5-24 (U/L)	01/12/91	24.00		16.00		17.00	
GAMMA GT	0-28 (U/L)	01/12/91	15.00		14.00		20.00	
LDH	120-240 (U/L)	01/12/91	173.00		152.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	01/12/91	95.00		101.00		157.00	
GLUCOSE	60-110 (MG/DL)	01/12/91	98.00		97.00		102.00	
BUN	10-50 (MG/DL)	01/12/91	27.00		31.00		34.00	
UREA	()	01/12/91						
CREATININE	0-1.4 (MG/DL)	01/12/91	1.00		0.95		1.44	>
URIC ACID	2.5-7 (MG/DL)	01/12/91	7.70	>	6.80		8.11	>
TOT BILIRUBIN	0-1 (MG/DL)	01/12/91			2.11	>>	1.37	>
DIR BILIRUBIN	0-0.25 (MG/DL)	01/12/91	0.39	>	0.56	>>	0.47	>
TOT. PROTEINS	6.2-8.5 (G/DL)	01/12/91	7.20		7.70		9.50	>
ALBUMINE	3500-5500 (MG/DL)	01/12/91	4580.00					
TOT. CHOLEST.	120-200 (MG/DL)	01/12/91	160.00		202.00	>	251.00	>
TRIGLYCERIDES	65-175 (MG/DL)	01/12/91	91.40		128.00		201.00	>
GLOBULINS ALPHA 1	1.5-4 (%)	01/12/91			2.90		2.60	
GLOBULINS ALPHA 2	5-12 (%)	01/12/91			7.20		6.20	
GLOBULINS BETA	7-13 (%)	01/12/91			12.40		11.70	
GLOBULINS GAMMA	10-19 (%)	01/12/91			15.00		15.90	
TSH	0.16-3.2 (UU/ML)	01/12/91	0.77					
T4	5-13 (UG/DL)	01/12/91	12.10					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 5990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/3 Patient: 418 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/06/91		08/07/91		29/07/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/05/91	14.20		13.90		13.20	
HT	36-48 (%)	01/05/91	41.30		41.30		40.00	
RBC	4.2-5.8 (10-6/MM3)	01/05/91	4.30		4.20		4.40	
WBC	4000-9000 (/MM3)	01/05/91	5800.00		9300.00	>	6000.00	
WBC: N	50-70 (%)	01/05/91	68.00		56.00		56.00	
WBC: L	25-40 (%)	01/05/91	23.00	<	38.00		40.00	
WBC: E	0-1 (%)	01/05/91	1.00		2.00	>>	2.00	>>
WBC: M	4-8 (%)	01/05/91	6.00		4.00		1.00	<
WBC: B	0-1 (%)	01/05/91	1.00		0.00		1.00	
PLATELETS	150-400 (10-3/MM3)	01/05/91	240.00		246.00		280.00	
NA+	134-148 (MMOL/L)	01/05/91	140.20		143.60		141.70	
K+	3.8-5.2 (MMOL/L)	01/05/91	4.20		4.00		4.30	
CL-	96-111 (MMOL/L)	01/05/91	99.50		99.80		107.10	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.30		2.30		2.40	
PO4--	0.8-1.6 (MMOL/L)	01/05/91	1.20		1.22		1.15	
SGOT	5-18 (U/L)	01/05/91	6.00		8.00		8.00	
SGPT	5-22 (U/L)	01/05/91	6.00		6.00		6.00	
GAMMA GT	4-28 (U/L)	01/05/91	9.00		8.00		11.00	
LDH	120-240 (U/L)	01/05/91	157.00		165.00		190.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	95.00		92.00		94.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	95.50		110.20	>	114.40	>
BUN	10-50 (MG/DL)	01/05/91	38.00		34.00		47.00	
UREA	()	01/05/91						
CREATININE	0.3-1.2 (MG/DL)	01/05/91	0.90		0.80		1.00	
URIC ACID	2.4-7 (MG/DL)	01/05/91	4.30		4.20		4.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.20		0.30		0.20	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.10		0.10		0.10	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	6.50	<	6.90		7.00	
ALBUMINE	57-68 (%)	01/05/91	65.70		56.20	<	57.30	
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	265.00	>>	219.00	>	337.00	>>
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	78.00		64.00		58.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	4.50		4.50		3.80	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	8.50		11.10	>	10.50	>
GLOBULINS BETA	9-13 (%)	01/05/91	10.70		11.60		11.70	
GLOBULINS GAMMA	10-20 (%)	01/05/91	10.60		16.60		16.70	
TSH	0.2-3.1 (UU/ML)	01/05/91	0.85					
T4	5-11.5 (UG/DL)	01/05/91	8.22					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/3 Patient: 420 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			04/07/91	
			value	(◊)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/05/91	15.00	
HT	36-48 (%)	01/05/91	43.60	
RBC	4.2-5.8 (10-6/MM3)	01/05/91	4.70	
WBC	4000-9000 (/MM3)	01/05/91	5000.00	
WBC: N	50-70 (%)	01/05/91	50.00	
WBC: L	25-40 (%)	01/05/91	46.00	>
WBC: E	0-1 (%)	01/05/91	2.00	>>
WBC: M	4-8 (%)	01/05/91	2.00	<
WBC: B	0-1 (%)	01/05/91	0.00	
PLATELETS	150-400 (10-3/MM3)	01/05/91	265.00	
NA+	134-148 (MMOL/L)	01/05/91	145.40	
K+	3.8-5.2 (MMOL/L)	01/05/91	3.70	<
CL-	96-111 (MMOL/L)	01/05/91	103.60	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.50	
PO4--	0.8-1.6 (MMOL/L)	01/05/91	1.09	
SGOT	5-18 (U/L)	01/05/91	8.00	
SGPT	5-22 (U/L)	01/05/91	7.00	
GAMMA GT	4-28 (U/L)	01/05/91	7.00	
LDH	120-240 (U/L)	01/05/91	152.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	96.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	112.00	>
BUN	10-50 (MG/DL)	01/05/91	18.00	
UREA	()	01/05/91		
CREATININE	0.3-1.2 (MG/DL)	01/05/91	0.80	
URIC ACID	2.4-7 (MG/DL)	01/05/91	3.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.50	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.10	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	8.00	
ALBUMINE	57-68 (%)	01/05/91	59.10	
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	183.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	76.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	2.70	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	5.60	
GLOBULINS BETA	9-13 (%)	01/05/91	8.60	<
GLOBULINS GAMMA	10-20 (%)	01/05/91	24.10	>
TSH	0.2-3.1 (UU/ML)	01/05/91	1.60	
T4	5-11.5 (UG/DL)	01/05/91	6.92	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/3 Patient: 427 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			18/09/91		09/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/05/91	14.20		14.10	
HT	36-48 (%)	01/05/91	40.90		41.10	
RBC	4.2-5.8 (10¬6/MM3)	01/05/91	4.70		4.70	
WBC	4000-9000 (/MM3)	01/05/91	5000.00		3900.00	<
WBC: N	50-70 (%)	01/05/91	59.00		56.00	
WBC: L	25-40 (%)	01/05/91	34.00		38.00	
WBC: E	0-1 (%)	01/05/91	2.00	>>	2.00	>>
WBC: M	4-8 (%)	01/05/91	5.00		4.00	
WBC: B	0-1 (%)	01/05/91	0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/91	261.00		240.00	
NA+	134-148 (MMOL/L)	01/05/91	144.20		145.50	
K+	3.8-5.2 (MMOL/L)	01/05/91	4.40		4.30	
CL-	96-111 (MMOL/L)	01/05/91	107.00		108.30	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.40		2.40	
PO4--	0.8-1.6 (MMOL/L)	01/05/91	1.56		1.57	
SGOT	5-18 (U/L)	01/05/91	9.00		15.00	
SGPT	5-22 (U/L)	01/05/91	9.00		23.00	>
GAMMA GT	4-28 (U/L)	01/05/91	11.00		16.00	
LDH	120-240 (U/L)	01/05/91	182.00		215.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	129.00		129.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	108.30		106.40	
BUN	10-50 (MG/DL)	01/05/91	40.00		43.00	
UREA	()	01/05/91				
CREATININE	0.3-1.2 (MG/DL)	01/05/91	1.10		1.00	
URIC ACID	2.4-7 (MG/DL)	01/05/91	5.10		4.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.20		0.40	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.20		0.00	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	7.40		7.20	
ALBUMINE	57-68 (%)	01/05/91	58.10		56.70	<
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	234.00	>	244.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	158.00		144.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	3.50		2.90	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	6.80		7.20	
GLOBULINS BETA	9-13 (%)	01/05/91	13.10	>	12.20	
GLOBULINS GAMMA	10-20 (%)	01/05/91	18.50		21.00	>
TSH	0.2-3.1 (UU/ML)	01/05/91	2.46			
T4	5-11.5 (UG/DL)	01/05/91	7.71			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/3 Patient: 428 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			25/10/91		14/11/91		05/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12-16 (G/DL)	01/05/91	13.60		13.80		13.80	
HT	36-48 (%)	01/05/91	40.60		39.00		38.10	
RBC	4.2-5.8 (10¬6/MM3)	01/05/91	4.50		4.60		4.50	
WBC	4000-9000 (/MM3)	01/05/91	7500.00		5000.00		6500.00	
WBC: N	50-70 (%)	01/05/91	50.00		67.00		66.00	
WBC: L	25-40 (%)	01/05/91	34.00		30.00		26.00	
WBC: E	0-1 (%)	01/05/91	4.00	>>	1.00		2.00	>>
WBC: M	4-8 (%)	01/05/91	12.00	>>	2.00	<	6.00	
WBC: B	0-1 (%)	01/05/91	0.00		0.00		0.00	
PLATELETS	150-400 (10¬3/MM3)	01/05/91	234.00		260.00		234.00	
NA+	134-148 (MMOL/L)	01/05/91	138.60		116.80	<<	138.60	
K+	3.8-5.2 (MMOL/L)	01/05/91	3.70	<	3.20	<<	3.70	<
CL-	96-111 (MMOL/L)	01/05/91					107.60	
Ca++	2-2.6 (MMOL/L)	01/05/91	2.30		2.00		2.20	
PO4--	0.8-1.6 (MMOL/L)	01/05/91					1.16	
SGOT	5-18 (U/L)	01/05/91	8.00		10.00		8.00	
SGPT	5-22 (U/L)	01/05/91	6.00		9.00		8.00	
GAMMA GT	4-28 (U/L)	01/05/91	10.00		8.00		11.00	
LDH	120-240 (U/L)	01/05/91	148.00		193.00		187.00	
ALK. PHOSPH.	60-170 (U/L)	01/05/91	79.00		108.00		100.00	
GLUCOSE	60-110 (MG/DL)	01/05/91	68.40		80.00		89.50	
BUN	10-50 (MG/DL)	01/05/91	30.00		34.00		19.00	
UREA	()	01/05/91						
CREATININE	0.3-1.2 (MG/DL)	01/05/91	0.70		0.70		0.80	
URIC ACID	2.4-7 (MG/DL)	01/05/91	3.60		4.10		3.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/05/91	0.10		0.20		0.40	
DIR BILIRUBIN	0-0.2 (MG/DL)	01/05/91	0.00		0.10		0.10	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/05/91	7.60		8.10		7.80	
ALBUMINE	57-68 (%)	01/05/91	52.40	<	64.40		58.40	
TOT. CHOLEST.	120-200 (MG/DL)	01/05/91	162.00		178.00		172.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/05/91	68.00		73.00		73.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/05/91	4.40		2.90		3.30	
GLOBULINS ALPHA 2	5-9 (%)	01/05/91	7.00		6.70		7.60	
GLOBULINS BETA	9-13 (%)	01/05/91	10.90		10.50		12.70	
GLOBULINS GAMMA	10-20 (%)	01/05/91	25.30	>	15.50		18.00	
TSH	0.2-3.1 (UU/ML)	01/05/91	1.74					
T4	5-11.5 (UG/DL)	01/05/91	6.25					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9950085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/4 Patient: 131 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/01/92		03/02/92		24/02/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	02/12/91	14.80		14.20		13.90	
HT	35.8-45.4 (%)	02/12/91	37.00		38.00		40.00	
RBC	3.9-5.6 (10-6/MM3)	02/12/91	4.80		4.60		4.50	
WBC	5-9 (10-3/MM3)	02/12/91	7.80		7.30		7.80	
WBC: N	50-70 (%)	02/12/91	66.00		64.00		59.00	
WBC: L	25-40 (%)	02/12/91	31.00		32.00		38.00	
WBC: E	2-4 (%)	02/12/91	2.00		2.00		2.00	
WBC: M	2-8 (%)	02/12/91	1.00	<	2.00		1.00	<
WBC: B	0-1 (%)	02/12/91	0.00		0.00		0.00	
PLATELETS	200-350 (10-3/MM3)	02/12/91	270.00		254.00		220.00	
NA+	137-147 (MMOL/L)	02/12/91	142.00		143.00		140.00	
K+	3.6-5.5 (MMOL/L)	02/12/91	3.90		4.70		4.20	
CL-	101-111 (MMOL/L)	02/12/91	104.00		102.00		112.00	>
Ca++	2.25-2.6 (MMOL/L)	02/12/91	2.30		2.43		2.48	
PO4--	0.8-1.6 (MMOL/L)	02/12/91	1.30		1.40		1.30	
SGOT	5-17 (U/L)	02/12/91	16.00		18.00	>	18.00	>
SGPT	5-23 (U/L)	02/12/91	20.00		22.00		22.00	
GAMMA GT	6-28 (U/L)	02/12/91	28.00		20.00		19.00	
LDH	80-240 (U/L)	02/12/91	195.00		220.00		210.00	
ALK. PHOSPH.	40-190 (U/L)	02/12/91	80.00		105.00		145.00	
GLUCOSE	70-115 (MG/DL)	02/12/91	104.00		98.00		101.00	
BUN	20-40 (MG/DL)	02/12/91	44.00	>	36.00		44.00	>
UREA	()	02/12/91						
CREATININE	0.6-1.1 (MG/DL)	02/12/91	0.80		1.10		0.90	
URIC ACID	2.4-5.7 (MG/DL)	02/12/91	5.20		5.40		5.20	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/12/91	0.80		0.60		0.80	
DIR BILIRUBIN	()	02/12/91						
TOT. PROTEINS	6.7-8.2 (G/DL)	02/12/91	7.70		7.40		7.70	
ALBUMINE	53-70 (%)	02/12/91	56.00		59.00		65.00	
TOT. CHOLEST.	140-240 (MG/DL)	02/12/91	213.00		244.00	>	224.00	
TRIGLYCERIDES	0-200 (MG/DL)	02/12/91	164.00		193.00		186.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	02/12/91	3.20		3.30		3.80	
GLOBULINS ALPHA 2	9-14 (%)	02/12/91	10.40		9.90		8.40	<
GLOBULINS BETA	8-12 (%)	02/12/91	9.30		10.40		11.10	
GLOBULINS GAMMA	10-18 (%)	02/12/91	13.40		13.20		13.30	
TSH	0.16-3.2 (MU/L)	02/12/91	1.84					
T4	48-120 (UG/L)	02/12/91	116.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/4 Patient: 132 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/01/92		03/02/92		24/02/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	02/12/91	13.60		13.40		13.20	
HT	35.8-45.4 (%)	02/12/91	37.00		38.00		37.00	
RBC	3.9-5.6 (10¬6/MM3)	02/12/91	4.80		4.70		4.50	
WBC	5-9 (10¬3/MM3)	02/12/91	8.40		7.90		8.20	
WBC: N	50-70 (%)	02/12/91	64.00		58.00		60.00	
WBC: L	25-40 (%)	02/12/91	34.00		38.00		35.00	
WBC: E	2-4 (%)	02/12/91	0.00	<	0.00	<	1.00	<
WBC: M	2-8 (%)	02/12/91	2.00		3.00		2.00	
WBC: B	0-1 (%)	02/12/91	0.00		0.00		2.00	>>
PLATELETS	200-350 (10¬3/MM3)	02/12/91	295.00		270.00		260.00	
NA+	137-147 (MMOL/L)	02/12/91	142.00		140.00		141.00	
K+	3.6-5.5 (MMOL/L)	02/12/91	3.70		3.90		3.60	
CL-	101-111 (MMOL/L)	02/12/91	109.00		104.00		109.00	
Ca++	2.25-2.6 (MMOL/L)	02/12/91	2.36		2.40		2.50	
PO4--	0.8-1.6 (MMOL/L)	02/12/91	1.10		1.10		1.30	
SGOT	5-17 (U/L)	02/12/91	18.00	>	17.00		18.00	>
SGPT	5-23 (U/L)	02/12/91	16.00		18.00		20.00	
GAMMA GT	6-28 (U/L)	02/12/91	24.00		27.00		24.00	
LDH	80-240 (U/L)	02/12/91	195.00		210.00		195.00	
ALK. PHOSPH.	40-190 (U/L)	02/12/91	165.00		180.00		160.00	
GLUCOSE	70-115 (MG/DL)	02/12/91	93.00		88.00		76.00	
BUN	20-40 (MG/DL)	02/12/91	36.00		44.00	>	36.00	
UREA	()	02/12/91						
CREATININE	0.6-1.1 (MG/DL)	02/12/91	0.92		0.80		1.10	
URIC ACID	2.4-5.7 (MG/DL)	02/12/91	4.60		4.70		4.60	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/12/91	0.90		0.80		0.90	
DIR BILIRUBIN	()	02/12/91						
TOT. PROTEINS	6.7-8.2 (G/DL)	02/12/91	7.30		7.40		7.30	
ALBUMINE	53-70 (%)	02/12/91	56.00		66.00		70.00	
TOT. CHOLEST.	140-240 (MG/DL)	02/12/91	193.00		214.00		195.00	
TRIGLYCERIDES	0-200 (MG/DL)	02/12/91	160.00		184.00		165.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	02/12/91	3.20		3.80		3.10	
GLOBULINS ALPHA 2	9-14 (%)	02/12/91	13.20		10.40		9.40	
GLOBULINS BETA	8-12 (%)	02/12/91	9.20		11.40		11.20	
GLOBULINS GAMMA	10-18 (%)	02/12/91	14.00		13.50		12.80	
TSH	0.16-3.2 (MU/L)	02/12/91	2.80					
T4	48-120 (UG/L)	02/12/91	116.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9350085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/4 Patient: 133 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			09/01/92		06/02/92		27/02/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	02/12/91	11.40		11.90		11.80	
HT	35.8-45.4 (%)	02/12/91	37.00		40.20		38.00	
RBC	3.9-5.6 (10-6/MM3)	02/12/91	4.10		4.80		4.60	
WBC	5-9 (10-3/MM3)	02/12/91	6.50		6.30		6.80	
WBC: N	50-70 (%)	02/12/91	51.00		54.00		56.00	
WBC: L	25-40 (%)	02/12/91	42.00	>	40.00		38.00	
WBC: E	2-4 (%)	02/12/91	4.00		3.00		3.00	
WBC: M	2-8 (%)	02/12/91	2.00		3.00		2.00	
WBC: B	0-1 (%)	02/12/91	0.00		0.00		1.00	
PLATELETS	200-350 (10-3/MM3)	02/12/91	190.00	<	240.00		210.00	
NA+	137-147 (MMOL/L)	02/12/91	140.00		141.00		140.00	
K+	3.6-5.5 (MMOL/L)	02/12/91	3.90		4.10		3.90	
CL-	101-111 (MMOL/L)	02/12/91	109.00		111.00		112.00	>
Ca++	2.25-2.6 (MMOL/L)	02/12/91	2.30		2.45		2.50	
PO4--	0.8-1.6 (MMOL/L)	02/12/91	0.80		0.90		1.30	
SGOT	5-17 (U/L)	02/12/91	17.00		19.00	>	16.00	
SGPT	5-23 (U/L)	02/12/91	20.00		23.00		20.00	
GAMMA GT	6-28 (U/L)	02/12/91	12.00		24.00		30.00	>
LDH	80-240 (U/L)	02/12/91	199.00		230.00		210.00	
ALK. PHOSPH.	40-190 (U/L)	02/12/91	93.00		120.00		145.00	
GLUCOSE	70-115 (MG/DL)	02/12/91	99.00		83.00		101.00	
BUN	20-40 (MG/DL)	02/12/91	36.00		44.00	>	41.00	>
UREA	()	02/12/91						
CREATININE	0.6-1.1 (MG/DL)	02/12/91	0.82		1.00		1.10	
URIC ACID	2.4-5.7 (MG/DL)	02/12/91	4.30		4.80		4.90	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/12/91	0.60		0.80		0.90	
DIR BILIRUBIN	()	02/12/91						
TOT. PROTEINS	6.7-8.2 (G/DL)	02/12/91	6.90		7.20		7.40	
ALBUMINE	53-70 (%)	02/12/91	61.00		64.00		58.00	
TOT. CHOLEST.	140-240 (MG/DL)	02/12/91	224.00		254.00	>	241.00	>
TRIGLYCERIDES	0-200 (MG/DL)	02/12/91	201.00	>	224.00	>	218.00	>
GLOBULINS ALPHA 1	2.5-4.5 (%)	02/12/91	3.80		3.20		3.80	
GLOBULINS ALPHA 2	9-14 (%)	02/12/91	9.80		10.20		11.40	
GLOBULINS BETA	8-12 (%)	02/12/91	11.40		14.60	>	11.80	
GLOBULINS GAMMA	10-18 (%)	02/12/91	16.20		15.20		14.80	
TSH	0.16-3.2 (MU/L)	02/12/91	2.80					
T4	48-120 (UG/L)	02/12/91	99.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 0550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 422 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/09/91		25/09/91		16/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	05/08/91	12.80		13.20		13.20	
HT	37-47 (%)	05/08/91	49.20	>	45.70		48.40	>
RBC	4.5-5 (10¬6/MM3)	05/08/91	4.20	<	4.30	<	4.50	
WBC	3500-9000 (/MM3)	05/08/91	5200.00		6300.00		6800.00	
WBC: N	37-73 (%)	05/08/91	62.00		44.00		52.00	
WBC: L	20-55 (%)	05/08/91	31.00		28.00		30.00	
WBC: E	0.5-11 (%)	05/08/91	2.00		3.00		2.00	
WBC: M	2.5-10 (%)	05/08/91	3.00		6.00		3.00	
WBC: B	0-2 (%)	05/08/91	0.00		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	05/08/91	295000		325000		325000	
NA+	134-148 (MMOL/L)	05/08/91	144.80		140.30		145.20	
K+	3.8-5.2 (MMOL/L)	05/08/91	3.80		4.50		4.20	
CL-	84-110 (MMOL/L)	05/08/91	96.00		96.80		98.00	
Ca++	2.2-2.6 (MMOL/L)	05/08/91	2.30		2.30		2.30	
PO4--	2.5-4.5 (MG/DL)	05/08/91	3.20		3.70		3.70	
SGOT	5-18 (U/L)	05/08/91	9.00		9.00		8.00	
SGPT	5-22 (U/L)	05/08/91	12.00		12.00		10.00	
GAMMA GT	4-28 (U/L)	05/08/91	23.00		26.00		21.00	
LDH	120-240 (U/L)	05/08/91	168.00		177.00		170.00	
ALK. PHOSPH.	60-170 (U/L)	05/08/91	146.00		145.00		148.00	
GLUCOSE	60-110 (MG/DL)	05/08/91	85.90		93.20		92.40	
BUN	10-50 (MG/DL)	05/08/91	25.40		24.50		23.40	
UREA	()	05/08/91						
CREATININE	0.3-1.2 (MG/DL)	05/08/91	1.00		1.10		0.90	
URIC ACID	2.4-7 (MG/DL)	05/08/91	6.10		6.90		5.70	
TOT BILIRUBIN	0-1 (MG/DL)	05/08/91	0.30		0.20		0.20	
DIR BILIRUBIN	()	05/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	05/08/91	7.70		7.60		6.40	<
ALBUMINE	3.7-5.5 (G/DL)	05/08/91	6.40	>	4.20		6.80	>
TOT. CHOLEST.	120-200 (MG/DL)	05/08/91	260.00	>	239.00	>	245.00	>
TRIGLYCERIDES	50-180 (MG/DL)	05/08/91	230.00	>	134.00		195.00	>
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	05/08/91	0.30		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	05/08/91	0.70		0.60		0.80	
GLOBULINS BETA	0.4-0.9 (G/DL)	05/08/91	0.80		0.70		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	05/08/91	1.20		1.00		1.20	
TSH	0.2-4 (UU/ML)	05/08/91	1.40					
T4	5-11.5 (UG/DL)	05/08/91	7.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 423 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			10/09/91		08/10/91		29/10/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	17.00	>	16.00		15.80	
HT	37-47 (%)	01/08/91	50.20	>	48.80	>	48.40	>
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.80		4.60		5.20	>
WBC	3500-9000 (/MM3)	01/08/91	7200.00		8400.00		7600.00	
WBC: N	37-73 (%)	01/08/91	68.00		62.00		60.00	
WBC: L	20-55 (%)	01/08/91	25.00		20.00		23.00	
WBC: E	0.5-11 (%)	01/08/91	3.00		2.00		1.00	
WBC: M	2.5-10 (%)	01/08/91	3.00		3.00		0.00	<
WBC: B	0-2 (%)	01/08/91	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	375000		320000		295000	
NA+	134-148 (MMOL/L)	01/08/91	139.30		142.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.30		4.50		4.10	
CL-	84-110 (MMOL/L)	01/08/91	87.00		97.00		96.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.30		4.40		4.50	
PO4--	23.3-49.8 (MG/L)	01/08/91	40.00		34.00		40.00	
SGOT	5-18 (U/L)	01/08/91	12.00		9.00		13.00	
SGPT	5-22 (U/L)	01/08/91	9.00		10.00		15.00	
GAMMA GT	4-28 (U/L)	01/08/91	4.00		4.00		8.00	
LDH	120-240 (U/L)	01/08/91	191.00		185.00		196.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	144.00		145.00		142.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	96.60		89.40		78.30	
BUN	10-50 (MG/DL)	01/08/91	28.00		22.80		20.80	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	0.80		0.70		0.80	
URIC ACID	2.4-7 (MG/DL)	01/08/91	5.40		5.30		5.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.50		0.60		0.80	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	7.20		6.80		6.40	<
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.80		4.30		4.40	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	215.00	>	228.00	>	232.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	61.00		72.00		105.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.10		0.10		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.50		0.40		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.70		0.80		0.90	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.00		1.20		1.00	
TSH	0.2-4 (UU/ML)	01/08/91	2.40					
T4	5-11.5 (UG/DL)	01/08/91	7.30					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 432 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/10/91		29/10/91		19/11/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/08/91	14.60		14.00		14.60	
HT	37-47 (%)	01/08/91	46.20		43.80		42.70	
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.40	<	4.60		4.70	
WBC	3500-9000 (/MM3)	01/08/91	8600.00		7400.00		5700.00	
WBC: N	37-73 (%)	01/08/91	68.00		66.00		64.00	
WBC: L	20-55 (%)	01/08/91	32.00		30.00		37.00	
WBC: E	0.5-11 (%)	01/08/91	7.40		7.20		1.40	
WBC: M	2.5-10 (%)	01/08/91	8.00		6.00		6.80	
WBC: B	0-2 (%)	01/08/91	1.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	425000	>	395000		345000	
NA+	134-148 (MMOL/L)	01/08/91	145.00		140.00		142.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.40		4.70		4.20	
CL-	84-110 (MMOL/L)	01/08/91	98.00		96.00		102.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.57		4.80		4.70	
PO4--	23.3-49.8 (MG/L)	01/08/91	42.00		40.00		32.40	
SGOT	5-18 (U/L)	01/08/91	9.00		12.30		14.20	
SGPT	5-22 (U/L)	01/08/91	17.00		19.40		20.40	
GAMMA GT	4-28 (U/L)	01/08/91	19.00		18.70		26.80	
LDH	120-240 (U/L)	01/08/91	190.00		210.00		194.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	63.50		98.40		102.80	
GLUCOSE	60-110 (MG/DL)	01/08/91	74.80		88.30		86.40	
BUN	10-50 (MG/DL)	01/08/91	33.00		31.20		29.40	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	1.19		1.10		1.00	
URIC ACID	2.4-7 (MG/DL)	01/08/91	6.13		6.70		6.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.26		0.40		0.60	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	6.80		6.40	<	7.20	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	5.10		4.90		5.40	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	240.00	>	253.00	>	249.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	116.00		102.00		98.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.20		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.60		0.70		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.60		0.30	<	0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.00		1.20		0.90	
TSH	0.2-4 (UU/ML)	01/08/91	3.10					
T4	5-11.5 (UG/DL)	01/08/91	7.20					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS S.p.A. 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 433 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/10/91		29/10/91		19/11/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/10/91	13.80		14.00		15.20	
HT	37-47 (%)	01/10/91	42.00		46.00		38.40	
RBC	4.5-5 (10→6/MM3)	01/10/91	4.70		4.40	<	4.80	
WBC	3500-9000 (/MM3)	01/10/91	8700.00		7900.00		8200.00	
WBC: N	37-73 (%)	01/10/91	68.00		62.00		58.00	
WBC: L	20-55 (%)	01/10/91	35.00		34.00		37.00	
WBC: E	0.5-11 (%)	01/10/91	7.50		7.30		6.40	
WBC: M	2.5-10 (%)	01/10/91	8.40		6.20		6.00	
WBC: B	0-2 (%)	01/10/91	1.00		0.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/10/91	370000		290000		320000	
NA+	134-148 (MMOL/L)	01/10/91	145.10		142.00		146.00	
K+	3.8-5.2 (MMOL/L)	01/10/91	4.96		4.80		5.00	
CL-	84-110 (MMOL/L)	01/10/91	96.00		97.00		99.00	
Ca++	4.2-5.5 (MEQ/L)	01/10/91	4.50		4.40		4.00	<
PO4--	23.3-49.8 (MG/L)	01/10/91	37.00				42.00	
	2.5-4.5 (MG/DL)	20/10/91			3.80			
SGOT	5-18 (U/L)	01/10/91	8.00		12.00		14.00	
SGPT	5-22 (U/L)	01/10/91	9.00		13.40		16.80	
GAMMA GT	4-28 (U/L)	01/10/91	8.00		12.80		22.40	
LDH	120-240 (U/L)	01/10/91	135.00		142.50		154.80	
ALK. PHOSPH.	60-170 (U/L)	01/10/91	98.00		168.30		145.20	
GLUCOSE	60-110 (MG/DL)	01/10/91	91.80		82.40		79.80	
BUN	10-50 (MG/DL)	01/10/91	28.00		26.00		23.00	
UREA	()	01/10/91						
CREATININE	0.3-1.2 (MG/DL)	01/10/91	0.63		0.80		0.90	
URIC ACID	2.4-7 (MG/DL)	01/10/91	3.65		4.30		5.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.46		0.70		0.10	
DIR BILIRUBIN	()	01/10/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/10/91	7.46		8.20		8.50	
ALBUMINE	3.7-5.5 (G/DL)	01/10/91	5.00		5.40		4.80	
TOT. CHOLEST.	120-200 (MG/DL)	01/10/91	252.00	>	248.00	>	253.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/10/91	90.00		82.00		102.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/10/91	0.10		0.10		0.30	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/10/91	0.60		0.70		0.80	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/10/91	0.70		0.80		0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/10/91	0.90		1.00		1.20	
TSH	0.2-4 (UU/ML)	01/10/91	1.40					
T4	5-11.5 (UG/DL)	01/10/91	6.90					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 440 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/11/91		02/12/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.20		14.60		13.80	
HT	37-47 (%)	01/08/91	41.30		40.20		41.60	
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.80		4.60		4.70	
WBC	3500-9000 (/MM3)	01/08/91	4800.00		8400.00		8200.00	
WBC: N	37-73 (%)	01/08/91	51.00		67.00		53.00	
WBC: L	20-55 (%)	01/08/91	37.00		45.00		42.00	
WBC: E	0.5-11 (%)	01/08/91	0.90		10.10		7.30	
WBC: M	2.5-10 (%)	01/08/91	7.40		8.40		8.20	
WBC: B	0-2 (%)	01/08/91	0.00		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	263000		282000		380000	
NA+	134-148 (MMOL/L)	01/08/91	141.60		145.80		142.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.70		4.80		4.10	
CL-	84-110 (MMOL/L)	01/08/91	99.00		104.00		95.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.30		4.40		4.90	
PO4--	23.3-49.8 (MG/L)	01/08/91	38.40		39.20		34.70	
SGOT	5-18 (U/L)	01/08/91	7.00		8.00		7.00	
SGPT	5-22 (U/L)	01/08/91	7.00		7.00		8.00	
GAMMA GT	4-28 (U/L)	01/08/91	8.00		12.00		11.00	
LDH	120-240 (U/L)	01/08/91	174.00		178.00		196.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	75.00		79.00		124.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	85.80		82.40		72.60	
BUN	10-50 (MG/DL)	01/08/91	24.00		23.00		24.00	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	1.00		0.70		0.80	
URIC ACID	2.4-7 (MG/DL)	01/08/91	5.40		4.80		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.20		0.20		0.80	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	8.20		8.40		7.20	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	5.50		4.80		4.30	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	223.00	>	202.00	>	179.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	134.00		102.00		82.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.20		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.50		0.50		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.70		0.60		0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.00		1.00		0.70	
TSH	0.2-4 (UU/ML)	01/08/91	2.40					
T4	5-11.5 (UG/DL)	01/08/91	7.80					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 441 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/11/91		02/12/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.20		14.60		13.80	
HT	37-47 (%)	01/08/91	42.00		45.00		42.00	
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.80		4.20	<	4.70	
WBC	3500-9000 (/MM3)	01/08/91	6300.00		7200.00		8000.00	
WBC: N	37-73 (%)	01/08/91	52.00		58.00		49.00	
WBC: L	20-55 (%)	01/08/91	35.00		45.00		42.00	
WBC: E	0.5-11 (%)	01/08/91	8.00		7.20		6.80	
WBC: M	2.5-10 (%)	01/08/91	2.80		5.80		4.30	
WBC: B	0-2 (%)	01/08/91	1.00		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	268000		270000		320000	
NA+	134-148 (MMOL/L)	01/08/91	143.10		142.80		147.20	
K+	3,8-5.2 (MMOL/L)	01/08/91	4.70		4.60		4.80	
CL-	84-110 (MMOL/L)	01/08/91	99.00		104.00		105.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.50		4.80		4.90	
PO4--	23.3-49.8 (MG/L)	01/08/91	26.80		46.20		43.40	
SGOT	5-18 (U/L)	01/08/91	10.00		12.00		13.40	
SGPT	5-22 (U/L)	01/08/91	8.00		16.00		18.00	
GAMMA GT	4-28 (U/L)	01/08/91	12.00		24.00		22.20	
LDH	120-240 (U/L)	01/08/91	127.00		138.00		134.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	112.00		167.00		142.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	108.30		98.40		89.00	
BUN	10-50 (MG/DL)	01/08/91	41.00		41.80		30.20	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	1.20		0.90		0.70	
URIC ACID	2.4-7 (MG/DL)	01/08/91	5.00		6.20		6.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.50		0.10		0.10	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	7.50		7.80		7.40	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.20		5.00		5.40	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	196.00		202.00	>	210.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	101.00		97.00		92.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.20		0.10		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.60		0.70		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.50		0.80		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	0.90		1.30		1.00	
TSH	0.2-4 (UU/ML)	01/08/91	3.80					
T4	5-11.5 (UG/DL)	01/08/91	8.40					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 442 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			08/11/91		02/12/91		23/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.20		15.30		15.80	
HT	37-47 (%)	01/08/91	45.00		43.00		46.00	
RBC	4.5-5 (10-6/MM3)	01/08/91	4.70		4.30	<	4.70	
WBC	3500-9000 (/MM3)	01/08/91	4700.00		8500.00		8700.00	
WBC: N	37-73 (%)	01/08/91	43.00		68.00		60.00	
WBC: L	20-55 (%)	01/08/91	35.00		50.00		40.00	
WBC: E	0.5-11 (%)	01/08/91	1.40		8.20		7.40	
WBC: M	2.5-10 (%)	01/08/91	8.40		5.40		8.40	
WBC: B	0-2 (%)	01/08/91	0.00		2.00		1.00	
PLATELETS	150000-400000 (/MM3)	01/08/91	320000		210000		295000	
NA+	134-148 (MMOL/L)	01/08/91	148.00		141.00		144.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.20		4.20		4.80	
CL-	84-110 (MMOL/L)	01/08/91	104.00		106.00		95.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.40		4.90		4.90	
P04--	23.3-49.8 (MG/L)	01/08/91	32.40		34.30		32.80	
SGOT	5-18 (U/L)	01/08/91	16.00		18.00		26.00	>
SGPT	5-22 (U/L)	01/08/91	18.00		17.00		24.00	>
GAMMA GT	4-28 (U/L)	01/08/91	20.00		24.00		56.00	>>
LDH	120-240 (U/L)	01/08/91	175.00		192.00		175.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	125.00		162.00		148.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	84.70		92.40		72.00	
BUN	10-50 (MG/DL)	01/08/91	22.80		20.40		30.20	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	0.70		0.80		1.00	
URIC ACID	2.4-7 (MG/DL)	01/08/91	5.40		5.20		4.50	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.40		0.50		1.00	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	7.50		8.00		6.80	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.30		4.80		4.20	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	196.00		202.00	>	212.00	>
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	102.00		100.00		98.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.10		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.40		0.60		0.70	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.70		0.60		0.60	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.00		0.90		1.20	
TSH	0.2-4 (UU/ML)	01/08/91	2.80					
T4	5-11.5 (UG/DL)	01/08/91	7.80					

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max range)
> out of range (value higher than max range)
() missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/7 Patient: 450 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			06/12/91		13/01/92		03/02/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	12.8-16 (G/DL)	01/08/91	14.00		13.80		15.20	
HT	37-47 (%)	01/08/91	45.00		42.00		46.80	
RBC	4.5-5 (10¬6/MM3)	01/08/91	4.70		4.80		4.70	
WBC	3500-9000 (/MM3)	01/08/91	8400.00		7600.00		8200.00	
WBC: N	37-73 (%)	01/08/91	45.00		63.00		65.00	
WBC: L	20-55 (%)	01/08/91	35.00		48.00		32.00	
WBC: E	0.5-11 (%)	01/08/91	10.10		7.20		6.40	
WBC: M	2.5-10 (%)	01/08/91	8.40		6.80		7.30	
WBC: B	0-2 (%)	01/08/91	0.80		1.00		0.80	
PLATELETS	150000-400000 (/MM3)	01/08/91	325000		358000		324000	
NA+	134-148 (MMOL/L)	01/08/91	142.00		141.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/08/91	4.40		4.60		4.40	
CL-	84-110 (MMOL/L)	01/08/91	100.00		99.00		104.00	
Ca++	4.2-5.5 (MEQ/L)	01/08/91	4.70		4.80		5.00	
PO4--	23.3-49.8 (MG/L)	01/08/91	36.80		42.40		46.80	
SGOT	5-18 (U/L)	01/08/91	10.00		9.00		12.00	
SGPT	5-22 (U/L)	01/08/91	11.00		11.00		14.00	
GAMMA GT	4-28 (U/L)	01/08/91	8.00		12.00		11.00	
LDH	120-240 (U/L)	01/08/91	194.00		186.00		145.00	
ALK. PHOSPH.	60-170 (U/L)	01/08/91	121.00		142.00		164.00	
GLUCOSE	60-110 (MG/DL)	01/08/91	54.00	<	87.40		102.00	
BUN	10-50 (MG/DL)	01/08/91	21.00		22.40		21.00	
UREA	()	01/08/91						
CREATININE	0.3-1.2 (MG/DL)	01/08/91	1.40	>	1.20		1.10	
URIC ACID	2.4-7 (MG/DL)	01/08/91	7.40	>	6.80		6.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/08/91	0.30		0.70		0.80	
DIR BILIRUBIN	()	01/08/91						
TOT. PROTEINS	6.6-8.7 (G/DL)	01/08/91	7.00		7.40		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/08/91	4.80		5.20		4.80	
TOT. CHOLEST.	120-200 (MG/DL)	01/08/91	197.00		184.00		186.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/08/91	110.00		102.00		84.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/08/91	0.10		0.20		0.30	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/08/91	0.30	<	0.40		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/08/91	0.90		0.70		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/08/91	1.20		1.00		1.10	
TSH	0.2-4 (UU/ML)	01/08/91	3.80					
T4	5-11.5 (UG/DL)	01/08/91	6.70					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 54 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/02/92		17/03/92		07/04/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	14.60		14.80		15.00	
HT	36-47 (%)	01/10/91	41.50		42.20		43.50	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.28		4.26		4.68	
WBC	5000-9000 (/MM3)	01/10/91	5200.00		3700.00	<	6100.00	
WBC: N	50-70 (%)	01/10/91	51.00		53.00		61.00	
WBC: L	25-40 (%)	01/10/91	43.00	>	41.00	>	31.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	4.00		5.00		7.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	256.00		107.00	<	305.00	>
NA+	137-147 (MMOL/L)	01/10/91	141.00		141.00		142.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.50		4.40		4.60	
CL-	85-120 (MMOL/L)	01/10/91	106.00		109.00		106.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.64	>	2.43		2.50	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.13		1.01		1.23	
SGOT	4-20 (U/L)	01/10/91	8.10		12.60		5.70	
SGPT	4-20 (U/L)	01/10/91	5.60		9.10		5.90	
GAMMA GT	4-18 (U/L)	01/10/91	9.70		9.60		9.10	
LDH	55-150 (U/L)	01/10/91	105.00		97.00		116.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	60.00		96.00		130.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	96.00		94.00		100.00	
BUN	20-40 (MG/DL)	01/10/91	38.00		24.00		40.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	1.03		0.93		0.84	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	5.08		4.19		3.62	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.33		0.61		0.30	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.07		0.17		0.06	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.54		6.83		7.70	
ALBUMINE	56-66 (%)	01/10/91	41.40	<	62.80		55.50	<
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	220.00		195.00		239.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	327.00	>>	303.00	>>	344.00	>>
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.60		3.70		2.10	<
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	10.80	>	8.30		9.80	
GLOBULINS BETA	8.5-14 (%)	01/10/91	20.70	>>	13.30		14.90	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	25.30	>>	11.90		17.70	
TSH	0.16-3.2 (MU/L)	01/10/91	3.35					
T4	48-120 (UG/L)	01/10/91	79.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9990085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 56 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			24/02/92		23/03/92		13/04/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	15.90		16.20	>	14.20	
HT	36-47 (%)	01/10/91	43.30		44.00		41.60	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.74		4.35		4.59	
WBC	5000-9000 (/MM3)	01/10/91	5900.00		7200.00		6100.00	
WBC: N	50-70 (%)	01/10/91	67.00		71.00	>	48.00	<
WBC: L	25-40 (%)	01/10/91	26.00		24.00	<	40.00	
WBC: E	2-4 (%)	01/10/91	0.00	<	1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	7.00		3.00		11.00	>>
WBC: B	0-1 (%)	01/10/91	0.00		1.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	302.00	>	195.00		322.00	>
NA+	137-147 (MMOL/L)	01/10/91	139.00		137.00		141.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		3.90		4.00	
CL-	85-120 (MMOL/L)	01/10/91	104.00		95.00		101.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.44		2.39		2.45	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.16		0.77	<	1.31	
SGOT	4-20 (U/L)	01/10/91	6.80		10.20		8.70	
SGPT	4-20 (U/L)	01/10/91	6.80		12.30		9.30	
GAMMA GT	4-18 (U/L)	01/10/91	15.60		4.20		12.00	
LDH	55-150 (U/L)	01/10/91	118.00		132.00		178.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	112.00		78.00		96.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	101.00		104.00		116.00	
BUN	20-40 (MG/DL)	01/10/91	39.00		26.00		36.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.94		0.81		0.90	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	6.61	>	5.25		4.97	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.29		0.38		0.44	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.05		0.13	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.32		7.60		7.93	>
ALBUMINE	56-66 (%)	01/10/91	64.30		64.40		54.50	<
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	217.00		264.00	>	290.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	409.00	>>	347.00	>>	359.00	>>
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.50		2.60		4.60	>
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	9.00		5.60	<	13.60	>>
GLOBULINS BETA	8.5-14 (%)	01/10/91	14.00		12.90		17.00	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	9.20	<	14.50		10.30	<
TSH	0.16-3.2 (MU/L)	01/10/91	0.85					
T4	48-120 (UG/L)	01/10/91	103.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 5590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 58 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			02/04/92		04/05/92		25/05/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	15.80		15.40		15.70	
HT	36-47 (%)	01/10/91	46.30		44.90		45.60	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.13		4.54		5.04	
WBC	5000-9000 (/MM3)	01/10/91	8000.00		4900.00	<	5850.00	
WBC: N	50-70 (%)	01/10/91	62.00		45.00	<	54.00	
WBC: L	25-40 (%)	01/10/91	29.00		48.00	>	40.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	7.00		6.00		6.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		0.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	158.00		211.00		223.00	
NA+	137-147 (MMOL/L)	01/10/91	139.00		142.00		139.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		4.20		4.30	
CL-	85-120 (MMOL/L)	01/10/91	101.00		100.00		105.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.39		2.39		2.43	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.06		0.97		0.84	
SGOT	4-20 (U/L)	01/10/91	7.50		8.30		14.30	
SGPT	4-20 (U/L)	01/10/91	9.20		9.70		32.00	>
GAMMA GT	4-18 (U/L)	01/10/91	21.20	>	9.80		26.20	>
LDH	55-150 (U/L)	01/10/91	102.00		153.00	>	150.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	93.00		80.00		102.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	98.00		120.00		108.00	
BUN	20-40 (MG/DL)	01/10/91	19.00	<	24.00		50.00	>
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.81		0.93		1.12	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.25		4.90		4.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.22		0.37		0.89	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.11		0.07	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.53		7.44		7.33	
ALBUMINE	56-66 (%)	01/10/91	59.50		61.60		65.30	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	207.00		267.00	>	264.00	>
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	221.00	>	192.00		320.00	>>
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.70		2.70		2.40	<
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	8.30		7.10		8.40	
GLOBULINS BETA	8.5-14 (%)	01/10/91	18.80	>>	14.80	>	11.10	
GLOBULINS GAMMA	11-19 (%)	01/10/91	10.70	<	13.80		9.90	<
TSH	0.16-3.2 (MU/L)	01/10/91	0.56					
T4	48-120 (UG/L)	01/10/91	52.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN5590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 59 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			16/04/92		14/05/92		05/06/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	15.20		15.00		15.20	
HT	36-47 (%)	01/10/91	44.80		43.90		44.60	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.48		5.08		4.88	
WBC	5000-9000 (/MM3)	01/10/91	12400.0	>>	5700.00		8200.00	
WBC: N	50-70 (%)	01/10/91	73.00	>	61.00		46.00	<
WBC: L	25-40 (%)	01/10/91	18.00	<	34.00		40.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	0.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	8.00		5.00		9.00	>
WBC: B	0-1 (%)	01/10/91	0.00		0.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	185.00		327.00	>	299.00	
NA+	137-147 (MMOL/L)	01/10/91	141.00		141.00		143.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		4.40		4.60	
CL-	85-120 (MMOL/L)	01/10/91	110.00		103.00		99.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.20	<	2.37		2.46	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.24		1.02		1.57	
SGOT	4-20 (U/L)	01/10/91	5.70		7.30		7.30	
SGPT	4-20 (U/L)	01/10/91	7.80		7.60		15.30	
GAMMA GT	4-18 (U/L)	01/10/91	9.10		10.40		8.10	
LDH	55-150 (U/L)	01/10/91	136.00		106.00		151.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	56.00		101.00		82.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	110.00		90.00		101.00	
BUN	20-40 (MG/DL)	01/10/91	36.00		38.00		26.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.97		1.15		0.84	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.26		5.93	>	3.59	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.88		1.11	>	0.40	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.20		0.05		0.21	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.19		7.31		7.05	
ALBUMINE	56-66 (%)	01/10/91	65.50		60.50		64.00	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	142.00		181.00		219.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	92.00		81.00		60.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.20		2.50		2.80	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	7.60		7.40		8.70	
GLOBULINS BETA	8.5-14 (%)	01/10/91	9.80		13.50		12.90	
GLOBULINS GAMMA	11-19 (%)	01/10/91	13.80		16.00		11.60	
TSH	0.16-3.2 (MU/L)	01/10/91	0.26					
T4	48-120 (UG/L)	01/10/91	74.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9350085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 138 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			21/01/92		18/02/92		10/03/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	13.80		13.80		13.90	
HT	36-47 (%)	01/10/91	39.80		39.10		38.90	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.39		4.29		5.00	
WBC	5000-9000 (/MM3)	01/10/91	4700.00	<	5400.00		7000.00	
WBC: N	50-70 (%)	01/10/91	54.00		63.00		59.00	
WBC: L	25-40 (%)	01/10/91	37.00		30.00		32.00	
WBC: E	2-4 (%)	01/10/91	0.00	<	0.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	8.00		7.00		7.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	263.00		200.00		180.00	
NA+	137-147 (MMOL/L)	01/10/91	141.00		142.00		142.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.90		4.80		4.10	
CL-	85-120 (MMOL/L)	01/10/91	95.00		104.00		96.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.49		2.53		2.31	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.18		1.34		0.74	<
SGOT	4-20 (U/L)	01/10/91	7.40		10.50		11.20	
SGPT	4-20 (U/L)	01/10/91	15.80		26.50	>	20.60	>
GAMMA GT	4-18 (U/L)	01/10/91	34.60	>	53.40	>>	14.30	
LDH	55-150 (U/L)	01/10/91	135.00		172.00	>	185.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	98.00		134.00		87.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	107.00		101.00		106.00	
BUN	20-40 (MG/DL)	01/10/91	42.00	>	27.00		42.00	>
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.25	<	0.80		1.10	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	5.30		5.90	>	5.84	>
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.70		0.78		0.72	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.08		0.05		0.10	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.40		7.44		7.26	
ALBUMINE	56-66 (%)	01/10/91	61.50		61.60		63.50	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	231.00		204.00		197.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	118.00		177.00		154.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.90		2.90		3.00	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	8.70		9.50		8.50	
GLOBULINS BETA	8.5-14 (%)	01/10/91	13.70		12.00		13.70	
GLOBULINS GAMMA	11-19 (%)	01/10/91	13.20		13.00		11.20	
TSH	0.16-3.2 (MU/L)	01/10/91	1.42					
T4	48-120 (UG/L)	01/10/91	66.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN5580 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 140 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			28/01/92		25/02/92		17/03/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	15.00		15.50		15.60	
HT	36-47 (%)	01/10/91	42.20		44.30		42.70	
RBC	3.9-5.6 (10¬6/MM3)	01/10/91	4.81		4.35		4.37	
WBC	5000-9000 (/MM3)	01/10/91	6600.00		8700.00		6000.00	
WBC: N	50-70 (%)	01/10/91	66.00		52.00		51.00	
WBC: L	25-40 (%)	01/10/91	29.00		41.00	>	42.00	>
WBC: E	2-4 (%)	01/10/91	2.00		1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	2.00		5.00		6.00	
WBC: B	0-1 (%)	01/10/91	1.00		1.00		1.00	
PLATELETS	150-300 (10¬3/MM3)	01/10/91	258.00		252.00		201.00	
NA+	137-147 (MMOL/L)	01/10/91	140.00		142.00		142.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.30		3.50	<	3.60	
CL-	85-120 (MMOL/L)	01/10/91	101.00		96.00		96.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.66	>	2.49		2.43	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.31		1.06		1.11	
SGOT	4-20 (U/L)	01/10/91	5.30		9.00		6.60	
SGPT	4-20 (U/L)	01/10/91	6.10		7.20		5.90	
GAMMA GT	4-18 (U/L)	01/10/91	6.00		6.50		5.50	
LDH	55-150 (U/L)	01/10/91	215.00	>	248.00	>	216.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	68.00		101.00		100.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	93.00		101.00		93.00	
BUN	20-40 (MG/DL)	01/10/91	26.00		17.00	<	30.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.84		0.86		0.92	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.25		5.01		6.09	>
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.24		0.62		0.57	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.05		0.05		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	6.80		7.07		7.32	
ALBUMINE	56-66 (%)	01/10/91	55.30	<	60.10		58.20	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	243.00		247.00		235.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	119.00		124.00		60.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.90		5.60	>	4.10	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	11.70	>	10.10	>	9.60	
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.00	>	13.30		13.90	
GLOBULINS GAMMA	11-19 (%)	01/10/91	13.10		10.90	<	14.10	
TSH	0.16-3.2 (MU/L)	01/10/91	1.10					
T4	48-120 (UG/L)	01/10/91	109.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS BRD 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 435 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			04/11/91		02/12/91		23/12/91	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/10/91	14.50		14.60		14.10	
HT	36-47 (%)	01/10/91	42.50		40.70		39.30	
RBC	3.9-5.6 (10~6/MM3)	01/10/91	4.53		4.81		5.10	
WBC	5000-9000 (/MM3)	01/10/91	6100.00		4900.00	<	6800.00	
WBC: N	50-70 (%)	01/10/91	40.00	<	45.00	<	54.00	
WBC: L	25-40 (%)	01/10/91	46.00	>	40.00		37.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	1.00	<	3.00	
WBC: M	2-8 (%)	01/10/91	11.00	>>	12.00	>>	5.00	
WBC: B	0-1 (%)	01/10/91	1.00		1.00		1.00	
PLATELETS	150-300 (10~3/MM3)	01/10/91	254.00		300.00		246.00	
NA+	137-147 (MMOL/L)	01/10/91	140.00		139.00		148.00	>
K+	3.6-5.5 (MMOL/L)	01/10/91	4.00		3.30	<	4.40	
CL-	85-120 (MMOL/L)	01/10/91	99.00		99.00		103.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.55		2.43		2.39	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.00		1.11		1.06	
SGOT	4-20 (U/L)	01/10/91	11.00		11.50		9.60	
SGPT	4-20 (U/L)	01/10/91	11.00		11.10		15.20	
GAMMA GT	4-18 (U/L)	01/10/91	11.00		8.90		13.10	
LDH	55-150 (U/L)	01/10/91	181.00	>	206.00	>	162.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	153.00		176.00		99.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	125.00	>	99.00		121.00	>
BUN	20-40 (MG/DL)	01/10/91	37.00		20.00		25.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.98		0.80		0.87	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	6.76	>	4.43		5.32	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.53		0.27		0.54	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.03		0.05		0.13	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.89		8.22	>	7.42	
ALBUMINE	56-66 (%)	01/10/91	52.10	<	57.70		54.80	<
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	269.00	>	279.00	>	233.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	163.00		70.00		130.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	4.00		3.30		3.70	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	11.90	>	7.20		12.40	>
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.70	>	17.20	>	14.50	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	15.20		14.60		14.60	
TSH	0.16-3.2 (MU/L)	01/10/91	0.18					
T4	48-120 (UG/L)	01/10/91	72.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 0[illegible]085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 438 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/11/91		05/12/91		27/12/91	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)	value	(◊)
HB	11-16 (G/DL)	01/10/91	12.80		13.30		13.70	
HT	36-47 (%)	01/10/91	35.90	<	37.30		39.00	
RBC	3.9-5.6 (10~6/MM3)	01/10/91	3.68	<	4.03		5.12	
WBC	5000-9000 (/MM3)	01/10/91	7600.00		5900.00		15100.0	>>
WBC: N	50-70 (%)	01/10/91	65.00		62.00		61.00	
WBC: L	25-40 (%)	01/10/91	26.00		32.00		33.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	1.00	<	0.00	<
WBC: M	2-8 (%)	01/10/91	6.00		5.00		6.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		0.00	
PLATELETS	150-300 (10~3/MM3)	01/10/91	290.00		249.00		285.00	
NA+	137-147 (MMOL/L)	01/10/91	144.00		142.00		143.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.70		4.30		4.20	
CL-	85-120 (MMOL/L)	01/10/91	108.00		99.00		97.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.36		2.47		2.29	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.18		1.10		1.37	
SGOT	4-20 (U/L)	01/10/91	6.10		8.00		12.70	
SGPT	4-20 (U/L)	01/10/91	10.10		10.20		7.40	
GAMMA GT	4-18 (U/L)	01/10/91	12.40		7.60		4.10	
LDH	55-150 (U/L)	01/10/91	178.00	>	173.00	>	177.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	79.00		99.00		103.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	111.00		98.00		85.00	
BUN	20-40 (MG/DL)	01/10/91	39.00		35.00		32.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.76		1.04		0.89	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.64		5.89	>	5.29	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.28		0.25		0.05	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.10		0.05		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.01		7.48		7.72	
ALBUMINE	56-66 (%)	01/10/91	63.60		58.30		60.00	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	187.00		218.00		130.00	<
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	81.00		116.00		98.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.30		2.80		2.80	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	12.70	>	8.70		9.60	
GLOBULINS BETA	8.5-14 (%)	01/10/91	11.50		12.80		14.10	>
GLOBULINS GAMMA	11-19 (%)	01/10/91	8.90	<	17.40		13.50	
TSH	0.16-3.2 (MU/L)	01/10/91	0.93					
T4	48-120 (UG/L)	01/10/91	113.00					

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 445 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 42	
			15/11/91		30/12/91	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	15.60		14.70	
HT	36-47 (%)	01/10/91	43.50		40.60	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.33		4.44	
WBC	5000-9000 (/MM3)	01/10/91	7100.00		5900.00	
WBC: N	50-70 (%)	01/10/91	66.00		62.00	
WBC: L	25-40 (%)	01/10/91	29.00		33.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	3.00		3.00	
WBC: B	0-1 (%)	01/10/91	1.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	249.00		249.00	
NA+	137-147 (MMOL/L)	01/10/91	137.00		146.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	3.90		4.80	
CL-	85-120 (MMOL/L)	01/10/91	95.00		105.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.39		2.44	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	0.77	<	1.26	
SGOT	4-20 (U/L)	01/10/91	10.20		7.10	
SGPT	4-20 (U/L)	01/10/91	12.30		14.60	
GAMMA GT	4-18 (U/L)	01/10/91	4.20		37.80	>>
LDH	55-150 (U/L)	01/10/91	132.00		98.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	78.00		122.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	100.00		85.00	
BUN	20-40 (MG/DL)	01/10/91	26.00		30.00	
UREA	()	01/10/91				
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.81		0.83	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	5.25		3.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.38		0.54	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.15		0.08	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.78		8.01	>
ALBUMINE	56-66 (%)	01/10/91	60.70		61.80	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	264.00	>	221.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	347.00	>>	172.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.50		3.10	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	10.30	>	7.60	
GLOBULINS BETA	8.5-14 (%)	01/10/91	11.00		13.60	
GLOBULINS GAMMA	11-19 (%)	01/10/91	15.50		13.90	
TSH	0.16-3.2 (MU/L)	01/10/91	0.60			
T4	48-120 (UG/L)	01/10/91	132.00			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 448 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			22/11/91		17/12/91		08/01/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	15.50		14.60		14.10	
HT	36-47 (%)	01/10/91	42.90		40.50		39.00	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.27		4.64		3.94	
WBC	5000-9000 (/MM3)	01/10/91	7100.00		6200.00		4700.00	<
WBC: N	50-70 (%)	01/10/91	63.00		72.00	>	67.00	
WBC: L	25-40 (%)	01/10/91	30.00		23.00	<	28.00	
WBC: E	2-4 (%)	01/10/91	1.00	<	1.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	5.00		4.00		3.00	
WBC: B	0-1 (%)	01/10/91	1.00		0.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	230.00		330.00	>	252.00	
NA+	137-147 (MMOL/L)	01/10/91	145.00		147.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		4.60		4.10	
CL-	85-120 (MMOL/L)	01/10/91	98.00		102.00		106.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.44		2.53		2.24	<
PO4--	0.8-1.6 (MMOL/L)	01/10/91	0.74	<	1.00		0.77	<
SGOT	4-20 (U/L)	01/10/91	9.10		5.90		7.60	
SGPT	4-20 (U/L)	01/10/91	12.60		6.50		6.60	
GAMMA GT	4-18 (U/L)	01/10/91	50.80	>>	9.30		17.80	
LDH	55-150 (U/L)	01/10/91	165.00	>	135.00		171.00	>
ALK. PHOSPH.	50-190 (U/L)	01/10/91	78.00		67.00		77.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	111.00		111.00		138.00	>
BUN	20-40 (MG/DL)	01/10/91	34.00		43.00	>	45.00	>
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.89		0.94		1.06	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	6.46	>	6.02	>	7.24	>
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.27		0.64		0.47	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.15		0.05		0.05	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.16		7.86		7.94	>
ALBUMINE	56-66 (%)	01/10/91	63.00		56.50		58.40	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	308.00	>	260.00	>	202.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	342.00	>>	216.00	>	233.00	>
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	2.90		5.00	>	3.60	
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	6.70		11.20	>	14.50	>>
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.50	>	13.30		12.00	
GLOBULINS GAMMA	11-19 (%)	01/10/91	10.90	<	13.90		11.40	
TSH	0.16-3.2 (MU/L)	01/10/91	1.12					
T4	48-120 (UG/L)	01/10/91	70.00					

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 3550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 14/10 Patient: 453 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			18/05/92		17/06/92		08/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11-16 (G/DL)	01/10/91	13.60		13.50		13.50	
HT	36-47 (%)	01/10/91	40.30		39.90		40.50	
RBC	3.9-5.6 (10-6/MM3)	01/10/91	4.23		4.79		4.25	
WBC	5000-9000 (/MM3)	01/10/91	5000.00		8500.00		6100.00	
WBC: N	50-70 (%)	01/10/91	60.00		61.00		70.00	
WBC: L	25-40 (%)	01/10/91	31.00		32.00		20.00	<
WBC: E	2-4 (%)	01/10/91	3.00		0.00	<	1.00	<
WBC: M	2-8 (%)	01/10/91	6.00		6.00		8.00	
WBC: B	0-1 (%)	01/10/91	0.00		1.00		1.00	
PLATELETS	150-300 (10-3/MM3)	01/10/91	298.00		254.00		234.00	
NA+	137-147 (MMOL/L)	01/10/91	140.00		139.00		143.00	
K+	3.6-5.5 (MMOL/L)	01/10/91	4.40		4.10		4.00	
CL-	85-120 (MMOL/L)	01/10/91	104.00		104.00		105.00	
Ca++	2.25-2.6 (MMOL/L)	01/10/91	2.35		2.26		2.30	
PO4--	0.8-1.6 (MMOL/L)	01/10/91	1.21		0.97		1.11	
SGOT	4-20 (U/L)	01/10/91	6.80		8.10		9.00	
SGPT	4-20 (U/L)	01/10/91	7.00		10.20		9.20	
GAMMA GT	4-18 (U/L)	01/10/91	7.80		17.00		8.30	
LDH	55-150 (U/L)	01/10/91	102.00		145.00		62.00	
ALK. PHOSPH.	50-190 (U/L)	01/10/91	98.00		85.00		105.00	
GLUCOSE	70-120 (MG/DL)	01/10/91	81.00		101.00		102.00	
BUN	20-40 (MG/DL)	01/10/91	22.00		23.00		34.00	
UREA	()	01/10/91						
CREATININE	0.7-1.3 (MG/DL)	01/10/91	0.98		0.94		0.76	
URIC ACID	2.4-5.7 (MG/DL)	01/10/91	4.01		4.61		5.66	
TOT BILIRUBIN	0-1 (MG/DL)	01/10/91	0.38		0.52		0.48	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/10/91	0.07		0.20		0.07	
TOT. PROTEINS	6.6-7.9 (G/DL)	01/10/91	7.17		6.91		6.90	
ALBUMINE	56-66 (%)	01/10/91	56.70		64.00		61.30	
TOT. CHOLEST.	140-250 (MG/DL)	01/10/91	184.00		189.00		218.00	
TRIGLYCERIDES	20-200 (MG/DL)	01/10/91	131.00		131.00		196.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/10/91	3.10		3.40		5.70	>
GLOBULINS ALPHA 2	6.5-10 (%)	01/10/91	11.10	>	9.70		7.40	
GLOBULINS BETA	8.5-14 (%)	01/10/91	16.30	>	11.00		12.80	
GLOBULINS GAMMA	11-19 (%)	01/10/91	12.70		11.10		12.80	
TSH	0.16-3.2 (MU/L)	01/10/91	0.32		0.67		0.30	
T4	48-120 (UG/L)	01/10/91	98.00		112.00		85.00	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 349 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			20/08/92		10/09/92		01/10/92	
			value	(◊)	value	(◊)	value	(◊)
Laboratory test	Range value	Range date						
HB	13.5-18 (G/DL)	01/03/92	15.80		15.40		15.20	
HT	0.4-0.54 (L/L)	01/03/92	0.49		0.45		0.44	
RBC	4.4-6 (10¬6/MM3)	01/03/92	5.47		4.96		4.97	
WBC	4-11 (10¬3/MM3)	01/03/92	8.20		5.70		6.40	
WBC: N	20-75 (%)	01/03/92	46.00		49.00		59.00	
WBC: L	10-40 (%)	01/03/92	48.00	>	46.00	>	32.00	
WBC: E	1-6 (%)	01/03/92	1.00		2.00		1.00	
WBC: M	2-10 (%)	01/03/92	4.00		3.00		8.00	
WBC: B	0-2 (%)	01/03/92	1.00		0.00		0.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92	293.00		266.00		253.00	
NA+	136-148 (MMOL/L)	01/03/92	140.00		142.00		143.00	
K+	3.8-5 (MMOL/L)	01/03/92	3.80		3.90		4.70	
CL-	97-106 (MMOL/L)	01/03/92	98.00		100.00		103.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.23	<	2.26		2.26	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.04		0.93		1.35	
SGOT	5-37 (U/L)	01/03/92	18.00		17.00		17.00	
SGPT	5-40 (U/L)	01/03/92	12.00		12.00		11.00	
GAMMA GT	11-50 (U/L)	01/03/92	9.00	<	10.00	<	9.00	<
LDH	230-460 (U/L)	01/03/92	215.00	<	251.00		284.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	80.00		78.00		79.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	4.90		5.80		5.80	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.60		2.50		4.80	
CREATININE	44-120 (UMOL/L)	01/03/92	85.00		91.60		103.00	
URIC ACID	0.19-0.43 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	18.00		12.00		11.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	3.00		5.00		5.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	84.00	>	79.00		70.00	
ALBUMINE	35-57 (G/L)	01/03/92	39.00		40.00		43.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	4.10		3.80		3.90	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.43		0.95		1.53	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	1.00		1.70			
T4	8-25 (PMOL/L)	01/03/92	14.90		12.10			

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9590085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 352 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 21	
			06/08/92		27/08/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	13.5-18 (G/DL)	01/03/92	15.80		16.80	
HT	0.4-0.54 (L/L)	01/03/92	0.50		0.51	
RBC	4.4-6 (10-6/MM3)	01/03/92	5.62		5.66	
WBC	4-11 (10-3/MM3)	01/03/92	6.50		8.10	
WBC: N	20-75 (%)	01/03/92	65.00		57.00	
WBC: L	10-40 (%)	01/03/92	26.00		38.00	
WBC: E	1-6 (%)	01/03/92	0.00	<	1.00	
WBC: M	2-10 (%)	01/03/92	9.00		3.00	
WBC: B	0-2 (%)	01/03/92	0.00		1.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	299.00			
NA+	136-148 (MMOL/L)	01/03/92	145.00		139.00	
K+	3.8-5 (MMOL/L)	01/03/92	5.00		4.90	
CL-	97-106 (MMOL/L)	01/03/92	101.00		96.00	<
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.22	<	2.51	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.01		1.31	
SGOT	5-37 (U/L)	01/03/92	25.00		20.00	
SGPT	5-40 (U/L)	01/03/92	29.00		35.00	
GAMMA GT	11-50 (U/L)	01/03/92	19.00		31.00	
LDH	230-460 (U/L)	01/03/92	259.00		244.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	93.00		100.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92			6.50	>
BUN	()	01/03/92				
UREA	2.5-6.6 (MMOL/L)	01/03/92	4.60		5.90	
CREATININE	44-120 (UMOL/L)	01/03/92	106.00		132.40	>
URIC ACID	0.19-0.43 (MMOL/L)	01/03/92				
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	6.00		5.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	73.00		87.00	>
ALBUMINE	35-57 (G/L)	01/03/92	37.00		42.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	4.50		6.00	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	0.64	<	1.26	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92				
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92				
GLOBULINS BETA	11-16 (%)	01/03/92				
GLOBULINS GAMMA	()	01/03/92				
TSH	0.4-4 (MU/L)	01/03/92	0.80		0.80	
T4	8-25 (PMOL/L)	01/03/92	21.50		18.30	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 364 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			29/07/92		19/08/92	
Laboratory test	Range value	Range date	value	(◊)	value	(◊)
HB	11.5-16.5 (G/DL)	01/03/92	14.20		14.00	
HT	0.35-0.49 (L/L)	01/03/92	0.43		0.42	
RBC	3.9-5.6 (10¬6/MM3)	01/03/92	4.54		4.55	
WBC	4-11 (10¬3/MM3)	01/03/92	7.20		5.20	
WBC: N	20-75 (%)	01/03/92	55.00		51.00	
WBC: L	10-40 (%)	01/03/92	38.00		39.00	
WBC: E	1-6 (%)	01/03/92	2.00		5.00	
WBC: M	2-10 (%)	01/03/92	4.00		5.00	
WBC: B	0-2 (%)	01/03/92	1.00		0.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92			278.00	
NA+	136-148 (MMOL/L)	01/03/92	149.00	>	146.00	
K+	3.8-5 (MMOL/L)	01/03/92	5.40	>	5.80	>>
CL-	97-106 (MMOL/L)	01/03/92	102.00		98.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.27		2.58	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.20		1.19	
SGOT	5-31 (U/L)	01/03/92	19.00		345.00	>>
SGPT	5-31 (U/L)	01/03/92	18.00		468.00	>>
GAMMA GT	7-32 (U/L)	01/03/92	18.00		79.00	>>
LDH	230-460 (U/L)	01/03/92	342.00		551.00	>
ALK. PHOSPH.	40-120 (U/L)	01/03/92	80.00		132.00	>
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	4.70		4.60	
BUN	()	01/03/92				
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.90		4.90	
CREATININE	44-120 (UMOL/L)	01/03/92	72.00		91.10	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92				
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	5.00		6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	84.00	>	83.00	>
ALBUMINE	35-57 (G/L)	01/03/92	41.00		38.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.00		6.70	>
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.66		1.29	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92				
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92				
GLOBULINS BETA	11-16 (%)	01/03/92				
GLOBULINS GAMMA	()	01/03/92				
TSH	0.4-4 (MU/L)	01/03/92	0.90		1.50	
T4	8-25 (PMOL/L)	01/03/92	20.60		12.10	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9990085

REBOXETINE - PROTOCOL Z0124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 367 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			31/08/92		21/09/92		12/10/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.5-18 (G/DL)	01/03/92	14.80		14.70		14.20	
HT	0.4-0.54 (L/L)	01/03/92	0.43		0.45		0.43	
RBC	4.4-6 (10¬6/MM3)	01/03/92	4.94		4.04	<	4.73	
WBC	4-11 (10¬3/MM3)	01/03/92	5.10		4.60		8.00	
WBC: N	20-75 (%)	01/03/92	48.00		35.00		74.00	
WBC: L	10-40 (%)	01/03/92	41.00	>	57.00	>>	21.00	
WBC: E	1-6 (%)	01/03/92	6.00		3.00		2.00	
WBC: M	2-10 (%)	01/03/92	5.00		4.00		3.00	
WBC: B	0-2 (%)	01/03/92	0.00		1.00		0.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92			362.00		242.00	
NA+	136-148 (MMOL/L)	01/03/92	146.00		146.00		146.00	
K+	3.8-5 (MMOL/L)	01/03/92	3.80		7.80	>>	4.80	
CL-	97-106 (MMOL/L)	01/03/92	104.00		102.00		101.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.22	<	2.26		2.22	<
PO4--	0.6-1.8 (MMOL/L)	01/03/92	0.38	<<	0.67		0.61	
SGOT	5-37 (U/L)	01/03/92	20.00		18.00		19.00	
SGPT	5-40 (U/L)	01/03/92	19.00		13.00		13.00	
GAMMA GT	11-50 (U/L)	01/03/92	17.00		18.00		17.00	
LDH	230-460 (U/L)	01/03/92	380.00		398.00		418.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	87.00		92.00		89.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	8.00	>>	5.80		5.10	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	3.60		3.70		3.40	
CREATININE	44-120 (UMOL/L)	01/03/92	90.90		81.30		81.30	
URIC ACID	0.19-0.43 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	7.00		6.00		6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	3.00		5.00		5.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	83.00	>	83.00	>	74.00	
ALBUMINE	35-57 (G/L)	01/03/92	40.00		39.00		44.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	4.60		3.80		4.30	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	3.16	>>	1.06		0.73	<
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	1.50		0.80		1.30	
T4	8-25 (PMOL/L)	01/03/92	12.20		22.70		21.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max rang
< out of range (value lower than min range) > out of range (value higher than max rang
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS-R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 370 Treatment: Imipramine Sex: Female

Laboratory test	Range value	Range date	Screen 16/07/92 value	(¢)	Day 42 27/08/92 value	(¢)
HB	11.5-16.5 (G/DL)	01/03/92	13.60		14.30	
HT	0.35-0.49 (L/L)	01/03/92	0.41		0.39	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.59		5.19	
WBC	4-11 (10-3/MM3)	01/03/92	5.90			
WBC: N	20-75 (%)	01/03/92	46.00		44.00	
WBC: L	10-40 (%)	01/03/92	40.00		41.00	>
WBC: E	1-6 (%)	01/03/92	2.00		1.00	
WBC: M	2-10 (%)	01/03/92	11.00	>	13.00	>
WBC: B	0-2 (%)	01/03/92	1.00		1.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	283.00		330.00	
NA+	136-148 (MMOL/L)	01/03/92	149.00	>	149.00	>
K+	3.8-5 (MMOL/L)	01/03/92	3.90		4.10	
CL-	97-106 (MMOL/L)	01/03/92	103.00		101.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.23	<	2.32	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.30		1.01	
SGOT	5-31 (U/L)	01/03/92	24.00		43.00	>
SGPT	5-31 (U/L)	01/03/92	28.00		76.00	>>
GAMMA GT	7-32 (U/L)	01/03/92	18.00		17.00	
LDH	230-460 (U/L)	01/03/92	414.00		399.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	82.00		95.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	5.50		5.70	
BUN	()	01/03/92				
UREA	2.5-6.6 (MMOL/L)	01/03/92	4.70		5.20	
CREATININE	44-120 (UMOL/L)	01/03/92	77.00		88.20	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92				
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	5.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	1.00		1.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	78.00		84.00	>
ALBUMINE	35-57 (G/L)	01/03/92	40.00		39.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	6.70	>		
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.42			
GLOBULINS ALPHA 1	1-5 (%)	01/03/92				
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92				
GLOBULINS BETA	11-16 (%)	01/03/92				
GLOBULINS GAMMA	()	01/03/92				
TSH	0.4-4 (MU/L)	01/03/92	1.40		1.00	
T4	8-25 (PMOL/L)	01/03/92	11.40		13.70	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS-R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 372 Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			17/06/92		08/07/92		29/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	13.5-18 (G/DL)	01/03/92	16.00		14.20		14.60	
HT	0.4-0.54 (L/L)	01/03/92	0.49		0.44		0.45	
RBC	4.4-6 (10-6/MM3)	01/03/92	5.06		4.59		4.72	
WBC	4-11 (10-3/MM3)	01/03/92	6.90		6.80		8.90	
WBC: N	20-75 (%)	01/03/92	45.00		41.00		39.00	
WBC: L	10-40 (%)	01/03/92	45.00	>	51.00	>	57.00	>>
WBC: E	1-6 (%)	01/03/92	4.00		2.00		0.00	<
WBC: M	2-10 (%)	01/03/92	6.00		6.00		4.00	
WBC: B	0-2 (%)	01/03/92	0.00		0.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92						
NA+	136-148 (MMOL/L)	01/03/92	139.00		150.00	>		
K+	3.8-5 (MMOL/L)	01/03/92	5.00		5.60	>		
CL-	97-106 (MMOL/L)	01/03/92	96.00	<	100.00			
Ca++	2.25-2.75 (MMOL/L)	01/03/92						
PO4--	0.6-1.8 (MMOL/L)	01/03/92						
SGOT	5-37 (U/L)	01/03/92	30.00		31.00		35.00	
SGPT	5-40 (U/L)	01/03/92	23.00		25.00		31.00	
GAMMA GT	11-50 (U/L)	01/03/92	18.00		18.00		17.00	
LDH	230-460 (U/L)	01/03/92						
ALK. PHOSPH.	40-120 (U/L)	01/03/92	91.00		84.00		70.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	6.00		4.00		4.30	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	5.40		4.50		5.40	
CREATININE	44-120 (UMOL/L)	01/03/92	54.00		70.00		49.00	
URIC ACID	0.19-0.43 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	7.00		7.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	4.00		2.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	70.00		84.00	>		
ALBUMINE	35-57 (G/L)	01/03/92	46.00		38.00			
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	5.00				4.60	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	0.62	<			0.87	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92	0.30		0.30		0.80	
T4	8-25 (PMOL/L)	01/03/92	15.30		12.50		15.40	

(¢) << clinically relevant (value lower than min range)
< out of range (value lower than min range)
** missing laboratory test value nd laboratory not done
>> clinically relevant (value higher than max range
> out of range (value higher than max range
() missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 373 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			25/06/92	
			value	(◊)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/03/92	14.30	
HT	0.35-0.49 (L/L)	01/03/92	0.43	
RBC	3.9-5.6 (10¬6/MM3)	01/03/92	4.74	
WBC	4-11 (10¬3/MM3)	01/03/92	8.90	
WBC: N	20-75 (%)	01/03/92	56.00	
WBC: L	10-40 (%)	01/03/92	36.00	
WBC: E	1-6 (%)	01/03/92	0.00	<
WBC: M	2-10 (%)	01/03/92	8.00	
WBC: B	0-2 (%)	01/03/92	0.00	
PLATELETS	140-400 (10¬3/MM3)	01/03/92	213.00	
NA+	136-148 (MMOL/L)	01/03/92	143.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.20	
CL-	97-106 (MMOL/L)	01/03/92	106.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.29	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.00	
SGOT	5-31 (U/L)	01/03/92	19.00	
SGPT	5-31 (U/L)	01/03/92	36.00	>
GAMMA GT	7-32 (U/L)	01/03/92	16.00	
LDH	230-460 (U/L)	01/03/92	283.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	51.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	5.00	
BUN	()	01/03/92		
UREA	2.5-6.6 (MMOL/L)	01/03/92	2.90	
CREATININE	44-120 (UMOL/L)	01/03/92	78.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92		
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	13.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	3.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	84.00	>
ALBUMINE	35-57 (G/L)	01/03/92	40.00	
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	4.10	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	0.85	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92		
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92		
GLOBULINS BETA	11-16 (%)	01/03/92		
GLOBULINS GAMMA	()	01/03/92		
TSH	0.4-4 (MU/L)	01/03/92	0.50	
T4	8-25 (PMOL/L)	01/03/92	25.00	

(◊) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 380 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			30/06/92		20/07/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)
HB	11.5-16.5 (G/DL)	01/03/92	13.40		13.20	
HT	0.35-0.49 (L/L)	01/03/92	0.40		0.39	
RBC	3.9-5.6 (10~6/MM3)	01/03/92	3.91		3.76	<
WBC	4-11 (10~3/MM3)	01/03/92	5.90		5.10	
WBC: N	20-75 (%)	01/03/92	33.00		46.00	
WBC: L	10-40 (%)	01/03/92	54.00	>>	36.00	
WBC: E	1-6 (%)	01/03/92			6.00	
WBC: M	2-10 (%)	01/03/92	8.00		11.00	>
WBC: B	0-2 (%)	01/03/92			1.00	
PLATELETS	140-400 (10~3/MM3)	01/03/92	195.00		389.00	
NA+	136-148 (MMOL/L)	01/03/92	137.00		143.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.60		5.00	
CL-	97-106 (MMOL/L)	01/03/92	98.00		100.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	1.94	<	2.00	<
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.00		1.40	
SGOT	5-31 (U/L)	01/03/92	47.00	>	35.00	>
SGPT	5-31 (U/L)	01/03/92	59.00	>	49.00	>
GAMMA GT	7-32 (U/L)	01/03/92	45.00	>	30.00	
LDH	230-460 (U/L)	01/03/92	305.00		294.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	81.00		79.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	7.00	>	4.10	
BUN	()	01/03/92				
UREA	2.5-6.6 (MMOL/L)	01/03/92	2.60		4.60	
CREATININE	44-120 (UMOL/L)	01/03/92	78.00		90.00	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92				
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	2.00	<	3.00	<
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	2.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	105.00	>	122.00	>>
ALBUMINE	35-57 (G/L)	01/03/92	29.00	<	32.00	<
TOT. CHOLEST.	3.1-6.5 (MMOL/L)	01/03/92	3.00	<	4.40	
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	1.04		1.32	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92				
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92				
GLOBULINS BETA	11-16 (%)	01/03/92				
GLOBULINS GAMMA	()	01/03/92				
TSH	0.4-4 (MU/L)	01/03/92	2.10			
T4	8-25 (PMOL/L)	01/03/92	23.30			

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS R&D 9550085

REBOXETINE - PROTOCOL 20124/017
Listing No.: 18.0

LABORATORY DATA
Centre: 15 Patient: 383 Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 42	
			07/07/92		28/07/92		18/08/92	
Laboratory test	Range value	Range date	value	(¢)	value	(¢)	value	(¢)
HB	11,5-16.5 (G/DL)	01/03/92	15.60		13.50		13.30	
HT	0.35-0.49 (L/L)	01/03/92	0.47		0.42		0.40	
RBC	3.9-5.6 (10-6/MM3)	01/03/92	4.92		4.45		4.71	
WBC	4-11 (10-3/MM3)	01/03/92	8.30		6.90		8.50	
WBC: N	20-75 (%)	01/03/92	58.00		58.00		44.00	
WBC: L	10-40 (%)	01/03/92	34.00		21.00		35.00	
WBC: E	1-6 (%)	01/03/92	2.00		8.00	>>	1.00	
WBC: M	2-10 (%)	01/03/92	4.00		13.00	>	20.00	>>
WBC: B	0-2 (%)	01/03/92	2.00		0.00		0.00	
PLATELETS	140-400 (10-3/MM3)	01/03/92	471.00	>	357.00		483.00	>
NA+	136-148 (MMOL/L)	01/03/92	144.00		145.00		148.00	
K+	3.8-5 (MMOL/L)	01/03/92	4.60		4.50		4.20	
CL-	97-106 (MMOL/L)	01/03/92	100.00		101.00		100.00	
Ca++	2.25-2.75 (MMOL/L)	01/03/92	2.26		2.04	<	2.25	
PO4--	0.6-1.8 (MMOL/L)	01/03/92	1.00		1.20		1.49	
SGOT	5-31 (U/L)	01/03/92	19.00		18.00		16.00	
SGPT	5-31 (U/L)	01/03/92	25.00		17.00		13.00	
GAMMA GT	7-32 (U/L)	01/03/92	23.00		19.00		21.00	
LDH	230-460 (U/L)	01/03/92	350.00		386.00		353.00	
ALK. PHOSPH.	40-120 (U/L)	01/03/92	76.00		82.00		67.00	
GLUCOSE	3.3-6.1 (MMOL/L)	01/03/92	5.60		4.90		4.80	
BUN	()	01/03/92						
UREA	2.5-6.6 (MMOL/L)	01/03/92	2.40	<	3.40		2.70	
CREATININE	44-120 (UMOL/L)	01/03/92	84.00		75.00		61.50	
URIC ACID	0.14-0.33 (MMOL/L)	01/03/92						
TOT BILIRUBIN	5-20 (UMOL/L)	01/03/92	5.00		2.00	<	3.00	<
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/92	5.00		1.00		1.00	
TOT. PROTEINS	62-82 (G/L)	01/03/92	78.00		79.00		82.00	
ALBUMINE	35-57 (G/L)	01/03/92	37.00		37.00		39.00	
TOT. CHOLEST.	3.1-6,5 (MMOL/L)	01/03/92	5.90		6.00		6.80	>
TRIGLYCERIDES	0.84-1.94 (MMOL/L)	01/03/92	2.21	>	1.79		1.23	
GLOBULINS ALPHA 1	1-5 (%)	01/03/92						
GLOBULINS ALPHA 2	4.5-9.5 (%)	01/03/92						
GLOBULINS BETA	11-16 (%)	01/03/92						
GLOBULINS GAMMA	()	01/03/92						
TSH	0.4-4 (MU/L)	01/03/92			0.80		1.40	
T4	8-25 (PMOL/L)	01/03/92			11.10		10.20	

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range
< out of range (value lower than min range) > out of range (value higher than max range
** missing laboratory test value nd laboratory not done () missing range value

1360

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
1	1	Reboxetine	Male	Evaluated	05/02/91	18/03/91	42	Screen	05/02/91	1	Not done	Absent	Absent	Absent	Absent
								Day 21	26/02/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	19/03/91	43	Not done	Present	Absent	Absent	Absent
	2	Reboxetine	Female	Evaluated	26/02/91	08/04/91	42	Screen	26/02/91	1	Not done	Absent	Absent	Present	Absent
								Day 21	19/03/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	09/04/91	43	Not done	Absent	Absent	Absent	Absent
	3	Imipramine	Female	Evaluated	16/04/91	27/05/91	42	Screen	16/04/91	1	Not done	Absent	Absent	Present	Absent
								Day 21	07/05/91	22	Not done	Present	Absent	Absent	Absent
								Day 42	28/05/91	43	Not done	Present	Absent	Absent	Present
	4	Imipramine	Male	Evaluated	17/04/91	28/05/91	42	Screen	17/04/91	1	Not done	Absent	Absent	Absent	Absent
								Day 21	07/05/91	21	Not done	Present	Absent	Absent	Present
								Day 42	29/05/91	43	Not done	Present	Absent	Absent	Absent
	5	Reboxetine	Female	Evaluated	17/07/91	27/08/91	42	Screen	17/07/91	1	Not done	Absent	Absent	Absent	Present
								Day 21	07/08/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	28/08/91	43	Not done	Absent	Absent	Absent	Absent
	6	Imipramine	Male	Evaluated	07/08/91	17/09/91	42	Screen	06/08/91	0	Not done	Absent	Absent	Present	Present
								Day 21	28/08/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	18/09/91	43	Not done	Absent	Absent	Absent	Absent
	7	Reboxetine	Male	Evaluated	09/10/91	20/11/91	43	Screen	08/10/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	30/10/91	22	Not done	Present	Absent	Absent	Absent
								Day 42	21/11/91	44	Not done	Absent	Absent	Absent	Absent
	8	Imipramine	Male	Only screening	29/10/91	31/10/91	3	Screen	29/10/91	1	Not done	Absent	Absent	Absent	Absent
	9	Imipramine	Female	Evaluated	08/11/91	19/12/91	42	Screen	06/11/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	28/11/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	19/12/91	42	Not done	Absent	Absent	Absent	Present
	10	Imipramine	Female	Evaluated	19/11/91	30/12/91	42	Screen	15/11/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	10/12/91	22	Not done	Absent	Present	Present	Present
								Day 42	30/12/91	42	Not done	Absent	Present	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
1	11	Reboxetine	Male	Evaluated	06/04/92	03/05/92	28	Screen	03/04/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	28/04/92	23	Not done	Absent	Absent	Absent	Absent
	12	Reboxetine	Male	Evaluated	15/04/92	05/05/92	21	Screen	13/04/92	0	Not done	Present	Absent	Absent	Absent
								Day 21	05/05/92	21	Not done	Absent	Absent	Absent	Absent
2	33	Reboxetine	Male	Evaluated	19/12/90	29/01/91	42	Screen	19/12/90	1	Normal	Absent	Absent	Absent	Absent
								Day 21	08/01/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	29/01/91	42	Normal	Absent	Absent	Present	Present
	34	Imipramine	Male	Evaluated	28/12/90	03/02/91	38	Screen	27/12/90	0	Normal	Absent	Absent	Absent	Present
								Day 21	17/01/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	07/02/91	42	Normal	Absent	Absent	Present	Present
	35	Reboxetine	Male	Evaluated	28/12/90	07/02/91	42	Screen	28/12/90	1	Normal	Absent	Absent	Absent	Absent
								Day 21	17/01/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	07/02/91	42	Not done	Absent	Absent	Absent	Absent
	36	Imipramine	Female	Evaluated	10/01/91	31/01/91	22	Screen	09/01/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	30/01/91	21	Normal	Absent	Absent	Absent	Absent
	37	Reboxetine	Male	Evaluated	18/01/91	28/02/91	42	Screen	17/01/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	07/02/91	21	Not done	Not done	Not done	Not done	Not done
								Day 42	28/02/91	42	Normal	Present	Absent	Absent	Absent
	38	Imipramine	Female	Without screen	25/01/91	07/03/91	42	Screen	25/01/91	1	Normal	Not done	Not done	Not done	Not done
								Day 21	14/02/91	21	Normal	Absent	Absent	Present	Present
								Day 42	07/03/91	42	Normal	Absent	Absent	Absent	Present
	39	Reboxetine	Female	Without screen	25/01/91	07/03/91	42	Screen	24/01/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	14/02/91	21	Normal	Not done	Not done	Not done	Present
								Day 42	07/03/91	42	Normal	Absent	Absent	Absent	Absent
	40	Imipramine	Male	Evaluated	20/02/91	02/04/91	42	Screen	20/02/91	1	Normal	Absent	Absent	Absent	Present
								Day 21	19/03/91	28	Normal	Absent	Absent	Absent	Present
								Day 42	02/04/91	42	Normal	Absent	Absent	Absent	Present
	41	Reboxetine	Male	Without screen	05/02/91	18/03/91	42	Screen	04/02/91	0	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
2	41	Reboxetine	Male	Without screen	05/02/91	18/03/91	42	Day 21	25/02/91	21	Normal	Absent	Absent	Absent	Present
								Day 42	18/03/91	42	Not done	Absent	Absent	Present	Present
	42	Imipramine	Male	Evaluated	09/02/91	22/03/91	42	Screen	08/02/91	0	Normal	Absent	Absent	Present	Present
								Day 21	01/03/91	21	Normal	Absent	Absent	Present	Absent
								Day 42	22/03/91	42	Normal	Absent	Absent	Present	Present
	43	Reboxetine	Female	Evaluated	26/03/91	06/05/91	42	Screen	25/03/91	0	Normal	Absent	Absent	Present	Present
								Day 21	15/04/91	21	Normal	Absent	Absent	Absent	Present
								Day 42	06/05/91	42	Normal	Absent	Absent	Present	Present
	44	Imipramine	Male	Only screening	11/04/91	11/04/91	1	Screen	10/04/91	0	Normal	Absent	Absent	Absent	Present
	45	Imipramine	Female	Only screening	30/04/91	03/05/91	4	Screen	29/04/91	0	Normal	Absent	Absent	Absent	Present
	46	Reboxetine	Female	Evaluated	16/05/91	26/06/91	42	Screen	15/05/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	05/06/91	21	Normal	Absent	Absent	Present	Present
								Day 42	26/06/91	42	Normal	Absent	Absent	Absent	Absent
	47	Reboxetine	Female	Evaluated	22/05/91	02/07/91	42	Screen	21/05/91	0	Normal	Absent	Absent	Present	Present
								Day 21	11/06/91	21	Normal	Absent	Absent	Present	Present
								Day 42	02/07/91	42	Normal	Absent	Absent	Present	Present
	48	Imipramine	Female	Evaluated	27/08/91	07/10/91	42	Screen	26/08/91	0	Normal	Absent	Absent	Present	Present
								Day 21	16/09/91	21	Normal	Absent	Absent	Present	Present
								Day 42	07/10/91	42	Normal	Absent	Absent	Absent	Present
	49	Imipramine	Female	Evaluated	29/08/91	09/10/91	42	Screen	28/08/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	18/09/91	21	Normal	Absent	Absent	Present	Present
								Day 42	09/10/91	42	Normal	Absent	Absent	Absent	Present
	50	Reboxetine	Male	Evaluated	06/11/91	15/12/91	40	Screen	04/11/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	26/11/91	21	Normal	Absent	Absent	Present	Present
	51	Reboxetine	Female	Only screening	06/11/91	17/11/91	12	Screen	04/11/91	0	Normal	Absent	Absent	Present	Present
	52	Imipramine	Male	Evaluated	27/11/91	07/01/92	42	Screen	15/11/91	0	Normal	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
2	52	Imipramine	Male	Evaluated	27/11/91	07/01/92	42	Day 21	17/12/91	21	Normal	Present	Absent	Present	Present
								Day 42	07/01/92	42	Normal	Absent	Absent	Present	Present
3	65	Reboxetine	Male	Evaluated	02/04/91	13/05/91	42	Screen	29/03/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	22/04/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	13/05/91	42	Normal	Absent	Absent	Absent	Absent
	66	Imipramine	Female	Evaluated	01/05/91	05/06/91	36	Screen	27/04/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	23/05/91	23	Not done	Absent	Absent	Absent	Absent
	67	Reboxetine	Female	Evaluated	10/04/91	21/05/91	42	Screen	05/04/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	30/04/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	23/05/91	44	Not done	Absent	Absent	Absent	Absent
	68	Imipramine	Female	Evaluated	03/08/91	13/09/91	42	Screen	02/08/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	23/08/91	21	Not done	Absent	Absent	Absent	Present
								Day 42	13/09/91	42	Not done	Absent	Absent	Absent	Absent
	69	Imipramine	Female	Evaluated	01/03/91	11/04/91	42	Screen	01/03/91	1	Not done	Absent	Absent	Absent	Absent
								Day 21	22/03/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	11/04/91	42	Not done	Absent	Absent	Absent	Absent
	70	Reboxetine	Female	Evaluated	23/10/91	19/11/91	28	Screen	22/10/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	12/11/91	21	Not done	Absent	Present	Absent	Present
	71	Imipramine	Female	Evaluated	14/11/91	25/12/91	42	Screen	12/11/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	04/12/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	25/12/91	42	Not done	Absent	Absent	Absent	Present
	72	Reboxetine	Female	Evaluated	31/01/92	12/03/92	42	Screen	28/01/92	0	Not done	Absent	Absent	Present	Present
								Day 21	21/02/92	22	Not done	Absent	Absent	Present	Present
								Day 42	13/03/92	43	Not done	Absent	Absent	Present	Absent
	73	Reboxetine	Female	Evaluated	15/02/92	27/03/92	42	Screen	11/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	06/03/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	27/03/92	42	Not done	Absent	Absent	Absent	Absent
4	97	Imipramine	Male	Evaluated	07/05/92	18/06/92	43	Screen	06/05/92	0	Not done	Absent	Absent	Absent	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
4	97	Imipramine	Male	Evaluated	07/05/92	18/06/92	43	Day 21	27/05/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	17/06/92	42	Not done	Absent	Absent	Absent	Absent
	100	Reboxetine	Female	Evaluated	07/05/92	24/06/92	49	Screen	01/05/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	27/05/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	17/06/92	42	Not done	Absent	Absent	Absent	Present
	101	Imipramine	Female	Evaluated	06/05/91	22/05/91	17	Screen	06/05/91	1	Not done	Present	Absent	Present	Present
								Day 21	23/05/91	18	Not done	Absent	Absent	Present	Present
6	161	Reboxetine	Male	Evaluated	29/03/91	09/05/91	42	Screen	27/03/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	18/04/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	08/05/91	41	Normal	Absent	Absent	Absent	Absent
	162	Reboxetine	Female	Evaluated	05/11/91	16/12/91	42	Screen	04/11/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	25/11/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	16/12/91	42	Not done	Absent	Absent	Absent	Present
8	193	Reboxetine	Female	Without Urinal	11/06/91	17/06/91	7	Screen	04/04/91	0	Not done	Not done	Not done	Not done	Not done
	194	Reboxetine	Male	Only screening	03/06/91	06/06/91	4	Screen	31/05/91	0	Not done	Absent	Absent	Present	Present
	196	Imipramine	Female	Evaluated	19/03/91	26/04/91	39	Screen	18/03/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	06/04/91	19	Not done	Not done	Not done	Present	Present
								Day 42	04/05/91	47	Not done	Absent	Absent	Present	Present
8	225	Imipramine	Female	Without Urinal	22/03/91	09/04/91	19	Screen	22/03/91	1	Not done	Not done	Not done	Not done	Not done
	226	Reboxetine	Female	Evaluated	03/05/91	13/06/91	42	Screen	02/05/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	24/05/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	14/06/91	43	Not done	Absent	Absent	Absent	Present
	227	Imipramine	Male	Evaluated	07/05/91	17/06/91	42	Screen	03/05/91	0	Not done	Not done	Not done	Absent	Absent
								Day 21	29/05/91	23	Not done	Absent	Absent	Absent	Not done
								Day 42	18/06/91	43	Not done	Not done	Not done	Absent	Absent
	228	Reboxetine	Male	Without Urinal	10/05/91	17/05/91	8	Screen	08/05/91	0	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

1372

9550085

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
8	229	Imipramine	Female	Evaluated	22/10/91	02/12/91	42	Screen	22/10/91	1	Normal	Absent	Absent	Absent	Absent
								Day 21	12/11/91	22	Not done	Not done	Absent	Absent	Absent
								Day 42	03/12/91	43	Not done	Not done	Not done	Not done	Not done
	230	Imipramine	Female	Evaluated	05/11/91	16/12/91	42	Screen	04/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	26/11/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	17/12/91	43	Not done	Absent	Absent	Absent	Absent
	231	Reboxetine	Female	Only screening	05/11/91	13/11/91	9	Screen	29/10/91	0	Not done	Absent	Absent	Absent	Absent
	232	Reboxetine	Male	Only screening	29/11/91	09/01/92	42	Screen	27/11/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	20/12/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	08/01/92	41	Not done	Not done	Not done	Not done	Not done
9	197	Reboxetine	Male	Evaluated	07/03/92	10/03/92	4	Screen	27/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 7	17/03/92	11	Normal	Absent	Absent	Absent	Absent
	198	Imipramine	Female	Evaluated	18/03/92	28/04/92	42	Screen	10/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	07/04/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	28/04/92	42	Not done	Not done	Not done	Not done	Not done
	199	Imipramine	Male	Evaluated	02/04/92	13/05/92	42	Screen	30/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	22/04/92	21	Not done	Absent	Absent	Absent	Present
	200	Reboxetine	Male	Evaluated	28/04/92	08/06/92	42	Screen	21/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	18/05/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	08/06/92	42	Not done	Not done	Not done	Not done	Not done
	201	Imipramine	Female	Evaluated	16/01/92	26/02/92	42	Screen	07/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	05/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	26/02/92	42	Not done	Absent	Absent	Present	Present
	202	Imipramine	Male	Evaluated	17/01/92	27/02/92	42	Screen	09/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	06/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	27/02/92	42	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9	203	Reboxetine	Female	Evaluated	15/01/92	18/01/92	4	Screen	10/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 7	28/01/92	14	Normal	Absent	Absent	Absent	Absent
	204	Reboxetine	Male	Without screen	17/01/92	28/02/92	43	Screen	09/01/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	06/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	28/02/92	43	Normal	Absent	Absent	Absent	Absent
	205	Imipramine	Female	Only screening	05/02/92	07/02/92	3	Screen	27/01/92	0	Normal	Absent	Absent	Absent	Absent
	206	Imipramine	Female	Evaluated	05/02/92	18/03/92	43	Screen	28/01/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	26/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/03/92	43	Normal	Absent	Absent	Absent	Absent
	207	Reboxetine	Female	Only screening	06/02/92	12/02/92	7	Screen	27/01/92	0	Normal	Absent	Absent	Absent	Absent
	208	Reboxetine	Male	Evaluated	15/02/92	27/03/92	42	Screen	10/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	06/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	30/03/92	45	Normal	Absent	Absent	Absent	Absent
	209	Imipramine	Male	Only screening	12/02/92	15/02/92	4	Screen	04/02/92	0	Normal	Absent	Absent	Absent	Absent
	210	Reboxetine	Female	Evaluated	20/02/92	01/04/92	42	Screen	05/02/92	0	Not done	Present	Absent	Present	Present
								Day 21	11/03/92	21	Not done	Absent	Absent	Absent	Present
								Day 42	01/04/92	42	Normal	Absent	Absent	Present	Present
	211	Reboxetine	Female	Evaluated	14/02/92	02/03/92	18	Screen	11/02/92	0	Normal	Absent	Absent	Present	Present
								Day 21	03/03/92	19	Normal	Absent	Absent	Absent	Absent
	212	Imipramine	Female	Evaluated	04/03/92	14/04/92	42	Screen	25/02/92	0	Not done	Absent	Absent	Absent	Present
								Day 21	24/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	14/04/92	42	Normal	Absent	Absent	Absent	Absent
	237	Reboxetine	Male	Evaluated	23/04/92	02/05/92	10	Screen	15/04/92	0	Not done	Absent	Absent	Present	Absent
								Day 14	06/05/92	14	Not done	Absent	Absent	Present	Present
	238	Imipramine	Female	Evaluated	20/05/92	30/06/92	42	Screen	12/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	09/06/92	21	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9	238	Imipramine	Female	Evaluated	20/05/92	30/06/92	42	Day 42	30/06/92	42	Not done	Not done	Absent	Absent	Absent
	239	Imipramine	Male	Evaluated	30/04/92	10/06/92	42	Screen	22/04/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	20/05/92	21	Not done	Absent	Absent	Absent	Absent
								Day 42	10/06/92	42	Not done	Absent	Absent	Absent	Absent
	240	Reboxetine	Female	Only screening	28/04/92	16/05/92	19	Screen	23/04/92	0	Normal	Absent	Absent	Absent	Present
	241	Imipramine	Female	Without Urinal	09/05/92	19/06/92	42	Screen	06/05/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	29/05/92	21	Not done	Not done	Not done	Not done	Not done
								Day 42	17/06/92	40	Not done	Absent	Absent	Not done	Not done
	242	Reboxetine	Male	Evaluated	07/05/92	17/06/92	42	Screen	30/04/92	0	Normal	Present	Absent	Present	Absent
								Day 21	27/05/92	21	Not done	Absent	Present	Absent	Absent
								Day 42	17/06/92	42	Not done	Not done	Present	Present	Absent
	243	Imipramine	Female	Evaluated	18/05/92	28/06/92	42	Screen	11/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	08/06/92	22	Not done	Not done	Absent	Absent	Absent
								Day 42	29/06/92	43	Not done	Not done	Not done	Not done	Not done
	244	Reboxetine	Male	Only screening	06/06/92	17/07/92	42	Screen	25/05/92	0	Not done	Not done	Absent	Absent	Absent
								Day 21	26/06/92	21	Not done	Not done	Absent	Not done	Not done
								Day 42	16/07/92	41	Not done	Not done	Not done	Not done	Not done
	257	Reboxetine	Female	Evaluated	17/07/91	27/08/91	42	Screen	10/07/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	07/08/91	22	Not done	Absent	Absent	Present	Present
								Day 42	28/08/91	43	Not done	Absent	Absent	Present	Present
	258	Reboxetine	Male	Only screening	17/07/91	06/08/91	21	Screen	10/07/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	07/08/91	22	Not done	Not done	Not done	Not done	Not done
	259	Imipramine	Female	Evaluated	17/07/91	27/08/91	42	Screen	05/07/91	0	Not done	Absent	Absent	Present	Present
								Day 21	07/08/91	22	Not done	Absent	Absent	Present	Present
								Day 42	28/08/91	43	Not done	Absent	Absent	Present	Present
	260	Imipramine	Female	Without screen	24/07/91	12/08/91	20	Screen	17/07/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	14/08/91	22	Not done	Present	Absent	Absent	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9	261	Imipramine	Female	Without Urinal	23/07/91	29/07/91	7	Screen	19/07/91	0	Not done	Not done	Not done	Not done	Not done
								Day 7	30/07/91	8	Not done	Not done	Not done	Not done	Not done
	262	Reboxetine	Male	Evaluated	23/07/91	03/09/91	43	Screen	16/07/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	13/08/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	03/09/91	43	Not done	Not done	Absent	Present	Absent
	263	Reboxetine	Female	Without screen	31/07/91	13/08/91	14	Screen	24/07/91	0	Not done	Not done	Not done	Not done	Not done
								Day 14	14/08/91	15	Not done	Absent	Absent	Present	Present
	264	Imipramine	Female	Evaluated	31/07/91	10/09/91	42	Screen	24/07/91	0	Not done	Absent	Absent	Present	Present
								Day 21	21/08/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	11/09/91	43	Not done	Absent	Absent	Absent	Present
	265	Reboxetine	Female	Evaluated	23/08/91	03/10/91	42	Screen	13/08/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	12/09/91	21	Not done	Absent	Absent	Absent	Present
								Day 42	03/10/91	42	Not done	Absent	Absent	Present	Present
	266	Reboxetine	Female	Evaluated	18/09/91	29/10/91	42	Screen	10/09/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	08/10/91	21	Not done	Absent	Absent	Absent	Present
								Day 42	28/10/91	41	Not done	Not done	Not done	Not done	Not done
	267	Imipramine	Male	Evaluated	02/09/91	13/10/91	42	Screen	30/08/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	23/09/91	22	Not done	Present	Absent	Present	Present
								Day 42	14/10/91	43	Not done	Absent	Absent	Absent	Absent
	268	Imipramine	Female	Evaluated	25/09/91	05/11/91	42	Screen	17/09/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	15/10/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	05/11/91	42	Not done	Absent	Absent	Absent	Absent
	269	Reboxetine	Male	Evaluated	25/09/91	05/11/91	42	Screen	19/09/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	15/10/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	05/11/91	42	Normal	Absent	Absent	Absent	Absent
	270	Imipramine	Female	Only screening	11/10/91	17/10/91	7	Screen	02/10/91	0	Not done	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9	271	Reboxetine	Female	Evaluated	30/10/91	20/11/91	22	Screen	22/10/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	19/11/91	21	Not done	Absent	Absent	Absent	Absent
	272	Imipramine	Male	Evaluated	30/10/91	10/12/91	42	Screen	22/10/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	19/11/91	21	Not done	Absent	Absent	Absent	Absent
								Day 42	10/12/91	42	Not done	Absent	Absent	Absent	Absent
	273	Imipramine	Female	Evaluated	30/10/91	20/11/91	22	Screen	24/10/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	19/11/91	21	Not done	Absent	Absent	Absent	Absent
	274	Reboxetine	Female	Evaluated	31/10/91	31/10/91	1	Screen	23/10/91	0	Not done	Absent	Absent	Absent	Absent
								Day 7	06/11/91	7	Not done	Absent	Absent	Present	Present
	274/A	Reboxetine	Female	Only screening	13/05/92	23/06/92	42	Screen	21/04/92	0	Not done	Absent	Absent	Present	Present
								Day 21	02/06/92	21	Not done	Not done	Not done	Not done	Not done
								Day 42	24/06/92	43	Not done	Not done	Not done	Not done	Not done
	275	Reboxetine	Female	Evaluated	06/11/91	17/12/91	42	Screen	31/10/91	0	Not done	Absent	Absent	Present	Present
								Day 21	26/11/91	21	Not done	Absent	Absent	Present	Absent
								Day 42	18/12/91	43	Not done	Not done	Not done	Not done	Not done
	276	Imipramine	Female	Evaluated	14/01/92	14/01/92	1	Screen	24/12/91	0	Normal	Absent	Absent	Absent	Absent
								Day 7	16/01/92	3	Normal	Absent	Absent	Absent	Absent
	276/A	Imipramine	Male	Evaluated	04/03/92	14/04/92	42	Screen	24/02/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	24/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	14/04/92	42	Not done	Absent	Not done	Not done	Not done
9/A	233	Imipramine	Male	Evaluated	14/05/92	24/06/92	42	Screen	13/05/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	24/06/92	42	Normal	Absent	Absent	Absent	Absent
	234	Reboxetine	Female	Evaluated	22/05/92	02/07/92	42	Screen	18/05/92	0	Not done	Absent	Absent	Present	Present
								Day 21	11/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	02/07/92	42	Normal	Absent	Absent	Absent	Absent
	235	Reboxetine	Male	Only screening	26/05/92	29/06/92	35	Screen	22/05/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/06/92	22	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9/A	236	Imipramine	Male	Evaluated	27/05/92	07/07/92	42	Screen	12/05/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	07/07/92	42	Normal	Absent	Absent	Absent	Absent
	277	Reboxetine	Female	Only screening	10/06/92	14/06/92	5	Screen	11/06/92	2	Normal	Absent	Absent	Absent	Absent
	278	Imipramine	Female	Evaluated	13/06/92	03/07/92	21	Screen	12/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/07/92	21	Normal	Absent	Absent	Present	Present
	279	Imipramine	Male	Only screening	07/08/92	21/08/92	15	Screen	05/08/92	0	Normal	Absent	Absent	Absent	Absent
	280	Reboxetine	Female	Only screening	08/08/92	14/08/92	7	Screen	07/08/92	0	Normal	Absent	Absent	Absent	Absent
	281	Reboxetine	Female	Evaluated	01/09/92	12/10/92	42	Screen	25/08/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	21/09/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	12/10/92	42	Normal	Absent	Absent	Absent	Present
	282	Reboxetine	Male	Evaluated	02/09/92	13/10/92	42	Screen	01/09/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	22/09/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	13/10/92	42	Not done	Not done	Not done	Not done	Not done
	283	Imipramine	Female	Evaluated	16/09/92	28/10/92	43	Screen	11/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	07/10/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	28/10/92	43	Not done	Absent	Absent	Absent	Absent
	284	Imipramine	Male	Evaluated	19/09/92	09/10/92	21	Screen	16/09/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	09/10/92	21	Not done	Absent	Absent	Absent	Absent
	301	Imipramine	Female	Evaluated	05/03/92	15/04/92	42	Screen	28/02/92	0	Not done	Absent	Absent	Absent	Present
								Day 21	25/03/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	15/04/92	42	Normal	Absent	Absent	Absent	Absent
	302	Imipramine	Male	Only screening	06/03/92	22/03/92	17	Screen	02/03/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	23/03/92	18	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
9/A	303	Reboxetine	Female	Evaluated	12/03/92	31/03/92	20	Screen	06/03/92	0	Not done	Absent	Absent	Present	Present
								Day 21	31/03/92	20	Normal	Absent	Absent	Present	Present
	304	Reboxetine	Female	Evaluated	26/03/92	06/05/92	42	Screen	12/03/92	0	Normal	Absent	Absent	Present	Absent
								Day 21	15/04/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	06/05/92	42	Normal	Absent	Absent	Absent	Absent
	305	Reboxetine	Male	Evaluated	31/03/92	11/05/92	42	Screen	25/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	20/04/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	11/05/92	42	Normal	Absent	Absent	Absent	Absent
	306	Reboxetine	Female	Evaluated	29/04/92	09/06/92	42	Screen	28/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/05/92	21	Normal	Absent	Absent	Present	Absent
								Day 42	09/06/92	42	Normal	Absent	Absent	Absent	Absent
	307	Imipramine	Female	Only screening	05/05/92	08/05/92	4	Screen	05/05/92	1	Normal	Absent	Absent	Absent	Absent
	308	Imipramine	Female	Evaluated	09/05/92	02/06/92	25	Screen	09/05/92	1	Normal	Absent	Absent	Absent	Present
								Day 21	29/05/92	21	Normal	Absent	Absent	Absent	Present
10	289	Imipramine	Female	Only screening	21/09/91	27/09/91	7	Screen	23/09/91	3	Normal	Absent	Absent	Absent	Absent
	290	Reboxetine	Male	Evaluated	14/10/91	24/11/91	42	Screen	07/10/91	0	Normal	Absent	Absent	Present	Present
								Day 21	04/11/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	25/11/91	43	Not done	Absent	Absent	Absent	Absent
	291	Imipramine	Male	Evaluated	17/02/92	29/03/92	42	Screen	13/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	09/03/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	30/03/92	43	Normal	Absent	Absent	Absent	Present
	292	Reboxetine	Female	Evaluated	13/12/91	23/01/92	42	Screen	06/12/91	0	Normal	Absent	Absent	Absent	Present
								Day 21	03/01/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	25/01/92	44	Normal	Absent	Absent	Absent	Absent
	293	Reboxetine	Female	Evaluated	24/12/91	01/02/92	40	Screen	16/12/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	14/01/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	04/02/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
10	294	Imipramine	Female	Only screening	03/01/92	23/01/92	21	Screen	07/01/92	5	Normal	Absent	Absent	Present	Absent
								Day 21	23/01/92	21	Not done	Not done	Not done	Not done	Not done
	295	Imipramine	Male	Evaluated	07/01/92	17/02/92	42	Screen	02/01/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	27/01/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	24/02/92	49	Normal	Absent	Absent	Absent	Present
	296	Reboxetine	Female	Evaluated	20/02/92	01/04/92	42	Screen	15/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	12/03/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	02/04/92	43	Normal	Absent	Absent	Absent	Absent
	297	Reboxetine	Male	Evaluated	21/03/92	02/05/92	43	Screen	19/03/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	10/04/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	01/05/92	42	Normal	Absent	Absent	Absent	Present
	298	Reboxetine	Female	Evaluated	27/03/92	07/05/92	42	Screen	19/03/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/04/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	11/05/92	46	Normal	Absent	Absent	Absent	Present
	299	Imipramine	Male	Evaluated	07/04/92	18/05/92	42	Screen	02/04/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	28/04/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	19/05/92	43	Normal	Absent	Absent	Absent	Absent
	300	Imipramine	Female	Without screen	14/04/92	25/05/92	42	Screen	07/04/92	0	Not done	Not done	Not done	Not done	Not done
								Day 21	05/05/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	26/05/92	43	Normal	Absent	Absent	Absent	Absent
11	321	Reboxetine	Female	Evaluated	11/06/92	23/07/92	43	Screen	11/06/92	1	Normal	Present	Absent	Absent	Absent
								Day 21	02/07/92	22	Not done	Not done	Not done	Present	Present
								Day 42	22/07/92	42	Normal	Absent	Absent	Absent	Absent
	322	Reboxetine	Female	Evaluated	11/06/92	24/07/92	44	Screen	08/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/07/92	23	Normal	Absent	Absent	Present	Present
								Day 42	27/07/92	47	Normal	Absent	Absent	Absent	Present
	323	Imipramine	Female	Evaluated	24/06/92	06/08/92	44	Screen	18/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	15/07/92	22	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
11	323	Imipramine	Female	Evaluated	24/06/92	06/08/92	44	Day 42	06/08/92	44	Normal	Absent	Absent	Absent	Absent
	324	Imipramine	Male	Evaluated	17/07/92	28/08/92	43	Screen	17/07/92	1	Normal	Absent	Absent	Absent	Present
								Day 21	07/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	28/08/92	43	Normal	Absent	Absent	Absent	Absent
	325	Reboxetine	Female	Evaluated	30/07/92	10/09/92	43	Screen	24/07/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	21/08/92	23	Normal	Absent	Absent	Present	Absent
								Day 42	11/09/92	44	Normal	Present	Absent	Absent	Absent
	326	Imipramine	Male	Evaluated	30/07/92	10/09/92	43	Screen	30/07/92	1	Normal	Absent	Absent	Absent	Present
								Day 21	20/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	10/09/92	43	Normal	Present	Absent	Absent	Absent
	327	Reboxetine	Female	Evaluated	20/08/92	01/10/92	43	Screen	18/08/92	0	Normal	Absent	Absent	Absent	Present
								Day 21	09/09/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	01/10/92	43	Normal	Absent	Absent	Absent	Absent
	328	Imipramine	Male	Evaluated	20/08/92	17/09/92	29	Screen	19/08/92	0	Normal	Absent	Absent	Present	Absent
								Day 21	10/09/92	22	Normal	Absent	Absent	Absent	Absent
								Day 28	18/09/92	30	Normal	Absent	Absent	Absent	Absent
	329	Imipramine	Female	Evaluated	21/08/92	02/10/92	43	Screen	18/08/92	0	Normal	Absent	Absent	Present	Present
								Day 21	11/09/92	22	Normal	Present	Present	Absent	Absent
								Day 42	02/10/92	43	Normal	Absent	Absent	Absent	Absent
	330	Reboxetine	Female	Evaluated	24/08/92	26/08/92	3	Screen	22/08/92	0	Normal	Absent	Absent	Absent	Present
								Day 7	31/08/92	8	Not done	Not done	Not done	Absent	Present
	331	Reboxetine	Male	Evaluated	03/09/92	15/10/92	43	Screen	01/09/92	0	Normal	Absent	Absent	Present	Absent
								Day 21	24/09/92	22	Normal	Absent	Absent	Present	Absent
								Day 42	15/10/92	43	Normal	Absent	Absent	Present	Absent
	332	Imipramine	Female	Evaluated	05/09/92	20/10/92	46	Screen	03/09/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	28/09/92	24	Normal	Absent	Absent	Absent	Absent
								Day 42	15/10/92	41	Normal	Absent	Absent	Absent	Absent
	333	Imipramine	Female	Evaluated	04/09/92	16/10/92	43	Screen	04/09/92	1	Normal	Absent	Absent	Absent	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
11	333	Imipramine	Female	Evaluated	04/09/92	16/10/92	43	Day 21	25/09/92	22	Normal	Present	Absent	Absent	Present
								Day 42	16/10/92	43	Normal	Absent	Absent	Absent	Present
12	337	Imipramine	Female	Evaluated	26/05/92	06/07/92	42	Screen	11/05/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	15/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	06/07/92	42	Normal	Absent	Absent	Absent	Absent
	338	Reboxetine	Female	Evaluated	20/06/92	31/07/92	42	Screen	15/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	10/07/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	31/07/92	42	Normal	Absent	Absent	Absent	Absent
	339	Imipramine	Male	Evaluated	23/06/92	03/08/92	42	Screen	02/06/92	0	Not done	Absent	Absent	Absent	Present
								Day 21	13/07/92	21	Normal	Absent	Absent	Absent	Present
								Day 42	03/08/92	42	Normal	Absent	Absent	Absent	Present
	340	Reboxetine	Female	Evaluated	07/08/92	17/09/92	42	Screen	04/08/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	27/08/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	17/09/92	42	Not done	Present	Absent	Absent	Absent
	341	Reboxetine	Female	Evaluated	21/08/92	24/09/92	35	Screen	18/08/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	10/09/92	21	Normal	Absent	Absent	Absent	Present
13	353	Reboxetine	Female	Without Urinal	05/06/92	07/07/92	33	Screen	05/06/92	1	Not done	Absent	Absent	Absent	Not done
								Day 21	29/06/92	25	Not done	Absent	Absent	Absent	Not done
	354	Imipramine	Female	Without screen	24/06/92	04/08/92	42	Screen	24/06/92	1	Not done	Absent	Absent	Absent	Not done
								Day 21	15/07/92	22	Not done	Absent	Absent	Absent	Not done
								Day 42	12/08/92	50	Normal	Absent	Absent	Absent	Absent
	355	Reboxetine	Female	Only screening	25/06/92	27/06/92	3	Screen	17/06/92	0	Not done	Present	Absent	Absent	Absent
	356	Imipramine	Male	Without Urinal	22/07/92	01/09/92	42	Screen	22/07/92	1	Normal	Absent	Absent	Absent	Not done
								Day 21	12/08/92	22	Normal	Absent	Absent	Absent	Not done
								Day 42	02/09/92	43	Normal	Absent	Absent	Absent	Not done
	357	Imipramine	Female	Without Urinal	05/08/92	09/08/92	5	Screen	05/08/92	1	Not done	Absent	Absent	Absent	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
13	358	Reboxetine	Male	Evaluated	06/08/92	05/09/92	31	Screen	06/08/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	27/08/92	22	Normal	Absent	Absent	Absent	Absent
	359	Reboxetine	Female	Evaluated	19/08/92	29/09/92	42	Screen	19/08/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	09/09/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	30/09/92	43	Normal	Absent	Absent	Absent	Not done
	360	Imipramine	Female	Without Urinal	19/08/92	21/08/92	3	Screen	19/08/92	1	Not done	Absent	Absent	Absent	Not done
	361	Reboxetine	Female	Without screen	26/08/92	06/10/92	42	Screen	26/08/92	1	Normal	Absent	Absent	Absent	Not done
								Day 21	16/09/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	07/10/92	43	Not done	Absent	Absent	Absent	Absent
14	457	Reboxetine	Female	Evaluated	07/07/92	17/08/92	42	Screen	07/07/92	1	Normal	Absent	Absent	Absent	Absent
								Day 21	28/07/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/08/92	43	Normal	Absent	Absent	Absent	Absent
	458	Imipramine	Female	Evaluated	14/07/92	24/08/92	42	Screen	10/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	04/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	25/08/92	43	Normal	Absent	Absent	Absent	Absent
	459	Reboxetine	Male	Evaluated	16/07/92	26/08/92	42	Screen	13/07/92	9	Normal	Absent	Absent	Absent	Absent
								Day 21	06/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	27/08/92	43	Normal	Absent	Absent	Absent	Absent
	460	Imipramine	Male	Evaluated	23/07/92	02/09/92	42	Screen	20/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	13/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	03/09/92	43	Normal	Absent	Absent	Absent	Absent
	461	Imipramine	Female	Evaluated	29/07/92	08/09/92	42	Screen	22/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	09/09/92	43	Normal	Absent	Absent	Absent	Absent
	462	Reboxetine	Female	Evaluated	31/07/92	10/09/92	42	Screen	24/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	21/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	11/09/92	43	Normal	Absent	Absent	Absent	Absent
	463	Imipramine	Male	Evaluated	03/08/92	13/09/92	42	Screen	27/07/92	0	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14	463	Imipramine	Male	Evaluated	03/08/92	13/09/92	42	Day 21	24/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	14/09/92	43	Normal	Absent	Absent	Absent	Absent
	464	Reboxetine	Female	Evaluated	05/08/92	16/09/92	43	Screen	29/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	27/08/92	23	Normal	Absent	Absent	Absent	Absent
								Day 42	17/09/92	44	Normal	Absent	Absent	Absent	Absent
	465	Reboxetine	Male	Evaluated	06/08/92	16/09/92	42	Screen	30/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	27/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	17/09/92	43	Normal	Absent	Absent	Absent	Absent
	466	Imipramine	Female	Evaluated	07/08/92	17/09/92	42	Screen	31/07/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	28/08/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	18/09/92	43	Normal	Absent	Absent	Absent	Absent
14/1	129	Reboxetine	Male	Only screening	19/12/91	19/12/91	1	Screen	11/12/91	0	Not done	Absent	Absent	Absent	Absent
	426	Reboxetine	Female	Evaluated	05/09/91	17/10/91	43	Screen	29/08/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	24/09/91	20	Not done	Absent	Absent	Absent	Absent
								Day 42	17/10/91	43	Not done	Absent	Absent	Absent	Absent
	429	Imipramine	Female	Only screening	26/09/91	29/09/91	4	Screen	18/09/91	0	Not done	Absent	Absent	Absent	Absent
	451	Imipramine	Male	Evaluated	28/11/91	07/01/92	41	Screen	14/11/91	0	Not done	Absent	Present	Absent	Absent
								Day 21	19/12/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	08/01/92	42	Not done	Absent	Present	Absent	Absent
	452	Reboxetine	Female	Evaluated	28/11/91	09/01/92	43	Screen	26/11/91	0	Not done	Absent	Absent	Absent	Absent
								Day 21	19/12/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	09/01/92	43	Not done	Absent	Absent	Absent	Absent
14/2	136	Imipramine	Female	Evaluated	15/01/92	25/02/92	42	Screen	08/01/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	11/02/92	28	Not done	Not done	Not done	Not done	Not done
								Day 42	25/02/92	42	Not done	Absent	Absent	Absent	Absent
	456	Imipramine	Male	Evaluated	15/04/92	26/05/92	42	Screen	09/04/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	07/05/92	23	Not done	Absent	Absent	Absent	Absent
								Day 42	29/05/92	45	Not done	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period: Start date	Treatment period: End date	Treatment period: Days	Urinalysis test: Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14/3	417	Reboxetine	Female	Evaluated	14/06/91	26/07/91	43	Screen	07/06/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	05/07/91	22	Normal	Absent	Absent	Absent	Absent
								Day 42	26/07/91	43	Normal	Absent	Absent	Absent	Absent
	418	Imipramine	Female	Evaluated	18/06/91	29/07/91	42	Screen	10/06/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	08/07/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	29/07/91	42	Normal	Absent	Absent	Absent	Absent
	419	Reboxetine	Female	Evaluated	05/07/91	15/08/91	42	Screen	03/07/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	25/07/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	15/08/91	42	Normal	Absent	Absent	Absent	Absent
	420	Imipramine	Female	Only screening	05/07/91	25/07/91	21	Screen	04/07/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/08/91	46	Not done	Not done	Not done	Not done	Not done
	421	Reboxetine	Female	Evaluated	19/07/91	12/09/91	56	Screen	11/07/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	08/08/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	22/08/91	35	Normal	Absent	Absent	Absent	Absent
	427	Imipramine	Female	Evaluated	18/09/91	15/10/91	28	Screen	18/09/91	1	Normal	Absent	Absent	Absent	Absent
								Day 21	09/10/91	22	Normal	Absent	Absent	Absent	Absent
	428	Imipramine	Female	Evaluated	25/10/91	05/12/91	42	Screen	25/10/91	1	Normal	Absent	Absent	Absent	Absent
								Day 21	14/11/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	05/12/91	42	Normal	Absent	Absent	Absent	Absent
14/4	131	Imipramine	Female	Evaluated	14/01/92	24/02/92	42	Screen	09/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	24/02/92	42	Normal	Absent	Absent	Absent	Absent
	132	Imipramine	Female	Evaluated	14/01/92	24/02/92	42	Screen	09/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	24/02/92	42	Normal	Absent	Absent	Absent	Absent
	133	Imipramine	Female	Evaluated	16/01/92	26/02/92	42	Screen	09/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	06/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	27/02/92	43	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14/4	134	Reboxetine	Female	Evaluated	16/01/92	26/02/92	42	Screen	13/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	06/02/92	22	Normal	Absent	Absent	Absent	Absent
								Day 42	27/02/92	43	Normal	Absent	Absent	Absent	Absent
	135	Reboxetine	Male	Evaluated	17/01/92	27/02/92	42	Screen	10/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	06/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	28/02/92	43	Normal	Absent	Absent	Absent	Absent
14/7	422	Imipramine	Female	Without Urinal	04/09/91	15/10/91	42	Screen	02/09/91	0	Normal	Not done	Not done	Not done	Not done
	423	Imipramine	Female	Without screen	17/09/91	28/10/91	42	Screen	10/09/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	08/10/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	29/10/91	43	Not done	Not done	Not done	Not done	Not done
	424	Reboxetine	Male	Without Urinal	19/09/91	30/10/91	42	Screen	06/09/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	10/10/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	31/10/91	43	Not done	Not done	Not done	Not done	Not done
	430	Reboxetine	Female	Without Urinal	07/10/91	17/11/91	42	Screen	07/10/91	1	Not done	Not done	Not done	Not done	Not done
								Day 21	28/10/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	18/11/91	43	Not done	Not done	Not done	Not done	Not done
	431	Reboxetine	Male	Without Urinal	08/10/91	18/11/91	42	Screen	08/10/91	1	Not done	Not done	Not done	Not done	Not done
								Day 21	29/10/91	22	Not done	Present	Not done	Not done	Not done
								Day 42	19/11/91	43	Not done	Not done	Not done	Not done	Not done
	432	Imipramine	Male	Without Urinal	08/10/91	18/11/91	42	Screen	08/10/91	1	Not done	Not done	Not done	Not done	Not done
								Day 21	29/10/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	19/11/91	43	Not done	Not done	Not done	Not done	Not done
	433	Imipramine	Female	Without Urinal	08/10/91	18/11/91	42	Screen	08/10/91	1	Not done	Not done	Not done	Not done	Not done
								Day 21	29/10/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	19/11/91	43	Not done	Not done	Not done	Not done	Not done
	434	Reboxetine	Male	Without screen	14/10/91	24/11/91	42	Screen	10/10/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	04/11/91	22	Not done	Not done	Not done	Present	Present
								Day 42	25/11/91	43	Not done	Not done	Not done	Not done	Not done

(*) days of treatment

1387

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14/7	439	Reboxetine	Male	Without Urinal	11/11/91	22/12/91	42	Screen	06/11/91	0	Not done	Present	Not done	Present	Not done
								Day 21	02/12/91	22	Not done	Present	Not done	Not done	Not done
								Day 42	23/12/91	43	Not done	Not done	Not done	Not done	Not done
	440	Imipramine	Female	Evaluated	11/11/91	22/12/91	42	Screen	07/11/91	0	Not done	Present	Absent	Present	Present
								Day 21	02/12/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	23/12/91	43	Not done	Absent	Absent	Absent	Absent
	441	Imipramine	Male	Without Urinal	11/11/91	22/12/91	42	Screen	08/11/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	02/12/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	23/12/91	43	Not done	Not done	Not done	Not done	Not done
	442	Imipramine	Male	Without Urinal	11/11/91	22/12/91	42	Screen	08/11/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	02/12/91	22	Not done	Not done	Not done	Not done	Not done
								Day 42	23/12/91	43	Not done	Present	Not done	Not done	Not done
	449	Reboxetine	Female	Without Urinal	20/12/91	30/01/92	42	Screen	16/12/91	0	Not done	Not done	Not done	Not done	Not done
								Day 21	10/01/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	31/01/92	43	Not done	Not done	Not done	Not done	Not done
	450	Imipramine	Male	Evaluated	23/12/91	02/02/92	42	Screen	06/12/91	0	Not done	Present	Absent	Absent	Absent
								Day 21	13/01/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	03/02/92	43	Not done	Absent	Absent	Absent	Absent
14/8	130	Reboxetine	Male	Evaluated	10/01/92	20/02/92	42	Screen	10/01/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	31/01/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	21/02/92	43	Not done	Absent	Absent	Absent	Absent
	425	Reboxetine	Female	Evaluated	09/09/91	20/10/91	42	Screen	06/09/91	0	Not done	Absent	Absent	Absent	Present
								Day 21	30/09/91	22	Not done	Absent	Absent	Absent	Absent
								Day 42	21/10/91	43	Not done	Absent	Absent	Absent	Present
	467	Reboxetine	Male	Evaluated	06/07/92	16/08/92	42	Screen	02/07/92	0	Not done	Absent	Absent	Absent	Absent
								Day 21	27/07/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	17/08/92	43	Not done	Absent	Absent	Absent	Absent
14/10	53	Reboxetine	Male	Evaluated	25/02/92	06/04/92	42	Screen	17/02/92	0	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14/10	53	Reboxetine	Male	Evaluated	25/02/92	06/04/92	42	Day 21	16/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	06/04/92	42	Normal	Absent	Absent	Absent	Absent
	54	Imipramine	Female	Evaluated	26/02/92	07/04/92	42	Screen	18/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	07/04/92	42	Normal	Absent	Absent	Absent	Absent
	55	Reboxetine	Female	Evaluated	28/02/92	09/04/92	42	Screen	20/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	19/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	07/04/92	40	Normal	Absent	Absent	Absent	Absent
	56	Imipramine	Female	Evaluated	03/03/92	13/04/92	42	Screen	24/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	23/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	13/04/92	42	Normal	Absent	Absent	Absent	Absent
	57	Reboxetine	Female	Evaluated	04/03/92	14/04/92	42	Screen	25/02/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	24/03/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	14/04/92	42	Normal	Absent	Absent	Absent	Absent
	58	Imipramine	Female	Evaluated	14/04/92	25/05/92	42	Screen	02/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	04/05/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	25/05/92	42	Normal	Absent	Absent	Absent	Absent
	59	Imipramine	Female	Evaluated	24/04/92	04/06/92	42	Screen	16/04/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	14/05/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	05/06/92	43	Normal	Absent	Absent	Absent	Absent
	60	Reboxetine	Female	Evaluated	13/05/92	23/06/92	42	Screen	06/05/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	02/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	23/06/92	42	Normal	Absent	Absent	Absent	Absent
	137	Reboxetine	Female	Evaluated	28/01/92	09/03/92	42	Screen	20/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	09/03/92	42	Normal	Absent	Absent	Absent	Absent
	138	Imipramine	Female	Evaluated	29/01/92	10/03/92	42	Screen	21/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	18/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	10/03/92	42	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14/10	139	Reboxetine	Female	Evaluated	04/02/92	16/03/92	42	Screen	27/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	24/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	16/03/92	42	Normal	Absent	Absent	Absent	Absent
	140	Imipramine	Female	Evaluated	05/02/92	17/03/92	42	Screen	28/01/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	25/02/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	17/03/92	42	Normal	Absent	Absent	Absent	Absent
	435	Imipramine	Female	Evaluated	12/11/91	23/12/91	42	Screen	04/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	02/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	23/12/91	42	Normal	Absent	Absent	Absent	Absent
	436	Reboxetine	Female	Evaluated	13/11/91	23/12/91	41	Screen	06/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	23/12/91	41	Normal	Absent	Absent	Absent	Absent
	437	Reboxetine	Female	Evaluated	14/11/91	23/12/91	40	Screen	05/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	03/12/91	20	Normal	Absent	Absent	Absent	Absent
								Day 42	23/12/91	40	Normal	Absent	Absent	Absent	Absent
	438	Imipramine	Female	Evaluated	15/11/91	27/12/91	43	Screen	07/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	05/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	27/12/91	43	Normal	Absent	Absent	Absent	Absent
	443	Reboxetine	Female	Evaluated	19/11/91	30/12/91	42	Screen	15/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	09/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	30/12/91	42	Normal	Absent	Absent	Absent	Absent
	444	Reboxetine	Male	Evaluated	16/11/91	27/12/91	42	Screen	15/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	06/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	27/12/91	42	Normal	Absent	Absent	Absent	Absent
	445	Imipramine	Female	Evaluated	20/11/91	30/12/91	41	Screen	15/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 42	30/12/91	41	Normal	Absent	Absent	Absent	Absent
	446	Reboxetine	Female	Evaluated	26/11/91	07/01/92	43	Screen	22/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	16/12/91	21	Normal	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
14/10	446	Reboxetine	Female	Evaluated	26/11/91	07/01/92	43	Day 42	07/01/92	43	Normal	Absent	Absent	Absent	Absent
	447	Reboxetine	Male	Evaluated	27/11/91	07/01/92	42	Screen	26/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/12/91	21	Normal	Absent	Absent	Absent	Absent
								Day 42	07/01/92	42	Normal	Absent	Absent	Absent	Absent
	448	Imipramine	Female	Evaluated	28/11/91	07/01/92	41	Screen	22/11/91	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/12/91	20	Normal	Absent	Absent	Absent	Absent
								Day 42	08/01/92	42	Normal	Absent	Absent	Absent	Absent
	453	Imipramine	Female	Evaluated	28/05/92	08/07/92	42	Screen	18/05/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	17/06/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	08/07/92	42	Normal	Absent	Absent	Absent	Absent
	454	Reboxetine	Female	Evaluated	12/06/92	23/07/92	42	Screen	03/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	02/07/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	23/07/92	42	Normal	Absent	Absent	Absent	Absent
	455	Reboxetine	Female	Evaluated	20/06/92	31/07/92	42	Screen	12/06/92	0	Normal	Absent	Absent	Absent	Absent
								Day 21	10/07/92	21	Normal	Absent	Absent	Absent	Absent
								Day 42	31/07/92	42	Normal	Absent	Absent	Absent	Absent
15	349	Imipramine	Male	Evaluated	20/08/92	01/10/92	43	Screen	20/08/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	10/09/92	22	Not done	Absent	Absent	Absent	Absent
								Day 42	01/10/92	43	Not done	Absent	Absent	Absent	Present
	351	Reboxetine	Male	Evaluated	02/09/92	14/10/92	43	Screen	02/09/92	1	Not done	Present	Absent	Absent	Present
								Day 21	23/09/92	22	Not done	Present	Absent	Absent	Present
								Day 42	14/10/92	43	Not done	Not done	Not done	Not done	Not done
	352	Imipramine	Male	Evaluated	06/08/92	27/08/92	22	Screen	06/08/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	27/08/92	22	Not done	Absent	Absent	Absent	Absent
	364	Imipramine	Female	Without Urinal	29/07/92	26/08/92	29	Screen	29/07/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	19/08/92	22	Not done	Not done	Not done	Not done	Not done
	366	Reboxetine	Male	Without screen	27/08/92	08/10/92	43	Screen	27/08/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	17/09/92	22	Not done	Absent	Absent	Absent	Absent

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
15	366	Reboxetine	Male	Without screen	27/08/92	08/10/92	43	Day 42	08/10/92	43	Not done	Absent	Absent	Absent	Absent
	367	Imipramine	Male	Evaluated	31/08/92	11/10/92	42	Screen	31/08/92	1	Not done	Absent	Absent	Absent	Absent
								Day 21	21/09/92	22	Not done	Present	Absent	Present	Absent
								Day 42	12/10/92	43	Not done	Not done	Not done	Not done	Not done
	368	Reboxetine	Female	Without Urinal	04/09/92	15/10/92	42	Screen	04/09/92	1	Normal	Not done	Not done	Not done	Not done
								Day 21	24/09/92	21	Not done	Not done	Absent	Not done	Not done
								Day 42	15/10/92	42	Not done	Not done	Not done	Not done	Not done
	369	Reboxetine	Female	Without screen	10/07/92	20/08/92	42	Screen	10/07/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	30/07/92	21	Not done	Present	Absent	Present	Present
								Day 42	20/08/92	42	Not done	Present	Absent	Absent	Absent
	370	Imipramine	Female	Without screen	16/07/92	27/08/92	43	Screen	16/07/92	1	Not done	Not done	Not done	Not done	Not done
								Day 42	27/08/92	43	Not done	Absent	Absent	Absent	Absent
	371	Reboxetine	Female	Evaluated	20/07/92	31/08/92	43	Screen	20/07/92	1	Not done	Present	Absent	Present	Present
								Day 21	10/08/92	22	Not done	Present	Absent	Absent	Present
								Day 42	31/08/92	43	Not done	Not done	Not done	Not done	Not done
	372	Imipramine	Male	Without Urinal	17/06/92	29/07/92	43	Screen	17/06/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	08/07/92	22	Not done	Not done	Not done	Not done	Not done
								Day 42	29/07/92	43	Normal	Not done	Not done	Not done	Not done
	373	Imipramine	Female	Without Urinal	25/06/92	26/06/92	2	Screen	25/06/92	1	Not done	Not done	Not done	Not done	Not done
	374	Reboxetine	Female	Without Urinal	09/04/92	20/05/92	42	Day 21	24/04/92	16	Not done	Not done	Not done	Not done	Not done
								Day 42	20/05/92	42	Normal	Not done	Not done	Not done	Not done
	375	Reboxetine	Female	Without Urinal	06/06/92	25/06/92	20	Day 21	25/06/92	20	Not done	Not done	Not done	Not done	Not done
	376	Imipramine	Female	Without Urinal	13/04/92	21/04/92	9								
	377	Reboxetine	Female	Only screening	13/05/92	25/06/92	44	Screen	13/05/92	1	Not done	Absent	Absent	Present	Present

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 19.0

URINALYSIS

					Treatment period			Urinalysis test							
Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
15	378	Reboxetine	Female	Without screen	15/06/92	27/07/92	43	Screen	15/06/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	06/07/92	22	Not done	Absent	Absent	Present	Present
								Day 42	27/07/92	43	Not done	Absent	Absent	Present	Present
	379	Imipramine	Female	Without Urinal	16/04/92	17/04/92	2	Screen	16/04/92	1	Not done	Not done	Not done	Not done	Not done
	380	Imipramine	Female	Without Urinal	30/06/92	10/08/92	42	Screen	30/06/92	1	Not done	Not done	Not done	Not done	Not done
								Day 21	20/07/92	21	Not done	Not done	Not done	Not done	Not done
	381	Reboxetine	Female	Without screen	21/05/92	01/07/92	42	Screen	21/05/92	1	Normal	Not done	Not done	Not done	Not done
								Day 21	11/06/92	22	Not done	Absent	Absent	Present	Present
								Day 42	02/07/92	43	Not done	Present	Absent	Present	Present
	382	Imipramine	Male	Without Urinal	09/04/92	10/04/92	2	Screen	09/04/92	1	Not done	Not done	Not done	Not done	Not done
	383	Imipramine	Female	Evaluated	07/07/92	18/08/92	43	Screen	07/07/92	1	Not done	Absent	Absent	Present	Present
								Day 21	28/07/92	22	Not done	Absent	Absent	Present	Present
								Day 42	18/08/92	43	Not done	Absent	Absent	Absent	Absent
	384	Reboxetine	Female	Without Urinal	28/07/92	05/08/92	9	Screen	28/07/92	1	Normal	Not done	Not done	Not done	Not done

(*) days of treatment

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
1	1	Reboxetine	Male	Screen	05/02/91				160	100	64	140	80	76
				Day 0	05/02/91			83.00	160	100	64	140	80	76
				Day 7	12/02/91			82.00	140	90	76	125	80	96
				Day 14	20/02/91			83.00	140	90	88	125	70	88
				Day 21	26/02/91			83.00	140	90	72	125	70	84
				Day 28	05/03/91			82.00	140	90	72	120	90	88
				Day 35	12/03/91			82.00	140	90	72	120	90	80
				Day 42	19/03/91			82.00	130	85	76	110	85	80
	2	Reboxetine	Female	Screen	26/02/91				160	100	88	150	95	88
				Day 0	26/02/91			70.00	160	100	88	150	95	88
				Day 7	05/03/91			70.00	155	95	62	130	100	76
				Day 14	12/03/91			70.00	140	80	72	120	90	80
				Day 21	19/03/91				120	75	70	110	75	80
				Day 28	26/03/91				140	80	70	120	75	76
				Day 35	02/04/91			83.00	140	85	72	130	80	72
				Day 42	09/04/91			83.00	160	85	82	160	100	82
	3	Imipramine	Female	Screen	12/04/91				110	75	92	105	80	96
				Day 0	15/04/91			63.00	130	80	80	125	80	
				Day 7	23/04/91			63.00	140	90	108	120	80	116
				Day 14	30/04/91			62.00	140	90	88	120	70	88
				Day 21	07/05/91			62.00	120	75	92	100	75	112
				Day 28	14/05/91			62.30	130	75	104	105	80	120
				Day 35	22/05/91			62.30	120	70	80	100	70	92
				Day 42	28/05/91			63.00	110	80	92	105	70	100
	4	Imipramine	Male	Screen	15/04/91				170	100	76	170	100	84
				Day 0	17/04/91			123.00	160	95	76	150	100	76
				Day 7	23/04/91			117.00	160	110	76	130	95	92
				Day 14	30/04/91			115.00	160	100	72	140	95	92
				Day 21	07/05/91			114.00	160	110	72	160	110	88
				Day 28	14/05/91			114.00	150	105	76	160	110	76
				Day 35	21/05/91			114.00	160	105	72	150	105	84
				Day 42	29/05/91			116.00	160	110	76	145	110	88
	5	Reboxetine	Female	Screen	16/07/91				110	70	80	120	80	88
				Day 0	17/07/91			70.30	120	90	60	110	70	80
				Day 7	24/07/91			70.00	110	80	60	110	70	96
				Day 14	31/07/91			69.50	120	80	76	110	70	92
				Day 21	07/08/91			69.50	115	90	76	100	80	92
				Day 28	14/08/91			71.00	115	75	72	100	70	84
				Day 35	21/08/91			69.00	105	70	80	90	60	92
				Day 42	28/08/91			69.50	120	80	76	100	70	88

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
1	6	Imipramine	Male	Screen	06/08/91				155	85	88	165	105	92
				Day 0	07/08/91			67.00	160	95	76	160	100	84
				Day 7	14/08/91			67.00	150	90	76	120	75	92
				Day 14	21/08/91			68.00	140	80	76	120	90	88
				Day 21	28/08/91			68.00	180	120	72	150	100	88
				Day 28	03/09/91	36.30			135	90	92	140	100	96
				Day 35	10/09/91				130	85	76	130	90	100
				Day 42	18/09/91				125	85	76	125	95	88
	7	Reboxetine	Male	Screen	08/10/91				150	90	80	140	85	80
				Day 0	09/10/91			85.00	150	90	80	140	85	80
				Day 7	16/10/91			83.00	120	80	72	100	85	96
				Day 14	23/10/91			83.00	120	80	80	100	85	100
				Day 21	30/10/91			83.00	115	85	80	95	80	92
				Day 28	06/11/91			80.00	150	90	68	125	85	80
				Day 35	13/11/91			79.00	130	80		105	75	
				Day 42	21/11/91			78.00	120	80	74	110	80	
	8	Imipramine	Male	Screen	25/10/91				120	70	88	110	70	92
				Day 0	28/10/91			88.50	120	70	88	110	70	92
				Day 7	31/10/91			88.00	110	80	84	120	80	84
	9	Imipramine	Female	Screen	06/11/91				140	80	72	140	85	84
				Day 0	06/11/91			53.00	165	80	84	165	85	84
				Day 7	15/11/91			53.00	120	75	80	100	70	92
				Day 14	21/11/91			53.00	110	70	88	95	60	96
				Day 21	28/11/91			53.00	130	80	80	120	80	88
				Day 28	05/12/91			53.00						
				Day 35	12/12/91			53.20	120	70	76	105	70	80
				Day 42	19/12/91			53.20	130	75	88	115	75	88
	10	Imipramine	Female	Screen	15/11/91				130	80	88	125	80	88
				Day 0	19/11/91			71.00	130	80	72	130	85	72
				Day 7	26/11/91			71.00	130	70	88	120	80	104
				Day 14	03/12/91			71.00	120	80	88	120	80	92
				Day 21	10/12/91			70.00	150	90	80	130	90	88
				Day 28	17/12/91			70.00	150	100	72	145	105	80
				Day 35	24/12/91			71.00	170	100	76	165	105	76
				Day 42	30/12/91			71.00	150	100	72	150	95	80
	11	Reboxetine	Male	Screen	02/04/92				150	95	88	150	100	92
				Day 0	06/04/92			71.80	140	100	76	130	80	92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
1	11	Reboxetine	Male	Day 7	13/04/92			71.00	120	80	84	110	75	92
				Day 14	20/04/92			73.00	155	100	80	140	90	92
				Day 21	27/04/92			73.00	160	100	84	120	75	96
				Day 28	04/05/92			74.00	150	90	72	130	80	88
	12	Reboxetine	Male	Screen	13/04/92				160	90	84	160	90	84
				Day 0	14/04/92			84.80	140	90	68	130	90	88
				Day 7	21/04/92			86.00	140	90	68	110	70	88
				Day 14	28/04/92			85.80	150	100	60	100	70	88
				Day 21	05/05/92			86.50	190	110	60	140	110	92
2	33	Reboxetine	Male	Screen	18/12/90	36.50	32		120	70	56	100	70	60
				Day 0	18/12/90	36.20		83.00	120	70	56	100	70	60
				Day 7	25/12/90	36.50		83.00	110	90	72	110	80	80
				Day 14	01/01/91	36.50		84.00	130	90	76	115	75	80
				Day 21	08/01/91	36.00		83.00	120	70	64	105	70	72
				Day 28	15/01/91	37.70		82.70	130	60	76	160	70	100
				Day 35	22/01/91	37.60		84.80	125	80	76	110	70	100
				Day 42	29/01/91	37.30		84.00	110	70	76	150	85	84
	34	Imipramine	Male	Screen	27/12/90	36.80	26		125	70	88	130	70	92
				Day 0	27/12/90	36.80		108.00	125	70	88	130	70	92
				Day 7	03/01/91	37.40		108.00	120	80	108	120	75	116
				Day 14	10/01/91	37.10		106.00	120	65	100	130	70	104
				Day 21	17/01/91	37.30		100.00	130	90	80	110	90	100
				Day 28	24/01/91	35.30		108.00	105	70	84	110	70	104
				Day 35	31/01/91	36.20		105.00	130	100	80	120	90	112
				Day 42	07/02/91	36.50		108.00	100	80	60	120	85	64
	35	Reboxetine	Male	Screen	27/12/90	36.20	33		130	80	72	130	90	80
				Day 0	27/12/90	36.20		80.00	130	80	72	130	90	80
				Day 7	03/01/91	36.80		80.00	130	90	72	120	90	84
				Day 14	10/01/91	36.00		81.80	100	70	76	110	70	92
				Day 21	17/01/91	36.20		82.80	110	70	92	120	90	104
				Day 28	24/01/91	36.00		83.90	120	80	84	130	80	84
				Day 35	31/01/91	36.50		83.50	140	90	96	120	80	96
				Day 42	07/02/91	38.00		82.50	140	90	72	110	80	96
	36	Imipramine	Female	Screen	09/01/91	37.40	18		110	70	76	120	80	84
				Day 0	09/01/91	37.40		49.30	110	70	76	120	80	84
				Day 7	16/01/91	37.70		49.80	100	70	68	100	70	100
				Day 14	23/01/91	37.20		49.50	120	70	100	110	70	120
				Day 21	30/01/91	37.20		47.80	130	80	72	130	95	132

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2	37	Reboxetine	Male	Screen	17/01/91	36.70	24		110	80	84	130	90	100
				Day 0	17/01/91	36.70		80.60	110	80	84	130	100	100
				Day 7	24/01/91	36.30		80.50	140	80	108	145	95	100
				Day 14	31/01/91	35.80		81.50	120	75	76	120	80	88
				Day 21	07/02/91	36.20		81.50	140	90	100	130	90	108
				Day 28	14/02/91	36.60		80.80	130	100	88	135	105	96
				Day 35	21/02/91	35.90		80.30	130	80	108	140	60	100
				Day 42	28/02/91	36.00		79.70	120	80	80	110	75	80
	38	Imipramine	Female	Screen	23/01/91	37.30	25		110	80	68	120	90	88
				Day 0	24/01/91	37.30		50.90	110	80	68	120	90	88
				Day 7	31/01/91	36.90		50.00	110	70	72	120	80	100
				Day 14	07/02/91	37.00		49.30	120	70	60	80	60	60
				Day 21	14/02/91	37.20		49.50	110	80	78	100	80	100
				Day 28	21/02/91	37.30		48.60	120	80	76	120	80	84
				Day 35	28/02/91	37.30		48.00	120	90	76	105	75	84
				Day 42	07/03/91	37.30		48.00	120	85	76	100	70	80
	39	Reboxetine	Female	Screen	24/01/91	37.90	22		120	80	86	120	80	86
				Day 0	24/01/91	37.90		64.70	120	80	86	120	80	86
				Day 7	31/01/91	36.50		66.00	120	80	84	130	80	84
				Day 14	07/02/91	35.90		65.80	120	80	80	120	80	80
				Day 21	14/02/91	36.80		68.00	120	80	68	135	80	76
				Day 28	21/02/91	35.90		69.60	120	80	76	120	80	84
				Day 35	28/02/91	36.30		70.00	120	80	76	115	80	80
				Day 42	07/03/91	36.20		70.30	130	90	72	115	80	76
	40	Imipramine	Male	Screen	18/02/91	36.50	27		120	85	84	125	90	76
				Day 0	18/02/91	36.50		73.00	120	85	84	125	90	76
				Day 7	26/02/91	37.00		74.00	130	85	92	115	85	100
				Day 14	05/03/91	36.80		74.20	115	70	92	110	80	120
				Day 21	12/03/91	36.30		73.00	105	70	88	120	90	100
				Day 28	19/03/91	36.80		75.00	120	90	108	120	80	120
				Day 35	26/03/91	36.90		76.70	120	90	108	110	90	96
				Day 42	02/04/91	36.50		76.10	110	75	104	110	85	132
	41	Reboxetine	Male	Screen	31/01/91	37.00	21		120	80	72	130	90	88
				Day 0	04/02/91	37.00		78.50	120	80	72	130	90	88
				Day 7	11/02/91	36.80		77.30	140	90	88	120	90	120
				Day 14	18/02/91	36.60		77.20	140	90	84	115	85	80
				Day 21	25/02/91	37.00		78.50	140	100	96	130	100	92
				Day 28	04/03/91	36.10		77.00	125	90	88	120	90	100
				Day 35	11/03/91	36.40		76.00	140	100	100	125	100	116

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2	41	Reboxetine	Male	Day 42	18/03/91	36.80		77.10	150	90	120	130	90	108
	42	Imipramine	Male	Screen	06/02/91	36.20	16		120	80	92	120	90	116
				Day 0	08/02/91	36.20		75.50	120	80	92	120	90	116
				Day 7	15/02/91	36.70		75.70	140	80	84	120	80	104
				Day 14	22/02/91	36.00		75.00	135	90	96	120	80	100
				Day 21	01/03/91	37.20		75.20	140	85	100	120	85	120
				Day 28	08/03/91	36.50		75.10	110	70	84	85	70	120
				Day 35	15/03/91	36.70		75.00	150	80	120	110	80	120
				Day 42	22/03/91	36.80		74.60	130	70	84	110	80	112
	43	Reboxetine	Female	Screen	20/03/91	36.50	15		110	80	72	110	80	80
				Day 0	25/03/91	36.50		56.00	110	80	72	110	80	80
				Day 7	01/04/91	36.70		55.80	115	70	88	115	70	92
				Day 14	08/04/91	36.60		58.00	120	75	88	100	65	92
				Day 21	15/04/91	36.80		59.00	110	80	72	115	80	120
				Day 28	22/04/91	36.50		59.00	100	70	64	110	70	80
				Day 35	29/04/91	36.00		59.00	110	80	60	110	90	80
				Day 42	06/05/91	36.60		63.50	140	90	68	110	80	120
	44	Imipramine	Male	Screen	08/04/91	36.50	19		125	80	88	130	80	92
				Day 0	10/04/91	36.50		67.50	125	80	88	130	80	92
	45	Imipramine	Female	Screen	26/04/91	37.10	25		110	75	84	110	80	88
				Day 0	29/04/91	37.10		62.60	110	75	84	110	80	88
	46	Reboxetine	Female	Screen	14/05/91	36.10	18		120	80	68	125	85	80
				Day 0	15/05/91	36.10		67.00	120	80	68	125	85	80
				Day 7	22/05/91	36.40		65.70	155	95	72	125	85	100
				Day 14	29/05/91	36.00		65.60	125	85	80	115	85	100
				Day 21	05/06/91	36.30		65.00	125	95	88	105	85	100
				Day 28	12/06/91	35.50		64.30	140	80	116	120	80	112
				Day 35	19/06/91	36.00		64.90	120	80	80	110	80	96
				Day 42	26/06/91	35.50		63.70	130	80	86	120	80	94
	47	Reboxetine	Female	Screen	17/05/91	37.00	16		120	85	60	115	85	64
				Day 0	21/05/91	37.00		73.50	120	85	60	115	85	64
				Day 7	28/05/91	36.60		72.30	120	80	84	115	85	100
				Day 14	04/06/91	36.30		72.20	135	90	76	120	90	76
				Day 21	11/06/91	37.10		72.00	135	90	76	130	90	94
				Day 28	18/06/91	36.20		72.00	130	80	80	120	85	100
				Day 35	25/06/91	36.50		71.00	120	80	88	110	70	88
				Day 42	02/07/91	36.40		70.00	130	90	84	120	90	88

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
2	48	Imipramine	Female	Screen	23/08/91	36.10	22		160	90	92	130	90	116
				Day 0	26/08/91	36.10		80.50	160	90	92	130	90	116
				Day 7	02/09/91	36.20		83.30	130	70	96	120	80	120
				Day 14	09/09/91	37.00		82.50	100	60	88	130	70	96
				Day 21	16/09/91	37.00		83.50	105	70	88	110	70	96
				Day 28	23/09/91	37.50		83.50	125	80	68	140	90	88
				Day 35	30/09/91	37.40		82.50	160	90	96	120	90	120
				Day 42	07/10/91	36.00		83.00	135	65	60	110	85	90
	49	Imipramine	Female	Screen	27/08/91	36.50	18		130	90	78	125	80	82
				Day 0	28/08/91	36.50		53.50	130	90	78	125	80	82
				Day 7	04/09/91	36.00		52.50	150	90	96	130	90	120
				Day 14	11/09/91	36.90		55.00	105	60	100	100	60	120
				Day 21	18/09/91	36.50		54.70	120	70	92	115	70	104
				Day 28	25/09/91	37.30		54.50	120	65	96	110	75	100
				Day 35	02/10/91	37.00		54.70	130	70	92	130	70	96
				Day 42	09/10/91	37.00		55.00	125	70	80	130	70	96
	50	Reboxetine	Male	Screen	31/10/91	36.50	21		120	60	68	120	65	104
				Day 0	05/11/91	36.40		78.00	95	65	96	100	70	108
				Day 7	12/11/91	35.70		78.00	120	75	92	120	80	110
				Day 14	19/11/91	35.80		79.50	110	80	100	90	70	100
				Day 21	26/11/91	36.20		77.30	115	80	92	110	70	96
				Day 28	03/12/91	36.00		77.50	100	75	90	100	70	112
				Day 35	10/12/91	37.10		78.50	130	80	104	110	80	116
	51	Reboxetine	Female	Screen	30/10/91	36.20	16		120	90	92	110	70	100
				Day 0	05/11/91	36.80		74.50	95	60	92	105	80	104
				Day 7	12/11/91	36.90		75.50	130	70	100	110	65	88
	52	Imipramine	Male	Screen	13/11/91	36.70	24		110	85	80	125	70	80
				Day 0	26/11/91	37.00		78.00	110	60	64	115	80	84
				Day 7	03/12/91	36.90		77.60	105	65	88	95	60	120
				Day 14	10/12/91	37.30		79.00	110	60	64	110	70	108
				Day 21	17/12/91	36.40		77.30	110	70	80	120	70	100
				Day 28	24/12/91	37.10		77.70	115	75	84	95	80	120
				Day 35	31/12/91	37.50		76.80	125	80	64	130	80	84
				Day 42	07/01/92	37.00		77.10	110	60	88	120	70	100
3	65	Reboxetine	Male	Screen	28/03/91	37.20	16		135	90	104	150	95	100
				Day 0	01/04/91	37.40		86.40	145	95	84	135	90	96
				Day 7	08/04/91	36.40		85.50	140	90	100	135	90	88

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
3	65	Reboxetine	Male	Day 14	15/04/91	36.00		86.50	145	95	96	135	90	116
				Day 21	22/04/91	36.00		85.50	152	110	116	145	115	120
				Day 28	29/04/91	36.10		85.50	130	90	128	125	90	124
				Day 35	06/05/91	36.20		85.50	135	90	96	135	95	100
				Day 42	13/05/91	36.40		84.50	140	100	104	145	105	104
	66	Imipramine	Female	Screen	27/04/91	37.40	12		120	70	80	120	80	96
				Day 0	30/04/91	37.50		52.00	125	75	80	135	85	100
				Day 7	07/05/91	37.20		52.00	120	70	90	130	90	116
				Day 14	14/05/91	37.00		52.50	120	75	88	120	80	100
				Day 21	21/05/91	37.50		53.80	130	90	72	140	90	96
				Day 28	28/05/91	37.20		53.00	130	75	104	130	80	112
				Day 35	04/06/91	37.10		52.60	110	80	120	110	80	124
	67	Reboxetine	Female	Screen	05/04/91	37.00	11		160	90	76	170	100	96
				Day 0	10/04/91	36.90		65.00	150	85	72	165	90	100
				Day 7	16/04/91	37.30		64.70	160	105	104	145	110	116
				Day 14	23/04/91	37.20		64.10	140	100	104	155	110	120
				Day 21	30/04/91	36.90		64.80	120	85	84	130	95	108
				Day 28	07/05/91	37.00		64.20	145	90	84	160	105	104
				Day 35	14/05/91	36.70		64.40	140	90	84	145	90	112
				Day 42	21/05/91	37.40		64.40	145	90	84	160	105	96
	68	Imipramine	Female	Screen	01/08/91	37.20	12		120	90	68	105	75	88
				Day 0	03/08/91	37.00		60.50	130	80	80	110	80	93
				Day 7	09/08/91	37.00		62.00	120	80	92	90	60	120
				Day 14	16/08/91	37.20		62.50	110	80	116	105	60	120
				Day 21	23/08/91	36.90		64.00	120	80	92	95	60	116
				Day 28	30/08/91	37.10		64.20	110	80	100	105	80	120
				Day 35	06/09/91	36.80		64.50	115	75	88	110	80	104
				Day 42	13/09/91	37.00		65.00	120	80	92	115	80	108
	69	Imipramine	Female	Screen	28/02/91	37.10	12		120	70	80	130	78	88
				Day 0	01/03/91	37.10		58.50	125	70	84	130	70	96
				Day 7	07/03/91	36.80		60.50	125	80	96	110	85	112
				Day 14	14/03/91	36.30		60.00	110	80	88	125	85	100
				Day 21	21/03/91	36.40		59.00	120	85	100	125	95	112
				Day 28	28/03/91	36.50		60.00	120	80	96	125	90	116
				Day 35	04/04/91	36.50		60.00	130	80	96	125	95	120
				Day 42	11/04/91	36.50		60.00	125	85	84	115	95	112
	70	Reboxetine	Female	Screen	21/10/91	36.90	8		120	80	60	125	90	76
				Day 0	23/10/91	37.00		78.00	130	80	64	130	80	88
				Day 7	29/10/91	36.80		80.00	160	90	96	115	80	132

1400

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
3	70	Reboxetine	Female	Day 14	05/11/91	37.00		79.00	130	85	88	115	80	108
				Day 21	12/11/91	37.00		79.40	125	80	88	120	80	96
				Day 28	19/11/91	36.80		77.00	125	75	100	110	85	120
	71	Imipramine	Female	Screen	12/11/91	36.60	12		130	70	80	125	80	88
				Day 0	14/11/91	36.60		55.40	120	75	76	125	85	102
				Day 7	20/11/91	36.80		55.40	110	75	80	120	80	106
				Day 14	27/11/91	36.80		54.00	120	80	88	130	85	104
				Day 21	04/12/91	37.00		55.00	115	80	100	120	85	128
				Day 28	11/12/91	37.00		54.70	120	85	100	125	85	116
				Day 35	18/12/91	36.80		55.10	125	75	104	120	85	134
				Day 42	25/12/91	36.80		55.00	125	80	112	115	80	128
	72	Reboxetine	Female	Screen	28/01/92	37.00	12		130	80	80	120	80	92
				Day 0	31/01/92	36.80		55.80	120	75	76	120	80	92
				Day 7	07/02/92	36.80		56.00	100	70	84	100	70	96
				Day 14	14/02/92	36.80		56.00	130	80	76	125	80	84
				Day 21	21/02/92	36.80		56.30	120	80	88	125	88	92
				Day 28	28/02/92	37.00		56.60	115	85	84	105	85	100
				Day 35	06/03/92	36.60		55.70	100	70	84	95	70	100
				Day 42	13/03/92	37.00		55.80	100	70	84	95	65	100
	73	Reboxetine	Female	Screen	11/02/92	36.90	12		120	70	80	130	80	84
				Day 0	13/02/92	36.80		82.00	120	70	80	125	80	88
				Day 7	21/02/92	36.80		82.00	110	80	80	110	80	96
				Day 14	28/02/92	37.60		83.90	140	95	72	145	100	84
				Day 21	06/03/92	38.00		82.80	145	105	64	150	110	76
				Day 28	13/03/92	36.60		83.90	130	90	68	140	85	72
				Day 35	21/03/92	36.60		83.20	140	90	70	130	85	74
				Day 42	28/03/92	36.70		83.90	150	95	92	145	90	92
4	97	Imipramine	Male	Screen	06/05/92	36.40	14		145	90	70	150	90	70
				Day 0	07/05/92	36.50		60.00	130	60	70	130	80	70
				Day 7	13/05/92	36.20		60.20	145	90	65	150	100	72
				Day 14	20/05/92	36.20		60.10	130	80		135	90	
				Day 21	27/05/92	36.10		60.00	130	90	66	130	95	67
				Day 28	03/06/92	36.20		60.60	130	80	62	130	80	66
				Day 35	10/06/92	36.50		60.40	140	95	68	140	100	72
				Day 42	18/06/92	36.40		59.80	125	80	65	135	85	70
	100	Reboxetine	Female	Screen	01/05/92	36.50	20		130	80	65	130	90	72
				Day 0	07/05/92	36.80		59.00	130	80	65	130	90	72
				Day 7	13/05/92	36.40		59.00	130	85	70	135	90	
				Day 14	20/05/92	36.40		59.50	120	80	70	120	85	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
4	100	Reboxetine	Female	Day 21	27/05/92	36.50		60.00	125	85	75	130	90	
				Day 28	03/06/92	36.50		60.20	120	80	68	130	80	70
				Day 35	10/06/92	36.40		60.50	130	85	75	130	90	80
				Day 42	17/06/92	36.30		60.80	125	80	68	130	80	70
	101	Imipramine	Female	Screen	06/05/91	36.50	21		125	80	84	130	90	120
				Day 0	06/05/91	36.50		66.50	125	80	84	130	90	100
				Day 7	13/05/91	37.00		67.00	140	85	84	140	100	94
				Day 14	21/05/91	36.50			140	80		130	80	
				Day 21	23/05/91				130	90	80	130	90	88
6	161	Reboxetine	Male	Screen	26/03/91	36.60	19		130	90	70	100	80	102
				Day 0	28/03/91	36.60		73.00	140	90	68	105	70	100
				Day 7	04/04/91	36.80		73.50	135	90	84	100	80	84
				Day 14	11/04/91	36.30		73.00	110	70	84	100	60	88
				Day 21	18/04/91	36.00		73.50	130	80	100	110	70	100
				Day 28	25/04/91	36.00		73.00	120	80	72	110	80	92
				Day 35	02/05/91	36.10		73.50	110	65	76	120	80	88
				Day 42	09/05/91	36.40		72.00	130	80	68	120	90	72
	162	Reboxetine	Female	Screen	02/11/91	36.90	20		120	60	80	130	70	96
				Day 0	04/11/91	36.70		65.00	120	80	100	120	80	100
				Day 7	11/11/91	36.50		66.00	120	80	84	120	90	88
				Day 14	18/11/91	36.40		65.50	110	80	80	110	80	100
				Day 21	25/11/91	36.70		66.00	120	80	80	120	85	84
				Day 28	02/12/91	36.80		66.00	100	70	80	110	80	92
				Day 35	09/12/91	36.60		67.00	120	80	84	110	85	80
				Day 42	16/12/91	36.20		66.00	115	80	82	120	80	80
7	193	Reboxetine	Female	Screen	07/06/91	37.00	20		100	60	76	95	60	76
				Day 0	11/06/91	38.00		73.50	110	60	88	100	60	88
	194	Reboxetine	Male	Screen	30/05/91	37.00	20		140	100	76	140	100	82
				Day 0	01/06/91	37.00		120.00	140	100	76	140	100	82
				Day 7	10/06/91	37.00		120.00	160	100	86	140	100	86
	196	Imipramine	Female	Screen	18/03/91	36.80	20		110	70	88	110	65	88
				Day 0	19/03/91	36.80		61.00	110	70	88	110	65	92
				Day 7	25/03/91	36.30		61.00	110	60	108	100	60	112
				Day 14	01/04/91	36.80		61.00	110	65	96	110	60	100
				Day 21	08/04/91	36.80		61.00	105	70	96	110	70	100
				Day 28	15/04/91	37.00		61.00	110	70	100	100	80	112
				Day 35	22/04/91	37.00		61.50	110	70	96	120	80	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
7	196	Imipramine	Female	Day 42	27/04/91	37.00		61.00	110	70	92	110	60	96
8	225	Imipramine	Female	Screen	22/03/91	36.80						105	55	92
				Day 0	22/03/91	36.80		75.00				105	55	92
				Day 7	29/03/91	36.80		75.00	100	60		90	60	98
				Day 14	05/04/91	37.20		76.00				110	60	120
	226	Reboxetine	Female	Screen	02/05/91	36.40	17		130	70	76	140	70	80
				Day 0	03/05/91	36.60		60.00	130	70	72	140	70	88
				Day 7	10/05/91	36.20		60.00	110	70	88	130	80	100
				Day 14	17/05/91	36.00		60.00	100	60	72	110	70	92
				Day 21	24/05/91	36.00		60.00	120	80	80	125	80	88
				Day 28	31/05/91	36.00		60.00	110	80	76	110	85	84
				Day 35	07/06/91	36.70		61.00	120	80	84	120	70	100
				Day 42	14/06/91	36.70		60.50	120	70	88	120	80	100
	227	Imipramine	Male	Screen	28/04/91	36.40	20		130	90	80	120	80	80
				Day 0	07/05/91	36.50		96.00	130	80	76	120	80	72
				Day 7	14/05/91	36.20		95.00	125	75	70	120	70	72
				Day 14	21/05/91	36.60		95.00	130	90	72	125	85	72
				Day 21	28/05/91	36.50		95.00	120	70	80	120	75	80
				Day 28	04/06/91	36.40		94.00	120	80	70	120	80	70
				Day 35	11/06/91	36.50		94.00	130	80	72	130	85	72
				Day 42	18/06/91	36.40		94.00	120	70	80	120	75	84
	228	Reboxetine	Male	Screen	06/05/91	36.50	14		120	80	78	120	75	80
				Day 0	10/05/91	36.40		82.50	120	80	80	120	75	80
				Day 7	17/05/91	36.40		82.50	120	80	75	120	80	75
				Day 14	18/05/91	36.50		82.00	120	80	78	120	80	78
	229	Imipramine	Female	Screen	18/10/91	37.00	16					110	70	72
				Day 0	22/10/91	36.50		68.50	120	80	80	120	70	88
				Day 7	29/10/91	35.50		69.00	135	80	80	130	85	92
				Day 14	05/11/91	36.00		69.00	120	80	80	110	80	88
				Day 21	12/11/91	36.50		69.00	120	80	80	120	70	88
				Day 28	19/11/91	37.00		70.00	120	80	88	130	90	92
				Day 35	26/11/91	37.00		70.00	120	80	88	130	90	92
				Day 42	03/12/91	35.70		69.00	130	80	84	120	80	96
	230	Imipramine	Female	Screen	31/10/91	36.50	20					110	80	108
				Day 0	05/11/91	37.10		64.00	105	60	88	90	60	108
				Day 7	12/11/91	36.70		64.00	120	75	88	100	80	108
				Day 14	19/11/91	35.80		62.50	110	70	92	95	60	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
8	230	Imipramine	Female	Day 21	26/11/91	35.80		63.00	100	60	92	95	60	120
				Day 28	03/12/91	35.30		62.80	120	80	92	110	70	96
				Day 35	10/12/91	35.80		63.00	110	70	96	120	70	104
				Day 42	17/12/91	36.20		64.00	115	80		120	80	112
	231	Reboxetine	Female	Screen	28/10/91	36.30			115	60	80	110	60	84
				Day 0	05/11/91			57.50	115	80				
				Day 7	12/11/91	36.60		57.00	120	60	80	100	80	88
	232	Reboxetine	Male	Screen	26/11/91	36.60	15		130	90	80	120	85	82
				Day 0	29/11/91	36.40		74.00	110	80	80	100	60	80
				Day 7	06/12/91	35.00		74.00	120	70	84	115	70	84
				Day 14	13/12/91	35.40		74.00	130	75	68	105	70	92
				Day 21	20/12/91	35.70		73.00	140	70	92	115	60	104
				Day 28	27/12/91	36.20		73.00	130	70	90	115	70	96
				Day 35	03/01/92	36.60		73.00	130	70	82	120	75	84
				Day 42	10/01/92	36.40		73.50	130	70	86	120	70	90
9	197	Reboxetine	Male	Screen	27/02/92	36.50	16		150	100	75	145	100	75
				Day 0	06/03/92	36.00		90.00	130	85	76	130	90	76
				Day 7	13/03/92	36.30		92.00	170	100	70	175	100	74
	198	Imipramine	Female	Screen	10/03/92	35.80	18		100	60	85	110	70	92
				Day 0	17/03/92	36.20		63.00	140	90	78	130	90	78
				Day 7	24/03/92	36.30		62.00	130	100	72	128	98	72
				Day 14	31/03/92	35.90		61.00	135	100	90	130	95	90
				Day 21	07/04/92	36.50		62.00	130	70	84	130	70	90
				Day 28	14/04/92	36.30		62.00	130	90	76	120	90	80
				Day 35	21/04/92	36.50		62.00	120	80	72	120	80	80
				Day 42	28/04/92	36.50		62.00	130	90	84	130	90	92
	199	Imipramine	Male	Screen	24/03/92	36.30	13		130	100	80	125	95	80
				Day 0	01/04/92	36.30		86.00	120	80	92	125	85	86
				Day 7	08/04/92	36.10		85.00	160	100	100	145	105	108
				Day 14	15/04/92	36.30		85.00	135	100	78	125	90	84
				Day 21	22/04/92	36.50		83.00	130	90	104	110	90	108
				Day 28	29/04/92	36.80		85.00	130	90	96	125	90	104
				Day 35	06/05/92	36.40		85.00	130	90	88	110	80	92
				Day 42	13/05/92	36.60		84.00	110	65	94	115	80	104
	200	Reboxetine	Male	Screen	21/04/92	36.50	18		140	90	68	145	100	78
				Day 0	27/04/92	36.50		84.00	120	80	72	120	80	80
				Day 7	04/05/92	36.50		84.00	140	90	72	120	80	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	200	Reboxetine	Male	Day 14	11/05/92	36.50		84.00	130	90	72	120	80	80
				Day 21	18/05/92	36.70		84.00	145	100	90	140	100	86
				Day 28	25/05/92	36.50		84.00	140	80	80	120	80	80
				Day 35	01/06/92	36.70		84.00	120	80	72	120	80	76
				Day 42	08/06/92	36.50		84.00	130	80	72	120	75	78
	201	Imipramine	Female	Screen	07/01/92	36.30			140	75	68	180	95	80
				Day 0	15/01/92	36.80		71.00	135	95	84	130	100	80
				Day 7	22/01/92	36.40		71.00	145	95	84	140	90	84
				Day 14	29/01/92	36.30		71.00	150	85	72	140	80	72
				Day 21	05/02/92	36.30		71.00	155	85	80	145	80	80
				Day 28	13/02/92	36.50		70.00	135	90	80	130	90	72
				Day 35	19/02/92	36.70			120	80	84	120	80	68
				Day 42	26/02/92	36.70		69.50	135	95	92	135	90	84
	202	Imipramine	Male	Screen	09/01/92	36.30	18		150	100	70	155	95	76
				Day 0	16/01/92	36.30		67.00	150	70	76	150	75	76
				Day 7	23/01/92	36.10		67.00	135	80	88	140	85	96
				Day 14	30/01/92	36.30			180	110	80	160	100	80
				Day 21	06/02/92	36.60		66.00	160	100	72	150	100	72
				Day 28	13/02/92	35.80		66.00	165	95	88	170	100	92
				Day 35	20/02/92	36.30		66.00	180	110	90	170	105	90
				Day 42	27/02/92	36.40		64.00	160	95	76	155	95	76
	203	Reboxetine	Female	Screen	09/01/92	36.70	18		110	80	68	110	80	68
				Day 0	14/01/92	36.70		78.00	135	100	80	140	95	84
				Day 7	28/01/92	36.30		78.00	95	55	80	110	60	84
	204	Reboxetine	Male	Screen	09/01/92	36.30	18		150	100	62	155	110	76
				Day 0	16/01/92	36.00		88.00	210	130	88	210	135	88
				Day 7	23/01/92	36.70		86.50	210	145	92	200	140	92
				Day 14	30/01/92	36.70		86.00	140	71	74	140	71	78
				Day 21	06/02/92	36.70		86.00	125	85	71	125	90	73
				Day 28	14/02/92	36.30		87.00	145	90	68	145	100	72
				Day 35	21/02/92	36.20		87.00	140	90	66	145	100	72
				Day 42	28/02/92	36.70		85.00	160	95	80	165	95	80
	205	Imipramine	Female	Screen	27/01/92	36.90	18		130	90	76	140	90	76
				Day 0	05/02/92	36.70		51.00	150	90	76	135	80	76
	206	Imipramine	Female	Screen	28/01/92	36.30	18		115	75	66	125	90	72
				Day 0	04/02/92	36.40			125	80	68	125	80	72
				Day 7	12/02/92	36.20		64.80	160	90	64	130	85	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	206	Imipramine	Female	Day 14	19/02/92	36.30		65.00	120	80	90	115	80	120
				Day 21	26/02/92	36.60		64.50	110	80	90	110	80	112
				Day 28	04/03/92	36.30		64.50	110	85	86	115	80	92
				Day 35	11/03/92	36.50		64.60	120	90	84	120	95	90
				Day 42	18/03/92	36.20		65.00	120	90	84	120	95	88
	207	Reboxetine	Female	Screen	27/01/92	36.40	24		120	70	72	145	65	84
				Day 0	05/02/92	36.70		72.00	120	80	84	110	80	84
				Day 7	12/02/92	36.70		72.00	125	90	90	115	90	80
	208	Reboxetine	Male	Screen	10/02/92	36.60	18		150	90	66	150	100	72
				Day 0	14/02/92	36.10		84.00	110	75	76	105	65	76
				Day 7	21/02/92	36.40		84.00	130	80	80	135	85	68
				Day 14	28/02/92	36.50		84.00	145	105	72	130	105	72
				Day 21	06/03/92	36.30		82.00	150	100	62	145	100	
				Day 28	13/03/92	36.70		84.00	130	70	76	130	65	76
				Day 35	20/03/92	36.50		83.50	130	60	80	120	70	84
				Day 42	27/03/92	36.20		82.00	150	100	63	140	90	63
	209	Imipramine	Male	Screen	04/02/92	36.70	15		120	90	60	125	100	60
				Day 0	11/02/92	36.10		65.00	130	75	72	135	80	78
				Day 7	18/02/92	36.00		65.00	135	80	78	135	85	80
	210	Reboxetine	Female	Screen	05/02/92		18		130	80	80	130	80	80
				Day 0	19/02/92	36.30		71.00	145	90	66	140	95	72
				Day 7	26/02/92	36.60		72.00	155	80	92	130	100	90
				Day 14	04/03/92	36.50		65.50	120	80	76	120	85	102
				Day 21	11/03/92	36.70		72.30	160	90	84	130	90	84
				Day 28	18/03/92	36.20		71.50	130	80	80	120	75	84
				Day 35	25/03/92	36.30		71.00	140	90	92	150	90	90
				Day 42	01/04/92	36.50		71.00	130	90	88	120	85	92
	211	Reboxetine	Female	Screen	11/02/92	36.80	18		110	70	63	110	80	63
				Day 0	14/02/92	36.80		63.00	110	80	66	115	80	66
				Day 7	21/02/92	36.30		61.40	110	75	84	115	80	84
				Day 14	28/02/92	36.60		60.30	120	60	72	120	60	76
				Day 21	03/03/92	36.20		60.00	120	65	72	135	65	78
	212	Imipramine	Female	Screen	24/02/92	36.90	17		150	90	70	140	90	70
				Day 0	03/03/92	36.30		61.00	120	75	84	110	70	84
				Day 7	10/03/92	36.70		61.00	135	85	84	130	80	84
				Day 14	17/03/92	36.20		61.00	130	80	82	130	80	84
				Day 21	24/03/92	36.90		61.00	130	70	80	135	75	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	212	Imipramine	Female	Day 28	31/03/92	37.10		62.00	140	80	76	145	85	82
				Day 35	07/04/92	36.30		61.00	135	80	92	140	85	96
				Day 42	14/04/92	36.50		61.00	160	90	94	140	80	94
	237	Reboxetine	Male	Screen	15/04/92	36.20	17		135	75	76	145	90	76
				Day 0	22/04/92	36.50		75.00	135	95	76	145	90	76
				Day 7	29/04/92	36.70		75.00	135	90	80	140	90	80
				Day 14	06/05/92	37.00		75.00	135	90	100	135	90	100
	238	Imipramine	Female	Screen	12/05/92	36.20	18		110	75	78	115	80	82
				Day 0	19/05/92	36.40		77.00	120	80	80	115	80	80
				Day 7	26/05/92	36.70		74.00	145	80	84	125	90	92
				Day 14	02/06/92	36.50		74.00	150	80	72	150	80	76
				Day 21	09/06/92	36.70		74.00	130	90	72	120	80	76
				Day 28	16/06/92	36.70		74.00	120	80	80	130	80	84
				Day 35	23/06/92	36.60		74.00	135	90	80	130	80	86
				Day 42	30/06/92	36.80		74.00	140	80	78	120	70	86
	239	Imipramine	Male	Screen	22/04/92	36.20	19		130	85	52	140	90	69
				Day 0	29/04/92	36.20		103.00	130	85	64	140	90	68
				Day 7	06/05/92	36.50		103.00	110	70	60	110	70	60
				Day 14	13/05/92	36.50		103.00	130	90	72	120	70	76
				Day 21	20/05/92	36.50		103.00	120	90	68	110	70	72
				Day 28	27/05/92	36.70		103.00	120	85	66	120	70	68
				Day 35	03/06/92	36.60		103.00	130	85	70	130	70	68
				Day 42	10/06/92	36.50		103.00	130	90	60	130	80	64
	240	Reboxetine	Female	Screen	23/04/92	36.40	18		120	80	70	125	85	78
				Day 0	28/04/92	36.50		61.00	120	80	70	120	80	78
				Day 7	05/05/92	36.30		62.00	120	80	76	110	70	80
				Day 14	12/05/92	37.00		62.00	125	85	72	115	80	80
	241	Imipramine	Female	Screen	05/05/92	37.30	18		130	100	96	125	95	100
				Day 0	08/05/92	36.50		80.30	120	90	84	130	100	92
				Day 7	15/05/92	37.40		79.50	125	80	80	120	80	92
				Day 14	22/05/92	36.80		79.70	140	100	76	105	70	84
				Day 21	29/05/92	36.70		79.00	140	70	76	155	75	76
				Day 28	05/06/92	36.70		82.80	130	70	76	100	70	84
				Day 35	12/06/92	36.60		82.80	120	75	76	110	70	88
				Day 42	19/06/92	36.50		82.00	120	75	76	120	75	76
	242	Reboxetine	Male	Screen	30/04/92	36.10	19		135	95	89	145	100	96
				Day 0	07/05/92	36.30		50.00	140	90	92	140	90	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	242	Reboxetine	Male	Day 7	14/05/92	36.10		50.00	105	80	92	110	80	104
				Day 14	21/05/92	35.90		50.00	110	65	96	115	70	104
				Day 21	27/05/92	35.90		50.00	105	55	89	90	45	84
				Day 28	03/06/92	35.70		50.00	110	60	92	100	60	100
				Day 35	10/06/92	36.10		50.00	110	60	100	110	60	100
				Day 42	17/06/92	36.60		50.00	100	68	102	90	70	102
	243	Imipramine	Female	Screen	11/05/92	36.50	20		120	70	80	130	80	80
				Day 0	18/05/92	36.60		54.50	125	75	84	130	85	104
				Day 7	25/05/92	36.70		53.50	140	80	88	100	90	108
				Day 14	01/06/92	36.90		53.80	100	70	80	75	60	88
				Day 21	08/06/92	36.80		53.80	100	75	76	95	75	80
				Day 28	15/06/92	36.80		53.30	110	70	80	115	80	96
				Day 35	22/06/92	36.50		53.00	120	85	76	120	80	84
				Day 42	29/06/92	36.60		53.30	105	75	76	110	85	80
	244	Reboxetine	Male	Screen	25/05/92	36.30			120	70	82	140	90	82
				Day 0	05/06/92	36.70		90.00	120	90	72	130	90	80
				Day 7	12/06/92	36.50		90.00	130	80	76	120	70	82
				Day 14	19/06/92	36.70		90.00	120	80	80	130	70	84
				Day 21	26/06/92	36.60		90.00	130	80	76	130	80	80
				Day 28	03/07/92	36.50		90.00	140	90	80	140	90	88
				Day 35	11/07/92	36.50		90.00	140	80	80	140	80	80
				Day 42	17/07/92	36.80		90.00	130	70	100	130	70	100
	257	Reboxetine	Female	Screen	10/07/91	36.70	22		115	95	76	120	80	88
				Day 0	17/07/91	36.60			110	70	80	120	80	80
				Day 7	24/07/91	37.10		79.00	115	85		115	90	
				Day 14	31/07/91			76.00			84	140	100	92
				Day 21	07/08/91	37.20		78.50	120	80	96	115	85	98
				Day 28	14/08/91	36.30		76.30	130	85	84	120	80	88
				Day 35	21/08/91	36.30		80.00	120	90	76	120	90	78
				Day 42	28/08/91			76.00	120	85	74	120	85	74
	258	Reboxetine	Male	Screen	10/07/91	36.70	21		130	80	76	135	80	80
				Day 0	17/07/91	36.70		79.00	140	90	84	150	90	86
				Day 7	24/07/91	36.40		79.00	130	80	84	155	95	84
				Day 14	31/07/91	36.40		78.00	130	75	96	135	70	96
				Day 21	07/08/91	36.90		77.50	125	100	72	130	105	72
	259	Imipramine	Female	Screen	10/07/91	36.40	22		130	50	60	135	75	68
				Day 0	17/07/91	36.30		65.00	135	85	80	130	85	86
				Day 7	24/07/91			65.00	130	85	82	125	80	86
				Day 14	31/07/91			65.00	125	80	76	120	80	82

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	259	Imipramine	Female	Day 21	07/08/91			65.00	125	80	84	125	80	86
				Day 28	14/08/91			65.00	130	80	76	130	80	78
				Day 35	21/08/91			65.00	120	80		120	80	
				Day 42	28/08/91	36.30		65.00	125	80	84	125	80	86
	260	Imipramine	Female	Screen	17/07/91	36.70	20		120	65	64	110	60	86
				Day 0	24/07/91	36.80		49.50	110	80	88	110	73	80
				Day 7	31/07/91							140	80	
				Day 14	07/08/91	36.70		49.00	130	75	96	105	65	92
				Day 21	14/08/91	36.80		49.90	115	95	72	115	60	72
	261	Imipramine	Female	Screen	19/07/91	36.40	24		145	80	76	145	80	76
				Day 0	23/07/91	36.70		94.00	135	95	80	140	90	76
				Day 7	30/07/91	36.90		97.00	150	90	96	160	95	92
	262	Reboxetine	Male	Screen	16/07/91	36.40	20		150	100	72	145	105	80
				Day 0	23/07/91	36.70		96.00	140	100	84	140	95	92
				Day 7	30/07/91	36.20		97.00	150	80	76	140	70	78
				Day 14	06/08/91	36.60		97.00	130	80	88	135	85	92
				Day 21	13/08/91	36.30		95.00	160	90	110	170	100	112
				Day 28	20/08/91	36.30		95.00	150	75	88	155	80	92
				Day 35	27/08/91	36.30		97.00	110	70	100	130	90	108
				Day 42	03/09/91	36.30		97.00	150	90	88	135	100	94
	263	Reboxetine	Female	Screen	24/07/91	36.90	18		115	90	76	130	90	72
				Day 0	31/07/91	36.90		59.00	115	70	80	110	70	86
				Day 7	07/08/91	36.80		59.00	115	90	82	120	85	92
				Day 14	14/08/91	36.30		59.00	110	80	80	115	85	84
	264	Imipramine	Female	Screen	21/07/91	36.90	21		135	65	80	130	80	88
				Day 0	31/07/91	36.90		69.00	140	90	72	150	80	68
				Day 7	07/08/91	36.70		68.00	120	60	96	95	60	92
				Day 14	14/08/91	36.70		68.00	130	90	80	100	90	80
				Day 21	21/08/91			65.00	100	70	99	100	70	99
				Day 28	28/08/91			65.00	120	70		110	70	
				Day 35	04/09/91			65.00	120	70	70	120	70	70
				Day 42	11/09/91	36.70		66.00	110	70	68	110	70	68
	265	Reboxetine	Female	Screen	13/08/91	36.70	20		130	70	76	135	80	84
				Day 0	22/08/91	36.30		60.00	130	70	76	135	80	84
				Day 7	29/08/91	36.80		60.00	100	60	90	85	45	94
				Day 14	05/09/91	36.40		60.00	95	45	74	95	50	92
				Day 21	12/09/91	36.30		60.00	120	70	82	115	75	86

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	265	Reboxetine	Female	Day 28	19/09/91	36.40		57.50	120	80	84	115	75	96
				Day 35	26/09/91	36.10		58.00	110	75	88	105	70	91
				Day 42	03/10/91	36.30		58.50	90	45	76	85	40	86
	266	Reboxetine	Female	Screen	10/09/91	36.30	20		130	75	76	135	80	84
				Day 0	17/09/91	35.90		59.00	110	70	72	105	60	78
				Day 7	24/09/91	35.90		60.50	110	65	74	105	70	104
				Day 14	01/10/91	36.00		59.50	95	45	96	95	55	104
				Day 21	08/10/91	36.30		59.50	90	45	85	95	50	90
				Day 28	15/10/91	36.30		61.00	105	70	86	110	75	90
				Day 35	22/10/91	36.30		60.00	120	90	90	125	95	103
				Day 42	29/10/91	36.30		61.00	120	80	96	115	85	104
	267	Imipramine	Male	Screen	30/08/91	37.30	24		105	65	73	100	70	100
				Day 0	30/08/91	36.00		72.00	120	80	80	100	80	89
				Day 7	09/09/91	35.90		69.00	120	80	84	110	80	100
				Day 14	16/09/91	36.50		73.90	130	80	78	120	90	80
				Day 21	23/09/91	36.40		74.50	120	75	90	120	80	95
				Day 28	30/09/91	36.70		74.00	130	85	112	135	90	110
				Day 35	07/10/91	36.30		78.00	120	75	100	125	90	96
				Day 42	14/10/91	36.50		80.00	140	90	92	130	90	96
	268	Imipramine	Female	Screen	17/09/91	36.10	20		130	80	80	140	70	84
				Day 0	24/09/91	36.70		92.00	145	75	102	125	80	112
				Day 7	01/10/91	36.70		91.00	120	85	108	125	85	112
				Day 14	08/10/91	36.30		90.50	120	80	110	130	95	114
				Day 21	15/10/91	36.30		90.50	155	95	112	160	100	120
				Day 28	22/10/91	36.30		90.50	130	80	104	135	85	120
				Day 35	29/10/91	36.40		90.00	135	90	96	120	85	96
				Day 42	05/11/91	35.30		91.00	130	80	80	140	100	84
	269	Reboxetine	Male	Screen	19/09/91	36.80	18		160	85	90	150	80	85
				Day 0	24/09/91	36.40		81.50	115	75	85	110	70	90
				Day 7	01/10/91	36.40		82.00	130	80	88	125	75	96
				Day 14	08/10/91	36.30		82.00	115	80	88	120	85	88
				Day 21	15/10/91	36.00		82.50	135	80	70	140	85	82
				Day 28	22/10/91	36.40		83.00	135	75	84	135	80	92
				Day 35	29/10/91	36.20		84.00	120	70	96	120	80	96
				Day 42	05/11/91	36.20		85.00	120	75	76	116	80	80
	270	Imipramine	Female	Screen	02/10/91	36.90	22		145	100	72	130	90	76
				Day 0	10/10/91	36.40		52.00	110	85	72	115	85	72
				Day 7	17/10/91	36.30		57.00	75	40	150	65	40	156

1410

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9	271	Reboxetine	Female	Screen	22/10/91	36.30	20		160	100	60	150	55	64
				Day 0	29/10/91	36.00		64.90	130	80	72	140	80	80
				Day 7	05/11/91	36.40		62.50	120	80	60	130	90	60
				Day 14	12/11/91	36.20		66.50	110	80	72	120	80	76
				Day 21	19/11/91	36.40		65.70	140	100	68	160	110	72
				Day 28	26/11/91	36.90		65.60	140	90	76	150	95	82
	272	Imipramine	Male	Screen	22/10/91	36.40	21		150	75	88	140	90	92
				Day 0	29/10/91	36.30		84.00	120	90	54	140	90	60
				Day 7	05/11/91	37.00		84.00	125	90	60	145	90	62
				Day 14	12/11/91	36.30		81.50	120	90	64	130	90	60
				Day 21	19/11/91	36.30		80.00	130	75	58	135	80	60
				Day 28	26/11/91	36.30		81.00	100	55	70	95	50	75
				Day 35	03/12/91	36.20		85.50	135	70	56	135	80	64
				Day 42	10/12/91	36.00		83.00	145	80	60	140	80	66
1411	273	Imipramine	Female	Screen	24/10/91	36.60	20		130	70	88	135	75	92
				Day 0	29/10/91	36.90		73.00	100	65	76	110	70	88
				Day 7	05/11/91	35.90		72.00	110	65	84	120	80	92
				Day 14	12/11/91	36.20		71.60	100	70	76	110	70	80
				Day 21	19/11/91	37.40		72.50	110	70	76	120	70	84
				Day 28	26/11/91	36.70		72.20	100	70	72	90	65	76
	274	Reboxetine	Female	Screen	23/10/91	36.40	21		130	65	88	130	55	88
				Day 0	30/10/91	36.90		62.50	130	90	84	130	95	72
				Day 7	06/11/91	36.30		61.00	110	65	72	115	65	87
	274/A	Reboxetine	Female	Screen	21/04/92	35.80	18		120	80	64	125	85	68
				Day 0	12/05/92	36.30		52.00	120	80	72	120	80	76
				Day 7	19/05/92	36.30		50.00	100	65	72	95	65	76
				Day 14	26/05/92	36.50		52.00	130	80	80	120	80	86
				Day 21	02/06/92	36.40		52.00	100	70	74	110	70	80
				Day 28	09/06/92	36.30		52.00	120	70	76	110	70	80
				Day 35	16/06/92	36.50		52.00	110	70	92	100	60	100
				Day 42	24/06/92	36.70		52.00	120	80	76	110	70	82
	275	Reboxetine	Female	Screen	31/10/91	36.00	18		160	100	88	150	100	80
				Day 0	05/11/91	37.00		69.50	120	75	68	130	65	72
				Day 7	12/11/91	36.80		69.40	120	80	76	120	70	80
				Day 14	19/11/91	36.90		68.80	130	90	80	120	80	88
				Day 21	26/11/91	36.70		68.50	110	70	68	120	80	72
				Day 28	03/12/91	36.70		68.50	110	75	70	125	85	72

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
9	275	Reboxetine	Female	Day 35	10/12/91	36.70		68.50	115	75	75	130	85	75
				Day 42	17/12/91	37.00		68.50	115	70	70	125	75	74
	276	Imipramine	Female	Screen	24/12/91	36.40	20		160	105	96	140	110	96
				Day 0	09/01/92	37.20		71.50	145	90	68	150	95	72
				Day 7	16/01/92	36.30		68.50	145	80	68	135	75	74
	276/A	Imipramine	Male	Screen	24/02/92	36.30	18		130	100	73	130	95	73
				Day 0	03/03/92	36.90		88.00	120	80	72	130	80	72
				Day 7	10/03/92	36.70		88.00	130	90	76	130	75	84
				Day 14	17/03/92	36.30		88.50	120	70	80	120	70	80
				Day 21	24/03/92	36.30		88.00	130	90	82	135	90	86
				Day 28	31/03/92	36.70		88.00	120	70	80	120	70	80
				Day 35	07/04/92	36.20		84.00	125	70	84	125	75	86
				Day 42	14/04/92	36.50		87.00	130	90	86	130	80	86
9/A	233	Imipramine	Male	Screen	11/05/92	36.50	20		140	70	76	130	70	76
				Day 0	13/05/92	36.50		72.00	130	70	76	130	70	76
				Day 7	20/05/92	36.80		72.00	120	60	76	110	50	84
				Day 14	27/05/92	36.50		72.00	115	60	72	100	50	80
				Day 21	03/06/92	36.80		72.50	110	60	80	100	50	84
				Day 28	10/06/92	36.70		73.00	120	70	76	110	70	80
				Day 35	17/06/92	36.70		72.00	110	60	76	110	50	84
				Day 42	24/06/92	36.80		72.50	120	70	76	110	65	76
	234	Reboxetine	Female	Screen	18/05/92	36.60	18		115	75	76	108	70	80
				Day 0	21/05/92	36.50		44.00	115	75	72	105	70	76
				Day 7	29/05/92	36.40		44.00	110	75	72	100	70	76
				Day 14	04/06/92	36.50		43.00	120	70	76	105	75	72
				Day 21	11/06/92	36.40		42.50	115	85	72	100	80	76
				Day 28	18/06/92	36.70		43.00	110	80	80	100	75	76
				Day 35	25/06/92	36.50		43.50	115	80	80	105	75	80
				Day 42	02/07/92	36.80		43.50	110	70	80	110	65	84
	235	Reboxetine	Male	Screen	22/05/92	36.80	18		120	80	96	95	70	104
				Day 0	26/05/92	36.50		63.00	120	80	92	100	70	96
				Day 7	01/06/92	36.70		63.00	120	80	90	110	70	94
				Day 14	08/06/92	36.80		65.00	110	70	88	95	70	96
				Day 21	16/06/92	36.80		64.00	110	65	80	105	65	100
				Day 28	22/06/92	36.70		65.00	115	80	88	110	80	108
				Day 35	29/06/92	36.80		65.00	125	70	90	110	70	100
	236	Imipramine	Male	Screen	12/05/92	36.80	18		120	70	76	120	70	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9/A	236	Imipramine	Male	Day 0	26/05/92	36.70		78.00	120	70	72	115	70	76
				Day 7	02/06/92	36.80		78.50	110	70	68	110	70	68
				Day 14	10/06/92	36.70		79.00	125	80	96	100	80	100
				Day 21	16/06/92	36.50		79.50	125	80	96	105	60	90
				Day 28	23/06/92	36.70		79.00	130	80	76	115	70	80
				Day 35	30/06/92	36.50		79.00	140	70	72	120	70	76
				Day 42	07/07/92	36.80		79.50	125	65	76	120	65	76
	277	Reboxetine	Female	Screen	05/06/92	36.20	16		120	70	60	110	70	60
				Day 0	09/06/92	36.40		77.00	115	65	64	100	60	64
				Day 7	16/06/92	36.50		77.00	120	70	66	110	60	70
	278	Imipramine	Female	Screen	10/06/92	36.80	16		150	70	76	140	70	80
				Day 0	12/06/92	36.70		56.30	160	80	80	160	80	80
				Day 7	19/06/92	36.50		57.20	140	80	96	125	80	100
				Day 14	26/06/92	36.60		59.00	130	80	84	120	80	80
				Day 21	03/07/92	36.50		59.00	135	80	80	120	80	80
	279	Imipramine	Male	Screen	03/08/92	36.70	20		125	80	64	120	80	68
				Day 0	06/08/92	36.80		78.00	125	80	60	120	90	68
				Day 7	14/08/92	36.60		78.00	130	90	72	120	95	76
				Day 14	21/08/92	36.50		77.50	140	90	76	135	90	80
	280	Reboxetine	Female	Screen	04/08/92	36.50	18		120	70	72	110	65	80
				Day 0	07/08/92	36.50		70.00	130	70	76	125	70	84
				Day 7	14/08/92	36.60		70.00	135	70	76	130	70	88
	281	Reboxetine	Female	Screen	25/08/92	36.20	18		150	100	68	140	100	68
				Day 0	31/08/92	36.50		66.00	150	100	72	135	90	76
				Day 7	07/09/92	36.70		67.50	110	70	88	100	70	88
				Day 14	14/09/92	36.80		68.50	110	60	84	105	60	88
				Day 21	21/09/92	36.80		69.00	140	90	88	110	80	88
				Day 28	28/09/92	36.80		68.00	135	70	96	110	70	100
				Day 35	05/10/92	36.50		70.50	130	80	100	120	80	100
				Day 42	12/10/92	36.80		70.00	120	80	88	115	80	100
	282	Reboxetine	Male	Screen	14/08/92	36.50	20		130	80	80	105	60	88
				Day 0	01/09/92	36.80		80.00	140	80	76	110	60	84
				Day 7	08/09/92	36.70		80.00	110	80	60	100	80	68
				Day 14	15/09/92	36.80		78.50	125	70	76	135	95	80
				Day 21	22/09/92	36.50		75.50	100	80	108	100	70	112
				Day 28	29/09/92	36.50		74.00	120	80	88	100	70	100
				Day 35	06/10/92	36.70		74.00	130	80	76	120	80	100

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
9/A	282	Reboxetine	Male	Day 42	13/10/92	36.50		74.00	120	80	64	110	80	80
	283	Imipramine	Female	Screen	11/09/92	36.50	16		130	70	72	110	65	76
				Day 0	16/09/92	36.70		73.00	140	80	68	130	75	72
				Day 7	23/09/92	36.80		73.00	145	85	72	140	85	76
				Day 14	30/09/92	36.70		73.00	140	80	72	130	80	72
				Day 21	07/10/92	36.70		74.00	120	70	80	110	60	84
				Day 28	14/10/92	36.50		74.00	125	75	76	110	65	80
				Day 35	21/10/92	36.80		74.00	120	70	76	120	70	76
				Day 42	28/10/92	36.70		74.50	110	60	76	110	60	84
	284	Imipramine	Male	Screen	16/09/92	36.80	20		140	75	68	130	70	72
				Day 0	18/09/92	36.80		78.00	130	70	72	125	70	72
				Day 7	25/09/92	36.80		78.00	105	60	68	100	60	72
				Day 14	02/10/92	36.90		79.00	110	70	72	100	60	72
				Day 21	09/10/92	36.70		78.50	110	70	68	110	60	76
	301	Imipramine	Female	Screen	28/02/92	36.50	20		120	70	72	120	70	76
				Day 0	04/03/92	36.80		60.00	125	75	76	120	65	72
				Day 7	12/03/92	36.50		60.00	105	70	76	100	65	80
				Day 14	18/03/92	36.80		60.50	110	60	72	105	60	76
				Day 21	25/03/92	36.50		61.00	100	70	68	100	60	76
				Day 28	01/04/92	36.80		61.00	110	70	72	100	70	72
				Day 35	08/04/92	36.80		61.00	100	70	72	100	60	80
				Day 42	15/04/92	36.80		62.00	110	70	72	100	60	84
	302	Imipramine	Male	Screen	02/03/92	36.80	24		140	75	80	125	70	76
				Day 0	05/03/92	36.80		76.00	140	70	72	130	70	72
				Day 7	13/03/92	36.70		76.00	120	70	72	110	60	76
				Day 14	20/03/92	36.70		76.00	120	70	76	110	70	84
				Day 21	23/03/92	36.70		76.00	130	70	80	120	70	84
	303	Reboxetine	Female	Screen	06/03/92	36.80	22		120	80	76	110	80	100
				Day 0	11/03/92	36.50		77.50	110	70	72	110	70	80
				Day 7	19/03/92	36.80		72.00	100	70	72	100	60	76
				Day 14	25/03/92	36.50		77.00	95	70	72	90	60	80
				Day 21	31/03/92	36.80		77.00	100	70	72	90	60	84
	304	Reboxetine	Female	Screen	11/03/92	36.80	20		120	70	72	120	70	72
				Day 0	25/03/92	36.50		65.50	120	70	72	130	80	72
				Day 7	01/04/92	36.80		64.50	120	80	64	120	80	68
				Day 14	08/04/92	36.60		64.00	125	80	80	115	70	88
				Day 21	15/04/92	36.50		64.00	105	65	92	95	60	96

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
9/A	304	Reboxetine	Female	Day 28	22/04/92	36.50		64.00	95	70	72	90	70	76
				Day 35	29/04/92	36.80			120	80	80	110	70	80
				Day 42	06/05/92	36.70		64.50	120	80	88	110	70	92
	305	Reboxetine	Male	Screen	25/03/92	36.50	18		120	70	64	100	60	72
				Day 0	30/03/92			70.00	115	75	64	95	60	96
				Day 7	06/04/92	36.80		70.00	100	70	84	95	75	104
				Day 14	13/04/92	36.50		69.80	130	80	72	120	70	104
				Day 21	20/04/92	36.80		68.50	100	70	80	90	60	92
				Day 28	27/04/92	36.50		70.50	125	70	84	110	70	108
				Day 35	04/05/92	36.80		70.50	120	70	80	110	70	100
				Day 42	11/05/92	36.50		70.50	110	75	76	110	70	84
	306	Reboxetine	Female	Screen	24/04/92	36.60	20		100	70	96	90	60	100
				Day 0	28/04/92	36.70		48.00	110	70	96	100	60	96
				Day 7	05/05/92	36.70		48.00	120	70	96	110	70	96
				Day 14	12/05/92	36.80		49.20	120	80	88	110	70	96
				Day 21	19/05/92	36.50		49.20	120	70	88	100	55	90
				Day 28	26/05/92	36.40		49.50	120	70	84	100	55	88
				Day 35	02/06/92	36.60		49.50	115	65	80	100	60	88
				Day 42	09/06/92	36.80		50.00	120	70	80	110	60	88
	307	Imipramine	Female	Screen	30/04/92	36.90	16		120	70	76	110	70	80
				Day 0	05/05/92	36.50		80.00	120	70	76	120	70	80
				Day 7	11/05/92	36.50		80.00	130	80	72	120	70	80
	308	Imipramine	Female	Screen	07/05/92	36.80	20		115	70	96	115	65	100
				Day 0	09/05/92	36.50		62.00	110	70	104	115	70	100
				Day 7	15/05/92	36.80		61.00	120	60	100	105	70	96
				Day 14	22/05/92	36.50		61.00	110	70	96	110	70	96
				Day 21	29/05/92	36.80		61.00	120	65	110	115	60	100
				Day 28	02/06/92	36.80		61.90	120	70	90	120	80	120
10	289	Imipramine	Female	Screen	16/09/91	36.40	14		150	110	64	140	90	64
				Day 0	20/09/91	36.60		79.50	150	110	64	140	90	64
				Day 7	27/09/91	36.40		79.00	145	80	60	140	90	64
	290	Reboxetine	Male	Screen	07/10/91	36.70	24		120	70	80	120	80	100
				Day 0	14/10/91	37.00		75.80	130	80	68	100	70	64
				Day 7	21/10/91	36.00		76.00	105	60	68	90	60	68
				Day 14	28/10/91	36.00		76.30	110	50	88	90	60	92
				Day 21	04/11/91	36.80		75.20	130	70	64	105	60	64
				Day 28	11/11/91	36.30		75.30	110	85	84	100		80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
10	290	Reboxetine	Male	Day 35	18/11/91	36.60		74.40	120	90	80	110	85	76
				Day 42	25/11/91	36.00		74.00	120	70	100	120	70	134
	291	Imipramine	Male	Screen	13/02/92	36.20	14		120	70	72	120	75	72
				Day 0	17/02/92	36.00		84.00	120	70	72	120	75	72
				Day 7	24/02/92	36.60		86.00	142	73	68	120	80	88
				Day 14	02/03/92	36.60		86.00	110	70	76	110	65	68
				Day 21	09/03/92	36.00		86.60	120	80	76	90	60	80
				Day 28	16/03/92	36.20		88.40	140	80	80	100	70	88
				Day 35	23/03/92	36.00		88.80	120	80	76	90	70	80
				Day 42	30/03/92	36.00		90.50	130	70	80	100	60	88
	292	Reboxetine	Female	Screen	06/12/91	36.60	20		90	60	52	120	80	60
				Day 0	13/12/91	36.00		70.00	110	60	88	110	70	80
				Day 7	20/12/91	36.60		69.00	100	60	72	120	70	80
				Day 14	27/12/91	36.50		67.90	140	80	80	125	70	84
				Day 21	03/01/92	37.10		68.30	120	75	72	110	70	68
				Day 28	10/01/92	36.60		67.00	115	75	72	110	70	68
				Day 35	18/01/92	36.00		68.00	120	80	74	110	75	72
				Day 42	25/01/92	36.00		68.60	120	80	72	110	70	72
	293	Reboxetine	Female	Screen	16/12/91	35.70	28		150	100	80	150	100	100
				Day 0	24/12/91	36.80		57.50	120	70	96	100	60	120
				Day 7	31/12/91	36.30		57.80	140	80	104	150	90	104
				Day 14	07/01/92	36.30		58.00	140	80	88	120	90	112
				Day 21	14/01/92	36.40		57.00	140	70	100	145	80	80
				Day 28	21/01/92	36.50		57.40	160	80	100	145	90	96
				Day 35	28/01/92	36.60		57.00	110	70	88	130	90	108
				Day 42	04/02/92	37.20		57.00	130	70	108	120	60	120
	294	Imipramine	Female	Screen	30/12/91	36.50	20		130	80	84	130	80	84
				Day 0	02/01/92	36.00		55.00	130	80	80	130	80	86
				Day 7	09/01/92	36.90		54.50	150	100	72	150	85	100
				Day 14	16/01/92	36.90		54.50	150	100	72	135	85	100
				Day 21	23/01/92	36.60		54.00	140	70	80	150	80	88
	295	Imipramine	Male	Screen	02/01/92	36.00	16		120	80	64	120	100	84
				Day 0	06/01/92	36.00		87.00	120	80	64	120	100	84
				Day 7	14/01/92	36.50		86.00	150	100	100	130	80	96
				Day 14	20/01/92	36.80		86.90	100	70	72	100	70	72
				Day 21	27/01/92	36.40		86.90	150	100	72	100	85	100
				Day 28	03/02/92	36.00		86.50	110	70	68	100	80	100
				Day 35	10/02/92	36.20		84.50	120	70		130	80	
				Day 42	17/02/92	36.50		85.00	95	60	76	95	70	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
10	296	Reboxetine	Female	Screen	15/02/92	36.40	18		110	70	76	90	65	76
				Day 0	20/02/92	36.40		64.50	110	70	76	90	65	76
				Day 7	27/02/92	36.40		67.00	85	50	100	80	60	100
				Day 14	05/03/92	36.20		65.50	140	80	72	100	60	68
				Day 21	12/03/92	36.40		66.00	120	80	76	90	60	76
				Day 28	19/03/92	36.10		67.50	130	80	76	90	60	88
				Day 35	26/03/92	36.60		67.50	140	80	72	110	70	72
				Day 42	02/04/92	36.20		67.80	120	70	72	110	70	76
	297	Reboxetine	Male	Screen	19/03/92	37.00	20		105	70	60	110	85	100
				Day 0	20/03/92	37.00		68.50	105	70	76	110	85	80
				Day 7	28/03/92	36.80		69.00	110	75	76	100	80	80
				Day 14	04/04/92	36.60		69.50	105	70	76	100	70	80
				Day 21	11/04/92	36.20		68.60	120	86	68	110	70	76
				Day 28	18/04/92	36.40		71.00	130	80	83	100	80	96
				Day 35	25/04/92	36.60		71.00	130	80	88	100	80	95
				Day 42	02/05/92	36.60		72.00	130	80	84	100	80	92
	298	Reboxetine	Female	Day 0	26/03/92	36.50		66.50	100	65	80	120	60	72
				Day 7	02/04/92	36.50		64.80	105	50	100	105	50	100
				Day 14	09/04/92	36.70		65.00	160	100	80	120	90	100
				Day 21	16/04/92	36.40		65.50	160	100	80	160	90	96
				Day 28	23/04/92	36.50		65.00	100	65	80	120	60	72
				Day 35	30/04/92	36.30		68.50	200	120	100	200	120	100
				Day 42	07/05/92	36.70		65.00	130	65	72	125	70	80
	299	Imipramine	Male	Screen	02/04/92	36.60			160	80	75	140	80	
				Day 0	07/04/92	36.60		82.50	160	90	80	160	100	85
				Day 7	14/04/92	36.40		83.00	160	90	84	160	80	80
				Day 14	21/04/92	36.50		83.00	120	80	76	120	90	80
				Day 21	28/04/92	36.60		83.00	150	90	84	150	100	84
				Day 28	05/05/92	36.40		82.50	140	80	105	120	80	98
				Day 35	12/05/92	36.00		83.50	110	80	80	130	90	80
				Day 42	19/05/92	36.40		83.00	160	110	98	160	120	90
	300	Imipramine	Female	Screen	07/04/92	37.00	20		160	90	84	150	80	86
				Day 0	14/04/92	37.20		102.00	160	100	104	160	90	100
				Day 7	21/04/92	36.80		102.00	160	120	92	160	100	92
				Day 21	05/05/92	36.80		103.00	180	100	84	200	120	84
				Day 28	12/05/92	36.40		103.00	165	100	84	160	90	84
				Day 35	19/05/92	36.40		103.00	160	90	84	140	80	86
				Day 42	26/05/92	36.80		102.00	180	100	94	180	100	98

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
11	321	Reboxetine	Female	Screen	09/06/92	36.50	19		120	90	90	110	80	80
				Day 0	10/06/92	37.40		76.00	115	80	74	120	85	80
				Day 7	18/06/92	36.50		75.00	120	90	90	110	80	80
				Day 14	25/06/92	36.00		74.00	105	80	104	105	80	120
				Day 21	02/07/92	36.70		74.50	120	80	80	105	80	84
				Day 28	09/07/92	36.80		73.20	125	90	72	120	90	80
				Day 35	16/07/92	37.00		73.20	120	90	98	120	80	102
				Day 42	23/07/92	36.00		73.00	130	90	88	120	85	90
	322	Reboxetine	Female	Screen	08/06/92	36.60	20		115	80	90	110	85	96
				Day 0	11/06/92	36.80		63.50	115	80	94	110	85	100
				Day 7	18/06/92	36.50		63.80	115	85	96	110	80	106
				Day 14	25/06/92	35.80		64.00	120	80	98	130	90	110
				Day 21	02/07/92	36.70		62.90	120	85	84	110	80	86
				Day 28	09/07/92	37.50		63.60	120	95	96	120	95	98
				Day 35	16/07/92	37.00		63.40	120	85	104	115	90	110
				Day 42	24/07/92	35.50		62.80	125	85	82	115	80	86
	323	Imipramine	Female	Screen	18/06/92	36.80	20		120	80	76	115	80	84
				Day 0	23/06/92	37.20		58.70	120	80	78	115	75	88
				Day 7	01/07/92	36.50		59.30	115	82	86	100	75	
				Day 14	08/07/92	35.00		60.00	125	80	82	115	80	84
				Day 21	15/07/92	36.40		60.40	115	70	88	110	70	98
				Day 28	22/07/92	37.00		61.10	110	75	88	105	70	92
				Day 35	30/07/92	36.50		61.40	120	75	90	115	70	98
				Day 42	06/08/92	36.20		60.60	115	80	90	110	80	92
	324	Imipramine	Male	Screen	06/07/92	36.50	18		120	80	64	120	90	70
				Day 0	17/07/92	36.50		70.80	120	80	64	120	90	70
				Day 7	24/07/92	36.70		69.40	130	85	78	115	80	84
				Day 14	31/07/92	36.20		70.00	130	85	80	125	90	100
				Day 21	07/08/92	36.20		70.00	125	90	84	125	85	98
				Day 28	14/08/92	36.50		70.50	115	85	80	115	90	88
				Day 35	21/08/92	37.00		70.50	135	85	98	125	80	120
				Day 42	28/08/92	36.80		72.50	135	75	90	130	80	112
	325	Reboxetine	Female	Screen	23/07/92	37.00	20		120	80	72	120	90	80
				Day 0	30/07/92	37.40		60.90	120	80	72	120	90	80
				Day 7	06/08/92	36.80		60.10	125	80	96	120	80	118
				Day 14	13/08/92	36.30		60.20	130	85	80	120	90	92
				Day 21	20/08/92	36.60		60.00	130	75	94	115	75	126
				Day 28	27/08/92	36.00		60.40	120	80	98	105	80	102
				Day 35	03/09/92	36.50		61.00	150	80	72	135	100	82

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
11	325	Reboxetine	Female	Day 42	10/09/92	36.30		59.00	130	80	84	110	85	100
	326	Imipramine	Male	Screen	24/07/92	36.50	18		135	80	82	125	90	90
				Day 0	30/07/92	36.50		83.70	135	80	82	125	90	90
				Day 7	06/08/92	36.40		82.80	135	85	76	125	85	88
				Day 14	13/08/92	36.00		82.00	125	75	76	110	80	86
				Day 21	20/08/92	36.40		81.40	120	70	98	125	80	126
				Day 28	27/08/92	35.80		80.80	130	80	88	120	85	102
				Day 35	03/09/92	37.00		81.50	160	100	92	135	90	102
				Day 42	10/09/92	36.50		80.00	125	90	88	110	90	96
	327	Reboxetine	Female	Screen	13/08/92	36.40	20		140	90	68	130	90	72
				Day 0	20/08/92	36.40		74.60	120	80	72	120	85	76
				Day 7	27/08/92	36.00		74.80	130	85	74	125	90	82
				Day 14	03/09/92	36.00		75.00	120	100	62	125	100	66
				Day 21	10/09/92	36.10		73.50	125	85	88	105	85	92
				Day 28	17/09/92	35.40		74.90	110	70	88	110	80	98
				Day 35	24/09/92	35.60		74.30	115	80	88	110	80	98
				Day 42	01/10/92	35.60		75.60	120	80	72	120	80	80
	328	Imipramine	Male	Screen	18/08/92	36.00	18		140	80	64	130	80	72
				Day 0	20/08/92	36.60		79.50	125	85	68	125	90	80
				Day 7	27/08/92	36.70		78.50	130	85	76	125	90	86
				Day 14	03/09/92	36.00		79.00	140	70	80	140	80	96
				Day 21	10/09/92	36.00		78.50	160	80	76	150	100	84
				Day 28	17/09/92	36.40		79.30	135	85	88	130	90	100
	329	Imipramine	Female	Screen	18/08/92	36.50	18		110	70	70	115	70	78
				Day 0	21/08/92	36.40		76.30	125	65	86	115	65	96
				Day 7	28/08/92	36.00		79.40	115	65	88	115	70	92
				Day 14	04/09/92	36.00		78.00	140	60	60	120	80	84
				Day 21	11/09/92	36.00		77.50	125	90	68	120	90	64
				Day 28	18/09/92	36.60		77.40	110	70	96	110	75	114
				Day 35	25/09/92	37.00		77.70	115	75	88	115	85	98
				Day 42	02/10/92	36.00		77.50	115	75	88	115	80	96
	330	Reboxetine	Female	Screen	21/08/92	36.80	18		120	70	68	110	75	76
				Day 0	24/08/92	36.50		75.50	115	70	64	110	80	72
				Day 7	31/08/92	36.00		74.50	100	80	80	110	80	78
	331	Reboxetine	Male	Screen	01/09/92	36.00	20		125	90	84	130	100	106
				Day 0	03/09/92	36.20		74.00	140	100	80	140	90	98
				Day 7	10/09/92	36.30		73.00	140	100	78	140	100	88

1413

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
11	331	Reboxetine	Male	Day 14	17/09/92	36.00		73.30	130	85	88	130	100	102
				Day 21	24/09/92	36.60		73.20	130	90	72	135	90	80
				Day 28	02/10/92	36.50		72.80	120	95	92	115	95	116
				Day 35	09/10/92	36.60		73.60	130	85	84	125	90	92
				Day 42	15/10/92	36.40		73.20	130	90	80	125	90	98
	332	Imipramine	Female	Screen	31/08/92	36.50	18		120	70	64	115	80	68
				Day 0	04/09/92	36.20		55.00	120	70	58	115	80	64
				Day 7	14/09/92	36.40		55.00	115	80	80	100	70	92
				Day 14	21/09/92	36.50		54.70	110	80	88	100	80	92
				Day 21	28/09/92	36.60		54.90	110	80	86	105	80	92
				Day 28	05/10/92	36.70		55.00	110	75	88	100	75	94
				Day 35	12/10/92	36.70		54.80	105	80	80	110	80	92
				Day 42	20/10/92	36.80		54.70	105	85	82	95	75	100
	333	Imipramine	Female	Screen	04/09/92	36.00	20		110	90	74	120	85	80
				Day 0	04/09/92	36.00		74.00	115	80	72	120	85	80
				Day 7	11/09/92	36.70		72.00	135	100	76	140	100	80
				Day 14	18/09/92	36.80		70.60	120	80	82	120	85	98
				Day 21	25/09/92	36.00		69.20	110	80	92	105	80	98
				Day 28	02/10/92	36.20		69.10	120	80	82	110	75	90
				Day 35	09/10/92	36.50		69.10	120	80	86	115	80	90
				Day 42	16/10/92	36.60		69.50	120	80	80	115	80	88
12	337	Imipramine	Female	Screen	11/05/92	35.80	24		130	80	76	110	80	88
				Day 0	25/05/92	36.00		72.00	130	90	72	110	90	86
				Day 7	01/06/92	36.00		71.00	120	70	80	115	80	81
				Day 14	08/06/92	35.80		70.00	140	80	96	130	90	96
				Day 21	15/06/92	37.00		71.00	140	80	80	120	75	75
				Day 28	22/06/92	36.00		71.00	120	80	98	120	80	100
				Day 35	29/06/92	36.00		69.00	115	85	80	100	70	96
				Day 42	06/07/92	35.50		70.00	140	80	94	120	90	94
	338	Reboxetine	Female	Screen	11/06/92	37.00	21		120	80	75	110	75	75
				Day 0	19/06/92	36.00		56.00	120	75	78	110	70	76
				Day 7	26/06/92	36.40		53.00	110	70	94	100	70	98
				Day 14	03/07/92	36.00		53.00	110	80	110	90	70	108
				Day 28	17/07/92	36.20		54.00	140	90	100	130	85	78
				Day 35	24/07/92	36.10		55.20	120	80	80	110	80	88
	339	Imipramine	Male	Screen	19/06/92	37.00	21		130	90	89	135	90	90
				Day 0	22/06/92	36.40		77.00	120	90	90	130	100	102
				Day 7	29/06/92	35.60		77.00	150	90	78	110	75	80
				Day 14	06/07/92	36.40		78.00	140	80	76	100	70	96

1420

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
12	339	Imipramine	Male	Day 28	20/07/92	36.20		80.00	150	100	92	130	80	90
				Day 35	27/07/92	35.00		80.00	135	90	94	130	80	84
	340	Reboxetine	Female	Screen	04/08/92	35.80	24		100	64	90	84	62	104
				Day 0	06/08/92	35.60		65.00	120	70	74	110	70	84
				Day 7	13/08/92	35.10		64.00	130	78	92	120	70	100
				Day 14	20/08/92	35.20		65.00	130	90	84	110	70	72
				Day 21	27/08/92	36.60		64.00	110	70	80	110	60	84
				Day 28	03/09/92	36.00		63.00	110	60	84	120	80	86
				Day 35	10/09/92	35.70		63.00	120	80	82	110	90	82
				Day 42	17/09/92	36.00		64.50	130	80	76	110	80	110
	341	Reboxetine	Female	Screen	17/08/92	37.00	18		120	70	92	130	90	86
				Day 0	20/08/92	36.00		56.00	140	80	82	130	90	86
				Day 7	27/08/92	36.50		55.00	130	80	96	130	90	96
				Day 14	03/09/92	36.60		54.90	110	60	84	120	70	96
				Day 21	10/09/92	36.60		53.70	130	70	86	120	70	88
				Day 28	17/09/92	36.00		53.80	128	70	94	120	68	90
				Day 35	24/09/92	36.00		54.00	120	80	100	120	80	96
13	353	Reboxetine	Female	Screen	05/06/92	37.00	19		122	70	66	118	80	68
				Day 0	05/06/92	37.00		73.50	122	70	66	118	80	68
				Day 7	15/06/92	37.00		70.00	110	70	68	90	70	68
				Day 14	22/06/92	37.00		71.00	140	90	96	90	70	
				Day 21	29/06/92	37.00		71.50	140	95	62	120	90	64
				Day 28	06/07/92	37.00		70.00	122	80	60	95	70	68
				Day 35	13/07/92	37.00		70.00	120	85	60	105	85	72
	354	Imipramine	Female	Screen	24/06/92	37.00			140	90	76	140	90	
				Day 0	24/06/92	37.00		47.00	140	90	76	140	90	
				Day 7	01/07/92	36.70		47.00	145	80	72	140	85	74
				Day 14	09/07/92	36.70		47.00	140	80	90	160	110	86
				Day 21	15/07/92	37.00		47.50	160	88	72	140	95	80
				Day 28	22/07/92	36.70		46.50	150	90	60	130	95	66
				Day 35	29/07/92	36.70		49.50	143	80	62	115	90	70
				Day 42	05/08/92	36.70		47.00	142	80	72	105	92	76
	355	Reboxetine	Female	Screen	17/06/92	37.00			90	65	58	85	60	60
				Day 0	24/06/92	37.00		56.00	95	70	54	90	70	56
				Day 7	01/07/92	37.00		55.00	116	82	60	105	65	64
	356	Imipramine	Male	Screen	22/07/92	36.30			105	60	58	105	70	68
				Day 0	22/07/92	36.30		56.00	105	60	58	105	70	68

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
13	356	Imipramine	Male	Day 7	29/07/92	36.30		56.00	105	75	84	90	75	104
				Day 14	05/08/92	36.40		56.00	95	60	96	105	80	100
				Day 21	12/08/92	36.70		55.50	90	60	88	110	80	112
				Day 28	19/08/92	36.70		55.00	118	90	68	115	95	72
				Day 35	26/08/92	36.50		57.50	105	70	84	100	70	96
				Day 42	02/09/92			57.50	80	50	88	90	60	88
	357	Imipramine	Female	Screen	05/08/92	37.20	16		150	70	84	130	73	92
				Day 0	05/08/92	37.20		56.50	150	70	84	130	73	92
				Day 7	12/08/92	36.30						130	80	100
	358	Reboxetine	Male	Screen	06/08/92	36.70	14		115	85	64	105	93	72
				Day 0	06/08/92	36.70		67.00	115	85	64	105	93	72
				Day 7	13/08/92	36.40		67.50	114	75	72	102	84	102
				Day 14	20/08/92	36.80		64.00	110	75	64	105	85	68
				Day 21	27/08/92	36.70		66.00	118	73	66	105	76	68
				Day 28	03/09/92	36.60		65.50	120	75	64	105	88	72
	359	Reboxetine	Female	Screen	19/08/92	37.00			130	70	80	120	80	84
				Day 0	19/08/92	37.00		58.00	130	70	80	120	80	84
				Day 7	26/08/92	36.10		59.00	150	85	64	130	80	76
				Day 14	02/09/92	36.40		57.00	130	70	64	110	70	88
				Day 21	09/09/92	36.60		60.00	118	72	60	122	84	68
				Day 28	16/09/92	37.10		58.00	125	80	56	110	80	80
				Day 35	23/09/92	35.90		56.00	140	80	64	125	80	64
				Day 42	30/09/92	36.40		58.00	108	72	60	110	80	64
	360	Imipramine	Female	Screen	19/08/92	36.60	16		115	88	60	110	85	68
				Day 0	19/08/92	36.60		67.50	115	88	60	110	85	68
				Day 7	26/08/92	36.60		63.50	120	95		115	95	
	361	Reboxetine	Female	Screen	26/08/92	36.60			120	80	70	125	80	82
				Day 0	26/08/92	36.60		51.00	120	80	70	125	80	82
				Day 7	02/09/92	36.30		49.00	150	100	68	115	80	76
				Day 14	09/09/92	36.30		50.00	120	85	76	105	70	92
				Day 21	16/09/92	35.50		50.00	130	90	80	120	90	96
				Day 28	23/09/92	36.50		52.00	120	80	92	110	80	98
				Day 35	30/09/92	36.30		50.00	130	85	80	120	90	96
				Day 42	07/10/92	36.50		50.00	130	80	92	120	80	104
14	457	Reboxetine	Female	Screen	07/07/92	36.20	18		120	80	60	120	70	64
				Day 0	07/07/92	36.20		62.00	120	80	64	120	70	68
				Day 7	14/07/92	36.40		62.30	115	75	64	120	70	66

1425

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14	457	Reboxetine	Female	Day 14	21/07/92	36.30		62.20	120	80	64	120	70	68
				Day 21	28/07/92	36.50		61.70	120	80	64	115	70	64
				Day 28	04/08/92	36.60		62.80	120	80	64	120	78	64
				Day 35	11/08/92	36.20		62.70	120	80	60	115	70	64
				Day 42	18/08/92	36.30		62.90	120	80	64	115	70	68
	458	Imipramine	Female	Screen	10/07/92	36.20	15		140	90	64	150	90	68
				Day 0	14/07/92	36.40		56.80	130	80	64	140	90	68
				Day 7	21/07/92	36.80		56.40	140	90	64	150	100	68
				Day 14	28/07/92	36.30		56.70	140	90	64	140	95	64
				Day 21	04/08/92	36.70		57.80	140	90	64	150	95	68
				Day 28	11/08/92	36.30		57.30	140	90	64	145	100	68
				Day 35	18/08/92	36.20		57.60	135	90	60	140	90	64
				Day 42	25/08/92	36.40		57.90	140	90	64	150	90	68
	459	Reboxetine	Male	Screen	13/07/92	36.20	16		130	80	64	130	80	68
				Day 0	16/07/92	36.40		68.00	130	80	64	140	90	68
				Day 7	23/07/92	36.50		67.50	120	80	64	130	90	68
				Day 14	30/07/92	36.20		67.80	130	80	64	130	90	60
				Day 21	06/08/92	36.40		68.00	130	80	64	130	80	64
				Day 28	13/08/92	36.20		67.60	130	80	60	130	80	64
				Day 35	20/08/92	36.40		67.90	130	80	60	130	80	64
				Day 42	27/08/92	36.50		68.20	130	80	64	130	90	68
	460	Imipramine	Male	Screen	20/07/92	35.80	14		110	70	56	100	70	60
				Day 0	23/07/92	36.00		66.00	110	70	60	100	60	72
				Day 7	30/07/92	36.10		65.70	100	70	60	90	60	68
				Day 14	06/08/92	36.20		65.50	105	70	60	100	60	64
				Day 21	13/08/92	36.30		65.40	110	70	56	100	60	60
				Day 28	20/08/92	36.80		65.50	110	80	60	110	70	64
				Day 35	27/08/92	36.20		65.70	110	70	60	110	60	64
				Day 42	03/09/92	36.30		66.00	110	70	60	105	60	60
	461	Imipramine	Female	Screen	22/07/92	36.00	17		110	70	64	110	80	68
				Day 0	29/07/92	36.20		59.00	110	70	68	105	70	68
				Day 7	05/08/92	36.00		58.60	110	70	60	110	80	64
				Day 14	12/08/92	36.20		58.00	110	70	60	110	80	64
				Day 21	19/08/92	36.30		58.10	115	70	68	110	70	68
				Day 28	26/08/92	36.10		58.00	110	80	64	110	60	68
				Day 35	02/09/92	36.30		58.20	115	70	64	110	70	64
				Day 42	09/09/92	36.30		58.00	110	70	68	110	70	68
	462	Reboxetine	Female	Screen	24/07/92	36.20	15		120	80	64	130	90	68
				Day 0	31/07/92	36.00		51.00	115	70	60	120	80	64

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14	462	Reboxetine	Female	Day 7	07/08/92	36.10		50.70	120	80	60	130	80	68
				Day 14	14/08/92	36.20		50.50	120	80	60	130	80	64
				Day 21	21/08/92	36.40		50.40	120	80	60	130	80	64
				Day 28	28/08/92	36.20		50.40	120	80	60	120	90	64
				Day 35	04/09/92	36.40		50.60	120	80	64	130	80	68
				Day 42	11/09/92	36.30		50.80	120	80	60	130	80	64
	463	Imipramine	Male	Screen	27/07/92	35.90	15		120	80	64	110	70	64
				Day 0	03/08/92	36.40		68.70	120	80	64	120	80	64
				Day 7	10/08/92	36.80		68.50	120	70	64	120	80	68
				Day 14	17/08/92	36.40		68.10	130	80	64	130	80	68
				Day 21	24/08/92	36.20		68.30	120	80	64	120	80	64
				Day 28	31/08/92	36.40		68.70	120	80	64	130	80	68
				Day 35	07/09/92	36.50		69.00	120	80	64	120	80	64
				Day 42	14/09/92	36.30		69.40	120	80	64	130	90	68
	464	Reboxetine	Female	Screen	29/07/92	36.70	15		100	70	64	90	60	68
				Day 0	05/08/92	36.40		50.60	100	70	64	90	60	68
				Day 7	13/08/92	36.40		50.20	100	70	64	100	60	64
				Day 14	20/08/92	36.20		50.00	100	70	64	100	60	60
				Day 21	27/08/92	36.30		50.10	100	70	60	100	60	64
				Day 28	03/09/92	36.70		50.00	100	70	64	100	60	64
				Day 35	10/09/92	36.30		50.20	100	70	60	100	60	64
				Day 42	17/09/92	36.60		50.70	110	70	64	110	80	64
	465	Reboxetine	Male	Screen	30/07/92	36.80	14		130	90	68	130	80	68
				Day 0	06/08/92	36.60		63.80	120	90	60	130	90	64
				Day 7	13/08/92	36.20		63.70	120	90	60	130	90	64
				Day 14	20/08/92	36.10		63.70	120	80	64	120	80	64
				Day 21	27/08/92	36.10		64.00	120	80	60	130	80	64
				Day 28	03/09/92	36.30		64.30	120	80	60	130	80	64
				Day 35	10/09/92	36.50		64.70	120	70	64	130	80	64
				Day 42	17/09/92	36.20		65.00	120	70	64	130	80	64
	466	Imipramine	Female	Screen	31/07/92	36.40	15		120	80	64	120	70	64
				Day 0	07/08/92	36.70		51.40	110	70	60	120	80	64
				Day 7	14/08/92	36.40		51.50	115	70	64	130	80	68
				Day 14	21/08/92	36.20		51.80	110	70	60	120	80	64
				Day 21	28/08/92	36.40		52.00	110	70	60	120	80	64
				Day 28	04/09/92	36.70		52.30	115	70	60	120	80	64
				Day 35	11/09/92	36.20		52.40	115	70	60	125	80	64
				Day 42	18/09/92	36.40		52.70	120	70	64	130	60	68
14/1	129	Reboxetine	Male	Screen	11/12/91				170	100	68	170	105	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/1	129	Reboxetine	Male	Day 0	18/12/91	36.70		75.10	165	95	72	170	100	76
				Day 7	19/12/91			75.00	160	100	96			
	426	Reboxetine	Female	Screen	28/08/91	36.20	21		160	110	55	140	110	52
				Day 0	04/09/91	36.20		81.70	150	105		140	110	
				Day 7	11/09/91	36.20		83.50	130	85	56	140	105	68
				Day 14	18/09/91	36.70		82.50	160	105	76	145	110	96
				Day 21	25/09/91	36.20		83.00	160	100	72	145	85	75
				Day 28	02/10/91	35.90		82.60	140	95	76	150	110	96
				Day 35	09/10/91	36.60		83.00	145	95	84	160	100	92
				Day 42	17/10/91	36.70		81.10	135	95	72	145	105	92
	429	Imipramine	Female	Screen	18/09/91		24		150	90	72	155	95	80
				Day 0	25/09/91	36.70		65.00	130	90	92	135	100	92
				Day 7	02/10/91	36.90		64.20	110	75	92	125	85	88
1425	451	Imipramine	Male	Screen	25/11/91	36.50	20		150	95	68	160	100	80
				Day 0	27/11/91	36.80		89.00	170	105	76	150	105	88
				Day 7	04/12/91			89.90	170	105	64	160	100	72
				Day 14	11/12/91			90.00	130	90	80	120	95	92
				Day 21	18/12/91	36.50		90.00	160	100	88	170	100	88
				Day 28	23/12/91	36.90		89.10	150	90		165	100	
				Day 35	30/12/91	36.70		89.70	155	105	68	150	100	76
				Day 42	08/01/92	36.60		90.00	160	105	80	160	110	84
	452	Reboxetine	Female	Screen	26/11/91	36.20	20		120	85	64	120	90	76
				Day 0	27/11/91	36.70		78.20	120	85	64	120	90	76
				Day 7	04/12/91	36.40		78.00	150	90	76	140	100	80
				Day 14	12/12/91	36.90		77.80	150	100	80	120	90	84
				Day 21	19/12/91	36.50		78.20	100	70	68	120	90	88
				Day 28	27/12/91	36.80		78.00	130	85	76	130	100	84
				Day 35	02/01/92	36.90		78.40	145	90	72	140	95	72
				Day 42	09/01/92	36.80		78.40	140	100	88	145	110	96
14/2	136	Imipramine	Female	Screen	08/01/92	36.90	22		115	80	88	105	75	92
				Day 0	14/01/92	37.10		56.00	115	80	80	120	80	80
				Day 7	21/01/92	37.20		56.00	110	70	88	105	70	88
				Day 14	28/01/92	37.40		56.50	135	90	92	140	90	96
				Day 21	04/02/92	37.30		56.00	120	80	92	120	75	88
				Day 28	11/02/92	37.50		57.00	125	85	96	120	75	92
				Day 35	18/02/92	36.90		55.00	120	85	88	120	80	92
				Day 42	25/02/92	37.20		55.50	110	80	76	125	85	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
14/2	456	Imipramine	Male	Screen	09/04/92	37.40	16		145	95	88	155	95	92
				Day 0	14/04/92	37.20		89.20	155	90	80	155	95	84
				Day 7	21/04/92	37.60		89.00	142	95	84	150	95	92
				Day 14	28/04/92	37.20		89.00	145	85	84	150	85	80
				Day 21	05/05/92	36.80		89.20	142	90	96	155	95	88
				Day 28	12/05/92	36.90		89.00	152	95	84	160	95	88
				Day 35	19/05/92	37.30		89.50	155	90	88	158	90	88
				Day 42	26/05/92	37.30		89.00	155	100	80	165	100	84
14/3	417	Reboxetine	Female	Screen	07/06/91	37.00	17		120	80	74	115	80	88
				Day 0	14/06/91	37.20		56.00	120	80	74	115	80	88
				Day 7	21/06/91	37.00		57.00	100	60	64	110	70	72
				Day 14	28/06/91	37.00		55.00	120	80	84	110	80	84
				Day 21	05/07/91	37.00		56.00	115	80	80	100	70	88
				Day 28	12/07/91	37.30		53.60	100	70	88	90	70	94
				Day 35	19/07/91	37.00		57.00	115	80	84	100	70	92
				Day 42	26/07/91	37.20		57.30	110	80	80	100	75	90
	418	Imipramine	Female	Screen	10/06/91	37.00	16		120	80	70	115	80	74
				Day 0	17/06/91	37.00		62.50	125	80	70	118	80	72
				Day 7	24/06/91	37.00		62.50	115	85	80	105	80	84
				Day 14	01/07/91	37.00		63.00	115	80	76	95	70	80
				Day 21	08/07/91	37.20		63.40	120	80	70	115	80	74
				Day 28	15/07/91	37.20		63.10	120	80	80	105	70	84
				Day 35	22/07/91	37.00		62.30	115	80	78	100	80	83
				Day 42	29/07/91	37.30		63.20	130	95	78	90	76	
	419	Reboxetine	Female	Screen	03/07/91	37.00	16		110	80	76	125	85	80
				Day 0	04/07/91	37.00		72.00	115	80	74	120	80	80
				Day 7	11/07/91	37.10		72.20	110	75	78	100	70	82
				Day 14	18/07/91	37.20		70.00	130	85	76	120	90	80
				Day 21	25/07/91	37.00		70.60	120	80	80	130	95	94
				Day 28	01/08/91	37.10		70.50	125	90	76	130	100	82
				Day 35	08/08/91	37.00		71.00	130	85	70	130	100	85
				Day 42	15/08/91	37.00		69.50	130	80	72	135	100	74
	420	Imipramine	Female	Screen	04/07/91	37.00	20		100	70	80	90	60	88
				Day 0	04/07/91	37.00		50.40	100	70	80	90	60	88
				Day 7	11/07/91	37.00		49.00	110	70	76	115	75	80
				Day 14	18/07/91	37.20		50.00	115	75	80	110	75	84
				Day 21	25/07/91	37.20		50.60	125	80	84	110	70	92
	421	Reboxetine	Female	Screen	11/07/91	37.00	16		120	80	80	105	75	86
				Day 0	18/07/91	37.20		64.20	120	80	78	105	75	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/3	421	Reboxetine	Female	Day 7	25/07/91	37.00		65.00	115	80	78	110	70	82
				Day 14	01/08/91	37.00		63.50	120	80	80	100	70	88
				Day 21	08/08/91	37.30		63.50	110	80	90	105	70	
				Day 28	15/08/91	37.10		63.50	110	75	80	105	70	82
				Day 35	22/08/91	37.00		63.00	110	70	74	105	75	78
	427	Imipramine	Female	Screen	18/09/91	37.00	15		130	80	76	145	90	80
				Day 0	18/09/91	37.00		85.00	135	80	72	130	85	76
				Day 7	25/09/91	37.00		85.40	115	80	76	120	80	74
				Day 21	09/10/91	37.20		86.40	120	80	72	135	85	75
				Day 28	16/10/91	37.00		86.00	145	80	76	130	85	80
	428	Imipramine	Female	Screen	25/10/91	37.00	16		120	80	72	115	80	80
				Day 0	25/10/91	37.00		54.00	120	80	80	115	80	84
				Day 7	01/11/91	37.00		56.00	115	75	74	110	80	82
				Day 14	08/11/91	37.00		58.00	115	80	76	110	80	80
				Day 21	15/11/91	37.20		57.00	100	70	80	90	60	88
				Day 28	22/11/91	37.00		57.20	125	80	78	115	82	80
				Day 35	29/11/91	37.00		57.60	105	70	84	100	80	86
				Day 42	05/12/91	37.20		58.00	100	80	82	95	80	86
14/4	131	Imipramine	Female	Screen	07/01/92	36.70	20		145	70	82	140	90	86
				Day 0	14/01/92	37.00		72.00	140	60	72	130	70	76
				Day 7	21/01/92	37.20		72.00	145	70	78	140	70	82
				Day 14	28/01/92	36.40		71.50	150	85	74	140	80	78
				Day 21	04/02/92	36.60		71.50	140	70	70	130	80	78
				Day 28	11/02/92	36.30		71.00	140	60	72	145	70	74
				Day 35	18/02/92	37.00		71.30	145	70	70	135	80	72
				Day 42	25/02/92	36.80		71.00	140	75	70	135	80	68
	132	Imipramine	Female	Screen	07/01/92	36.50	28		110	60	84	115	80	92
				Day 0	14/01/92	36.50		64.00	105	60	80	115	70	88
				Day 7	21/01/92	37.10		64.50	100	60	76	110	70	84
				Day 14	28/01/92	36.40		65.00	110	70	74	110	80	78
				Day 21	04/02/92	36.10		65.00	110	70	68	105	85	78
				Day 28	11/02/92	36.70		65.00	115	70	70	110	70	74
				Day 35	18/02/92	36.40		65.00	110	60	64	110	70	68
				Day 42	25/02/92	36.30		65.00	115	60	72	110	70	78
	133	Imipramine	Female	Screen	09/01/92	36.80	18		125	70	72	120	70	76
				Day 0	16/01/92	36.90		70.00	120	70	80	115	80	84
				Day 7	23/01/92	36.50		69.50	110	60	78	115	60	84
				Day 14	30/01/92	36.20		70.00	115	80	68	125	70	72
				Day 21	06/02/92	36.40		70.00	120	75	64	130	80	72

1427

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/4	133	Imipramine	Female	Day 28	13/02/92	36.10		70.00	120	60	70	120	70	74
				Day 35	20/02/92	36.20		70.00	125	80	74	120	80	76
				Day 42	27/02/92	36.10		70.00	120	70	68	115	70	72
	134	Reboxetine	Female	Screen	09/01/92	36.70	20		125	70	84	120	70	88
				Day 0	16/01/92	36.90		58.00	120	60	88	110	70	88
				Day 7	23/01/92	37.10		57.30	115	60	84	115	70	88
				Day 14	30/01/92	36.60		57.00	110	70	82	120	75	86
				Day 21	06/02/92	36.30		56.70	120	70	84	110	80	88
				Day 28	13/02/92	36.20		57.00	125	70	80	115	80	84
				Day 35	20/02/92	36.40		57.00	120	70	76	115	65	84
				Day 42	27/02/92	36.70		57.50	130	70	92	120	85	98
	135	Reboxetine	Male	Screen	10/01/92	36.90	22		150	70	84	155	90	86
				Day 0	17/01/92	36.20		85.00	145	70	87	150	85	90
				Day 7	24/01/92	36.40		85.00	135	70	82	145	75	88
				Day 14	31/01/92	36.40		85.00	130	70	70	135	70	74
				Day 21	07/02/92	36.10		85.00	140	70	70	135	80	74
				Day 28	14/02/92	36.40		85.00	145	70	76	135	70	80
				Day 35	21/02/92	36.30		85.00	140	80	70	140	70	72
				Day 42	28/02/92	36.40		85.00	145	70	62	140	80	68
14/7	422	Imipramine	Female	Screen	02/09/91	37.40	12		120	75	62	125	75	68
				Day 0	04/09/91	36.80		74.00	120	70	66	130	75	72
				Day 7	11/09/91	37.40		73.20	125	70	62	135	80	74
				Day 14	18/09/91	36.80		72.80	120	70	68	130	65	76
				Day 21	25/09/91	37.10		73.20	125	75	68	130	75	74
				Day 28	02/10/91	36.80		71.80	125	70	69	125	75	77
				Day 35	09/10/91	36.90		70.80	130	70	68	130	80	74
				Day 42	16/10/91	36.80		70.60	125	75	70	125	75	74
	423	Imipramine	Female	Screen	10/09/91	37.20	16		130	80	66	130	75	82
				Day 0	17/09/91	36.40		70.20	140	80	66	140	75	73
				Day 7	24/09/91	37.10		70.20	125	75	68	125	70	76
				Day 14	01/10/91	36.40		69.80	120	70	72	125	75	78
				Day 21	08/10/91	36.80		70.00	110	70	68	120	70	76
				Day 28	15/10/91	36.80		70.20	115	70	76	120	75	80
				Day 35	22/10/91	37.00		69.60	115	75	74	120	75	82
				Day 42	29/10/91	36.80		70.60	130	80	72	130	75	78
	424	Reboxetine	Male	Screen	06/09/91	37.10	24		130	65	69	130	70	78
				Day 0	19/09/91	37.20		63.00	125	75	73	130	75	82
				Day 7	26/09/91	37.00		63.20	130	70	72	130	75	84
				Day 14	03/10/91	37.40		62.80	125	70	68	130	85	82

1428

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/7	424	Reboxetine	Male	Day 21	10/10/91	36.90		63.30	120	70	74	125	75	80
				Day 28	17/10/91	36.40		62.40	120	70	69	125	75	76
				Day 35	24/10/91	36.80		62.60	120	70	68	120	75	75
				Day 42	31/10/91	37.20		63.00	165	80	103	170	80	105
	430	Reboxetine	Female	Screen	07/10/91	37.20	22		110	80	70	115	80	75
				Day 0	07/10/91	37.20		70.40	120	65	68	125	65	74
				Day 7	14/10/91	36.80		70.40	110	60	68	115	65	76
				Day 14	21/10/91	36.80		69.80	120	70	64	125	75	70
				Day 21	28/10/91	36.90		70.80	125	70	69	130	80	78
				Day 28	04/11/91	37.00		70.10	125	65	68	130	70	74
				Day 35	11/11/91	36.70		70.00	120	65	62	130	70	78
				Day 42	18/11/91	37.00		79.40	125	70	77	125	75	85
	431	Reboxetine	Male	Screen	08/10/91	37.30	22		120	60	68	125	65	76
				Day 0	08/10/91	36.40		62.80	100	60	70	115	65	82
				Day 7	15/10/91	37.10		63.20	110	65	62	120	70	72
				Day 14	22/10/91	36.80		62.10	140	85	82	160	95	93
				Day 21	29/10/91	36.40		58.20	110	60	58	125	65	78
				Day 28	05/11/91	37.40		61.00	120	70	98	125	70	102
				Day 35	12/11/91	36.80		62.80	115	60	87	120	65	98
				Day 42	19/11/91	38.10		61.40	115	70	67	125	75	83
	432	Imipramine	Male	Screen	08/10/91	37.20	18		120	70	72	125	80	78
				Day 0	08/10/91	36.80		80.90	110	65	66	115	70	72
				Day 7	15/10/91	37.00		80.50	115	65	68	125	70	74
				Day 14	22/10/91	36.80		80.80	120	65	62	125	65	70
				Day 21	29/10/91	36.80		80.20	125	80	59	130	80	73
				Day 28	05/11/91	37.00		81.00	115	70	68	120	75	76
				Day 35	12/11/91	37.10		81.20	120	70	62	125	70	78
				Day 42	19/11/91	36.60		80.80	130	65	70	135	70	84
	433	Imipramine	Female	Screen	08/10/91	37.20	18		120	65	68	125	70	74
				Day 0	08/10/91	37.20		53.00	120	65	68	125	70	74
				Day 7	15/10/91	36.80		53.10	115	65	64	120	65	72
				Day 14	22/10/91	36.80		53.10	115	70	68	125	75	78
				Day 21	29/10/91	36.90		53.10	115	70	80	120	70	92
				Day 28	05/11/91	36.20		53.30	125	75	68	135	80	78
				Day 35	12/11/91	36.60		53.80	120	70	70	125	75	78
				Day 42	19/11/91	37.20		53.20	120	75	78	125	80	89
	434	Reboxetine	Male	Screen	10/10/91	37.20	21		120	75	82	130	80	87
				Day 0	14/10/91	37.60		79.40	130	80	84	130	85	92
				Day 7	21/10/91	36.80		78.20	125	75	86	125	80	90

1428

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Height (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/7	434	Reboxetine	Male	Day 14	28/10/91	36.90		80.20	115	60	65	120	60	72
				Day 21	04/11/91	37.00		79.30	110	60	54	125	75	72
				Day 28	11/11/91	36.80		80.20	110	60	64	120	65	74
				Day 35	18/11/91	37.00		80.60	120	75	68	125	75	76
				Day 42	25/11/91	36.80		80.20	125	70	64	125	75	78
	439	Reboxetine	Male	Screen	06/11/91	36.90	20		120	70	70	140	80	82
				Day 0	11/11/91	37.20		65.20	120	65	74	125	70	86
				Day 7	18/11/91	36.80		65.10	130	65	76	130	70	82
				Day 14	25/11/91	37.00		64.90	125	75	74	125	70	80
				Day 21	02/12/91	37.20		63.20	130	70	82	130	75	86
				Day 28	09/12/91	36.50		63.40	120	65	72	120	70	80
				Day 35	16/12/91	37.00		63.80	115	60	68	120	65	76
				Day 42	23/12/91	35.20		64.20	130	80	98	140	85	120
	440	Imipramine	Female	Screen	07/11/91	37.20	22		90	60	87	105	60	98
				Day 0	11/11/91	37.00		50.20	120	60	70	120	65	82
				Day 7	18/11/91	36.80		50.10	110	60	68	115	60	74
				Day 14	25/11/91	36.80		50.30	125	60	68	125	65	76
				Day 21	02/12/91	37.50		51.20	115	80	115	125	80	120
				Day 28	09/12/91	37.20		50.10	120	60	68	120	65	78
				Day 35	16/12/91	36.60		50.10	110	60	72	115	65	78
				Day 42	23/12/91	37.20		51.20	115	70	74	120	70	78
	441	Imipramine	Male	Screen	08/11/91	36.80	20		120	70	56	135	80	68
				Day 0	11/11/91	36.80		78.20	120	70	58	125	70	64
				Day 7	18/11/91	36.70		79.10	110	60	52	120	60	68
				Day 14	25/11/91	37.20		79.00	120	60	62	125	65	76
				Day 21	02/12/91	37.40		78.20	125	65	66	125	70	78
				Day 28	09/12/91	36.90		79.20	120	65	58	120	70	64
				Day 35	16/12/91	37.00		79.10	125	65	62	125	70	74
				Day 42	23/12/91	37.20		78.40	115	65	51	120	65	62
	442	Imipramine	Male	Screen	08/11/91	36.90	25		130	75	77	135	75	82
				Day 0	11/11/91	36.80		73.20	120	60	68	125	65	72
				Day 7	18/11/91	37.40		73.40	125	70	62	125	75	68
				Day 14	25/11/91	37.20		72.80	125	70	68	125	75	74
				Day 21	02/12/91	37.80		72.40	145	90	114	145	90	121
				Day 28	08/12/91	36.90		72.80	120	65	68	125	65	72
				Day 35	16/12/91	37.20		72.40	120	65	68	125	65	76
				Day 42	23/12/91	37.40		72.80	140	85	96	145	90	99
	449	Reboxetine	Female	Screen	16/12/91	36.90	22		125	70	78	130	80	87
				Day 0	20/12/91	36.80		83.70	130	75	68	135	75	73

1430

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/7	449	Reboxetine	Female	Day 7	27/12/91	37.20		83.40	125	75	92	130	78	98
				Day 14	03/01/92	36.70		83.80	125	70	82	130	78	91
				Day 21	10/01/92	37.20		84.20	130	70	67	135	75	72
				Day 28	17/01/92	37.10		83.90	120	70	62	130	75	74
				Day 35	24/01/92	36.80		83.40	125	65	62	130	70	76
				Day 42	31/01/92	37.30		82.00	120	70	72	125	75	78
	450	Imipramine	Male	Screen	06/12/91	37.80	24		140	90	59	140	90	68
				Day 0	23/12/91	36.80		80.20	140	80	59	145	80	68
				Day 7	30/12/91	37.20		80.20	135	80	65	135	80	72
				Day 14	06/01/92	37.40		80.40	130	75	68	130	80	74
				Day 21	13/01/92	37.20		80.00	130	85	60	140	85	68
				Day 28	20/01/92	36.80		80.20	130	70	68	130	75	72
				Day 35	27/01/92	37.00		80.80	130	70	62	130	75	68
				Day 42	03/02/92	37.20		80.40	130	70	59	140	80	68
14/8	130	Reboxetine	Male	Screen	10/01/92	37.10	17		130	75	78	145	85	84
				Day 0	10/01/92	37.20		81.00	130	75	78	145	85	84
				Day 7	17/01/92	37.40		81.00	135	75	76	140	80	84
				Day 14	24/01/92	37.20		81.00	145	80	72	140	95	84
				Day 21	31/01/92	37.30		81.00	140	75	76	145	70	88
				Day 28	07/02/92	37.20			145	80	78	135	85	84
				Day 35	14/02/92	37.30			140	85	74	135	80	84
				Day 42	21/02/92	37.20			150	80	78	145	85	80
	425	Reboxetine	Female	Screen	06/09/91	37.10	17		145	80	84	140	85	88
				Day 0	09/09/91	37.10		68.00	150	75	76	145	75	78
				Day 7	16/09/91	37.20		68.00	145	80	70	140	85	80
				Day 14	23/09/91	37.20		68.00	140	85	72	140	90	80
				Day 21	30/09/91	37.20		68.00	140	80	84	145	85	88
				Day 28	07/10/91	37.10		68.00	145	85	80	140	80	84
				Day 35	14/10/91	37.20		68.00	150	90	88	145	95	88
				Day 42	21/10/91	37.10		68.00	150	85	74	155	90	74
	467	Reboxetine	Male	Screen	02/07/92	37.00	18		145	80	78	140	85	80
				Day 0	06/07/92	37.00		80.00	145	80	78	145	75	74
				Day 7	13/07/92	37.10		80.00	150	80	84	150	85	88
				Day 14	20/07/92	37.20		80.00	145	90	80	150	85	84
				Day 21	27/07/92	37.10		80.00	140	80	76	140	75	80
				Day 28	03/08/92	37.20		80.00	140	80	74	145	75	70
				Day 35	10/08/92	37.10		80.50	135	80	78	130	75	74
				Day 42	17/08/92	37.10		80.00	140	80	74	135	85	78
14/10	53	Reboxetine	Male	Screen	17/02/92	37.20	17		150	80	80	140	85	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/10	53	Reboxetine	Male	Day 0	24/02/92	37.20		68.00	155	85	76	150	90	84
				Day 7	02/03/92	37.20		66.90	145	75	76	150	80	84
				Day 14	09/03/92	37.40		67.20	150	75	70	145	70	84
				Day 21	16/03/92	37.00		67.30	140	80	84	155	90	80
				Day 28	23/03/92	36.90		67.80	140	75	76	135	80	80
				Day 35	30/03/92	37.20		68.10	145	75	72	150	80	76
				Day 42	06/04/92	37.10		68.50	150	80	82	140	80	86
	54	Imipramine	Female	Screen	18/02/92	37.20	14		160	85	84	155	90	88
				Day 0	25/02/92	37.10		72.90	155	80	76	150	85	84
				Day 7	03/03/92	37.00		73.00	160	80	70	150	85	84
				Day 14	10/03/92	37.50		73.20	160	85	76	155	90	84
				Day 21	17/03/92	37.20		73.00	150	80	80	150	85	84
				Day 28	24/03/92	37.10		71.80	145	68	68	150	75	72
				Day 35	31/03/92	37.20		72.20	145	75	72	140	80	76
				Day 42	07/04/92	37.00		72.50	150	80	72	105	85	80
	55	Reboxetine	Female	Screen	20/02/92	37.40	17		125	70	88	120	75	92
				Day 0	27/02/92	36.90		55.10	130	75	72	125	80	80
				Day 7	05/03/92	37.10		55.30	130	70	76	120	75	84
				Day 14	12/03/92	37.40		55.10	125	75	70	130	70	84
				Day 21	19/03/92	37.10		55.30	130	65	80	120	75	88
				Day 28	26/03/92	37.10		55.60	125	75	76	120	80	80
				Day 35	02/04/92	36.90		55.40	130	75	72	125	80	80
				Day 42	09/04/92	37.10		55.80	120	60	72	125	65	76
	56	Imipramine	Female	Screen	24/02/92	37.60	14		125	70	76	120	80	84
				Day 0	02/03/92	37.20		67.00	130	75	76	125	80	80
				Day 7	09/03/92	37.00		66.80	125	65	80	120	75	84
				Day 14	16/03/92	36.90		67.10	130	75	76	120	80	80
				Day 21	23/03/92	36.80		67.40	130	75	72	120	80	80
				Day 28	30/03/92	37.10		67.10	125	75	80	120	80	84
				Day 35	06/04/92	37.00		66.80	135	75	76	125	80	80
				Day 42	13/04/92	37.20		67.40	130	70	82	125	75	86
	57	Reboxetine	Female	Screen	25/02/92	37.20	14		150	75	72	145	85	76
				Day 0	03/03/92	37.10		61.90	155	80	76	150	85	80
				Day 7	10/03/92	37.30		61.50	155	80	80	150	85	84
				Day 14	17/03/92	37.20		61.90	160	85	76	150	90	80
				Day 21	24/03/92	36.90		62.20	155	80	72	150	85	80
				Day 28	31/03/92	37.20		62.80	160	85	80	150	85	84
				Day 35	07/04/92	36.90		62.70	150	75	80	155	80	84
				Day 42	14/04/92	37.10		62.20	150	75	76	152	80	84

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/10	58	Imipramine	Female	Screen	02/04/92	36.80	16		140	85	84	130	75	88
				Day 0	13/04/92	37.10		58.30	135	75	80	130	70	84
				Day 7	21/04/92	36.80		58.40	145	85	76	135	80	80
				Day 14	27/04/92	37.10		58.50	135	70	72	130	75	80
				Day 21	04/05/92	37.10		58.30	135	75	76	130	70	80
				Day 28	11/05/92	37.10		58.00	145	80	72	140	75	76
				Day 35	18/05/92	37.10		58.50	150	80	84	140	75	80
				Day 42	25/05/92	37.20		58.90	155	85	88	140	70	80
	59	Imipramine	Female	Screen	15/04/92	37.00	15		140	80	76	135	85	80
				Day 0	23/04/92	37.20		62.00	135	75	76	130	70	80
				Day 7	30/04/92	37.00		61.70	140	75	72	130	80	76
				Day 14	07/05/92	37.20		62.20	145	70	76	135	75	80
				Day 21	14/05/92	36.80		62.30	135	70	72	130	75	80
				Day 28	21/05/92	37.20		62.10	145	75	72	140	80	80
				Day 35	29/05/92	36.90		62.40	140	75	76	140	80	80
				Day 42	05/06/92	37.00		62.60	130	65	76	135	70	80
	60	Reboxetine	Female	Screen	04/05/92	36.90	15		150	80	76	145	85	80
				Day 0	12/05/92	37.10		71.20	155	75	76	150	80	84
				Day 7	19/05/92	37.30		70.90	150	80	76	145	85	80
				Day 14	26/05/92	37.00		72.10	155	75		150	80	
				Day 21	02/06/92	37.10		71.20	150	75	72	145	80	76
				Day 28	09/06/92	37.10		71.60	145	70	72	150	75	80
				Day 35	16/06/92	37.00		71.30	155	80	76	150	75	80
				Day 42	23/06/92	36.80		71.00	160	80	76	150	85	80
	137	Reboxetine	Female	Screen	20/01/92	36.20	16		115	65	80	110	70	88
				Day 0	27/01/92	37.20		62.10	120	80	76	110	85	84
				Day 7	03/02/92	37.10		61.60	125	75	72	120	85	81
				Day 14	10/02/92	37.20		61.90	130	75	76	120	80	84
				Day 21	17/02/92	37.20		62.20	135	80	76	125	75	80
				Day 28	24/02/92	37.20		61.30	130	75	72	120	80	80
				Day 35	02/03/92	37.20		61.90	125	75	80	120	80	84
				Day 42	09/03/92	37.20		62.20	135	80	72	125	85	80
	138	Imipramine	Female	Screen	21/01/92	36.90	15		130	70	76	120	75	80
				Day 0	28/01/92	37.10		58.60	135	80	72	130	80	80
				Day 7	04/02/92	37.20		58.30	130	75	72	120	80	80
				Day 14	11/02/92	37.20		58.60	125	70	80	120	75	84
				Day 21	18/02/92	37.20		58.30	130	75	72	120	80	80
				Day 28	25/02/92	37.30		59.20	125	75	80	120	80	84
				Day 35	03/03/92	37.10		59.90	140	80	72	130	85	80
				Day 42	10/03/92	37.20		60.20	130	65	76	120	75	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/10	139	Reboxetine	Female	Screen	27/01/92	37.10	16		120	75	76	115	80	84
				Day 0	03/02/92	37.20		66.90	120	75	84	115	80	88
				Day 7	10/02/92	37.10		66.60	125	75	76	120	80	84
				Day 14	17/02/92	37.20		66.30	130	75	72	125	80	80
				Day 21	24/02/92	37.20		66.20	130	75	76	120	80	84
				Day 28	02/03/92	37.10		66.10	130	70	72	125	75	80
				Day 35	09/03/92	37.20		66.80	130	70	72	120	75	80
				Day 42	16/03/92	37.20		66.20	135	70	76	130	75	84
	140	Imipramine	Female	Screen	28/01/92	37.20	16		135	80	72	130	85	76
				Day 0	04/02/92	37.20		67.00	140	75	68	130	80	76
				Day 7	11/02/92	37.20		67.20	140	80	72	130	85	76
				Day 14	18/02/92	37.20		66.90	135	75	80	130	80	84
				Day 21	25/02/92	37.20		67.50	140	80	72	135	75	80
				Day 28	03/03/92	37.20		67.60	150	80	84	135	75	80
				Day 35	10/03/92	37.20		67.20	140	75	72	135	80	76
				Day 42	17/03/92	37.20		67.10	135	75	80	130	75	84
	435	Imipramine	Female	Screen	04/11/91	36.80	18		155	80	84	150	85	88
				Day 0	11/11/91	36.80		77.00	160	80	80	155	85	84
				Day 7	18/11/91	36.90		77.40	150	80	72	150	85	76
				Day 14	25/11/91	36.70		77.20	155	85	68	150	80	72
				Day 21	02/12/91	36.20		77.00	155	80	76	150	85	84
				Day 28	09/12/91	36.30		77.50	160	80	80	150	75	84
				Day 35	16/12/91	36.70		77.30	155	80	68	150	85	72
				Day 42	23/12/91	36.90		77.10	150	80	68	145	80	72
	436	Reboxetine	Female	Screen	05/11/91	36.70	16		120	75	76	115	80	84
				Day 0	12/11/91	36.90		67.90	125	75	76	120	80	84
				Day 7	19/11/91	36.30		67.30	130	75	72	120	80	76
				Day 14	26/11/91	36.00		67.80	135	70	76	130	80	80
				Day 21	03/12/91	36.20		67.30	140	80	76	130	85	80
				Day 28	09/12/91	36.30		67.30	145	75	72	140	80	76
				Day 35	16/12/91	36.80		67.50	140	65	68	130	70	72
				Day 42	23/12/91	36.50		67.10	145	80	72	140	85	80
	437	Reboxetine	Female	Screen	05/11/91	36.20	15		125	70	76	120	75	80
				Day 0	13/11/91	36.60		70.80	130	70	72	120	75	80
				Day 7	19/11/91	36.80		69.90	130	70	72	125	80	80
				Day 14	26/11/91	36.60		69.10	135	75	76	125	80	80
				Day 21	03/12/91	36.70		68.90	130	70	80	130	75	84
				Day 28	10/12/91	36.50		69.10	140	80	72	130	85	80
				Day 35	17/12/91	36.90		68.70	145	85	72	140	80	76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/10	437	Reboxetine	Female	Day 42	23/12/91	37.10		68.80	150	80	68	145	83	72
	438	Imipramine	Female	Screen	07/11/91	36.20	13		130	70	80	120	75	81
				Day 0	14/11/91	36.20		67.90	125	70	76	120	75	80
				Day 7	21/11/91	36.70		67.60	125	65	80	120	70	84
				Day 14	28/11/91	36.90		67.50	120	65	72	125	70	80
				Day 21	05/12/91	36.20		67.30	125	70	76	120	75	80
				Day 28	12/12/91	36.70		67.50	125	65	76	120	70	80
				Day 35	19/12/91	37.50		67.40	120	65	80	120	70	88
				Day 42	27/12/91	36.90		67.60	125	60	72	120	70	80
	443	Reboxetine	Female	Screen	14/11/91	36.60	14		150	85	82	145	85	88
				Day 0	18/11/91	36.70		63.40	155	80	80	150	85	84
				Day 7	25/11/91	36.70		63.20	150	75	82	150	70	86
				Day 14	02/12/91	36.50		63.50	155	80	80	150	80	84
				Day 21	09/12/91	36.70		63.20	150	75	76	150	80	84
				Day 28	16/12/91	37.00		63.80	145	80	80	140	80	84
				Day 35	23/12/91	37.10		63.20	150	80	76	145	85	80
				Day 42	30/12/91	36.20		63.60	150	75	72	140	80	76
	444	Reboxetine	Male	Screen	15/11/91	36.70	15		140	85	72	135	85	76
				Day 0	15/11/91	36.70		66.30	150	75	72	140	80	76
				Day 7	22/11/91	36.70		66.00	145	75	76	140	80	80
				Day 14	29/11/91	36.30		60.20	145	75	72	150	80	76
				Day 21	06/12/91	36.40		66.50	150	75	68	145	80	76
				Day 28	13/12/91	36.90		66.50	135	70	72	130	75	76
				Day 35	20/12/91	37.10		66.20	160	80	68	160	85	72
				Day 42	27/12/91	36.70		66.50	145	75	76	140	80	76
	445	Imipramine	Female	Screen	15/11/91	36.80	16		155	80	84	150	85	88
				Day 0	19/11/91	36.90		71.90	160	80	80	150	85	84
				Day 7	26/11/91	36.70		70.50	155	75	76	150	80	80
				Day 14	03/12/91	36.50		70.20	165	80	76	160	90	84
				Day 21	10/12/91	36.50		70.30	160	85	78	155	80	84
				Day 28	17/12/91	36.80		70.80	150	80	72	155	85	76
				Day 35	23/12/91	36.50		70.70	155	85	72	150	80	76
				Day 42	30/12/91	36.50		70.90	150	80	76	145	85	80
	446	Reboxetine	Female	Screen	22/11/91	36.10	15		125	70	80	120	75	84
				Day 0	25/11/91	36.60		63.00	130	70	72	120	75	80
				Day 7	02/12/91	37.00		62.90	130	70	76	120	75	84
				Day 14	09/12/91	36.50		63.10	125	70	76	125	80	84
				Day 21	16/12/91	36.50		63.40	130	65	72	120	70	76
				Day 28	23/12/91	36.90		63.20	120	60	76	120	65	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/10	446	Reboxetine	Female	Day 35	30/12/91	36.90		64.00	130	70	68	125	75	72
				Day 42	07/01/92	36.20		64.10	140	80	72	130	85	76
	447	Reboxetine	Male	Screen	26/11/91	36.90	16		150	80	72	150	85	76
				Day 0	26/11/91	36.90		64.20	150	80	72	150	85	76
				Day 7	03/12/91	36.80		64.00	155	85	76	150	85	84
				Day 14	10/12/91	36.50		64.30	160	80	80	150	85	88
				Day 21	17/12/91	36.20		64.10	150	80	72	140	85	76
				Day 28	23/12/91	36.90		69.10	150	75	68	150	80	76
				Day 35	30/12/91	37.10		69.30	155	75	72	145	80	80
				Day 42	07/01/92	36.70		63.90	150	75	76	145	80	84
	448	Imipramine	Female	Screen	22/11/91	37.10	17		145	75	76	140	80	84
				Day 0	27/11/91	37.10		65.00	150	80	76	140	90	84
				Day 7	04/12/91	36.90		64.80	150	80	72	145	85	80
				Day 14	10/12/91	36.90		64.70	145	75	80	150	80	88
				Day 21	17/12/91	36.80		64.50	150	80	76	140	85	80
				Day 28	23/12/91	36.20		64.40	145	75	72	140	80	80
				Day 35	30/12/91	36.50		64.60	150	80	76	145	90	80
				Day 42	07/01/92	36.50		65.00	150	80	72	140	85	76
	453	Imipramine	Female	Screen	18/05/92	37.20	14		135	70	88	130	75	88
				Day 0	27/05/92	37.00		66.10	140	75	72	135	80	76
				Day 7	03/06/92	36.90		66.30	135	80	76	130	85	84
				Day 14	10/06/92	37.20		66.00	150	75	72	140	80	76
				Day 21	17/06/92	37.20		66.30	140	70	80	135	75	84
				Day 28	24/06/92	37.20		66.70	145	70	72	140	75	80
				Day 35	01/07/92	37.20		66.30	145	70	76	140	75	84
				Day 42	08/07/92	36.80		66.90	135	65	72	130	70	80
	454	Reboxetine	Female	Screen	02/06/92	37.30	13		145	80	76	140	85	80
				Day 0	11/06/92	37.00		61.90	140	75	72	145	80	80
				Day 7	17/06/92	36.70		61.80	135	65	68	140	70	76
				Day 14	25/06/92	37.10		62.30	145	70	72	140	80	84
				Day 21	02/07/92	37.00		62.20	150	75	76	140	80	84
				Day 28	09/07/92	36.50		62.50	145	65	72	140	70	80
				Day 35	16/07/92	36.80		62.20	140	65	76	135	75	80
				Day 42	23/07/92	37.10		62.30	145	70	72	140	75	76
	455	Reboxetine	Female	Screen	11/06/92	37.20	14		125	65	84	120	70	88
				Day 0	19/06/92	36.50		57.90	130	65	72	120	70	80
				Day 7	26/06/92	36.40		58.10	125	60	80	120	75	84
				Day 14	03/07/92	36.70		58.20	125	65	76	115	70	84
				Day 21	10/07/92	36.70		58.00	135	70	72	125	80	80

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
14/10	455	Reboxetine	Female	Day 28	17/07/92	37.10		58.20	140	75	76	125	80	80
				Day 35	24/07/92	36.70		58.40	135	70	72	130	75	80
				Day 42	31/07/92	36.80		58.20	140	75	64	130	60	68
15	349	Imipramine	Male	Screen	18/08/92	36.40	20		110	70	84	120	70	88
				Day 0	20/08/92	36.40		62.00	110	70	84	120	70	88
				Day 7	27/08/92	36.00		62.00	106	70	72	110	70	74
				Day 14	03/09/92	36.00		62.00	110	70	68	110	70	72
				Day 21	10/09/92	35.70		62.00	120	80	84	100	70	86
				Day 28	17/09/92	36.00		61.00	108	60	84	110	70	80
				Day 35	24/09/92	36.60		61.00	110	80	68	110	90	72
				Day 42	01/10/92	36.00		61.00	90	70	70	100	80	80
	351	Reboxetine	Male	Screen	02/09/92	36.50	20		170	110	88	160	95	92
				Day 0	02/09/92	36.50		60.00	170	110	88	160	102	92
				Day 7	09/09/92	39.00		60.00	120	80	80	120	80	84
				Day 14	16/09/92	36.60		61.00	120	80	78	120	80	84
				Day 21	23/09/92	36.60		61.00	120	80	78	120	80	84
				Day 28	30/09/92	36.60		61.00	130	90	80	130	80	84
				Day 35	07/10/92	37.00		61.00	130	90	80	130	90	88
				Day 42	14/10/92	37.00		61.00	130	90	74	130	90	80
	352	Imipramine	Male	Screen	06/08/92	36.30	22		130	70	60	130	80	60
				Day 0	06/08/92	36.30		75.00	130	70	60	130	80	64
				Day 7	12/08/92	37.00		75.00	130	80	84	130	90	84
				Day 14	20/08/92	36.60		79.00	130	80	76	120	70	84
				Day 21	27/08/92	36.40		76.00	120	80	76	120	90	82
	364	Imipramine	Female	Screen	29/07/92	36.80	20		110	70	88	100	70	92
				Day 0	29/07/92	36.80		55.00	110	70	88	100	70	92
				Day 7	05/08/92	36.60		53.00	120	80	84	110	80	88
				Day 14	12/08/92	36.40		55.00	110	70	80	100	70	88
				Day 21	19/08/92	36.40		55.00	110	70	88	100	70	92
	366	Reboxetine	Male	Screen	27/08/92	35.90	18		100	60	62	110	70	62
				Day 0	27/08/92	35.70		49.80	100	60	62	110	70	60
				Day 7	03/09/92	36.00		50.00	100	65	64	120	75	68
				Day 14	10/09/92	35.60		50.00	120	80	60	100	60	60
				Day 21	17/09/92	36.40		51.00	130	80	70	130	80	88
				Day 28	24/09/92	36.20		50.00	120	90	68	120	80	70
				Day 35	01/10/92	36.60		53.00	90	70	80	110	90	90
				Day 42	08/10/92	36.00		53.00	110	90	88	120	90	70

1437

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
15	367	Imipramine	Male	Screen	31/08/92	36.60	18		120	90	80	125	90	86
				Day 0	31/08/92	36.60		81.00	120	90	80	125	90	86
				Day 7	07/09/92	36.80		81.00	140	120	86	145	110	80
				Day 14	14/09/92	36.20		79.00	170	120	96	160	120	90
				Day 21	21/09/92	37.40		80.00	160	110	88	160	120	86
				Day 28	28/09/92	36.80		80.00	150	100	88	150	120	86
				Day 35	05/10/92	36.00		79.50	170	120	74	165	140	72
				Day 42	12/10/92	36.40		79.00	170	120	72	160	118	74
	368	Reboxetine	Female	Screen	04/09/92	36.50	15		150	100	84	130	100	106
				Day 0	04/09/92	36.50		80.00	150	100	84	130	100	106
				Day 7	10/09/92	37.00		78.00	160	110	102	140	100	96
				Day 14	17/09/92	36.00		78.40	155	90	84	160	100	86
				Day 21	24/09/92	36.40		76.00	130	100	88	130	100	86
				Day 28	01/10/92	36.80		78.40	150	90	84	160	100	86
				Day 35	08/10/92	36.50		78.40	150	90	84	160	90	86
				Day 42	15/10/92	37.00		79.00	150	90	84	150	90	94
	369	Reboxetine	Female	Screen	10/07/92	36.00	16		120	80	80	110	70	84
				Day 0	10/07/92	36.00		63.00	120	80	80	120	70	84
				Day 7	16/07/92	36.40		63.50	130	70	88	110	60	90
				Day 14	23/07/92	36.60		62.50	120	85	82	110	75	88
				Day 28	06/08/92	36.00		63.00	110	80	100	110	70	110
				Day 35	13/08/92	36.50		62.00	115	85	80	120	90	80
				Day 42	20/08/92	36.50		62.00	140	100	108	130	90	116
	370	Imipramine	Female	Screen	16/07/92	36.00	16		120	60	100	100	60	100
				Day 0	16/07/92	36.00		96.00	120	60	100	100	60	100
				Day 7	23/07/92	36.00		95.50	130	70	88	130	60	98
				Day 14	30/07/92	36.50		95.00	130	70	96	130	60	104
				Day 21	06/08/92	36.40		100.00	120	70	90	130	70	100
				Day 28	13/08/92	36.20		101.00	110	70	90	120	80	112
				Day 35	20/08/92	36.00		100.00	100	60	84	110	90	80
				Day 42	27/08/92	36.00		100.00	100	60	84	110	90	80
	371	Reboxetine	Female	Screen	17/07/92	37.30	18		120	70	68	120	80	74
				Day 0	20/07/92	37.30		65.00	120	70	68	120	80	74
				Day 7	26/07/92	36.60		65.00	100	70	88	95	70	84
				Day 14	03/08/92	36.80		64.50	130	80	106	110	60	112
				Day 28	17/08/92	36.00		63.00	130	90	100	120	80	114
				Day 35	24/08/92	36.30		63.00	125	85	98	120	80	106
	372	Imipramine	Male	Screen	17/06/92	35.20			90	60	88	85	60	88
				Day 0	17/06/92	35.20		37.50	90	60	88	85	60	88

1432

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

									BLOOD PRESSURE AND HEART RATE					
									lying			standing		
Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
15	372	Imipramine	Male	Day 7	24/06/92	35.00		36.50	85	60	90	85	60	96
				Day 14	01/07/92	35.00		38.00	88	60	96	80	60	98
				Day 21	08/07/92	35.80		38.00	90	60	88	85	60	92
				Day 28	15/07/92	36.20		37.00	100	65	78	110	60	88
				Day 35	22/07/92	35.60		35.30	118	65	78	110	60	80
				Day 42	29/07/92	36.50		36.00	130	70	76	120	70	78
	373	Imipramine	Female	Screen	25/06/92	37.00	18		120	80	84	110	70	82
				Day 0	25/06/92	37.00		68.00	120	80	84	110	70	82
	374	Reboxetine	Female	Screen	09/04/92	36.70	18		100	60	96	110	70	94
				Day 0	08/04/92	36.00		50.00	100	60	88	100	60	92
				Day 28	06/05/92	36.60		51.00	110	60	80	100	70	92
				Day 35	13/05/92	36.50		50.00	120	60	80	100	60	96
				Day 42	20/05/92	36.50		51.00	120	60	80	100	60	96
	375	Reboxetine	Female	Screen	06/06/92	36.20	20		110	70	88	120	80	90
				Day 0	06/06/92	36.00		60.00	110	70	88	120	80	90
				Day 7	13/06/92	36.40		60.50	110	70	86	100	70	88
				Day 14	20/06/92	36.50		61.00	110	80	84	100	80	86
				Day 21	27/06/92	36.60		63.50	120	80	88	110	70	84
	376	Imipramine	Female	Screen	13/04/92	36.00	22		130	80	72	130	80	76
				Day 0	13/04/92	36.00		59.00	130	80	72	130	80	76
				Day 7	20/04/92	36.00		58.00	140	80	80	100	60	96
	377	Reboxetine	Female	Screen	13/05/92	36.60	28		120	80	88	115	70	70
				Day 0	13/05/92	36.60		63.50	120	80	88	115	70	94
				Day 7	20/05/92	36.50		62.20	130	80	88	140	100	104
				Day 14	27/05/92	36.60		62.00	125	80	86	135	90	98
				Day 21	03/06/92	36.60		63.50	120	80	84	110	70	88
				Day 28	11/06/92	35.00		62.00	110	60	88	100	60	84
				Day 35	18/06/92	36.80		65.00	125	70	120	130	70	125
	378	Reboxetine	Female	Screen	15/06/92	36.60	20		100	60	86	100	50	80
				Day 0	15/06/92	36.60		62.00	100	60	86	100	50	80
				Day 7	22/06/92	36.00		64.00	100	70	68	110	70	72
				Day 14	29/06/92	37.00		64.00	100	60	78	85	60	82
				Day 21	06/07/92	37.00		62.00	100	60	78	80	60	80
				Day 28	13/07/92	37.30		65.00	110	80	88	110	80	104
				Day 35	20/07/92	36.50		66.50	110	70	70	110	70	70
				Day 42	27/07/92	36.60		67.00	110	80	84	110	70	92

1430

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE lying S.B.P. (mmHg)	lying D.B.P. (mmHg)	lying Heart Rate (beats/min)	standing S.B.P. (mmHg)	standing D.B.P. (mmHg)	standing Heart Rate (beats/min)
15	379	Imipramine	Female	Screen	16/04/92	36.20	18		130	70	60	120	60	68
				Day 0	16/04/92	36.20		55.00	130	70	60	120	60	68
	380	Imipramine	Female	Screen	30/06/92		22		100	60	80	90	60	84
				Day 0	30/06/92	36.60		53.00	100	60	80	90	60	84
				Day 7	06/07/92	36.80		51.50	100	60	84	105	70	88
				Day 14	13/07/92	37.00		51.50	95	60	88	100	65	94
				Day 21	20/07/92	37.00		51.00	100	70	86	75	45	84
				Day 28	27/07/92	36.00		55.00	100	50	80	100	50	80
	381	Reboxetine	Female	Screen	21/05/92	36.70	20		110	60	96	100	70	94
				Day 0	21/05/92	36.70		65.00	110	60	96	100	70	94
				Day 7	28/05/92	36.50		63.00	110	70	78	120	80	84
				Day 14	04/06/92	37.00		62.00	100	60	84	110	70	92
				Day 21	11/06/92	36.60		62.00	100	60	86	100	70	104
				Day 28	18/06/92	36.00		63.00	100	60	84	100	70	92
				Day 35	25/06/92	36.00		63.00	100	70	78	110	80	88
				Day 42	02/07/92	36.00			100	70	80	110	80	84
	382	Imipramine	Male	Screen	09/04/92	36.60	24		100	80	60	90	88	60
				Day 0	09/04/92	36.00		66.00	100	60	80	90	60	88
	383	Imipramine	Female	Screen	07/07/92	36.00	20		110	65	92	110	60	96
				Day 0	07/07/92	36.00		63.00	110	65	92	110	60	96
				Day 7	14/07/92	36.80		60.00	100	60	84	100	50	86
				Day 14	21/07/92	36.90		61.00	120	80	100	110	70	105
				Day 21	28/07/92	37.00		61.00	125	85	102	115	80	104
				Day 28	04/08/92	36.80		61.00	120	80	88	120	70	100
				Day 35	11/08/92	36.30		63.00	120	70	102	119	80	110
				Day 42	18/08/92	36.40		63.00	120	80	92	130	70	90
	384	Reboxetine	Female	Screen	28/07/92	35.80	18		130	85	78	140	90	88
				Day 0	29/07/92	35.80		47.00	130	88	78	140	90	88
				Day 7	04/08/92	36.00		46.60				110	70	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
1	1	Reboxetine	Male	05/02/91	18/03/91	Screen	0	0 - Screening	05/02/91	Normal	
						Day 21	21	1-21 days	26/02/91	Normal	
						Day 42	42	22-42 days	19/03/91	Normal	
	2	Reboxetine	Female	26/02/91	08/04/91	Screen	0	0 - Screening	26/02/91	Normal	
						Day 21	21	1-21 days	19/03/91	Normal	
						Day 42	42	22-42 days	09/04/91	Normal	
	3	Imipramine	Female	16/04/91	27/05/91	Screen	-4	0 - Screening	12/04/91	Normal	
						Day 21	21	1-21 days	07/05/91	Normal	
						Day 42	42	22-42 days	28/05/91	Normal	
	4	Imipramine	Male	17/04/91	28/05/91	Screen	-2	0 - Screening	15/04/91	Normal	
						Day 21	20	1-21 days	07/05/91	Normal	
						Day 42	42	22-42 days	29/05/91	Normal	
	5	Reboxetine	Female	17/07/91	27/08/91	Screen	0	0 - Screening	17/07/91	Normal	
						Day 21	21	1-21 days	07/08/91	Normal	
						Day 42	42	22-42 days	28/08/91	Normal	
	6	Imipramine	Male	07/08/91	17/09/91	Screen	-1	0 - Screening	06/08/91	Normal	
						Day 21	21	1-21 days	28/08/91	Normal	
						Day 42	42	22-42 days	18/09/91	Normal	
	7	Reboxetine	Male	09/10/91	20/11/91	Screen	-1	0 - Screening	08/10/91	Abnormal	LEFT ANTERIOR HEMIBLOCK
						Day 21	21	1-21 days	30/10/91	Abnormal	LEFT BUNDLE BRANCH BLOCK
						Day 42	43	22-42 days	21/11/91	Abnormal	LEFT POSTERIOR HEMIBLOCK
	8	Imipramine	Male	29/10/91	31/10/91	Screen	-1	0 - Screening	28/10/91	Normal	
	9	Imipramine	Female	08/11/91	19/12/91	Screen	-2	0 - Screening	06/11/91	Normal	
						Day 21	20	1-21 days	28/11/91	Normal	
						Day 42	41	22-42 days	19/12/91	Normal	
	10	Imipramine	Female	19/11/91	30/12/91	Screen	-4	0 - Screening	15/11/91	Normal	
						Day 21	21	1-21 days	10/12/91	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH BLOCK
						Day 42	41	22-42 days	30/12/91	Normal	
	11	Reboxetine	Male	06/04/92	03/05/92	Screen	-3	0 - Screening	03/04/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 21	29	1-21 days	05/05/92	Abnormal	SINUS TACHYCARDIA (> 100)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
1	12	Reboxetine	Male	15/04/92	05/05/92	Screen	-2	0 - Screening	13/04/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 21	15	1-21 days	30/04/92	Normal	
2	33	Reboxetine	Male	19/12/90	29/01/91	Screen	-1	0 - Screening	18/12/90	Normal	
						Day 21	20	1-21 days	08/01/91	Normal	
						Day 42	41	22-42 days	29/01/91	Abnormal	OTHER
	34	Imipramine	Male	28/12/90	03/02/91	Screen	-1	0 - Screening	27/12/90	Normal	
						Day 21	20	1-21 days	17/01/91	Normal	
						Day 42	41	22-42 days	07/02/91	Normal	
	35	Reboxetine	Male	28/12/90	07/02/91	Screen	-1	0 - Screening	27/12/90	Normal	
						Day 21	20	1-21 days	17/01/91	Normal	
						Day 42	41	22-42 days	07/02/91	Abnormal	RIPOLARIZATION DISTURBANCES
	36	Imipramine	Female	10/01/91	31/01/91	Screen	-1	0 - Screening	09/01/91	Normal	
						Day 21	20	1-21 days	30/01/91	Abnormal	SINUS TACHYCARDIA (> 100)
	37	Reboxetine	Male	18/01/91	28/02/91	Screen	-1	0 - Screening	17/01/91	Normal	
						Day 21	20	1-21 days	07/02/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	41	22-42 days	28/02/91	Normal	
	38	Imipramine	Female	25/01/91	07/03/91	Screen	-2	0 - Screening	23/01/91	Normal	
						Day 21	20	1-21 days	14/02/91	Normal	
						Day 42	41	22-42 days	07/03/91	Normal	
	39	Reboxetine	Female	25/01/91	07/03/91	Screen	-1	0 - Screening	24/01/91	Normal	
						Day 21	20	1-21 days	14/02/91	Normal	
						Day 42	41	22-42 days	07/03/91	Normal	
	40	Imipramine	Male	20/02/91	02/04/91	Screen	-1	0 - Screening	19/02/91	Normal	
						Day 21	20	1-21 days	12/03/91	Normal	
						Day 42	41	22-42 days	02/04/91	Abnormal	SINUS TACHYCARDIA (> 100) RIGHT BUNDLE BRANCH BLOCK
	41	Reboxetine	Male	05/02/91	18/03/91	Screen	-5	0 - Screening	31/01/91	Normal	
						Day 21	20	1-21 days	25/02/91	Normal	
						Day 42	41	22-42 days	18/03/91	Abnormal	SINUS TACHYCARDIA (> 100)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
2	42	Imipramine	Male	09/02/91	22/03/91	Screen	-1	0 - Screening	08/02/91	Normal	
						Day 21	20	1-21 days	01/03/91	Abnormal	SINUS TACHYCARDIA (> 100) A-V BLOCK 1ST DEGREE
						Day 42	41	22-42 days	22/03/91	Abnormal	SINUS TACHYCARDIA (> 100)
	43	Reboxetine	Female	26/03/91	06/05/91	Screen	-1	0 - Screening	25/03/91	Normal	
						Day 21	20	1-21 days	15/04/91	Normal	
						Day 42	41	22-42 days	06/05/91	Normal	
	44	Imipramine	Male	11/04/91	11/04/91	Screen	-1	0 - Screening	10/04/91	Normal	
	45	Imipramine	Female	30/04/91	03/05/91	Screen	-1	0 - Screening	29/04/91	Normal	
	46	Reboxetine	Female	16/05/91	26/06/91	Screen	-1	0 - Screening	15/05/91	Normal	
						Day 21	20	1-21 days	05/06/91	Normal	
						Day 42	41	22-42 days	26/06/91	Abnormal	SINUS TACHYCARDIA (> 100)
	47	Reboxetine	Female	22/05/91	02/07/91	Screen	-1	0 - Screening	21/05/91	Normal	
						Day 21	22	1-21 days	13/06/91	Normal	
						Day 42	41	22-42 days	02/07/91	Normal	
	48	Imipramine	Female	27/08/91	07/10/91	Screen	-1	0 - Screening	26/08/91	Abnormal	SINUS TACHYCARDIA (> 100) A-V BLOCK 1ST DEGREE
						Day 21	20	1-21 days	16/09/91	Abnormal	SINUS TACHYCARDIA (> 100) A-V BLOCK 1ST DEGREE
						Day 42	41	22-42 days	07/10/91	Abnormal	SINUS TACHYCARDIA (> 100) VENTRICULAR ECTOPIC BEATS - OCCASIONAL
	49	Imipramine	Female	29/08/91	09/10/91	Screen	-1	0 - Screening	28/08/91	Normal	
						Day 21	20	1-21 days	18/09/91	Normal	
						Day 42	41	22-42 days	09/10/91	Normal	
	50	Reboxetine	Male	06/11/91	15/12/91	Screen	-2	0 - Screening	04/11/91	Normal	
						Day 21	20	1-21 days	26/11/91	Abnormal	LEFT BUNDLE BRANCH BLOCK
	51	Reboxetine	Female	06/11/91	17/11/91	Screen	-2	0 - Screening	04/11/91	Normal	
	52	Imipramine	Male	27/11/91	07/01/92	Screen	-13	0 - Screening	14/11/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
2	52	Imipramine	Male	27/11/91	07/01/92	Day 21	20	1-21 days	17/12/91	Normal	
						Day 42	41	22-42 days	07/01/92	Normal	
3	65	Reboxetine	Male	02/04/91	13/05/91	Screen	-5	0 - Screening	28/03/91	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 21	20	1-21 days	22/04/91	Abnormal	SINUS TACHYCARDIA (> 100) PREVIOUS MYOCARDIAL INFARCTION
						Day 42	41	22-42 days	13/05/91	Abnormal	SINUS TACHYCARDIA (> 100) PREVIOUS MYOCARDIAL INFARCTION
	66	Imipramine	Female	01/05/91	05/06/91	Screen	-4	0 - Screening	27/04/91	Normal	
						Day 21	20	1-21 days	21/05/91	Normal	
	67	Reboxetine	Female	10/04/91	21/05/91	Screen	-2	0 - Screening	08/04/91	Normal	
						Day 21	20	1-21 days	30/04/91	Normal	
						Day 42	41	22-42 days	21/05/91	Abnormal	SINUS TACHYCARDIA (> 100)
	68	Imipramine	Female	03/08/91	13/09/91	Screen	-2	0 - Screening	01/08/91	Abnormal	MYOCARDIAL ISCHEMIA
						Day 21	23	1-21 days	26/08/91	Normal	
						Day 42	41	22-42 days	13/09/91	Abnormal	MYOCARDIAL ISCHEMIA
	69	Imipramine	Female	01/03/91	11/04/91	Screen	0	0 - Screening	01/03/91	Normal	
						Day 21	20	1-21 days	21/03/91	Normal	
						Day 42	41	22-42 days	11/04/91	Normal	
	70	Reboxetine	Female	23/10/91	19/11/91	Screen	-1	0 - Screening	22/10/91	Normal	
						Day 21	20	1-21 days	12/11/91	Normal	
	71	Imipramine	Female	14/11/91	25/12/91	Screen	-2	0 - Screening	12/11/91	Normal	
						Day 21	20	1-21 days	04/12/91	Normal	
						Day 42	41	22-42 days	25/12/91	Abnormal	SINUS TACHYCARDIA (> 100)
	72	Reboxetine	Female	31/01/92	12/03/92	Screen	-3	0 - Screening	28/01/92	Normal	
						Day 21	21	1-21 days	21/02/92	Normal	
						Day 42	42	22-42 days	13/03/92	Normal	
	73	Reboxetine	Female	15/02/92	27/03/92	Screen	-4	0 - Screening	11/02/92	Normal	
						Day 21	20	1-21 days	06/03/92	Normal	
						Day 42	42	22-42 days	28/03/92	Normal	
4	97	Imipramine	Male	07/05/92	18/06/92	Screen	-1	0 - Screening	06/05/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
4	97	Imipramine	Male	07/05/92	18/06/92	Day 21	20	1-21 days	27/05/92	Normal	
						Day 42	46	22-42 days	22/06/92	Normal	
	100	Reboxetine	Female	07/05/92	24/06/92	Screen	-6	0 - Screening	01/05/92	Normal	
						Day 21	20	1-21 days	27/05/92	Normal	
						Day 42	41	22-42 days	17/06/92	Normal	
	101	Imipramine	Female	06/05/91	22/05/91	Screen	0	0 - Screening	06/05/91	Normal	
						Day 21	17	1-21 days	23/05/91	Normal	
6	161	Reboxetine	Male	29/03/91	09/05/91	Screen	-2	0 - Screening	27/03/91	Normal	
						Day 21	20	1-21 days	18/04/91	Normal	
						Day 42	40	22-42 days	08/05/91	Abnormal	SINUS TACHYCARDIA (> 100)
	162	Reboxetine	Female	05/11/91	16/12/91	Screen	-1	0 - Screening	04/11/91	Normal	
						Day 21	20	1-21 days	25/11/91	Normal	
						Day 42	41	22-42 days	16/12/91	Abnormal	CONDUCTION DISORDER
7	193	Reboxetine	Female	11/06/91	17/06/91	Screen	-3	0 - Screening	08/06/91	Normal	
	194	Reboxetine	Male	03/06/91	06/06/91	Screen	-4	0 - Screening	30/05/91	Normal	
	196	Imipramine	Female	19/03/91	26/04/91	Screen	-1	0 - Screening	18/03/91	Normal	
8	225	Imipramine	Female	22/03/91	09/04/91			0 - Screening			
	226	Reboxetine	Female	03/05/91	13/06/91	Screen	0	0 - Screening	03/05/91	Normal	
						Day 21	21	1-21 days	24/05/91	Normal	
						Day 42	45	22-42 days	17/06/91	Normal	
	227	Imipramine	Male	07/05/91	17/06/91	Screen	-4	0 - Screening	03/05/91	Normal	
	228	Reboxetine	Male	10/05/91	17/05/91	Screen	-7	0 - Screening	03/05/91	Normal	
	229	Imipramine	Female	22/10/91	02/12/91	Screen	-5	0 - Screening	17/10/91	Normal	
						Day 21	13	1-21 days	04/11/91	Normal	
						Day 42	42	22-42 days	03/12/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
8	230	Imipramine	Female	05/11/91	16/12/91	Screen	-5	0 - Screening	31/10/91	Normal	
						Day 21	20	1-21 days	25/11/91	Normal	
						Day 42	41	22-42 days	16/12/91	Normal	
	231	Reboxetine	Female	05/11/91	13/11/91	Screen	0	0 - Screening	05/11/91	Normal	
	232	Reboxetine	Male	29/11/91	09/01/92	Screen	-3	0 - Screening	26/11/91	Normal	
						Day 21	21	1-21 days	20/12/91	Abnormal	SINUS TACHYCARDIA (> 100)
9	197	Reboxetine	Male	07/03/92	10/03/92	Screen	-9	0 - Screening	27/02/92	Normal	
						Day 7	6	1-21 days	13/03/92	Normal	
	198	Imipramine	Female	18/03/92	28/04/92	Screen	-8	0 - Screening	10/03/92	Normal	
						Day 21	20	1-21 days	07/04/92	Normal	
						Day 42	41	22-42 days	28/04/92	Normal	
	199	Imipramine	Male	02/04/92	13/05/92	Screen	-9	0 - Screening	24/03/92	Normal	
						Day 21	20	1-21 days	22/04/92	Normal	
						Day 42	41	22-42 days	13/05/92	Normal	
	200	Reboxetine	Male	28/04/92	08/06/92	Screen	-7	0 - Screening	21/04/92	Normal	
						Day 21	20	1-21 days	18/05/92	Normal	
						Day 42	41	22-42 days	08/06/92	Normal	
	201	Imipramine	Female	16/01/92	26/02/92	Screen	-9	0 - Screening	07/01/92	Normal	
						Day 21	20	1-21 days	05/02/92	Normal	
						Day 42	41	22-42 days	26/02/92	Normal	
	202	Imipramine	Male	17/01/92	27/02/92	Screen	-8	0 - Screening	09/01/92	Normal	
						Day 21	20	1-21 days	06/02/92	Normal	
						Day 42	41	22-42 days	27/02/92	Normal	
	203	Reboxetine	Female	15/01/92	18/01/92	Screen	-6	0 - Screening	09/01/92	Normal	
						Day 7	13	1-21 days	28/01/92	Normal	
	204	Reboxetine	Male	17/01/92	28/02/92	Screen	-8	0 - Screening	09/01/92	Normal	
						Day 21	20	1-21 days	06/02/92	Normal	
						Day 42	42	22-42 days	28/02/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
9	205	Imipramine	Female	05/02/92	07/02/92	Screen	-9	0 - Screening	27/01/92	Normal	
	206	Imipramine	Female	05/02/92	18/03/92	Screen	-8	0 - Screening	28/01/92	Normal	
						Day 21	21	1-21 days	26/02/92	Normal	
						Day 42	42	22-42 days	18/03/92	Normal	
	207	Reboxetine	Female	06/02/92	12/02/92	Screen	-1	0 - Screening	05/02/92	Normal	
						Day 7	6	1-21 days	12/02/92	Normal	
	208	Reboxetine	Male	15/02/92	27/03/92	Screen	-5	0 - Screening	10/02/92	Normal	
						Day 21	20	1-21 days	06/03/92	Normal	
						Day 42	41	22-42 days	27/03/92	Normal	
	209	Imipramine	Male	12/02/92	15/02/92	Screen	-8	0 - Screening	04/02/92	Normal	
	210	Reboxetine	Female	20/02/92	01/04/92	Screen	-15	0 - Screening	05/02/92	Normal	
						Day 42	41	22-42 days	01/04/92	Normal	
	211	Reboxetine	Female	14/02/92	02/03/92	Screen	-3	0 - Screening	11/02/92	Normal	
						Day 21	18	1-21 days	03/03/92	Normal	
	212	Imipramine	Female	04/03/92	14/04/92	Screen	-9	0 - Screening	24/02/92	Normal	
						Day 21	20	1-21 days	24/03/92	Normal	
						Day 42	41	22-42 days	14/04/92	Normal	
	237	Reboxetine	Male	23/04/92	02/05/92	Screen	-1	0 - Screening	22/04/92	Normal	
	238	Imipramine	Female	20/05/92	30/06/92	Screen	-8	0 - Screening	12/05/92	Normal	
						Day 21	20	1-21 days	09/06/92	Normal	
						Day 42	41	22-42 days	30/06/92	Normal	
	239	Imipramine	Male	30/04/92	10/06/92	Screen	-8	0 - Screening	22/04/92	Normal	
						Day 21	20	1-21 days	20/05/92	Normal	
						Day 42	41	22-42 days	10/06/92	Normal	
	240	Reboxetine	Female	28/04/92	16/05/92	Screen	-5	0 - Screening	23/04/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	Visit	days of treat.	E.C.G. Assessment	E.C.G. Date	E.C.G. Value	E.C.G. Abnormality
9	241	Imipramine	Female	09/05/92	19/06/92	Screen	-3	0 - Screening	06/05/92	Normal	
	242	Reboxetine	Male	07/05/92	17/06/92	Screen	-7	0 - Screening	30/04/92	Normal	
						Day 21	20	1-21 days	27/05/92	Normal	
						Day 42	41	22-42 days	17/06/92	Normal	
	243	Imipramine	Female	18/05/92	28/06/92	Screen	-7	0 - Screening	11/05/92	Normal	
						Day 21	21	1-21 days	08/06/92	Normal	
						Day 42	42	22-42 days	29/06/92	Normal	
	244	Reboxetine	Male	06/06/92	17/07/92	Screen	-12	0 - Screening	25/05/92	Normal	
						Day 21	20	1-21 days	26/06/92	Normal	
						Day 42	40	22-42 days	16/07/92	Normal	
	257	Reboxetine	Female	17/07/91	27/08/91	Screen	0	0 - Screening	17/07/91	Normal	
						Day 21	21	1-21 days	07/08/91	Normal	
						Day 42	42	22-42 days	28/08/91	Normal	
	258	Reboxetine	Male	17/07/91	06/08/91	Screen	-7	0 - Screening	10/07/91	Normal	
	259	Imipramine	Female	17/07/91	27/08/91	Screen	-12	0 - Screening	05/07/91	Normal	
						Day 21	21	1-21 days	07/08/91	Normal	
						Day 42	42	22-42 days	28/08/91	Normal	
	260	Imipramine	Female	24/07/91	12/08/91	Screen	0	0 - Screening	24/07/91	Normal	
						Day 21	21	1-21 days	14/08/91	Normal	
	261	Imipramine	Female	23/07/91	29/07/91	Screen	-4	0 - Screening	19/07/91	Normal	
						Day 7	7	1-21 days	30/07/91	Normal	
	262	Reboxetine	Male	23/07/91	03/09/91	Screen	-7	0 - Screening	16/07/91	Normal	
						Day 21	21	1-21 days	13/08/91	Normal	
						Day 42	42	22-42 days	03/09/91	Normal	
	263	Reboxetine	Female	31/07/91	13/08/91	Screen	-10	0 - Screening	21/07/91	Normal	
						Day 14	14	1-21 days	14/08/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
9	264	Imipramine	Female	31/07/91	10/09/91	Screen	1	0 - Screening	01/08/91	Normal	
						Day 21	21	1-21 days	21/08/91	Normal	
						Day 42	42	22-42 days	11/09/91	Normal	
	265	Reboxetine	Female	23/08/91	03/10/91	Screen	-10	0 - Screening	13/08/91	Normal	
						Day 21	20	1-21 days	12/09/91	Normal	
						Day 42	41	22-42 days	03/10/91	Normal	
	266	Reboxetine	Female	18/09/91	29/10/91	Screen	-8	0 - Screening	10/09/91	Normal	
						Day 21	20	1-21 days	08/10/91	Normal	
						Day 42	41	22-42 days	29/10/91	Normal	
	267	Imipramine	Male	02/09/91	13/10/91	Screen	-3	0 - Screening	30/08/91	Normal	
						Day 21	21	1-21 days	23/09/91	Normal	
						Day 42	42	22-42 days	14/10/91	Normal	
	268	Imipramine	Female	25/09/91	05/11/91	Screen	-8	0 - Screening	17/09/91	Normal	
						Day 21	20	1-21 days	15/10/91	Normal	
						Day 42	41	22-42 days	05/11/91	Normal	
	269	Reboxetine	Male	25/09/91	05/11/91	Screen	-6	0 - Screening	19/09/91	Normal	
						Day 21	20	1-21 days	15/10/91	Normal	
						Day 42	41	22-42 days	05/11/91	Normal	
	270	Imipramine	Female	11/10/91	17/10/91	Screen	-9	0 - Screening	02/10/91	Normal	
	271	Reboxetine	Female	30/10/91	20/11/91	Screen	-8	0 - Screening	22/10/91	Normal	
						Day 21	20	1-21 days	19/11/91	Normal	
	272	Imipramine	Male	30/10/91	10/12/91	Screen	-8	0 - Screening	22/10/91	Normal	
						Day 21	20	1-21 days	19/11/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 42	41	22-42 days	10/12/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
	273	Imipramine	Female	30/10/91	20/11/91	Screen	-6	0 - Screening	24/10/91	Normal	
						Day 21	20	1-21 days	19/11/91	Normal	
	274	Reboxetine	Female	31/10/91	31/10/91	Screen	-8	0 - Screening	23/10/91	Normal	
						Day 7	6	1-21 days	06/11/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
9	274/A	Reboxetine	Female	13/05/92	23/06/92	Screen	-22	0 - Screening	21/04/92	Normal	
						Day 21	20	1-21 days	02/06/92	Normal	
						Day 42	42	22-42 days	24/06/92	Normal	
	275	Reboxetine	Female	06/11/91	17/12/91	Screen	-6	0 - Screening	31/10/91	Normal	
						Day 21	20	1-21 days	26/11/91	Normal	
						Day 42	41	22-42 days	17/12/91	Normal	
	276	Imipramine	Female	14/01/92	14/01/92	Screen	-21	0 - Screening	24/12/91	Normal	
						Day 7	2	1-21 days	16/01/92	Normal	
	276/A	Imipramine	Male	04/03/92	14/04/92	Screen	-9	0 - Screening	24/02/92	Normal	
						Day 21	20	1-21 days	24/03/92	Normal	
						Day 42	41	22-42 days	14/04/92	Normal	
9/A	233	Imipramine	Male	14/05/92	24/06/92	Screen	-3	0 - Screening	11/05/92	Normal	
						Day 21	20	1-21 days	03/06/92	Normal	
						Day 42	41	22-42 days	24/06/92	Normal	
	234	Reboxetine	Female	22/05/92	02/07/92	Screen	-4	0 - Screening	18/05/92	Normal	
						Day 21	20	1-21 days	11/06/92	Normal	
						Day 42	41	22-42 days	02/07/92	Normal	
	235	Reboxetine	Male	26/05/92	29/06/92	Screen	-4	0 - Screening	22/05/92	Normal	
						Day 21	21	1-21 days	16/06/92	Normal	
	236	Imipramine	Male	27/05/92	07/07/92	Screen	-15	0 - Screening	12/05/92	Normal	
						Day 21	21	1-21 days	17/06/92	Normal	
						Day 42	41	22-42 days	07/07/92	Normal	
	277	Reboxetine	Female	10/06/92	14/06/92	Screen	-1	0 - Screening	09/06/92	Normal	
	278	Imipramine	Female	13/06/92	03/07/92	Screen	-3	0 - Screening	10/06/92	Normal	
	279	Imipramine	Male	07/08/92	21/08/92	Screen	-4	0 - Screening	03/08/92	Normal	
	280	Reboxetine	Female	08/08/92	14/08/92	Screen	-4	0 - Screening	04/08/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
9/A	281	Reboxetine	Female	01/09/92	12/10/92	Screen	-7	0 - Screening	25/08/92	Normal	
						Day 21	20	1-21 days	21/09/92	Normal	
						Day 42	41	22-42 days	12/10/92	Abnormal	SINUS TACHYCARDIA (> 100)
	282	Reboxetine	Male	02/09/92	13/10/92	Screen	-19	0 - Screening	14/08/92	Normal	
						Day 21	20	1-21 days	22/09/92	Normal	
						Day 42	41	22-42 days	13/10/92	Normal	
	283	Imipramine	Female	16/09/92	28/10/92	Screen	-5	0 - Screening	11/09/92	Normal	
						Day 21	21	1-21 days	07/10/92	Normal	
						Day 42	42	22-42 days	28/10/92	Normal	
	284	Imipramine	Male	19/09/92	09/10/92	Screen	-3	0 - Screening	16/09/92	Normal	
						Day 21	20	1-21 days	09/10/92	Normal	
	301	Imipramine	Female	05/03/92	15/04/92	Screen	-6	0 - Screening	28/02/92	Normal	
						Day 21	20	1-21 days	25/03/92	Normal	
						Day 42	41	22-42 days	15/04/92	Normal	
	302	Imipramine	Male	06/03/92	22/03/92	Screen	-4	0 - Screening	02/03/92	Normal	
	303	Reboxetine	Female	12/03/92	31/03/92	Screen	-2	0 - Screening	10/03/92	Normal	
						Day 21	19	1-21 days	31/03/92	Normal	
	304	Reboxetine	Female	26/03/92	06/05/92	Screen	-9	0 - Screening	17/03/92	Normal	
						Day 21	20	1-21 days	15/04/92	Normal	
						Day 42	41	22-42 days	06/05/92	Normal	
	305	Reboxetine	Male	31/03/92	11/05/92	Screen	-6	0 - Screening	25/03/92	Normal	
						Day 21	20	1-21 days	20/04/92	Normal	
						Day 42	41	22-42 days	11/05/92	Normal	
	306	Reboxetine	Female	29/04/92	09/06/92	Screen	-1	0 - Screening	28/04/92	Normal	
						Day 21	20	1-21 days	19/05/92	Normal	
						Day 42	41	22-42 days	09/06/92	Normal	
	307	Imipramine	Female	05/05/92	08/05/92	Screen	0	0 - Screening	05/05/92	Normal	
	308	Imipramine	Female	09/05/92	02/06/92	Screen	-1	0 - Screening	08/05/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
9/A	308	Imipramine	Female	09/05/92	02/06/92	Day 21	20	1-21 days	29/05/92	Normal	
10	289	Imipramine	Female	21/09/91	27/09/91	Screen	-2	0 - Screening	19/09/91	Normal	
	290	Reboxetine	Male	14/10/91	24/11/91	Screen	-7	0 - Screening	07/10/91	Normal	
						Day 21	21	1-21 days	04/11/91	Normal	
						Day 42	42	22-42 days	25/11/91	Normal	
	291	Imipramine	Male	17/02/92	29/03/92	Screen	-4	0 - Screening	13/02/92	Normal	
						Day 21	21	1-21 days	09/03/92	Normal	
						Day 42	42	22-42 days	30/03/92	Normal	
	292	Reboxetine	Female	13/12/91	23/01/92	Screen	-7	0 - Screening	06/12/91	Normal	
						Day 21	21	1-21 days	03/01/92	Normal	
						Day 42	43	22-42 days	25/01/92	Normal	
	293	Reboxetine	Female	24/12/91	01/02/92	Screen	0	0 - Screening	24/12/91	Abnormal	SINUS TACHYCARDIA (> 100) PREVIOUS MYOCARDIAL INFARCTION RIPOLARIZATION DISTURBANCES
						Day 21	21	1-21 days	14/01/92	Normal	
						Day 42	42	22-42 days	04/02/92	Normal	
	294	Imipramine	Female	03/01/92	23/01/92	Screen	-4	0 - Screening	30/12/91	Normal	
	295	Imipramine	Male	07/01/92	17/02/92	Screen	-5	0 - Screening	02/01/92	Normal	
						Day 21	20	1-21 days	27/01/92	Normal	
						Day 42	41	22-42 days	17/02/92	Normal	
	296	Reboxetine	Female	20/02/92	01/04/92	Screen	-5	0 - Screening	15/02/92	Normal	
						Day 21	21	1-21 days	12/03/92	Normal	
						Day 42	42	22-42 days	02/04/92	Normal	
	297	Reboxetine	Male	21/03/92	02/05/92	Screen	-2	0 - Screening	19/03/92	Normal	
						Day 21	20	1-21 days	10/04/92	Normal	
						Day 42	48	22-42 days	08/05/92	Normal	
	298	Reboxetine	Female	27/03/92	07/05/92	Screen	-8	0 - Screening	19/03/92	Normal	
						Day 21	20	1-21 days	16/04/92	Normal	
						Day 42	41	22-42 days	07/05/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
10	299	Imipramine	Male	07/04/92	18/05/92	Screen	-5	0 - Screening	02/04/92	Normal	
						Day 21	28	1-21 days	05/05/92	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	42	22-42 days	19/05/92	Normal	
	300	Imipramine	Female	14/04/92	25/05/92	Screen	-7	0 - Screening	07/04/92	Normal	
						Day 21	21	1-21 days	05/05/92	Normal	
						Day 42	42	22-42 days	26/05/92	Normal	
11	321	Reboxetine	Female	11/06/92	23/07/92	Screen	-6	0 - Screening	05/06/92	Normal	
						Day 21	17	1-21 days	28/06/92	Normal	
						Day 42	41	22-42 days	22/07/92	Normal	
	322	Reboxetine	Female	11/06/92	24/07/92	Screen	-7	0 - Screening	04/06/92	Normal	
						Day 21	21	1-21 days	02/07/92	Normal	
						Day 42	43	22-42 days	24/07/92	Normal	
	323	Imipramine	Female	24/06/92	06/08/92	Screen	-1	0 - Screening	23/06/92	Normal	
						Day 21	21	1-21 days	15/07/92	Normal	
						Day 42	43	22-42 days	06/08/92	Normal	
	324	Imipramine	Male	17/07/92	28/08/92	Screen	0	0 - Screening	17/07/92	Normal	
						Day 21	21	1-21 days	07/08/92	Normal	
						Day 42	42	22-42 days	28/08/92	Normal	
	325	Reboxetine	Female	30/07/92	10/09/92	Screen	0	0 - Screening	30/07/92	Normal	
						Day 21	21	1-21 days	20/08/92	Normal	
						Day 42	42	22-42 days	10/09/92	Normal	
	326	Imipramine	Male	30/07/92	10/09/92	Screen	-2	0 - Screening	28/07/92	Normal	
						Day 21	21	1-21 days	20/08/92	Normal	
						Day 42	42	22-42 days	10/09/92	Normal	
	327	Reboxetine	Female	20/08/92	01/10/92	Screen	-3	0 - Screening	17/08/92	Normal	
						Day 21	21	1-21 days	10/09/92	Normal	
						Day 42	42	22-42 days	01/10/92	Normal	
	328	Imipramine	Male	20/08/92	17/09/92	Screen	-1	0 - Screening	19/08/92	Normal	
						Day 21	21	1-21 days	10/09/92	Normal	
						Day 28	29	22-42 days	18/09/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
11	329	Imipramine	Female	21/08/92	02/10/92	Screen	-3	0 - Screening	18/08/92	Normal	
						Day 21	21	1-21 days	11/09/92	Normal	
						Day 42	42	22-42 days	02/10/92	Normal	
	330	Reboxetine	Female	24/08/92	26/08/92	Screen	-42	0 - Screening	13/07/92	Normal	
						Day 7	7	1-21 days	31/08/92	Normal	
	331	Reboxetine	Male	03/09/92	15/10/92	Screen	-2	0 - Screening	01/09/92	Normal	
						Day 21	21	1-21 days	24/09/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 42	42	22-42 days	15/10/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	332	Imipramine	Female	05/09/92	20/10/92	Screen	-2	0 - Screening	03/09/92	Normal	
						Day 21	23	1-21 days	28/09/92	Normal	
						Day 42	40	22-42 days	15/10/92	Normal	
	333	Imipramine	Female	04/09/92	16/10/92	Screen	0	0 - Screening	04/09/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 21	21	1-21 days	25/09/92	Normal	
						Day 42	42	22-42 days	16/10/92	Normal	
12	337	Imipramine	Female	26/05/92	06/07/92	Screen	-15	0 - Screening	11/05/92	Normal	
						Day 21	20	1-21 days	15/06/92	Normal	
						Day 42	41	22-42 days	06/07/92	Normal	
	338	Reboxetine	Female	20/06/92	31/07/92			0 - Screening			
	339	Imipramine	Male	23/06/92	03/08/92			0 - Screening			
	340	Reboxetine	Female	07/08/92	17/09/92	Day 21	20	1-21 days	27/08/92	Normal	
						Day 42	41	22-42 days	17/09/92	Normal	
	341	Reboxetine	Female	21/08/92	24/09/92	Screen	-4	0 - Screening	17/08/92	Abnormal	SINUS TACHYCARDIA (> 100) RIGHT INCOMPLETE BUNDLE BRANCH BLOCK
						Day 21	20	1-21 days	10/09/92	Normal	
13	353	Reboxetine	Female	05/06/92	07/07/92	Screen	0	0 - Screening	05/06/92	Normal	
						Day 21	24	1-21 days	29/06/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
13	354	Imipramine	Female	24/06/92	04/08/92	Screen	0	0 - Screening	24/06/92	Normal	
						Day 21	21	1-21 days	15/07/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 42	42	22-42 days	05/08/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY PREVIOUS MYOCARDIAL INFARCTION
	355	Reboxetine	Female	25/06/92	27/06/92	Screen	-8	0 - Screening	17/06/92	Abnormal	Not relevant
	356	Imipramine	Male	22/07/92	01/09/92	Screen	0	0 - Screening	22/07/92	Normal	
						Day 21	21	1-21 days	12/08/92	Normal	
						Day 42	42	22-42 days	02/09/92	Normal	
	357	Imipramine	Female	05/08/92	09/08/92	Screen	0	0 - Screening	05/08/92	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
	358	Reboxetine	Male	06/08/92	05/09/92	Screen	0	0 - Screening	06/08/92	Normal	
						Day 21	21	1-21 days	27/08/92	Normal	
	359	Reboxetine	Female	19/08/92	29/09/92	Screen	0	0 - Screening	19/08/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	09/09/92	Normal	
						Day 42	42	22-42 days	30/09/92	Normal	
	360	Imipramine	Female	19/08/92	21/08/92	Screen	0	0 - Screening	19/08/92	Normal	
	361	Reboxetine	Female	26/08/92	06/10/92	Screen	0	0 - Screening	26/08/92	Normal	
						Day 21	21	1-21 days	16/09/92	Normal	
						Day 42	42	22-42 days	07/10/92	Normal	
14	457	Reboxetine	Female	07/07/92	17/08/92	Screen	0	0 - Screening	07/07/92	Normal	
						Day 21	21	1-21 days	28/07/92	Normal	
						Day 42	42	22-42 days	18/08/92	Normal	
	458	Imipramine	Female	14/07/92	24/08/92	Screen	-4	0 - Screening	10/07/92	Normal	
						Day 21	21	1-21 days	04/08/92	Normal	
						Day 42	42	22-42 days	25/08/92	Normal	
	459	Reboxetine	Male	16/07/92	26/08/92	Screen	-3	0 - Screening	13/07/92	Normal	
						Day 21	21	1-21 days	06/08/92	Normal	
						Day 42	42	22-42 days	27/08/92	Normal	
	460	Imipramine	Male	23/07/92	02/09/92	Screen	-3	0 - Screening	20/07/92	Abnormal	SINUS BRADYCARDIA (< 60)

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14	460	Imipramine	Male	23/07/92	02/09/92	Day 21	21	1-21 days	13/08/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	41	22-42 days	02/09/92	Normal	
	461	Imipramine	Female	29/07/92	08/09/92	Screen	-7	0 - Screening	22/07/92	Normal	
						Day 21	21	1-21 days	19/08/92	Normal	
						Day 42	42	22-42 days	09/09/92	Normal	
	462	Reboxetine	Female	31/07/92	10/09/92	Screen	-7	0 - Screening	24/07/92	Normal	
						Day 21	21	1-21 days	21/08/92	Normal	
						Day 42	42	22-42 days	11/09/92	Normal	
	463	Imipramine	Male	03/08/92	13/09/92	Screen	-7	0 - Screening	27/07/92	Normal	
						Day 21	21	1-21 days	24/08/92	Normal	
						Day 42	42	22-42 days	14/09/92	Normal	
	464	Reboxetine	Female	05/08/92	16/09/92	Screen	-7	0 - Screening	29/07/92	Normal	
						Day 21	22	1-21 days	27/08/92	Normal	
						Day 42	43	22-42 days	17/09/92	Normal	
	465	Reboxetine	Male	06/08/92	16/09/92	Screen	-7	0 - Screening	30/07/92	Normal	
						Day 21	21	1-21 days	27/08/92	Normal	
						Day 42	42	22-42 days	17/09/92	Normal	
	466	Imipramine	Female	07/08/92	17/09/92	Screen	-7	0 - Screening	31/07/92	Normal	
						Day 21	21	1-21 days	28/08/92	Normal	
						Day 42	42	22-42 days	18/09/92	Normal	
14/1	129	Reboxetine	Male	19/12/91	19/12/91	Screen	-8	0 - Screening	11/12/91	Normal	
	426	Reboxetine	Female	05/09/91	17/10/91	Screen	-8	0 - Screening	28/08/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 21	19	1-21 days	24/09/91	Normal	
						Day 42	42	22-42 days	17/10/91	Normal	
	429	Imipramine	Female	26/09/91	29/09/91	Screen	-8	0 - Screening	18/09/91	Normal	
	451	Imipramine	Male	28/11/91	07/01/92	Screen	-1	0 - Screening	27/11/91	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
						Day 21	20	1-21 days	18/12/91	Abnormal	A-V BLOCK 1ST DEGREE
						Day 42	41	22-42 days	08/01/92	Abnormal	A-V BLOCK 1ST DEGREE

1456

955808

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14/1	452	Reboxetine	Female	28/11/91	09/01/92	Screen	-2	0 - Screening	26/11/91	Normal	
						Day 21	21	1-21 days	19/12/91	Normal	
						Day 42	41	22-42 days	08/01/92	Normal	
14/2	136	Imipramine	Female	15/01/92	25/02/92	Screen	-6	0 - Screening	09/01/92	Normal	
						Day 21	27	1-21 days	11/02/92	Normal	
						Day 42	41	22-42 days	25/02/92	Normal	
	456	Imipramine	Male	15/04/92	26/05/92	Screen	-6	0 - Screening	09/04/92	Normal	
						Day 21	22	1-21 days	07/05/92	Normal	
						Day 42	44	22-42 days	29/05/92	Normal	
14/3	417	Reboxetine	Female	14/06/91	26/07/91	Screen	-4	0 - Screening	10/06/91	Normal	
						Day 21	21	1-21 days	05/07/91	Normal	
						Day 42	42	22-42 days	26/07/91	Normal	
	418	Imipramine	Female	18/06/91	29/07/91	Screen	-8	0 - Screening	10/06/91	Normal	
						Day 21	20	1-21 days	08/07/91	Normal	
						Day 42	41	22-42 days	29/07/91	Normal	
	419	Reboxetine	Female	05/07/91	15/08/91	Screen	-2	0 - Screening	03/07/91	Normal	
						Day 21	20	1-21 days	25/07/91	Normal	
						Day 42	41	22-42 days	15/08/91	Normal	
	420	Imipramine	Female	05/07/91	25/07/91	Screen	-1	0 - Screening	04/07/91	Normal	
						Day 21	45	1-21 days	19/08/91	Normal	
	421	Reboxetine	Female	19/07/91	12/09/91	Screen	-8	0 - Screening	11/07/91	Normal	
						Day 21	20	1-21 days	08/08/91	Normal	
						Day 42	34	22-42 days	22/08/91	Normal	
	427	Imipramine	Female	18/09/91	15/10/91	Screen	0	0 - Screening	18/09/91	Normal	
						Day 21	21	1-21 days	09/10/91	Normal	
	428	Imipramine	Female	25/10/91	05/12/91	Screen	0	0 - Screening	25/10/91	Normal	
						Day 21	20	1-21 days	14/11/91	Normal	
						Day 42	41	22-42 days	05/12/91	Normal	
14/4	131	Imipramine	Female	14/01/92	24/02/92	Screen	-7	0 - Screening	07/01/92	Normal	
						Day 21	21	1-21 days	04/02/92	Normal	

1457

955-00 85

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14/4	131	Imipramine	Female	14/01/92	24/02/92	Day 42	42	22-42 days	25/02/92	Normal	
	132	Imipramine	Female	14/01/92	24/02/92	Screen	-7	0 - Screening	07/01/92	Normal	
						Day 21	21	1-21 days	04/02/92	Normal	
						Day 42	42	22-42 days	25/02/92	Normal	
	133	Imipramine	Female	16/01/92	26/02/92	Screen	-7	0 - Screening	09/01/92	Normal	
						Day 21	21	1-21 days	06/02/92	Normal	
						Day 42	42	22-42 days	27/02/92	Normal	
	134	Reboxetine	Female	16/01/92	26/02/92	Screen	-7	0 - Screening	09/01/92	Normal	
						Day 21	21	1-21 days	06/02/92	Normal	
						Day 42	42	22-42 days	27/02/92	Normal	
	135	Reboxetine	Male	17/01/92	27/02/92	Screen	-7	0 - Screening	10/01/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 21	21	1-21 days	07/02/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 42	42	22-42 days	28/02/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
14/7	422	Imipramine	Female	04/09/91	15/10/91	Screen	-2	0 - Screening	02/09/91	Normal	
						Day 21	21	1-21 days	25/09/91	Normal	
						Day 42	48	22-42 days	22/10/91	Normal	
	423	Imipramine	Female	17/09/91	28/10/91	Screen	-7	0 - Screening	10/09/91	Normal	
						Day 21	21	1-21 days	08/10/91	Normal	
						Day 42	42	22-42 days	29/10/91	Normal	
	424	Reboxetine	Male	19/09/91	30/10/91	Screen	-13	0 - Screening	06/09/91	Normal	
						Day 21	21	1-21 days	10/10/91	Normal	
						Day 42	42	22-42 days	31/10/91	Abnormal	SINUS TACHYCARDIA (> 100)
	430	Reboxetine	Female	07/10/91	17/11/91	Screen	0	0 - Screening	07/10/91	Normal	
						Day 21	21	1-21 days	28/10/91	Normal	
						Day 42	42	22-42 days	18/11/91	Normal	
	431	Reboxetine	Male	08/10/91	18/11/91	Screen	0	0 - Screening	08/10/91	Normal	
						Day 21	21	1-21 days	29/10/91	Normal	
						Day 42	42	22-42 days	19/11/91	Normal	
	432	Imipramine	Male	08/10/91	18/11/91	Screen	0	0 - Screening	08/10/91	Normal	
						Day 21	21	1-21 days	29/10/91	Normal	

1438

9550085

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14/7	432	Imipramine	Male	08/10/91	18/11/91	Day 42	42	22-42 days	19/11/91	Normal	
	433	Imipramine	Female	08/10/91	18/11/91	Screen	0	0 - Screening	08/10/91	Normal	
						Day 21	21	1-21 days	29/10/91	Normal	
						Day 42	42	22-42 days	19/11/91	Normal	
	434	Reboxetine	Male	14/10/91	24/11/91	Screen	-4	0 - Screening	10/10/91	Normal	
						Day 21	21	1-21 days	04/11/91	Normal	
						Day 42	42	22-42 days	25/11/91	Normal	
	439	Reboxetine	Male	11/11/91	22/12/91	Screen	-5	0 - Screening	06/11/91	Normal	
						Day 21	36	1-21 days	17/12/91	Normal	
						Day 42	42	22-42 days	23/12/91	Abnormal	SINUS TACHYCARDIA (> 100)
	440	Imipramine	Female	11/11/91	22/12/91	Screen	-4	0 - Screening	07/11/91	Normal	
						Day 21	21	1-21 days	02/12/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	42	22-42 days	23/12/91	Normal	
	441	Imipramine	Male	11/11/91	22/12/91	Screen	-3	0 - Screening	08/11/91	Normal	
						Day 21	21	1-21 days	02/12/91	Normal	
						Day 42	42	22-42 days	23/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
	442	Imipramine	Male	11/11/91	22/12/91	Screen	-3	0 - Screening	08/11/91	Normal	
						Day 21	21	1-21 days	02/12/91	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 42	36	22-42 days	17/12/91	Normal	
	449	Reboxetine	Female	20/12/91	30/01/92	Screen	-4	0 - Screening	16/12/91	Normal	
						Day 21	21	1-21 days	10/01/92	Normal	
						Day 42	42	22-42 days	31/01/92	Normal	
	450	Imipramine	Male	23/12/91	02/02/92	Screen	-17	0 - Screening	06/12/91	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 21	21	1-21 days	13/01/92	Normal	
						Day 42	42	22-42 days	03/02/92	Abnormal	SINUS BRADYCARDIA (< 60)
14/8	130	Reboxetine	Male	10/01/92	20/02/92	Screen	0	0 - Screening	10/01/92	Normal	
						Day 21	21	1-21 days	31/01/92	Normal	
						Day 42	42	22-42 days	21/02/92	Normal	
	425	Reboxetine	Female	09/09/91	20/10/91	Screen	-3	0 - Screening	06/09/91	Normal	
						Day 21	21	1-21 days	30/09/91	Abnormal	LEFT ANTERIOR HEMIBLOCK

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14/8	425	Reboxetine	Female	09/09/91	20/10/91	Day 42	42	22-42 days	21/10/91	Normal	
	467	Reboxetine	Male	06/07/92	16/08/92	Screen	-4	0 - Screening	02/07/92	Normal	
						Day 21	21	1-21 days	27/07/92	Normal	
						Day 42	42	22-42 days	17/08/92	Normal	
14/10	53	Reboxetine	Male	25/02/92	06/04/92	Screen	-8	0 - Screening	17/02/92	Normal	
						Day 21	20	1-21 days	16/03/92	Normal	
						Day 42	41	22-42 days	06/04/92	Normal	
	54	Imipramine	Female	26/02/92	07/04/92	Screen	-8	0 - Screening	18/02/92	Normal	
						Day 21	20	1-21 days	17/03/92	Normal	
						Day 42	41	22-42 days	07/04/92	Normal	
	55	Reboxetine	Female	28/02/92	09/04/92	Screen	-8	0 - Screening	20/02/92	Normal	
						Day 21	20	1-21 days	19/03/92	Normal	
						Day 42	41	22-42 days	09/04/92	Normal	
	56	Imipramine	Female	03/03/92	13/04/92	Screen	-8	0 - Screening	24/02/92	Normal	
						Day 21	20	1-21 days	23/03/92	Normal	
						Day 42	41	22-42 days	13/04/92	Normal	
	57	Reboxetine	Female	04/03/92	14/04/92	Screen	-8	0 - Screening	25/02/92	Normal	
						Day 21	20	1-21 days	24/03/92	Normal	
						Day 42	41	22-42 days	14/04/92	Normal	
	58	Imipramine	Female	14/04/92	25/05/92	Screen	-12	0 - Screening	02/04/92	Normal	
						Day 21	20	1-21 days	04/05/92	Normal	
						Day 42	41	22-42 days	25/05/92	Normal	
	59	Imipramine	Female	24/04/92	04/06/92	Screen	-9	0 - Screening	15/04/92	Normal	
						Day 21	20	1-21 days	14/05/92	Normal	
						Day 42	42	22-42 days	05/06/92	Normal	
	60	Reboxetine	Female	13/05/92	23/06/92	Screen	-9	0 - Screening	04/05/92	Normal	
						Day 21	20	1-21 days	02/06/92	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 42	41	22-42 days	23/06/92	Normal	
	137	Reboxetine	Female	28/01/92	09/03/92	Screen	-8	0 - Screening	20/01/92	Normal	
						Day 21	20	1-21 days	17/02/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14/10	137	Reboxetine	Female	28/01/92	09/03/92	Day 42	41	22-42 days	09/03/92	Normal	
	138	Imipramine	Female	29/01/92	10/03/92	Screen	-8	0 - Screening	21/01/92	Normal	
						Day 21	20	1-21 days	18/02/92	Normal	
						Day 42	41	22-42 days	10/03/92	Normal	
	139	Reboxetine	Female	04/02/92	16/03/92	Screen	-8	0 - Screening	27/01/92	Normal	
						Day 21	20	1-21 days	24/02/92	Normal	
						Day 42	41	22-42 days	16/03/92	Normal	
	140	Imipramine	Female	05/02/92	17/03/92	Screen	-8	0 - Screening	28/01/92	Normal	
						Day 21	20	1-21 days	25/02/92	Normal	
						Day 42	41	22-42 days	17/03/92	Normal	
	435	Imipramine	Female	12/11/91	23/12/91	Screen	-8	0 - Screening	04/11/91	Normal	
						Day 21	20	1-21 days	02/12/91	Normal	
						Day 42	41	22-42 days	23/12/91	Normal	
	436	Reboxetine	Female	13/11/91	23/12/91	Screen	-8	0 - Screening	05/11/91	Normal	
						Day 21	20	1-21 days	03/12/91	Normal	
						Day 42	40	22-42 days	23/12/91	Normal	
	437	Reboxetine	Female	14/11/91	23/12/91	Screen	-9	0 - Screening	05/11/91	Normal	
						Day 21	19	1-21 days	03/12/91	Normal	
						Day 42	39	22-42 days	23/12/91	Normal	
	438	Imipramine	Female	15/11/91	27/12/91	Screen	-8	0 - Screening	07/11/91	Normal	
						Day 21	20	1-21 days	05/12/91	Normal	
						Day 42	42	22-42 days	27/12/91	Normal	
	443	Reboxetine	Female	19/11/91	30/12/91	Screen	-5	0 - Screening	14/11/91	Normal	
						Day 21	20	1-21 days	09/12/91	Normal	
						Day 42	41	22-42 days	30/12/91	Normal	
	444	Reboxetine	Male	16/11/91	27/12/91	Screen	-1	0 - Screening	15/11/91	Normal	
						Day 21	20	1-21 days	06/12/91	Normal	
						Day 42	41	22-42 days	27/12/91	Normal	
	445	Imipramine	Female	20/11/91	30/12/91	Screen	-5	0 - Screening	15/11/91	Normal	
						Day 21	20	1-21 days	10/12/91	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
14/10	445	Imipramine	Female	20/11/91	30/12/91	Day 42	40	22-42 days	30/12/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
	446	Reboxetine	Female	26/11/91	07/01/92	Screen	-4	0 - Screening	22/11/91	Normal	
						Day 21	20	1-21 days	16/12/91	Normal	
						Day 42	42	22-42 days	07/01/92	Normal	
	447	Reboxetine	Male	27/11/91	07/01/92	Screen	-1	0 - Screening	26/11/91	Normal	
						Day 21	20	1-21 days	17/12/91	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 42	41	22-42 days	07/01/92	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
	448	Imipramine	Female	28/11/91	07/01/92	Screen	-6	0 - Screening	22/11/91	Normal	
						Day 21	19	1-21 days	17/12/91	Normal	
						Day 42	40	22-42 days	07/01/92	Normal	
	453	Imipramine	Female	28/05/92	08/07/92	Screen	-10	0 - Screening	18/05/92	Normal	
						Day 21	20	1-21 days	17/06/92	Normal	
						Day 42	41	22-42 days	08/07/92	Normal	
	454	Reboxetine	Female	12/06/92	23/07/92	Screen	-10	0 - Screening	02/06/92	Normal	
						Day 21	20	1-21 days	02/07/92	Normal	
						Day 42	41	22-42 days	23/07/92	Normal	
	455	Reboxetine	Female	20/06/92	31/07/92	Screen	-9	0 - Screening	11/06/92	Normal	
						Day 21	20	1-21 days	10/07/92	Normal	
						Day 42	41	22-42 days	31/07/92	Abnormal	SINUS BRADYCARDIA (< 60)
15	349	Imipramine	Male	20/08/92	01/10/92	Screen	0	0 - Screening	20/08/92	Abnormal	A-V BLOCK 1ST DEGREE
						Day 42	42	22-42 days	01/10/92	Normal	
	351	Reboxetine	Male	02/09/92	14/10/92	Screen	0	0 - Screening	02/09/92	Abnormal	A-V BLOCK 1ST DEGREE
						Day 42	42	22-42 days	14/10/92	Abnormal	A-V BLOCK 1ST DEGREE
	352	Imipramine	Male	06/08/92	27/08/92	Screen	0	0 - Screening	06/08/92	Abnormal	SINUS BRADYCARDIA (< 60)
	364	Imipramine	Female	29/07/92	26/08/92			0 - Screening			
	366	Reboxetine	Male	27/08/92	08/10/92	Day 42	42	22-42 days	08/10/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period Start date	Treatment period End date	E.C.G. Visit	days of treat.	Assessment	Date	Value	Abnormality
15	367	Imipramine	Male	31/08/92	11/10/92	Screen	0	0 - Screening	31/08/92	Normal	
						Day 42	42	22-42 days	12/10/92	Normal	
	368	Reboxetine	Female	04/09/92	15/10/92	Screen	0	0 - Screening	04/09/92	Normal	
						Day 42	41	22-42 days	15/10/92	Normal	
	369	Reboxetine	Female	10/07/92	20/08/92			0 - Screening			
	370	Imipramine	Female	16/07/92	27/08/92	Screen	0	0 - Screening	16/07/92	Normal	
	371	Reboxetine	Female	20/07/92	31/08/92			0 - Screening			
	372	Imipramine	Male	17/06/92	29/07/92	Screen	0	0 - Screening	17/06/92	Abnormal	SINUS TACHYCARDIA (> 100) LEFT ANTERIOR HEMIBLOCK
						Day 21	18	1-21 days	05/07/92	Normal	
	373	Imipramine	Female	25/06/92	26/06/92	Screen	0	0 - Screening	25/06/92	Normal	
	374	Reboxetine	Female	09/04/92	20/05/92	Screen	0	0 - Screening	09/04/92	Normal	
						Day 42	41	22-42 days	20/05/92	Normal	
	375	Reboxetine	Female	06/06/92	25/06/92	Screen	0	0 - Screening	06/06/92	Normal	
						Day 21	19	1-21 days	25/06/92	Abnormal	OTHER
	376	Imipramine	Female	13/04/92	21/04/92	Screen	0	0 - Screening	13/04/92	Normal	
	377	Reboxetine	Female	13/05/92	25/06/92	Day 21	21	1-21 days	03/06/92	Normal	
						Day 42	42	22-42 days	24/06/92	Abnormal	SINUS TACHYCARDIA (> 100)
	378	Reboxetine	Female	15/06/92	27/07/92	Screen	0	0 - Screening	15/06/92	Normal	
						Day 21	21	1-21 days	06/07/92	Normal	
						Day 42	42	22-42 days	27/07/92	Normal	
	379	Imipramine	Female	16/04/92	17/04/92			0 - Screening			
	380	Imipramine	Female	30/06/92	10/08/92	Screen	0	0 - Screening	30/06/92	Normal	
						Day 21	20	1-21 days	20/07/92	Normal	

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/017
Listing No.: 21.0

ECG TRACINGS

				Treatment period					E.C.G.		
Centre	Patient	Treatment	Sex	Start date	End date	Visit	days of treat.	Assessment	Date	Value	Abnormality
15	381	Reboxetine	Female	21/05/92	01/07/92	Screen	1	0 - Screening	22/05/92	Normal	
						Day 42	42	22-42 days	02/07/92	Normal	
	382	Imipramine	Male	09/04/92	10/04/92			0 - Screening			
	383	Imipramine	Female	07/07/92	18/08/92	Screen	0	0 - Screening	07/07/92	Normal	
	384	Reboxetine	Female	28/07/92	05/08/92			0 - Screening			

12.2.3 CRFS

Individual Patient CRFs are filed in the Study Master File